PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Raju, TNK				Raju, TNK			The Nobel Chronicles - 1955: Axel Hugo Theodor Theorell (1903-82)	LANCET			English	Biographical-Item									Univ Chicago, Chicago, IL 60637 USA	University of Chicago	Raju, TNK (corresponding author), Univ Chicago, Chicago, IL 60637 USA.								0	4	4	0	2	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAY 22	1999	353	9166					1807	1807		10.1016/S0140-6736(05)75919-5	http://dx.doi.org/10.1016/S0140-6736(05)75919-5			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	202TF	10359453				2022-12-28	WOS:000080667700076
J	Green, GE; Scott, DA; McDonald, JM; Woodworth, GG; Sheffield, VC; Smith, RJH				Green, GE; Scott, DA; McDonald, JM; Woodworth, GG; Sheffield, VC; Smith, RJH			Carrier rates in the midwestern United States for GJB2 mutations causing inherited deafness	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							SYNDROMIC RECESSIVE DEAFNESS; CONNEXIN 26 GENE; MYOSIN-VIIA GENE; SENSORINEURAL DEAFNESS; HEARING IMPAIRMENT; DFNB1	Context Mutations in the GJB2 gene are the most common known cause of inherited congenital severe-to-profound deafness, The carrier frequency of these mutations is not known. Objectives To determine the carrier rate of deafness-causing mutations in GJB2 in the midwestern United States and the prevalence of these mutations in persons with congenital sensorineural hearing loss ranging in severity from moderate to profound, and to derive revised data for counseling purposes. Design Laboratory analysis, performed in 1998, of samples from probands with hearing loss for mutations in GJB2 using an allele-specific polymerase chain reaction assay, single-strand conformation polymorphism analysis, and direct sequencing. Setting and Subjects Fifty-two subjects younger than 19 years sequentially referred to a midwestern tertiary referral center for hearing loss or cochlear implantation, with moderate-to-profound congenital hearing loss of unknown cause, parental nonconsanguinity, and nonsyndromic deafness with hearing loss limited to a single generation; 560 control neonates were screened for the 35delG mutation. Main Outcome Measure Prevalence of mutations in the GJB2 gene by congenital deafness status. Results Of 52 sequential probands referred for congenital sensorineural hearing loss, 22 (42%) were found to have GJB2 mutations. The 35delG mutation was identified in 29 of the 41 mutant alleles. Of probands' sibs, all homozygotes and compound heterozygotes had deafness. Fourteen of 560 controls were 35delG heterozygotes, for a carrier rate expressed as a mean (SE) of 2.5% (0.66%). The carrier rate for all recessive deafness-causing GJB2 mutations was determined to be 3.01% (probable range, 2.54%-3.56%). Calculated sensitivity and specificity for a screening test based on 35delG mutation alone were 96.9% and 97.4%, respectively, and observed values were 94% and 97%, respectively. Conclusions Our data suggest that mutations in GJB2 are the leading cause of moderate-to-profound congenital inherited deafness in the midwestern United States. Screening of the GJB2 mutation can be offered to individuals with congenital deafness with high sensitivity and specificity by screening only for the 35delG mutation,A positive finding should establish an etiologic diagnosis and affect genetic counseling.	Univ Iowa Hosp & Clin, Dept Otolaryngol Head & Neck Surg, Mol Otolaryngol Res Labs, Iowa City, IA 52242 USA; Univ Iowa Hosp & Clin, Dept Pediat, Iowa City, IA 52242 USA; Univ Iowa Hosp & Clin, Howard Hughes Med Inst, Iowa City, IA 52242 USA; Univ Iowa, Dept Stat & Actuarial Sci, Iowa City, IA 52242 USA	University of Iowa; University of Iowa; Howard Hughes Medical Institute; University of Iowa; University of Iowa	Smith, RJH (corresponding author), Dept Otolaryngol Head & Neck Surg, Mol Otolaryngol Res Labs, 200 Hawkins Dr, Iowa City, IA 52242 USA.	richard-smith@uiowa.edu		Smith, Richard/0000-0003-1201-6731; Sheffield, Val/0000-0002-6282-0835	NHGRI NIH HHS [HG-00457] Funding Source: Medline; NIDCD NIH HHS [R01-DC02842] Funding Source: Medline; NATIONAL HUMAN GENOME RESEARCH INSTITUTE [R01HG000457] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS [R01DC002842] Funding Source: NIH RePORTER	NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NIDCD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD)); NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD))		Antonarakis SE, 1998, HUM MUTAT, V11, P1; Cohen M. M., 1995, HEREDITARY HEARING L, P9; CREMERS CWRJ, 1991, ANN NY ACAD SCI, V630, P191, DOI 10.1111/j.1749-6632.1991.tb19587.x; DAUSSET J, 1990, GENOMICS, V6, P575, DOI 10.1016/0888-7543(90)90491-C; Denoyelle F, 1997, HUM MOL GENET, V6, P2173, DOI 10.1093/hmg/6.12.2173; Estivill X, 1998, LANCET, V351, P394, DOI 10.1016/S0140-6736(97)11124-2; Holden-Pitt L, 1998, AM ANN DEAF, V143, P72; Kelley PM, 1998, AM J HUM GENET, V62, P792, DOI 10.1086/301807; Kelsell DP, 1997, NATURE, V387, P80, DOI 10.1038/387080a0; KOEHN D, 1990, Genetic Counseling, V1, P127; Lench N, 1998, LANCET, V351, P415, DOI 10.1016/S0140-6736(98)24006-2; Li XC, 1998, NAT GENET, V18, P215, DOI 10.1038/ng0398-215; LITTLE S, 1998, CURRENT PROTOCOLS HU; Liu XZ, 1997, NAT GENET, V16, P188, DOI 10.1038/ng0697-188; LYSAUGHT MT, 1998, STORED TISSUE SAMPLE, P3; MARAZITA ML, 1993, AM J MED GENET, V46, P486, DOI 10.1002/ajmg.1320460504; Morell RJ, 1998, NEW ENGL J MED, V339, P1500, DOI 10.1056/NEJM199811193392103; MORTON NE, 1991, ANN NY ACAD SCI, V630, P16, DOI 10.1111/j.1749-6632.1991.tb19572.x; ROSE SP, 1975, THESIS INDIANA U IND; Scott DA, 1998, HUM MUTAT, V11, P387, DOI 10.1002/(SICI)1098-1004(1998)11:5<387::AID-HUMU6>3.3.CO;2-#; US Bureau of the Census, 1998, STAT ABSTR US 1998; VanCamp G, 1997, AM J HUM GENET, V60, P758; Wang AH, 1998, SCIENCE, V280, P1447, DOI 10.1126/science.280.5368.1447; Weil D, 1997, NAT GENET, V16, P191, DOI 10.1038/ng0697-191; Zbar RIS, 1998, OTOLARYNG HEAD NECK, V118, P333, DOI 10.1016/S0194-5998(98)70311-0; Zelante L, 1997, HUM MOL GENET, V6, P1605, DOI 10.1093/hmg/6.9.1605	26	282	302	0	14	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 16	1999	281	23					2211	2216		10.1001/jama.281.23.2211	http://dx.doi.org/10.1001/jama.281.23.2211			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	204RB	10376574	Bronze			2022-12-28	WOS:000080777000035
J	Rosenberg, RN; Anderson, ER				Rosenberg, RN; Anderson, ER			Editorial governance of the Journal of the American Medical Association - A report	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									Univ Texas, SW Med Ctr, Dept Neurol, Dallas, TX 75235 USA; Amer Med Assoc, Chicago, IL 60610 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; American Medical Association	Rosenberg, RN (corresponding author), Univ Texas, SW Med Ctr, Dept Neurol, 5323 Hines Blvd, Dallas, TX 75235 USA.							1999, JAMA, V281, P2240	1	20	20	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 16	1999	281	23					2239	2240		10.1001/jama.281.23.2239	http://dx.doi.org/10.1001/jama.281.23.2239			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	204RB	10376578	Bronze			2022-12-28	WOS:000080777000039
J	Fox, DL; Fisher, DC; Leighton, LR				Fox, DL; Fisher, DC; Leighton, LR			Reconstructing phylogeny with and without temporal data	SCIENCE			English	Article								Conventional cladistic methods of inferring evolutionary relationships exclude temporal data from the initial search for optimal hypotheses, but stratocladistics includes such data. A comparison of the ability of these methods to recover known, simulated evolutionary histories given the same, evolved character data shows that stratocladistics recovers the true phylogeny in over twice as many cares as cladistics (42 versus 18 percent). The comparison involved 550 unique taxon-by-character matrices, representing 15 evolutionary models and fossil records ranging from 100 to 10 percent complete.	Univ Michigan, Museum Paleontol, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan	Fox, DL (corresponding author), Univ Michigan, Museum Paleontol, 1109 Geddes Rd, Ann Arbor, MI 48109 USA.			Fox, David L/0000-0002-2291-6146				CLYDE WC, 1996, PALEOBIOLOGY, V23, P1; Eldredge N., 1980, PHYLOGENETIC PATTERN; Farris J.S., 1983, Advances in Cladistics, V2, P7; FARRIS JS, 1989, CLADISTICS, V5, P417, DOI 10.1111/j.1096-0031.1989.tb00573.x; FISHER DC, 1994, INTERPRETING HIERARC, P133; Foote M, 1996, PALEOBIOLOGY, V22, P121, DOI 10.1017/S0094837300016134; Gjelsvik A, 1981, THEORY THIN WALLED B, DOI DOI 10.1115/1.3162198; Hull D. L., 1988, SCI PROCESS; MADDISON WP, 1984, SYST ZOOL, V33, P83, DOI 10.2307/2413134; MADDISON WP, 1992, MACCLADE VER 3 0; NELSON G, 1978, SYST ZOOL, V27, P324, DOI 10.2307/2412883; Nelson G., 1981, SYSTEMATICS BIOGEORA; Paul CRC, 1998, ADEQUACY OF THE FOSSIL RECORD, P1; POLLY PD, 1997, CONTRIB MUS PALEONTO, P1; SCHAEFFER B, 1972, EVOLUTIONARY BIOL, V6, pCH2; SMITH AB, 1998, NATURE          1119; SMITH AB, 1984, SYSTEMATICS FOSSIL R; SOBER E, 1988, RECONSTRUCTING PAST; [No title captured]; [No title captured]; [No title captured]	21	71	72	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 11	1999	284	5421					1816	1819		10.1126/science.284.5421.1816	http://dx.doi.org/10.1126/science.284.5421.1816			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	205EU	10364549				2022-12-28	WOS:000080809000043
J	Ferraccioli, GF; De Vita, S				Ferraccioli, GF; De Vita, S			Leflunomide for active rheumatoid arthritis	LANCET			English	Letter							CYCLOSPORINE		Univ Udine, Sch Med, DPMSC, Rheumatol Unit, I-33100 Udine, Italy	University of Udine	Ferraccioli, GF (corresponding author), Univ Udine, Sch Med, DPMSC, Rheumatol Unit, I-33100 Udine, Italy.							FORRE O, 1994, ARTHRITIS RHEUM, V37, P1506; Madhok R, 1999, LANCET, V353, P257, DOI 10.1016/S0140-6736(05)74938-2; Pasero G, 1996, ARTHRITIS RHEUM, V39, P1006, DOI 10.1002/art.1780390618; Smolen JS, 1999, LANCET, V353, P259, DOI 10.1016/S0140-6736(98)09403-3	4	0	0	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAY 29	1999	353	9167					1883	1883		10.1016/S0140-6736(05)75089-3	http://dx.doi.org/10.1016/S0140-6736(05)75089-3			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	202TG	10359440	Bronze			2022-12-28	WOS:000080667800060
J	Hirose, K; Kadowaki, S; Tanabe, M; Takeshima, H; Iino, M				Hirose, K; Kadowaki, S; Tanabe, M; Takeshima, H; Iino, M			Spatiotemporal dynamics of inositol 1,4,5-trisphosphate that underlies complex Ca2+ mobilization patterns	SCIENCE			English	Article							PLECKSTRIN HOMOLOGY DOMAIN; CALCIUM SPIKING; PLASMA-MEMBRANE; PHOSPHOLIPASE C-DELTA(1); CELLS; OSCILLATIONS; BINDING; TRISPHOSPHATE; 5-PHOSPHATASE; ATP	Inositol 1,4,5-trisphosphate (IP3) is a second messenger that elicits complex spatiotemporal patterns of calcium ion (Ca2+) mobilization and has essential soles in the regulation of many cellular functions. In Madin-Darby canine kidney epithelial cells, green fluorescent protein-tagged pleckstrin homology domain translocated from the plasma membrane to the cytoplasm in response to increased concentration of IP3. The detection of translocation enabled monitoring of IP3 concentration changes within single cells and revealed spatiotemporal dynamics in the concentration of IP3 synchronous with Ca2+ oscillations and intracellular and intercellular IP3 waves that accompanied Ca2+ waves. Such changes in IP3 concentration may be fundamental to Ca2+ signaling.	Univ Tokyo, Fac Med, Dept Pharmacol, Tokyo 1138654, Japan; Japan Sci & Technol Corp, CREST, Tokyo 1138654, Japan	University of Tokyo; Japan Science & Technology Agency (JST)	Hirose, K (corresponding author), Univ Tokyo, Fac Med, Dept Pharmacol, Tokyo 1138654, Japan.			Takeshima, Hiroshi/0000-0003-4525-3725; Hirose, Kenzo/0000-0002-8944-6513				BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BERRIDGE MJ, 1990, J BIOL CHEM, V265, P9583; BOITANO S, 1992, SCIENCE, V258, P292, DOI 10.1126/science.1411526; Bootman MD, 1996, BIOCHEM J, V314, P347, DOI 10.1042/bj3140347; CIFUENTES ME, 1994, J BIOL CHEM, V269, P1945; DeSmedt F, 1997, J BIOL CHEM, V272, P17367, DOI 10.1074/jbc.272.28.17367; Dolmetsch RE, 1997, NATURE, V386, P855, DOI 10.1038/386855a0; DOWNES CP, 1982, BIOCHEM J, V203, P169, DOI 10.1042/bj2030169; HAROOTUNIAN AT, 1991, SCIENCE, V251, P75, DOI 10.1126/science.1986413; HIROSE K, UNPUB; KASAI H, 1994, TRENDS NEUROSCI, V17, P95, DOI 10.1016/0166-2236(94)90112-0; LAXMINARAYAN KM, 1994, J BIOL CHEM, V269, P17305; LEMMON MA, 1995, P NATL ACAD SCI USA, V92, P10472, DOI 10.1073/pnas.92.23.10472; Li WH, 1998, NATURE, V392, P936, DOI 10.1038/31965; MAJERUS PW, 1992, ANNU REV BIOCHEM, V61, P225, DOI 10.1146/annurev.bi.61.070192.001301; MEYER T, 1988, P NATL ACAD SCI USA, V85, P5051, DOI 10.1073/pnas.85.14.5051; MEYER T, 1991, ANNU REV BIOPHYS BIO, V20, P153, DOI 10.1146/annurev.bb.20.060191.001101; Miyawaki A, 1997, NATURE, V388, P882, DOI 10.1038/42264; OSIPCHUK Y, 1992, NATURE, V359, P241, DOI 10.1038/359241a0; Paterson HF, 1995, BIOCHEM J, V312, P661, DOI 10.1042/bj3120661; PUTNEY JW, 1993, SCIENCE, V262, P676, DOI 10.1126/science.8235587; ROONEY TA, 1993, CELL CALCIUM, V14, P674, DOI 10.1016/0143-4160(93)90094-M; Rottingen JA, 1997, CELL CALCIUM, V21, P195, DOI 10.1016/S0143-4160(97)90044-0; SMITH RJ, 1990, J PHARMACOL EXP THER, V253, P688; SNEYD J, 1995, AM J PHYSIOL-CELL PH, V268, pC1537, DOI 10.1152/ajpcell.1995.268.6.C1537; Stauffer TP, 1998, CURR BIOL, V8, P343, DOI 10.1016/S0960-9822(98)70135-6; TSIEN RW, 1990, ANNU REV CELL BIOL, V6, P715, DOI 10.1146/annurev.cb.06.110190.003435; Tsien RY, 1998, SCIENCE, V280, P1954, DOI 10.1126/science.280.5371.1954; VERJANS B, 1994, BIOCHEM J, V300, P85, DOI 10.1042/bj3000085; YAGISAWA H, 1994, J BIOL CHEM, V269, P20179; Yagisawa H, 1998, J BIOL CHEM, V273, P417, DOI 10.1074/jbc.273.1.417	31	428	444	1	9	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAY 28	1999	284	5419					1527	1530		10.1126/science.284.5419.1527	http://dx.doi.org/10.1126/science.284.5419.1527			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	200PD	10348740				2022-12-28	WOS:000080548100037
J	Mastrianni, JA; Nixon, R; Layzer, R; Telling, GC; Han, D; DeArmond, SJ; Prusiner, SB				Mastrianni, JA; Nixon, R; Layzer, R; Telling, GC; Han, D; DeArmond, SJ; Prusiner, SB			Prion protein conformation in a patient with sporadic fatal insomnia	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CREUTZFELDT-JAKOB-DISEASE; FAMILIAL INSOMNIA; DNA POLYMORPHISM; TRANSGENIC MICE; MOLECULAR-BASIS; GENE; MUTATION; CODON-178; PRP; PROPAGATION		Univ Calif San Francisco, Dept Neurol, Inst Neurodegenerat Dis, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Pathol, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Biochem & Biophys, San Francisco, CA 94143 USA; Univ Chicago, Dept Neurol, Chicago, IL 60637 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of Chicago	Prusiner, SB (corresponding author), Univ Calif San Francisco, Dept Neurol, Inst Neurodegenerat Dis, Box 0518, San Francisco, CA 94143 USA.		Telling, Glenn C/G-1217-2019	Telling, Glenn C/0000-0002-6294-1805	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P50NS014069, P01NS014069] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P01AG002132, R35AG008967] Funding Source: NIH RePORTER; NIA NIH HHS [AG02132, AG08967] Funding Source: Medline; NINDS NIH HHS [NS14069] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BESSEN RA, 1994, J VIROL, V68, P7859, DOI 10.1128/JVI.68.12.7859-7868.1994; BOSQUE PJ, 1992, NEUROLOGY, V42, P1864, DOI 10.1212/WNL.42.10.1864; CARLSON GA, 1994, P NATL ACAD SCI USA, V91, P5690, DOI 10.1073/pnas.91.12.5690; Cohen FE, 1998, ANNU REV BIOCHEM, V67, P793, DOI 10.1146/annurev.biochem.67.1.793; DeArmond SJ, 1997, NEURON, V19, P1337, DOI 10.1016/S0896-6273(00)80424-9; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; GAMBETTI P, 1995, BRAIN PATHOL, V5, P43, DOI 10.1111/j.1750-3639.1995.tb00576.x; GAMBETTI P, 1991, PRION DIS HUM AN S L; GOLDFARB LG, 1992, SCIENCE, V258, P806, DOI 10.1126/science.1439789; Kaneko K, 1997, P NATL ACAD SCI USA, V94, P10069, DOI 10.1073/pnas.94.19.10069; KASCSAK RJ, 1987, J VIROL, V61, P3688, DOI 10.1128/JVI.61.12.3688-3693.1987; MANETTO V, 1992, NEUROLOGY, V42, P312, DOI 10.1212/WNL.42.2.312; MASTRIANNI JA, 1995, NEUROLOGY S, V45, P201; McLean CA, 1997, NEUROLOGY, V49, P552, DOI 10.1212/WNL.49.2.552; MEDORI R, 1992, NEW ENGL J MED, V326, P444, DOI 10.1056/NEJM199202133260704; MEDORI R, 1992, NEUROLOGY, V42, P669, DOI 10.1212/WNL.42.3.669; MEYER RK, 1986, P NATL ACAD SCI USA, V83, P2310, DOI 10.1073/pnas.83.8.2310; MONARI L, 1994, P NATL ACAD SCI USA, V91, P2839, DOI 10.1073/pnas.91.7.2839; Nagayama M, 1996, NEUROLOGY, V47, P1313, DOI 10.1212/WNL.47.5.1313; OESCH B, 1985, CELL, V40, P735, DOI 10.1016/0092-8674(85)90333-2; PALMER MS, 1993, HUM MUTAT, V2, P168, DOI 10.1002/humu.1380020303; PAN KM, 1993, P NATL ACAD SCI USA, V90, P10962, DOI 10.1073/pnas.90.23.10962; PARCHI P, 1995, ANN NEUROL, V38, P21, DOI 10.1002/ana.410380107; Parchi P, 1996, ANN NEUROL, V39, P767, DOI 10.1002/ana.410390613; Parchi P, 1997, NATURE, V386, P232, DOI 10.1038/386232a0; PERANI D, 1993, NEUROLOGY, V43, P2565, DOI 10.1212/WNL.43.12.2565; PETERSEN RB, 1993, FASEB J, V7, pA627; PETERSEN RB, 1992, NEUROLOGY, V42, P1859, DOI 10.1212/WNL.42.10.1859; Prusiner SB, 1998, P NATL ACAD SCI USA, V95, P13363, DOI 10.1073/pnas.95.23.13363; REDER AT, 1995, NEUROLOGY, V45, P1068, DOI 10.1212/WNL.45.6.1068; Safar J, 1998, NAT MED, V4, P1157, DOI 10.1038/2654; Sambrook J., 2002, MOL CLONING LAB MANU; Silburn P, 1996, NEUROLOGY, V47, P1326, DOI 10.1212/WNL.47.5.1326; TARABOULOS A, 1992, P NATL ACAD SCI USA, V89, P7620, DOI 10.1073/pnas.89.16.7620; TELLING GC, 1995, CELL, V83, P79, DOI 10.1016/0092-8674(95)90236-8; Telling GC, 1996, SCIENCE, V274, P2079, DOI 10.1126/science.274.5295.2079; TELLING GC, 1994, P NATL ACAD SCI USA, V91, P9936, DOI 10.1073/pnas.91.21.9936	37	130	134	0	8	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAY 27	1999	340	21					1630	1638		10.1056/NEJM199905273402104	http://dx.doi.org/10.1056/NEJM199905273402104			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	199QY	10341275				2022-12-28	WOS:000080494200004
J	Powell, JJ; Wojnarowska, F				Powell, JJ; Wojnarowska, F			Lichen sclerosus	LANCET			English	Article							SQUAMOUS-CELL CARCINOMA; BALANITIS-XEROTICA-OBLITERANS; BORRELIA-BURGDORFERI DNA; ET-ATROPHICUS; HUMAN-PAPILLOMAVIRUS; TOPICAL TESTOSTERONE; VULVAR DISEASE; MORPHEA; ASSOCIATION; CHILDHOOD	Lichen sclerosis is a chronic inflammatory skin disease that causes substantial discomfort and morbidity, most commonly in adult women, but also in men and children. Any skin site may be affected (and, rarely, the oral mucosa) but Lichen sclerosus is most common in the anogenital area, where it causes intractable itching and soreness. In children, the disorder may be confused with changes seen in sexual abuse. progression to destructive scarring is common. There is increased risk of developing vulval cancer, and there are links with penile cancer. Patients should be kept under longterm review. Lichen sclerosus can occur without symptoms, and the exact prevalence is uncertain. It occurs most commonly in women at times of low sex hormone output. The underlying cause is unknown, but there seems to be a genetic susceptibility and a link with autoimmune mechanisms. The wart virus and the spirochaete borrelia have been suggested but not substantiated as infective triggers. The Koebner phenomenon is known to occur (lichen sclerosus occurs in skin already scarred or damaged), so trauma, injury, and sexual abuse have been suggested as possible triggers of symptoms in genetically predisposed people. The treatment of choice for anogenital lichen sclerosus is potent topical corticosteroid ointment for a limited time. Circumcision may be indicated in men, and surgery may be considered in women, to relieve effects of scarring or to treat coexisting carcinoma. Current research aims to identify a treatable cause of lichen sclerosus, to identify patients at risk of scarring and of malignant disorders, and to find target pathways for therapeutic intervention.	Oxford Radcliffe Hosp, Dept Dermatol, Oxford OX3 7LJ, England	University of Oxford	Powell, JJ (corresponding author), Oxford Radcliffe Hosp, Dept Dermatol, The Churchill, Oxford OX3 7LJ, England.							ABERER E, 1987, AM J DERMATOPATH, V9, P374, DOI 10.1097/00000372-198710000-00002; ANDERSEN WA, 1991, AM J OBSTET GYNECOL, V165, P329, DOI 10.1016/0002-9378(91)90086-7; ANSINK AC, 1994, GYNECOL ONCOL, V52, P180, DOI 10.1006/gyno.1994.1028; BERTHJONES J, 1991, CLIN EXP DERMATOL, V16, P14, DOI 10.1111/j.1365-2230.1991.tb00285.x; BOUSEMA MT, 1994, J AM ACAD DERMATOL, V30, P225, DOI 10.1016/S0190-9622(94)70021-4; BRACCO GL, 1993, J REPROD MED, V38, P37; BRIESKI A, 1885, Z HEILKR, V6, P69; BUNCE M, 1993, HUM IMMUNOL, V37, P201, DOI 10.1016/0198-8859(93)90502-R; CAMPUS GV, 1984, PLAST RECONSTR SURG, V73, P652, DOI 10.1097/00006534-198404000-00024; CANTWELL AR, 1984, INT J DERMATOL, V23, P45, DOI 10.1111/j.1365-4362.1984.tb05662.x; CHALMERS RJG, 1984, ARCH DERMATOL, V120, P1025, DOI 10.1001/archderm.120.8.1025; Chan LS, 1997, J INVEST DERMATOL, V108, P129, DOI 10.1111/1523-1747.ep12332352; CLAY FE, 1994, HUM GENET, V94, P407; COX NH, 1986, BRIT J DERMATOL, V115, P743, DOI 10.1111/j.1365-2133.1986.tb06659.x; DALZIEL KL, 1995, J REPROD MED, V40, P351; DALZIEL KL, 1991, BRIT J DERMATOL, V124, P461, DOI 10.1111/j.1365-2133.1991.tb00626.x; DALZIEL KL, 1993, J REPROD MED, V38, P25; Darier J., 1892, ANN DERMATOL SYPHIL, V23, P833; Datta C, 1993, J Indian Med Assoc, V91, P146; DILLON WI, 1995, J AM ACAD DERMATOL, V33, P617, DOI 10.1016/0190-9622(95)91281-9; Drut RM, 1998, PEDIATR DERMATOL, V15, P85, DOI 10.1046/j.1525-1470.1998.1998015085.x; Farrell A. M., 1997, British Journal of Dermatology, V136, P462; Farrell AM, 1997, BRIT J DERMATOL, V137, P25; FARRELL MA, 1998, BR J DERMATOL S51, V139, P83; Fischer G, 1997, PEDIATR DERMATOL, V14, P235, DOI 10.1111/j.1525-1470.1997.tb00247.x; FISHER G, 1995, BRIT J OBSTET GYNAEC, V102, P773; Freeman C, 1941, ARCH DERMATOL SYPH, V44, P547, DOI 10.1001/archderm.1941.01500040002001; FRIEDRICH EG, 1984, NEW ENGL J MED, V310, P488, DOI 10.1056/NEJM198402233100803; FRIEDRICH EG, 1976, OBSTET GYNECOL, V47, P122; Fujiwara H, 1997, ARCH DERMATOL, V133, P41, DOI 10.1001/archderm.133.1.41; GARCIABRAVO B, 1988, J AM ACAD DERMATOL, V19, P482, DOI 10.1016/S0190-9622(88)70201-7; GOOLAMALI SK, 1974, BRIT MED J, V6, P78; HALLOPEEU H, 1987, UNION MED CAN, V14, P729; HARRINGTON CI, 1981, BRIT J DERMATOL, V104, P563, DOI 10.1111/j.1365-2133.1981.tb08172.x; Jacyk W K, 1979, J Natl Med Assoc, V71, P387; Johnson B., 1997, LEVERS HISTOPATHOLOG, V8th; Jones RW, 1997, OBSTET GYNECOL, V90, P448, DOI 10.1016/S0029-7844(97)00298-6; JONES SEH, 1987, BRIT MED J, V294, P144; KAIBI W, 1991, CHINESE MED J, V104, P868; KAUFMAN RH, 1994, BENIGN DIS VULVA, P260; KIENE P, 1991, ARCH DERMATOL RES, V283, P445, DOI 10.1007/BF00371780; KURMAN RJ, 1997, P 14 ISSVD INT C, P55; LEIBOWITCH M, 1990, BRIT J OBSTET GYNAEC, V97, P1135, DOI 10.1111/j.1471-0528.1990.tb02502.x; LIPSCOMBE T, 1997, AUST J DERMATOL, V38, P123; LOENINGBAUCKE V, 1991, AM J DIS CHILD, V145, P1058, DOI 10.1001/archpedi.1991.02160090110035; MANN PR, 1973, BRIT J DERMATOL, V89, P223, DOI 10.1111/j.1365-2133.1973.tb02968.x; Marren P, 1997, BRIT J DERMATOL, V136, P508, DOI 10.1046/j.1365-2133.1997.6061582.x; Marren P, 1997, J EUR ACAD DERMATOL, V8, P212; MARREN P, 1995, BRIT J DERMATOL, V132, P197; MARREN P, 1994, BRIT J DERMATOL, V131, P118, DOI 10.1111/j.1365-2133.1994.tb08468.x; Marren P, 1995, BRIT J DERMATOL, V133, P21; MCADAMS AJ, 1958, CANCER, V11, P740, DOI 10.1002/1097-0142(195807/08)11:4<740::AID-CNCR2820110411>3.0.CO;2-1; MEFFERT JJ, 1995, J AM ACAD DERMATOL, V32, P393, DOI 10.1016/0190-9622(95)90060-8; MERREN P, 1992, BRIT J DERMATOL, V126, P52; MIHARA Y, 1994, ARCH DERMATOL RES, V286, P434, DOI 10.1007/BF00371568; Montgomery H, 1940, ARCH DERMATOL SYPH, V42, P755, DOI 10.1001/archderm.1940.01490170003001; PARKER LU, 1991, CLEV CLIN J MED, V58, P43, DOI 10.3949/ccjm.58.1.43; PATTERSON JAK, 1984, AM J DERMATOPATH, V6, P323, DOI 10.1097/00000372-198408000-00007; POWELL J, 1998, BRIT J DERMATOL, V139, P23; POWELL W, 1998, BR J DERMATOL S51, V139, P47; PRETI M, 1994, J REPROD MED, V39, P961; PRIDE HB, 1993, J AM ACAD DERMATOL, V29, P469, DOI 10.1016/0190-9622(93)70213-D; PURCELL KG, 1990, ARCH DERMATOL, V126, P1043, DOI 10.1001/archderm.126.8.1043; RIDLEY CM, 1989, HUM PATHOL, V20, P495; RIDLEY CM, 1993, J ROY SOC MED, V86, P69; RIDLEY CM, 1987, ARCH DERMATOL, V123, P457, DOI 10.1001/archderm.123.4.457; RIDLEY CM, 1988, VULVA, P172; SAHN EE, 1994, PEDIATR DERMATOL, V11, P160, DOI 10.1111/j.1525-1470.1994.tb00572.x; SCHEMPP C, 1993, J INVEST DERMATOL, V100, P717, DOI 10.1111/1523-1747.ep12472369; SCHULTEN EAJM, 1993, J ORAL PATHOL MED, V22, P374, DOI 10.1111/j.1600-0714.1993.tb01092.x; SIDERI M, 1989, AM J OBSTET GYNECOL, V161, P38, DOI 10.1016/0002-9378(89)90228-7; SIDERI M, 1994, INT J GYNECOL OBSTET, V46, P53, DOI 10.1016/0020-7292(94)90309-3; TAN SH, 1994, J CUTAN PATHOL, V21, P316, DOI 10.1111/j.1600-0560.1994.tb00706.x; THOMAS RHM, 1983, BRIT J DERMATOL, V109, P661, DOI 10.1111/j.1365-2133.1983.tb00546.x; THOMAS RHM, 1987, CLIN EXP DERMATOL, V12, P126, DOI 10.1111/j.1365-2230.1987.tb01880.x; THOMAS RHM, 1984, CLIN EXP DERMATOL, V9, P290, DOI 10.1111/j.1365-2230.1984.tb00799.x; THOMAS RHM, 1988, BR J DERAMTOL, V114, P377; THOMAS RHM, 1986, BRIT J DERMATOL, V108, P41; TODD P, 1994, CLIN EXP DERMATOL, V19, P262, DOI 10.1111/j.1365-2230.1994.tb01183.x; TREMAINE R, 1990, INT J DERMATOL, V29, P486, DOI 10.1111/j.1365-4362.1990.tb04840.x; UITTO J, 1980, J AM ACAD DERMATOL, V3, P271, DOI 10.1016/S0190-9622(80)80190-3; von Zumbusch LR, 1906, ARCH DERMATOL SYPH-G, V82, P339; Walkden Valerie, 1997, Journal of Obstetrics and Gynaecology (Abingdon), V17, P551; Wallace H J, 1971, Trans St Johns Hosp Dermatol Soc, V57, P9; Warrington SA, 1996, ARCH DIS CHILD, V75, P512, DOI 10.1136/adc.75.6.512; WEBER P, 1987, J DERMATOL SURG ONC, V13, P529; WHIMSTER IW, 1965, BRIT J DERMATOL, V77, P534; ZAINO RJ, 1982, INT J GYNECOL PATHOL, V1, P173, DOI 10.1097/00004347-198202000-00005	88	376	394	2	28	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAY 22	1999	353	9166					1777	1783		10.1016/S0140-6736(98)08228-2	http://dx.doi.org/10.1016/S0140-6736(98)08228-2			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	202TF	10348006				2022-12-28	WOS:000080667700045
J	Holash, J; Maisonpierre, PC; Compton, D; Boland, P; Alexander, CR; Zagzag, D; Yancopoulos, GD; Wiegand, SJ				Holash, J; Maisonpierre, PC; Compton, D; Boland, P; Alexander, CR; Zagzag, D; Yancopoulos, GD; Wiegand, SJ			Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF	SCIENCE			English	Article							RECEPTOR TYROSINE KINASE; IN-VIVO; MOLECULAR-CLONING; TIE2 RECEPTOR; ANGIOGENESIS; EXPRESSION; CELLS; GENES; TEK; VASCULOGENESIS	In contrast with the prevailing view that most tumors and metastases begin as avascular masses, evidence is presented here that a subset of tumors instead initially grows by coopting existing host vessels. This coopted host vasculature does not immediately undergo angiogenesis to support the tumor but instead regresses, leading to a secondarily avascular tumor and massive tumor cell loss. Ultimately, however, the remaining tumor is rescued by robust angiogenesis at the tumor margin. The expression patterns of the angiogenic antagonist angiopoietin-2 and of pro-angiogenic vascular endothelial growth factor (VEGF) suggest that these proteins may be critical regulators of this balance between vascular regression and growth.	Regeneron Pharmaceut Inc, Tarrytown, NY 10591 USA; NYU, Med Ctr, Kaplan Canc Ctr, Dept Pathol,Microvasc & Mol Neurooncol Lab, New York, NY 10016 USA	Regeneron; New York University	Yancopoulos, GD (corresponding author), Regeneron Pharmaceut Inc, 777 Old Saw Mill River Rd, Tarrytown, NY 10591 USA.							ANAKA S, 1999, J CLIN INVEST, V103, P341; Benjamin LE, 1999, J CLIN INVEST, V103, P159, DOI 10.1172/JCI5028; Carmeliet P, 1996, NATURE, V380, P435, DOI 10.1038/380435a0; Davis S, 1996, CELL, V87, P1161, DOI 10.1016/S0092-8674(00)81812-7; DUMONT DJ, 1992, ONCOGENE, V7, P1471; DUMONT DJ, 1994, GENE DEV, V8, P1897, DOI 10.1101/gad.8.16.1897; Enholm B, 1997, ONCOGENE, V14, P2475, DOI 10.1038/sj.onc.1201090; Ferrara N, 1996, NATURE, V380, P439, DOI 10.1038/380439a0; Ferrara N, 1999, CURR TOP MICROBIOL, V237, P1; FOLKMAN J, 1971, NEW ENGL J MED, V285, P1182; FOLKMAN J, 1990, JNCI-J NATL CANCER I, V82, P4, DOI 10.1093/jnci/82.1.4; Goldman CK, 1998, P NATL ACAD SCI USA, V95, P8795, DOI 10.1073/pnas.95.15.8795; Hanahan D, 1996, CELL, V86, P353, DOI 10.1016/S0092-8674(00)80108-7; HOLASH J, UNPUB; HOLMGREN L, 1995, NAT MED, V1, P149, DOI 10.1038/nm0295-149; IWAMA A, 1993, BIOCHEM BIOPH RES CO, V195, P301, DOI 10.1006/bbrc.1993.2045; KIM KJ, 1993, NATURE, V362, P741; Maisonpierre PC, 1997, SCIENCE, V277, P55, DOI 10.1126/science.277.5322.55; MAISONPIERRE PC, 1993, ONCOGENE, V8, P1631; Millauer B, 1996, CANCER RES, V56, P1615; MILLAUER B, 1994, NATURE, V367, P576, DOI 10.1038/367576a0; MORGENBESSER SD, 1995, EMBO J, V14, P743, DOI 10.1002/j.1460-2075.1995.tb07053.x; MORSE JK, 1993, J NEUROSCI, V13, P4146; NAGANO N, 1993, ACTA NEUROPATHOL, V86, P117, DOI 10.1007/BF00334878; Papapetropoulos A, 1999, LAB INVEST, V79, P213; PARTANEN J, 1992, MOL CELL BIOL, V12, P1698, DOI 10.1128/MCB.12.4.1698; Pezzella F, 1997, AM J PATHOL, V151, P1417; SATO TN, 1993, P NATL ACAD SCI USA, V90, P9355, DOI 10.1073/pnas.90.20.9355; SCHNURCH H, 1993, DEVELOPMENT, V119, P957; SHALABY F, 1995, NATURE, V376, P62, DOI 10.1038/376062a0; SHWEIKI D, 1995, P NATL ACAD SCI USA, V92, P768, DOI 10.1073/pnas.92.3.768; Stratmann A, 1998, AM J PATHOL, V153, P1459, DOI 10.1016/S0002-9440(10)65733-1; Suri C, 1996, CELL, V87, P1171, DOI 10.1016/S0092-8674(00)81813-9; Suri C, 1998, SCIENCE, V282, P468, DOI 10.1126/science.282.5388.468; Valenzuela DM, 1999, P NATL ACAD SCI USA, V96, P1904, DOI 10.1073/pnas.96.5.1904; VALENZUELA DM, 1993, NEURON, V10, P963, DOI 10.1016/0896-6273(93)90211-9; WARREN RS, 1995, J CLIN INVEST, V95, P1789, DOI 10.1172/JCI117857; WESSELING P, 1994, J NEUROSURG, V81, P902, DOI 10.3171/jns.1994.81.6.0902; Wong AL, 1997, CIRC RES, V81, P567, DOI 10.1161/01.RES.81.4.567; ZAGZAG D, IN PRESS EXP NEUROL; ZIEGLER SF, 1993, ONCOGENE, V8, P663	41	1697	1831	2	82	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 18	1999	284	5422					1994	1998		10.1126/science.284.5422.1994	http://dx.doi.org/10.1126/science.284.5422.1994			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	207JA	10373119				2022-12-28	WOS:000080932700049
J	Heymann, SJ; Brewer, TF; Wilson, ME; Fineberg, HV				Heymann, SJ; Brewer, TF; Wilson, ME; Fineberg, HV			The need for global action against multidrug-resistant tuberculosis	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							ANTITUBERCULOSIS-DRUG-RESISTANCE; UNITED-STATES; EPIDEMIOLOGY; SURVEILLANCE; PROGRAM; HEALTH		Harvard Univ, Sch Publ Hlth, Dept Hlth & Social Behav, Boston, MA 02115 USA; Brigham & Womens Hosp, Dept Med, Channing Lab, Boston, MA USA; Harvard Univ, Sch Med, Boston, MA USA	Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School	Heymann, SJ (corresponding author), Harvard Univ, Sch Publ Hlth, Dept Hlth & Social Behav, 677 Huntington Ave, Boston, MA 02115 USA.							AISU T, 1995, AIDS, V9, P267, DOI 10.1097/00002030-199509030-00008; BASS J, 1992, AM REV RESPIR DIS, V146, P1623; Boulahbal F, 1989, Bull Int Union Tuberc Lung Dis, V64, P23; BROWN RE, 1995, ARCH INTERN MED, V155, P1595, DOI 10.1001/archinte.155.15.1595; *CDCP, 1997, REP TUB US 1996; COLDITZ GA, 1994, JAMA-J AM MED ASSOC, V271, P698, DOI 10.1001/jama.271.9.698; Crofton J., 1997, GUIDELINES MANAGEMEN; ESPINAL MA, 1998, INT J TUBERC LUNG S2, V2, pS371; Farmer P, 1998, BRIT MED J, V317, P671, DOI 10.1136/bmj.317.7159.671; FRIEDEN TR, 1995, NEW ENGL J MED, V333, P229, DOI 10.1056/NEJM199507273330406; Heath TC, 1998, INT J TUBERC LUNG D, V2, P647; Kim SJ, 1997, INT J TUBERC LUNG D, V1, P302; Lambregts-van Weezenbeek CSB, 1998, INT J TUBERC LUNG D, V2, P288; Laszlo A, 1997, INT J TUBERC LUNG D, V1, P231; Manns BJ, 1997, INT J TUBERC LUNG D, V1, P225; MARTIN A, 1996, AIDS WORLD, V2, P390; MCKENNA MT, 1995, NEW ENGL J MED, V332, P1071, DOI 10.1056/NEJM199504203321606; NAZARSTEWART V, 1992, AM REV RESPIR DIS, V146, P57, DOI 10.1164/ajrccm/146.1.57; Pablos-Mendez A, 1998, NEW ENGL J MED, V338, P1641, DOI 10.1056/NEJM199806043382301; RAVIGLIONE MC, 1995, JAMA-J AM MED ASSOC, V273, P220, DOI 10.1001/jama.273.3.220; REICHMAN LB, 1993, AM J PUBLIC HEALTH, V83, P639, DOI 10.2105/AJPH.83.5.639; TELZAK EE, 1995, NEW ENGL J MED, V333, P907, DOI 10.1056/NEJM199510053331404; WHO, 1997, ANT DRUG RES WORLD W, P60; *WHO TUB PROGR, 1995, WHO REP TUB EP 1995; WILSON ME, 1995, EMERG INFECT DIS, V1, P39, DOI 10.3201/eid0102.950201; Zhao FZ, 1996, LANCET, V347, P358, DOI 10.1016/S0140-6736(96)90537-1; 1998, TUBERC MONITOR   MAY, P53	27	26	29	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 9	1999	281	22					2138	2140		10.1001/jama.281.22.2138	http://dx.doi.org/10.1001/jama.281.22.2138			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	202TJ	10367825				2022-12-28	WOS:000080668000037
J	Elting, LS; Martin, CG; Cantor, SB; Rubenstein, EB				Elting, LS; Martin, CG; Cantor, SB; Rubenstein, EB			Influence of data display formats on physician investigators' decisions to stop clinical trials: prospective trial with repeated measures	BRITISH MEDICAL JOURNAL			English	Article							RESPIRATORY DATA; INFORMATION	Objective To examine the effect of the method of data display on physician investigators' decisions to stop hypothetical clinical trials for an unplanned statistical analysis. Design Prospective, mixed model design with variables between subjects and within subjects (repeated measures). Setting Comprehensive cancer centre. Participants 34 physicians, stratified by academic rank, who were conducting clinical trials. Interventions Participants were shown tables, pie charts, bar graphs, and icon displays containing hypothetical data from a clinical trial and were asked to decide whether to continue the trial or stop for an unplanned statistical analysis. Main outcome measure Percentage of accurate decisions with each type of display. Results Accuracy of decisions was affected by the type of data display and positive or negative framing of the data. More correct decisions were made with icon displays than with tables, pie charts, and bar graphs (82% v 68%, 56%, and 43%, respectively; P = 0.03) and when data were negatively framed rather than positively framed in tables (93% v 47%; P = 0.004). Conclusions Clinical investigators' decisions can be affected by factors unrelated to the actual data. In the design of clinical trials information systems, careful consideration should be given to the method by which data are framed and displayed in order to reduce the impact of these extraneous factors.	Univ Texas, MD Anderson Canc Ctr, Dept Med Specialties, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center	Elting, LS (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Med Specialties, 1515 Holcombe Blvd,Box 40, Houston, TX 77030 USA.			Cantor, Scott/0000-0002-7072-6048				CARTMILL RSV, 1992, LANCET, V339, P1520, DOI 10.1016/0140-6736(92)91275-D; CLEVELAND WS, 1987, J ROY STAT SOC A STA, V150, P192, DOI 10.2307/2981473; COCHRAN WG, 1950, BIOMETRIKA, V37, P256, DOI 10.1093/biomet/37.3-4.256; COLE WG, 1993, INT J CLIN MONIT COM, V10, P91, DOI 10.1007/BF01142279; COLE WG, 1994, METHOD INFORM MED, V33, P390; DWYER FM, 1970, PERCEPT MOTOR SKILL, V30, P51, DOI 10.2466/pms.1970.30.1.51; ELTING LS, 1991, METHOD INFORM MED, V30, P145; Friedman LM, 1985, FUNDAMENTALS CLIN TR; KAHNEMAN D, 1984, AM PSYCHOL, V39, P341, DOI 10.1037/0003-066X.39.4.341; KAHNEMAN D, 1991, J ECON PERSPECT, V5, P193, DOI 10.1257/jep.5.1.193; McNemar Q, 1947, PSYCHOMETRIKA, V12, P153, DOI 10.1007/BF02295996; MORGAN RL, THESIS; Samuelson W, 1988, J RISK UNCERTAINTY, V1, P7, DOI 10.1007/BF00055564; SPAULDING S, 1956, AV COMMUN REV, V4, P31; THALER R, 1980, J ECON BEHAV ORGAN, V1, P39, DOI 10.1016/0167-2681(80)90051-7	15	97	97	0	5	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JUN 5	1999	318	7197					1527	1531		10.1136/bmj.318.7197.1527	http://dx.doi.org/10.1136/bmj.318.7197.1527			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	204HC	10356010	Bronze, Green Published, Green Submitted			2022-12-28	WOS:000080757300028
J	Wall, S; Hotopf, M; Wessely, S; Churchill, R				Wall, S; Hotopf, M; Wessely, S; Churchill, R			Trends in the use of the Mental Health Act: England, 1984-96	BRITISH MEDICAL JOURNAL			English	Article									Guys Kings Coll & St Thomas Sch Med, Dept Psychol Med, London SE5 8AZ, England; Inst Psychiat, London SE5 8AZ, England; Inst Psychiat, Sect Epidemiol & Gen Practice, London SE5 8AF, England	University of London; King's College London; University of London; King's College London; University of London; King's College London	Hotopf, M (corresponding author), Guys Kings Coll & St Thomas Sch Med, Dept Psychol Med, London SE5 8AZ, England.		Wessely, Simon C/A-8713-2008; Hotopf, Matthew/E-4971-2010	Churchill, Rachel/0000-0002-1751-0512; Wessely, Simon Charles/0000-0002-6743-9929				CUFFEL BJ, 1992, J NERV MENT DIS, V180, P589, DOI 10.1097/00005053-199209000-00008; DAVIDGE M, 1994, SURVEY ENGLISH MENTA; JOHNSON S, 1998, LONDON MENTAL HLTH R	3	36	36	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JUN 5	1999	318	7197					1520	1521		10.1136/bmj.318.7197.1520	http://dx.doi.org/10.1136/bmj.318.7197.1520			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	204HC	10356005	Green Published, Green Submitted, Bronze			2022-12-28	WOS:000080757300024
J	Kohen, A; Cannio, R; Bartolucci, S; Klinman, JP				Kohen, A; Cannio, R; Bartolucci, S; Klinman, JP			Enzyme dynamics and hydrogen tunnelling in a thermophilic alcohol dehydrogenase	NATURE			English	Article							ELIMINATION-REACTIONS; FLEXIBILITY; CATALYSIS; STABILITY	Biological catalysts (enzymes) speed up reactions by many orders of magnitude using fundamental physical processes to increase chemical reactivity. Hydrogen tunnelling has increasingly been found to contribute to enzyme reactions at room temperature(1), Tunnelling is the phenomenon by which a particle transfers through a reaction barrier as a result of its wave-like property(1-3). In reactions involving small molecules, the relative importance of tunnelling increases as the temperature is reduced(4). We have now investigated whether hydrogen tunnelling occurs at elevated temperatures in a biological system that functions physiologically under such conditions, Using a thermophilic alcohol dehydrogenase (ADH), we find that hydrogen tunnelling makes a significant contribution at 65 degrees C; this is analogous to previous findings with mesophilic ADH at 25 degrees C (ref. 5), Contrary to predictions for tunnelling through a rigid barrier, the tunnelling with. the thermophilic ADH decreases at and below room temperature. These findings provide experimental evidence for a role of thermally excited enzyme fluctuations in modulating enzyme-catalysed bond cleavage.	Univ Calif Berkeley, Dept Chem, Berkeley, CA 94720 USA; Univ Calif Berkeley, Dept Mol & Cell Biol, Berkeley, CA 94720 USA; CNR, ISA, I-83100 Avellino, Italy; Univ Naples Federico 2, Dipartimento Chim Organ & Biol, I-80134 Naples, Italy	University of California System; University of California Berkeley; University of California System; University of California Berkeley; Consiglio Nazionale delle Ricerche (CNR); Istituto di Scienze dell' Alimentazione (ISA-CNR); University of Naples Federico II	Klinman, JP (corresponding author), Univ Calif Berkeley, Dept Chem, Berkeley, CA 94720 USA.	klinman@socrates.berkeley.edu		Bartolucci, Simonetta/0000-0002-1968-2959				Antoniou D, 1998, J CHEM PHYS, V108, P3620, DOI 10.1063/1.475756; Antoniou D, 1997, P NATL ACAD SCI USA, V94, P12360, DOI 10.1073/pnas.94.23.12360; Bell R P, 1980, TUNNELING EFFECT CHE; BENDERSKII VA, 1994, ADV CHEM PHYS, V88, P151; BORGIS D, 1993, CHEM PHYS, V170, P315, DOI 10.1016/0301-0104(93)85117-Q; BORGIS D, 1989, NATO ADV SCI I A-LIF, V178, P293; Brooks C. L., 1988, ADV CHEM PHYS, VLXXI, P75; BROOKS CL, 1988, ADV CHEM PHYS, V71, P14; Brooks III C. L., 1988, ADV CHEM PHYS, VLXXI, P33; BRUNO WJ, 1992, BIOPHYS J, V63, P689, DOI 10.1016/S0006-3495(92)81654-5; CANNIO R, 1994, EUR J BIOCHEM, V222, P345, DOI 10.1111/j.1432-1033.1994.tb18873.x; CHA Y, 1989, SCIENCE, V243, P1325, DOI 10.1126/science.2646716; Guagliardi A, 1996, INT J BIOCHEM CELL B, V28, P239, DOI 10.1016/1357-2725(95)00138-7; Hwang JK, 1997, CHEM PHYS LETT, V271, P223, DOI 10.1016/S0009-2614(97)00482-X; Kohen A, 1997, BIOCHEMISTRY-US, V36, P2603, DOI 10.1021/bi962492r; Kohen A, 1998, ACCOUNTS CHEM RES, V31, P397, DOI 10.1021/ar9701225; Lakatos S, 1978, BIOCHEM SOC T, V6, P1195, DOI 10.1042/bst0061195; LIN S, 1994, J AM CHEM SOC, V116, P6107, DOI 10.1021/ja00093a007; Melander L., 1987, REACTION RATES ISOTO; RASMUSSEN BF, 1992, NATURE, V357, P423, DOI 10.1038/357423a0; Rucker J, 1999, J AM CHEM SOC, V121, P1997, DOI 10.1021/ja9824425; RUDD PM, 1994, BIOCHEMISTRY-US, V33, P17, DOI 10.1021/bi00167a003; SAUNDERS WH, 1985, J AM CHEM SOC, V107, P164, DOI 10.1021/ja00287a029; SOMERO GN, 1979, NATURE, V282, P100, DOI 10.1038/282100a0; Steinfeld J.I., 1998, CHEM KINETICS DYNAMI; VARLEY PG, 1991, J MOL BIOL, V220, P531, DOI 10.1016/0022-2836(91)90028-5; VIHINEN M, 1987, PROTEIN ENG, V1, P477, DOI 10.1093/protein/1.6.477; VOL'KENSHTEIN M V, 1972, Molecular Biology (English Translation of Molekulyarnaya Biologiya (Moscow)), V6, P347; WRBA A, 1990, BIOCHEMISTRY-US, V29, P7584, DOI 10.1021/bi00485a007; Zavodszky P, 1998, P NATL ACAD SCI USA, V95, P7406, DOI 10.1073/pnas.95.13.7406	30	470	477	6	127	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUN 3	1999	399	6735					496	499		10.1038/20981	http://dx.doi.org/10.1038/20981			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	202TH	10365965				2022-12-28	WOS:000080667900055
J	McConnaughey, D; Thornton, JD; Wu, D				McConnaughey, D; Thornton, JD; Wu, D			Disorientation and vertebral fractures	LANCET			English	Article							MULTIPLE-MYELOMA		Vet Adm Med Ctr, Seattle, WA 98108 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA)	Thornton, JD (corresponding author), Vet Adm Med Ctr, 1660 S Columbian Way, Seattle, WA 98108 USA.							CAVO M, 1985, ACTA HAEMATOL-BASEL, V74, P27, DOI 10.1159/000206159; DREICER R, 1982, AM J HEMATOL, V13, P313, DOI 10.1002/ajh.2830130406; HOBBS JR, 1969, BRIT J HAEMATOL, V16, P599, DOI 10.1111/j.1365-2141.1969.tb00440.x; JOYNER MV, 1979, BRIT J HAEMATOL, V43, P559, DOI 10.1111/j.1365-2141.1979.tb03788.x; SMITH DB, 1986, HEMATOL ONCOL, V4, P307, DOI 10.1002/hon.2900040407	5	2	2	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAY 29	1999	353	9167					1848	1848		10.1016/S0140-6736(99)02342-9	http://dx.doi.org/10.1016/S0140-6736(99)02342-9			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	202TG	10359411				2022-12-28	WOS:000080667800015
J	Heidenreich, PA; McDonald, KM; Hastie, T; Fadel, B; Hagan, V; Lee, BK; Hlatky, MA				Heidenreich, PA; McDonald, KM; Hastie, T; Fadel, B; Hagan, V; Lee, BK; Hlatky, MA			Meta-analysis of trials comparing beta-blockers, calcium antagonists, and nitrates for stable angina	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Review							LEFT-VENTRICULAR FUNCTION; GASTROINTESTINAL THERAPEUTIC SYSTEM; RESPIRATORY GAS-EXCHANGE; TOTAL ISCHEMIC BURDEN; TRANSIENT MYOCARDIAL-ISCHEMIA; RANDOMIZED CROSSOVER TRIAL; SLOW-RELEASE NIFEDIPINE; DOUBLE-BLIND EVALUATION; ISOSORBIDE DINITRATE; EXERTIONAL ANGINA	Context Which drug is most effective as a first-line treatment for stable angina is not known. Objective To compare the relative efficacy and tolerability of treatment with beta-blockers, calcium antagonists, and long-acting nitrates for patients who have stable angina. Data Sources We identified English-language studies published between 1966 and 1997 by searching the MEDLINE and EMBASE databases and reviewing the bibliographies of identified articles to locate additional relevant studies. Study Selection Randomized or crossover studies comparing antianginal drugs from 2 or 3 different classes (beta-blockers, calcium antagonists, and long-acting nitrates) lasting at least 1 week were reviewed. Studies were selected if they reported at least 1 of the following outcomes: cardiac death, myocardial infarction, study withdrawal due to adverse events, angina frequency, nitroglycerin use, or exercise duration. Ninety (63%) of 143 identified studies met the inclusion criteria. Data Extraction Two independent reviewers extracted data from selected articles, settling any differences by consensus. Outcome data were extracted a third time by 1 of the investigators. We combined results using odds ratios (ORs) for discrete data and mean differences for continuous data. Studies of calcium antagonists were grouped by duration and type of drug (nifedipine vs nonnifedipine). Data Synthesis Rates of cardiac death and myocardial infarction were not significantly different for treatment with beta-blockers vs calcium antagonists (OR, 0.97; 95% confidence interval [CI], 0.67-1.38; P = .79). There were 0.31 (95% CI, 0.00-0.62; P = .05) fewer episodes of angina per week with beta-blockers than with calcium antagonists. beta-Blockers were discontinued because of adverse events less often than were calcium antagonists (OR, 0.72; 95% CI, 0.60-0.86; P<.001). The differences between beta-blockers and calcium antagonists were most striking for nifedipine (OR for adverse events with beta-blockers vs nifedipine, 0.60; 95% CI, 0.47-0.77). Too few trials compared nitrates with calcium antagonists or beta-blockers to draw firm conclusions about relative efficacy. Conclusions beta-Blockers provide similar clinical outcomes and are associated with fewer adverse events than calcium antagonists in randomized trials of patients who have stable angina.	Vet Affairs Palo Alto Hlth Care Syst, Palo Alto, CA USA; Stanford Univ, Dept Hlth Care Res & Policy, Stanford, CA 94305 USA; Stanford Univ, Dept Med, Stanford, CA 94305 USA; Stanford Univ, Dept Stat, Stanford, CA 94305 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Palo Alto Health Care System; Stanford University; Stanford University; Stanford University	Heidenreich, PA (corresponding author), Palo Alto VA Med Ctr, 3801 Miranda Ave, Palo Alto, CA 94304 USA.	pah@smi.stanford.edu	Heidenreich, Paul/AAU-6864-2021	Heidenreich, Paul/0000-0001-7730-8490; Hastie, Trevor/0000-0002-0164-3142; Hlatky, Mark/0000-0003-4686-9441	PHS HHS [290-97-0013] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Adams P, 1996, BMJ-BRIT MED J, V312, P827; AHUJA RC, 1993, INT J CARDIOL, V41, P191, DOI 10.1016/0167-5273(93)90115-W; AKHRAS F, 1989, INT J CARDIOL, V24, P191, DOI 10.1016/0167-5273(89)90304-5; Alderman MH, 1997, LANCET, V349, P594, DOI 10.1016/S0140-6736(96)08359-6; *AM HEART ASS, 1998, 1998 HEART STROK STA; ANKIER SI, 1989, J INT MED RES, V17, P172, DOI 10.1177/030006058901700210; ARDISSINO D, 1991, AM J CARDIOL, V67, P946, DOI 10.1016/0002-9149(91)90165-H; ARDISSINO D, 1995, J AM COLL CARDIOL, V25, P1516, DOI 10.1016/0735-1097(95)00042-3; ARNMAN K, 1982, AM J CARDIOL, V49, P821, DOI 10.1016/0002-9149(82)91964-6; AUBERT A, 1970, BMJ-BRIT MED J, V1, P203, DOI 10.1136/bmj.1.5690.203; Binak K, 1974, New Istanbul Contrib Clin Sci, V11, P8; BJERLE P, 1986, BRIT J CLIN PHARMACO, V22, pS339, DOI 10.1111/j.1365-2125.1986.tb00342.x; BLAKE P, 1991, CARDIOLOGY, V79, P249, DOI 10.1159/000174887; BOWLES MJ, 1983, AM HEART J, V106, P1297, DOI 10.1016/0002-8703(83)90037-6; BOWLES MJ, 1981, BMJ-BRIT MED J, V282, P1754, DOI 10.1136/bmj.282.6278.1754; BROUWER J, 1995, AM J CARDIOL, V76, P759, DOI 10.1016/S0002-9149(99)80222-7; Califf RM, 1998, CIRCULATION, V97, P1529, DOI 10.1161/01.CIR.97.16.1529; CARBONI GP, 1992, J CARDIOVASC PHARM, V20, pS64, DOI 10.1097/00005344-199200207-00012; Catipovic-Veselica Katija, 1993, Croatian Medical Journal, V34, P319; CHAN PK, 1988, AM HEART J, V116, P838, DOI 10.1016/0002-8703(88)90346-8; COCCO G, 1979, EUR J CARDIOL, V10, P59; CONNELLY CM, 1995, AM J CARDIOL, V75, P291, DOI 10.1016/0002-9149(95)80041-P; CRAKE T, 1988, EUR HEART J, V9, P1200, DOI 10.1093/oxfordjournals.eurheartj.a062430; Dargie HJ, 1996, EUR HEART J, V17, P104; De Divitiis O, 1987, Eur Heart J, V8 Suppl M, P43; DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2; DESTORS JM, 1989, FUNDAM CLIN PHARM, V3, P597, DOI 10.1111/j.1472-8206.1989.tb00462.x; DEVRIES RJM, 1994, AM J CARDIOL, V74, P1201, DOI 10.1016/0002-9149(94)90548-7; deVries RJM, 1996, INT J CARDIOL, V57, P143, DOI 10.1016/S0167-5273(96)02806-9; Di Somma S, 1996, Cardiologia, V41, P635; DONALDSON KM, 1993, EUR HEART J, V14, P534, DOI 10.1093/eurheartj/14.4.534; EASTERBROOK PJ, 1991, LANCET, V337, P867, DOI 10.1016/0140-6736(91)90201-Y; Egger E, 1997, LANCET, V350, P326, DOI 10.1016/S0140-6736(97)02419-7; EGSTRUP K, 1993, AM J CARDIOL, V71, P177, DOI 10.1016/0002-9149(93)90735-U; EGSTRUP K, 1988, AM HEART J, V116, P971, DOI 10.1016/0002-8703(88)90147-0; ELDRIDGE JE, 1987, J CARDIOVASC PHARM, V10, P315, DOI 10.1097/00005344-198709000-00010; EMANUELSSON H, 1989, EUR J CLIN PHARMACOL, V36, P561, DOI 10.1007/BF00637736; FINDLAY IN, 1987, BRIT HEART J, V57, P336; FINDLAY IN, 1986, BRIT HEART J, V55, P240; FINDLAY IN, 1983, POSTGRAD MED J, V59, P70; Fox KM, 1997, EUR HEART J, V18, pA113; FRIEDENSOHN A, 1991, CARDIOLOGY, V79, P31, DOI 10.1159/000174922; FRISHMAN WH, 1982, AM J CARDIOL, V50, P1164, DOI 10.1016/0002-9149(82)90438-6; FRISHMAN WH, 1992, AM J CARDIOL, V69, pD50; Furberg CD, 1996, CIRCULATION, V93, P1475; FURBERG CD, 1995, CIRCULATION, V92, P1326, DOI 10.1161/01.CIR.92.5.1326; Gersh B, 1997, HEART DIS, P307; Glasser SP, 1997, AM J CARDIOL, V79, P1401, DOI 10.1016/S0002-9149(97)00382-2; GOLDBARG AN, 1969, CIRCULATION, V40, P847, DOI 10.1161/01.CIR.40.6.847; HaufZachariou U, 1997, EUR J CLIN PHARMACOL, V52, P95, DOI 10.1007/s002280050256; HEDGES L, 1994, HDB RES SYNTHESIS, P307; HETZEL M, 1994, Z KARDIOL, V83, P83; HIGGINBOTHAM MB, 1989, AM J MED, V86, P1, DOI 10.1016/0002-9343(89)90002-8; HILL JA, 1991, AM J CARDIOL, V67, P671, DOI 10.1016/0002-9149(91)90519-Q; HOEKENGA D, 1984, AM J MED, V76, P309, DOI 10.1016/0002-9343(84)90791-5; HOPKINSON ND, 1991, EUR HEART J, V12, P1273, DOI 10.1093/eurheartj/12.12.1273; HUMEN DP, 1991, CAN J CARDIOL, V7, P74; HUNG J, 1983, CIRCULATION, V68, P560, DOI 10.1161/01.CIR.68.3.560; JOHNSON SM, 1981, AM J MED, V71, P443, DOI 10.1016/0002-9343(81)90180-7; JOHNSTON DL, 1983, CIRCULATION, V68, P1280, DOI 10.1161/01.CIR.68.6.1280; JOHNSTON DL, 1984, CAN MED ASSOC J, V130, P1449; Julian DG, 1997, EUR HEART J, V18, P394; KAWANISHI DT, 1992, J AM COLL CARDIOL, V19, P409, DOI 10.1016/0735-1097(92)90499-D; KENMURE ACF, 1979, BRIT J CLIN PRACT, V33, P49; KENNY J, 1985, BRIT HEART J, V53, P43; KHURMI NS, 1987, EUR J CLIN PHARMACOL, V32, P443, DOI 10.1007/BF00637667; KREPP HP, 1991, CARDIOLOGY, V79, P14, DOI 10.1159/000174919; LAI C, 1992, DRUG INVEST, V4, P30, DOI 10.1007/BF03258375; LAI C, 1988, DRUG EXP CLIN RES, V14, P699; LESSEM J, 1984, ACTA MED SCAND, P83; LIANG CS, 1985, AM J CARDIOL, V55, pE9, DOI 10.1016/0002-9149(85)91205-6; Licciardello G, 1997, CLIN DRUG INVEST, V13, P119, DOI 10.2165/00044011-199700131-00021; LIVESLEY B, 1973, BRIT MED J, V1, P375, DOI 10.1136/bmj.1.5850.375; LOGAN RL, 1986, BRIT J CLIN PHARMACO, V22, pS345, DOI 10.1111/j.1365-2125.1986.tb00343.x; LYNCH P, 1980, BRIT MED J, V281, P184, DOI 10.1136/bmj.281.6234.184; MCGILL D, 1986, AM J CARDIOL, V57, P39, DOI 10.1016/0002-9149(86)90948-3; MEYER EC, 1991, CARDIOLOGY, V78, P179, DOI 10.1159/000174784; MILLER WE, 1988, AM J CARDIOL, V62, P372, DOI 10.1016/0002-9149(88)90961-7; NADAZDIN A, 1994, AM HEART J, V127, P312, DOI 10.1016/0002-8703(94)90118-X; OHARA MJ, 1984, AM J CARDIOL, V54, P477; Pandolfo L, 1997, CLIN DRUG INVEST, V13, P113, DOI 10.2165/00044011-199700131-00020; PARAMESHWAR J, 1993, INT J CARDIOL, V40, P135, DOI 10.1016/0167-5273(93)90276-M; PARKER JO, 1986, AM J CARDIOL, V58, P449, DOI 10.1016/0002-9149(86)90013-5; PFLUGFELDER PW, 1987, AM J CARDIOL, V59, P1283, DOI 10.1016/0002-9149(87)90905-2; PSATY BM, 1995, JAMA-J AM MED ASSOC, V274, P620, DOI 10.1001/jama.274.8.620; RAE AP, 1985, BRIT J CLIN PHARMACO, V19, P343, DOI 10.1111/j.1365-2125.1985.tb02653.x; Rehnqvist N, 1996, EUR HEART J, V17, P76; RILEY M, 1992, EUR HEART J, V13, P1116, DOI 10.1093/oxfordjournals.eurheartj.a060323; ROBERTS R, 1985, CIRCULATION, V72, P145; ROMANO M, 1986, INT J CLIN PHARM TH, V24, P551; ROMANO M, 1988, INT J CLIN PHARM TH, V26, P468; ROUSSEAU MF, 1986, CIRCULATION, V73, P1270, DOI 10.1161/01.CIR.73.6.1270; SADICK NN, 1982, CIRCULATION, V66, P574, DOI 10.1161/01.CIR.66.3.574; Savonitto S, 1996, J AM COLL CARDIOL, V27, P311, DOI 10.1016/0735-1097(95)00489-0; SCHNEIDER W, 1988, EUR HEART J, V9, P149, DOI 10.1093/oxfordjournals.eurheartj.a062468; SCHULTE KL, 1995, EUR HEART J, V16, P171, DOI 10.1093/oxfordjournals.eurheartj.a060881; SHADISH W, 1994, HDB RES SYNTHESIS, P307; SHAPIRO W, 1989, AM J CARDIOL, V64, P186, DOI 10.1016/0002-9149(89)90454-2; SIGURD B, 1984, ACTA MED SCAND, P75; SINGH S, 1993, CLIN CARDIOL, V16, P54, DOI 10.1002/clc.4960160112; SIU SC, 1993, AM J CARDIOL, V71, P887, DOI 10.1016/0002-9149(93)90901-N; SOUTHALL E, 1982, J INT MED RES, V10, P361, DOI 10.1177/030006058201000509; Steffensen R, 1997, CARDIOVASC DRUG THER, V11, P629, DOI 10.1023/A:1007726722284; STEFFENSEN R, 1993, INT J CARDIOL, V40, P143, DOI 10.1016/0167-5273(93)90277-N; VANDERDOES R, 1992, J CARDIOVASC PHARM, V19, pS122, DOI 10.1097/00005344-199219001-00024; VANDEVEN LLM, 1995, INT J CARDIOL, V47, P217, DOI 10.1016/0167-5273(94)02194-N; VANDIJK RB, 1988, EUR HEART J, V9, P1194, DOI 10.1093/oxfordjournals.eurheartj.a062429; VLIEGEN HW, 1993, J CARDIOVASC PHARM, V21, P552, DOI 10.1097/00005344-199304000-00007; VONARNIM T, 1995, J AM COLL CARDIOL, V25, P231, DOI 10.1016/0735-1097(94)00345-Q; VONARNIM T, 1988, EUR HEART J, V9, P113; WALLACE WA, 1994, AM J CARDIOL, V73, P23, DOI 10.1016/0002-9149(94)90721-8; Wang TJ, 1998, ARCH INTERN MED, V158, P1901, DOI 10.1001/archinte.158.17.1901; WAYSBORT J, 1991, CARDIOLOGY, V79, P19, DOI 10.1159/000174920; WHEATLEY D, 1985, POSTGRAD MED J, V61, P785, DOI 10.1136/pgmj.61.719.785; WIESHAMMER S, 1991, KLIN WOCHENSCHR, V69, P645, DOI 10.1007/BF01649425; YUSUF S, 1985, PROG CARDIOVASC DIS, V27, P335, DOI 10.1016/S0033-0620(85)80003-7; Zanolla L, 1997, BRIT J CLIN PRACT, P27; [No title captured]	118	213	223	0	12	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 26	1999	281	20					1927	1936		10.1001/jama.281.20.1927	http://dx.doi.org/10.1001/jama.281.20.1927			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	198ME	10349897				2022-12-28	WOS:000080427300033
J	Gallagher, RB				Gallagher, RB			Evolutionary biology - The male's dilemma	SCIENCE			English	Editorial Material							GONADAL-STEROIDS; IMMUNOCOMPETENCE							Gallagher, Richard/0000-0001-5639-2187				FOLSTAD I, 1992, AM NAT, V139, P603, DOI 10.1086/285346; HASSELQUIST D, IN PRESS BEHAV ECOL; Leitner G, 1996, POULTRY SCI, V75, P1373, DOI 10.3382/ps.0751373; McCurdy DG, 1998, OIKOS, V82, P303, DOI 10.2307/3546970; Ros AFH, 1997, AM NAT, V150, P201, DOI 10.1086/286063; Verhulst S, 1999, P NATL ACAD SCI USA, V96, P4478, DOI 10.1073/pnas.96.8.4478	6	4	4	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAY 14	1999	284	5417					1140	1140		10.1126/science.284.5417.1140	http://dx.doi.org/10.1126/science.284.5417.1140			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	197HJ	10366348				2022-12-28	WOS:000080359100028
J	Lack, T				Lack, T			Water and health in Europe: an overview	BRITISH MEDICAL JOURNAL			English	Article									European Top Ctr Inland Waters, Water Res Ctr, Medmenham SL7 2HD, Bucks, England		Lack, T (corresponding author), European Top Ctr Inland Waters, Water Res Ctr, Medmenham SL7 2HD, Bucks, England.							BARTRAM J, 1999, WATER HLTH EUROPE; CHERNOGAEVA GM, 1999, WATER QUALITY ASSESS, P64; *EUR ENV AG, 1999, ENV ASS REP SUST W 1; *EUR ENV AG, 1999, ENV ASS REP GROUNDW; European Environment Agency, 1998, EUR ENV 2 ASS; KRISTENSEN P, 1994, ENV MONOGRAPHS EUROP, V1; SHIKLOMANOV IA, 1991, INT S COMM 25 YEARS; STANNERS D, 1995, EUROPES ENV DEBRIS A; WHO, 1992, GUID DRINK WAT QUAL, V1, P41	9	16	17	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JUN 19	1999	318	7199					1678	1682		10.1136/bmj.318.7199.1678	http://dx.doi.org/10.1136/bmj.318.7199.1678			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	210KY	10373175	Green Published			2022-12-28	WOS:000081105600033
J	Losty, PD				Losty, PD			Paediatric surgery	BRITISH MEDICAL JOURNAL			English	Review							CONGENITAL DIAPHRAGMATIC-HERNIA; ANTEGRADE CONTINENCE ENEMA; HIRSCHSPRUNGS-DISEASE; LIVER-TRANSPLANTATION; SURGICAL-MANAGEMENT; TRACHEAL OCCLUSION; PEDIATRIC-SURGERY; GROWTH-FACTOR; WILMS-TUMOR; IN-UTERO		Alder Hey Childrens Hosp, Inst Child Hlth, Dept Paediat Surg, Liverpool L12 2AP, Merseyside, England	Alder Hey Children's NHS Foundation Trust; Alder Hey Children's Hospital; University of Liverpool	Losty, PD (corresponding author), Alder Hey Childrens Hosp, Inst Child Hlth, Dept Paediat Surg, Liverpool L12 2AP, Merseyside, England.							Adzick NS, 1998, LANCET, V352, P1675, DOI 10.1016/S0140-6736(98)00070-1; ADZICK NS, 1994, LANCET, V343, P897, DOI 10.1016/S0140-6736(94)90012-4; Andrassy R J, 1997, Semin Pediatr Surg, V6, P17; Arul GS, 1998, ARCH DIS CHILD, V79, P65, DOI 10.1136/adc.79.1.65; Cass DL, 1997, PEDIATR SURG INT, V12, P484, DOI 10.1007/s003830050189; Clark RH, 1998, J PEDIATR SURG, V33, P1004, DOI 10.1016/S0022-3468(98)90522-X; DIFIORE JW, 1995, PEDIATR SURG INT, V10, P2; Folkman J, 1995, NEW ENGL J MED, V333, P1757, DOI 10.1056/NEJM199512283332608; Geiger James D., 1996, Current Opinion in Pediatrics, V8, P276, DOI 10.1097/00008480-199606000-00016; Georgeson KE, 1998, SEMIN PAEDIAT SURG, V7, P193; GOON HK, 1990, PEDIATR SURG INT, V5, P246; GROSFELD JL, 1998, PEDIAT SURG, P405; Haase Gerald M., 1996, Current Opinion in Pediatrics, V8, P268, DOI 10.1097/00008480-199606000-00015; Harrison MR, 1996, J PEDIATR SURG, V31, P1339, DOI 10.1016/S0022-3468(96)90824-6; Harrison MR, 1998, J PEDIATR SURG, V33, P1017, DOI 10.1016/S0022-3468(98)90524-3; Huddart SN, 1998, ANN ROY COLL SURG, V80, P46; Kato Y, 1998, J PEDIATR SURG, V33, P235, DOI 10.1016/S0022-3468(98)90438-9; Kumar R, 1998, J UROLOGY, V160, P1450, DOI 10.1016/S0022-5347(01)62588-6; LOSTY PD, 1996, SEMIN NEONATOL, V1, P193; MALONE PS, 1990, LANCET, V336, P1217, DOI 10.1016/0140-6736(90)92834-5; Martucciello G, 1998, EUR J PEDIATR SURG, V8, P131, DOI 10.1055/s-2008-1071138; Pena A., 1997, SEMIN PEDIATR SURG, V6, P165; Pollok J M, 1996, Semin Pediatr Surg, V5, P191; Rela M, 1998, BRIT J SURG, V85, P881; Reyes J, 1998, J PEDIATR SURG, V33, P243, DOI 10.1016/S0022-3468(98)90440-7; RICKHAM PP, 1992, J PEDIATR SURG, V27, P1, DOI 10.1016/0022-3468(92)90091-K; Rudin CM, 1997, ANNU REV MED, V48, P267; Schnitzer JJ, 1996, ANN SURG, V224, P430, DOI 10.1097/00000658-199610000-00002; Shankar KR, 1998, BRIT J SURG, V85, P980; Spitz L, 1996, J PEDIATR SURG, V31, P19, DOI 10.1016/S0022-3468(96)90313-9; Spitz L, 1996, BRIT J HOSP MED, V56, P281; Swaniker F, 1996, J PEDIATR SURG, V31, P56, DOI 10.1016/S0022-3468(96)90319-X; Sylvester KG, 1997, J PEDIATR SURG, V32, P964, DOI 10.1016/S0022-3468(97)90378-X; Talbot D, 1997, J PEDIATR SURG, V32, P710, DOI 10.1016/S0022-3468(97)90011-7; Teitelbaum D H, 1998, Semin Pediatr Surg, V7, P103; Thomsen L, 1998, NAT MED, V4, P848, DOI 10.1038/nm0798-848; Wiener JS, 1998, J UROLOGY, V159, P1316, DOI 10.1016/S0022-5347(01)63608-5; WIGGLESWORTH J S, 1987, Pediatric Pathology, V7, P515; WILMORE DW, 1997, RE CROSS LECT 28 ANN; WILSON JM, 1993, J PEDIATR SURG, V28, P1433, DOI 10.1016/0022-3468(93)90426-L	40	8	8	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JUN 19	1999	318	7199					1668	1672		10.1136/bmj.318.7199.1668	http://dx.doi.org/10.1136/bmj.318.7199.1668			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	210KY	10373172	Green Published, Green Submitted			2022-12-28	WOS:000081105600023
J	Cook, PR				Cook, PR			Molecular biology - The organization of replication and transcription	SCIENCE			English	Review							RNA-POLYMERASE-II; HUMAN NUCLEI; ULTRAVIOLET-LIGHT; DNA-REPLICATION; HUMAN-CELLS; HELA-CELLS; CHROMOSOME STRUCTURE; NASCENT TRANSCRIPTS; EUKARYOTIC CELLS; S-PHASE	Models for replication and transcription often display polymerases that track like locomotives along their DNA templates, However, recent evidence supports an alternative model in which DNA and RNA polymerases are immobilized by attachment to larger structures, where they reel in their templates and extrude newly made nucleic acids, These polymerases do not act independently; they are concentrated in discrete "factories," where they work together on many different templates. Evidence for models involving tracking and immobile polymerases is reviewed.	Univ Oxford, Sir William Dunn Sch Pathol, Oxford OX1 3RE, England	University of Oxford	Cook, PR (corresponding author), Univ Oxford, Sir William Dunn Sch Pathol, S Parks Rd, Oxford OX1 3RE, England.			Cook, Peter/0000-0002-6639-188X	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Alberts B., 1994, MOL BIOL CELL; ARGOS P, 1988, NUCLEIC ACIDS RES, V16, P9909, DOI 10.1093/nar/16.21.9909; BEREZNEY R, 1975, SCIENCE, V189, P291, DOI 10.1126/science.1145202; BEREZNEY R, 1977, J CELL BIOL, V73, P616, DOI 10.1083/jcb.73.3.616; BEYER AL, 1981, J MOL BIOL, V147, P269, DOI 10.1016/0022-2836(81)90441-1; BRAITHWAITE DK, 1993, NUCLEIC ACIDS RES, V21, P787, DOI 10.1093/nar/21.4.787; Cho H, 1998, MOL CELL BIOL, V18, P5355, DOI 10.1128/MCB.18.9.5355; COOK PR, 1988, J CELL SCI, V90, P1; COOK PR, 1991, CELL, V66, P627, DOI 10.1016/0092-8674(91)90109-C; Cook PR, 1997, J CELL SCI, V110, P1033; COOK PR, 1995, J CELL SCI, V108, P2927; COOK PR, 1992, NUCLEIC ACIDS RES, V20, P3591, DOI 10.1093/nar/20.14.3591; COOK PR, 1993, J GEN VIROL, V74, P691, DOI 10.1099/0022-1317-74-4-691; CULOTTA VC, 1985, MOL CELL BIOL, V5, P1582, DOI 10.1128/MCB.5.7.1582; DAVE VP, 1991, BIOCHEMISTRY-US, V30, P4763, DOI 10.1021/bi00233a018; DICKINSON P, 1990, EMBO J, V9, P2207, DOI 10.1002/j.1460-2075.1990.tb07390.x; ECHEVERRIA M, 1991, PLANT MOL BIOL, V16, P301, DOI 10.1007/BF00020561; FAKAN S, 1986, J CELL BIOL, V103, P1153, DOI 10.1083/jcb.103.4.1153; Fay FS, 1997, EXP CELL RES, V231, P27, DOI 10.1006/excr.1996.3460; Femino A, 1998, SCIENCE, V280, P585, DOI 10.1126/science.280.5363.585; HAAF T, 1995, P NATL ACAD SCI USA, V92, P2298, DOI 10.1073/pnas.92.6.2298; HAAF T, 1991, EXP CELL RES, V193, P78, DOI 10.1016/0014-4827(91)90540-B; HASSAN AB, 1993, J CELL SCI, V105, P541; HOZAK P, 1993, CELL, V73, P361, DOI 10.1016/0092-8674(93)90235-I; HOZAK P, 1994, J CELL SCI, V107, P639; HOZAK P, 1996, EUKARYOTIC DNA REPLI, P124; HUBERMAN JA, 1968, J MOL BIOL, V32, P327, DOI 10.1016/0022-2836(68)90013-2; Iborra FJ, 1996, EXP CELL RES, V229, P167, DOI 10.1006/excr.1996.0355; Iborra FJ, 1998, J CELL SCI, V111, P2269; Iborra FJ, 1996, J CELL SCI, V109, P1427; JACKSON DA, 1985, EMBO J, V4, P919, DOI 10.1002/j.1460-2075.1985.tb03719.x; JACKSON DA, 1986, EMBO J, V5, P1403, DOI 10.1002/j.1460-2075.1986.tb04374.x; JACKSON DA, 1994, J CELL SCI, V107, P1745; Jackson DA, 1996, NUCLEIC ACIDS RES, V24, P1212, DOI 10.1093/nar/24.7.1212; JACKSON DA, 1994, J CELL SCI, V107, P1753; Jackson DA, 1998, MOL BIOL CELL, V9, P1523, DOI 10.1091/mbc.9.6.1523; JACKSON DA, 1993, J CELL SCI, V105, P1143; JACKSON DA, 1981, NATURE, V292, P552, DOI 10.1038/292552a0; JACKSON DA, 1993, EMBO J, V12, P1059, DOI 10.1002/j.1460-2075.1993.tb05747.x; Jackson DA, 1998, J CELL BIOL, V140, P1285, DOI 10.1083/jcb.140.6.1285; JACOB F, 1963, COLD SPRING HARB SYM, V28, P329, DOI 10.1101/SQB.1963.028.01.048; JOYCE CM, 1994, ANNU REV BIOCHEM, V63, P77; KAWANO S, 1985, EXP CELL RES, V161, P460, DOI 10.1016/0014-4827(85)90101-6; KONG XP, 1992, CELL, V69, P425, DOI 10.1016/0092-8674(92)90445-I; Kornberg A., 1992, DNA REPLICATION; KRAWIEC S, 1990, MICROBIOL REV, V54, P502, DOI 10.1128/MMBR.54.4.502-539.1990; LAIRD CD, 1976, CHROMOSOMA, V58, P193, DOI 10.1007/BF00701359; Lemon KP, 1998, SCIENCE, V282, P1516, DOI 10.1126/science.282.5393.1516; LIU LF, 1987, P NATL ACAD SCI USA, V84, P7024, DOI 10.1073/pnas.84.20.7024; Lodish H., 1995, MOL CELL BIOL; Maldonado E, 1996, NATURE, V381, P86, DOI 10.1038/381086a0; Manders EMM, 1999, J CELL BIOL, V144, P813, DOI 10.1083/jcb.144.5.813; McCracken S, 1997, NATURE, V385, P357, DOI 10.1038/385357a0; MCCREADY SJ, 1984, J CELL SCI, V70, P189; MCCREADY SJ, 1980, J CELL SCI, V46, P365; MCKNIGHT SL, 1979, CELL, V17, P551; MILLER OL, 1972, ACTA ENDOCRINOL-COP, P155; Myer VE, 1998, J BIOL CHEM, V273, P27757, DOI 10.1074/jbc.273.43.27757; NAKAMURA H, 1986, EXP CELL RES, V165, P291, DOI 10.1016/0014-4827(86)90583-5; NAKAYASU H, 1989, J CELL BIOL, V108, P1, DOI 10.1083/jcb.108.1.1; Newport J, 1996, CURR OPIN CELL BIOL, V8, P365, DOI 10.1016/S0955-0674(96)80011-1; Noy A, 1997, CHEM BIOL, V4, P519, DOI 10.1016/S1074-5521(97)90324-0; OBRIEN T, 1991, MOL CELL BIOL, V11, P5285, DOI 10.1128/MCB.11.10.5285; OGDEN GB, 1988, CELL, V54, P127, DOI 10.1016/0092-8674(88)90186-9; PARDOLL DM, 1980, CELL, V19, P527, DOI 10.1016/0092-8674(80)90527-9; Pederson T, 1998, J MOL BIOL, V277, P147, DOI 10.1006/jmbi.1997.1618; PETTIJOHN DE, 1973, COLD SPRING HARB SYM, V38, P31; Pombo A, 1998, EMBO J, V17, P1768, DOI 10.1093/emboj/17.6.1768; Pombo A, 1999, EMBO J, V18, P2241, DOI 10.1093/emboj/18.8.2241; Prasad BVV, 1996, NATURE, V382, P471, DOI 10.1038/382471a0; SCHAFER DA, 1991, NATURE, V352, P444, DOI 10.1038/352444a0; Scully R, 1997, CELL, V88, P265, DOI 10.1016/S0092-8674(00)81847-4; Scully R, 1997, P NATL ACAD SCI USA, V94, P5605, DOI 10.1073/pnas.94.11.5605; Shaw PJ, 1995, ANNU REV CELL DEV BI, V11, P93, DOI 10.1146/annurev.cb.11.110195.000521; Tashiro S, 1996, ONCOGENE, V12, P2165; TUBO RA, 1987, J BIOL CHEM, V262, P5827; Uptain SM, 1997, ANNU REV BIOCHEM, V66, P117, DOI 10.1146/annurev.biochem.66.1.117; Waga S, 1998, ANNU REV BIOCHEM, V67, P721, DOI 10.1146/annurev.biochem.67.1.721; Wang MD, 1997, BIOPHYS J, V72, P1335, DOI 10.1016/S0006-3495(97)78780-0; Wansink DG, 1996, J CELL BIOCHEM, V62, P10, DOI 10.1002/(SICI)1097-4644(199607)62:1<10::AID-JCB2>3.0.CO;2-4; WANSINK DG, 1993, J CELL BIOL, V122, P283, DOI 10.1083/jcb.122.2.283; Webb CD, 1997, CELL, V88, P667, DOI 10.1016/S0092-8674(00)81909-1; WESSEL R, 1992, J VIROL, V66, P804, DOI 10.1128/JVI.66.2.804-815.1992; West SC, 1997, ANNU REV GENET, V31, P213, DOI 10.1146/annurev.genet.31.1.213; WOLGEMUTH DJ, 1981, J MOL BIOL, V147, P247, DOI 10.1016/0022-2836(81)90440-X; YANOFSKY C, 1981, NATURE, V289, P751, DOI 10.1038/289751a0; YIN H, 1995, SCIENCE, V270, P1653, DOI 10.1126/science.270.5242.1653	87	615	629	2	36	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 11	1999	284	5421					1790	1795		10.1126/science.284.5421.1790	http://dx.doi.org/10.1126/science.284.5421.1790			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	205EU	10364545				2022-12-28	WOS:000080809000039
J	Fuhrman, JA				Fuhrman, JA			Marine viruses and their biogeochemical and ecological effects	NATURE			English	Review							NORTHERN ADRIATIC SEA; TRANSMISSION ELECTRON-MICROSCOPY; GULF-OF-MEXICO; MICROBIAL COMMUNITIES; EMILIANIA-HUXLEYI; COASTAL SEAWATER; VIRAL-INFECTION; SIZE FRACTION; AUREOCOCCUS-ANOPHAGEFFERENS; EPIFLUORESCENCE MICROSCOPY	Viruses are the most common biological agents in the sea, typically numbering ten billion per litre, They probably infect all organisms, can undergo vapid decay and replenishment, and influence many biogeochemical and ecological processes, including nutrient cycling, system respiration, particle sire-distributions and sinking rates, bacterial and algal biodiversity and species distributions, algal bloom control, dimethyl sulphide formation and genetic transfer. Newly developed fluorescence and molecular techniques leave the field poised to make significant advances towards evaluating and quantifying such effects.	Univ So Calif, Dept Biol Sci, Los Angeles, CA 90089 USA; Univ So Calif, Wrigley Inst Environm Studies, Los Angeles, CA 90089 USA	University of Southern California; University of Southern California	Fuhrman, JA (corresponding author), Univ So Calif, Dept Biol Sci, Los Angeles, CA 90089 USA.		Fuhrman, Jed A/C-6461-2013	Fuhrman, Jed A/0000-0002-2361-1985				Ackermann HW, 1987, VIRUSES PROKARYOTES, V1; AZAM F, 1983, MAR ECOL PROG SER, V10, P257, DOI 10.3354/meps010257; BERGH O, 1989, NATURE, V340, P467, DOI 10.1038/340467a0; BOEHME J, 1993, MAR ECOL PROG SER, V97, P1, DOI 10.3354/meps097001; Bohannan BJM, 1997, ECOLOGY, V78, P2303; BORSHEIM KY, 1993, FEMS MICROBIOL ECOL, V102, P141, DOI 10.1016/0378-1097(93)90197-A; Bratbak G, 1996, FEMS MICROBIOL ECOL, V19, P263, DOI 10.1111/j.1574-6941.1996.tb00218.x; BRATBAK G, 1990, APPL ENVIRON MICROB, V56, P1400, DOI 10.1128/AEM.56.5.1400-1405.1990; Bratbak G, 1995, MAR ECOL PROG SER, V128, P133, DOI 10.3354/meps128133; BRATBAK G, 1992, MAR ECOL PROG SER, V83, P273, DOI 10.3354/meps083273; BRATBAK G, 1993, MAR ECOL PROG SER, V93, P39, DOI 10.3354/meps093039; Brussaard CPD, 1996, AQUAT MICROB ECOL, V10, P105, DOI 10.3354/ame010105; Chen F, 1996, APPL ENVIRON MICROB, V62, P2869, DOI 10.1128/AEM.62.8.2869-2874.1996; Chiura HX, 1997, AQUAT MICROB ECOL, V13, P75, DOI 10.3354/ame013075; COCHLAN WP, 1993, MAR ECOL PROG SER, V92, P77, DOI 10.3354/meps092077; Cochran PK, 1998, APPL ENVIRON MICROB, V64, P2308; Cochran PK, 1998, MAR ECOL PROG SER, V164, P125, DOI 10.3354/meps164125; COTTRELL MT, 1995, LIMNOL OCEANOGR, V40, P730, DOI 10.4319/lo.1995.40.4.0730; DYMOND J, 1985, LIMNOL OCEANOGR, V30, P699, DOI 10.4319/lo.1985.30.4.0699; FUHRMAN J, 1992, ENVIR SCI R, V43, P361; Fuhrman J. A., 1997, MANUAL ENV MICROBIOL, P1; FUHRMAN JA, 1989, MAR ECOL PROG SER, V57, P207, DOI 10.3354/meps057207; Fuhrman JA, 1995, LIMNOL OCEANOGR, V40, P1236, DOI 10.4319/lo.1995.40.7.1236; FUHRMAN JA, 1993, OCEANOGRAPHY, V6, P51; Fuhrman Jed. A., 1998, Aquatic Ecology, V32, P3, DOI 10.1023/A:1009974817127; Gobler CJ, 1997, LIMNOL OCEANOGR, V42, P1492, DOI 10.4319/lo.1997.42.7.1492; GONZALEZ JM, 1993, MAR ECOL PROG SER, V94, P1, DOI 10.3354/meps094001; GuixaBoixareu N, 1996, AQUAT MICROB ECOL, V11, P215, DOI 10.3354/ame011215; Hara S, 1996, MAR ECOL PROG SER, V145, P269, DOI 10.3354/meps145269; HARA S, 1991, APPL ENVIRON MICROB, V57, P2731, DOI 10.1128/AEM.57.9.2731-2734.1991; HELDAL M, 1991, MAR ECOL PROG SER, V72, P205, DOI 10.3354/meps072205; HENNES KP, 1995, APPL ENVIRON MICROB, V61, P3623, DOI 10.1128/AEM.61.10.3623-3627.1995; HENNES KP, 1995, LIMNOL OCEANOGR, V40, P1050, DOI 10.4319/lo.1995.40.6.1050; HENNES KP, 1995, APPL ENVIRON MICROB, V61, P333, DOI 10.1128/AEM.61.1.333-340.1995; Hill RW, 1998, AQUAT MICROB ECOL, V14, P1, DOI 10.3354/ame014001; HOLLIBAUGH JT, 1983, LIMNOL OCEANOGR, V28, P1104, DOI 10.4319/lo.1983.28.6.1104; HUTCHINSON G, 1961, AM NAT, V95, P137, DOI 10.1086/282171; Jacobsen A, 1996, J PHYCOL, V32, P923, DOI 10.1111/j.0022-3646.1996.00923.x; Jiang SC, 1998, MICROBIAL ECOL, V35, P235, DOI 10.1007/s002489900079; Jiang SC, 1996, MAR ECOL PROG SER, V142, P27, DOI 10.3354/meps142027; Jiang SC, 1998, APPL ENVIRON MICROB, V64, P2780; KLEIN RP, 1990, NATURE, V345, P702; LENSKI RE, 1988, ADV MICROB ECOL, V10, P1; LEVIN BR, 1977, AM NAT, V111, P3, DOI 10.1086/283134; Malin G, 1998, LIMNOL OCEANOGR, V43, P1389, DOI 10.4319/lo.1998.43.6.1389; MALIN G, 1992, J PHYCOL, V28, P590, DOI 10.1111/j.0022-3646.1992.00590.x; Maranger R, 1996, MICROBIAL ECOL, V31, P141, DOI 10.1007/BF00167860; MARANGER R, 1994, MAR ECOL PROG SER, V111, P121, DOI 10.3354/meps111121; Marie D, 1999, APPL ENVIRON MICROB, V65, P45; MATHIAS CB, 1995, APPL ENVIRON MICROB, V61, P3734, DOI 10.1128/AEM.61.10.3734-3740.1995; MAYER JA, 1979, NATURE, V281, P299, DOI 10.1038/281299a0; Middelboe M, 1996, APPL ENVIRON MICROB, V62, P1991, DOI 10.1128/AEM.62.6.1991-1997.1996; MILLIGAN KLD, 1994, SCIENCE, V266, P805, DOI 10.1126/science.266.5186.805; Moebus K, 1997, MAR ECOL PROG SER, V148, P229, DOI 10.3354/meps148229; Moebus K, 1996, MAR ECOL PROG SER, V144, P13, DOI 10.3354/meps144013; MURRAY AG, 1992, MAR ECOL PROG SER, V89, P103, DOI 10.3354/meps089103; Nagasaki K, 1998, AQUAT MICROB ECOL, V14, P109, DOI 10.3354/ame014109; Noble RT, 1998, AQUAT MICROB ECOL, V14, P113, DOI 10.3354/ame014113; Noble RT, 1997, APPL ENVIRON MICROB, V63, P77, DOI 10.1128/AEM.63.1.77-83.1997; NOBLE RT, IN PRESS AQUAT MICRO; NOBLE RT, 1998, THESIS U SO CALIFORN; PAUL JH, 1993, APPL ENVIRON MICROB, V59, P718, DOI 10.1128/AEM.59.3.718-724.1993; PEDUZZI P, 1993, LIMNOL OCEANOGR, V38, P1562, DOI 10.4319/lo.1993.38.7.1562; PROCTOR LM, 1990, NATURE, V343, P60, DOI 10.1038/343060a0; PROCTOR LM, 1992, MAR ECOL PROG SER, V87, P283, DOI 10.3354/meps087283; Proctor LM, 1997, MICROSC RES TECHNIQ, V37, P136, DOI 10.1002/(SICI)1097-0029(19970415)37:2<136::AID-JEMT3>3.0.CO;2-M; PROCTOR LM, 1993, MICROBIAL ECOL, V25, P161, DOI 10.1007/BF00177193; PROCTOR LM, 1991, MAR ECOL PROG SER, V69, P133, DOI 10.3354/meps069133; RIPP S, 1994, MOL ECOL, V3, P121, DOI 10.1111/j.1365-294X.1994.tb00112.x; Ripp S, 1997, MICROBIOL-UK, V143, P2065, DOI 10.1099/00221287-143-6-2065; SHARP DG, 1949, P SOC EXP BIOL MED, V70, P54, DOI 10.3181/00379727-70-16822; Shibata A, 1997, MAR ECOL PROG SER, V155, P303, DOI 10.3354/meps155303; SIEBURTH JM, 1988, J PHYCOL, V24, P416, DOI 10.1111/j.1529-8817.1988.tb00192.x; Siegel DA, 1998, LIMNOL OCEANOGR, V43, P1133, DOI 10.4319/lo.1998.43.6.1133; Steward GF, 1996, MAR ECOL PROG SER, V131, P287, DOI 10.3354/meps131287; STEWARD GF, 1999, MICROBIAL BIOSYSTEMS; Steward Grieg F., 1992, Marine Microbial Food Webs, V6, P79; SUTTLE CA, 1994, MICROBIAL ECOL, V28, P237, DOI 10.1007/BF00166813; SUTTLE CA, 1992, MAR ECOL PROG SER, V87, P105, DOI 10.3354/meps087105; SUTTLE CA, 1995, MAR ECOL PROG SER, V118, P275, DOI 10.3354/meps118275; SUTTLE CA, 1990, NATURE, V347, P467, DOI 10.1038/347467a0; SUTTLE CA, 1991, APPL ENVIRON MICROB, V57, P721, DOI 10.1128/AEM.57.3.721-726.1991; SUTTLE CA, 1994, APPL ENVIRON MICROB, V60, P3167, DOI 10.1128/AEM.60.9.3167-3174.1994; SUTTLE CA, 1992, APPL ENVIRON MICROB, V58, P3721, DOI 10.1128/AEM.58.11.3721-3729.1992; Sverdrup H.U., 1942, OCEANS; Tapper MA, 1998, LIMNOL OCEANOGR, V43, P95, DOI 10.4319/lo.1998.43.1.0095; Thingstad TF, 1997, AQUAT MICROB ECOL, V13, P19, DOI 10.3354/ame013019; WATERBURY JB, 1993, APPL ENVIRON MICROB, V59, P3393, DOI 10.1128/AEM.59.10.3393-3399.1993; WEINBAUER MG, 1995, MAR ECOL PROG SER, V127, P245, DOI 10.3354/meps127245; WEINBAUER MG, 1995, J PLANKTON RES, V17, P1851, DOI 10.1093/plankt/17.9.1851; WEINBAUER MG, 1995, MICROBIAL ECOL, V30, P25, DOI 10.1007/BF00184511; WEINBAUER MG, 1994, MAR ECOL PROG SER, V108, P11, DOI 10.3354/meps108011; Weinbauer MG, 1998, APPL ENVIRON MICROB, V64, P431; Weinbauer MG, 1997, AQUAT MICROB ECOL, V13, P225, DOI 10.3354/ame013225; WEINBAUER MG, 1993, APPL ENVIRON MICROB, V59, P4074, DOI 10.1128/AEM.59.12.4074-4082.1993; Weinbauer MG, 1996, APPL ENVIRON MICROB, V62, P4374, DOI 10.1128/AEM.62.12.4374-4380.1996; WILCOX RM, 1994, MAR ECOL PROG SER, V114, P35, DOI 10.3354/meps114035; Wilhelm SW, 1998, AQUAT MICROB ECOL, V14, P215, DOI 10.3354/ame014215; Wilhelm SW, 1998, LIMNOL OCEANOGR, V43, P586, DOI 10.4319/lo.1998.43.4.0586; WOMMACK KE, 1992, APPL ENVIRON MICROB, V58, P2965, DOI 10.1128/AEM.58.9.2965-2970.1992; Wommack KE, 1999, APPL ENVIRON MICROB, V65, P241; Wommack KE, 1999, APPL ENVIRON MICROB, V65, P231; Wommack KE, 1996, APPL ENVIRON MICROB, V62, P1336, DOI 10.1128/AEM.62.4.1336-1341.1996; Xenopoulos MA, 1997, LIMNOL OCEANOGR, V42, P1648, DOI 10.4319/lo.1997.42.7.1648; ZACHARY A, 1978, CAN J MICROBIOL, V24, P321, DOI 10.1139/m78-053	105	1525	1660	11	428	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 10	1999	399	6736					541	548		10.1038/21119	http://dx.doi.org/10.1038/21119			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	204RR	10376593				2022-12-28	WOS:000080778400045
J	Fankhauser, C; Yeh, KC; Lagarias, JC; Zhang, H; Elich, TD; Chory, J				Fankhauser, C; Yeh, KC; Lagarias, JC; Zhang, H; Elich, TD; Chory, J			PKS1, a substrate phosphorylated by phytochrome that modulates light signaling in Arabidopsis	SCIENCE			English	Article							HISTIDINE KINASE; PROTEIN-KINASES; EXPRESSION; GENE; PHOTOMORPHOGENESIS; TRANSDUCTION; PATTERNS; PATHWAY; SYSTEM; FAMILY	Plants constantly monitor their light environment in order to grow and develop optimally, in part through use of the phytochromes, which sense red/far-red Light. A phytochrome binding protein, PKS1 (phytochrome kinase substrate 1), was identified that is a substrate for Light-regulated phytochrome kinase activity in vitro, In vivo experiments suggest that PKS1 is phosphorylated in a phytochrome-dependent manner and negatively regulates phytochrome signaling. The data suggest that phytochromes signal by serine-threonine phosphorylation.	Salk Inst Biol Studies, Plant Biol Lab, La Jolla, CA 92037 USA; Salk Inst Biol Studies, Howard Hughes Med Inst, La Jolla, CA 92037 USA; Univ Calif Davis, Sect Mol & Cellular Biol, Davis, CA 95616 USA; Texas Tech Univ, Dept Biol Sci, Lubbock, TX 79409 USA	Salk Institute; Howard Hughes Medical Institute; Salk Institute; University of California System; University of California Davis; Texas Tech University System; Texas Tech University	Chory, J (corresponding author), Salk Inst Biol Studies, Plant Biol Lab, La Jolla, CA 92037 USA.	chory@salk.edu	Fankhauser, Christian/ABE-8757-2021; Fankhauser, Christian/C-4291-2018; Lagarias, John Clark/L-3139-2013; Yeh, Kuo-Chen/AAG-4485-2021	Fankhauser, Christian/0000-0003-4719-5901; Fankhauser, Christian/0000-0003-4719-5901; Lagarias, John Clark/0000-0002-2093-0403; Yeh, Kuo-Chen/0000-0002-3791-3423	NIGMS NIH HHS [R01GM52413] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM052413] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ahmad M, 1998, MOL CELL, V1, P939, DOI 10.1016/S1097-2765(00)80094-5; Aukerman MJ, 1997, PLANT CELL, V9, P1317, DOI 10.1105/tpc.9.8.1317; BEEMON K, 1978, J VIROL, V28, P551, DOI 10.1128/JVI.28.2.551-566.1978; Brown JM, 1998, CURR BIOL, V8, pR662, DOI 10.1016/S0960-9822(07)00417-4; Chang C, 1998, PLANT PHYSIOL, V117, P723, DOI 10.1104/pp.117.3.723; Devlin PF, 1998, PLANT CELL, V10, P1479, DOI 10.1105/tpc.10.9.1479; Elich TD, 1997, CELL, V91, P713, DOI 10.1016/S0092-8674(00)80458-4; Elich TD, 1997, PLANT CELL, V9, P2271, DOI 10.1105/tpc.9.12.2271; Forsburg SL, 1997, GENE, V191, P191, DOI 10.1016/S0378-1119(97)00058-9; FORSBURG SL, 1993, NUCLEIC ACIDS RES, V21, P2955, DOI 10.1093/nar/21.12.2955; Goosey L, 1997, PLANT PHYSIOL, V115, P959, DOI 10.1104/pp.115.3.959; GYURIS J, 1993, CELL, V75, P791, DOI 10.1016/0092-8674(93)90498-F; Harris RA, 1997, ADV ENZYME REGUL, V37, P271, DOI 10.1016/S0065-2571(96)00009-X; JACK T, 1994, CELL, V76, P703, DOI 10.1016/0092-8674(94)90509-6; KIEBER JJ, 1993, CELL, V72, P427, DOI 10.1016/0092-8674(93)90119-B; Krek W, 1998, CURR OPIN GENET DEV, V8, P36, DOI 10.1016/S0959-437X(98)80059-2; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lagarias DM, 1997, PLANT CELL, V9, P675, DOI 10.1105/tpc.9.5.675; Lanker S, 1996, SCIENCE, V271, P1597, DOI 10.1126/science.271.5255.1597; Lapko VN, 1999, PROTEIN SCI, V8, P1032, DOI 10.1110/ps.8.5.1032; MCMICHAEL RWJ, 1991, THESIS U CALIFORNIA; Neff MM, 1998, PLANT PHYSIOL, V118, P27, DOI 10.1104/pp.118.1.27; Ni M, 1998, CELL, V95, P657, DOI 10.1016/S0092-8674(00)81636-0; Quail PH, 1997, PLANT CELL ENVIRON, V20, P657, DOI 10.1046/j.1365-3040.1997.d01-108.x; Sakamoto K, 1996, PLANT J, V10, P859, DOI 10.1046/j.1365-313X.1996.10050859.x; SCHNEIDERPOETSCH HAW, 1992, PHOTOCHEM PHOTOBIOL, V56, P839, DOI 10.1111/j.1751-1097.1992.tb02241.x; Shinomura T, 1996, P NATL ACAD SCI USA, V93, P8129, DOI 10.1073/pnas.93.15.8129; SMITH H, 1995, ANNU REV PLANT PHYS, V46, P289, DOI 10.1146/annurev.pp.46.060195.001445; SOMERS DE, 1995, PLANT J, V7, P413, DOI 10.1046/j.1365-313X.1995.7030413.x; Stancovski I, 1997, CELL, V91, P299, DOI 10.1016/S0092-8674(00)80413-4; Whitelam GC, 1997, PLANT CELL ENVIRON, V20, P752, DOI 10.1046/j.1365-3040.1997.d01-100.x; WONG YS, 1989, PLANT PHYSIOL, V91, P709, DOI 10.1104/pp.91.2.709; YANG XO, 1992, SCIENCE, V257, P680, DOI 10.1126/science.1496382; Yeh KC, 1998, P NATL ACAD SCI USA, V95, P13976, DOI 10.1073/pnas.95.23.13976; Yeh KC, 1997, SCIENCE, V277, P1505, DOI 10.1126/science.277.5331.1505; Zhang H, 1997, BBA-GENE STRUCT EXPR, V1353, P199, DOI 10.1016/S0167-4781(97)00096-1	36	305	329	2	33	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 28	1999	284	5419					1539	1541		10.1126/science.284.5419.1539	http://dx.doi.org/10.1126/science.284.5419.1539			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	200PD	10348744				2022-12-28	WOS:000080548100041
J	Li, DY; Sorensen, LK; Brooke, BS; Urness, LD; Davis, EC; Taylor, DG; Boak, BB; Wendel, DP				Li, DY; Sorensen, LK; Brooke, BS; Urness, LD; Davis, EC; Taylor, DG; Boak, BB; Wendel, DP			Defective angiogenesis in mice lacking endoglin	SCIENCE			English	Article							GROWTH-FACTOR-BETA; TGF-BETA; ENDOTHELIAL-CELLS; BINDING-PROTEIN; SMOOTH-MUSCLE; VASCULOGENESIS; RECEPTOR; HEMATOPOIESIS; PDGF; INVITRO	Endoglin is a transforming growth factor-beta (TCF-beta) binding protein expressed on the surface of endothelial cells. Loss-of-function mutations in the human endoglin gene ENG cause hereditary hemorrhagic telangiectasia (HHT1), a disease characterized by vascular malformations. Here it is shown that by gestational day 11.5, mice lacking endoglin die from defective vascular development. However, in contrast to mice lacking TGF-beta, vasculogenesis was unaffected. Loss of endoglin caused poor vascular smooth muscle development and arrested endothelial remodeling. These results demonstrate that endoglin is essential for angiogenesis and suggest a pathogenic mechanism for HHT1.	Univ Utah, Program Human Mol Biol & Genet, Salt Lake City, UT 84112 USA; Univ Utah, Dept Human Genet, Salt Lake City, UT 84112 USA; Univ Utah, Dept Oncol Sci, Salt Lake City, UT 84112 USA; Univ Utah, Dept Med, Salt Lake City, UT 84112 USA; Univ Utah, Howard Hughes Med Inst, Salt Lake City, UT 84112 USA; Univ Texas, SW Med Ctr, Dept Cell Biol & Physiol, Dallas, TX 75235 USA	Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah; Howard Hughes Medical Institute; Utah System of Higher Education; University of Utah; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Li, DY (corresponding author), Univ Utah, Program Human Mol Biol & Genet, Salt Lake City, UT 84112 USA.		Davis, Elaine/F-3449-2012		NHLBI NIH HHS [K08 HL03490-03, T35 HL07744-06] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T35HL007744, K08HL003490] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Barbara NP, 1999, J BIOL CHEM, V274, P584, DOI 10.1074/jbc.274.2.584; CHEIFETZ S, 1992, J BIOL CHEM, V267, P19027; DICKSON MC, 1995, DEVELOPMENT, V121, P1845; FLAMME I, 1992, DEVELOPMENT, V116, P435; Folkman J, 1996, CELL, V87, P1153, DOI 10.1016/S0092-8674(00)81810-3; GUTTMACHER AE, 1995, NEW ENGL J MED, V333, P918, DOI 10.1056/NEJM199510053331407; Hirschi KK, 1998, J CELL BIOL, V141, P805, DOI 10.1083/jcb.141.3.805; KINGSLEY DM, 1994, GENE DEV, V8, P133, DOI 10.1101/gad.8.2.133; Li DY, 1998, NATURE, V393, P276, DOI 10.1038/30522; Li L, 1996, CIRC RES, V78, P188, DOI 10.1161/01.RES.78.2.188; Lindahl P, 1997, SCIENCE, V277, P242, DOI 10.1126/science.277.5323.242; Maisonpierre PC, 1997, SCIENCE, V277, P55, DOI 10.1126/science.277.5322.55; Massague Joan, 1994, Trends in Cell Biology, V4, P172, DOI 10.1016/0962-8924(94)90202-X; MCALLISTER KA, 1994, NAT GENET, V8, P345, DOI 10.1038/ng1294-345; Oshima M, 1996, DEV BIOL, V179, P297, DOI 10.1006/dbio.1996.0259; Pepper Michael S., 1997, Cytokine and Growth Factor Reviews, V8, P21, DOI 10.1016/S1359-6101(96)00048-2; Reddi A. Hari, 1997, Cytokine and Growth Factor Reviews, V8, P11, DOI 10.1016/S1359-6101(96)00049-4; SATO T, 1995, NATURE, V376, P7074; SHALABY F, 1995, NATURE, V376, P62, DOI 10.1038/376062a0; SORENSEN LB, UNPUB; SORIANO P, 1994, GENE DEV, V8, P1888, DOI 10.1101/gad.8.16.1888; STJACQUES S, 1994, ENDOCRINOLOGY, V134, P2645, DOI 10.1210/en.134.6.2645; Suri C, 1996, CELL, V87, P1171, DOI 10.1016/S0092-8674(00)81813-9; WENDEL D, UNPUB; WESTPHAL JR, 1993, J INVEST DERMATOL, V100, P27, DOI 10.1111/1523-1747.ep12349946; YAMASHITA H, 1994, J BIOL CHEM, V269, P1995; Yancopoulos GD, 1998, CELL, V93, P661, DOI 10.1016/S0092-8674(00)81426-9	27	662	701	0	23	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAY 28	1999	284	5419					1534	1537		10.1126/science.284.5419.1534	http://dx.doi.org/10.1126/science.284.5419.1534			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	200PD	10348742				2022-12-28	WOS:000080548100039
J	Parker, RA; Delbanco, TL; Foley, K				Parker, RA; Delbanco, TL; Foley, K			A 44-year-old woman with severe pain at the end of life	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							CANCER PAIN; MANAGEMENT; METHADONE; MORPHINE; CARE; NARCOTICS; ATTITUDES		Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA	Memorial Sloan Kettering Cancer Center	Parker, RA (corresponding author), Beth Israel Deaconess Med Ctr, Div Gen Med, 330 Brokline Ave,LY318, Boston, MA 02215 USA.							American Board of Internal Medicine, 1996, CAR DYING ID PROM PH; Billings JA, 1997, JAMA-J AM MED ASSOC, V278, P733, DOI 10.1001/jama.278.9.733; Bookbinder M, 1996, J PAIN SYMPTOM MANAG, V12, P334, DOI 10.1016/S0885-3924(96)00204-7; Bruera E, 1996, CANCER, V78, P852, DOI 10.1002/(SICI)1097-0142(19960815)78:4<852::AID-CNCR23>3.0.CO;2-T; BRUERA E, 1987, CANCER TREAT REP, V71, P67; BRUERA E, 1993, CLIN AUDIT PALLIATIV, P61; Buckman R., 1998, PRACTICAL GUIDE COMM; Capello C F, 1998, J Palliat Med, V1, P155, DOI 10.1089/jpm.1998.1.155; Carron A T, 1999, Ann Intern Med, V130, P82; Cassel CK, 1996, NEW ENGL J MED, V335, P1232, DOI 10.1056/NEJM199610173351612; CASSEL EJ, 1982, NEW ENGL J MED, V306, P639, DOI 10.1056/NEJM198203183061104; CASSEM NH, 1991, MASSACHUSETTS GEN HO, P343; Cherny N I, 1994, J Palliat Care, V10, P57; Cherny N I, 1994, J Palliat Care, V10, P71; CHERNY NI, 1996, HEMATOL ONCOL, P235; CHERNY NJ, 1995, CANCER-AM CANCER SOC, V76, P1283, DOI 10.1002/1097-0142(19951001)76:7<1283::AID-CNCR2820760728>3.0.CO;2-0; CHRISTAKIS NA, 1996, NEW ENGL J MED, V1, P3; DAALEMAN TP, 1994, J FAM PRACTICE, V39, P564; Doyle D, 1998, OXFORD TXB PALLIATIV; ELLIOTT K, 1995, NEUROPSYCHOPHARMACOL, V13, P347, DOI 10.1038/sj.npp.1380294; Ellis MR, 1999, J FAM PRACTICE, V48, P105; Foley K.M, 1991, NEW PHARMACOTHERAPY, P181; Foley Kathleen M., 1997, P2807; Foley KM, 1997, NEW ENGL J MED, V336, P54, DOI 10.1056/NEJM199701023360109; Foley KM, 1998, J CLIN ONCOL, V16, P3213, DOI 10.1200/JCO.1998.16.10.3213; Foley KM, 1993, OXFORD TXB PALLIATIV, P148; FORREST WH, 1977, NEW ENGL J MED, V296, P712, DOI 10.1056/NEJM197703312961303; FOX WP, 1995, PSYCHO-ONCOL, V4, P87; *GALL I, 1997, SPIR BEL DYING PROC; GIBSON R, 1998, J PALLIAT MED, V1, P415; Ingham JM, 1996, HEMATOL ONCOL CLIN N, V10, P21, DOI 10.1016/S0889-8588(05)70325-7; Jacox A, 1994, CLIN PRACTICE GUIDEL; JADAD A, 1998, TOPICS PALLIATIVE CA, P31; LEVIN DN, 1985, CANCER, V56, P2337, DOI 10.1002/1097-0142(19851101)56:9<2337::AID-CNCR2820560935>3.0.CO;2-W; Levy MH, 1996, NEW ENGL J MED, V335, P1124, DOI 10.1056/NEJM199610103351507; LIPSYTE R, 1998, COUNTRY ILLNESS COMF; MAX MB, 1995, JAMA-J AM MED ASSOC, V274, P1874, DOI 10.1001/jama.1995.03530230060032; Meier DE, 1997, ANN INTERN MED, V127, P225, DOI 10.7326/0003-4819-127-3-199708010-00008; Mercadante S, 1998, J CLIN ONCOL, V16, P3656, DOI 10.1200/JCO.1998.16.11.3656; MOULIN D, 1998, NEUROPATHIC CANC PAI, V2; PORTENOY RK, 1994, EUR J CANCER, V30A, P1326, DOI 10.1016/0959-8049(94)90182-1; PORTENOY RP, 1998, TXB PALLIATIVE MED, P361; PORTER J, 1980, NEW ENGL J MED, V302, P123; Posner J.B., 1995, NEUROLOGICAL COMPLIC; Pritchard RS, 1998, J AM GERIATR SOC, V46, P1242, DOI 10.1111/j.1532-5415.1998.tb04540.x; Ripamonti C, 1998, J CLIN ONCOL, V16, P3216, DOI 10.1200/JCO.1998.16.10.3216; VENTAFRIDDA V, 1987, CANCER, V59, P851; VONROENN JH, 1993, ANN INTERN MED, V119, P121, DOI 10.7326/0003-4819-119-2-199307150-00005; WEISSMAN DE, 1989, PAIN, V36, P363, DOI 10.1016/0304-3959(89)90097-3; World Health Organization, 1990, CANC PAIN REL PALL C; 1998, CBS NEWS POLL   0420	51	12	12	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 26	1999	281	20					1937	1945		10.1001/jama.281.20.1937	http://dx.doi.org/10.1001/jama.281.20.1937			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	198ME	10349898				2022-12-28	WOS:000080427300034
J	Hachinski, V				Hachinski, V			Post-stroke depression, not to be underestimated	LANCET			English	Editorial Material									Univ Western Ontario, London Hlth Sci Ctr, Dept Neurol Sci, London, ON N6A 5A5, Canada	London Health Sciences Centre; Western University (University of Western Ontario)	Hachinski, V (corresponding author), Univ Western Ontario, London Hlth Sci Ctr, Dept Neurol Sci, London, ON N6A 5A5, Canada.							ASTROM M, 1992, STROKE, V23, P527, DOI 10.1161/01.STR.23.4.527; Enserink M, 1999, SCIENCE, V284, P238, DOI 10.1126/science.284.5412.238; EVANS RL, 1988, STROKE, V19, P1243, DOI 10.1161/01.STR.19.10.1243; Kotila M, 1998, STROKE, V29, P368, DOI 10.1161/01.STR.29.2.368; MORRIS PLP, 1992, MED J AUSTRALIA, V157, P239, DOI 10.5694/j.1326-5377.1992.tb137126.x; Palomaki H, 1999, J NEUROL NEUROSUR PS, V66, P490, DOI 10.1136/jnnp.66.4.490; SHARPE M, 1994, BRIT J PSYCHIAT, V164, P380, DOI 10.1192/bjp.164.3.380; WADE DT, 1987, BRIT J PSYCHIAT, V151, P200, DOI 10.1192/bjp.151.2.200	8	17	22	0	3	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAY 22	1999	353	9166					1728	1728		10.1016/S0140-6736(99)00139-7	http://dx.doi.org/10.1016/S0140-6736(99)00139-7			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	202TF	10347982				2022-12-28	WOS:000080667700007
J	Greenspan, SL; Greenspan, FS				Greenspan, SL; Greenspan, FS			The effect of thyroid hormone on skeletal integrity	ANNALS OF INTERNAL MEDICINE			English	Review							BONE-MINERAL DENSITY; LEVOTHYROXINE SUPPRESSIVE THERAPY; TERM L-THYROXINE; FORMER HYPERTHYROID PATIENTS; POSTMENOPAUSAL WOMEN; PREMENOPAUSAL WOMEN; SUBCLINICAL HYPERTHYROIDISM; REPLACEMENT THERAPY; TREATMENT GUIDELINES; CALCIUM HOMEOSTASIS	Background: Thyroid disease and osteoporosis are common problems often managed by primary care physicians, Despite many studies, confusion still exists about the effect of thyroid hormone on skeletal health. Purpose: To review evidence on. the effect of thyroid hormone(from hyperthyroidism, exogenous or endogenous suppression of thyroid-stimulating hormone [TSH], and thyroid hormone replacement therapy) on skeletal integrity. Data Sources: A MEDLINE search of papers published between 1966 and 1997. Data Selection: Cross-sectional studies, longitudinal studies, and meta-analyses that had appropriate control groups (patients matched for age, sex, and menopausal status), made comparisons with established databases, or defined thyroid state by TSH level or thyroid hormone dose were reviewed. Data Extraction and Synthesis: Data synthesis was not straightforward because of changes in doses and types of thyroid hormone preparations; changes in definitions of thyroid hormone replacement therapy and suppressive therapies; problems with study design; differences in skeletal sites assessed (hip, spine, forearm, or heel) and techniques used to measure bone mineral density; and inclusion of heterogenous and changing thyroid disease states. Overall, hyperthyroidism and use of thyroid hormone to suppress TSH because of thyroid cancer, goiters, or nodules seem to have an adverse effect on bone, especially in postmenopausal women; the largest effect is on cortical bone. Thyroid hormone replacement seems to have a minimal clinical effect on bone. Conclusion: Women with a history of hyperthyroidism or TSH suppression by thyroid hormone should have skeletal status assessed by bone mineral densitometry, preferably at a site containing cortical bone, such as the hip or forearm.	Beth Israel Deaconess Med Ctr, Div Bone & Mineral Metab, Boston, MA 02215 USA; Harvard Univ, Sch Med, Boston, MA USA; Univ Calif San Francisco, San Francisco, CA 94143 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School; University of California System; University of California San Francisco	Greenspan, SL (corresponding author), Beth Israel Deaconess Med Ctr, Div Bone & Mineral Metab, E-GZ-800,330 Brookline Ave, Boston, MA 02215 USA.				NCRR NIH HHS [MO1-RR01032] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR001032] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		ADLIN EV, 1991, AM J MED, V90, P360, DOI 10.1016/0002-9343(91)90577-K; Baran DT, 1997, CALCIFIED TISSUE INT, V61, P433, DOI 10.1007/s002239900362; Bauer DC, 1997, J CLIN ENDOCR METAB, V82, P2931, DOI 10.1210/jc.82.9.2931; BURMEISTER LA, 1992, J CLIN ENDOCR METAB, V75, P344, DOI 10.1210/jc.75.2.344; CAMPOSPASTOR MM, 1993, BONE MINER, V21, P1, DOI 10.1016/S0169-6009(08)80115-8; CUMMINGS SR, 1995, NEW ENGL J MED, V332, P767, DOI 10.1056/NEJM199503233321202; *DEP HLTH HUM SERV, 1998, FED REGISTER, V63, P34321; DEROSA G, 1995, HORM METAB RES, V27, P503, DOI 10.1055/s-2007-980012; *DIAGN THER TECHN, 1992, JAMA-J AM MED ASSOC, V261, P917; DIAMOND T, 1991, J CLIN ENDOCR METAB, V72, P1184, DOI 10.1210/jcem-72-6-1184; Dong BJ, 1997, JAMA-J AM MED ASSOC, V277, P1205, DOI 10.1001/jama.277.15.1205; DUNCAN WE, 1994, THYROID, V4, P183, DOI 10.1089/thy.1994.4.183; ERIKSEN EF, 1986, ENDOCR REV, V7, P379, DOI 10.1210/edrv-7-4-379; ESCALANTE DA, 1995, AM J MED, V98, P374, DOI 10.1016/S0002-9343(99)80316-7; FABER J, 1994, EUR J ENDOCRINOL, V130, P350, DOI 10.1530/eje.0.1300350; FLORKOWSKI CM, 1993, NEW ZEAL MED J, V106, P443; FOLDES J, 1993, CLIN ENDOCRINOL, V39, P521, DOI 10.1111/j.1365-2265.1993.tb02403.x; FRANKLYN J, 1994, CLIN ENDOCRINOL, V41, P425, DOI 10.1111/j.1365-2265.1994.tb02572.x; FRANKLYN JA, 1995, THYROID, V5, P359, DOI 10.1089/thy.1995.5.359; FRANKLYN JA, 1992, LANCET, V340, P9, DOI 10.1016/0140-6736(92)92423-D; GARTON M, 1994, CLIN ENDOCRINOL, V41, P747, DOI 10.1111/j.1365-2265.1994.tb02789.x; Genant HK, 1996, J BONE MINER RES, V11, P707; Gharib H, 1998, ANN INTERN MED, V128, P386, DOI 10.7326/0003-4819-128-5-199803010-00008; GIANNINI S, 1994, CLIN SCI, V87, P593, DOI 10.1042/cs0870593; Gorres G, 1996, EUR J NUCL MED, V23, P690, DOI 10.1007/BF00834532; GRANT DJ, 1993, CLIN ENDOCRINOL, V39, P529, DOI 10.1111/j.1365-2265.1993.tb02404.x; GRANT DJ, 1995, CLIN ENDOCRINOL, V43, P339, DOI 10.1111/j.1365-2265.1995.tb02041.x; GREENSPAN SL, 1991, AM J MED, V91, P5, DOI 10.1016/0002-9343(91)90066-7; HAWKINS F, 1994, CALCIFIED TISSUE INT, V54, P16, DOI 10.1007/BF00316283; KLEE GG, 1993, CLIN LAB MED, V13, P673, DOI 10.1016/S0272-2712(18)30432-3; KROLNER B, 1983, CLIN ENDOCRINOL, V18, P439, DOI 10.1111/j.1365-2265.1983.tb02873.x; Kung AWC, 1996, J CLIN ENDOCR METAB, V81, P1232, DOI 10.1210/jc.81.3.1232; KUNG AWC, 1993, CLIN ENDOCRINOL, V39, P535, DOI 10.1111/j.1365-2265.1993.tb02405.x; KUNG AWC, 1991, JAMA-J AM MED ASSOC, V265, P2688, DOI 10.1001/jama.265.20.2688; Langdahl BL, 1996, THYROID, V6, P161; Langdahl BL, 1996, THYROID, V6, P169; LEE MS, 1990, J CLIN ENDOCR METAB, V70, P766, DOI 10.1210/jcem-70-3-766; LEHMKE J, 1992, CLIN ENDOCRINOL, V36, P511, DOI 10.1111/j.1365-2265.1992.tb02254.x; Lima N, 1997, THYROID, V7, P691, DOI 10.1089/thy.1997.7.691; LIPS P, 1998, AM J MED, V103, pS3; MANDEL SJ, 1993, ANN INTERN MED, V119, P492, DOI 10.7326/0003-4819-119-6-199309150-00009; MARCOCCI C, 1994, J CLIN ENDOCR METAB, V78, P818, DOI 10.1210/jc.78.4.818; Marcocci C, 1997, J BONE MINER RES, V12, P72, DOI 10.1359/jbmr.1997.12.1.72; MCDERMOTT MT, 1995, CALCIFIED TISSUE INT, V56, P521, DOI 10.1007/BF00298581; MOSEKILDE L, 1990, ENDOCRIN METAB CLIN, V19, P35, DOI 10.1016/S0889-8529(18)30338-4; MUDDE AH, 1992, CLIN ENDOCRINOL, V37, P35, DOI 10.1111/j.1365-2265.1992.tb02280.x; MULLER CG, 1995, THYROID, V5, P81, DOI 10.1089/thy.1995.5.81; *NAT OST FDN, 1998, PHYS GUID PREV TREAT, P1; Nguyen TT, 1997, J BONE MINER RES, V12, P1092, DOI 10.1359/jbmr.1997.12.7.1092; Papini E, 1998, J CLIN ENDOCR METAB, V83, P780, DOI 10.1210/jc.83.3.780; PAUL TL, 1988, JAMA-J AM MED ASSOC, V259, P3137, DOI 10.1001/jama.259.21.3137; PIOLI G, 1992, ACTA ENDOCRINOL-COP, V126, P238, DOI 10.1530/acta.0.1260238; POOR G, 1995, J BONE MINER RES, V10, P1900; RIBOT C, 1990, CLIN ENDOCRINOL, V33, P143, DOI 10.1111/j.1365-2265.1990.tb00477.x; Ridgway EC, 1998, ANN INTERN MED, V128, P403, DOI 10.7326/0003-4819-128-5-199803010-00010; ROSEN CJ, 1992, J CLIN ENDOCR METAB, V75, P1531, DOI 10.1210/jc.75.6.1531; Rosen HN, 1998, J CLIN ENDOCR METAB, V83, P2324, DOI 10.1210/jc.83.7.2324; ROSEN HN, 1993, J CLIN ENDOCR METAB, V77, P664, DOI 10.1210/jc.77.3.664; Ross Douglas S., 1996, P1016; ROSS DS, 1993, AM J MED, V95, P385, DOI 10.1016/0002-9343(93)90307-B; ROSS DS, 1994, THYROID, V4, P319, DOI 10.1089/thy.1994.4.319; ROSS DS, 1987, AM J MED, V82, P1167, DOI 10.1016/0002-9343(87)90219-1; Saggese G, 1996, EUR J PEDIATR, V155, P452, DOI 10.1007/BF01955180; SAWIN CT, 1989, JAMA-J AM MED ASSOC, V261, P2653, DOI 10.1001/jama.261.18.2653; SCHNEIDER DL, 1994, JAMA-J AM MED ASSOC, V271, P1245, DOI 10.1001/jama.271.16.1245; SCHNEIDER DL, 1995, ARCH INTERN MED, V155, P2005, DOI 10.1001/archinte.155.18.2005; SINGER PA, 1995, JAMA-J AM MED ASSOC, V273, P808, DOI 10.1001/jama.273.10.808; Singer PA, 1996, ARCH INTERN MED, V156, P2165, DOI 10.1001/archinte.156.19.2165; SOLOMON BL, 1993, THYROID, V3, P17, DOI 10.1089/thy.1993.3.17; STALL GM, 1990, ANN INTERN MED, V113, P265, DOI 10.7326/0003-4819-113-4-265; TAELMAN P, 1990, CLIN ENDOCRINOL, V33, P107, DOI 10.1111/j.1365-2265.1990.tb00471.x; TOH SH, 1985, ARCH INTERN MED, V145, P883, DOI 10.1001/archinte.145.5.883; TOH SH, 1990, J BONE MINER RES, V5, P463, DOI 10.1002/jbmr.5650050507; TUNBRIDGE WMG, 1977, CLIN ENDOCRINOL, V7, P481, DOI 10.1111/j.1365-2265.1977.tb01340.x; U.S. Preventive Services Task Force, 1996, GUID CLIN PREV SERV, P209; Uzzan B, 1996, J CLIN ENDOCR METAB, V81, P4278, DOI 10.1210/jc.81.12.4278; VONRECKLINGHAUS.D, 1891, FIBROSE DEFORMIEREND, P1; Wartofsky L, 1997, ENDOCRINOLOGIST, V7, P322, DOI 10.1097/00019616-199707050-00007; WEJDA B, 1995, J INTERN MED, V237, P241, DOI 10.1111/j.1365-2796.1995.tb01172.x; Werner SC, 1978, THYROID, P965; WERNER SC, 1978, THYROID, P525	81	158	168	0	10	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAY 4	1999	130	9					750	758		10.7326/0003-4819-130-9-199905040-00016	http://dx.doi.org/10.7326/0003-4819-130-9-199905040-00016			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	192DE	10357695				2022-12-28	WOS:000080062300007
J	Charman, C				Charman, C			Clinical evidence - Atopic eczema	BMJ-BRITISH MEDICAL JOURNAL			English	Review							MITE ALLERGEN AVOIDANCE; HIGH-RISK INFANTS; TOPICAL GLUCOCORTICOIDS; CONTROLLED TRIAL; FOLLOW-UP; DERMATITIS; CREAM; ATROPHOGENICITY; PREVALENCE; ULTRASOUND		Queens Med Ctr, Nottingham NG7 2UH, England	University of Nottingham	Charman, C (corresponding author), Queens Med Ctr, Nottingham NG7 2UH, England.							ATHERTON DJ, 1978, LANCET, V1, P401; CHANDRA RK, 1989, BMJ-BRIT MED J, V299, P228, DOI 10.1136/bmj.299.6693.228; Chandra RK, 1997, J PEDIATR GASTR NUTR, V24, P380, DOI 10.1097/00005176-199704000-00005; COLLOFF MJ, 1989, BRIT J DERMATOL, V121, P199, DOI 10.1111/j.1365-2133.1989.tb01799.x; Hill VA, 1998, J DERMATOL TREAT, V9, P15, DOI 10.3109/09546639809160683; HJORTH N, 1985, PHARMATHERAPEUTICA, V4, P126; JAFFE GV, 1986, PHARMATHERAPEUTICA, V4, P628; KAY J, 1994, J AM ACAD DERMATOL, V30, P35, DOI 10.1016/S0190-9622(94)70004-4; KERSCHER MJ, 1995, INT J CLIN PHARM TH, V33, P187; KERSCHER MJ, 1992, ACTA DERM-VENEREOL, V72, P214; KERSCHER MJ, 1992, SKIN PHARMACOL, V5, P77; KORTING HC, 1992, EUR J CLIN PHARMACOL, V42, P159, DOI 10.1007/BF00278477; KRAMER MS, 1998, COCHRANE COLLABORATI; Lawlor F, 1995, J DERMATOL TREAT, V6, P233, DOI 10.3109/09546639509086850; Maloney JM, 1998, INT J DERMATOL, V37, P142, DOI 10.1046/j.1365-4362.1998.00394.x; MEENAN FOC, 1988, BRIT J CLIN PRACT, V42, P200; NEILD VS, 1986, BRIT J DERMATOL, V114, P117, DOI 10.1111/j.1365-2133.1986.tb02786.x; Nishioka K, 1998, J ALLERGY CLIN IMMUN, V101, P28, DOI 10.1016/S0091-6749(98)70189-7; OWEN S, 1990, LANCET, V335, P396, DOI 10.1016/0140-6736(90)90219-U; PATEL L, 1995, BRIT J DERMATOL, V132, P950; Poyner T.F., 1996, J EUR ACAD DERMATOL, V7, pS23; Ramsay CA, 1996, J EUR ACAD DERMAT S1, V7, pS15, DOI DOI 10.1016/0926-9959(96)00032-3; ROTH HL, 1978, CUTIS, V21, P695; SAARINEN UM, 1995, LANCET, V346, P1065, DOI 10.1016/S0140-6736(95)91742-X; SAMPSON HA, 1985, J PEDIATR-US, V107, P669, DOI 10.1016/S0022-3476(85)80390-5; SANDA T, 1992, J ALLERGY CLIN IMMUN, V89, P653, DOI 10.1016/0091-6749(92)90370-H; Tan BB, 1996, LANCET, V347, P15, DOI 10.1016/S0140-6736(96)91556-1; WILLIAMS HC, 1992, CLIN EXP DERMATOL, V17, P385, DOI 10.1111/j.1365-2230.1992.tb00244.x; WILLIAMS HC, 1994, BRIT J DERMATOL, V131, P406, DOI 10.1111/j.1365-2133.1994.tb08532.x	29	21	22	1	2	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUN 12	1999	318	7198					1600	1604		10.1136/bmj.318.7198.1600	http://dx.doi.org/10.1136/bmj.318.7198.1600			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	207AL	10364122	Green Published			2022-12-28	WOS:000080913100032
J	Lishman, WA				Lishman, WA			Robert Hugh Cawley - Obituary	BRITISH MEDICAL JOURNAL			English	Biographical-Item																			0	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JUN 12	1999	318	7198					1626	1626		10.1136/bmj.318.7198.1626	http://dx.doi.org/10.1136/bmj.318.7198.1626			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	207AL	10364138	Green Published			2022-12-28	WOS:000080913100061
J	Cochrane, MA; Alencar, A; Schulze, MD; Souza, CM; Nepstad, DC; Lefebvre, P; Davidson, EA				Cochrane, MA; Alencar, A; Schulze, MD; Souza, CM; Nepstad, DC; Lefebvre, P; Davidson, EA			Positive feedbacks in the fire dynamic of closed canopy tropical forests	SCIENCE			English	Article							EASTERN AMAZON; RAIN-FOREST; DEFORESTATION	The incidence and importance of fire in the Amazon have increased substantially during the past decade, but the effects of this disturbance force are still poorly understood. The forest fire dynamics in two regions of the eastern Amazon were studied. Accidental fires have affected nearly 50 percent of the remaining forests and have caused more deforestation than has intentional clearing in recent years. Forest fires create positive feedbacks in future fire susceptibility, fuel loading, and fire intensity. Unless current land use and fire use practices are changed, fire has the potential to transform large areas of tropical forest into scrub or savanna.	Woods Hole Res Ctr, Woods Hole, MA 02543 USA; Inst Homen & Meio Ambiente Amazona IMAZON, BR-66017000 Belem, Para, Brazil; UFPa, Inst Pesquisa Ambiental Amazona, BR-66075900 Belem, Para, Brazil; Penn State Univ, Dept Biol, University Pk, PA 16802 USA	Woods Hole Research Center; Universidade Federal do Para; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park	Cochrane, MA (corresponding author), Woods Hole Res Ctr, POB 296, Woods Hole, MA 02543 USA.		Schulze, Mark D/H-4921-2013; Souza, CARLOS/AAK-8207-2021; Davidson, Eric A/K-4984-2013; Cochrane, Mark A/A-1735-2018; /AAX-3684-2020	Schulze, Mark D/0000-0003-0438-4091; Souza, CARLOS/0000-0002-0205-6134; Davidson, Eric A/0000-0002-8525-8697; Cochrane, Mark A/0000-0002-4573-568X; /0000-0001-5605-7469				Agee, 1993, FIRE ECOLOGY PACIFIC; Brown J.K., 1974, HDB INVENTORYING DOW; Cochrane MA, 1999, BIOTROPICA, V31, P2, DOI 10.1111/j.1744-7429.1999.tb00112.x; Cochrane MA, 1998, INT J REMOTE SENS, V19, P3433, DOI 10.1080/014311698214109; Holdsworth AR, 1997, ECOL APPL, V7, P713, DOI 10.1890/1051-0761(1997)007[0713:FIASLR]2.0.CO;2; *INPE, 1996, INPE DESFL 1993 1994; *INPE, 1997, INPE I NAC PESQ ESP; JACKSON WD, 1968, P ECOL SOC AUST, V3; KAUFFMAN JB, 1991, BIOTROPICA, V23, P219, DOI 10.2307/2388198; MEGGERS BJ, 1994, CLIMATIC CHANGE, V28, P321, DOI 10.1007/BF01104077; MUELLERDOMBOIS M, 1981, P C FIR REG EC PROP, P137; Nepstad DC, 1999, NATURE, V398, P505, DOI 10.1038/19066; PETERSON DL, 1986, ENVIRON MANAGE, V10, P797, DOI 10.1007/BF01867732; Pyne S.J., 1984, INTRO WILDLAND FIRE; ROTHERMEL RC, 1983, INT143 US FOR SERV; SALDARRIAGA JG, 1986, QUATERNARY RES, V26, P358, DOI 10.1016/0033-5894(86)90095-5; SANFORD RL, 1985, SCIENCE, V227, P53, DOI 10.1126/science.227.4682.53; SHUKLA J, 1990, SCIENCE, V247, P1322, DOI 10.1126/science.247.4948.1322; SILVA E, 1996, THESIS PENNSYLVANIA; SKOLE D, 1993, SCIENCE, V260, P1905, DOI 10.1126/science.260.5116.1905; Turcq B, 1998, AMBIO, V27, P139; UHL C, 1985, BIOTROPICA, V17, P265, DOI 10.2307/2388588; UHL C, 1988, OIKOS, V53, P176, DOI 10.2307/3566060; UHL C, 1990, ECOLOGY, V71, P437, DOI 10.2307/1940299; Van Wagner CE, 1973, CAN J FOREST RES, V3, P373, DOI DOI 10.1139/X73-055; VANWAGNER CE, 1978, CAN J FOREST RES, V8, P220, DOI 10.1139/x78-034	26	634	663	4	107	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 11	1999	284	5421					1832	1835		10.1126/science.284.5421.1832	http://dx.doi.org/10.1126/science.284.5421.1832			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	205EU	10364555				2022-12-28	WOS:000080809000049
J	Moss, SM; Coleman, DA; Chamberlain, J; Mapp, TJ; Preece, PE; Alexander, FE; Alexander, TJ; Kirkpatrick, AE; Forrest, AP; Thomas, BA; Boulter, PS; Gibbs, NM; Price, JL; Philip, J; Joslin, C; Blamey, RW; Elston, CW; Roebuck, EJ; Vessey, MP; Greenall, MJ; Bradfield, PC; Summerly, ME; Scoble, JE				Moss, SM; Coleman, DA; Chamberlain, J; Mapp, TJ; Preece, PE; Alexander, FE; Alexander, TJ; Kirkpatrick, AE; Forrest, AP; Thomas, BA; Boulter, PS; Gibbs, NM; Price, JL; Philip, J; Joslin, C; Blamey, RW; Elston, CW; Roebuck, EJ; Vessey, MP; Greenall, MJ; Bradfield, PC; Summerly, ME; Scoble, JE		UK Trial Early Detection Breast Canc Grp	16-year mortality from breast cancer in the UK Trial of Early Detection of Breast Cancer	LANCET			English	Article							MAMMOGRAPHY; AGE	Background. The UK Trial of Early Detection of Breast Cancer (TEDBC) is a non-randomised study, which was set up in 1979 to investigate the effect of screening and education about breast self-examination on breast-cancer mortality. We report mortality results after 16 years of follow-up, including results by age at trial entry. Methods. Eight centres (two screening, two breast self-examination, and four comparison) in England and Scotland recruited women aged 45-64 years into the initial cohort, with women reaching age 45 years during the 7-year study period included in later cohorts. The observed number of deaths from breast cancer in each centre was compared with the expected number, which was calculated by Poisson regression model; expected numbers were adjusted for pretrial breast-cancer mortality. Results were analysed by 5-year age-groups, and for women aged 45-46 years and 47-49 years at entry. Findings. Breast-cancer mortality was 27% lower (rate ratio 0.73 [95% CI 0.63-0.84]), adjusted for pretrial rates, in cohort 1 in the two screening centres combined than in the comparison centres. No reduction in mortality in the two breast self-examination centres combined was seen (rate ratio 0.99 [0.87-1.12]). The mortality reduction in the screening centres did not differ significantly across age-groups; a 35% reduction was seen in women in all cohorts aged 45-46 years at entry (rate ratio 0.65 [0.50-0.86]). Results were similar when deaths were restricted to those in patients diagnosed within 10 years of trial entry. Interpretation. The results from TEDBC support those from randomised trials in Edinburgh and elsewhere, and show that reduction in breast-cancer mortality resulting from screening can be achieved in the UK. There was no evidence of less benefit in women aged 45-46 years at the start of screening; the effect of screening in this age-group begins to emerge after 3-4 years.	Inst Canc Res, Canc Screening Evaluat Unit, Sutton SM2 5NG, Surrey, England; Univ Dundee, Ninewells Hosp & Med Sch, Clin Skills Ctr, Dundee DD1 9SY, Scotland; Univ Edinburgh, Dept Publ Hlth Sci, Edinburgh EH8 9YL, Midlothian, Scotland; Univ Edinburgh, Dept Pathol, Edinburgh EH8 9YL, Midlothian, Scotland; Scottish Breast Screening Programme, Edinburgh, Midlothian, Scotland; Univ Edinburgh, Royal Infirm, Dept Surg, Edinburgh EH3 9YW, Midlothian, Scotland; Jarvis Breast Screening Ctr, Huddersfield, W Yorkshire, England; Guildford Hosp, Huddersfield, W Yorkshire, England; Univ Leeds, Leeds LS2 9JT, W Yorkshire, England; City Hosp, Dept Pathol, Nottingham NG5 1PB, England; Nottingham Breast Screening Unit, Nottingham, England; Univ Oxford, Div Publ Hlth & Primary Hlth Care, Oxford, England; John Radcliffe Hosp, Dept Surg, Oxford OX3 9DU, England; N Staffordshire Royal Infirm, Dept Surg, Stoke On Trent, Staffs, England; N Staffordshire Royal Infirm, Dept Publ Hlth, Stoke On Trent, Staffs, England; Pennine Breast Screening Ctr, Huddersfield, W Yorkshire, England; City Hosp, Dept Surg, Nottingham NG5 1PB, England	University of London; Institute of Cancer Research - UK; University of Dundee; University of Edinburgh; University of Edinburgh; Royal Infirmary of Edinburgh; University of Edinburgh; University of Leeds; University of Nottingham; University of Oxford; University of Oxford; Keele University; University Hospital of North Staffordshire NHS Trust; Keele University; University Hospital of North Staffordshire NHS Trust; University of Nottingham	Moss, SM (corresponding author), Inst Canc Res, Canc Screening Evaluat Unit, Sutton SM2 5NG, Surrey, England.							ALEXANDER F, 1989, J EPIDEMIOL COMMUN H, V43, P29, DOI 10.1136/jech.43.1.29; Alexander FE, 1999, LANCET, V353, P1903, DOI 10.1016/S0140-6736(98)07413-3; Brewster D, 1996, BRIT MED J, V312, P639, DOI 10.1136/bmj.312.7031.639b; CHAMBERLAIN J, 1991, BRIT J CANCER, V64, P1151, DOI 10.1038/bjc.1991.480; CHAMBERLAIN J, 1981, BRIT J CANCER, V44, P618; CHAMBERLAIN J, 1988, LANCET, V2, P411; DEKONING HJ, 1995, JNCI-J NATL CANCER I, V87, P1217; ELLMAN R, 1993, BRIT J CANCER, V68, P208, DOI 10.1038/bjc.1993.315; ELWOOD JM, 1994, ONLINE J CURR C 0331; ELWOOD JM, 1993, ONLINE J CURR C 0225; ELWOOD JM, 1993, ONLINE J CURR L 0305; Hendrick R E, 1997, J Natl Cancer Inst Monogr, P87; Kerlikowske K, 1996, JAMA-J AM MED ASSOC, V276, P33, DOI 10.1001/jama.276.1.33; LARSSON LG, 1997, MONOGR NATL CANC I, V22, P57; MOSS SM, 1993, EUR J CANCER, V29A, P255, DOI 10.1016/0959-8049(93)90187-K; QUINN M, 1995, BMJ-BRIT MED J, V311, P1319; ROBERTS MM, 1984, BRIT J CANCER, V50, P1, DOI 10.1038/bjc.1984.132; SMART CR, 1995, CANCER, V75, P1619, DOI 10.1002/1097-0142(19950401)75:7<1619::AID-CNCR2820750711>3.0.CO;2-T; UK Trial of Early Detection of Breast Cancer Group, 1993, BREAST, V2, P13; WALD NJ, 1994, CLIN ONCOL, V4, P261	20	125	128	0	3	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUN 5	1999	353	9168					1909	1914		10.1016/S0140-6736(98)07412-1	http://dx.doi.org/10.1016/S0140-6736(98)07412-1			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	202TP	10371568				2022-12-28	WOS:000080668500009
J	Bennett, D; Bion, J				Bennett, D; Bion, J			ABC of intensive care - Organisation of intensive care	BRITISH MEDICAL JOURNAL			English	Article									Univ London St Georges Hosp, Sch Med, London SW17 0RE, England; Queen Elizabeth Med Ctr, Birmingham, W Midlands, England	St Georges University London; Birmingham City University; University of Birmingham	Bennett, D (corresponding author), Univ London St Georges Hosp, Sch Med, London SW17 0RE, England.			Bion, Julian/0000-0003-0344-5403					0	28	30	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	MAY 29	1999	318	7196					1468	1470		10.1136/bmj.318.7196.1468	http://dx.doi.org/10.1136/bmj.318.7196.1468			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	202TL	10346777	Green Published			2022-12-28	WOS:000080668200027
J	Bradley, KA; Merrill, JO				Bradley, KA; Merrill, JO			"Doctor, is wine good for my heart?"	LANCET			English	Editorial Material							ALCOHOL-CONSUMPTION; DRINKING; WOMEN; AUDIT; RISK		VA Puget Sound Hlth Care Syst, Hlth Serv Res & Dev & Primary & Specialty Med Car, Seattle, WA 98108 USA; Univ Washington, Dept Med, Seattle, WA 98195 USA; Univ Washington, Dept Hlth Serv, Seattle, WA 98195 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); Vet Affairs Puget Sound Health Care System; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	Bradley, KA (corresponding author), VA Puget Sound Hlth Care Syst, Hlth Serv Res & Dev & Primary & Specialty Med Car, Seattle, WA 98108 USA.							Andreasson S, 1998, ALCOHOL CLIN EXP RES, V22, p359S, DOI 10.1111/j.1530-0277.1998.tb04391.x; Bradley KA, 1998, J GEN INTERN MED, V13, P627, DOI 10.1046/j.1525-1497.1998.cr187.x; Bradley KA, 1998, JAMA-J AM MED ASSOC, V280, P166, DOI 10.1001/jama.280.2.166; Bush K, 1998, ARCH INTERN MED, V158, P1789, DOI 10.1001/archinte.158.16.1789; O'Connor PG, 1998, NEW ENGL J MED, V338, P592, DOI 10.1056/NEJM199802263380907; Rimm EB, 1996, BRIT MED J, V312, P731, DOI 10.1136/bmj.312.7033.731; Samet JH, 1996, ARCH INTERN MED, V156, P2287, DOI 10.1001/archinte.156.20.2287; Volk RJ, 1997, ADDICTION, V92, P197, DOI 10.1046/j.1360-0443.1997.9221978.x; WALLACE P, 1988, BRIT MED J, V297, P663, DOI 10.1136/bmj.297.6649.663	9	6	6	2	5	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAY 29	1999	353	9167					1815	1816		10.1016/S0140-6736(99)90188-5	http://dx.doi.org/10.1016/S0140-6736(99)90188-5			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	202TG	10359402				2022-12-28	WOS:000080667800005
J	Furtado, MR; Callaway, DS; Phair, JP; Kunstman, KJ; Stanton, JL; Macken, CA; Perelson, AS; Wolinsky, SM				Furtado, MR; Callaway, DS; Phair, JP; Kunstman, KJ; Stanton, JL; Macken, CA; Perelson, AS; Wolinsky, SM			Persistence of HIV-1 transcription in peripheral-blood mononuclear cells in patients receiving potent antiretroviral therapy	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; DYNAMICS IN-VIVO; RNA EXPRESSION; LYMPHOID-TISSUES; VIRAL LOAD; INFECTION; LYMPHOCYTES; RESERVOIR; LATENCY; INDIVIDUALS	Background and Methods Although potent antiretroviral therapy can control infection with human immunodeficiency virus type 1 (HIV-1), a long-lived reservoir of infectious virus persists in CD4+ T cells. We investigated this viral reservoir by measuring the levels of cell-associated viral DNA and messenger RNA (mRNA) that are essential for HIV-1 replication. Approximately every 6 months, we obtained samples of peripheral-blood mononuclear cells from five men with long-standing HIV-1 infection who had had undetectable levels of plasma HIV-1 RNA for 20 months or more during treatment with potent antiretroviral drugs. Results Before treatment, plasma levels of HIV-1 RNA correlated with the levels of cell-associated unintegrated HIV-1 DNA and unspliced viral mRNA. After treatment, plasma levels of HIV-1 RNA fell by more than 2.7 log to undetectable levels. The decrease in cell-associated integrated and unintegrated HIV-1 DNA and mRNA occurred in two phases. The first phase occurred during the initial 500 days of treatment and was characterized by substantial decreases in the levels of DNA and mRNA, but not to undetectable levels. The concentrations of cell-associated unintegrated viral DNA, integrated proviral DNA, and unspliced viral mRNA decreased by 1.25 to 1.46 log. The second phase occurred during the subsequent 300 days or more of treatment and was characterized by a plateau in the levels of HIV-1 DNA and unspliced mRNA. After an initial rapid decline, the ratio of unspliced to multiply spliced viral mRNA (a measure of active viral transcription) stabilized and remained greater than zero at each measurement. Conclusions Despite treatment with potent antiretroviral drugs and the suppression of plasma HIV-1 RNA to undetectable levels for 20 months or more, HIV-1 transcription persists in peripheral-blood mononuclear cells. Unless the quasi-steady state levels of HIV DNA and mRNA eventually disappear with longer periods of therapy, these findings suggest that HIV-1 infection cannot be eradicated with current treatments. (N Engl J Med 1999;340:1614-22.) (C) 1999, Massachusetts Medical Society.	Northwestern Univ, Sch Med, Dept Med, Div Infect Dis, Chicago, IL 60611 USA; Northwestern Univ, Sch Med, Dept Pathol, Chicago, IL 60611 USA; Univ Calif Los Alamos Natl Lab, Div Theoret, Los Alamos, NM USA	Northwestern University; Northwestern University; United States Department of Energy (DOE); Los Alamos National Laboratory	Wolinsky, SM (corresponding author), Northwestern Univ, Sch Med, Dept Med, Div Infect Dis, Tarry 3-735,303 E Chicago Ave, Chicago, IL 60611 USA.		Wolinsky, Steven/B-2893-2012; Perelson, Alan S/Z-1959-2019	Perelson, Alan S/0000-0002-2455-0002; Wolinsky, Steven/0000-0002-9625-6697; Callaway, Duncan/0000-0003-3316-9008; Furtado, Manohar/0000-0001-6016-1357	NCRR NIH HHS [RR06555] Funding Source: Medline; NIAID NIH HHS [AI035039] Funding Source: Medline; NICHD NIH HHS [HD37356-01] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD037356] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [R01RR006555] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		Autran B, 1997, SCIENCE, V277, P112, DOI 10.1126/science.277.5322.112; BUKRINSKY MI, 1991, SCIENCE, V254, P423, DOI 10.1126/science.1925601; BUTERA ST, 1994, J VIROL, V68, P2726, DOI 10.1128/JVI.68.4.2726-2730.1994; Cavert W, 1997, SCIENCE, V276, P1321; Cavert W, 1997, SCIENCE, V276, P960, DOI 10.1126/science.276.5314.960; Chun TW, 1997, NATURE, V387, P183, DOI 10.1038/387183a0; Chun TW, 1997, P NATL ACAD SCI USA, V94, P13193, DOI 10.1073/pnas.94.24.13193; CLOUSE KA, 1989, J IMMUNOL, V142, P431; Coffin J, 1997, RETROVIRUSES; COFFIN JM, 1995, SCIENCE, V267, P483, DOI 10.1126/science.7824947; Finzi D, 1997, SCIENCE, V278, P1295, DOI 10.1126/science.278.5341.1295; FURTADO MR, 1995, J VIROL, V69, P2092, DOI 10.1128/JVI.69.4.2092-2100.1995; Haase AT, 1996, SCIENCE, V274, P985, DOI 10.1126/science.274.5289.985; HAMMOND J, 1997, HUMAN RETROVIRUSES A; HO DD, 1995, NATURE, V373, P123, DOI 10.1038/373123a0; KASLOW RA, 1987, AM J EPIDEMIOL, V126, P310, DOI 10.1093/aje/126.2.310; Kepler TB, 1998, P NATL ACAD SCI USA, V95, P11514, DOI 10.1073/pnas.95.20.11514; MCLEAN AR, 1995, P NATL ACAD SCI USA, V92, P3707, DOI 10.1073/pnas.92.9.3707; MICHAEL NL, 1991, J VIROL, V65, P7084, DOI 10.1128/JVI.65.12.7084-.1991; MICHAEL NL, 1991, J VIROL, V65, P1291, DOI 10.1128/JVI.65.3.1291-1303.1991; Notermans DW, 1998, AIDS, V12, P1483, DOI 10.1097/00002030-199812000-00010; Palella FJ, 1998, NEW ENGL J MED, V338, P853, DOI 10.1056/NEJM199803263381301; Perelson AS, 1996, SCIENCE, V271, P1582, DOI 10.1126/science.271.5255.1582; Perelson AS, 1997, NATURE, V387, P188, DOI 10.1038/387188a0; POMERANTZ RJ, 1990, CELL, V61, P1271, DOI 10.1016/0092-8674(90)90691-7; SESHAMMA T, 1992, P NATL ACAD SCI USA, V89, P10663, DOI 10.1073/pnas.89.22.10663; Sokal R. R., 1981, BIOMETRY; Teo I, 1997, J VIROL, V71, P2928, DOI 10.1128/JVI.71.4.2928-2933.1997; WEI XP, 1995, NATURE, V373, P117, DOI 10.1038/373117a0; Wein LM, 1998, J THEOR BIOL, V192, P81, DOI 10.1006/jtbi.1997.0622; Wolinsky SM, 1996, SCIENCE, V272, P537, DOI 10.1126/science.272.5261.537; Wong JK, 1997, SCIENCE, V278, P1291, DOI 10.1126/science.278.5341.1291; ZACK JA, 1990, CELL, V61, P213, DOI 10.1016/0092-8674(90)90802-L; Zhang H, 1998, NEW ENGL J MED, V339, P1803, DOI 10.1056/NEJM199812173392502; Zhang ZQ, 1998, P NATL ACAD SCI USA, V95, P1154, DOI 10.1073/pnas.95.3.1154	35	529	540	0	13	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAY 27	1999	340	21					1614	1622		10.1056/NEJM199905273402102	http://dx.doi.org/10.1056/NEJM199905273402102			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	199QY	10341273				2022-12-28	WOS:000080494200002
J	Platzman, PM; Dykman, MI				Platzman, PM; Dykman, MI			Quantum computing with electrons floating on liquid helium	SCIENCE			English	Article							SURFACE; STATES	A quasi-two-dimensionaI set of electrons (1 < N < 10(9)) in vacuum, trapped in one-dimensional hydrogenic Levels above a micrometer-thick film of liquid helium, is proposed as an easily manipulated strongly interacting set of quantum bits. Individual electrons are laterally confined by micrometer-sized metal pads below the helium. Information is stored in the lowest hydrogenic levels. With electric fields, at temperatures of 10(-2) kelvin, changes in the wave function can be made in nanoseconds. Wave function coherence times are 0.1 millisecond. The wave function is read out with an inverted dc voltage, which releases excited electrons from the surface.	Lucent Technol, Bell Labs, Murray Hill, NJ 07974 USA; Michigan State Univ, Dept Phys & Astron, E Lansing, MI 48824 USA	Alcatel-Lucent; Lucent Technologies; AT&T; Michigan State University	Platzman, PM (corresponding author), Lucent Technol, Bell Labs, Murray Hill, NJ 07974 USA.							ANDREI EY, 1991, 2 DIMENSIONAL ELECT; CIRAC JI, 1995, PHYS REV LETT, V74, P4091, DOI 10.1103/PhysRevLett.74.4091; DYKMAN MI, 1978, PHYS STATUS SOLIDI B, V88, P463, DOI 10.1002/pssb.2220880211; FEYNMAN RP, 1997, FEYNMAN LECT COMPUTA, pCH6; GRIMES CC, 1976, PHYS REV B, V13, P140, DOI 10.1103/PhysRevB.13.140; GRIMES CC, 1979, PHYS REV LETT, V42, P795, DOI 10.1103/PhysRevLett.42.795; Grover LK, 1997, PHYS REV LETT, V79, P325, DOI 10.1103/PhysRevLett.79.325; Kane BE, 1998, NATURE, V393, P133, DOI 10.1038/30156; LANDAU LD, 1977, QUANTUM MECH, P145; LLOYD S, 1995, SCI AM, V273, P140, DOI 10.1038/scientificamerican1095-140; LLOYD S, 1993, SCIENCE, V261, P1569, DOI 10.1126/science.261.5128.1569; Loss D, 1998, PHYS REV A, V57, P120, DOI 10.1103/PhysRevA.57.120; Preskill J, 1998, P ROY SOC A-MATH PHY, V454, P385, DOI 10.1098/rspa.1998.0167; SAVILLE GF, 1993, PHYS REV LETT, V70, P1517, DOI 10.1103/PhysRevLett.70.1517; SHIRAHAMA K, 1995, J LOW TEMP PHYS, V101, P439, DOI 10.1007/BF00753334; Shor P. W., 1994, Proceedings. 35th Annual Symposium on Foundations of Computer Science (Cat. No.94CH35717), P124, DOI 10.1109/SFCS.1994.365700; TURCHETTE QA, 1995, PHYS REV LETT, V75, P4710, DOI 10.1103/PhysRevLett.75.4710	17	277	282	0	29	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 18	1999	284	5422					1967	1969		10.1126/science.284.5422.1967	http://dx.doi.org/10.1126/science.284.5422.1967			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	207JA	10373109				2022-12-28	WOS:000080932700039
J	Will, CL; Schneider, C; Reed, R; Luhrmann, R				Will, CL; Schneider, C; Reed, R; Luhrmann, R			Identification of both shared and distinct proteins in the major and minor spliceosomes	SCIENCE			English	Article							MESSENGER-RNA INTRONS; AT-AC INTRON; BRANCH SITE; U5 SNRNPS; IN-VIVO; COMPLEX; U11	In metazoa ns, two distinct spliceosomes catalyzing pre-messenger RNA splicing have been identified. Here, the human U11/U12 small nuclear ribonucleoprotein (snRNP), a subunit of the minor (U12-dependent) spliceosome, was isolated. Twenty U11/U72 proteins were identified, including subsets unique to the minor spliceosome or common to both spliceosomes. Common proteins include four U2 snRNP polypeptides that constitute the essential splicing factor SF3b. A 35-kilodalton U11-associated protein homologous to the U1 snRNP 70K protein was also identified. These data provide fundamental information about proteins of the minor spliceosome and shed light on its evolutionary relationship to the major spliceosome.	Univ Marburg, Inst Mol Biol & Tumorforsch, D-35037 Marburg, Germany; Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA; Max Planck Inst Biophys Chem, Dept Cellular Biochem, D-37070 Gottingen, Germany	Philipps University Marburg; Harvard University; Harvard Medical School; Max Planck Society	Luhrmann, R (corresponding author), Univ Marburg, Inst Mol Biol & Tumorforsch, Emil Mannkopff Str 2, D-35037 Marburg, Germany.			Schneider, Claudia/0000-0001-5597-2489				Abovich N, 1997, CELL, V89, P403, DOI 10.1016/S0092-8674(00)80221-4; Bedford MT, 1998, P NATL ACAD SCI USA, V95, P10602, DOI 10.1073/pnas.95.18.10602; BEHRENS SE, 1993, MOL CELL BIOL, V13, P307, DOI 10.1128/MCB.13.1.307; Berglund JA, 1997, CELL, V89, P781, DOI 10.1016/S0092-8674(00)80261-5; Burge CB, 1998, MOL CELL, V2, P773, DOI 10.1016/S1097-2765(00)80292-0; Burge CB, 1999, RNA WORLD, P525; CHAMPIONARNAUD P, 1994, GENE DEV, V8, P1974, DOI 10.1101/gad.8.16.1974; Das B., UNPUB; Frilander MJ, 1999, GENE DEV, V13, P851, DOI 10.1101/gad.13.7.851; Gozani O, 1996, GENE DEV, V10, P233, DOI 10.1101/gad.10.2.233; HALL SL, 1994, J MOL BIOL, V239, P357, DOI 10.1006/jmbi.1994.1377; Hall SL, 1996, SCIENCE, V271, P1716, DOI 10.1126/science.271.5256.1716; Kolossova I, 1997, RNA, V3, P227; Kramer A, 1996, ANNU REV BIOCHEM, V65, P367, DOI 10.1146/annurev.biochem.65.1.367; Laggerbauer B, 1996, NUCLEIC ACIDS RES, V24, P868, DOI 10.1093/nar/24.5.868; LAMOND A, 1996, RNA PROCESSING PRACT, P103; NEUGEBAUER KM, 1995, J CELL BIOL, V129, P899, DOI 10.1083/jcb.129.4.899; Reed R, 1996, CURR OPIN GENET DEV, V6, P215, DOI 10.1016/S0959-437X(96)80053-0; Schneider C., UNPUB; Sharp PA, 1997, CELL, V91, P875, DOI 10.1016/S0092-8674(00)80479-1; Tarn WY, 1996, SCIENCE, V273, P1824, DOI 10.1126/science.273.5283.1824; Tarn WY, 1996, CELL, V84, P801, DOI 10.1016/S0092-8674(00)81057-0; Teigelkamp S, 1997, RNA, V3, P1313; Wang CY, 1998, GENE DEV, V12, P1409, DOI 10.1101/gad.12.10.1409; WASSARMAN KM, 1992, MOL CELL BIOL, V12, P1276, DOI 10.1128/MCB.12.3.1276; Will CL, 1997, CURR OPIN CELL BIOL, V9, P320, DOI 10.1016/S0955-0674(97)80003-8; WILL CL, 1997, EUKARYOTIC MRNA PROC, P130; WILL CM, UNPUB; Wu Q, 1996, SCIENCE, V274, P1005, DOI 10.1126/science.274.5289.1005; Yu YT, 1997, P NATL ACAD SCI USA, V94, P6030, DOI 10.1073/pnas.94.12.6030	30	103	107	1	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 18	1999	284	5422					2003	2005		10.1126/science.284.5422.2003	http://dx.doi.org/10.1126/science.284.5422.2003			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	207JA	10373121	Green Submitted			2022-12-28	WOS:000080932700051
J	Wainberg, MA				Wainberg, MA			A new source of resistance to HIV drugs	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							THERAPY; ZIDOVUDINE		McGill Univ, Jewish Gen Hosp, AIDS Ctr, Montreal, PQ H3T 1E2, Canada	McGill University	Wainberg, MA (corresponding author), McGill Univ, Jewish Gen Hosp, AIDS Ctr, Montreal, PQ H3T 1E2, Canada.							BLOOR S, 1998, 2 INT WORKSH HIV DRU; DEJONG JJ, 1998, 2 INT WORKSH HIV DRU; Iversen AKN, 1996, J VIROL, V70, P1086, DOI 10.1128/JVI.70.2.1086-1090.1996; KELLAM P, 1992, P NATL ACAD SCI USA, V89, P1934, DOI 10.1073/pnas.89.5.1934; LARDER BA, 1989, SCIENCE, V243, P1731, DOI 10.1126/science.2467383; Learn GH, 1996, J VIROL, V70, P5720, DOI 10.1128/JVI.70.8.5720-5730.1996; SCHINAZI RF, 1997, INT ANTIVIRAL NEWS, V5, P2; SHIRASAKA T, 1995, P NATL ACAD SCI USA, V92, P2398, DOI 10.1073/pnas.92.6.2398; WHITCOMB JM, 1998, 2 INT WORKSH HIV DRU; Winters MA, 1998, J CLIN INVEST, V102, P1769, DOI 10.1172/JCI4948	10	2	3	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 16	1999	281	23					2169	2170		10.1001/jama.281.23.2169	http://dx.doi.org/10.1001/jama.281.23.2169			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	204RB	10376549				2022-12-28	WOS:000080777000002
J	Beppu, H				Beppu, H			Japan's loss of leadership role in access to drug data	LANCET			English	Editorial Material									Informed Prescriber, Tokyo 1850013, Japan		Beppu, H (corresponding author), Informed Prescriber, 1-43-8-404 Nishikoigakubo, Tokyo 1850013, Japan.							Dong BJ, 1997, JAMA-J AM MED ASSOC, V277, P1205, DOI 10.1001/jama.277.15.1205; *INT SOC DRUG B, 1999, ISDS NEWSLETTER  JUN; Rennie D, 1997, JAMA-J AM MED ASSOC, V277, P1238, DOI 10.1001/jama.277.15.1238; Sykes R, 1998, BRIT MED J, V317, P1172, DOI 10.1136/bmj.317.7167.1172	4	0	0	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUN 12	1999	353	9169					1992	1992		10.1016/S0140-6736(99)00184-1	http://dx.doi.org/10.1016/S0140-6736(99)00184-1			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	205GD	10376612				2022-12-28	WOS:000080812200007
J	Cader, MZ; Winer, JB				Cader, MZ; Winer, JB			Lesson of the week - Cavernous haemangioma mimicking multiple sclerosis	BRITISH MEDICAL JOURNAL			English	Article							ANGIOMA		Queen Elizabeth Hosp, Dept Neurol, Birmingham B15 2TT, W Midlands, England	University of Birmingham	Winer, JB (corresponding author), Queen Elizabeth Hosp, Dept Neurol, Birmingham B15 2TT, W Midlands, England.			Cader, Zameel/0000-0002-6952-406X				CURLING OD, 1991, J NEUROSURG, V75, P702; Honczarenko K, 1995, FOLIA NEUROPATHOL, V33, P251; REQUENA I, 1991, J NEUROL NEUROSUR PS, V54, P590, DOI 10.1136/jnnp.54.7.590; Russell D, 1989, PATHOLOGY TUMOURS NE; STAHL SM, 1980, ARCH NEUROL-CHICAGO, V37, P25, DOI 10.1001/archneur.1980.00500500055007; Vrethem M, 1997, NEW ENGL J MED, V336, P875, DOI 10.1056/NEJM199703203361213	6	10	11	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JUN 12	1999	318	7198					1604	1605		10.1136/bmj.318.7198.1604	http://dx.doi.org/10.1136/bmj.318.7198.1604			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	207AL	10364123	Green Published			2022-12-28	WOS:000080913100033
J	Barnett, HJM; Eliasziw, M; Meldrum, HE				Barnett, HJM; Eliasziw, M; Meldrum, HE			Evidence based cardiology - Prevention of ischaemic stroke	BMJ-BRITISH MEDICAL JOURNAL			English	Review							ASYMPTOMATIC CAROTID STENOSIS; ACUTE ISCHEMIC STROKE; SECONDARY PREVENTION; RANDOMIZED TRIALS; ENDARTERECTOMY; MORTALITY; THERAPY; DISEASE; CAPRIE; ESPS-2		John P Robarts Res Inst, London, ON N6A 5K8, Canada	Western University (University of Western Ontario)	Barnett, HJM (corresponding author), John P Robarts Res Inst, 100 Perth Dr,POB 5015, London, ON N6A 5K8, Canada.	barnett@ni.on.ca						ALTMAN R, 1994, BMJ-BRIT MED J, V308, P81, DOI 10.1136/bmj.308.6921.81; Anderson DC, 1998, JAMA-J AM MED ASSOC, V279, P1273; [Anonymous], 1998, JAMA, V279, P1265; Barnett HJM, 1998, NEW ENGL J MED, V339, P1415, DOI 10.1056/NEJM199811123392002; BARNETT HJM, 1995, NEW ENGL J MED, V333, P460; BARNETT HJM, 1984, STROKE, V15, P941, DOI 10.1161/01.STR.15.6.941; BARNETT HJM, 1995, NEW ENGL J MED, V332, P238, DOI 10.1056/NEJM199501263320408; Barnett HJM, 1996, NEUROLOGY, V46, P603, DOI 10.1212/WNL.46.3.603; BARNETT HJM, 1998, EVIDENCE BASED CARDI, P992; Bennett CL, 1998, ANN INTERN MED, V128, P541, DOI 10.7326/0003-4819-128-7-199804010-00004; Biller J, 1998, STROKE, V29, P554, DOI 10.1161/01.STR.29.2.554; Blackshear JL, 1996, LANCET, V348, P633; Cebul RD, 1998, JAMA-J AM MED ASSOC, V279, P1282, DOI 10.1001/jama.279.16.1282; Chassin MR, 1998, NEW ENGL J MED, V339, P1468, DOI 10.1056/NEJM199811123392010; Davis SM, 1998, CEREBROVASC DIS, V8, P73; Diener HC, 1996, J NEUROL SCI, V143, P1, DOI 10.1016/S0022-510X(96)00308-5; Dyken ML, 1998, CEREBROVASC DIS, V8, P75; EASTCOTT HHG, 1954, LANCET, V2, P994; Elmore JR, 1998, ANN VASC SURG, V12, P156, DOI 10.1007/s100169900134; Enserink M, 1996, SCIENCE, V274, P2004, DOI 10.1126/science.274.5295.2004; Farrell B, 1998, LANCET, V351, P1379, DOI 10.1016/s0140-6736(97)09292-1; Gent M, 1996, LANCET, V348, P1329, DOI 10.1016/s0140-6736(96)09457-3; Gorelick PB, 1998, STROKE, V29, P1737, DOI 10.1161/01.STR.29.8.1737; HAKIM AM, 1983, STROKE, V14, P668; Hebert PR, 1997, JAMA-J AM MED ASSOC, V278, P313, DOI 10.1001/jama.278.4.313; HENNERICI M, 1987, BRAIN, V110, P777, DOI 10.1093/brain/110.3.777; HOBSON RW, 1993, NEW ENGL J MED, V328, P221, DOI 10.1056/NEJM199301283280401; JONAS S, 1998, STROKE CLIN UPDATES, V8, P1; KAY R, 1995, NEW ENGL J MED, V333, P1588, DOI 10.1056/NEJM199512143332402; Kucey DS, 1998, J VASC SURG, V28, P1051, DOI 10.1016/S0741-5214(98)70031-X; MCBRIDE R, 1994, LANCET, V343, P687; MOHR JP, 1995, CEREBROVASC DIS, V5, P156, DOI 10.1159/000107841; Murray CJL, 1997, LANCET, V349, P1269, DOI 10.1016/S0140-6736(96)07493-4; NORRIS JW, 1991, STROKE, V22, P1485, DOI 10.1161/01.STR.22.12.1485; *PREV REV ISCH TRI, 1997, ANN NEUROL, V49, P857; Refsum H, 1998, ANNU REV MED, V49, P31, DOI 10.1146/annurev.med.49.1.31; Sandercock P, 1997, LANCET, V349, P1569; SANDERCOCK PAG, 1993, J NEUROL NEUROSUR PS, V56, P17, DOI 10.1136/jnnp.56.1.17; SHAMOON H, 1993, NEW ENGL J MED, V329, P977, DOI 10.1056/nejm199309303291401; TAYLOR DW, 1991, NEW ENGL J MED, V325, P445; VAITKUS PT, 1992, ARCH INTERN MED, V152, P2020, DOI 10.1001/archinte.152.10.2020; WALKER MD, 1995, JAMA-J AM MED ASSOC, V273, P1421, DOI 10.1001/jama.1995.03520420037035; WARLOW C, 1995, LANCET, V345, P1254, DOI 10.1016/S0140-6736(95)90920-6; Wennberg DE, 1998, JAMA-J AM MED ASSOC, V279, P1278, DOI 10.1001/jama.279.16.1278; WOLF PA, 1997, PRIMER CEREBROVASCUL, P751	45	28	29	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUN 5	1999	318	7197					1539	1543		10.1136/bmj.318.7197.1539	http://dx.doi.org/10.1136/bmj.318.7197.1539			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	204HC	10356014	Green Published			2022-12-28	WOS:000080757300032
J	Clutton-Brock, TH; O'Riain, MJ; Brotherton, PNM; Gaynor, D; Kansky, R; Griffin, AS; Manser, M				Clutton-Brock, TH; O'Riain, MJ; Brotherton, PNM; Gaynor, D; Kansky, R; Griffin, AS; Manser, M			Selfish sentinels in cooperative mammals	SCIENCE			English	Article							FLORIDA SCRUB JAY; SURICATA-SURICATTA; VIGILANCE BEHAVIOR; MEERKATS	Like humans engaged in risky activities, group members of some animal societies take turns acting as sentinels. Explanations of the evolution of sentinel behavior have frequently relied on kin selection or reciprocal altruism, but recent models suggest that guarding may be an individual's optimal activity once its stomach is full if no other animal is on guard. This paper provides support for this Last explanation by showing that, in groups of meerkats (Suricata suricatta), animals guard from safe sites, and solitary individuals as well as group members spend part of their time on guard. Though individuals seldom take successive guarding bouts, there is no regular rota, and the provision of food increases contributions to guarding and reduces the Latency between bouts by the same individual.	Univ Cambridge, Dept Zool, Large Anim Res Grp, Cambridge CB2 3EJ, England; Univ Pretoria, Mammal Res Inst, ZA-0002 Pretoria, South Africa; Univ Edinburgh, Inst Cell Anim & Populat Biol, Edinburgh EH9 3JT, Midlothian, Scotland	University of Cambridge; University of Pretoria; University of Edinburgh	Clutton-Brock, TH (corresponding author), Univ Cambridge, Dept Zool, Large Anim Res Grp, Downing St, Cambridge CB2 3EJ, England.		Griffin, Ashleigh/C-6244-2014	Griffin, Ashleigh/0000-0001-7674-9825; O'Riain, M. Justin/0000-0001-5233-8327				Bednekoff PA, 1997, AM NAT, V150, P373, DOI 10.1086/286070; Clutton-Brock TH, 1998, P ROY SOC B-BIOL SCI, V265, P185, DOI 10.1098/rspb.1998.0281; Clutton-Brock TH, 1999, AFR J ECOL, V37, P69, DOI 10.1046/j.1365-2028.1999.00160.x; CLUTTONBROCK TH, IN PRESS J ANIM ECOL; Doolan SP, 1996, J ZOOL, V239, P697, DOI 10.1111/j.1469-7998.1996.tb05472.x; FERGUSON JWH, 1986, ETHOLOGY, V76, P233; GASTON AJ, 1977, ANIM BEHAV, V25, P828, DOI 10.1016/0003-3472(77)90036-7; GRIFFIN AS, 1999, THESIS U EDINBURGH; HAILMAN JP, 1994, ETHOLOGY, V97, P119; HAMILTON WD, 1964, J THEOR BIOL, V7, P1, DOI [10.1016/0022-5193(64)90038-4, 10.1016/0022-5193(64)90039-6]; Macdonald D. W., 1992, VELVET CLAW; MCGOWAN KJ, 1989, ANIM BEHAV, V37, P1000, DOI 10.1016/0003-3472(89)90144-9; MORAN G, 1984, Z TIERPSYCHOL, V65, P228; RASA OAE, 1987, S AFR J SCI, V83, P587; TRIVERS RL, 1971, Q REV BIOL, V46, P35, DOI 10.1086/406755; Zar J. H., 1996, BIOSTATISTICAL ANAL; [No title captured]	17	289	302	5	257	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 4	1999	284	5420					1640	1644		10.1126/science.284.5420.1640	http://dx.doi.org/10.1126/science.284.5420.1640			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	202TM	10356387				2022-12-28	WOS:000080668300035
J	Nightingale, SL				Nightingale, SL			Hypotension and bedside leukocyte reduction filters	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	News Item									US FDA, Off Hlth Affairs, Rockville, MD 20857 USA	US Food & Drug Administration (FDA)	Nightingale, SL (corresponding author), US FDA, Off Hlth Affairs, Parklawn Bldg,5600 Fishers Ln, Rockville, MD 20857 USA.								0	4	4	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 2	1999	281	21					1978	1978		10.1001/jama.281.21.1978	http://dx.doi.org/10.1001/jama.281.21.1978			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	200NN	10359372				2022-12-28	WOS:000080546700006
J	Sullivan, DH; Sun, S; Walls, RC				Sullivan, DH; Sun, S; Walls, RC			Protein-energy undernutrition among elderly hospitalized patients - A prospective study	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							RESTING METABOLIC-RATE; GERIATRIC-PATIENTS; MALNUTRITION; COMPLICATIONS; POPULATION; NUTRITION; MORBIDITY; EQUATION; ILLNESS	Context Numerous studies have identified strong correlations between the severity of nutritional deficits and an increased risk of subsequent morbid events among the hospitalized elderly, but whether inadequate nutrient intake during hospitalization contributes to such nutritional deficits or the risk of adverse outcomes is not known. Objectives To identify the distribution of average daily nutrient intake among the nonterminally ill hospitalized elderly, ascertain what factors contribute to persistently low intakes, and determine whether the adequacy of nutrient intake correlates with the risk of mortality. Design Prospective cohort study conducted from 1994 to 1997, Setting University-affiliated Department of Veterans Affairs hospital. Patients A total of 497 patients 65 years or older (mean [SD] age, 74 [6] years; 97% male; 86% white) with a length of stay of 4 days or more. Main Outcome Measures Daily in-hospital nutrient intake, in-hospital mortality, and 90-day mortality. Results A total of 102 patients (21%) had an average daily in-hospital nutrient intake of less than 50% of their calculated maintenance energy requirements. Admission illness severity, average length of stay, and admission albumin and prealbumin levels for this low nutrient group did not differ significantly from those of the remaining patients. However, the low nutrient group had lower mean (SD) discharge serum total cholesterol (154 [44] mg/dL [4 {1.1} mmol/L] vs 173 [42] mg/dL [4.5 {1.1} mmol/L]; P = .001), albumin (29.1 [6.7] vs 33.2 [6.1] g/L, P = .001), and prealbumin (162 [69] vs 205 [68] mg/L; P = .001) concentrations and a higher rate of in-hospital mortality (relative risk, 8.0; 95% confidence interval, 2.8-22.6) and 90-day mortality (relative risk, 2.9; 95% confidence interval, 1.4-6.1). Contributing to the problem of inadequate nutrient intake, patients were frequently ordered to have nothing by mouth and were not fed by another route. Neither canned supplements nor nutritional support were used effectively. Conclusions Throughout their hospitalization, many elderly patients were maintained on nutrient intakes far less than their estimated maintenance energy requirements, which may contribute to an increased risk of mortality. Given the difficulties reversing established nutritional deficits in the elderly, greater efforts should be made to prevent the development of such deficits during hospitalization.	Univ Arkansas Med Sci, Cent Arkansas Vet Healthcare Syst, Geriatr Res Educ & Clin Ctr 182LR, Little Rock, AR 72205 USA; Univ Arkansas Med Sci, Dept Med, Div Biometry, Little Rock, AR 72205 USA; Univ Arkansas Med Sci, Donald W Reynolds Dept Geriatr, Little Rock, AR 72205 USA	Geriatric Research Education & Clinical Center; University of Arkansas System; University of Arkansas Medical Sciences; US Department of Veterans Affairs; Veterans Health Administration (VHA); Central Arkansas Veterans Healthcare System; University of Arkansas System; University of Arkansas Medical Sciences; University of Arkansas System; University of Arkansas Medical Sciences	Sullivan, DH (corresponding author), Univ Arkansas Med Sci, Cent Arkansas Vet Healthcare Syst, Geriatr Res Educ & Clin Ctr 182LR, 4300 W 7th St, Little Rock, AR 72205 USA.							ALPERS DH, 1985, MANUAL NUTR THERAPEU; ANDERSON CF, 1984, MAYO CLIN PROC, V59, P477, DOI 10.1016/S0025-6196(12)60437-6; ARCIERO PJ, 1993, METABOLISM, V42, P950, DOI 10.1016/0026-0495(93)90006-A; BADEN AL, 1992, J AM DIET ASSOC, V92, P77; BIENIA R, 1982, J AM GERIATR SOC, V30, P433, DOI 10.1111/j.1532-5415.1982.tb03378.x; BUZBY GP, 1980, AM J SURG, V139, P160, DOI 10.1016/0002-9610(80)90246-9; CHARLSON ME, 1987, J CHRON DIS, V40, P373, DOI 10.1016/0021-9681(87)90171-8; CONSTANS T, 1992, J AM GERIATR SOC, V40, P263, DOI 10.1111/j.1532-5415.1992.tb02080.x; EPSTEIN AM, 1988, NEW ENGL J MED, V318, P1579, DOI 10.1056/NEJM198806163182405; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; HESSOV I, 1977, ACTA CHIR SCAND, V143, P145; Incalzi RA, 1996, ARCH INTERN MED, V156, P425, DOI 10.1001/archinte.156.4.425; Jeejeebhoy KN, 1976, ANN R COL PHYS SURG, V9, P287; JONES EW, 1973, PUBLICATION HRA; KAMATH SK, 1986, J AM DIET ASSOC, V86, P203; KATZ S, 1963, JAMA-J AM MED ASSOC, V185, P914, DOI 10.1001/jama.1963.03060120024016; KLIPSTEINGROBUSCH K, 1995, BRIT J NUTR, V73, P323, DOI 10.1079/BJN19950033; LAWTON MP, 1972, RES PLANNING ACTION, P123; LOCKREM JD, 1991, CLEV CLIN J MED, V58, P477, DOI 10.3949/ccjm.58.6.477; Morley JE, 1997, AM J CLIN NUTR, V66, P760, DOI 10.1093/ajcn/66.4.760; NARAIN P, 1988, J AM GERIATR SOC, V36, P775, DOI 10.1111/j.1532-5415.1988.tb04259.x; PINCHCOFSKY GD, 1985, J AM COLL NUTR, V4, P471, DOI 10.1080/07315724.1985.10720089; POEHLMAN ET, 1992, METABOLISM, V41, P915, DOI 10.1016/0026-0495(92)90177-C; PREVOST EA, 1974, AM J CLIN NUTR, V27, P432; RAMMOHAN M, 1989, J AM DIET ASSOC, V89, P1774; ROZA AM, 1984, AM J CLIN NUTR, V40, P168, DOI 10.1093/ajcn/40.1.168; SANDSTROM B, 1985, HUM NUTR-APPL NUTR, V39A, P87; *SAS I INC, 1990, SAS US GUID STAT VER, V2; SULLIVAN DH, 1995, CLIN GERIATR MED, V11, P661, DOI 10.1016/S0749-0690(18)30264-7; SULLIVAN DH, 1989, JPEN-PARENTER ENTER, V13, P249, DOI 10.1177/0148607189013003249; SULLIVAN DH, 1995, J AM COLL NUTR, V14, P29; TOBIAS AL, 1977, J AM DIET ASSOC, V71, P253; TODD EA, 1984, HUM NUTR-APPL NUTR, V38A, P294; TOMAIOLO PP, 1981, JPEN-PARENTER ENTER, V5, P46, DOI 10.1177/014860718100500146; VOLKERT D, 1992, ANN NUTR METAB, V36, P97, DOI 10.1159/000177704; Yesavage JA, 1983, J PSYCHIATR RES, V17, P31	36	341	353	0	13	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 2	1999	281	21					2013	2019		10.1001/jama.281.21.2013	http://dx.doi.org/10.1001/jama.281.21.2013			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	200NN	10359390	Bronze			2022-12-28	WOS:000080546700031
J	Barsky, AJ; Borus, JF				Barsky, AJ; Borus, JF			Functional somatic syndromes	ANNALS OF INTERNAL MEDICINE			English	Review							CHRONIC-FATIGUE-SYNDROME; IRRITABLE-BOWEL-SYNDROME; RANDOMIZED CONTROLLED TRIAL; TERM FOLLOW-UP; MULTIPLE CHEMICAL SENSITIVITIES; POSTTRAUMATIC-STRESS-DISORDER; COGNITIVE-BEHAVIORAL THERAPY; MASS PSYCHOGENIC ILLNESS; CARE-SEEKING BEHAVIOR; UPPER LIMB PAIN	The term functional somatic syndrome has been applied to several related syndromes characterized more by symptoms, suffering, and disability than by consistently demonstrable tissue abnormality. These syndromes include multiple chemical sensitivity, the sick building syndrome, repetition stress injury, the side effects of silicone breast implants, the Gulf War syndrome, chronic whiplash, the chronic fatigue syndrome, the irritable bowel syndrome, and fibromyalgia. Patients with functional somatic syndromes have explicit and highly elaborated self-diagnoses, and their symptoms are often refractory to reassurance, explanation, and standard treatment of symptoms. They share similar phenomenologies, high rates of co-occurrence, similar epidemiologic characteristics, and higher-than-expected prevalences of psychiatric comorbidity. Although discrete pathophysiologic causes may ultimately be found in some patients with functional somatic syndromes, the suffering of these patients is exacerbated by a self-perpetuating, self-validating cycle in which common, endemic, somatic symptoms are incorrectly attributed to serious abnormality, reinforcing the patient's belief that he or she has a serious disease. Four psychosocial factors propel this cycle of symptom amplification: the belief that one has a serious disease; the expectation that one's condition is likely to worsen; the "sick role," including the effects of litigation and compensation; and the alarming portrayal of the condition as catastrophic and disabling. The climate surrounding functional somatic syndromes includes sensationalized media coverage, profound suspicion of medical expertise and physicians, the mobilization of parties with a vested self-interest in the status of functional somatic syndromes, litigation, and a clinical approach that overemphasizes the biomedical and ignores psychosocial factors. All of these influences exacerbate and perpetuate the somatic distress of patients with functional somatic syndromes, heighten their fears and pessimistic expectations, prolong their disability, and reinforce their sick role. A six-step strategy for helping patients with functional somatic syndromes is presented here.	Brigham & Womens Hosp, Div Psychiat, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital	Barsky, AJ (corresponding author), Brigham & Womens Hosp, Div Psychiat, 75 Francis St, Boston, MA 02115 USA.				NIMH NIH HHS [MH-40487] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH040487] Funding Source: NIH RePORTER	NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		Aaron LA, 1996, ARTHRITIS RHEUM-US, V39, P436, DOI 10.1002/art.1780390311; AFFLECK G, 1994, J PERS SOC PSYCHOL, V66, P329, DOI 10.1037/0022-3514.66.2.329; ALDERMAN MH, 1990, J CLIN EPIDEMIOL, V43, P195, DOI 10.1016/0895-4356(90)90185-R; ALLEN PN, 1994, NEW ENGL J MED, V231, P414; ANDERSON KO, 1985, PSYCHOL BULL, V98, P358, DOI 10.1037/0033-2909.98.2.358; Angell Marcia, 1996, SCI TRIAL CLASH MED; BAKER DB, 1988, ARCH ENVIRON HEALTH, V43, P325; BARSKY AJ, 1995, JAMA-J AM MED ASSOC, V274, P1931, DOI 10.1001/jama.274.24.1931; BARSKY AJ, 1992, PSYCHOSOMATICS, V33, P28, DOI 10.1016/S0033-3182(92)72018-0; BARSKY AJ, 1990, BRIT J PSYCHIAT, V157, P404, DOI 10.1192/bjp.157.3.404; BARSKY AJ, 1988, WORRIED SICK OUR TRO; BEEBE GW, 1975, AM J EPIDEMIOL, V101, P400, DOI 10.1093/oxfordjournals.aje.a112108; Bellamy R, 1997, CLIN ORTHOP RELAT R, P94; BLACK DW, 1990, JAMA-J AM MED ASSOC, V264, P3166, DOI 10.1001/jama.264.24.3166; Black DW, 1996, PSYCHOSOMATICS, V37, P390, DOI 10.1016/S0033-3182(96)71554-2; BLACKWELL B, 1992, PSYCHOTHER PSYCHOSOM, V58, P79, DOI 10.1159/000288614; BLANCHARD EB, 1990, J CONSULT CLIN PSYCH, V58, P210, DOI 10.1037/0022-006X.58.2.210; BLOCK AR, 1980, PAIN, V9, P243, DOI 10.1016/0304-3959(80)90011-1; BOXER PA, 1990, J OCCUP ENVIRON MED, V32, P425, DOI 10.1097/00043764-199005000-00007; BRAVO M, 1990, AM J COMMUN PSYCHOL, V18, P661, DOI 10.1007/BF00931236; BRODSKY CM, 1983, PSYCHOSOMATICS, V24, P731, DOI 10.1016/S0033-3182(83)73168-3; Brown J, 1996, SOC SCI MED, V43, P1685, DOI 10.1016/0277-9536(95)00402-5; BUCHWALD D, 1995, ANN INTERN MED, V123, P81, DOI 10.7326/0003-4819-123-2-199507150-00001; BUCHWALD D, 1994, ARCH INTERN MED, V154, P2049, DOI 10.1001/archinte.154.18.2049; BUCKELEW SP, 1989, AM J PHYS MED REHAB, V68, P37, DOI 10.1097/00002060-198902000-00010; CAMPBELL SM, 1983, ARTHRITIS RHEUM, V26, P817, DOI 10.1002/art.1780260701; Campion EW, 1997, NEW ENGL J MED, V337, P44, DOI 10.1056/NEJM199707033370109; Chester AC, 1997, J PSYCHIAT RES, V31, P51, DOI 10.1016/S0022-3956(96)00054-4; Clark DM, 1998, BRIT J PSYCHIAT, V173, P218, DOI 10.1192/bjp.173.3.218; Clauw DJ, 1997, NEUROIMMUNOMODULAT, V4, P134, DOI 10.1159/000097332; COPE H, 1994, LANCET, V344, P864, DOI 10.1016/S0140-6736(94)92833-9; CRAIG TKJ, 1994, BRIT J PSYCHIAT, V165, P248, DOI 10.1192/bjp.165.2.248; CRISP AH, 1965, BRIT J PSYCHIAT, V111, P841, DOI 10.1192/bjp.111.478.841; CROYLE RT, 1988, J APPL SOC PSYCHOL, V18, P473, DOI 10.1111/j.1559-1816.1988.tb00030.x; CUNNINGHAM LS, 1984, AM J PUBLIC HEALTH, V74, P574, DOI 10.2105/AJPH.74.6.574; DAILEY PA, 1990, J RHEUMATOL, V17, P1380; DAVID AS, 1995, J PSYCHOSOM RES, V39, P1, DOI 10.1016/0022-3999(94)00085-J; Deale A, 1997, AM J PSYCHIAT, V154, P408; DECOUFLE P, 1992, AM J EPIDEMIOL, V135, P312, DOI 10.1093/oxfordjournals.aje.a116285; DEGUIRE S, 1992, AM J CARDIOL, V70, P673, DOI 10.1016/0002-9149(92)90211-G; DEROGATIS LR, 1974, BEHAV SCI, V19, P1, DOI 10.1002/bs.3830190102; DROSSMAN DA, 1982, AM J PSYCHIAT, V139, P1549; DROSSMAN DA, 1988, GASTROENTEROLOGY, V95, P701, DOI 10.1016/S0016-5085(88)80017-9; DROSSMAN DA, 1985, CLIN GASTROENTEROL, V14, P559; Dunnell Karen, 1972, MED TAKERS PRESCRIBE; DWORKIN RH, 1992, J ABNORM PSYCHOL, V101, P200, DOI 10.1037/0021-843X.101.1.200; DWORKIN SF, 1990, ARCH GEN PSYCHIAT, V47, P239; ELKS ML, 1994, MED HYPOTHESES, V43, P151, DOI 10.1016/0306-9877(94)90141-4; Epstein SA, 1999, PSYCHOSOMATICS, V40, P57, DOI 10.1016/S0033-3182(99)71272-7; ESCOBAR JI, 1992, AM J PSYCHIAT, V149, P965; EVANS RW, 1992, NEUROL CLIN, V10, P975, DOI 10.1016/S0733-8619(18)30191-9; Fiedler N, 1996, PSYCHOSOM MED, V58, P38, DOI 10.1097/00006842-199601000-00007; FORD CV, 1983, SOMATIZING DISORDERS; FRENCH MA, 1960, CAN MED ASSOC J, V82, P665; Fukuda K, 1997, J PSYCHIAT RES, V31, P19, DOI 10.1016/S0022-3956(96)00046-5; Fukuda K, 1998, JAMA-J AM MED ASSOC, V280, P981, DOI 10.1001/jama.280.11.981; Fulcher KY, 1997, BRIT MED J, V314, P1647, DOI 10.1136/bmj.314.7095.1647; GOLD D, 1990, JAMA-J AM MED ASSOC, V264, P48, DOI 10.1001/jama.264.1.48; GOLDENBERG D L, 1989, Journal of Rheumatology, V16, P127; GOLDENBERG D L, 1989, Journal of Rheumatology, V16, P12; GOLDENBERG DL, 1987, JAMA-J AM MED ASSOC, V257, P2782, DOI 10.1001/jama.257.20.2782; GOLDENBERG DL, 1995, J RHEUMATOL, V22, P2313; GOLDENBERG DL, 1990, ARTHRITIS RHEUM, V33, P381, DOI 10.1002/art.1780330311; GOTHE CJ, 1995, PSYCHOSOMATICS, V36, P1; GOUGH HG, 1977, MED EDUC, V11, P380, DOI 10.1111/j.1365-2923.1977.tb00636.x; GREENBERG DB, 1990, PSYCHOSOMATICS, V31, P129, DOI 10.1016/S0033-3182(90)72185-8; Gruber AJ, 1996, PSYCHIAT CLIN N AM, V19, P351, DOI 10.1016/S0193-953X(05)70292-6; Hadler NM, 1997, SPINE, V22, P935, DOI 10.1097/00007632-199705010-00001; Hadler NM, 1997, NEW ENGL J MED, V337, P341, DOI 10.1056/NEJM199707313370511; Hadler NM, 1996, SPINE, V21, P2397, DOI 10.1097/00007632-199610150-00021; HALL EM, 1989, J OCCUP ENVIRON MED, V31, P243, DOI 10.1097/00043764-198903000-00010; HALL W, 1988, SOC SCI MED, V27, P645, DOI 10.1016/0277-9536(88)90013-5; HAMMAREN M, 1989, SWED DENT J, V13, P77; Hannay DR., 1979, SYMPTOM ICEBERG STUD; HAYNES RB, 1978, NEW ENGL J MED, V299, P741, DOI 10.1056/NEJM197810052991403; HAZLETT RL, 1992, J BEHAV MED, V15, P541, DOI 10.1007/BF00844855; HELLMAN CJC, 1990, BEHAV MED, V16, P165, DOI 10.1080/08964289.1990.9934605; HICKIE I, 1995, PSYCHOL MED, V25, P925, DOI 10.1017/S0033291700037417; HIGGS PE, 1995, J HAND SURG-AM, V20A, P354, DOI 10.1016/S0363-5023(05)80086-3; Hudson J I, 1989, J Rheumatol Suppl, V19, P15; HUDSON JI, 1985, AM J PSYCHIAT, V142, P441; HUDSON JI, 1992, AM J MED, V92, P363, DOI 10.1016/0002-9343(92)90265-D; Hyams KC, 1998, PSYCHOSOM MED, V60, P137, DOI 10.1097/00006842-199803000-00001; Hyams KC, 1996, ANN INTERN MED, V125, P398, DOI 10.7326/0003-4819-125-5-199609010-00007; IMBODEN JB, 1961, ARCH INTERN MED, V108, P393, DOI 10.1001/archinte.1961.03620090065008; Institute of Medicine, 1996, HLTH CONS SERV PERS; IRELAND DCR, 1988, J HAND SURG-BRIT EUR, V13B, P5, DOI 10.1016/0266-7681(88)90041-1; IRELAND DCR, 1995, J HAND SURG-AM, V20A, pS53, DOI 10.1016/S0363-5023(95)80170-7; JAMISON RN, 1990, BEHAV RES THER, V28, P283, DOI 10.1016/0005-7967(90)90079-X; JAUCHEM JR, 1992, J CLIN EPIDEMIOL, V45, P1137, DOI 10.1016/0895-4356(92)90154-F; JERRETT WA, 1981, PRACTITIONER, V225, P731; Johanning E, 1998, NEW ENGL J MED, V338, P1070; Karlsborg M, 1997, ACTA NEUROL SCAND, V95, P65, DOI 10.1111/j.1600-0404.1997.tb00071.x; KATERNDAHL DA, 1983, FAM MED REV, V1, P26; KATON W, 1992, ARCH INTERN MED, V152, P1604, DOI 10.1001/archinte.152.8.1604; KATON WJ, 1991, J GEN INTERN MED, V6, P277, DOI 10.1007/BF02597420; KEEFE FJ, 1992, J CONSULT CLIN PSYCH, V60, P528, DOI 10.1037/0022-006X.60.4.528; Kellner R., 1986, SOMATIZATION HYPOCHO; Kellner R, 1991, PSYCHOSOMATIC SYNDRO; Kirmayer L. J., 1997, ADULT PSYCHOPATHOLOG, P333; KIRMAYER LJ, 1994, J ABNORM PSYCHOL, V103, P125, DOI 10.1037/0021-843X.103.1.125; Kisely S, 1997, PSYCHOL MED, V27, P1011, DOI 10.1017/S0033291797005485; KOSS MP, 1991, ARCH INTERN MED, V151, P342, DOI 10.1001/archinte.151.2.342; Kouyanou K, 1997, PSYCHOSOM MED, V59, P597, DOI 10.1097/00006842-199711000-00007; Kroenke K, 1994, Arch Fam Med, V3, P774; LARSEN RJ, 1992, J PERS SOC PSYCHOL, V62, P480, DOI 10.1037/0022-3514.62.3.480; LEESHALEY PR, 1992, PERCEPT MOTOR SKILL, V75, P531, DOI 10.2466/PMS.75.5.531-544; LEVINE PH, 1992, ARCH INTERN MED, V152, P1611, DOI 10.1001/archinte.152.8.1611; Lidbeck J, 1997, ACTA PSYCHIAT SCAND, V96, P14, DOI 10.1111/j.1600-0447.1997.tb09899.x; LINTON SJ, 1989, J OCCUP ENVIRON MED, V31, P609, DOI 10.1097/00043764-198907000-00012; LUCIRE Y, 1986, MED J AUSTRALIA, V145, P323, DOI 10.5694/j.1326-5377.1986.tb113838.x; Lucock MP, 1997, BRIT MED J, V315, P572; MAGORA A, 1973, SCAND J REHABIL MED, V5, P191; MANU P, 1989, PSYCHOSOMATICS, V30, P388, DOI 10.1016/S0033-3182(89)72244-1; MANU P, 1988, ANN INTERN MED, V109, P554, DOI 10.7326/0003-4819-109-7-554; MARSHALL PD, 1995, INJURY, V26, P17, DOI 10.1016/0020-1383(95)90546-A; MARTIN PR, 1989, BRIT J CLIN PSYCHOL, V28, P347, DOI 10.1111/j.2044-8260.1989.tb00839.x; Mayou R, 1996, J PSYCHOSOM RES, V40, P461, DOI 10.1016/0022-3999(95)00586-2; Mayou RA, 1997, PSYCHOL MED, V27, P1021, DOI 10.1017/S0033291797005254; McDaniel S.H., 1992, MED FAMILY THERAPY B; MCFARLAND C, 1989, J PERS SOC PSYCHOL, V57, P522, DOI 10.1037/0022-3514.57.3.522; MCFARLANE AC, 1994, J PSYCHOSOM RES, V38, P715, DOI 10.1016/0022-3999(94)90024-8; MECHANIC D, 1978, J HUM STRESS, V4, P26, DOI 10.1080/0097840X.1978.10545983; MENDELOFF AI, 1970, NEW ENGL J MED, V282, P14, DOI 10.1056/NEJM197001012820104; MERSKEY H, 1989, Journal of Rheumatology, V16, P72; MILLER CS, 1994, TOXICOL IND HEALTH, V10, P253; MILLER MH, 1988, J RHEUMATOL, V15, P1705; MITTENBERG W, 1992, J NEUROL NEUROSUR PS, V55, P200, DOI 10.1136/jnnp.55.3.200; MORRISON JD, 1980, J FAM PRACTICE, V10, P795; MYERS MG, 1987, CLIN PHARMACOL THER, V42, P250, DOI 10.1038/clpt.1987.142; Papageorgiou AC, 1997, SPINE, V22, P1137, DOI 10.1097/00007632-199705150-00014; PAWLIKOWSKA T, 1994, BRIT MED J, V308, P763, DOI 10.1136/bmj.308.6931.763; PAYNE A, 1995, J CONSULT CLIN PSYCH, V63, P779, DOI 10.1037/0022-006X.63.5.779; PAYNE TC, 1982, ARTHRITIS RHEUM, V25, P213, DOI 10.1002/art.1780250216; PENNEBAKER JW, 1983, J PERS, V51, P468, DOI 10.1111/j.1467-6494.1983.tb00341.x; PENNEBAKER JW, 1994, TOXICOL IND HEALTH, V10, P497; PENNEBAKER JW, 1991, CURRENT CONCEPTS SOM, P24; PENNEBAKER JW, 1982, PSYCHOL PHSYICAL SYM; PENNIE B, 1991, INJURY, V22, P57, DOI 10.1016/0020-1383(91)90166-C; PETRIE K, 1995, J PSYCHOSOM RES, V39, P31, DOI 10.1016/0022-3999(94)00071-C; POTTS SG, 1993, Q J MED, V86, P583; RADANOV BP, 1995, MEDICINE, V74, P281, DOI 10.1097/00005792-199509000-00005; RAHE RH, 1978, J HUM STRESS, V4, P3, DOI 10.1080/0097840X.1978.9934972; REIDENBERG MM, 1968, NEW ENGL J MED, V279, P678, DOI 10.1056/NEJM196809262791304; ROBBINS PR, 1974, J PERS ASSESS, V38, P578, DOI 10.1080/00223891.1974.10120020; ROBERTSON LS, 1983, J HEALTH POLIT POLIC, V8, P581, DOI 10.1215/03616878-8-3-581; ROHT LH, 1985, AM J EPIDEMIOL, V122, P418, DOI 10.1093/oxfordjournals.aje.a114123; RUSSO J, 1994, PSYCHOSOMATICS, V35, P546, DOI 10.1016/S0033-3182(94)71723-0; RYAN GA, 1988, COMMUNITY HEALTH ST, V12, P63; SALKOVSKIS PM, 1989, COGNITIVE BEHAV THER, P235; SALOVEY P, 1989, J PERS SOC PSYCHOL, V57, P539, DOI 10.1037/0022-3514.57.3.539; SANDLER RS, 1984, GASTROENTEROLOGY, V87, P314; SATEL SL, 1995, NEW ENGL J MED, V333, P794, DOI 10.1056/NEJM199509213331210; Schrader H, 1996, LANCET, V347, P1207, DOI 10.1016/S0140-6736(96)90733-3; Schwartz DA, 1997, JAMA-J AM MED ASSOC, V277, P238, DOI 10.1001/jama.277.3.238; SCHWEIGER A, 1981, PAVLOVIAN J BIOL SCI, V16, P140; SELDEN BS, 1989, ANN EMERG MED, V18, P892, DOI 10.1016/S0196-0644(89)80221-5; SHALEV A, 1990, PSYCHOSOMATICS, V31, P197, DOI 10.1016/S0033-3182(90)72195-0; Sharpe M, 1996, BRIT MED J, V312, P22, DOI 10.1136/bmj.312.7022.22; SHARPE M, 1992, J PSYCHOSOM RES, V36, P515, DOI 10.1016/0022-3999(92)90037-3; Sharpe M, 1995, TREATMENT OF FUNCTIONAL SOMATIC SYMPTOMS, P122; SHORTER E, 1995, J PSYCHOSOM RES, V39, P115, DOI 10.1016/0022-3999(94)00119-P; Shorter E., 1992, PARALYSIS FATIGUE HI; Showalter Elaine, 1997, HYSTORIES HYSTERICAL; SIMON GE, 1990, AM J PSYCHIAT, V147, P901; SIMON GE, 1993, ANN INTERN MED, V119, P97, DOI 10.7326/0003-4819-119-2-199307150-00001; SKINNER JB, 1990, J PSYCHOSOM RES, V34, P13, DOI 10.1016/0022-3999(90)90003-M; Small G W, 1987, Psychiatr Q, V58, P269, DOI 10.1007/BF01064608; SMALL GW, 1991, AM J PSYCHIAT, V148, P1200; Smed A, 1997, ACTA NEUROL SCAND, V95, P73, DOI 10.1111/j.1600-0404.1997.tb00072.x; SOLOMON Z, 1988, BEHAV MED, V14, P179, DOI 10.1080/08964289.1988.9935143; SPAULDING W B, 1964, Appl Ther, V6, P911; SPECKENS AEM, 1995, BRIT MED J, V311, P1328, DOI 10.1136/bmj.311.7016.1328; Sternbach R.A., 1978, HDB PERCEPTION, P231; STEWART DE, 1985, CAN MED ASSOC J, V133, P1001; STEWART DE, 1990, PSYCHOSOMATICS, V31, P153, DOI 10.1016/S0033-3182(90)72188-3; STEWART DE, 1987, CAN FAM PHYSICIAN, V33, P405; STRUEWING JP, 1990, AM J EPIDEMIOL, V132, P1120, DOI 10.1093/oxfordjournals.aje.a115755; Stuart S, 1999, PSYCHOSOMATICS, V40, P34, DOI 10.1016/S0033-3182(99)71269-7; SUAREZ FL, 1995, NEW ENGL J MED, V333, P1, DOI 10.1056/NEJM199507063330101; SUGARMAN JR, 1984, J FAM PRACTICE, V19, P643; TERR AI, 1986, ARCH INTERN MED, V146, P145, DOI 10.1001/archinte.146.1.145; TESSLER R, 1978, J HEALTH SOC BEHAV, V19, P254, DOI 10.2307/2136558; Trimble M. R., 1981, POSTTRAUMATIC NEUROS; Twemlow SW, 1997, PSYCHOL REP, V80, P643, DOI 10.2466/pr0.1997.80.2.643; vanDulmen AM, 1996, PSYCHOSOM MED, V58, P508, DOI 10.1097/00006842-199609000-00013; VERBRUGGE LM, 1987, MED CARE, V25, P539, DOI 10.1097/00005650-198706000-00008; Vercoulen JHMM, 1996, J NEUROL NEUROSUR PS, V60, P489, DOI 10.1136/jnnp.60.5.489; WADSOWRTH ME, 1971, HLTH SICKNESS CHOICE; Walker EA, 1997, PSYCHOSOM MED, V59, P565, DOI 10.1097/00006842-199711000-00002; WALKER EA, 1993, J GEN INTERN MED, V8, P436, DOI 10.1007/BF02599621; WALKER EA, 1990, AM J PSYCHIAT, V147, P1656; WAXLER NE, 1980, RELEVANCE SOCIAL SCI, P283; WAYLONIS GW, 1994, AM J PHYS MED REHABI, V15, P541; Weber BE, 1996, AM J MED, V100, P138, DOI 10.1016/S0002-9343(97)89451-X; WESSELY S, 1990, PSYCHOL MED, V20, P35, DOI 10.1017/S0033291700013210; WESSELY S, 1997, PSYCHOL DISORDERS ME, P82; WHITE KL, 1961, NEW ENGL J MED, V265, P885, DOI 10.1056/NEJM196111022651805; WHITEHEAD WE, 1982, DIGEST DIS SCI, V27, P202, DOI 10.1007/BF01296915; WIELGOSZ AT, 1986, PSYCHOSOM MED, V48, P118, DOI 10.1097/00006842-198601000-00010; WILSON A, 1994, BRIT MED J, V308, P756, DOI 10.1136/bmj.308.6931.756; WOOD GC, 1991, PSYCHOL MED, V21, P619, DOI 10.1017/S003329170002225X; YONTCHEV E, 1992, J ORAL REHABIL, V19, P13, DOI 10.1111/j.1365-2842.1992.tb01586.x; YUNUS M, 1981, SEMIN ARTHRITIS RHEU, V11, P151, DOI 10.1016/0049-0172(81)90096-2	204	594	604	0	60	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 1	1999	130	11					910	921		10.7326/0003-4819-130-11-199906010-00016	http://dx.doi.org/10.7326/0003-4819-130-11-199906010-00016			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	200PB	10375340				2022-12-28	WOS:000080547900006
J	Hamerman, D				Hamerman, D			Toward an understanding of frailty	ANNALS OF INTERNAL MEDICINE			English	Review							FAILURE-TO-THRIVE; NECROSIS-FACTOR-ALPHA; C-REACTIVE PROTEIN; GROWTH-HORMONE; FUNCTIONAL DECLINE; OLDER PERSONS; CARDIOVASCULAR-DISEASE; PHYSICAL-ACTIVITY; PERCEIVED HEALTH; ELDERLY PATIENTS		Albert Einstein Coll Med, Resnick Gerontol Ctr, Bronx, NY 10467 USA	Yeshiva University; Albert Einstein College of Medicine	Hamerman, D (corresponding author), Albert Einstein Coll Med, Resnick Gerontol Ctr, 111 E 210th St, Bronx, NY 10467 USA.							Andersen RE, 1997, ANN INTERN MED, V127, P395, DOI 10.7326/0003-4819-127-5-199709010-00010; Anker SD, 1997, CIRCULATION, V96, P526; Arend WP, 1998, ANNU REV IMMUNOL, V16, P27, DOI 10.1146/annurev.immunol.16.1.27; Ashcroft GS, 1998, LAB INVEST, V78, P47; Auwerx J, 1998, LANCET, V351, P737, DOI 10.1016/S0140-6736(97)06348-4; Ballou SP, 1997, CLIN GERIATR MED, V13, P653; Bartke A, 1998, EXP GERONTOL, V33, P675, DOI 10.1016/S0531-5565(98)00032-1; Barton BE, 1997, CLIN IMMUNOL IMMUNOP, V85, P16, DOI 10.1006/clin.1997.4420; Barzilai N, 1997, J CLIN INVEST, V100, P3105, DOI 10.1172/JCI119865; Beckman KB, 1998, PHYSIOL REV, V78, P547, DOI 10.1152/physrev.1998.78.2.547; Behl C, 1997, CELL TISSUE RES, V290, P471, DOI 10.1007/s004410050955; Bessesen DH, 1998, SEMIN ONCOL, V25, P28; BONNEFOY M, 1995, AGE AGEING, V24, P37, DOI 10.1093/ageing/24.1.37; BORST SE, 1994, J AM GERIATR SOC, V42, P528, DOI 10.1111/j.1532-5415.1994.tb04976.x; Boult C, 1996, AM J PUBLIC HEALTH, V86, P1388, DOI 10.2105/AJPH.86.10.1388; Branch L G, 1987, Clin Geriatr Med, V3, P29; Bristow MR, 1998, CIRCULATION, V97, P1340, DOI 10.1161/01.CIR.97.14.1340; Brody KK, 1997, GERONTOLOGIST, V37, P182, DOI 10.1093/geront/37.2.182; BROWN I, 1995, INT J REHABIL RES, V18, P93, DOI 10.1097/00004356-199506000-00001; Brown K, 1997, BRIT J GEN PRACT, V47, P31; Buchner D M, 1992, Clin Geriatr Med, V8, P1; Bunn PA, 1998, SEMIN ONCOL, V25, P1; Campisi J, 1997, J AM GERIATR SOC, V45, P482, DOI 10.1111/j.1532-5415.1997.tb05175.x; CANNON JG, 1995, J GERONTOL A-BIOL, V50, P120; Caro JF, 1996, DIABETES, V45, P1455, DOI 10.2337/diab.45.11.1455; Casson PR, 1998, ENDOCRINOLOGIST, V8, P187, DOI 10.1097/00019616-199805000-00010; Cauley JA, 1997, ARCH INTERN MED, V157, P2181, DOI 10.1001/archinte.157.19.2181; Cefalu WT, 1998, METABOLISM, V47, P401, DOI 10.1016/S0026-0495(98)90050-6; CLARK LP, 1990, J AM GERIATR SOC, V38, P967, DOI 10.1111/j.1532-5415.1990.tb04417.x; Cohen HJ, 1997, J GERONTOL A-BIOL, V52, pM201, DOI 10.1093/gerona/52A.4.M201; CZAJA SJ, 1993, J GERONTOL, V48, P44, DOI 10.1093/geronj/48.Special_Issue.44; De Blaauw I, 1997, CLIN NUTR, V16, P223, DOI 10.1016/S0261-5614(97)80033-7; Dentino AN, 1999, J AM GERIATR SOC, V47, P6, DOI 10.1111/j.1532-5415.1999.tb01894.x; DIPLOCK AT, 1991, AM J CLIN NUTR, V53, pS189, DOI 10.1093/ajcn/53.1.189Sb; Dutta C, 1997, MUSCLE NERVE, pS5; EGBERT AM, 1993, POSTGRAD MED, V94, P199, DOI 10.1080/00325481.1993.11945740; ERSHLER WB, 1993, J AM GERIATR SOC, V41, P176, DOI 10.1111/j.1532-5415.1993.tb02054.x; EVANS WJ, 1995, J GERONTOL A-BIOL, V50, P5, DOI 10.1093/gerona/50A.Special_Issue.5; Fox KM, 1996, J AM GERIATR SOC, V44, P371, DOI 10.1111/j.1532-5415.1996.tb06404.x; FRETWELL MD, 1994, PRINCIPLES GERIATRIC, P241; Fried Lind P, 1993, AGING MUSCULOSKELETA, P3; Fried LP, 1997, J AM GERIATR SOC, V45, P92, DOI 10.1111/j.1532-5415.1997.tb00986.x; Fried LP, 1994, PRINCIPLES GERIATRIC, P1149; FRIES JF, 1988, PERSPECT BIOL MED, V31, P407; FRISONI GB, 1995, J GERONTOL A-BIOL, V50, pM203, DOI 10.1093/gerona/50A.4.M203; Gealey S G, 1997, J Am Acad Nurse Pract, V9, P505, DOI 10.1111/j.1745-7599.1997.tb01013.x; GHIRON LJ, 1995, J BONE MINER RES, V10, P1844; Gill TM, 1998, ANN INTERN MED, V128, P96, DOI 10.7326/0003-4819-128-2-199801150-00004; Gonski PN, 1997, MED J AUSTRALIA, V167, P421, DOI 10.5694/j.1326-5377.1997.tb126652.x; Granville DJ, 1998, LAB INVEST, V78, P893; GRAYDONALD K, 1995, J AM DIET ASSOC, V95, P538, DOI 10.1016/S0002-8223(95)00147-6; Grunfeld C, 1996, J CLIN INVEST, V97, P2152, DOI 10.1172/JCI118653; Guralnik JM, 1997, MUSCLE NERVE, pS14; GURALNIK JM, 1994, J GERONTOL, V49, pM85, DOI 10.1093/geronj/49.2.M85; HADLEY EC, 1993, J GERONTOL, V48, pR7, DOI 10.1093/geronj/48.Special_Issue.vii; Hamerman D, 1997, ANN RHEUM DIS, V56, P578, DOI 10.1136/ard.56.10.578; HAMERMAN D, 1997, OSTEOARTHRITIS PUBLI, P99; Harrison JF, 1997, J ROY SOC MED, V90, P5, DOI 10.1177/014107689709032S03; Hazzard WR, 1997, WESTERN J MED, V167, P206; Hebert R, 1997, CAN MED ASSOC J, V157, P1037; Hildebrand JK, 1997, J AM GERIATR SOC, V45, P1113, DOI 10.1111/j.1532-5415.1997.tb05976.x; HOCHBERG MC, 1991, J RHEUMATOL, V18, P1438; Holden RJ, 1996, MED HYPOTHESES, V47, P423, DOI 10.1016/S0306-9877(96)90153-X; ISAACS B, 1971, LANCET, V1, P1115; JARRETT PG, 1995, ARCH INTERN MED, V155, P1060, DOI 10.1001/archinte.155.10.1060; JUDGE JO, 1997, OSTEOARTHRITIS PUBLI, P125; Katz IR, 1997, CLIN GERIATR MED, V13, P623; Kim SH, 1997, J AM GERIATR SOC, V45, P420, DOI 10.1111/j.1532-5415.1997.tb05165.x; Kirchgessner TG, 1997, J CLIN INVEST, V100, P2777, DOI 10.1172/JCI119824; Koopman WJ, 1998, ANN INTERN MED, V128, P231, DOI 10.7326/0003-4819-128-3-199802010-00010; Lamberts SWJ, 1997, SCIENCE, V278, P419, DOI 10.1126/science.278.5337.419; Lee IM, 1997, AGING CLIN EXP RES, V9, P2, DOI 10.1007/BF03340123; Li H, 1997, DIABETES, V46, P2035, DOI 10.2337/diabetes.46.12.2035; Lieberman SA, 1997, CLIN GERIATR MED, V13, P671; Lithgow GJ, 1996, SCIENCE, V273, P80, DOI 10.1126/science.273.5271.80; Manton KG, 1997, FASEB J, V11, P923, DOI 10.1096/fasebj.11.12.9337144; MARCUS R, 1995, J GERONTOL A-BIOL, V50, P86; Markson EW, 1997, CLIN GERIATR MED, V13, P639; Matthys P, 1997, NUTRITION, V13, P763, DOI 10.1016/S0899-9007(97)00185-8; Mobbs Charles V., 1996, P234; Moldawer LL, 1997, CANCER-AM CANCER SOC, V79, P1828; Morin CL, 1997, J GERONTOL A-BIOL, V52, pB190, DOI 10.1093/gerona/52A.4.B190; Morley JE, 1997, CLIN GERIATR MED, V13, P685, DOI 10.1016/s0749-0690(18)30144-7; MULROW CD, 1994, J AM GERIATR SOC, V42, P374, DOI 10.1111/j.1532-5415.1994.tb07484.x; Mysliwska J, 1998, MECH AGEING DEV, V100, P313, DOI 10.1016/S0047-6374(97)00154-1; Olshansky S. J., 1997, OSTEOARTHRITIS PUBLI, P15; Orban Z, 1998, HORM METAB RES, V30, P231, DOI 10.1055/s-2007-978872; ORIANDER PR, 1996, LANCET S2, V348, P116; ORY MG, 1993, J AM GERIATR SOC, V41, P283, DOI 10.1111/j.1532-5415.1993.tb06707.x; Ostlund RE, 1996, J CLIN ENDOCR METAB, V81, P3909, DOI 10.1210/jc.81.11.3909; Papanicolaou DA, 1998, ANN INTERN MED, V128, P127, DOI 10.7326/0003-4819-128-2-199801150-00009; PATE RR, 1995, JAMA-J AM MED ASSOC, V273, P402, DOI 10.1001/jama.273.5.402; Powell C, 1997, J ROY SOC MED, V90, P23, DOI 10.1177/014107689709032S07; PUGHHUMPHREYS RGP, 1994, CYTOKINE HDB, P525; Raisz LG, 1997, ANN INTERN MED, V126, P458, DOI 10.7326/0003-4819-126-6-199703150-00007; Ravaglia G, 1996, J CLIN ENDOCR METAB, V81, P1173, DOI 10.1210/jc.81.3.1173; Resnick NM, 1997, LANCET, V350, P1157, DOI 10.1016/S0140-6736(05)63817-2; Reuben DB, 1998, ANN INTERN MED, V128, P138, DOI 10.7326/0003-4819-128-2-199801150-00010; Richards CD, 1995, HUMAN CYTOKINES THEI, P253; Ridker PM, 1998, CIRCULATION, V97, P2007, DOI 10.1161/01.CIR.97.20.2007; Ritchie CS, 1997, AM J CLIN NUTR, V66, P815, DOI 10.1093/ajcn/66.4.815; ROCKWOOD K, 1994, CAN MED ASSOC J, V150, P489; Rockwood K, 1997, CAN MED ASSOC J, V157, P1081; Rosenthal AJ, 1998, J GERONTOL A-BIOL, V53, pM81, DOI 10.1093/gerona/53A.2.M81; Roses AD, 1997, ARCH NEUROL-CHICAGO, V54, P1226, DOI 10.1001/archneur.1997.00550220036011; Rothwell N, 1997, J CLIN INVEST, V100, P2648, DOI 10.1172/JCI119808; Roubenoff R, 1997, J NUTR, V127, pS1014, DOI 10.1093/jn/127.5.1014S; Roubenoff R, 1997, CLIN GERIATR MED, V13, P613; Rowe JW, 1997, GERONTOLOGIST, V37, P433, DOI 10.1093/geront/37.4.433; Rowe JW, 1997, SCIENCE, V278, P367, DOI 10.1126/science.278.5337.367; RUBENSTEIN LZ, 1987, J AM GERIATR SOC, V35, P829, DOI 10.1111/j.1532-5415.1987.tb06365.x; RUBENSTEIN LZ, 1984, NEW ENGL J MED, V311, P1664, DOI 10.1056/NEJM198412273112604; Sarkisian CA, 1996, ANN INTERN MED, V124, P1072, DOI 10.7326/0003-4819-124-12-199606150-00008; SCHULZ R, 1993, J GERONTOL, V48, P39, DOI 10.1093/geronj/48.Special_Issue.39; Seeman TE, 1997, ARCH INTERN MED, V157, P2259; SEEMAN TE, 1994, ENDOCR REV, V15, P233, DOI 10.1210/er.15.2.233; SHETTY KR, 1993, MUSCULOSKELETAL SOFT-TISSUE AGING: IMPACT ON MOBILITY, P61; Spector TD, 1997, ARTHRITIS RHEUM, V40, P723, DOI 10.1002/art.1780400419; SPEECHLEY M, 1991, J AM GERIATR SOC, V39, P46, DOI 10.1111/j.1532-5415.1991.tb05905.x; SRIDHAR MK, 1995, LANCET, V345, P1190, DOI 10.1016/S0140-6736(95)91984-8; Sternberg EM, 1997, J CLIN INVEST, V100, P2641, DOI 10.1172/JCI119807; Strawbridge WJ, 1998, J GERONTOL B-PSYCHOL, V53, pS9, DOI 10.1093/geronb/53B.1.S9; Streckfus CF, 1997, J GERONTOL A-BIOL, V52, pM343, DOI 10.1093/gerona/52A.6.M343; Suzman Richard, 1992, P3; Toogood AA, 1996, J CLIN ENDOCR METAB, V81, P460, DOI 10.1210/jc.81.2.460; Tracy RP, 1997, ARTERIOSCL THROM VAS, V17, P1121, DOI 10.1161/01.ATV.17.6.1121; Tritos NA, 1998, AM J MED, V105, P44, DOI 10.1016/S0002-9343(98)00135-1; TSENG BS, 1995, J GERONTOL A-BIOL, V50, P113; vanWeel C, 1997, LANCET, V350, P1159, DOI 10.1016/S0140-6736(97)08312-8; VERBRUGGE LM, 1984, MILBANK FUND Q, V62, P475, DOI 10.2307/3349861; Verdery RB, 1996, J AM GERIATR SOC, V44, P465, DOI 10.1111/j.1532-5415.1996.tb06420.x; Verdery RB, 1997, J GERONTOL A-BIOL, V52, pM333, DOI 10.1093/gerona/52A.6.M333; VERDERY RB, 1994, PRINCIPLES GERIATRIC, P1205; Vita AJ, 1998, NEW ENGL J MED, V338, P1035, DOI 10.1056/NEJM199804093381506; Wagner EH, 1997, WESTERN J MED, V167, P295; WALLACE JI, 1995, J AM GERIATR SOC, V43, P329, DOI 10.1111/j.1532-5415.1995.tb05803.x; Weindruch R, 1997, NEW ENGL J MED, V337, P986, DOI 10.1056/NEJM199710023371407; WILLIAMSON J, 1964, LANCET, V1, P1117; Williamson JD, 1997, MUSCLE NERVE, pS21; WINOGRAD CH, 1991, J AM GERIATR SOC, V39, P778, DOI 10.1111/j.1532-5415.1991.tb02700.x	140	296	309	0	18	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 1	1999	130	11					945	950		10.7326/0003-4819-130-11-199906010-00022	http://dx.doi.org/10.7326/0003-4819-130-11-199906010-00022			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	200PB	10375351				2022-12-28	WOS:000080547900020
J	Dunn, D; Wallon, M; Peyron, F; Petersen, E; Peckham, C; Gilbert, R				Dunn, D; Wallon, M; Peyron, F; Petersen, E; Peckham, C; Gilbert, R			Mother-to-child transmission of toxoplasmosis: risk estimates for clinical counselling	LANCET			English	Article							CONGENITAL TOXOPLASMOSIS; FOLLOW-UP; PREGNANCY; INFECTION; DIAGNOSIS; PREVENTION; INFANTS; WOMEN; AIDS	Background. Women who acquire toxoplasmosis infection during pregnancy (in most cases detected through serological screening) require counselling about the risk of congenital infection and its clinical sequelae, Reliable estimates of risk are not currently available, We undertook an analysis of data from women referred to the toxoplasmosis reference laboratory, Lyon, France, between 1987 and 1995. Methods. Information was collected from clinical notes kept at the laboratory and, where necessary, from the relevant obstetrician or paediatrician via telephone. Methods were developed to derive estimates of the risk of congenital toxoplasmosis by exact duration of gestation at maternal seroconversion. Findings. We analysed obstetric and paediatric data on 603 confirmed maternal toxoplasmosis infections. At least 564 women received antiparasitic drugs according to a standard protocol. Congenital infection status was ascertained in 554 cases, and infected children were followed-up for a median of 54 months. The overall maternal-fetal transmission rate was 29% (95% CI 25-33), which masked a sharp increase in risk with duration of gestation from 6% at 13 weeks to 72% at 36 weeks. However, fetuses infected in early pregnancy were much more likely to show clinical signs of infection. These effects counterbalance, and women who seroconverted at 24-30 weeks of gestation carried the highest risk (10%) of having a congenitally infected child with early clinical signs who was thus at risk of long-term complications. Interpretation. This information will assist the clinical counselling of pregnant women diagnosed with acute toxoplasmosis and may guide individual decisions on investigative and therapeutic options. Further studies are required to determine the long-term risks of clinical symptoms and disability due to congenital toxoplasmosis.	UCL, Sch Med, Inst Child Hlth, Dept Epidemiol & Publ Hlth, London WC1N 1EH, England; Hop Croix Rousse, Lab Parasitol & Pathol Exot, F-69317 Lyon, France; Statens Serum Inst, Parasitol Lab, DK-2300 Copenhagen, Denmark	University of London; University College London; UCL Medical School; CHU Lyon; Statens Serum Institut	Gilbert, R (corresponding author), UCL, Sch Med, Inst Child Hlth, Dept Epidemiol & Publ Hlth, London WC1N 1EH, England.	r.gilbert@ich.ucl.ac.uki	Wallon, martine/D-1340-2013; peckham, catherine s/I-6300-2013	Wallon, martine/0000-0001-8285-8550; Gilbert, Ruth/0000-0001-9347-2709; Dunn, David/0000-0003-1836-4446	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ADES AE, 1991, EPIDEMIOL INFECT, V107, P527, DOI 10.1017/S0950268800049220; BACCHETTI P, 1990, J AM STAT ASSOC, V85, P1002, DOI 10.2307/2289596; BERREBI A, 1994, LANCET, V344, P36, DOI 10.1016/S0140-6736(94)91054-5; COUVREUR J, 1985, SEM HOP PARIS, V61, P3015; COZON G, 1993, CYTOMETRY, V14, P569, DOI 10.1002/cyto.990140518; DAFFOS F, 1988, NEW ENGL J MED, V318, P271, DOI 10.1056/NEJM198802043180502; DEGRUTTOLA V, 1989, BIOMETRICS, V45, P1; DESMONTS G, 1984, ANN PEDIATR-PARIS, V31, P805; Desmonts G., 1982, LYON MED, V248, P115; GILBERT RE, 1995, BRIT MED J, V310, P1037, DOI 10.1136/bmj.310.6986.1037; GUERINA NG, 1994, NEW ENGL J MED, V330, P1858, DOI 10.1056/NEJM199406303302604; HALL SM, 1992, BMJ-BRIT MED J, V305, P291, DOI 10.1136/bmj.305.6848.291; HINKLEY DV, 1991, J ROYAL STAT SOC B, V10, P1753; HOHLFELD P, 1989, J PEDIATR-US, V115, P765, DOI 10.1016/S0022-3476(89)80660-2; HOHLFELD P, 1994, NEW ENGL J MED, V331, P695, DOI 10.1056/NEJM199409153311102; JEANNEL D, 1990, LANCET, V336, P359, DOI 10.1016/0140-6736(90)91890-M; KOPPE JG, 1989, INT OPHTHALMOL, V13, P387, DOI 10.1007/BF02306486; MCAULEY J, 1994, CLIN INFECT DIS, V18, P38, DOI 10.1093/clinids/18.1.38; *NUM ALG GROUP, 1990, NAG FORTR LIB MAN MA; Peyron F, 1996, NEW ENGL J MED, V334, P993, DOI 10.1056/NEJM199604113341517; PONS JC, 1995, PRESSE MED, V24, P179; PRATLONG F, 1994, PRENATAL DIAG, V14, P191, DOI 10.1002/pd.1970140309; RAEBER PA, 1995, SCHWEIZ MED WSCHR, V125, pS96; Remington JS., 1995, INFECT DIS FETUS NEW, V4, P140; ROIZEN N, 1995, PEDIATRICS, V95, P11; THULLIEZ P, 1992, SCAND J INFECT DIS, P43	26	390	428	1	25	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	MAY 29	1999	353	9167					1829	1833		10.1016/S0140-6736(98)08220-8	http://dx.doi.org/10.1016/S0140-6736(98)08220-8			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	202TG	10359407				2022-12-28	WOS:000080667800011
J	Perutz, MF				Perutz, MF			Will biomedicine outgrow support?	NATURE			English	Editorial Material									MRC, Mol Biol Lab, Cambridge CB2 2QH, England	MRC Laboratory Molecular Biology	Perutz, MF (corresponding author), MRC, Mol Biol Lab, Hills Rd, Cambridge CB2 2QH, England.								0	12	11	0	1	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAY 27	1999	399	6734					299	301		10.1038/20538	http://dx.doi.org/10.1038/20538			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	200PA	10360567				2022-12-28	WOS:000080547800031
J	Shaneyfelt, TM; Mayo-Smith, MF; Rothwangl, J				Shaneyfelt, TM; Mayo-Smith, MF; Rothwangl, J			Are guidelines following guidelines? The methodological quality of clinical practice guidelines in the peer-reviewed medical literature	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							SYSTEMATIC REVIEWS; HEALTH-CARE; SERVICES; TRIALS	Context Practice guidelines play an important role in medicine. Methodological principles have been formulated to guide their development. Objective To determine whether practice guidelines in peer-reviewed medical literature adhered to established methodological standards for practice guidelines, Design Structured review of guidelines published from 1985 through June 1997 identified by a MEDLINE search. Main Outcome Measures Mean number of standards met based on a 25-item instrument and frequency of adherence, Results We evaluated 279 guidelines, published from 1985 through June 1997, produced by 69 different developers. Mean overall adherence to standards by each guideline was 43.1% (10.77/25), Mean (SD) adherence to methodological standards on guideline development and format was 51.1% (25.3%); on identification and summary of evidence, 33.6% (29.9%); and on the formulation of recommendations, 46% (45%). Mean adherence to standards by each guideline improved from 36.9% (9.2/25) in 1985 to 50.4% (12.6/25) in 1997 (P<.001). However, there was little improvement over time in adherence to standards on identification and summary of evidence from 34.6% prior to 1990 to 36.1% after 1995 (P = .11), There was no difference in the mean number of standards satisfied by guidelines produced by subspecialty medical societies, general medical societies, or government agencies (P = .55). Guideline length was positively correlated with adherence to methodological standards (P = .001). Conclusion Guidelines published in the peer-reviewed medical literature during the past decade do not adhere well to established methodological standards. While all areas of guideline development need improvement, greatest improvement is needed in the identification, evaluation, and synthesis of the scientific evidence.	Harvard Univ, Beth Israel Deaconess Med Ctr, Div Gen Internal Med, Dept Med, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Med, Boston, MA 02115 USA; Vet Affairs Med Ctr, Ambulatory Care Serv, Manchester, NH USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School; US Department of Veterans Affairs; Veterans Health Administration (VHA)	Shaneyfelt, TM (corresponding author), Univ Alabama, Div Gen Internal Med, 621 Med Educ Bldg,1813 6th Ave S, Birmingham, AL 35294 USA.							*AG HLTH CAR POL R, 1997, RES ACTIV, V205, P16; *AM MED ASS, 1990, ATTR GUID DEV EV PRA; *AM MED ASS, 1995, DIR PRACT PAR 1995; [Anonymous], 1992, MANUAL ASSESSING HLT; Begg C, 1996, JAMA-J AM MED ASSOC, V276, P637, DOI 10.1001/jama.276.8.637; Berg AO, 1997, J GEN INTERN MED, V12, pS25, DOI 10.1046/j.1525-1497.12.s2.4.x; *CAN MED ASS, 1993, QUAL CAR PROGR GUID; Chalmers I, 1995, SYSTEMATIC REV; CHASSIN MR, 1987, JAMA-J AM MED ASSOC, V258, P2533, DOI 10.1001/jama.258.18.2533; CHASSIN MR, 1986, NEW ENGL J MED, V314, P285, DOI 10.1056/NEJM198601303140505; Coley CM, 1997, ANN INTERN MED, V126, P480; *COMM ADV PUBL HLT, 1990, CLIN PRACT GUID DIR; Cook DJ, 1997, ANN INTERN MED, V127, P210, DOI 10.7326/0003-4819-127-3-199708010-00006; COOK DJ, 1995, J CLIN EPIDEMIOL, V48, P167, DOI 10.1016/0895-4356(94)00172-M; Counsell C, 1997, ANN INTERN MED, V127, P380, DOI 10.7326/0003-4819-127-5-199709010-00008; Gordis L, 1997, J NATL CANCER I, V89, P1015, DOI 10.1093/jnci/89.14.1015; Hayward R S, 1993, Ann Intern Med, V118, P731; HAYWARD RSA, 1995, JAMA-J AM MED ASSOC, V274, P570, DOI 10.1001/jama.274.7.570; HLATKY MA, 1995, JAMA-J AM MED ASSOC, V273, P1219, DOI 10.1001/jama.273.15.1219; LANDIS JR, 1977, BIOMETRICS, V33, P159, DOI 10.2307/2529310; Leitch AM, 1997, CA-CANCER J CLIN, V47, P150, DOI 10.3322/canjclin.47.3.150; LEWIS CE, 1969, NEW ENGL J MED, V281, P880, DOI 10.1056/NEJM196910162811606; Meade MO, 1997, ANN INTERN MED, V127, P531, DOI 10.7326/0003-4819-127-7-199710010-00005; OXMAN AD, 1993, ANN NY ACAD SCI, V703, P125, DOI 10.1111/j.1749-6632.1993.tb26342.x; ROOS NP, 1984, AM J PUBLIC HEALTH, V74, P327, DOI 10.2105/AJPH.74.4.327; STOCKWELL H, 1979, MED CARE, V17, P390, DOI 10.1097/00005650-197904000-00007; US Preventive Services Task Force, 1996, GUID CLIN PREV SERV, P18; WENNBERG J, 1973, SCIENCE, V182, P1102, DOI 10.1126/science.182.4117.1102; WOOLF SH, 1990, ARCH INTERN MED, V150, P1811, DOI 10.1001/archinte.150.9.1811; Woolf SH, 1996, MANUAL CONDUCTING SY; WOOLF SH, 1991, AHCPR PUBLICATION	31	593	626	0	15	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 26	1999	281	20					1900	1905		10.1001/jama.281.20.1900	http://dx.doi.org/10.1001/jama.281.20.1900			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	198ME	10349893	Bronze			2022-12-28	WOS:000080427300029
J	Wei, J; Buriak, JM; Siuzdak, G				Wei, J; Buriak, JM; Siuzdak, G			Desorption-ionization mass spectrometry on porous silicon	NATURE			English	Article							LASER; LUMINESCENCE; FABRICATION; MOLECULES; CHEMISTRY; WAFERS	Desorption mass spectrometry has undergone significant improvements since the original experiments were performed more than 90 years ago(1). The most dramatic change occurred in the early 1980s with the introduction of an organic matrix(2-4) to transfer energy to the analyte. This reduces ion fragmentation but also introduces background ions from the matrix. Here we describe a matrix-free strategy for biomolecular mass spectrometry based on pulsed-laser desorption-ionization from a porous silicon(5) surface. Our method uses porous silicon to trap analytes deposited on the surface, and laser irradiation to vaporize and ionize them. We show that the method works at femtomole and attomole levels of analyte, and induces little or no fragmentation, in contrast to what is typically observed with other such approaches(6-11). The ability to perform these measurements without a matrix(3,4,12,13) also makes it more amenable to small-molecule analysis. Chemical(14) and structural(15) modification of the porous silicon has enabled optimization of the ionization characteristics of the surface. Our technique offers good sensitivity as well as compatibility with silicon-based microfluidics and microchip technologies.	Purdue Univ, Dept Chem, W Lafayette, IN 47907 USA; Scripps Res Inst, Dept Mol Biol, La Jolla, CA 92037 USA; Scripps Res Inst, Dept Chem, La Jolla, CA 92037 USA	Purdue University System; Purdue University; Purdue University West Lafayette Campus; Scripps Research Institute; Scripps Research Institute	Buriak, JM (corresponding author), Purdue Univ, Dept Chem, W Lafayette, IN 47907 USA.	buriak@purdue.edu; siuzdak@scripps.edu		Siuzdak, Gary/0000-0002-4749-0014; Buriak, Jillian Mary/0000-0002-9567-4328				BARBER M, 1981, NATURE, V293, P270, DOI 10.1038/293270a0; Buriak JM, 1998, J AM CHEM SOC, V120, P1339, DOI 10.1021/ja9740125; Canham L.T., 1997, PROPERTIES POROUS SI, P83; CANHAM LT, 1990, APPL PHYS LETT, V57, P1046, DOI 10.1063/1.103561; CANHAM LT, 1997, PROPERTIES POROUS SI, P44; CANHAM LT, 1997, PROPERTIES POROUS SI, P154; Cullis AG, 1997, J APPL PHYS, V82, P909, DOI 10.1063/1.366536; DOAN VV, 1992, APPL PHYS LETT, V60, P619, DOI 10.1063/1.106572; Hillenkamp F, 1991, Anal Chem, V63, p1193A, DOI 10.1021/ac00024a002; HRUBOWCHAK DM, 1991, ANAL CHEM, V63, P1947, DOI 10.1021/ac00018a010; KARAS M, 1988, ANAL CHEM, V60, P2299, DOI 10.1021/ac00171a028; Knochenmuss R, 1996, RAPID COMMUN MASS SP, V10, P871, DOI 10.1002/(SICI)1097-0231(19960610)10:8<871::AID-RCM559>3.0.CO;2-R; LIDGARD R, 1995, RAPID COMMUN MASS SP, V9, P128, DOI 10.1002/rcm.1290090205; MACFARLANE RD, 1976, SCIENCE, V191, P920, DOI 10.1126/science.1251202; ODonnell MJ, 1997, ANAL CHEM, V69, P2438, DOI 10.1021/ac961007v; POSTHUMUS MA, 1978, ANAL CHEM, V50, P985, DOI 10.1021/ac50029a040; Rudenauer H.W, 1987, SECONDARY ION MASS S, P1227; Sailor MJ, 1997, ADV MATER, V9, P783, DOI 10.1002/adma.19970091004; Schmuki P, 1998, PHYS REV LETT, V80, P4060, DOI 10.1103/PhysRevLett.80.4060; Stewart MP, 1998, ANGEW CHEM INT EDIT, V37, P3257, DOI 10.1002/(SICI)1521-3773(19981217)37:23<3257::AID-ANIE3257>3.0.CO;2-1; Thomson JJ, 1910, PHILOS MAG, V20, P752, DOI 10.1080/14786441008636962; VARAKIN VN, 1994, HIGH ENERG CHEM+, V28, P406; Wang SL, 1996, APPL SURF SCI, V93, P205, DOI 10.1016/0169-4332(95)00370-3; Zenobi R, 1997, CHIMIA, V51, P801; Zhan Q, 1997, J AM SOC MASS SPECTR, V8, P525, DOI 10.1016/S1044-0305(97)00005-6; [No title captured]; [No title captured]; [No title captured]; [No title captured]	29	926	981	4	237	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAY 20	1999	399	6733					243	246		10.1038/20400	http://dx.doi.org/10.1038/20400			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	198MF	10353246				2022-12-28	WOS:000080427400050
J	Duff, C				Duff, C			These people are like you and me	BRITISH MEDICAL JOURNAL			English	Editorial Material																			0	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JUN 19	1999	318	7199					1707	1707		10.1136/bmj.318.7199.1707	http://dx.doi.org/10.1136/bmj.318.7199.1707			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	210KY	10373200	Green Published			2022-12-28	WOS:000081105600073
J	Shelly, MP; Nightingale, P				Shelly, MP; Nightingale, P			ABC of intensive care - Respiratory support	BRITISH MEDICAL JOURNAL			English	Article									Withington Hosp, Manchester M20 8LR, Lancs, England		Shelly, MP (corresponding author), Withington Hosp, Manchester M20 8LR, Lancs, England.								0	17	18	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JUN 19	1999	318	7199					1674	1677		10.1136/bmj.318.7199.1674	http://dx.doi.org/10.1136/bmj.318.7199.1674			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	210KY	10373174	Green Published			2022-12-28	WOS:000081105600032
J	Jung, JN; Zheng, MH; Goldfarb, M; Zaret, KS				Jung, JN; Zheng, MH; Goldfarb, M; Zaret, KS			Initiation of mammalian liver development from endoderm by fibroblast growth factors	SCIENCE			English	Article							EMBRYONIC MOUSE LUNG; HEART TUBE FORMATION; TRANSCRIPTION FACTOR; ALPHA-FETOPROTEIN; GENE-EXPRESSION; MICE LACKING; HEPATOCYTE DIFFERENTIATION; BRANCHING MORPHOGENESIS; PANCREATIC MESENCHYME; VENTRAL MORPHOGENESIS	The signaling molecules that elicit embryonic induction of the liver from the mammalian gut endoderm or induction of other gut-derived organs are unknown. Close proximity of cardiac mesoderm, which expresses fibroblast growth factors (FGFs) 1, 2, and 8, causes the foregut endoderm to develop into the liver. Treatment of isolated foregut endoderm from mouse embryos with FGF1 or FGF2, but not FGF8, was sufficient to replace cardiac mesoderm as an inducer of the Liver gene expression program, the latter being the first step of hepatogenesis. The hepatogenic; response was restricted to endoderm tissue, which selectively coexpresses FGF receptors 1 and 4. Further studies with FGFs and their specific inhibitors showed that FGF8 contributes to the morphogenetic outgrowth of the hepatic endoderm. Thus, different FGF signals appear to initiate distinct phases of liver development during mammalian organogenesis.	Brown Univ, Dept Mol Biol Cell Biol & Biochem, Providence, RI 02912 USA; CUNY Mt Sinai Sch Med, Brookdale Ctr Mol Biol, New York, NY 10029 USA	Brown University; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai	Zaret, KS (corresponding author), Brown Univ, Dept Mol Biol Cell Biol & Biochem, Box G-J363, Providence, RI 02912 USA.				NIGMS NIH HHS [GM36477] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM036477, R37GM036477] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ahlgren U, 1996, DEVELOPMENT, V122, P1409; Ahlgren U, 1997, NATURE, V385, P257, DOI 10.1038/385257a0; AMAYA E, 1991, CELL, V66, P257, DOI 10.1016/0092-8674(91)90616-7; ANG SL, 1994, CELL, V78, P561, DOI 10.1016/0092-8674(94)90522-3; BEG AA, 1995, NATURE, V376, P167, DOI 10.1038/376167a0; Bellusci S, 1997, DEVELOPMENT, V124, P4867; Bikfalvi A, 1997, ENDOCR REV, V18, P26, DOI 10.1210/er.18.1.26; BLADT F, 1995, NATURE, V376, P768, DOI 10.1038/376768a0; Cardoso WV, 1997, DEV DYNAM, V208, P398, DOI 10.1002/(SICI)1097-0177(199703)208:3<398::AID-AJA10>3.0.CO;2-X; CASCIO S, 1991, DEVELOPMENT, V113, P217; Celli G, 1998, EMBO J, V17, P1642, DOI 10.1093/emboj/17.6.1642; CHEN WS, 1994, GENE DEV, V8, P2466, DOI 10.1101/gad.8.20.2466; Crossley PH, 1996, CELL, V84, P127, DOI 10.1016/S0092-8674(00)80999-X; CROSSLEY PH, 1995, DEVELOPMENT, V121, P439; DIONNE CA, 1990, EMBO J, V9, P2685, DOI 10.1002/j.1460-2075.1990.tb07454.x; Dono R, 1998, EMBO J, V17, P4213, DOI 10.1093/emboj/17.15.4213; Dufort D, 1998, DEVELOPMENT, V125, P3015; Ericson J, 1998, DEVELOPMENT, V125, P1005; FUKUDATAIRA S, 1981, J EMBRYOL EXP MORPH, V63, P111; GITTES GK, 1992, P NATL ACAD SCI USA, V89, P1128, DOI 10.1073/pnas.89.3.1128; GREEN JBA, 1992, CELL, V71, P731, DOI 10.1016/0092-8674(92)90550-V; Gualdi R, 1996, GENE DEV, V10, P1670, DOI 10.1101/gad.10.13.1670; GUZ Y, 1995, DEVELOPMENT, V121, P11; Hentsch B, 1996, GENE DEV, V10, P70, DOI 10.1101/gad.10.1.70; HILBERG F, 1993, NATURE, V365, P179, DOI 10.1038/365179a0; HOUSSAINT E, 1980, CELL DIFFER DEV, V9, P269, DOI 10.1016/0045-6039(80)90026-3; IMMERGLUCK K, 1990, CELL, V62, P261, DOI 10.1016/0092-8674(90)90364-K; ISAACS HV, 1994, EMBO J, V13, P4469, DOI 10.1002/j.1460-2075.1994.tb06769.x; JONSSON J, 1994, NATURE, V371, P606, DOI 10.1038/371606a0; Jung J. H., UNPUB; Kettunen P, 1998, DEV DYNAM, V211, P256, DOI 10.1002/(SICI)1097-0177(199803)211:3<256::AID-AJA7>3.0.CO;2-G; Kimura S, 1996, GENE DEV, V10, P60, DOI 10.1101/gad.10.1.60; Klagsbrun M, 1989, Prog Growth Factor Res, V1, P207, DOI 10.1016/0955-2235(89)90012-4; Kuo CT, 1997, GENE DEV, V11, P1048, DOI 10.1101/gad.11.8.1048; LEDOUARIN NM, 1975, MED BIOL, V53, P427; MACIAG T, 1984, SCIENCE, V225, P932, DOI 10.1126/science.6382607; MAKOVER A, 1989, DIFFERENTIATION, V40, P17, DOI 10.1111/j.1432-0436.1989.tb00809.x; MANLEY NR, 1995, DEVELOPMENT, V121, P1989; MATSUZAKI K, 1989, P NATL ACAD SCI USA, V86, P9911, DOI 10.1073/pnas.86.24.9911; Min HS, 1998, GENE DEV, V12, P3156, DOI 10.1101/gad.12.20.3156; Molkentin JD, 1997, GENE DEV, V11, P1061, DOI 10.1101/gad.11.8.1061; NAHON JL, 1988, J BIOL CHEM, V263, P11436; Neubuser A, 1997, CELL, V90, P247, DOI 10.1016/S0092-8674(00)80333-5; NISWANDER L, 1993, NATURE, V361, P68, DOI 10.1038/361068a0; NOGAWA H, 1995, DEVELOPMENT, V121, P1015; Offield MF, 1996, DEVELOPMENT, V122, P983; OHTA T, 1995, BRIT J CANCER, V72, P824, DOI 10.1038/bjc.1995.420; Ohuchi H, 1997, DEVELOPMENT, V124, P2235; OLWIN BB, 1992, J CELL BIOL, V118, P631, DOI 10.1083/jcb.118.3.631; Ornitz DM, 1996, J BIOL CHEM, V271, P15292, DOI 10.1074/jbc.271.25.15292; Ortega S, 1998, P NATL ACAD SCI USA, V95, P5672, DOI 10.1073/pnas.95.10.5672; PARLOW MH, 1991, DEV BIOL, V146, P139, DOI 10.1016/0012-1606(91)90454-B; PETERS K, 1994, EMBO J, V13, P3296, DOI 10.1002/j.1460-2075.1994.tb06631.x; POLIARD A, 1988, DIFFERENTIATION, V39, P59, DOI 10.1111/j.1432-0436.1988.tb00081.x; Pontoglio M, 1996, CELL, V84, P575, DOI 10.1016/S0092-8674(00)81033-8; REUTER R, 1990, DEVELOPMENT, V110, P1031; SASAKI H, 1993, DEVELOPMENT, V118, P47; SCHMIDT C, 1995, NATURE, V373, P699, DOI 10.1038/373699a0; SELL S, 1985, DEV BRAIN RES, V22, P49, DOI 10.1016/0165-3806(85)90067-7; SHIROJRI N, 1991, CANCER RES, V51, P2611; SosaPineda B, 1997, NATURE, V386, P399, DOI 10.1038/386399a0; STARK KL, 1991, DEVELOPMENT, V113, P641; SUGI Y, 1995, DEV DYNAM, V202, P115, DOI 10.1002/aja.1002020203; TEITELMAN G, 1993, DEVELOPMENT, V118, P1031; Tucker AS, 1998, EUR J ORAL SCI, V106, P122, DOI 10.1111/j.1600-0722.1998.tb02163.x; UEHARA Y, 1995, NATURE, V373, P702, DOI 10.1038/373702a0; WANG JK, 1994, MOL CELL BIOL, V14, P181, DOI 10.1128/MCB.14.1.181; WEINSTEIN DC, 1994, CELL, V78, P575, DOI 10.1016/0092-8674(94)90523-1; Weinstein M, 1998, DEVELOPMENT, V125, P3615; YAMAGUCHI TP, 1994, GENE DEV, V8, P3032, DOI 10.1101/gad.8.24.3032; Zhu XL, 1996, DEV DYNAM, V207, P429, DOI 10.1002/(SICI)1097-0177(199612)207:4<429::AID-AJA7>3.0.CO;2-J	71	544	580	0	31	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 18	1999	284	5422					1998	2003		10.1126/science.284.5422.1998	http://dx.doi.org/10.1126/science.284.5422.1998			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	207JA	10373120				2022-12-28	WOS:000080932700050
J	Gross, CP; Anderson, GF; Rowe, NR				Gross, CP; Anderson, GF; Rowe, NR			The relation between funding by the National Institutes of Health and the burden of disease	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							GLOBAL BURDEN; LIFE; PERSPECTIVE; MORTALITY; ILLNESS; QALYS; COST	Background. The Institute of Medicine has proposed that the amount of disease-specific research funding provided by the National Institutes of Health (NIH) be systematically and consistently compared with the burden of disease for society. Methods. We performed a cross-sectional study comparing estimates of disease-specific funding in 1996 with data on six measures of the burden of disease. The measures were total mortality, years of life lost, and number of hospital days in 1994 and incidence, prevalence, and disability-adjusted life-years (one disability-adjusted life-year is defined as the loss of one year of healthy life to disease) in 1990. With the use of these measures as explanatory variables in a regression analysis, predicted funding was calculated and compared with actual funding. Results. There was no relation between the amount of NIH funding and the incidence, prevalence, or number of hospital days attributed to each condition or disease (P = 0.82, P = 0.23, and P = 0.21, respectively). The numbers of deaths (r = 0.40, P = 0.03) and years of life lost (r = 0.42, P = 0.02) were weakly associated with funding, whereas the number of disability-adjusted life-years was strongly predictive of fundi ng (r = 0.62, P < 0.001). When the latter th ree measures were used to predict expected funding, the conclusions about the appropriateness of funding for some diseases varied according to the measure used. However, the acquired immunodeficiency syndrome, breast cancer, diabetes mellitus, and dementia all received relatively generous funding, regardless of which measure was used as the basis for calculating support. Research on chronic obstructive pulmonary disease, perinatal conditions, and peptic ulcer was relatively underfunded. Conclusions. The amount of NIH funding for research on a disease is associated with the burden of the disease; however, different measures of the burden of disease may yield different conclusions about the appropriateness of disease-specific funding levels. (N Engl J Med 1999;340:1881-7). (C) 1999, Massachusetts Medical Society.	Johns Hopkins Univ, Sch Med, Robert Wood Johnson Clin Scholars Program, Baltimore, MD USA; Johns Hopkins Univ, Sch Hyg & Publ Hlth, Dept Hlth Policy & Management, Baltimore, MD USA; Johns Hopkins Univ, Sch Hyg & Publ Hlth, Welch Ctr Prevent Epidemiol & Clin Res, Baltimore, MD USA; Johns Hopkins Univ, Sch Hyg & Publ Hlth, Dept Epidemiol, Baltimore, MD USA	Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University	Gross, CP (corresponding author), Yale Univ, Sch Med, Primary Care Ctr, 333 Cedar St,POB 208025, New Haven, CT 06520 USA.							AHRENS EH, 1992, CRISIS CLIN RES OVER, P236; ANDERSON C, 1993, SCIENCE, V260, P483, DOI 10.1126/science.8475380; [Anonymous], SCI OPP PUBL NEEDS I; Davidoff AJ, 1996, INT J TECHNOL ASSESS, V12, P9, DOI 10.1017/S026646230000934X; *DEP HLTH HUM SERV, 1989, DHHS PUBL; Glied S, 1996, AM J PUBLIC HEALTH, V86, P1723, DOI 10.2105/AJPH.86.12.1723; Gold MR, 1996, COST EFFECTIVENESS H, P425; Graves EJ, 1997, VITAL HLTH STAT, V13; HAENSZEL W, 1950, AM J PUBLIC HEALTH, V40, P17, DOI 10.2105/AJPH.40.1.17; HATZIANDREU E, 1988, REV INFECT DIS, V10, P159; Istook Jr. Ernest, 1997, J NIH RES, V9, P26; KINDIG DA, 1997, PURCHASING POPULATIO, P47; KOOPMANSCHAP MA, 1994, HEALTH ECON, V3, P385, DOI 10.1002/hec.4730030606; LOOMES G, 1989, SOC SCI MED, V28, P299, DOI 10.1016/0277-9536(89)90030-0; Marshall E, 1997, SCIENCE, V276, P344, DOI 10.1126/science.276.5311.344; MORROW RH, 1995, AM J PUBLIC HEALTH, V85, P1356, DOI 10.2105/AJPH.85.10.1356; MURRAY C, 1996, GLOBAL HLTH STAT COM, V2, P20; MURRAY CJ, 1995, SUMMARY GLOBAL BURDE, P43; MURRAY CJL, 1994, B WORLD HEALTH ORGAN, V72, P495; MURRAY CJL, 1994, B WORLD HEALTH ORGAN, V72, P429; Murray CJL, 1997, LANCET, V349, P1269, DOI 10.1016/S0140-6736(96)07493-4; *NAT CTR HLTH STAT, 1996, WORK TABL 1 DEATH EA; *NAT CTR HLTH STAT, 1993, VIT STAT US 1989, V2, P1; *NIH, 1996, C JUST; *NIH, 1995, NIH EXTR TRENDS FISC; *OFF FIN MAN, 1996, NIH EXTR DAT TRENDS; *OFF FIN MAN, 1996, NIH KEY FACTS HIST F; Office of the Director, 1997, DIS SPEC EST DIR IND; ROMEDER JM, 1977, INT J EPIDEMIOL, V6, P143, DOI 10.1093/ije/6.2.143; ROSSER R, 1978, INT J EPIDEMIOL, V7, P347, DOI 10.1093/ije/7.4.347; SONDIK EJ, 1990, J NATL CANCER I, V82, P825; WEINSTEIN MC, 1977, NEW ENGL J MED, V296, P716, DOI 10.1056/NEJM197703312961304; Williams A, 1996, SOC SCI MED, V43, P1795, DOI 10.1016/S0277-9536(96)00082-2; *WORK GROUP PRIOR, 1995, SETT RES PRIOR NAT I	34	325	328	1	27	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 17	1999	340	24					1881	1887		10.1056/NEJM199906173402406	http://dx.doi.org/10.1056/NEJM199906173402406			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	206EC	10369852				2022-12-28	WOS:000080863500006
J	Wolfe, MM; Lichtenstein, DR; Singh, G				Wolfe, MM; Lichtenstein, DR; Singh, G			Gastrointestinal toxicity of nonsteroidal antiinflammatory drugs	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							PEPTIC-ULCER DISEASE; ANTI-INFLAMMATORY DRUGS; HELICOBACTER-PYLORI INFECTION; PLACEBO-CONTROLLED TRIAL; CHRONIC ASPIRIN THERAPY; GASTRIC-MUCOSAL INJURY; RHEUMATOID-ARTHRITIS; DOUBLE-BLIND; NITRIC-OXIDE; DUODENAL-ULCERS		Boston Med Ctr, Gastroenterol Sect, Boston, MA 02118 USA; Boston Univ, Sch Med, Gastroenterol Sect, Boston, MA 02118 USA; Stanford Univ, Sch Med, Div Rheumatol & Immunol, Palo Alto, CA 94304 USA	Boston Medical Center; Boston University; Stanford University	Wolfe, MM (corresponding author), Boston Med Ctr, Gastroenterol Sect, 88 E Newton St, Boston, MA 02118 USA.	michael.wolfe@bmc.org		Lichtenstein, David/0000-0001-6756-0190				Agrawal N, 1998, GASTROENTEROLOGY, V114, pA52, DOI 10.1016/S0016-5085(98)80213-8; AGRAWAL NM, 1991, ANN INTERN MED, V115, P195, DOI 10.7326/0003-4819-115-3-195; [Anonymous], 1980, JAMA, V243, P661; ARMSTRONG CP, 1987, GUT, V28, P527, DOI 10.1136/gut.28.5.527; Barkin Jamie, 1998, American Journal of Medicine, V105, p22S, DOI 10.1016/S0002-9343(98)00277-0; BERKOWITZ JM, 1987, ARCH INTERN MED, V147, P2137, DOI 10.1001/archinte.147.12.2137; BIJLSMA JWJ, 1988, ALIMENT PHARM THERAP, V2, P85; Bjarnason I, 1997, SCAND J GASTROENTERO, V32, P126, DOI 10.3109/00365529709000182; Bjorkman David J., 1996, American Journal of Medicine, V101, p25S; CALDWELL JR, 1987, AM J MED, V83, P74, DOI 10.1016/0002-9343(87)90832-1; CARSON JL, 1987, ARCH INTERN MED, V147, P1054, DOI 10.1001/archinte.147.6.1054; Chan FKL, 1997, LANCET, V350, P975, DOI 10.1016/S0140-6736(97)04523-6; Crofford LJ, 1997, J RHEUMATOL, V24, P15; CROKER JR, 1980, ANN RHEUM DIS, V39, P275, DOI 10.1136/ard.39.3.275; DAVIES J, 1986, BRIT J RHEUMATOL, V25, P54; Davies NM, 1997, ALIMENT PHARM THER, V11, P69, DOI 10.1046/j.1365-2036.1997.115286000.x; DEWITT DL, 1988, P NATL ACAD SCI USA, V85, P1412, DOI 10.1073/pnas.85.5.1412; DEWITT DL, 1988, P NATL ACAD SCI USA, V85, P5056; Distel M, 1996, BRIT J RHEUMATOL, V35, P68; Donnelly MT, 1998, GASTROENTEROLOGY, V114, pA107; Douthwaite AH, 1938, LANCET, V2, P1222; Dreser M. H., 1970, PFLUGERS ARCH, V76, P306, DOI [10.1007/bf01662127, DOI 10.1007/BF01662127]; EBERHART CE, 1994, GASTROENTEROLOGY, V107, P1183, DOI 10.1016/0016-5085(94)90246-1; EHSANULLAH RSB, 1988, BRIT MED J, V297, P1017, DOI 10.1136/bmj.297.6655.1017; FRIES JF, 1989, GASTROENTEROLOGY, V96, P647, DOI 10.1016/S0016-5085(89)80061-7; GABRIEL SE, 1991, ANN INTERN MED, V115, P787, DOI 10.7326/0003-4819-115-10-787; GOGGIN PM, 1993, GUT, V34, P1677, DOI 10.1136/gut.34.12.1677; GRAHAM DY, 1988, LANCET, V2, P1277; GRAHAM DY, 1986, ANN INTERN MED, V104, P390, DOI 10.7326/0003-4819-104-3-390; GRAHAM DY, 1993, ANN INTERN MED, V119, P257, DOI 10.7326/0003-4819-119-4-199308150-00001; GRAHAM DY, 1988, AM J GASTROENTEROL, V83, P1081; GRAHAM DY, 1985, CLIN PHARMACOL THER, V38, P65, DOI 10.1038/clpt.1985.136; GREENE JM, 1992, ARCH INTERN MED, V152, P1995, DOI 10.1001/archinte.152.10.1995; GRIFFIN MR, 1991, ANN INTERN MED, V114, P257, DOI 10.7326/0003-4819-114-4-257; HALLAS J, 1995, SCAND J GASTROENTERO, V30, P438, DOI 10.3109/00365529509093304; Hawkey CJ, 1998, LANCET, V352, P1634; Hawkey CJ, 1998, LANCET, V352, P1016, DOI 10.1016/S0140-6736(98)04206-8; HENRY D, 1993, GASTROENTEROLOGY, V105, P1078, DOI 10.1016/0016-5085(93)90952-9; HLA T, 1992, P NATL ACAD SCI USA, V89, P7384, DOI 10.1073/pnas.89.16.7384; HOCHAIN P, 1995, EUR J GASTROEN HEPAT, V7, P419; HUDSON N, 1993, GUT, V34, P742, DOI 10.1136/gut.34.6.742; Kim Jong G., 1994, American Journal of Gastroenterology, V89, P203; KIRALY A, 1993, EUR J PHARMACOL, V240, P299, DOI 10.1016/0014-2999(93)90913-3; KITAGAWA H, 1990, J PHARMACOL EXP THER, V253, P1133; KONTUREK SJ, 1986, GUT, V27, P1450, DOI 10.1136/gut.27.12.1450; LAINE L, 1995, ALIMENT PHARM THERAP, V9, P127; LANGENBACH R, 1995, CELL, V83, P483, DOI 10.1016/0092-8674(95)90126-4; LANGMAN MJS, 1989, GASTROENTEROLOGY, V96, P640, DOI 10.1016/S0016-5085(89)80060-5; LANGMAN MJS, 1994, LANCET, V343, P1302; Lanza FL, 1998, AM J GASTROENTEROL, V93, P2037; LANZA FL, 1984, AM J MED, V77, P19, DOI 10.1016/S0002-9343(84)80014-5; Lanza FL, 1997, GASTROENTEROLOGY, V112, pA194; LANZA FL, 1988, GASTROENTEROLOGY, V95, P289, DOI 10.1016/0016-5085(88)90482-9; LANZA FL, 1980, NEW ENGL J MED, V303, P136, DOI 10.1056/NEJM198007173030305; LARKAI EN, 1987, AM J GASTROENTEROL, V82, P1153; LEE M, 1994, ANN INTERN MED, V120, P184, DOI 10.7326/0003-4819-120-3-199402010-00002; LEVY M, 1974, NEW ENGL J MED, V290, P1158, DOI 10.1056/NEJM197405232902102; LICHTENSTEIN DR, 1995, ARTHRITIS RHEUM, V38, P5, DOI 10.1002/art.1780380103; Lipsky PE, 1997, J RHEUMATOL, V24, P9; LONGSTRETH GF, 1995, AM J GASTROENTEROL, V90, P206; MALIEKAL J, 1995, ANN PHARMACOTHER, V29, P698, DOI 10.1177/106002809502907-808; MASFERRER JL, 1992, P NATL ACAD SCI USA, V89, P3917, DOI 10.1073/pnas.89.9.3917; MASUDA E, 1995, GASTROENTEROLOGY, V108, P58, DOI 10.1016/0016-5085(95)90008-X; McAdam BF, 1999, P NATL ACAD SCI USA, V96, P272, DOI 10.1073/pnas.96.1.272; MCCAFFERTY DM, 1995, GASTROENTEROLOGY, V109, P1173, DOI 10.1016/0016-5085(95)90576-6; MCCARTHY DM, 1991, NEW ENGL J MED, V325, P1017; MEADE EA, 1993, J BIOL CHEM, V268, P6610; MEHTA S, 1992, AM J GASTROENTEROL, V87, P996; Mizuno H, 1997, GASTROENTEROLOGY, V112, P387, DOI 10.1053/gast.1997.v112.pm9024292; NAWKEY CJ, 1998, NEW ENGL J MED, V338, P727; Needleman P, 1997, J RHEUMATOL, V24, P6; ODDSSON E, 1992, SCAND J GASTROENTERO, V27, P1045, DOI 10.3109/00365529209028136; OLAUGHLIN JC, 1982, DIGEST DIS SCI, V27, P976, DOI 10.1007/BF01391742; PIPER JM, 1991, ANN INTERN MED, V114, P735, DOI 10.7326/0003-4819-114-9-735; Porro GB, 1996, GUT, V39, P22, DOI 10.1136/gut.39.1.22; POUNDER R, 1989, GASTROENTEROLOGY, V96, P626, DOI 10.1016/S0016-5085(89)80058-7; RASKIN JB, 1995, ANN INTERN MED, V123, P344, DOI 10.7326/0003-4819-123-5-199509010-00004; ROBINSON MG, 1989, DIGEST DIS SCI, V34, P424, DOI 10.1007/BF01536266; RODRIGUEZ LAG, 1994, LANCET, V343, P769, DOI 10.1016/S0140-6736(94)91843-0; RODRIGUEZ LAG, 1994, LANCET, V343, P1048; ROTH SH, 1993, ARCH INTERN MED, V153, P2565, DOI 10.1001/archinte.153.22.2565; Saha JK, 1998, GASTROENTEROLOGY, V114, pA274, DOI 10.1016/S0016-5085(98)81113-X; SALVEMINI D, 1993, P NATL ACAD SCI USA, V90, P7240, DOI 10.1073/pnas.90.15.7240; SANTUCCI L, 1994, GUT, V35, P909, DOI 10.1136/gut.35.7.909; SAUNDERS JHB, 1986, BMJ-BRIT MED J, V292, P665, DOI 10.1136/bmj.292.6521.665; SCHATTENKIRCHNER M, 1990, European Journal of Rheumatology and Inflammation, V10, P56; SCHEIMAN JM, 1994, DIGEST DIS SCI, V39, P97, DOI 10.1007/BF02090067; SCHOEN RT, 1989, AM J MED, V86, P449, DOI 10.1016/0002-9343(89)90344-6; SHORR RI, 1993, ARCH INTERN MED, V153, P1665, DOI 10.1001/archinte.153.14.1665; SILVERSTEIN FE, 1995, ANN INTERN MED, V123, P241, DOI 10.7326/0003-4819-123-4-199508150-00001; SILVOSO GR, 1979, ANN INTERN MED, V91, P517, DOI 10.7326/0003-4819-91-4-517; Singh G, 1999, J RHEUMATOL, V26, P18; Singh G, 1998, ARTHRITIS RHEUM, V41, pS75; Singh G, 1996, ARCH INTERN MED, V156, P1530, DOI 10.1001/archinte.156.14.1530; Singh G., 1997, Arthritis and Rheumatism, V40, pS93; Singh Gurkirpal, 1998, American Journal of Medicine, V105, p31S, DOI 10.1016/S0002-9343(98)00072-2; SOLL AH, 1991, ANN INTERN MED, V114, P307, DOI 10.7326/0003-4819-114-4-307; SUN DCH, 1974, AM J DIG DIS, V19, P405, DOI 10.1007/BF01255603; Taha AS, 1996, NEW ENGL J MED, V334, P1435, DOI 10.1056/NEJM199605303342204; THILLAINAYAGAM AV, 1994, DIGEST DIS SCI, V39, P1085, DOI 10.1007/BF02087562; VAANANEN PM, 1992, INFLAMMATION, V16, P227, DOI 10.1007/BF00918812; Vane JR, 1998, CLINICAL SIGNIFICANCE AND POTENTIAL OF SELECTIVE COX-2 INHIBITORS, P1; VANE JR, 1990, STROKE, V21, P12; Vane JR, 1996, SCAND J RHEUMATOL, P9; VanGroenendael JHLM, 1996, CLIN RHEUMATOL, V15, P450, DOI 10.1007/BF02229641; WALAN A, 1989, NEW ENGL J MED, V320, P69, DOI 10.1056/NEJM198901123200201; Wallace JL, 1997, GASTROENTEROLOGY, V112, P1000, DOI 10.1053/gast.1997.v112.pm9041264; WALLACE JL, 1990, AM J PHYSIOL, V259, pG462, DOI 10.1152/ajpgi.1990.259.3.G462; Wallace JL, 1995, J CLIN INVEST, V96, P2711, DOI 10.1172/JCI118338; WALLACE JL, 1994, GASTROENTEROLOGY, V107, P173, DOI 10.1016/0016-5085(94)90074-4; WALLACE JL, 1993, AM J PHYSIOL, V265, pG993, DOI 10.1152/ajpgi.1993.265.5.G993; WHITTLE BJR, 1977, BRIT J PHARMACOL, V60, P455, DOI 10.1111/j.1476-5381.1977.tb07522.x; Wolfe M. Michael, 1998, American Journal of Medicine, V105, p44S, DOI 10.1016/S0002-9343(98)00281-2; WOLFE MM, 1988, NEW ENGL J MED, V319, P1707; Yeomans ND, 1998, NEW ENGL J MED, V338, P719, DOI 10.1056/NEJM199803123381104	115	1533	1606	2	83	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUN 17	1999	340	24					1888	1899		10.1056/NEJM199906173402407	http://dx.doi.org/10.1056/NEJM199906173402407			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	206EC	10369853				2022-12-28	WOS:000080863500007
J	Mendelsohn, ME; Karas, RH				Mendelsohn, ME; Karas, RH			The protective effects of estrogen on the cardiovascular system	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							VASCULAR SMOOTH-MUSCLE; HORMONE-REPLACEMENT THERAPY; ATHEROSCLEROTIC CORONARY-ARTERIES; VEIN ENDOTHELIAL-CELLS; NITRIC-OXIDE SYNTHASE; RAT CAROTID-ARTERY; POSTMENOPAUSAL WOMEN; MESSENGER-RNA; RECEPTOR GENE; IN-VITRO		Tufts Univ, New England Med Ctr, Sch Med, Mol Cardiol Res Inst, Boston, MA 02111 USA; Tufts Univ, New England Med Ctr, Sch Med, Dept Med, Boston, MA 02111 USA	Tufts Medical Center; Tufts University; Tufts Medical Center; Tufts University	Mendelsohn, ME (corresponding author), Tufts Univ, New England Med Ctr, Sch Med, Mol Cardiol Res Inst, 750 Washington St,No 80, Boston, MA 02111 USA.	michael.mendelsohn@es.nemc.org			NHLBI NIH HHS [HL61298, HL55309, HL56069] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL056069, R01HL061298] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Arnal JF, 1996, P NATL ACAD SCI USA, V93, P4108, DOI 10.1073/pnas.93.9.4108; Ashcroft GS, 1997, NAT MED, V3, P1209, DOI 10.1038/nm1197-1209; BarrettConnor E, 1997, CIRCULATION, V95, P252, DOI 10.1161/01.CIR.95.1.252; Best PJM, 1998, ANN INTERN MED, V128, P285, DOI 10.7326/0003-4819-128-4-199802150-00006; Bhalla RC, 1997, AM J PHYSIOL-HEART C, V272, pH1996, DOI 10.1152/ajpheart.1997.272.4.H1996; Binko J, 1998, AM J PHYSIOL-HEART C, V274, pH853, DOI 10.1152/ajpheart.1998.274.3.H853; Bjarnason NH, 1997, CIRCULATION, V96, P1964, DOI 10.1161/01.CIR.96.6.1964; Blumenthal RS, 1997, AM J CARDIOL, V80, P1021, DOI 10.1016/S0002-9149(97)00596-1; Bourassa PAK, 1996, P NATL ACAD SCI USA, V93, P10022, DOI 10.1073/pnas.93.19.10022; Braunwald E, 1997, NEW ENGL J MED, V337, P1360, DOI 10.1056/NEJM199711063371906; BROWN M, 1994, HEMATOL ONCOL CLIN N, V8, P101, DOI 10.1016/S0889-8588(18)30189-8; Bryant HU, 1998, P SOC EXP BIOL MED, V217, P45; Brzozowski AM, 1997, NATURE, V389, P753, DOI 10.1038/39645; BUSH TL, 1987, CIRCULATION, V75, P1102, DOI 10.1161/01.CIR.75.6.1102; CaulinGlaser T, 1997, CIRC RES, V81, P885; CaulinGlaser T, 1996, J CLIN INVEST, V98, P36, DOI 10.1172/JCI118774; Chen Z, 1999, J CLIN INVEST, V103, P401, DOI 10.1172/JCI5347; CID MC, 1994, J CLIN INVEST, V93, P17, DOI 10.1172/JCI116941; CITARELLA F, 1993, BIOCHIM BIOPHYS ACTA, V1172, P197, DOI 10.1016/0167-4781(93)90294-N; Clarkson TB, 1998, J CLIN ENDOCR METAB, V83, P721, DOI 10.1210/jc.83.3.721; CLARKSON TB, 1994, DRUGS, V47, P42, DOI 10.2165/00003495-199400472-00008; COLLINS P, 1994, CIRCULATION, V90, P1964, DOI 10.1161/01.CIR.90.4.1964; COLLINS P, 1995, CIRCULATION, V92, P24, DOI 10.1161/01.CIR.92.1.24; CORNWELL TL, 1994, AM J PHYSIOL-CELL PH, V267, pC1405, DOI 10.1152/ajpcell.1994.267.5.C1405; Cowley SM, 1997, J BIOL CHEM, V272, P19858, DOI 10.1074/jbc.272.32.19858; Crosignani PG, 1996, THROMB HAEMOSTASIS, V75, P476; DAVIS MD, 1995, J STEROID BIOCHEM, V52, P421, DOI 10.1016/0960-0760(94)00194-Q; Drici MD, 1996, CIRCULATION, V94, P1471, DOI 10.1161/01.CIR.94.6.1471; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; Farhat MY, 1996, FASEB J, V10, P615, DOI 10.1096/fasebj.10.5.8621060; Freay AD, 1997, CIRC RES, V81, P242, DOI 10.1161/01.RES.81.2.242; Garcia-Cardena G, 1998, NATURE, V392, P821, DOI 10.1038/33934; GEBARA OCE, 1995, CIRCULATION, V91, P1952, DOI 10.1161/01.CIR.91.7.1952; GILLIGAN DM, 1994, CIRCULATION, V90, P786, DOI 10.1161/01.CIR.90.2.786; GILLIGAN DM, 1994, CIRCULATION, V89, P2545, DOI 10.1161/01.CIR.89.6.2545; GRADY D, 1992, ANN INTERN MED, V117, P1016, DOI 10.7326/0003-4819-117-12-1016; Grodstein F, 1996, NEW ENGL J MED, V335, P1406; Grodstein F, 1997, NEW ENGL J MED, V336, P1769, DOI 10.1056/NEJM199706193362501; Grohe C, 1997, FEBS LETT, V416, P107, DOI 10.1016/S0014-5793(97)01179-4; Guetta V, 1997, CIRCULATION, V96, P2795, DOI 10.1161/01.CIR.96.9.2795; HALACHMI S, 1994, SCIENCE, V264, P1455, DOI 10.1126/science.8197458; Hanke H, 1996, ATHEROSCLEROSIS, V121, P129, DOI 10.1016/0021-9150(95)05710-2; HERRINGTON DM, 1994, AM J CARDIOL, V73, P951, DOI 10.1016/0002-9149(94)90136-8; Hulley S, 1998, JAMA-J AM MED ASSOC, V280, P605, DOI 10.1001/jama.280.7.605; Iafrati MD, 1997, NAT MED, V3, P545, DOI 10.1038/nm0597-545; Inoue S, 1996, BIOCHEM BIOPH RES CO, V219, P766, DOI 10.1006/bbrc.1996.0308; JIANG CW, 1991, BRIT J PHARMACOL, V104, P1033, DOI 10.1111/j.1476-5381.1991.tb12545.x; Karas RH, 1995, FEBS LETT, V377, P103, DOI 10.1016/0014-5793(95)01293-1; Karas RH, 1998, J CLIN INVEST, V101, P2851, DOI 10.1172/JCI1416; KARAS RH, 1994, CIRCULATION, V89, P1943, DOI 10.1161/01.CIR.89.5.1943; KEANEY JF, 1994, CIRCULATION, V89, P2251, DOI 10.1161/01.CIR.89.5.2251; KimSchulze S, 1996, CIRCULATION, V94, P1402, DOI 10.1161/01.CIR.94.6.1402; Kitazawa T, 1997, J PHYSIOL-LONDON, V499, P497, DOI 10.1113/jphysiol.1997.sp021944; Knight DC, 1995, MATURITAS, V22, P167, DOI 10.1016/0378-5122(95)00937-G; Koh KK, 1997, NEW ENGL J MED, V336, P683, DOI 10.1056/NEJM199703063361002; Koike H, 1996, J VASC SURG, V23, P477, DOI 10.1016/S0741-5214(96)80014-0; Kolodgie FD, 1996, AM J PATHOL, V148, P969; Krasinski K, 1997, CIRCULATION, V95, P1768; Krikun G, 1998, J CLIN ENDOCR METAB, V83, P926, DOI 10.1210/jc.83.3.926; Kuiper GGJM, 1996, P NATL ACAD SCI USA, V93, P5925, DOI 10.1073/pnas.93.12.5925; Kuiper GGJM, 1997, ENDOCRINOLOGY, V138, P863, DOI 10.1210/en.138.3.863; LantinHermoso RL, 1997, AM J PHYSIOL-LUNG C, V273, pL119, DOI 10.1152/ajplung.1997.273.1.L119; Levine RL, 1996, CIRCULATION, V94, P2221, DOI 10.1161/01.CIR.94.9.2221; LIEBERMAN EH, 1994, ANN INTERN MED, V121, P936, DOI 10.7326/0003-4819-121-12-199412150-00005; Liehr JG, 1996, J LAB CLIN MED, V128, P344, DOI 10.1016/S0022-2143(96)80002-3; Lindner V, 1998, CIRC RES, V83, P224, DOI 10.1161/01.RES.83.2.224; LOSORDO DW, 1994, CIRCULATION, V89, P1501, DOI 10.1161/01.CIR.89.4.1501; Lou H, 1996, CIRCULATION, V94, P3355, DOI 10.1161/01.CIR.94.12.3355; McCrohon JA, 1997, J AM COLL CARDIOL, V29, P1432, DOI 10.1016/S0735-1097(97)00063-6; MCDONNELL DP, 1995, MOL ENDOCRINOL, V9, P659, DOI 10.1210/me.9.6.659; McDonnell DP, 1998, BIOCHEM SOC T, V26, P54, DOI 10.1042/bst0260054; MENDELSON ME, 1994, CURR OPIN CARDIOL, V9, P619, DOI 10.1097/00001573-199409000-00018; Migliaccio A, 1996, EMBO J, V15, P1292, DOI 10.1002/j.1460-2075.1996.tb00471.x; MILLER VT, 1995, JAMA-J AM MED ASSOC, V273, P199, DOI 10.1001/jama.1995.03520270033028; MOGRANO MM, 1998, ENDOCRINOLOGY, V98, P96; MONCADA S, 1993, NEW ENGL J MED, V329, P2002; MORALES DE, 1995, CIRCULATION, V91, P755, DOI 10.1161/01.CIR.91.3.755; NABULSI AA, 1993, NEW ENGL J MED, V328, P1069, DOI 10.1056/NEJM199304153281501; Nathan L, 1997, ANNU REV PHARMACOL, V37, P477, DOI 10.1146/annurev.pharmtox.37.1.477; New G, 1997, J AM COLL CARDIOL, V29, P1437, DOI 10.1016/S0735-1097(97)00080-6; Nickenig G, 1998, CIRCULATION, V97, P2197, DOI 10.1161/01.CIR.97.22.2197; OBrien JE, 1996, J AM COLL CARDIOL, V28, P1111, DOI 10.1016/S0735-1097(96)00306-3; OKeefe JH, 1997, J AM COLL CARDIOL, V29, P1; Oparil S, 1997, CIRCULATION, V95, P1301; Paech K, 1997, SCIENCE, V277, P1508, DOI 10.1126/science.277.5331.1508; PAPPAS TC, 1995, FASEB J, V9, P404, DOI 10.1096/fasebj.9.5.7896011; Pervin S, 1998, ARTERIOSCL THROM VAS, V18, P1575, DOI 10.1161/01.ATV.18.10.1575; POWER RF, 1991, SCIENCE, V254, P1636, DOI 10.1126/science.1749936; PROUDLER AJ, 1995, LANCET, V346, P89, DOI 10.1016/S0140-6736(95)92114-1; Register TC, 1998, J STEROID BIOCHEM, V64, P187, DOI 10.1016/S0960-0760(97)00155-6; Reis SE, 1998, CIRCULATION, V97, P23, DOI 10.1161/01.CIR.97.1.23; REIS SE, 1994, CIRCULATION, V89, P52, DOI 10.1161/01.CIR.89.1.52; Roque M, 1998, J AM COLL CARDIOL, V31, P139, DOI 10.1016/S0735-1097(97)00436-1; ROSANO GMC, 1993, LANCET, V342, P133, DOI 10.1016/0140-6736(93)91343-K; Rubanyi GM, 1997, J CLIN INVEST, V99, P2429, DOI 10.1172/JCI119426; SACK MN, 1994, LANCET, V343, P269, DOI 10.1016/S0140-6736(94)91117-7; SALOMAA V, 1995, ARTERIOSCL THROM VAS, V15, P1549, DOI 10.1161/01.ATV.15.10.1549; Santanam N, 1998, J LIPID RES, V39, P2111; Schunkert H, 1997, CIRCULATION, V95, P39, DOI 10.1161/01.CIR.95.1.39; SHANKER G, 1995, LIFE SCI, V56, P499, DOI 10.1016/0024-3205(94)00479-C; Shibata H, 1997, RECENT PROG HORM RES, V52, P141; Shimizu H, 1997, J ENDOCRINOL, V154, P285, DOI 10.1677/joe.0.1540285; Shwaery GT, 1997, CIRCULATION, V95, P1378; Simpson ER, 1997, RECENT PROG HORM RES, V52, P185; SOMLYO AP, 1994, NATURE, V372, P812; SOMLYO AP, 1994, NATURE, V372, P231, DOI 10.1038/372231a0; Sorensen KE, 1998, CIRCULATION, V97, P1234, DOI 10.1161/01.CIR.97.13.1234; Spyridopoulos I, 1997, CIRCULATION, V95, P1505; STAMPFER MJ, 1991, NEW ENGL J MED, V325, P756, DOI 10.1056/NEJM199109123251102; Sudhir K, 1997, CIRCULATION, V96, P3774; Sudhir K, 1997, CIRCULATION, V96, P3626; Sudhir K, 1997, LANCET, V349, P1146, DOI 10.1016/S0140-6736(05)63022-X; SUGIOKA K, 1987, FEBS LETT, V210, P37, DOI 10.1016/0014-5793(87)81293-0; Sullivan JM, 1997, AM J CARDIOL, V79, P847, DOI 10.1016/S0002-9149(97)00001-5; SULLIVAN TR, 1995, J CLIN INVEST, V96, P2482, DOI 10.1172/JCI118307; Venkov CD, 1996, CIRCULATION, V94, P727, DOI 10.1161/01.CIR.94.4.727; Walsh BW, 1998, JAMA-J AM MED ASSOC, V279, P1445, DOI 10.1001/jama.279.18.1445; WALTER P, 1985, P NATL ACAD SCI USA, V82, P7889, DOI 10.1073/pnas.82.23.7889; Wehling M, 1997, ANNU REV PHYSIOL, V59, P365, DOI 10.1146/annurev.physiol.59.1.365; WEINER CP, 1994, P NATL ACAD SCI USA, V91, P5212, DOI 10.1073/pnas.91.11.5212; Wellman GC, 1996, CIRC RES, V79, P1024, DOI 10.1161/01.RES.79.5.1024; WHITE RE, 1995, CIRC RES, V77, P936, DOI 10.1161/01.RES.77.5.936; Williams JK, 1997, CIRCULATION, V96, P1970, DOI 10.1161/01.CIR.96.6.1970; WILLIAMS JK, 1992, J AM COLL CARDIOL, V20, P452, DOI 10.1016/0735-1097(92)90116-5; WILLIAMS JK, 1990, CIRCULATION, V81, P1680, DOI 10.1161/01.CIR.81.5.1680; Wingrove CS, 1998, BBA-MOL BASIS DIS, V1406, P169, DOI 10.1016/S0925-4439(97)00097-5; WISEMAN H, 1994, BIOCHEM PHARMACOL, V47, P493, DOI 10.1016/0006-2952(94)90180-5; *WRIT GROUP PEPI T, 1995, JAMA-J AM MED ASSOC, V274, P1676; Yen S. S. C., 1991, REPROD ENDOCRINOLOGY; YLIKORKALA O, 1995, J CLIN ENDOCR METAB, V80, P3384, DOI 10.1210/jc.80.11.3384	130	2228	2313	2	108	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUN 10	1999	340	23					1801	1811		10.1056/NEJM199906103402306	http://dx.doi.org/10.1056/NEJM199906103402306			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	203UU	10362825				2022-12-28	WOS:000080726800006
J	Andersen, B; Arnason, E				Andersen, B; Arnason, E			Iceland's database is ethically questionable	BRITISH MEDICAL JOURNAL			English	Editorial Material									Univ San Diego, San Diego, CA 92110 USA; Univ Iceland, IS-101 Reykjavik, Iceland	University of San Diego; University of Iceland	Andersen, B (corresponding author), Univ San Diego, San Diego, CA 92110 USA.		Arnason, Einar/M-3090-2015	Arnason, Einar/0000-0003-3686-6407					0	15	15	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JUN 5	1999	318	7197					1565	1565		10.1136/bmj.318.7197.1565	http://dx.doi.org/10.1136/bmj.318.7197.1565			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	204HC	10356045	Green Published			2022-12-28	WOS:000080757300071
J	Roomi, R				Roomi, R			Saadi Hussain Al-Roumani - Obituary	BRITISH MEDICAL JOURNAL			English	Biographical-Item																			0	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JUN 5	1999	318	7197					1561	1561		10.1136/bmj.318.7197.1561	http://dx.doi.org/10.1136/bmj.318.7197.1561			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	204HC	10356039	Green Published			2022-12-28	WOS:000080757300065
J	Dasen, JS; O'Connell, SM; Flynn, SE; Treier, M; Gleiberman, AS; Szeto, DP; Hooshmand, F; Aggarwal, AK; Rosenfeld, MG				Dasen, JS; O'Connell, SM; Flynn, SE; Treier, M; Gleiberman, AS; Szeto, DP; Hooshmand, F; Aggarwal, AK; Rosenfeld, MG			Reciprocal interactions of Pit1 and GATA2 mediate signaling gradient-induced determination of pituitary cell types	CELL			English	Article							BINDING TRANSCRIPTION FACTORS; HEART TUBE FORMATION; SYNERGISTIC INTERACTIONS; VENTRAL MORPHOGENESIS; HEMATOPOIETIC DEFECT; HOMEODOMAIN PROTEIN; GONADAL DEVELOPMENT; NUCLEAR RECEPTOR; GENE-EXPRESSION; DNA-BINDING	The mechanisms by which transient gradients of signaling molecules lead to emergence of specific cell types remain a central question in mammalian organogenesis. Here, we demonstrate that the appearance of four ventral pituitary cell types is mediated via the reciprocal interactions of two transcription factors, Pit1 and GATA2, which are epistatic to the remainder of the cell type-specific transcription programs and serve as the molecular memory of the transient signaling events. Unexpectedly, this program includes a DNA binding-independent function of Pit1, suppressing the ventral GATA2-dependent gonadotrope program by inhibiting GATA2 binding to gonadotrope- but not thyrotrope-specific genes, indicating that both DNA binding-dependent and -independent actions of abundant determining factors contribute to generate distinct cell phenotypes.	Univ Calif San Diego, Howard Hughes Med Inst, La Jolla, CA 92093 USA; Univ Calif San Diego, Biomed Sci Grad Program, La Jolla, CA 92093 USA; Mt Sinai Sch Med, Dept Physiol & Biophys, New York, NY 10029 USA	Howard Hughes Medical Institute; University of California System; University of California San Diego; University of California System; University of California San Diego; Icahn School of Medicine at Mount Sinai	Rosenfeld, MG (corresponding author), Univ Calif San Diego, Howard Hughes Med Inst, La Jolla, CA 92093 USA.		Treier, Mathias/AAD-6388-2021	gleiberman, anatoli/0000-0001-8491-0826				Bieberich CJ, 1996, J BIOL CHEM, V271, P31779, DOI 10.1074/jbc.271.50.31779; COULY G, 1988, DEVELOPMENT, V103, P101; CRENSHAW EB, 1989, GENE DEV, V3, P959, DOI 10.1101/gad.3.7.959; DiMattia GE, 1997, DEV BIOL, V182, P180, DOI 10.1006/dbio.1996.8472; Durocher D, 1997, EMBO J, V16, P5687, DOI 10.1093/emboj/16.18.5687; EAGLESON GW, 1990, J NEUROBIOL, V21, P427, DOI 10.1002/neu.480210305; Ericson J, 1998, DEVELOPMENT, V125, P1005; Firulli AB, 1997, TRENDS GENET, V13, P364, DOI 10.1016/S0168-9525(97)01171-2; Gordon DF, 1997, J BIOL CHEM, V272, P24339, DOI 10.1074/jbc.272.39.24339; GSTAIGER M, 1995, NATURE, V373, P360, DOI 10.1038/373360a0; HALDER G, 1995, SCIENCE, V267, P1788, DOI 10.1126/science.7892602; HAN KY, 1993, EMBO J, V12, P2723, DOI 10.1002/j.1460-2075.1993.tb05934.x; INGRAHAM HA, 1994, GENE DEV, V8, P2302, DOI 10.1101/gad.8.19.2302; JACOBSON AG, 1979, J EXP ZOOL, V207, P351, DOI 10.1002/jez.1402070303; Jacobson EM, 1997, GENE DEV, V11, P198, DOI 10.1101/gad.11.2.198; JAPON MA, 1994, J HISTOCHEM CYTOCHEM, V42, P117; JAYNES JB, 1991, EMBO J, V10, P1427, DOI 10.1002/j.1460-2075.1991.tb07663.x; JONAT C, 1990, CELL, V62, P1189, DOI 10.1016/0092-8674(90)90395-U; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; Kuo CT, 1997, GENE DEV, V11, P1048, DOI 10.1101/gad.11.8.1048; LI S, 1990, NATURE, V347, P528, DOI 10.1038/347528a0; LIN SC, 1994, DEVELOPMENT, V120, P515; LUO XR, 1994, CELL, V77, P481, DOI 10.1016/0092-8674(94)90211-9; LUO Y, 1992, CELL, V71, P231, DOI 10.1016/0092-8674(92)90352-D; Ma GT, 1997, DEVELOPMENT, V124, P907; Mann RS, 1996, TRENDS GENET, V12, P258, DOI 10.1016/0168-9525(96)10026-3; Molkentin JD, 1997, GENE DEV, V11, P1061, DOI 10.1101/gad.11.8.1061; Molkentin JD, 1995, CELL, V83, P1125, DOI 10.1016/0092-8674(95)90139-6; OMICHINSKI JG, 1993, SCIENCE, V261, P438, DOI 10.1126/science.8332909; PANDOLFI PP, 1995, NAT GENET, V11, P40, DOI 10.1038/ng0995-40; PEVNY L, 1991, NATURE, V349, P257, DOI 10.1038/349257a0; Reichardt HM, 1998, CELL, V93, P531, DOI 10.1016/S0092-8674(00)81183-6; RHODES SJ, 1993, GENE DEV, V7, P913, DOI 10.1101/gad.7.6.913; RUSCH J, 1996, CURR OPIN GENE DEV, V6, P16; SIMMONS DM, 1990, GENE DEV, V4, P695, DOI 10.1101/gad.4.5.695; SOMSON MW, 1996, NATURE, V384, P327; STRUBIN M, 1995, CELL, V80, P497, DOI 10.1016/0092-8674(95)90500-6; Takuma N, 1998, DEVELOPMENT, V125, P4835; Tanabe Y, 1998, CELL, V95, P67, DOI 10.1016/S0092-8674(00)81783-3; Treier M, 1996, CURR OPIN CELL BIOL, V8, P833, DOI 10.1016/S0955-0674(96)80085-8; Treier M, 1998, GENE DEV, V12, P1691, DOI 10.1101/gad.12.11.1691; TSAI FY, 1994, NATURE, V371, P221, DOI 10.1038/371221a0; Tsang AP, 1997, CELL, V90, P109, DOI 10.1016/S0092-8674(00)80318-9; Viger RS, 1998, DEVELOPMENT, V125, P2665; WEINTRAUB H, 1993, CELL, V75, P1241, DOI 10.1016/0092-8674(93)90610-3; Woods B, 1997, AGING MENT HEALTH, V1, P11, DOI 10.1080/13607869757335; Zhou YH, 1998, EMBO J, V17, P6689, DOI 10.1093/emboj/17.22.6689	47	236	243	1	5	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	MAY 28	1999	97	5					587	598		10.1016/S0092-8674(00)80770-9	http://dx.doi.org/10.1016/S0092-8674(00)80770-9			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	202VD	10367888	Bronze			2022-12-28	WOS:000080672100008
J	McKenney, D; Pouliot, KL; Wang, Y; Murthy, V; Ulrich, M; Doring, G; Lee, JC; Goldmann, DA; Pier, GB				McKenney, D; Pouliot, KL; Wang, Y; Murthy, V; Ulrich, M; Doring, G; Lee, JC; Goldmann, DA; Pier, GB			Broadly protective vaccine for Staphylococcus aureus based on an in vivo-expressed antigen	SCIENCE			English	Article							CAPSULAR POLYSACCHARIDE ADHESIN; COAGULASE-NEGATIVE STAPHYLOCOCCI; BACTERIAL VIRULENCE GENES; IN-VIVO; HOST TISSUES; TYPE-5; IDENTIFICATION; ENDOCARDITIS; EPIDERMIDIS; SELECTION	Vaccines based on preferential expression of bacterial antigens during human infection have not been described. Staphylococcus aureus synthesized poly-N-succinyl beta-1-6 glucosamine (PNSG) as a surface polysaccharide during human and animal infection, but few strains expressed PNSC in vitro. All S. aureus strains examined carried genes for PNSG synthesis. Immunization protected mice against kidney infections and death from strains that produced little PNSG in vitro. Nonimmune infected animals made antibody to PNSG, but serial in vitro cultures of kidney isolates yielded mostly cells that did not produce PNSC. PNSG is a candidate for use in a vaccine to protect against S. aureus infection.	Brigham & Womens Hosp, Dept Med, Channing Lab, Boston, MA 02115 USA; Harvard Univ, Childrens Hosp, Sch Med, Dept Med, Boston, MA 02115 USA; Univ Klinikum, Inst Hyg, Dept Gen & Environm Hyg, D-72074 Tubingen, Germany	Harvard University; Brigham & Women's Hospital; Harvard University; Boston Children's Hospital; Harvard Medical School; Eberhard Karls University of Tubingen	Pier, GB (corresponding author), Brigham & Womens Hosp, Dept Med, Channing Lab, 75 Francis St, Boston, MA 02115 USA.		Pier, Gerald/AAO-2692-2021	Pier, Gerald/0000-0002-9112-2331; Lee, Jean/0000-0002-8094-5180	NIAID NIH HHS [AI2335] Funding Source: Medline	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALBUS A, 1991, INFECT IMMUN, V59, P1008, DOI 10.1128/IAI.59.3.1008-1014.1991; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; Archer GL, 1998, CLIN INFECT DIS, V26, P1179, DOI 10.1086/520289; Balaban N, 1998, SCIENCE, V280, P438, DOI 10.1126/science.280.5362.438; FATTOM A, 1992, INFECT IMMUN, V60, P584, DOI 10.1128/IAI.60.2.584-589.1992; FATTOM A, 1993, INFECT IMMUN, V61, P1023, DOI 10.1128/IAI.61.3.1023-1032.1993; Fattom AI, 1996, INFECT IMMUN, V64, P1659, DOI 10.1128/IAI.64.5.1659-1665.1996; FOURNIER JM, 1984, INFECT IMMUN, V45, P87, DOI 10.1128/IAI.45.1.87-93.1984; Heilmann C, 1996, MOL MICROBIOL, V20, P1083, DOI 10.1111/j.1365-2958.1996.tb02548.x; HENSEL M, 1995, SCIENCE, V269, P400, DOI 10.1126/science.7618105; Herbert S, 1997, J INFECT DIS, V176, P431, DOI 10.1086/514061; Hiramatsu K, 1997, LANCET, V350, P1670, DOI 10.1016/S0140-6736(97)07324-8; Jarvis WR, 1997, AM J INFECT CONTROL, V25, P477; KARAKAWA WW, 1985, J CLIN MICROBIOL, V22, P445, DOI 10.1128/JCM.22.3.445-447.1985; KOJIMA Y, 1990, J INFECT DIS, V162, P435, DOI 10.1093/infdis/162.2.435; Lee JC, 1997, INFECT IMMUN, V65, P4146, DOI 10.1128/IAI.65.10.4146-4151.1997; LEE JC, 1990, J CLIN MICROBIOL, V28, P2612, DOI 10.1128/JCM.28.12.2612-2615.1990; LEE JC, 1987, INFECT IMMUN, V55, P2191, DOI 10.1128/IAI.55.9.2191-2197.1987; LEE JC, 1997, STAPHYLOCOCCI HUMAN, P631; Lowe AM, 1998, MOL MICROBIOL, V27, P967, DOI 10.1046/j.1365-2958.1998.00741.x; Lowy FD, 1998, NEW ENGL J MED, V339, P520, DOI 10.1056/NEJM199808203390806; MAHAN MJ, 1995, P NATL ACAD SCI USA, V92, P669, DOI 10.1073/pnas.92.3.669; MAHAN MJ, 1993, SCIENCE, V259, P686, DOI 10.1126/science.8430319; MAMO W, 1994, FEMS IMMUNOL MED MIC, V10, P47, DOI 10.1111/j.1574-695X.1994.tb00010.x; McKenney D, 1998, INFECT IMMUN, V66, P4711, DOI 10.1128/IAI.66.10.4711-4720.1998; MCKENNEY D, UNPUB; Mei JM, 1997, MOL MICROBIOL, V26, P399, DOI 10.1046/j.1365-2958.1997.5911966.x; MILES H, 1992, J DAIRY SCI, V75, P596, DOI 10.3168/jds.S0022-0302(92)77797-2; MOREAU M, 1990, CARBOHYD RES, V201, P285, DOI 10.1016/0008-6215(90)84244-O; MULLER E, 1993, J INFECT DIS, V168, P1211, DOI 10.1093/infdis/168.5.1211; MURTHY SVKN, 1983, CARBOHYD RES, V117, P113, DOI 10.1016/0008-6215(83)88080-X; NICKERSON SC, 1995, J DAIRY SCI, V78, P1607, DOI 10.3168/jds.S0022-0302(95)76785-6; Nilsson IM, 1998, J CLIN INVEST, V101, P2640, DOI 10.1172/JCI1823; SCHENNINGS T, 1993, MICROB PATHOGENESIS, V15, P227, DOI 10.1006/mpat.1993.1073; Schwan WR, 1998, INFECT IMMUN, V66, P567, DOI 10.1128/IAI.66.2.567-572.1998; SHIRO H, 1995, CIRCULATION, V92, P2715, DOI 10.1161/01.CIR.92.9.2715; SLAUCH JM, 1994, METHOD ENZYMOL, V235, P481; Smith TL, 1999, NEW ENGL J MED, V340, P493, DOI 10.1056/NEJM199902183400701; SOMPOLINSKY D, 1985, J CLIN MICROBIOL, V22, P828, DOI 10.1128/JCM.22.5.828-834.1985; TAKEDA S, 1991, CIRCULATION, V84, P2539, DOI 10.1161/01.CIR.84.6.2539; Tenover FC, 1998, J CLIN MICROBIOL, V36, P1020, DOI 10.1128/JCM.36.4.1020-1027.1998; WANG Y, 1994, CARBOHYD RES, V260, P305, DOI 10.1016/0008-6215(94)84048-2; WEST TE, 1987, J GEN MICROBIOL, V133, P431	43	275	294	0	17	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAY 28	1999	284	5419					1523	1527		10.1126/science.284.5419.1523	http://dx.doi.org/10.1126/science.284.5419.1523			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	200PD	10348739				2022-12-28	WOS:000080548100036
J	Thiemann, DR; Coresh, J; Oetgen, WJ; Powe, NR				Thiemann, DR; Coresh, J; Oetgen, WJ; Powe, NR			The association between hospital volume and survival after acute myocardial infarction in elderly patients	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							COOPERATIVE CARDIOVASCULAR PROJECT; CORONARY ANGIOPLASTY VOLUME; SHORT-TERM MORTALITY; THROMBOLYTIC THERAPY; CARDIOLOGISTS; PHYSICIAN; OUTCOMES; MODELS; TRIAL; CARE	Background Patients with chest pain thought to be due to acute coronary ischemia are typically taken by ambulance to the nearest hospital. The potential benefit of field triage directly to a hospital that treats a large number of patients with myocardial infarction is unknown. Methods We conducted a retrospective cohort study of the relation between the number of Medicare patients with myocardial infarction that each hospital in the study treated (hospital volume) and longterm survival among 98,898 Medicare patients 65 years of age or older. We used proportional-hazards methods to adjust for clinical, demographic, and health-system-related variables, including the availability of invasive procedures, the specialty of the attending physician, and the area of residence of the patient (rural, urban, or metropolitan). Results The patients in the quartile admitted to hospitals with the lowest volume were 17 percent more likely to die within 30 days after admission than patients in the quartile admitted to hospitals with the highest volume (hazard ratio, 1.17; 95 percent confidence interval, 1.09 to 1.26; P<0.001), which resulted in 2.3 more deaths per 100 patients. The crude mortality rate at one year was 29.8 percent among the patients admitted to the lowest-volume hospitals, as compared with 27.0 percent among those admitted to the highest-volume hospitals. There was a continuous inverse dose-response relation between hospital volume and the risk of death. In an analysis of subgroups defined according to age, history of cardiac disease, Killip class of infarction, presence or absence of contraindications to thrombolytic therapy, and time from the onset of symptoms, survival at high-volume hospitals was consistently better than at low-volume hospitals. The availability of technology for angioplasty and bypass surgery was not independently associated with overall mortality. Conclusions Patients with acute myocardial infarction who are admitted directly to hospitals that have more experience treating myocardial infarction, as reflected by their case volume, are more likely to survive than are patients admitted to low-volume hospitals. (N Engl J Med 1999;340:1640-8.) (C) 1999. Massachusetts Medical Society.	Johns Hopkins Univ, Dept Med, Baltimore, MD 21287 USA; Johns Hopkins Univ, Dept Epidemiol, Baltimore, MD 21287 USA; Johns Hopkins Univ, Dept Biostat, Baltimore, MD 21287 USA; Johns Hopkins Univ, Dept Hlth Policy & Management, Baltimore, MD 21287 USA; Johns Hopkins Univ, Program Med Technol & Practice Assessment, Baltimore, MD 21287 USA; Johns Hopkins Univ, Welch Ctr Prevent Epidemiol & Clin Res, Baltimore, MD 21287 USA; Maryland Healthcare Associates, Clinton, MD USA; Delmarva Fdn Med Care, Easton, MD USA	Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University	Thiemann, DR (corresponding author), Johns Hopkins Univ, Dept Med, Carnegie 568, Baltimore, MD 21287 USA.				NCRR NIH HHS [RR00035, RR00072] Funding Source: Medline; PHS HHS [K01 A600561] Funding Source: Medline	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		*AM HOSP ASS, 1997, 1994 ANN SURV HOSP D; APPLEBY P, 1994, LANCET, V343, P311, DOI 10.1016/S0140-6736(94)91161-4; Begg CB, 1998, JAMA-J AM MED ASSOC, V280, P1747, DOI 10.1001/jama.280.20.1747; Boersma E, 1996, LANCET, V348, P771, DOI 10.1016/S0140-6736(96)02514-7; BRODIE BR, 1994, CIRCULATION, V90, P156, DOI 10.1161/01.CIR.90.1.156; Casale PN, 1998, J AM COLL CARDIOL, V32, P885, DOI 10.1016/S0735-1097(98)00325-8; *CENS BUR, 1992, CENS POP HOUS 1990 S; Chen J, 1999, NEW ENGL J MED, V340, P286, DOI 10.1056/NEJM199901283400407; COX DR, 1972, J R STAT SOC B, V34, P187; *DEP AGR EC RES SE, 1997, ZIPFIP FIL; Every NR, 1997, CIRCULATION, V96, P1770, DOI 10.1161/01.CIR.96.6.1770; *FIBR THER TRIAL C, 1994, LANCET, V343, P742; GRINES CL, 1993, NEW ENGL J MED, V328, P673, DOI 10.1056/NEJM199303113281001; HANNAN EL, 1992, HEALTH SERV RES, V27, P517; Hannan EL, 1997, JAMA-J AM MED ASSOC, V277, P892, DOI 10.1001/jama.277.11.892; HOSMER DW, 1989, APPL LOGISTIC REGRES; HUGHES RG, 1988, MED CARE, V26, P1057, DOI 10.1097/00005650-198811000-00004; Jollis JG, 1997, CIRCULATION, V95, P2485, DOI 10.1161/01.CIR.95.11.2485; Jollis JG, 1998, NEW ENGL J MED, V338, P983, DOI 10.1056/NEJM199804023381410; Jollis JG, 1996, NEW ENGL J MED, V335, P1880, DOI 10.1056/NEJM199612193352505; JOLLIS JG, 1994, NEW ENGL J MED, V331, P1625, DOI 10.1056/NEJM199412153312406; Krumholz HM, 1998, JAMA-J AM MED ASSOC, V280, P623, DOI 10.1001/jama.280.7.623; LEE KL, 1995, CIRCULATION, V91, P1659, DOI 10.1161/01.CIR.91.6.1659; LEIZOROVICZ A, 1993, NEW ENGL J MED, V329, P383; LIANG KY, 1986, BIOMETRIKA, V73, P13, DOI 10.1093/biomet/73.1.13; LUFT HS, 1979, NEW ENGL J MED, V301, P1364, DOI 10.1056/NEJM197912203012503; Marciniak TA, 1998, JAMA-J AM MED ASSOC, V279, P1351, DOI 10.1001/jama.279.17.1351; Nash IS, 1997, J AM COLL CARDIOL, V29, P475, DOI 10.1016/S0735-1097(96)00528-1; Newby LK, 1996, J AM COLL CARDIOL, V27, P1646; Nieto FJ, 1996, AM J EPIDEMIOL, V143, P1059; Normand SLT, 1996, JAMA-J AM MED ASSOC, V275, P1322, DOI 10.1001/jama.275.17.1322; Phibbs CS, 1996, JAMA-J AM MED ASSOC, V276, P1054, DOI 10.1001/jama.276.13.1054; RAWLES J, 1994, J AM COLL CARDIOL, V23, P1, DOI 10.1016/0735-1097(94)90494-4; SHOWSTACK JA, 1987, JAMA-J AM MED ASSOC, V257, P2438; *STAT, 1997, STATA VERS 5 0; TOPOL E, 1993, NEW ENGL J MED, V329, P673, DOI 10.1056/nejm199309023291001; *TX MED FDN, 1998, COOP CARD PROJ; White HD, 1998, CIRCULATION, V97, P1632, DOI 10.1161/01.CIR.97.16.1632	38	307	311	0	11	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAY 27	1999	340	21					1640	1648		10.1056/NEJM199905273402106	http://dx.doi.org/10.1056/NEJM199905273402106			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	199QY	10341277				2022-12-28	WOS:000080494200006
J	Johnson, MF				Johnson, MF			The doctor in the family	ANNALS OF INTERNAL MEDICINE			English	Editorial Material									Univ Colorado, Hlth Sci Ctr, Div Geriatr, Denver, CO 80262 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Johnson, MF (corresponding author), Univ Colorado, Hlth Sci Ctr, Div Geriatr, 4200 E 9th Ave,Box B179, Denver, CO 80262 USA.	Marie.Johnson@uchsc.edu							0	2	2	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAY 18	1999	130	10					859	860		10.7326/0003-4819-130-10-199905180-00022	http://dx.doi.org/10.7326/0003-4819-130-10-199905180-00022			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	196JJ	10366378				2022-12-28	WOS:000080305000011
J	Meinardi, JR; Middeldorp, S; de Kam, PJ; Koopman, MMW; van Pampus, ECM; Hamulyak, K; Prins, MH; Buller, HR; van der Meer, J				Meinardi, JR; Middeldorp, S; de Kam, PJ; Koopman, MMW; van Pampus, ECM; Hamulyak, K; Prins, MH; Buller, HR; van der Meer, J			Increased risk for fetal loss in carriers of the factor V Leiden mutation	ANNALS OF INTERNAL MEDICINE			English	Article							ACTIVATED PROTEIN-C; COAGULATION-FACTOR-V; VENOUS THROMBOEMBOLISM; RECURRENT MISCARRIAGE; RESISTANCE; THROMBOSIS; ASSOCIATION; INFARCTION; ABORTION; WOMEN	Background: An increased risk for fetal loss caused by placental thrombosis is probable in carriers of the factor V Leiden mutation but has not been demonstrated consistently in previous studies. Objective: To determine the overall risk for fetal loss and the separate risks for miscarriage and stillbirth in carriers of the factor V Leiden mutation. Design: Retrospective cohort study. Setting: Three university hospitals. Participants: 228 carriers of the factor V Leiden mutation (77 propositi, 151 relatives) and 121 noncarrier relatives (controls). All participants had been pregnant at least once. Measurements: Risks for fetal loss, miscarriage (defined as fetal loss within 20 weeks of gestation),and stillbirth (defined as fetal loss after >20 weeks of gestation) in women and in pregnancies were estimated and compared in carriers and noncarriers. Adjusted odds ratios were calculated by using multiple regression analysis. A random-effects model was used for comparisons of pregnancies. Results: Fetal loss occurred in 31.6% of carriers and 22.3% of noncarriers, miscarriage occurred in 29.4% of carriers and 17.4% of noncarriers. and stillbirth occurred in 5.7% of carriers and 5.0% of noncarriers. Fetal loss recurred in 10.1% of carriers and 4.1% of noncarriers (odds ratio, 2.60 [95% CI, 0.96 to 7.03]). Adjusted odds ratios were 2.12 (CI, 1.35 to 3.33) for fetal loss, 2.08 (CI, 1.33 to 3.25) for miscarriage, and 1.60 (CI, 0.58 to 4.43) for stillbirth when pregnancies in carriers and noncarriers were compared. Homozygous carriers had a greater risk for fetal loss (odds ratio; 2.01 [CI, 0.94 to 4.32]) and stillbirth (odds ratio, 4.85 [CI, 0.82 to 25.58]) than heterozygous carriers. Conclusions: Carriers of the factor V Leiden mutation have a greater risk for fetal loss (particularly miscarriage) than noncarriers. These data further suggest a greater risk for recurrence of fetal loss in carriers than in noncarriers and a greater risk for fetal loss and stillbirth in homozygous carriers than in heterozygous carriers.	Univ Groningen Hosp, Div Haemostasis Thrombosis & Rheol, NL-9713 GZ Groningen, Netherlands	University of Groningen	Meinardi, JR (corresponding author), Univ Groningen Hosp, Div Haemostasis Thrombosis & Rheol, Hanzeplein 1, NL-9713 GZ Groningen, Netherlands.		Middeldorp, Saskia/ABI-8197-2020	Middeldorp, Saskia/0000-0002-1006-6420				Balasch J, 1997, HUM REPROD, V12, P1094; BERTINA RM, 1994, NATURE, V369, P64, DOI 10.1038/369064a0; Brenner B, 1997, BRIT J HAEMATOL, V97, P551, DOI 10.1046/j.1365-2141.1997.882901.x; Diggle PJ, 1994, ANAL LONGITUDINAL DA; DizonTomson DS, 1997, AM J OBSTET GYNECOL, V177, P402, DOI 10.1016/S0002-9378(97)70205-9; DizonTownson DS, 1997, J REPROD IMMUNOL, V34, P217, DOI 10.1016/S0165-0378(97)00039-9; Grandone E, 1997, THROMB HAEMOSTASIS, V77, P822; Middeldorp S, 1998, ANN INTERN MED, V128, P15, DOI 10.7326/0003-4819-128-1-199801010-00003; Preston FE, 1996, LANCET, V348, P913, DOI 10.1016/S0140-6736(96)04125-6; Rai R, 1996, BRIT J HAEMATOL, V92, P489, DOI 10.1046/j.1365-2141.0000.d01-1465.x; Rai RS, 1996, BRIT J OBSTET GYNAEC, V103, P842, DOI 10.1111/j.1471-0528.1996.tb09887.x; Ridker PM, 1998, ANN INTERN MED, V128, P1000, DOI 10.7326/0003-4819-128-12_Part_1-199806150-00007; RIDKER PM, 1995, NEW ENGL J MED, V332, P912, DOI 10.1056/NEJM199504063321403; ROSENDAAL FR, 1995, BLOOD, V85, P1504, DOI 10.1182/blood.V85.6.1504.bloodjournal8561504; Sanson BJ, 1996, THROMB HAEMOSTASIS, V75, P387; STIRRAT GM, 1990, LANCET, V336, P673, DOI 10.1016/0140-6736(90)92159-F; VOORBERG J, 1994, LANCET, V343, P1535, DOI 10.1016/S0140-6736(94)92939-4	17	130	131	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAY 4	1999	130	9					736	739		10.7326/0003-4819-130-9-199905040-00013	http://dx.doi.org/10.7326/0003-4819-130-9-199905040-00013			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	192DE	10357692				2022-12-28	WOS:000080062300004
J	Gough, P				Gough, P			Courteous containment is not enough - Commentary	BRITISH MEDICAL JOURNAL			English	Editorial Material									Royal Coll Nursing, London W1M 0AB, England		Gough, P (corresponding author), Royal Coll Nursing, London W1M 0AB, England.							*UK CENTR COUNC NU, 1992, COD PROF COND	1	6	6	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	APR 24	1999	318	7191					1131	1131						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	193YU	10366261				2022-12-28	WOS:000080166000038
J	Blelloch, R; Kimble, J				Blelloch, R; Kimble, J			Control of organ shape by a secreted metalloprotease in the nematode Caenorhabditis elegans	NATURE			English	Article							SEQUENCE-TAGGED SITES; I N-PROTEINASE; PROGELATINASE-A; GENE; SUPERFAMILY; EXPRESSION; ACTIVATION; CLONING	The molecular controls governing organ shape are poorly understood. In the nematode Caenorhabditis elegans, the gonad acquires a U-shape by the directed migration of a specialized 'leader' cell, which is located at the tip of the growing gonadal 'arm'(1). The gon-1 gene is essential for gonadal morphogenesis: in gon-1 mutants, no arm elongation occurs and somatic gonadal structures are severely malformed(2). Here we report that gon-1 encodes a secreted protein with a metalloprotease domain and multiple thrombospondin type-1-like repeats. This motif architecture is typical of a small family of genes that include bovine procollagen I N-protease (P1NP), which cleaves collagen(3), and murine ADAMTS-1, the expression of which correlates with tumour cell progression(4). We find that gon-1 is expressed in two sites, leader cells and muscle, and that expression in each site has a unique role in forming the gonad. We speculate that GON-1 controls morphogenesis by remodelling basement membranes and that regulation of its activity is crucial for achieving organ shape.	Univ Wisconsin, Howard Hughes Med Inst, Madison, WI 53706 USA; Univ Wisconsin, Cell & Mol Biol Program, Madison, WI 53706 USA; Univ Wisconsin, Dept Biochem, Madison, WI 53706 USA; Univ Wisconsin, Dept Med Genet, Madison, WI 53706 USA; Univ Wisconsin, Mol Biol Lab, Madison, WI 53706 USA	Howard Hughes Medical Institute; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison	Kimble, J (corresponding author), Univ Wisconsin, Howard Hughes Med Inst, Madison, WI 53706 USA.	jekimble@facstaff.wisc.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008692] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Adams J. C., 1995, THROMBOSPONDIN GENE; BLELLOCH R, GON 1 GENE REGULATES; C elegans Sequencing Consortium, 1998, SCIENCE, V282, P2012, DOI 10.1126/science.282.5396.2012; Cha J, 1997, BIOCHEMISTRY-US, V36, P16019, DOI 10.1021/bi972223g; COLIGE A, 1995, J BIOL CHEM, V270, P16724, DOI 10.1074/jbc.270.28.16724; Colige A, 1997, P NATL ACAD SCI USA, V94, P2374, DOI 10.1073/pnas.94.6.2374; Fire A, 1998, NATURE, V391, P806, DOI 10.1038/35888; HENDERSON ST, 1994, DEVELOPMENT, V120, P2913; Hiraoka N, 1998, CELL, V95, P365, DOI 10.1016/S0092-8674(00)81768-7; KIMBLE JE, 1981, DEV BIOL, V81, P208, DOI 10.1016/0012-1606(81)90284-0; Korswagen HC, 1996, P NATL ACAD SCI USA, V93, P14680, DOI 10.1073/pnas.93.25.14680; KRAUSE M, 1995, CAENORHABDITIS ELEGA, P513; Kuno K, 1997, J BIOL CHEM, V272, P556, DOI 10.1074/jbc.272.1.556; Lelongt B, 1997, J CELL BIOL, V136, P1363, DOI 10.1083/jcb.136.6.1363; Mello C, 1995, CAENORHABDITIS ELEGA, P451; OKKEMA PG, 1993, GENETICS, V135, P385; PEI DQ, 1995, NATURE, V375, P244, DOI 10.1038/375244a0; Pei DQ, 1996, J BIOL CHEM, V271, P9135, DOI 10.1074/jbc.271.15.9135; RAWLINGS ND, 1995, METHOD ENZYMOL, V248, P183; SCHEDL T, 1997, C ELEGANS, V2, P241; STOCKER W, 1995, PROTEIN SCI, V4, P823; Will H, 1996, J BIOL CHEM, V271, P17119, DOI 10.1074/jbc.271.29.17119; WILLIAMS BD, 1992, GENETICS, V131, P609; [No title captured]	24	159	166	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 10	1999	399	6736					586	590		10.1038/21196	http://dx.doi.org/10.1038/21196			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	204RR	10376599				2022-12-28	WOS:000080778400056
J	Voltz, R; Gultekin, SH; Rosenfeld, MR; Gerstner, E; Eichen, J; Posner, JB; Dalmau, J				Voltz, R; Gultekin, SH; Rosenfeld, MR; Gerstner, E; Eichen, J; Posner, JB; Dalmau, J			A serologic marker of paraneoplastic limbic and brain-stem encephalitis in patients with testicular cancer	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ENCEPHALOMYELITIS SENSORY NEURONOPATHY; ANTIGENS; EXPRESSION; CARCINOMA; ANTIBODY; TISSUE	Background In patients with cancer, symptoms of limbic and brain-stem dysfunction may result from a paraneoplastic disorder. Paraneoplastic limbic or brain-stem encephalitis occurs more frequently with testicular cancer than with most other cancers. We sought antineuronal antibodies that might be used in a diagnostic test for this syndrome. Methods Immunohistochemical and immunoblotting techniques were used to detect serum and cerebrospinal fluid antibodies. Serologic screening of a complementary DNA library and Northern blotting were used to clone the target antigen and determine which tissues expressed it. RESULTS Of 13 patients with testicular cancer and paraneoplastic limbic or brain-stem encephalitis (or both), 10 had antibodies in serum and cerebrospinal fluid against a 40-kd neuronal protein. These antibodies were used to clone a gene that we call Ma2, which codes for a protein (Ma2) that was recognized by serum from the 10 patients, but not by serum from 344 control subjects. Ma2 was selectively expressed by normal brain tissue and by the testicular tumors of the patients. Ma2 shares homology with Ma?, a "brain-testis-cancer" gene related to other paraneoplastic syndromes and tumors. Conclusions The serum of patients with subacute limbic and brain-stem dysfunction and testicular cancer contains antibodies against a protein found in normal brain and in testicular tumors. Detection of these antibodies supports the paraneoplastic origin of the neurologic disorder and could be of diagnostic importance. (N Engl J Med 1999;340:1788-95.) (C) 1999, Massachusetts Medical Society.	Mem Sloan Kettering Canc Ctr, Dept Neurol, New York, NY 10021 USA; Mem Sloan Kettering Canc Ctr, Cotzias Lab Neurooncol, New York, NY 10021 USA; Mem Sloan Kettering Canc Ctr, Dept Pathol, New York, NY 10021 USA	Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center	Dalmau, J (corresponding author), Mem Sloan Kettering Canc Ctr, Dept Neurol, 1275 York Ave, New York, NY 10021 USA.			Dalmau, Josep/0000-0001-5856-2813	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS026064] Funding Source: NIH RePORTER; NINDS NIH HHS [NS-26064] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		AHERN GL, 1994, NEUROLOGY, V44, P1270, DOI 10.1212/WNL.44.7.1270; Alamowitch S, 1997, BRAIN, V120, P923, DOI 10.1093/brain/120.6.923; BAKHEIT AMO, 1990, J NEUROL NEUROSUR PS, V53, P1084, DOI 10.1136/jnnp.53.12.1084; Bennett JL, 1999, NEUROLOGY, V52, P864, DOI 10.1212/WNL.52.4.864; BURTON GV, 1988, CANCER, V62, P2248, DOI 10.1002/1097-0142(19881115)62:10<2248::AID-CNCR2820621029>3.0.CO;2-X; CATTORETTI G, 1993, J PATHOL, V171, P83, DOI 10.1002/path.1711710205; Chen YT, 1998, P NATL ACAD SCI USA, V95, P6919, DOI 10.1073/pnas.95.12.6919; CORSELLIS JA, 1968, BRAIN, V91, P481, DOI 10.1093/brain/91.3.481; Dalmau J, 1999, BRAIN, V122, P27, DOI 10.1093/brain/122.1.27; DALMAU J, 1992, MEDICINE, V71, P59, DOI 10.1097/00005792-199203000-00001; DALMAU J, 1990, ANN NEUROL, V27, P544, DOI 10.1002/ana.410270515; DALMAU J, 1992, AM J PATHOL, V141, P881; Dalmau JO, 1997, SEMIN ONCOL, V24, P318; Darnell RB, 1996, P NATL ACAD SCI USA, V93, P4529, DOI 10.1073/pnas.93.10.4529; DIRR LY, 1990, NEUROLOGY, V40, P1304, DOI 10.1212/WNL.40.8.1304; DROPCHO EJ, 1994, ANN NEUROL, V36, P200, DOI 10.1002/ana.410360212; FURNEAUX HM, 1990, NEW ENGL J MED, V322, P1844, DOI 10.1056/NEJM199006283222604; Henson RA., 1982, CANC NERVOUS SYSTEM, P314; LEE LG, 1992, NUCLEIC ACIDS RES, V20, P2471, DOI 10.1093/nar/20.10.2471; POSNER JB, 1995, NEUROLOGIC COMPLICAT, P353; SCHULLER E, 1990, TRENDS IN NEUROIMMUNOLOGY, P3; SZABO A, 1991, CELL, V67, P325, DOI 10.1016/0092-8674(91)90184-Z	22	247	262	0	4	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 10	1999	340	23					1788	1795		10.1056/NEJM199906103402303	http://dx.doi.org/10.1056/NEJM199906103402303			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	203UU	10362822				2022-12-28	WOS:000080726800003
J	Smeeth, L; Haines, A; Ebrahim, S				Smeeth, L; Haines, A; Ebrahim, S			Numbers needed to treat derived from meta-analyses - sometimes informative, usually misleading	BMJ-BRITISH MEDICAL JOURNAL			English	Article							MYOCARDIAL-INFARCTION; RANDOMIZED TRIALS; CLINICAL-TRIALS; PREVENTION; METAANALYSIS; HYPERTENSION; PERCEPTIONS; THERAPY; MEN		Univ Bristol, Dept Social Med, MRC, Hlth Serv Res Collaborat, Bristol BS8 2PR, Avon, England; UCL, Royal Free & Univ Coll Med Sch, Dept Primary Care & Populat Sci, London NW3 2PF, England	University of Bristol; University of London; University College London	Ebrahim, S (corresponding author), Univ Bristol, Dept Social Med, MRC, Hlth Serv Res Collaborat, Bristol BS8 2PR, Avon, England.	shah.ebrahim@bristol.ac.uk	; Smeeth, Liam/X-5862-2018	Haines, Andy/0000-0002-8053-4605; Smeeth, Liam/0000-0002-9168-6022				Altman DG, 1998, BRIT MED J, V317, P1309, DOI 10.1136/bmj.317.7168.1309; ALTMAN R, 1994, BMJ-BRIT MED J, V308, P81, DOI 10.1136/bmj.308.6921.81; *COCHR COLL, 1998, COCHR LIB; COOK RJ, 1995, BRIT MED J, V310, P452, DOI 10.1136/bmj.310.6977.452; Cranney M, 1996, BRIT J GEN PRACT, V46, P661; Crouse JR, 1997, ARCH INTERN MED, V157, P1305, DOI 10.1001/archinte.157.12.1305; CUCHERAT M, 1997, EASYMA 1997 METAANAL; Downs JR, 1998, JAMA-J AM MED ASSOC, V279, P1615, DOI 10.1001/jama.279.20.1615; EBRAHIM S, 1996, HLTH PROMOTION OLDER; Egger M, 1997, BMJ-BRIT MED J, V315, P1533, DOI 10.1136/bmj.315.7121.1533; FAHEY T, 1995, BRIT MED J, V311, P1056, DOI 10.1136/bmj.311.7012.1056; Fleiss J L, 1993, Stat Methods Med Res, V2, P121, DOI 10.1177/096228029300200202; HUX JE, 1995, MED DECIS MAKING, V15, P152, DOI 10.1177/0272989X9501500208; Jackson RT, 1996, BRIT MED J, V313, P64, DOI 10.1136/bmj.313.7049.64; LAUPACIS A, 1988, NEW ENGL J MED, V318, P1728, DOI 10.1056/NEJM198806303182605; McColl A, 1998, BRIT MED J, V316, P361, DOI 10.1136/bmj.316.7128.361; Morris S, 1997, J Health Serv Res Policy, V2, P231; MULROW C, 1998, COCHRANE LIB; MULROW CD, 1994, JAMA-J AM MED ASSOC, V272, P1932, DOI 10.1001/jama.272.24.1932; NAYLOR CD, 1992, ANN INTERN MED, V117, P916, DOI 10.7326/0003-4819-117-11-916; *OFF NAT STAT, 1997, SERIES DH, V2; PEDERSEN TR, 1994, LANCET, V344, P1383; Rembold CM, 1996, J FAM PRACTICE, V42, P577; ROTHWELL PM, 1995, LANCET, V345, P1616, DOI 10.1016/S0140-6736(95)90120-5; SAKS FM, 1996, NEW ENGL J MED, V14, P1001; Sharp SJ, 1996, BRIT MED J, V313, P735; SHEPHERD J, 1995, NEW ENGL J MED, V333, P1301, DOI 10.1056/NEJM199511163332001; Smith GD, 1998, BMJ-BRIT MED J, V316, P221; Smith GD, 1997, BMJ-BRIT MED J, V315, P1610, DOI 10.1136/bmj.315.7122.1610; Tonkin A, 1998, NEW ENGL J MED, V339, P1349; YUSUF S, 1985, PROG CARDIOVASC DIS, V27, P335, DOI 10.1016/S0033-0620(85)80003-7; 1998, BANDOLIER, V5, P2; 1998, EVIDENCE BASED MED, V3, P10	33	200	202	1	5	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUN 5	1999	318	7197					1548	1551		10.1136/bmj.318.7197.1548	http://dx.doi.org/10.1136/bmj.318.7197.1548			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	204HC	10356018	Green Published			2022-12-28	WOS:000080757300036
J	Smets, YFC; Westendorp, RGJ; van der Pijl, JW; de Charro, FT; Ringers, J; de Fijter, JW; Lemkes, HHPJ				Smets, YFC; Westendorp, RGJ; van der Pijl, JW; de Charro, FT; Ringers, J; de Fijter, JW; Lemkes, HHPJ			Effect of simultaneous pancreas-kidney transplantation on mortality of patients with type-1 diabetes mellitus and end-stage renal failure	LANCET			English	Article							COMPLICATIONS; MORBIDITY; DIALYSIS; SURVIVAL; MEDICINE	Background. Long-term prognosis of patients with type-1 diabetes mellitus and end-stage renal failure appears to be better after kidney transplantation compared with dialysis. Controversy exists about the additional benefit of a simultaneously transplanted pancreatic graft. We studied the effect on mortality of simultaneous pancreas-kidney transplantation compared with kidney transplantation alone from regional differences in transplantation protocols. Methods. All 415 patients with type-1 diabetes (aged 18-52 years) who started renal-replacement therapy in the Netherlands between 1985 and 1996 were included in the! analysis. Patients were allocated to a centre based on their. place of residence at onset of renal failure. In the Leiden area, the primary intention to treat was with a simultaneous pancreas-kidney transplantation, whereas in the non-Leiden area, kidney transplantation alone was the predominant type, of treatment. All patients were followed up to July, 1997. Analyses, mortality, and graft failure were by Cox proportional-hazard model adjusted for age and sex. Findings. Simultaneous pancreas-kidney transplantation was done in 41 (73%) of 56 transplanted patients in the Leiden area compared with 59 (37%) of 158 transplanted patients in the non-leiden area (p < 0.001). The hazard ratio for mortality after the start of renal-replacement therapy was 0.53 (95% CI, 0.36-0.77, p < 0.001) in the Leiden area compared with the non-leiden area. When just the transplanted patients were analysed the mortality ratio was 0.4 (95% CI 0.20-0.77, p = 0.008) and was independent of duration of dialysis and early transplant-related deaths. Equal survival was found for patients on dialysis only. Interpretation. These data support the hypothesis that simultaneous pancreas-kidney transplantation prolongs survival in patients with diabetes and end-stage renal failure.	Leiden Univ, Med Ctr, Dept Metab Dis & Endocrinol, Leiden, Netherlands; Leiden Univ, Med Ctr, Dept Clin Epidemiol, Leiden, Netherlands; Leiden Univ, Med Ctr, Dept Nephrol, Leiden, Netherlands; Leiden Univ, Med Ctr, Dept Surg, Leiden, Netherlands; Dutch Renal Replacement Therapy Registry RENINE, Rotterdam, Netherlands	Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC	Smets, YFC (corresponding author), Leiden Univ, Med Ctr, Dept Metab Dis & Endocrinol C4R, Albinusdreef 2, NL-2333 ZA Leiden, Netherlands.		Ringers, Jan/Q-8382-2016	Ringers, Jan/0000-0001-5007-7354				*AM DIAB ASS, 1997, DIABETES CARE S1, V20, pS54; CHEUNG AHS, 1992, KIDNEY INT, V41, P924, DOI 10.1038/ki.1992.141; Commenges D, 1995, Lifetime Data Anal, V1, P145, DOI 10.1007/BF00985764; DECHARRO FT, 1995, NEPHROL DIAL TRANSPL, V10, P436, DOI 10.1093/ndt/10.4.436; Ibrahim HN, 1997, J AM SOC NEPHROL, V8, P487; Landgraf R, 1996, DIABETOLOGIA, V39, P1415, DOI 10.1007/s001250050593; Luzi L, 1998, NEW ENGL J MED, V339, P115, DOI 10.1056/NEJM199807093390210; MANKSE CL, 1995, LANCET, V346, P1658; MCMILLAN MA, 1990, BMJ-BRIT MED J, V301, P540, DOI 10.1136/bmj.301.6751.540; Mogensen CE, 1997, DIABETES, V46, pS104, DOI 10.2337/diab.46.2.S104; NELSON CB, 1992, J AM SOC NEPHROL, V3, P1147; PORT FK, 1993, JAMA-J AM MED ASSOC, V270, P1339, DOI 10.1001/jama.270.11.1339; REMUZZI G, 1994, LANCET, V343, P27, DOI 10.1016/S0140-6736(94)90880-X; RISCHENVOS J, 1992, NEPHROL DIAL TRANSPL, V7, P433; ROBERTSON RP, 1992, NEW ENGL J MED, V327, P1861; Robertson RP, 1998, J CLIN ENDOCR METAB, V83, P1868, DOI 10.1210/jc.83.6.1868; Ryan EA, 1998, LANCET, V351, P1072, DOI 10.1016/S0140-6736(98)22015-0; SCHULAK JA, 1992, TRANSPLANTATION, V53, P685; STRATTA RJ, 1993, TRANSPLANTATION, V55, P1097, DOI 10.1097/00007890-199305000-00031	19	189	194	0	5	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUN 5	1999	353	9168					1915	1919		10.1016/S0140-6736(98)07513-8	http://dx.doi.org/10.1016/S0140-6736(98)07513-8			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	202TP	10371569				2022-12-28	WOS:000080668500010
J	He, G; Muser, MH; Robbins, MO				He, G; Muser, MH; Robbins, MO			Adsorbed layers and the origin of static friction	SCIENCE			English	Article							QUARTZ-CRYSTAL MICROBALANCE; MOLECULARLY THIN-FILMS; INTERFACIAL FRICTION; SLIDING FRICTION; SHEAR PROPERTIES; DYNAMICS; SUPERLUBRICITY; TRANSITIONS; TRIBOLOGY; CONTACTS	Analytic results and experiments in ultrahigh vacuum indicate that the static friction between-two clean crystalline surfaces should almost always vanish, yet macroscopic objects always exhibit static friction. A simple and general explanation for-the prevalence of static friction is proposed. "Third bodies," such as small hydrocarbon molecules, adsorb on any surface exposed to air and can arrange to Lock two contacting surfaces together. The resulting static friction is consistent with experimental behavior, including Amontons' Laws.	Johns Hopkins Univ, Dept Phys & Astron, Baltimore, MD 21218 USA	Johns Hopkins University	Muser, MH (corresponding author), Johns Hopkins Univ, Dept Phys & Astron, Baltimore, MD 21218 USA.	mr@pha.jhu.edu	Müser, Martin/B-7412-2008; Müser, Martin/ABH-4626-2020	Müser, Martin/0000-0003-0919-0843; Robbins, Mark Owen/0000-0001-7160-3608				ALSTEN JV, 1990, LANGMUIR, V6, P876; Berthoud P, 1998, P ROY SOC A-MATH PHY, V454, P1615, DOI 10.1098/rspa.1998.0223; Bowden F.P., 1958, FRICTION LUBRICATION; BRISCOE BJ, 1982, P ROY SOC LOND A MAT, V380, P389, DOI 10.1098/rspa.1982.0048; BRISCOE BJ, 1978, J ADHESION, V9, P145, DOI 10.1080/00218467808075110; CIEPLAK M, 1994, SCIENCE, V265, P1209, DOI 10.1126/science.265.5176.1209; Demirel AL, 1998, J CHEM PHYS, V109, P6889, DOI 10.1063/1.477256; DIETERICH JH, 1994, PURE APPL GEOPHYS, V143, P283, DOI 10.1007/BF00874332; Dieterich JH, 1996, TECTONOPHYSICS, V256, P219, DOI 10.1016/0040-1951(95)00165-4; Dowson D, 1979, HIST TRIBOLOGY; Gao JP, 1997, PHYS REV LETT, V79, P705, DOI 10.1103/PhysRevLett.79.705; GEE ML, 1990, J CHEM PHYS, V93, P1895, DOI 10.1063/1.459067; GLOSLI JN, 1993, PHYS REV LETT, V70, P1960, DOI 10.1103/PhysRevLett.70.1960; GREENWOOD JA, 1966, PROC R SOC LON SER-A, V295, P300, DOI 10.1098/rspa.1966.0242; Hirano M, 1997, PHYS REV LETT, V78, P1448, DOI 10.1103/PhysRevLett.78.1448; HOMOLA AM, 1990, WEAR, V136, P65, DOI 10.1016/0043-1648(90)90072-I; Kontorova TA, 1938, ZH EKSP TEOR FIZ, V8, P1340; KREMER K, 1990, J CHEM PHYS, V92, P5057, DOI 10.1063/1.458541; KRIM J, 1991, PHYS REV LETT, V66, P181, DOI 10.1103/PhysRevLett.66.181; Mak C, 1998, PHYS REV B, V58, P5157, DOI 10.1103/PhysRevB.58.5157; MANIAS E, 1994, J CHEM PHYS, V101, P1721, DOI 10.1063/1.467794; MARTIN JM, 1993, PHYS REV B, V48, P10583, DOI 10.1103/PhysRevB.48.10583; MCCLELLAND GM, 1990, FUNDAMENTALS FRICTIO, P405; Perry MD, 1997, J PHYS CHEM B, V101, P1364, DOI 10.1021/jp962561b; Perry MD, 1996, THIN SOLID FILMS, V290, P211, DOI 10.1016/S0040-6090(96)09025-6; Persson BNJ, 1996, SURF SCI, V367, P261, DOI 10.1016/S0039-6028(96)00814-X; Robbins MO, 1996, LANGMUIR, V12, P4543, DOI 10.1021/la9505576; SCHOEN M, 1989, SCIENCE, V245, P1223, DOI 10.1126/science.245.4923.1223; SHINJO K, 1993, SURF SCI, V283, P473, DOI 10.1016/0039-6028(93)91022-H; SINGER IL, 1992, NATO ADV SCI I E-APP, V220, P237; THOMPSON PA, 1995, ISR J CHEM, V35, P93; THOMPSON PA, 1990, SCIENCE, V250, P792, DOI 10.1126/science.250.4982.792; Tomassone MS, 1997, PHYS REV LETT, V79, P4798, DOI 10.1103/PhysRevLett.79.4798; Tomlinson GA, 1929, PHILOS MAG, V7, P905, DOI 10.1080/14786440608564819; Volmer A, 1997, Z PHYS B CON MAT, V104, P363, DOI 10.1007/s002570050462	35	351	359	6	174	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 4	1999	284	5420					1650	1652		10.1126/science.284.5420.1650	http://dx.doi.org/10.1126/science.284.5420.1650			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	202TM	10356390				2022-12-28	WOS:000080668300038
J	Marston, A				Marston, A			Gut rot	LANCET			English	Editorial Material											Marston, A (corresponding author), 4 Hereford Sq, London SW7 4TT, England.								0	0	0	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAY 29	1999	353	9167					1875	1877		10.1016/S0140-6736(98)11456-3	http://dx.doi.org/10.1016/S0140-6736(98)11456-3			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	202TG	10359430				2022-12-28	WOS:000080667800048
J	Spencer, JR; Tamppari, LK; Martin, TZ; Travis, LD				Spencer, JR; Tamppari, LK; Martin, TZ; Travis, LD			Temperatures on Europa from Galileo photopolarimeter-radiometer: Nighttime thermal anomalies	SCIENCE			English	Article							SATELLITES; ICE; SURFACE; STATE; PHOTOMETRY; OCEAN; WATER	Galileo observations of Europa's thermal emission show low-latitude diurnal brightness temperatures in the range of 86 to 132 kelvin. Nighttime temperatures form an unexpected pattern, with high temperatures on the bright ejecta blanket of the crater Pwyll and an equatorial minimum in temperatures after sunset, uncorrelated with surface albedo or geology, The nighttime anomalies may be due to regional thermal inertia variations of an unknown origin, which are equivalent to a two- to threefold variation in thermal conductivity, or to endogenic heat fluxes locally reaching 1 watt per square meter. Endogenic heat flow at this high level, although consistent with some geological evidence, is theoretically unlikely.	Lowell Observ, Flagstaff, AZ 86001 USA; CALTECH, Jet Prop Lab, Pasadena, CA 91109 USA; NASA, Goddard Inst Space Studies, New York, NY 10025 USA	California Institute of Technology; National Aeronautics & Space Administration (NASA); NASA Jet Propulsion Laboratory (JPL); National Aeronautics & Space Administration (NASA); NASA Goddard Space Flight Center	Spencer, JR (corresponding author), Lowell Observ, 1400 W Mars Hill Rd, Flagstaff, AZ 86001 USA.							Alley R., 1986, J GLACIOL, V32, P425, DOI [10.3189/s0022143000012132, DOI 10.3189/S0022143000012132]; BLANEY DL, 1999, LUNAR PLANET SCI, V30, P1657; BROWN RH, 1987, ICARUS, V72, P84, DOI 10.1016/0019-1035(87)90122-9; BURATTI B, 1983, ICARUS, V55, P93, DOI 10.1016/0019-1035(83)90053-2; Carr MH, 1998, NATURE, V391, P363, DOI 10.1038/34857; CLARK RN, 1983, ICARUS, V56, P233, DOI 10.1016/0019-1035(83)90036-2; DOMINGUE DL, 1991, ICARUS, V90, P30, DOI 10.1016/0019-1035(91)90066-3; ELUSZKIEWICZ J, 1991, J GEOPHYS RES-PLANET, V96, P19217, DOI 10.1029/91JA01858; Greeley R, 1998, ICARUS, V135, P4, DOI 10.1006/icar.1998.5969; HANSEN GJ, COMMUNICATION; Helfenstein P, 1998, ICARUS, V135, P41, DOI 10.1006/icar.1998.5975; HOBBS PV, 1974, ICE PHYSICS; Ip WH, 1998, GEOPHYS RES LETT, V25, P829, DOI 10.1029/98GL00472; Kivelson MG, 1997, SCIENCE, V276, P1239, DOI 10.1126/science.276.5316.1239; MCEWEN AS, 1986, J GEOPHYS RES-SOLID, V91, P8077, DOI 10.1029/JB091iB08p08077; Moore JM, 1998, ICARUS, V135, P127, DOI 10.1006/icar.1998.5973; MORRISON D, 1977, PLANETARY SATELLITES, P269; OJAKANGAS GW, 1989, ICARUS, V81, P220, DOI 10.1016/0019-1035(89)90052-3; Orton GS, 1996, SCIENCE, V274, P389, DOI 10.1126/science.274.5286.389; PAPPALARDO RT, IN PRESS J GEOPHYS R; PHILLIPS CK, COMMUNICATION; POSPIESZALSKA MK, 1989, ICARUS, V78, P1, DOI 10.1016/0019-1035(89)90065-1; ROSS MN, 1987, NATURE, V325, P133, DOI 10.1038/325133a0; SAARI JM, 1963, ICARUS, V2, P115, DOI 10.1016/0019-1035(63)90011-3; SPENCER JR, 1987, ICARUS, V69, P297, DOI 10.1016/0019-1035(87)90107-2; SPENCER JR, 1987, THESIS U ARIZONA TUC; SQUYRES SW, 1983, NATURE, V301, P225, DOI 10.1038/301225a0; TITTEMORE WC, 1989, ICARUS, V77, P82, DOI 10.1016/0019-1035(89)90008-0; Urquhart ML, 1996, J GEOPHYS RES-PLANET, V101, P21169, DOI 10.1029/96JE02239; VANCLEVE JE, UNPUB; WARREN SG, 1984, APPL OPTICS, V23, P1206, DOI 10.1364/AO.23.001206; WECHSLER AE, 1972, THERMAL CHARACTERIST, P215; WILDEY RL, 1967, J GEOPHYS RES, V72, P3743, DOI 10.1029/JZ072i014p03743; Williams KK, 1998, GEOPHYS RES LETT, V25, P4273, DOI 10.1029/1998GL900144	34	191	194	0	13	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAY 28	1999	284	5419					1514	1516		10.1126/science.284.5419.1514	http://dx.doi.org/10.1126/science.284.5419.1514			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	200PD	10348736				2022-12-28	WOS:000080548100033
J	Gibson, CM				Gibson, CM			Primary angioplasty compared with thrombolysis: New issues in the era of glycoprotein IIb IIIa inhibition and intracoronary stenting	ANNALS OF INTERNAL MEDICINE			English	Article							ACUTE MYOCARDIAL-INFARCTION; TISSUE-PLASMINOGEN-ACTIVATOR; IMMEDIATE CORONARY ANGIOPLASTY; INTRAVENOUS STREPTOKINASE; RECEPTOR BLOCKADE; TRIAL; THERAPY; FLOW	The past decade has witnessed a dramatic expansion in the scope of both mechanical and pharmacologic methods for opening occluded arteries in patients with acute myocardial infarction. Although the relative merits of conventional balloon angioplasty and thrombolysis have been evaluated, this old debate is being eclipsed by new comparisons. New device technologies, such as intracoronary stenting; more potent and more fibrin-specific thrombolytic agents; and new antithrombotic and antiplatelet agents all offer the potential for improved outcomes. But despite these recent developments, the time-dependent open artery hypothesis-which states that the achievement of early, full, and sustained reperfusion is associated with better outcomes-remains essentially unchanged. This article reviews data on the ability of six revascularization strategies-stand-alone thrombolysis, conventional percutaneous transluminal coronary angioplasty, stenting, glycoprotein IIb/IIIa inhibitors plus thrombolytic agents, glycoprotein IIb/IIIa inhibitors plus interventions, and the combination of pharmacologic and mechanical interventions-to produce early, full, and sustained reperfusion.	Allegheny Gen Hosp, Pittsburgh, PA 15212 USA	Allegheny General Hospital	Gibson, CM (corresponding author), Allegheny Gen Hosp, 320 E North Ave, Pittsburgh, PA 15212 USA.		Gibson, C. Michael/AAE-8212-2019					Antman EM, 1998, J AM COLL CARDIOL, V31, p191A, DOI 10.1016/S0735-1097(97)84535-4; ANTMAN EM, IN PRESS CIRCULATION; Betriu A, 1997, NEW ENGL J MED, V336, P1621; Bode C, 1996, CIRCULATION, V94, P891, DOI 10.1161/01.CIR.94.5.891; Braunwald E, 1996, J AM COLL CARDIOL, V27, P1333, DOI 10.1016/0735-1097(96)00007-1; Brener SJ, 1998, CIRCULATION, V98, P734, DOI 10.1161/01.CIR.98.8.734; Cannon CP, 1998, CIRCULATION, V98, P2805, DOI 10.1161/01.CIR.98.25.2805; Cannon CP, 1997, CIRCULATION, V95, P351; DEBOER MJ, 1994, J AM COLL CARDIOL, V23, P1004, DOI 10.1016/0735-1097(94)90582-7; Every NR, 1996, NEW ENGL J MED, V335, P1253, DOI 10.1056/NEJM199610243351701; GIBBONS RJ, 1993, NEW ENGL J MED, V328, P685, DOI 10.1056/NEJM199303113281003; Gibson CM, 1996, CIRCULATION, V93, P879, DOI 10.1161/01.CIR.93.5.879; GIBSON CM, 1998, CONT MANAGEMENT ACUT; GIBSON CM, 1999, PRIMARY RESCUE ANGIO; Gibson M, 1998, CIRCULATION, V98, P559; GRINES CL, 1993, NEW ENGL J MED, V328, P673, DOI 10.1056/NEJM199303113281001; HEIJER P, 1998, CIRCULATION, V98, P2117; Kawai C, 1997, J AM COLL CARDIOL, V29, P1447, DOI 10.1016/S0735-1097(97)00074-0; Kleiman NS, 1993, J AM COLL CARDIOL, V22, P381, DOI 10.1016/0735-1097(93)90041-X; KNATTERUD G, 1988, JAMA-J AM MED ASSOC, V260, P2849; Kong DF, 1998, CIRCULATION, V98, P2829, DOI 10.1161/01.CIR.98.25.2829; Miller JM, 1998, J AM COLL CARDIOL, V31, p191A, DOI 10.1016/S0735-1097(97)84536-6; Neumann FJ, 1998, CIRCULATION, V98, P2695, DOI 10.1161/01.CIR.98.24.2695; Ohman EM, 1997, CIRCULATION, V95, P846; OHMAN EM, 1990, CIRCULATION, V82, P781, DOI 10.1161/01.CIR.82.3.781; Ribeiro EE, 1993, J AM COLL CARDIOL, V22, P376, DOI 10.1016/0735-1097(93)90040-8; ROSS AM, 1993, NEW ENGL J MED, V329, P1615; SIMOONS ML, 1988, LANCET, V1, P199; Suryapranata H, 1998, CIRCULATION, V97, P2502, DOI 10.1161/01.CIR.97.25.2502; Topol E, 1997, NEW ENGL J MED, V337, P1118; TOPOL EJ, 1987, NEW ENGL J MED, V317, P581, DOI 10.1056/NEJM198709033171001; Weaver WD, 1997, JAMA-J AM MED ASSOC, V278, P2093, DOI 10.1001/jama.278.23.2093; ZIJLSTRA F, 1993, NEW ENGL J MED, V328, P680, DOI 10.1056/NEJM199303113281002	33	25	28	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAY 18	1999	130	10					841	847		10.7326/0003-4819-130-10-199905180-00019	http://dx.doi.org/10.7326/0003-4819-130-10-199905180-00019			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	196JJ	10366375				2022-12-28	WOS:000080305000008
J	McLaughlin, VV; Genthner, DE; Panella, MM; Hess, DM; Rich, S				McLaughlin, VV; Genthner, DE; Panella, MM; Hess, DM; Rich, S			Compassionate use of continuous prostacyclin in the management of secondary pulmonary hypertension: A case series	ANNALS OF INTERNAL MEDICINE			English	Article							EPOPROSTENOL PROSTACYCLIN; VASCULAR-DISEASE; THERAPY; REDUCTION; INFUSION; VESSELS	Background: Treatment of patients with secondary pulmonary hypertension has been unsatisfactory. Objective: To describe exercise capacity, functional class, and hemodynamic variables after long-term intravenous infusion of prostacyclin in patients with secondary pulmonary hypertension. Design: Case series. Setting: Academic referral center. Patients: 33 patients with secondary, precapillary pulmonary hypertension (New York Heart Association class III or IV). Intervention: Continuous intravenous prostacyclin administered by portable infusion pump on a compassionate-use basis. Measurements: Functional class, treadmill time, and hemodynamic variables. Results: Patients were followed for an average of 12.7 +/- 5.6 months. Exercise tolerance and New York Heart Association class improved in each patient. The duration of treadmill exercise increased from 186 seconds to 491 seconds, an increase of 305 seconds (95% CI, 194 to 417 seconds; P < 0.001). Mean pulmonary artery pressure decreased from 60 mm Hg to 46 mm Hg. a decrease of 14 mm Hg (Cl, 9 to 19 mm Hg; P < 0.001). Cardiac output increased from 3.90 L/min to 6.30 L/min, an increase of 2.40 L/min (CI, 1.56 to 3.25 L/min; P < 0.001). The pulmonary vascular resistance decreased from 1143 dynes . s/cm(5) to 575 dynes . s/cm(5), a decrease of 567 dynes s/cm(5) (CI, 407 to 727 dynes . s/cm(5); P < 0.001). Patients with collagen vascular disease, congenital heart disease, and portopulmonary hypertension were analyzed with other patients and separately. All groups had a statistically significant reduction in mean pulmonary artery pressure and a statistically significant increase in cardiac output. Conclusion: Intravenous prostacyclin may be effective in the treatment of patients with certain types of secondary pulmonary hypertension.	Rush Presbyterian St Lukes Med Ctr, Chicago, IL 60612 USA	Rush University	McLaughlin, VV (corresponding author), Rush Heart Inst, Ctr Pulm Heart Dis, 1725 W Harrison St,Suite 020, Chicago, IL 60612 USA.							Barst RJ, 1996, NEW ENGL J MED, V334, P296, DOI 10.1056/NEJM199602013340504; BERMANROSENZWEI.E, 1998, AM J RESP, V157, pA596; FUSTER V, 1984, CIRCULATION, V70, P580, DOI 10.1161/01.CIR.70.4.580; HAWORTH SG, 1984, BRIT HEART J, V52, P557; Higenbottam TW, 1998, HEART, V79, P175, DOI 10.1136/hrt.79.2.175; Humbert M, 1998, CHEST, V114, p80S, DOI 10.1378/chest.114.1_Supplement.80S; Koh ET, 1996, BRIT J RHEUMATOL, V35, P989; Kuo PC, 1997, TRANSPLANTATION, V63, P604, DOI 10.1097/00007890-199702270-00020; Mandell MS, 1996, CLIN CHEST MED, V17, P17, DOI 10.1016/S0272-5231(05)70296-3; McLaughlin VV, 1998, NEW ENGL J MED, V338, P273, DOI 10.1056/NEJM199801293380501; PIETRA GG, 1989, CIRCULATION, V80, P1198, DOI 10.1161/01.CIR.80.5.1198; RABINOVITCH M, 1984, CIRCULATION, V69, P655, DOI 10.1161/01.CIR.69.4.655; RICH S, 1987, ANN INTERN MED, V107, P216, DOI 10.7326/0003-4819-107-2-216; RICH S, 1992, NEW ENGL J MED, V327, P76, DOI 10.1056/NEJM199207093270203; RICH S, 1987, CIRCULATION, V76, P135, DOI 10.1161/01.CIR.76.1.135; Rich S, 1998, WORLD S PRIM PULM HY; WAGENVOORT CA, 1970, CIRCULATION, V42, P1163, DOI 10.1161/01.CIR.42.6.1163; WAGENVOORT CA, 1985, MINN MED, V68, P45; YAMAKI S, 1985, BRIT HEART J, V54, P428; YOUNG RH, 1978, AM J MED, V64, P998, DOI 10.1016/0002-9343(78)90455-2	20	156	159	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAY 4	1999	130	9					740	743		10.7326/0003-4819-130-9-199905040-00014	http://dx.doi.org/10.7326/0003-4819-130-9-199905040-00014			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	192DE	10357693				2022-12-28	WOS:000080062300005
J	Min, KT; Benzer, S				Min, KT; Benzer, S			Preventing neurodegeneration in the Drosophila mutant bubblegum	SCIENCE			English	Article							X-LINKED ADRENOLEUKODYSTROPHY; CHILDHOOD ADRENOLEUKODYSTROPHY; BRAIN DEGENERATION; FATTY-ACIDS; ADRENOMYELONEUROPATHY; GENE; MICE	The Drosophila melanogaster recessive mutant bubblegum (bgm) exhibits adult neurodegeneration, with marked dilation of photoreceptor axons. The bubblegum mutant shows elevated levels of very long chain fatty acids (VLCFAs), as seen in the human disease adrenoleukodystrophy (ALD). In ALD, the excess can be lowered by dietary treatment with "Lorenzo's oil," a mixture of unsaturated fatty acids. Feeding the fly mutant one of the components, glyceryl trioleate oil, blocked the accumulation of excess VLCFAs as well as development of the pathology. Mutant flies thus provide a potential model system for studying mechanisms of neurodegenerative disease and screening drugs for treatment.	CALTECH, Div Biol 156 29, Pasadena, CA 91125 USA	California Institute of Technology	Benzer, S (corresponding author), CALTECH, Div Biol 156 29, Pasadena, CA 91125 USA.			min, kyung-tai/0000-0003-0983-4258				AUBOURG P, 1993, NEW ENGL J MED, V329, P745, DOI 10.1056/NEJM199309093291101; BENZER S, 1967, P NATL ACAD SCI USA, V58, P1112, DOI 10.1073/pnas.58.3.1112; COHEN SMZ, 1983, AM J OPHTHALMOL, V95, P82; ForssPetter S, 1997, J NEUROSCI RES, V50, P829, DOI 10.1002/(SICI)1097-4547(19971201)50:5<829::AID-JNR19>3.0.CO;2-W; HAYARAN A, UNPUB; Kobayashi T, 1997, BIOCHEM BIOPH RES CO, V232, P631, DOI 10.1006/bbrc.1997.6340; KOIKE R, 1991, J NEUROL SCI, V103, P188, DOI 10.1016/0022-510X(91)90163-2; Kretzschmar D, 1997, J NEUROSCI, V17, P7425; LAZO O, 1988, P NATL ACAD SCI USA, V85, P7647, DOI 10.1073/pnas.85.20.7647; Lu JF, 1997, P NATL ACAD SCI USA, V94, P9366, DOI 10.1073/pnas.94.17.9366; Min KT, 1997, CURR BIOL, V7, P885, DOI 10.1016/S0960-9822(06)00378-2; Moser HW, 1991, TECHNIQUES DIAGNOSTI, P177; Moser HW, 1995, METABOLIC MOL BASES, V7h, P2325; MOSSER J, 1993, NATURE, V361, P726, DOI 10.1038/361726a0; Mutsuddi M, 1998, CURR BIOL, V8, pR809, DOI 10.1016/S0960-9822(07)00506-4; POULOS A, 1995, LIPIDS, V30, P1, DOI 10.1007/BF02537036; Powers JM, 1998, BRAIN PATHOL, V8, P101; RIZZO WB, 1986, NEUROLOGY, V36, P357, DOI 10.1212/WNL.36.3.357; Uchiyama A, 1996, J BIOL CHEM, V271, P30360, DOI 10.1074/jbc.271.48.30360; UCHIYAMA A, 1998, DNA RES, V5, P169; Watkins PA, 1997, PROG LIPID RES, V36, P55, DOI 10.1016/S0163-7827(97)00004-0	21	145	152	0	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 18	1999	284	5422					1985	1988		10.1126/science.284.5422.1985	http://dx.doi.org/10.1126/science.284.5422.1985			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	207JA	10373116				2022-12-28	WOS:000080932700046
J	Wahr, JA; Parks, R; Boisvert, D; Comunale, M; Fabian, J; Ramsay, J; Mangano, DT				Wahr, JA; Parks, R; Boisvert, D; Comunale, M; Fabian, J; Ramsay, J; Mangano, DT		Multicenter Study Perioperative Ischemia Res Gr	Preoperative serum potassium levels and perioperative outcomes in cardiac surgery patients	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ACUTE MYOCARDIAL-INFARCTION; PRIOR DIURETIC THERAPY; VENTRICULAR-FIBRILLATION; CHRONIC HYPOKALEMIA; ARRHYTHMIAS; RISK; DYSRHYTHMIAS; HYPERTENSION; MAGNESIUM	Context Although potassium is critical for normal electrophysiology, the association between abnormal preoperative serum potassium level and perioperative adverse events such as arrhythmias has not been examined rigorously. Objective To determine the prevalence of abnormal preoperative serum potassium levels and whether such abnormal levels are associated with adverse perioperative events. Design and Setting Prospective, observational, case-control study of data collected from 24 diverse US medical centers in a 2-year period from September 1, 1991, to September 1, 1993. Patients A total of 2402 patients (mean [SD] age, 65.1 [10.3] years; 24% female) undergoing elective coronary artery bypass grafting who were not enrolled in another protocol. The study population was identified using systematic sampling of every nth patient, in which n was based on expected total number of procedures at that center during the study period. Main Outcome Measures Intraoperative and postoperative arrhythmias, the need for cardiopulmonary resuscitation (CPR), cardiac death, and death due to any cause prior to discharge, by preoperative serum potassium level. Results Perioperative arrhythmias occurred in 1290 (53.7%) of 2402 patients, with 238 patients (10.7%) having intraoperative arrhythmias, 329 (13.7%) having postoperative nonatrial arrhythmias, and 865 (36%) having postoperative atrial flutter or fibrillation. The incidence of adverse outcomes was 3.6% for death, 2.0% for cardiac death, and 3.5% for CPR. Serum potassium level less than 3.5 mmol/L was a predictor of serious perioperative arrhythmia (odds ratio [OR], 2.2; 95% confidence interval [CI], 1.2-4.0), intraoperative arrhythmia (OR, 2.0; 95% CI, 1.0-3.6), and postoperative atrial fibrillation/flutter (OR, 1.7, 95% CI, 1.0-2.7), and these relationships were unchanged after adjusting for confounders. The significant univariate association between increased need for CPR and serum potassium level less than 3.3 mmol/L (OR, 3.3; 95% CI, 1.2-9.5) and greater than 5.2 mmol/L (OR, 3.0; 95% CI, 1.1-8.7) became nonsignificant after adjusting for confounders. Conclusions Perioperative arrhythmia and the need for CPR increased as preoperative serum potassium level decreased below 3.5 mmol/L. Although interventional trials are required to determine whether preoperative intervention mitigates these adverse associations, preoperative repletion is low cost and low risk, and our data suggest that screening and repletion be considered in patients scheduled for cardiac surgery.	Univ Michigan, Dept Anesthesiol, Ann Arbor, MI 48109 USA; Ischemia Res & Educ Fdn, San Francisco, CA USA; Harvard Univ, Sch Med, Dept Anesthesiol, Boston, MA USA; Univ New Mexico, Dept Anesthesiol, Albuquerque, NM 87131 USA; Emory Univ, Med Ctr, Dept Anesthesiol, Atlanta, GA 30322 USA; Vet Affairs Med Ctr, San Francisco, CA 94121 USA	University of Michigan System; University of Michigan; Harvard University; Harvard Medical School; University of New Mexico; Emory University; US Department of Veterans Affairs; Veterans Health Administration (VHA)	Wahr, JA (corresponding author), Univ Michigan Hosp, Dept Anesthesiol, 1G323-0048,1500 E Med Ctr Dr, Ann Arbor, MI 48109 USA.	jwahr@umich.edu						Blackburn H, 1969, J Electrocardiol, V2, P305; Blackburn H, 1969, J Electrocardiol, V2, P5, DOI 10.1016/S0022-0736(69)80044-0; COHEN JD, 1987, AM J CARDIOL, V60, P548, DOI 10.1016/0002-9149(87)90303-1; COOPER WD, 1984, EUR HEART J, V5, P464, DOI 10.1093/oxfordjournals.eurheartj.a061692; DYCKNER T, 1984, ACTA MED SCAND, V216, P127; FRIEDENSOHN A, 1991, INT J CARDIOL, V32, P331, DOI 10.1016/0167-5273(91)90295-Z; GOULD RJ, 1985, NEUROLOGY, V35, P1208, DOI 10.1212/WNL.35.8.1208; GRUMBACH L, 1954, CIRC RES, V2, P452; HIRSCH IA, 1988, ANESTH ANALG, V67, P131; HOLLAND OB, 1981, AM J MED, V70, P762, DOI 10.1016/0002-9343(81)90530-1; HOLLIFIELD JW, 1981, ACTA MED SCAND, P67; HOLLIFIELD JW, 1986, AM J MED, V80, P8, DOI 10.1016/0002-9343(86)90335-9; HULTING J, 1981, ACTA MED SCAND, P109; JANKO O, 1992, WIEN MED WOCHENSCHR, V142, P78; JOHANSSON BW, 1984, DRUGS, V28, P77, DOI 10.2165/00003495-198400281-00008; LOGIC JR, 1973, CARDIOVASC RES, V7, P501, DOI 10.1093/cvr/7.4.501; MIALL WE, 1983, BMJ-BRIT MED J, V287, P1249; NORDREHAUG JE, 1983, BRIT HEART J, V50, P525; NORDREHAUG JE, 1981, ACTA MED SCAND, P101; OBEID AI, 1978, CIRC RES, V43, P601, DOI 10.1161/01.RES.43.4.601; SHAH KB, 1990, ANESTH ANALG, V70, P240; SISCOVICK DS, 1994, NEW ENGL J MED, V330, P1852, DOI 10.1056/NEJM199406303302603; SOLOMON RJ, 1981, ACTA MED SCAND, P87; VITEZ TS, 1985, ANESTHESIOLOGY, V63, P130, DOI 10.1097/00000542-198508000-00002; WONG KC, 1993, ANESTH ANALG, V77, P1238; YANO K, 1991, ANGIOLOGY, V42, P878, DOI 10.1177/000331979104201103; Zehender M, 1997, J AM COLL CARDIOL, V29, P1028, DOI 10.1016/S0735-1097(97)00053-3	27	86	91	0	6	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 16	1999	281	23					2203	2210		10.1001/jama.281.23.2203	http://dx.doi.org/10.1001/jama.281.23.2203			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	204RB	10376573	Bronze			2022-12-28	WOS:000080777000034
J	Wong, JG				Wong, JG			Cold blue	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																			0	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 16	1999	281	23					2168	2168		10.1001/jama.281.23.2168	http://dx.doi.org/10.1001/jama.281.23.2168			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	204RB	10376548				2022-12-28	WOS:000080777000001
J	Ebrahim, S				Ebrahim, S			Disability in older people: a mass problem requiring mass solutions	LANCET			English	Editorial Material							RISK		Univ Bristol, Dept Social Med, Bristol BS8 2PR, Avon, England	University of Bristol	Ebrahim, S (corresponding author), Univ Bristol, Dept Social Med, Bristol BS8 2PR, Avon, England.							Beck JC, 1996, JAMA-J AM MED ASSOC, V276, P1756, DOI 10.1001/jama.276.21.1756; deLeon CFM, 1997, AM J EPIDEMIOL, V145, P488; Dunlop DD, 1998, J CLIN EPIDEMIOL, V51, P1253, DOI 10.1016/S0895-4356(98)00128-0; Ebrahim S, 1997, BMJ-BRIT MED J, V314, P1666, DOI 10.1136/bmj.314.7095.1666; EISENBERG L, 1984, AM J MED, V77, P524, DOI 10.1016/0002-9343(84)90114-1; HARWOOD RH, 1996, EPIDEMIOLOGY OLD AGE, P378; MARTIN J, 1987, OPCS SURVEYS DISABIL; Stuck AE, 1999, SOC SCI MED, V48, P445, DOI 10.1016/S0277-9536(98)00370-0; VERBRUGGE LM, 1994, SOC SCI MED, V38, P1, DOI 10.1016/0277-9536(94)90294-1; Vita AJ, 1998, NEW ENGL J MED, V338, P1035, DOI 10.1056/NEJM199804093381506; Wannamethee SG, 1998, ARCH INTERN MED, V158, P2433, DOI 10.1001/archinte.158.22.2433	11	30	32	0	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUN 12	1999	353	9169					1990	1992		10.1016/S0140-6736(99)00195-6	http://dx.doi.org/10.1016/S0140-6736(99)00195-6			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	205GD	10376611				2022-12-28	WOS:000080812200006
J	Phillips, M; Gleeson, K; Hughes, JMB; Greenberg, J; Cataneo, RN; Baker, L; McVay, WP				Phillips, M; Gleeson, K; Hughes, JMB; Greenberg, J; Cataneo, RN; Baker, L; McVay, WP			Volatile organic compounds in breath as markers of lung cancer: a cross-sectional study	LANCET			English	Article							FIBEROPTIC BRONCHOSCOPY; LIPID-PEROXIDATION; DIAGNOSIS; PENTANE; TUMORS	Background. Many volatile organic compounds (VOCs), principally alkanes and benzene derivatives, have been identified in breath from patients with lung cancer. We investigated whether a combination of VOCs could identify such patients. Methods. We collected breath samples from 108 patients with an abnormal chest radiograph who were scheduled for bronchoscopy. The samples were collected with a portable apparatus, then essayed by gas chromatography and mass spectroscopy. The alveolar gradient of each breath VOC, the difference between the amount in breath and in air, was calculated. Forward stepwise discriminant analysis was used to identify VOCs that discriminated between patients with and without lung cancer. Findings. Lung cancer was confirmed histologically in 60 patients. A combination of 22 breath VOCs, predominantly alkanes, alkane derivatives, and benzene derivatives, discriminated between patients with and without lung cancer, regardless of stage (all p < 0.0003). For stage 1 lung cancer, the 22 VOCs had 100% sensitivity and 81.3% specificity. Cross-validation of the combination correctly predicted the diagnosis in 71.7% patients with lung cancer and 66.7% of those without lung cancer. Interpretation. In patients with an abnormal chest radiograph, a combination of 22 VOCs in breath samples distinguished between patients with and without lung cancer. Prospective studies are needed to confirm the usefulness of breath VOCS for detecting lung cancer in the general population.	St Vincents Med Ctr, Dept Med, Staten Isl, NY 10310 USA; Menssana Res Inc, Ft Lee, NJ USA; New York Med Coll, Dept Med, Valhalla, NY 10595 USA; Penn State Univ, Milton S Hershey Med Ctr, Dept Med, Penn State Geisenger Hlth Syst,Pulm Crit Care Div, Hershey, PA 17033 USA; Hammersmith Hosp, Imperial Coll Sch Med, Dept Resp Med, London, England; McVay Consulting Associates, Doylestown, PA USA	Saint Vincents Hospital Manhattan; New York Medical College; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health; Imperial College London	Phillips, M (corresponding author), St Vincents Med Ctr, Dept Med, Staten Isl, NY 10310 USA.	menssana@bellatlantic.net						BOREK C, 1993, ENVIRON HEALTH PERSP, V101, P237, DOI 10.2307/3431732; BRAWLEY OW, 1998, HARRISONS PRINCIPLES; Crosbie SJ, 1997, HUM EXP TOXICOL, V16, P131, DOI 10.1177/096032719701600301; Dreher D, 1996, EUR J CANCER, V32A, P30, DOI 10.1016/0959-8049(95)00531-5; FEIG DI, 1994, CANC RES S, V43, pS1890; GORDON SM, 1990, J CHROMATOGR, V511, P291, DOI 10.1016/S0021-9673(01)93292-3; GORDON SM, 1985, CLIN CHEM, V31, P1278; Govert JA, 1996, CHEST, V109, P451, DOI 10.1378/chest.109.2.451; HIETANEN E, 1994, EUR J CLIN NUTR, V48, P575; HUMAD S, 1988, FREE RADICAL RES COM, V5, P101, DOI 10.3109/10715768809066917; Khyshiktuev B. S., 1994, Voprosy Onkologii (St. Petersburg), V40, P161; KNEEPKENS CMF, 1992, CLIN INVEST MED, V15, P163; KNEEPKENS CMF, 1994, FREE RADICAL BIO MED, V17, P127; KNIGHT JA, 1995, ANN CLIN LAB SCI, V25, P111; MAK VHF, 1990, THORAX, V45, P373, DOI 10.1136/thx.45.5.373; MINNA JD, 1998, HARRISONS PRINCIPLES; Olopade CO, 1997, CHEST, V111, P862, DOI 10.1378/chest.111.4.862; ONEILL HJ, 1988, CLIN CHEM, V34, P1613; PAULING L, 1971, P NATL ACAD SCI USA, V68, P2374, DOI 10.1073/pnas.68.10.2374; Phillips M, 1997, ANAL BIOCHEM, V247, P272, DOI 10.1006/abio.1997.2069; PHILLIPS M, 1992, SCI AM, V267, P74, DOI 10.1038/scientificamerican0792-74; PHILLIPS M, 1994, FREE RADICAL RES, V20, P333, DOI 10.3109/10715769409145633; PHILLIPS M, IN PRESS J CHROMAT B; POPP W, 1991, CANCER, V67, P72, DOI 10.1002/1097-0142(19910101)67:1<72::AID-CNCR2820670114>3.0.CO;2-L; POPP W, 1992, CANCER, V70, P2278, DOI 10.1002/1097-0142(19921101)70:9<2278::AID-CNCR2820700911>3.0.CO;2-T; PRAKASH UBS, 1994, J BRONCHOLOGY, V1, P4; PRETI G, 1988, J CHROMATOGR-BIOMED, V432, P1, DOI 10.1016/S0378-4347(00)80627-1; Scheller U, 1996, ARCH BIOCHEM BIOPHYS, V328, P245, DOI 10.1006/abbi.1996.0170; SOBOTKA PA, 1994, J HEART LUNG TRANSPL, V13, P224; WEITZ ZW, 1991, LANCET, V337, P933, DOI 10.1016/0140-6736(91)91569-G	30	691	734	13	317	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JUN 5	1999	353	9168					1930	1933		10.1016/S0140-6736(98)07552-7	http://dx.doi.org/10.1016/S0140-6736(98)07552-7			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	202TP	10371572				2022-12-28	WOS:000080668500013
J	Wallon, M; Liou, C; Garner, P; Peyron, F				Wallon, M; Liou, C; Garner, P; Peyron, F			Congenital toxoplasmosis: systematic review of evidence of efficacy of treatment in pregnancy	BRITISH MEDICAL JOURNAL			English	Article							POLYMERASE-CHAIN-REACTION; FOLLOW-UP; PYRIMETHAMINE; PREVENTION; DIAGNOSIS; GONDII	Objective To summarise the evidence that treating toxoplasmosis in pregnancy reduces the risk of congenital toxoplasma infection and improves infant outcomes. Design Systematic review of studies comparing at least two concurrent groups of pregnant women with proved or likely acute toxoplasma infection in which treatments were compared with no treatment and outcomes in the children were reported. Subjects Studies were identified from Medline (1966-97), Pascal (1990-7), Embase (1993-7), and Biological abstracts (1993-5) plus contact with experts in the field, including the European Research Network on Congenital Toxoplasmosis. Main outcome measure Proportion of infected children at 1 year born to infected pregnant women who were or were not treated. Results Out of 2591 papers identified, nine met the inclusion criteria, There were no randomised comparisons, and control groups were generally not directly comparable with the treatment groups. Congenital infection was common in treated groups, five studies showed that treatment was effective and four that it nas not. Conclusion It is unclear whether antenatal treatment in women with presumed toxoplasmosis reduces congenital transmission of Toxoplasma gondii. Screening is expensive, so the effects of treatment and impact of screening programmes need to be evaluated. In countries where screening or treatment is not routine, these technologies should not be introduced outside carefully controlled trials.	Hop Croix Rousse, Serv Parasitol, F-69004 Lyon, France; Univ Lyon 1, Fac Med, Serv Parasitol, F-69365 Lyon, France; Univ Liverpool, Liverpool Sch Trop Med, Int Hlth Div, Infect Dis Grp, Liverpool L3 5QA, Merseyside, England	CHU Lyon; UDICE-French Research Universities; Universite Claude Bernard Lyon 1; Liverpool School of Tropical Medicine; University of Liverpool	Wallon, M (corresponding author), Hop Croix Rousse, Serv Parasitol, F-69004 Lyon, France.		Wallon, martine/D-1340-2013; Garner, Paul/Y-8385-2019; Garner, Paul/HII-5856-2022	Wallon, martine/0000-0001-8285-8550; Garner, Paul/0000-0002-0607-6941; 				Ancelle T., 1996, Bulletin Epidemiologique Hebdomadaire, P227; Bader TJ, 1997, OBSTET GYNECOL, V90, P457, DOI 10.1016/S0029-7844(97)00291-3; BERREBI A, 1994, LANCET, V344, P36, DOI 10.1016/S0140-6736(94)91054-5; DEAN A, 1995, EPI INFO VERSION 6 W; DESMONTS G, 1984, ANN PEDIATR-PARIS, V31, P805; DESMONTS G, 1974, NEW ENGL J MED, V290, P1110, DOI 10.1056/NEJM197405162902003; DESMONTS G, 1974, B NEW YORK ACAD MED, V50, P146; Douche C, 1996, J FR OPHTALMOL, V19, P330; Eskild A, 1996, J Med Screen, V3, P188; EXCLER JL, 1985, LYON MED, V253, P33; GARIN JP, 1984, ANN PEDIATR-PARIS, V31, P841; HOHLFELD P, 1989, J PEDIATR-US, V115, P765, DOI 10.1016/S0022-3476(89)80660-2; HOHLFELD P, 1994, NEW ENGL J MED, V331, P695, DOI 10.1056/NEJM199409153311102; JEANNEL D, 1990, LANCET, V336, P359, DOI 10.1016/0140-6736(90)91890-M; KNERER B, 1995, WIEN KLIN WOCHENSCHR, V107, P137; KRAUBIG H, 1966, TAXOPLASMOSE PRAKTIS; Lambotte R, 1976, J Gynecol Obstet Biol Reprod (Paris), V5, P265; Peyron F, 1996, NEW ENGL J MED, V334, P993, DOI 10.1056/NEJM199604113341517; PORTER SB, 1992, NEW ENGL J MED, V327, P1643, DOI 10.1056/NEJM199212033272306; REMINGTON JS, 1992, INFECT DIS FETUS NEW, P349; Roux C, 1976, J Gynecol Obstet Biol Reprod (Paris), V5, P249; *ROYAL COLL OBSTET, 1992, PREN SCREEN TAX UK R; SHEFFIELD HG, 1975, J PARASITOL, V61, P704, DOI 10.2307/3279470; THOUMSIN H, 1992, SCAND J INFECT DIS S, V84, P84; WALLON M, 1994, LANCET, V344, P541; Wallon Martine, 1997, Pediatric Research, V42, P400, DOI 10.1203/00006450-199709000-00114	26	98	108	0	13	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JUN 5	1999	318	7197					1511	1514		10.1136/bmj.318.7197.1511	http://dx.doi.org/10.1136/bmj.318.7197.1511			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	204HC	10356003	Green Published, Green Submitted, Bronze			2022-12-28	WOS:000080757300022
J	Tortorella, MD; Burn, TC; Pratta, MA; Abbaszade, I; Hollis, JM; Liu, R; Rosenfeld, SA; Copeland, RA; Decicco, CP; Wynn, R; Rockwell, A; Yang, F; Duke, JL; Solomon, K; George, H; Bruckner, R; Nagase, H; Itoh, Y; Ellis, DM; Ross, H; Wiswall, BH; Murphy, K; Hillman, MC; Hollis, GF; Newton, RC; Magolda, RL; Trzaskos, JM; Arner, EC				Tortorella, MD; Burn, TC; Pratta, MA; Abbaszade, I; Hollis, JM; Liu, R; Rosenfeld, SA; Copeland, RA; Decicco, CP; Wynn, R; Rockwell, A; Yang, F; Duke, JL; Solomon, K; George, H; Bruckner, R; Nagase, H; Itoh, Y; Ellis, DM; Ross, H; Wiswall, BH; Murphy, K; Hillman, MC; Hollis, GF; Newton, RC; Magolda, RL; Trzaskos, JM; Arner, EC			Purification and cloning of aggrecanase-1: A member of the ADAMTS family of proteins	SCIENCE			English	Article							CARTILAGE PROTEOGLYCAN DEGRADATION; DROSOPHILA-MELANOGASTER CELLS; HUMAN SYNOVIAL-FLUID; INTERGLOBULAR DOMAIN; ARTICULAR-CARTILAGE; CLEAVAGE SITE; I REPEATS; THROMBOSPONDIN; CATABOLISM; ADHESION	We purified,cloned, and expressed aggrecanase, a protease that is thought to be responsible for the:degradation of cartilage aggrecan in arthritic diseases. Aggrecanase-1 [a disintegrin and metalloproteinase with thrombospondin motifs-4 (ADAMTS-4)] is a member of the: ADAMTS protein family that cleaves aggrecan at the glutamic acid-373-alanine-374 bond. The identification of this protease provides a specific target for the development of therapeutics to prevent cartilage degradation in arthritis.	Dupont Merck Pharmaceut Co, Dept Inflammatory Dis Res, Wilmington, DE 19880 USA; Dupont Merck Pharmaceut Co, Dept Appl Biotechnol, Wilmington, DE 19880 USA; Dupont Merck Pharmaceut Co, Dept Enzymol, Wilmington, DE 19880 USA; Dupont Merck Pharmaceut Co, Dept Chem & Phys Sci, Wilmington, DE 19880 USA; Univ Kansas, Sch Med, Dept Biochem & Mol Biol, Kansas City, KS 66160 USA	DuPont; DuPont; DuPont; DuPont; University of Kansas; University of Kansas Medical Center	Arner, EC (corresponding author), Dupont Merck Pharmaceut Co, Dept Inflammatory Dis Res, Wilmington, DE 19880 USA.	elizabeth.c.arner@dupontpharma.com		Burn, Timothy/0000-0001-6648-4333; Itoh, Yoshifumi/0000-0002-2128-2823				Arner EC, 1998, OSTEOARTHR CARTILAGE, V6, P214, DOI 10.1053/joca.1998.0114; Arner EC, 1999, J BIOL CHEM, V274, P6594, DOI 10.1074/jbc.274.10.6594; Arner EC, 1996, BIOCHEM J, V318, P417, DOI 10.1042/bj3180417; ARNER EC, UNPUB; BARR PJ, 1991, CELL, V66, P1, DOI 10.1016/0092-8674(91)90129-M; BUNCH TA, 1988, NUCLEIC ACIDS RES, V16, P1043, DOI 10.1093/nar/16.3.1043; BURN TC, IN PRESS J BIOL CHEM; DURR J, 1993, EXP CELL RES, V207, P235, DOI 10.1006/excr.1993.1189; FLANNERY CR, 1992, J BIOL CHEM, V267, P1008; FOSANG AJ, 1991, J BIOL CHEM, V266, P15579; FOSANG AJ, 1993, BIOCHEM J, V295, P273, DOI 10.1042/bj2950273; Fosang AJ, 1996, FEBS LETT, V380, P17, DOI 10.1016/0014-5793(95)01539-6; Gantt SM, 1997, J BIOL CHEM, V272, P19205, DOI 10.1074/jbc.272.31.19205; GUO NH, 1992, J BIOL CHEM, V267, P19349; HUGHES CE, 1995, BIOCHEM J, V305, P799, DOI 10.1042/bj3050799; ILIC MZ, 1992, ARCH BIOCHEM BIOPHYS, V294, P115, DOI 10.1016/0003-9861(92)90144-L; Ishikawa K, 1998, DNA Res, V5, P169, DOI 10.1093/dnares/5.3.169; Kuno K, 1997, J BIOL CHEM, V272, P556, DOI 10.1074/jbc.272.1.556; Kuno K, 1998, J BIOL CHEM, V273, P13912, DOI 10.1074/jbc.273.22.13912; LARK MW, 1995, J BIOL CHEM, V270, P2550, DOI 10.1074/jbc.270.6.2550; LOHMANDER LS, 1993, ARTHRITIS RHEUM, V36, P1214; LOULAKIS P, 1992, BIOCHEM J, V284, P589, DOI 10.1042/bj2840589; PRATER CA, 1991, J CELL BIOL, V112, P1031, DOI 10.1083/jcb.112.5.1031; PRATTA MA, 1997, T ORTHOP RES SOC, V22, P453; RIO DC, 1985, MOL CELL BIOL, V5, P1833, DOI 10.1128/MCB.5.8.1833; SALTER DM, 1992, BRIT J RHEUMATOL, V31, P231; SANDY JD, 1992, J CLIN INVEST, V89, P1512, DOI 10.1172/JCI115742; SANDY JD, 1991, J BIOL CHEM, V266, P8683; SOLOMON K, UNPUB; TORTORELLA MD, UNPUB; VANWART HE, 1990, P NATL ACAD SCI USA, V87, P5578, DOI 10.1073/pnas.87.14.5578	31	569	606	1	31	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 4	1999	284	5420					1664	1666		10.1126/science.284.5420.1664	http://dx.doi.org/10.1126/science.284.5420.1664			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	202TM	10356395				2022-12-28	WOS:000080668300043
J	Samaras, K; Kelly, PJ; Chiano, MN; Spector, TD; Campbell, LV				Samaras, K; Kelly, PJ; Chiano, MN; Spector, TD; Campbell, LV			Genetic and environmental influences on total-body and central abdominal fat: The effect of physical activity in female twins	ANNALS OF INTERNAL MEDICINE			English	Article						twin studies; obesity; body composition; exercise genetic predisposition to disease	DEPENDENT DIABETES-MELLITUS; X-RAY ABSORPTIOMETRY; INSULIN-RESISTANCE; WEIGHED RECORDS; NATIONAL-HEALTH; DIETARY-INTAKE; UNITED-STATES; HEART-DISEASE; RISK-FACTORS; FOLLOW-UP	Background: The increasing prevalence of obesity has focused attention on the contribution of physical activity and its interaction with predisposing genetic factors. Objective: To examine 1) the relation between physical activity and total-body and central abdominal fat, independent of genetic and other environmental factors, and 2) the influence of physical activity in persons who are genetically susceptible to generalized or central adiposity. Design: Cross-sectional study. Setting: A London academic teaching hospital. Patients: 970 healthy female twins (mean age, 55.5 years [range, 39 to 70 years]; body mass index, 24.4 kg/m(2) [range, 16.4 to 44.0 kg/mg(2)]). There were 241 monozygotic pairs, 228 dizygotic pairs, and 32 women whose co-twin lacked complete data. Fifty-six percent of participants were of normal weight, 30% were overweight, 7% were obese, and 7% were underweight. Measurements: Total-body and central abdominal fat were measured by dual-energy x-ray absorptiometry. Physical activity was assessed by quantitative and semiquantitative questionnaires. Data on dietary intake, socioeconomic status, smoking status, and use of hormone replacement therapy (HRT) were also gathered. Results: Total-body and abdominal central adiposity were lower with higher levels of home, sporting, and sweating-associated activity. Total-body and central abdominal fat were 5.6 kg and 0.44 kg lower, respectively, in participants who reported vigorous weight-bearing activity. Physical activity was the strongest independent predic tor of total-body fat (P = -0.6 [CI, -1.06 to -0.15]; P = 0.009) and central abdominal fat (P = -0.07 [CI, -0.1 to -0.03]; P < 0.001) in a regression model that included age, diet, smoking, HRT use, and socioeconomic status. Monozygotic twin pairs who were concordant for smoking and HRT status but were discordant for moderate-intensity sport showed greater within-pair differences in total-body fat than those who were concordant for activity level. In this model, 1 and 2 hours of moderate-intensity sport accounted for within-pair differences of 1.0 kg (P = 0.050) and 1.4 kg (P = 0.040), respectively, of total-body fat. In participants who had an overweight twin, higher levels of physical activity were still associated with 3.96-kg lower total-body fat and 0.53-kg lower central abdominal fat. Conclusions: Current physical activity predicts lower total-body and central abdominal adiposity in healthy middle-aged women. After controlling for genetic and environmental factors, the influence of physical activity was greater than that of other measured environmental factors. Participants with a genetic predisposition to adiposity did not show a lesser effect of physical activity on body fat mass.	St Thomas Hosp, Twin Res & Genet Epidemiol Unit, London SE1 7EH, England; Gemini Holdings PLC, Cambridge CB4 4GH, England; St Vincents Hosp, Ctr Diabet, Darlinghurst, NSW 2010, Australia; St Vincents Clin, Darlinghurst, NSW 2010, Australia	Guy's & St Thomas' NHS Foundation Trust; St Vincents Hospital Sydney	Campbell, LV (corresponding author), St Vincents Hosp, Ctr Diabet, 372 Victoria St, Darlinghurst, NSW 2010, Australia.	l.campbell@garvan.unsw.edu.a	Spector, Tim D/F-6533-2012; Campbell, Lesley V/B-2271-2008		Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Abate N, 1996, DIABETES, V45, P1684, DOI 10.2337/diabetes.45.12.1684; BALLOR DL, 1991, INT J OBESITY, V15, P717; BASSEY EJ, 1990, EUR J APPL PHYSIOL, V60, P385, DOI 10.1007/BF00713504; BINGHAM SA, 1994, BRIT J NUTR, V72, P619, DOI 10.1079/BJN19940064; BINGHAM SA, 1995, BRIT J NUTR, V73, P531, DOI 10.1079/BJN19950057; Boomsma D I, 1998, Twin Res, V1, P34, DOI 10.1375/136905298320566465; Bouchard C, 1994, Obes Res, V2, P400; BOUCHARD C, 1990, ACTA GENET MED GEMEL, V39, P85, DOI 10.1017/S0001566000005596; Carey DG, 1996, DIABETES, V45, P633, DOI 10.2337/diabetes.45.5.633; Carey DGP, 1996, INT J OBESITY, V20, P722; Eriksson J, 1997, DIABETOLOGIA, V40, P125; ERIKSSON KF, 1991, DIABETOLOGIA, V34, P891, DOI 10.1007/BF00400196; Flegal KM, 1998, INT J OBESITY, V22, P39, DOI 10.1038/sj.ijo.0800541; FREEDMAN DS, 1995, AM J EPIDEMIOL, V142, P53, DOI 10.1093/oxfordjournals.aje.a117545; GARBY L, 1988, EUR J CLIN NUTR, V42, P301; GARROW JS, 1995, EUR J CLIN NUTR, V49, P1; GOLDSMITH HH, 1991, BEHAV GENET, V21, P257; Heitmann BL, 1997, AM J CLIN NUTR, V66, P672, DOI 10.1093/ajcn/66.3.672; HELMRICH SP, 1991, NEW ENGL J MED, V325, P147, DOI 10.1056/NEJM199107183250302; *HLTH ED COUNC SPO, 1992, ALL DUNB NAT FITN SU; HOPPER JL, 1994, NEW ENGL J MED, V330, P387, DOI 10.1056/NEJM199402103300603; JENSEN MD, 1995, AM J CLIN NUTR, V61, P274, DOI 10.1093/ajcn/61.2.274; KUCZMARSKI RJ, 1994, JAMA-J AM MED ASSOC, V272, P205, DOI 10.1001/jama.272.3.205; LAPIDUS L, 1984, BMJ-BRIT MED J, V289, P1257, DOI 10.1136/bmj.289.6454.1257; Lauderdale DS, 1997, MED SCI SPORT EXER, V29, P1062, DOI 10.1097/00005768-199708000-00012; LAWS A, 1989, J CLIN ENDOCR METAB, V69, P343, DOI 10.1210/jcem-69-2-343; LICHTMAN SW, 1992, NEW ENGL J MED, V327, P1893, DOI 10.1056/NEJM199212313272701; LILLIOJA S, 1987, DIABETES, V36, P1329, DOI 10.2337/diabetes.36.11.1329; LUNDGREN H, 1989, INT J OBESITY, V13, P413; MANSON JE, 1992, JAMA-J AM MED ASSOC, V268, P63, DOI 10.1001/jama.268.1.63; MANSON JE, 1991, LANCET, V338, P774, DOI 10.1016/0140-6736(91)90664-B; Martin N, 1997, NAT GENET, V17, P387, DOI 10.1038/ng1297-387; Mattsson E, 1997, INT J OBESITY, V21, P380, DOI 10.1038/sj.ijo.0800417; Montgomery HE, 1998, NATURE, V393, P221, DOI 10.1038/30374; OHLSON LO, 1985, DIABETES, V34, P1055, DOI 10.2337/diabetes.34.10.1055; OTTMAN R, 1990, GENET EPIDEMIOL, V7, P177, DOI 10.1002/gepi.1370070302; PAFFENBARGER RS, 1993, NEW ENGL J MED, V328, P538, DOI 10.1056/NEJM199302253280804; PAFFENBARGER RS, 1986, NEW ENGL J MED, V314, P605, DOI 10.1056/NEJM198603063141003; PERUSSE L, 1988, CAN J SPORT SCI, V13, P8; PRENTICE AM, 1995, BRIT MED J, V311, P437, DOI 10.1136/bmj.311.7002.437; REAVEN GM, 1988, DIABETES, V37, P1595, DOI 10.2337/diabetes.37.12.1595; RISSANEN AM, 1991, EUR J CLIN NUTR, V45, P419; Ronnemaa T, 1997, ANN INTERN MED, V126, P26, DOI 10.7326/0003-4819-126-1-199701010-00004; Samaras K, 1998, INT J OBESITY, V22, P149, DOI 10.1038/sj.ijo.0800558; Samaras K, 1998, DIABETES CARE, V21, P2069, DOI 10.2337/diacare.21.12.2069; Samaras K, 1997, J CLIN ENDOCR METAB, V82, P781, DOI 10.1210/jc.82.3.781; SANDVIK L, 1993, NEW ENGL J MED, V328, P533, DOI 10.1056/NEJM199302253280803; SEDGWICK AW, 1988, AUST NZ J MED, V18, P600, DOI 10.1111/j.1445-5994.1988.tb00131.x; SIMONEAU JA, 1995, FASEB J, V9, P1091, DOI 10.1096/fasebj.9.11.7649409; SLATTERY ML, 1992, AM J CLIN NUTR, V55, P943, DOI 10.1093/ajcn/55.5.943; Spector TD, 1996, ARTHRITIS RHEUM, V39, P988, DOI 10.1002/art.1780390616; SVENDSEN OL, 1993, INT J OBESITY, V17, P45; Tregouet DA, 1997, AM J HUM GENET, V61, P189, DOI 10.1086/513895; TROISI RJ, 1991, AM J CLIN NUTR, V53, P1104, DOI 10.1093/ajcn/53.5.1104; vandenBree MBM, 1996, CIRCULATION, V94, P1864, DOI 10.1161/01.CIR.94.8.1864; WILMORE JH, 1995, INT J OBESITY, V19, pS107; WING RR, 1991, ARTERIOSCLER THROMB, V11, P1250, DOI 10.1161/01.ATV.11.5.1250; ZEGER SL, 1986, BIOMETRICS, V42, P121, DOI 10.2307/2531248; Zhang YQ, 1996, J RHEUMATOL, V23, P1130; [No title captured]	60	87	91	0	4	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 1	1999	130	11					873	+		10.7326/0003-4819-130-11-199906010-00002	http://dx.doi.org/10.7326/0003-4819-130-11-199906010-00002			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	200PB	10375335				2022-12-28	WOS:000080547900001
J	Hattersley, AT; Tooke, JE				Hattersley, AT; Tooke, JE			The fetal insulin hypothesis: an alternative explanation of the association of low birthweight with diabetes and vascular disease	LANCET			English	Article							PERSISTENT HYPERINSULINEMIC HYPOGLYCEMIA; IMPAIRED GLUCOSE-TOLERANCE; BIRTH-WEIGHT; ADULT LIFE; PANCREATIC AGENESIS; NONDIABETIC WOMEN; GROWTH; GENE; GLUCOKINASE; MUTATIONS	Low birthweight is associated with insulin resistance, hypertension, coronary-artery disease, and non-insulin-dependent diabetes (NIDDM). A suggested explanation for this association is intrauterine programming in response to maternal malnutrition. We propose, however, that genetically determined insulin resistance results In impaired insulin-mediated growth in the fetus as well as insulin resistance In adult life. Low birthweight, measures of insulin resistance in life, and ultimately glucose intolerance, diabetes, end hypertension could all be phenotypes of the same insulin-resistant genotype. There is evidence to support this hypothesis. Insulin secreted by the fetal pancreas in response to maternal glucose concentrations is a key growth factor. Monogenic diseases that impair sensing of glucose, lower insulin secretion, or increase insulin resistance are associated with impaired fetal growth. Polygenic influences resulting in insulin resistance In the normal population are therefore likely to result in lower birthweight. Abnormal vascular development during fetal life and early childhood, as a result of genetic insulin resistance, could also explain the increased risk of hypertension and vascular disease. The predisposition to NIDDM and vascular disease is likely to be the result of both genetic and fetal environmental factors.	Sch Postgrad Med & Hlth Sci, Dept Diabet & Vasc Med, Exeter EX2 5AX, Devon, England	University of Exeter	Hattersley, AT (corresponding author), Sch Postgrad Med & Hlth Sci, Dept Diabet & Vasc Med, Barrack Rd, Exeter EX2 5AX, Devon, England.			Hattersley, Andrew/0000-0001-5620-473X	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		APARICIO L, 1993, ACTA PAEDIATR, V83, P683; Barker D J, 1992, Paediatr Perinat Epidemiol, V6, P35, DOI 10.1111/j.1365-3016.1992.tb00741.x; BARKER DJP, 1995, MOL MED TODAY, V1, P418, DOI 10.1016/S1357-4310(95)90793-9; BARKER DJP, 1990, BRIT MED J, V301, P259, DOI 10.1136/bmj.301.6746.259; BRESCHI MC, 1993, DIABETOLOGIA, V36, P1315, DOI 10.1007/BF00400812; BYRNE MM, 1994, J CLIN INVEST, V93, P1120, DOI 10.1172/JCI117064; Chapman N, 1997, J HYPERTENS, V15, P1449, DOI 10.1097/00004872-199715120-00012; Clausen JO, 1997, AM J EPIDEMIOL, V146, P23, DOI 10.1093/oxfordjournals.aje.a009188; DONOHUE WL, 1954, J PEDIATR-US, V45, P505, DOI 10.1016/S0022-3476(54)80113-2; ELSAS LJ, 1985, AM J HUM GENET, V37, P73; FARMER G, 1988, DIABETOLOGIA, V31, P134, DOI 10.1007/BF00276845; FEENER EP, 1997, LANCET S1, V350, pS19; FROGUEL P, 1993, NEW ENGL J MED, V328, P697, DOI 10.1056/NEJM199303113281005; HALES CN, 1991, BMJ-BRIT MED J, V303, P1019, DOI 10.1136/bmj.303.6809.1019; HALES CN, 1994, DIABETOLOGIA, V37, pS162, DOI 10.1007/BF00400840; Hattersley AT, 1998, NAT GENET, V19, P268, DOI 10.1038/953; Hattersley AT, 1998, DIABETIC MED, V15, P15, DOI 10.1002/(SICI)1096-9136(199801)15:1<15::AID-DIA562>3.0.CO;2-M; HSEUH WA, 1997, DIABETES REV, V5, P343; HUDLICKA O, 1992, PHYSIOL REV, V72, P369, DOI 10.1152/physrev.1992.72.2.369; Kroder G, 1996, J CLIN INVEST, V97, P1471, DOI 10.1172/JCI118569; LAW CM, 1992, J EPIDEMIOL COMMUN H, V46, P184, DOI 10.1136/jech.46.3.184; LAW CM, 1995, DIABETIC MED, V12, P24, DOI 10.1111/j.1464-5491.1995.tb02057.x; MATSCHINSKY F, 1993, J CLIN INVEST, V92, P2092, DOI 10.1172/JCI116809; Naylor CD, 1996, JAMA-J AM MED ASSOC, V275, P1165, DOI 10.1001/jama.275.15.1165; Noon JP, 1997, J CLIN INVEST, V99, P1873, DOI 10.1172/JCI119354; Pedersen J, 1977, PREGNANT DIABETIC HE, P211; PHILLIPS DIW, 1995, DIABETIC MED, V12, P796, DOI 10.1111/j.1464-5491.1995.tb02082.x; PHIPPS K, 1993, DIABETOLOGIA, V36, P225, DOI 10.1007/BF00399954; SERMER M, 1995, AM J OBSTET GYNECOL, V173, P146, DOI 10.1016/0002-9378(95)90183-3; Serne E. H., 1997, Diabetologia, V40, pA256; Sherman RC, 1998, CLIN SCI, V94, P373, DOI 10.1042/cs0940373; SHIELD JPH, 1996, CHILDHOOD DIABETES, P681; Shimomura I, 1996, NAT MED, V2, P800, DOI 10.1038/nm0796-800; STEINBERG HO, 1994, J CLIN INVEST, V94, P1172, DOI 10.1172/JCI117433; Stoffers DA, 1997, NAT GENET, V15, P106, DOI 10.1038/ng0197-106; TALLARIGO L, 1986, NEW ENGL J MED, V315, P989, DOI 10.1056/NEJM198610163151603; TEMPLE IK, 1995, NAT GENET, V9, P110, DOI 10.1038/ng0295-110; Temple IK, 1996, HUM MOL GENET, V5, P1117, DOI 10.1093/hmg/5.8.1117; Thomas P, 1996, HUM MOL GENET, V5, P1809, DOI 10.1093/hmg/5.11.1809; THOMAS PM, 1995, SCIENCE, V268, P426, DOI 10.1126/science.7716548; VANDERPOLL T, 1992, THROMB HAEMOSTASIS, V67, P623; WRIGHT NM, 1993, AM J DIS CHILD, V147, P607; YAJNIK CS, 1995, DIABETIC MED, V12, P330, DOI 10.1111/j.1464-5491.1995.tb00487.x	43	638	654	2	22	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAY 22	1999	353	9166					1789	1792		10.1016/S0140-6736(98)07546-1	http://dx.doi.org/10.1016/S0140-6736(98)07546-1			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	202TF	10348008				2022-12-28	WOS:000080667700047
J	Hoff, R; McNamara, J				Hoff, R; McNamara, J			Therapeutic vaccines for preventing AIDS: their use with HAART	LANCET			English	Editorial Material							VIRUS TYPE-1 INFECTION; HIV-1 INFECTION; IMMUNODEFICIENCY; VACCINATION; SAFETY; TRIAL		NIAID, Vaccine & Prevent Res Program, NIH, Bethesda, MD 20892 USA; NIAID, Therapeut Res Program, Div Aids, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	Hoff, R (corresponding author), NIAID, Vaccine & Prevent Res Program, NIH, Bethesda, MD 20892 USA.							Calarota S, 1998, LANCET, V351, P1320, DOI 10.1016/S0140-6736(97)09440-3; Churdboonchart V, 1998, AIDS, V12, P1521, DOI 10.1097/00002030-199812000-00015; Eron JJ, 1996, LANCET, V348, P1547; Klein MR, 1997, AIDS RES HUM RETROV, V13, P393, DOI 10.1089/aid.1997.13.393; Luzuriaga K, 1997, NEW ENGL J MED, V336, P1343, DOI 10.1056/NEJM199705083361902; MacGregor RR, 1998, J INFECT DIS, V178, P92, DOI 10.1086/515613; Ratto-Kim S, 1999, J INFECT DIS, V179, P337, DOI 10.1086/314587; Rinaldo CR, 1999, J INFECT DIS, V179, P329, DOI 10.1086/314599; Rosenberg ES, 1997, SCIENCE, V278, P1447, DOI 10.1126/science.278.5342.1447; SALK J, 1993, SCIENCE, V260, P1270, DOI 10.1126/science.8098553; TRAUGER RJ, 1995, J ACQ IMMUN DEF SYND, V10, pS74; Tsoukas CM, 1998, AIDS RES HUM RETROV, V14, P483, DOI 10.1089/aid.1998.14.483; Tubiana R, 1997, AIDS, V11, P819; VALENTINE FT, 1998, 12 WORLD AIDS C GEN	14	8	9	0	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAY 22	1999	353	9166					1723	1724		10.1016/S0140-6736(99)90025-9	http://dx.doi.org/10.1016/S0140-6736(99)90025-9			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	202TF	10347978				2022-12-28	WOS:000080667700003
J	Kandela, P				Kandela, P			The Thames	LANCET			English	Editorial Material											Kandela, P (corresponding author), 29 Greenlands Rd, Staines TW18 4LR, Middx, England.							1855, LANCET          0714, P37; 1905, LANCET          0805, P390; 1856, LANCET          1122, P575; 1999, LANCET          0508, P1631; 1855, LANCET          0714, P41	5	0	0	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAY 22	1999	353	9166					1809	1809		10.1016/S0140-6736(05)75922-5	http://dx.doi.org/10.1016/S0140-6736(05)75922-5			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	202TF	10348034				2022-12-28	WOS:000080667700077
J	Winston, FK; Rineer, C; Menon, R; Baker, SP				Winston, FK; Rineer, C; Menon, R; Baker, SP			The carnage wrought by major economic change: ecological study of traffic related mortality and the reunification of Germany	BRITISH MEDICAL JOURNAL			English	Article							DRIVERS; ALCOHOL	Objective To document the effects of sudden economic change on death rates for occupants of cars in the former German Democratic Republic (East Germany). Design Ecological time series study of East Germany in comparison with the former Federal Republic of German); (West Germany) before and after reunification in 1990 Setting East and West Germany, from 1985 to 1996, Subjects Populations of East and West Germany between 1985 and 1996. Main outcome measures Death rates for occupants of cars. Results After the reunification of Germany, East German) experienced a sudden, temporary affluence and a concomitant fourfold increase in death rates for car occupants between 1989 and 1991. Although death rates increased in all age groups, young adults (aged 18-24) were most affected. The death rate per 100 000 population for those aged 18-20 years increased 11-fold between 1989 and 1991;for those aged 21-24 years the increase was eightfold. Conclusion A tragic consequence of the reunification of Germany was a dramatic increase in the death rate for car occupants. Sudden economic change and availability of cars resulted in both a rise in vehicle ownership and an increase in the number of inexperienced drivers on roads that were ill prepared for the increased traffic. The lesson learnt from Germany is that during times of economic change and modernisation, measures to prevent the predictable injury deaths that will result need to be considered.	Childrens Hosp Philadelphia, Philadelphia, PA 19104 USA; Univ Penn, Abramson Res Ctr, Philadelphia, PA 19104 USA; Johns Hopkins Univ, Sch Hyg & Publ Hlth, Dept Hlth Policy & Management, Baltimore, MD 21205 USA	University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of Pennsylvania; Pennsylvania Medicine; Johns Hopkins University	Winston, FK (corresponding author), Childrens Hosp Philadelphia, Suite 706,34th St & Civ Ctr Blvd, Philadelphia, PA 19104 USA.							Baker SP, 1992, THE INJURY FACT BOOK, V2nd; BARSS P, 1998, INJURY PREVENTION IN; BRUHNING E, 1993, STRUKTURVERGLEICH UN; *BUND STRASS, 1997, IRTAD PC US GUID; *BUND STRASS, 1993, VERK VER DEUTSCHL; *BUND VERK, 1999, TRANSP INFR INV FED; GALLAHER MM, 1989, JAMA-J AM MED ASSOC, V262, P2243; HINGSON R, 1994, PUBLIC HEALTH REP, V109, P738; KUHNEN MA, 1993, UNFALLSITUATION MOTO; LEWIS D, 1995, NEW GERMANY SOCIAL P; Li GH, 1998, EPIDEMIOLOGY, V9, P379, DOI 10.1097/00001648-199807000-00006; Rivara FP, 1999, AM J PREV MED, V16, P30, DOI 10.1016/S0749-3797(98)00113-5; Robertson LS, 1996, AM J PUBLIC HEALTH, V86, P31, DOI 10.2105/AJPH.86.1.31; WILLIAMS AF, 1995, J PUBLIC HEALTH POL, V16, P347, DOI 10.2307/3342863; Williams AF, 1997, J PUBLIC HEALTH POL, V18, P334, DOI 10.2307/3343314	15	23	23	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JUN 19	1999	318	7199					1647	1649		10.1136/bmj.318.7199.1647	http://dx.doi.org/10.1136/bmj.318.7199.1647			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	210KY	10373165	Bronze, Green Submitted, Green Published			2022-12-28	WOS:000081105600016
J	DeParle, NA				DeParle, NA			Common sense about claims	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																			0	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 16	1999	281	23					2176	2176		10.1001/jama.281.23.2176	http://dx.doi.org/10.1001/jama.281.23.2176			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	204RB	10376554				2022-12-28	WOS:000080777000011
J	LeDuc, P; Haber, C; Bao, G; Wirtz, D				LeDuc, P; Haber, C; Bao, G; Wirtz, D			Dynamics of individual flexible polymers in a shear flow	NATURE			English	Article							SINGLE DNA MOLECULE; STAINING METHOD; MICROSCOPY	Polymer dynamics are of central importance in materials science, mechanical engineering, biology and medicine(1,2). The dynamics of macromolecular solutions and melts in shear flow are typically studied using bulk experimental methods such as light and neutron scattering and birefringence(3,4). But the effect of shear on the conformation and dynamics of individual polymers is still not well understood(5-7). Here we describe observations of the real-time dynamics of individual, flexible polymers (fluorescently labelled DNA molecules(8-15)) under a shear flow. The sheared polymers exhibit many types of extended conformation with an overall orientation ranging from parallel to perpendicular with respect to the flow direction. For shear rates much smaller than the inverse of the relaxation time of the molecule, the relative populations of these two main types of conformation are controlled by the rate of the shear flow. These results question the adequacy of assumptions made in standard models of polymer dynamics(5,6).	Johns Hopkins Univ, Dept Chem Engn, Baltimore, MD 21218 USA; Johns Hopkins Univ, Dept Mech Engn, Baltimore, MD 21218 USA; Johns Hopkins Univ, Dept Mat Sci & Engn, Baltimore, MD 21218 USA	Johns Hopkins University; Johns Hopkins University; Johns Hopkins University	Wirtz, D (corresponding author), Johns Hopkins Univ, Dept Chem Engn, Baltimore, MD 21218 USA.		Wirtz, Denis/A-3257-2010					ARCHER LA, 1995, J FLUID MECH, V301, P133, DOI 10.1017/S0022112095003831; de Gennes P. G., 1991, SCALING CONCEPTS POL; DEGENNES PG, 1997, SCIENCE, V276, P199; Doi M., 1988, THEORY POLYM DYNAMIC; FULLER GG, 1995, OPTICLA RHEOMETRY CO; HINCH EJ, 1977, PHYS FLUIDS, V20, pS22, DOI 10.1063/1.861735; HINCH EJ, 1976, J FLUID MECH, V75, P765, DOI 10.1017/S0022112076000529; HINCH EJ, 1976, J FLUID MECH, V74, P317, DOI 10.1017/S002211207600181X; HOFFMAN A, 1995, POLYM BIOMATERIALS; JANESCHITZKRIEG.H, 1983, POLYM MELT RHEOLOGY; Jeffery GB, 1922, P R SOC LOND A-CONTA, V102, P161, DOI 10.1098/rspa.1922.0078; LEAL LG, 1971, J FLUID MECH, V46, P685, DOI 10.1017/S0022112071000788; MATSUMOTO M, 1992, J POLYM SCI POL PHYS, V30, P779, DOI 10.1002/polb.1992.090300716; MATSUMOTO S, 1981, J MOL BIOL, V152, P501, DOI 10.1016/0022-2836(81)90255-2; MORIKAWA K, 1981, J BIOCHEM-TOKYO, V89, P693, DOI 10.1093/oxfordjournals.jbchem.a133247; MUNK P, 1989, INTRO MACROMOLECULAR; OSTAP EM, 1992, BIOPHYS J, V63, P966, DOI 10.1016/S0006-3495(92)81684-3; Perkins TT, 1997, SCIENCE, V276, P2016, DOI 10.1126/science.276.5321.2016; PERKINS TT, 1994, SCIENCE, V264, P822, DOI 10.1126/science.8171336; SCHWARTZ DC, 1989, NATURE, V338, P520, DOI 10.1038/338520a0; SHIVASHANKAR G, 1997, APPL PHYS LETT, V7, P3727; Smith DE, 1996, MACROMOLECULES, V29, P1372, DOI 10.1021/ma951455p; SMITH SB, 1992, SCIENCE, V258, P1122, DOI 10.1126/science.1439819; WIRTZ D, 1995, PHYS REV LETT, V75, P2436, DOI 10.1103/PhysRevLett.75.2436; Xu JY, 1998, MACROMOLECULES, V31, P6486, DOI 10.1021/ma9717754	25	189	192	1	50	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUN 10	1999	399	6736					564	566		10.1038/21148	http://dx.doi.org/10.1038/21148			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	204RR	10376595				2022-12-28	WOS:000080778400049
J	Qin, HX; Srinivasula, SM; Wu, G; Fernandes-Alnemri, T; Alnemri, ES; Shi, YG				Qin, HX; Srinivasula, SM; Wu, G; Fernandes-Alnemri, T; Alnemri, ES; Shi, YG			Structural basis of procaspase-9 recruitment by the apoptotic protease-activating factor 1	NATURE			English	Article							PROGRAMMED CELL-DEATH; ADAPTER MOLECULE; CYTOCHROME-C; CED-4; OLIGOMERIZATION; ASSOCIATION; CASPASE-2; APAF-1; RAIDD; CARD	Caspase-9-mediated apoptosis (programmed cell death) plays a central role in the development and homeostasis of all multicellular organisms. Mature caspase-9 is derived from its procaspase precursor as a result of recruitment by the activating factor Apaf-1. The crystal structures of the caspase-recruitment domain of Apaf-1 by itself and In complex with the prodomain of procaspase-9 have been determined at 1.6 and 2.5 Angstrom resolution, respectively. These structures and other evidence reveal that each molecule of Apaf-1 interacts with a molecule of procaspase-9 through two highly charged and complementary surfaces formed by non-conserved residues; these surfaces determine recognition specificity through networks of intermolecular hydrogen bonds and van der Waals interactions. Mutation of the important interface residues in procaspase-9 or Apaf-1 prevents or reduces activation of procaspase-9 In a cell-free system. Wild-type, but not mutant, prodomains of caspase-9 completely inhibit catalytic processing of procaspase-9. Furthermore, analysis of homologues from Caenorhabditis elegans indicates that recruitment of CED-3 by CED-4 is probably mediated by the same set of: conserved structural motifs, with a corresponding change in the specificity-determining residues.	Princeton Univ, Dept Mol Biol, Princeton, NJ 08544 USA; Princeton Univ, Dept Chem, Princeton, NJ 08544 USA; Thomas Jefferson Univ, Dept Microbiol & Immunol, Kimmel Canc Ctr, Philadelphia, PA 19107 USA	Princeton University; Princeton University; Jefferson University	Shi, YG (corresponding author), Princeton Univ, Dept Mol Biol, Washington Rd, Princeton, NJ 08544 USA.	ygshi@princeto.edu	Alnemri, Emad S/B-4526-2010	Shi, Yigong/0000-0003-2030-168X				Ahmad M, 1997, CANCER RES, V57, P615; Alnemri ES, 1996, CELL, V87, P171, DOI 10.1016/S0092-8674(00)81334-3; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BRUNGER AT, 1991, X PLOR SYSTEM CRYSTA; Cecconi F, 1998, CELL, V94, P727, DOI 10.1016/S0092-8674(00)81732-8; Chinnaiyan AM, 1996, CURR BIOL, V6, P555; Chou JJ, 1998, CELL, V94, P171, DOI 10.1016/S0092-8674(00)81417-8; Duan H, 1997, NATURE, V385, P86, DOI 10.1038/385086a0; Fearnhead HO, 1998, P NATL ACAD SCI USA, V95, P13664, DOI 10.1073/pnas.95.23.13664; GREEN DR, 1995, CURR OPIN IMMUNOL, V7, P694, DOI 10.1016/0952-7915(95)80079-4; Hengartner MO, 1996, CURR OPIN GENET DEV, V6, P34, DOI 10.1016/S0959-437X(96)90007-6; Hofmann K, 1997, TRENDS BIOCHEM SCI, V22, P155, DOI 10.1016/S0968-0004(97)01043-8; Horvitz HR, 1999, CANCER RES, V59, p1701S; Hu YM, 1998, J BIOL CHEM, V273, P33489, DOI 10.1074/jbc.273.50.33489; Jacobson MD, 1997, CELL, V88, P347, DOI 10.1016/S0092-8674(00)81873-5; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KLAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; SALEH A, IN PRESS J BIOL CHEM; Seol DW, 1999, J BIOL CHEM, V274, P2072, DOI 10.1074/jbc.274.4.2072; Slee EA, 1999, J CELL BIOL, V144, P281, DOI 10.1083/jcb.144.2.281; Soengas MS, 1999, SCIENCE, V284, P156, DOI 10.1126/science.284.5411.156; Srinivasula SM, 1998, MOL CELL, V1, P949, DOI 10.1016/S1097-2765(00)80095-7; Srinivasula SM, 1999, CANCER RES, V59, P999; STELLER H, 1995, SCIENCE, V267, P1445, DOI 10.1126/science.7878463; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; Yang XL, 1998, SCIENCE, V281, P1355, DOI 10.1126/science.281.5381.1355; Yoshida H, 1998, CELL, V94, P739, DOI 10.1016/S0092-8674(00)81733-X; Zou H, 1997, CELL, V90, P405, DOI 10.1016/S0092-8674(00)80501-2; Zou H, 1999, J BIOL CHEM, V274, P11549, DOI 10.1074/jbc.274.17.11549	32	350	358	0	47	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 10	1999	399	6736					549	557		10.1038/21124	http://dx.doi.org/10.1038/21124			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	204RR	10376594				2022-12-28	WOS:000080778400046
J	Owerkowicz, T; Farmer, CG; Hicks, JW; Brainerd, EL				Owerkowicz, T; Farmer, CG; Hicks, JW; Brainerd, EL			Contribution of gular pumping to lung ventilation in monitor lizards	SCIENCE			English	Article							GAS-EXCHANGE; EVOLUTION; EXERCISE; VARANUS; CONSTRAINT; WALKING; IGUANA	A controversial hypothesis has proposed that Lizards are subject to a speed dependent axial constraint that prevents effective Lung ventilation during moderate- and high-speed Locomotion. This hypothesis has been challenged by results demonstrating that monitor lizards (genus Varanus) experience no axial constraint. Evidence presented here shows that, during locomotion, varanids use a positive pressure gular pump to assist Lung ventilation. Disabling the gular pump reveals that the axial constraint is present in varanids but it is masked by gular pumping under normal conditions. These findings support the prediction that the axial constraint may be found in other tetrapods that breathe by costal aspiration and locomote with a lateral undulatory gait.	Harvard Univ, Museum Comparat Zool, Cambridge, MA 02138 USA; Univ Calif Irvine, Dept Ecol & Evolutionary Biol, Irvine, CA 92697 USA; Univ Massachusetts, Dept Biol, Amherst, MA 01003 USA; Univ Massachusetts, Prod Organism & Evolutionary biol, Amherst, MA 01003 USA	Harvard University; University of California System; University of California Irvine; University of Massachusetts System; University of Massachusetts Amherst; University of Massachusetts System; University of Massachusetts Amherst	Owerkowicz, T (corresponding author), Harvard Univ, Museum Comparat Zool, Cambridge, MA 02138 USA.				NHLBI NIH HHS [1F32-HL09796-01] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [F32HL009796] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALGHAMDI MS, 1995, J PHYSIOL-LONDON, V483P, pP6; Auffenberg W., 1981, BEHAV ECOLOGY KOMODO; BARTHOLOMEW G. A., 1964, PHYSIOL ZOOL, V37, P341; BELS VL, 1995, J ZOOL LOND, V235, P95; BENNETT AF, 1994, ADV VET SCI COMP MED, V38, P113; BENNETT AF, 1982, BIOL REPTILIA, V13, P153; BRAINERD EL, 1994, AM ZOOL, V34, P289; CARRIER D, 1990, J EXP BIOL, V152, P453; CARRIER DR, 1987, PALEOBIOLOGY, V13, P326; CARRIER DR, 1987, EXP BIOL, V47, P33; CARRIER DR, 1991, AM ZOOL, V31, P644; CHRISTIAN KA, 1994, AUST J ZOOL, V42, P185, DOI 10.1071/ZO9940185; DEBAN SM, 1994, J EXP ZOOL, V270, P451, DOI 10.1002/jez.1402700506; Dial BE, 1996, J EXP ZOOL, V276, P415, DOI 10.1002/(SICI)1097-010X(19961215)276:6<415::AID-JEZ5>3.0.CO;2-Q; Estes R., 1988, P119; GANS C, 1970, Forma et Functio, V3, P61; GANS C, 1970, Evolution, V24, P723, DOI 10.1111/j.1558-5646.1970.tb01807.x; GLEESON TT, 1980, AM J PHYSIOL, V239, pR174, DOI 10.1152/ajpregu.1980.239.1.R174; Hicks James W., 1998, V19, P425; HOPKINS SR, 1995, J EXP BIOL, V198, P1783; JOHNALDER HB, 1981, AM J PHYSIOL, V241, pR342, DOI 10.1152/ajpregu.1981.241.5.R342; KING D, 1993, GOANNA BIOL VARANID; Liem K.F., 1985, P185; MITCHELL GS, 1981, RESP PHYSIOL, V43, P365, DOI 10.1016/0034-5687(81)90116-X; PARSONS TS, 1970, BIOLOGY REPTILIA, V2, P99; PERRY SF, 1983, ADV ANAT EMBRYOL CEL, V79, P1; PHILLIPS JA, 1995, J HERPETOL, V29, P407, DOI 10.2307/1564991; Ritter D, 1996, J EXP BIOL, V199, P2499; Wang T, 1997, J EXP BIOL, V200, P2629; WEBB G, 1971, J MORPHOL, V134, P335, DOI 10.1002/jmor.1051340306; WOOD SC, 1977, AM J PHYSIOL, V233, pR89, DOI 10.1152/ajpregu.1977.233.3.R89	31	93	95	2	14	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 4	1999	284	5420					1661	1663		10.1126/science.284.5420.1661	http://dx.doi.org/10.1126/science.284.5420.1661			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	202TM	10356394				2022-12-28	WOS:000080668300042
J	Fan, HW; Marcopito, LF; Cardoso, JLC; Franca, FOS; Malaque, CMS; Ferrari, RA; Theakston, RDG; Warrell, DA				Fan, HW; Marcopito, LF; Cardoso, JLC; Franca, FOS; Malaque, CMS; Ferrari, RA; Theakston, RDG; Warrell, DA			Sequential randomised and double blind trial of promethazine prophylaxis against early anaphylactic reactions to antivenom for bothrops snake bites	BRITISH MEDICAL JOURNAL			English	Article							ADVERSE REACTIONS; PREMEDICATION; AUSTRALIA; THERAPY	Objective. To investigate the efficacy of the H-1 antihistamine promethazine against early anaphylactic reactions to antivenom. Design. Sequential randomised, double blind, placebo controlled trial. Setting Public hospital in a venom research institute, S (a) over tilde o Paulo, Brazil. Participants. 101 patients requiring antivenom treatment after being bitten by bothrops snakes. Intervention. Intramuscular injection of promethazine (25 mg for adults and 0.5/kg for children) or placebo given 15-20 min before starting intravenous infusion of antivenom. Main outcome measures. Incidence and severity of anaphylactic reactions occurring within 24 hours after antivenom. Results. Reactions occurred in 12 of 49 patients treated with promethazine (24%) and in 13 of 52 given placebo (25%); most were mild or moderate. Continuous sequential analysis indicated that the study could be interrupted at the 22nd untied pair, without preference for promethazine or placebo. Conclusion. Prophylaxis with promethazine does not prevent early reactions. Patients should be observed carefully during antivenom infusion and the subsequent few hours.	Hosp Vital Brazil, Inst Butantan, BR-05503900 Sao Paulo, Brazil; UNIFESP, Escola Paulista Med, Div Epidemiol, BR-04039032 Sao Paulo, Brazil; Univ Liverpool, Liverpool Sch Trop Med, Alistair Reid Venom Res Unit, Liverpool L3 5QA, Merseyside, England; Univ Oxford, John Radcliffe Hosp, Ctr Trop Med, Oxford OX3 9DU, England	Instituto Butantan; Universidade Federal de Sao Paulo (UNIFESP); Liverpool School of Tropical Medicine; University of Liverpool; University of Oxford	Fan, HW (corresponding author), Hosp Vital Brazil, Inst Butantan, Ave Vital Brazil 1500, BR-05503900 Sao Paulo, Brazil.		Fan, Hui Wen/F-8649-2015; Ferrari, Raquel/I-4419-2016; Fan, Hui Wen/C-3750-2019; de Siqueira França, Francisco Oscar/AAE-6314-2019	Fan, Hui Wen/0000-0002-8191-559X; Ferrari, Raquel/0000-0001-5142-9526; de Siqueira França, Francisco Oscar/0000-0001-8510-7939				ARMITAGE P, 1972, SEQUENTIAL MED TRIAL, P21; BRIAN MJ, 1987, T ROY SOC TROP MED H, V81, P850, DOI 10.1016/0035-9203(87)90051-4; CARDOSO JLC, 1993, Q J MED, V86, P315; CUPO P, 1991, REV I MED TROP, V33, P115, DOI 10.1590/S0036-46651991000200005; DACHMAN WD, 1994, J ALLERGY CLIN IMMUN, V93, P606, DOI 10.1016/S0091-6749(94)70072-9; Fan H.W., 1995, HDB CLIN TOXICOLOGY, P667; FORD RM, 1992, MED J AUSTRALIA, V156, P223, DOI 10.5694/j.1326-5377.1992.tb139731.x; MALASIT P, 1986, BRIT MED J, V292, P17, DOI 10.1136/bmj.292.6512.17; *MIN SAUD, 1998, MAN DIAGN TRAT AC AN; Moran NF, 1998, T ROY SOC TROP MED H, V92, P69, DOI 10.1016/S0035-9203(98)90959-2; Pocock SJ, 1983, CLIN TRIALS PRACTICA, P66; SCHWARTZ D, 1980, CLIN TRIALS, P149; SCHWINGHAMMER TL, 1984, BIOPHARMACEUTICS DRU, V5, P85; SUTHERLAND SK, 1992, MED J AUSTRALIA, V157, P734; SUTHERLAND SK, 1979, MED J AUSTRALIA, V2, P671, DOI 10.5694/j.1326-5377.1979.tb104266.x; SUTHERLAND SK, 1991, MED J AUSTRALIA, V155, P722, DOI 10.5694/j.1326-5377.1991.tb93992.x; TIBALLS J, 1994, MED J AUSTRALIA, V160, P4; Wald A., 1947, SEQUENTIAL ANAL; WARRELL DA, 1977, Q J MED, V46, P33; WARRELL DA, 1986, AM J TROP MED HYG, V35, P1235, DOI 10.4269/ajtmh.1986.35.1235; WHO (World Health Organization), 1981, INSTR DET SUSC RES A	21	60	65	1	7	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	MAY 29	1999	318	7196					1451	1453		10.1136/bmj.318.7196.1451	http://dx.doi.org/10.1136/bmj.318.7196.1451			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	202TL	10346769	Green Published, Green Submitted, Bronze			2022-12-28	WOS:000080668200021
J	Law, M; Wald, N				Law, M; Wald, N			Why heart disease mortality is low in France: the time lag explanation	BRITISH MEDICAL JOURNAL			English	Article							CARDIOVASCULAR RISK-FACTORS; HIGH-DENSITY-LIPOPROTEIN; MALE BRITISH DOCTORS; SERUM-CHOLESTEROL; RED WINE; ALCOHOL-CONSUMPTION; HEALTHY-VOLUNTEERS; MYOCARDIAL-INFARCTION; MODERATE CONSUMPTION; HDL-CHOLESTEROL		St Bartholomews & Royal London Sch Med & Dent, Wolfson Inst Prevent Med, London EC1M 6BQ, England	University of London; Queen Mary University London	Law, M (corresponding author), St Bartholomews & Royal London Sch Med & Dent, Wolfson Inst Prevent Med, London EC1M 6BQ, England.		Wald, Nicholas/AAY-2814-2021; Wald, Nicholas/AAY-8924-2021					Arnetz BB, 1994, EUR J PUBLIC HEALTH, V4, P38; ARTAUDWILD SM, 1993, CIRCULATION, V88, P2771, DOI 10.1161/01.CIR.88.6.2771; BENNETT SA, 1994, MED J AUSTRALIA, V161, P519, DOI 10.5694/j.1326-5377.1994.tb127594.x; BLOT WJ, 1992, CANCER RES, V52, pS2119; Boffetta P, 1990, Epidemiology, V1, P342, DOI 10.1097/00001648-199009000-00003; BONITHONKOPP C, 1993, ATHEROSCLEROSIS, V104, P173, DOI 10.1016/0021-9150(93)90188-Z; BUCK C, 1982, INT J EPIDEMIOL, V11, P294; CAMBIEN F, 1980, AM J EPIDEMIOL, V112, P388, DOI 10.1093/oxfordjournals.aje.a113004; CRIQUI MH, 1994, LANCET, V344, P1719, DOI 10.1016/S0140-6736(94)92883-5; deLorgeril M, 1997, EUR J CLIN NUTR, V51, P116, DOI 10.1038/sj.ejcn.1600374; DOLL R, 1976, BRIT MED J, V2, P1525, DOI 10.1136/bmj.2.6051.1525; DOLL R, 1994, BRIT MED J, V309, P911, DOI 10.1136/bmj.309.6959.911; Doll R., 1981, JNCI-J NATL CANCER I, V66, P1292; Duthie GG, 1998, EUR J CLIN NUTR, V52, P733, DOI 10.1038/sj.ejcn.1600635; FONNEBO V, 1992, AM J EPIDEMIOL, V135, P504, DOI 10.1093/oxfordjournals.aje.a116317; FORMAN MR, 1995, AM J CLIN NUTR, V62, P131, DOI 10.1093/ajcn/62.1.131; FRANKEL EN, 1993, LANCET, V341, P454, DOI 10.1016/0140-6736(93)90206-V; GAZIANO JM, 1993, NEW ENGL J MED, V329, P1829, DOI 10.1056/NEJM199312163292501; HEGSTED DM, 1988, J NUTR, V118, P1184, DOI 10.1093/jn/118.10.1184; HENDRIKS HFJ, 1994, BRIT MED J, V308, P1003, DOI 10.1136/bmj.308.6935.1003; Hertog MGL, 1996, EUR J CLIN NUTR, V50, P63; HOLLINGSWORTH D, 1957, ENGLISHMANS FOOD; JACOBSEN BK, 1992, SCAND J SOC MED, V20, P184, DOI 10.1177/140349489202000309; JOLLIFFE N, 1959, J Chronic Dis, V9, P636, DOI 10.1016/0021-9681(59)90114-6; Klatsky AL, 1997, AM J CARDIOL, V80, P416, DOI 10.1016/S0002-9149(97)00388-3; KLATSKY AL, 1992, ANN INTERN MED, V117, P646, DOI 10.7326/0003-4819-117-8-646; KUZUYA F, 1995, ANN NY ACAD SCI, V748, P510; LAURIER D, 1992, EUR J EPIDEMIOL, V8, P693, DOI 10.1007/BF00145386; LAW MR, 1994, EUR J CLIN NUTR, V48, P305; LAW MR, 1994, BMJ-BRIT MED J, V308, P367, DOI 10.1136/bmj.308.6925.367; Law MR, 1998, J EPIDEMIOL COMMUN H, V52, P344, DOI 10.1136/jech.52.6.344; LINDEBERG S, 1994, J INTERN MED, V236, P331, DOI 10.1111/j.1365-2796.1994.tb00804.x; MALASPINA JP, 1981, ATHEROSCLEROSIS, V40, P373, DOI 10.1016/0021-9150(81)90149-0; MANN JI, 1988, BRIT MED J, V296, P1702, DOI 10.1136/bmj.296.6638.1702; MarquesVidal P, 1996, AM J EPIDEMIOL, V143, P1089, DOI 10.1093/oxfordjournals.aje.a008683; MCMICHAEL J, 1979, LANCET, V1, P1186; *MIN AGR FISH FOOD, 1956, HOUS FOOD CONS EXP 1; *MIN AGR FISH FOOD, 1982, HOUS FOOD CONS EXP 1; *MIN AGR FISH FOOD, 1973, HOUS FOOD CONS EXP 1; *MIN AGR FISH FOOD, 1962, HOUS FOOD CONS EXP 1; Muldoon MF, 1996, BRIT MED J, V312, P458, DOI 10.1136/bmj.312.7029.458; Neil HAW, 1996, J ROY COLL PHYS LOND, V30, P329; NICOLAIDESBOUMA.A, 1993, INT SMOKING STAT; *OFF POP CENS SURV, 1993, HLTH SURV ENGL 1991; *OFF POP CENS SURV, 1996, LIV BRIT RES 1994 GE; *OFF POP CENS SURV, 1993, 1992 MORT STAT CAUS; *OFF POP CENS SURV, 1990, DIET NUTR SURV BRIT; OKAYAMA A, 1995, J CLIN EPIDEMIOL, V48, P329, DOI 10.1016/0895-4356(94)00146-H; PEKKANEN J, 1995, J EPIDEMIOL COMMUN H, V49, P144, DOI 10.1136/jech.49.2.144; Pellegrini N, 1996, EUR J CLIN NUTR, V50, P209; Pellegrini N, 1996, EUR J CLIN NUTR, V50, P535; PUJIA A, 1993, ATHEROSCLEROSIS, V102, P1, DOI 10.1016/0021-9150(93)90079-A; RENAUD S, 1992, LANCET, V339, P1523, DOI 10.1016/0140-6736(92)91277-F; Rimm EB, 1996, BRIT MED J, V312, P731, DOI 10.1136/bmj.312.7033.731; ROSE G, 1982, BRIT MED J, V284, P1600, DOI 10.1136/bmj.284.6329.1600; SCHLIENGER JL, 1991, PATHOL BIOL, V39, P195; *SENECA INV, 1991, EUR J CLIN NUTR S3, V45, P53; *SENECA INV, 1996, EUR J CLIN NUTR, V50, pS25; SHAPER AG, 1994, INT J EPIDEMIOL, V23, P482, DOI 10.1093/ije/23.3.482; SHELLEY E, 1995, EUR HEART J, V16, P752, DOI 10.1093/oxfordjournals.eurheartj.a060993; SIMONS LA, 1995, ATHEROSCLEROSIS, V113, P219, DOI 10.1016/0021-9150(94)05449-S; STLEGER AS, 1979, LANCET, V1, P1017, DOI 10.1016/S0140-6736(79)92765-X; STRANDBERG TE, 1995, BRIT HEART J, V74, P449; SUH I, 1992, ANN INTERN MED, V116, P881, DOI 10.7326/0003-4819-116-11-881; Thun MJ, 1997, NEW ENGL J MED, V337, P1705, DOI 10.1056/NEJM199712113372401; TUNSTALLPEDOE H, 1988, BRIT MED J, V297, P1559, DOI 10.1136/bmj.297.6663.1559; VACCARINO V, 1995, EUR HEART J, V16, P761, DOI 10.1093/oxfordjournals.eurheartj.a060994; VARTIAINEN E, 1994, INT J EPIDEMIOL, V23, P495, DOI 10.1093/ije/23.3.495; VERSCHUREN WMM, 1994, INT J EPIDEMIOL, V23, P948, DOI 10.1093/ije/23.5.948; Wald N, 1991, UK SMOKING STAT; *WHO, 1986, WORLD HLTH STAT ANN; *WHO, 1990, WHO MONICA PROJ WORL; WOODHOUSE PR, 1994, LANCET, V343, P435, DOI 10.1016/S0140-6736(94)92689-1; [No title captured]	74	119	122	0	7	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	MAY 29	1999	318	7196					1471	1476		10.1136/bmj.318.7196.1471	http://dx.doi.org/10.1136/bmj.318.7196.1471			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	202TL	10346778	Green Published			2022-12-28	WOS:000080668200028
J	Hastings, A; Botsford, LW				Hastings, A; Botsford, LW			Equivalence in yield from marine reserves and traditional fisheries management	SCIENCE			English	Article							REEF FISHES; RECRUITMENT; POPULATIONS	Marine reserves have been proposed as a remedy for overfishing and declining marine biodiversity, but concern that reserves would inherently reduce yields has impeded their implementation. It was found that management of fisheries through reserves and management through effort control produce identical yields under a reasonable set of simplifying assumptions corresponding to a broad range of biological conditions. Indeed, for populations with sedentary adults (invertebrates and reef fishes), reserves have important advantages for sustainability, making marine reserves the preferred management approach.	Univ Calif Davis, Dept Environm Sci & Policy, Davis, CA 95616 USA; Univ Calif Davis, Dept Wildlife Fish & Conservat Biol, Davis, CA 95616 USA	University of California System; University of California Davis; University of California System; University of California Davis	Hastings, A (corresponding author), Univ Calif Davis, Dept Environm Sci & Policy, Davis, CA 95616 USA.		Hastings, Alan/O-6864-2019; Hastings, Alan/A-7423-2008	Hastings, Alan/0000-0002-0717-8026; 				Allison GW, 1998, ECOL APPL, V8, pS79, DOI 10.1890/1051-0761(1998)8[S79:MRANBN]2.0.CO;2; Attwood CG, 1995, S AFR J MARINE SCI, V16, P227; Beverton R.J.H., 1957, FISH INVEST LONDON S, V19; Botsford Louis W., 1995, ICES Marine Science Symposia, V199, P157; Botsford LW, 1997, SCIENCE, V277, P509, DOI 10.1126/science.277.5325.509; CADDY JF, 1986, CAN J FISH AQUAT SCI, V43, P2330, DOI 10.1139/f86-285; Caley MJ, 1996, ANNU REV ECOL SYST, V27, P477, DOI 10.1146/annurev.ecolsys.27.1.477; CARR MH, 1993, CAN J FISH AQUAT SCI, V50, P2019, DOI 10.1139/f93-226; Clark CW, 1996, ECOL APPL, V6, P369, DOI 10.2307/2269374; DEMARTINI EE, 1993, FISH B-NOAA, V91, P414; FOLKVORD A, 1997, EARLY LIFE HIST RECR, P251; Hixon MA, 1997, SCIENCE, V277, P946, DOI 10.1126/science.277.5328.946; Holland D. S., 1996, MAR RESOUR ECON, V11, P157, DOI DOI 10.1086/MRE.11.3.42629158; Lauck T, 1998, ECOL APPL, V8, pS72, DOI 10.1890/1051-0761(1998)8[S72:ITPPIF]2.0.CO;2; MEYERS RA, 1995, CAN TECH REP FISH AQ, V2024, P1; NOWLIS JS, IN RPESS FISH B; OLAFSSON EB, 1994, OCEANOGR MAR BIOL, V32, P65; Polacheck T., 1990, NAT RESOUR MODEL, V4, P327; QUINN JF, 1994, AM ZOOL, V33, P537; TRIPPEL EA, 1997, EARLY LIFE HIST RECR, P31; WAHLE RA, 1991, MAR ECOL PROG SER, V69, P231, DOI 10.3354/meps069231	21	240	244	0	37	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAY 28	1999	284	5419					1537	1538		10.1126/science.284.5419.1537	http://dx.doi.org/10.1126/science.284.5419.1537			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	200PD	10348743				2022-12-28	WOS:000080548100040
J	Hsin, H; Kenyon, C				Hsin, H; Kenyon, C			Signals from the reproductive system regulate the lifespan of C-elegans	NATURE			English	Article							CAENORHABDITIS-ELEGANS; FAMILY MEMBER; LONGEVITY; GENE; DAF-2; HERMAPHRODITE; BEHAVIOR; MUTATION; DIAPAUSE; AGE-1	Understanding hew the ageing process is regulated is a fascinating and fundamental problem in biology. Here we demonstrate that signals from the reproductive system influence the Lifespan of the nematode Cacnorhabditis elegans. If the cells that give rise to the germ line are killed with a laser microbeam, the lifespan of the animal is extended. Our findings suggest that germline signals act by modulating the activity of an insulin/IGF-1 (insulin-like growth factor) pathway that is known to regulate the ageing of this organism. Mutants with reduced activity of the insulin/IGF-1-receptor homologue DAF-2 have been shown to live twice as long as normal(1-3), and their longevity requires the activity of DAF-16, a member of the forkhead/winged-helix family of transcriptional regulators(1,2,4,5). We find that, in order for germline ablation to extend lifespan, DAF-16 is required, as well as a putative nuclear hormone receptor, DAF-12 (refs 6, 7). In addition, our findings suggest that signals from the somatic gonad also influence ageing, and that this effect requires DAF-2 activity. Together, our findings imply that the C. elegans insulin/IGF-1 system integrates multiple signals to define the animal's rate of ageing. This study demonstrates an inherent relationship between the reproductive state of this animal and its lifespan, and may have implications for the co-evolution of reproductive capability and longevity.	Univ Calif San Francisco, Dept Biochem & Biophys, San Francisco, CA 94143 USA	University of California System; University of California San Francisco	Kenyon, C (corresponding author), Univ Calif San Francisco, Dept Biochem & Biophys, San Francisco, CA 94143 USA.			Hsin, Honor/0000-0002-0510-7494				AUSTIN J, 1994, DEVELOPMENT, V120, P313; de Bono M, 1998, CELL, V94, P679, DOI 10.1016/S0092-8674(00)81609-8; DORMAN JB, 1995, GENETICS, V141, P1399; Eizinger A, 1997, SCIENCE, V278, P452, DOI 10.1126/science.278.5337.452; FRIEDMAN DB, 1988, GENETICS, V118, P75; Gems D, 1998, GENETICS, V150, P129; Gregoire FM, 1998, BIOCHEM BIOPH RES CO, V249, P385, DOI 10.1006/bbrc.1998.9164; KENYON C, 1993, NATURE, V366, P461, DOI 10.1038/366461a0; KIMBLE J, 1979, DEV BIOL, V70, P396, DOI 10.1016/0012-1606(79)90035-6; KIMBLE JE, 1981, DEV BIOL, V81, P208, DOI 10.1016/0012-1606(81)90284-0; Kimura KD, 1997, SCIENCE, V277, P942, DOI 10.1126/science.277.5328.942; LARSEN PL, 1995, GENETICS, V139, P1567; Lin K, 1997, SCIENCE, V278, P1319, DOI 10.1126/science.278.5341.1319; Morris JZ, 1996, NATURE, V382, P536, DOI 10.1038/382536a0; Ogg S, 1997, NATURE, V389, P994, DOI 10.1038/40194; Riddle DL, 1997, C ELEGANS, P739; YEH WH, 1991, THESIS U MISSOURI	17	657	682	7	75	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAY 27	1999	399	6734					362	366		10.1038/20694	http://dx.doi.org/10.1038/20694			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	200PA	10360574				2022-12-28	WOS:000080547800061
J	Zhao, HB; Santos-Sacchi, J				Zhao, HB; Santos-Sacchi, J			Auditory collusion and a coupled couple of outer hair cells	NATURE			English	Article							MOTILITY VOLTAGE SENSOR; GUINEA-PIG; MECHANICAL RESPONSES; MEMBRANE CAPACITANCE; COCHLEAR AMPLIFIER; BASILAR-MEMBRANE; FREQUENCY LIMIT; CHARGE; DEPENDENCE	The discrepancies between measured frequency responses of the basilar membrane in the inner ear and the frequency tuning found in psychophysical experiments led to Bekesy's idea of lateral inhibition in the auditory nervous system(1). We now know that basilar membrane tuning can account for neural tuning(2), and that sharpening of the passive travelling wave depends on the mechanical activity of outer hair cells (OHCs)(3), but the mechanism by which OHCs enhance tuning remains unclear. OHCs generate voltage-dependent length changes at acoustic rates(4-8), which deform the cochlear partition(9-11). Here we use an electrical correlate of OHC mechanical activity, the motility-related gating current, to investigate mechano-electrical interactions among adjacent OHCs. We show that the motility caused by voltage stimulation of one cell in a group evokes gating currents in adjacent OHCs. The resulting polarization in adjacent cells is opposite to that within the stimulated cell, which may be indicative of lateral inhibition. Also such interactions promote distortion and suppression in the electrical and, consequently, the mechanical activity of OHCs. Lateral interactions may provide a basis for enhanced frequency selectivity in the basilar membrane of mammals.	Yale Univ, Sch Med, Otolaryngol Sect, New Haven, CT 06510 USA; Yale Univ, Sch Med, Neurobiol Sect, New Haven, CT 06510 USA	Yale University; Yale University	Santos-Sacchi, J (corresponding author), Yale Univ, Sch Med, Otolaryngol Sect, 333 Cedar St, New Haven, CT 06510 USA.				NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS [R01DC000273] Funding Source: NIH RePORTER; NIDCD NIH HHS [R01 DC000273] Funding Source: Medline	NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD)); NIDCD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD))		ASHMORE JF, 1990, NEUROSCI RES       S, V12, P39; BEZANILLA F, 1977, J GEN PHYSIOL, V70, P549, DOI 10.1085/jgp.70.5.549; BROWNELL WE, 1985, SCIENCE, V227, P194, DOI 10.1126/science.3966153; DALLOS P, 1992, J NEUROSCI, V12, P4575; DALLOS P, 1995, SCIENCE, V267, P2006, DOI 10.1126/science.7701325; DALLOS P, 1980, PSYCHOPHYSICAL PHYSL, P242; DALLOS P, 1977, PSYCHOPHYSICS PHYSL, P147; Gale JE, 1997, NATURE, V389, P63, DOI 10.1038/37968; GALE JE, 1994, P ROY SOC B-BIOL SCI, V255, P243, DOI 10.1098/rspb.1994.0035; GOLDSTEI.JL, 1968, PR INST ELECTR ELECT, V56, P981, DOI 10.1109/PROC.1968.6449; GOLDSTEIN JL, 1967, J ACOUST SOC AM, V41, P676, DOI 10.1121/1.1910396; HUANG GJ, 1994, P NATL ACAD SCI USA, V91, P12268, DOI 10.1073/pnas.91.25.12268; HUANG GJ, 1993, BIOPHYS J, V65, P2228, DOI 10.1016/S0006-3495(93)81248-7; IWASA KH, 1993, BIOPHYS J, V65, P492, DOI 10.1016/S0006-3495(93)81053-1; JARAMILLO F, 1993, NATURE, V364, P527, DOI 10.1038/364527a0; KAKEHATA S, 1995, BIOPHYS J, V68, P2190, DOI 10.1016/S0006-3495(95)80401-7; KAKEHATA S, 1967, J ACOUST SOC AM, V41, P676; MAMMANO F, 1993, NATURE, V365, P838, DOI 10.1038/365838a0; Narayan SS, 1998, SCIENCE, V282, P1882, DOI 10.1126/science.282.5395.1882; Nuttall AL, 1995, HEARING RES, V92, P170, DOI 10.1016/0378-5955(95)00216-2; SANTOS-SACCHI J, 1988, HEARING RES, V35, P143, DOI 10.1016/0378-5955(88)90113-X; SANTOS-SACCHI J, 1993, BIOPHYS J, V65, P2217, DOI 10.1016/S0006-3495(93)81247-5; SANTOS-SACCHI J, 1991, J NEUROSCI, V11, P3096, DOI 10.1523/jneurosci.11-10-03096.1991; Santos-Sacchi J, 1998, J PHYSIOL-LONDON, V510, P225, DOI 10.1111/j.1469-7793.1998.225bz.x; SANTOS-SACCHI J, 1992, J NEUROSCI, V12, P1906; TAKAHASHI S, IN PRESS J MEMBR BIO; TUNSTALL MJ, 1995, J PHYSIOL-LONDON, V485, P739, DOI 10.1113/jphysiol.1995.sp020765; VATER M, 1992, J COMP NEUROL, V318, P380, DOI 10.1002/cne.903180404; vonBekesy G., 1960, EXPT HEARING; XUE SW, 1995, J ACOUST SOC AM, V97, P3030, DOI 10.1121/1.413103	30	69	73	0	2	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAY 27	1999	399	6734					359	362		10.1038/20686	http://dx.doi.org/10.1038/20686			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	200PA	10360573				2022-12-28	WOS:000080547800060
J	Geddes, DM; Shah, PL				Geddes, DM; Shah, PL			Where we are now with rhDNase	LANCET			English	Editorial Material							RECOMBINANT HUMAN DNASE; CYSTIC-FIBROSIS		Royal Brompton Hosp, London SW3 6NP, England	Royal Brompton Hospital	Geddes, DM (corresponding author), Royal Brompton Hosp, London SW3 6NP, England.		Shah, Pallav L/AAB-2758-2019	Shah, Pallav L/0000-0002-9052-4638				Davies J, 1997, PEDIATR PULM, V23, P243, DOI 10.1002/(SICI)1099-0496(199704)23:4<243::AID-PPUL1>3.0.CO;2-N; Eng PA, 1996, PEDIATR PULM, V21, P77, DOI 10.1002/(SICI)1099-0496(199602)21:2<77::AID-PPUL3>3.0.CO;2-M; FUCHS HJ, 1994, NEW ENGL J MED, V331, P637, DOI 10.1056/NEJM199409083311003; Milla CE, 1998, THORAX, V53, P1014, DOI 10.1136/thx.53.12.1014; SHAH PL, 1995, RESP MED, V89, P499, DOI 10.1016/0954-6111(95)90126-4	5	6	6	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAY 22	1999	353	9166					1727	1727		10.1016/S0140-6736(98)00411-5	http://dx.doi.org/10.1016/S0140-6736(98)00411-5			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	202TF	10347981				2022-12-28	WOS:000080667700006
J	Ramanan, SV				Ramanan, SV			The virus and the bookworm	BRITISH MEDICAL JOURNAL			English	Article									Univ Connecticut, Sch Med, Storrs, CT 06269 USA	University of Connecticut	Ramanan, SV (corresponding author), Univ Connecticut, Sch Med, Storrs, CT 06269 USA.								0	0	0	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JUN 19	1999	318	7199					1693	1693		10.1136/bmj.318.7199.1693	http://dx.doi.org/10.1136/bmj.318.7199.1693			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	210KY	10373180	Green Published			2022-12-28	WOS:000081105600038
J	Sibert, JR; Mott, A; Rolfe, K; James, R; Evans, R; Kemp, A; Dunstan, FDJ				Sibert, JR; Mott, A; Rolfe, K; James, R; Evans, R; Kemp, A; Dunstan, FDJ			Preventing injuries in public playgrounds through partnership between health services and local authority: community intervention study	BRITISH MEDICAL JOURNAL			English	Article									Univ Wales Coll Med, Acad Ctr, Llandough Hosp, Dept Child Hlth, Penarth CF64 2XX, S Glam, Wales; Cardiff Cty Council, Sports & Leisure Dept, Cardiff CF14 4EP, S Glam, Wales; Univ Wales Hosp, Dept Accid & Emergency, Cardiff CF4 4XW, S Glam, Wales	Cardiff University; Cardiff University	Sibert, JR (corresponding author), Univ Wales Coll Med, Acad Ctr, Llandough Hosp, Dept Child Hlth, Penarth CF64 2XX, S Glam, Wales.							HESELTINE P, 1989, PLAYGROUND MANAGEMEN; MOTT A, 1994, ARCH DIS CHILD, V71, P328, DOI 10.1136/adc.71.4.328; Mott A, 1997, LANCET, V349, P1874, DOI 10.1016/S0140-6736(96)10343-3; Stone DH, 1998, ARCH DIS CHILD, V78, P108, DOI 10.1136/adc.78.2.108	4	17	18	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JUN 12	1999	318	7198					1595	1595		10.1136/bmj.318.7198.1595	http://dx.doi.org/10.1136/bmj.318.7198.1595			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	207AL	10364118	Green Published, Bronze, Green Submitted			2022-12-28	WOS:000080913100030
J	Li, XY; Virbasius, A; Zhu, XC; Green, MR				Li, XY; Virbasius, A; Zhu, XC; Green, MR			Enhancement of TBP binding by activators and general transcription factors	NATURE			English	Article							RNA-POLYMERASE-II; IN-VIVO; SACCHAROMYCES-CEREVISIAE; PROMOTER SELECTIVITY; TATA-ELEMENT; YEAST; PROTEIN; COMPLEX; MOT1; CORE	Eukaryotic transcriptional activators function, at least in part, by promoting assembly of the preinitiation complex(1-3), which comprises RNA polymerase II and its general transcription factors (GTFs). Activator-mediated stimulation of the assembly of the preinitiation complex has been studied in vitro but has been relatively refractory to in vivo analysis, Here we use a DNA-crosslinking/immunoprecipitation assay to study in living cells the first step in the assembly of the preinitiation complex, the interaction between the TATA-box-binding protein (TBP) and its binding site, the TATA box. Analysis of a variety of endogenous yeast genes, and of a series of activators of differing strength, reveals a general correlation between TBP binding and transcriptional activity. Using mutant yeast strains, we show that Mot1 prevents the binding of TBP to inactive promoters and that activator-mediated stimulation of TBP binding requires additional GTFs, including TFIIB and Srb4. Taken together, our results indicate that TBP binding in vivo is stringently controlled, and that the ability of activators to stimulate this step in the assembly of the preinitiation complex is a highly cooperative process involving multiple transcription factors.	Univ Massachusetts, Sch Med, Howard Hughes Med Inst, Program Mol Med, Worcester, MA 01605 USA	Howard Hughes Medical Institute; University of Massachusetts System; University of Massachusetts Worcester	Green, MR (corresponding author), Univ Massachusetts, Sch Med, Howard Hughes Med Inst, Program Mol Med, 373 Plantat St,Suite 309, Worcester, MA 01605 USA.	michael.green@ummed.edu						AUBLE DT, 1994, GENE DEV, V8, P1920, DOI 10.1101/gad.8.16.1920; Bryant GO, 1996, GENE DEV, V10, P2491, DOI 10.1101/gad.10.19.2491; Burley SK, 1996, ANNU REV BIOCHEM, V65, P769, DOI 10.1146/annurev.bi.65.070196.004005; CHEN JJ, 1994, P NATL ACAD SCI USA, V91, P11909, DOI 10.1073/pnas.91.25.11909; Collart MA, 1996, MOL CELL BIOL, V16, P6668; DAVIS JL, 1992, MOL CELL BIOL, V12, P1879, DOI 10.1128/MCB.12.4.1879; GIARDINA C, 1995, MOL CELL BIOL, V15, P2737; Halle JP, 1996, TRENDS GENET, V12, P161, DOI 10.1016/0168-9525(96)30035-8; KIM YJ, 1994, CELL, V77, P599, DOI 10.1016/0092-8674(94)90221-6; Koh SS, 1998, MOL CELL, V1, P895, DOI 10.1016/S1097-2765(00)80088-X; KOLESKE AJ, 1995, TRENDS BIOCHEM SCI, V20, P113, DOI 10.1016/S0968-0004(00)88977-X; Lee M, 1997, MOL CELL BIOL, V17, P1336, DOI 10.1128/MCB.17.3.1336; LIN YS, 1991, CELL, V64, P971, DOI 10.1016/0092-8674(91)90321-O; LUE NF, 1989, P NATL ACAD SCI USA, V86, P486, DOI 10.1073/pnas.86.2.486; MA J, 1987, CELL, V48, P847, DOI 10.1016/0092-8674(87)90081-X; Madison JM, 1997, MOL CELL BIOL, V17, P287, DOI 10.1128/MCB.17.1.287; NIKOLOV DB, 1995, NATURE, V377, P119, DOI 10.1038/377119a0; ORLANDO V, 1993, CELL, V75, P1187, DOI 10.1016/0092-8674(93)90328-N; Orphanides G, 1996, GENE DEV, V10, P2657, DOI 10.1101/gad.10.21.2657; Ptashne M, 1997, NATURE, V386, P569, DOI 10.1038/386569a0; Roeder RG, 1996, TRENDS BIOCHEM SCI, V21, P327, DOI 10.1016/0968-0004(96)10050-5; SELLECK SB, 1988, P NATL ACAD SCI USA, V85, P5399, DOI 10.1073/pnas.85.15.5399; Shen WC, 1997, CELL, V90, P615, DOI 10.1016/S0092-8674(00)80523-1; StrahlBolsinger S, 1997, GENE DEV, V11, P83, DOI 10.1101/gad.11.1.83; Tang H, 1996, P NATL ACAD SCI USA, V93, P1119, DOI 10.1073/pnas.93.3.1119; THOMPSON CM, 1993, CELL, V73, P1361, DOI 10.1016/0092-8674(93)90362-T; THOMPSON CM, 1995, P NATL ACAD SCI USA, V92, P4587, DOI 10.1073/pnas.92.10.4587; Verrijzer CP, 1996, TRENDS BIOCHEM SCI, V21, P338, DOI 10.1016/0968-0004(96)10044-X	28	201	203	0	18	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 10	1999	399	6736					605	609		10.1038/21232	http://dx.doi.org/10.1038/21232			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	204RR	10376604				2022-12-28	WOS:000080778400061
J	Wilcox, AJ; Baird, DD; Wenberg, CR				Wilcox, AJ; Baird, DD; Wenberg, CR			Time of implantation of the conceptus and loss of pregnancy	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							HUMAN CHORIONIC-GONADOTROPIN; URINARY ESTROGEN; PROGESTERONE METABOLITES; INVITRO FERTILIZATION; RADIOIMMUNOASSAY; BLASTOCYST; OVULATION; SECRETION; WINDOW; WOMEN	Background Implantation of the conceptus is a key step in pregnancy, but little is known about the time of implantation or the relation between the time of implantation and the outcome of pregnancy. Methods We collected daily urine samples for up to six months from 221 women attempting to conceive after ceasing to use contraception. Ovulation was identified on the basis of the ratio of urinary estrogen metabolites to progesterone metabolites, which changes rapidly with luteinization of the ovarian follicle, The time of implantation was defined by the appearance of chorionic gonadotropin in maternal urine. Results There were 199 conceptions, for 95 percent of which (189) we had sufficient data for analysis. Of these 189 pregnancies, 141 (75 percent) lasted at least six weeks past the last menstrual period, and the remaining 48 pregnancies (25 percent) ended in early loss. Among the pregnancies that lasted 6 weeks or more, the first appearance of chorionic gonadotropin occurred 6 to 12 days after ovulation; 118 women (84 percent) had implantation on day 8, 9, or 10, The risk of early pregnancy loss increased with later implantation (P < 0.001), Among the 102 conceptuses that implanted by the ninth day, 13 percent ended in early loss. This proportion rose to 26 percent with implantation on day 10, to 52 percent on day 11, and to 82 percent after day 11. Conclusions In most successful human pregnancies, the conceptus implants 8 to 10 days after ovulation, The risk of early pregnancy loss increases with later implantation. (N Engl J Med 1999;340:1796-9,) (C) 1999, Massachusetts Medical Society.	NIEHS, Epidemiol Branch, Res Triangle Pk, NC 27709 USA; NIEHS, Biostat Branch, Res Triangle Pk, NC 27709 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)	Wilcox, AJ (corresponding author), NIEHS, Epidemiol Branch, MD A3-05, Res Triangle Pk, NC 27709 USA.		Baird, Donna D/D-5214-2017; Wilcox, Allen J/C-7723-2019	Baird, Donna D/0000-0002-5544-2653; Wilcox, Allen J/0000-0002-3376-1311; Weinberg, Clarice/0000-0002-7713-8556	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [ZIAES044003, Z01ES044003, Z01ES049003, ZIAES049003] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ARMSTRONG EG, 1984, J CLIN ENDOCR METAB, V59, P867, DOI 10.1210/jcem-59-5-867; BAIRD DD, 1991, J CLIN ENDOCR METAB, V72, P793, DOI 10.1210/jcem-72-4-793; BAIRD DD, 1991, STAT MED, V10, P255, DOI 10.1002/sim.4780100209; BAIRD DD, 1995, EPIDEMIOLOGY, V6, P547, DOI 10.1097/00001648-199509000-00015; BEIER HM, 1994, HUM REPROD, V9, P98, DOI 10.1093/humrep/9.suppl_1.98; BOLTON VN, 1989, J IN VITRO FERTIL EM, V6, P30, DOI 10.1007/BF01134578; BONDUELLE ML, 1988, HUM REPROD, V3, P909, DOI 10.1093/oxfordjournals.humrep.a136808; CANFIELD RE, 1976, B WORLD HEALTH ORGAN, V54, P463; COLLINS WP, 1983, CURRENT TOPICS REPRO, V3, P49; England M.A., 1996, LIFE BIRTH; HEARN JP, 1991, J REPROD FERTIL, V92, P497; HERTIG AT, 1959, PEDIATRICS, V23, P202; Klentzeris Lucas D., 1997, Human Reproduction (Oxford), V12, P170; LENTON EA, 1991, J REPROD FERTIL, V92, P555; Lessey BA, 1996, AM J REPROD IMMUNOL, V35, P195; LIU HC, 1993, FERTIL STERIL, V60, P871; LIU HC, 1991, J IN VITRO FERTIL EM, V8, P65, DOI 10.1007/BF01138657; NORMAN RJ, 1987, OBSTET GYNECOL, V69, P590; Psychoyos A, 1976, J Reprod Fertil Suppl, P17; RINGLER GE, 1990, CURR OPIN OBSTET GYN, V2, P703; Rogers PAW, 1995, REPROD FERT DEVELOP, V7, P1395, DOI 10.1071/RD9951395; ROYSTON JP, 1983, CURRENT TOPICS REPRO, V3, P19; SAMARAJEEWA P, 1979, J STEROID BIOCHEM, V11, P1165, DOI 10.1016/0022-4731(79)90169-9; Speroff L, 1994, CLIN GYNECOLOGIC END, V5th; STEWART DR, 1993, CLIN ENDOCRINOL, V38, P379, DOI 10.1111/j.1365-2265.1993.tb00518.x; TURKASPA I, 1990, FERTIL STERIL, V53, P859; Wilcox A J, 1990, Epidemiology, V1, P382, DOI 10.1097/00001648-199009000-00008; WILCOX AJ, 1988, NEW ENGL J MED, V319, P189, DOI 10.1056/NEJM198807283190401; WILCOX AJ, 1985, FERTIL STERIL, V44, P366; WOODWARD AJ, 1992, J CLIN ENDOCR METAB, V74, P999, DOI 10.1210/jc.74.5.999; WOODWARD BJ, 1993, HUM REPROD, V8, P1463, DOI 10.1093/oxfordjournals.humrep.a138280; WRIGHT K, 1978, STEROIDS, V31, P407, DOI 10.1016/0039-128X(78)90053-3; YOSHINAGA K, 1988, ANN NY ACAD SCI, V541, P424, DOI 10.1111/j.1749-6632.1988.tb22279.x; Younis JS, 1996, FERTIL STERIL, V66, P873	34	650	681	2	46	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUN 10	1999	340	23					1796	1799		10.1056/NEJM199906103402304	http://dx.doi.org/10.1056/NEJM199906103402304			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	203UU	10362823				2022-12-28	WOS:000080726800004
J	von Grafenstein, U; Erlenkeuser, H; Brauer, A; Jouzel, J; Johnsen, SJ				von Grafenstein, U; Erlenkeuser, H; Brauer, A; Jouzel, J; Johnsen, SJ			A mid-European decadal isotope-climate record from 15,500 to 5000 years BP	SCIENCE			English	Article							CANADIAN ARCTIC ARCHIPELAGO; YOUNGER DRYAS EVENT; GREENLAND ICE; NORTHWEST EUROPE; LAKE-SEDIMENTS; SEA; PRECIPITATION; OSCILLATIONS; DEGLACIATION; TEMPERATURE	Oxygen-isotope ratios of precipitation (delta(18)O(P)) inferred from deep-lake ostracods from the Ammersee (southern Germany) provide a climate record with decadal resolution. The record in detail shows many of the rapid climate shifts seen in central Greenland Ice cores between 15,000 and 5000 years before the present (B.P.), Negative excursions in the estimated delta(18)O(P) from both of these records Likely reflect short weakenings of the thermohaline circulation caused by episodic discharges of continental freshwater into the North Atlantic. Deviating millennial-scale trends,however, indicate that climate gradients between Europe and Greenland changed systematically, reflecting a gradual rearrangement of North Atlantic circulation during deglaciation.	Lab Sci Climat & Environm, F-91198 Gif Sur Yvette, France; Univ Kiel, Leibniz Lab Altersbestimmung & Isotopenforsch, D-24098 Kiel, Germany; Fac Sci & Tech St Jerome, Lab Bot Hist & Palynol, F-13397 Marseille, France; GeoForsch Zentrum Potsdam, Potsdam, Germany; Univ Copenhagen, Dept Geophys, Copenhagen, Denmark; Univ Iceland, Inst Sci, IS-107 Reykjavik, Iceland	UDICE-French Research Universities; Universite Paris Saclay; CEA; Centre National de la Recherche Scientifique (CNRS); University of Kiel; UDICE-French Research Universities; Aix-Marseille Universite; University of Copenhagen; University of Iceland	von Grafenstein, U (corresponding author), Lab Sci Climat & Environm, F-91198 Gif Sur Yvette, France.		von Grafenstein, Ulrich/F-6991-2010	von Grafenstein, Ulrich/0000-0002-3338-5627; Brauer, Achim/0000-0002-6655-9451				ALLEY RB, 1993, NATURE, V362, P527, DOI 10.1038/362527a0; BARBER DP, UNPUB; Bjorck S, 1996, SCIENCE, V274, P1155, DOI 10.1126/science.274.5290.1155; BOND G, 1993, NATURE, V365, P143, DOI 10.1038/365143a0; BOND GC, 1995, SCIENCE, V267, P1005, DOI 10.1126/science.267.5200.1005; BRAUER A, IN PRESS CLIM DYN; Dyke AS, 1997, ARCTIC, V50, P1; Dyke AS, 1996, ARCTIC, V49, P235; Eicher U, 1987, GEOGR HELV, V42, P99; FAIRBANKS RG, 1989, NATURE, V342, P637, DOI 10.1038/342637a0; Friedman I., 1977, 440 US GEOL SURV; GOSLAR T, 1995, RADIOCARBON, V37, P1; HAFLIDASON H, 1995, GEOLOGY, V23, P1059, DOI 10.1130/0091-7613(1995)023<1059:CROTLG>2.3.CO;2; Hammarlund D, 1996, BOREAS, V25, P8; JOHNSEN SJ, 1992, NATURE, V359, P311, DOI 10.1038/359311a0; JOHNSEN SJ, 1995, TELLUS B, V47, P624, DOI 10.1034/j.1600-0889.47.issue5.9.x; JOHNSON WR, 1992, PSYCHOLOGY, V29, P1; JOUSSAURNE S, COMMUNICATION; Karpuz N. K., 1992, PALEOCEANOGRAPHY, V7, P449; KEIGWIN LD, 1995, PALEOCEANOGRAPHY, V10, P973, DOI 10.1029/95PA02643; Klee Rolf, 1993, Limnologica, V23, P131; Klitgaard-Kristensen D, 1998, J QUATERNARY SCI, V13, P165, DOI 10.1002/(SICI)1099-1417(199803/04)13:2<165::AID-JQS365>3.0.CO;2-#; KOC N, 1994, GEOLOGY, V22, P523, DOI 10.1130/0091-7613(1994)022<0523:ROTHLN>2.3.CO;2; LISTER GS, 1988, QUATERNARY RES, V29, P129, DOI 10.1016/0033-5894(88)90056-7; MCAYEAL DR, 1993, PALEOCEANOGRAPHY, V8, P775; ROZANSKI K, 1992, SCIENCE, V258, P981, DOI 10.1126/science.258.5084.981; Sakai K, 1997, J CLIMATE, V10, P949, DOI 10.1175/1520-0442(1997)010<0949:DOOIAC>2.0.CO;2; Schwalb A, 1994, J PALEOLIMNOL, V11, P3, DOI 10.1007/BF00683267; THOUVENY N, 1994, NATURE, V371, P503, DOI 10.1038/371503a0; von Grafenstein U, 1994, J PALEOLIMNOL, V11, P349, DOI 10.1007/BF00677994; von Grafenstein U, 1999, PALAEOGEOGR PALAEOCL, V148, P133, DOI 10.1016/S0031-0182(98)00180-1; von Grafenstein U, 1998, CLIM DYNAM, V14, P73, DOI 10.1007/s003820050210; VONGRAFENSTEIN U, 1992, NATURWISSENSCHAFTEN, V79, P145, DOI 10.1007/BF01134431; vonGrafenstein U, 1996, GEOCHIM COSMOCHIM AC, V60, P4025, DOI 10.1016/S0016-7037(96)00230-X	34	469	475	1	79	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 4	1999	284	5420					1654	1657						4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	202TM	10356392				2022-12-28	WOS:000080668300040
J	Sharp, D				Sharp, D			Acronymania	LANCET			English	Editorial Material									Lancet, London WC1B 3SL, England		Sharp, D (corresponding author), Lancet, London WC1B 3SL, England.							CHENG TO, 1999, AM J CARDIOL, V137, P26	1	4	4	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAY 22	1999	353	9166					1728	1728		10.1016/S0140-6736(99)00191-9	http://dx.doi.org/10.1016/S0140-6736(99)00191-9			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	202TF	10347983				2022-12-28	WOS:000080667700008
J	Butterworth, B				Butterworth, B			Perspectives: Neuroscience - A head for figures	SCIENCE			English	Editorial Material							HUMAN INFANTS; SKILLS		UCL, Inst Cognit Neurosci, London WC1N 3AR, England	University of London; University College London	Butterworth, B (corresponding author), UCL, Inst Cognit Neurosci, London WC1N 3AR, England.	ucjtsbb@ucl.ac.uk						Butterworth B., 1999, MATH BRAIN; BUTTERWORTH B, IN PRESS DEV ARITHME; Dehaene S, 1997, CORTEX, V33, P219, DOI 10.1016/S0010-9452(08)70002-9; Dehaene S, 1999, SCIENCE, V284, P970, DOI 10.1126/science.284.5416.970; Delazer M, 1997, CORTEX, V33, P697, DOI 10.1016/S0010-9452(08)70727-5; JACKSON M, 1986, CORTEX, V22, P611, DOI 10.1016/S0010-9452(86)80020-X; JEANNEROD M, 1995, TRENDS NEUROSCI, V18, P314, DOI 10.1016/0166-2236(95)93921-J; LeFevre J, 1996, J EXP PSYCHOL LEARN, V22, P216, DOI 10.1037/0278-7393.22.1.216; STARKEY P, 1980, SCIENCE, V210, P1033, DOI 10.1126/science.7434014; WARRINGTON EK, 1982, Q J EXP PSYCHOL-A, V34, P31, DOI 10.1080/14640748208400856; WYNN K, 1992, NATURE, V358, P749, DOI 10.1038/358749a0; Wynn K, 1995, MATH COGNITION, V1, P35, DOI DOI 10.1016/S0010-0277(99)00066-9	13	62	62	0	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 7	1999	284	5416					928	929		10.1126/science.284.5416.928	http://dx.doi.org/10.1126/science.284.5416.928			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	194MU	10357680				2022-12-28	WOS:000080198800035
J	Verheugt, FWA				Verheugt, FWA			Acute coronary syndromes: interventions	LANCET			English	Article							UNSTABLE ANGINA; MYOCARDIAL-INFARCTION; BYPASS-SURGERY; SURGICAL-MANAGEMENT; ANGIOPLASTY; SURVIVAL; OUTCOMES; MORTALITY; PECTORIS; TRIAL		Univ Nijmegen Hosp, Dept Cardiol, Heartctr, NL-6500 HB Nijmegen, Netherlands	Radboud University Nijmegen	Verheugt, FWA (corresponding author), Univ Nijmegen Hosp, Dept Cardiol, Heartctr, POB 9101, NL-6500 HB Nijmegen, Netherlands.		Verheugt, F.W.A./H-8105-2014					ALDERMAN EL, 1990, CIRCULATION, V82, P1629, DOI 10.1161/01.CIR.82.5.1629; Boden WE, 1998, NEW ENGL J MED, V338, P1785, DOI 10.1056/NEJM199806183382501; BRAUNWALD E, 1994, CIRCULATION, V89, P1545; BRAUNWALD E, 1994, CIRCULATION, V90, P613, DOI 10.1161/01.CIR.90.1.613; Cameron A, 1996, NEW ENGL J MED, V334, P216, DOI 10.1056/NEJM199601253340402; Cannon CP, 1998, AM J CARDIOL, V82, P731, DOI 10.1016/S0002-9149(98)00540-2; DEFEYTER PJ, 1985, NEW ENGL J MED, V313, P342, DOI 10.1056/NEJM198508083130602; HULTGREN HN, 1977, AM J CARDIOL, V39, P734, DOI 10.1016/S0002-9149(77)80137-9; Marzocchi A, 1997, AM J CARDIOL, V79, P1314, DOI 10.1016/S0002-9149(97)00131-8; MCCORMICK JR, 1985, J THORAC CARDIOV SUR, V89, P683; MORRISON DA, 1995, AM J CARDIOL, V75, P237, DOI 10.1016/0002-9149(95)80027-P; Olivieri NF, 1997, LANCET, V350, P491, DOI 10.1016/S0140-6736(05)63080-2; PARISI AF, 1992, NEW ENGL J MED, V326, P10, DOI 10.1056/NEJM199201023260102; PARISI AF, 1989, CIRCULATION, V80, P1176, DOI 10.1161/01.CIR.80.5.1176; PLOKKER HWM, 1998, CATHETER CARDIO DIAG, V14, P15; RAHIMTOOLA SH, 1983, NEW ENGL J MED, V308, P676, DOI 10.1056/NEJM198303243081202; Schomig A, 1996, NEW ENGL J MED, V334, P1084, DOI 10.1056/NEJM199604253341702; Serruys PW, 1998, LANCET, V352, P673, DOI 10.1016/S0140-6736(97)11128-X; Simoons ML, 1996, NEW ENGL J MED, V335, P275, DOI 10.1056/NEJM199607253350409; Topol EJ, 1998, LANCET, V352, P87, DOI 10.1016/S0140-6736(98)85010-1; Topol EJ, 1997, JAMA-J AM MED ASSOC, V278, P479, DOI 10.1001/jama.278.6.479; Topol EJ, 1997, NEW ENGL J MED, V336, P1689; VARNAUSKAS E, 1982, LANCET, V2, P1173; WALLENTIN L, 1999, 48 ANN SCI SESS AM C; Yusuf S, 1998, LANCET, V352, P507, DOI 10.1016/S0140-6736(97)11162-X	25	0	0	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet		1999	353			2			SII16	SII19						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	205GJ	10374761				2022-12-28	WOS:000080812700004
J	Dobson, R				Dobson, R			Welsh Office to review consultant's lengthy suspension	BRITISH MEDICAL JOURNAL			English	News Item																			0	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JUN 12	1999	318	7198					1576	1576		10.1136/bmj.318.7198.1576	http://dx.doi.org/10.1136/bmj.318.7198.1576			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	207AL	10364108	Green Published			2022-12-28	WOS:000080913100012
J	Sattler, R; Xiang, ZG; Lu, WY; Hafner, M; MacDonald, JF; Tymianski, M				Sattler, R; Xiang, ZG; Lu, WY; Hafner, M; MacDonald, JF; Tymianski, M			Specific coupling of NMDA receptor activation to nitric oxide neurotoxicity by PSD-95 protein	SCIENCE			English	Article							LONG-TERM POTENTIATION; CALCIUM NEUROTOXICITY; POSTSYNAPTIC PROTEIN; SYNTHASE; NEURONS; BRAIN; HIPPOCAMPUS; MECHANISMS; CHANNELS; PATHWAYS	The efficiency with which N-methyl-D-aspartate receptors (NMDARs) trigger intracellular signaling pathways governs neuronal plasticity, development, senescence, and disease. In cultured cortical neurons, suppressing the expression of the NM DAR scaffolding protein PSD-95 (postsynaptic density-95) selectively attenuated excitotoxicity triggered via NMDARs, but not by other glutamate or calcium ion (Ca2+) channels. NMDAR function was unaffected, because receptor expression, NMDA currents, and Ca-45(2+) loading were unchanged. Suppressing PSD-95 blocked Ca2+-activated nitric oxide production by NMDARs selectively, without affecting neuronal nitric oxide synthase expression or function. Thus, PSD-95 is required for efficient coupling of NMDAR activity to nitric oxide toxicity, and imparts specificity to excitotoxic Ca2+ signaling.	Univ Toronto, Toronto Western Hosp, Lab 11 416, Toronto, ON M5T 2S8, Canada; Univ Toronto, Dept Physiol, Toronto, ON M5G 1X8, Canada; Mannheim Univ Appl Sci, D-68163 Mannheim, Germany	University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto	Tymianski, M (corresponding author), Univ Toronto, Toronto Western Hosp, Lab 11 416, 399 Bathurst St, Toronto, ON M5T 2S8, Canada.		Lu, Wei-Yang/K-4404-2013	Tymianski, Mike/0000-0002-6311-9565	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS039060] Funding Source: NIH RePORTER; NINDS NIH HHS [NS 39060] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0; Brakeman PR, 1997, NATURE, V386, P284, DOI 10.1038/386284a0; Brenman JE, 1996, CELL, V84, P757, DOI 10.1016/S0092-8674(00)81053-3; Brenman JE, 1996, J NEUROSCI, V16, P7407; Brorson JR, 1999, J NEUROSCI, V19, P147, DOI 10.1523/JNEUROSCI.19-01-00147.1999; BURNASHEV N, 1995, J PHYSIOL-LONDON, V485, P403, DOI 10.1113/jphysiol.1995.sp020738; CHO KO, 1992, NEURON, V9, P929, DOI 10.1016/0896-6273(92)90245-9; CHOI DW, 1994, ANN NY ACAD SCI, V747, P162; Craven SE, 1998, CELL, V93, P495, DOI 10.1016/S0092-8674(00)81179-4; DAWSON TM, 1991, P NATL ACAD SCI USA, V88, P7797, DOI 10.1073/pnas.88.17.7797; DAWSON VL, 1993, J NEUROSCI, V13, P2651; DAWSON VL, 1991, P NATL ACAD SCI USA, V88, P6368, DOI 10.1073/pnas.88.14.6368; Dong HL, 1997, NATURE, V386, P279, DOI 10.1038/386279a0; GHOSH A, 1995, SCIENCE, V268, P239, DOI 10.1126/science.7716515; JAFFE DA, 1995, LEONARDO MUSIC J, V5, P11, DOI 10.2307/1513155; Jones OT, 1997, J NEUROSCI, V17, P6152; Kim JH, 1998, NEURON, V20, P683, DOI 10.1016/S0896-6273(00)81008-9; KOMAU HC, 1995, SCIENCE, V269, P1737; LIPTON SA, 1994, NEW ENGL J MED, V330, P613; Migaud M, 1998, NATURE, V396, P433, DOI 10.1038/24790; Muller BM, 1996, NEURON, V17, P255, DOI 10.1016/S0896-6273(00)80157-9; NELSON RJ, 1995, NATURE, V378, P383, DOI 10.1038/378383a0; Niethammer M, 1998, NEURON, V20, P693, DOI 10.1016/S0896-6273(00)81009-0; Olney J.W., 1978, KAINIC ACID TOOL NEU, P95; ROTHMAN SM, 1987, TRENDS NEUROSCI, V10, P299, DOI 10.1016/0166-2236(87)90177-9; Sattler R, 1998, J NEUROCHEM, V71, P2349; Sattler R, 1997, J CEREBR BLOOD F MET, V17, P455, DOI 10.1097/00004647-199704000-00011; Tezuka T, 1999, P NATL ACAD SCI USA, V96, P435, DOI 10.1073/pnas.96.2.435; TYMIANSKI M, 1993, J NEUROSCI, V13, P2085; TYMIANSKI M, UNPUB; Xiong ZG, 1997, P NATL ACAD SCI USA, V94, P7012, DOI 10.1073/pnas.94.13.7012; Yamada Y, 1999, J BIOL CHEM, V274, P6647, DOI 10.1074/jbc.274.10.6647	32	674	707	0	39	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 11	1999	284	5421					1845	1848		10.1126/science.284.5421.1845	http://dx.doi.org/10.1126/science.284.5421.1845			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	205EU	10364559				2022-12-28	WOS:000080809000053
J	Dimmeler, S; Fleming, I; Fisslthaler, B; Hermann, C; Busse, R; Zeiher, AM				Dimmeler, S; Fleming, I; Fisslthaler, B; Hermann, C; Busse, R; Zeiher, AM			Activation of nitric oxide synthase in endothelial cells by Akt-dependent phosphorylation	NATURE			English	Article							PROTEIN-KINASE-B; FLUID SHEAR-STRESS; SIGNAL-TRANSDUCTION; CALCIUM; SUPPRESSION; EXPRESSION; APOPTOSIS; PATHWAY; ANGIOGENESIS; CALMODULIN	Nitric oxide (NO) produced by the endothelial NO synthase (eNOS) is a fundamental determinant of cardiovascular homesotasis: it regulates systemic blood pressure, vascular remodelling and angiogenesis(1-3). Physiologically, the most important stimulus for the continuous formation of NO is the viscous drag (shear stress) generated by the streaming blood on the endothelial layer(4-8). Although shear-stress-mediated phosphorylation of eNOS is thought to regulate enzyme activity(9,10), the mechanism of activation of eNOS is not yet known. Here we demonstrate that the serine/threonine protein kinase Akt/PKB (11-13) mediates the activation of eNOS, leading to increased NO production. Inhibition of the phosphatidylinositol-3-OH kinase/Akt pathway or mutation of the Akt site on eNOS protein (at serine 1177) attenuates the serine phosphorylation and prevents the activation of eNOS, Mimicking the phosphorylation of Ser1177 directly enhances enzyme activity and alters the sensitivity of the enzyme to Ca2+, rendering its activity maximal at sub-physiological concentrations of Ca2+. Thus, phosphorylation of eNOS by Akt represents a novel Ca2+-independent regulatory mechanism for activation of eNOS.	Univ Frankfurt, Dept Internal Med 4, D-60590 Frankfurt, Germany; Univ Frankfurt, Inst Cardiovasc Physiol, D-60590 Frankfurt, Germany	Goethe University Frankfurt; Goethe University Frankfurt	Zeiher, AM (corresponding author), Univ Frankfurt, Dept Internal Med 4, Theodor Stern Kai 7, D-60590 Frankfurt, Germany.		Fleming, Ingrid/AAB-6123-2022; Fleming, Ingrid/L-1225-2014	Fleming, Ingrid/0000-0003-1881-3635; Fleming, Ingrid/0000-0003-1881-3635; Dimmeler, Stefanie/0000-0002-1045-2436				Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x; Ayajiki K, 1996, CIRC RES, V78, P750, DOI 10.1161/01.RES.78.5.750; BREDT DS, 1991, NATURE, V351, P714, DOI 10.1038/351714a0; BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0; BUSSE R, 1990, FEBS LETT, V265, P133, DOI 10.1016/0014-5793(90)80902-U; Busse R, 1998, J VASC RES, V35, P73, DOI 10.1159/000025568; COPPER JA, 1983, METHOD ENZYMOL, V99, P387; Corson MA, 1996, CIRC RES, V79, P984, DOI 10.1161/01.RES.79.5.984; DAVIES PF, 1995, PHYSIOL REV, V75, P519, DOI 10.1152/physrev.1995.75.3.519; Dimmeler S, 1997, J EXP MED, V185, P601, DOI 10.1084/jem.185.4.601; Dimmeler S, 1998, CIRC RES, V83, P334, DOI 10.1161/01.RES.83.3.334; Downward J, 1998, SCIENCE, V279, P673, DOI 10.1126/science.279.5351.673; FLEMING L, 1996, CIRC RES, V79, P984; FORSTERMANN U, 1991, BIOCHEM PHARMACOL, V42, P1849, DOI 10.1016/0006-2952(91)90581-O; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; Gerber HP, 1998, J BIOL CHEM, V273, P13313, DOI 10.1074/jbc.273.21.13313; KauffmanZeh A, 1997, NATURE, V385, P544, DOI 10.1038/385544a0; Khwaja A, 1997, EMBO J, V16, P2783, DOI 10.1093/emboj/16.10.2783; KUCHAN MJ, 1994, AM J PHYSIOL, V266, pC628, DOI 10.1152/ajpcell.1994.266.3.C628; MONCADA S, 1993, NEW ENGL J MED, V329, P2002; Moroi M, 1998, J CLIN INVEST, V101, P1225, DOI 10.1172/JCI1293; Murohara T, 1998, J CLIN INVEST, V101, P2567, DOI 10.1172/JCI1560; RUBANYI GM, 1986, AM J PHYSIOL, V250, P1145, DOI 10.1152/ajpheart.1986.250.6.H1145; SESSA WC, 1994, CIRC RES, V74, P349, DOI 10.1161/01.RES.74.2.349; vanderZee R, 1997, CIRCULATION, V95, P1030; Yano S, 1998, NATURE, V396, P584, DOI 10.1038/25147; Zeiher AM, 1996, LANCET, V348, pS10, DOI 10.1016/S0140-6736(96)98004-6; ZEIHER AM, 1995, CIRC RES, V76, P980, DOI 10.1161/01.RES.76.6.980; Ziche M, 1997, J CLIN INVEST, V99, P2625, DOI 10.1172/JCI119451	29	2900	2989	11	212	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUN 10	1999	399	6736					601	605		10.1038/21224	http://dx.doi.org/10.1038/21224			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	204RR	10376603				2022-12-28	WOS:000080778400060
J	Henry, TD				Henry, TD			Science, medicine, and the future - Therapeutic angiogenesis	BMJ-BRITISH MEDICAL JOURNAL			English	Review							CORONARY COLLATERAL CIRCULATION; HEART-DISEASE; GROWTH-FACTOR; EXPRESSION; MECHANISMS; MYOCARDIUM; ISCHEMIA		Hennepin Cty Med Ctr, Div Cardiol, Minneapolis, MN 55415 USA	Hennepin County Medical Center	Henry, TD (corresponding author), Hennepin Cty Med Ctr, Div Cardiol, 701 Pk Ave, Minneapolis, MN 55415 USA.	henry003@maroon.tc.umn.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL080584] Funding Source: NIH RePORTER	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Baumgartner I, 1998, CIRCULATION, V97, P1114, DOI 10.1161/01.CIR.97.12.1114; CHARNEY R, 1993, AM HEART J, V126, P937, DOI 10.1016/0002-8703(93)90710-Q; Ferrara N, 1997, ENDOCR REV, V18, P4, DOI 10.1210/er.18.1.4; Folkman J, 1995, NEW ENGL J MED, V333, P1757, DOI 10.1056/NEJM199512283332608; Henry TD, 1998, J AM COLL CARDIOL, V31, p65A, DOI 10.1016/S0735-1097(97)83989-7; Henry TD, 1998, LANCET, V351, P1826, DOI 10.1016/S0140-6736(98)22025-3; Inoue M, 1998, CIRCULATION, V98, P2108, DOI 10.1161/01.CIR.98.20.2108; IruelaArispe ML, 1997, THROMB HAEMOSTASIS, V78, P672; LAWSON WE, 1995, AM J CARDIOL, V75, P840, DOI 10.1016/S0002-9149(99)80427-5; Lazarous DF, 1998, CIRCULATION, V98, P456; Losordo DW, 1998, CIRCULATION, V98, P2800, DOI 10.1161/01.CIR.98.25.2800; Murray CJL, 1997, LANCET, V349, P1269, DOI 10.1016/S0140-6736(96)07493-4; Risau W, 1997, NATURE, V386, P671, DOI 10.1038/386671a0; SASAYAMA S, 1992, CIRCULATION, V85, P1197, DOI 10.1161/01.CIR.85.3.1197; Schaper W, 1996, CIRC RES, V79, P911, DOI 10.1161/01.RES.79.5.911; Schumacher B, 1998, CIRCULATION, V97, P645, DOI 10.1161/01.CIR.97.7.645; Sellke FW, 1998, ANN THORAC SURG, V65, P1540, DOI 10.1016/S0003-4975(98)00340-3; Ware JA, 1997, NAT MED, V3, P158, DOI 10.1038/nm0297-158; Yamamoto N, 1998, J AM COLL CARDIOL, V31, P1426, DOI 10.1016/S0735-1097(98)00086-2	19	82	89	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUN 5	1999	318	7197					1536	1539		10.1136/bmj.318.7197.1536	http://dx.doi.org/10.1136/bmj.318.7197.1536			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	204HC	10356013	Green Published			2022-12-28	WOS:000080757300031
J	Standen, G; Birchall, J; Morse, C; Chamberlain-Webber, R				Standen, G; Birchall, J; Morse, C; Chamberlain-Webber, R			A large bruise	LANCET			English	Article							FACTOR-XIII; IGG INHIBITOR		Univ Bristol, Bristol Royal Infirm, Dept Haematol, Mol Haematol Unit, Bristol BS2 8HW, Avon, England; Univ Bristol, Bristol Royal Infirm, Dept Cardiol, Bristol BS2 8HW, Avon, England	Bristol Royal Infirmary; University of Bristol; Bristol Royal Infirmary; University of Bristol	Standen, G (corresponding author), Univ Bristol, Bristol Royal Infirm, Dept Haematol, Mol Haematol Unit, Bristol BS2 8HW, Avon, England.							BOARD PG, 1993, BLOOD REV, V7, P229, DOI 10.1016/0268-960X(93)90010-2; DALY HM, 1991, BLOOD COAGUL FIBRIN, V2, P507, DOI 10.1097/00001721-199108000-00003; GAILANI D, 1992, AM J MED, V92, P110, DOI 10.1016/0002-9343(92)90028-A; NAKAMURA S, 1988, BRIT J HAEMATOL, V68, P313, DOI 10.1111/j.1365-2141.1988.tb04208.x	4	6	6	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUN 5	1999	353	9168					1934	1934		10.1016/S0140-6736(99)03208-0	http://dx.doi.org/10.1016/S0140-6736(99)03208-0			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	202TP	10371573				2022-12-28	WOS:000080668500014
J	Guinan, EC; Boussiotis, VA; Neuberg, D; Brennan, LL; Hirano, N; Nadler, LM; Gribben, JG				Guinan, EC; Boussiotis, VA; Neuberg, D; Brennan, LL; Hirano, N; Nadler, LM; Gribben, JG			Transplantation of anergic histoincompatible bone marrow allografts	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							VERSUS-HOST DISEASE; MISMATCHED RELATED DONORS; ACUTE MYELOID-LEUKEMIA; ACUTE GRAFT; RISK-FACTORS; LYMPHOPROLIFERATIVE DISORDERS; LYMPHOCYTES-T; CELLS; CYCLOSPORINE; PROPHYLAXIS	Background Successful allogeneic bone marrow transplantation relies on global immunosuppression or elimination of T cells. In contrast, the induction of anergy can inactivate specific sets of alloreactive T cells in the donor marrow. Previous work has shown that anergy can be induced by blocking the interaction of the B7 molecule on the surface of antigen-presenting cells with the CD28 molecule on the surface of T cells, thus preventing key signaling events essential for the activation of T cells. To investigate the feasibility of this approach with respect to transplantation of histoincompatible bone marrow, we undertook a clinical trial of ex vivo induction of anergy in T cells present in donor marrow to recipient alloantigens. Methods Outcomes in 12 transplant recipients were evaluated. The recipients' peripheral-blood lymphocytes were collected before myeloablation and served as alloantigen-presenting cells. To induce alloantigen-specific anergy, bone marrow from a donor mismatched with the recipient for one HLA haplotype was cocultured with irradiated cells from the recipient for 36 hours in the presence of CTLA-4-Ig, an agent that inhibits B7:CD28-mediated costimulation. After conventional myeloablation and immunoprophylaxis, the treated donor cells were transfused into the recipient. Results After the induction of anergy, the frequency of T cells capable of recognizing alloantigens of the recipient in donor marrow was sharply reduced (P<0.001), whereas the responsiveness to alloantigens from persons unrelated to the recipient or the donor was unaffected (P=0.51). In the 11 patients who could be evaluated, the haploidentical bone marrow cells engrafted. Of these 11 patients, 3 had acute graft-versus-host disease (GVHD) confined to the gastrointestinal tract. No deaths were attributable to GVHD. Five of the 12 patients were alive and in remission 4.5 to 29 months after transplantation. Conclusions Donor bone marrow treated ex vivo to induce anergy to alloantigens from the recipient can reconstitute hematopoiesis in vivo with a relatively low risk of GVHD. (N Engl J Med 1999;340: 1704-14.) (C) 1999, Massachusetts Medical Society.	Dana Farber Canc Inst, Dept Pediat Oncol, Boston, MA 02115 USA; Dana Farber Canc Inst, Dept Adult Oncol, Boston, MA 02115 USA; Dana Farber Canc Inst, Dept Biostat, Boston, MA 02115 USA; Childrens Hosp, Div Hematol & Oncol, Boston, MA USA; Brigham & Womens Hosp, Div Med Oncol, Boston, MA USA; Harvard Univ, Sch Med, Dept Pediat, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Med, Boston, MA USA	Harvard University; Dana-Farber Cancer Institute; Harvard University; Dana-Farber Cancer Institute; Harvard University; Dana-Farber Cancer Institute; Harvard University; Boston Children's Hospital; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School	Guinan, EC (corresponding author), Dana Farber Canc Inst, Dept Pediat Oncol, 44 Binney St, Boston, MA 02115 USA.	eva_guinan@dfci.harvard.edu	Jones, Jeffrey A/E-9827-2013		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL054785] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P01AI041584] Funding Source: NIH RePORTER; NHLBI NIH HHS [P50 HL54785] Funding Source: Medline; NIAID NIH HHS [P01 AI41584] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ANASETTI C, 1990, HUM IMMUNOL, V29, P79, DOI 10.1016/0198-8859(90)90071-V; Andersen NS, 1997, BLOOD, V90, P4212, DOI 10.1182/blood.V90.10.4212; ATKINSON K, 1987, BONE MARROW TRANSPL, V2, P51; AVERSA F, 1994, BLOOD, V84, P3948, DOI 10.1182/blood.V84.11.3948.bloodjournal84113948; Aversa F, 1998, NEW ENGL J MED, V339, P1186, DOI 10.1056/NEJM199810223391702; BACIGALUPO A, 1991, BLOOD, V77, P1423; BEATTY PG, 1992, SEMIN ONCOL, V19, P13; BEATTY PG, 1985, NEW ENGL J MED, V313, P765, DOI 10.1056/NEJM198509263131301; Blazar BR, 1998, J CLIN INVEST, V102, P473, DOI 10.1172/JCI3741; BOUSSIOTIS VA, 1994, CURR OPIN IMMUNOL, V6, P797, DOI 10.1016/0952-7915(94)90087-6; BOZDECH MJ, 1985, EXP HEMATOL, V13, P1201; BRETSCHER P, 1970, SCIENCE, V169, P1042, DOI 10.1126/science.169.3950.1042; BRETSCHER P, 1992, IMMUNOL TODAY, V13, P74, DOI 10.1016/0167-5699(92)90138-W; BROSS DS, 1984, BLOOD, V63, P1265; CLIFT RA, 1990, BLOOD, V76, P1867; Delgado J. C., 1998, Human Immunology, V59, P106; FAUCI AS, 1976, ANN INTERN MED, V84, P304, DOI 10.7326/0003-4819-84-3-304; FERRARA JLM, 1991, NEW ENGL J MED, V324, P667; Fishman JA, 1998, NEW ENGL J MED, V338, P1741, DOI 10.1056/NEJM199806113382407; GALE RP, 1987, BRIT J HAEMATOL, V67, P397, DOI 10.1111/j.1365-2141.1987.tb06160.x; Gribben JG, 1996, BLOOD, V87, P4887, DOI 10.1182/blood.V87.11.4887.bloodjournal87114887; GUINAN EC, 1989, BLOOD, V73, P619; Hanson MN, 1996, BLOOD, V88, P3626, DOI 10.1182/blood.V88.9.3626.bloodjournal8893626; HensleeDowney PJ, 1997, BLOOD, V89, P3864, DOI 10.1182/blood.V89.10.3864.3864_3864_3872; HITCHINGS GH, 1963, PHARMACOL REV, V15, P365; HOROWITZ MM, 1990, BLOOD, V75, P555; JENKINS MK, 1993, CURR OPIN IMMUNOL, V5, P361, DOI 10.1016/0952-7915(93)90054-V; JUNE CH, 1994, IMMUNOL TODAY, V15, P321, DOI 10.1016/0167-5699(94)90080-9; KERNAN NA, 1986, BLOOD, V68, P770; Kirk AD, 1997, P NATL ACAD SCI USA, V94, P8789, DOI 10.1073/pnas.94.16.8789; KORNGOLD R, 1987, TRANSPLANTATION, V44, P335, DOI 10.1097/00007890-198709000-00002; KWOK S, 1989, NATURE, V339, P237, DOI 10.1038/339237a0; Lamb LS, 1998, BONE MARROW TRANSPL, V21, P461; LAZARUS HM, 1984, BLOOD, V64, P215; LENSCHOW DJ, 1992, SCIENCE, V257, P789, DOI 10.1126/science.1323143; LIN H, 1993, J EXP MED, V178, P1801, DOI 10.1084/jem.178.5.1801; LINSLEY PS, 1991, J EXP MED, V174, P561, DOI 10.1084/jem.174.3.561; MARTIN PJ, 1991, BLOOD, V77, P1821; MARTIN PJ, 1997, GRAFT VS HOST DIS, P615; MEYERS JD, 1988, NEW ENGL J MED, V318, P70, DOI 10.1056/NEJM198801143180202; MITCHELL DM, 1983, IMMUNOLOGY, V50, P239; Munn RK, 1997, BONE MARROW TRANSPL, V19, P421, DOI 10.1038/sj.bmt.1700681; NASH RA, 1992, BLOOD, V80, P1838; PENN I, 1987, TRANSPLANTATION, V43, P32, DOI 10.1097/00007890-198701000-00008; POWLES R, 1984, SEMIN HEMATOL, V21, P182; POWLES RL, 1983, LANCET, V1, P612; Provan D, 1996, BLOOD, V88, P2228, DOI 10.1182/blood.V88.6.2228.bloodjournal8862228; REISNER Y, 1983, BLOOD, V61, P341; Rowlings PA, 1997, BRIT J HAEMATOL, V97, P855, DOI 10.1046/j.1365-2141.1997.1112925.x; SCHWARTZ R, 1959, J CLIN INVEST, V38, P1394, DOI 10.1172/JCI103915; SCHWARTZ RH, 1992, CELL, V71, P1065, DOI 10.1016/S0092-8674(05)80055-8; SCOTT JP, 1988, MED TOXICOL ADV DRUG, V3, P107, DOI 10.1007/BF03259936; STEINMAN RM, 1991, CURR OPIN IMMUNOL, V3, P361, DOI 10.1016/0952-7915(91)90039-4; STORB R, 1986, NEW ENGL J MED, V314, P729, DOI 10.1056/NEJM198603203141201; SULLIVAN KM, 1986, BLOOD, V67, P1172; SULLIVAN KM, 1988, BLOOD, V72, P555; SULLIVAN KM, 1994, BONE MARROW TRANSPL, P339; THOMAS ED, 1962, BLOOD, V19, P217, DOI 10.1182/blood.V19.2.217.217; WAGEMAKER G, 1981, TRANSPLANT P, V13, P875; WEAVER CH, 1994, BONE MARROW TRANSPL, V14, P885; WEISDORF D, 1991, TRANSPLANTATION, V51, P1197, DOI 10.1097/00007890-199106000-00010; YUNIS EJ, 1974, P NATL ACAD SCI USA, V71, P2544, DOI 10.1073/pnas.71.6.2544	63	331	355	0	2	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUN 3	1999	340	22					1704	1714		10.1056/NEJM199906033402202	http://dx.doi.org/10.1056/NEJM199906033402202			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	201WQ	10352162				2022-12-28	WOS:000080620200002
J	Shimizu, S; Narita, M; Tsujimoto, Y				Shimizu, S; Narita, M; Tsujimoto, Y			Bcl-2 family proteins regulate the release of apoptogenic cytochrome c by the mitochondrial channel VDAC	NATURE			English	Article							PERMEABILITY TRANSITION PORE; ION-CHANNEL; BAX; APOPTOSIS; MEMBRANE; YEAST; INHIBITION; BCL-X(L); FORMS	During transduction of an apoptotic (death) signal into the cell, there is an alteration in the permeability of the membranes of the cell's mitochondria, which causes the translocation of the apoptogenic protein cytochrome c into the cytoplasm, which in turn activates death-driving proteolytic proteins known as caspases(1,2). The Bcl-2 family of proteins, whose members may be anti-apoptotic or pro-apoptotic, regulates cell death by controlling this mitochondrial membrane permeability during apoptosis(3-5), but how that is achieved is unclear. Here we create liposomes that carry the mitochondrial porin channel (also called the voltage-dependent anion channel, or VDAC) to show that the recombinant pro-apoptotic proteins Bax and Bak accelerate the opening of VDAC, whereas the anti-apoptotic protein Bd-x(L) doses VDAC by binding to it directly. pax and Bak allow cytochrome c to pass through VDAC out of liposomes, but passage is prevented by Bcl-X-L. In agreement with this, VDAC1-deficient mitochondria from a mutant yeast did not exhibit a Bax/Bak-induced loss in membrane potential and cytochrome c release, both of which were inhibited by Bcl-x(L). Our results indicate that the Bcl-2 family of proteins bind to the VDAC in order to regulate the mitochondrial membrane potential and the release of cytochrome c during apoptosis.	Japan Sci & Technol Corp, CREST, Osaka 5650871, Japan; Osaka Univ, Sch Med, Biomed Res Ctr, Dept Med Genet, Osaka 5650871, Japan	Japan Science & Technology Agency (JST); Osaka University	Tsujimoto, Y (corresponding author), Japan Sci & Technol Corp, CREST, 2-2 Yamadaoka, Osaka 5650871, Japan.			Narita, Masashi/0000-0001-7764-577X				Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; Antonsson B, 1997, SCIENCE, V277, P370, DOI 10.1126/science.277.5324.370; BATHORI G, 1993, BIOCHIM BIOPHYS ACTA, V1145, P168, DOI 10.1016/0005-2736(93)90394-F; BERNARDI P, 1994, J BIOENERG BIOMEMBR, V26, P509, DOI 10.1007/BF00762735; BLACHLYDYSON E, 1990, SCIENCE, V247, P1233, DOI 10.1126/science.1690454; Cheng EHY, 1996, NATURE, V379, P554, DOI 10.1038/379554a0; COLOMBINI M, 1989, J MEMBRANE BIOL, V111, P103, DOI 10.1007/BF01871775; DAUM G, 1982, J BIOL CHEM, V257, P3028; DEPINTO V, 1987, BIOCHIM BIOPHYS ACTA, V905, P499, DOI 10.1016/0005-2736(87)90480-9; Eskes R, 1998, J CELL BIOL, V143, P217, DOI 10.1083/jcb.143.1.217; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Greenhalf W, 1996, FEBS LETT, V380, P169, DOI 10.1016/0014-5793(96)00044-0; Jurgensmeier JM, 1998, P NATL ACAD SCI USA, V95, P4997, DOI 10.1073/pnas.95.9.4997; KELVIN H, 1990, CURRENT PROTOCOLS IM; Lee AC, 1998, J MEMBRANE BIOL, V161, P173, DOI 10.1007/s002329900324; Mannella CA, 1998, J STRUCT BIOL, V121, P207, DOI 10.1006/jsbi.1997.3954; Marzo I, 1998, SCIENCE, V281, P2027, DOI 10.1126/science.281.5385.2027; Matsuyama S, 1998, MOL CELL, V1, P327, DOI 10.1016/S1097-2765(00)80033-7; Merry DE, 1997, ANNU REV NEUROSCI, V20, P245, DOI 10.1146/annurev.neuro.20.1.245; Minn AJ, 1997, NATURE, V385, P353, DOI 10.1038/385353a0; Narita M, 1998, P NATL ACAD SCI USA, V95, P14681, DOI 10.1073/pnas.95.25.14681; Ruck A, 1998, FEBS LETT, V426, P97, DOI 10.1016/S0014-5793(98)00317-2; Schendel SL, 1997, P NATL ACAD SCI USA, V94, P5113, DOI 10.1073/pnas.94.10.5113; Schlesinger PH, 1997, P NATL ACAD SCI USA, V94, P11357, DOI 10.1073/pnas.94.21.11357; Shimizu S, 1998, P NATL ACAD SCI USA, V95, P1455, DOI 10.1073/pnas.95.4.1455; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; Tsujimoto Y, 1998, GENES CELLS, V3, P697, DOI 10.1046/j.1365-2443.1998.00223.x; ZORATTI M, 1995, BBA-REV BIOMEMBRANES, V1241, P139, DOI 10.1016/0304-4157(95)00003-A	28	1820	1930	0	96	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUN 3	1999	399	6735					483	487		10.1038/20959	http://dx.doi.org/10.1038/20959			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	202TH	10365962				2022-12-28	WOS:000080667900052
J	Horn, MO				Horn, MO			The other side of the bed rail	ANNALS OF INTERNAL MEDICINE			English	Editorial Material									St Mary Hosp, Long Beach, CA 90813 USA		Horn, MO (corresponding author), St Mary Hosp, 1050 Linden Ave, Long Beach, CA 90813 USA.								0	7	7	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 1	1999	130	11					940	941		10.7326/0003-4819-130-11-199906010-00020	http://dx.doi.org/10.7326/0003-4819-130-11-199906010-00020			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	200PB	10375344				2022-12-28	WOS:000080547900010
J	Fuster, V; Fayad, ZA; Badimon, JJ				Fuster, V; Fayad, ZA; Badimon, JJ			Acute coronary syndromes: biology	LANCET			English	Article							HUMAN ATHEROSCLEROTIC PLAQUES; MYOCARDIAL-INFARCTION; ARTERY DISEASE; TISSUE FACTOR; UNSTABLE ANGINA; RISK-FACTORS; RUPTURE; THROMBOGENICITY; PATHOGENESIS; CHOLESTEROL		CUNY, Mt Sinai Med Ctr, Cardiovasc Inst, New York, NY 10029 USA	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai	Fuster, V (corresponding author), CUNY, Mt Sinai Med Ctr, Cardiovasc Inst, Box 1030, New York, NY 10029 USA.		Fuster, Valentin/H-4319-2015; Fayad, Zahi/Z-3272-2019	Fuster, Valentin/0000-0002-9043-9986; Fayad, Zahi/0000-0002-3439-7347				Aikawa M, 1998, CIRCULATION, V97, P2433, DOI 10.1161/01.CIR.97.24.2433; AMBROSE JA, 1988, J AM COLL CARDIOL, V12, P56, DOI 10.1016/0735-1097(88)90356-7; Badimon JJ, 1999, CIRCULATION, V99, P1780, DOI 10.1161/01.CIR.99.14.1780; Banner DW, 1996, NATURE, V380, P41, DOI 10.1038/380041a0; Biasucci LM, 1999, CIRCULATION, V99, P855, DOI 10.1161/01.CIR.99.7.855; BOGATY P, 1994, CIRCULATION, V90, P5, DOI 10.1161/01.CIR.90.1.5; Burke AP, 1997, NEW ENGL J MED, V336, P1276, DOI 10.1056/NEJM199705013361802; Dangas G, 1999, J AM COLL CARDIOL, V33, P1294, DOI 10.1016/S0735-1097(99)00018-2; DAVIES MJ, 1993, BRIT HEART J, V69, P377; Davies MJ, 1996, CIRCULATION, V94, P2013, DOI 10.1161/01.CIR.94.8.2013; FALK E, 1995, CIRCULATION, V92, P657, DOI 10.1161/01.CIR.92.3.657; Farb A, 1996, CIRCULATION, V93, P1354, DOI 10.1161/01.CIR.93.7.1354; Fayad ZA, 1998, CIRCULATION, V98, P515; Fayad ZA, 1998, CIRCULATION, V98, P1541, DOI 10.1161/01.CIR.98.15.1541; FERNANDEZORTIZ A, 1994, J AM COLL CARDIOL, V23, P1562, DOI 10.1016/0735-1097(94)90657-2; Fuster V, 1996, J AM COLL CARDIOL, V27, P964, DOI 10.1016/0735-1097(96)00014-9; FUSTER V, 1992, NEW ENGL J MED, V326, P242, DOI 10.1056/NEJM199201233260406; FUSTER V, 1994, CIRCULATION, V90, P2126, DOI 10.1161/01.CIR.90.4.2126; FUSTER V, 1992, NEW ENGL J MED, V326, P310; Fuster V, 1996, LANCET, V348, pS7, DOI 10.1016/S0140-6736(96)98003-4; Giesen PLA, 1999, P NATL ACAD SCI USA, V96, P2311, DOI 10.1073/pnas.96.5.2311; Gould AL, 1998, CIRCULATION, V97, P946; Koenig W, 1999, CIRCULATION, V99, P237, DOI 10.1161/01.CIR.99.2.237; Libby P, 1997, CIRCULATION, V96, P4095; LIBBY P, 1995, CIRCULATION, V91, P2844, DOI 10.1161/01.CIR.91.11.2844; LITTLE WC, 1988, CIRCULATION, V78, P1157, DOI 10.1161/01.CIR.78.5.1157; Mallat Z, 1999, CIRCULATION, V99, P348, DOI 10.1161/01.CIR.99.3.348; MASERI A, 1978, NEW ENGL J MED, V299, P1271, DOI 10.1056/NEJM197812072992303; Moreno PR, 1996, CIRCULATION, V94, P3090, DOI 10.1161/01.CIR.94.12.3090; MORENO PR, 1994, CIRCULATION, V90, P775, DOI 10.1161/01.CIR.90.2.775; Ridker PM, 1998, CIRCULATION, V97, P2007, DOI 10.1161/01.CIR.97.20.2007; Ridker PM, 1998, CIRCULATION, V98, P839, DOI 10.1161/01.CIR.98.9.839; Ross R, 1999, NEW ENGL J MED, V340, P115, DOI 10.1056/NEJM199901143400207; SHAH PK, 1995, CIRCULATION, V92, P1565; SHINNAR M, IN PRESS ARTERIOSCLE; STARY HC, 1995, CIRCULATION, V92, P1355, DOI 10.1161/01.CIR.92.5.1355; Steinberg D, 1997, CIRCULATION, V95, P1062; Theroux P, 1998, CIRCULATION, V97, P1195, DOI 10.1161/01.CIR.97.12.1195; Toschi V, 1997, CIRCULATION, V95, P594, DOI 10.1161/01.CIR.95.3.594; WILLERSON JT, 1989, CIRCULATION, V80, P198, DOI 10.1161/01.CIR.80.1.198; Xu XP, 1999, CIRCULATION, V99, P993, DOI 10.1161/01.CIR.99.8.993	41	74	80	0	3	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet		1999	353			2			SII5	SII9						5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	205GJ	10374759				2022-12-28	WOS:000080812700002
J	Altman, DG; Bland, JM				Altman, DG; Bland, JM			Variables and parameters	BMJ-BRITISH MEDICAL JOURNAL			English	Article									Inst Hlth Sci, Ctr Stat Med, Imperial Canc Res Fund, Med Stat Grp, Oxford OX3 7LF, England; Univ London St Georges Hosp, Sch Med, Dept Publ Hlth Sci, London SW17 0RE, England	University of Oxford; St Georges University London	Altman, DG (corresponding author), Inst Hlth Sci, Ctr Stat Med, Imperial Canc Res Fund, Med Stat Grp, Oxford OX3 7LF, England.							ALTMAN DG, 1995, BRIT MED J, V310, P298, DOI 10.1136/bmj.310.6975.298; 1998, BMJ, V316, P1877	2	25	26	1	2	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUN 19	1999	318	7199					1667	1667		10.1136/bmj.318.7199.1667	http://dx.doi.org/10.1136/bmj.318.7199.1667			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	210KY	10373171	Bronze, Green Published, Green Submitted			2022-12-28	WOS:000081105600022
J	Fukumura, T; Sugawara, H; Hasegawa, T; Tanaka, K; Sakaki, H; Kimura, T; Tokura, Y				Fukumura, T; Sugawara, H; Hasegawa, T; Tanaka, K; Sakaki, H; Kimura, T; Tokura, Y			Spontaneous bubble domain formation in a layered ferromagnetic crystal	SCIENCE			English	Article							INTERPLANE TUNNELING MAGNETORESISTANCE; MANGANITE CRYSTAL; PEROVSKITE	Magnetic domain structure on the surface of the Layer-structured ferromagnet La1.4Sr1.6Mn2O7 was observed in the temperature range from 37 to 97 kelvin with a scanning Hall probe microscope. The sensitivity to temperature of the domain structure changes was targe relative to that in conventional ferromagnets. The stable and spontaneous appearance of magnetic bubble domains without an external magnetic field was observed in the neighborhood of 70 kelvin. The phenomenon observed could provide a potential route toward magnetic bubble memory.	Univ Tokyo, Dept Appl Chem, Tokyo 1138656, Japan; Tokyo Inst Technol, Mat & Struct Lab, Yokohama, Kanagawa 2268503, Japan; Univ Tokyo, Adv Sci & Technol Res Ctr, Tokyo 1538904, Japan; Joint Res Ctr Atom Technol, Tsukuba, Ibaraki 3050046, Japan; Univ Tokyo, Dept Appl Phys, Tokyo 1138656, Japan	University of Tokyo; Tokyo Institute of Technology; University of Tokyo; National Institute of Advanced Industrial Science & Technology (AIST); University of Tokyo	Fukumura, T (corresponding author), Tokyo Inst Technol, Dept Innovat & Engineered Mat, Yokohama, Kanagawa 2268502, Japan.		Gao, Jinlong/C-1489-2010; Tokura, Yoshinori/C-7352-2009; Kimura, Tsuyoshi/F-8090-2018; Fukumura, Tomoteru/C-2081-2009	Tokura, Yoshinori/0000-0002-2732-4983; Fukumura, Tomoteru/0000-0002-8957-3520				Bobeck H., 1975, MAGNETIC BUBBLES; FUKUMURA T, 1998, THESIS U TOKYO; Heffner RH, 1998, PHYS REV LETT, V81, P1706, DOI 10.1103/PhysRevLett.81.1706; KAPLAN B, 1993, J MAGN MAGN MATER, V128, P111, DOI 10.1016/0304-8853(93)90863-W; Kimura T, 1996, SCIENCE, V274, P1698, DOI 10.1126/science.274.5293.1698; Kimura T, 1997, PHYS REV LETT, V79, P3720, DOI 10.1103/PhysRevLett.79.3720; KITTEL C, 1949, REV MOD PHYS, V21, P541, DOI 10.1103/RevModPhys.21.541; Lu QY, 1997, SCIENCE, V276, P2006, DOI 10.1126/science.276.5321.2006; Moritomo Y, 1996, NATURE, V380, P141, DOI 10.1038/380141a0; Perring TG, 1998, PHYS REV B, V58, P14693, DOI 10.1103/PhysRevB.58.R14693	10	74	74	2	45	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 18	1999	284	5422					1969	1971		10.1126/science.284.5422.1969	http://dx.doi.org/10.1126/science.284.5422.1969			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	207JA	10373110				2022-12-28	WOS:000080932700040
J	Blumenthal, D				Blumenthal, D			Health care reform at the close of the 20th century	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							MANAGED CARE; QUALITY; FUTURE; PERFORMANCE; PHYSICIANS		Massachusetts Gen Hosp, Boston, MA 02114 USA	Harvard University; Massachusetts General Hospital	Blumenthal, D (corresponding author), Massachusetts Gen Hosp, Boston, MA 02114 USA.							ABELSON R, 1999, NY TIMES        0103, P4; Altmann S.A., 1998, FUTURE US HEALTHCARE, P1; Angell M, 1996, NEW ENGL J MED, V335, P883, DOI 10.1056/NEJM199609193351209; Blendon RJ, 1998, HEALTH AFFAIR, V17, P80, DOI 10.1377/hlthaff.17.4.80; Blumenthal D, 1996, NEW ENGL J MED, V335, P1328, DOI 10.1056/NEJM199610243351721; BLUMENTHAL D, 1995, NEW ENGL J MED, V332, P465, DOI 10.1056/NEJM199502163320711; Brook RH, 1996, NEW ENGL J MED, V335, P966, DOI 10.1056/NEJM199609263351311; *CTR STUD HLTH SYS, 1997, 1997 ANN REP CHART C; DAVIS K, 1998, FUTURE US HLTH CARE, P247; DEBAKEY M, 1998, WALL STREET J   1008, pA18; Eddy DM, 1998, HEALTH AFFAIR, V17, P7, DOI 10.1377/hlthaff.17.4.7; FARLEY D, 1998, ASSESSING QUALITY MA; Ginsburg PB, 1998, HEALTH AFFAIR, V17, P141, DOI 10.1377/hlthaff.17.5.141; GOLDBERG RM, 1998, WALL STREET J   0717, pA14; Hellinger FJ, 1998, ARCH INTERN MED, V158, P833, DOI 10.1001/archinte.158.8.833; *HLTH RIGHTS HOTL, 1998, ANN REP JUL 1 1997 J; Iglehart JK, 1999, NEW ENGL J MED, V340, P70, DOI 10.1056/NEJM199901073400122; Iglehart JK, 1996, NEW ENGL J MED, V335, P995, DOI 10.1056/NEJM199609263351322; Iglehart JK, 1998, HEALTH AFFAIR, V17, P90, DOI 10.1377/hlthaff.17.1.90; Kilborn Peter T, 1998, N Y Times Web, P30; Kuttner R, 1999, NEW ENGL J MED, V340, P163, DOI 10.1056/NEJM199901143400226; Kuttner R, 1998, NEW ENGL J MED, V339, P1952, DOI 10.1056/NEJM199812243392625; Levit KR, 1998, HEALTH AFFAIR, V17, P35, DOI 10.1377/hlthaff.17.1.35; MILLER RH, 1994, JAMA-J AM MED ASSOC, V271, P1512, DOI 10.1001/jama.271.19.1512; President's Advisory Commission on Consumer Protection and Quality in the Health Care Industry, 1998, QUAL 1 BETT HLTH CAR; RICE T, 1998, POLICY REPORT TRENDS; Roper WL, 1998, HEALTH AFFAIR, V17, P152, DOI 10.1377/hlthaff.17.2.152; ROWLAND D, 1998, FUTURE US HEALTHCARE, P25; Selden TM, 1999, HEALTH AFFAIR, V18, P126, DOI 10.1377/hlthaff.18.2.126; SHORT PF, 1998, IMPROVING HLTH CARE; Smith S, 1998, HEALTH AFFAIR, V17, P128, DOI 10.1377/hlthaff.17.5.128; SWARTZ K, 1998, FUTURE US HLTH CARE, P45; WEISSMAN JS, 1994, FALLING SAFETY NET; WINSLOW R, 1998, WALL STREET J   0519, pA1	34	18	18	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 17	1999	340	24					1916	1920		10.1056/NEJM199906173402412	http://dx.doi.org/10.1056/NEJM199906173402412			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	206EC	10369858				2022-12-28	WOS:000080863500012
J	Wilcken, NRC				Wilcken, NRC			Tamoxifen hits the target in situ	LANCET			English	Editorial Material							SURGICAL-ADJUVANT-BREAST; CANCER		Westmead Hosp, Dept Med Oncol & Pallat Care, Sydney, NSW 2145, Australia; Nepean Hosp, Nepean Canc Care Ctr, Penrith, Australia	University of Sydney; Nepean Hospital	Wilcken, NRC (corresponding author), Westmead Hosp, Dept Med Oncol & Pallat Care, Sydney, NSW 2145, Australia.							BARNES R, 1990, AM J CLIN PATHOL, V94, P533, DOI 10.1093/ajcp/94.5.533; Clarke M, 1998, LANCET, V351, P1451; Fisher B, 1998, J NATL CANCER I, V90, P1371, DOI 10.1093/jnci/90.18.1371; Fisher B, 1998, J CLIN ONCOL, V16, P441, DOI 10.1200/JCO.1998.16.2.441; Silverstein MJ, 1999, NEW ENGL J MED, V340, P1455, DOI 10.1056/NEJM199905133401902	5	12	12	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUN 12	1999	353	9169					1986	1987		10.1016/S0140-6736(99)00194-4	http://dx.doi.org/10.1016/S0140-6736(99)00194-4			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	205GD	10376607				2022-12-28	WOS:000080812200002
J	Beecham, L				Beecham, L			EU supports delay in reducing doctors' hours	BRITISH MEDICAL JOURNAL			English	News Item																			0	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JUN 5	1999	318	7197					1508	1508		10.1136/bmj.318.7197.1508	http://dx.doi.org/10.1136/bmj.318.7197.1508			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	204HC	10355994	Green Published			2022-12-28	WOS:000080757300013
J	White, NJ; Nosten, F; Looareesuwan, S; Watkins, WM; Marsh, K; Snow, RW; Kokwaro, G; Ouma, J; Hien, TT; Molyneux, ME; Taylor, TE; Newbold, CI; Ruebush, TK; Danis, M; Greenwood, BM; Anderson, RM; Olliaro, P				White, NJ; Nosten, F; Looareesuwan, S; Watkins, WM; Marsh, K; Snow, RW; Kokwaro, G; Ouma, J; Hien, TT; Molyneux, ME; Taylor, TE; Newbold, CI; Ruebush, TK; Danis, M; Greenwood, BM; Anderson, RM; Olliaro, P			Averting a malaria disaster	LANCET			English	Editorial Material							RESISTANT FALCIPARUM-MALARIA; PLASMODIUM-FALCIPARUM; DRUG-RESISTANCE; PYRIMETHAMINE; CHLOROQUINE; SULFADOXINE; ARTEMETHER; AFRICA		Mahidol Univ, Fac Trop Med, Bangkok 10400, Thailand; Wellcome Mahidol Univ Oxford, Trop Med Res Programme, Bangkok, Thailand; KEMRI Wellcome Trust Collaborat Res Programme, Nairobi, Kenya; Minist Hlth, Natl Malaria Control Programme, Nairobi, Kenya; Cho Quan Hosp, Ctr Trop Dis, Ho Chi Minh City, Vietnam; Univ Malawi, Coll Med, Zomba, Malawi; Univ Liverpool, Liverpool Sch Trop Med, Liverpool L3 5QA, Merseyside, England; Univ Oxford, Inst Mol Med, Oxford, England; Ctr Dis Control & Prevent, Atlanta, GA USA; Grp Hosp Pitie Salpetriere, F-75634 Paris, France; London Sch Hyg & Trop Med, London WC1, England; Univ Oxford, Dept Zool, Oxford OX1 3PS, England; WHO, CH-1211 Geneva, Switzerland	Mahidol University; Mahidol Oxford Tropical Medicine Research Unit (MORU); Mahidol University; University of Malawi; Liverpool School of Tropical Medicine; University of Liverpool; University of Oxford; Centers for Disease Control & Prevention - USA; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; UDICE-French Research Universities; Sorbonne Universite; University of London; London School of Hygiene & Tropical Medicine; University of Oxford; World Health Organization	White, NJ (corresponding author), Mahidol Univ, Fac Trop Med, 420-6 Rajvithi Rd, Bangkok 10400, Thailand.		Nosten, Francois/AAC-5509-2019; White, Nicholas J/I-4629-2012; White, Nick/AAC-6527-2019; Snow, Robert William/AFR-1436-2022	Nosten, Francois/0000-0002-7951-0745; White, Nick/0000-0002-1897-1978; Snow, Robert William/0000-0003-3725-6088; Anderson, Roy/0000-0002-9528-3175; Newbold, Chris/0000-0002-9274-3789				BLOLAND PB, 1993, J INFECT DIS, V167, P932, DOI 10.1093/infdis/167.4.932; BREWER TG, 1994, AM J TROP MED HYG, V51, P251, DOI 10.4269/ajtmh.1994.51.251; Brundtland G. H., 1998, 51 WORLD HLTH ASS GE; Handunnetti SM, 1996, T ROY SOC TROP MED H, V90, P563, DOI 10.1016/S0035-9203(96)90325-9; Marsh K, 1998, LANCET, V352, P924, DOI 10.1016/S0140-6736(05)61510-3; Price RN, 1996, LANCET, V347, P1654, DOI 10.1016/S0140-6736(96)91488-9; Price RN, 1997, T ROY SOC TROP MED H, V91, P574, DOI 10.1016/S0035-9203(97)90032-8; Ronn AM, 1996, T ROY SOC TROP MED H, V90, P179, DOI 10.1016/S0035-9203(96)90129-7; SNOW RW, 1992, T ROY SOC TROP MED H, V86, P237, DOI 10.1016/0035-9203(92)90290-S; van Vugt M, 1998, ANTIMICROB AGENTS CH, V42, P135, DOI 10.1128/AAC.42.1.135; WATKINS WM, 1993, T ROY SOC TROP MED H, V87, P75, DOI 10.1016/0035-9203(93)90431-O; White NJ, 1997, ANTIMICROB AGENTS CH, V41, P1413, DOI 10.1128/AAC.41.7.1413; White NJ, 1998, DRUG RESIST UPDATE, V1, P3, DOI 10.1016/S1368-7646(98)80208-2	13	440	451	0	27	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUN 5	1999	353	9168					1965	1967		10.1016/S0140-6736(98)07367-X	http://dx.doi.org/10.1016/S0140-6736(98)07367-X			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	202TP	10371589				2022-12-28	WOS:000080668500047
J	Keppler, H				Keppler, H			Experimental evidence for the source of excess sulfur in explosive volcanic eruptions	SCIENCE			English	Article							PINATUBO; MAGMA	The amounts of sulfur released in explosive volcanic eruptions are often orders of magnitude Larger than those expected to result from the degassing of the erupted SiO2-rich magma, Experimentally measured fluid/melt partition coefficients of sulfur ranged from 47 under oxidizing conditions (where SO2 is the dominant sulfur species in the fluid) to 468 under reducing conditions (where H2S dominates). Therefore, a few weight percent of hydrous fluid accumulated in the top of a magma chamber may extract most of the sulfur out of the entire magma reservoir and generate sulfur-excesses upon eruption.	Univ Bayreuth, Bayer Geoinst, D-95440 Bayreuth, Germany	University of Bayreuth	Keppler, H (corresponding author), Univ Bayreuth, Bayer Geoinst, Postfach 101251, D-95440 Bayreuth, Germany.							Bekki S, 1996, GEOPHYS RES LETT, V23, P2669, DOI 10.1029/96GL02088; BLUTH GJS, 1993, NATURE, V366, P327, DOI 10.1038/366327a0; Briffa KR, 1998, NATURE, V393, P450, DOI 10.1038/30943; CARROLL MR, 1988, AM MINERAL, V73, P845; CHOU IM, 1986, AM J SCI, V286, P638, DOI 10.2475/ajs.286.8.638; DEVINE JD, 1984, J GEOPHYS RES, V89, P6309, DOI 10.1029/JB089iB07p06309; Gerlach TM, 1996, FIRE AND MUD, P415; GERLACH TM, 1994, GEOPHYS RES LETT, V21, P2833, DOI 10.1029/94GL02761; GERLACH TM, 1994, J VOLCANOL GEOTH RES, V62, P317, DOI 10.1016/0377-0273(94)90039-6; Kress V, 1997, NATURE, V389, P591, DOI 10.1038/39299; LUHR JF, 1984, J VOLCANOL GEOTH RES, V23, P69, DOI 10.1016/0377-0273(84)90057-X; MCCORMICK MP, 1995, NATURE, V373, P399, DOI 10.1038/373399a0; MORI J, 1993, EOS, V74, P667; Oppenheimer C, 1996, GEOPHYS RES LETT, V23, P2057, DOI 10.1029/96GL02061; Pyle DM, 1998, NATURE, V393, P415, DOI 10.1038/30848; RAMPINO MR, 1992, NATURE, V359, P50, DOI 10.1038/359050a0; Scaillet B, 1998, J GEOPHYS RES-SOL EA, V103, P23937, DOI 10.1029/98JB02301; SIGURDSSON H, 1990, J VOLCANOL GEOTH RES, V41, P127, DOI 10.1016/0377-0273(90)90086-U; WALLACE PJ, 1994, SCIENCE, V265, P497, DOI 10.1126/science.265.5171.497; WILLIAMS SN, 1990, J VOLCANOL GEOTH RES, V42, P53, DOI 10.1016/0377-0273(90)90069-R	20	86	87	1	29	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 4	1999	284	5420					1652	1654		10.1126/science.284.5420.1652	http://dx.doi.org/10.1126/science.284.5420.1652			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	202TM	10356391				2022-12-28	WOS:000080668300039
J	Barratt, A; Irwig, L; Glasziou, P; Cumming, RG; Raffle, A; Hicks, N; Gray, JAM; Guyatt, GH				Barratt, A; Irwig, L; Glasziou, P; Cumming, RG; Raffle, A; Hicks, N; Gray, JAM; Guyatt, GH		Evidence-Based Med Working Grp	Users' guides to the medical literature - XVII. How to use guidelines and recommendations about screening	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CLINICAL-PRACTICE GUIDELINES; COST-EFFECTIVENESS; BREAST-CANCER; HELP ME; TRIAL; ARTICLE; WILL; PREVENTION; MORTALITY; DECISION		Univ Sydney, Dept Publ Hlth & Community Med, Sydney, NSW 2006, Australia; Univ Queensland, Dept Social & Prevent Med, Herston, Qld, Australia; Avon Hlth Author, Bristol, Avon, England; Oxfordshire Hlth Author, Oxford OX3 9DZ, England; Univ Oxford, Inst Hlth Sci, Oxford OX1 2JD, England; McMaster Univ, Dept Clin Epidemiol & Biostat, Hamilton, ON L8S 4L8, Canada	University of Sydney; University of Queensland; University of Oxford; McMaster University	Guyatt, GH (corresponding author), McMaster Univ, Hlth Sci Ctr, 1200 Main St W,Room 2C12, Hamilton, ON L8N 3Z5, Canada.		Barratt, Alexandra/A-7349-2011; Cumming, Robert G/R-1548-2016; Glasziou, Paul/A-7832-2008	Barratt, Alexandra/0000-0002-2561-3319; Cumming, Robert G/0000-0002-0261-6103; Glasziou, Paul/0000-0001-7564-073X; Hicks, Nicholas/0000-0002-7214-9678				ANDERSSON I, 1988, BRIT MED J, V297, P943, DOI 10.1136/bmj.297.6654.943; [Anonymous], 1991, JAMA, V265, P3255; [Anonymous], 1986, BMJ-BRIT MED J, V293, P659; Drummond MF, 1997, JAMA-J AM MED ASSOC, V277, P1552, DOI 10.1001/jama.277.19.1552; EDDY DM, 1990, JAMA-J AM MED ASSOC, V263, P2493, DOI 10.1001/jama.263.18.2493; EDDY DM, 1990, JAMA-J AM MED ASSOC, V263, P2505; FLETCHER J, 1995, BRIT MED J, V311, P351, DOI 10.1136/bmj.311.7001.351; Flood AB, 1996, J GEN INTERN MED, V11, P342, DOI 10.1007/BF02600045; FRAME PS, 1993, ANN INTERN MED, V119, P411, DOI 10.7326/0003-4819-119-5-199309010-00010; FRICK MH, 1987, NEW ENGL J MED, V317, P1237, DOI 10.1056/NEJM198711123172001; GRAY JAM, 1997, EVIDENCE BASED HEALT; GUYATT GH, 1994, JAMA-J AM MED ASSOC, V271, P59, DOI 10.1001/jama.271.1.59; HAYWARD RSA, 1995, JAMA-J AM MED ASSOC, V274, P570, DOI 10.1001/jama.274.7.570; KHAW KT, 1989, BRIT MED J, V299, P606, DOI 10.1136/bmj.299.6699.606; KJELSBERG MO, 1982, JAMA-J AM MED ASSOC, V248, P1465; OBrien BJ, 1997, JAMA-J AM MED ASSOC, V277, P1802; Raffle AE, 1998, LANCET, V351, P297, DOI 10.1016/S0140-6736(05)78229-5; ROBERTS MM, 1990, LANCET, V335, P241; Sackett DL, 1991, CLIN EPIDEMIOLOGY BA, V2nd; Salzmann P, 1997, ANN INTERN MED, V127, P955, DOI 10.7326/0003-4819-127-11-199712010-00001; TABAR L, 1989, J EPIDEMIOL COMMUN H, V43, P107, DOI 10.1136/jech.43.2.107; Towler B, 1998, BRIT MED J, V317, P559, DOI 10.1136/bmj.317.7158.559; Welch HG, 1997, J GEN INTERN MED, V12, P118, DOI 10.1046/j.1525-1497.1997.00017.x; Wilson JMG, 1968, PRINCIPLES PRACTICE; WILSON MC, 1995, JAMA-J AM MED ASSOC, V274, P1630, DOI 10.1001/jama.274.20.1630; Winawer SJ, 1997, GASTROENTEROLOGY, V112, P594, DOI 10.1053/gast.1997.v112.agast970594; Wolf AMD, 1996, ARCH INTERN MED, V156, P1333, DOI 10.1001/archinte.156.12.1333; Yin DP, 1998, J VASC SURG, V27, P245, DOI 10.1016/S0741-5214(98)70355-6	28	122	123	0	10	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 2	1999	281	21					2029	2034		10.1001/jama.281.21.2029	http://dx.doi.org/10.1001/jama.281.21.2029			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	200NN	10359392				2022-12-28	WOS:000080546700033
J	Almond, WR				Almond, WR			George Duncan Stewart Beechey - Obituary	BRITISH MEDICAL JOURNAL			English	Biographical-Item																			0	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	MAY 29	1999	318	7196					1492	1492		10.1136/bmj.318.7196.1492	http://dx.doi.org/10.1136/bmj.318.7196.1492			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	202TL	10346794	Green Published			2022-12-28	WOS:000080668200064
J	Freemantle, N; Mason, J				Freemantle, N; Mason, J			Not playing with a full DEC: why development and evaluation committee methods for appraising new drugs may be inadequate	BRITISH MEDICAL JOURNAL			English	Article							PRIMARY-CARE MANAGEMENT; DEVELOPMENT PROJECT; GUIDELINES; NORTH		Univ York, Ctr Hlth Econ, Med Evaluat Grp, York YO10 5DD, N Yorkshire, England	University of York - UK	Mason, J (corresponding author), Univ York, Ctr Hlth Econ, Med Evaluat Grp, York YO10 5DD, N Yorkshire, England.		Mason, James M/D-9904-2011	Mason, James M/0000-0001-9210-4082; Freemantle, Nick/0000-0001-5807-5740				*DEV EV COMM, 1998, 84 NHS RES DEV DEV E; Eccles M, 1998, BRIT MED J, V316, P1232, DOI 10.1136/bmj.316.7139.1232; Eccles M, 1998, BMJ-BRIT MED J, V317, P802, DOI 10.1136/bmj.317.7161.802; Eccles M, 1998, BMJ-BRIT MED J, V316, P1369, DOI 10.1136/bmj.316.7141.1369; ECCLES M, IN PRESS FAM PRACT; Freemantle N, 1997, BMJ-BRIT MED J, V315, P826, DOI 10.1136/bmj.315.7112.826; MASON J, 1995, HEALTH ECON, V4, P85, DOI 10.1002/hec.4730040202; *NHS EX, 1998, 1 CLASS SERV QUAL NE; Roberts I, 1998, BRIT MED J, V317, P763, DOI 10.1136/bmj.317.7161.763; Rogers SL, 1996, DEMENTIA, V7, P293, DOI 10.1159/000106895; *WESS DEV EV COMM, 1997, 69 NHS RES DEV WESS	11	20	20	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	MAY 29	1999	318	7196					1480	1482		10.1136/bmj.318.7196.1480	http://dx.doi.org/10.1136/bmj.318.7196.1480			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	202TL	10346779	Green Published			2022-12-28	WOS:000080668200033
J	Misra, S; Hurley, JH				Misra, S; Hurley, JH			Crystal structure of a phosphatidylinositol 3-phosphate-specific membrane-targeting motif, the FYVE domain of Vps27p	CELL			English	Article							PROTEIN-KINASE-C; BINDING DOMAIN; X-RAY; DIFFRACTION DATA; PHOSPHOLIPASE-C; NMR STRUCTURE; FINGERS; REFINEMENT; PTDINS(3)P; COMPLEX	Phosphatidylinositol 3-phosphate regulates membrane trafficking and signaling pathways by interacting with the FYVE domains of target proteins. The 1.15 Angstrom structure of the Vps27p FYVE domain reveals two antiparallel beta sheets and an alpha helix stabilized by two Zn2+-binding clusters. The core secondary structures are similar to a rabphilin-3A Zn2+-binding domain and to the C1 and LIM domains. Phosphatidylinositol 3-phosphate binds to a pocket formed by the (R/K)(R/K)HHCR motif. A lattice contact shows how anionic ligands can interact with the phosphatidylinositol 3-phosphate-binding site. The tip of the FYVE domain has basic and hydrophobic surfaces positioned so that nonspecific interactions with the phospholipid bilayer can abet specific binding to phosphatidylinositol 3-phosphate.	NIDDKD, Mol Biol Lab, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	Hurley, JH (corresponding author), NIDDKD, Mol Biol Lab, NIH, Bethesda, MD 20892 USA.			Misra, Saurav/0000-0002-1385-8554	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [Z01DK036118] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BARLOW PN, 1994, J MOL BIOL, V237, P201, DOI 10.1006/jmbi.1994.1222; Bateman A, 1999, NUCLEIC ACIDS RES, V27, P260, DOI 10.1093/nar/27.1.260; Bean AJ, 1997, NATURE, V385, P826, DOI 10.1038/385826a0; BORDEN KLB, 1995, EMBO J, V14, P1532, DOI 10.1002/j.1460-2075.1995.tb07139.x; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; Burd CG, 1998, MOL CELL, V2, P157, DOI 10.1016/S1097-2765(00)80125-2; Christoforidis S, 1999, NATURE, V397, P621, DOI 10.1038/17618; Corvera S, 1998, TRENDS CELL BIOL, V8, P442, DOI 10.1016/S0962-8924(98)01366-X; Cowtan K., 1994, JOINT CCP4 ESF EACBM, V31, P34; DeCamilli P, 1996, SCIENCE, V271, P1533, DOI 10.1126/science.271.5255.1533; ENGH RA, 1991, ACTA CRYSTALLOGR A, V47, P392, DOI 10.1107/S0108767391001071; Esnouf RM, 1997, J MOL GRAPH MODEL, V15, P132, DOI 10.1016/S1093-3263(97)00021-1; FERGUSON KM, 1995, CELL, V83, P1037, DOI 10.1016/0092-8674(95)90219-8; Fruman DA, 1998, ANNU REV BIOCHEM, V67, P481, DOI 10.1146/annurev.biochem.67.1.481; Gary JD, 1998, J CELL BIOL, V143, P65, DOI 10.1083/jcb.143.1.65; Gaullier JM, 1998, NATURE, V394, P432, DOI 10.1038/28767; Gibrat JF, 1996, CURR OPIN STRUC BIOL, V6, P377, DOI 10.1016/S0959-440X(96)80058-3; GIEDROC DP, 1986, P NATL ACAD SCI USA, V83, P8452, DOI 10.1073/pnas.83.22.8452; GROSSEKUNSTLEVE RW, 1998, ACTA CRYSTALLOGR D, V54, P905; HENDRICKSON WA, 1991, SCIENCE, V254, P51, DOI 10.1126/science.1925561; HONIG B, 1995, SCIENCE, V268, P1144, DOI 10.1126/science.7761829; Hurley JH, 1997, CURR OPIN STRUC BIOL, V7, P557, DOI 10.1016/S0959-440X(97)80122-4; Hurley JH, 1997, PROTEIN SCI, V6, P477; Irvine R, 1998, CURR BIOL, V8, pR557, DOI 10.1016/S0960-9822(07)00360-0; JANCARIK J, 1991, J APPL CRYSTALLOGR, V24, P409, DOI 10.1107/S0021889891004430; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KLUG A, 1995, FASEB J, V9, P597, DOI 10.1096/fasebj.9.8.7768350; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Laskowski R. A., 1993, J APPL CRYSTALLOGR, V24, P946; LI C, 1994, NEURON, V13, P885, DOI 10.1016/0896-6273(94)90254-2; MATTHEWS BW, 1968, J MOL BIOL, V33, P491, DOI 10.1016/0022-2836(68)90205-2; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; MISCHAK H, 1991, BIOCHEMISTRY-US, V30, P7925, DOI 10.1021/bi00246a008; MU FT, 1995, J BIOL CHEM, V270, P13503, DOI 10.1074/jbc.270.22.13503; Murray D, 1997, STRUCTURE, V5, P985, DOI 10.1016/S0969-2126(97)00251-7; Odorizzi G, 1998, CELL, V95, P847, DOI 10.1016/S0092-8674(00)81707-9; OMICHINSKI JG, 1993, SCIENCE, V261, P438, DOI 10.1126/science.8332909; Ostermeier C, 1999, CELL, V96, P363, DOI 10.1016/S0092-8674(00)80549-8; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; PASTERIS NG, 1994, CELL, V79, P669; Patki V, 1998, NATURE, V394, P433, DOI 10.1038/28771; Patki V, 1997, P NATL ACAD SCI USA, V94, P7326, DOI 10.1073/pnas.94.14.7326; Pawson T, 1997, SCIENCE, V278, P2075, DOI 10.1126/science.278.5346.2075; PerezAlvarado GC, 1996, J MOL BIOL, V257, P153, DOI 10.1006/jmbi.1996.0153; PIPER RC, 1995, J CELL BIOL, V131, P603, DOI 10.1083/jcb.131.3.603; Rao VD, 1998, CELL, V94, P829, DOI 10.1016/S0092-8674(00)81741-9; Shisheva A, 1999, MOL CELL BIOL, V19, P623; Simonsen A, 1998, NATURE, V394, P494, DOI 10.1038/28879; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; Stenmark H, 1996, J BIOL CHEM, V271, P24048, DOI 10.1074/jbc.271.39.24048; TERWILLIGER TC, 1994, ACTA CRYSTALLOGR D, V50, P11, DOI 10.1107/S0907444993008224; TERWILLIGER TC, 1994, ACTA CRYSTALLOGR D, V50, P17, DOI 10.1107/S0907444993008236; Terwilliger TC, 1996, ACTA CRYSTALLOGR D, V52, P749, DOI 10.1107/S0907444996000832; Toker A, 1997, NATURE, V387, P673, DOI 10.1038/42648; Tronrud DE, 1996, J APPL CRYSTALLOGR, V29, P100, DOI 10.1107/S002188989501421X; Tsukazaki T, 1998, CELL, V95, P779, DOI 10.1016/S0092-8674(00)81701-8; WEISMAN LS, 1992, J BIOL CHEM, V267, P618; WHITE SH, 1994, CURR OPIN STRUC BIOL, V4, P79, DOI 10.1016/S0959-440X(94)90063-9; Wiedemann C, 1998, NATURE, V394, P426, DOI 10.1038/28752; WIENER MC, 1992, BIOPHYS J, V61, P434, DOI 10.1016/S0006-3495(92)81849-0; Wurmser AE, 1999, J BIOL CHEM, V274, P9129, DOI 10.1074/jbc.274.14.9129; Xu RX, 1997, BIOCHEMISTRY-US, V36, P10709, DOI 10.1021/bi970833a; YAMAMOTO A, 1995, MOL BIOL CELL, V6, P525, DOI 10.1091/mbc.6.5.525; ZHANG GG, 1995, CELL, V81, P917, DOI 10.1016/0092-8674(95)90011-X	64	206	208	0	10	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	MAY 28	1999	97	5					657	666		10.1016/S0092-8674(00)80776-X	http://dx.doi.org/10.1016/S0092-8674(00)80776-X			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	202VD	10367894	Bronze			2022-12-28	WOS:000080672100014
J	Abdul-Manan, N; Aghazadeh, B; Liu, GA; Majumdar, A; Ouerfelli, O; Siminovitch, KA; Rosen, MK				Abdul-Manan, N; Aghazadeh, B; Liu, GA; Majumdar, A; Ouerfelli, O; Siminovitch, KA; Rosen, MK			Structure of Cdc42 in complex with the GTPase-binding domain of the 'Wiskott-Aldrich syndrome' protein	NATURE			English	Article							ACTIN POLYMERIZATION; CRYSTAL-STRUCTURE; TARGET PROTEINS; KINASE; NMR; EFFECTOR; WASP; RAC; ASSIGNMENT; SURFACE	The Rho-family GTP-hydrolysing proteins (GTPases), Cdc42, Rac and Rho, act as molecular switches in signalling pathways that regulate cytoskeletal architecture, gene expression and progression of the cell cycle(1). Cdc42 and Rac transmit many signals through GTP-dependent binding to effector proteins containing a Cdc42/Rac-interactive-binding (CRIB) motif(2). One such effector, the Wiskott-Aldrich syndrome protein (WASP), is postulated to link activation of Cdc42 directly to the rearrangement of acting(3). Human mutations in WASP cause severe defects in haematopoietic cell function, leading to clinical symptoms of thrombocytopenia, immunodeficiency and eczema. Here we report the solution structure of a complex between activated Cdc42 and a minimal GTPase-binding domain (GBD) from WASP. An extended amino-terminal GBD peptide that includes the CRIB motif contacts the switch I, beta 2 and alpha 5 regions of Cdc42. A carboxy-terminal beta-hairpin and alpha-helix pack against switch II. The Phe-X-His-X-2-His portion of the CRIB motif and the alpha-helix appear to mediate sensitivity to the nucleotide switch through contacts to residues 36-40 of Cdc42. Discrimination between the Rho-family members is likely to be governed by GBD contacts to the switch I and alpha 5 regions of the GTPases. Structural and biochemical data suggest that GBD-sequence divergence outside the CRIB motif may reflect additional regulatory interactions with functional domains that are specific to individual effecters.	Mem Sloan Kettering Canc Ctr, Cellular Biochem & Biophys Program, New York, NY 10021 USA; Cornell Univ, Grad Sch Med Sci, Grad Program Physiol & Biophys, New York, NY 10021 USA; Cornell Univ, Grad Sch Med Sci, Grad Program Physiol & Biophys, New York, NY 10021 USA; Cornell Univ, Grad Sch Med Sci, Grad Program Biochem & Struct Biol, New York, NY 10021 USA; Mt Sinai Hosp, Samuel Lunenfeld Res Inst, Toronto, ON M5G 1X5, Canada	Memorial Sloan Kettering Cancer Center; Cornell University; Cornell University; Cornell University; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute	Rosen, MK (corresponding author), Mem Sloan Kettering Canc Ctr, Cellular Biochem & Biophys Program, 1275 York Ave, New York, NY 10021 USA.	rosen@mmmrl.ski.mskcc.org	Siminovitch, Katherine/K-1475-2013					Bagrodia S, 1998, J BIOL CHEM, V273, P23633, DOI 10.1074/jbc.273.37.23633; Banin S, 1996, CURR BIOL, V6, P981, DOI 10.1016/S0960-9822(02)00642-5; Brown JL, 1996, CURR BIOL, V6, P598, DOI 10.1016/S0960-9822(02)00546-8; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; BURBELO PD, 1995, J BIOL CHEM, V270, P29071, DOI 10.1074/jbc.270.49.29071; CARSON M, 1991, J APPL CRYSTALLOGR, V24, P958, DOI 10.1107/S0021889891007240; Cornilescu G, 1999, J BIOMOL NMR, V13, P289, DOI 10.1023/A:1008392405740; DIEKMANN D, 1995, EMBO J, V14, P5297, DOI 10.1002/j.1460-2075.1995.tb00214.x; Feltham JL, 1997, BIOCHEMISTRY-US, V36, P8755, DOI 10.1021/bi970694x; Gardner KH, 1997, J AM CHEM SOC, V119, P7599, DOI 10.1021/ja9706514; Gardner KH, 1996, J BIOMOL NMR, V8, P351, DOI 10.1007/BF00410333; Guo W, 1998, BIOCHEMISTRY-US, V37, P14030, DOI 10.1021/bi981352+; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Hirshberg M, 1997, NAT STRUCT BIOL, V4, P147, DOI 10.1038/nsb0297-147; Huang L, 1998, NAT STRUCT BIOL, V5, P422, DOI 10.1038/nsb0698-422; Ihara K, 1998, J BIOL CHEM, V273, P9656, DOI 10.1074/jbc.273.16.9656; Lamarche N, 1996, CELL, V87, P519, DOI 10.1016/S0092-8674(00)81371-9; Laskowski RA, 1996, J BIOMOL NMR, V8, P477, DOI 10.1007/BF00228148; Leonard DA, 1997, BIOCHEMISTRY-US, V36, P1173, DOI 10.1021/bi9622837; Leung T, 1998, MOL CELL BIOL, V18, P130, DOI 10.1128/MCB.18.1.130; MANSER E, 1993, NATURE, V363, P364, DOI 10.1038/363364a0; Miki H, 1998, NATURE, V391, P93, DOI 10.1038/34208; Mott HR, 1999, NATURE, V399, P384, DOI 10.1038/20732; NASSAR M, 1995, NATURE, V375, P554, DOI 10.1038/375554a0; Nassar N, 1996, NAT STRUCT BIOL, V3, P723, DOI 10.1038/nsb0896-723; Nilges M, 1997, J MOL BIOL, V269, P408, DOI 10.1006/jmbi.1997.1044; Rudel T, 1997, SCIENCE, V276, P1571, DOI 10.1126/science.276.5318.1571; Rudolph MG, 1998, J BIOL CHEM, V273, P18067, DOI 10.1074/jbc.273.29.18067; Symons M, 1996, CELL, V84, P723, DOI 10.1016/S0092-8674(00)81050-8; YAMAZAKI T, 1994, J AM CHEM SOC, V116, P11655, DOI 10.1021/ja00105a005	30	262	270	0	17	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAY 27	1999	399	6734					379	383		10.1038/20726	http://dx.doi.org/10.1038/20726			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	200PA	10360578				2022-12-28	WOS:000080547800065
J	Baird, DD; Wilcox, AJ; Kramer, MS				Baird, DD; Wilcox, AJ; Kramer, MS			Why might infertile couples have problem pregnancies?	LANCET			English	Editorial Material							TIME; IVF		NIEHS, Epidemiol Branch, Res Triangle Pk, NC 27709 USA; McGill Univ, Dept Paediat, Montreal, PQ, Canada; McGill Univ, Dept Epidemiol, Montreal, PQ, Canada	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); McGill University; McGill University	Baird, DD (corresponding author), NIEHS, Epidemiol Branch, Res Triangle Pk, NC 27709 USA.		Wilcox, Allen J/C-7723-2019; Baird, Donna D/D-5214-2017	Wilcox, Allen J/0000-0002-3376-1311; Baird, Donna D/0000-0002-5544-2653	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [ZIAES044003, Z01ES049003, Z01ES044003, ZIAES049003] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		BERAL V, 1990, BMJ-BRIT MED J, V300, P1229; BHALLA AK, 1992, AUST NZ J OBSTET GYN, V32, P249; Copper RL, 1996, AM J OBSTET GYNECOL, V175, P1286, DOI 10.1016/S0002-9378(96)70042-X; Dudley DJ, 1999, AM J OBSTET GYNECOL, V180, pS251, DOI 10.1016/S0002-9378(99)70711-8; Henriksen TB, 1997, OBSTET GYNECOL, V89, P594; JOFFE M, 1994, FERTIL STERIL, V62, P71; Khattak S, 1999, JAMA-J AM MED ASSOC, V281, P1106, DOI 10.1001/jama.281.12.1106; Lansac J, 1997, EUR J OBSTET GYN R B, V74, P223, DOI 10.1016/S0301-2115(97)00102-4; LI TC, 1991, BRIT J OBSTET GYNAEC, V98, P1087, DOI 10.1111/j.1471-0528.1991.tb15359.x; Lockwood CJ, 1999, AM J OBSTET GYNECOL, V180, pS264, DOI 10.1016/S0002-9378(99)70713-1; OLIVENNES F, 1993, HUM REPROD, V8, P1297, DOI 10.1093/oxfordjournals.humrep.a138245; Reubinoff BE, 1997, FERTIL STERIL, V67, P1077, DOI 10.1016/S0015-0282(97)81442-2; SAUNDERS DM, 1988, ANN NY ACAD SCI, V541, P7, DOI 10.1111/j.1749-6632.1988.tb22237.x; Sundstrom I, 1997, ACTA OBSTET GYN SCAN, V76, P238, DOI 10.1111/j.1600-0412.1997.tb07852.x; TAN SL, 1992, AM J OBSTET GYNECOL, V167, P778, DOI 10.1016/S0002-9378(11)91589-0; VARMA TR, 1988, ACTA OBSTET GYN SCAN, V67, P115, DOI 10.3109/00016348809004181; VENN A, 1994, AUST NZ J OBSTET GYN, V34, P56, DOI 10.1111/j.1479-828X.1994.tb01040.x; WANG JX, 1994, HUM REPROD, V9, P141, DOI 10.1093/oxfordjournals.humrep.a138304; Weissman A, 1999, FERTIL STERIL, V71, P147, DOI 10.1016/S0015-0282(98)00413-0	19	28	29	0	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAY 22	1999	353	9166					1724	1725		10.1016/S0140-6736(99)90050-8	http://dx.doi.org/10.1016/S0140-6736(99)90050-8			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	202TF	10347979				2022-12-28	WOS:000080667700004
J	Carrillo, JE; Green, AR; Betancourt, JR				Carrillo, JE; Green, AR; Betancourt, JR			Cross-cultural primary care: A patient-based approach	ANNALS OF INTERNAL MEDICINE			English	Article							GENERAL INTERNAL-MEDICINE; HEALTH-CARE; ILLNESS; ETHNICITY; DELIVERY; SOCIETY; FOLK	In today's multicultural society, assuring quality health care for all persons requires that physicians understand how each patient's sociocultural background affects his or her health beliefs and behaviors. Cross-cultural curricula have been developed to address these issues but are not widely used in medical education. Many curricula take a categorical and potentially stereotypic approach to "cultural competence" that weds patients of certain cultures to a set of specific, unifying characteristics. In addition, curricula frequently overlook the importance of social factors on the cross-cultural encounter. This paper discusses a patient-based cross-cultural curriculum for residents and medical students that teaches a framework for analysis of the individual patient's social context and cultural health beliefs and behaviors. The curriculum consists of five thematic units taught in four 2-hour sessions. The goal is to help physicians avoid cultural generalizations while improving their ability to understand, communicate with, and care for patients from diverse backgrounds.	New York Presbyterian Hosp, Cornell Internal Med Associates, New York Weill Cornell Med Ctr, New York, NY 10021 USA	Cornell University; NewYork-Presbyterian Hospital; Qatar Foundation (QF); Weill Cornell Medical College Qatar	Carrillo, JE (corresponding author), New York Presbyterian Hosp, Cornell Internal Med Associates, New York Weill Cornell Med Ctr, 505 E 70th St,HT4, New York, NY 10021 USA.			, Alexander/0000-0001-7232-5144				American Psychiatric Association, 1994, DIAGN STAT MAN MENT, P843; BERLIN EA, 1983, WESTERN J MED, V139, P934; BLACKHALL LJ, 1995, JAMA-J AM MED ASSOC, V274, P820, DOI 10.1001/jama.274.10.820; BOBO L, 1991, AM J MED SCI, V302, P244, DOI 10.1097/00000441-199110000-00010; BOTELHO RJ, 1992, FAM PRACT, V9, P210, DOI 10.1093/fampra/9.2.210; BULLOUGH B, 1972, POVERTY ETHNIC IDENT; CARRILLO JE, 1987, DISCUSSION PAPERS SE, P1; CHUGH U, 1993, MED TEACH, V15, P83, DOI 10.3109/01421599309029015; DELACANCELA V, 1986, HUMANITY SOC, V10, P431; DEMERS RY, 1980, J FAM PRACTICE, V11, P1085; DOBOS RJ, 1987, MIRAGE HLTH UTOPIAS; Eisenberg L, 1977, Cult Med Psychiatry, V1, P9, DOI 10.1007/BF00114808; EISENBRUCH M, 1989, MED J AUSTRALIA, V151, P574, DOI 10.5694/j.1326-5377.1989.tb101285.x; FEINSTEIN JS, 1993, MILBANK Q, V71, P279, DOI 10.2307/3350401; GOLDSTEIN E, 1996, CURRICULUM INTERNAL; Harwood A, 1981, ETHNICITY MED CARE; HAUTMAN MA, 1979, NURSE PRACT, V4, P24; Health Resources and Services Administration, 1998, HLTH CAR RX ACC ALL; Helman C G, 1981, J R Coll Gen Pract, V31, P548; Helman CG, 1994, CULTURE HLTH ILLNESS; KAPLAN GA, 1993, CIRCULATION, V88, P1973, DOI 10.1161/01.CIR.88.4.1973; KATON W, 1980, RELEVANCE SOCIAL SCI; KLEINMAN A, 1978, ANN INTERN MED, V88, P251, DOI 10.7326/0003-4819-88-2-251; Kleinman A., 1980, PATIENTS HEALERS CON; LOW SM, 1984, SOC WORK HEALTH CARE, V9, P13, DOI 10.1300/J010v09n03_02; LUM CK, 1994, ACAD MED, V69, P239, DOI 10.1097/00001888-199403000-00021; MUECKE MA, 1983, AM J PUBLIC HEALTH, V73, P431, DOI 10.2105/AJPH.73.4.431; Novack Dennis, 1995, MED INTERVIEW CLIN C, P32; PACHTER LM, 1994, JAMA-J AM MED ASSOC, V271, P690, DOI 10.1001/jama.271.9.690; POULTON J, 1986, MED EDUC, V20, P492, DOI 10.1111/j.1365-2923.1986.tb01388.x; QUESADA GM, 1976, SOC SCI MED, V10, P323, DOI 10.1016/0037-7856(76)90078-0; Quill Timothy E., 1995, MED INTERVIEW, P110; RIVO ML, 1993, JAMA-J AM MED ASSOC, V270, P1074, DOI 10.1001/jama.270.9.1074; RUBENSTEIN HL, 1992, ACAD MED, V67, P566, DOI 10.1097/00001888-199209000-00003; Scott C J, 1997, Md Med J, V46, P175; Slonim M. B., 1991, CHILDREN CULTURE ETH; SORLIE PD, 1995, AM J PUBLIC HEALTH, V85, P949, DOI 10.2105/AJPH.85.7.949; SPECTOR RE, 1992, CULTURAL DIVERSITY H; TAKEUCHI DT, 1995, AM J PUBLIC HEALTH, V85, P638, DOI 10.2105/AJPH.85.5.638; Tuckett D., 1985, M EXPERTS APPROACH S; *US BUR CENS, 1992, STAT ABSTR US; *US DEP HHS, 1998, P NAT C CULT COMP WO; WARE NC, 1992, PSYCHOSOM MED, V54, P546, DOI 10.1097/00006842-199209000-00003; Welch M, 1998, J Am Med Womens Assoc (1972), V53, P121	44	334	336	1	31	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAY 18	1999	130	10					829	834		10.7326/0003-4819-130-10-199905180-00017	http://dx.doi.org/10.7326/0003-4819-130-10-199905180-00017			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	196JJ	10366373				2022-12-28	WOS:000080305000006
J	Dupuy, A; Benchikhi, H; Roujeau, JC; Bernard, P; Vaillant, L; Chosidov, O; Sassolas, B; Guillaume, JC; Grob, JJ; Bastuji-Garin, S				Dupuy, A; Benchikhi, H; Roujeau, JC; Bernard, P; Vaillant, L; Chosidov, O; Sassolas, B; Guillaume, JC; Grob, JJ; Bastuji-Garin, S			Risk factors for erysipelas of the leg (cellulitis): case-control study	BRITISH MEDICAL JOURNAL			English	Article							CUTANEOUS CELLULITIS; ASSOCIATION; INFECTIONS; CULTURES	Objective To assess risk factors for erysipelas of the leg (cellulitis). Design Case-control study. Setting 7 hospital centres in France. Subjects 167 patients admitted to hospital for erysipelas of the leg and 294 controls. Results In multivariate analysis, a disruption of the cutaneous barrier (leg ulcer, wound, fissurated toe-web intertrigo, pressure ulcer, or leg dermatosis) (odds ratio 23.8, 95% confidence interval 10.7 to 52.5), lymphoedema (71.2, 5.6 to 908), venous insufficiency (2.9, 1.0 to 8.7), leg oedema (2.5, 1.2 to 5.1) and being overweight (2.0, 1.1 to 3.7) were independently associated with erysipelas of the leg. No association was observed with diabetes, alcohol, or smoking. Population attributable risk for toe-web intertrigo was 61%. Conclusion This first case-control study highlights the major role of local risk factors (mainly lymphoedema and site of entry) in erysipelas of the leg: From a public health perspective, detecting and treating toe-web intertrigo should be evaluated in the secondary prevention of erysipelas of the leg.	Hop Henri Mondor, Dept Publ Hlth, F-94010 Creteil, France; Hop Henri Mondor, Dept Dermatol, F-94010 Creteil, France; Hop Robert Debre, Dept Dermatol, F-51092 Reims, France; Hop Trousseau, Dept Dermatol, F-37044 Tours, France; Hop La Pitie Salpetriere, Dept Dermatol, F-75013 Paris, France; CHU Brest, Dept Dermatol, F-29285 Brest, France; Hop Louis Pasteur, Dept Dermatol, F-68024 Colmar, France; Hop St Marguerite, Dept Dermatol, F-13009 Marseille, France	Assistance Publique Hopitaux Paris (APHP); Universite Paris-Est-Creteil-Val-de-Marne (UPEC); Hopital Universitaire Henri-Mondor - APHP; Assistance Publique Hopitaux Paris (APHP); Universite Paris-Est-Creteil-Val-de-Marne (UPEC); Hopital Universitaire Henri-Mondor - APHP; CHU de Reims; Universite de Reims Champagne-Ardenne; CHU Tours; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; UDICE-French Research Universities; Sorbonne Universite; CHU Brest; UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille	Bastuji-Garin, S (corresponding author), Hop Henri Mondor, Dept Publ Hlth, F-94010 Creteil, France.		Bastuji-Garin, Sylvie/R-3479-2018; Dupuy, Alain/AFU-6822-2022	Bastuji-Garin, Sylvie/0000-0001-9855-5183; Grob, Jean-Jacques/0000-0002-0667-153X				BADDOUR LM, 1984, JAMA-J AM MED ASSOC, V251, P1049, DOI 10.1001/jama.251.8.1049; BERNARD P, 1989, ARCH DERMATOL, V125, P779, DOI 10.1001/archderm.125.6.779; Bernard P, 1992, Eur J Med, V1, P97; Bisno AL, 1996, NEW ENGL J MED, V334, P240, DOI 10.1056/NEJM199601253340407; Breslow NE, 1980, STAT METHODS CANC RE; BRUZZI P, 1985, AM J EPIDEMIOL, V122, P904, DOI 10.1093/oxfordjournals.aje.a114174; BUSH B, 1987, AM J MED, V82, P231, DOI 10.1016/0002-9343(87)90061-1; Chartier C, 1996, INT J DERMATOL, V35, P779, DOI 10.1111/j.1365-4362.1996.tb02971.x; CRICKX B, 1991, ANN DERMATOL VENER, V118, P11; DUVANEL T, 1989, ARCH INTERN MED, V149, P293, DOI 10.1001/archinte.149.2.293; Eriksson B, 1996, CLIN INFECT DIS, V23, P1091, DOI 10.1093/clinids/23.5.1091; GREENBERG J, 1982, ANN INTERN MED, V97, P565, DOI 10.7326/0003-4819-97-4-565; HOOK EW, 1987, ARCH DERMATOL, V123, P460, DOI 10.1001/archderm.123.4.460; JORUPRONSTROM C, 1986, SCAND J INFECT DIS, V18, P519, DOI 10.3109/00365548609021656; KREMER M, 1991, J INFECTION, V22, P37, DOI 10.1016/0163-4453(91)90898-3; Rogers D, 1996, Australas J Dermatol, V37, P178, DOI 10.1111/j.1440-0960.1996.tb01049.x; RONNEN M, 1985, INT J DERMATOL, V24, P169, DOI 10.1111/j.1365-4362.1985.tb05415.x; SACHS MK, 1991, ARCH DERMATOL, V127, P493, DOI 10.1001/archderm.127.4.493; Semel JD, 1996, CLIN INFECT DIS, V23, P1162, DOI 10.1093/clinids/23.5.1162; SJOBLOM AC, 1993, INFECTION, V21, P390, DOI 10.1007/BF01728920; WACHOLDER S, 1992, AM J EPIDEMIOL, V135, P1029, DOI 10.1093/oxfordjournals.aje.a116397	21	290	302	0	15	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JUN 12	1999	318	7198					1591	1594		10.1136/bmj.318.7198.1591	http://dx.doi.org/10.1136/bmj.318.7198.1591			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	207AL	10364117	Green Published, Green Submitted, Bronze			2022-12-28	WOS:000080913100029
J	Dhalluin, C; Carlson, JE; Zeng, L; He, C; Aggarwal, AK; Zhou, MM				Dhalluin, C; Carlson, JE; Zeng, L; He, C; Aggarwal, AK; Zhou, MM			Structure and ligand of a histone acetyltransferase bromodomain	NATURE			English	Article							PROTEINS; NMR; COACTIVATOR; ACETYLATION; ACTIVATION; ASSIGNMENT; C-13; CBP	Histone acetylation is important in chromatin remodelling and gene activation(1-4). Nearly all known histone-acetyltransferase (HAT)-associated transcriptional co-activators contain bromodomains, which are similar to 110-amino-acid modules found in many chromatin-associated proteins(5-9). Despite the wide occurrence of these bromodomains, their three-dimensional structure and binding partners remain unknown. Here we report the solution structure of the bromodomain of the HAT co-activator P/CAF (p300/CBP-associated factor)(10,11). The structure reveals an unusual left-handed up-and-down four-helix bundle. In addition, we show by a combination of structural and site-directed mutagenesis studies that bromodomains can interact specifically with acetylated lysine, making them the first known protein modules to do so, The nature of the recognition of acetyl-lysine by the P/CAF bromodomain is similar to that of acetyl-CoA by histone acetyltransferase. Thus, the bromodomain is functionally linked to the HAT activity of co-activators in the regulation of gene transcription.	CUNY Mt Sinai Sch Med, Dept Physiol & Biophys, Struct Biol Program, New York, NY 10029 USA	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai	Zhou, MM (corresponding author), CUNY Mt Sinai Sch Med, Dept Physiol & Biophys, Struct Biol Program, Box 1218, New York, NY 10029 USA.							Bannister AJ, 1996, NATURE, V384, P641, DOI 10.1038/384641a0; Brownell JE, 1996, CELL, V84, P843, DOI 10.1016/S0092-8674(00)81063-6; Brownell JE, 1996, CURR OPIN GENET DEV, V6, P176, DOI 10.1016/S0959-437X(96)80048-7; Brunger A.T., 1993, X PLOR VERSION 3 1 S; CARSON M, 1991, J APPL CRYSTALLOGR, V24, P958, DOI 10.1107/S0021889891007240; Chen HW, 1997, CELL, V90, P569, DOI 10.1016/S0092-8674(00)80516-4; CLORE GM, 1994, METHOD ENZYMOL, V239, P249; Dutnall RN, 1998, CELL, V94, P427, DOI 10.1016/S0092-8674(00)81584-6; GEOGAKOPOULOS T, 1995, MOL GEN GENET, V246, P723; Grunstein M, 1997, NATURE, V389, P349, DOI 10.1038/38664; HAYNES SR, 1992, NUCLEIC ACIDS RES, V20, P2603, DOI 10.1093/nar/20.10.2603; Jeanmougin F, 1997, TRENDS BIOCHEM SCI, V22, P151, DOI 10.1016/S0968-0004(97)01042-6; JOHNSON BA, 1994, J BIOMOL NMR, V4, P603, DOI 10.1007/BF00404272; Kuo CH, 1996, IEEE SIGNAL PROC LET, V3, P269, DOI 10.1109/97.536598; KUROKAWA R, 1998, NATURE, V279, P700; Laskowski RA, 1996, J BIOMOL NMR, V8, P477, DOI 10.1007/BF00228148; LOGAN TM, 1993, J BIOMOL NMR, V3, P225; NERI D, 1989, BIOCHEMISTRY-US, V28, P7510, DOI 10.1021/bi00445a003; Nilges M, 1998, PROG NUCL MAG RES SP, V32, P107, DOI 10.1016/S0079-6565(97)00025-3; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; PRESNELL SR, 1989, P NATL ACAD SCI USA, V86, P6592, DOI 10.1073/pnas.86.17.6592; PURI PL, 1997, CELL, V1, P35; Richardson J S, 1981, Adv Protein Chem, V34, P167, DOI 10.1016/S0065-3233(08)60520-3; WEBER PC, 1980, NATURE, V287, P82, DOI 10.1038/287082a0; Wolffe AP, 1997, NATURE, V387, P16, DOI 10.1038/387016a0; YAMAZAKI T, 1994, J AM CHEM SOC, V116, P11655, DOI 10.1021/ja00105a005; Yang XJ, 1996, NATURE, V382, P319, DOI 10.1038/382319a0; [No title captured]	29	1230	1272	6	131	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUN 3	1999	399	6735					491	496		10.1038/20974	http://dx.doi.org/10.1038/20974			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	202TH	10365964				2022-12-28	WOS:000080667900054
J	Romo, R; Brody, CD; Hernandez, A; Lemus, L				Romo, R; Brody, CD; Hernandez, A; Lemus, L			Neuronal correlates of parametric working memory in the prefrontal cortex	NATURE			English	Article							PSYCHOPHYSICAL MEASUREMENTS; FRONTAL-CORTEX; MONKEYS; DISCRIMINATION; FLUTTER; FIELDS; SENSE; TASK	Humans and monkeys have similar abilities to discriminate the difference in frequency between two mechanical vibrations applied sequentially to the fingertips(1-3). A key component of this sensory task is that the second stimulus is compared with the trace left by the first (base) stimulus, which must involve working memory,Where and how is this trace held in the brain? This question was investigated by recording from single neurons in the prefrontal cortex of monkeys while they performed the somatosensory discrimination task, Here we describe neurons in the inferior convexity of the prefrontal cortex whose discharge rates varied, during the delay period between the two stimuli, as a monotonic function of the base stimulus frequency. We describe this as 'monotonic stimulus encoding: and we suggest that the result may generalize: monotonic stimulus encoding may be the basic representation of one-dimensional sensory stimulus quantities in working memory. Thus we predict that other behavioural tasks that require ordinal comparisons between scalar analogue stimuli would give rise to monotonic responses similar to those reported here.	Univ Nacl Autonoma Mexico, Inst Fisiol Celular, Mexico City 04510, DF, Mexico	Universidad Nacional Autonoma de Mexico	Romo, R (corresponding author), Univ Nacl Autonoma Mexico, Inst Fisiol Celular, Mexico City 04510, DF, Mexico.		Lemus, Luis/E-6760-2019	Lemus, Luis/0000-0002-6608-3684; romo, ranulfo/0000-0003-3529-3635				Asaad WF, 1998, NEURON, V21, P1399, DOI 10.1016/S0896-6273(00)80658-3; Bodner M, 1996, NEUROREPORT, V7, P1905, DOI 10.1097/00001756-199608120-00006; BRUCE CJ, 1985, J NEUROPHYSIOL, V53, P603, DOI 10.1152/jn.1985.53.3.603; Chafee MV, 1998, J NEUROPHYSIOL, V79, P2919, DOI 10.1152/jn.1998.79.6.2919; FUNAHASHI S, 1990, J NEUROPHYSIOL, V63, P814, DOI 10.1152/jn.1990.63.4.814; FUNAHASHI S, 1989, J NEUROPHYSIOL, V61, P331, DOI 10.1152/jn.1989.61.2.331; Fuster J.M., 1989, PREFRONTAL CORTEX; Hernandez A, 1997, J NEUROSCI, V17, P6391; Hoshi E, 1998, J NEUROPHYSIOL, V80, P3392, DOI 10.1152/jn.1998.80.6.3392; KOJIMA S, 1982, BRAIN RES, V248, P43, DOI 10.1016/0006-8993(82)91145-3; Miller EK, 1996, J NEUROSCI, V16, P5154; MOUNTCASTLE VB, 1990, J NEUROSCI, V10, P3032; MOUNTCASTLE VB, 1991, J NEUROSCI METH, V36, P77, DOI 10.1016/0165-0270(91)90140-U; Perecman E., 1987, FRONTAL LOBES REVISI, P41; PRESS WH, 1992, NUMERICAL RECIPES; PREUSS TM, 1989, J COMP NEUROL, V282, P293, DOI 10.1002/cne.902820210; QUINTANA J, 1992, NEUROREPORT, V3, P721, DOI 10.1097/00001756-199208000-00018; Rainer G, 1998, P NATL ACAD SCI USA, V95, P15008, DOI 10.1073/pnas.95.25.15008; Rao SC, 1997, SCIENCE, V276, P821, DOI 10.1126/science.276.5313.821; Romo R, 1998, NATURE, V392, P387, DOI 10.1038/32891; Ross S.M, 1987, INTRO PROBABILITY SC; Salinas E., 1998, Society for Neuroscience Abstracts, V24, P1126; SCHULTZ W, 1992, EXP BRAIN RES, V91, P363; Seung HS, 1996, P NATL ACAD SCI USA, V93, P13339, DOI 10.1073/pnas.93.23.13339; TALBOT WH, 1968, J NEUROPHYSIOL, V31, P301, DOI 10.1152/jn.1968.31.2.301; WILSON FAW, 1993, SCIENCE, V260, P1955, DOI 10.1126/science.8316836; Zhou YD, 1996, P NATL ACAD SCI USA, V93, P10533, DOI 10.1073/pnas.93.19.10533	27	572	579	1	49	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUN 3	1999	399	6735					470	473		10.1038/20939	http://dx.doi.org/10.1038/20939			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	202TH	10365959				2022-12-28	WOS:000080667900049
J	Irvine, L; Crombie, IK; Clark, RA; Slane, PW; Feyerabend, C; Goodman, KE; Cater, JI				Irvine, L; Crombie, IK; Clark, RA; Slane, PW; Feyerabend, C; Goodman, KE; Cater, JI			Advising parents of asthmatic children on passive smoking randomised controlled trial	BRITISH MEDICAL JOURNAL			English	Article							GENERAL-PRACTICE; TOBACCO-SMOKE; QUIT SMOKING; INTERVENTION; COTININE; INFANCY; ADVICE; PRACTITIONER; PREDICTORS; CESSATION	Objective. To investigate whether parents of asthmatic children would stop smoking or alter their smoking habits to protect their children from environmental tobacco smoke. Design. Randomised controlled trial. Setting. Tayside and Fife, Scotland. Participants. 501 families with an asthmatic child aged 2-12 years living with a parent who smoked. Intervention. Parents were told about the impact of passive smoking on asthma and were advised to stop smoking or change their smoking habits to protect their child's health. Main outcome measures. Salivary cotinine concentrations in children, and changes in reported smoking habits of the parents 1 year after the intervention. Results. At the second visit, about 1 year after the baseline visit, a small decrease in salivary cotinine concentrations was found in both groups of children: the mean decrease in the intervention group (0.70 ng/ml) was slightly smaller than that of the control group (0.88 ng/ml), but the net difference of 0.19 ng/ml had a wide 95% confidence interval (- 0.86 to 0.48). Overall, 98% of parents in both groups still smoked at follow up. However, there was a non-significant tendency for parents in the intervention group to report smoking more at follow up and to having a reduced desire to stop smoking. Conclusions. A brief intervention to advise parents of asthmatic children about the risks from passive smoking uas ineffective in reducing their children's exposure to environmental tobacco smoke. The intervention may have made some parents less inclined to stop smoking. Ifa clinician believes that a child's health is being affected by parental smoking, the parent's smoking needs to be addressed as a separate issue from the child's health.	Univ Dundee, Ninewells Hosp & Med Sch, Dept Child Hlth, Dundee DD1 9SY, Scotland; Univ Dundee, Ninewells Hosp & Med Sch, Dept Epidemiol & Publ Hlth, Dundee DD1 9SY, Scotland; Univ Dundee, Ninewells Hosp & Med Sch, Dept Med, Dundee DD1 9SY, Scotland; Wallacetown Hlth Ctr, Dundee DD4 6RB, Scotland; Nicotine Lab, London SE14 5ER, England	University of Dundee; University of Dundee; University of Dundee	Irvine, L (corresponding author), Univ Dundee, Ninewells Hosp & Med Sch, Dept Child Hlth, Dundee DD1 9SY, Scotland.			Irvine, Linda/0000-0002-8527-876X	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Ashenden R, 1997, FAM PRACT, V14, P160, DOI 10.1093/fampra/14.2.160; BAILLIE AJ, 1995, AUST J PUBLIC HEALTH, V19, P129; Butler C, 1996, CAN MED ASSOC J, V154, P1357; Butler CC, 1998, BMJ-BRIT MED J, V316, P1878; CHILMONCZYK BA, 1992, AM J DIS CHILD, V146, P357, DOI 10.1001/archpedi.1992.02160150097031; COOK DG, 1993, THORAX, V48, P14, DOI 10.1136/thx.48.1.14; Cook DG, 1997, THORAX, V52, P1081, DOI 10.1136/thx.52.12.1081; DICLEMENTE CC, 1991, J CONSULT CLIN PSYCH, V59, P294; Eriksen W, 1996, ACTA PAEDIATR, V85, P209, DOI 10.1111/j.1651-2227.1996.tb13994.x; FEYERABEND C, 1990, J PHARM PHARMACOL, V42, P450, DOI 10.1111/j.2042-7158.1990.tb06592.x; FOWLER G, 1994, MATERNAL CHILD HLTH, P340; Goldman LK, 1998, JAMA-J AM MED ASSOC, V279, P772, DOI 10.1001/jama.279.10.772; Irvine L, 1997, THORAX, V52, P766, DOI 10.1136/thx.52.9.766; JACKSON PH, 1986, PREV MED, V15, P244, DOI 10.1016/0091-7435(86)90044-7; KVIZ FJ, 1994, PREV MED, V23, P211, DOI 10.1006/pmed.1994.1029; LAW M, 1995, ARCH INTERN MED, V155, P1933, DOI 10.1001/archinte.155.18.1933; MCINTOSH NA, 1994, J ASTHMA, V31, P453, DOI 10.3109/02770909409089487; ROLLNICK S, 1993, BRIT MED J, V307, P188, DOI 10.1136/bmj.307.6897.188; Royal College of Physicians, 1992, SMOK YOUNG; RUSSELL MAH, 1979, BRIT MED J, V2, P231, DOI 10.1136/bmj.2.6184.231; SANDERS D, 1993, ADDICTION, V88, P1699, DOI 10.1111/j.1360-0443.1993.tb02045.x; Strachan DP, 1997, THORAX, V52, P905, DOI 10.1136/thx.52.10.905; Strachan DP, 1998, THORAX, V53, P204, DOI 10.1136/thx.53.3.204; WOODWARD A, 1987, PEDIATR PULM, V3, P173, DOI 10.1002/ppul.1950030311	24	89	92	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	MAY 29	1999	318	7196					1456	1459		10.1136/bmj.318.7196.1456	http://dx.doi.org/10.1136/bmj.318.7196.1456			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	202TL	10346773	Green Submitted, Bronze, Green Published			2022-12-28	WOS:000080668200024
J	Shelley, JH; Baur, MP				Shelley, JH; Baur, MP			Paul Martini: the first clinical pharmacologist?	LANCET			English	Biographical-Item									Rosecroft, Newbury RG14 IRR, Berks, England; Univ Bonn, Inst Med Stat Dokumentat & Datenverarbeitung, D-53127 Bonn, Germany	University of Bonn	Shelley, JH (corresponding author), Rosecroft, Croft Lane, Newbury RG14 IRR, Berks, England.							Armitage P, 1982, Stat Med, V1, P345, DOI 10.1002/sim.4780010412; BIER R, 1929, MUNCH MED WSCHR, V76, P1027; DOLL R, 1992, BMJ-BRIT MED J, V305, P1521, DOI 10.1136/bmj.305.6868.1521; Evans GM, 1938, LANCET, V2, P14; FIBIGER J, 1898, HOSP TID KJOBENH, V4, P309; FIBIGER J, 1898, HOSP TID KJOBENH, V4, P337; GROSSEBROCKOFF F, 1964, DEUT MED WOCHENSCHR, V48, P2300; Gunn JA, 1932, BRIT MED J, V1932, P389, DOI 10.1136/bmj.2.3738.389; GUYATT G, 1986, NEW ENGL J MED, V314, P889, DOI 10.1056/NEJM198604033141406; Loeb RF, 1935, MARTINIS PRINCIPLES; MARTINI P, PUBLICATION LIST; Martini P., 1932, METHODENLEHRE THERAP; MARTINI P, 1962, DEUT MED WOCHENSCHR, V58, P1771; MCCANCE RA, 1951, P ROY SOC MED, V44, P189, DOI 10.1177/003591575104400301; MORITZ F, 1932, MUNCH MED WSCHR, V79, P1608; Park WH, 1928, J AMER MED ASSOC, V91, P1503, DOI 10.1001/jama.1928.02700200001001; THOMPSON AL, 1975, HALF CENTURY MED RES, V2; Wagle P M, 1941, Ind Med Gaz, V76, P29; Wayne EJ, 1933, CLIN SCI, V1, P103; 1932, LANCET, V2, P740; 1932, MED RES COUNC ANN RE	21	17	17	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	MAY 29	1999	353	9167					1870	1873		10.1016/S0140-6736(98)09152-1	http://dx.doi.org/10.1016/S0140-6736(98)09152-1			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	202TG	10359428				2022-12-28	WOS:000080667800046
J	Mills, KD; Sinclair, DA; Guarente, L				Mills, KD; Sinclair, DA; Guarente, L			MEC1-dependent redistribution of the Sir3 silencing protein from telomeres to DNA double-strand breaks	CELL			English	Article							YEAST SACCHAROMYCES-CEREVISIAE; ATAXIA-TELANGIECTASIA GENE; END-JOINING REPAIR; CELL-CYCLE; II TRANSCRIPTION; CHECKPOINT GENES; BUDDING YEAST; LIGASE-IV; KU; DAMAGE	The yeast Sir2/3/4p complex is found in abundance at telomeres, where it participates in the formation of silent heterochromatin and telomere maintenance. Here, we show that Sir3p is released from telomeres in response to DNA double-strand breaks (DSBs), binds to DSBs, and mediates their repair, independent of cell mating type. Sir3p relocalization is S phase specific and, importantly, requires the DNA damage checkpoint genes MEC1 and RADS. MEC1 is a homolog of ATM, mutations in which cause ataxia telangiectasia (A-T), a disease characterized by various neurologic and immunologic abnormalities, a predisposition for cancer, and a cellular defect in repair of DSBs. This novel mode by which preformed DNA repair machinery is mobilized by DNA damage sensors may have implications for human diseases resulting from defective DSB repair.	MIT, Dept Biol, Cambridge, MA 02139 USA	Massachusetts Institute of Technology (MIT)	Guarente, L (corresponding author), MIT, Dept Biol, 77 Massachusetts Ave, Cambridge, MA 02139 USA.			Sinclair, David/0000-0002-9936-436X	NIA NIH HHS [AG11119] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [R37AG011119, R01AG011119] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Ahne F, 1997, NUCLEIC ACIDS RES, V25, P743, DOI 10.1093/nar/25.4.743; APARICIO OM, 1991, CELL, V66, P1279, DOI 10.1016/0092-8674(91)90049-5; Astrom SU, 1999, NATURE, V397, P310, DOI 10.1038/16833; BARNES G, 1985, P NATL ACAD SCI USA, V82, P1354, DOI 10.1073/pnas.82.5.1354; Barnes G, 1997, P NATL ACAD SCI USA, V94, P867, DOI 10.1073/pnas.94.3.867; BELL SP, 1993, SCIENCE, V262, P1844, DOI 10.1126/science.8266072; Bentley NJ, 1996, EMBO J, V15, P6641, DOI 10.1002/j.1460-2075.1996.tb01054.x; BLOCHER D, 1991, INT J RADIAT BIOL, V60, P791, DOI 10.1080/09553009114552601; Boulton SJ, 1996, NUCLEIC ACIDS RES, V24, P4639, DOI 10.1093/nar/24.23.4639; Boulton SJ, 1998, EMBO J, V17, P1819, DOI 10.1093/emboj/17.6.1819; Carney JP, 1998, CELL, V93, P477, DOI 10.1016/S0092-8674(00)81175-7; Emili A, 1998, MOL CELL, V2, P183, DOI 10.1016/S1097-2765(00)80128-8; Fan HY, 1996, GENETICS, V142, P749; Foray N, 1997, INT J RADIAT BIOL, V72, P271, DOI 10.1080/095530097143266; Gotta M, 1996, J CELL BIOL, V134, P1349, DOI 10.1083/jcb.134.6.1349; GOTTSCHLING DE, 1990, CELL, V63, P751, DOI 10.1016/0092-8674(90)90141-Z; Gravel S, 1998, SCIENCE, V280, P741, DOI 10.1126/science.280.5364.741; Grunstein M, 1997, CURR OPIN CELL BIOL, V9, P383, DOI 10.1016/S0955-0674(97)80011-7; HARTLEY KO, 1995, CELL, V82, P849, DOI 10.1016/0092-8674(95)90482-4; Hecht A, 1996, NATURE, V383, P92, DOI 10.1038/383092a0; HECHT SM, 1986, FASEB J, V45, P2784; HEUDE M, 1993, GENETICS, V133, P489; HITTELMAN WN, 1988, CANCER RES, V48, P276; Jeggo PA, 1998, TRENDS GENET, V14, P312, DOI 10.1016/S0168-9525(98)01511-X; Jin YJ, 1997, J BIOL CHEM, V272, P7352, DOI 10.1074/jbc.272.11.7352; Kanaar Roland, 1997, Genes and Function, V1, P165; KATO R, 1994, NUCLEIC ACIDS RES, V22, P3104, DOI 10.1093/nar/22.15.3104; Kennedy BK, 1997, CELL, V89, P381, DOI 10.1016/S0092-8674(00)80219-6; Laroche T, 1998, CURR BIOL, V8, P653, DOI 10.1016/S0960-9822(98)70252-0; Lee SE, 1998, CELL, V94, P399, DOI 10.1016/S0092-8674(00)81482-8; Lewis LK, 1998, MOL CELL BIOL, V18, P1891, DOI 10.1128/MCB.18.4.1891; Mages GJ, 1996, J BIOL CHEM, V271, P7910, DOI 10.1074/jbc.271.14.7910; Maillet L, 1996, GENE DEV, V10, P1796, DOI 10.1101/gad.10.14.1796; Marcand S, 1996, GENE DEV, V10, P1297, DOI 10.1101/gad.10.11.1297; MARSHALL M, 1987, MOL CELL BIOL, V7, P4441, DOI 10.1128/MCB.7.12.4441; Martin SG, 1999, CELL, V97, P621, DOI 10.1016/S0092-8674(00)80773-4; Milne GT, 1996, MOL CELL BIOL, V16, P4189; MIMORI T, 1990, P NATL ACAD SCI USA, V87, P1777, DOI 10.1073/pnas.87.5.1777; MITCHEL REJ, 1987, MUTAT RES, V183, P149, DOI 10.1016/0167-8817(87)90057-5; Moore JK, 1996, MOL CELL BIOL, V16, P2164, DOI 10.1128/mcb.16.5.2164; MORROW DM, 1995, CELL, V82, P831, DOI 10.1016/0092-8674(95)90480-8; PANDITA TK, 1992, RADIAT RES, V131, P214, DOI 10.2307/3578443; Robins P, 1996, J BIOL CHEM, V271, P24257, DOI 10.1074/jbc.271.39.24257; SAVITSKY K, 1995, SCIENCE, V268, P1749, DOI 10.1126/science.7792600; SCHWARTZ JL, 1989, MUTAT RES, V216, P111, DOI 10.1016/0165-1161(89)90011-3; Shiloh Y, 1996, J CLIN IMMUNOL, V16, P254, DOI 10.1007/BF01541389; Siede W, 1996, GENETICS, V142, P91; Sinclair DA, 1997, CELL, V91, P1033, DOI 10.1016/S0092-8674(00)80493-6; Smith JS, 1998, GENETICS, V149, P1205; Stone EM, 1998, BIOESSAYS, V20, P30; StrahlBolsinger S, 1997, GENE DEV, V11, P83, DOI 10.1101/gad.11.1.83; SULLIVAN N, 1990, MUTAT RES, V245, P171, DOI 10.1016/0165-7992(90)90046-M; Takiguchi Y, 1996, GENOMICS, V35, P129, DOI 10.1006/geno.1996.0331; TAYLOR AMR, 1975, NATURE, V258, P427, DOI 10.1038/258427a0; TAYLOR AMR, 1994, INT J RADIAT BIOL, V65, P65, DOI 10.1080/09553009414550091; Teo SH, 1997, EMBO J, V16, P4788, DOI 10.1093/emboj/16.15.4788; Tsukamoto Y, 1997, NATURE, V388, P900, DOI 10.1038/42288; Vamvakas S, 1997, CRIT REV TOXICOL, V27, P155, DOI 10.3109/10408449709021617; Varon R, 1998, CELL, V93, P467, DOI 10.1016/S0092-8674(00)81174-5; Vialard JE, 1998, EMBO J, V17, P5679, DOI 10.1093/emboj/17.19.5679; WEI YF, 1995, MOL CELL BIOL, V15, P3206; Weinert T, 1998, CELL, V94, P555, DOI 10.1016/S0092-8674(00)81597-4; WEINERT TA, 1994, GENE DEV, V8, P652, DOI 10.1101/gad.8.6.652; Zhao XL, 1998, MOL CELL, V2, P329, DOI 10.1016/S1097-2765(00)80277-4; Zhou PK, 1998, RADIOTHER ONCOL, V47, P271, DOI 10.1016/S0167-8140(97)00200-4	65	279	289	0	8	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	MAY 28	1999	97	5					609	620		10.1016/S0092-8674(00)80772-2	http://dx.doi.org/10.1016/S0092-8674(00)80772-2			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	202VD	10367890	Bronze			2022-12-28	WOS:000080672100010
J	Heaney, ML; Golde, DV				Heaney, ML; Golde, DV			Myelodysplasia	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							ACUTE MYELOID-LEUKEMIA; COLONY-STIMULATING FACTOR; BONE-MARROW-TRANSPLANTATION; ACUTE PROMYELOCYTIC LEUKEMIA; POLYMERASE CHAIN-REACTION; IN-SITU HYBRIDIZATION; PRIMITIVE HEMATOPOIETIC PROGENITORS; RECOMBINANT HUMAN INTERLEUKIN-11; CHRONIC MYELOMONOCYTIC LEUKEMIA; DOSE CYTOSINE-ARABINOSIDE		Mem Sloan Kettering Canc Ctr, Dept Med, New York, NY 10021 USA; Mem Sloan Kettering Canc Ctr, Program Mol Pharmacol & Therapeut, New York, NY 10021 USA	Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center	Golde, DV (corresponding author), Mem Sloan Kettering Canc Ctr, Dept Med, 1275 York Ave, New York, NY 10021 USA.	d-golde@ski.mskcc.org			NCI NIH HHS [CA30388, CA08748] Funding Source: Medline; NHLBI NIH HHS [HL42107] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R37CA030388, P30CA008748, R01CA030388] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL042107] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Abruzzese E, 1996, LEUKEMIA RES, V20, P551, DOI 10.1016/0145-2126(95)00130-1; Anderson JE, 1996, J CLIN ONCOL, V14, P220, DOI 10.1200/JCO.1996.14.1.220; ANDERSON JE, 1995, LEUKEMIA LYMPHOMA, V17, P95, DOI 10.3109/10428199509051708; Anderson JE, 1996, BRIT J HAEMATOL, V93, P59, DOI 10.1046/j.1365-2141.1996.4811022.x; ANDERSON RL, 1981, CANCER, V47, P1867, DOI 10.1002/1097-0142(19810401)47:7<1867::AID-CNCR2820470725>3.0.CO;2-S; Androulakis IP, 1997, J GLOBAL OPTIM, V11, P1, DOI 10.1023/A:1008224308626; ANTIN JH, 1988, BLOOD, V72, P705; Appelbaum FR, 1998, LEUKEMIA, V12, pS25; APPELBAUM FR, 1987, BLOOD, V69, P92; APPELBAUM FR, 1987, EXP HEMATOL, V15, P1134; AUL C, 1992, LEUKEMIA, V6, P52; BaderMeunier B, 1996, BRIT J HAEMATOL, V92, P344, DOI 10.1046/j.1365-2141.0000.d01-1480.x; BARELI M, 1989, BLOOD, V73, P281; BENNETT JM, 1982, BRIT J HAEMATOL, V51, P189, DOI 10.1111/j.1365-2141.1982.tb08475.x; BenYehuda D, 1996, BLOOD, V88, P4296; Beran M, 1996, BLOOD, V88, P2473, DOI 10.1182/blood.V88.7.2473.bloodjournal8872473; Beran M, 1998, BLOOD, V92, p714A; Berman E, 1997, CANCER-AM CANCER SOC, V80, P2181; BERMAN E, 1991, BLOOD, V77, P1666; Bernell P, 1996, LEUKEMIA, V10, P662; Bernstein SH, 1996, J CLIN ONCOL, V14, P2486, DOI 10.1200/JCO.1996.14.9.2486; Biesma DH, 1997, CANCER-AM CANCER SOC, V79, P1548, DOI 10.1002/(SICI)1097-0142(19970415)79:8<1548::AID-CNCR16>3.0.CO;2-Y; BLANK J, 1981, J PEDIATR-US, V98, P565, DOI 10.1016/S0022-3476(81)80761-5; BLOCK M, 1953, JAMA-J AM MED ASSOC, V152, P1018, DOI 10.1001/jama.1953.03690110032010; BOULTWOOD J, 1994, BLOOD, V84, P3253; Brown D, 1997, P NATL ACAD SCI USA, V94, P2551, DOI 10.1073/pnas.94.6.2551; Caron PC, 1998, CLIN CANCER RES, V4, P1421; CASTAIGNE S, 1983, BLOOD, V62, P85; Champlin R, 1996, ACTA HAEMATOL-BASEL, V95, P157; COLE P, 1995, LEUKEMIA RES, V19, P361, DOI 10.1016/0145-2126(94)00152-Z; CROCE CM, 1991, ORIGINS OF HUMAN CANCER, P527; Davis RE, 1998, LEUKEMIA RES, V22, P767, DOI 10.1016/S0145-2126(98)00051-4; DELFORGE M, 1995, BLOOD, V86, P3660, DOI 10.1182/blood.V86.10.3660.bloodjournal86103660; Demuynck H, 1996, BONE MARROW TRANSPL, V17, P745; DEWITTE T, 1995, LEUKEMIA, V9, P1805; DeWitte T, 1997, BLOOD, V90, P3853; DEWITTE T, 1990, BRIT J HAEMATOL, V74, P151; DREYFUS B, 1976, NOUV REV FR HEMATOL, V1, P33; Economopoulos T, 1996, LEUKEMIA RES, V20, P385, DOI 10.1016/0145-2126(95)00169-7; Escudier SM, 1996, LEUKEMIA, V10, P473; Estey E, 1998, BLOOD, V92, p232A; Estey E, 1997, BLOOD, V90, P2969, DOI 10.1182/blood.V90.8.2969; Fanucchi M, 1997, NEW ENGL J MED, V336, P404, DOI 10.1056/NEJM199702063360603; FOUCAR K, 1985, CANCER, V56, P553, DOI 10.1002/1097-0142(19850801)56:3<553::AID-CNCR2820560323>3.0.CO;2-Q; GANSER A, 1989, BLOOD, V73, P31; GAUWERKY CE, 1993, SEMIN CANCER BIOL, V4, P333; GERRITSEN WR, 1992, BLOOD, V80, P217; GLOVER D, 1986, J CLIN ONCOL, V4, P584, DOI 10.1200/JCO.1986.4.4.584; GOLDE DW, 1991, SCI AM, V265, P86, DOI 10.1038/scientificamerican1291-86; GOLDE DW, 1973, NEW ENGL J MED, V288, P1083, DOI 10.1056/NEJM197305242882101; GOLOMB HM, 1982, BLOOD, V60, P404; GORDON MS, 1995, BLOOD, V85, P3066, DOI 10.1182/blood.V85.11.3066.bloodjournal85113066; Gordon MS, 1996, BLOOD, V87, P3615, DOI 10.1182/blood.V87.9.3615.bloodjournal8793615; GRALNICK HR, 1977, ANN INTERN MED, V87, P740, DOI 10.7326/0003-4819-87-6-740; Greenberg, 1998, BLOOD, V91, P1100; GREENBERG P, 1993, BLOOD, V82, pA196; Greenberg P, 1997, BLOOD, V89, P2079, DOI 10.1182/blood.V89.6.2079; GREENBERG PL, 1983, BLOOD, V61, P1035; GRIFFIN JD, 1985, J CLIN ONCOL, V3, P982, DOI 10.1200/JCO.1985.3.7.982; HAMILTONPATERSON JL, 1949, ACTA HAEMATOL-BASEL, V2, P309, DOI 10.1159/000203474; He LZ, 1997, P NATL ACAD SCI USA, V94, P5302, DOI 10.1073/pnas.94.10.5302; HELLSTROM E, 1988, EUR J HAEMATOL, V40, P449; Hellstrom-Lindberg E, 1998, BLOOD, V92, P68, DOI 10.1182/blood.V92.1.68.413k23_68_75; HellstromLindberg E, 1997, BRIT J HAEMATOL, V99, P344, DOI 10.1046/j.1365-2141.1997.4013211.x; HELLSTROMLINDBERG E, 1995, BRIT J HAEMATOL, V89, P67, DOI 10.1111/j.1365-2141.1995.tb08909.x; Hoefsloot LH, 1997, BLOOD, V89, P1690, DOI 10.1182/blood.V89.5.1690.1690_1690_1700; Hofmann WK, 1996, SEMIN HEMATOL, V33, P177; HOLCOMBE RF, 1993, LEUKEMIA, V7, P192; HUANG ME, 1988, BLOOD, V72, P567, DOI 10.1182/blood.V72.2.567.567; Jonasova A, 1998, BRIT J HAEMATOL, V100, P304, DOI 10.1046/j.1365-2141.1998.00551.x; KAUSHANSKY K, 1995, BLOOD, V86, P419, DOI 10.1182/blood.V86.2.419.bloodjournal862419; Khouri IF, 1998, J CLIN ONCOL, V16, P2817, DOI 10.1200/JCO.1998.16.8.2817; KIBBELAAR RE, 1992, BLOOD, V79, P1823; KIZAKI M, 1992, SEMIN ONCOL, V19, P95; KOEFFLER HP, 1980, ANN INTERN MED, V93, P347, DOI 10.7326/0003-4819-93-2-347; KOEFFLER HP, 1978, BLOOD, V52, P355; KOEFFLER HP, 1988, BLOOD, V71, P703; Kroef MJPL, 1997, LEUKEMIA, V11, P519, DOI 10.1038/sj.leu.2400597; KROEF MJPL, 1993, BLOOD, V81, P1849; KUSEC R, 1994, LEUKEMIA, V8, P735; LAMBERTENGHIDELILIERS G, 1991, BRIT J HAEMATOL, V78, P161, DOI 10.1111/j.1365-2141.1991.tb04411.x; LAMBERTENGHIDELILIERS G, 1992, LEUKEMIA LYMPHOMA, V8, P51, DOI 10.3109/10428199209049817; Legare R D, 1995, Curr Opin Hematol, V2, P283; LEPELLEY P, 1994, LEUKEMIA, V8, P1342; List AF, 1996, SEMIN ONCOL, V23, P58; Luna-Fineman S, 1999, BLOOD, V93, P459, DOI 10.1182/blood.V93.2.459.402k19_459_466; MALLARME PJ, 1949, SANG, V20, P429; MATHEW P, 1993, BLOOD, V81, P1040; Matthews DC, 1998, LEUKEMIA, V12, pS33; MICHAUX JL, 1993, LEUKEMIA LYMPHOMA, V9, P35, DOI 10.3109/10428199309148501; MINEISHI S, 1994, BLOOD, V84, pA315; Molldrem JJ, 1997, BRIT J HAEMATOL, V99, P699, DOI 10.1046/j.1365-2141.1997.4423249.x; Morel P, 1996, BRIT J HAEMATOL, V94, P116, DOI 10.1046/j.1365-2141.1996.6122056.x; MOREL P, 1993, LEUKEMIA, V7, P1315; Morosetti R, 1996, SEMIN HEMATOL, V33, P236; Mundle SD, 1996, BLOOD, V88, P2640, DOI 10.1182/blood.V88.7.2640.bloodjournal8872640; NAJEAN Y, 1979, CANCER, V44, P1976, DOI 10.1002/1097-0142(197912)44:6<1976::AID-CNCR2820440603>3.0.CO;2-#; NAND S, 1988, CANCER, V62, P958, DOI 10.1002/1097-0142(19880901)62:5<958::AID-CNCR2820620519>3.0.CO;2-P; NEGENDANK W, 1991, BLOOD, V78, P2872; NEGRIN RS, 1989, ANN INTERN MED, V110, P976, DOI 10.7326/0003-4819-110-12-976; Negrin RS, 1996, BLOOD, V87, P4076, DOI 10.1182/blood.V87.10.4076.bloodjournal87104076; NEGRIN RS, 1990, BLOOD, V76, P36; Nevill TJ, 1998, BLOOD, V92, P1910, DOI 10.1182/blood.V92.6.1910.418k30_1910_1917; NIMER SD, 1987, BLOOD, V70, P1705; OGAWA M, 1993, BLOOD, V81, P2844; Pallisgaard N, 1998, BLOOD, V92, P574, DOI 10.1182/blood.V92.2.574; Parker JE, 1997, BRIT J HAEMATOL, V99, P939, DOI 10.1046/j.1365-2141.1997.4763281.x; PASSMORE SJ, 1995, BLOOD, V85, P1742, DOI 10.1182/blood.V85.7.1742.bloodjournal8571742; PEDERSENBJERGAARD J, 1995, BLOOD, V86, P3542, DOI 10.1182/blood.V86.9.3542.bloodjournal8693542; PEDERSENBJERGAARD J, 1994, BLOOD, V83, P2780, DOI 10.1182/blood.V83.10.2780.2780; Quesnel B, 1998, BLOOD, V91, P2985, DOI 10.1182/blood.V91.8.2985.2985_2985_2990; Rajapaksa R, 1996, BLOOD, V88, P4275; Raza A, 1997, EXP HEMATOL, V25, P530; ROSE EH, 1995, BRIT J HAEMATOL, V89, P831; ROWLEY JD, 1981, BLOOD, V58, P759; RUSSELL M, 1994, BLOOD, V84, P1243, DOI 10.1182/blood.V84.4.1243.bloodjournal8441243; RUSSELL NH, 1979, BRIT J HAEMATOL, V41, P417, DOI 10.1111/j.1365-2141.1979.tb05876.x; RUUTU P, 1977, NATURE, V265, P146, DOI 10.1038/265146a0; Saitoh K, 1998, BLOOD, V92, P2886, DOI 10.1182/blood.V92.8.2886.420k11_2886_2892; SANZ GF, 1989, BLOOD, V74, P395; SOENEN V, 1995, BRIT J HAEMATOL, V90, P701, DOI 10.1111/j.1365-2141.1995.tb05604.x; STEIN RS, 1991, BLOOD, V78, P1658; SUPER HJG, 1993, BLOOD, V82, P3705; Takagi S, 1999, J CLIN ONCOL, V17, P277, DOI 10.1200/JCO.1999.17.1.277; Tepler I, 1996, BLOOD, V87, P3607; THIRMAN MJ, 1993, NEW ENGL J MED, V329, P909, DOI 10.1056/NEJM199309233291302; TICHELLI A, 1988, BRIT J HAEMATOL, V68, P139, DOI 10.1111/j.1365-2141.1988.tb04194.x; TOYAMA K, 1993, LEUKEMIA, V7, P499; TUZUNER N, 1995, BRIT J HAEMATOL, V91, P612, DOI 10.1111/j.1365-2141.1995.tb05356.x; Uchida T, 1997, BLOOD, V90, P1403, DOI 10.1182/blood.V90.4.1403.1403_1403_1409; VADHANRAJ S, 1987, NEW ENGL J MED, V317, P1545, DOI 10.1056/NEJM198712173172501; VANDENBERGHE H, 1974, NATURE, V251, P437, DOI 10.1038/251437a0; VARMUS HE, 1994, BLOOD, V83, P5; Veldman T, 1997, NAT GENET, V15, P406, DOI 10.1038/ng0497-406; VOGELSTEIN B, 1988, NEW ENGL J MED, V319, P525, DOI 10.1056/NEJM198809013190901; WARRELL RP, 1991, NEW ENGL J MED, V324, P1385, DOI 10.1056/NEJM199105163242002; WATTS EJ, 1991, BRIT J HAEMATOL, V78, P120, DOI 10.1111/j.1365-2141.1991.tb04393.x; WIERNIK PH, 1992, BLOOD, V79, P313; WILLMAN CL, 1993, SCIENCE, V259, P968, DOI 10.1126/science.8438156; WISCH JS, 1983, NEW ENGL J MED, V309, P1599, DOI 10.1056/NEJM198312293092602; Wolfe KQ, 1997, J PATHOL, V181, P359; YOSHIDA Y, 1988, J CLIN PATHOL, V41, P763, DOI 10.1136/jcp.41.7.763; YOSHIDA Y, 1995, LEUKEMIA LYMPHOMA, V18, P457, DOI 10.3109/10428199509059645	143	369	389	0	5	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAY 27	1999	340	21					1649	1660		10.1056/NEJM199905273402107	http://dx.doi.org/10.1056/NEJM199905273402107			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	199QY	10341278				2022-12-28	WOS:000080494200007
J	Hines, SC; Glover, JJ; Holley, JL; Babrow, AS; Badzek, LA; Moss, AH				Hines, SC; Glover, JJ; Holley, JL; Babrow, AS; Badzek, LA; Moss, AH			Dialysis patients' preferences for family-based advance care planning	ANNALS OF INTERNAL MEDICINE			English	Article							CONTROLLED TRIAL; HEALTH-CARE; DIRECTIVES	Background: Most patients do not participate in advance care planning with physicians. Objective: To examine patients' preferences for involving their physicians and families in advance care planning. Design: Pace-to-face interviews with randomly selected patients. Setting: Community-based dialysis units in one rural and one urban region. Participants: 400 hemodialysis patients. Measurements: Questions about whom patients involve in advance care planning, whom patients would like to include in this planning, and patients' reactions to state legislation on surrogate decision makers in End-of-life care. Results: Patients more frequently discussed preferences for end-of-life care with family members than with physicians (50% compared with 6%; P < 0.001). More patients wanted to include family members in future discussions of advance care planning than wanted to include physicians (91% compared with 36%; P < 0.001). Patients were most comfortable with legislation that granted their family end-of-life decision-making authority in the event of their own incapacity (P < 0.001). Conclusion: Most patients want to include their families more than their physicians in advance care planning.	W Virginia Univ, Robert C Byrd Hlth Sci Ctr, Ctr Hlth Eth & Law, Morgantown, WV 26506 USA; Univ Rochester, Sch Med, Rochester, NY 14642 USA; Purdue Univ, W Lafayette, IN 47907 USA	West Virginia University; University of Rochester; Purdue University System; Purdue University; Purdue University West Lafayette Campus	Moss, AH (corresponding author), W Virginia Univ, Robert C Byrd Hlth Sci Ctr, Ctr Hlth Eth & Law, Box 9022, Morgantown, WV 26506 USA.	amoss@wvu.edu						*AM HLTH DEC, 1997, QUEST DIE DIGN AN AM, P5; *CHOIC DYING INC, 1997, STAT STAT GOV SURR D; EMANUEL L, 1995, JAMA-J AM MED ASSOC, V274, P501, DOI 10.1001/jama.274.6.501; HARE J, 1991, J GEN INTERN MED, V6, P41, DOI 10.1007/BF02599390; Hofmann JC, 1997, ANN INTERN MED, V127, P1, DOI 10.7326/0003-4819-127-1-199707010-00001; JOHNSTON SC, 1995, ARCH INTERN MED, V155, P1025, DOI 10.1001/archinte.155.10.1025; Laine C, 1996, JAMA-J AM MED ASSOC, V275, P152, DOI 10.1001/jama.275.2.152; MARKSON LJ, 1994, ARCH INTERN MED, V154, P2321, DOI 10.1001/archinte.154.20.2321; Martin DK, 1999, ARCH INTERN MED, V159, P86, DOI 10.1001/archinte.159.1.86; MENIKOFF JA, 1992, NEW ENGL J MED, V327, P1165, DOI 10.1056/NEJM199210153271612; Miles SH, 1996, ARCH INTERN MED, V156, P1062, DOI 10.1001/archinte.156.10.1062; Moss AH, 1996, CHEST, V110, P249, DOI 10.1378/chest.110.1.249; *NIH NAT I DIAB DI, 1997, US REN DAT SYST 1997; RUBIN SM, 1994, JAMA-J AM MED ASSOC, V271, P209, DOI 10.1001/jama.271.3.209; SACHS GA, 1992, J AM GERIATR SOC, V40, P269, DOI 10.1111/j.1532-5415.1992.tb02081.x; Sehgal AR, 1996, JAMA-J AM MED ASSOC, V276, P1652, DOI 10.1001/jama.276.20.1652; Singer PA, 1998, ARCH INTERN MED, V158, P879, DOI 10.1001/archinte.158.8.879; Singer PA, 1999, JAMA-J AM MED ASSOC, V281, P163, DOI 10.1001/jama.281.2.163; Sulmasy DP, 1998, ANN INTERN MED, V128, P621, DOI 10.7326/0003-4819-128-8-199804150-00002; *VERM ETH NETW, 1997, VERM VOIC CAR DYING	20	77	77	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAY 18	1999	130	10					825	828		10.7326/0003-4819-130-10-199905180-00016	http://dx.doi.org/10.7326/0003-4819-130-10-199905180-00016			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	196JJ	10366372				2022-12-28	WOS:000080305000005
J	Karlawish, JHT; Quill, T; Meier, DE				Karlawish, JHT; Quill, T; Meier, DE		ACP ASIM End Life Care Consensus Panel	A consensus-based approach to providing palliative care to patients who lack decision-making capacity	ANNALS OF INTERNAL MEDICINE			English	Article							ADVANCE DIRECTIVES; PREFERENCES; NUTRITION; HYDRATION; FAMILY	Making palliative care decisions for a patient who lacks decision-making capacity presents several challenges. Other people, such as family and caregivers, must choose for the patient. The goals and values of these decision makers may conflict with those of each other and with those of the patient, who now lacks the capacity to participate in the decision. This paper presents a case study of a patient with severe Alzheimer disease who has two common clinical problems: neurogenic dysphagia and aspiration pneumonia. The case study describes a consensus-based decision-making strategy that keeps what is known about the patient's wishes and values in the foreground but also expects guidance from the physician and elicits input from family members and other people who care for and have knowledge about the patient. The steps of this process, including key clinical prompts and potential transition statements, are outlined and described. The overall goal of the case commentary is to demonstrate that physicians can guide a highly emotional and personal process in a structured manner that has meaning for the patient, family, physician, and other caregivers.	Amer Coll Physicians, Amer Soc Internal Med, Philadelphia, PA 19106 USA	American College of Physicians	Karlawish, JHT (corresponding author), Amer Coll Physicians, Amer Soc Internal Med, 190 N Independence Mall W, Philadelphia, PA 19106 USA.				NATIONAL INSTITUTE ON AGING [K01AG000931] Funding Source: NIH RePORTER; NIA NIH HHS [1K01-AG00931-01] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Ahronheim JC, 1996, CLIN GERIATR MED, V12, P379; Brock DW, 1996, MILBANK Q, V74, P599, DOI 10.2307/3350394; Bruner J. S., 1990, ACTS MEANING; Buchanan Allen E., 1989, DECIDING OTHERS ETHI; Doyle D, 1998, OXFORD TXB PALLIATIV; Dresser R, 1995, HASTINGS CENT REP, V25, P32, DOI 10.2307/3527839; FINUCANE TE, 1995, J AM GERIATR SOC, V43, P447, DOI 10.1111/j.1532-5415.1995.tb05822.x; Finucane TE, 1996, LANCET, V348, P1421, DOI 10.1016/S0140-6736(96)03369-7; Fischer GS, 1998, J GEN INTERN MED, V13, P447, DOI 10.1046/j.1525-1497.1998.00133.x; Grant MD, 1998, JAMA-J AM MED ASSOC, V279, P1973, DOI 10.1001/jama.279.24.1973; HENDERSON CT, 1992, J AM COLL NUTR, V11, P309; HURLEY AC, 1995, ADV NURS SCI, V18, P33, DOI 10.1097/00012272-199512000-00005; JANOFSKY JS, 1993, J GERIATR PSYCH NEUR, V6, P214, DOI 10.1177/089198879300600406; KNAUS WA, 1995, JAMA-J AM MED ASSOC, V274, P1591, DOI 10.1001/jama.1995.03530200027032; Kuczewski MG, 1996, HASTINGS CENT REP, V26, P30, DOI 10.2307/3528574; LO B, 1984, NEW ENGL J MED, V311, P402, DOI 10.1056/NEJM198408093110611; Meisel A, 1995, AM J LAW MED, V21, P335; MEISEL A, 1996, RIGHT DIE; Montgomery Hunter K, 1991, DOCTORS STORIES NARR; Prendergast TJ, 1997, AM J RESP CRIT CARE, V155, P15, DOI 10.1164/ajrccm.155.1.9001282; Pritchard RS, 1998, J AM GERIATR SOC, V46, P1242, DOI 10.1111/j.1532-5415.1998.tb04540.x; Quill TE, 1996, ANN INTERN MED, V125, P763, DOI 10.7326/0003-4819-125-9-199611010-00010; SCHNEIDERMAN LJ, 1990, ANN INTERN MED, V112, P949, DOI 10.7326/0003-4819-112-12-949; Sulmasy DP, 1998, ANN INTERN MED, V128, P621, DOI 10.7326/0003-4819-128-8-199804150-00002; VIRMANI J, 1994, ARCH INTERN MED, V154, P909, DOI 10.1001/archinte.154.8.909; Volicer L, 1989, J Geriatr Psychiatry Neurol, V2, P188, DOI 10.1177/089198878900200404	26	76	76	2	8	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAY 18	1999	130	10					835	840		10.7326/0003-4819-130-10-199905180-00018	http://dx.doi.org/10.7326/0003-4819-130-10-199905180-00018			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	196JJ	10366374				2022-12-28	WOS:000080305000007
J	Maurer, SM; Scotchmer, S				Maurer, SM; Scotchmer, S			Intellectual property rights - Database protection: Is it broken and should we fix lit?	SCIENCE			English	Article									Univ Calif Berkeley, Dept Econ, Berkeley, CA 94720 USA; Univ Calif Berkeley, Goldman Sch Publ Policy, Berkeley, CA 94720 USA	University of California System; University of California Berkeley; University of California System; University of California Berkeley	Maurer, SM (corresponding author), 2632 Hilgard St, Berkeley, CA 94709 USA.							ABRAMS HB, 1998, LAW COPYRIGHT; Firestone RB, 1996, TABLE ISOTOPES; Gardner W, 1998, SCIENCE, V281, P786, DOI 10.1126/science.281.5378.786; Heller MA, 1998, SCIENCE, V280, P698, DOI 10.1126/science.280.5364.698; MAURER S, PROMOTING ACCESS SCI; MCCABE MJ, 1998, UNPUB ACAD J PRICING; *NAT RES COUNC, 1997, BITS POW ACC GLOB SC; REICHMAN JH, 1997, VANDERBILT LAW REV, V50, P51; SCOTCHMER S, 1991, J ECON PERSPECT, V5, P29, DOI 10.1257/jep.5.1.29; The European Parliament and the Council of the European Union, 1996, OJ, P20; TYSON LD, 1997, STATUTORY PROTECTION	11	17	17	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAY 14	1999	284	5417					1129	1130		10.1126/science.284.5417.1129	http://dx.doi.org/10.1126/science.284.5417.1129			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	197HJ	10366346				2022-12-28	WOS:000080359100022
J	Neuberger, J				Neuberger, J			A role for personal values ... and management - Commentary	BRITISH MEDICAL JOURNAL			English	Editorial Material									Kings Fund, London W1M 0AN, England		Neuberger, J (corresponding author), Kings Fund, London W1M 0AN, England.								0	5	5	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	APR 24	1999	318	7191					1130	1130						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	193YU	10366259				2022-12-28	WOS:000080166000036
J	Pacifico, A; Hohnloser, SH; Williams, JH; Tao, B; Saksena, S; Henry, PD; Prystowsky, EN				Pacifico, A; Hohnloser, SH; Williams, JH; Tao, B; Saksena, S; Henry, PD; Prystowsky, EN		dl-Sotalol Implant Cardiovert-Defibrillat	Prevention of implantable-defibrillator shocks by treatment with sotalol	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							SUDDEN CARDIAC DEATH; MYOCARDIAL-INFARCTION; VENTRICULAR TACHYARRHYTHMIAS; CARDIOVERTER-DEFIBRILLATORS; RANDOMIZED TRIAL; CLINICAL-TRIALS; HEART-FAILURE; BETA-BLOCKADE; MORTALITY; DRUGS	Background. Patients with implantable cardioverter-defibrillators often receive adjunctive antiarrhythmic therapy to prevent frequent shocks. We tested the efficacy and safety of sotalol, a beta-blocker with class III antiarrhythmic effects, for this purpose. Methods. In a multicenter trial, patients were stratified according to left ventricular ejection fraction (less than or equal to 0.30 or > 0.30), randomly assigned to double-blind treatment with 160 to 320 mg of sotalol per day (151 patients) or matching placebo (151 patients), and followed for 12 months. Kaplan-Meier analyses of the time to an event were performed. Three end points were used: the delivery of a first shock for any reason or death from any cause, the first appropriate shock for a ventricular arrhythmia or death from any cause, and the first inappropriate shock for a supraventricular arrhythmia or death from any cause. Results. Compliance with double-blind treatment was similar in the two groups. There were seven deaths in the placebo group and four in the sotalol group. As compared with placebo, treatment with sotalol was associated with a lower risk of death from any cause or the delivery of a first shock for any reason (reduction in risk, 48 percent; P < 0.001 by the log-rank test), death from any cause or the delivery of a first appropriate shock (reduction in risk, 44 percent; P = 0.007), or death from any cause or the delivery of a first inappropriate shock (reduction in risk, 64 percent; P = 0.004). Sotalol also reduced the mean (+/-SD) frequency of shocks due to any cause (1.43 +/- 3.53 shocks per year, as compared with 3.89 +/- 10.65 in the placebo group; P = 0.008). In the sotalol group, the reduction in the risk of death from any cause or the delivery of a first shock for any reason did not differ significantly between patients with ejection fractions of more than 0.30 and those with ejection fractions of 0.30 or less. Conclusions. Oral sotalol was safe and efficacious in reducing the risk of death or the delivery of a first defibrillator shock whether or not ventricular function was depressed. (N Engl J Med 1999;340:1855-62.) (C) 1999, Massachusetts Medical Society.	Texas Arrhythmia Inst, Houston, TX 77030 USA; Goethe Univ Frankfurt, D-6000 Frankfurt, Germany; Berlex Labs Inc, Montville, NJ USA; Eastern Heart Inst, Millburn, NJ USA; St Vincent Hosp, Indianapolis, IN USA	Goethe University Frankfurt	Pacifico, A (corresponding author), Texas Arrhythmia Inst, 6560 Fannin St,Suite 620, Houston, TX 77030 USA.	apacifico@tmh.tmc.edu						BENDITT DG, IN PRESS AM J CARDIO; Bocker D, 1998, CIRCULATION, V98, P1636, DOI 10.1161/01.CIR.98.16.1636; Bourke JP, 1997, HEART, V78, P581, DOI 10.1136/hrt.78.6.581; Cairns JA, 1997, LANCET, V349, P675, DOI 10.1016/S0140-6736(96)08171-8; Cairns JA, 1997, LANCET, V349, P1776; de Vries JW, 1998, ANESTH ANALG, V87, P16, DOI 10.1097/00000539-199807000-00005; Domanski MJ, 1997, CIRCULATION, V95, P2694, DOI 10.1161/01.CIR.95.12.2694; DORIAN P, 1993, AM J CARDIOL, V72, pA72, DOI 10.1016/0002-9149(93)90028-B; ECHT DS, 1991, NEW ENGL J MED, V324, P781, DOI 10.1056/NEJM199103213241201; GREENE HL, 1993, AM J CARDIOL, V72, P280; Hegel MT, 1997, INT J PSYCHIAT MED, V27, P57, DOI 10.2190/1G9V-EQMD-MTLQ-E0BW; Heidenreich PA, 1997, J AM COLL CARDIOL, V30, P27, DOI 10.1016/S0735-1097(97)00104-6; Hjalmarson A, 1997, AM J CARDIOL, V80, pJ35, DOI 10.1016/S0002-9149(97)00837-0; HOHNLOSER SH, 1994, NEW ENGL J MED, V331, P31; Joglar JA, 1999, AM J CARDIOL, V83, P270, DOI 10.1016/S0002-9149(98)00836-4; Julian DG, 1997, LANCET, V349, P667, DOI 10.1016/S0140-6736(96)09145-3; Julian DG, 1997, LANCET, V349, P1776; JULIAN DG, 1997, LANCET, V349, P1180; MASON JW, 1993, NEW ENGL J MED, V329, P452, DOI 10.1056/NEJM199308123290702; McAnulty J, 1997, NEW ENGL J MED, V337, P1576; Moss AJ, 1996, NEW ENGL J MED, V335, P1933, DOI 10.1056/NEJM199612263352601; Murkin JM, 1997, ANESTH ANALG, V84, P1186, DOI 10.1097/00000539-199706000-00003; Pacifico A, 1997, CIRCULATION, V95, P946; Pacifico A, 1998, AM J CARDIOL, V82, P875, DOI 10.1016/S0002-9149(98)00495-0; Reiffel JA, 1997, AM J CARDIOL, V79, P1048, DOI 10.1016/S0002-9149(97)00045-3; *SAS I INC, 1997, SAS STAT SOFTW CHANG, P1; SIEBELS J, 1993, PACE, V16, P552, DOI 10.1111/j.1540-8159.1993.tb01624.x; Tokano T, 1998, J CARDIOVASC ELECTR, V9, P791, DOI 10.1111/j.1540-8167.1998.tb00118.x; ZELEN M, 1974, J CHRON DIS, V27, P365, DOI 10.1016/0021-9681(74)90015-0	29	283	289	0	3	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUN 17	1999	340	24					1855	1862		10.1056/NEJM199906173402402	http://dx.doi.org/10.1056/NEJM199906173402402			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	206EC	10369848				2022-12-28	WOS:000080863500002
J	Choudhry, NK; Etchells, EE				Choudhry, NK; Etchells, EE			Does this patient have aortic regurgitation?	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PULSED DOPPLER ECHOCARDIOGRAPHY; M-MODE ECHOCARDIOGRAPHY; HEALTH-CARE FACILITY; VALVULAR REGURGITATION; MITRAL-STENOSIS; BLOOD-PRESSURE; INSUFFICIENCY; MURMURS; DIAGNOSIS; PREVALENCE	Objective To review evidence as to the precision and accuracy of clinical examination for aortic regurgitation (AR), Methods We conducted a structured MEDLINE search of English-language articles (January 1966-July 1997), manually reviewed all reference lists of potentially relevant articles, and contacted authors of relevant studies for additional information. Each study (n = 16) was independently reviewed by both authors and graded for methodological quality. Results Most studies assessed cardiologists as examiners. Cardiologists' precision for detecting diastolic murmurs was moderate using audiotapes (kappa = 0.51) and was good in the clinical setting (simple agreement, 94%), The most useful finding for ruling in AR is the presence of an early diastolic murmur (positive likelihood ratio [LR], 8.8-32.0 [95% confidence interval {CI}, 2.8-32 to 16-63] for detecting mild or greater AR and 4.0-8.3 [95% CI, 2.5-6.9 to 6.2-11] for detecting moderate or greater AR) (2 grade A studies). The most useful finding for ruling out AR is the absence of early diastolic murmur (negative LR, 0.2-0.3 [95% CI, 0.1-0.3 to 0.2-0.4) for mild or greater AR and 0.1 [95% CI, 0.0-0.3] for moderate or greater AR) (2 grade A studies). Except for a test evaluating the response to transient arterial occlusion (positive LR, 8.4 [95% CI, 1.3-81.0]; negative LR, 0.3 [95% CI, 0.1-0.8]), most signs display poor sensitivity and specificity for AR. Conclusion Clinical examination by cardiologists is accurate for detecting AR, but not enough is known about the examinations of less-expert clinicians.	Univ Toronto, Dept Med, Div Gen Internal Med & Clin Epidemiol, Toronto, ON, Canada; Univ Hlth Network, Toronto, ON M5G 2C4, Canada	University of Toronto; University of Toronto; University Toronto Affiliates; University Health Network Toronto	Etchells, EE (corresponding author), Univ Hlth Network, 200 Elizabeth St,Eng-248, Toronto, ON M5G 2C4, Canada.							ABBAS F, 1987, SOUTHERN MED J, V80, P1051, DOI 10.1097/00007611-198708000-00027; ALEXANDER WD, 1977, BRIT HEART J, V39, P900; ARONOW WS, 1987, AM J CARDIOL, V59, P181, DOI 10.1016/S0002-9149(87)80105-4; ARONOW WS, 1989, AM J CARDIOL, V63, P128, DOI 10.1016/0002-9149(89)91098-9; Ballard D J, 1989, Int J Technol Assess Health Care, V5, P249; BETHEL CS, 1963, AM J CARDIOL, V11, P763, DOI 10.1016/0002-9149(63)90104-8; Blumgart HL, 1933, J AMER MED ASSOC, V100, P173, DOI 10.1001/jama.1933.02740030021007; CENTOR R, 1992, 2 2 ANAL; COHN LH, 1967, AM J CARDIOL, V19, P177, DOI 10.1016/0002-9149(67)90530-9; COME PC, 1986, J AM COLL CARDIOL, V8, P1355, DOI 10.1016/S0735-1097(86)80308-4; CONSTANT J, 1985, BEDSIDE CARDIOLOGY; CONSTANT J, 1965, AM HEART J, V70, P322; Dajani AS, 1997, JAMA-J AM MED ASSOC, V277, P1794, DOI 10.1001/jama.277.22.1794; Desjardins VA, 1996, AM J MED, V100, P149, DOI 10.1016/S0002-9343(97)89452-1; DITTMANN H, 1987, EUR HEART J, V8, P53, DOI 10.1093/eurheartj/8.suppl_C.53; DUBROW RJ, 1964, MED ANN DIST COLUMBI, V33, P305; ESPER RJ, 1982, AM J CARDIOL, V50, P1037, DOI 10.1016/0002-9149(82)90414-3; Etchells E, 1997, JAMA-J AM MED ASSOC, V277, P564, DOI 10.1001/jama.277.7.564; FEINSTEIN AR, 1959, NEW ENGL J MED, V260, P1331, DOI 10.1056/NEJM195906252602608; FLINT A, 1862, AM J MED SCI, V44, P29; FRANK MJ, 1965, ARCH INTERN MED, V116, P357, DOI 10.1001/archinte.1965.03870030037008; Freeman AR, 1933, ANN INTERN MED, V6, P1371, DOI 10.7326/0003-4819-6-11-1371; GRAYBURN PA, 1986, ANN INTERN MED, V104, P599, DOI 10.7326/0003-4819-104-5-599; HARVEY WP, 1994, DIS MON, V40, P43; HEGGLIN R, 1968, CIRCULATION S5, V37, P77; Hill L, 1909, HEART-J STUD CIRC, V1, P73; HOLLEMAN DR, 1995, JAMA-J AM MED ASSOC, V273, P313, DOI 10.1001/jama.273.4.313; KOOPMAN PAR, 1984, BIOMETRICS, V40, P513, DOI 10.2307/2531405; LABBE KA, 1987, ANN INTERN MED, V107, P224, DOI 10.7326/0003-4819-107-2-224; LANDZBERG JS, 1992, J AM COLL CARDIOL, V20, P408, DOI 10.1016/0735-1097(92)90110-9; LEE D, 1995, CHIN MED J, V56, P152; LEMBO NJ, 1986, ANN INTERN MED, V105, P368, DOI 10.7326/0003-4819-105-3-368; LINDROOS M, 1993, J AM COLL CARDIOL, V21, P1220, DOI 10.1016/0735-1097(93)90249-Z; Linhart J W, 1971, Ann Thorac Surg, V11, P27; Mangione S, 1997, JAMA-J AM MED ASSOC, V278, P717, DOI 10.1001/jama.278.9.717; MEYERS DG, 1982, SOUTHERN MED J, V75, P1192, DOI 10.1097/00007611-198210000-00009; MEYERS DG, 1985, AM J CARDIOL, V56, P811, DOI 10.1016/0002-9149(85)91151-8; NIENABER CA, 1993, NEW ENGL J MED, V328, P1, DOI 10.1056/NEJM199301073280101; PEREZ JE, 1985, ANN INTERN MED, V103, P497, DOI 10.7326/0003-4819-103-4-497; RAFTERY EB, 1967, AM J EPIDEMIOL, V85, P438, DOI 10.1093/oxfordjournals.aje.a120705; RAHKO PS, 1989, ANN INTERN MED, V111, P466, DOI 10.7326/0003-4819-111-6-466; REEVES RA, 1995, JAMA-J AM MED ASSOC, V273, P1211, DOI 10.1001/jama.1995.03520390071036; Roldan CA, 1996, AM J CARDIOL, V77, P1327, DOI 10.1016/S0002-9149(96)00200-7; RUSHMER RF, 1952, AMA AM J DIS CHILD, V83, P740, DOI 10.1001/archpedi.1952.02040100038003; SAAL AK, 1985, J AM COLL CARDIOL, V5, P176; SAPIRA JD, 1981, SOUTHERN MED J, V74, P459, DOI 10.1097/00007611-198104000-00022; Sapira JD, 1990, ART SCI BEDSIDE DIAG; SCOGNAMIGLIO R, 1994, NEW ENGL J MED, V331, P689, DOI 10.1056/NEJM199409153311101; SHARMA R S, 1981, Lancet, V2, P612; SHAVER JA, 1995, CURR PROB CARDIOLOGY, V20, P445; SOFFER A, 1967, AM J CARDIOL, V20, P285; STCLAIR EW, 1992, ANN INTERN MED, V117, P751, DOI 10.7326/0003-4819-117-9-751; WARD JM, 1977, J CLIN ULTRASOUND, V5, P5, DOI 10.1002/jcu.1870050103; WARNES CA, 1983, AM J CARDIOL, V51, P1551, DOI 10.1016/0002-9149(83)90675-6	54	17	17	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 16	1999	281	23					2231	2238		10.1001/jama.281.23.2231	http://dx.doi.org/10.1001/jama.281.23.2231			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	204RB	10376577				2022-12-28	WOS:000080777000038
J	Haslam, D				Haslam, D			The beginning of the end	BRITISH MEDICAL JOURNAL			English	Editorial Material																			0	1	1	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JUN 12	1999	318	7198					1633	1633		10.1136/bmj.318.7198.1633	http://dx.doi.org/10.1136/bmj.318.7198.1633			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	207AL	10364144	Green Published			2022-12-28	WOS:000080913100076
J	Maxwell, K; Streetly, A; Bevan, D				Maxwell, K; Streetly, A; Bevan, D			Experiences of hospital care and treatment seeking for pain from sickle cell disease: qualitative study	BRITISH MEDICAL JOURNAL			English	Article							HEALTH-SERVICES; CRISIS; PERCEPTIONS; MANAGEMENT; DEPENDENCE; BRITAIN; OPIATES; MODEL	Objective To investigate how sociocultural factors influence management of pain from sickle cell disease by comparing the experiences of those who usually manage their pain at home with those who are more frequently admitted to hospital for management of their pain. Design Qualitative analysis of semistructured individual interviews and focus group discussions. Participants 57 participants with genotype SS or S/beta-thal (44 subjects) or SC (9) (4 were unknown). 40 participants took part in focus groups, six took part in both focus groups and interviews, and nine were interviewed only. Participants were allocated to focus groups according to number of hospital admissions for painful crisis management during the precious year, ethnic origin, and sex. Results The relation between patients with sickle cell disease and hospital services is one of several major non-clinical dimensions shaping experiences of pain management and behaviour for seeking health care. Experiences of hospital care show a range of interrelated themes, which are common to most participants across variables of sex, ethnicity, and hospital attended: mistrust of patients with sickle cell disease; stigmatisation; excessive control (including both over- and undertreatment of pain); and neglect Individuals respond to the challenge of negotiating care with various strategies. Patients with sickle cell disease who are frequently admitted to hospital may try to develop long term relationships with their carers, may become passive or aggressive in their interactions with health professionals, or may regularly attend different hospitals. Those individuals who usually manage their pain at home express a strong sense of self responsibility for their management of pain and advocate self education, assertiveness, and resistance as strategies towards hospital services. Conclusions The current organisation and delivery of management of pain for sickle cell crisis discourage self reliance and encourage hospital dependence. Models of care should recognise the chronic nature of sickle cell disorders and prioritise patients' involvement in their care.	Univ London Kings Coll, Guys Sch Med Dent & Biomed Sci, Dept Publ Hlth Sci, London SE1 3QD, England; Univ London Kings Coll, Kings Sch Med Dent & Biomed Sci, London SE1 3QD, England; Univ London Kings Coll, St Thomass Sch Med Dent & Biomed Sci, London SE1 3QD, England; Univ London St Georges Hosp, Sch Med, Dept Haematol, London SW17 0QT, England	University of London; King's College London; University of London; King's College London; University of London; King's College London; St Georges University London	Streetly, A (corresponding author), Univ London Kings Coll, Guys Sch Med Dent & Biomed Sci, Dept Publ Hlth Sci, London SE1 3QD, England.							ALLEYNE J, 1994, J ADV NURS, V19, P725, DOI 10.1111/j.1365-2648.1994.tb01144.x; Atkin K., 1998, HEALTH, V2, P305; BALLAS SK, 1998, SICKLE CELL PAIN; Black Janet, 1986, LIVING SICKLE CELL D; BROZOVIC M, 1987, BRIT MED J, V294, P1206, DOI 10.1136/bmj.294.6581.1206; *DEP HLTH, 1993, REP WORK PART STAND; DONOVAN JL, 1986, WE DONT BUY SICKNESS; Gignac MAM, 1998, SOC SCI MED, V47, P739, DOI 10.1016/S0277-9536(98)00149-X; Glaser B.G., 1965, AWARENESS DYING; GOOD MJD, 1992, PAIN HUMAN EXPERIENC, P169; HELMAN CG, 1994, CULTURE HLTH ILLNESS, P171; Konotey-Ahulu FID, 1998, LANCET, V351, P1438, DOI 10.1016/S0140-6736(05)79487-3; Layton DM, 1998, LANCET, V351, P1964, DOI 10.1016/S0140-6736(05)78656-6; LAYZELL S, 1992, AIDS CARE, V4, P203, DOI 10.1080/09540129208253091; Lorig K, 1996, AM BEHAV SCI, V39, P676, DOI 10.1177/0002764296039006005; MURRAY N, 1988, BRIT MED J, V297, P452, DOI 10.1136/bmj.297.6646.452; Olujohungbe A, 1998, BRIT MED J, V316, P1689, DOI 10.1136/bmj.316.7146.1689; ONeill B, 1997, BRIT MED J, V315, P801, DOI 10.1136/bmj.315.7111.801; PLATT OS, 1991, NEW ENGL J MED, V325, P11, DOI 10.1056/NEJM199107043250103; POPE C, 1995, BRIT MED J, V311, P42, DOI 10.1136/bmj.311.6996.42; Serjeant G R, 1995, Curr Opin Hematol, V2, P103; SHAPIRO B, 1990, ADV PAIN RES THER, P313; Shapiro BS, 1997, J PAIN SYMPTOM MANAG, V14, P168, DOI 10.1016/S0885-3924(97)00019-5; STREETLY A, 1993, BRIT MED J, V306, P1491, DOI 10.1136/bmj.306.6891.1491; STREETLY A, 1997, SICKLE CELL DISORDER; WALDROP RD, 1995, AM J EMERG MED, V13, P529, DOI 10.1016/0735-6757(95)90163-9; Westerman MP, 1997, AM J HEMATOL, V54, P183, DOI 10.1002/(SICI)1096-8652(199703)54:3<183::AID-AJH2>3.0.CO;2-S	27	104	105	1	7	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JUN 12	1999	318	7198					1585	1590		10.1136/bmj.318.7198.1585	http://dx.doi.org/10.1136/bmj.318.7198.1585			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	207AL	10364116	Green Published, Bronze, Green Submitted			2022-12-28	WOS:000080913100028
J	Pearson, PN; Palmer, MR				Pearson, PN; Palmer, MR			Middle eocene seawater pH and atmospheric carbon dioxide concentrations	SCIENCE			English	Article							BORON ISOTOPIC COMPOSITION; EQUATORIAL PACIFIC; PHANEROZOIC TIME; LATE PALEOCENE; OCEAN PH; CO2; FORAMINIFERA; CLIMATE; DEPTH; BOUNDARY	The carbon dioxide content of the atmosphere [measured as the partial pressure of CO2 (pCO(2))] affects the content of the surface ocean, which in turn affects seawater pH, The boron isotope composition (delta(11)B) of contemporaneous planktonic foraminifera that calcified their tests at different water depths can be used to reconstruct the pH-depth profile of ancient seawater. Construction of a pH profile for the middle Eocene tropical Pacific Ocean shows that atmospheric pCO(2) was probably similar to modern concentrations or slightly higher.	Univ Bristol, Dept Earth Sci, Bristol BS8 1RJ, Avon, England; Univ London Imperial Coll Sci Technol & Med, Royal Sch Mines, TH Huxley Sch, London SW7 2BP, England	University of Bristol; Imperial College London	Pearson, PN (corresponding author), Univ Bristol, Dept Earth Sci, Wills Mem Bldg, Bristol BS8 1RJ, Avon, England.		Palmer, Martin R/I-6765-2012; Pearson, Paul N/B-2276-2009	Palmer, Martin R/0000-0003-1660-3714; Pearson, Paul N/0000-0003-4628-9818				ARTHUR M., 1991, EOS T AGU S, V72, P166; BARRON EJ, 1985, PALAEOGEOGR PALAEOCL, V50, P45, DOI 10.1016/S0031-0182(85)80005-5; Berggren WA, 1992, EOCENE OLIGOCENE CLI, P1; BERNER RA, 1983, AM J SCI, V283, P641, DOI 10.2475/ajs.283.7.641; BERNER RA, 1991, AM J SCI, V291, P339, DOI 10.2475/ajs.291.4.339; BERNER RA, 1994, AM J SCI, V294, P56, DOI 10.2475/ajs.294.1.56; Boersma A, 1987, PALEOCEANOGRAPHY, V2, P287, DOI 10.1029/PA002i003p00287; BRADY PV, 1991, J GEOPHYS RES-SOL EA, V96, P18101, DOI 10.1029/91JB01898; BRALOWER TJ, 1995, PALEOCEANOGRAPHY, V10, P841, DOI 10.1029/95PA01143; Broecker W.S., 1982, TRACERS SEA; CERLING TE, 1993, AM J SCI, V293, P377; ELDHOLM O, 1993, EARTH PLANET SC LETT, V117, P319, DOI 10.1016/0012-821X(93)90087-P; Freeman KH, 1992, GLOBAL BIOGEOCHEM CY, V6, P185, DOI 10.1029/92GB00190; HEMMING NG, 1992, GEOCHIM COSMOCHIM AC, V56, P537, DOI 10.1016/0016-7037(92)90151-8; HERSHEY JP, 1986, GEOCHIM COSMOCHIM AC, V50, P143, DOI 10.1016/0016-7037(86)90059-1; KAKIHANA H, 1977, B CHEM SOC JPN, V50, P158, DOI 10.1246/bcsj.50.158; KENNETT JP, 1982, MAR GEOL, P695; Kerrick DM, 1998, CHEM GEOL, V145, P213, DOI 10.1016/S0009-2541(97)00144-7; KROOPNICK PM, 1985, DEEP-SEA RES, V32, P57, DOI 10.1016/0198-0149(85)90017-2; Lu GY, 1996, J FORAMIN RES, V26, P103, DOI 10.2113/gsjfr.26.2.103; McElwain JC, 1998, PHILOS T R SOC B, V353, P83, DOI 10.1098/rstb.1998.0193; Miller KG, 1987, PALEOCEANOGRAPHY, V2, P1, DOI 10.1029/PA002i001p00001; MILLERO FJ, 1995, GEOCHIM COSMOCHIM AC, V59, P661, DOI 10.1016/0016-7037(94)00354-O; OWEN RM, 1985, SCIENCE, V227, P166, DOI 10.1126/science.11536555; Palmer MR, 1998, SCIENCE, V282, P1468, DOI 10.1126/science.282.5393.1468; Pearson Paul N., 1998, Paleontological Society Papers, V4, P138; PEARSON PN, 1993, J FORAMIN RES, V23, P123, DOI 10.2113/gsjfr.23.2.123; RAYMO ME, 1992, NATURE, V359, P117, DOI 10.1038/359117a0; REA DK, 1990, PALAEOGEOGR PALAEOCL, V79, P117, DOI 10.1016/0031-0182(90)90108-J; Sanyal A, 1997, GLOBAL BIOGEOCHEM CY, V11, P125, DOI 10.1029/97GB00223; Sanyal A, 1996, PALEOCEANOGRAPHY, V11, P513, DOI 10.1029/96PA01858; Scotese C.R., 1994, PANGEA PALEOCLIMATE, V288, P57, DOI DOI 10.1130/SPE288-P57; SPIVACK AJ, 1993, NATURE, V363, P149, DOI 10.1038/363149a0; VANANDEL TH, 1975, EARTH PLANET SC LETT, V26, P187, DOI 10.1016/0012-821X(75)90086-2; VANEIJDEN AJM, 1995, PALAEOGEOGR PALAEOCL, V113, P267, DOI 10.1016/0031-0182(95)00057-S; ZACHOS JC, 1993, J GEOL, V101, P191, DOI 10.1086/648216	36	140	164	3	83	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 11	1999	284	5421					1824	1826		10.1126/science.284.5421.1824	http://dx.doi.org/10.1126/science.284.5421.1824			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	205EU	10364552				2022-12-28	WOS:000080809000046
J	Iribarren, C; Tekawa, IS; Sidney, S; Friedman, GD				Iribarren, C; Tekawa, IS; Sidney, S; Friedman, GD			Effect of cigar smoking on the risk of cardiovascular disease, chronic obstructive pulmonary disease, and cancer in men	NEW ENGLAND JOURNAL OF MEDICINE			English	Article; Proceedings Paper	Annual Meeting of the Society-for-Epidemiological-Research	JUN 24-26, 1998	CHICAGO, ILLINOIS	Soc Epidemiol Res			PASSIVE SMOKING; MYOCARDIAL-INFARCTION; TOBACCO-SMOKE; PIPE SMOKERS; LUNG-CANCER; MORTALITY; EXPOSURE; PHARYNX; ALCOHOL; LARYNX	Background The sale of cigars in the United States has been increasing since 1993. Cigar smoking is a known risk factor for certain cancers and for chronic obstructive pulmonary disease (COPD). However, unlike the relation between cigarette smoking and cardiovascular disease, the association between cigar smoking and cardiovascular disease has not been clearly established. Methods We performed a cohort study among 17,774 men 30 to 85 years of age at base line (from 1964 through 1973) who were enrolled in the Kaiser Permanente health plan and who reported that they had never smoked cigarettes and did not currently smoke a pipe. Those who smoked cigars (1546 men) and those who did not (16,228) were followed from 1971 through the end of 1995 for a first hospitalization for or death from a major cardiovascular disease or COPD, and through the end of 1996 for a diagnosis of cancer. Results In multivariate analyses, cigar smokers, as compared with nonsmokers, were at higher risk for coronary heart disease (relative risk, 1.27; 95 percent confidence interval, 1.12 to 1.45), COPD (relative risk, 1.45; 95 percent confidence interval, 1.10 to 1.91), and cancers of the upper aerodigestive tract (relative risk, 2.02; 95 percent confidence interval, 1.01 to 4.06) and lung (relative risk, 2.14; 95 percent confidence interval, 1.12 to 4.11), with evidence of dose-response effects. There appeared to be a synergistic relation between cigar smoking and alcohol consumption with respect to the risk of oropharyngeal cancers and cancers of the upper aerodigestive tract. Conclusions Independently of other risk factors, regular cigar smoking can increase the risk of coronary heart disease, COPD, and cancers of the upper aerodigestive tract and lung. (N Engl J Med 1999;340: 1773-80.) (C) 1999, Massachusetts Medical Society.	Kaiser Permanente Med Care Program, Div Res, Oakland, CA 94611 USA	Kaiser Permanente	Iribarren, C (corresponding author), Kaiser Permanente Med Care Program, Div Res, 3505 Broadway, Oakland, CA 94611 USA.				NATIONAL CANCER INSTITUTE [R35CA049761] Funding Source: NIH RePORTER; NCI NIH HHS [R35CA 49761] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		APPEL BR, 1990, AM J PUBLIC HEALTH, V80, P560, DOI 10.2105/AJPH.80.5.560; ARELLANO MG, 1984, AM J PUBLIC HEALTH, V74, P1324, DOI 10.2105/AJPH.74.12.1324; ARMITAGE A, 1978, CLIN PHARMACOL THER, V23, P143; BROWN CA, 1993, THORAX, V48, P1163, DOI 10.1136/thx.48.11.1163; BRUNNEMANN KD, 1974, J CHROMATOGR SCI, V12, P70, DOI 10.1093/chromsci/12.2.70; Cendon SP, 1997, BRAZ J MED BIOL RES, V30, P1241, DOI 10.1590/S0100-879X1997001000017; Cohen MF, 1978, MULTIPHASIC HLTH TES; COLLEN MF, 1969, JOM-J OCCUP MED, V11, P355; COX DR, 1972, J R STAT SOC B, V34, P187; DALHAMN T, 1970, ARCH ENVIRON HEALTH, V20, P252, DOI 10.1080/00039896.1970.10665581; *DEP AGR, 1997, EC RES SERV SER; *DEP HHS, 1989, DHHS PHS PUBL; *DEP HLTH HUM SERV, 1982, DHHS PHS PUBL; DIEZROUX AV, 1995, PREV MED, V24, P48, DOI 10.1006/pmed.1995.1007; FRANCESCHI S, 1990, CANCER RES, V50, P6502; FRIEDMAN GD, 1972, AM J EPIDEMIOL, V96, P23, DOI 10.1093/oxfordjournals.aje.a121429; FRIEDMAN GD, 1997, SMOKING TOBACCO CONT, V8, P477; GOLDMAN AL, 1977, CHEST, V72, P33, DOI 10.1378/chest.72.1.33; GYNTELBERG F, 1981, LANCET, V1, P987; HAMMOND EC, 1958, JAMA-J AM MED ASSOC, V166, P1294, DOI 10.1001/jama.1958.02990110030007; Henningfield JE, 1996, JAMA-J AM MED ASSOC, V276, P1857, DOI 10.1001/jama.1996.03540230007003; HICKEY N, 1983, BRIT HEART J, V49, P423, DOI 10.1136/hrt.49.5.423; HIGGINS ITT, 1988, PREV MED, V17, P116, DOI 10.1016/0091-7435(88)90077-1; HUBER GL, 1977, B EUR PHYSIOPATH RES, V13, P513; International Agency for Research on Cancer, 1986, IARC MON EV CARC RIS, V38; Iribarren C, 1998, CIRCULATION, V97, P822; KAUFMAN DW, 1987, BRIT MED J, V294, P1315, DOI 10.1136/bmj.294.6583.1315; KRIEGER N, 1992, AM J PUBLIC HEALTH, V82, P703, DOI 10.2105/AJPH.82.5.703; LANGE P, 1992, EUR RESPIR J, V5, P1111; LUBIN JH, 1984, J NATL CANCER I, V73, P377, DOI 10.1093/jnci/73.2.377; MUSCAT JE, 1992, CANCER, V69, P2244, DOI 10.1002/1097-0142(19920501)69:9&lt;2244::AID-CNCR2820690906&gt;3.0.CO;2-O; *NCI, 1998, SMOK TOB CONTR MON, V9; *OFF SMOK HLTH, 1992, PUBL HLTH SERV BIBL, V46; PECHACEK TF, 1985, JAMA-J AM MED ASSOC, V254, P3330, DOI 10.1001/jama.254.23.3330; ROGOT E, 1980, PUBLIC HEALTH REP, V95, P213; ROTHMAN K, 1972, J CHRON DIS, V25, P711, DOI 10.1016/0021-9681(72)90006-9; Schmid P, 1996, THROMB RES, V81, P451, DOI 10.1016/0049-3848(96)00017-5; Selby JV, 1996, NEW ENGL J MED, V335, P1888, DOI 10.1056/NEJM199612193352506; SINZINGER H, 1989, WIEN KLIN WOCHENSCHR, V101, P694; Slattery ML, 1997, INT J CANCER, V71, P706; Steenland K, 1996, CIRCULATION, V94, P622, DOI 10.1161/01.CIR.94.4.622; STRACHAN DP, 1991, BRIT J SURG, V78, P401, DOI 10.1002/bjs.1800780407; Terry MB, 1998, AM J EPIDEMIOL, V147, P903; Valkonen M, 1998, CIRCULATION, V97, P2012, DOI 10.1161/01.CIR.97.20.2012; WYNDER EL, 1976, CANCER-AM CANCER SOC, V38, P1591, DOI 10.1002/1097-0142(197610)38:4<1591::AID-CNCR2820380425>3.0.CO;2-R; 1997, MMWR MORB MORTAL WKL, V46, P433; [No title captured]	47	144	154	0	9	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 10	1999	340	23					1773	1780		10.1056/NEJM199906103402301	http://dx.doi.org/10.1056/NEJM199906103402301			8	Medicine, General & Internal	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	203UU	10362820	Bronze			2022-12-28	WOS:000080726800001
J	Palmer, S; Raftery, J				Palmer, S; Raftery, J			Economics notes - Opportunity cost	BRITISH MEDICAL JOURNAL			English	Article									Univ York, Ctr Hlth Econ, York YO1 5DD, N Yorkshire, England; Univ Birmingham, Hlth Serv Management Ctr, Birmingham B15 2RT, W Midlands, England	University of York - UK; University of Birmingham	Palmer, S (corresponding author), Univ York, Ctr Hlth Econ, York YO1 5DD, N Yorkshire, England.							Byford S, 1998, BRIT MED J, V316, P1529, DOI 10.1136/bmj.316.7143.1529; Dawson D, 1994, COSTS PRICES INTERNA; Gold MR, 1996, COST EFFECTIVENESS H; Koopmanschap MA, 1996, PHARMACOECONOMICS, V10, P460, DOI 10.2165/00019053-199610050-00003; Posnett J, 1996, HEALTH ECON, V5, P13, DOI 10.1002/(SICI)1099-1050(199601)5:1<13::AID-HEC182>3.0.CO;2-J; ROBINSON R, 1993, BRIT MED J, V307, P726, DOI 10.1136/bmj.307.6906.726; RUSSELL LB, 1992, HEALTH AFFAIR, V11, P162, DOI 10.1377/hlthaff.11.2.162; Stiglitz J., 1986, EC PUBLIC SECTOR; TORGERSORI DJ, 1996, BRIT MED J, V307, P726	9	84	89	0	24	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JUN 5	1999	318	7197					1551	1552		10.1136/bmj.318.7197.1551	http://dx.doi.org/10.1136/bmj.318.7197.1551			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	204HC	10356019	Green Published			2022-12-28	WOS:000080757300037
J	Smith, G; Nielsen, M				Smith, G; Nielsen, M			ABC of intensive care - Criteria for admission	BRITISH MEDICAL JOURNAL			English	Article									Queen Alexandra Hosp, Portsmouth, Hants, England; Southampton Gen Hosp, Southampton SO9 4XY, Hants, England	Portsmouth Hospitals NHS Trust; Queen Alexandra Hospital; University of Southampton	Smith, G (corresponding author), Queen Alexandra Hosp, Portsmouth, Hants, England.								0	56	59	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JUN 5	1999	318	7197					1544	1547		10.1136/bmj.318.7197.1544	http://dx.doi.org/10.1136/bmj.318.7197.1544			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	204HC	10356016	Green Published			2022-12-28	WOS:000080757300034
J	Leonardo, A; Konishi, M				Leonardo, A; Konishi, M			Decrystallization of adult birdsong by perturbation of auditory feedback	NATURE			English	Article							SONG; FINCHES; MAINTENANCE; SYRINX	Young birds learn to sing by using auditory feedback to compare their own vocalizations to a memorized or innate song pattern; if they are deafened as juveniles, they will not develop normal songs(1,2). The completion of song development is called crystallization. After this stage, song shows little variation in its temporal or spectral properties. However, the mechanisms underlying this stability are largely unknown. Here we present evidence that auditory feedback is actively used in adulthood to maintain the stability of song structure. We found that perturbing auditory feedback during singing in adult zebra finches caused their song to deteriorate slowly. This 'decrystallization' consisted of a marked loss of the spectral and temporal stereotypy seen in crystallized song, including stuttering, creation, deletion and distortion of song syllables. After normal feedback was restored, these deviations gradually disappeared and the original song was recovered. Thus, adult birds that do not learn new songs nevertheless retain a significant amount of plasticity in the brain.	CALTECH, Computat & Neural Syst Program, Pasadena, CA 91125 USA; CALTECH, Div Biol, Pasadena, CA 91125 USA	California Institute of Technology; California Institute of Technology	Leonardo, A (corresponding author), CALTECH, Computat & Neural Syst Program, MC 216-76, Pasadena, CA 91125 USA.	leonardo@cns.caltech.edu						Bradley E, 1993, INTRO BOOTSTRAP; Cover TM., 2006, ELEMENTS INFORM THEO, DOI [10.1002/047174882X, DOI 10.1002/047174882X]; Fee MS, 1998, NATURE, V395, P67, DOI 10.1038/25725; FELLER W, 1971, INTRO PROBABILITY TH, V1; Ho C, 1998, P JOINT S NEUR COMP, V5, P76; Houde JF, 1998, SCIENCE, V279, P1213, DOI 10.1126/science.279.5354.1213; Konishi M., 1965, Zeitschrift fuer Tierpsychologie, V22, P770; MARLER P, 1987, ETHOLOGY, V76, P89; NORDEEN KW, 1992, BEHAV NEURAL BIOL, V57, P58, DOI 10.1016/0163-1047(92)90757-U; NOTTEBOH.F, 1968, IBIS, V110, P549, DOI 10.1111/j.1474-919X.1968.tb00063.x; Okanoya K, 1997, J NEUROBIOL, V33, P343; SELIM SZ, 1984, IEEE T PATTERN ANAL, V6, P81, DOI 10.1109/TPAMI.1984.4767478; SOSSINKA R, 1980, Z TIERPSYCHOL, V53, P123; SUTHERS RA, 1990, NATURE, V347, P473, DOI 10.1038/347473a0; THOMSON DJ, 1982, P IEEE, V70, P1055, DOI 10.1109/PROC.1982.12433; Woolley SMN, 1997, J NEUROSCI, V17, P6380	16	253	258	1	23	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 3	1999	399	6735					466	470		10.1038/20933	http://dx.doi.org/10.1038/20933			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	202TH	10365958				2022-12-28	WOS:000080667900048
J	Ashburn, MA; Staats, PS				Ashburn, MA; Staats, PS			Management of chronic pain	LANCET			English	Article							RANDOMIZED CONTROLLED TRIAL; NONSTEROIDAL ANTIINFLAMMATORY DRUGS; CHRONIC NONMALIGNANT PAIN; GABAPENTIN; NEUROPATHY; EFFICACY; PROGRAM	Chronic pain is a common condition for which patients seek care from various health-care providers. This type of pain causes much suffering and disability and is frequently mistreated or undertreated. Patients who present for evaluation for chronic pain should undergo a careful assessment before therapy. Patients with chronic pain commonly experience depression, sleep disturbance, fatigue, and decreased overall physical and mental functioning. They frequently require an interdisciplinary model of care to allow care givers to address the multiple components of the patient's pain experience. After a careful evaluation, therapy may include medication, nerve blocks, active physical therapy, behavioural interventions, and assistance with vocational evaluation and training. Less frequently therapy may include placement of implantable devices to alter the pain experience. these patients suffer from a chronic condition and often require long-term care, with frequent reassessment and adjustment of therapy. Although cure is possible, it is also infrequent. Therefore, therapy is provided with the aim of decreasing pain and suffering while improving physical and mental functioning.	Univ Utah, Hlth Sci Ctr, Dept Anesthesiol, Salt Lake City, UT 84132 USA; Johns Hopkins Univ, Pain Management Ctr, Dept Anesthesiol, Baltimore, MD USA	Utah System of Higher Education; University of Utah; Johns Hopkins University	Ashburn, MA (corresponding author), Univ Utah, Hlth Sci Ctr, Dept Anesthesiol, Salt Lake City, UT 84132 USA.							ALLISON MC, 1992, NEW ENGL J MED, V327, P749, DOI 10.1056/NEJM199209103271101; ASHBURN M, 1999, ACUTE PAIN CONTROL, V6, P10; Backonja M, 1998, JAMA-J AM MED ASSOC, V280, P1831, DOI 10.1001/jama.280.21.1831; BONICA JJ, 1991, ANIMAL PAIN, P1; Bove G, 1998, JAMA-J AM MED ASSOC, V280, P1576, DOI 10.1001/jama.280.18.1576; CLIVE DM, 1984, NEW ENGL J MED, V310, P563, DOI 10.1056/NEJM198403013100905; Dellemijn PLI, 1998, J PAIN SYMPTOM MANAG, V16, P220, DOI 10.1016/S0885-3924(98)00070-0; Eisenberg DM, 1998, JAMA-J AM MED ASSOC, V280, P1569, DOI 10.1001/jama.280.18.1569; *FED STAT MED BOAR, 1998, FED STAT MED BOARDS; Feine JS, 1997, PAIN, V71, P5, DOI 10.1016/S0304-3959(96)03287-3; FORDYCE WE, 1973, ARCH PHYS MED REHAB, V54, P399; FRICTON JR, 1995, OROFASCIAL PAIN TEMP, P485; Garfinkel MS, 1998, JAMA-J AM MED ASSOC, V280, P1601, DOI 10.1001/jama.280.18.1601; GOLDENBERG DL, 1987, JAMA-J AM MED ASSOC, V257, P2782, DOI 10.1001/jama.257.20.2782; GUPTA MA, 1999, PRACTICAL MANAGEMENT; Gureje O, 1998, JAMA-J AM MED ASSOC, V280, P147, DOI 10.1001/jama.280.2.147; Hill PA, 1996, PAIN CLINIC, V9, P181; Hubbard JE, 1996, CLIN J PAIN, V12, P330, DOI 10.1097/00002508-199612000-00013; Jacobson L, 1997, ANESTHESIOLOGY, V87, P1210, DOI 10.1097/00000542-199711000-00026; JANFAZA D, 1988, ANESTHESIOL ANALG, V87, P1242; Koes BW, 1995, PAIN, V63, P279, DOI 10.1016/0304-3959(95)00124-7; LIPMAN A, 1998, MANAGEMENT PAIN, P99; Loeser J., 1990, MANAGEMENT PAIN, P2040; Long SP, 1998, MANAGEMENT PAIN, P299; OAKLEY J, 1999, PRACTICAL MANAGEMENT; ONGHENA P, 1992, PAIN, V49, P205, DOI 10.1016/0304-3959(92)90144-Z; Portenoy RK, 1999, LANCET, V353, P1695, DOI 10.1016/S0140-6736(99)01310-0; Richmond J, 1996, JAMA-J AM MED ASSOC, V276, P313; Rowbotham M, 1998, JAMA-J AM MED ASSOC, V280, P1837, DOI 10.1001/jama.280.21.1837; Shlay JC, 1998, JAMA-J AM MED ASSOC, V280, P1590, DOI 10.1001/jama.280.18.1590; STAATS P, 1997, PROGR ANESTHESIOL, V19, P367; Staats PS, 1996, PAIN FORUM, V5, P194; SWERDLOW M, 1984, CLIN NEUROPHARMACOL, V7, P51, DOI 10.1097/00002826-198403000-00003; TURK DC, 1996, ADULT SPINE PRINCIPL, P253; TURK DC, 1998, MANAGEMENT PAIN, P235; Winkelmuller M, 1996, J NEUROSURG, V85, P458, DOI 10.3171/jns.1996.85.3.0458; WOOLF CJ, IN PRESS LANCET	37	171	188	1	12	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAY 29	1999	353	9167					1865	1869		10.1016/S0140-6736(99)04088-X	http://dx.doi.org/10.1016/S0140-6736(99)04088-X			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	202TG	10359427				2022-12-28	WOS:000080667800045
J	Pattyn, A; Morin, X; Cremer, H; Goridis, C; Brunet, JF				Pattyn, A; Morin, X; Cremer, H; Goridis, C; Brunet, JF			The homeobox gene Phox2b is essential for the development of autonomic neural crest derivatives	NATURE			English	Article							MICE LACKING GDNF; ENTERIC NERVOUS-SYSTEM; MOUSE MODEL; EXPRESSION; KIDNEY; NEURONS; DEFECTS; SOX10; RET; PRECURSORS	The sympathetic, parasympathetic and enteric ganglia are the main components of the peripheral autonomic nervous system(1), and are all derived from the neural crest(2). The factors needed for these structures to develop include the transcription factor Mash 1 (refs 3-5), the glial-derived neurotrophic factor GNDF (refs 6-8) and its receptor subunits(9-12), and the neuregulin signalling system(13), each of which is essential for the differentiation and survival of subsets of autonomic neurons. Here we show that all autonomic ganglia fail to form properly and degenerate in mice lacking the homeodomain transcription factor Phox2b, as do the three cranial sensory ganglia that are part of the autonomic reflex circuits. in the anlagen of the enteric nervous system and the sympathetic ganglia, Phox2b is needed for the expression of the GDNF-receptor subunit Ret and for maintaining Mash1 expression. Mutant ganglionic anlagen also fail to switch on the genes that encode two enzymes needed for the biosynthesis of the neurotransmitter noradrenaline, dopamine-beta-hydroxylase and tyrosine hydroxylase, demonstrating that Phox2b regulates the noradrenergic phenotype in vertebrates.	Univ Meditterranee, AP Marseille, INSERM, CNRS,Dev Biol Inst Marseille,Lab Genet & Physiol, F-13288 Marseille 9, France	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille	Brunet, JF (corresponding author), Univ Meditterranee, AP Marseille, INSERM, CNRS,Dev Biol Inst Marseille,Lab Genet & Physiol, Luminy Case 907, F-13288 Marseille 9, France.		morin, xavier/AAI-3306-2020; Alexandre, Pattyn/ABF-1346-2020	Morin, Xavier/0000-0001-9999-0355; Pattyn, Alexandre/0000-0003-1215-1482; Brunet, Jean-Francois/0000-0002-1985-6103; Cremer, Harold/0000-0002-8673-5176				Blaugrund E, 1996, DEVELOPMENT, V122, P309; BLESSING WW, 1997, LOWER BRAINSTEM BODI, P1; Britsch S, 1998, GENE DEV, V12, P1825, DOI 10.1101/gad.12.12.1825; Cacalano G, 1998, NEURON, V21, P53, DOI 10.1016/S0896-6273(00)80514-0; Durbec PL, 1996, DEVELOPMENT, V122, P349; Enomoto H, 1998, NEURON, V21, P317, DOI 10.1016/S0896-6273(00)80541-3; Fode C, 1998, NEURON, V20, P483, DOI 10.1016/S0896-6273(00)80989-7; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; GUILLEMOT F, 1993, CELL, V75, P463, DOI 10.1016/0092-8674(93)90381-Y; Herbarth B, 1998, P NATL ACAD SCI USA, V95, P5161, DOI 10.1073/pnas.95.9.5161; Hirsch MR, 1998, DEVELOPMENT, V125, P599; JOHNSON JE, 1990, NATURE, V346, P858, DOI 10.1038/346858a0; KNITTEL T, 1995, DEVELOPMENT, V121, P1077; Kuhlbrodt K, 1998, J NEUROSCI, V18, P237, DOI 10.1523/jneurosci.18-01-00237.1998; LANGLEY JN, 1921, AUTONOMIC NEVOUS SYS; Le Douarin N.M., 1982, NEURAL CREST; Lo LC, 1998, DEVELOPMENT, V125, P609; Moore MW, 1996, NATURE, V382, P76, DOI 10.1038/382076a0; Morin X, 1997, NEURON, V18, P411, DOI 10.1016/S0896-6273(00)81242-8; Pattyn A, 1997, DEVELOPMENT, V124, P4065; Pichel JG, 1996, NATURE, V382, P73, DOI 10.1038/382073a0; Sanchez MP, 1996, NATURE, V382, P70, DOI 10.1038/382070a0; SCHUCHARDT A, 1994, NATURE, V367, P380, DOI 10.1038/367380a0; Southard-Smith EM, 1998, NAT GENET, V18, P60, DOI 10.1038/ng0198-60; THOMAS SA, 1995, NATURE, V374, P643, DOI 10.1038/374643a0; Tiveron MC, 1996, J NEUROSCI, V16, P7649; Young HM, 1998, DEV BIOL, V202, P67, DOI 10.1006/dbio.1998.8987	27	630	647	2	21	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAY 27	1999	399	6734					366	370		10.1038/20700	http://dx.doi.org/10.1038/20700			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	200PA	10360575				2022-12-28	WOS:000080547800062
J	Nawroth, PP; Haring, HU				Nawroth, PP; Haring, HU			Thrombomodulin and coronary heart disease	LANCET			English	Editorial Material							CELLS		Univ Tubingen, Dept Med 4, Sect Vasc Med, D-72072 Tubingen, Germany	Eberhard Karls University of Tubingen	Nawroth, PP (corresponding author), Univ Tubingen, Dept Med 4, Sect Vasc Med, D-72072 Tubingen, Germany.							ESMON CT, 1995, FASEB J, V9, P946, DOI 10.1096/fasebj.9.10.7615164; Esmon CT, 1997, CIRCULATION, V96, P9; HEALY AM, 1995, P NATL ACAD SCI USA, V92, P850, DOI 10.1073/pnas.92.3.850; Hofmann MA, 1998, DIABETES CARE, V21, P841, DOI 10.2337/diacare.21.5.841; ISHII H, 1991, THROMB HAEMOSTASIS, V65, P618; JANSSON JM, 1977, CIRCULATION, V96, P2938; Zhang YM, 1998, J CLIN INVEST, V101, P1301, DOI 10.1172/JCI925	7	11	11	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAY 22	1999	353	9166					1722	1723		10.1016/S0140-6736(99)90039-9	http://dx.doi.org/10.1016/S0140-6736(99)90039-9			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	202TF	10347977				2022-12-28	WOS:000080667700002
J	Lo, B; Quill, T; Tulsky, J				Lo, B; Quill, T; Tulsky, J		ACP ASIM End Life Care Consensus Panel	Discussing palliative care with patients	ANNALS OF INTERNAL MEDICINE			English	Article							TERMINALLY ILL; DEPRESSION; PHYSICIANS; AUTONOMY	Palliative care focuses on relief of suffering, psychosocial support, and closure near the end of life. Even experienced physicians often struggle when initiating complex, emotionally laden discussions about palliative care with seriously ill patients and their families. We use two hypothetical case scenarios to illustrate how physicians can initiate these discussions and to emphasize and illustrate several communication techniques. Physicians can elicit a patient's concerns, goals, and values by using open-ended questions and following up on the patient's response before discussing specific clinical decisions. Physicians can acknowledge patients' emotions, explore the meaning of these emotions, and encourage patients to say more about difficult topics. Physicians should also screen for unaddressed spiritual and existential concerns. Some patients may make statements or ask questions that are difficult for physicians to respond to. We provide examples of responses that align the physician with patients' wishes without reinforcing unrealistic plans. Exploring such difficult issues may lessen feelings of aloneness even when the physician cannot "fix" the problem, and it raises new opportunities for patients to find comfort. In addition to addressing physical suffering, physicians can extend their caring by acknowledging and exploring psychosocial, existential, or spiritual suffering. As patients struggle to find closure in their lives, active listening and empathy have therapeutic value in and of themselves.	Amer Soc Internal Med, Amer Coll Phys, Ctr Eth Professionalism, Philadelphia, PA 19106 USA	American College of Physicians	Lo, B (corresponding author), Amer Soc Internal Med, Amer Coll Phys, Ctr Eth Professionalism, 190 N Independence Mall W, Philadelphia, PA 19106 USA.				NIMH NIH HHS [MH42459] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTH [P50MH042459] Funding Source: NIH RePORTER	NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		Billings J A, 1998, J Palliat Med, V1, P73, DOI 10.1089/jpm.1998.1.73; BLACKHALL LJ, 1995, JAMA-J AM MED ASSOC, V274, P820, DOI 10.1001/jama.274.10.820; Breitbart W., 1998, OXFORD TXB PALLIATIV, P933; BUCKMAN R, 1992, BREAK BAD NEWS, P98; Byock I, 1997, DYING WELL PROSPECT; CARRESE JA, 1995, JAMA-J AM MED ASSOC, V274, P826, DOI 10.1001/jama.274.10.826; Chochinov HM, 1997, AM J PSYCHIAT, V154, P674; CHRISTAKIS NA, 1994, J GEN INTERN MED, V9, P314, DOI 10.1007/BF02599178; Doyle D, 1998, OXFORD TXB PALLIATIV; Field MJ, 1997, APPROACHING DEATH IM; Foley KM, 1998, OXFORD TXB PALLIATIV, P310; KATHOL RG, 1990, AM J PSYCHIAT, V147, P1021; KNAUS WA, 1995, JAMA-J AM MED ASSOC, V274, P1591, DOI 10.1001/jama.1995.03530200027032; Levy MH, 1996, NEW ENGL J MED, V335, P1124, DOI 10.1056/NEJM199610103351507; Lipkin M, 1995, MED INTERVIEW; LO B, 1995, RESOLVING ETHICAL DI, P158; Maguire P, 1996, EUR J CANCER, V32A, P78, DOI 10.1016/0959-8049(95)00527-7; MATTHEWS DA, 1993, ANN INTERN MED, V118, P973, DOI 10.7326/0003-4819-118-12-199306150-00010; MONROE B, 1998, OXFORD TXB PALLIATIV, P867; *N CUMM FDN FETZ I, 1997, SPIR BEL DYING PROC; Quill TE, 1996, ANN INTERN MED, V125, P763, DOI 10.7326/0003-4819-125-9-199611010-00010; QUILL TE, 1995, ANN INTERN MED, V122, P368, DOI 10.7326/0003-4819-122-5-199503010-00008; Speck P., 1998, OXFORD TXB PALLIATIV, P805; Suchman AL, 1997, JAMA-J AM MED ASSOC, V277, P678, DOI 10.1001/jama.277.8.678; TULSKY JA, 1995, J GEN INTERN MED, V10, P436, DOI 10.1007/BF02599915; Tulsky JA, 1998, ANN INTERN MED, V129, P441, DOI 10.7326/0003-4819-129-6-199809150-00003	26	198	201	0	11	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAY 4	1999	130	9					744	749		10.7326/0003-4819-130-9-199905040-00015	http://dx.doi.org/10.7326/0003-4819-130-9-199905040-00015			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	192DE	10357694				2022-12-28	WOS:000080062300006
J	Nelson, JE				Nelson, JE			Saving lives and saving deaths	ANNALS OF INTERNAL MEDICINE			English	Editorial Material									CUNY Mt Sinai Sch Med, Med Intens Care Unit, New York, NY 10029 USA	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai	Nelson, JE (corresponding author), CUNY Mt Sinai Sch Med, Med Intens Care Unit, Box 1232,1 Gustave L Levy Pl, New York, NY 10029 USA.	jnelson@smtplink.mssm.edu							0	18	19	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAY 4	1999	130	9					776	777		10.7326/0003-4819-130-9-199905040-00020	http://dx.doi.org/10.7326/0003-4819-130-9-199905040-00020			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	192DE	10357699				2022-12-28	WOS:000080062300011
J	Brugnara, C; Zurakowski, D; DiCanzio, J; Boyd, T; Platt, O				Brugnara, C; Zurakowski, D; DiCanzio, J; Boyd, T; Platt, O			Reticulocyte hemoglobin content to diagnose iron deficiency in children	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							RECOMBINANT-HUMAN-ERYTHROPOIETIN; SOLUBLE TRANSFERRIN RECEPTOR; HEMODIALYSIS-PATIENTS; ZINC PROTOPORPHYRIN; CELLULAR INDEXES; CLINICAL UTILITY; LABORATORY TESTS; SERUM FERRITIN; MICROCYTOSIS; DISORDERS	Context Early identification of iron deficiency in children is essential to prevent the damaging long-term consequences of this disease. However, it is not clear which indices should be included in a diagnostic panel for iron deficiency and iron deficiency anemia in children. Objective To develop an effective approach for the diagnosis of iron deficiency and iron deficiency anemia in young children. Design and Setting Retrospective laboratory analysis, carried out over 7 weeks in 1996, using blood samples ordered by pediatricians and sent to a large metropolitan hospital for analysis. Patients A total of 210 children (mean [SD] age, 2.9 [2.0] years; 120 were male) who had a lead screening test (complete blood cell count and plasma lead level) ordered by a primary care pediatrician. Main Outcome Measures Levels of hemoglobin (Hb), iron, transferrin, transferrin saturation (Tfsat), ferritin, and circulating transferrin receptor and reticulocyte Hb content (CHr) among patients with and without iron deficiency, defined as Tfsat of less than 20%, and iron deficiency anemia, defined as Tfsat of less than 20% and Hb level of less than 110 g/L. Results Of the 210 subjects, 43 (20.5%) were iron deficient; 24 of these had iron deficiency anemia. Reticulocyte Hb content and Hb levels were the only significant predictors of iron deficiency (likelihood ratio test [LRT] = 15.96; P<.001 for CHr, and LRT=6.59; P=.01 for Hb), and CHr was the only significant multivariate predictor of iron deficiency anemia (LRT = 30.43; P<.001). Plasma ferritin level had no predictive value (P=.97), Subjects with CHr of less than 26 pg (optimal cutoff value based on sensitivity/specificity analysis) had lower Hb level, mean corpuscular volume, mean corpuscular Hb level, serum iron level, and Tfsat, and increased red blood cell distribution width vs those with CHr of 26 pg or more (P<.001 for all). Conclusions Reticulocyte Hb content level was the strongest predictor of iron deficiency and iron deficiency anemia in children. It holds promise as an alternative to biochemical iron studies in diagnosis.	Harvard Univ, Childrens Hosp, Sch Med, Dept Lab Med, Boston, MA 02115 USA; Harvard Univ, Childrens Hosp, Sch Med, Dept Pathol, Boston, MA 02115 USA; Harvard Univ, Childrens Hosp, Sch Med, Dept Med, Boston, MA 02115 USA; Harvard Univ, Childrens Hosp, Sch Med, Dept Biostat, Boston, MA 02115 USA; Baystate Med Ctr, Springfield, MA USA	Harvard University; Boston Children's Hospital; Harvard Medical School; Harvard University; Boston Children's Hospital; Harvard Medical School; Harvard University; Boston Children's Hospital; Harvard Medical School; Harvard University; Boston Children's Hospital; Harvard Medical School; Baystate Medical Center	Brugnara, C (corresponding author), Harvard Univ, Childrens Hosp, Sch Med, Dept Lab Med, 300 Longwood Ave,Bader 760, Boston, MA 02115 USA.		Brugnara, Carlo/A-8041-2010	Brugnara, Carlo/0000-0001-8192-8713				Bhandari S, 1997, AM J KIDNEY DIS, V30, P814, DOI 10.1016/S0272-6386(97)90087-1; BRUGNARA C, 1994, J LAB CLIN MED, V123, P660; BRUGNARA C, 1994, BLOOD, V83, P3100, DOI 10.1182/blood.V83.10.3100.3100; BRUGNARA C, 1994, AM J CLIN PATHOL, V102, P623, DOI 10.1093/ajcp/102.5.623; Brugnara C, 1998, INT J CLIN LAB RES, V28, P1, DOI 10.1007/s005990050011; Bruner AB, 1996, LANCET, V348, P992, DOI 10.1016/S0140-6736(96)02341-0; BURNS ER, 1990, AM J CLIN PATHOL, V93, P240, DOI 10.1093/ajcp/93.2.240; Buttarello M, 1995, ARCH PATHOL LAB MED, V119, P1141; Cazzola M, 1997, BLOOD, V89, P4248, DOI 10.1182/blood.V89.12.4248; DALLMAN PR, 1981, J PEDIATR, V98, P376; DONOFRIO G, 1992, ARCH PATHOL LAB MED, V116, P84; DONOFRIO G, 1995, BLOOD, V85, P818, DOI 10.1182/blood.V85.3.818.bloodjournal853818; FAIRBANKS VF, 1991, HOSP PRACT, V26, P17; FERGUSON BJ, 1992, J LAB CLIN MED, V119, P385; Fishbane S, 1997, KIDNEY INT, V52, P217, DOI 10.1038/ki.1997.323; GREEN R, 1991, HOSP PRACT, V26, P25; HALLBERG L, 1993, BRIT J HAEMATOL, V85, P787, DOI 10.1111/j.1365-2141.1993.tb03225.x; HANLEY JA, 1982, RADIOLOGY, V143, P29, DOI 10.1148/radiology.143.1.7063747; Hastka J, 1996, CLIN CHEM, V42, P718; HASTKA J, 1994, CLIN CHEM, V40, P768; KAIRISTO V, 1995, SCAND J CLIN LAB INV, V55, P43, DOI 10.3109/00365519509088450; Lafferty JD, 1996, AM J CLIN PATHOL, V106, P201; Looker AC, 1997, JAMA-J AM MED ASSOC, V277, P973, DOI 10.1001/jama.277.12.973; LOZOFF B, 1991, NEW ENGL J MED, V325, P687, DOI 10.1056/NEJM199109053251004; Mast AE, 1998, CLIN CHEM, V44, P45; Mittman N, 1997, AM J KIDNEY DIS, V30, P912, DOI 10.1016/S0272-6386(97)90104-9; OSKI FA, 1993, NEW ENGL J MED, V329, P190, DOI 10.1056/NEJM199307153290308; osmer D. W, 1989, APPL LOGISTIC REGRES, P38; PIZARRO F, 1991, J PEDIATR-US, V118, P687, DOI 10.1016/S0022-3476(05)80027-7; ROOT CB, 1998, CODEMAP 98 LAB PATHO; SIEGEL RM, 1994, CLIN PEDIATR, V33, P473, DOI 10.1177/000992289403300805; SKIKNE BS, 1990, BLOOD, V75, P1870; Suominen P, 1997, CLIN CHEM, V43, P1641; ZAR JH, 1996, BIOSTAT ANAL, P474	34	165	178	1	5	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 16	1999	281	23					2225	2230		10.1001/jama.281.23.2225	http://dx.doi.org/10.1001/jama.281.23.2225			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	204RB	10376576	Bronze			2022-12-28	WOS:000080777000037
J	Pathak, S				Pathak, S			An incident which changed my medical life - Something to celebrate	BRITISH MEDICAL JOURNAL			English	Article																			0	0	0	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JUN 12	1999	318	7198					1609	1609		10.1136/bmj.318.7198.1609	http://dx.doi.org/10.1136/bmj.318.7198.1609			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	207AL	10364126	Green Published			2022-12-28	WOS:000080913100035
J	Weidle, PJ; Mbidde, E; Djomand, G; Lackritz, EM				Weidle, PJ; Mbidde, E; Djomand, G; Lackritz, EM			Relevance of AIDS treatment with two nucleoside analogues alone	LANCET			English	Editorial Material							INFECTION; MORTALITY		Ctr Dis Control & Prevent, Div HIV AIDS Prevent Surveillance & Epidemiol, Natl Ctr HIV STD & TB Prevent, Atlanta, GA 30333 USA; Projet RETRO CI, Abidjan, Cote Ivoire; Uganda Canc Inst, Kampala, Uganda	Centers for Disease Control & Prevention - USA	Weidle, PJ (corresponding author), Ctr Dis Control & Prevent, Div HIV AIDS Prevent Surveillance & Epidemiol, Natl Ctr HIV STD & TB Prevent, Atlanta, GA 30333 USA.			Lackritz, Eve/0000-0002-5397-7291				[Anonymous], 1998, MMWR Recomm Rep, V47, P1; CAMERON B, 1998, 3 C RETR OPP INF WAS; Carpenter CCJ, 1997, JAMA-J AM MED ASSOC, V277, P1962, DOI 10.1001/jama.277.24.1962; *CDCP, 1998, HIV AIDS SURVEILLANC, V10, P1; CHOO V, 1995, LANCET, V346, P895, DOI 10.1016/S0140-6736(95)92725-5; Forsythe SS, 1998, AIDS, V12, pS11; Gilks C F, 1997, AIDS, V11 Suppl B, pS99; GULICK R, 1998, 3 C RETR OPP INF WAS; HAMMER S, 1995, 35 INT C ANT AG CHEM; Mocroft A, 1998, LANCET, V352, P1725, DOI 10.1016/S0140-6736(98)03201-2; Palella FJ, 1998, NEW ENGL J MED, V338, P853, DOI 10.1056/NEJM199803263381301	11	4	4	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUN 12	1999	353	9169					1989	1990		10.1016/S0140-6736(99)00161-0	http://dx.doi.org/10.1016/S0140-6736(99)00161-0			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	205GD	10376610				2022-12-28	WOS:000080812200005
J	Czerwenka, W; Gruenwald, C; Conen, D				Czerwenka, W; Gruenwald, C; Conen, D			Aseptic meningitis after treatment with amoxicillin	BRITISH MEDICAL JOURNAL			English	Letter							THERAPY		Canton Hosp, Dept Internal Med, CH-5001 Aarau, Switzerland		Czerwenka, W (corresponding author), Canton Hosp, Dept Internal Med, CH-5001 Aarau, Switzerland.							Dang CT, 1996, CLIN INFECT DIS, V22, P729, DOI 10.1093/clinids/22.4.729; Durand JM, 1996, BRIT MED J, V312, P886; RIVER Y, 1994, J NEUROL NEUROSUR PS, V57, P705, DOI 10.1136/jnnp.57.6.705; SEKUL EA, 1994, ANN INTERN MED, V121, P259, DOI 10.7326/0003-4819-121-4-199408150-00004; WEKSLER BB, 1991, DICP ANN PHARMAC, V25, P1183, DOI 10.1177/106002809102501106	5	13	13	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JUN 5	1999	318	7197					1521	1521		10.1136/bmj.318.7197.1521	http://dx.doi.org/10.1136/bmj.318.7197.1521			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	204HC	10356006	Green Published, Bronze, Green Submitted			2022-12-28	WOS:000080757300025
J	King, DS; Sharp, RL; Vukovich, MD; Brown, GA; Reifenrath, TA; Uhl, NL; Parsons, KA				King, DS; Sharp, RL; Vukovich, MD; Brown, GA; Reifenrath, TA; Uhl, NL; Parsons, KA			Effect of oral androstenedione on serum testosterone and adaptations to resistance training in young men - A randomized controlled trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							DENSITY LIPOPROTEIN CHOLESTEROL; ANABOLIC-STEROIDS; PROSTATIC-CANCER; BODY-COMPOSITION; BLOOD-PRESSURE; HORMONE LEVELS; MUSCLE; AROMATIZATION; ANDROGENS; AGE	Context Androstenedione, a precursor to testosterone, is marketed to increase blood testosterone concentrations as a natural alternative to anabolic steroid use. However, whether androstenedione actually increases blood testosterone levels or produces anabolic androgenic effects is not known. Objectives To determine if short- and long-term oral androstenedione supplementation in men increases serum testosterone levels and skeletal muscle fiber size and strength and to examine its effect on blood lipids and markers of liver function. Design and Setting Eight-week randomized controlled trial conducted between February and June 1998, Participants Thirty healthy, normotestosterogenic men (aged 19-29 years) not taking any nutritional supplements or androgenic-anabolic steroids or engaged in resistance training. Interventions Twenty subjects performed 8 weeks of whole-body resistance training. During weeks 1, 2, 4, 5, 7, and 8, the men were randomized to either androstenedione, 300 mg/d (n =10), or placebo (n = 10). The effect of a single 100-mg androstenedione dose on serum testosterone and estrogen concentrations was determined in 10 men, Main Outcome Measures Changes in serum testosterone and estrogen concentrations, muscle strength, muscle fiber cross-sectional area, body composition, blood lipids, and liver transaminase activities based on assessments before and after short- and long-term androstenedione administration. Results Serum free and total testosterone concentrations were not affected by short- or long-term androstenedione administration. Serum estradiol concentration (mean [SEM]) was higher (P<.05) in the androstenedione group after 2 (310 [20] pmol/L), 5 (300 [30] pmol/L), and 8 (280 [20] pmol/L) weeks compared with presupplementation values (220 [20] pmol/L). The serum estrone concentration was significantly higher (P<.05) after 2 (153 [12] pmol/L) and 5 (142 [15] pmol/L) weeks of androstenedione supplementation compared with baseline (106 [11] pmol/L), Knee extension strength increased significantly (P<.05) and similarly in the placebo (770 [55] N vs 1095 [52] N) and androstenedione (717 [46] N vs 1024 [57] N) groups, The increase of the mean cross-sectional area of type 2 muscle fibers was also similar in androstenedione (4703 [471] vs 5307 [604] mm(2); P<.05) and placebo (5271 [485] vs 5728 [451] mm(2); P<.05) groups, The significant (P<.05) increases in lean body mass and decreases in fat mass were also not different in the androstenedione and placebo groups. In the androstenedione group, the serum high-density lipoprotein cholesterol concentration was reduced after 2 weeks (1.09 [0.08] mmol/L [42 (3) mg/dL] vs 0.96 [0.08] mmol/L [37 (3) mg/dL]; P<.05) and remained low after 5 and 8 weeks of training and supplementation. Conclusions Androstenedione supplementation does not increase serum testosterone concentrations or enhance skeletal muscle adaptations to resistance training in normotestosterogenic young men and may result in adverse health consequences.	Iowa State Univ, Dept Hlth & Human Performance, Exercise Biochem Lab, Ames, IA 50011 USA; Expt & Appl Sci, Golden, CO USA	Iowa State University	King, DS (corresponding author), Iowa State Univ, Dept Hlth & Human Performance, Exercise Biochem Lab, 248 Forker Bldg, Ames, IA 50011 USA.		King, Douglas S/H-2539-2017	King, Douglas S/0000-0001-8497-6913; Vukovich, Matthew/0000-0001-6621-8588; Sharp, Rick/0000-0002-4637-6156				ALEN M, 1985, INT J SPORTS MED, V6, P139, DOI 10.1055/s-2008-1025827; ALEN M, 1988, SPORTS MED, V6, P327, DOI 10.2165/00007256-198806060-00001; ALEN M, 1984, ACTA PHYSIOL SCAND, V122, P535, DOI 10.1111/j.1748-1716.1984.tb07542.x; ALEN M, 1987, AM J SPORT MED, V15, P357, DOI 10.1177/036354658701500411; ANDERSSON SO, 1993, BRIT J CANCER, V68, P97, DOI 10.1038/bjc.1993.293; BARRETTCONNOR E, 1990, CANCER RES, V50, P169; BERGSTROM J, 1967, SCAND J CLIN LAB I S, V17, P68; Bhasin S, 1996, NEW ENGL J MED, V335, P1, DOI 10.1056/NEJM199607043350101; Cauley JA, 1999, ANN INTERN MED, V130, P270, DOI 10.7326/0003-4819-130-4_Part_1-199902160-00004; CHAPDELAINE A, 1969, J CLIN INVEST, V48, P2063, DOI 10.1172/JCI106172; COSTILL DL, 1984, PHYSICIAN SPORTSMED, V12, P113; DOWBEN RM, 1958, J CLIN ENDOCR METAB, V18, P1308, DOI 10.1210/jcem-18-11-1308; EPSTEIN BJ, 1966, CAN J BIOCHEM CELL B, V44, P971, DOI 10.1139/o66-113; FERNANDEZDELCASTILLO C, 1990, PANCREAS, V5, P515, DOI 10.1097/00006676-199009000-00003; FORNEY JP, 1981, J CLIN ENDOCR METAB, V53, P192, DOI 10.1210/jcem-53-1-192; FOSS GL, 1957, JAMA-J AM MED ASSOC, V164, P486; FREED DL, 1975, BRIT MED J, V31, P471; Fyssas I, 1997, HORM METAB RES, V29, P115, DOI 10.1055/s-2007-979002; GARDNER FH, 1961, ARCH INTERN MED, V107, P112; GOLDMAN HI, 1959, AM REV TUBERC PULM, V79, P457; GORDON DJ, 1989, CIRCULATION, V79, P8, DOI 10.1161/01.CIR.79.1.8; GRUNDY SM, 1993, JAMA-J AM MED ASSOC, V269, P3015, DOI 10.1001/jama.269.23.3015; HACKER R, 1995, Patent No. 4214953; HAFFNER SM, 1983, METABOLISM, V32, P413, DOI 10.1016/0026-0495(83)90052-5; HERVEY GR, 1981, CLIN SCI, V60, P457, DOI 10.1042/cs0600457; HORTON R, 1966, J CLIN INVEST, V45, P301, DOI 10.1172/JCI105344; HURLEY BF, 1984, JAMA-J AM MED ASSOC, V252, P507, DOI 10.1001/jama.252.4.507; KANTOR MA, 1985, MED SCI SPORT EXER, V17, P462, DOI 10.1249/00005768-198508000-00010; KUIPERS H, 1991, INT J SPORTS MED, V12, P413, DOI 10.1055/s-2007-1024704; LENDERS JWM, 1988, INT J SPORTS MED, V9, P19, DOI 10.1055/s-2007-1024972; Lewin ML, 1941, J CLIN ENDOCRINOL, V1, P511, DOI 10.1210/jcem-1-6-511; LEWIS JG, 1976, ACTA ENDOCRINOL-COP, V82, P444; LONGCOPE C, 1978, J CLIN ENDOCR METAB, V46, P146, DOI 10.1210/jcem-46-1-146; LONGCOPE C, 1969, J CLIN INVEST, V48, P2191, DOI 10.1172/JCI106185; MACDONALD PC, 1967, J CLIN ENDOCR METAB, V27, P1103, DOI 10.1210/jcem-27-8-1103; MAHESH VB, 1962, ACTA ENDOCRINOL-COP, V41, P400, DOI 10.1530/acta.0.0410400; MATSUMINE H, 1986, J CLIN ENDOCR METAB, V63, P717, DOI 10.1210/jcem-63-3-717; PETERSON GE, 1984, PHYSICIAN SPORTSMED, V12, P120; PHILLIPS GB, 1996, ARTERIOSCLER THROMB, V16, P13583; RANDALL VA, 1982, J ENDOCRINOL, V93, P253, DOI 10.1677/joe.0.0930253; SAVARD K, 1961, J CLIN ENDOCR METAB, V21, P165, DOI 10.1210/jcem-21-2-165; Siri W., 1961, TECHNIQUES MEASURING, P223; STAMFORD BA, 1974, J SPORT MED PHYS FIT, V14, P191; THOMAS PZ, 1964, J BIOL CHEM, V239, P762; VANDERMOLEN HJ, 1968, ACTA ENDOCRINOL-COP, V58, P419; ZUMOFF B, 1982, J CLIN ENDOCR METAB, V54, P534, DOI 10.1210/jcem-54-3-534	46	143	149	1	7	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 2	1999	281	21					2020	2028		10.1001/jama.281.21.2020	http://dx.doi.org/10.1001/jama.281.21.2020			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	200NN	10359391	Bronze			2022-12-28	WOS:000080546700032
J	Stewart, P				Stewart, P			Exposure assessment in community-based epidemiological studies	LANCET			English	Editorial Material									NCI, Occupat Epidemiol Branch, Rockville, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Stewart, P (corresponding author), NCI, Occupat Epidemiol Branch, Rockville, MD 20892 USA.							Benke G, 1997, INT J EPIDEMIOL, V26, P635, DOI 10.1093/ije/26.3.635; KROMHOUT H, 1987, AM J IND MED, V12, P551, DOI 10.1002/ajim.4700120509; STEWART WF, 1994, AM J IND MED, V26, P297, DOI 10.1002/ajim.4700260304; Tielemans E, 1999, OCCUP ENVIRON MED, V56, P145, DOI 10.1136/oem.56.3.145	4	6	6	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAY 29	1999	353	9167					1816	1817		10.1016/S0140-6736(99)90075-2	http://dx.doi.org/10.1016/S0140-6736(99)90075-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	202TG	10359403				2022-12-28	WOS:000080667800006
J	Stringer, JSA; Rouse, DJ; Goldenberg, RL				Stringer, JSA; Rouse, DJ; Goldenberg, RL			Prophylactic cesarean delivery for the prevention of perinatal human immunodeficiency virus transmission - The case for restraint	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							MOTHER-TO-CHILD; ANTIRETROVIRAL THERAPY; CONTROLLED TRIALS; HIV-INFECTION; ZIDOVUDINE; PREECLAMPSIA; INDINAVIR; MORTALITY; CALCIUM; SECTION		Univ Alabama Birmingham, Ctr Res Womens Hlth, Dept Obstet & Gynecol, Birmingham, AL 35233 USA	University of Alabama System; University of Alabama Birmingham	Stringer, JSA (corresponding author), Univ Alabama Birmingham, Ctr Res Womens Hlth, Dept Obstet & Gynecol, 618 S 20th St,340 OHB, Birmingham, AL 35233 USA.	uabobgyn@aol.com	Stringer, Jeffrey S. A./AAU-2342-2021	Stringer, Jeffrey/0000-0002-9590-7216				Andiman W, 1999, NEW ENGL J MED, V340, P977, DOI 10.1056/NEJM199904013401301; [Anonymous], 1998, MMWR Recomm Rep, V47, P1; Bailar JC, 1999, NEW ENGL J MED, V340, P958, DOI 10.1056/NEJM199903253401211; BEROYZ G, 1994, LANCET, V343, P619; Birchard K, 1998, LANCET, V352, P796, DOI 10.1016/S0140-6736(05)60698-8; BROSSARD Y, 1995, AIDS, V9, P359, DOI 10.1097/00002030-199509040-00007; Bucher HC, 1996, JAMA-J AM MED ASSOC, V275, P1113, DOI 10.1001/jama.275.14.1113; Carpenter CCJ, 1998, JAMA-J AM MED ASSOC, V280, P78, DOI 10.1001/jama.280.1.78; Dabis F, 1999, LANCET, V353, P786, DOI 10.1016/S0140-6736(98)11046-2; Dickover RE, 1996, JAMA-J AM MED ASSOC, V275, P599, DOI 10.1001/jama.275.8.599; DUNN J, 1994, PROF ENG, V7, P10; Fiscus SA, 1996, JAMA-J AM MED ASSOC, V275, P1483, DOI 10.1001/jama.275.19.1483; Gulick RM, 1997, NEW ENGL J MED, V337, P734, DOI 10.1056/NEJM199709113371102; Hammer SM, 1997, NEW ENGL J MED, V337, P725, DOI 10.1056/NEJM199709113371101; HAVERKAMP AD, 1979, AM J OBSTET GYNECOL, V134, P399, DOI 10.1016/S0002-9378(16)33082-4; IMPERIALE T F, 1991, Journal of the American Medical Association, V266, P260, DOI 10.1001/jama.266.2.260; KIND C, 1995, EUR J PEDIATR, V154, P542, DOI 10.1007/s004310050339; Landesman SH, 1996, NEW ENGL J MED, V334, P1617, DOI 10.1056/NEJM199606203342501; LeLorier J, 1997, NEW ENGL J MED, V337, P536, DOI 10.1056/NEJM199708213370806; Levine RJ, 1997, NEW ENGL J MED, V337, P69, DOI 10.1056/NEJM199707103370201; Mandelbrot L, 1996, AM J OBSTET GYNECOL, V175, P661; Mandelbrot L, 1998, JAMA-J AM MED ASSOC, V280, P55, DOI 10.1001/jama.280.1.55; Mayaux MJ, 1997, J PEDIATR-US, V131, P857, DOI 10.1016/S0022-3476(97)70033-7; MORRIS A, 1999, 6 C RETR OPP INF JAN; MSELLATI P, 1995, J ACQ IMMUN DEF SYND, V8, P506; NEWELL ML, 1994, LANCET, V343, P1464; O'Sullivan M. J., 1999, American Journal of Obstetrics and Gynecology, V180, pS105; Palella FJ, 1998, NEW ENGL J MED, V338, P853, DOI 10.1056/NEJM199803263381301; Parazzini F, 1999, LANCET, V353, P1035, DOI 10.1016/S0140-6736(98)08084-2; READ J, 1999, 6 C RETR OPP INF JAN; Schuitemaker N, 1997, ACTA OBSTET GYN SCAN, V76, P332, DOI 10.1111/j.1600-0412.1997.tb07987.x; SEMPRINI AE, 1995, AIDS, V9, P913, DOI 10.1097/00002030-199508000-00013; Shaffer N, 1999, LANCET, V353, P773, DOI 10.1016/S0140-6736(98)10411-7; Simonds RJ, 1998, AIDS, V12, P301, DOI 10.1097/00002030-199803000-00008; STEK A, 1999, AM J OBSTET GYNECOL, V180, pS6; THACKER SB, 1995, OBSTET GYNECOL, V86, P613, DOI 10.1016/0029-7844(95)00232-G; THOMAS PA, 1994, PEDIATR INFECT DIS J, V13, P489, DOI 10.1097/00006454-199406000-00005; Tovo PA, 1996, J ACQ IMMUN DEF SYND, V11, P88, DOI 10.1097/00042560-199601010-00012; U.S. Preventive Service Task Force, 1989, GUID CLIN PREV SERV; WATTS H, 1999, 6 C RETR OPP INF JAN; Wiktor SZ, 1999, LANCET, V353, P781, DOI 10.1016/S0140-6736(98)10412-9	41	35	35	0	1	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 26	1999	281	20					1946	1949		10.1001/jama.281.20.1946	http://dx.doi.org/10.1001/jama.281.20.1946			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	198ME	10349900				2022-12-28	WOS:000080427300036
J	Falkenburg, JHF; Kluin-Nelemans, HC				Falkenburg, JHF; Kluin-Nelemans, HC			Mismatched transplants for refractory lymphoma?	LANCET			English	Editorial Material							BONE-MARROW TRANSPLANTATION; STEM-CELL TRANSPLANTATION; CHRONIC MYELOID-LEUKEMIA; T-CELL; CHEMOTHERAPY; MALIGNANCY; INFUSIONS		Leiden Univ, Med Ctr, Dept Haematol, NL-2300 RC Leiden, Netherlands	Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC	Falkenburg, JHF (corresponding author), Leiden Univ, Med Ctr, Dept Haematol, NL-2300 RC Leiden, Netherlands.		Kluin-Nelemans, Johanna C/F-8658-2018	Kluin-Nelemans, Johanna C/0000-0003-2617-9427				BACHARLUSTIG E, 1995, NAT MED, V1, P1268, DOI 10.1038/nm1295-1268; Collins RH, 1997, J CLIN ONCOL, V15, P433, DOI 10.1200/JCO.1997.15.2.433; Falkenburg JHF, 1997, IMMUNOL REV, V157, P223, DOI 10.1111/j.1600-065X.1997.tb00985.x; FISHER RI, 1982, CANCER RES, V42, P2465; Goulmy E, 1997, IMMUNOL REV, V157, P125, DOI 10.1111/j.1600-065X.1997.tb00978.x; Khouri IF, 1998, J CLIN ONCOL, V16, P2817, DOI 10.1200/JCO.1998.16.8.2817; KLIMO P, 1985, ANN INTERN MED, V102, P596, DOI 10.7326/0003-4819-102-5-596; KOLB HJ, 1995, BLOOD, V86, P2041, DOI 10.1182/blood.V86.5.2041.bloodjournal8652041; Slavin S, 1998, BLOOD, V91, P756, DOI 10.1182/blood.V91.3.756.756_756_763; Smit WM, 1998, P NATL ACAD SCI USA, V95, P10152, DOI 10.1073/pnas.95.17.10152	10	1	1	0	2	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAY 22	1999	353	9166					1725	1726		10.1016/S0140-6736(98)00402-4	http://dx.doi.org/10.1016/S0140-6736(98)00402-4			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	202TF	10347980				2022-12-28	WOS:000080667700005
J	Kogevinas, M; Anto, JM; Sunyer, J; Tobias, A; Kromhout, H; Burney, P				Kogevinas, M; Anto, JM; Sunyer, J; Tobias, A; Kromhout, H; Burney, P		European Community Resp Hlth Survey Study Grp	Occupational asthma in Europe and other industrialised areas: a population-based study	LANCET			English	Article							RESPIRATORY-HEALTH-SURVEY; BRONCHIAL RESPONSIVENESS; GENERAL-POPULATION; EXPOSURE; QUESTIONNAIRE; CHLORINE; SYMPTOMS; SPAIN; RISK	Background. There are no large population-based studies on occupational asthma, and few estimates of the proportion of asthma attributed to occupation, even though asthma is the most common occupational respiratory disorder in industrialised countries. Methods. We assessed data on 15637 people aged 20-44, randomly selected from the general population of 26 areas in 12 industrialised countries. Asthma was assessed by methacholine challenge test and by questionnaire data on respiratory symptoms and use of medication. Occupation was defined by job-titles and a job exposure matrix was constructed. Findings. Highest risk of asthma, defined as bronchial hyperresponsiveness and reported asthma symptoms or medication, was shown for farmers (odds ratio 2.62 [95% Cl 1.29-5.35]), painters (2.34 [1.04-5.28]), plastic workers (2.20 [0.59-8.29]), cleaners (1.97 [1.33-2.92]), spray painters (1.96 [0.72-5.34]), and agricultural workers (1.79 [1.02-3.16]). Similar risks were shown for asthma defined as reported asthma symptoms or medication. The most consistent results across countries were shown for farmers and cleaners. Excess asthma risk was associated with high exposure to biological dusts, mineral dusts, and gases and fumes. The proportion of asthma among young adults attributed to occupation was 5%-10%. Interpretation. The prevalence of occupational asthma in women and in specific occupations has been underestimated. Given a mean prevalence of asthma of about 5%, about 0.2%-0.5% of young adults become asthmatics or have their asthma exacerbated because of their occupations.	Inst Municipal Invest Med, Resp & Environm Hlth Res Unit, Barcelona 08003, Spain; Agr Univ Wageningen, Environm & Occupat Hlth Grp, Wageningen, Netherlands; Guys & St Thomass Med & Dent Sch, Dept Publ Hlth Med, London, England	Wageningen University & Research; University of London; King's College London	Kogevinas, M (corresponding author), Inst Municipal Invest Med, Resp & Environm Hlth Res Unit, 80 Doctor Aiguador Rd, Barcelona 08003, Spain.		Kromhout, Hans/A-9159-2008; Kogevinas, Manolis/C-3918-2017; Tobias, Aurelio/ABE-5682-2020; Anto, J M/H-2676-2014; Sunyer, Jordi/G-6909-2014	Kromhout, Hans/0000-0002-4233-1890; Kogevinas, Manolis/0000-0002-9605-0461; Tobias, Aurelio/0000-0001-6428-6755; Anto, J M/0000-0002-4736-8529; Sunyer, Jordi/0000-0002-2602-4110; Burney, Peter/0000-0001-8635-5678	NATIONAL CENTER FOR RESEARCH RESOURCES [S07RR005521] Funding Source: NIH RePORTER; NCRR NIH HHS [2 S07 RR05521-28] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		Bernstein David I., 1993, P103; BERNSTEIN JA, 1994, J ALLERGY CLIN IMMUN, V94, P257, DOI 10.1016/0091-6749(94)90048-5; BHERER L, 1994, OCCUP ENVIRON MED, V51, P225, DOI 10.1136/oem.51.4.225; BLANC P, 1987, CHEST, V92, P613, DOI 10.1378/chest.92.4.613; BRUZZI P, 1985, AM J EPIDEMIOL, V122, P904, DOI 10.1093/oxfordjournals.aje.a114174; BURGE PS, 1994, THORAX, V49, P842, DOI 10.1136/thx.49.8.842; Burney P, 1996, EUR RESPIR J, V9, P687; Burney P, 1997, J ALLERGY CLIN IMMUN, V99, P314, DOI 10.1016/S0091-6749(97)70048-4; BURNEY PGJ, 1994, EUR RESPIR J, V7, P954, DOI 10.1183/09031936.94.07050954; CHANYEUNG M, 1994, AM J RESP CRIT CARE, V149, P1676, DOI 10.1164/ajrccm.149.6.8004329; Checkoway H., 1989, RES METHODS OCCUPATI; Chinn S, 1997, EUR RESPIR J, V10, P2495, DOI 10.1183/09031936.97.10112495; DAVID AP, 1976, BIOMETRICS, V32, P647; Fishwick D, 1997, OCCUP ENVIRON MED, V54, P301, DOI 10.1136/oem.54.5.301; Jenkins MA, 1996, INT J EPIDEMIOL, V25, P609, DOI 10.1093/ije/25.3.609; KOBAYASHI S, 1974, ALLERGOLOGIE, P124; Kogevinas M, 1996, AM J RESP CRIT CARE, V154, P137, DOI 10.1164/ajrccm.154.1.8680669; KRZYZANOWSKI M, 1988, INT J EPIDEMIOL, V17, P397, DOI 10.1093/ije/17.2.397; Leroyer C, 1998, OCCUP ENVIRON MED, V55, P356, DOI 10.1136/oem.55.5.356; MEREDITH S, 1993, J EPIDEMIOL COMMUN H, V47, P459, DOI 10.1136/jech.47.6.459; NEMERY B, 1996, EUR RESPIR J, V10, P1977; NG TP, 1994, AM J IND MED, V25, P709, DOI 10.1002/ajim.4700250510; Nielsen J, 1996, CONTACT DERMATITIS, V34, P284, DOI 10.1111/j.1600-0536.1996.tb02201.x; REILLY MJ, 1995, ARCH ENVIRON HEALTH, V50, P26, DOI 10.1080/00039896.1995.9955009; STINGENI L, 1995, CONTACT DERMATITIS, V33, P172, DOI 10.1111/j.1600-0536.1995.tb00540.x; Sunyer J, 1998, AM J RESP CRIT CARE, V157, P512, DOI 10.1164/ajrccm.157.2.9705029; VENABLES KM, 1987, BRIT J IND MED, V44, P73; Venables KM, 1997, LANCET, V349, P1465, DOI 10.1016/S0140-6736(96)07219-4; VIEGI G, 1991, AM REV RESPIR DIS, V143, P510, DOI 10.1164/ajrccm/143.3.510; XU XP, 1993, CHEST, V104, P1364, DOI 10.1378/chest.104.5.1364	30	329	335	0	22	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAY 22	1999	353	9166					1750	1754		10.1016/S0140-6736(98)07397-8	http://dx.doi.org/10.1016/S0140-6736(98)07397-8			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	202TF	10347988				2022-12-28	WOS:000080667700013
J	Xu, QL; Mellitzer, G; Robinson, V; Wilkinson, DG				Xu, QL; Mellitzer, G; Robinson, V; Wilkinson, DG			In vivo cell sorting in complementary segmental domains mediated by Eph receptors and ephrins	NATURE			English	Article							CHICK-EMBRYO HINDBRAIN; TYROSINE KINASE; TRANSMEMBRANE LIGANDS; ADHESION MOLECULES; GENE-EXPRESSION; SEK-1; PHOSPHORYLATION; SPECIFICITY; RESTRICTION; KROX-20	The restriction of intermingling between specific cell populations is crucial for the maintenance of organized patterns during development. A striking example is the restriction of cell mixing between segments in the insect epidermis' and the vertebrate hindbrain(2) that may enable each segment to maintain a distinct identity. In the hindbrain, this is a result of different adhesive properties of odd- and even-numbered segments (rhombomeres)(3,4), but an adhesion molecule with alternating segmental expression has not been found. However, blocking experiments suggest that Eph-receptor tyrosine kinases may be required for the segmental restriction of cells(5). Eph receptors and their membrane-bound ligands, ephrins, are expressed in complementary rhombomeres(6) and, by analogy with their roles in axon pathfinding(7,8), could mediate cell repulsion at boundaries. Remarkably, transmembrane ephrins can themselves transduce signals(9,10), raising the possibility that bi-directional signalling occurs between adjacent ephrin- and Eph-receptor-expressing cells. We report here that mosaic activation of Eph receptors leads to sorting of cells to boundaries in odd-numbered rhombomeres, whereas mosaic activation of ephrins results in sorting to boundaries in even-numbered rhombomeres. These data implicate Eph receptors and ephrins in the segmental restriction of cell intermingling.	Natl Inst Med Res, Div Dev Neurobiol, London NW7 1AA, England	MRC National Institute for Medical Research	Wilkinson, DG (corresponding author), Natl Inst Med Res, Div Dev Neurobiol, Ridgeway,Mill Hill, London NW7 1AA, England.		Georg, Mellitzer/R-4180-2016	Georg, Mellitzer/0000-0003-4467-0789; Wilkinson, David/0000-0001-6757-7080				Bruckner K, 1997, SCIENCE, V275, P1640, DOI 10.1126/science.275.5306.1640; Ellis C, 1996, ONCOGENE, V12, P1727; Flanagan JG, 1998, ANNU REV NEUROSCI, V21, P309, DOI 10.1146/annurev.neuro.21.1.309; Flanagan JG, 1997, CELL, V90, P403; FRASER S, 1990, NATURE, V344, P431, DOI 10.1038/344431a0; FRIEDLANDER DR, 1989, P NATL ACAD SCI USA, V86, P7043, DOI 10.1073/pnas.86.18.7043; Gale NW, 1996, NEURON, V17, P9, DOI 10.1016/S0896-6273(00)80276-7; Godt D, 1998, NATURE, V395, P387, DOI 10.1038/26493; Gonzalez-Reyes A, 1998, DEVELOPMENT, V125, P3635; GUTHRIE S, 1993, DEVELOPMENT, V118, P527; HEYMAN I, 1993, DEV DYNAM, V198, P241, DOI 10.1002/aja.1001980402; Holland SJ, 1996, NATURE, V383, P722, DOI 10.1038/383722a0; Irving C, 1996, DEV BIOL, V173, P26, DOI 10.1006/dbio.1996.0004; LAWRENCE PA, 1981, CELL, V26, P3, DOI 10.1016/0092-8674(81)90027-1; LUMSDEN A, 1989, NATURE, V337, P424, DOI 10.1038/337424a0; Meima L, 1997, EUR J NEUROSCI, V9, P177, DOI 10.1111/j.1460-9568.1997.tb01365.x; NOSE A, 1988, CELL, V54, P993, DOI 10.1016/0092-8674(88)90114-6; O'Leary DDM, 1999, CURR OPIN NEUROBIOL, V9, P65, DOI 10.1016/S0959-4388(99)80008-7; STEINBERG MS, 1970, J EXP ZOOL, V173, P395, DOI 10.1002/jez.1401730406; Theil T, 1998, DEVELOPMENT, V125, P443; TOWNES PL, 1955, J EXP ZOOL, V128, P53, DOI 10.1002/jez.1401280105; Wizenmann A, 1997, MOL CELL NEUROSCI, V9, P448, DOI 10.1006/mcne.1997.0642; WOO K, 1995, DEVELOPMENT, V121, P2595; XU QL, 1994, DEVELOPMENT, V120, P287; Xu QL, 1997, J MOL MED-JMM, V75, P576, DOI 10.1007/s001090050142; Xu QL, 1995, DEVELOPMENT, V121, P4005; Zisch AH, 1997, J NEUROSCI RES, V47, P655, DOI 10.1002/(SICI)1097-4547(19970315)47:6<655::AID-JNR12>3.0.CO;2-U	27	364	365	1	9	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAY 20	1999	399	6733					267	271		10.1038/20452	http://dx.doi.org/10.1038/20452			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	198MF	10353250				2022-12-28	WOS:000080427400058
J	Stryker, MP				Stryker, MP			Perspectives: Neuroscience - Sensory maps on the move	SCIENCE			English	Editorial Material							INFERIOR COLLICULUS; EXPERIENCE; PLASTICITY		Univ Calif San Francisco, Dept Physiol, Keck Ctr Integrat Neurosci, San Francisco, CA 94143 USA	University of California System; University of California San Francisco	Stryker, MP (corresponding author), Univ Calif San Francisco, Dept Physiol, Keck Ctr Integrat Neurosci, San Francisco, CA 94143 USA.			Stryker, Michael/0000-0003-1546-5831	NEI NIH HHS [R37 EY002874, R37 EY002874-20] Funding Source: Medline; NATIONAL EYE INSTITUTE [R37EY002874] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Feldman DE, 1997, J NEUROSCI, V17, P6820; Feldman DE, 1996, SCIENCE, V271, P525, DOI 10.1126/science.271.5248.525; Hensch TK, 1998, SCIENCE, V282, P1504, DOI 10.1126/science.282.5393.1504; KNUDSEN E.I, 1999, FUNDAMENTAL NEUROSCI, P637; Knudsen EI, 1998, SCIENCE, V279, P1531, DOI 10.1126/science.279.5356.1531; KONISHI M, 1992, HARVEY LECT, V86, P47; MERZENICH MM, 1990, COLD SPRING HARB SYM, V55, P873; Rutherford LC, 1998, NEURON, V21, P521, DOI 10.1016/S0896-6273(00)80563-2; SILLITO AM, 1981, NATURE, V291, P318, DOI 10.1038/291318a0; WAGNER H, 1987, J NEUROSCI, V7, P3105; Zheng WM, 1999, SCIENCE, V284, P962, DOI 10.1126/science.284.5416.962	11	4	4	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAY 7	1999	284	5416					925	926		10.1126/science.284.5416.925	http://dx.doi.org/10.1126/science.284.5416.925			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	194MU	10357679	Green Accepted			2022-12-28	WOS:000080198800033
J	Delehanty, JM; Ling, FS; Berk, BC				Delehanty, JM; Ling, FS; Berk, BC			If I had an acute coronary syndrome ...	LANCET			English	Article							UNSTABLE ANGINA; DISEASE; TRIAL		Univ Rochester, Med Ctr, Cardiol Unit, Rochester, NY 14642 USA	University of Rochester	Berk, BC (corresponding author), Univ Rochester, Med Ctr, Cardiol Unit, Rochester, NY 14642 USA.	bradford_berk@urmc.rochester.edu		Berk, Bradford/0000-0002-2767-4115				Antman EM, 1996, NEW ENGL J MED, V335, P1342, DOI 10.1056/NEJM199610313351802; Bazzino O, 1998, NEW ENGL J MED, V338, P1498; Bazzino O, 1998, NEW ENGL J MED, V338, P1488; BRAUNWALD E, 1994, CIRCULATION, V90, P613, DOI 10.1161/01.CIR.90.1.613; Cannon CP, 1998, AM J CARDIOL, V82, P731, DOI 10.1016/S0002-9149(98)00540-2; Cohen M, 1997, NEW ENGL J MED, V337, P447, DOI 10.1056/NEJM199708143370702; Simoons ML, 1997, LANCET, V349, P1429; Stephens NG, 1996, LANCET, V347, P781, DOI 10.1016/S0140-6736(96)90866-1; Tardif JC, 1997, NEW ENGL J MED, V337, P365, DOI 10.1056/NEJM199708073370601; TOPOL E, 1993, NEW ENGL J MED, V329, P673, DOI 10.1056/nejm199309023291001; Topol E, 1998, NEW ENGL J MED, V339, P436; Topol EJ, 1998, LANCET, V352, P87, DOI 10.1016/S0140-6736(98)85010-1	12	0	0	0	2	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet		1999	353			2			SII24	SII26						3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	205GJ	10374763				2022-12-28	WOS:000080812700006
J	Simoons, ML; Boersma, E; van der Zwaan, C; Deckers, JW				Simoons, ML; Boersma, E; van der Zwaan, C; Deckers, JW			The challenge of acute coronary syndromes	LANCET			English	Article							ACUTE MYOCARDIAL-INFARCTION; THROMBOLYTIC THERAPY; CHEST PAIN; TRIAL; REPERFUSION; ISCHEMIA; DISEASE; COST; CARE		Erasmus Univ, Acad Hosp Rotterdam Dijkzigt, Thoraxctr, NL-3015 GD Rotterdam, Netherlands	Erasmus University Rotterdam; Erasmus MC	Simoons, ML (corresponding author), Erasmus Univ, Acad Hosp Rotterdam Dijkzigt, Thoraxctr, Bd 434, NL-3015 GD Rotterdam, Netherlands.							APPLEBY P, 1994, LANCET, V343, P311, DOI 10.1016/S0140-6736(94)91161-4; Armstrong PW, 1998, CIRCULATION, V98, P1860, DOI 10.1161/01.CIR.98.18.1860; Aufderheide T P, 1996, Prehosp Disaster Med, V11, P162; BLOOM BS, 1973, NEW ENGL J MED, V288, P72, DOI 10.1056/NEJM197301112880205; Boersma E, 1996, LANCET, V348, P771, DOI 10.1016/S0140-6736(96)02514-7; Boersma E, 1998, DRUGS, V56, P31, DOI 10.2165/00003495-199856010-00004; BOERSMA H, 1998, CARDIOLOGIE, V5, P562; BOUTEN MJM, 1992, EUR HEART J, V13, P925, DOI 10.1093/oxfordjournals.eurheartj.a060294; BROWN KWG, 1963, LANCET, V2, P349; COBB LA, 1975, CIRCULATION, V52, P223; DARGIE HJ, 1993, EUR HEART J, V14, P969; DAY HW, 1963, DIS CHEST, V44, P423, DOI 10.1378/chest.44.4.423; DURRER D, 1979, P NETH AC SCI, P507; FINEBERG HV, 1984, NEW ENGL J MED, V310, P1301, DOI 10.1056/NEJM198405173102006; Geleijnse ML, 1998, J AM SOC ECHOCARDIOG, V11, P606, DOI 10.1016/S0894-7317(98)70036-7; GRIJSEELS EWM, 1995, EUR HEART J, V16, P325; Holmvang L, 1998, CIRCULATION, V98, P2004, DOI 10.1161/01.CIR.98.19.2004; Julian DG, 1996, EUR HEART J, V17, P43; Kong DF, 1998, CIRCULATION, V98, P2829, DOI 10.1161/01.CIR.98.25.2829; LEE KL, 1995, CIRCULATION, V91, P1659, DOI 10.1161/01.CIR.91.6.1659; LEIZOROVICZ A, 1993, NEW ENGL J MED, V329, P383; LOWN B, 1967, J AMER MED ASSOC, V199, P188, DOI 10.1001/jama.199.3.188; LUBSEN J, 1986, BRIT HEART J, V56, P400; Roberts RR, 1997, JAMA-J AM MED ASSOC, V278, P1670, DOI 10.1001/jama.278.20.1670; Ronner E, 1998, EUR HEART J, V19, P1608, DOI 10.1053/euhj.1998.1222; SIMOONS ML, 1983, EUR HEART J, V4, P129, DOI 10.1093/eurheartj/4.suppl_D.129; SIMOONS ML, 1993, CIRCULATION, V88, P2556, DOI 10.1161/01.CIR.88.6.2556; SIMOONS ML, 1993, LANCET, V342, P1523, DOI 10.1016/S0140-6736(05)80089-3; SIMOONS ML, 1985, LANCET, V2, P578; SIMOONS ML, IN PRESS EUR HEART J; Theroux P, 1998, CIRCULATION, V97, P1195, DOI 10.1161/01.CIR.97.12.1195; VanderWerf F, 1997, EUR HEART J, V18, P1371; WACKERS FJT, 1975, BRIT HEART J, V37, P741; Wood D, 1998, EUR HEART J, V19, P1434	34	2	2	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet		1999	353			2			SII1	SII4						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	205GJ	10374758	Bronze			2022-12-28	WOS:000080812700001
J	Postma, MJ; Beck, EJ; Mandalia, S; Sherr, L; Walters, MDS; Houweling, H; Jager, JC				Postma, MJ; Beck, EJ; Mandalia, S; Sherr, L; Walters, MDS; Houweling, H; Jager, JC			Universal HIV screening of pregnant women in England: cost effectiveness analysis	BMJ-BRITISH MEDICAL JOURNAL			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; ZIDOVUDINE PROPHYLAXIS; UNITED-KINGDOM; TRANSMISSION; TYPE-1	Objective To estimate the cost effectiveness of universal, voluntary HIV screening of pregnant women in England. Design Cost effectiveness analysis. Cost estimates of caring for HIV positive children were based on the stage of HIV infection and calculated using data obtained from a London hospital between 1986 and 1996. These were combined with estimates of the health benefits and costs of antenatal screening so that the cost effectiveness of universal, voluntary antenatal screening for HIV infection in England could be estimated. Main outcome measures Lifetime, direct costs of medical care of childhood HIV infection; life years gained as a result of the screening programme; net cost per life year gained fur different pretest counselling costs; and different prevalence rates of pregnant women who were unaware that they were HIV positive. Results Estimated direct lifetime medical and social care costs of childhood HIV infection were pound 178 300 using a 5% discount rate fur time preference (1995-6 prices). In high prevalence areas screening pregnant women for HIV is estimated to be a cost effective intervention with a net cost of less than pound 4000 for each life year gained. For areas with comparatively low prevalence rates, cost effectiveness could be less than pound 20 000 per life year gained, depending on the number of pregnant women who are unaware that they are infected and local screening costs. Conclusions Our results confirm recent recommendations that universal, voluntary antenatal HIV screening should be implemented in the London ar ea. Serious consideration of the policy should be given for other areas in England depending on local prevalence and screening costs.	Univ London Imperial Coll Sci Technol & Med, Sch Med, Dept Epidemiol & Publ Hlth, London W2 1PG, England; Natl Inst Publ Hlth & Environm, Dept Hlth Serv Res, NL-3720 BA Bilthoven, Netherlands; Natl Inst Publ Hlth & Environm, Dept Infect Dis & Epidemiol, NL-3720 BA Bilthoven, Netherlands; Univ London Imperial Coll Sci Technol & Med, Sch Med, Dept Paediat, London W2 1PG, England; Royal Free Hosp, Sch Med, Dept Primary Care & Populat Sci, London NW3 2PF, England	Imperial College London; Netherlands National Institute for Public Health & the Environment; Netherlands National Institute for Public Health & the Environment; Imperial College London; University of London; University College London; Royal Free London NHS Foundation Trust; UCL Medical School	Beck, EJ (corresponding author), Univ London Imperial Coll Sci Technol & Med, Sch Med, Dept Epidemiol & Publ Hlth, St Marys Campus, London W2 1PG, England.	e.beck@ic.ac.uk		Sherr, Lorraine/0000-0002-5902-8011; Postma, Maarten/0000-0002-6306-3653				BECK EJ, 1997, HOSP COMMUNITY SERVI; BECK EJ, IN PRESS INT J STD A; Boer R, 1998, BRIT MED J, V317, P376; Centers for Disease Control (CDC), 1987, MMWR Morb Mortal Wkly Rep, V36, P225; CLUYSTIE IL, 1995, AIDS CARE, V7, P135; CONNOR EM, 1994, NEW ENGL J MED, V331, P1173, DOI 10.1056/NEJM199411033311801; DUNN DT, 1992, LANCET, V340, P585, DOI 10.1016/0140-6736(92)92115-V; Gibb DM, 1997, AIDS, V11, pF53, DOI 10.1097/00002030-199707000-00001; *INT WORK PART ENH, 1998, RED MOTH TO CHILD TR; JEFFERSON T, 1996, ELEMENTARY EC EVALUA; JORDAN R, 1997, J MED SCREEN, V3, P117; LAUPACIS A, 1992, CAN MED ASSOC J, V146, P473; Mandelbrot L, 1998, JAMA-J AM MED ASSOC, V280, P55, DOI 10.1001/jama.280.1.55; McIntosh K, 1998, NEW ENGL J MED, V339, P1467, DOI 10.1056/NEJM199811123392009; Mercey D, 1998, BMJ-BRIT MED J, V316, P241, DOI 10.1136/bmj.316.7127.241; MUGFORD M, 1996, THESIS U OXFORD OXFO; NEWELL ML, 1994, LANCET, V343, P1464; *NHS EX, 1997, HOSP COMM HLTH SERV; Nicoll A, 1998, BRIT MED J, V316, P253, DOI 10.1136/bmj.316.7127.253; Owens DK, 1998, J GEN INTERN MED, V13, P716, DOI 10.1046/j.1525-1497.1998.00211.x; Parsonage M, 1992, Health Econ, V1, P71, DOI 10.1002/hec.4730010110; Public Health Service guidelines for the management of health-care worker exposures to HIV and recommendations for postexposure prophylaxis. Centers for Disease Control and Prevention, 1998, MMWR RECOMMENDATIONS, V47, P1; *ROYAL COLL OBST G, 1997, NAT STUD HIV PREGN; SAVAGEKING F, 1998, BREAST FEEDING PROGR; Wade NA, 1998, NEW ENGL J MED, V339, P1409, DOI 10.1056/NEJM199811123392001; 1997, J MED SCREENING, V4, P177	26	50	50	0	3	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	JUN 19	1999	318	7199					1656	1660		10.1136/bmj.318.7199.1656	http://dx.doi.org/10.1136/bmj.318.7199.1656			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	210KY	10373167	Green Published, Green Submitted, Bronze			2022-12-28	WOS:000081105600019
J	Dunn, N; Thorogood, M; Faragher, B; de Caestecker, L; MacDonald, TM; McCollum, C; Thomas, S; Mann, R				Dunn, N; Thorogood, M; Faragher, B; de Caestecker, L; MacDonald, TM; McCollum, C; Thomas, S; Mann, R			Oral contraceptives and myocardial infarction: results of the MICA case-control study	BRITISH MEDICAL JOURNAL			English	Article							CORONARY HEART-DISEASE; YOUNG-WOMEN; RISK; HEALTH	Objectives To determine the association between myocardial infarction and use of different types of oral contraception in young women. Design Community based case-control study. Data from interviews and general practice records. Setting England, Scotland, and Wales. Participants Cases (n = 448) were recruited from women aged between 16 and 44 who had suffered an incident myocardial infarction between 1 October 1993 and 16 October 1995. Controls (n = 1728) were women without a diagnosis of myocardial infarction matched for age and general practice. Main outcome measures Odds ratios for myocardial infarction in current users of all combined oral contraceptives stratified by their progestagen content compared with non-users; current users of third generation versus second generation oral contraceptives. Results The adjusted odds ratio for myocardial infarction was 1.40 (95% confidence interval 0.78 to 2.52) for all combined oral contraceptive users, 1.10 (0.52 to 2.30) for second generation users, and 1.96 (0.87 to 4.39) for third generation users. Subgroup analysis by progestagen content did not show any significant difference from 1, and there was no effect of duration of use. The adjusted odds ratio for third generation users versus second generation users was 1.78 (0.66 to 4.83). 87% of cases were not exposed to an oral contraceptive, and 88% had clinical cardiovascular risk factors or were smokers, or both. Smoking was strongly associated with myocardial infarction: adjusted odds ratio 12.5 (7.29 to 21.5) for smoking 20 or more cigarettes a day. Conclusions There was no significant association between the use of oral contraceptives and myocardial infarction. The modest and non-significant point estimates for this association have wide confidence intervals. There was no significant difference between second and third generation products.	Drug Safety Res Unit, Southampton SO31 1AA, Hants, England; London Sch Hyg & Trop Med, London WC1 6FH, England; UMIST, Manchester Sch Management, Dept Org Psychol, Manchester M60 1QD, Lancs, England; Greater Glasgow Hlth Board, Dept Publ Hlth, Glasgow G3 8YU, Lanark, Scotland; Ninewells Hosp, Sch Med, Dept Clin Pharmacol & Therapeut, Med Monitoring Unit, Dundee DD1 9SY, Scotland; Univ S Manchester Hosp, Dept Surg, Manchester M20 8LR, Lancs, England; Univ Newcastle Upon Tyne, Wolfson Unit Clin Pharmacol, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England	University of London; London School of Hygiene & Tropical Medicine; University of Manchester; University of Dundee; Wythenshawe Hospital NHS Foundation Trust; Wythenshawe Hospital; Newcastle University - UK	Dunn, N (corresponding author), Drug Safety Res Unit, Bursledon Hall, Southampton SO31 1AA, Hants, England.			MacDonald, Thomas/0000-0001-5189-6669				DebertRibeiro M, 1995, J CLIN EPIDEMIOL, V48, P1513; Dunn NR, 1997, PHARMACOEPIDEM DR S, V6, P283, DOI 10.1002/(SICI)1099-1557(199707)6:4<283::AID-PDS270>3.3.CO;2-6; Jick H, 1996, LANCET, V347, P627, DOI 10.1016/S0140-6736(96)91334-3; LAVECCHIA C, 1987, AM J EPIDEMIOL, V125, P832, DOI 10.1093/oxfordjournals.aje.a114599; Lewis MA, 1997, CONTRACEPTION, V56, P129, DOI 10.1016/S0010-7824(97)00118-2; McAlpine R, 1998, PHARMACOEPIDEM DR S, V7, P311, DOI 10.1002/(SICI)1099-1557(199809/10)7:5<311::AID-PDS371>3.3.CO;2-F; OLIVER MF, 1986, MYOCARDIAL INFARCTIO, P215; Poulter NR, 1997, LANCET, V349, P1202, DOI 10.1016/S0140-6736(97)02358-1; RICHEDWARDS JW, 1995, NEW ENGL J MED, V332, P1758, DOI 10.1056/NEJM199506293322607; ROSENBERG L, 1990, AM J EPIDEMIOL, V131, P1009, DOI 10.1093/oxfordjournals.aje.a115592; SYDNEY S, 1996, OBSTET GYNECOL, V88, P939; TunstallPedoe H, 1997, BRIT MED J, V315, P722, DOI 10.1136/bmj.315.7110.722	12	130	132	1	6	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JUN 12	1999	318	7198					1579	1583		10.1136/bmj.318.7198.1579	http://dx.doi.org/10.1136/bmj.318.7198.1579			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	207AL	10364115	Green Submitted, Bronze, Green Published			2022-12-28	WOS:000080913100019
J	Duong, DH; Hartmann, A; Isaacson, S; Lazar, RM; Marshall, RS; Mast, H; Mohr, JP; Pile-Spellman, J; Sciacca, RR; Sisti, M; Solomon, RA; Stapf, C; Young, WL; Levin, B; Thompson, JLP; Hartmann, A; Hofmeister, C; Mast, H; Stapf, C; Mast, H; Meisel, J				Duong, DH; Hartmann, A; Isaacson, S; Lazar, RM; Marshall, RS; Mast, H; Mohr, JP; Pile-Spellman, J; Sciacca, RR; Sisti, M; Solomon, RA; Stapf, C; Young, WL; Levin, B; Thompson, JLP; Hartmann, A; Hofmeister, C; Mast, H; Stapf, C; Mast, H; Meisel, J		Arteriovenous Malformation Study Grp	Arteriovenous malformations of the brain in adults	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							FEEDING ARTERY PRESSURE; STEREOTAXIC RADIOSURGERY; NATURAL-HISTORY; FOLLOW-UP; INTRACRANIAL HEMORRHAGE; GRADING SYSTEM; RISK; MANAGEMENT; COMPLICATIONS; EMBOLIZATION		Columbia Presbyterian Med Ctr, Stroke Ctr, Neurol Inst, New York, NY 10032 USA	Columbia University; NewYork-Presbyterian Hospital	Duong, DH (corresponding author), Columbia Presbyterian Med Ctr, Stroke Ctr, Neurol Inst, 710 W 168th St, New York, NY 10032 USA.		Mohr, J/AAO-9694-2020		NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS034949, R01NS027713] Funding Source: NIH RePORTER; NINDS NIH HHS [NS 27713, NS 34949] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Abdulrauf SI, 1999, NEUROSURGERY, V44, P280, DOI 10.1097/00006123-199902000-00021; AUGER RG, 1992, NEUROSURGERY, V30, P561; BATJER HH, 1992, NEUROSURGERY, V31, P213, DOI 10.1227/00006123-199208000-00006; Brown RD, 1996, J NEUROSURG, V85, P29, DOI 10.3171/jns.1996.85.1.0029; BROWN RD, 1988, J NEUROSURG, V68, P352, DOI 10.3171/jns.1988.68.3.0352; BURCHIEL KJ, 1989, NEUROSURGERY, V24, P322, DOI 10.1227/00006123-198903000-00002; CARTER LP, 1995, STROKE, V26, P2371; CRAWFORD PM, 1986, J NEUROL NEUROSUR PS, V49, P1, DOI 10.1136/jnnp.49.1.1; DAVID CA, 1997, PRIMER CEREBROVASCUL, P520; DEMERITT JS, 1995, AM J NEURORADIOL, V16, P1801; Duong DH, 1998, STROKE, V29, P1167, DOI 10.1161/01.STR.29.6.1167; Evans RW, 1996, NEUROL CLIN, V14, P1, DOI 10.1016/S0733-8619(05)70240-1; Flickinger JC, 1998, INT J RADIAT ONCOL, V40, P273, DOI 10.1016/S0360-3016(97)00718-9; Friedman WA, 1996, J NEUROSURG, V84, P912, DOI 10.3171/jns.1996.84.6.0912; Frishberg BM, 1997, SEMIN NEUROL, V17, P373, DOI 10.1055/s-2008-1040951; FULTS D, 1984, NEUROSURGERY, V15, P658, DOI 10.1227/00006123-198411000-00003; Gabriel EM, 1996, J NEUROSURG, V84, P879, DOI 10.3171/jns.1996.84.5.0879; Gallina P, 1998, NEUROSURGERY, V42, P996, DOI 10.1097/00006123-199805000-00024; Gobin YP, 1996, J NEUROSURG, V85, P19, DOI 10.3171/jns.1996.85.1.0019; GROSS CR, 1984, STROKE, V15, P249, DOI 10.1161/01.STR.15.2.249; HAMILTON MG, 1994, NEUROSURGERY, V34, P2; Hartmann A, 1998, STROKE, V29, P931, DOI 10.1161/01.STR.29.5.931; Hartmann A, 1999, NEUROLOGY, V52, pA148; Heffez DS, 1998, SURG NEUROL, V49, P373, DOI 10.1016/S0090-3019(97)00441-2; HOFMEISTER C, 1998, CEREBROVASC DIS, V8, P65; ITOYAMA Y, 1989, J NEUROSURG, V71, P805, DOI 10.3171/jns.1989.71.6.0805; KADER A, 1994, NEUROSURGERY, V34, P801, DOI 10.1227/00006123-199405000-00003; Kader A, 1996, J NEUROSURG, V85, P14, DOI 10.3171/jns.1996.85.1.0014; Karlsson B, 1997, RADIOTHER ONCOL, V43, P275, DOI 10.1016/S0167-8140(97)00060-1; KILPATRICK CJ, 1990, ARCH NEUROL-CHICAGO, V47, P157, DOI 10.1001/archneur.1990.00530020053014; LASJAUNIAS P, 1997, VASCULAR DIS NEONATE, P51; LATCHAW RE, 1995, NEUROSURGERY, V37, P619, DOI 10.1227/00006123-199510000-00003; LAWTON MT, 1997, PRIMER CEREBROVASCUL, P511; Lax I, 1996, ACTA ONCOL, V35, P392; Lazar RM, 1997, NEUROLOGY, V49, P802, DOI 10.1212/WNL.49.3.802; Lazar RM, 1999, ARCH NEUROL-CHICAGO, V56, P103, DOI 10.1001/archneur.56.1.103; Lewis AI, 1997, J NEUROSURG, V87, P198, DOI 10.3171/jns.1997.87.2.0198; LUNSFORD LD, 1991, J NEUROSURG, V75, P512, DOI 10.3171/jns.1991.75.4.0512; MACFARLANE R, 1991, J NEUROSURG, V75, P845, DOI 10.3171/jns.1991.75.6.0845; MARKS MP, 1990, RADIOLOGY, V176, P807, DOI 10.1148/radiology.176.3.2389040; Mast H, 1997, LANCET, V350, P1065, DOI 10.1016/S0140-6736(97)05390-7; MAST H, 1995, STROKE, V26, P1215, DOI 10.1161/01.STR.26.7.1215; Mast H, 1998, NERVENARZT, V69, P287, DOI 10.1007/s001150050272; McCormick WF., 1978, WKLY UPDATE NEUROL N, V14, P2; MIYACHI S, 1993, NEURORADIOLOGY, V35, P205, DOI 10.1007/BF00588495; Miyasaka Y, 1997, NEUROSURGERY, V41, P1060, DOI 10.1097/00006123-199711000-00008; Morgan MK, 1997, J NEUROSURG, V86, P801, DOI 10.3171/jns.1997.86.5.0801; NELSON MD, 1991, AM J NEURORADIOL, V12, P215; NORNES H, 1980, J NEUROSURG, V53, P456, DOI 10.3171/jns.1980.53.4.0456; ONDRA SL, 1990, J NEUROSURG, V73, P387, DOI 10.3171/jns.1990.73.3.0387; Osipov A, 1997, Interv Neuroradiol, V3, P37; PADGET DH, 1956, AM J ANAT, V98, P307, DOI 10.1002/aja.1000980302; PERRET G, 1966, J NEUROSURG, V25, P467, DOI 10.3171/jns.1966.25.4.0467; Pikus HJ, 1998, J NEUROSURG, V88, P641, DOI 10.3171/jns.1998.88.4.0641; Pile-Spellman J, 1999, NEUROSURGERY, V44, P881, DOI 10.1097/00006123-199904000-00117; PILESPELLMAN JMD, 1986, AM J NEURORADIOL, V7, P811; Pollock BE, 1996, J NEUROSURG, V84, P437, DOI 10.3171/jns.1996.84.3.0437; Pollock BE, 1996, STROKE, V27, P1, DOI 10.1161/01.STR.27.1.1; PORTER PJ, 1998, J NEUROSURG, V88, pA184; PRITZ MB, 1994, ACTA NEUROCHIR, V131, P314, DOI 10.1007/BF01808635; Redekop G, 1998, J NEUROSURG, V89, P539, DOI 10.3171/jns.1998.89.4.0539; SAMSON DS, 1991, NEUROSURGERY UPDATE, V2, P129; Sasaki T, 1998, J NEUROSURG, V88, P285, DOI 10.3171/jns.1998.88.2.0285; Schaller C, 1998, J NEUROL NEUROSUR PS, V65, P547, DOI 10.1136/jnnp.65.4.547; SISTI MB, 1993, J NEUROSURG, V79, P653, DOI 10.3171/jns.1993.79.5.0653; Smith KA, 1997, STEREOT FUNCT NEUROS, V69, P136, DOI 10.1159/000099865; Spetzler R F, 1978, Clin Neurosurg, V25, P651; SPETZLER RF, 1992, J NEUROSURG, V76, P918, DOI 10.3171/jns.1992.76.6.0918; SPETZLER RF, 1986, J NEUROSURG, V65, P476, DOI 10.3171/jns.1986.65.4.0476; STATHAM P, 1990, J NEUROL NEUROSUR PS, V53, P476, DOI 10.1136/jnnp.53.6.476; Thompson RC, 1998, NEUROSURGERY, V43, P202, DOI 10.1097/00006123-199808000-00006; TURJMAN F, 1994, AM J NEURORADIOL, V15, P1601; TURJMAN F, 1995, AM J NEURORADIOL, V16, P345; VINUELA F, 1991, J NEUROSURG, V75, P856, DOI 10.3171/jns.1991.75.6.0856; Yamamoto M, 1998, SURG NEUROL, V49, P385, DOI 10.1016/S0090-3019(97)00531-4; YOUNG WL, 1994, NEUROSURGERY, V34, P601, DOI 10.1227/00006123-199404000-00006; Young WL, 1996, NEUROSURGERY, V38, P1085, DOI 10.1097/00006123-199606000-00005	77	199	199	0	3	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUN 10	1999	340	23					1812	1818						7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	203UU	10362826				2022-12-28	WOS:000080726800007
J	Modlin, RL; Brightbill, HD; Godowski, PJ				Modlin, RL; Brightbill, HD; Godowski, PJ			The toll of innate immunity on microbial pathogens	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							LIPOPOLYSACCHARIDE; ACTIVATION		Univ Calif Los Angeles, Sch Med, Los Angeles, CA 90095 USA; Genentech Inc, San Francisco, CA 94080 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; Roche Holding; Genentech	Modlin, RL (corresponding author), Univ Calif Los Angeles, Sch Med, Los Angeles, CA 90095 USA.		Modlin, Robert L/M-7941-2014	Modlin, Robert L/0000-0003-4720-031X				Kirschning CJ, 1998, J EXP MED, V188, P2091, DOI 10.1084/jem.188.11.2091; Medzhitov R, 1997, NATURE, V388, P394, DOI 10.1038/41131; Muzio M, 1998, J EXP MED, V187, P2097, DOI 10.1084/jem.187.12.2097; Poltorak A, 1998, SCIENCE, V282, P2085, DOI 10.1126/science.282.5396.2085; Yang RB, 1998, NATURE, V395, P284, DOI 10.1038/26239	5	106	116	0	2	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUN 10	1999	340	23					1834	1835		10.1056/NEJM199906103402312	http://dx.doi.org/10.1056/NEJM199906103402312			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	203UU	10362831				2022-12-28	WOS:000080726800012
J	Light, RW; Rogers, JT; Cheng, DS; Rodriguez, RM				Light, RW; Rogers, JT; Cheng, DS; Rodriguez, RM		Cardiovascular Surg Associates PC	Large pleural effusions occurring after coronary artery bypass grafting	ANNALS OF INTERNAL MEDICINE			English	Article						coronary artery bypass; pleural effusion; thoracenteses; thoracostomy; anti-inflammatory agents; sclerosing solutions	INTERNAL MAMMARY ARTERY; RESPIRATORY COMPLICATIONS; PULMONARY COMPLICATIONS; SAPHENOUS-VEIN; REVASCULARIZATION; SURGERY; INJURY	Background: Large pleural effusions sometimes occur after coronary artery bypass grafting (CABG), but their characteristics and clinical course are largely unknown. Objective: To describe the clinical course and pleural fluid findings in patients with large pleural effusions occurring after CABG. Design: Retrospective case series. Setting: Tertiary care, university-affiliated, nonprofit teaching hospital. Patients: 3707 patients who had CABC between 1 February 1996 and 1 August 1997. Measurements: Chest radiographs were reviewed, and information on pleural fluid findings, pleural effusion treatment, and cardiac surgery was obtained from medical records and a cardiac surgery database. Results: Pleural effusions that occupied more than 25% of the hemithorax were found in 29 patients (0.78%). Seven of the effusions were attributed to congestive heart failure, 2 were attributed to pericarditis, and 1 was attributed to pulmonary embolism. The explanation for the remaining 19 effusions was unclear. All but 2 effusions were predominantly left-sided. Of these 19 effusions, 8 were bloody and 11 were nonbloody. Bloody effusions usually occurred earlier, contained higher lactic acid dehydrogenase levels, and were frequently eosinophilic. Nonbloody effusions tended to be more difficult to manage. Conclusions: Large pleural effusions may develop in a small proportion of patients after CABG. The cause of many of these effusions is unclear. Most bloody effusions can be managed with one to three therapeutic thoracenteses. Resolution of nonbloody effusions may require antiinflammatory agents, tube thoracostomy, or intrapleural injection of sclerosing agents.	St Thomas Hosp, Pulm Dis Program, Nashville, TN 37202 USA; Vanderbilt Univ, Nashville, TN USA	Saint Thomas Hospital; Vanderbilt University	Light, RW (corresponding author), St Thomas Hosp, Pulm Dis Program, POB 380,4220 Harding Rd, Nashville, TN 37202 USA.	RLIGHT98@yahoo.com						AARNIO P, 1991, SCAND J THORAC CARD, V25, P175, DOI 10.3109/14017439109099035; Ali IM, 1996, CAN J SURG, V39, P42; COHEN ML, 1994, CHEST, V105, P1874, DOI 10.1378/chest.105.6.1874; Daganou M, 1998, CHEST, V113, P1285, DOI 10.1378/chest.113.5.1285; GALE GD, 1979, CAN ANAESTH SOC J, V26, P15, DOI 10.1007/BF03039447; HURLBUT D, 1990, ANN THORAC SURG, V50, P959, DOI 10.1016/0003-4975(90)91129-Y; KIM YK, 1988, AM HEART J, V115, P1077, DOI 10.1016/0002-8703(88)90079-8; KOLLEF MH, 1990, HEART LUNG, V19, P671; KOLLEF MH, 1990, CHEST, V97, P750, DOI 10.1378/chest.97.3.750; KOLLEF MH, 1993, SOUTHERN MED J, V86, P585, DOI 10.1097/00007611-199305000-00022; KOLLEF MH, 1988, CHEST, V94, P68, DOI 10.1378/chest.94.1.68; LANDYMORE RW, 1990, EUR J CARDIO-THORAC, V4, P156, DOI 10.1016/1010-7940(90)90187-5; Light R, 1995, PLEURAL DIS; Nikas DJ, 1998, ANN THORAC SURG, V65, P28, DOI 10.1016/S0003-4975(97)01261-7; PENG MJ, 1992, CHEST, V101, P327, DOI 10.1378/chest.101.2.327; ROLLA G, 1994, RESP MED, V88, P417, DOI 10.1016/S0954-6111(05)80043-5; SCHANDENE L, 1993, CLIN EXP IMMUNOL, V93, P115; WILSON JM, 1979, J THORAC CARDIOV SUR, V77, P489	18	68	70	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 1	1999	130	11					891	+		10.7326/0003-4819-130-11-199906010-00004	http://dx.doi.org/10.7326/0003-4819-130-11-199906010-00004			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	200PB	10375337				2022-12-28	WOS:000080547900003
J	Hemingway, H; Marmot, M				Hemingway, H; Marmot, M			Evidence based cardiology - Psychosocial factors in the aetiology and prognosis of coronary heart disease: systematic review of prospective cohort studies	BMJ-BRITISH MEDICAL JOURNAL			English	Review							ACUTE MYOCARDIAL-INFARCTION; WESTERN-COLLABORATIVE-GROUP; SOCIAL SUPPORT; A BEHAVIOR; FOLLOW-UP; ARTERY DISEASE; RISK-FACTORS; JOB STRAIN; SWEDISH MEN; MORTALITY		UCL, Sch Med, Int Ctr Hlth & Soc, Dept Epidemiol & Publ Hlth, London WC1E 6BT, England	University of London; University College London; UCL Medical School	Hemingway, H (corresponding author), Kensington & Chelsea & Westminster Hlth Author, Dept Res & Dev, London W2 6LX, England.	hhemingway@public-health.ucl.ac.uk	Hemingway, Harry/C-1219-2009; Marmot, M G/Y-3920-2019	Hemingway, Harry/0000-0003-2279-0624; Marmot, M G/0000-0002-2431-6419	AGENCY FOR HEALTHCARE RESEARCH AND QUALITY [R01HS006516] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL036310] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG013196] Funding Source: NIH RePORTER; AHRQ HHS [5 RO1 HS06516] Funding Source: Medline; Medical Research Council [G19/35, G8802774] Funding Source: Medline; NHLBI NIH HHS [2RO1 HL36310, R01 HL036310] Funding Source: Medline; NIA NIH HHS [R01 AG13196-02, R01 AG013196] Funding Source: Medline	AGENCY FOR HEALTHCARE RESEARCH AND QUALITY(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ALLOWAY R, 1987, PSYCHOL MED, V17, P91, DOI 10.1017/S0033291700013015; ALTERMAN T, 1994, AM J EPIDEMIOL, V139, P620, DOI 10.1093/oxfordjournals.aje.a117051; ANDA R, 1993, EPIDEMIOLOGY, V4, P285, DOI 10.1097/00001648-199307000-00003; AROMAA A, 1994, ACTA PSYCHIAT SCAND, V89, P77, DOI 10.1111/j.1600-0447.1994.tb05807.x; BAREFOOT JC, 1995, AM J EPIDEMIOL, V142, P477, DOI 10.1093/oxfordjournals.aje.a117663; Barefoot JC, 1996, AM J CARDIOL, V78, P613, DOI 10.1016/S0002-9149(96)00380-3; BAREFOOT JC, 1989, AM J CARDIOL, V64, P427, DOI 10.1016/0002-9149(89)90416-5; Bosma H, 1997, BRIT MED J, V314, P558, DOI 10.1136/bmj.314.7080.558; BOSMA H, 1995, CARDIOLOGY, V2, P54; BUCHER HC, 1994, J GEN INTERN MED, V9, P409, DOI 10.1007/BF02629526; CASE RB, 1992, JAMA-J AM MED ASSOC, V267, P515, DOI 10.1001/jama.267.4.515; CASE RB, 1985, NEW ENGL J MED, V312, P737, DOI 10.1056/NEJM198503213121201; CHANDRA V, 1983, AM J EPIDEMIOL, V117, P320, DOI 10.1093/oxfordjournals.aje.a113544; COHEN JB, 1985, J BEHAV MED, V8, P343, DOI 10.1007/BF00848368; DEMBROSKI TM, 1989, PSYCHOSOM MED, V51, P514, DOI 10.1097/00006842-198909000-00003; Everson SA, 1997, AM J EPIDEMIOL, V146, P142; FRIEDMANN E, 1995, AM J CARDIOL, V76, P1213, DOI 10.1016/S0002-9149(99)80343-9; GORKIN L, 1993, AM J CARDIOL, V71, P263, DOI 10.1016/0002-9149(93)90788-E; HAGMAN M, 1987, J CHRON DIS, V40, P265, DOI 10.1016/0021-9681(87)90163-9; HALLSTROM T, 1986, J PSYCHOSOM RES, V30, P451, DOI 10.1016/0022-3999(86)90084-X; HAYNES SG, 1980, AM J EPIDEMIOL, V111, P37, DOI 10.1093/oxfordjournals.aje.a112873; HEARN MD, 1989, J BEHAV MED, V12, P105, DOI 10.1007/BF00846545; HECKER MHL, 1988, PSYCHOSOM MED, V50, P153, DOI 10.1097/00006842-198803000-00005; HEDBLAD B, 1992, EUR HEART J, V13, P433, DOI 10.1093/oxfordjournals.eurheartj.a060193; HLATKY MA, 1995, CIRCULATION, V92, P327, DOI 10.1161/01.CIR.92.3.327; JENKINS CD, 1974, NEW ENGL J MED, V290, P1271, DOI 10.1056/NEJM197406062902301; JENKINSON CM, 1993, PUBLIC HEALTH, V107, P305, DOI 10.1016/S0033-3506(05)80122-2; JOHNSTON DW, 1987, BRIT MED J, V295, P86, DOI 10.1136/bmj.295.6590.86; KAPLAN GA, 1993, CIRCULATION, V88, P1973, DOI 10.1161/01.CIR.88.4.1973; Kawachi I, 1996, CIRCULATION, V94, P2090, DOI 10.1161/01.CIR.94.9.2090; KAWACHI I, 1994, CIRCULATION, V89, P1992, DOI 10.1161/01.CIR.89.5.1992; KHANSARI DN, 1990, IMMUNOL TODAY, V11, P170, DOI 10.1016/0167-5699(90)90069-L; KOP WJ, 1994, PSYCHOSOM MED, V56, P281, DOI 10.1097/00006842-199407000-00001; Marmot MG, 1998, LANCET, V351, P57, DOI 10.1016/S0140-6736(97)08084-7; Marmot MG, 1997, LANCET, V350, P235, DOI 10.1016/S0140-6736(97)04244-X; Miller TQ, 1996, PSYCHOL BULL, V119, P322, DOI 10.1037/0033-2909.119.2.322; Mittleman MA, 1997, ARCH INTERN MED, V157, P769, DOI 10.1001/archinte.157.7.769; NUNES EV, 1987, PSYCHOSOM MED, V49, P159, DOI 10.1097/00006842-198703000-00006; ORTHGOMER K, 1993, PSYCHOSOM MED, V55, P37, DOI 10.1097/00006842-199301000-00007; PIEPER C, 1989, AM J EPIDEMIOL, V129, P483, DOI 10.1093/oxfordjournals.aje.a115159; RAGLAND DR, 1988, NEW ENGL J MED, V318, P65, DOI 10.1056/NEJM198801143180201; RAGLAND DR, 1988, AM J EPIDEMIOL, V127, P462, DOI 10.1093/oxfordjournals.aje.a114823; REED DM, 1989, AM J EPIDEMIOL, V129, P495, DOI 10.1093/oxfordjournals.aje.a115160; RUBERMAN W, 1984, NEW ENGL J MED, V311, P552, DOI 10.1056/NEJM198408303110902; SHEKELLE RB, 1985, AM J EPIDEMIOL, V122, P559, DOI 10.1093/oxfordjournals.aje.a114135; SHEKELLE RB, 1983, PSYCHOSOM MED, V45, P109, DOI 10.1097/00006842-198305000-00003; SHEKELLE RB, 1985, AM J CARDIOL, V56, P221; SIEGRIST J, 1990, SOC SCI MED, V31, P1127, DOI 10.1016/0277-9536(90)90234-J; TunstallPedoe H, 1997, BRIT MED J, V315, P722, DOI 10.1136/bmj.315.7110.722; VOGT TM, 1992, J CLIN EPIDEMIOL, V45, P659, DOI 10.1016/0895-4356(92)90138-D; WassertheilSmoller S, 1996, ARCH INTERN MED, V156, P553, DOI 10.1001/archinte.156.5.553; WILLIAMS RB, 1992, JAMA-J AM MED ASSOC, V267, P520, DOI 10.1001/jama.267.4.520; Williams RB, 1997, ARCH GEN PSYCHIAT, V54, P543	54	906	932	2	66	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAY 29	1999	318	7196					1460	+		10.1136/bmj.318.7196.1460	http://dx.doi.org/10.1136/bmj.318.7196.1460			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	202TL	10346775	Green Submitted, Green Published			2022-12-28	WOS:000080668200025
J	Mann, DL				Mann, DL			Inflammatory mediators in heart failure: homogeneity through heterogeneity	LANCET			English	Editorial Material							TUMOR-NECROSIS-FACTOR; CARDIOMYOPATHY; EXPRESSION		Baylor Coll Med, Dept Med, Winters Ctr Heart Failure Res, Cardiol Sect, Houston, TX 77030 USA; Houston Vet Adm Med Ctr, Houston, TX 77030 USA	Baylor College of Medicine; US Department of Veterans Affairs; Veterans Health Administration (VHA); Michael E DeBakey VA Medical Center	Mann, DL (corresponding author), Baylor Coll Med, Dept Med, Winters Ctr Heart Failure Res, Cardiol Sect, Houston, TX 77030 USA.		Mann, Douglas Lowell/AAQ-3524-2021	Mann, Douglas/0000-0002-2516-0145				Habib FM, 1996, LANCET, V347, P1151, DOI 10.1016/S0140-6736(96)90610-8; MATSUMORI A, 1994, BRIT HEART J, V72, P561; Seta Y, 1996, J Card Fail, V2, P243, DOI 10.1016/S1071-9164(96)80047-9; TorreAmione G, 1996, J AM COLL CARDIOL, V27, P1201, DOI 10.1016/0735-1097(95)00589-7; TORREAMIONE G, 1995, CIRCULATION, V92, P1487, DOI 10.1161/01.CIR.92.6.1487; Wagner DR, 1998, CIRC RES, V82, P47	6	19	19	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAY 29	1999	353	9167					1812	1813		10.1016/S0140-6736(99)90069-7	http://dx.doi.org/10.1016/S0140-6736(99)90069-7			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	202TG	10359399				2022-12-28	WOS:000080667800002
J	Roman, E; Doyle, P; Maconochie, N; Davies, G; Smith, PG; Beral, V				Roman, E; Doyle, P; Maconochie, N; Davies, G; Smith, PG; Beral, V			Cancer in children of nuclear industry employees: report on children aged under 25 years from nuclear industry family study	BRITISH MEDICAL JOURNAL			English	Article							NON-HODGKINS-LYMPHOMA; YOUNG-PEOPLE; WEST CUMBRIA; CHILDHOOD LEUKEMIA; SELLAFIELD PLANT; MORTALITY; RADIATION; INSTALLATION; SEASCALE; WORKERS	Objective. To determine whether children of men and women occupationally exposed to ionising radiation are at increased risk of developing leukaemia or other cancers before their 25th birthday. Design. Cohort study of children of nuclear industry employees. Setting. Nuclear establishments operated by the Atomic Energy Authority, Atomic Weapons Establishment, and British Nuclear Fuels. Subjects. 39557 children of male employees and 8883 children of female employees. Main outcome measures. Cancer incidence in offspring reported by parents. Employment and radiation monitoring data (including annual external dose) supplied by the nuclear authorities. Results. 111 cancers were reported, of which 28 were leukaemia. The estimated standardised incidence ratios for children of male and female employees who were born in 1965 or later were 98 (95% confidence interval 73 to 129) and 96 (50 to 168) for all malignancies and 109 (61 to 180) and 95 (20 to 277) for leukaemia. The leukaemia rate in children whose fathers had accumulated a preconceptual dose of greater than or equal to 100 mSv was 5.8 times that in children conceived before their fathers' employment in the nuclear industry (95% confidence interval 1.3 to 24.8) but this was based on only three exposed cases. Two of these cases were included in the west Cumbrian ("Gardner") case-control study. No significant treads were found between increasing dose and leukaemia. Conclusions. Cancer in young people is rare, and our results are based on small numbers of events. Overall, the findings suggest that the incidence of cancer and leukaemia among children of nuclear industry employees is similar to that in the general population. The possibility that exposure of fathers to relatively high doses of ionising radiation before their child's conception might be related to an increased risk of leukaemia in their offspring could not be disproved, but this result was based on only three cases, two of which have been previously reported. High conceptual doses are rare, and even if the occupational association were causal, the number of leukaemias involved would be small; in this study of over 46000 children, fewer than three leukaemias could potentially be attributed to such an exposure.	Univ Leeds, Inst Epidemiol, Leukaemia Res Fund, Leeds LS2 9LN, W Yorkshire, England; Univ London London Sch Hyg & Trop Med, London WC1E 7HT, England; Univ Oxford, Radcliffe Infirm, Imperial Canc Res Fund, Oxford OX2 6HE, England	University of Leeds; University of London; London School of Hygiene & Tropical Medicine; Radcliffe Infirmary; University of Oxford	Roman, E (corresponding author), Univ Leeds, Inst Epidemiol, Leukaemia Res Fund, Leeds LS2 9LN, W Yorkshire, England.		smith, peter/ABH-9627-2020	smith, peter/0000-0003-0080-7560; Roman, Eve/0000-0001-7603-3704				BAILAR JC, 1964, BIOMETRICS, V20, P639; BERAL V, 1985, BRIT MED J, V291, P440, DOI 10.1136/bmj.291.6493.440; BERAL V, 1988, BRIT MED J, V297, P757, DOI 10.1136/bmj.297.6651.757; BLACK D, 1984, INVESTIGATION POSSIB; Bobrow M, 1993, CHILDHOOD CANC NUCL; Breslow NE, 1980, STAT METHODS CANC RE, V2; CARPENTER L, 1994, RADIAT RES, V138, P224, DOI 10.2307/3578592; *COMM MED ASP RAD, 1989, REP INC CHILDH CANC; *COMM MED ASP RAD, 1988, INV POSS INCR INC LE; *COMM MED ASP RAD, 1996, INC CANC LEUK YOUNG; *COMM MED ASP RAD, 1986, IMPL NEW DAT REL SEL; DOLL R, 1994, NATURE, V367, P678, DOI 10.1038/367678a0; DOUGLAS AJ, 1994, BRIT J CANCER, V70, P1232, DOI 10.1038/bjc.1994.479; Draper GJ, 1997, BRIT MED J, V315, P1181, DOI 10.1136/bmj.315.7117.1181; DRAPER GJ, 1993, BRIT MED J, V306, P89, DOI 10.1136/bmj.306.6870.89; DRAPER GJ, 1997, NRPBR298 NAT RAD PRO; EVANS HJ, 1990, NATURE, V345, P16, DOI 10.1038/345016a0; GARDNER MJ, 1992, BRIT MED J, V305, P715, DOI 10.1136/bmj.305.6855.715; GARDNER MJ, 1984, LANCET, V1, P216; GARDNER MJ, 1987, BRIT MED J, V295, P819, DOI 10.1136/bmj.295.6602.819; GARDNER MJ, 1990, BRIT MED J, V300, P429, DOI 10.1136/bmj.300.6722.429; GARDNER MJ, 1990, BRIT MED J, V300, P423, DOI 10.1136/bmj.300.6722.423; GARDNER MJ, 1987, BRIT MED J, V295, P822, DOI 10.1136/bmj.295.6602.822; Goodhill A. A., 1992, 1 ANAL NATL REGISTRY; GREAVES MF, 1990, LEUKEMIA, V4, P391; HEASMAN MA, 1986, LANCET, V1, P266; *HLTH SAF EX, 1993, INV LEUK OTH CANC CH; Inskip HM, 1996, J ROY STAT SOC A STA, V159, P41, DOI 10.2307/2983467; KINLEN LJ, 1993, BRIT MED J, V306, P1153, DOI 10.1136/bmj.306.6886.1153; KINLEN LJ, 1993, BRIT MED J, V306, P1718, DOI 10.1136/bmj.306.6894.1718; KORN EL, 1990, AM STAT, V44, P270, DOI 10.2307/2684345; MACONOCHIE N, 1999, BRIT MED J, V318, P53; MCLAUGHLIN JR, 1992, 71571 AECB AT EN CON; *OFF POP CENS SURV, 1987, CANC STAT REG; PARKER L, 1993, BRIT MED J, V307, P966, DOI 10.1136/bmj.307.6910.966; Pobel D, 1997, BRIT MED J, V314, P101, DOI 10.1136/bmj.314.7074.101; Rogers WH, 1993, STATA TECHN B, V13, P19; ROMAN E, 1987, BRIT MED J, V294, P597, DOI 10.1136/bmj.294.6572.597; ROMAN E, 1993, BMJ-BRIT MED J, V306, P615, DOI 10.1136/bmj.306.6878.615; Skinner C.J., 1989, ANAL COMPLEX SURVEYS; SMITH PG, 1986, BRIT MED J, V293, P845, DOI 10.1136/bmj.293.6551.845; Stata Corporation, 1996, STAT STAT SOFTW REL; URQUHART J, 1984, LANCET, V1, P217; URQUHART JD, 1991, BRIT MED J, V302, P687, DOI 10.1136/bmj.302.6778.687; Wakeford R, 1998, J R STAT SOC A STAT, V161, P313, DOI 10.1111/1467-985X.00111; [No title captured]	46	40	46	0	9	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	MAY 29	1999	318	7196					1443	1450		10.1136/bmj.318.7196.1443	http://dx.doi.org/10.1136/bmj.318.7196.1443			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	202TL	10346768	Green Published, Bronze, Green Submitted			2022-12-28	WOS:000080668200020
J	McIntosh, AR; Rajah, MN; Lobaugh, NJ				McIntosh, AR; Rajah, MN; Lobaugh, NJ			Interactions of prefrontal cortex in relation to awareness in sensory learning	SCIENCE			English	Article							FUNCTIONAL CONNECTIVITY; PET; EXPERIENCE; RESPONSES; CORTICES; PATTERN; SYSTEMS; HUMANS; IMAGES	In an associative Learning paradigm, human subjects could be divided based on whether they were aware that one tone predicted a visual event and another did not. Only aware subjects acquired a differential behavioral response to the tones, Regional cerebral blood flow in left prefrontal cortex showed learning-related changes only in aware subjects. Left prefrontal cortex also showed changes in functional connectivity with contralateral prefrontal cortex, sensory association cortices, and cerebellum. Several of the interacting areas correlated with aware subjects' behavior, These results suggest cerebral processes underlying awareness are mediated through interactions of large-scale neurocognitive systems.	Baycrest Ctr Geriatr Care, Rotman Res Inst, Toronto, ON M6A 2E1, Canada	University of Toronto; University Toronto Affiliates; Baycrest	McIntosh, AR (corresponding author), Baycrest Ctr Geriatr Care, Rotman Res Inst, 3560 Bathurst St, Toronto, ON M6A 2E1, Canada.	mcintosh@psych.utoronto.ca	McIntosh, Anthony R/G-4955-2011; Rajah, Maria Natasha/AAE-8429-2019	Rajah, Maria Natasha/0000-0001-6177-7049; McIntosh, Anthony/0000-0002-1784-5662				Berns GS, 1997, SCIENCE, V276, P1272, DOI 10.1126/science.276.5316.1272; Braun AR, 1998, SCIENCE, V279, P91, DOI 10.1126/science.279.5347.91; Buchel C, 1999, SCIENCE, V283, P1538, DOI 10.1126/science.283.5407.1538; Clark RE, 1998, SCIENCE, V280, P77, DOI 10.1126/science.280.5360.77; CRICK F, 1995, NATURE, V375, P121, DOI 10.1038/375121a0; Friston K. J., 1993, Human Brain Mapping, V1, P69, DOI 10.1002/hbm.460010108; FRISTON KJ, 1993, J CEREBR BLOOD F MET, V13, P5, DOI 10.1038/jcbfm.1993.4; Friston KJ, 1997, NEUROIMAGE, V5, P213, DOI 10.1006/nimg.1997.0260; FRISTON KJ, 1995, HUMAN BRAIN MAPPING, V2, P165; GRAFTON ST, 1995, J COGNITIVE NEUROSCI, V7, P497, DOI 10.1162/jocn.1995.7.4.497; KNIGHT RT, 1995, ADV NEUROL, V66, P21; McIntosh AR, 1996, NEUROIMAGE, V3, P143, DOI 10.1006/nimg.1996.0016; McIntosh AR, 1997, HUM BRAIN MAPP, V5, P323, DOI 10.1002/(SICI)1097-0193(1997)5:4<323::AID-HBM20>3.0.CO;2-D; McIntosh AR, 1998, J NEUROPHYSIOL, V80, P3148, DOI 10.1152/jn.1998.80.6.3148; McIntosh AR, 1998, CEREB CORTEX, V8, P648, DOI 10.1093/cercor/8.7.648; MCINTOSH AR, 1994, J NEUROSCI, V14, P655; Mesulam MM, 1998, BRAIN, V121, P1013, DOI 10.1093/brain/121.6.1013; MOLCHAN SE, 1994, P NATL ACAD SCI USA, V91, P8122, DOI 10.1073/pnas.91.17.8122; Morris JS, 1998, P ROY SOC B-BIOL SCI, V265, P649, DOI 10.1098/rspb.1998.0343; PETRIDES M, 1985, NEUROPSYCHOLOGIA, V23, P601, DOI 10.1016/0028-3932(85)90062-4; PETRIDES M, 1993, P NATL ACAD SCI USA, V90, P873, DOI 10.1073/pnas.90.3.873; PICTON TW, 1994, CURR OPIN NEUROBIOL, V4, P256, DOI 10.1016/0959-4388(94)90082-5; RAICHLE ME, 1994, CEREB CORTEX, V4, P8, DOI 10.1093/cercor/4.1.8; Sakai K, 1998, J NEUROSCI, V18, P1827; SHALLICE T, 1991, FRONTAL LOBE FUNCTION AND DYSFUNCTION, P125; STUSS DT, IN PRESS FRONTAL LOB; STUSS DT, 1987, FRONTAL LOBES REVIS; Talairach J., 1988, COPLANAR STEREOTAXIC; Thomas G., 1987, BIOL PSYCHOL, V25, P187, DOI [10.1016/0301-0511(87)90037-8, DOI 10.1016/0301-0511(87)90037-8]; Tononi G, 1998, SCIENCE, V282, P1846, DOI 10.1126/science.282.5395.1846; Wong PS, 1997, CONSCIOUS COGN, V6, P519, DOI 10.1006/ccog.1997.0322; WOODS RP, 1992, J COMPUT ASSIST TOMO, V16, P620, DOI 10.1097/00004728-199207000-00024	32	146	150	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAY 28	1999	284	5419					1531	1533		10.1126/science.284.5419.1531	http://dx.doi.org/10.1126/science.284.5419.1531			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	200PD	10348741				2022-12-28	WOS:000080548100038
J	Draper, ES; Kurinczuk, JJ; Abrams, KR; Clarke, M				Draper, ES; Kurinczuk, JJ; Abrams, KR; Clarke, M			Assessment of separate contributions to perinatal mortality of infertility history and treatment: a case-control analysis	LANCET			English	Article							INVITRO FERTILIZATION; MULTIPLE BIRTHS; PREGNANCIES	Background. Few studies have described the perinatal risks associated with infertility, other than for infertility treated by in-vitro fertilisation or gamete intrafallopian transfer, The aim of this analysis was to estimate the risks of perinatal death associated with treated and untreated infertility. Methods. A population-based case-control study of perinatal deaths was carried out in Leicestershire Health District over the period 1990-94, during which 60922 babies were delivered. Of these, 567 perinatal deaths were associated with 542 women. 972 mothers were randomly selected as controls. Medical. obstetric, and social data were collected for cases and controls from the medical notes and interviews with the women,The relative risks of perinatal death associated with treated and untreated infertility before the index pregnancy were estimated as odds ratios by means of unconditional logistic regression analysis. Findings. 65 (10%) of cases and 34 (3.5%) of the controls had infertility before the index pregnancy. History of infertility in the index pregnancy, irrespective of treatment, increased the risk of perinatal death (odds ratio 2.9 [95% Cl 1.8-4.5]). The population attributable risk fraction for perinatal death related to infertility was 62% (3.4-9.0). 45 (54%) of the deaths, even in the untreated group, were associated with immaturity. Compared with women without infertility, women with untreated infertility were at increased risk of perinatal death (3.3 [1.6-6.8]). The risk of perinatal death associated with multiple births did not explain this finding. Similarly, treated infertility also increased the risk of perinatal death (2.7 [1.5-4.7]); the risks associated with multiple births explained some, but not all, of this excess. In Leicestershire, the overall underlying risk of a mother experiencing at least one perinatal death over the study was 9.0 per 1000 women. For women who experience infertility, this risk increases by about 18 per 1000 (6-30). Interpretation. Counselling for women before any form of infertility treatment should include discussion of the risks of perinatal death. Our results would benefit from confirmation. However, we advocate that at antenatal booking a history of infertility, irrespective of treatment, should be sought, because these women have a significantly increased risk of perinatal death, particularly associated with prematurity.	Univ Leicester, Dept Epidemiol & Publ Hlth, Leicester LE1 6TP, Leics, England; TVW Telethon Inst Child Hlth Res, W Perth, Australia	University of Leicester; Telethon Kids Institute; University of Western Australia	Draper, ES (corresponding author), Univ Leicester, Dept Epidemiol & Publ Hlth, Leicester LE1 6TP, Leics, England.		Draper, Elizabeth/S-6874-2019; Draper, Elizabeth S/I-6304-2018; Abrams, Keith/AAA-2557-2020	Draper, Elizabeth/0000-0001-9340-8176; Draper, Elizabeth S/0000-0001-9340-8176; Abrams, Keith/0000-0002-7557-1567				BOTTING BJ, 1987, ARCH DIS CHILD, V62, P941, DOI 10.1136/adc.62.9.941; CLARKE M, 1988, BMJ-BRIT MED J, V297, P384, DOI 10.1136/bmj.297.6645.384; CLARKE M, 1993, BRIT MED J, V306, P824, DOI 10.1136/bmj.306.6881.824; CLARKE M, 1988, BRIT MED J, V296, P466, DOI 10.1136/bmj.296.6620.466; CLARKE M, 1981, AM J EPIDEMIOL, V113, P636, DOI 10.1093/oxfordjournals.aje.a113142; EZRA Y, 1993, EUR J OBSTET GYN R B, V48, P127, DOI 10.1016/0028-2243(93)90253-9; *HUM FERT EMBR AUT, 1996, 5 HFEA; KURINCZUK JJ, 1995, AUST NZ J OBSTET GYN, V35, P27, DOI 10.1111/j.1479-828X.1995.tb01825.x; LEVENE MI, 1992, BRIT J OBSTET GYNAEC, V99, P607, DOI 10.1111/j.1471-0528.1992.tb13831.x; MCFAUL PB, 1993, BRIT J OBSTET GYNAEC, V100, P820, DOI 10.1111/j.1471-0528.1993.tb14306.x; PETTERSON B, 1993, BRIT MED J, V307, P1239, DOI 10.1136/bmj.307.6914.1239; TAN SL, 1992, AM J OBSTET GYNECOL, V167, P778, DOI 10.1016/S0002-9378(11)91589-0; VENN A, 1993, AUST NZ J OBSTET GYN, V33, P379, DOI 10.1111/j.1479-828X.1993.tb02114.x; WIGGLESWORTH JS, 1980, LANCET, V2, P684; WILLIAMS MA, 1991, FERTIL STERIL, V56, P668	15	126	127	0	5	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAY 22	1999	353	9166					1746	1749		10.1016/S0140-6736(98)08500-6	http://dx.doi.org/10.1016/S0140-6736(98)08500-6			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	202TF	10347987				2022-12-28	WOS:000080667700012
J	Turk, DC; Okifuji, A				Turk, DC; Okifuji, A			Assessment of patients' reporting of pain: an integrated perspective	LANCET			English	Article							LOW-BACK-PAIN; FUNCTIONAL STATUS; DISABILITY; DEPRESSION; IMPACT; AGE	A common assumption about pain is that it always results from the presence of underlying organic pathology. In the absence of objective pathology, an individual's report of pain may be ascribed to psychological causes. There is a wide variation in patient's experience of pain and organic factors alone cannot explain individual differences in patients' reports. Assessment of patients who report pain requires attention to psychosocial, behavioural, and organic factors. We describe a comprehensive approach to the assessment of psychological and behavioural variables that affect patients' reports of pain. We counter the duality of the somatogenic versus psychogenic perspective and suggest a more integrated assessment that encompasses not only the severity of pain and related physical pathology but also the person who is reporting the presence of pain.	Univ Washington, Dept Anesthesiol, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle	Turk, DC (corresponding author), Univ Washington, Dept Anesthesiol, Mailbox 356540, Seattle, WA 98195 USA.				EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [P01HD033989] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R55AR044230, R01AR044724] Funding Source: NIH RePORTER; NIAMS NIH HHS [R55 AR44230, R01 AR 44724] Funding Source: Medline; NICHD NIH HHS [P01 HD33989] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		BECK AT, 1961, ARCH GEN PSYCHIAT, V4, P561, DOI 10.1001/archpsyc.1961.01710120031004; BERGNER M, 1981, MED CARE, V19, P787, DOI 10.1097/00005650-198108000-00001; BODEN SD, 1990, J BONE JOINT SURG AM, V72A, P403, DOI 10.2106/00004623-199072030-00013; BONICA J, 1990, MANAGEMENT PAIN, P12; CASEY KL, 1994, J NEUROPHYSIOL, V71, P802, DOI 10.1152/jn.1994.71.2.802; CHAPMAN CR, IN PRESS LANCET; Derbyshire SWG, 1998, PAIN, V76, P127, DOI 10.1016/S0304-3959(98)00034-7; DEYO RA, 1988, ARCH PHYS MED REHAB, V69, P1044; DEYO RA, 1983, SPINE, V8, P635, DOI 10.1097/00007632-198309000-00009; Fairbank J C, 1980, Physiotherapy, V66, P271; FLOR H, 1988, J BEHAV MED, V11, P251, DOI 10.1007/BF00844431; FORDYCE WE, 1976, BEHAV METHODS CHRONI; FRYMOYER J W, 1978, Spine, V3, P1, DOI 10.1097/00007632-197803000-00001; JENSEN MC, 1994, NEW ENGL J MED, V331, P69, DOI 10.1056/NEJM199407143310201; JENSEN MP, 1986, PAIN, V27, P117, DOI 10.1016/0304-3959(86)90228-9; JENSEN MP, 1991, PAIN, V47, P249, DOI 10.1016/0304-3959(91)90216-K; JETTE AM, 1987, J RHEUMATOL, V14, P15; MELLIN G, 1987, SPINE, V12, P464, DOI 10.1097/00007632-198706000-00008; MELZACK R, 1975, PAIN, V1, P277, DOI 10.1016/0304-3959(75)90044-5; MELZACK R, 1987, PAIN, V30, P191, DOI 10.1016/0304-3959(87)91074-8; MELZACK R, 1968, SKIN SENSE; NORTH RB, 1991, NEUROSURGERY, V28, P685, DOI 10.1227/00006123-199105000-00008; Osterweis M., 1987, PAIN DISABILITY CLIN; RADLOFF L S, 1977, Applied Psychological Measurement, V1, P385, DOI 10.1177/014662167700100306; RESSOR K, 1988, PAIN, V32, P35; ROLAND M, 1983, SPINE, V8, P141, DOI 10.1097/00007632-198303000-00004; ROMANO JM, 1985, PSYCHOL BULL, V97, P18, DOI 10.1037/0033-2909.97.1.18; Turk D. C., 1994, TXB PAIN; TURK DC, 1995, PAIN, V61, P93, DOI 10.1016/0304-3959(94)00167-D; TURK DC, 1994, BEHAV RES THER, V32, P9, DOI 10.1016/0005-7967(94)90078-7; TURK DC, 1992, HDB PAIN ASSESSMENT; WADDELL G, 1987, SPINE, V12, P632, DOI 10.1097/00007632-198709000-00002	32	123	126	1	6	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAY 22	1999	353	9166					1784	1788		10.1016/S0140-6736(99)01309-4	http://dx.doi.org/10.1016/S0140-6736(99)01309-4			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	202TF	10348007				2022-12-28	WOS:000080667700046
J	Diskin, CJ; Stokes, TJ; Dansby, LM; Carter, TB; Radcliff, L; Thomas, SG				Diskin, CJ; Stokes, TJ; Dansby, LM; Carter, TB; Radcliff, L; Thomas, SG			Towards an understanding of oedema	BRITISH MEDICAL JOURNAL			English	Article							ONCOTIC PRESSURE; EDEMA		Auburn Univ, Sch Pharm, Hypertens Nephrol Dialysis & Transplantat Clin, Auburn, AL 36849 USA	Auburn University System; Auburn University	Diskin, CJ (corresponding author), Auburn Univ, Sch Pharm, Hypertens Nephrol Dialysis & Transplantat Clin, Auburn, AL 36849 USA.			Diskin, Charles/0000-0002-1403-6261				BREASTED JH, 1930, E SMITH SURG PAPYRUS, P140; Bright R., 1827, REPORT MED CASES SEL; CANAANKUHL S, 1993, AM J PHYSIOL, V264, pF1052, DOI 10.1152/ajprenal.1993.264.6.F1052; Diskin CJ, 1998, NEPHRON, V78, P131, DOI 10.1159/000044900; Guardia JA, 1997, AM J KIDNEY DIS, V30, P822, DOI 10.1016/S0272-6386(97)90088-3; HAMMEL HT, 1995, AM J PHYSIOL-HEART C, V268, pH2133, DOI 10.1152/ajpheart.1995.268.5.H2133; JOLES JA, 1989, AM J PHYSIOL, V257, P23; MILROTO M, 1993, J COLLOID INTERF SCI, V159, P354; MIMRAN A, 1979, NEW ENGL J MED, V301, P1289; RICHET G, 1993, KIDNEY INT, V43, P1385, DOI 10.1038/ki.1993.195; SHARP KA, 1995, BIOPOLYMERS, V36, P227, DOI 10.1002/bip.360360210; Smorenburg C H, 1997, Ned Tijdschr Geneeskd, V141, P719; SPENCER WG, 1938, MEDICINA, P180; Starling EH., 1896, LANCET, V1, P1267	14	24	25	0	5	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JUN 12	1999	318	7198					1610	1613		10.1136/bmj.318.7198.1610	http://dx.doi.org/10.1136/bmj.318.7198.1610			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	207AL	10364127	Green Published			2022-12-28	WOS:000080913100036
J	Rowe, BH; Bota, GW; Fabris, L; Therrien, SA; Milner, RA; Jacono, J				Rowe, BH; Bota, GW; Fabris, L; Therrien, SA; Milner, RA; Jacono, J			Inhaled budesonide in addition to oral corticosteroids to prevent asthma relapse following discharge from the emergency department - A randomized controlled trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							QUALITY-OF-LIFE; DOUBLE-BLIND; FLUTICASONE PROPIONATE; ACUTE EXACERBATIONS; CLINICAL-TRIALS; THERAPY; QUESTIONNAIRE; CHILDREN; PLACEBO; ADULTS	Context. Relapses of acute asthma following emergency department (ED) discharge can be reduced with systemic corticosteroid treatment. However, whether inhaled corticosteroids (ICSs) provide additional benefit is not known. Objective. To determine whether the addition of ICSs to oral corticosteroid treatment would reduce relapses in patients with acute asthma discharged from the ED. Design and Setting. Placebo-controlled, double-blind, randomized clinical trial conducted in a community teaching hospital ED in Canada between November 1995 and September 1997, with a 21-day follow-up. Participants. A total of 1006 consecutive patients aged 16 to 60 years presented to the ED with acute asthma; after excluding those using oral and/or inhaled corticosteroids as well as those meeting other exclusion criteria, 188 were included in the study. Interventions. Patients were discharged with a nontapering course of oral prednisone (50 mg/d) for 7 days. In a double-blind fashion, patients were randomly assigned to 1600 mu g/d of inhaled budesonide (n = 94) or identical placebo (n = 94) for 21 days. Main Outcome Measures. Incidence of relapse, defined as an unscheduled visit for worsening asthma symptoms, in budesonide vs placebo groups. Secondary outcomes included response to the Asthma Quality of Life Questionnaire, beta(2)-agonist use, symptom score, global asthma improvement assessment, and pulmonary function. Results. Five patients in the budesonide group and 3 in the placebo group either dropped out or were lost to follow-up but were included in primary analyses. After 21 days, 12 (12.8%) of 94 patients in the budesonide group experienced a relapse compared with 23 (24.5%) of 94 in the placebo group, a 48% relapse reduction (P = .049). Asthma Quality of Life Questionnaire scores were higher (better quality) in the budesonide group (P = .001), as well as for all domain scores (P = .001 to .01). Fewer beta(2)-agonist activations were used at the end of the trial by patients receiving budesonide (2.4/d vs 4.2/d; P = .01). Symptom scores (P = .001 to .004) and self-assessed asthma improvement scores (based on a 7-point Likert scale) (6.2 vs 5.2; P < .001) were higher (indicating fewer symptoms) for budesonide vs placebo. There were no differences in pulmonary function between the groups (peak expiratory flow rate: budesonide, 437 vs placebo, 453 L/min; P = .39) at 21 days. Using this approach, as few as 9 patients would require budesonide to prevent 1 relapse. Conclusions. Patients discharged from the ED following treatment for acute asthma benefit from added treatment with high-dose inhaled budesonide for 21 days compared with oral corticosteroids alone.	Univ Alberta, Div Emergency Med, Edmonton, AB T6G 2B7, Canada; Sudbury Reg Hosp, Dept Emergency Med, Sudbury, ON, Canada; Sudbury Reg Hosp, Acute Care Res Grp, Sudbury, ON, Canada; Univ British Columbia, Vancouver, BC V5Z 1M9, Canada; Univ Malta, Inst Hlth Care, Guardamangia, Malta	University of Alberta; Health Sciences North; Health Sciences North; University of British Columbia; University of Malta	Rowe, BH (corresponding author), Univ Alberta, Div Emergency Med, Room 1G1-63 WMC,8440-112 St, Edmonton, AB T6G 2B7, Canada.							AYRES JG, 1995, EUR RESPIR J, V8, P579; Beveridge RC, 1996, CAN MED ASSOC J, V155, P25; Boulet LP, 1998, CHEST, V113, P587, DOI 10.1378/chest.113.3.587; BRENNER BE, 1998, CHEST S, V114, pS298; BRITTON J, 1992, BRIT MED J, V304, P857, DOI 10.1136/bmj.304.6831.857; CAMARGO CA, 1998, AM J RESP CRIT CARE, V157, pA623; CATES C, 1998, COCHRANE REV COMP HO; CHAPMAN KR, 1991, NEW ENGL J MED, V324, P788, DOI 10.1056/NEJM199103213241202; CHUNG KF, 1990, ASTHMA INFLAMMATORY, P159; DESHPANDE A, 1986, BRIT MED J, V293, P169, DOI 10.1136/bmj.293.6540.169; Emerman CL, 1999, CHEST, V115, P919, DOI 10.1378/chest.115.4.919; FIEL SB, 1983, AM J MED, V75, P259, DOI 10.1016/0002-9343(83)91202-0; FITZGERALD JM, 1990, CAN MED ASSOC J, V142, P591; FitzGerald JM, 1997, CHEST, V111, P311, DOI 10.1378/chest.111.2.311; GRUNFELD A, 1997, CLIN INVEST MED S, V20, pS14; HOFFMAN IB, 1988, CHEST, V93, P11, DOI 10.1378/chest.93.1.11; JUNIPER EF, 1994, J CLIN EPIDEMIOL, V47, P81, DOI 10.1016/0895-4356(94)90036-1; JUNIPER EF, 1992, THORAX, V47, P76, DOI 10.1136/thx.47.2.76; JUNIPER EF, 1993, AM REV RESPIR DIS, V147, P832, DOI 10.1164/ajrccm/147.4.832; JUNIPER L, 1992, DRUGS, V44, P375; Krahn MD, 1996, CAN MED ASSOC J, V154, P821; LEDERLE FA, 1987, ARCH INTERN MED, V147, P2201, DOI 10.1001/archinte.147.12.2201; Lee C H, 1993, Changgeng Yi Xue Za Zhi, V16, P25; Levy ML, 1996, THORAX, V51, P1087, DOI 10.1136/thx.51.11.1087; MAO Y, 1988, CMAJ, V137, P620; MCFADDEN ER, 1992, NEW ENGL J MED, V327, P1928, DOI 10.1056/NEJM199212313272708; MCNAMARA RM, 1993, ANN EMERG MED, V22, P1829, DOI 10.1016/S0196-0644(05)80409-3; Nana A, 1998, J ASTHMA, V35, P647, DOI 10.3109/02770909809048967; *NAT ASTHM ED PROG, 1991, PUBL NIH; *NAT ASTHM ED PROG, 1997, 2 NIH NAT ASTHM ED P; OBYRNE PM, 1994, CAN RESPIR J, V1, P189; ODRISCOLL BR, 1993, LANCET, V341, P324, DOI 10.1016/0140-6736(93)90134-3; ROWE BH, 1992, AM J EMERG MED, V10, P301, DOI 10.1016/0735-6757(92)90007-K; ROWE BH, 1993, AM REV RESPIR DIS, V148, P675, DOI 10.1164/ajrccm/148.3.675; ROWE BH, 1993, AM J EMERG MED, V11, P374, DOI 10.1016/0735-6757(93)90171-7; ROWE BH, 1998, EFFECTIVENESS CORTIC; SALMERON S, 1989, AM REV RESPIR DIS, V140, P167, DOI 10.1164/ajrccm/140.1.167; SHAPIRO GG, 1983, PEDIATRICS, V71, P510; Singh AK, 1999, AM J EMERG MED, V17, P144, DOI 10.1016/S0735-6757(99)90047-5; SMITH MJ, 1987, DRUGS, V33, P423, DOI 10.2165/00003495-198733050-00001; STABLEFORTH D, 1983, THORAX, V38, P801, DOI 10.1136/thx.38.11.801; STEPHENSON BJ, 1993, JAMA-J AM MED ASSOC, V269, P2779, DOI 10.1001/jama.269.21.2779; Verbeek PR, 1995, J EMERGENCY MED, V13, P15; WARD MJ, 1986, THORAX, V41, P824, DOI 10.1136/thx.41.11.824; WEISS KB, 1992, NEW ENGL J MED, V326, P862, DOI 10.1056/NEJM199203263261304; WILKINS K, 1993, CAN MED ASSOC J, V148, P185; WILSON NM, 1990, ARCH DIS CHILD, V65, P407, DOI 10.1136/adc.65.4.407; WOOLCOCK AJ, 1989, J ALLERGY CLIN IMMUN, V84, P975, DOI 10.1016/0091-6749(89)90397-7	48	118	123	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 9	1999	281	22					2119	2126		10.1001/jama.281.22.2119	http://dx.doi.org/10.1001/jama.281.22.2119			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	202TJ	10367823	Bronze			2022-12-28	WOS:000080668000035
J	Arai, Y; Yasuda, R; Akashi, K; Harada, Y; Miyata, H; Kinosita, K; Itoh, H				Arai, Y; Yasuda, R; Akashi, K; Harada, Y; Miyata, H; Kinosita, K; Itoh, H			Tying a molecular knot with optical tweezers	NATURE			English	Article							SINGLE ACTIN-FILAMENTS; TORSIONAL RIGIDITY; F-ACTIN; DNA; FORCE; MOTOR; MECHANICS; MYOSIN; STEPS; BOND	Filamentous structures are abundant in cells. Relatively rigid filaments, such as microtubules and actin, serve as intracellular scaffolds that support movement and force, and their mechanical properties are crucial to their function in the cell. Some aspects of the behaviour of DNA, meanwhile, depend critically on ins flexibility-for example, DNA-binding proteins can induce sharp bends in the helix(1). The mechanical characterization of such filaments has generally been conducted without controlling the filament shape, by the observation of thermal motions(2-5) or of the response to external forces(6-9) or flows(10-12). Controlled buckling of a microtubule has been reported(13), but the analysis of the buckled shape was complicated. Here we report the continuous control of the radius of curvature of a molecular strand by tying a knot in it, using optical tweezers to manipulate the strand's ends. We find that actin filaments break at the knot when the knot diameter falls below 0.4 mu m. The pulling force at breakage is around 1 pN, two orders of magnitude smaller than the tensile stress of a straight filament. The flexural rigidity of the filament remained unchanged down to this diameter. We have also knotted a single DNA molecule, opening up the possibility of studying curvature-dependent interactions with associated proteins. We find that the knotted DNA is stronger than actin.	Keio Univ, Fac Sci & Technol, Dept Phys, Kohoku Ku, Yokohama, Kanagawa 2238522, Japan; CREST Genet Programming Team 13, Miyamae Ku, Kawasaki, Kanagawa 2160001, Japan; Hamamatsu Photon KK, Tsukuba Res Lab, Tsukuba, Ibaraki 3002635, Japan	Keio University; Japan Science & Technology Agency (JST); Hamamatsu Photonics	Harada, Y (corresponding author), Keio Univ, Fac Sci & Technol, Dept Phys, Kohoku Ku, Hiyoshi 3-14-1, Yokohama, Kanagawa 2238522, Japan.		Yasuda, Ryohei/E-7726-2011	Yasuda, Ryohei/0000-0001-6263-9297				BENSIMON D, 1995, PHYS REV LETT, V74, P4754, DOI 10.1103/PhysRevLett.74.4754; Cluzel P, 1996, SCIENCE, V271, P792, DOI 10.1126/science.271.5250.792; Dupuis DE, 1997, J MUSCLE RES CELL M, V18, P17, DOI 10.1023/A:1018672631256; FINER JT, 1994, NATURE, V368, P113, DOI 10.1038/368113a0; GITTES F, 1993, J CELL BIOL, V120, P923, DOI 10.1083/jcb.120.4.923; Harada Y, 1999, BIOPHYS J, V76, P709, DOI 10.1016/S0006-3495(99)77237-1; HOLMES KC, 1990, NATURE, V347, P44, DOI 10.1038/347044a0; KURACHI M, 1995, CELL MOTIL CYTOSKEL, V30, P221, DOI 10.1002/cm.970300306; Landau L.D., 1970, THEORY ELASTICITY; Miyata H, 1996, BBA-GEN SUBJECTS, V1290, P83, DOI 10.1016/0304-4165(96)00003-7; MIYATA H, 1995, BIOPHYS J, V68, pS286; NISHIZAKA T, 1995, NATURE, V377, P251, DOI 10.1038/377251a0; OOSAWA F, 1973, COLD SPRING HARB SYM, V37, P277, DOI 10.1101/SQB.1973.037.01.038; PERKINS TT, 1994, SCIENCE, V264, P822, DOI 10.1126/science.8171336; Saitta AM, 1999, NATURE, V399, P46, DOI 10.1038/19935; SCHULTZ SC, 1991, SCIENCE, V253, P1001, DOI 10.1126/science.1653449; Smith DE, 1998, SCIENCE, V281, P1335, DOI 10.1126/science.281.5381.1335; Smith SB, 1996, SCIENCE, V271, P795, DOI 10.1126/science.271.5250.795; Suzuki N, 1996, BIOPHYS J, V70, P401, DOI 10.1016/S0006-3495(96)79583-8; Tsuda Y, 1996, P NATL ACAD SCI USA, V93, P12937, DOI 10.1073/pnas.93.23.12937; Yanagida M, 1983, Cold Spring Harb Symp Quant Biol, V47 Pt 1, P177; YANAGIDA T, 1984, NATURE, V307, P58, DOI 10.1038/307058a0; Yasuda R, 1998, CELL, V93, P1117, DOI 10.1016/S0092-8674(00)81456-7; Yasuda R, 1996, J MOL BIOL, V263, P227, DOI 10.1006/jmbi.1996.0571	24	250	267	3	79	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUN 3	1999	399	6735					446	448		10.1038/20894	http://dx.doi.org/10.1038/20894			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	202TH	10365955				2022-12-28	WOS:000080667900042
J	Ibdah, JA; Bennett, MJ; Rinaldo, P; Zhao, YW; Gibson, B; Sims, HF; Strauss, AW				Ibdah, JA; Bennett, MJ; Rinaldo, P; Zhao, YW; Gibson, B; Sims, HF; Strauss, AW			A fetal fatty-acid oxidation disorder as a cause of liver disease in pregnant women	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CHAIN 3-HYDROXYACYL-COA DEHYDROGENASE; TRIFUNCTIONAL PROTEIN-DEFICIENCY; ALPHA-SUBUNIT; MOLECULAR CHARACTERIZATION; G1528C MUTATION; BETA-OXIDATION; DIAGNOSIS; ENZYMES; NEUROPATHY; HEMOLYSIS	Background Acute fatty liver of pregnancy and the HELLP syndrome (hemolysis, elevated liver-enzyme levels, and a low platelet count) are serious hepatic disorders that may occur during pregnancy in women whose fetuses are later found to have a deficiency of long-chain 3-hydroxyacyl-coenzyme A (CoA) dehydrogenase. This enzyme resides in the mitochondrial trifunctional protein, which also contains the active site of long-chain 2,3-enoyl-CoA hydratase and long-chain 3-ketoacyl-CoA thiolase. We undertook this study to determine the relation between mutations in the trifunctional protein in infants with defects in fatty-acid oxidation and acute liver disease during pregnancy in their mothers. Methods In 24 children with 3-hydroxyacyl-CoA dehydrogenase deficiency, we used DNA amplification and nucleotide-sequence analyses to identify mutations in the alpha subunit of the trifunctional protein. We then correlated the results with the presence of liver disease during pregnancy in the mothers. Results Nineteen children had a deficiency only of long-chain 3-hydroxyacyl-CoA dehydrogenase and presented with hypoketotic hypoglycemia and fatty liver. In eight children, we identified a homozygous mutation in which glutamic acid at residue 474 was changed to glutamine. Eleven other children were compound heterozygotes, with this mutation in one allele of the alpha-subunit gene and a different mutation in the other allele. While carrying fetuses with the Glu474Gln mutation, 79 percent of the heterozygous mothers had fatty liver of pregnancy or the HELLP syndrome. Five other children, who presented with neonatal dilated cardiomyopathy or progressive neuromyopathy, had complete deficiency of the trifunctional protein (loss of activity of all three enzymes). None had the Glu474Gln mutation, and none of their mothers had liver disease during pregnancy. Conclusions Women with acute liver disease during pregnancy may have a Glu474Gln mutation in long-chain hydroxyacyl-CoA dehydrogenase. Their infants are at risk for hypoketotic hypoglycemia and fatty liver. (N Engl J Med 1999;340:1723-31.) (C) 1999, Massachusetts Medical Society.	Wake Forest Univ, Dept Internal Med, Winston Salem, NC USA; Univ Texas, SW Med Ctr, Dept Pathol, Dallas, TX USA; Univ Texas, SW Med Ctr, Dept Pediat, Dallas, TX USA; Mayo Clin, Dept Lab Med, Rochester, MN USA; Mayo Clin, Dept Pathol, Rochester, MN USA; Washington Univ, Sch Med, Dept Pediat, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Mol Biol & Pharmacol, St Louis, MO 63110 USA	Wake Forest University; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Mayo Clinic; Mayo Clinic; Washington University (WUSTL); Washington University (WUSTL)	Strauss, AW (corresponding author), St Louis Childrens Hosp, 1 Childrens Pl, St Louis, MO 63110 USA.			Ibdah, Jamal/0000-0002-5646-9014	NIADDK NIH HHS [AM-20407] Funding Source: Medline; NIDDK NIH HHS [5T32 DK-07130, DK-02574] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K08DK002574, T32DK007130] Funding Source: NIH RePORTER	NIADDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Ausubel FM., 1987, CURRENT PROTOCOLS MO, DOI 10.1002/mrd.1080010210; BENNETT MJ, 1990, ANN CLIN BIOCHEM, V27, P519, DOI 10.1177/000456329002700602; BRACKETT JC, 1995, J CLIN INVEST, V95, P2076, DOI 10.1172/JCI117894; GRIMBERT S, 1993, HEPATOLOGY, V17, P628, DOI 10.1002/hep.1840170417; IJLST L, 1994, BBA-LIPID LIPID MET, V1215, P347, DOI 10.1016/0005-2760(94)90064-7; Ijlst L, 1996, J CLIN INVEST, V98, P1028, DOI 10.1172/JCI118863; Isaacs JD, 1996, PEDIATR RES, V40, P393, DOI 10.1203/00006450-199609000-00005; JACKSON S, 1992, J CLIN INVEST, V90, P1219, DOI 10.1172/JCI115983; JACKSON S, 1991, PEDIATR RES, V29, P406, DOI 10.1203/00006450-199104000-00016; Knox TA, 1996, NEW ENGL J MED, V335, P569, DOI 10.1056/NEJM199608223350807; Mansouri A, 1996, J HEPATOL, V25, P781, DOI 10.1016/S0168-8278(96)80254-6; ORITA M, 1989, P NATL ACAD SCI USA, V86, P2766, DOI 10.1073/pnas.86.8.2766; PEREZCERDA C, 1993, PRENATAL DIAG, V13, P529, DOI 10.1002/pd.1970130616; REYES H, 1994, GUT, V35, P101, DOI 10.1136/gut.35.1.101; RIELY CA, 1987, ANN INTERN MED, V106, P703, DOI 10.7326/0003-4819-106-5-703; Rinaldo Piero, 1998, Current Opinion in Pediatrics, V10, P615; SCHOEMAN MN, 1991, GASTROENTEROLOGY, V100, P544, DOI 10.1016/0016-5085(91)90228-D; SIBAI BM, 1993, AM J OBSTET GYNECOL, V169, P1000, DOI 10.1016/0002-9378(93)90043-I; SIMS HF, 1995, P NATL ACAD SCI USA, V92, P841, DOI 10.1073/pnas.92.3.841; TEIN I, 1995, PEDIATR NEUROL, V12, P68, DOI 10.1016/0887-8994(94)00109-F; Treem WR, 1996, AM J GASTROENTEROL, V91, P2293; Tyni T, 1998, OPHTHALMOLOGY, V105, P810, DOI 10.1016/S0161-6420(98)95019-9; Tyni T, 1997, J PEDIATR-US, V130, P67, DOI 10.1016/S0022-3476(97)70312-3; Tyni T, 1998, AM J OBSTET GYNECOL, V178, P603, DOI 10.1016/S0002-9378(98)70446-6; UCHIDA Y, 1992, J BIOL CHEM, V267, P1034; Ushikubo S, 1996, AM J HUM GENET, V58, P979; USTA IM, 1994, AM J OBSTET GYNECOL, V171, P1342, DOI 10.1016/0002-9378(94)90158-9; VICI CD, 1991, J PEDIATR-US, V118, P744, DOI 10.1016/S0022-3476(05)80039-3; WANDERS RJA, 1989, LANCET, V2, P52, DOI 10.1016/S0140-6736(89)90300-0; WANDERS RJA, 1992, BIOCHEM BIOPH RES CO, V188, P1139, DOI 10.1016/0006-291X(92)91350-Y; WILCKEN B, 1993, LANCET, V341, P407, DOI 10.1016/0140-6736(93)92993-4	31	291	308	0	9	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 3	1999	340	22					1723	1731		10.1056/NEJM199906033402204	http://dx.doi.org/10.1056/NEJM199906033402204			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	201WQ	10352164				2022-12-28	WOS:000080620200004
J	Kruuk, LEB; Clutton-Brock, TH; Albon, SD; Pemberton, JM; Guinness, FE				Kruuk, LEB; Clutton-Brock, TH; Albon, SD; Pemberton, JM; Guinness, FE			Population density affects sex ratio variation in red deer	NATURE			English	Article							PARENTAL INVESTMENT; BREEDING SUCCESS; DOMINANCE RANK; CERVUS-ELAPHUS; ROE DEER; DAUGHTERS; SONS; SELECTION; PATTERNS; MAMMALS	Many mammal populations show significant deviations from an equal sex ratio at birth, but these effects are notoriously inconsistent(1). This may be because more than one mechanism affects the sex ratio and the action of these mechanisms depends on environmental conditions. Here we show that the adaptive relationship between maternal dominance and offspring sex ratio previously demonstrated in red deer (Cervus elaphus)(2,3), where dominant females produced more males, disappeared at high population density. The proportion of males born each year declined with increasing population density and with winter rainfall, both of which are environmental variables associated with nutritional stress during pregnancy. These changes in the sex ratio corresponded to reductions in fecundity, suggesting that they were caused by differential fetal loss. In contrast, the earlier association with maternal dominance is presumed to have been generated pre-implantation. The effects of one source of variation superseded the other within about two generations. Comparison with other ungulate studies indicates that positive associations between maternal quality and the proportion of male offspring born have only been documented in populations below carrying capacity.	Univ Cambridge, Dept Zool, Cambridge CB2 3EJ, England; Univ Edinburgh, Inst Cell Anim & Populat Biol, Edinburgh EH9 3JT, Midlothian, Scotland; Inst Terr Ecol, Banchory AB31 4BY, Kincardine, Scotland	University of Cambridge; University of Edinburgh; UK Centre for Ecology & Hydrology (UKCEH)	Kruuk, LEB (corresponding author), Univ Cambridge, Dept Zool, Downing St, Cambridge CB2 3EJ, England.	Loeske.Kruuk@ed.ac.uk	ALBON, Stephen D/C-6304-2011; Pemberton, Josephine M/F-3100-2010; Kruuk, Loeske/AAB-8714-2019; Kruuk, Loeske E. B./J-3295-2012	ALBON, Stephen D/0000-0002-0811-1333; Kruuk, Loeske/0000-0001-8588-1123; Kruuk, Loeske E. B./0000-0001-8588-1123				ALBON SD, 1987, J ANIM ECOL, V56, P69, DOI 10.2307/4800; Birgersson B, 1998, BEHAV ECOL, V9, P404, DOI 10.1093/beheco/9.4.404; Cassinello J, 1996, BEHAV ECOL SOCIOBIOL, V38, P417, DOI 10.1007/s002650050259; CLUTTONBROCK TH, 1986, ANIM BEHAV, V34, P460, DOI 10.1016/S0003-3472(86)80115-4; CLUTTONBROCK TH, 1986, Q REV BIOL, V61, P339, DOI 10.1086/415033; CLUTTONBROCK TH, 1984, NATURE, V308, P358, DOI 10.1038/308358a0; CLUTTONBROCK TH, 1985, NATURE, V313, P131, DOI 10.1038/313131a0; FESTABIANCHET M, 1991, ANIM BEHAV, V42, P71, DOI 10.1016/S0003-3472(05)80607-4; Flint APF, 1997, HORM BEHAV, V31, P296, DOI 10.1006/hbeh.1997.1391; Flint APF, 1997, GEN COMP ENDOCR, V106, P374, DOI 10.1006/gcen.1997.6879; GOMENDIO M, 1990, NATURE, V343, P261, DOI 10.1038/343261a0; GREEN WCH, 1991, BEHAV ECOL SOCIOBIOL, V29, P373, DOI 10.1007/BF00165963; Hewison AJM, 1996, BEHAV ECOL, V7, P461, DOI 10.1093/beheco/7.4.461; HIRAIWAHASEGAWA M, 1993, TRENDS ECOL EVOL, V8, P395, DOI 10.1016/0169-5347(93)90040-V; KENT JP, 1995, BEHAV ECOL SOCIOBIOL, V36, P101, DOI 10.1007/BF00170714; KOJOLA I, 1989, EVOLUTION, V43, P1331, DOI [10.2307/2409370, 10.1111/j.1558-5646.1989.tb02582.x]; LLOYD PH, 1989, BEHAV ECOL SOCIOBIOL, V25, P411, DOI 10.1007/BF00300187; Meikle DB, 1996, ETHOLOGY, V102, P969, DOI 10.1111/j.1439-0310.1996.tb01174.x; RUTBERG AT, 1986, AM NAT, V127, P89, DOI 10.1086/284469; SCHALL R, 1991, BIOMETRIKA, V78, P719; TRIVERS RL, 1973, SCIENCE, V179, P90, DOI 10.1126/science.179.4068.90; WAUTERS LA, 1995, BEHAV ECOL SOCIOBIOL, V37, P189, DOI 10.1007/s002650050180; [No title captured]; [No title captured]; [No title captured]	25	282	288	2	114	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	JUN 3	1999	399	6735					459	461		10.1038/20917	http://dx.doi.org/10.1038/20917			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	202TH	10365956				2022-12-28	WOS:000080667900046
J	Recker, RR; Davies, KM; Dowd, RM; Heaney, RP				Recker, RR; Davies, KM; Dowd, RM; Heaney, RP			The effect of low-dose continuous estrogen and progesterone therapy with calcium and vitamin D on bone in elderly women - A randomized, controlled trial	ANNALS OF INTERNAL MEDICINE			English	Article						estrogen replacement therapy; dose-response relationship, drug; osteoporosis, postmenopausal; calcium; vitamin D	POSTMENOPAUSAL WOMEN; REPLACEMENT THERAPY; OOPHORECTOMIZED WOMEN; HORMONE REPLACEMENT; ENDOMETRIAL CANCER; HIP-FRACTURES; PREVENTION; OSTEOPOROSIS; RISK; MASS	Background: Hormone replacement therapy (HRT), the mainstay of osteoporosis prevention, is limited because of dose-related risks, side effects, and patient acceptance. The bone-sparing efficacy and tolerability of the lowest available doses of HRT have not been adequately studied in elderly women. Objective: To determine the bone-sparing effect of continuous low-dose HRT in elderly women. Design: Randomized, double-blind, placebo-controlled trial. Setting: University osteoporosis research and clinical center. Patients: 128 healthy white women (age > 65 years) with low bone mass recruited by word of mouth and by local advertisement. The principal eligibility criterion was spinal bone mineral density of 0.90 g/cm(2) or less. Intervention: Continuous therapy with conjugated equine estrogen, 0.3 mg/d, and medroxyprogesterone, 2.5 mg/d, or matching placebo. Sufficient calcium supplementation was given to bring all calcium intakes above 1000 mg/d in both groups; supplemental oral 25-hydroxyvitamin D was given to maintain serum 25-hydroxyvitamin D levels of at least 75 nmol/L in both groups. Measurements: Bone mineral density of the spine, hip, total body, and forearm; serum total alkaline phosphatase and serum osteocalcin levels at 6-month intervals; and 24-hour urine creatinine and hydroxyproline excretion at baseline, 12 months, and 42 months. Results: During 3.5 years of observation, spinal bone mineral density increased by 3.5% (P < 0.001) in an intention-to-treat analysis and by 5.2% among patients with greater than 90% adherence to therapy. Significant increases were seen in total-body and forearm bone density (P < 0.01). Symptoms related to HRT (breast tenderness, spotting, pelvic discomfort, and mood changes) were mild and short-lived. Conclusions: Continuous low-dose HRT with conjugated equine estrogen and oral medroxyprogesterone combined with adequate calcium and vitamin D provides a bone-sparing effect that is similar or superior to that provided by other, higher-dose HRT regimens in elderly women. This combination is well tolerated by most patients.	Creighton Univ, Osteoporosis Res Ctr, Sch Med, Omaha, NE 68131 USA	Creighton University	Recker, RR (corresponding author), Creighton Univ, Osteoporosis Res Ctr, Sch Med, 601 N 30th St 5766, Omaha, NE 68131 USA.				NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P50AR039221] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR-39221] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ARNOLD J. S., 1966, CLIN ORTHOP RELATED RES, V49, P17; Barger-Lux MJ, 1998, OSTEOPOROSIS INT, V8, P222, DOI 10.1007/s001980050058; Beresford SAA, 1997, LANCET, V349, P458, DOI 10.1016/S0140-6736(96)07365-5; BURING JE, 1986, AM J EPIDEMIOL, V124, P434, DOI 10.1093/oxfordjournals.aje.a114414; Bush TL, 1996, JAMA-J AM MED ASSOC, V276, P1389, DOI 10.1001/jama.276.17.1389; CANN CE, 1980, JAMA-J AM MED ASSOC, V244, P2056; CHAPUY MC, 1992, NEW ENGL J MED, V327, P1637, DOI 10.1056/NEJM199212033272305; CHRISTIANSEN C, 1980, EUR J CLIN INVEST, V10, P273, DOI 10.1111/j.1365-2362.1980.tb00033.x; COLDITZ GA, 1995, NEW ENGL J MED, V332, P1589, DOI 10.1056/NEJM199506153322401; Cushing KL, 1998, OBSTET GYNECOL, V91, P35, DOI 10.1016/S0029-7844(97)00577-2; DAVIES KM, 1993, OSTEOPOROSIS INT, V3, P265, DOI 10.1007/BF01623831; DAVIES KM, 1989, J BONE MINER RES, V4, P341; DAWSONHUGHES B, 1991, ANN INTERN MED, V115, P505, DOI 10.7326/0003-4819-115-7-505; DawsonHughes B, 1997, AM J CLIN NUTR, V65, P67, DOI 10.1093/ajcn/65.1.67; ETTINGER B, 1993, CLIN THER, V15, P950; ETTINGER B, 1992, AM J OBSTET GYNECOL, V166, P479, DOI 10.1016/0002-9378(92)91653-R; ETTINGER B, 1987, ANN INTERN MED, V106, P40, DOI 10.7326/0003-4819-106-1-40; GALLAGHER JC, 1991, AM J MED, V90, P171; Gambrell RD, 1997, AM J OBSTET GYNECOL, V177, P1196, DOI 10.1016/S0002-9378(97)70040-1; GENANT HK, 1990, OBSTET GYNECOL, V76, P579; Genant HK, 1997, ARCH INTERN MED, V157, P2609, DOI 10.1001/archinte.157.22.2609; GLUER CC, 1995, OSTEOPOROSIS INT, V5, P262, DOI 10.1007/BF01774016; GRADY D, 1992, ANN INTERN MED, V117, P1038; HAHN RG, 1989, AM J OBSTET GYNECOL, V161, P1854, DOI 10.1016/S0002-9378(89)80006-7; HARRIS ST, 1991, ARCH INTERN MED, V151, P1980, DOI 10.1001/archinte.151.10.1980; HEANEY RP, 1994, J BONE MINER RES, V9, P1515; HORSMAN A, 1977, BRIT MED J, V2, P789, DOI 10.1136/bmj.2.6090.789; HORSMAN A, 1983, NEW ENGL J MED, V309, P1405, DOI 10.1056/NEJM198312083092301; Hulley S, 1998, JAMA-J AM MED ASSOC, V280, P605, DOI 10.1001/jama.280.7.605; KRALL EA, 1989, NEW ENGL J MED, V321, P1777, DOI 10.1056/NEJM198912283212602; LINDSAY R, 1980, LANCET, V2, P1151; LINDSAY R, 1976, LANCET, V1, P1038; LINDSAY R, 1978, LANCET, V1, P1325; LINDSAY R, 1984, OBSTET GYNECOL, V63, P759; LINDSAY R, 1993, AM J MED, V95, pS37, DOI 10.1016/0002-9343(93)90380-8; Littell R. C., 2006, SAS SYSTEMS MIXED MO, V2nd; MACLENNAN AH, 1993, MED J AUSTRALIA, V159, P102, DOI 10.5694/j.1326-5377.1993.tb137744.x; NACHTIGALL LE, 1979, OBSTET GYNECOL, V53, P277; NILAS L, 1987, J CLIN ENDOCR METAB, V65, P697, DOI 10.1210/jcem-65-4-697; Notelovitz M, 1997, MENOPAUSE, V4, P80; PAGANINIHILL A, 1981, ANN INTERN MED, V95, P28, DOI 10.7326/0003-4819-95-1-28; Parfitt A. M., 1983, BONE HISTOMORPHOMETR, P86; Raisz LG, 1996, J CLIN ENDOCR METAB, V81, P37, DOI 10.1210/jc.81.1.37; RAVNIKAR VA, 1987, AM J OBSTET GYNECOL, V156, P1332, DOI 10.1016/0002-9378(87)90173-6; RECKER RR, 1993, J BONE MINER RES, V8, pS154; RECKER RR, 1977, ANN INTERN MED, V87, P649, DOI 10.7326/0003-4819-87-6-649; RICHELSON LS, 1984, NEW ENGL J MED, V311, P1273, DOI 10.1056/NEJM198411153112002; RIGGS BL, 1990, NEW ENGL J MED, V322, P802, DOI 10.1056/NEJM199003223221203; Riggs BL, 1998, J BONE MINER RES, V13, P168, DOI 10.1359/jbmr.1998.13.2.168; SELBY PL, 1986, BRIT MED J, V293, P1337, DOI 10.1136/bmj.293.6558.1337; Speroff L, 1996, JAMA-J AM MED ASSOC, V276, P1397, DOI 10.1001/jama.276.17.1397; WEBBER CE, 1994, MATURITAS, V19, P13, DOI 10.1016/0378-5122(94)90037-X; WEISS NS, 1980, NEW ENGL J MED, V303, P1195, DOI 10.1056/NEJM198011203032102; Westerlind KC, 1998, J BONE MINER RES, V13, P1023, DOI 10.1359/jbmr.1998.13.6.1023; Zumoff B, 1998, P SOC EXP BIOL MED, V217, P30	56	178	186	0	6	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 1	1999	130	11					897	+		10.7326/0003-4819-130-11-199906010-00005	http://dx.doi.org/10.7326/0003-4819-130-11-199906010-00005			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	200PB	10375338				2022-12-28	WOS:000080547900004
J	Martin, SG; Laroche, T; Suka, N; Grunstein, M; Gasser, SM				Martin, SG; Laroche, T; Suka, N; Grunstein, M; Gasser, SM			Relocalization of telomeric Ku and SIR proteins in response to DNA strand breaks in yeast	CELL			English	Article							ASSEMBLY FACTOR-I; MATING-TYPE LOCI; SACCHAROMYCES-CEREVISIAE; V(D)J RECOMBINATION; SILENCING FACTORS; REPAIR; CHROMATIN; DAMAGE; REPRESSION; GENES	Telomeric TG-rich repeats and their associated proteins protect the termini of eukaryotic chromosomes from end-to-end fusions. Associated with the cap structure at yeast telomeres is a subtelomeric domain of heterochromatin, containing the silent information regulator (SIR) complex. The Ku70/80 heterodimer (yKu) is associated both with the chromosome end and with subtelomeric chromatin. Surprisingly, both yKu and the chromatin-associated Rap1 and SIR proteins are released from telomeres in a RADS-dependent response to DNA damage. yKu is recruited rapidly to double-strand cuts, while low levels of SIR proteins are detected near cleavage sites at later time points. Consistently, yKu- or SIR-deficient strains are hypersensitive to DNA-damaging agents. The release of yKu from telomeric chromatin may allow efficient scanning of the genome for DNA strand breaks.	Swiss Inst Expt Canc Res, CH-1066 Epalinges, Switzerland; Univ Calif Los Angeles, Sch Med, Dept Biol Chem, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Inst Mol Biol, Los Angeles, CA 90095 USA	Swiss Institute Experimental Cancer Research; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles	Gasser, SM (corresponding author), Swiss Inst Expt Canc Res, Ch Boveresses 155, CH-1066 Epalinges, Switzerland.	sgasser@eliot.unil.ch	Martin, Sophie/AAE-3198-2019	Martin, Sophie/0000-0002-5317-2557; Gasser, Susan/0000-0003-3610-9123				Andrulis ED, 1998, NATURE, V394, P592, DOI 10.1038/29100; APARICIO OM, 1991, CELL, V66, P1279, DOI 10.1016/0092-8674(91)90049-5; Astrom SU, 1999, NATURE, V397, P310, DOI 10.1038/16833; Boscheron C, 1996, EMBO J, V15, P2184, DOI 10.1002/j.1460-2075.1996.tb00572.x; Boulton SJ, 1998, EMBO J, V17, P1819, DOI 10.1093/emboj/17.6.1819; Cockell M, 1998, COLD SPRING HARB SYM, V63, P401, DOI 10.1101/sqb.1998.63.401; Critchlow SE, 1998, TRENDS BIOCHEM SCI, V23, P394, DOI 10.1016/S0968-0004(98)01284-5; Dynan WS, 1998, NUCLEIC ACIDS RES, V26, P1551, DOI 10.1093/nar/26.7.1551; Enomoto S, 1997, GENE DEV, V11, P358, DOI 10.1101/gad.11.3.358; Gaillard PHL, 1996, CELL, V86, P887, DOI 10.1016/S0092-8674(00)80164-6; Gotta M, 1996, J CELL BIOL, V134, P1349, DOI 10.1083/jcb.134.6.1349; GOTTSCHLING DE, 1990, CELL, V63, P751, DOI 10.1016/0092-8674(90)90141-Z; Gravel S, 1998, SCIENCE, V280, P741, DOI 10.1126/science.280.5364.741; Gu YS, 1997, IMMUNITY, V7, P653, DOI 10.1016/S1074-7613(00)80386-6; Haber JE, 1998, CELL, V95, P583, DOI 10.1016/S0092-8674(00)81626-8; Hayashi A, 1998, GENES CELLS, V3, P587, DOI 10.1046/j.1365-2443.1998.00215.x; Jackson SP, 1997, NATURE, V388, P829, DOI 10.1038/42136; JEGGO PA, 1995, BIOESSAYS, V17, P949, DOI 10.1002/bies.950171108; Kaufman PD, 1997, GENE DEV, V11, P345, DOI 10.1101/gad.11.3.345; Kennedy BK, 1997, CELL, V89, P381, DOI 10.1016/S0092-8674(00)80219-6; KIMMERLY WJ, 1987, MOL CELL BIOL, V7, P4225, DOI 10.1128/MCB.7.12.4225; Laroche T, 1998, CURR BIOL, V8, P653, DOI 10.1016/S0960-9822(98)70252-0; Lee SE, 1998, CELL, V94, P399, DOI 10.1016/S0092-8674(00)81482-8; Lieber MR, 1997, CURR OPIN GENET DEV, V7, P99, DOI 10.1016/S0959-437X(97)80116-5; Longtine MS, 1998, YEAST, V14, P953, DOI 10.1002/(SICI)1097-0061(199807)14:10<953::AID-YEA293>3.3.CO;2-L; Mages GJ, 1996, J BIOL CHEM, V271, P7910, DOI 10.1074/jbc.271.14.7910; Maillet L, 1996, GENE DEV, V10, P1796, DOI 10.1101/gad.10.14.1796; Marcand S, 1996, GENE DEV, V10, P1297, DOI 10.1101/gad.10.11.1297; Martini E, 1998, J CELL BIOL, V143, P563, DOI 10.1083/jcb.143.3.563; MILLER AM, 1984, NATURE, V312, P247, DOI 10.1038/312247a0; Nugent CI, 1998, CURR BIOL, V8, P657, DOI 10.1016/S0960-9822(98)70253-2; Nussenzweig A, 1996, NATURE, V382, P551, DOI 10.1038/382551a0; PALLADINO F, 1993, CELL, V75, P543, DOI 10.1016/0092-8674(93)90388-7; Polotnianka RM, 1998, CURR BIOL, V8, P831, DOI 10.1016/S0960-9822(98)70325-2; Porter SE, 1996, NUCLEIC ACIDS RES, V24, P582, DOI 10.1093/nar/24.4.582; Povirk LF, 1996, MUTAT RES-FUND MOL M, V355, P71, DOI 10.1016/0027-5107(96)00023-1; Rose MD., 1990, METHODS YEAST GENETI; SANDELL LL, 1993, CELL, V75, P729, DOI 10.1016/0092-8674(93)90493-A; SCHWARTZ JL, 1989, MUTAT RES, V216, P111, DOI 10.1016/0165-1161(89)90011-3; Shore D, 1998, SCIENCE, V281, P1818, DOI 10.1126/science.281.5384.1818; Siede W, 1996, GENETICS, V142, P91; StrahlBolsinger S, 1997, GENE DEV, V11, P83, DOI 10.1101/gad.11.1.83; Toczyski DP, 1997, CELL, V90, P1097, DOI 10.1016/S0092-8674(00)80375-X; Tsukamoto Y, 1997, NATURE, V388, P900, DOI 10.1038/42288; Weinert T, 1998, CURR OPIN GENET DEV, V8, P185, DOI 10.1016/S0959-437X(98)80140-8	45	393	402	0	7	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAY 28	1999	97	5					621	633		10.1016/S0092-8674(00)80773-4	http://dx.doi.org/10.1016/S0092-8674(00)80773-4			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	202VD	10367891	Bronze			2022-12-28	WOS:000080672100011
J	Nelson, KE; Clayton, RA; Gill, SR; Gwinn, ML; Dodson, RJ; Haft, DH; Hickey, EK; Peterson, LD; Nelson, WC; Ketchum, KA; McDonald, L; Utterback, TR; Malek, JA; Linher, KD; Garrett, MM; Stewart, AM; Cotton, MD; Pratt, MS; Phillips, CA; Richardson, D; Heidelberg, J; Sutton, GG; Fleischmann, RD; Eisen, JA; White, O; Salzberg, SL; Smith, HO; Venter, JC; Fraser, CM				Nelson, KE; Clayton, RA; Gill, SR; Gwinn, ML; Dodson, RJ; Haft, DH; Hickey, EK; Peterson, LD; Nelson, WC; Ketchum, KA; McDonald, L; Utterback, TR; Malek, JA; Linher, KD; Garrett, MM; Stewart, AM; Cotton, MD; Pratt, MS; Phillips, CA; Richardson, D; Heidelberg, J; Sutton, GG; Fleischmann, RD; Eisen, JA; White, O; Salzberg, SL; Smith, HO; Venter, JC; Fraser, CM			Evidence for lateral gene transfer between Archaea and Bacteria from genome sequence of Thermotoga maritima	NATURE			English	Article							ESCHERICHIA-COLI; PROTEIN; EUBACTERIA; SPIROCHETE; TREES	The 1,860,725-base-pair genome of Thermotoga maritima MSB8 contains 1,877 predicted coding regions, 1,014 (54%) of which have functional assignments and 863 (46%) of which are of unknown function. Genome analysis reveals numerous pathways involved in degradation of sugars and plant polysaccharides, and 108 genes that have orthologues only in the genomes of other thermophilic Eubacteria and Archaea. Of the Eubacteria sequenced to date, T. maritima has the highest percentage (24%) of genes that are most similar to archaeal genes. Eighty-one archaeal-like genes are clustered in 15 regions of the T. maritima genome that range in sire from 4 to 20 kilobases. Conservation of gene order between T. maritima and Archaea in many of the clustered regions suggests that lateral gene transfer may have occurred between thermophilic Eubacteria and Archaea.	Inst Genome Res, Rockville, MD 20850 USA	J. Craig Venter Institute	Fraser, CM (corresponding author), Inst Genome Res, 9712 Med Ctr Dr, Rockville, MD 20850 USA.	btm@tigi.org	Salzberg, Steven L/F-6162-2011; Eisen, Jonathan A./H-2706-2019; Nelson, William C/E-9263-2016; Salzberg, Steven/Q-6514-2019	Salzberg, Steven L/0000-0002-8859-7432; Eisen, Jonathan A./0000-0002-0159-2197; Nelson, William C/0000-0002-1873-3929; Salzberg, Steven/0000-0002-8859-7432; Fraser, Claire/0000-0003-1462-2428; Heidelberg, John/0000-0003-0673-3224				ACHENBACHRICHTER L, 1987, SYST APPL MICROBIOL, V9, P34, DOI 10.1016/S0723-2020(87)80053-X; Altschul Stephen F., J MOL BIOL, V215, P403, DOI [10.1016/S0022-2836(05)80360-2, DOI 10.1016/S0022-2836(05)80360-2]; Blattner FR, 1997, SCIENCE, V277, P1453, DOI 10.1126/science.277.5331.1453; BOOS W, 1996, ESCHERICHIA COLI SAL, P1175; BRONNENMEIER K, 1995, APPL ENVIRON MICROB, V61, P1399, DOI 10.1128/AEM.61.4.1399-1407.1995; Brown JR, 1997, MICROBIOL MOL BIOL R, V61, P456, DOI 10.1128/.61.4.456-502.1997; Bult CJ, 1996, SCIENCE, V273, P1058, DOI 10.1126/science.273.5278.1058; CLAROS MG, 1994, COMPUT APPL BIOSCI, V10, P685; Cole ST, 1998, NATURE, V393, P537, DOI 10.1038/31159; Curnow AW, 1996, NATURE, V382, P589, DOI 10.1038/382589b0; Deckert G, 1998, NATURE, V392, P353, DOI 10.1038/32831; Dubnau D, 1997, GENE, V192, P191, DOI 10.1016/S0378-1119(96)00804-9; Eisen JA, 1995, J MOL EVOL, V41, P1105; FELIX CR, 1993, ANNU REV MICROBIOL, V47, P791, DOI 10.1146/annurev.micro.47.1.791; FLEISCHMANN RD, 1995, SCIENCE, V269, P496, DOI 10.1126/science.7542800; FRASER CM, 1995, SCIENCE, V270, P397, DOI 10.1126/science.270.5235.397; Fraser CM, 1997, NATURE, V390, P580, DOI 10.1038/37551; Fraser CM, 1998, SCIENCE, V281, P375, DOI 10.1126/science.281.5375.375; GLUCH MF, 1995, J BACTERIOL, V177, P5473, DOI 10.1128/jb.177.19.5473-5479.1995; Goffeau A, 1996, SCIENCE, V274, P546, DOI 10.1126/science.274.5287.546; Gruber TM, 1997, J BACTERIOL, V179, P1734, DOI 10.1128/jb.179.5.1734-1747.1997; Himmelreich R, 1996, NUCLEIC ACIDS RES, V24, P4420, DOI 10.1093/nar/24.22.4420; Huang YP, 1998, NUCLEIC ACIDS RES, V26, P5300, DOI 10.1093/nar/26.23.5300; HUBER R, 1986, ARCH MICROBIOL, V144, P324, DOI 10.1007/BF00409880; Huber R, 1992, PROKARYOTES, P3809; Hueck CJ, 1998, MICROBIOL MOL BIOL R, V62, P379, DOI 10.1128/MMBR.62.2.379-433.1998; JANSSEN PH, 1992, FEMS MICROBIOL LETT, V96, P213; Kaneko T, 1996, DNA Res, V3, P185, DOI 10.1093/dnares/3.3.185; Kawarabayasi Y, 1998, DNA Res, V5, P55, DOI 10.1093/dnares/5.2.55; Klenk HP, 1997, NATURE, V390, P364, DOI 10.1038/37052; Kunst F, 1997, NATURE, V390, P249, DOI 10.1038/36786; Lawrence JG, 1997, J MOL EVOL, V44, P383, DOI 10.1007/PL00006158; Lee PJ, 1996, J BACTERIOL, V178, P5579, DOI 10.1128/jb.178.19.5579-5585.1996; Lobry JR, 1996, MOL BIOL EVOL, V13, P660, DOI 10.1093/oxfordjournals.molbev.a025626; Macnab R., 1996, ESCHERICHIA COLI SAL, V2nd ed, P119; RILEY M, 1993, MICROBIOL REV, V57, P862, DOI 10.1128/MMBR.57.4.862-952.1993; SAIER MH, 1994, MICROBIOL REV, V58, P71, DOI 10.1128/MMBR.58.1.71-93.1994; SAITOU N, 1987, MOL BIOL EVOL, V4, P406, DOI 10.1093/oxfordjournals.molbev.a040454; Salzberg SL, 1998, NUCLEIC ACIDS RES, V26, P544, DOI 10.1093/nar/26.2.544; Salzberg SL, 1998, GENE, V217, P57, DOI 10.1016/S0378-1119(98)00374-6; Smith DR, 1997, J BACTERIOL, V179, P7135, DOI 10.1128/jb.179.22.7135-7155.1997; Sutton G. G., 1995, GENOME SCI TECHNOL, V1, P9, DOI [10.1089/gst.1995.1.9, DOI 10.1089/GST.1995.1.9]; Tomb JF, 1997, NATURE, V388, P539, DOI 10.1038/41483; Vargas M, 1998, NATURE, V395, P65, DOI 10.1038/25720; Zhang JR, 1997, CELL, V89, P275, DOI 10.1016/S0092-8674(00)80206-8	45	1157	1793	5	122	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAY 27	1999	399	6734					323	329		10.1038/20601	http://dx.doi.org/10.1038/20601			23	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	200PA	10360571				2022-12-28	WOS:000080547800050
J	Bogardus, ST; Concato, J; Feinstein, AR				Bogardus, ST; Concato, J; Feinstein, AR			Clinical epidemiological quality in molecular genetic research - The need for methodological standards	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Review							ANGIOTENSIN-CONVERTING-ENZYME; CORONARY HEART-DISEASE; BONE-MARROW TRANSPLANTATION; THYROTROPIN-RECEPTOR GENE; POLYMERASE CHAIN-REACTION; SQUAMOUS-CELL CARCINOMA; FACTOR-V LEIDEN; APOLIPOPROTEIN-E; CYSTIC-FIBROSIS; MYOCARDIAL-INFARCTION	Context A genetic basis has been identified for many medical conditions and some molecular tests have been commercialized. However, little attention has been given to the quality of clinical epidemiology in molecular studies. Objective To examine the clinical epidemiological quality of recent publications on molecular genetic analysis. Design Cross-sectional study of original research articles published in 1995, identified by manually searching 4 general clinical journals. Of 83 articles identified, 40 were selected for analysis; these 40 discussed molecular genetic techniques, studied 10 or more patients, and had inferential conclusions, Main Outcome Measure Compliance of the selected articles with 7 methodological standards for clinical epidemiological science (reproducibility, objectivity, delineation of case group, adequacy of spectrum in case group, delineation of comparison group, adequacy of comparison group, and quantitative summary of results). Results Among the 40 inferential articles that studied 10 or more patients, only 5 (12.5%) complied with all 7 applicable standards, and 10 (25.0%) complied with all but 1 standard, whereas 25 articles (62.5%) failed to comply with 2 or more standards and 9 (22.5%) failed 4 or 5 standards. Most articles did not comply with standards for reproducibility (n = 25, 62.5%) or objectivity (n = 27, 67.5%); however, the majority of articles did comply with standards for adequacy of case group (n = 35, 87.5%), adequacy of comparison group (n = 35, 87.5%), and quantitative summary of results (n = 36, 90%). Conclusions Despite major laboratory advances in molecular genetic analysis, our data suggest that reported applications in clinical journals often have troubling omissions, deficiencies, and lack of attention to the different, but necessary, principles of clinical epidemiological science. Without suitable attention to fundamental methodological standards, the expected benefits of molecular genetic testing may not be achieved.	Yale Univ, Sch Med, Robert Wood Johnson Clin Scholars Program, New Haven, CT 06504 USA; Yale Univ, Sch Med, Dept Med, New Haven, CT 06504 USA; Vet Affairs Connecticut Healthcare Syst, W Haven Vet Affairs Med Ctr, Clin Epidemiol Unit, W Haven, CT USA	Yale University; Yale University; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Connecticut Healthcare System	Bogardus, ST (corresponding author), Yale Univ, Sch Med, Robert Wood Johnson Clin Scholars Program, 20 York St,Tompkins 15, New Haven, CT 06504 USA.							ABRAHAMOV A, 1995, LANCET, V346, P1000, DOI 10.1016/S0140-6736(95)91688-1; AGUNDEZ JAG, 1995, LANCET, V345, P830, DOI 10.1016/S0140-6736(95)92965-7; ANGIER N, 1996, NY TIMES        1101, pA22; AONO S, 1995, LANCET, V345, P958, DOI 10.1016/S0140-6736(95)90702-5; ARRANZ M, 1995, LANCET, V346, P281, DOI 10.1016/S0140-6736(95)92168-0; ARROLL B, 1988, J GEN INTERN MED, V3, P443, DOI 10.1007/BF02595920; BARR FG, 1995, JAMA-J AM MED ASSOC, V273, P553, DOI 10.1001/jama.273.7.553; BARRETT TG, 1995, LANCET, V346, P1458, DOI 10.1016/S0140-6736(95)92473-6; BATES AS, 1993, J PEDIATR-US, V122, P585, DOI 10.1016/S0022-3476(05)83540-1; BAYERDORFFER E, 1995, LANCET, V345, P1591, DOI 10.1016/S0140-6736(95)90113-2; BECKER DM, 1989, ARCH INTERN MED, V149, P1731, DOI 10.1001/archinte.149.8.1731; BEGG CB, 1987, STAT MED, V6, P411, DOI 10.1002/sim.4780060402; BLOEMENKAMP KWM, 1995, LANCET, V346, P1593, DOI 10.1016/S0140-6736(95)91929-5; BOHN M, 1993, CLIN GENET, V44, P292; BOSMA PJ, 1995, NEW ENGL J MED, V333, P1171, DOI 10.1056/NEJM199511023331802; BRAHE C, 1995, LANCET, V346, P741, DOI 10.1016/S0140-6736(95)91507-9; BRENNAN JA, 1995, NEW ENGL J MED, V332, P712, DOI 10.1056/NEJM199503163321104; BRENNAN JA, 1995, NEW ENGL J MED, V332, P429, DOI 10.1056/NEJM199502163320704; BRITZCUNNINGHAM SH, 1995, NEW ENGL J MED, V332, P1323, DOI 10.1056/NEJM199505183322002; CALVERT R, 1995, LANCET, V345, P26, DOI 10.1016/S0140-6736(95)91154-5; CAMBIEN F, 1992, NATURE, V359, P641, DOI 10.1038/359641a0; Campbell DA, 1996, LANCET, V347, P1706, DOI 10.1016/S0140-6736(96)91545-7; CANDELIERE GA, 1995, NEW ENGL J MED, V332, P1546, DOI 10.1056/NEJM199506083322304; CHABRIAT H, 1995, LANCET, V346, P934, DOI 10.1016/S0140-6736(95)91557-5; Chapman J, 1996, LANCET, V348, P206, DOI 10.1016/S0140-6736(05)66162-4; CHILLON M, 1995, NEW ENGL J MED, V332, P1475, DOI 10.1056/NEJM199506013322204; CLAUSEN JO, 1995, LANCET, V346, P397, DOI 10.1016/S0140-6736(95)92779-4; CLEMENT K, 1995, NEW ENGL J MED, V333, P352, DOI 10.1056/NEJM199508103330605; CLONINGER CR, 1994, AM J MED GENET, V54, P83, DOI 10.1002/ajmg.1320540202; COLLINS FS, 1995, P NATL ACAD SCI USA, V92, P10821, DOI 10.1073/pnas.92.24.10821; COOPER LS, 1988, JAMA-J AM MED ASSOC, V259, P3277, DOI 10.1001/jama.259.22.3277; CUI KH, 1995, BRIT MED J, V311, P536, DOI 10.1136/bmj.311.7004.536; DONG F, 1995, NEW ENGL J MED, V333, P487, DOI 10.1056/NEJM199508243330804; EVANS AE, 1994, Q J MED, V87, P211; FEINSTEIN AR, 1988, J CLIN INVEST, V81, P1, DOI 10.1172/JCI113279; Feinstein AR, 1985, CLIN EPIDEMIOLOGY AR; FERRARI S, 1995, LANCET, V345, P423, DOI 10.1016/S0140-6736(95)90404-2; FINEBERG HV, 1979, NEW ENGL J MED, V301, P1086, DOI 10.1056/NEJM197911153012004; FLETCHER RH, 1986, ANN INTERN MED, V104, P66, DOI 10.7326/0003-4819-104-1-66; Gallagher PM, 1996, CIRCULATION, V94, P2154, DOI 10.1161/01.CIR.94.9.2154; GAN KH, 1995, NEW ENGL J MED, V333, P95, DOI 10.1056/NEJM199507133330204; GARRED P, 1995, LANCET, V346, P941, DOI 10.1016/S0140-6736(95)91559-1; GELERNTER J, 1993, JAMA-J AM MED ASSOC, V269, P1673, DOI 10.1001/jama.269.13.1673; GJERTSEN MK, 1995, LANCET, V346, P1399, DOI 10.1016/S0140-6736(95)92408-6; GODDARD AD, 1995, NEW ENGL J MED, V333, P1093, DOI 10.1056/NEJM199510263331701; GOLDSTEIN AM, 1995, NEW ENGL J MED, V333, P970, DOI 10.1056/NEJM199510123331504; GOLIGHTLY MG, 1993, AM J CLIN PATHOL, V99, P168, DOI 10.1093/ajcp/99.2.168; GOTODA T, 1995, NEW ENGL J MED, V333, P1313, DOI 10.1056/NEJM199511163332003; GREENES RA, 1985, INVEST RADIOL, V20, P751, DOI 10.1097/00004424-198510000-00018; GUO WW, 1995, JAMA-J AM MED ASSOC, V274, P324, DOI 10.1001/jama.274.4.324; GUYATT GH, 1986, CAN MED ASSOC J, V134, P587; GUYER MS, 1995, P NATL ACAD SCI USA, V92, P10841, DOI 10.1073/pnas.92.24.10841; HALL IP, 1995, LANCET, V345, P1213, DOI 10.1016/S0140-6736(95)91994-5; HAMILTON SR, 1995, NEW ENGL J MED, V332, P839, DOI 10.1056/NEJM199503303321302; HARDEN PN, 1995, LANCET, V345, P1540, DOI 10.1016/S0140-6736(95)91088-3; HAYASHI N, 1995, LANCET, V345, P1257, DOI 10.1016/S0140-6736(95)90922-2; HENDERSON AS, 1995, LANCET, V346, P1387, DOI 10.1016/S0140-6736(95)92405-1; HILL MR, 1995, BRIT MED J, V311, P776, DOI 10.1136/bmj.311.7008.776; HODGKINSON N, 1994, SUNDAY TIMES LO 0102; HOLTZMAN NA, PROMOTING SAFE EFFEC, P97; Hubbard R, 1996, NEW ENGL J MED, V334, P1192, DOI 10.1056/NEJM199605023341812; HUDSON KL, 1995, SCIENCE, V270, P391, DOI 10.1126/science.270.5235.391; HUMMEL M, 1995, NEW ENGL J MED, V333, P901, DOI 10.1056/NEJM199510053331403; HUNG J, 1995, JAMA-J AM MED ASSOC, V273, P558, DOI 10.1001/jama.273.7.558; ISSARAGRISIL S, 1995, NEW ENGL J MED, V332, P367, DOI 10.1056/NEJM199502093320605; JAESCHKE R, 1994, JAMA-J AM MED ASSOC, V271, P389, DOI 10.1001/jama.271.5.389; JAESCHKE R, 1994, JAMA-J AM MED ASSOC, V271, P703, DOI 10.1001/jama.271.9.703; JAMIESON A, 1994, J ROY COLL PHYS LOND, V28, P512; JASS JR, 1995, LANCET, V346, P1200, DOI 10.1016/S0140-6736(95)92902-9; JOUET M, 1995, LANCET, V345, P161, DOI 10.1016/S0140-6736(95)90170-1; Jukema JW, 1996, CIRCULATION, V94, P1913, DOI 10.1161/01.CIR.94.8.1913; KATSUYA T, 1995, LANCET, V345, P1600, DOI 10.1016/S0140-6736(95)90115-9; KAUFMANN Y, 1995, NEW ENGL J MED, V332, P507, DOI 10.1056/NEJM199502233320805; KENT DL, 1992, INVEST RADIOL, V27, P245, DOI 10.1097/00004424-199203000-00014; KENT DL, 1994, ANN INTERN MED, V120, P856, DOI 10.7326/0003-4819-120-10-199405150-00007; KIDD KK, 1993, AM J MED GENET, V48, P71, DOI 10.1002/ajmg.1320480202; KNOWLES MR, 1995, NEW ENGL J MED, V333, P823, DOI 10.1056/NEJM199509283331302; KOPP P, 1995, NEW ENGL J MED, V332, P150, DOI 10.1056/NEJM199501193320304; KRAMER MHH, 1995, LANCET, V345, P488, DOI 10.1016/S0140-6736(95)90585-5; KWAK LW, 1995, LANCET, V345, P1016, DOI 10.1016/S0140-6736(95)90757-2; LANDIS JR, 1977, BIOMETRICS, V33, P159, DOI 10.2307/2529310; Laupacis A, 1997, JAMA-J AM MED ASSOC, V277, P488, DOI 10.1001/jama.277.6.488; LEHRMAN S, 1995, NATURE, V378, P529, DOI 10.1038/378529b0; LENSING AWA, 1993, THROMB HAEMOSTASIS, V69, P2; LINDPAINTNER K, 1995, NEW ENGL J MED, V332, P706, DOI 10.1056/NEJM199503163321103; LINDPAINTNER K, 1993, CLIN RES, V41, P216; Malhotra AK, 1996, MOL PSYCHIATR, V1, P388; MATTU RK, 1995, CIRCULATION, V91, P270, DOI 10.1161/01.CIR.91.2.270; MCLEAN SAM, 1994, SOC SCI MED, V39, P1221, DOI 10.1016/0277-9536(94)90354-9; MIEDZYBRODZKA ZH, 1995, BRIT MED J, V310, P353, DOI 10.1136/bmj.310.6976.353; MIETTINEN HE, 1994, HUM GENET, V94, P189; MULLERHILL B, 1993, NATURE, V362, P491, DOI 10.1038/362491a0; NAKAO S, 1995, NEW ENGL J MED, V333, P288, DOI 10.1056/NEJM199508033330504; NEUMANN HPH, 1995, JAMA-J AM MED ASSOC, V274, P1149; NIERENBERG AA, 1988, JAMA-J AM MED ASSOC, V259, P1699, DOI 10.1001/jama.259.11.1699; ORAHILLY S, 1995, NEW ENGL J MED, V333, P1386, DOI 10.1056/NEJM199511233332104; ORSCHESCHEK K, 1995, LANCET, V345, P87, DOI 10.1016/S0140-6736(95)90061-6; Owerbach D, 1996, DIABETES, V45, P544, DOI 10.2337/diabetes.45.5.544; PATO CN, 1993, AM J MED GENET, V48, P78, DOI 10.1002/ajmg.1320480204; PETERSEN RC, 1995, JAMA-J AM MED ASSOC, V273, P1274, DOI 10.1001/jama.273.16.1274; POLVIKOSKI T, 1995, NEW ENGL J MED, V333, P1242, DOI 10.1056/NEJM199511093331902; POSTMA DS, 1995, NEW ENGL J MED, V333, P894, DOI 10.1056/NEJM199510053331402; POWER EJ, 1994, ANNU REV PUBL HEALTH, V15, P561; Preston Jennifer, 1996, N Y Times Web, pB6; RANSOHOFF DF, 1978, NEW ENGL J MED, V299, P926, DOI 10.1056/NEJM197810262991705; REES DC, 1995, LANCET, V346, P1133, DOI 10.1016/S0140-6736(95)91803-5; REID MC, 1995, JAMA-J AM MED ASSOC, V274, P645, DOI 10.1001/jama.274.8.645; RIDKER PM, 1995, NEW ENGL J MED, V332, P912, DOI 10.1056/NEJM199504063321403; ROONEY CM, 1995, LANCET, V345, P9, DOI 10.1016/S0140-6736(95)91150-2; Roy B, 1996, J NATL MED ASSOC, V88, P315; RUIZ J, 1995, LANCET, V346, P869, DOI 10.1016/S0140-6736(95)92709-3; SACK C, 1997, NEW REPUBLIC    0602, P46; SAMANI NJ, 1995, LANCET, V345, P1013, DOI 10.1016/S0140-6736(95)90756-4; SHATTUCKEIDENS D, 1995, JAMA-J AM MED ASSOC, V273, P535, DOI 10.1001/jama.273.7.535; SHEPS SB, 1984, JAMA-J AM MED ASSOC, V252, P2418, DOI 10.1001/jama.252.17.2418; SMALL GW, 1995, JAMA-J AM MED ASSOC, V273, P942, DOI 10.1001/jama.273.12.942; SMITH JD, 1995, LANCET, V346, P1318, DOI 10.1016/S0140-6736(95)92341-1; SPECTOR TD, 1995, BRIT MED J, V310, P1357, DOI 10.1136/bmj.310.6991.1357; STENGARD JH, 1995, CIRCULATION, V91, P265, DOI 10.1161/01.CIR.91.2.265; STERN RC, 1995, LANCET, V346, P274, DOI 10.1016/S0140-6736(95)92165-6; SUMMERFIELD JA, 1995, LANCET, V345, P886, DOI 10.1016/S0140-6736(95)90009-8; SUNTHORNTHEPVARAKUL T, 1995, NEW ENGL J MED, V332, P155, DOI 10.1056/NEJM199501193320305; TAPLIN ME, 1995, NEW ENGL J MED, V332, P1393, DOI 10.1056/NEJM199505253322101; THOMAS C, 1995, NEW ENGL J MED, V333, P426, DOI 10.1056/NEJM199508173330705; THORLACIUS S, 1995, LANCET, V346, P544, DOI 10.1016/S0140-6736(95)91383-1; THURSZ MR, 1995, NEW ENGL J MED, V332, P1065, DOI 10.1056/NEJM199504203321604; TOKGOZOGLU LS, 1995, JAMA-J AM MED ASSOC, V274, P813, DOI 10.1001/jama.274.10.813; *US DEP EN, 1992, HUM GEN 1991 92 PROG, P111; VANDERPUT NMJ, 1995, LANCET, V346, P1070, DOI 10.1016/S0140-6736(95)91743-8; VANDUIJN CM, 1995, BMJ-BRIT MED J, V310, P627, DOI 10.1136/bmj.310.6980.627; VANHERWERDEN L, 1995, LANCET, V346, P1262, DOI 10.1016/S0140-6736(95)91863-9; WAGNER JE, 1995, LANCET, V346, P214, DOI 10.1016/S0140-6736(95)91268-1; WALSTON J, 1995, NEW ENGL J MED, V333, P343, DOI 10.1056/NEJM199508103330603; WALTER EA, 1995, NEW ENGL J MED, V333, P1038, DOI 10.1056/NEJM199510193331603; WATKINS H, 1995, NEW ENGL J MED, V332, P1058, DOI 10.1056/NEJM199504203321603; WHATLEY SD, 1995, LANCET, V346, P1007, DOI 10.1016/S0140-6736(95)91692-X; WHELAN AJ, 1995, NEW ENGL J MED, V333, P975, DOI 10.1056/NEJM199510123331505; WIDEN E, 1995, NEW ENGL J MED, V333, P348, DOI 10.1056/NEJM199508103330604; Winkelmann BR, 1996, ANN INTERN MED, V125, P19, DOI 10.7326/0003-4819-125-1-199607010-00004; WOLF HM, 1995, NEW ENGL J MED, V332, P86, DOI 10.1056/NEJM199501123320204; YANG L, 1993, AM J MED GENET, V48, P83, DOI 10.1002/ajmg.1320480205; Yu QT, 1996, J INVEST MED, V44, P154; ZAAIJER HL, 1993, LANCET, V341, P722, DOI 10.1016/0140-6736(93)90488-3	143	142	147	0	9	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 26	1999	281	20					1919	1926		10.1001/jama.281.20.1919	http://dx.doi.org/10.1001/jama.281.20.1919			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	198ME	10349896				2022-12-28	WOS:000080427300032
J	Chook, YM; Blobel, G				Chook, YM; Blobel, G			Structure of the nuclear transport complex karyopherin-beta 2-Ran center dot GppNHp	NATURE			English	Article							GTPASE-ACTIVATING PROTEIN; TRANSCRIPTION FACTOR PHO4; KARYOPHERIN-BETA; RAN-GTP; PORE COMPLEX; IMPORT; ASSOCIATION; RAN/TC4; ALPHA; REPEATS	Transport factors in the karyopherin-beta (also called importin-beta) family mediate the movement of macromolecules in nuclear-cytoplasmic transport pathways. Karyopherin-beta 2 (transportin) binds a cognate import substrate and targets It to the nuclear pore complex. In the nucleus, Ran GTP binds karyopherin-beta 2 and dissociates the substrate. Here we present the 3.0 Angstrom structure of the karyopherin-beta 2-Ran GppNHp complex where GppNHp is a non-hydrolysable GTP analogue. Karyopherin-beta 2 contains eighteen HEAT repeats arranged into two continuous orthogonal arches. Ran is clamped in the amino-terminal arch and substrate-binding activity Is mapped to the carboxy-terminal arch. A large loop In HEAT repeat 7 spans both arches. Interactions of the loop with Ran and the C-terminal arch implicate it in GTPase-mediated dissociation of the import-substrate. Ran GppNHp In the complex shows extensive structural rearrangement, compared to Ran GDP, in regions contacting karyopherin-beta 2. This provides a structural basis for the specificity of the karyopherin-beta family for the GTP-bound state of Ran, as well as a rationale for interactions of the karyopherin-Ran complex with the regulatory proteins ranGAP, ranGEF and ranBP1.	Rockefeller Univ, Howard Hughes Med Inst, Cell Biol Lab, New York, NY 10021 USA	Howard Hughes Medical Institute; Rockefeller University	Chook, YM (corresponding author), Rockefeller Univ, Howard Hughes Med Inst, Cell Biol Lab, New York, NY 10021 USA.		Chook, Yuh Min/AAA-9549-2019					Albertini M, 1998, J CELL BIOL, V143, P1447, DOI 10.1083/jcb.143.6.1447; ANDRADE MA, 1995, NAT GENET, V11, P115, DOI 10.1038/ng1095-115; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BISCHOFF FR, 1995, METHOD ENZYMOL, V257, P135; Bischoff FR, 1997, FEBS LETT, V419, P249, DOI 10.1016/S0014-5793(97)01467-1; Bonifaci N, 1997, P NATL ACAD SCI USA, V94, P5055, DOI 10.1073/pnas.94.10.5055; Boriack-Sjodin PA, 1998, NATURE, V394, P337, DOI 10.1038/28548; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Chi NC, 1997, J BIOL CHEM, V272, P6818, DOI 10.1074/jbc.272.10.6818; Conti E, 1998, CELL, V94, P193, DOI 10.1016/S0092-8674(00)81419-1; COUTAVAS E, 1993, NATURE, V366, P585, DOI 10.1038/366585a0; Enenkel C, 1996, P NATL ACAD SCI USA, V93, P12986, DOI 10.1073/pnas.93.23.12986; Floer M, 1996, J BIOL CHEM, V271, P5313, DOI 10.1074/jbc.271.10.5313; Fridell RA, 1997, J CELL SCI, V110, P1325; Gorlich D, 1996, EMBO J, V15, P5584, DOI 10.1002/j.1460-2075.1996.tb00943.x; Groves MR, 1999, CELL, V96, P99, DOI 10.1016/S0092-8674(00)80963-0; HIDEA M, 1959, J CELL BIOL, V144, P645; Huber AH, 1997, CELL, V90, P871, DOI 10.1016/S0092-8674(00)80352-9; Izaurralde E, 1997, EMBO J, V16, P6535, DOI 10.1093/emboj/16.21.6535; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kaffman A, 1998, GENE DEV, V12, P2673, DOI 10.1101/gad.12.17.2673; Kaffman A, 1998, NATURE, V396, P482, DOI 10.1038/24898; Kose S, 1997, J CELL BIOL, V139, P841, DOI 10.1083/jcb.139.4.841; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Kuhlmann J, 1997, BIOCHEMISTRY-US, V36, P12027, DOI 10.1021/bi970524k; Kutay U, 1997, EMBO J, V16, P1153, DOI 10.1093/emboj/16.6.1153; Lounsbury KM, 1997, J BIOL CHEM, V272, P551; Malik HS, 1997, P NATL ACAD SCI USA, V94, P13738, DOI 10.1073/pnas.94.25.13738; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; Moroianu J, 1996, P NATL ACAD SCI USA, V93, P7059, DOI 10.1073/pnas.93.14.7059; Nehrbass U, 1996, SCIENCE, V272, P120, DOI 10.1126/science.272.5258.120; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; PAI EF, 1989, NATURE, V341, P209, DOI 10.1038/341209a0; Pemberton LF, 1998, CURR OPIN CELL BIOL, V10, P392, DOI 10.1016/S0955-0674(98)80016-1; Pollard VW, 1996, CELL, V86, P985, DOI 10.1016/S0092-8674(00)80173-7; REXACH M, 1995, CELL, V83, P683, DOI 10.1016/0092-8674(95)90181-7; Ribbeck K, 1998, EMBO J, V17, P6587, DOI 10.1093/emboj/17.22.6587; RICHARDS SA, 1995, J BIOL CHEM, V270, P14405, DOI 10.1074/jbc.270.24.14405; Rittinger K, 1997, NATURE, V389, P758, DOI 10.1038/39651; Scheffzek K, 1997, SCIENCE, V277, P333, DOI 10.1126/science.277.5324.333; SCHEFFZEK K, 1995, NATURE, V374, P378, DOI 10.1038/374378a0; SHELDRICK GM, 1993, ACTA CRYSTALLOGR D, V49, P18, DOI 10.1107/S0907444992007364; Siomi MC, 1997, J CELL BIOL, V138, P1181, DOI 10.1083/jcb.138.6.1181; Stewart M, 1998, J MOL BIOL, V284, P1517, DOI 10.1006/jmbi.1998.2204; VANDUYNE GD, 1991, SCIENCE, V252, P839, DOI 10.1126/science.1709302; Vetter IR, 1999, NATURE, V398, P39, DOI 10.1038/17969; Westbrook EM, 1997, METHOD ENZYMOL, V276, P244, DOI 10.1016/S0076-6879(97)76063-4; WU J, 1995, J BIOL CHEM, V270, P14209, DOI 10.1074/jbc.270.23.14209; YOKOYAMA N, 1995, NATURE, V376, P184, DOI 10.1038/376184a0	50	290	296	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAY 20	1999	399	6733					230	237		10.1038/20375	http://dx.doi.org/10.1038/20375			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	198MF	10353245				2022-12-28	WOS:000080427400047
J	Maxwell, PH; Wiesener, MS; Chang, GW; Clifford, SC; Vaux, EC; Cockman, ME; Wykoff, CC; Pugh, CW; Maher, ER; Ratcliffe, PJ				Maxwell, PH; Wiesener, MS; Chang, GW; Clifford, SC; Vaux, EC; Cockman, ME; Wykoff, CC; Pugh, CW; Maher, ER; Ratcliffe, PJ			The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis	NATURE			English	Article							ERYTHROPOIETIN GENE; FACTOR 1-ALPHA; ALPHA-SUBUNIT; HEME PROTEIN; EXPRESSION; STABILIZATION; TRANSCRIPTION; ANGIOGENESIS; HIF-1-ALPHA; PRODUCT	Hypoxia-inducible factor-1 (HIF-1) has a key role in cellular responses to hypoxia, including the regulation of genes involved in energy metabolism, angiogenesis and apoptosis(1-4). The alpha subunits of HIF are rapidly degraded by the proteasome under normal conditions, but are stabilized by hypoxia(5). Cobaltous ions or iron chelators mimic hypoxia, indicating that the stimuli may interact through effects on a ferroprotein oxygen sensor(6,7). Here we demonstrate a critical role for the von Hippel-Lindau (VHL) tumour suppressor gene product pVHL in HIF-1 regulation. In VHL-defective cells, HIF alpha-subunits are constitutively stabilized and HIF-1 is activated. Re-expression of pVHL restored oxygen-dependent instability. pVHL and HIF alpha-subunits co-immunoprecipitate, and pVHL is present in the hypoxic HIF-1 DNA-binding complex. In cells exposed to iron chelation or cobaltous ions, HIF-1 is dissociated from pVHL. These findings indicate that the interaction between HIF-1 and pVHL is iron dependent, and that it is necessary for the oxygen-dependent degradation of HIF alpha-subunits. Thus, constitutive HIF-1 activation may underlie the angiogenic phenotype of VHL-associated tumours. The pVHL/HIF-1 interaction provides a new focus for understanding cellular oxygen sensing.	Wellcome Trust Ctr Human Genet, Oxford OX3 7BN, England; Univ Birmingham, Dept Paediat & Child Hlth, Sect Med & Mol Genet, Birmingham B15 2TT, W Midlands, England; John Radcliffe Hosp, Inst Mol Med, Oxford OX3 9DS, England	University of Oxford; Wellcome Centre for Human Genetics; University of Birmingham; University of Oxford	Ratcliffe, PJ (corresponding author), Wellcome Trust Ctr Human Genet, Windmill Rd, Oxford OX3 7BN, England.	peter.ratcliffe@imm.ox.ac.uk	Maxwell, Patrick H/C-5557-2008; Cockman, Matthew/V-9619-2019; MAHER, EAMONN R/A-9507-2008	Maxwell, Patrick H/0000-0002-0338-2679; Cockman, Matthew/0000-0002-3310-4821; MAHER, EAMONN R/0000-0002-6226-6918; Pugh, Chris/0000-0002-5170-1662; Clifford, Steve/0000-0003-4893-2184; Ratcliffe, Peter/0000-0002-2853-806X	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		An WG, 1998, NATURE, V392, P405, DOI 10.1038/32925; Bunn HF, 1996, PHYSIOL REV, V76, P839, DOI 10.1152/physrev.1996.76.3.839; Carmeliet P, 1998, NATURE, V394, P485, DOI 10.1038/28867; Chandel NS, 1998, P NATL ACAD SCI USA, V95, P11715, DOI 10.1073/pnas.95.20.11715; Dang CV, 1999, TRENDS BIOCHEM SCI, V24, P68, DOI 10.1016/S0968-0004(98)01344-9; DUAN DR, 1995, SCIENCE, V269, P1402, DOI 10.1126/science.7660122; FANDREY J, 1994, BIOCHEM J, V303, P507, DOI 10.1042/bj3030507; GNARRA JR, 1994, NAT GENET, V7, P85, DOI 10.1038/ng0594-85; Gnarra JR, 1996, P NATL ACAD SCI USA, V93, P10589, DOI 10.1073/pnas.93.20.10589; GOLDBERG MA, 1988, SCIENCE, V242, P1412, DOI 10.1126/science.2849206; Hanahan D, 1996, CELL, V86, P353, DOI 10.1016/S0092-8674(00)80108-7; Ho VT, 1996, BIOCHEM BIOPH RES CO, V223, P175, DOI 10.1006/bbrc.1996.0865; Huang LE, 1996, J BIOL CHEM, V271, P32253, DOI 10.1074/jbc.271.50.32253; Huang LE, 1998, P NATL ACAD SCI USA, V95, P7987, DOI 10.1073/pnas.95.14.7987; Iliopoulos O, 1996, P NATL ACAD SCI USA, V93, P10595, DOI 10.1073/pnas.93.20.10595; ILIOPOULOS O, 1995, NAT MED, V1, P822, DOI 10.1038/nm0895-822; Iwai K, 1998, P NATL ACAD SCI USA, V95, P4924, DOI 10.1073/pnas.95.9.4924; Kaelin WG, 1998, TRENDS GENET, V14, P423, DOI 10.1016/S0168-9525(98)01558-3; Lonergan KM, 1998, MOL CELL BIOL, V18, P732, DOI 10.1128/MCB.18.2.732; Maxwell PH, 1997, P NATL ACAD SCI USA, V94, P8104, DOI 10.1073/pnas.94.15.8104; Ohh M, 1998, MOL CELL, V1, P959, DOI 10.1016/S1097-2765(00)80096-9; Pause A, 1997, P NATL ACAD SCI USA, V94, P2156, DOI 10.1073/pnas.94.6.2156; Salceda S, 1997, J BIOL CHEM, V272, P22642, DOI 10.1074/jbc.272.36.22642; SHWEIKI D, 1992, NATURE, V359, P843, DOI 10.1038/359843a0; WANG GL, 1993, BLOOD, V82, P3610; WANG GL, 1995, P NATL ACAD SCI USA, V92, P5510, DOI 10.1073/pnas.92.12.5510; Warburg O. H., 1930, METABOLISM TUMOURS I; Wiesener MS, 1998, BLOOD, V92, P2260, DOI 10.1182/blood.V92.7.2260.2260_2260_2268; Wood SM, 1998, J BIOL CHEM, V273, P8360, DOI 10.1074/jbc.273.14.8360; Zelzer E, 1998, EMBO J, V17, P5085, DOI 10.1093/emboj/17.17.5085	30	3863	4018	13	336	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAY 20	1999	399	6733					271	275		10.1038/20459	http://dx.doi.org/10.1038/20459			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	198MF	10353251				2022-12-28	WOS:000080427400059
J	Garber, AM; Solomon, NA				Garber, AM; Solomon, NA			Cost-effectiveness of alternative test strategies for the diagnosis of coronary artery disease	ANNALS OF INTERNAL MEDICINE			English	Article						cost-benefit analysis; coronary disease; outcome and process assessment (health care); coronary angiography; echocardiography	EMISSION COMPUTED-TOMOGRAPHY; DOBUTAMINE STRESS ECHOCARDIOGRAPHY; DIPYRIDAMOLE STRESS; EXERCISE ECHOCARDIOGRAPHY; ARTERIOGRAPHY 1984-1987; CARDIAC ANGIOGRAPHY; PROGNOSTIC VALUE; HEART-DISEASE; META-ANALYSIS; SCINTIGRAPHY	Background: The appropriate roles for several diagnostic tests for coronary disease are uncertain. Objective: To evaluate the cost-effectiveness of alternative approaches to diagnosis of coronary disease. Design: Meta-analysis of the accuracy of alternative diagnostic tests plus decision analysis to assess the health outcomes and costs of alternative diagnostic strategies for patients at intermediate pretest risk for coronary disease. Data Sources: Studies of test accuracy that met inclusion criteria; published information on treatment effectiveness and disease prevalence. Target Population: Men and women 45, 55, and 65 years of age with a 25% to 75% pretest risk for coronary disease. Time Horizon: 30 years. Perspective: Societal. Interventions: Diagnostic strategies were initial angiography and initial testing with one of five noninvasive tests-exercise treadmill testing, planar thallium imaging, single-photon emission computed tomography (SPECT), stress echocardiography, and positron emission tomography (PET)-followed by coronary angiography if noninvasive test results were positive. Testing was followed by observation, medical treatment, or revascularization. Outcome Measures: Life-years, quality-adjusted life-years (QALYs), costs, and costs per QALY. Results of Base-Case Analysis: Life expectancy varied little with the initial diagnostic test; for a 55-year-old man, the best-performing test increased life expectancy by 7 more days than the worst-performing test. More sensitive tests increased QALYs more. Echocardiography improved health outcomes and reduced costs relative to stress testing and planar thallium imaging. The incremental cost-effectiveness ratio was $75 000/QALY for SPECT relative to echocardiography and was greater than $640 000 for PET relative to SPECT. Compared with SPECT, immediate angiography had an incremental cost-effectiveness ratio of $94 000/QALY. Results of Sensitivity Analysis: Qualitative findings varied little with age, sex, pretest probability of disease, or the test indeterminacy rate. Results varied most with sensitivity to severe coronary disease. Conclusions: Echocardiography, SPECT, and immediate angiography are cost-effective alternatives to PET and other diagnostic approaches. Test selection should reflect local variation in test accuracy.	Stanford Univ, Sch Med, Ctr Primary Care & Outcomes Res, Stanford, CA 94305 USA; Vet Affairs Palo Alto Hlth Care Syst, Stanford, CA 94305 USA; Kaiser Permanente, CAre Management Inst, Oakland, CA 94612 USA	Stanford University; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Palo Alto Health Care System; Kaiser Permanente	Garber, AM (corresponding author), Stanford Univ, Sch Med, Ctr Primary Care & Outcomes Res, 30 Alta Rd, Stanford, CA 94305 USA.		Garber, Alan M/F-1476-2010					BONOW RO, 1991, CIRCULATION, V84, P447, DOI 10.1161/01.CIR.84.1.447; BROWN KA, 1991, CIRCULATION, V83, P363, DOI 10.1161/01.CIR.83.2.363; BUNGO MW, 1983, CHEST, V83, P112, DOI 10.1378/chest.83.1.112; CHAITMAN BR, 1981, CIRCULATION, V64, P360, DOI 10.1161/01.CIR.64.2.360; CHOU TM, 1994, WESTERN J MED, V161, P173; CHRISTIAN TF, 1994, ANN INTERN MED, V121, P825, DOI 10.7326/0003-4819-121-11-199412010-00001; CINOTTI L, 1983, J NUCL MED, V24, P768; COHEN JL, 1991, AM J CARDIOL, V67, P1311, DOI 10.1016/0002-9149(91)90457-V; DETRANO R, 1989, PROG CARDIOVASC DIS, V32, P173, DOI 10.1016/0033-0620(89)90025-X; DIAMOND GA, 1979, NEW ENGL J MED, V300, P1350, DOI 10.1056/NEJM197906143002402; EMOND M, 1994, CIRCULATION, V90, P2645, DOI 10.1161/01.CIR.90.6.2645; Fleischmann KE, 1998, JAMA-J AM MED ASSOC, V280, P913, DOI 10.1001/jama.280.10.913; GALANTI G, 1991, AM HEART J, V122, P1609, DOI 10.1016/0002-8703(91)90278-P; Gewirtz H, 1991, R I Med J, V74, P527; GIANROSSI R, 1989, CIRCULATION, V80, P87, DOI 10.1161/01.CIR.80.1.87; GO RT, 1990, J NUCL MED, V31, P1899; Gold MR, 1996, COST EFFECTIVENESS H; GOULD KL, 1991, CIRCULATION, V84, pI22; GROVERMCKAY M, 1992, AM HEART J, V123, P646, DOI 10.1016/0002-8703(92)90502-M; HACKSHAW BT, 1992, AM J MED, V92, pS46, DOI 10.1016/0002-9343(92)80056-6; JOHNSON LW, 1989, CATHETER CARDIO DIAG, V17, P5, DOI 10.1002/ccd.1810170103; Keeney RL, 1993, DECISIONS MULTIPLE O, DOI DOI 10.1017/CBO9781139174084; LOZNER EC, 1989, CATHETER CARDIO DIAG, V17, P11, DOI 10.1002/ccd.1810170104; MADDAHI J, 1989, J AM COLL CARDIOL, V14, P1689, DOI 10.1016/0735-1097(89)90017-X; MAHMARIAN JJ, 1990, J AM COLL CARDIOL, V15, P318, DOI 10.1016/S0735-1097(10)80055-5; MARANGELLI V, 1994, J AM COLL CARDIOL, V24, P117, DOI 10.1016/0735-1097(94)90551-7; MARWICK T, 1993, CIRCULATION, V87, P345, DOI 10.1161/01.CIR.87.2.345; MARWICK T, 1993, J AM COLL CARDIOL, V22, P159, DOI 10.1016/0735-1097(93)90830-T; MASON JR, 1984, AM HEART J, V107, P481, DOI 10.1016/0002-8703(84)90089-9; MAZEIKA P, 1992, BRIT HEART J, V67, P144; MAZEIKA PK, 1992, J AM COLL CARDIOL, V19, P1203, DOI 10.1016/0735-1097(92)90325-H; NEASE RF, 1995, JAMA-J AM MED ASSOC, V273, P1185, DOI 10.1001/jama.273.15.1185; NISHIMURA S, 1991, J AM COLL CARDIOL, V18, P736, DOI 10.1016/0735-1097(91)90797-D; PATTERSON RE, 1995, CIRCULATION, V91, P54, DOI 10.1161/01.CIR.91.1.54; PREVITALI M, 1993, AM J CARDIOL, V72, P865, DOI 10.1016/0002-9149(93)91097-2; ROGERS WJ, 1990, CIRCULATION, V82, P1647, DOI 10.1161/01.CIR.82.5.1647; SALUSTRI A, 1992, EUR HEART J, V13, P70, DOI 10.1093/oxfordjournals.eurheartj.a060051; SCHWAIGER M, 1994, J NUCL MED, V35, P693; SEGAR DS, 1992, J AM COLL CARDIOL, V19, P1197, DOI 10.1016/0735-1097(92)90324-G; SEVERI S, 1994, CIRCULATION, V89, P1160, DOI 10.1161/01.CIR.89.3.1160; SIM I, 1995, AM J CARDIOL, V76, P1025, DOI 10.1016/S0002-9149(99)80289-6; Sox HC, 1988, MED DECISION MAKING; STEWART RE, 1991, AM J CARDIOL, V67, P1303, DOI 10.1016/0002-9149(91)90456-U; TAMAKI N, 1984, J AM COLL CARDIOL, V4, P1213, DOI 10.1016/S0735-1097(84)80140-0; Torrance GW, 1987, METHODS EC EVALUATIO; TSEVAT J, 1993, MED DECIS MAKING, V13, P161, DOI 10.1177/0272989X9301300210; VANTRAIN KF, 1986, J NUCL MED, V27, P17; VERANI MS, 1978, J NUCL MED, V19, P773; WEINSTEIN MC, 1976, HYPERTENSION POLICY; WEINTRAUB WS, 1984, AM J CARDIOL, V54, P43, DOI 10.1016/0002-9149(84)90301-1	50	174	178	0	3	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAY 4	1999	130	9					719	+		10.7326/0003-4819-130-9-199905040-00003	http://dx.doi.org/10.7326/0003-4819-130-9-199905040-00003			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	192DE	10357690				2022-12-28	WOS:000080062300002
J	Farley, D				Farley, D			Pride before a fall	BRITISH MEDICAL JOURNAL			English	Article																			0	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JUN 19	1999	318	7199					1685	1685		10.1136/bmj.318.7199.1685	http://dx.doi.org/10.1136/bmj.318.7199.1685			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	210KY	10373177	Green Published			2022-12-28	WOS:000081105600035
J	Iverson, TM; Luna-Chavez, C; Cecchini, G; Rees, DC				Iverson, TM; Luna-Chavez, C; Cecchini, G; Rees, DC			Structure of the Escherichia coli fumarate reductase respiratory complex	SCIENCE			English	Article							SUCCINATE-UBIQUINONE REDUCTASE; ELECTRON-PARAMAGNETIC-RESONANCE; BOVINE HEART-MITOCHONDRIA; CYTOCHROME BC(1) COMPLEX; MAXIMUM-LIKELIHOOD; PARACOCCUS-DENITRIFICANS; 2.8-ANGSTROM RESOLUTION; QUINONE OXIDOREDUCTASES; NUCLEOTIDE-SEQUENCE; ANGSTROM RESOLUTION	The integral membrane protein fumarate reductase catalyzes the final step of anaerobic respiration when fumarate is the terminal electron acceptor. The homologous enzyme succinate dehydrogenase also plays a prominent role in cellular energetics as a member of the Krebs cycle and as complex II of the aerobic respiratory chain. Fumarate reductase consists of four subunits that contain a covalently linked flavin adenine dinucleotide, three different iron-sulfur clusters, and at Least two quinones, The crystal structure of intact fumarate reductase has been solved at 3.3 angstrom resolution and demonstrates that the cofactors are arranged in a nearly linear manner from the membrane-bound quinone to the active site flavin. Although fumarate reductase is not associated with any proton-pumping function, the two quinones are positioned on opposite sides of the membrane in an arrangement similar to that of the Q-cycle organization observed for cytochrome bc(1).	Dept Vet Affairs Med Ctr, Div Mol Biol, San Francisco, CA 94121 USA; CALTECH, Div Chem & Chem Engn, Howard Hughes Med Inst, Pasadena, CA 91125 USA; Univ Calif San Francisco, Dept Biochem & Biophys, San Francisco, CA 94143 USA	California Institute of Technology; Howard Hughes Medical Institute; University of California System; University of California San Francisco	Cecchini, G (corresponding author), Dept Vet Affairs Med Ctr, Div Mol Biol, San Francisco, CA 94121 USA.	ceccini@itsa.ucsf.edu; dcrees@caltech.edu						ABRAHAMS JP, 1994, NATURE, V370, P621, DOI 10.1038/370621a0; Ackrell B. A.C, 1992, CHEM BIOCH FLAVOPROT, V3, P229; ACKRELL BAC, 1989, ARCH BIOCHEM BIOPHYS, V268, P26, DOI 10.1016/0003-9861(89)90561-4; ADMAN ET, 1976, J BIOL CHEM, V251, P3801; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BEINERT H, 1977, ARCH BIOCHEM BIOPHYS, V182, P95, DOI 10.1016/0003-9861(77)90287-9; BOURGERON T, 1995, NAT GENET, V11, P144, DOI 10.1038/ng1095-144; BRANDT U, 1994, CRIT REV BIOCHEM MOL, V29, P165, DOI 10.3109/10409239409086800; CAMMACK R, 1986, BIOCHIM BIOPHYS ACTA, V870, P545, DOI 10.1016/0167-4838(86)90264-5; CECCHINI G, 1986, P NATL ACAD SCI USA, V83, P8898, DOI 10.1073/pnas.83.23.8898; CECCHINI G, 1986, J BIOL CHEM, V261, P1808; COLE ST, 1982, EUR J BIOCHEM, V122, P479; COLE ST, 1982, EUR J BIOCHEM, V126, P211, DOI 10.1111/j.1432-1033.1982.tb06768.x; COWAN SW, 1992, NATURE, V358, P727, DOI 10.1038/358727a0; Cowtan K., 1994, JOINT CCP4 ESF EACBM, V31, P34; DEISENHOFER J, 1985, NATURE, V318, P618, DOI 10.1038/318618a0; delaFortelle E, 1997, METHOD ENZYMOL, V276, P472, DOI 10.1016/S0076-6879(97)76073-7; DUTTON PL, 1988, BIOL ELECT TRANSFER, P3; Esnouf RM, 1997, J MOL GRAPH MODEL, V15, P132, DOI 10.1016/S1093-3263(97)00021-1; FEHER G, 1989, NATURE, V339, P111, DOI 10.1038/339111a0; FUKUYAMA K, 1995, J BIOCHEM-TOKYO, V117, P1017, DOI 10.1093/oxfordjournals.jbchem.a124800; Gottschalk G., 1986, BACTERIAL METABOLISM; GRUNDSTROM T, 1982, P NATL ACAD SCI-BIOL, V79, P1111, DOI 10.1073/pnas.79.4.1111; GUEST JR, 1981, J GEN MICROBIOL, V122, P171; Hagerhall C, 1997, BBA-BIOENERGETICS, V1320, P107, DOI 10.1016/S0005-2728(97)00019-4; Hagerhall C, 1996, FEBS LETT, V389, P25, DOI 10.1016/0014-5793(96)00529-7; HOLM L, 1993, J MOL BIOL, V233, P123, DOI 10.1006/jmbi.1993.1489; Ishii N, 1998, NATURE, V394, P694, DOI 10.1038/29331; IWATA S, 1995, NATURE, V376, P660, DOI 10.1038/376660a0; Iwata S, 1998, SCIENCE, V281, P64, DOI 10.1126/science.281.5373.64; Jones TA, 1997, METHOD ENZYMOL, V277, P173, DOI 10.1016/S0076-6879(97)77012-5; Kleywegt GJ, 1999, ACTA CRYSTALLOGR D, V55, P941, DOI 10.1107/S0907444999001031; KOWAL AT, 1995, BIOCHEMISTRY-US, V34, P12284, DOI 10.1021/bi00038a024; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KROGER A, 1992, ARCH MICROBIOL, V158, P311, DOI 10.1007/BF00245358; Locher KP, 1998, CELL, V95, P771, DOI 10.1016/S0092-8674(00)81700-6; LOCHER KP, IN PRESS CRC MONOGRA; Lu GG, 1999, J APPL CRYSTALLOGR, V32, P365, DOI 10.1107/S0021889898015052; LUNACHAVEZ C, UNPUB; Maklashina E, 1998, J BACTERIOL, V180, P5989, DOI 10.1128/JB.180.22.5989-5996.1998; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; MIKI T, 1992, ARCH BIOCHEM BIOPHYS, V293, P61, DOI 10.1016/0003-9861(92)90365-4; MITCHELL P, 1966, BIOL REV, V41, P445, DOI 10.1111/j.1469-185X.1966.tb01501.x; MORNINGSTAR JE, 1985, J BIOL CHEM, V260, P3631; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; OHNISHI T, 1981, J BIOL CHEM, V256, P5577; OHNISHI T, 1980, J BIOL CHEM, V255, P3278; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Pannu NS, 1996, ACTA CRYSTALLOGR A, V52, P659, DOI 10.1107/S0108767396004370; PebayPeyroula E, 1997, SCIENCE, V277, P1676, DOI 10.1126/science.277.5332.1676; RUZICKA FJ, 1975, P NATL ACAD SCI USA, V72, P2886, DOI 10.1073/pnas.72.8.2886; SALERNO JC, 1980, BIOCHEM J, V192, P769, DOI 10.1042/bj1920769; SALERNO JC, 1977, FEBS LETT, V82, P179, DOI 10.1016/0014-5793(77)80579-6; Saraste M, 1999, SCIENCE, V283, P1488, DOI 10.1126/science.283.5407.1488; SCHRODER I, 1991, J BIOL CHEM, V266, P13572; Shenoy SK, 1997, J BIOL CHEM, V272, P17867, DOI 10.1074/jbc.272.28.17867; SINGER TP, 1968, BIOLOGICAL OXIDATION, P339; TSUKIHARA T, 1995, SCIENCE, V269, P1069, DOI 10.1126/science.7652554; VANHELLEMOND JJ, 1994, BIOCHEM J, V304, P321, DOI 10.1042/bj3040321; Waldeck AR, 1997, J BIOL CHEM, V272, P19373, DOI 10.1074/jbc.272.31.19373; WALKER WH, 1970, J BIOL CHEM, V245, P4224; WEINER JH, 1986, P NATL ACAD SCI USA, V83, P2056, DOI 10.1073/pnas.83.7.2056; WEINER JH, 1979, J BIOL CHEM, V254, P8590; WESTENBERG DJ, 1993, J BIOL CHEM, V268, P815; WESTENBERG DJ, 1990, J BIOL CHEM, V265, P19560; Xia D, 1997, SCIENCE, V277, P60, DOI 10.1126/science.277.5322.60; Yang XD, 1998, J BIOL CHEM, V273, P31916, DOI 10.1074/jbc.273.48.31916; Yeh JI, 1996, BIOCHEMISTRY-US, V35, P9951, DOI 10.1021/bi961037s; Zhang ZL, 1998, NATURE, V392, P677, DOI 10.1038/33612	70	342	385	5	56	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 18	1999	284	5422					1961	1966		10.1126/science.284.5422.1961	http://dx.doi.org/10.1126/science.284.5422.1961			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	207JA	10373108				2022-12-28	WOS:000080932700038
J	Wagner, F; Bohncke, SJP; Dilcher, DL; Kurschner, WM; van Geel, B; Visscher, H				Wagner, F; Bohncke, SJP; Dilcher, DL; Kurschner, WM; van Geel, B; Visscher, H			Century-scale shifts in early holocene atmospheric CO2 concentration	SCIENCE			English	Article							STOMATAL DENSITY RECORD; LAST GLACIAL MAXIMUM; PAST 2 CENTURIES; POLAR ICE CORES; FOSSIL LEAVES; GREENLAND ICE; OAK LEAVES; GISP2; TERRESTRIAL; RESPONSES	The inverse relation between atmospheric carbon dioxide concentration and stomatal frequency in tree leaves provides an accurate method for detecting and quantifying century-scale carbon dioxide fluctuations. Stomatal frequency signatures of fossil birch leaves reflect an abrupt carbon dioxide increase at the beginning of the Holocene. A succeeding carbon dioxide decline matches the Preboreal Oscillation, a 150-year cooling pulse that occurred about 300 years after the onset of the Holocene. In contrast to conventional ice core estimates of 270 to 280 parts per million by volume (ppmv), the stomatal frequency signal suggests that early Holocene carbon dioxide concentrations were well above 300 ppmv.	Univ Utrecht, Palaeobot & Palynol Lab, NL-3584 CD Utrecht, Netherlands; Free Univ Amsterdam, Fac Earth Sci, Netherlands Ctr Geoecol Res, NL-1081 HV Amsterdam, Netherlands; Univ Florida, Florida Museum Nat Hist, Paleobot Lab, Gainesville, FL 32611 USA; Univ Amsterdam, Dept Palynol & Paleoactuoecol, Netherlands Ctr Geoecol Res, NL-1098 SM Amsterdam, Netherlands	Utrecht University; Vrije Universiteit Amsterdam; State University System of Florida; University of Florida; University of Amsterdam	Wagner, F (corresponding author), Univ Utrecht, Palaeobot & Palynol Lab, Budapestlaan 4, NL-3584 CD Utrecht, Netherlands.		Kürschner, Wolfram Michael/AAC-7769-2020; Kürschner, Wolfram Michael/B-4724-2009; Wagner-Cremer, Friederike/B-4225-2009	Kürschner, Wolfram Michael/0000-0001-6883-6486; Kürschner, Wolfram Michael/0000-0001-6883-6486; Wagner-Cremer, Friederike/0000-0002-8119-3558				Alley RB, 1997, GEOLOGY, V25, P483, DOI 10.1130/0091-7613(1997)025<0483:HCIAPW>2.3.CO;2; ANKLIN M, 1995, TELLUS B, V47, P461, DOI 10.1034/j.1600-0889.47.issue4.6.x; Beerling DJ, 1995, J QUATERNARY SCI, V10, P379, DOI 10.1002/jqs.3390100407; BEERLING DJ, 1994, REV PALAEOBOT PALYNO, V81, P11, DOI 10.1016/0034-6667(94)90123-6; BEERLING DJ, 1993, SPEC PAP PALAEONTOL, V49, P181; Bjorck S, 1996, SCIENCE, V274, P1155, DOI 10.1126/science.274.5290.1155; Bjorck S, 1997, J QUATERNARY SCI, V12, P455; Fischer H, 1999, SCIENCE, V283, P1712, DOI 10.1126/science.283.5408.1712; FRIEDLI H, 1986, NATURE, V324, P237, DOI 10.1038/324237a0; GROOTES PM, 1993, NATURE, V366, P552, DOI 10.1038/366552a0; He XQ, 1998, CHINESE SCI BULL, V43, P928; Indermuhle A, 1999, NATURE, V398, P121, DOI 10.1038/18158; KEELING CD, 1995, NATURE, V375, P666, DOI 10.1038/375666a0; KEELING CD, 1998, COOPERATIVE ATMOSPHE; KROMER B, 1993, RADIOCARBON, V35, P125, DOI 10.1017/S0033822200013862; Kurschner WM, 1996, MAR MICROPALEONTOL, V27, P299, DOI 10.1016/0377-8398(95)00067-4; Kurschner WM, 1998, ANN BOT-LONDON, V81, P657, DOI 10.1006/anbo.1998.0605; Kurschner WM, 1997, GEOL RUNDSCH, V86, P512, DOI 10.1007/s005310050158; NEFTEL A, 1985, NATURE, V315, P45, DOI 10.1038/315045a0; PAOLETTI E, 1993, ACTA OECOL, V14, P173; PENUELAS J, 1990, J EXP BOT, V41, P1119, DOI 10.1093/jxb/41.9.1119; Poole I, 1996, PLANT CELL ENVIRON, V19, P705, DOI 10.1111/j.1365-3040.1996.tb00405.x; POOLE I, 1999, FOSSIL PLANTS SPORES, pCH48; RAYNAUD D, 1993, SCIENCE, V259, P926, DOI 10.1126/science.259.5097.926; Smith HJ, 1997, GEOPHYS RES LETT, V24, P1, DOI 10.1029/96GL03700; STAFFELBACH T, 1991, TELLUS B, V43, P91, DOI 10.1034/j.1600-0889.1991.t01-1-00003.x; Stauffer B, 1998, NATURE, V392, P59, DOI 10.1038/32133; Stuiver M, 1995, QUATERNARY RES, V44, P341, DOI 10.1006/qres.1995.1079; VANDERBURGH J, 1993, SCIENCE, V260, P1788, DOI 10.1126/science.260.5115.1788; VANDEWATER PK, 1994, SCIENCE, V264, P239, DOI 10.1126/science.264.5156.239; VANGEEL B, 1981, REV PALAEOBOT PALYNO, V31, P367; Wagner F, 1996, P NATL ACAD SCI USA, V93, P11705, DOI 10.1073/pnas.93.21.11705; Wagner F. R., UNPUB; WOODWARD FI, 1987, NATURE, V327, P617, DOI 10.1038/327617a0; WOODWARD FI, 1988, J EXP BOT, V39, P1771, DOI 10.1093/jxb/39.12.1771	35	91	93	2	14	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 18	1999	284	5422					1971	1973		10.1126/science.284.5422.1971	http://dx.doi.org/10.1126/science.284.5422.1971			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	207JA	10373111				2022-12-28	WOS:000080932700041
J	Cummings, P; Quan, L				Cummings, P; Quan, L			Trends in unintentional drowning - The role of alcohol and medical care	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							REGRESSION-ANALYSES; RATES; CHILDREN; RISK	Context During the last few decades, mortality from drowning has decreased in the United States for unknown reasons. It has been hypothesized that this decline may be due to decreased use of alcohol in and around water or improved medical treatment after a submersion. Objectives To estimate changes in unintentional mortality due to submersion, estimate trends in drownings attributable to alcohol use, and assess the role of medical care in these mortality trends. Design A 21-year longitudinal study of case findings, from January 1, 1975, through December 31, 1995. Setting and Participants All residents of King County, Washington, who died unintentionally from submersion and 284 persons hospitalized for submersion who survived. Main Outcome Measures Changes in submersion-related mortality incidence over time, proportion of this mortality that could be attributed to alcohol use, changes over time in the case-fatality rate of treated patients, and estimate of deaths prevented in 1995 compared with projected estimates had there been no change in incidence since 1975, Results There were 539 deaths due to drowning in King County during 21 years. Mortality rates during this period declined by 59% (95% confidence interval [CI], -70% to -46%), The incidence of death attributable to alcohol use decreased by 81% (95% CI, -91% to -57%); this could account for 51% of deaths prevented in 1995, Among 249 comatose patients who received prehospital care, 205 died; the odds of survival decreased 40% over 21 years (P = .40). Among 101 comatose patients who were hospitalized, 63 died; the odds of survival decreased 29% (P = .75). The incidence of survival of comatose hospital patients decreased by 29% from 1975 to 1995 (95% CI, -78% to +125%). We found no evidence that trends in medical treatment prevented any deaths due to drowning in 1995. Conclusions Drowning incidence in King County, Washington, declined because of a decrease in severe submersion episodes rather than an increase in success of medical interventions. Our data support the theory that less use of alcohol around water prevents some deaths, About half of the decrease was unexplained.	Univ Washington, Harborview Injury Prevent & Res Ctr, Seattle, WA 98104 USA; Univ Washington, Sch Publ Hlth & Community Med, Dept Epidemiol, Seattle, WA 98195 USA; Univ Washington, Sch Med, Dept Pediat, Seattle, WA 98195 USA; Childrens Hosp & Med Ctr, Seattle, WA 98105 USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; Seattle Children's Hospital	Cummings, P (corresponding author), Univ Washington, Harborview Injury Prevent & Res Ctr, Box 359960,325 9th Ave, Seattle, WA 98104 USA.				PHS HHS [R49/CCR010141-03] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		BAKER SP, 1992, INJURY FACT BOOK, P181; BENNETT EE, IN PRESS INJ PREV; BIGGART MJ, 1990, J PEDIATR-US, V117, P179, DOI 10.1016/S0022-3476(05)80526-8; BORKENSTEIN RF, 1964, ROLE DRINKING DRIVER, P166; BRENNER RA, 1994, JAMA-J AM MED ASSOC, V271, P1606, DOI 10.1001/jama.271.20.1606; Bureau of the Census, 1992, 1990 CENS POP GEN PO; *CDCP, 1998, CDC WONDER WEBS; CONN AW, 1980, CAN ANAESTH SOC J, V27, P201, DOI 10.1007/BF03007429; FISER DH, 1992, J PEDIATR-US, V121, P68, DOI 10.1016/S0022-3476(05)82544-2; GARDNER W, 1995, PSYCHOL BULL, V118, P392, DOI 10.1037/0033-2909.118.3.392; Glynn RJ, 1996, BMJ-BRIT MED J, V312, P364; GRAF WD, 1995, ANN EMERG MED, V26, P312, DOI 10.1016/S0196-0644(95)70079-X; Greenland S, 1995, AM J EPIDEMIOL, V142, P1255, DOI 10.1093/oxfordjournals.aje.a117592; GULAID JA, 1988, MMWR-MORBID MORTAL W, V37, pSS27; HOWLAND J, 1988, ACCIDENT ANAL PREV, V20, P19, DOI 10.1016/0001-4575(88)90011-5; HOWLAND J, 1993, JAMA-J AM MED ASSOC, V270, P91, DOI 10.1001/jama.270.1.91; Howland J., 1993, Morbidity and Mortality Weekly Report, V42, P675; HOWLAND J, 1990, MMWR-MORBID MORTAL W, V39, P332; HURST PM, 1994, ACCIDENT ANAL PREV, V26, P647, DOI 10.1016/0001-4575(94)90026-4; LITTLE RJA, 1987, STAT ANAL MISSING DA, P255; LONG JS, 1997, REGRESSION MODELS CA, P87; MCCARROLL JR, 1962, J CHRON DIS, V15, P811, DOI 10.1016/0021-9681(62)90051-6; McCullagh P, 1989, GEN LINEAR MODELS, P198; MODELL JH, 1980, CAN ANAESTH SOC J, V27, P211, DOI 10.1007/BF03007430; *NAT CTR HLTH STAT, 1997, HLTH US 1996 97 INJ; NICHTER MA, 1989, CRIT CARE MED, V17, P993, DOI 10.1097/00003246-198910000-00005; QUAN L, 1990, J ENVIRON HEALTH, V52, P344; Quan L, 1998, Inj Prev, V4, P203; Rivara FP, 1996, PEDIATRICS, V97, P791; ROTHMAN KJ, 1998, MODERN EPIDEMIOLOGY, P54; Rubin DB, 1987, MULTIPLE IMPUTATION, P75; Smith G S, 1998, Inj Prev, V4, P135; SMITH GS, 1994, 122 ANN M AM PUBL HL, P323; *STAT, 1999, STAT STAT SOFTW REL; Treser CD, 1997, J PUBLIC HEALTH POL, V18, P346, DOI 10.2307/3343315; *US BUR CENS, 1998, EL FIL KING COUNT WA; *US DHHS, 1991, DHHS PUBL PHS, P277; WINTEMUTE GJ, 1990, ACCIDENT ANAL PREV, V22, P291, DOI 10.1016/0001-4575(90)90020-L; ZADOR PL, 1991, J STUD ALCOHOL, V52, P302, DOI 10.15288/jsa.1991.52.302	39	59	59	0	5	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 16	1999	281	23					2198	2202		10.1001/jama.281.23.2198	http://dx.doi.org/10.1001/jama.281.23.2198			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	204RB	10376572				2022-12-28	WOS:000080777000033
J	Kuras, L; Struhl, K				Kuras, L; Struhl, K			Binding of TBP to promoters in vivo is stimulated by activators and requires Pol II holoenzyme	NATURE			English	Article							RNA-POLYMERASE-II; TRANSCRIPTIONAL ACTIVATION; IN-VIVO; SACCHAROMYCES-CEREVISIAE; TATA BOXES; YEAST; RECRUITMENT; COMPLEXES; DNA; REPRESSOR	In eukaryotes, transcriptional activators have been proposed to function by recruiting the RNA polymerase II (Pol II) machinery(1-3), by altering the conformation of this machinery(4,5), or by affecting steps after initiation(6-8), but the evidence is not definitive. Genomic footprinting of yeast TATA-box elements reveals activator-dependent alterations of chromatin structure(9) and activator-independent protection(10), but little is known about the association of specific components of the Pol II machinery with promoters in vivo. Here we analyse TATA-box-binding-protein (TBP) occupancy of 30 yeast promoters in vivo. We find that TBP association with promoters is stimulated by activators and inhibited by the Cyc8-Tup1 repressor, and that transcriptional activity correlates strongly with the degree of TBP occupancy. In a small subset of promoters, TBP occupancy is higher than expected when gene activity is low, and the activator-dependent increase is modest. TBP association depends on the Pol II holoenzyme component Srb4, but not on the Kin28 subunit of the transcription factor TFIIH, even though both proteins are generally required for transcription. Thus in yeast cells, TBP association with promoters occurs in concert with the Pol II holoenzyme, activator-dependent recruitment of the Pol II machinery occurs at the vast majority of promoters, and Kin28 acts after the initial recruitment.	Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA	Harvard University; Harvard Medical School	Struhl, K (corresponding author), Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA.			Kuras, Laurent/0000-0003-2932-0940				Akhtar A, 1996, EMBO J, V15, P4654, DOI 10.1002/j.1460-2075.1996.tb00842.x; Aparicio OM, 1997, CELL, V91, P59, DOI 10.1016/S0092-8674(01)80009-X; Blaiseau PL, 1998, EMBO J, V17, P6327, DOI 10.1093/emboj/17.21.6327; CHEN JJ, 1994, P NATL ACAD SCI USA, V91, P11909, DOI 10.1073/pnas.91.25.11909; Chi TH, 1996, GENE DEV, V10, P2540, DOI 10.1101/gad.10.20.2540; CISMOWSKI MJ, 1995, MOL CELL BIOL, V15, P2983; CORMACK BP, 1991, CELL, V65, P341, DOI 10.1016/0092-8674(91)90167-W; GonzalezCouto E, 1997, P NATL ACAD SCI USA, V94, P8036, DOI 10.1073/pnas.94.15.8036; Hengartner CJ, 1998, MOL CELL, V2, P43, DOI 10.1016/S1097-2765(00)80112-4; Keaveney M, 1998, MOL CELL, V1, P917, DOI 10.1016/S1097-2765(00)80091-X; KELEHER CA, 1992, CELL, V68, P709, DOI 10.1016/0092-8674(92)90146-4; KIM YJ, 1994, CELL, V77, P599, DOI 10.1016/0092-8674(94)90221-6; KLEIN C, 1994, SCIENCE, V266, P280, DOI 10.1126/science.7939664; KOLESKE AJ, 1994, NATURE, V368, P466, DOI 10.1038/368466a0; KRUMM A, 1995, GENE DEV, V9, P559, DOI 10.1101/gad.9.5.559; Meluh PB, 1997, GENE DEV, V11, P3401, DOI 10.1101/gad.11.24.3401; NONET M, 1987, MOL CELL BIOL, V7, P1602, DOI 10.1128/MCB.7.5.1602; Orphanides G, 1996, GENE DEV, V10, P2657, DOI 10.1101/gad.10.21.2657; Patikoglou G, 1997, ANNU REV BIOPH BIOM, V26, P289, DOI 10.1146/annurev.biophys.26.1.289; Ptashne M, 1997, NATURE, V386, P569, DOI 10.1038/386569a0; ROBERTS SGE, 1994, NATURE, V371, P717, DOI 10.1038/371717a0; ROUGVIE AE, 1990, MOL CELL BIOL, V10, P6041, DOI 10.1128/MCB.10.11.6041; SELLECK SB, 1987, NATURE, V325, P173, DOI 10.1038/325173a0; Stargell LA, 1996, MOL CELL BIOL, V16, P4456; StrahlBolsinger S, 1997, GENE DEV, V11, P83, DOI 10.1101/gad.11.1.83; THOMPSON CM, 1995, P NATL ACAD SCI USA, V92, P4587, DOI 10.1073/pnas.92.10.4587; TZAMARIAS D, 1994, NATURE, V369, P758, DOI 10.1038/369758a0; YANKULOV K, 1994, CELL, V77, P749, DOI 10.1016/0092-8674(94)90058-2	28	398	400	0	20	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUN 10	1999	399	6736					609	613		10.1038/21239	http://dx.doi.org/10.1038/21239			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	204RR	10376605				2022-12-28	WOS:000080778400062
J	Tahirkheli, NK; Greipp, PR				Tahirkheli, NK; Greipp, PR			Treatment of the systemic capillary leak syndrome with terbutaline and theophylline - A case series	ANNALS OF INTERNAL MEDICINE			English	Article; Proceedings Paper	45th Scientific Session of the American-Heart-Association	MAR 24-27, 1996	ORLANDO, FL	Amer Heart Assoc			MONOCLONAL IGG; INHIBITION	Background: The systemic capillary leak syndrome is a rare idiopathic disorder characterized by recurrent episodes of hypotension and hemoconcentration due to sudden transient extravasation of 10% to 70% of plasma. Mortality rates 5 years after diagnosis have been reported to be 76%. Objective: To assess the efficacy of a prophylactic regimen for the systemic capillary leak syndrome. Design: Case series. Setting: Tertiary referral center. Patients: Eight patients followed over the past 18 years. Intervention: Oral terbutaline plus aminophylline or theophylline. Measurements: Long-term clinical follow-up. Results: During a median follow-up of 9 years (range, 2 to 18 years), two patients (25%) died: one during an acute episode and one of complications related to long-term corticosteroid therapy. The other six patients are alive and healthy. The frequency and severity of the episodes decreased by a median of 30-fold. Recurrences were associated with decreased serum theophylline levels, possibly caused by enzyme induction or autoinduction. The extended-release form of medication was more successful. Sympathomimetic side effects were significant. Conclusions: A regimen of terbutaline and theophylline seems to be effective prophylaxis against the systemic capillary leak syndrome. Maintenance of therapeutic drug levels was associated with favorable results.	Mayo Clin & Mayo Fdn, Rochester, MN 55905 USA	Mayo Clinic	Greipp, PR (corresponding author), Mayo Clin & Mayo Fdn, 200 1st St SW, Rochester, MN 55905 USA.				NATIONAL CANCER INSTITUTE [P01CA062242] Funding Source: NIH RePORTER; NCI NIH HHS [CA62242] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Amoura Z, 1997, AM J MED, V103, P514, DOI 10.1016/S0002-9343(97)00272-6; ATKINSON JP, 1977, MEDICINE, V56, P225, DOI 10.1097/00005792-197705000-00004; Bertorini TE, 1997, SOUTHERN MED J, V90, P1060, DOI 10.1097/00007611-199710000-00020; BOUHAJA B, 1994, INTENS CARE MED, V20, P307, DOI 10.1007/BF01708975; CICARDI M, 1990, ANN INTERN MED, V113, P475, DOI 10.7326/0003-4819-113-6-475; CLARKSON B, 1960, AM J MED, V29, P193, DOI 10.1016/0002-9343(60)90018-8; DENLINGER CL, 1987, CLIN PHARMACOL THER, V41, P522, DOI 10.1038/clpt.1987.67; DOLBERGSTOLIK OC, 1993, CHEST, V104, P123, DOI 10.1378/chest.104.1.123; DRODER RM, 1992, AM J MED, V92, P523, DOI 10.1016/0002-9343(92)90749-2; GUIDET B, 1990, INTENS CARE MED, V16, P332, DOI 10.1007/BF01706361; JOHANSSON BR, 1979, ACTA MED SCAND, V206, P413; LOFDAHL CG, 1979, ACTA MED SCAND, V206, P405; RONDEAU E, 1987, EUR J CLIN INVEST, V17, P53, DOI 10.1111/j.1365-2362.1987.tb01225.x; SVENSJO E, 1977, ACTA PHYSIOL SCAND, V101, P504, DOI 10.1111/j.1748-1716.1977.tb06038.x; TEELUCKSINGH S, 1990, Q J MED, V75, P515; ZHANG W, 1993, CLIN EXP IMMUNOL, V93, P424, DOI 10.1111/j.1365-2249.1993.tb08195.x	16	88	99	0	4	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 1	1999	130	11					905	909		10.7326/0003-4819-130-11-199906010-00015	http://dx.doi.org/10.7326/0003-4819-130-11-199906010-00015			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine	200PB	10375339				2022-12-28	WOS:000080547900005
J	Billings, PR; Hubbard, R; Newman, SA				Billings, PR; Hubbard, R; Newman, SA			Human germline gene modification: a dissent	LANCET			English	Editorial Material							THERAPY; LINE; ENHANCEMENT; PREVENTION; MEDICINE		New York Med Coll, Dept Cell Biol & Anat, Valhalla, NY 10595 USA; Harvard Univ, Biol Labs, Cambridge, MA 02138 USA; Heart Texas Hlth Care Syst, Vet Hlth Adm, Grand Prairie, TX 75050 USA	New York Medical College; Harvard University; US Department of Veterans Affairs; Veterans Health Administration (VHA)	Newman, SA (corresponding author), New York Med Coll, Dept Cell Biol & Anat, Valhalla, NY 10595 USA.		Newman, Stuart/W-1617-2019					AGIUS E, 1994, WHAT FUTURE FUTURE G, P305; ANDERSON WF, 1992, HUM GENE THER, V3, P1, DOI 10.1089/hum.1992.3.1-1; ANNAS GJ, 1992, GENE MAPPING USING L, P142; BILLINGS PR, 1992, AM J HUM GENET, V50, P476; Bonnicksen AL, 1998, NAT GENET, V19, P10, DOI 10.1038/ng0598-10; BOUQUET M, 1993, BIOL REPROD, V49, P764, DOI 10.1095/biolreprod49.4.764; Cohen CB, 1996, HASTINGS CENT REP, V26, P19, DOI 10.2307/3528572; COOKDEEGAN RM, 1994, POL LIFE SCI, V3, P217; DANIELSON H, 1988, LANCET, V1, P1271; DAVIS BD, 1992, HUM GENE THER, V3, P361, DOI 10.1089/hum.1992.3.4-361; Ewbank J, 1998, NATURE, V392, P645; FLETCHER JC, 1992, LAW MED HEALTHCARE, V20, P2; Fowler G, 1989, Theor Med, V10, P151, DOI 10.1007/BF00539880; FRIEDMAN T, 1991, THERAPY GENETIC DIS; JAENISCH R, 1985, COLD SPRING HARB SYM, V50, P439, DOI 10.1101/SQB.1985.050.01.055; Juengst ET, 1997, J MED PHILOS, V22, P125; KOLATA G, 1998, NY TIMES        0908, pA1; KRIMSKY S, 1990, HUM GENE THER, V1, P171, DOI 10.1089/hum.1990.1.2-171; LAPPE M, 1991, J MED PHILOS, V16, P621, DOI 10.1093/jmp/16.6.621; LEDER A, 1986, CELL, V45, P485, DOI 10.1016/0092-8674(86)90280-1; LIPPMAN A, 1993, HUM GENE THER, V4, P35; McDonough PG, 1997, ANN NY ACAD SCI, V816, P378, DOI 10.1111/j.1749-6632.1997.tb52165.x; McLaren A, 1998, NATURE, V392, P645, DOI 10.1038/33511; MILLER HI, 1994, LANCET, V344, P316, DOI 10.1016/S0140-6736(94)91345-5; NEEL JV, 1993, HUM GENE THER, V4, P127, DOI 10.1089/hum.1993.4.2-127; NEWMAN SA, INTERPLAY GENETIC PH, P3; *PC, 1982, PRES COMM STUD ETH P, P1; RIFKIN J, 1983, ALGENY; Robertson JA., 1994, CHILDREN CHOICE FREE; STROHMAN RC, 1993, PERSPECT BIOL MED, V37, P112; Tsukui T, 1996, NAT BIOTECHNOL, V14, P982, DOI 10.1038/nbt0896-982; Vishwanath R, 1997, REPROD FERT DEVELOP, V9, P321, DOI 10.1071/R96088; Wadman M, 1998, NATURE, V392, P317, DOI 10.1038/32721; Walters L., 1997, ETHICS HUMAN GENE TH; Wilkins AS, 1997, BIOESSAYS, V19, P257, DOI 10.1002/bies.950190312; WIVEL NA, 1993, SCIENCE, V262, P533, DOI 10.1126/science.8211180; *WORLD COUNC CHURC, 1983, MAN LIF ETH ISS GEN; 1981, FED REG, V46, P6386; 1983, FED REG, V48, P9269	39	16	16	0	11	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAY 29	1999	353	9167					1873	1875		10.1016/S0140-6736(99)01173-3	http://dx.doi.org/10.1016/S0140-6736(99)01173-3			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	202TG	10359429				2022-12-28	WOS:000080667800047
J	Mundy, AR				Mundy, AR			Metabolic complications of urinary diversion	LANCET			English	Editorial Material							CYSTOPLASTY		UCL, Inst Urol & Nephrol, London W1P 7PN, England	University of London; University College London	Mundy, AR (corresponding author), UCL, Inst Urol & Nephrol, London W1P 7PN, England.							FILMER RB, 1990, J UROLOGY, V143, P671, DOI 10.1016/S0022-5347(17)40055-3; KOCH MO, 1992, J UROLOGY, V147, P1343, DOI 10.1016/S0022-5347(17)37560-2; KOCH MO, 1985, SURGERY, V98, P561; MCDOUGAL WS, 1992, J UROLOGY, V147, P1199, DOI 10.1016/S0022-5347(17)37517-1; MUNDY AR, 1992, BRIT J UROL, V69, P257, DOI 10.1111/j.1464-410X.1992.tb15524.x; NURSE DE, 1989, BRIT J UROL, V64, P489, DOI 10.1111/j.1464-410X.1989.tb05283.x; Nurse DE, 1996, BRIT J UROL, V77, P684, DOI 10.1046/j.1464-410X.1996.97311.x; NURSE DE, 1989, BRIT J UROL, V63, P165, DOI 10.1111/j.1464-410X.1989.tb05157.x; Stein R, 1998, BRIT J UROL, V82, P798; STEWART M, 1986, ANN ROY COLL SURG, V68, P98	10	20	21	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	MAY 29	1999	353	9167					1813	1814		10.1016/S0140-6736(99)90023-5	http://dx.doi.org/10.1016/S0140-6736(99)90023-5			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	202TG	10359400				2022-12-28	WOS:000080667800003
J	Williams, N; Jackson, D; Lambert, PC; Johnstone, JM				Williams, N; Jackson, D; Lambert, PC; Johnstone, JM			Incidence of non-specific abdominal pain in children during school term: population survey based on discharge diagnoses	BRITISH MEDICAL JOURNAL			English	Article									Leicester Royal Infirm, Dept Surg, Leicester LE1 5WW, Leics, England; Leicestershire Hlth Author, Leicester LE5 4QF, Leics, England; Univ Leicester, Dept Epidemiol & Publ Hlth, Leicester LE1 6TP, Leics, England	University of Leicester; University of Leicester	Williams, N (corresponding author), Leicester Royal Infirm, Dept Surg, Leicester LE1 5WW, Leics, England.			Lambert, Paul/0000-0002-5337-663X				HENDERSON J, 1992, ARCH DIS CHILD, V67, P83, DOI 10.1136/adc.67.1.83; Hills, 1993, STAT MODELS EPIDEMIO; IRVIN TT, 1989, BRIT J SURG, V76, P1121, DOI 10.1002/bjs.1800761105; JONES PF, 1969, BRIT MED J, V1, P284, DOI 10.1136/bmj.1.5639.284; JONES PF, 1990, BRIT J SURG, V77, P365, DOI 10.1002/bjs.1800770404	5	18	19	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	MAY 29	1999	318	7196					1455	1455		10.1136/bmj.318.7196.1455	http://dx.doi.org/10.1136/bmj.318.7196.1455			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	202TL	10346771	Bronze, Green Submitted			2022-12-28	WOS:000080668200023
J	Ramirez-Weber, FA; Kornberg, TB				Ramirez-Weber, FA; Kornberg, TB			Cytonemes: Cellular processes that project to the principal signaling center in Drosophila imaginal discs	CELL			English	Article							WING DISK; DEVELOPMENTAL COMPARTMENTALIZATION; POSTERIOR COMPARTMENTS; HEDGEHOG ACTIVITY; ENGRAILED GENE; MIGRATION; PATTERN; EMBRYO; CELLS; EXPRESSION	Wing imaginal disc cells in Drosophila develop by using information received from a signaling center associated with the anterior/posterior compartment border. We show here that disc cells have thin, actin-based extensions (cytonemes) that project to this signaling center. Cytonemes can be induced when cells from the lateral flanks of a wing disc are cultured next to cells from the A/P border or next to a source of fibroblast growth factor. Mouse limb bud cells also grow projections during a brief culture period, indicating that cytonemes are an attribute of both vertebrate and invertebrate cells. We suggest that cytonemes may be responsible for some forms of long-range cell-cell communication.	Univ Calif San Francisco, Dept Biochem & Biophys, San Francisco, CA 94143 USA	University of California System; University of California San Francisco	Kornberg, TB (corresponding author), Univ Calif San Francisco, Dept Biochem & Biophys, San Francisco, CA 94143 USA.							BASLER K, 1994, NATURE, V368, P208, DOI 10.1038/368208a0; Beiman M, 1996, GENE DEV, V10, P2993, DOI 10.1101/gad.10.23.2993; BERLETH T, 1988, EMBO J, V7, P1749, DOI 10.1002/j.1460-2075.1988.tb03004.x; Burdine RD, 1998, DEVELOPMENT, V125, P1083; CAPDEVILA J, 1994, EMBO J, V13, P4459, DOI 10.1002/j.1460-2075.1994.tb06768.x; DRIEVER W, 1989, NATURE, V340, P363, DOI 10.1038/340363a0; DRIEVER W, 1988, CELL, V54, P95, DOI 10.1016/0092-8674(88)90183-3; GARCIABELLIDO A, 1976, DEV BIOL, V48, P132, DOI 10.1016/0012-1606(76)90052-X; GARCIABELLIDO A, 1973, NATURE-NEW BIOL, V245, P251, DOI 10.1038/newbio245251a0; GARCIABELLIDO A, 1972, GENETICS, V72, P87; Gisselbrecht S, 1996, GENE DEV, V10, P3003, DOI 10.1101/gad.10.23.3003; GUSTAFSON T, 1967, BIOL REV, V42, P442, DOI 10.1111/j.1469-185X.1967.tb01482.x; KARP GC, 1985, DEV BIOL, V112, P276, DOI 10.1016/0012-1606(85)90398-7; KORNBERG T, 1981, DEV BIOL, V86, P363, DOI 10.1016/0012-1606(81)90194-9; LAWRENCE PA, 1976, DEV BIOL, V50, P321, DOI 10.1016/0012-1606(76)90155-X; Lecuit T, 1996, NATURE, V381, P387, DOI 10.1038/381387a0; LEE JJ, 1992, CELL, V71, P33, DOI 10.1016/0092-8674(92)90264-D; Lee T, 1996, GENE DEV, V10, P2912, DOI 10.1101/gad.10.22.2912; LOCKE M, 1987, TISSUE CELL, V19, P301, DOI 10.1016/0040-8166(87)90014-0; MCFARLANE S, 1995, NEURON, V15, P1017, DOI 10.1016/0896-6273(95)90091-8; MILLER J, 1995, DEVELOPMENT, V121, P2501; Minami M, 1999, NATURE, V398, P242, DOI 10.1038/18451; MORATA G, 1978, NATURE, V274, P473, DOI 10.1038/274473a0; MORATA G, 1975, NATURE, V255, P614, DOI 10.1038/255614a0; Mullor JL, 1997, DEVELOPMENT, V124, P1227; Nellen D, 1996, CELL, V85, P357, DOI 10.1016/S0092-8674(00)81114-9; Pepinsky RB, 1998, J BIOL CHEM, V273, P14037, DOI 10.1074/jbc.273.22.14037; PORTER JA, 1995, NATURE, V374, P363, DOI 10.1038/374363a0; Porter JA, 1996, SCIENCE, V274, P255, DOI 10.1126/science.274.5285.255; STEINER E, 1976, ROUX ARCH DEV BIOL, V180, P9, DOI 10.1007/BF00848882; Strigini M, 1997, DEVELOPMENT, V124, P4697; STRUHL G, 1981, DEV BIOL, V84, P372, DOI 10.1016/0012-1606(81)90406-1; Sutherland D, 1996, CELL, V87, P1091, DOI 10.1016/S0092-8674(00)81803-6; TABATA T, 1994, CELL, V76, P89, DOI 10.1016/0092-8674(94)90175-9; TABATA T, 1992, GENE DEV, V6, P2635, DOI 10.1101/gad.6.12b.2635; Taipale J, 1997, FASEB J, V11, P51, DOI 10.1096/fasebj.11.1.9034166; TILNEY LG, 1982, J CELL BIOL, V93, P820, DOI 10.1083/jcb.93.3.820; Tsuneizumi K, 1997, NATURE, V389, P627, DOI 10.1038/39362; Ursprung H, 1972, BIOL IMAGINAL DISKS, P93; WEIR MP, 1982, P NATL ACAD SCI-BIOL, V79, P3232, DOI 10.1073/pnas.79.10.3232; XU T, 1993, DEVELOPMENT, V117, P1223	41	458	464	1	13	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	MAY 28	1999	97	5					599	607		10.1016/S0092-8674(00)80771-0	http://dx.doi.org/10.1016/S0092-8674(00)80771-0			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	202VD	10367889	Bronze			2022-12-28	WOS:000080672100009
J	Gould, MK; Dembitzer, AD; Sanders, GD; Garber, AM				Gould, MK; Dembitzer, AD; Sanders, GD; Garber, AM			Low-molecular-weight heparins compared with unfractionated heparin for treatment of acute deep venous thrombosis - A cost-effectiveness analysis	ANNALS OF INTERNAL MEDICINE			English	Article						heparin, low-molecular weight; cost-benefit analysis; thrombophlebitis; quality-adjusted life years; heparin	CONTINUOUS INTRAVENOUS HEPARIN; DAILY SUBCUTANEOUS DALTEPARIN; PROXIMAL-VEIN-THROMBOSIS; STANDARD HEPARIN; HEALTH; PREVENTION; UTILITIES; MEDICINE; HOME	Background: Low-molecular-weight heparins are effective for treating venous thrombosis, but their cost effectiveness has not been rigorously assessed. Objective: To evaluate the cost-effectiveness of low-molecular-weight hepa ri ns com pa red with unfractionated heparin for treatment of acute deep venous thrombosis. Design: Decision model. Data Sources: Probabilities for clinical outcomes were obtained from a meta-analysis of randomized trials. Cost estimates were derived from Medicare reimbursement and other sources. Target Population: Two hypothetical cohorts of 60-year-old men with acute deep venous thrombosis. Time Horizon: Patient lifetime. Perspective: Societal. Intervention: Fixed-dose low-molecular-weight heparin or adjusted-dose unfractionated heparin. Outcome Measures: Costs, quality-adjusted life-years (QALYs), and incremental cost-effectiveness ratios. An inpatient hospital setting was used for the base-case analysis. Secondary analyses examined outpatient treatment with low-molecular-weight heparin. Results of Base-Case Analysis: Total costs for inpatient treatment were $26 516 for low-molecular-weight heparin and $26 361 for unfractionated heparin. The cost of initial care was higher in patients who received low-molecular-weight heparin, but this was partly offset by reduced costs for early complications. Low-molecular-weight heparin treatment increased quality-adjusted life expectancy by approximately 0.02 years. The incremental cost-effectiveness of inpatient low-molecular-weight heparin treatment was $7820 per QALY gained. Treatment with low-molecular-weight heparin was cost saving when as few as 8% of patients were treated at home. Results of Sensitivity Analysis: When late complications were assumed to occur 25% less frequently in patients who received unfractionated heparin, the incremental cost-effectiveness ratio increased to almost $75 000 per QALY gained. When late complications were assumed to occur 25% less frequently in patients who received low-molecular-weight hepa rin, th is treatment resulted in a net cost savings. Inpatient low-molecular-weight heparin treatment became cost saving when its pharmacy cost was reduced by 31% or more, when it reduced the yearly incidence of late complications by at least 7%, when as few as 8% of patients were treated entirely as outpatients, or when at least 13% of patients were eligible for early discharge. Conclusions: Low-molecular-weight heparins are highly cost-effective for inpatient management of venous thrombosis. This treatment reduces costs when small numbers of patients are eligible for outpatient management.	Vet Affairs Palo Alto Hlth Care Syst, Pulm & Crit Care Sect, Palo Alto, CA 94304 USA; Stanford Univ, Med Ctr, Stanford, CA 94305 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Palo Alto Health Care System; Stanford University	Gould, MK (corresponding author), Vet Affairs Palo Alto Hlth Care Syst, Pulm & Crit Care Sect, 111P,3801 Miranda Ave, Palo Alto, CA 94304 USA.	gould@stanford.edu	Garber, Alan M/F-1476-2010		AHRQ HHS [HS00028-11] Funding Source: Medline	AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)		*AM MED ASS, 1996, PHYS CURR PROC TERM; ANDERSON DR, 1993, ANN INTERN MED, V119, P1105, DOI 10.7326/0003-4819-119-11-199312010-00008; [Anonymous], 1996, COST EFFECTIVENESS H; Bergqvist D, 1997, ANN INTERN MED, V126, P454, DOI 10.7326/0003-4819-126-6-199703150-00006; *BUR LAB STAT, 1997, NAT CURR EMPL STAT; *BUR LAB STAT, 1995, CONS EXP SURV; Drummond MF, 1997, JAMA-J AM MED ASSOC, V277, P1552, DOI 10.1001/jama.277.19.1552; Fiessinger JN, 1996, THROMB HAEMOSTASIS, V76, P195; FROBERG DG, 1989, J CLIN EPIDEMIOL, V42, P459, DOI 10.1016/0895-4356(89)90136-4; FRYBACK DG, 1993, MED DECIS MAKING, V13, P89, DOI 10.1177/0272989X9301300202; Gold MR, 1996, COST EFFECTIVENESS H; Gould MK, 1999, ANN INTERN MED, V130, P800, DOI 10.7326/0003-4819-130-10-199905180-00003; *HCIA INC, 1997, LENGTH STAY DIAGN; *HLTH CAR FIN ADM, 1995, MED PROV AN REV; Hull RD, 1997, ARCH INTERN MED, V157, P289; HULL RD, 1992, NEW ENGL J MED, V326, P975, DOI 10.1056/NEJM199204093261502; Koopman MMW, 1996, NEW ENGL J MED, V334, P682, DOI 10.1056/NEJM199603143341102; LEIZOROVICZ A, 1997, THROM HAEMOST, V290; Lenert LA, 1997, J AM MED INFORM ASSN, V4, P49, DOI 10.1136/jamia.1997.0040049; Levine M, 1996, NEW ENGL J MED, V334, P677, DOI 10.1056/NEJM199603143341101; LINDMARKER P, 1994, THROMB HAEMOSTASIS, V72, P186; Lindmarker P, 1996, J INTERN MED, V240, P395, DOI 10.1046/j.1365-2796.1996.81877000.x; LOPACIUK S, 1992, THROMB HAEMOSTASIS, V68, P14; Luce BR, 1996, COST EFFECTIVENESS H, P176; Luomanmaki K, 1996, J INTERN MED, V240, P85, DOI 10.1046/j.1365-2796.1996.18845000.x; *MED EC, 1997, DRUG TOP RED BOOK; MENZIN J, 1995, ARCH INTERN MED, V155, P757, DOI 10.1001/archinte.155.7.757; *NAT CTR HLTH STAT, 1994, ABR US LIF TABL; Passman MA, 1997, J VASC SURG, V25, P39, DOI 10.1016/S0741-5214(97)70319-7; PHILBRICK JT, 1988, ARCH INTERN MED, V148, P2131, DOI 10.1001/archinte.148.10.2131; PRANDONI P, 1992, LANCET, V339, P441, DOI 10.1016/0140-6736(92)91054-C; Prandoni P, 1996, ANN INTERN MED, V125, P1, DOI 10.7326/0003-4819-125-1-199607010-00001; Russell LB, 1996, JAMA-J AM MED ASSOC, V276, P1172, DOI 10.1001/jama.276.14.1172; SIMONNEAU G, 1993, ARCH INTERN MED, V153, P1541, DOI 10.1001/archinte.153.13.1541; tenCate JW, 1997, NEW ENGL J MED, V337, P657; TORRANCE GW, 1986, J HEALTH ECON, V5, P1, DOI 10.1016/0167-6296(86)90020-2; Torrance GW, 1996, COST EFFECTIVENESS H, P276; Weinstein MC, 1996, JAMA-J AM MED ASSOC, V276, P1253, DOI 10.1001/jama.276.15.1253; Weitz JI, 1997, NEW ENGL J MED, V337, P688, DOI 10.1056/NEJM199709043371007; 1991, THROM HAEMOST, V65, P251	40	201	203	0	6	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAY 18	1999	130	10					789	+		10.7326/0003-4819-130-10-199905180-00002	http://dx.doi.org/10.7326/0003-4819-130-10-199905180-00002			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	196JJ	10366368				2022-12-28	WOS:000080305000001
J	Verheugt, FWA				Verheugt, FWA			Acute coronary syndromes: drug treatments	LANCET			English	Article							ACUTE MYOCARDIAL-INFARCTION; MOLECULAR-WEIGHT HEPARIN; UNSTABLE ANGINA; UNFRACTIONATED HEPARIN; ARTERY DISEASE; ASPIRIN; ANGIOPLASTY; TRIAL; DEATH		Univ Nijmegen Hosp, Dept Cardiol, Heartctr, NL-6500 HB Nijmegen, Netherlands	Radboud University Nijmegen	Verheugt, FWA (corresponding author), Univ Nijmegen Hosp, Dept Cardiol, Heartctr, POB 9101, NL-6500 HB Nijmegen, Netherlands.	f.verheugt@cardio.azn.nl	Verheugt, F.W.A./H-8105-2014					[Anonymous], 1994, Circulation, V89, P1545; [Anonymous], 1988, LANCET, V1, P921; [Anonymous], 1988, LANCET, V2, P349; [Anonymous], 1986, LANCET, V2, P57; ANTMAN EM, 1998, 20 C EUR SOC CARD VI; BALSANO F, 1990, CIRCULATION, V82, P17, DOI 10.1161/01.CIR.82.1.17; Bazzino O, 1998, NEW ENGL J MED, V338, P1498; Bazzino O, 1998, NEW ENGL J MED, V338, P1488; CAIRNS JA, 1985, NEW ENGL J MED, V313, P1369, DOI 10.1056/NEJM198511283132201; CANNON C, 1999, 48 ANN SCI SESS AM C; Cohen M, 1997, NEW ENGL J MED, V337, P447, DOI 10.1056/NEJM199708143370702; COLLINS R, 1995, LANCET, V345, P669; *GISSI 3, 1994, LANCET, V343, P115; HELD PH, 1989, BMJ-BRIT MED J, V299, P1187, DOI 10.1136/bmj.299.6709.1187; HJALMARSON A, 1985, EUR HEART J, V6, P199; Klein W, 1997, CIRCULATION, V96, P61; LEIZOROVICZ A, 1998, 20 C EUR SOC CARD VI; LEWIS HD, 1983, NEW ENGL J MED, V309, P396, DOI 10.1056/NEJM198308183090703; LUBSEN J, 1986, BRIT HEART J, V56, P400; Oler A, 1996, JAMA-J AM MED ASSOC, V276, P811, DOI 10.1001/jama.276.10.811; PEDERSEN AK, 1984, NEW ENGL J MED, V311, P1206, DOI 10.1056/NEJM198411083111902; PEDERSEN TR, 1994, LANCET, V344, P1383; SAKCS FM, 1996, N ENGL J MED, V335; SERRUYS PW, 1995, NEW ENGL J MED, V333, P757, DOI 10.1056/NEJM199509213331203; THEROUX P, 1992, NEW ENGL J MED, V327, P141, DOI 10.1056/NEJM199207163270301; THEROUX P, 1988, NEW ENGL J MED, V319, P1105, DOI 10.1056/NEJM198810273191701; Topol E, 1998, NEW ENGL J MED, V339, P436; Topol E, 1998, CIRCULATION, V97, P2386; Topol EJ, 1996, NEW ENGL J MED, V335, P775; Wallentin L, 1996, LANCET, V347, P561; WALLENTIN L, 1990, LANCET, V336, P827; Weaver WD, 1997, JAMA-J AM MED ASSOC, V278, P2093, DOI 10.1001/jama.278.23.2093; White HD, 1998, CIRCULATION, V97, P1632, DOI 10.1161/01.CIR.97.16.1632; WILCOX RG, 1999, 48 ANN SCI SESS AM C; YUSUF S, 1985, PROG CARDIOVASC DIS, V27, P335, DOI 10.1016/S0033-0620(85)80003-7; YUSUF S, 1998, 20 C EUR SOC CARD VI	36	17	17	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet		1999	353			2			SII20	SII23						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	205GJ	10374762				2022-12-28	WOS:000080812700005
J	Franc, NC; Heitzler, P; Ezekowitz, RAB; White, K				Franc, NC; Heitzler, P; Ezekowitz, RAB; White, K			Requirement for croquemort in phagocytosis of apoptotic cells in Drosophila	SCIENCE			English	Article							MONOCYTE-DERIVED MACROPHAGES; GENE-EXPRESSION; C-ELEGANS; VITRONECTIN RECEPTOR; SCAVENGER RECEPTOR; DEATH; PROTEIN; CD36; RECOGNITION; MELANOGASTER	Macrophages in the Drosophila embryo are responsible for the phagocytosis of apoptotic cells and are competent to engulf bacteria. Croquemort (CRQ) is a CD36-related receptor expressed exclusively on these macrophages. Genetic evidence showed that crq was essential for efficient phagocytosis of apoptotic corpses but was not required for the engulfment of bacteria. The expression of CRQ was regulated by the amount of apoptosis. These data define distinct pathways for the phagocytosis of corpses and bacteria in Drosophila.	Harvard Univ, Massachusetts Gen Hosp, Sch Med, Cutaneous Biol Res Ctr, Charlestown, MA 02129 USA; Harvard Univ, Massachusetts Gen Hosp, Sch Med, Lab Dev Immunol, Charlestown, MA 02129 USA; Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Pediat, Charlestown, MA 02129 USA; Univ Strasbourg 1, CNRS, INSERM, IGBMC, F-67404 Illkirch Graffenstaden, France	Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	White, K (corresponding author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Cutaneous Biol Res Ctr, Charlestown, MA 02129 USA.		White, Kristin/D-7936-2013; Franc, Nathalie/C-2208-2009	Franc, Nathalie/0000-0002-1617-385X	NIGMS NIH HHS [R01 GM055568] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABRAMS JM, 1992, P NATL ACAD SCI USA, V89, P10375, DOI 10.1073/pnas.89.21.10375; Ashburner M., 2004, DROSOPHILA LAB MANUA, V2nd; BOEDIGHEIMER M, 1993, DEVELOPMENT, V118, P1291; Chen P, 1996, GENE DEV, V10, P1773, DOI 10.1101/gad.10.14.1773; Devitt A, 1998, NATURE, V392, P505, DOI 10.1038/33169; Dimarcq JL, 1997, INSECT BIOCHEM MOLEC, V27, P877, DOI 10.1016/S0965-1748(97)00072-6; ENDEMANN G, 1993, J BIOL CHEM, V268, P11811; Fearon DT, 1996, SCIENCE, V272, P50, DOI 10.1126/science.272.5258.50; Franc NC, 1996, IMMUNITY, V4, P431, DOI 10.1016/S1074-7613(00)80410-0; Franc NC, 1999, CURR OPIN IMMUNOL, V11, P47, DOI 10.1016/S0952-7915(99)80009-0; Frank LH, 1996, DEVELOPMENT, V122, P1343; Gateff E., 1980, INVERTEBRATE SYSTEMS, P517; GRETHER ME, 1995, GENE DEV, V9, P1694, DOI 10.1101/gad.9.14.1694; Harvey AJ, 1997, MOL CELL BIOL, V17, P2835, DOI 10.1128/MCB.17.5.2835; HEITZLER P, UNPUB; Hortsch M, 1998, INT J DEV BIOL, V42, P33; Jack RS, 1997, NATURE, V389, P742, DOI 10.1038/39622; Liu QA, 1998, CELL, V93, P961, DOI 10.1016/S0092-8674(00)81202-7; Nagy L, 1998, CELL, V93, P229, DOI 10.1016/S0092-8674(00)81574-3; NELSON RE, 1994, EMBO J, V13, P3438, DOI 10.1002/j.1460-2075.1994.tb06649.x; NICHOLSON A, 1995, THROMB VASC BIOL, V15, P269; NOZAKI S, 1995, J CLIN INVEST, V96, P1859, DOI 10.1172/JCI118231; PEARSON A, 1995, P NATL ACAD SCI USA, V92, P4056, DOI 10.1073/pnas.92.9.4056; Phelps CB, 1998, METHODS, V14, P367, DOI 10.1006/meth.1998.0592; Platt N, 1998, TRENDS CELL BIOL, V8, P365, DOI 10.1016/S0962-8924(98)01329-4; PUGIN J, 1994, IMMUNITY, V1, P509, DOI 10.1016/1074-7613(94)90093-0; REN Y, 1995, J EXP MED, V181, P1857, DOI 10.1084/jem.181.5.1857; RODRIGUES V, 1995, EMBO J, V14, P3007, DOI 10.1002/j.1460-2075.1995.tb07303.x; Ryeom SW, 1996, J CELL SCI, V109, P387; SAVILL J, 1992, J CLIN INVEST, V90, P1513, DOI 10.1172/JCI116019; Savill J, 1997, BRIT MED BULL, V53, P491; SAVILL J, 1990, NATURE, V343, P170, DOI 10.1038/343170a0; SCHNEITZ K, 1993, GENE DEV, V7, P114, DOI 10.1101/gad.7.1.114; Suzuki H, 1997, NATURE, V386, P292, DOI 10.1038/386292a0; TEPASS U, 1994, DEVELOPMENT, V120, P1829; WHITE K, 1994, SCIENCE, V264, P677, DOI 10.1126/science.8171319; Wu YC, 1998, NATURE, V392, P501, DOI 10.1038/33163; Wu YC, 1998, CELL, V93, P951, DOI 10.1016/S0092-8674(00)81201-5	38	295	302	0	16	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 18	1999	284	5422					1991	1994		10.1126/science.284.5422.1991	http://dx.doi.org/10.1126/science.284.5422.1991			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	207JA	10373118				2022-12-28	WOS:000080932700048
J	DeStefano, F; Chen, RT				DeStefano, F; Chen, RT			Negative association between MMR and autism	LANCET			English	Editorial Material							UK		Ctr Dis Control & Prevent, Natl Immunizat Program, Vaccine Safety & Dev Branch, Atlanta, GA 30333 USA	Centers for Disease Control & Prevention - USA	DeStefano, F (corresponding author), Ctr Dis Control & Prevent, Natl Immunizat Program, Vaccine Safety & Dev Branch, Atlanta, GA 30333 USA.		Chen, Robert T/AIA-8164-2022	Chen, Robert T/0000-0002-3094-8367				Bignall J, 1998, LANCET, V351, P966; Chadwick N, 1998, J MED VIROL, V55, P305, DOI 10.1002/(SICI)1096-9071(199808)55:4&lt;305::AID-JMV9&gt;3.0.CO;2-4; Chen RT, 1998, LANCET, V351, P611, DOI 10.1016/S0140-6736(05)78423-3; Duclos P, 1998, DRUG SAFETY, V19, P435, DOI 10.2165/00002018-199819060-00002; Medicines Commission Agency/Committee on Safety of Medicines, 1999, CURR PROBL CURR PHAR, V25, P9; MONTGOMERY SM, GASTROENTEROLOGY, V161, P796; Rodier PM, 1998, MENT RETARD DEV D R, V4, P121, DOI 10.1002/(SICI)1098-2779(1998)4:2<121::AID-MRDD9>3.0.CO;2-S; Thomas DR, 1998, LANCET, V351, P1927, DOI 10.1016/S0140-6736(98)24026-8; Wakefield AJ, 1998, LANCET, V351, P637, DOI 10.1016/S0140-6736(97)11096-0	9	18	20	1	19	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUN 12	1999	353	9169					1987	1988		10.1016/S0140-6736(99)00160-9	http://dx.doi.org/10.1016/S0140-6736(99)00160-9			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	205GD	10376608				2022-12-28	WOS:000080812200003
J	Shi, SH; Hayashi, Y; Petralia, RS; Zaman, SH; Wenthold, RJ; Svoboda, K; Malinow, R				Shi, SH; Hayashi, Y; Petralia, RS; Zaman, SH; Wenthold, RJ; Svoboda, K; Malinow, R			Rapid spine delivery and redistribution of AMPA receptors after synaptic NMDA receptor activation	SCIENCE			English	Article							LONG-TERM POTENTIATION; CULTURED HIPPOCAMPAL-NEURONS; EVOKED DENDRITIC EXOCYTOSIS; GLUTAMATE RECEPTORS; SILENT SYNAPSES; PHOSPHORYLATION; CA1; LTP; TRANSMISSION; EXPRESSION	To monitor changes in alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionate (AMPA) receptor distribution in living neurons, the AMPA receptor subunit GluR1 was tagged with green fluorescent protein (GFP), This protein (GluR1-GFP) was functional and was transiently expressed in hippocampal CA1 neurons, in dendrites visualized with two-photon Laser scanning microscopy or electron microscopy, most of the GluR1-GFP was intracellular, mimicking endogenous GluR1 distribution. Tetanic synaptic stimulation induced a rapid delivery of tagged receptors into dendritic spines as well as clusters in dendrites. These postsynaptic trafficking events required synaptic N-methyl-D-aspartate (NMDA) receptor activation and may contribute to the enhanced AMPA receptor-mediated transmission observed during long-term potentiation and activity-dependent synaptic maturation.	Cold Spring Harbor Lab, Cold Spring Harbor, NY 11724 USA; NIDODS, Neurochem Lab, NIH, Bethesda, MD 20892 USA	Cold Spring Harbor Laboratory; National Institutes of Health (NIH) - USA	Malinow, R (corresponding author), Cold Spring Harbor Lab, POB 100, Cold Spring Harbor, NY 11724 USA.	malinow@cshl.org	Hayashi, Yasunori/C-2249-2008; Hayashi, Yasunori/AAF-1408-2019	Hayashi, Yasunori/0000-0002-7560-3004; Hayashi, Yasunori/0000-0002-7560-3004; Zaman, Shahid/0000-0003-1639-6014	NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS [Z01DC000003, ZIADC000003] Funding Source: NIH RePORTER	NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD))		Barria A, 1997, SCIENCE, V276, P2042, DOI 10.1126/science.276.5321.2042; BEKKERS JM, 1990, NATURE, V346, P724, DOI 10.1038/346724a0; BenAri Y, 1997, TRENDS NEUROSCI, V20, P523, DOI 10.1016/S0166-2236(97)01147-8; Benke TA, 1998, NATURE, V393, P793, DOI 10.1038/31709; BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0; DAVIES SN, 1989, NATURE, V338, P500, DOI 10.1038/338500a0; Denk W, 1997, NEURON, V18, P351, DOI 10.1016/S0896-6273(00)81237-4; Derkach V, 1999, P NATL ACAD SCI USA, V96, P3269, DOI 10.1073/pnas.96.6.3269; Durand GM, 1996, NATURE, V381, P71, DOI 10.1038/381071a0; Frey U, 1997, NATURE, V385, P533, DOI 10.1038/385533a0; Frolov I, 1996, P NATL ACAD SCI USA, V93, P11371, DOI 10.1073/pnas.93.21.11371; HARRIS KM, 1992, J NEUROSCI, V12, P2685; Hayashi Y, 1997, MOL BRAIN RES, V46, P338, DOI 10.1016/S0169-328X(97)00073-9; HOLLMANN M, 1994, ANNU REV NEUROSCI, V17, P31, DOI 10.1146/annurev.ne.17.030194.000335; ISAAC JTR, 1995, NEURON, V15, P427, DOI 10.1016/0896-6273(95)90046-2; KAUER JA, 1988, NEURON, V1, P911, DOI 10.1016/0896-6273(88)90148-1; LIAO DZ, 1995, NATURE, V375, P400, DOI 10.1038/375400a0; Lledo PM, 1998, SCIENCE, V279, P399, DOI 10.1126/science.279.5349.399; MAINEN ZF, IN PRESS METHODS; Maletic-Savatic M, 1998, J NEUROSCI, V18, P6814; Maletic-Savatic M, 1999, SCIENCE, V283, P1923, DOI 10.1126/science.283.5409.1923; Maletic-Savatic M, 1998, J NEUROSCI, V18, P6803; MALINOW R, 1994, P NATL ACAD SCI USA, V91, P8170, DOI 10.1073/pnas.91.17.8170; MALINOW R, IN PRESS IMAGING LIV; Miyawaki A, 1997, NATURE, V388, P882, DOI 10.1038/42264; MULLER D, 1988, P NATL ACAD SCI USA, V85, P9346, DOI 10.1073/pnas.85.23.9346; Musleh W, 1997, P NATL ACAD SCI USA, V94, P9451, DOI 10.1073/pnas.94.17.9451; Nishimune A, 1998, NEURON, V21, P87, DOI 10.1016/S0896-6273(00)80517-6; Nusser Z, 1998, NEURON, V21, P545, DOI 10.1016/S0896-6273(00)80565-6; Osten P, 1998, NEURON, V21, P99, DOI 10.1016/S0896-6273(00)80518-8; Petralia RS, 1997, J COMP NEUROL, V385, P456, DOI 10.1002/(SICI)1096-9861(19970901)385:3<456::AID-CNE9>3.0.CO;2-2; Petralia RS, 1999, NAT NEUROSCI, V2, P31, DOI 10.1038/4532; PETTIT DL, 1994, SCIENCE, V266, P1881, DOI 10.1126/science.7997883; Roche KW, 1996, NEURON, V16, P1179, DOI 10.1016/S0896-6273(00)80144-0; Song I, 1998, NEURON, V21, P393, DOI 10.1016/S0896-6273(00)80548-6; Spacek J, 1997, J NEUROSCI, V17, P190, DOI 10.1523/JNEUROSCI.17-01-00190.1997; STOPPINI L, 1991, J NEUROSCI METH, V37, P173, DOI 10.1016/0165-0270(91)90128-M; Svoboda K, 1996, SCIENCE, V272, P716, DOI 10.1126/science.272.5262.716; Takechi H, 1998, NATURE, V396, P757, DOI 10.1038/25547; Wenthold RJ, 1996, J NEUROSCI, V16, P1982; Worley P, 1998, NEURON, V21, P936, DOI 10.1016/S0896-6273(00)80609-1; YUSTE R, 1995, NATURE, V375, P682, DOI 10.1038/375682a0	42	973	1006	0	88	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 11	1999	284	5421					1811	1816		10.1126/science.284.5421.1811	http://dx.doi.org/10.1126/science.284.5421.1811			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	205EU	10364548				2022-12-28	WOS:000080809000042
J	Oda, R; Huc, I; Schmutz, M; Candau, SJ; MacKintosh, FC				Oda, R; Huc, I; Schmutz, M; Candau, SJ; MacKintosh, FC			Tuning bilayer twist using chiral counterions	NATURE			English	Article							LIPID TUBULES; HELICAL CRYSTALLIZATION; SURFACTANTS; MORPHOLOGY; DEPENDENCE; MEMBRANES; RIBBONS	From seashells to DNA, chirality is expressed at every level of biological structures. In self-assembled structures it may emerge cooperatively from chirality at the molecular scale. Amphiphilic molecules, for example, can form a variety of aggregates and mesophases that express the chirality of their constituent molecules at a supramolecular scale of micrometres (refs 1-3), Quantitative prediction of the large-scale chirality based on that at the molecular scale remains a largely unsolved problem. Furthermore, experimental control over the expression of chirality at the supramolecular level is difficult to achieve(4-7): mixing of different enantiomers usually results in phase separation(18). Here we present an experimental and theoretical description of a system in which chirality can be varied continuously and controllably ('tuned') in micrometre-scale structures. we observe the formation of twisted ribbons consisting of bilayers of gemini surfactants (two surfactant molecules covalently linked at their charged head groups). We find that the degree of twist and the pitch of the ribbons can be tuned by the introduction of opposite-handed chiral counterions in various proportions. This degree of control might be of practical value; for example, in the use of the helical structures as templates for helical crystallization of macromolecules(8,9).	ENSCPB, Inst Europeen Chim & Biol, F-33402 Talence, France; Lab Dynam Fluides Complexes, F-67000 Strasbourg, France; ULP, Inst Genet & Biol Mol & Cellulaire, INSERM, CNRS, F-67404 Illkirch, France; Univ Michigan, Dept Phys, Ann Arbor, MI 48109 USA	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; University of Michigan System; University of Michigan	Oda, R (corresponding author), ENSCPB, Inst Europeen Chim & Biol, Av Pey Berland,BP 108, F-33402 Talence, France.		Oda, Reiko/AAE-4185-2021; MacKintosh, Fred C/A-9450-2008; MacKintosh, Frederick/AAB-9332-2021; Schmutz, Marc/A-4953-2012; oda, reiko/B-2214-2013	MacKintosh, Fred C/0000-0002-2607-9541; MacKintosh, Frederick/0000-0002-2607-9541; Schmutz, Marc/0000-0003-4059-7609; oda, reiko/0000-0003-3273-8635				CHUNG DS, 1993, P NATL ACAD SCI USA, V90, P11341, DOI 10.1073/pnas.90.23.11341; DEGENNES PG, 1993, PHYSICS LIQUID CRYST; FUHRHOP JH, 1993, CHEM REV, V93, P1565, DOI 10.1021/cr00020a008; HELFRICH W, 1988, PHYS REV A, V38, P3065, DOI 10.1103/PhysRevA.38.3065; HELFRICH W, 1973, Z NATURFORSCH C, VC 28, P693, DOI 10.1515/znc-1973-11-1209; Oda R, 1998, ANGEW CHEM INT EDIT, V37, P2689, DOI 10.1002/(SICI)1521-3773(19981016)37:19<2689::AID-ANIE2689>3.0.CO;2-Z; Oda R, 1999, LANGMUIR, V15, P2384, DOI 10.1021/la9814889; Prins LJ, 1999, NATURE, V398, P498, DOI 10.1038/19053; Ringler P, 1997, CHEM-EUR J, V3, P620, DOI 10.1002/chem.19970030419; Rowan AE, 1998, ANGEW CHEM INT EDIT, V37, P63, DOI 10.1002/(SICI)1521-3773(19980202)37:1/2<63::AID-ANIE63>3.0.CO;2-4; SCHNUR JM, 1993, SCIENCE, V262, P1669, DOI 10.1126/science.262.5140.1669; Selinger JV, 1996, PHYS REV E, V53, P3804, DOI 10.1103/PhysRevE.53.3804; SINGH A, 1988, CHEM PHYS LIPIDS, V47, P135, DOI 10.1016/0009-3084(88)90083-7; Spector MS, 1998, LANGMUIR, V14, P3493, DOI 10.1021/la980086y; THOMAS BN, 1995, SCIENCE, V267, P1635, DOI 10.1126/science.267.5204.1635; Wilson-Kubalek EM, 1998, P NATL ACAD SCI USA, V95, P8040, DOI 10.1073/pnas.95.14.8040; Yashima E, 1999, NATURE, V399, P449, DOI 10.1038/20900; ZANA R, 1993, NATURE, V362, P228, DOI 10.1038/362228a0	18	562	563	4	223	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUN 10	1999	399	6736					566	569		10.1038/21154	http://dx.doi.org/10.1038/21154			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	204RR	10376596	Green Published			2022-12-28	WOS:000080778400050
J	Sugiura, R; Toda, T; Dhut, S; Shuntoh, H; Kuno, T				Sugiura, R; Toda, T; Dhut, S; Shuntoh, H; Kuno, T			The MAPK kinase Pek1 acts as a phosphorylation-dependent molecular switch	NATURE			English	Article							FISSION YEAST; PROTEIN-KINASE; SCHIZOSACCHAROMYCES-POMBE; GENE; PATHWAY; GROWTH; STRESS; MEK; INTEGRITY; POLARITY	The mitogen-activated protein kinase (MAPK) pathway is a highly conserved eukaryotic signalling: cascade that converts extracellular signals into various outputs, such as cell growth and differentiation(1-3), MAPK is phosphorylated and activated by a specific MAPK kinase (MAPKK)(4): MAPKK is therefore considered to be an activating regulator of MAPK. Pmk1 is a MAPK that regulates cell integrity(5) and which, with calcineurin phosphatase, antagonizes chloride homeostasis(6) in fission yeast. We have now identified Pek1, a MAPKK for Pmk1 MAPK. We show here that Pek1, in its unphosphorylated form, acts as a potent negative regulator of Pmk1 MAPK sig-nailing. Mkh1(7), an upstream MAPKK kinase (MAPKKK), converts Pek1 from being an inhibitor to an activator. Our results indicate that Pek1 has a dual stimulatory and inhibitory function which depends on its phosphorylation state. This switch-like mechanism could contribute to the all-or-none physiological response mediated by the MAPK signalling pathway.	Kobe Univ, Sch Med, Dept Pharmacol, Chuo Ku, Kobe, Hyogo 6500017, Japan; Imperial Canc Res Fund, Cell Regulat Lab, London WC2A 3PX, England; Kobe Univ, Sch Med, Fac Hlth Sci, Suma Ku, Kobe, Hyogo 6500142, Japan	Kobe University; Cancer Research UK; Kobe University	Kuno, T (corresponding author), Kobe Univ, Sch Med, Dept Pharmacol, Chuo Ku, Kusunoki Cho, Kobe, Hyogo 6500017, Japan.	tkuno@kobe-u.ac.jp						BARBET N, 1992, GENE, V114, P59, DOI 10.1016/0378-1119(92)90707-V; BEACH D, 1982, MOL GEN GENET, V187, P326, DOI 10.1007/BF00331138; Cook JG, 1997, NATURE, V390, P85, DOI 10.1038/36355; CREWS CM, 1992, SCIENCE, V258, P478, DOI 10.1126/science.1411546; Ferrell JE, 1998, SCIENCE, V280, P895, DOI 10.1126/science.280.5365.895; HERSKOWITZ I, 1995, CELL, V80, P187, DOI 10.1016/0092-8674(95)90402-6; IRIE K, 1993, MOL CELL BIOL, V13, P3076, DOI 10.1128/MCB.13.5.3076; Kato T, 1996, FEBS LETT, V378, P207, DOI 10.1016/0014-5793(95)01442-X; LEVIN DE, 1990, P NATL ACAD SCI USA, V87, P8272, DOI 10.1073/pnas.87.21.8272; LEVIN DE, 1995, CURR OPIN CELL BIOL, V7, P197, DOI 10.1016/0955-0674(95)80028-X; Madhani HD, 1997, CELL, V91, P673, DOI 10.1016/S0092-8674(00)80454-7; MARSHALL CJ, 1994, CURR OPIN GENET DEV, V4, P82, DOI 10.1016/0959-437X(94)90095-7; MCLEOD M, 1987, EMBO J, V6, P729, DOI 10.1002/j.1460-2075.1987.tb04814.x; MILLAR JBA, 1995, GENE DEV, V9, P2117, DOI 10.1101/gad.9.17.2117; MORENO S, 1991, METHOD ENZYMOL, V194, P795; Murray AW, 1998, CELL, V92, P157, DOI 10.1016/S0092-8674(00)80910-1; NEIMAN AM, 1994, P NATL ACAD SCI USA, V91, P3398, DOI 10.1073/pnas.91.8.3398; NISHIDA E, 1993, TRENDS BIOCHEM SCI, V18, P128, DOI 10.1016/0968-0004(93)90019-J; ROTHSTEIN RJ, 1983, METHOD ENZYMOL, V101, P202; Sengar AS, 1997, MOL CELL BIOL, V17, P3508, DOI 10.1128/MCB.17.7.3508; SHIOZAKI K, 1995, NATURE, V378, P739, DOI 10.1038/378739a0; Sugiura R, 1998, EMBO J, V17, P140, DOI 10.1093/emboj/17.1.140; TODA T, 1991, GENE DEV, V5, P60, DOI 10.1101/gad.5.1.60; Toda T, 1996, MOL CELL BIOL, V16, P6752; YOSHIDA T, 1994, J CELL SCI, V107, P1725; ZaitsevskayaCarter T, 1997, EMBO J, V16, P1318, DOI 10.1093/emboj/16.6.1318; Zarzov P, 1996, EMBO J, V15, P83, DOI 10.1002/j.1460-2075.1996.tb00336.x	27	67	72	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 3	1999	399	6735					479	483		10.1038/20951	http://dx.doi.org/10.1038/20951			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	202TH	10365961				2022-12-28	WOS:000080667900051
J	Bruyn, GAW; Griep, EN; Korff, KJ				Bruyn, GAW; Griep, EN; Korff, KJ			Leflunomide for active rheumatoid arthritis	LANCET			English	Letter									Med Ctr Leeuwarden, NL-8934 AD Leeuwarden, Netherlands; Rivierenland Hosp, Tiel, Netherlands	Medical Center Leeuwarden	Bruyn, GAW (corresponding author), Med Ctr Leeuwarden, NL-8934 AD Leeuwarden, Netherlands.			Ferraccioli, Gianfranco/0000-0002-6884-4301				Smolen JS, 1999, LANCET, V353, P259, DOI 10.1016/S0140-6736(98)09403-3	1	10	10	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAY 29	1999	353	9167					1883	1883		10.1016/S0140-6736(05)75088-1	http://dx.doi.org/10.1016/S0140-6736(05)75088-1			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	202TG	10359439	Bronze			2022-12-28	WOS:000080667800059
J	Sharp, TG; El Goresy, A; Wopenka, B; Chen, M				Sharp, TG; El Goresy, A; Wopenka, B; Chen, M			A post-stishovite SiO2 polymorph in the meteorite Shergotty: Implications for impact events	SCIENCE			English	Article							LOWER-MANTLE PRESSURES; ELNES SPECTROSCOPY; PEROVSKITE MGSIO3; PHASE-TRANSITION; SILICA; TRANSFORMATIONS; DISSOCIATION; TEMPERATURE; CHONDRITES	Transmission electron microscopy and electron diffraction show that the martian meteorite Shergotty, a shocked achondrite, contains a dense orthorhombic SiO2 phase similar to post-stishovite SiO2 with the alpha-PbO2 structure. If an SiO2 mineral exists in Earth's Lower mantle, it would probably occur in a post-stishovite SiO2 structure, The presence of such a high-density polymorph in a shocked sample indicates that post-stishovite SiO2 structures may be used as indicators of extreme shock pressures.	Arizona State Univ, Dept Geol, Tempe, AZ 85287 USA; Max Planck Inst Kernphys, D-69029 Heidelberg, Germany; Washington Univ, Dept Earth & Planetary Sci, St Louis, MO 63130 USA; Acad Sinica, Guangzhou Inst Geochem, Guangzhou 510640, Peoples R China	Arizona State University; Arizona State University-Tempe; Max Planck Society; Washington University (WUSTL); Chinese Academy of Sciences; Guangzhou Institute of Geochemistry, CAS	Sharp, TG (corresponding author), Arizona State Univ, Dept Geol, Tempe, AZ 85287 USA.							AHRENS TJ, 1996, ADV MAT 96 NEW TREND, P1; Belonoshko AB, 1996, AM MINERAL, V81, P785; BOGARD D, 1987, GEOCHIM COSMOCHIM AC, V51, P2035, DOI 10.1016/0016-7037(87)90192-X; CHAO ECT, 1962, J GEOPHYS RES, V67, P419, DOI 10.1029/JZ067i001p00419; Dubrovinsky LS, 1997, NATURE, V388, P362, DOI 10.1038/41066; ElGoresy A, 1997, METEORIT PLANET SCI, V32, pA38; ELGORESY A, 1998, LUNAR PLANET SCI C, V29, P1707; GALEENER FL, 1982, J NON-CRYST SOLIDS, V49, P53, DOI 10.1016/0022-3093(82)90108-9; German V. N., 1973, Soviet Physics - JETP, V37; GILLET P, 1984, EARTH PLANET SC LETT, V70, P426, DOI 10.1016/0012-821X(84)90026-8; HEANEY PJ, 1994, REV MINERAL, V29, P1; HEMLEY RJ, 1994, REV MINERAL, V29, P41; HEMLEY RJ, 1986, PHYS REV LETT, V57, P747, DOI 10.1103/PhysRevLett.57.747; Karki BB, 1997, PHYS REV B, V55, P3465, DOI 10.1103/PhysRevB.55.3465; KINGMA KJ, 1995, NATURE, V374, P243, DOI 10.1038/374243a0; KNITTLE E, 1991, SCIENCE, V251, P1438, DOI 10.1126/science.251.5000.1438; LIU LG, 1978, J GEOPHYS RES, V83, P2301, DOI 10.1029/JB083iB05p02301; MCMILLAN P, 1984, J CHEM PHYS, V81, P4234, DOI 10.1063/1.447455; MEADE C, 1995, SCIENCE, V268, P1743, DOI 10.1126/science.268.5218.1743; Poe B, 1997, PHYS CHEM MINER, V24, P477, DOI 10.1007/s002690050062; Saxena SK, 1998, EUR J MINERAL, V10, P1275; Saxena SK, 1996, SCIENCE, V274, P1357, DOI 10.1126/science.274.5291.1357; SCHMITT RT, 1995, METEORITICS, V30, P574; SEKINE T, 1987, GEOCHIM COSMOCHIM AC, V51, P379, DOI 10.1016/0016-7037(87)90250-X; Sharp T, 1996, PHYS CHEM MINER, V23, P17, DOI 10.1007/BF00202989; Sharp TG, 1998, METEORIT PLANET SCI, V33, pA144; Sharp TG, 1997, SCIENCE, V277, P352, DOI 10.1126/science.277.5324.352; SMITH JV, 1979, METEORITICS, V14, P121, DOI 10.1111/j.1945-5100.1979.tb00486.x; Stishov S., 1961, GEOCHEMISTRY-USSR, P837; STOFFLER D, 1986, GEOCHIM COSMOCHIM AC, V50, P889, DOI 10.1016/0016-7037(86)90371-6; Stoffler D., 1988, METEORITES EARLY SOL, P165; STOLPER EM, 1979, GEOCHIM COSMOCHIM AC, V43, P598; Teter DM, 1998, PHYS REV LETT, V80, P2145, DOI 10.1103/PhysRevLett.80.2145; Tomioka N, 1997, SCIENCE, V277, P1084, DOI 10.1126/science.277.5329.1084; TSCHERMAK MG, 1872, SITZUNGSBERICHTE MAT, V65, P122; TSUCHIDA Y, 1990, NATURE, V347, P267, DOI 10.1038/347267a0; TSUCHIDA Y, 1989, NATURE, V339, P209; Xie X, 1997, METEORIT PLANET SCI, V32, pA143	38	109	121	1	34	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAY 28	1999	284	5419					1511	1513		10.1126/science.284.5419.1511	http://dx.doi.org/10.1126/science.284.5419.1511			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	200PD	10348735				2022-12-28	WOS:000080548100032
J	Voisine, C; Craig, EA; Zufall, N; von Ahsen, O; Pfanner, N; Voos, W				Voisine, C; Craig, EA; Zufall, N; von Ahsen, O; Pfanner, N; Voos, W			The protein import motor of mitochondria: Unfolding and trapping of preproteins ave distinct and separable functions of matrix Hsp70	CELL			English	Article							HEAT-SHOCK PROTEIN-70; INTERMEMBRANE SPACE; PRECURSOR PROTEINS; INNER MEMBRANE; SORTING SIGNAL; ATP HYDROLYSIS; TRANSLOCATION; COMPLEX; BINDING; REQUIREMENT	Mitochondrial heat shock protein 70 (mtHsp70) functions in unfolding, translocation, and folding of imported proteins. Controversial models of mtHsp70 action have been discussed: (1) physical trapping of preproteins is sufficient to explain the various mtHsp70 functions, and (2) unfolding of preproteins requires an active motor function of mtHsp70 ("pulling"). Intragenic suppressors of a mutant mtHsp70 separate two functions: a nonlethal folding defect caused by enhanced trapping of preproteins, and a conditionally lethal unfolding defect caused by an impaired interaction of mtHsp70 with the membrane anchor Tim44. Even enhanced trapping in wild-type mitochondria does not generate a pulling force. The motor function of mtHsp70 cannot be explained by passive trapping alone but includes an essential ATP-dependent interaction with Tim44 to generate a pulling force and unfold preproteins.	Univ Wisconsin, Dept Biomol Chem, Madison, WI 53706 USA; Univ Freiburg, Inst Biochem & Mol Biol, D-79104 Freiburg, Germany	University of Wisconsin System; University of Wisconsin Madison; University of Freiburg	Craig, EA (corresponding author), Univ Wisconsin, Dept Biomol Chem, Madison, WI 53706 USA.		Pfanner, Nikolaus/AAV-7878-2021; Voisine, Cindy/AAG-9045-2019	Voisine, Cindy/0000-0001-7165-9636	NIGMS NIH HHS [GM27870, 5T32GM08349] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM027870, T32GM008349] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bomer U, 1997, EMBO J, V16, P2205, DOI 10.1093/emboj/16.9.2205; Bomer U, 1998, EMBO J, V17, P4226, DOI 10.1093/emboj/17.15.4226; Brodsky JL, 1996, TRENDS BIOCHEM SCI, V21, P122, DOI 10.1016/0968-0004(96)20010-6; Chauwin JF, 1998, BIOPHYS J, V74, P1732, DOI 10.1016/S0006-3495(98)77884-1; Dekker PJT, 1997, EMBO J, V16, P5408, DOI 10.1093/emboj/16.17.5408; Duong F, 1997, CELL, V91, P567, DOI 10.1016/S0092-8674(00)80444-4; EILERS M, 1986, NATURE, V322, P228, DOI 10.1038/322228a0; GAMBILL BD, 1993, J CELL BIOL, V123, P109, DOI 10.1083/jcb.123.1.109; GARTNER F, 1995, EMBO J, V14, P6043, DOI 10.1002/j.1460-2075.1995.tb00293.x; Gaume B, 1998, EMBO J, V17, P6497, DOI 10.1093/emboj/17.22.6497; GLICK BS, 1993, PROTEIN SCI, V2, P1901, DOI 10.1002/pro.5560021112; GLICK BS, 1995, CELL, V80, P11, DOI 10.1016/0092-8674(95)90444-1; Hamman BD, 1998, CELL, V92, P747, DOI 10.1016/S0092-8674(00)81403-8; Horst M, 1996, PROTEIN SCI, V5, P759; KANG PJ, 1990, NATURE, V348, P137, DOI 10.1038/348137a0; KRONIDOU NG, 1994, P NATL ACAD SCI USA, V91, P12818, DOI 10.1073/pnas.91.26.12818; Lyman SK, 1997, CELL, V88, P85, DOI 10.1016/S0092-8674(00)81861-9; Matouschek A, 1997, EMBO J, V16, P6727, DOI 10.1093/emboj/16.22.6727; Neupert W, 1997, ANNU REV BIOCHEM, V66, P863, DOI 10.1146/annurev.biochem.66.1.863; ORRWEAVER TL, 1988, MOL CELL BIOL, V8, P5292, DOI 10.1128/MCB.8.12.5292; OSTERMANN J, 1989, NATURE, V341, P125, DOI 10.1038/341125a0; PANZNER S, 1995, CELL, V81, P561, DOI 10.1016/0092-8674(95)90077-2; Peitsch MC, 1996, BIOCHEM SOC T, V24, P274, DOI 10.1042/bst0240274; PFANNER N, 1995, CURR BIOL, V5, P132; Pfanner N, 1997, ANNU REV CELL DEV BI, V13, P25, DOI 10.1146/annurev.cellbio.13.1.25; RASSOW J, 1990, FEBS LETT, V275, P190, DOI 10.1016/0014-5793(90)81469-5; RASSOW J, 1994, J CELL BIOL, V127, P1547, DOI 10.1083/jcb.127.6.1547; RYAN KR, 1995, CELL, V83, P517, DOI 10.1016/0092-8674(95)90089-6; Schatz G, 1996, SCIENCE, V271, P1519, DOI 10.1126/science.271.5255.1519; Schneider HC, 1996, EMBO J, V15, P5796, DOI 10.1002/j.1460-2075.1996.tb00966.x; SCHNEIDER HC, 1994, NATURE, V371, P768, DOI 10.1038/371768a0; SCHWARZ E, 1993, EMBO J, V12, P2295, DOI 10.1002/j.1460-2075.1993.tb05883.x; SIMON SM, 1992, P NATL ACAD SCI USA, V89, P3770, DOI 10.1073/pnas.89.9.3770; STUART RA, 1994, EUR J BIOCHEM, V220, P9, DOI 10.1111/j.1432-1033.1994.tb18593.x; UNGERMANN C, 1994, SCIENCE, V266, P1250, DOI 10.1126/science.7973708; Ungermann C, 1996, EMBO J, V15, P735, DOI 10.1002/j.1460-2075.1996.tb00409.x; VONAHSEN O, 1995, J BIOL CHEM, V270, P29848; Voos W, 1996, EMBO J, V15, P2668, DOI 10.1002/j.1460-2075.1996.tb00627.x; VOOS W, 1993, J CELL BIOL, V123, P119, DOI 10.1083/jcb.123.1.119; Zhu XT, 1996, SCIENCE, V272, P1606, DOI 10.1126/science.272.5268.1606	40	205	214	0	8	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	MAY 28	1999	97	5					565	574		10.1016/S0092-8674(00)80768-0	http://dx.doi.org/10.1016/S0092-8674(00)80768-0			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	202VD	10367886	Bronze			2022-12-28	WOS:000080672100006
J	Ybe, JA; Brodsky, FM; Hofmann, K; Lin, K; Liu, SH; Chen, L; Earnest, TN; Fletterick, RJ; Hwang, PK				Ybe, JA; Brodsky, FM; Hofmann, K; Lin, K; Liu, SH; Chen, L; Earnest, TN; Fletterick, RJ; Hwang, PK			Clathrin self-assembly is mediated by a tandemly repeated superhelix	NATURE			English	Article							PROTEIN COMPLEX; TRIMERIZATION; RESOLUTION; PROGRAM; ALPHA; CHAIN	Clathrin is a triskelion-shaped cytoplasmic protein that polymerizes into a polyhedral lattice on intracellular membranes to form protein-coated membrane vesicles. Lattice formation induces the sorting of membrane proteins during endocytosis and organelle biogenesis by interacting with membrane-associated adaptor molecules(1). The clathrin triskelion is a trimer of heavy-chain subunits (1,675 residues), each binding a single light-chain subunit, in the hub domain (residues 1,074-1,675), Light chains negatively modulate polymerization so that intracellular clathrin assembly is adaptor-dependent(2). Here we report the atomic structure, to 2.6 Angstrom resolution, of hub residues 1,210-1,516 involved in mediating spontaneous clathrin heavy-chain polymerization and light-chain association(3,4), The hub fragment folds into an elongated coil of alpha-helices, and alignment analyses reveal a 145-residue motif that is repeated seven times along the filamentous leg and appears in other proteins involved in vacuolar protein sorting. The resulting model provides a three-dimensional framework for understanding clathrin heavy-chain self-assembly, light-chain binding and trimerization.	Univ Calif San Francisco, Dept Microbiol & Immunol, GW Hooper Fdn, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Biopharmaceut Sci, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Pharmaceut Chem, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Biochem & Biophys, San Francisco, CA 94143 USA; MEMOREC Stoffel Gmbh, Bioinformat Grp, D-50829 Cologne, Germany; Lawrence Berkeley Natl Lab, Phys Biosci Div, Adv Light Source, Macromol Crystallog Facil, Berkeley, CA 94720 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; United States Department of Energy (DOE); Lawrence Berkeley National Laboratory	Brodsky, FM (corresponding author), Univ Calif San Francisco, Dept Microbiol & Immunol, GW Hooper Fdn, San Francisco, CA 94143 USA.	fmarbro@itsa.ucsf.edu	Hofmann, Kay/D-6714-2011	Hofmann, Kay/0000-0002-2289-9083; Brodsky, Frances/0000-0002-1334-9258				Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Bucher P, 1996, COMPUT CHEM, V20, P3, DOI 10.1016/S0097-8485(96)80003-9; CHOTHIA C, 1981, J MOL BIOL, V145, P215, DOI 10.1016/0022-2836(81)90341-7; CONIBEAR E, 1996, BIOCHIM BIOPHYS ACTA, V1404, P211; Conti E, 1998, CELL, V94, P193, DOI 10.1016/S0092-8674(00)81419-1; Das AK, 1998, EMBO J, V17, P1192, DOI 10.1093/emboj/17.5.1192; Esnouf RM, 1997, J MOL GRAPH MODEL, V15, P132, DOI 10.1016/S1093-3263(97)00021-1; Groves MR, 1999, CELL, V96, P99, DOI 10.1016/S0092-8674(00)80963-0; Huber AH, 1997, CELL, V90, P871, DOI 10.1016/S0092-8674(00)80352-9; KIRCHHAUSEN T, 1987, SCIENCE, V236, P320, DOI 10.1126/science.3563513; Kleywegt G.J., 1994, PROTEIN CRYSTALLOGR, V31, P9; LIU SH, 1995, CELL, V83, P257, DOI 10.1016/0092-8674(95)90167-1; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; MURZIN AG, 1995, J MOL BIOL, V247, P536, DOI 10.1006/jmbi.1995.0159; Nakamura N, 1997, J BIOL CHEM, V272, P11344; NATHKE IS, 1992, CELL, V68, P899, DOI 10.1016/0092-8674(92)90033-9; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Peters JW, 1996, NAT STRUCT BIOL, V3, P991, DOI 10.1038/nsb1296-991; RAAG R, 1988, J MOL BIOL, V200, P553, DOI 10.1016/0022-2836(88)90542-6; Schmid SL, 1997, ANNU REV BIOCHEM, V66, P511, DOI 10.1146/annurev.biochem.66.1.511; Smith CJ, 1998, EMBO J, V17, P4943, DOI 10.1093/emboj/17.17.4943; Strickland CL, 1998, BIOCHEMISTRY-US, V37, P16601, DOI 10.1021/bi981197z; ter Haar E, 1998, CELL, V95, P563, DOI 10.1016/S0092-8674(00)81623-2; Terwilliger TC, 1997, METHOD ENZYMOL, V276, P530; THUNNISSEN AMWH, 1994, NATURE, V367, P750, DOI 10.1038/367750a0; VANDUYNE GD, 1993, J MOL BIOL, V229, P105, DOI 10.1006/jmbi.1993.1012; Wilde A, 1999, CELL, V96, P677, DOI 10.1016/S0092-8674(00)80578-4; WINKLER FK, 1983, EMBO J, V2, P1393, DOI 10.1002/j.1460-2075.1983.tb01597.x; Ybe JA, 1998, EMBO J, V17, P1297, DOI 10.1093/emboj/17.5.1297	30	126	127	0	19	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAY 27	1999	399	6734					371	375		10.1038/20708	http://dx.doi.org/10.1038/20708			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	200PA	10360576				2022-12-28	WOS:000080547800063
J	Kannus, P; Parkkari, J; Koskinen, S; Niemi, S; Palvanen, M; Jarvinen, M; Vuori, I				Kannus, P; Parkkari, J; Koskinen, S; Niemi, S; Palvanen, M; Jarvinen, M; Vuori, I			Fall-induced injuries and deaths among older adults	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							OSTEOPOROTIC FRACTURES; ELDERLY PEOPLE; RISK; PREVENTION; COMMUNITY; EXERCISE; HOME	Context Although various fall-induced injuries and deaths among older adults are increasing, little is known about the epidemiology of these events. Objective To determine the trends in the number and incidence of fall-induced injuries and deaths of older adults in a well-defined white population. Design and Setting Secular trend analysis of the population of Finland, using the Finnish National Hospital Discharge Register and the Official Cause-of-Death Statistics of Finland. Participants All persons aged 50 years or older who were admitted to hospitals in Finland for primary treatment of a first fall-induced injury from the years of 1970 to 1995, and for com parison, all fall-induced deaths in the same age group from the years 1971 to 1995. Main Outcome Measure The number and the age-specific and age-adjusted incidence rate (per 100 000 persons) of fall-induced injuries and deaths in each year of the study. Results For the study period, both the total and population-adjusted number (per 100 000 persons) of Finns aged 50 years or older with fall-induced injury increased substantially. Total fall-induced injuries increased from 5622 in 1970 to 21 574 in 1995, a 284% increase, and the rate increased from 494 to 1398 per 100 000 persons, a 183% increase. The age-adjusted incidence also increased in both women (from 648 in 1970 to 1469 in 1995, a 127% increase) and men (from 434 in 1970 to 972 in 1995, a 124% increase), Moreover, the number of deaths due to falls in the overall population increased from 441 in 1971 to 793 in 1995, an 80% increase, and the rate increased from 38 in 1971 to 51 in 1995, a 34% increase. However, after age adjustment the incidence of fall-induced death did not show a clear upward trend, Conclusions In a well-defined white population, the number of older persons with fall-induced injuries is increasing at a rate that cannot be explained simply by demographic changes. Preventive measures should be adopted to control the increasing burden of these injuries. Fortunately, the age-adjusted incidence of the fall-induced deaths shows no increasing trend over time.	Tampere Univ, Sch Med, Tampere, Finland; Tampere Univ, Dept Surg, Tampere, Finland; Tampere Univ Hosp, Tampere, Finland; Natl Publ Hlth Inst, Helsinki, Finland; Urho Kaleva Kekkonen Inst Hlth Promot Res, Accident & Trauma Res Ctr, Tampere, Finland; Urho Kaleva Kekkonen Inst Hlth Promot Res, Tampere Res Ctr Sports Med, Tampere, Finland	Tampere University; Tampere University; Tampere University; Tampere University Hospital; Finland National Institute for Health & Welfare	Kannus, P (corresponding author), UKK Inst, Kaupinpuistonkatu 1, FIN-33500 Tampere, Finland.							Campbell AJ, 1997, BMJ-BRIT MED J, V315, P1065, DOI 10.1136/bmj.315.7115.1065; Close J, 1999, LANCET, V353, P93, DOI 10.1016/S0140-6736(98)06119-4; CUMMINGS SR, 1985, EPIDEMIOL REV, V7, P178, DOI 10.1093/oxfordjournals.epirev.a036281; GREENSPAN SL, 1994, JAMA-J AM MED ASSOC, V271, P128, DOI 10.1001/jama.271.2.128; GRUNDY E, 1997, OFFICE NATL STAT S, V13, P182; HONKONEN R, 1990, HOSP DUE INJURIES FI, V1; Kannus P, 1996, BRIT MED J, V313, P1051; Kannus P, 1999, AM J EPIDEMIOL, V149, P143; KANNUS P, 1995, LANCET, V346, P50, DOI 10.1016/S0140-6736(95)92679-8; Keskimaki I, 1991, INT J HLTH SCI, V2, P15, DOI DOI 10.1177/1403494812456637; KIVELA SL, 1986, SCAND J SOC MED, V14, P31, DOI 10.1177/140349488601400106; LAHTI R, 1996, FINN MED J, V51, P64; LAURITZEN JB, 1993, OSTEOPOROSIS INT, V3, P127, DOI 10.1007/BF01623273; LIIMATTA M, 1994, PUBLICATIONS NATL PU; LUTHJE P, 1995, ACTA ORTHOP SCAND, V66, P245; Manton KG, 1997, DEMOGRAPHY, V34, P135, DOI 10.2307/2061664; MELTON LJ, 1993, BONE, V14, pS1; OAKLEY A, 1996, EFFECTIVE HLTH CARE, V2, P1; *OFF STAT FINL, 1996, OFF CAUS OF DEATH ST; *OFF STAT FINL, 1996, STRUCT POP VIT STAT; POHJOLAINEN P, 1997, SCAND J SOC MED, V52, pS1; PROVINCE MA, 1995, JAMA-J AM MED ASSOC, V273, P1341, DOI 10.1001/jama.273.17.1341; Rivara FP, 1997, NEW ENGL J MED, V337, P543, DOI 10.1056/NEJM199708213370807; ROMANOV K, 1994, PSYCHOSOM MED, V56, P328, DOI 10.1097/00006842-199407000-00008; RUBENSTEIN LZ, 1994, ANN INTERN MED, V121, P442, DOI 10.7326/0003-4819-121-6-199409150-00009; Salmela R, 1987, SAIRAALA, V49, P480; SATTIN RW, 1998, 4 WORLD C INJ PREV C, P529; SCHNEIDER EL, 1990, JAMA-J AM MED ASSOC, V263, P2354; TINETTI ME, 1989, NEW ENGL J MED, V320, P1055; TINETTI ME, 1994, NEW ENGL J MED, V331, P821, DOI 10.1056/NEJM199409293311301; VANWEEL C, 1995, LANCET, V345, P1549, DOI 10.1016/S0140-6736(95)91091-3	31	381	393	1	27	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 26	1999	281	20					1895	1899		10.1001/jama.281.20.1895	http://dx.doi.org/10.1001/jama.281.20.1895			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	198ME	10349892				2022-12-28	WOS:000080427300028
J	Schuckit, MA				Schuckit, MA			New findings in the genetics of alcoholism	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							MEN; ASSOCIATION; DEPENDENCE; SAMPLE; ABUSE; TWINS; RISK		Univ Calif San Diego, Sch Med, Dept Psychiat, San Diego, CA 92161 USA; San Diego Vet Affairs Med Ctr, Alcohol & Drug Treatment Program, San Diego, CA USA	University of California System; University of California San Diego	Schuckit, MA (corresponding author), Univ Calif San Diego, Sch Med, Dept Psychiat, 3350 LaJolla Village Dr, San Diego, CA 92161 USA.	mschuckit@ucsd.edu			NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [R01AA005526, U10AA008403] Funding Source: NIH RePORTER; NIAAA NIH HHS [AA05526, 5U10AA08403] Funding Source: Medline	NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		BAUMEISTER M, 1999, BIOL PSYCHIAT, V45, P522; Begleiter H, 1998, EVOKED POTENTIAL, V108, P244, DOI 10.1016/S0168-5597(98)00002-1; Bierut LJ, 1998, ARCH GEN PSYCHIAT, V55, P982, DOI 10.1001/archpsyc.55.11.982; CHAO HM, 1995, ALCOHOL CLIN EXP RES, V19, P104, DOI 10.1111/j.1530-0277.1995.tb01477.x; Edenberg HJ, 1998, ALCOHOL CLIN EXP RES, V22, P505, DOI 10.1097/00000374-199804000-00030; Ehlers CL, 1999, BIOL PSYCHIAT, V45, P776, DOI 10.1016/S0006-3223(98)00113-9; GOODWIN DW, 1973, ARCH GEN PSYCHIAT, V28, P238; Heath AC, 1997, PSYCHOL MED, V27, P1381, DOI 10.1017/S0033291797005643; Kendler KS, 1997, ARCH GEN PSYCHIAT, V54, P178; Malhotra AK, 1999, BIOL PSYCHIAT, V45, P544, DOI 10.1016/S0006-3223(98)00365-5; Murayama M, 1998, ALCOHOL CLIN EXP RES, V22, P524, DOI 10.1097/00000374-199804000-00033; Neumark YD, 1998, J STUD ALCOHOL, V59, P133, DOI 10.15288/jsa.1998.59.133; PICKENS RW, 1991, ARCH GEN PSYCHIAT, V48, P19; Prescott CA, 1999, AM J PSYCHIAT, V156, P34, DOI 10.1176/ajp.156.1.34; Sander T, 1998, ALCOHOL CLIN EXP RES, V22, P2108, DOI 10.1097/00000374-199812000-00030; Schuckit MA, 1996, ARCH GEN PSYCHIAT, V53, P202; Schuckit MA, 1998, J STUD ALCOHOL, V59, P485, DOI 10.15288/jsa.1998.59.485; Schuckit MA, 1999, BIOL PSYCHIAT, V45, P647, DOI 10.1016/S0006-3223(98)00248-0; SCHUCKIT MA, 1972, AM J PSYCHIAT, V128, P1132, DOI 10.1176/ajp.128.9.1132; Tsuang MT, 1998, ARCH GEN PSYCHIAT, V55, P967, DOI 10.1001/archpsyc.55.11.967; Wall TL, 1995, ALCOHOL HEALTH RES W, V19, P184	21	51	51	0	7	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 26	1999	281	20					1875	1876		10.1001/jama.281.20.1875	http://dx.doi.org/10.1001/jama.281.20.1875			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	198ME	10349877				2022-12-28	WOS:000080427300001
J	Rosen, AB; Fowler, VG; Corey, GR; Downs, SM; Biddle, AK; Li, J; Jollis, JG				Rosen, AB; Fowler, VG; Corey, GR; Downs, SM; Biddle, AK; Li, J; Jollis, JG			Cost-effectiveness of transesophageal echocardiography to determine the duration of therapy for intravascular catheter-associated Staphylococcus aureus bacteremia	ANNALS OF INTERNAL MEDICINE			English	Review						echocardiography, transesophageal; staphylococcus aureus; bacteremia; cost-benefit analysis; endocarditis, bacterial	ACTIVE INFECTIVE ENDOCARDITIS; ACUTE BACTERIAL-ENDOCARDITIS; TEICHOIC-ACID ANTIBODY; VALVE-REPLACEMENT; NATIVE VALVE; EARLY SURGERY; CONVENIENT APPROXIMATION; NEUROLOGIC COMPLICATIONS; PROGNOSTIC IMPLICATIONS; CLINICAL-SIGNIFICANCE	Background: The appropriate duration of therapy for catheter-associated Staphylococcus aureus bacteremia is controversial. Conventional practice dictates that all patients receive prolonged courses of intravenous antibiotics. Some clinicians recommend abbreviated therapeutic courses, but an alternate approach involves prospectively identifying patients for whom abbreviated therapy is appropriate. Objective: To determine the cost-effectiveness of transesophageal echocardiography (TEE) in establishing duration of therapy for catheter-associated S aureus bacteremia. Design: Cost-effectiveness analysis. Data Sources: MEDLINE search of literature; clinical data from patients with S. aureus bacteremia (n = 196) and patients with endocarditis (n = 60); and costs obtained from the study institution, regional home health agency, and national estimates of professional and technical fees. Target Population: Patients with catheter-associated S aureus bacteremia on native heart valves without intravenous drug use or clinically apparent metastatic infection, immunosuppression, or indwelling prosthetic devices. Time Horizon: Patient lifetime. Perspective: Societal. Interventions: Antibiotic treatment based on TEE results compared with 2- or 4-week empirical therapy. Outcome Measures: Quality-adjusted life expectancy, costs, and incremental cost-effectiveness ratios. Results of Base-Case Analysis: Compared with empirical short-course therapy, the TEE strategy cost $4938 per quality-adjusted life-year (QALY) gained. The effectiveness of the TEE strategy and the effectiveness of the long-course strategy were sufficiently similar that the additional cost of empirical long-course therapy ($1 667 971 per QALY) was higher than that which society usually considers cost-effective. Results of Sensitivity Analyses: In a four-way sensitivity analysis (endocarditis prevalence, TEE cost, short-course relapse rate, and TEE specificity), compared with empirical short-course therapy, the TEE strategy results ranged from cost savings to $155 624 per QALY. Conclusion: Within the limitations of existing empirical data, this study suggests that for patients with clinically uncomplicated catheter-associated 5. aureus bacteremia, the use of TEE to determine therapy duration is a cost-effective alternative to 2- or 4-week empirical therapy.	Duke Univ, Med Ctr, Durham, NC 27710 USA; Univ N Carolina, Chapel Hill, NC 27599 USA	Duke University; University of North Carolina; University of North Carolina Chapel Hill	Rosen, AB (corresponding author), Duke Univ, Med Ctr, Box 3254, Durham, NC 27710 USA.		Fowler, Vance/AAW-2017-2021	Biddle, Andrea/0000-0003-0273-7439				ABDELNOOR M, 1990, EUR HEART J, V11, P23, DOI 10.1093/oxfordjournals.eurheartj.a059586; ANTONISKIS A, 1978, WESTERN J MED, V128, P203; AUSTIN TW, 1973, INFECTION, V1, P214, DOI 10.1007/BF01639652; BAYER AS, 1980, WESTERN J MED, V132, P294; BECK JR, 1982, AM J MED, V73, P883, DOI 10.1016/0002-9343(82)90786-0; BECK JR, 1982, AM J MED, V73, P889, DOI 10.1016/0002-9343(82)90787-2; BOGERS AJJC, 1991, THORAC CARDIOV SURG, V39, P284, DOI 10.1055/s-2007-1019987; BRYAN CS, 1984, SOUTHERN MED J, V77, P693, DOI 10.1097/00007611-198406000-00007; *BUR CENS, 1996, STAT ABST US; *BUR CENS, 1997, STAT ABSTR US; *BUR LAB STAT, 1998, CONS PRIC IND PUBL U; CHAMBERS HF, 1983, MEDICINE, V62, P170, DOI 10.1097/00005792-198305000-00004; COOPER G, 1982, AM J MED, V73, P658, DOI 10.1016/0002-9343(82)90407-7; CROFT CH, 1983, AM J CARDIOL, V51, P1650, DOI 10.1016/0002-9149(83)90203-5; DAGOSTINO RS, 1985, ANN THORAC SURG, V40, P429, DOI 10.1016/S0003-4975(10)60097-5; DANIEL WG, 1991, CIRCULATION, V83, P817, DOI 10.1161/01.CIR.83.3.817; DANIEL WG, 1995, NEW ENGL J MED, V332, P1268, DOI 10.1056/NEJM199505113321906; DANIEL WG, 1991, NEW ENGL J MED, V324, P795, DOI 10.1056/NEJM199103213241203; DAVID TE, 1990, ANN THORAC SURG, V49, P701, DOI 10.1016/0003-4975(90)90006-R; DEHLER S, 1995, THORAC CARDIOV SURG, V43, P83, DOI 10.1055/s-2007-1013776; DELAHAYE F, 1995, EUR HEART J, V16, P48, DOI 10.1093/eurheartj/16.suppl_B.48; DENNIS MS, 1993, STROKE, V24, P796, DOI 10.1161/01.STR.24.6.796; dUdekem Y, 1997, EUR J CARDIO-THORAC, V11, P46, DOI 10.1016/S1010-7940(96)01020-2; DUGDALE DC, 1990, AM J MED, V89, P137, DOI 10.1016/0002-9343(90)90290-T; DURACK D, 1993, HOSP PRACT, V28, P6, DOI 10.1080/21548331.1993.11442939; DURANDZALESKI I, 1994, MED DECIS MAKING, V14, P98, DOI 10.1177/0272989X9401400112; ECKMAN MH, 1995, JAMA-J AM MED ASSOC, V273, P712, DOI 10.1001/jama.273.9.712; ECKMAN MH, 1992, CHEST, V102, pS538, DOI 10.1378/chest.102.4_Supplement.538S; EHNI WF, 1989, ARCH INTERN MED, V149, P533, DOI 10.1001/archinte.149.3.533; EISENSTAEDT RS, 1988, AM J PUBLIC HEALTH, V78, P450, DOI 10.2105/AJPH.78.4.450; EISHI K, 1995, J THORAC CARDIOV SUR, V110, P1745, DOI 10.1016/S0022-5223(95)70038-2; ERBEL R, 1988, EUR HEART J, V9, P43; ESPERSEN F, 1986, ARCH INTERN MED, V146, P1118, DOI 10.1001/archinte.146.6.1118; FINKELSTEIN R, 1984, J MED, V15, P193; Fowler VG, 1997, J AM COLL CARDIOL, V30, P1072, DOI 10.1016/S0735-1097(97)00250-7; FOWLER VG, 1997, INF DIS SOC AM 35 AN, P99; FRYBACK DG, 1993, MED DECIS MAKING, V13, P89, DOI 10.1177/0272989X9301300202; FUJITA T, 1985, JPN CIRC J, V49, P562, DOI 10.1253/jcj.49.562; GAGE BF, 1995, JAMA-J AM MED ASSOC, V274, P1839, DOI 10.1001/jama.274.23.1839; Gold MR, 1996, COST EFFECTIVENESS H; HEDSTROM SA, 1983, SCAND J INFECT DIS, P38; HORNBERGER JC, 1992, J CLIN EPIDEMIOL, V45, P505, DOI 10.1016/0895-4356(92)90099-9; IANNINI PB, 1976, ANN INTERN MED, V84, P558, DOI 10.7326/0003-4819-84-5-558; JERNIGAN JA, 1993, ANN INTERN MED, V119, P304, DOI 10.7326/0003-4819-119-4-199308150-00010; JONES HR, 1969, ANN INTERN MED, V71, P21, DOI 10.7326/0003-4819-71-1-21; JULANDER I, 1985, SCAND J INFECT DIS, V17, P179, DOI 10.3109/inf.1985.17.issue-2.09; KHANDHERIA BK, 1993, J AM COLL CARDIOL, V21, P222, DOI 10.1016/0735-1097(93)90740-R; KIMOSE HH, 1990, SCAND J THORAC CARD, V24, P111, DOI 10.3109/14017439009098053; KNUDSEN AM, 1993, J HOSP INFECT, V23, P123, DOI 10.1016/0195-6701(93)90016-S; KORZENIOWSKI O, 1982, ANN INTERN MED, V97, P496, DOI 10.7326/0003-4819-97-4-496; KOYANAGI H, 1985, JPN CIRC J, V49, P553, DOI 10.1253/jcj.49.553; LARBALESTIER RI, 1992, CIRCULATION, V86, P68; LAUTENSCHLAGER S, 1993, CLIN INFECT DIS, V16, P567, DOI 10.1093/clind/16.4.567; LECAM B, 1984, EUR HEART J, V5, P97, DOI 10.1093/eurheartj/5.suppl_C.97; LEW EA, 1990, MED RISKS TRENDS MOR, V2; LIBMAN H, 1984, ARCH INTERN MED, V144, P541, DOI 10.1001/archinte.144.3.541; Lipscomb J., 1996, COST EFFECTIVENESS H; LOWRY RW, 1994, AM J CARDIOL, V73, P1089, DOI 10.1016/0002-9149(94)90288-7; Luce BR, 1996, COST EFFECTIVENESS H; MAKI DG, 1981, AM J MED, V70, P719, DOI 10.1016/0002-9343(81)90603-3; MALANOSKI GJ, 1995, ARCH INTERN MED, V155, P1161, DOI 10.1001/archinte.155.11.1161; Marr KA, 1997, ANN INTERN MED, V127, P275, DOI 10.7326/0003-4819-127-4-199708150-00003; Mathias SD, 1997, STROKE, V28, P1888, DOI 10.1161/01.STR.28.10.1888; MATSUSHITA K, 1993, EUR NEUROL, V33, P267, DOI 10.1159/000116952; MIDDLEMOST S, 1991, J AM COLL CARDIOL, V18, P663, DOI 10.1016/0735-1097(91)90785-8; Miller D C, 1989, J Card Surg, V4, P331, DOI 10.1111/j.1540-8191.1989.tb00300.x; MIRIMANOFF RO, 1982, ARCH INTERN MED, V142, P1311, DOI 10.1001/archinte.142.7.1311; MORTARA LA, 1993, INFECT DIS CLIN N AM, V7, P53; MUGGE A, 1993, INFECT DIS CLIN N AM, V7, P877; MUGGE A, 1989, J AM COLL CARDIOL, V14, P631; MYLOTTE JM, 1987, AM J INFECT CONTROL, V15, P1, DOI 10.1016/0196-6553(87)90069-1; MYLOTTE JM, 1987, REV INFECT DIS, V9, P891; NIHOYANNOPOULOS P, 1985, EUR HEART J, V6, P380, DOI 10.1093/oxfordjournals.eurheartj.a061876; NOLAN CM, 1976, AM J MED, V60, P495, DOI 10.1016/0002-9343(76)90715-4; Olaison L, 1996, QJM-MON J ASSOC PHYS, V89, P267; Pearson ML, 1996, AM J INFECT CONTROL, V24, P262; PELLETIER LL, 1977, MEDICINE, V56, P287, DOI 10.1097/00005792-197707000-00002; *PMIC, 1998, PHYS FEES; PRUITT AA, 1978, MEDICINE, V57, P329, DOI 10.1097/00005792-197807000-00004; RAAD II, 1992, CLIN INFECT DIS, V15, P197, DOI 10.1093/clinids/15.2.197; RAHAL JJ, 1986, AM J MED, V81, P43, DOI 10.1016/0002-9343(86)90180-4; RAJASHEKARAIAH KR, 1980, ANN INTERN MED, V93, P796, DOI 10.7326/0003-4819-93-6-796; REVICKI DA, 1992, MED CARE, V30, pMS274, DOI 10.1097/00005650-199205001-00027; RICHARDSON JV, 1978, CIRCULATION, V58, P589, DOI 10.1161/01.CIR.58.4.589; ROBERTS GW, 1994, ANN PHARMACOTHER, V28, P11, DOI 10.1177/106002809402800101; Roder BL, 1997, AM J MED, V102, P379, DOI 10.1016/S0002-9343(97)00090-9; SANABRIA TJ, 1990, ARCH INTERN MED, V150, P1305, DOI 10.1001/archinte.150.6.1305; SCHULZE G, 1990, NEUROCHEM INT, V17, P281, DOI 10.1016/0197-0186(90)90150-R; SHAH M, 1979, AM J MED SCI, V278, P115, DOI 10.1097/00000441-197909000-00002; SHAPIRO SM, 1994, CHEST, V105, P377, DOI 10.1378/chest.105.2.377; Siddiq S, 1996, ARCH INTERN MED, V156, P2454, DOI 10.1001/archinte.156.21.2454; SOMA Y, 1991, JPN CIRC J, V55, P799, DOI 10.1253/jcj.55.799; Sox HC, 1988, MED DECISION MAKING; STAMBOULIAN D, 1995, EUR J CLIN MICROBIOL, V14, P648, DOI 10.1007/BF01690747; Steinberg JP, 1996, CLIN INFECT DIS, V23, P255, DOI 10.1093/clinids/23.2.255; SYMBAS PN, 1982, ANN SURG, V195, P721, DOI 10.1097/00000658-198206000-00007; TORNOS MP, 1992, ANN INTERN MED, V117, P567, DOI 10.7326/0003-4819-117-7-567; Torrance G W, 1989, Int J Technol Assess Health Care, V5, P559; VERHEUL HA, 1993, AM J CARDIOL, V72, P682, DOI 10.1016/0002-9149(93)90885-G; WATANAKUNAKORN C, 1977, AM J MED, V63, P253, DOI 10.1016/0002-9343(77)90239-X; WATANAKUNAKORN C, 1994, ARCH INTERN MED, V154, P2330, DOI 10.1001/archinte.154.20.2330; WATANAKUNAKORN C, 1973, AM J MED, V54, P473, DOI 10.1016/0002-9343(73)90043-0; WEINSTEIN MC, 1982, CIRCULATION, V66, P56; Weinstein MP, 1997, CLIN INFECT DIS, V24, P584, DOI 10.1093/clind/24.4.584; Werner GS, 1996, AM J MED, V100, P90, DOI 10.1016/S0002-9343(96)90017-0; WILSON R, 1957, AM J MED, V22, P437, DOI 10.1016/0002-9343(57)90099-2; WILSON WR, 1979, MAYO CLIN PROC, V54, P223; YOSHIDA K, 1991, JPN CIRC J, V55, P794, DOI 10.1253/jcj.55.794	108	116	121	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAY 18	1999	130	10					810	+		10.7326/0003-4819-130-10-199905180-00004	http://dx.doi.org/10.7326/0003-4819-130-10-199905180-00004			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	196JJ	10366370				2022-12-28	WOS:000080305000003
J	Kuntz, KM; Fleischmann, KE; Hunink, MGM; Douglas, PS				Kuntz, KM; Fleischmann, KE; Hunink, MGM; Douglas, PS			Cost-effectiveness of diagnostic strategies for patients with chest pain	ANNALS OF INTERNAL MEDICINE			English	Article						cost-benefit analysis; chest pain; exercise test; tomography, emission-computed, single-photon; coronary angiography	CORONARY-ARTERY DISEASE; CHRONIC STABLE ANGINA; LONG-TERM SURVIVAL; BYPASS-SURGERY; HEART-DISEASE; ARTERIOGRAPHY 1984-1987; CARDIAC ANGIOGRAPHY; RANDOMIZED TRIALS; ANGIOPLASTY; REGISTRY	Background: Many noninvasive tests exist to determine whether patients should undergo coronary angiography. The routine use of coronary angiography without previous noninvasive testing is typically not advocated. Objective: To determine the cost-effectiveness of diagnostic strategies for patients with chest pain. Design: Cost-effectiveness analysis, Data Sources: Published data. Target Population: Patients who present with chest pain, have no history of myocardial infarction, and are able to perform an exercise stress test. Time Horizon: Lifetime. Perspective: Societal. Interventions: No testing, exercise electrocardiography, exercise echocardiography, exercise single-photon emission computed tomography (SPECT), and coronary angiography alone. Outcome Measures: quality-adjusted life expectancy, lifetime cost, and incremental cost-effectiveness. Results of Base-Case Analysis: The incremental cost-effectiveness ratio of routine coronary angiography compared with exercise echocardiography was $36 400 per quality-adjusted life-year (QALY) saved for 55-year-old men with typical angina. For 55-year-old men with atypical angina, exercise echocardiography compared with exercise electrocardiography cost $41 900 per QALY saved. If adequate exercise echocardiography was not available, exercise SPECT cost $54 800 per QALY saved compared with exercise electrocardiography for these patients. For 55-year-old men with nonspecific chest pain, the incremental cost-effectiveness ratio of exercise electrocardiography compared with no testing was $57 700 per QALY saved. Results of Sensitivity Analysis: On the basis of a probabilistic sensitivity analysis, there is a 75% chance that exercise echocardiography costs less than $50 900 per QALY saved for 55-year-old men with atypical angina. Conclusions: Exercise electrocardiography or exercise echocardiography resulted in reasonable cost-effectiveness ratios for patients at mild to moderate risk for coronary artery disease in terms of age, sex, and type of chest pain. Coronary angiography without previous noninvasive testing resulted in reasonable cost-effectiveness ratios for patients with a high pretest probability of coronary artery disease.	Harvard Univ, Sch Publ Hlth, Ctr Risk Anal, Boston, MA 02115 USA; Brigham & Womens Hosp, Boston, MA 02115 USA; Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Boston, MA USA; Univ Groningen, Groningen, Netherlands	Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Brigham & Women's Hospital; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; University of Groningen	Kuntz, KM (corresponding author), Harvard Univ, Sch Publ Hlth, Ctr Risk Anal, 718 Huntington Ave, Boston, MA 02115 USA.	kmk@hsph.harvard.edu		Douglas, Pamela/0000-0001-9876-4049	PHS HHS [1K08H102964-01] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ADLER DS, 1986, AM J CARDIOL, V58, P195, DOI 10.1016/0002-9149(86)90046-9; BRUNELLI C, 1989, EUR HEART J, V10, P292, DOI 10.1093/oxfordjournals.eurheartj.a059486; CALIFF RM, 1988, J AM COLL CARDIOL, V11, P20, DOI 10.1016/0735-1097(88)90160-X; CHAITMAN BR, 1981, CIRCULATION, V64, P360, DOI 10.1161/01.CIR.64.2.360; CHAITMAN BR, 1990, J AM COLL CARDIOL, V16, P1071, DOI 10.1016/0735-1097(90)90534-V; DESERVI S, 1989, INT J CARDIOL, V22, P43, DOI 10.1016/0167-5273(89)90134-4; DIAMOND GA, 1979, NEW ENGL J MED, V300, P1350, DOI 10.1056/NEJM197906143002402; Doubilet P, 1985, Med Decis Making, V5, P157, DOI 10.1177/0272989X8500500205; Doubilet P, 1985, Med Decis Making, V5, P293, DOI 10.1177/0272989X8500500305; ELVEBACK LR, 1981, MAYO CLIN PROC, V56, P665; FISHER L, 1984, NEW ENGL J MED, V310, P750; FISHER L, 1983, CIRCULATION, V68, P939, DOI 10.1161/01.CIR.68.5.939; FISHER L, 1983, CIRCULATION, V68, P951; Fleischmann KE, 1998, JAMA-J AM MED ASSOC, V280, P913, DOI 10.1001/jama.280.10.913; GIANROSSI R, 1989, CIRCULATION, V80, P87, DOI 10.1161/01.CIR.80.1.87; GOLDMAN L, 1991, JAMA-J AM MED ASSOC, V265, P1145, DOI 10.1001/jama.265.9.1145; HAMM CW, 1994, NEW ENGL J MED, V331, P1037, DOI 10.1056/NEJM199410203311601; HAMPTON JR, 1993, LANCET, V341, P573; HANNAN EL, 1990, JAMA-J AM MED ASSOC, V264, P2768, DOI 10.1001/jama.264.21.2768; HILBORNE LH, 1991, PERCUTANEOUS TRANSLU; HOLMES DR, 1988, J AM COLL CARDIOL, V12, P1149, DOI 10.1016/0735-1097(88)92593-4; JOHNSON LW, 1989, CATHETER CARDIO DIAG, V17, P5, DOI 10.1002/ccd.1810170103; KATZ DA, 1994, J VASC SURG, V19, P980, DOI 10.1016/S0741-5214(94)70209-8; KING SB, 1994, NEW ENGL J MED, V331, P1044, DOI 10.1056/NEJM199410203311602; LAVE JR, 1932, MED CARE S, V32, pJS77; LAWRIE GM, 1987, ANN THORAC SURG, V44, P180, DOI 10.1016/S0003-4975(10)62037-1; LEE TH, 1988, MED DECIS MAKING, V8, P268, DOI 10.1177/0272989X8800800408; LOZNER EC, 1989, CATHETER CARDIO DIAG, V17, P11, DOI 10.1002/ccd.1810170104; MARK DB, 1994, CIRCULATION, V89, P2015, DOI 10.1161/01.CIR.89.5.2015; MARK DB, 1987, ANN INTERN MED, V106, P793, DOI 10.7326/0003-4819-106-6-793; MIRANDA CP, 1991, ANN INTERN MED, V114, P649, DOI 10.7326/0003-4819-114-8-649; MYERS WO, 1987, ANN THORAC SURG, V43, P599, DOI 10.1016/S0003-4975(10)60230-5; *NAT CTR HLTH STAT, 1991, VIT STAT US 1988 A, V1; NEASE RF, 1995, JAMA-J AM MED ASSOC, V273, P1185, DOI 10.1001/jama.273.15.1185; NWASOKWA ON, 1991, ANN INTERN MED, V114, P1035, DOI 10.7326/0003-4819-114-12-1035; PALMAS W, 1995, J AM COLL CARDIOL, V25, P1024, DOI 10.1016/0735-1097(94)00523-S; POCOCK SJ, 1995, LANCET, V346, P1184, DOI 10.1016/S0140-6736(95)92897-9; PRYOR DB, 1993, ANN INTERN MED, V118, P81, DOI 10.7326/0003-4819-118-2-199301150-00001; RODRIGUEZ A, 1993, J AM COLL CARDIOL, V22, P1060, DOI 10.1016/0735-1097(93)90416-X; Russell LB, 1996, JAMA-J AM MED ASSOC, V276, P1172, DOI 10.1001/jama.276.14.1172; Ryan T, 1993, J Am Soc Echocardiogr, V6, P186; SOLOT G, 1993, NUCL MED COMMUN, V14, P23, DOI 10.1097/00006231-199301000-00006; SONNENBERG FA, 1993, MED DECIS MAKING, V13, P322, DOI 10.1177/0272989X9301300409; Stinett AA, 1996, COST EFFECTIVENESS H, P349; WONG JB, 1990, ANN INTERN MED, V113, P852, DOI 10.7326/0003-4819-113-11-852; YUSUF S, 1994, LANCET, V344, P563, DOI 10.1016/S0140-6736(94)91963-1; Yusuf S, 1994, ONLINE J CURR CLIN T	47	127	127	0	6	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAY 4	1999	130	9					709	+		10.7326/0003-4819-130-9-199905040-00002	http://dx.doi.org/10.7326/0003-4819-130-9-199905040-00002			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	192DE	10357689				2022-12-28	WOS:000080062300001
J	Oral, H; Souza, JJ; Michaud, GF; Knight, BP; Goyal, R; Strickberger, SA; Morady, F				Oral, H; Souza, JJ; Michaud, GF; Knight, BP; Goyal, R; Strickberger, SA; Morady, F			Facilitating transthoracic cardioversion of atrial fibrillation with ibutilide pretreatment	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ENERGY INTRACARDIAC CARDIOVERSION; CONVENTIONAL EXTERNAL CARDIOVERSION; INTERNAL CARDIOVERSION; DEFIBRILLATION THRESHOLD; ANTIARRHYTHMIC DRUGS; CONVERSION EFFICACY; FLUTTER; AMIODARONE; SAFETY; PROCAINAMIDE	Background. Atrial fibrillation cannot always be converted to sinus rhythm by transthoracic electrical cardioversion. We examined the effect of ibutilide, a class iii antiarrhythmic agent, on the energy requirement for atrial defibrillation and assessed the value of this agent in facilitating cardioversion in patients with atrial fibrillation that is resistant to conventional transthoracic cardioversion. Methods. One hundred patients who had had atrial fibrillation for a mean (+/-SD) of 117 +/- 201 days were randomly assigned to undergo transthoracic cardioversion with or without pretreatment with 1 mg of ibutilide. We designed a step-up protocol in which shocks at 50, 100, 200, 300, and 360 J were used for transthoracic cardioversion. if transthoracic cardioversion was unsuccessful in a patient who had not received ibutilide pretreatment, ibutilide was administered and transthoracic cardioversion attempted again. Results. Conversion to sinus rhythm occurred in 36 of 50 patients who had not received ibutilide (72 percent) and in ail 50 patients who had received ibutilide (100 percent, P < 0.001). In all 14 patients in whom transthoracic cardioversion alone failed, sinus rhythm was restored when cardioversion was attempted again after the administration of ibutilide. Pretreatment with ibutilide was associated with a reduction in the mean energy required for defibrillation (166 +/- 80 J, as compared with 228 +/- 93 J without pretreatment; P < 0.001). Sustained polymorphic ventricular tachycardia occurred in 2 of the 64 patients who received ibutilide (3 percent), both of whom had an ejection fraction of 0.20 or less. The rates of freedom from atrial fibrillation after six months of follow-up were similar in the two randomized groups. Conclusions. The efficacy of transthoracic cardioversion for converting atrial fibrillation to sinus rhythm was enhanced by pretreatment with ibutilide. However, use of this drug should be avoided in patients with very low ejection fractions. (N Engl J Med 1999; 340:1849-54.) (C) 1999, Massachusetts Medical Society.	Univ Michigan, Med Ctr, Div Cardiol, Dept Internal Med, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan	Morady, F (corresponding author), Univ Michigan, Med Ctr, Div Cardiol, Dept Internal Med, B1F245,1500 E Med Ctr Dr, Ann Arbor, MI 48109 USA.	fmorady@umich.edu						Alt E, 1997, EUR HEART J, V18, P1796; Alt E, 1997, AM J CARDIOL, V79, P621, DOI 10.1016/S0002-9149(96)00827-2; Bazett HC, 1920, HEART-J STUD CIRC, V7, P353; BENSER ME, 1997, CIRCULATION S1, V96, P383; CONNELL PN, 1973, J ELECTROCARDIOL, V6, P313, DOI 10.1016/S0022-0736(73)80053-6; Dahl C F, 1976, Med Instrum, V10, P151; Daoud EG, 1997, AM J CARDIOL, V79, P97, DOI 10.1016/S0002-9149(96)00689-3; Ellenbogen KA, 1996, J AM COLL CARDIOL, V28, P1082; EPSTEIN AE, 1992, CIRCULATION, V86, P1206, DOI 10.1161/01.CIR.86.4.1206; EWY GA, 1992, CIRCULATION, V86, P1645, DOI 10.1161/01.CIR.86.5.1645; EWY GA, 1980, CRIT CARE MED, V8, P164, DOI 10.1097/00003246-198003000-00015; EWY GA, 1977, HEART LUNG, V6, P847; FOGOROS RN, 1984, ANN INTERN MED, V100, P699, DOI 10.7326/0003-4819-100-5-699; GUARNIERI T, 1987, AM J CARDIOL, V60, P1061, DOI 10.1016/0002-9149(87)90352-3; GUARNIERI T, 1991, PACE, V14, P1007, DOI 10.1111/j.1540-8159.1991.tb04150.x; JUNG W, 1992, AM J CARDIOL, V70, P1023, DOI 10.1016/0002-9149(92)90354-2; Kerber R E, 1996, Am J Cardiol, V78, P22, DOI 10.1016/S0002-9149(96)00562-0; KERBER RE, 1981, CIRCULATION, V63, P676, DOI 10.1161/01.CIR.63.3.676; KERBER RE, 1984, J AM COLL CARDIOL, V3, P815, DOI 10.1016/S0735-1097(84)80258-2; KERBER RE, 1981, NEW ENGL J MED, V305, P658, DOI 10.1056/NEJM198109173051202; LABHASETWAR V, 1994, J CARDIOVASC PHARM, V24, P826, DOI 10.1097/00005344-199424050-00019; Lau CP, 1997, PACE, V20, P2442, DOI 10.1111/j.1540-8159.1997.tb06084.x; Lawton JS, 1996, AM J CARDIOL, V78, P647, DOI 10.1016/S0002-9149(96)00387-6; LEVY S, 1988, J AM COLL CARDIOL, V12, P514, DOI 10.1016/0735-1097(88)90428-7; LEVY S, 1992, CIRCULATION, V86, P1415, DOI 10.1161/01.CIR.86.5.1415; LOWN B, 1967, BRIT HEART J, V29, P469; Luderitz B, 1996, AM J CARDIOL, V77, pA45, DOI 10.1016/S0002-9149(97)89117-5; Mansourati J, 1997, PACE, V20, P1919, DOI 10.1111/j.1540-8159.1997.tb03597.x; Murray KT, 1998, CIRCULATION, V97, P493; Neri R, 1997, PACE, V20, P2237, DOI 10.1111/j.1540-8159.1997.tb04242.x; RESNEKOV L, 1971, BRIT HEART J, V33, P339; Schmit C, 1996, J AM COLL CARDIOL, V28, P994, DOI 10.1016/S0735-1097(96)00274-4; Sopher SM, 1996, HEART, V75, P635, DOI 10.1136/hrt.75.6.635; Stambler BS, 1997, CIRCULATION, V96, P4298; Stambler BS, 1996, CIRCULATION, V94, P1613, DOI 10.1161/01.CIR.94.7.1613; VanGelder IC, 1997, PACE, V20, P2675; Volgman AS, 1998, J AM COLL CARDIOL, V31, P1414, DOI 10.1016/S0735-1097(98)00078-3; WESLEY RC, 1993, AM J PHYSIOL, V264, pH1269	38	241	247	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUN 17	1999	340	24					1849	1854		10.1056/NEJM199906173402401	http://dx.doi.org/10.1056/NEJM199906173402401			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	206EC	10369847	Bronze			2022-12-28	WOS:000080863500001
J	Lu, YQ; Zhu, YY; Chen, YF; Zhu, SN; Ming, NB; Feng, YJ				Lu, YQ; Zhu, YY; Chen, YF; Zhu, SN; Ming, NB; Feng, YJ			Optical properties of an ionic-type phononic crystal	SCIENCE			English	Article							PERIODIC ELASTIC COMPOSITES; BAND-STRUCTURE; 2ND-HARMONIC GENERATION; FERROELECTRIC DOMAINS; WAVE-GUIDES; LINBO3; GAP; SUPERLATTICE; LIGHT	An ionic-type phononic crystal composed of two ferroelectric media with opposite spontaneous polarization aligned periodically in a superlattice structure was studied theoretically and experimentally, The coupling between vibrations of the superlattice and the electromagnetic waves results in various Long-wavelength optical properties, such as microwave absorption, dielectric abnormality, and polariton excitation, that exist originally in ionic crystals. The results show that this artificial crystal structure can be used to simulate the microscopic physical processes in real crystals.	Nanjing Univ, Natl Lab Solid State Microstruct, Nanjing 210093, Peoples R China; Nanjing Univ, Dept Elect Sci & Engn, Nanjing 210093, Peoples R China	Nanjing University; Nanjing University	Ming, NB (corresponding author), Nanjing Univ, Natl Lab Solid State Microstruct, Nanjing 210093, Peoples R China.		Feng, Yijun/L-2864-2019; Feng, Yijun/K-8957-2019; Lu, Yan-qing/A-5314-2009	Feng, Yijun/0000-0002-7118-7509; Lu, Yan-qing/0000-0001-6151-8557				Born M., 1954, DYNAMICAL THEORY CRY; Chan YS, 1998, PHYS REV LETT, V80, P956, DOI 10.1103/PhysRevLett.80.956; de Espinosa FRM, 1998, PHYS REV LETT, V80, P1208, DOI 10.1103/PhysRevLett.80.1208; DONG H, 1993, J PHYS-CONDENS MAT, V5, P8849, DOI 10.1088/0953-8984/5/47/010; DOWLING JP, 1992, J ACOUST SOC AM, V91, P2539, DOI 10.1121/1.402990; FEJER MM, 1992, IEEE J QUANTUM ELECT, V28, P2631, DOI 10.1109/3.161322; FENG D, 1980, APPL PHYS LETT, V37, P607, DOI 10.1063/1.92035; Foresi JS, 1997, NATURE, V390, P143, DOI 10.1038/36514; HENRY CH, 1965, PHYS REV LETT, V15, P964, DOI 10.1103/PhysRevLett.15.964; HO KM, 1990, PHYS REV LETT, V65, P3152, DOI 10.1103/PhysRevLett.65.3152; HUANG K, 1951, PROC R SOC LON SER-A, V208, P352, DOI 10.1098/rspa.1951.0166; Joannopoulos J. D., 1995, PHOTONIC CRYSTALS; KUSHWAHA MS, 1994, APPL PHYS LETT, V64, P1085, DOI 10.1063/1.110940; KUSHWAHA MS, 1993, PHYS REV LETT, V71, P2022, DOI 10.1103/PhysRevLett.71.2022; Lu YL, 1997, SCIENCE, V276, P2004, DOI 10.1126/science.276.5321.2004; Lu YL, 1996, APPL PHYS LETT, V68, P1467, DOI 10.1063/1.116256; LU YL, 1991, APPL PHYS LETT, V59, P516, DOI 10.1063/1.105424; Lu YQ, 1996, APPL PHYS LETT, V69, P3155, DOI 10.1063/1.116813; MEIROVITCH L, 1975, ELEMENTS VIBRATION A, P281; Mekis A, 1996, PHYS REV LETT, V77, P3787, DOI 10.1103/PhysRevLett.77.3787; PENDRY JB, 1992, PHYS REV LETT, V69, P2772, DOI 10.1103/PhysRevLett.69.2772; SHENG P, 1990, SCATTERING LOCALIZAT; SIGALAS MM, 1994, PHYS REV B, V50, P3393, DOI 10.1103/PhysRevB.50.3393; Sigalas MM, 1997, MICROW OPT TECHN LET, V15, P153, DOI 10.1002/(SICI)1098-2760(19970620)15:3<153::AID-MOP10>3.0.CO;2-8; SIGALAS MM, 1995, PHYS REV B, V51, P2780, DOI 10.1103/PhysRevB.51.2780; Sigalas MM, 1997, J ACOUST SOC AM, V101, P1256, DOI 10.1121/1.418156; TURNER JD, 1991, ACOUSTICS ENG, P27; YABLONOVITCH E, 1987, PHYS REV LETT, V58, P2059, DOI 10.1103/PhysRevLett.58.2059; YABLONOVITCH E, 1991, PHYS REV LETT, V67, P2295, DOI 10.1103/PhysRevLett.67.2295; YE L, 1992, PHYS REV LETT, V69, P3080, DOI 10.1103/PhysRevLett.69.3080; Zhu S, 1997, SCIENCE, V278, P843, DOI 10.1126/science.278.5339.843	31	138	149	2	112	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 11	1999	284	5421					1822	1824		10.1126/science.284.5421.1822	http://dx.doi.org/10.1126/science.284.5421.1822			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	205EU	10364551				2022-12-28	WOS:000080809000045
J	Atzpodien, J; Dittmar, KEJ				Atzpodien, J; Dittmar, KEJ			Immunologic crosstalk	NEW ENGLAND JOURNAL OF MEDICINE			English	Article									Med Hsch Hannover, D-30623 Hannover, Germany; Gesell Brotechnol Forsch, D-38124 Braunschweig, Germany	Hannover Medical School	Atzpodien, J (corresponding author), Med Hsch Hannover, D-30623 Hannover, Germany.								0	6	6	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 3	1999	340	22					1732	1732		10.1056/NEJM199906033402205	http://dx.doi.org/10.1056/NEJM199906033402205			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	201WQ	10352165				2022-12-28	WOS:000080620200005
J	Corcoran, C; Grinspoon, S				Corcoran, C; Grinspoon, S			Treatments for wasting in patients with the acquired immunodeficiency syndrome	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							HUMAN GROWTH-HORMONE; PLACEBO-CONTROLLED TRIAL; TOTAL PARENTERAL-NUTRITION; VIRUS-INFECTED PATIENTS; LEAN BODY-MASS; MEGESTROL-ACETATE; ENERGY-EXPENDITURE; HIV-INFECTION; DOUBLE-BLIND; WEIGHT-LOSS		Massachusetts Gen Hosp, Neuroendocrine Unit, Boston, MA 02114 USA; Harvard Univ, Sch Med, Boston, MA USA	Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School	Grinspoon, S (corresponding author), Massachusetts Gen Hosp, Neuroendocrine Unit, Bulfinch 457B, Boston, MA 02114 USA.				NCRR NIH HHS [MO1-RR01066] Funding Source: Medline; NIDDK NIH HHS [R01-DK49302, R01-DK54167] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR001066] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK049302, R01DK054167] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Balog DL, 1998, ANN PHARMACOTHER, V32, P446, DOI 10.1345/aph.17072; Baum HBA, 1996, ANN INTERN MED, V125, P883, DOI 10.7326/0003-4819-125-11-199612010-00003; BEAL JE, 1995, J PAIN SYMPTOM MANAG, V10, P89, DOI 10.1016/0885-3924(94)00117-4; BERGER D, 1998, 12 WORLD AIDS C GEN; Berger JR, 1996, AIDS, V10, P1657, DOI 10.1097/00002030-199612000-00010; Bhasin S, 1998, J CLIN ENDOCR METAB, V83, P3155, DOI 10.1210/jc.83.9.3155; CHABON AB, 1987, UROLOGY, V29, P658, DOI 10.1016/0090-4295(87)90118-X; CHLEBOWSKI RT, 1989, AM J GASTROENTEROL, V84, P1288; Coodley GO, 1997, AIDS, V11, P1347, DOI 10.1097/00002030-199711000-00008; DEZUBE BJ, 1993, J ACQ IMMUN DEF SYND, V6, P787; DOBS AS, 1988, AM J MED, V84, P611, DOI 10.1016/0002-9343(88)90144-1; FISHER A, 1998, 12 WORLD AIDS C GEN; Flexner C, 1998, NEW ENGL J MED, V338, P1281, DOI 10.1056/NEJM199804303381808; FORBES GB, 1987, NUTR REV, V45, P225; GIBERT CL, 1998, 12 WORLD AIDS C GEN; Gold J, 1996, AIDS, V10, P745, DOI 10.1097/00002030-199606001-00008; Grinspoon S, 1998, AM J CLIN NUTR, V68, P720, DOI 10.1093/ajcn/68.3.720; Grinspoon S, 1996, J CLIN ENDOCR METAB, V81, P4051, DOI 10.1210/jc.81.11.4051; Grinspoon S, 1997, J CLIN ENDOCR METAB, V82, P3360; Grinspoon S, 1999, J CLIN ENDOCR METAB, V84, P201, DOI 10.1210/jc.84.1.201; Grinspoon S, 1997, J CLIN ENDOCR METAB, V82, P1332, DOI 10.1210/jc.82.5.1332; Grinspoon S, 1997, ENDOCRINOLOGIST, V7, P32, DOI 10.1097/00019616-199707010-00005; Grinspoon S, 1998, J CLIN ENDOCR METAB, V83, P4251, DOI 10.1210/jc.83.12.4251; GRISNPOON S, 1999, CLIN INFECT DIS, V28, P634; GRUNFELD C, 1992, NEW ENGL J MED, V327, P329, DOI 10.1056/NEJM199207303270506; GRUNFELD C, 1992, AM J CLIN NUTR, V55, P455, DOI 10.1093/ajcn/55.2.455; GUENTER P, 1993, J ACQ IMMUN DEF SYND, V6, P1130; Haslett P, 1997, AIDS RES HUM RETROV, V13, P1047, DOI 10.1089/aid.1997.13.1047; HELLERSTEIN MK, 1993, J CLIN ENDOCR METAB, V76, P559, DOI 10.1210/jc.76.3.559; HENRY K, 1992, ANN INTERN MED, V116, P53, DOI 10.7326/0003-4819-116-1-53; Jacobson JM, 1997, NEW ENGL J MED, V336, P1487, DOI 10.1056/NEJM199705223362103; Klausner JD, 1996, J ACQ IMMUN DEF SYND, V11, P247, DOI 10.1097/00042560-199603010-00005; KOTLER DP, 1985, AM J CLIN NUTR, V42, P1255, DOI 10.1093/ajcn/42.6.1255; KOTLER DP, 1990, JPEN-PARENTER ENTER, V14, P454, DOI 10.1177/0148607190014005454; KRENTZ AJ, 1993, J ACQ IMMUN DEF SYND, V6, P245; LAHDEVIRTA J, 1988, AM J MED, V85, P289, DOI 10.1016/0002-9343(88)90576-1; Lee PDK, 1996, J CLIN ENDOCR METAB, V81, P2968, DOI 10.1210/jc.81.8.2968; Lee PDK, 1996, J CLIN ENDOCR METAB, V81, P3696; LEINUNG MC, 1995, ANN INTERN MED, V122, P843, DOI 10.7326/0003-4819-122-11-199506010-00006; Lo JC, 1998, LANCET, V351, P867, DOI 10.1016/S0140-6736(97)11443-X; LOPRINZI CL, 1992, MAYO CLIN PROC, V67, P1160, DOI 10.1016/S0025-6196(12)61145-8; MACALLAN DC, 1995, NEW ENGL J MED, V333, P83, DOI 10.1056/NEJM199507133330202; Melchior JC, 1996, AIDS, V10, P379, DOI 10.1097/00002030-199604000-00005; MHIRI C, 1992, T ROY SOC TROP MED H, V86, P303, DOI 10.1016/0035-9203(92)90323-5; Miller K, 1998, J CLIN ENDOCR METAB, V83, P2717, DOI 10.1210/jc.83.8.2717; Miller KD, 1998, LANCET, V351, P871, DOI 10.1016/S0140-6736(97)11518-5; Miller KK, 1998, CLIN INFECT DIS, V27, P68, DOI 10.1086/514638; Mulligan K, 1997, J ACQ IMMUN DEF SYND, V15, P43, DOI 10.1097/00042560-199705010-00007; MULLIGAN K, 1993, J CLIN ENDOCR METAB, V77, P956, DOI 10.1210/jc.77.4.956; MUURAHAINEN N, 1998, 12 WORLD AIDS C GEN; OSTER MH, 1994, ANN INTERN MED, V121, P400, DOI 10.7326/0003-4819-121-6-199409150-00002; OTT M, 1993, AM J CLIN NUTR, V57, P15, DOI 10.1093/ajcn/57.1.15; Padmanabhan S, 1998, CLIN INFECT DIS, V27, P217, DOI 10.1086/517681; PALENICEK JP, 1995, J ACQ IMMUN DEF SYND, V10, P366; PATON N, 1998, 12 WORLD AIDS C GEN; RAGHAVAN S, 1998, 12 WORLD AIDS C GEN; RATHMACHER JA, 1998, 12 WORLD AIDS C GEN; ReyesTeran G, 1996, AIDS, V10, P1501, DOI 10.1097/00002030-199611000-00007; RIGSBY LW, 1992, MED SCI SPORT EXER, V24, P6; ROUBENOFF R, 1991, NUTR REV, V49, P163, DOI 10.1111/j.1753-4887.1991.tb03013.x; ROUBENOFF R, 1998, 12 WORLD AIDS C GEN; Schambelan M, 1996, ANN INTERN MED, V125, P873, DOI 10.7326/0003-4819-125-11-199612010-00002; SCHWENK A, 1998, 12 WORLD AIDS C GEN; SHABERT J, 1998, 12 WORLD AIDS C GEN; Silva M, 1998, AIDS, V12, P1645, DOI 10.1097/00002030-199813000-00012; Sinha-Hikim I, 1998, J CLIN ENDOCR METAB, V83, P1312, DOI 10.1210/jc.83.4.1312; Sinha-Hikim I, 1998, J CLIN ENDOCR METAB, V83, P2959; SPARK RF, 1998, 80 ANN M END SOC NEW, P109; SPENCE DW, 1990, ARCH PHYS MED REHAB, V71, P644; SUTTMANN U, 1995, J ACQ IMMUN DEF SYND, V8, P239, DOI 10.1097/00042560-199503010-00004; Timpone JG, 1997, AIDS RES HUM RETROV, V13, P305, DOI 10.1089/aid.1997.13.305; TORRES R, 1998, 12 WORLD AIDS C GEN; Volberding PA, 1998, JAMA-J AM MED ASSOC, V279, P1343, DOI 10.1001/jama.279.17.1343; VONROENN JH, 1994, ANN INTERN MED, V121, P393, DOI 10.7326/0003-4819-121-6-199409150-00001; Waters D, 1996, ANN INTERN MED, V125, P865, DOI 10.7326/0003-4819-125-11-199612010-00001; WESTABY D, 1977, LANCET, V2, P261; WILMORE DW, 1974, SURG GYNECOL OBSTET, V138, P875; Yarasheski KE, 1998, AM J PHYSIOL-ENDOC M, V275, pE577, DOI 10.1152/ajpendo.1998.275.4.E577; ZIEGLER TR, 1992, J CLIN ENDOCR METAB, V74, P865, DOI 10.1210/jc.74.4.865; [No title captured]	80	72	77	0	2	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUN 3	1999	340	22					1740	1750		10.1056/NEJM199906033402207	http://dx.doi.org/10.1056/NEJM199906033402207			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	201WQ	10352167				2022-12-28	WOS:000080620200007
J	Ivanov, PC; Amaral, LAN; Goldberger, AL; Havlin, S; Rosenblum, MG; Struzik, ZR; Stanley, HE				Ivanov, PC; Amaral, LAN; Goldberger, AL; Havlin, S; Rosenblum, MG; Struzik, ZR; Stanley, HE			Multifractality in human heartbeat dynamics	NATURE			English	Article							RATE-VARIABILITY; TIME-SERIES; FLUCTUATION; TURBULENCE; FORMALISM; WAVELETS; MODEL; CHAOS	There is evidence that physiological signals under healthy conditions may have a fractal temporal structure(1). Here we investigate the possibility that time series generated by certain physiological control systems may be members of a special class of complex processes, termed multifractal, which require a large number of exponents to characterize their scaling properties(2-6). We report on evidence for multifractality in a biological dynamical system, the healthy human heartbeat, and show that the multifractal character and nonlinear properties of the healthy heart rate are encoded in the Fourier phases. We uncover a loss of multifractality for a life-threatening condition, congestive heart failure.	Boston Univ, Ctr Polymer Studies, Boston, MA 02215 USA; Boston Univ, Dept Phys, Boston, MA 02215 USA; Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA; Bar Ilan Univ, Gonda Goldschmid Ctr, Ramat Gan, Israel; Bar Ilan Univ, Dept Phys, Ramat Gan, Israel; Univ Potsdam, Dept Phys, D-14415 Potsdam, Germany; Ctr Math & Comp Sci, NL-1098 SJ Amsterdam, Netherlands	Boston University; Boston University; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Bar Ilan University; Bar Ilan University; University of Potsdam	Ivanov, PC (corresponding author), Boston Univ, Ctr Polymer Studies, Boston, MA 02215 USA.		Ivanov, Plamen Ch./E-8004-2012; Amaral, Luis N./C-5485-2009; Struzik, Zbigniew/E-4295-2012; Havlin, Shlomo/ABF-1527-2020; Amaral, LAN/A-4980-2008	Ivanov, Plamen Ch./0000-0001-7629-762X; Struzik, Zbigniew/0000-0002-1352-8897; Amaral, LAN/0000-0002-3762-789X				AKSELROD S, 1981, SCIENCE, V213, P220, DOI 10.1126/science.6166045; Amaral LAN, 1998, PHYS REV LETT, V81, P2388, DOI 10.1103/PhysRevLett.81.2388; BARABASI AL, 1995, FRACTAL CONCEPTS SUR, pCH24; BASSINGTHWAIGHT.JB, 1994, FRACTAL PHYSL; Daubechies I, 1992, 10 LECT WAVELETS; Dewey T. G., 1997, FRACTALS MOL BIOPHYS; Hausdorff JM, 1996, J APPL PHYSIOL, V80, P1448, DOI 10.1152/jappl.1996.80.5.1448; HURST HE, 1951, T AM SOC CIV ENG, V116, P770; Ivanov PC, 1998, EUROPHYS LETT, V43, P363, DOI 10.1209/epl/i1998-00366-3; Ivanov PC, 1996, NATURE, V383, P323, DOI 10.1038/383323a0; KANTERS JK, 1994, J CARDIOVASC ELECTR, V5, P128; KOBAYASHI M, 1982, IEEE T BIO-MED ENG, V29, P456, DOI 10.1109/TBME.1982.324972; Lefebvre J. H., 1993, Chaos, V3, P267, DOI 10.1063/1.165990; Malik M., 1995, HEART RATE VARIABILI; MENEVEAU C, 1987, PHYS REV LETT, V59, P1424, DOI 10.1103/PhysRevLett.59.1424; MOODY GB, 1983, COMPUTERS CARDIOL, V9, P39; MUZY JF, 1994, INT J BIFURCAT CHAOS, V4, P245, DOI 10.1142/S0218127494000204; MUZY JF, 1991, PHYS REV LETT, V67, P3515, DOI 10.1103/PhysRevLett.67.3515; Peng CK, 1995, J ELECTROCARDIOL, V28, P59, DOI 10.1016/S0022-0736(95)80017-4; PENG CK, 1995, CHAOS, V5, P82, DOI 10.1063/1.166141; Poon CS, 1997, NATURE, V389, P492, DOI 10.1038/39043; SHLESINGER MF, 1987, ANN NY ACAD SCI, V504, P214, DOI 10.1111/j.1749-6632.1987.tb48734.x; STANLEY HE, 1988, NATURE, V335, P405, DOI 10.1038/335405a0; STNALEY HE, 1996, FRACTALS DISORDERED, P1; Sugihara G, 1996, P NATL ACAD SCI USA, V93, P2608, DOI 10.1073/pnas.93.6.2608; TAKAYASU H, 1997, FRACTALS PHYSICAL SC; Thurner S, 1998, PHYS REV LETT, V80, P1544, DOI 10.1103/PhysRevLett.80.1544; VICSEK T, 1991, J PHYS A-MATH GEN, V24, pL845, DOI 10.1088/0305-4470/24/15/010; VICSEK T, 1993, FRACTAL GROWTH PHENO; YAMAMOTO Y, 1993, BIOL CYBERN, V69, P205, DOI 10.1007/BF00198960	30	1257	1317	2	128	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUN 3	1999	399	6735					461	465		10.1038/20924	http://dx.doi.org/10.1038/20924			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	202TH	10365957	Green Submitted, Green Published			2022-12-28	WOS:000080667900047
J	Tsubota, K; Satake, Y; Kaido, M; Shinozaki, N; Shimmura, S; Bissen-Miyajima, H; Shimazaki, J				Tsubota, K; Satake, Y; Kaido, M; Shinozaki, N; Shimmura, S; Bissen-Miyajima, H; Shimazaki, J			Treatment of severe ocular-surface disorders with corneal epithelial stem-cell transplantation	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							DRY-EYE; RECONSTRUCTION; ALLOGRAFT; SURVIVAL	Background Conditions that destroy the limbal area of the peripheral cornea, such as the Stevens-Johnson syndrome, ocular pemphigoid, and chemical and thermal injuries, can deplete stem cells of the corneal epithelium. The result is scarring and opacification of the normally clear cornea. Standard corneal transplantation cannot treat this form of functional blindness. Methods We performed and evaluated 70 transplantations of corneal epithelial stem cells from cadaveric eyes into 43 eyes of 39 patients with severe ocular-surface disorders and limbal dysfunction. Medical treatment had failed in all patients. The patients had a mean preoperative visual acuity of 0.004 (only being able to count the number of fingers presented by the examiner) in the affected eyes, which satisfies the criteria for legal blindness in most countries. In 28 eyes, we also performed standard corneal transplantation. Stem-cell transplantations were performed as many as four times on 1 eye if the initial results were not satisfactory; 19 eyes had multiple transplantations. Patients were followed for at least one year after transplantation. Results A mean of 1163 days after stem-cell transplantation, 22 of the 43 eyes (51 percent) had corneal epithelialization; of the 22 eyes, 7 eyes had corneal stromal edema and 15 eyes had clear corneas. Mean visual acuity improved from 0.004 to 0.02 (vision sufficient to distinguish the largest symbol on the visual-acuity chart from a distance of 1 m) (P<0.001). The 15 eyes in which the cornea remained clear had a final mean visual acuity of 0.11 (the ability to distinguish the largest symbol from a distance of 5 m). Complications of the first transplantation included persistent defects in the corneal epithelium in 26 eyes, ocular hypertension in 16 eyes, and rejection of the corneal graft in 13 of 28 eyes. The epithelial defects eventually healed in all but two of the eyes. Conclusions Transplantation of corneal epithelial stem cells can restore useful vision in some patients with severe ocular-surface disorders. (N Engl J Med 1999;340:1697-703.) (C) 1999, Massachusetts Medical Society.	Tokyo Dent Coll, Dept Ophthalmol, Chiba 2728513, Japan; Keio Univ, Sch Med, Dept Ophthalmol, Tokyo, Japan	Tokyo Dental College; Keio University	Tsubota, K (corresponding author), Tokyo Dent Coll, Dept Ophthalmol, 11-13 Sugano 5 Chome, Chiba 2728513, Japan.		Shimmura, Shigeto/J-4678-2013; Jun, Shimazaki/K-5976-2019					BECK RW, 1992, NEW ENGL J MED, V326, P581, DOI 10.1056/NEJM199202273260901; DOHLMAN C H, 1957, Acta Ophthalmol (Copenh), V35, P286; Holland EJ, 1996, CORNEA, V15, P549; KENYON KR, 1989, OPHTHALMOLOGY, V96, P709; KIN JC, 1995, CORNEA, V14, P473; KINOSHITA S, 1981, INVEST OPHTH VIS SCI, V21, P434; KINOSHITA S, 1986, JPN J CLIN OPHTHAL, V40, P363; Pfister Roswell R., 1994, CLAO (Contact Lens Association of Ophthalmologists) Journal, V20, P64; PUANGSRICHARERN V, 1995, OPHTHALMOLOGY, V102, P1476; Shimazaki J, 1997, OPHTHALMOLOGY, V104, P2068, DOI 10.1016/S0161-6420(97)30057-8; SHIMAZAKI J, IN PRESS INVEST OPHT; Swift GJ, 1996, TRANSPLANTATION, V62, P568, DOI 10.1097/00007890-199609150-00005; TSAI RJF, 1994, CORNEA, V13, P389, DOI 10.1097/00003226-199409000-00003; Tsubota K, 1996, LANCET, V348, P123, DOI 10.1016/S0140-6736(96)24028-0; Tsubota K, 1996, AM J OPHTHALMOL, V122, P38, DOI 10.1016/S0002-9394(14)71962-2; TSUBOTA K, 1994, CORNEA, V13, P197, DOI 10.1097/00003226-199405000-00001; TSUBOTA K, 1995, OPHTHALMOLOGY, V102, P1486; WILLIAMS KA, 1995, AM J OPHTHALMOL, V120, P342, DOI 10.1016/S0002-9394(14)72164-6	18	376	389	0	11	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 3	1999	340	22					1697	1703		10.1056/NEJM199906033402201	http://dx.doi.org/10.1056/NEJM199906033402201			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	201WQ	10352161	Bronze			2022-12-28	WOS:000080620200001
J	Finckh, W				Finckh, W			Studying for the MRCP - was it worth while?	BRITISH MEDICAL JOURNAL			English	Article																			0	1	1	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	MAY 29	1999	318	7196					1467	1467		10.1136/bmj.318.7196.1467	http://dx.doi.org/10.1136/bmj.318.7196.1467			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	202TL	10346776	Green Published			2022-12-28	WOS:000080668200026
J	Vestbo, J; Sorensen, T; Lange, P; Brix, A; Torre, P; Viskum, K				Vestbo, J; Sorensen, T; Lange, P; Brix, A; Torre, P; Viskum, K			Long-term effect of inhaled budesonide in mild and moderate chronic obstructive pulmonary disease: a randomised controlled trial	LANCET			English	Article							EUROPEAN RESPIRATORY SOCIETY; CORTICOSTEROID-THERAPY; LUNG-FUNCTION; DECLINE; ASTHMA; BRONCHODILATOR; RESPONSIVENESS; SMOKING; MODELS; FEV(1)	Background. Little is known about the long-term efficacy of inhaled corticosteroids in chronic obstructive pulmonary disease (COPD). We investigated the efficacy of inhaled budesonide on decline in lung function and respiratory symptoms in a 3-year placebo-controlled study of patients with COPD. Methods. We used a parallel-group, randomised, double-blind, placebo-controlled design in a single-centre study, nested in a continuing epidemiological survey (the Copenhagen City Heart Study). Inclusion criteria were as follows: no asthma; a ratio of forced expiratory volume in 1 s (FEV1) and vital capacity of 0.7 or less; FEV, which showed no response (<15% change) to 1 mg inhaled terbutaline or prednisolone 37.5 mg orally once daily for 10 days. 290 patients were randomly assigned budesonide, 800 mu g plus 400 mu g daily for 6 months followed by 400 mu g twice daily for 30 months, or placebo for 36 months. The mean age of the participants was 59 years and the mean FEV1 2.37 L or 86% of predicted. The main outcome measure was rate of FEV, decline. Analyses were by intention to treat. Findings. The crude rates of FEV, decline were slightly smaller than expected (placebo group 41.8 mt per year, budesonide group 45.1 mL per year). The estimated rates of decline from the regression model did not differ significantly (49.1 mL vs 46.0 mL per year; difference 3.1 mL per year [95% Cl -12.8 to 19.0]; p = 0.7). Before the study, the minimum relevant difference was defined as 20 mL per year; this difference was outside the 95% CI. No effect of inhaled budesonide was seen on respiratory symptoms. 316 exacerbations occurred during the study period, 155 in the budesonide group and 161 in the placebo group. Treatment was well tolerated. Interpretation. Inhaled budesonide was of no clinical benefit in COPD patients recruited from the general population by screening. We question the role of long-term inhaled corticosteroids in the treatment of mild to moderate COPD.	Univ Copenhagen, Hvidovre Hosp, Dept Resp Med, DK-2650 Hvidovre, Denmark; Bispebjerg Hosp, Epidemiol Res Unit, Copenhagen City Heart Study, DK-2400 Copenhagen, Denmark; Univ Copenhagen, Panum Inst, Dept Biostat, DK-2200 Copenhagen, Denmark; ASTRA Danmark AS, Albertslund, Denmark; Natl Univ Hosp, RHIMA Ctr, Dept Pulm Med, Copenhagen, Denmark	University of Copenhagen; University of Copenhagen; Bispebjerg Hospital; University of Copenhagen	Vestbo, J (corresponding author), Univ Copenhagen, Hvidovre Hosp, Dept Resp Med, DK-2650 Hvidovre, Denmark.	jvestbo@inet.uni2.dk	Vestbo, Jorgen/Y-2912-2019	Vestbo, Jorgen/0000-0001-6355-6362				AGRESTI A, 1989, STAT MED, V8, P1209, DOI 10.1002/sim.4780081005; ANTHONISEN NR, 1994, JAMA-J AM MED ASSOC, V272, P1497, DOI 10.1001/jama.272.19.1497; Appleyard M., 1989, SCAND J SOC MED, V41, P1; BURGE PS, 1996, AM J RESP CRIT CARE, V153, pA126; BURGE PS, 1997, EUR RESPIR J, V10, pS391; BURROWS B, 1987, AM REV RESPIR DIS, V135, P788, DOI 10.1164/arrd.1987.135.4.788; CALLAHAN CM, 1991, ANN INTERN MED, V114, P216, DOI 10.7326/0003-4819-114-3-216; Derenne JP, 1995, AM J RESP CRIT CARE, V151, pA463; HAAHTELA T, 1991, NEW ENGL J MED, V325, P388, DOI 10.1056/NEJM199108083250603; Jackevicius CA, 1997, ANN PHARMACOTHER, V31, P160, DOI 10.1177/106002809703100204; Keatings VM, 1997, AM J RESP CRIT CARE, V155, P449, DOI 10.1164/ajrccm.155.2.9032177; Keatings VM, 1997, AM J RESP CRIT CARE, V155, P542, DOI 10.1164/ajrccm.155.2.9032192; KERSTJENS HAM, 1992, NEW ENGL J MED, V327, P1413, DOI 10.1056/NEJM199211123272003; LACOSTE JY, 1993, J ALLERGY CLIN IMMUN, V92, P537, DOI 10.1016/0091-6749(93)90078-T; LANGE P, 1992, DAN MED BULL, V39, P30; LENFANT C, 1995, NIH PUBLICATION NATL; Leynaert B, 1997, AM J RESP CRIT CARE, V156, P1413, DOI 10.1164/ajrccm.156.5.9701060; Orie NG, 1961, BRONCHITIS; Paggiaro PL, 1998, LANCET, V351, P773, DOI 10.1016/S0140-6736(97)03471-5; PAUWELS RA, 1992, EUR RESPIR J, V5, P1254; POSTMA DS, 1985, EUR J RESPIR DIS, V67, P56; POSTMA DS, 1988, EUR RESPIR J, V1, P22; QUANJER PH, 1993, EUR RESPIR J, V6, P5, DOI 10.1183/09041950.005s1693; Renkema TEJ, 1996, CHEST, V109, P1156, DOI 10.1378/chest.109.5.1156; Rijcken B, 1996, AM J RESP CRIT CARE, V154, pS246, DOI 10.1164/ajrccm/154.6_Pt_2.S246; Tashkin DP, 1996, AM J RESP CRIT CARE, V153, P1802, DOI 10.1164/ajrccm.153.6.8665038; van Grunsven PM, 1999, THORAX, V54, P7, DOI 10.1136/thx.54.1.7; Vestbo J, 1996, AM J RESP CRIT CARE, V153, P1530, DOI 10.1164/ajrccm.153.5.8630597; Vestbo J, 1998, THORAX, V53, pS15, DOI 10.1136/thx.53.2008.S15; Xu XP, 1997, LANCET, V350, P1431, DOI 10.1016/S0140-6736(97)10041-1	31	548	565	20	37	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAY 29	1999	353	9167					1819	1823		10.1016/S0140-6736(98)10019-3	http://dx.doi.org/10.1016/S0140-6736(98)10019-3			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	202TG	10359405				2022-12-28	WOS:000080667800009
J	Mott, HR; Owen, D; Nietlispach, D; Lowe, PN; Manser, E; Lim, L; Laue, ED				Mott, HR; Owen, D; Nietlispach, D; Lowe, PN; Manser, E; Lim, L; Laue, ED			Structure of the small G protein Cdc42 bound to the GTPase-binding domain of ACK	NATURE			English	Article							WISKOTT-ALDRICH-SYNDROME; CRYSTAL-STRUCTURE; TARGET PROTEINS; RAC; EFFECTOR; KINASE; FAMILY; RHO; SURFACE; PROGRAM	The proteins Cdc42 and Rac are members of the Rho family of small GTPases (G proteins), which control signal-transduction pathways that lead to rearrangements of the cell cytoskeleton, cell differentiation and cell proliferation. They do so by binding to downstream effector proteins(1). Some of these, known as CRIB (for Cdc42/Rac interactive-binding) proteins(2), bind to both Cdc42 and : Rac, such as the PAK1-3 serine/threonine kinases(3), whereas others are specific for Cdc42, such as the ACK tyrosine kinases(4,5) and the Wiscott-Aldrich-syndrome proteins (WASPs)(6,7). The effector loop of Cdc42 and Rac (comprising residues 30-40, also called switch I), is one of two regions which change conformation on exchange of GDP for GTP, This region is almost identical in Cdc42 and Racs, indicating that it does not determine the specificity of these G proteins. Here we report the solution structure of the complex of Cdc42 with the GTPase-binding domain of ACK(4,5). Both proteins undergo significant conformational changes on binding, to form a new type of G-protein/effector complex. The interaction extends the beta-sheet in Cdc42 by binding an extended strand from ACK, as seen in Ras/effector interactions(8,9), but it also involves other regions of the G protein that are important for determining the specificity of effector binding.	Univ Cambridge, Dept Biochem, Cambridge Ctr Mol Recognit, Cambridge CB2 1GA, England; Glaxo Wellcome Med Res Ctr, Stevenage SG1 2NY, Herts, England; Natl Univ Singapore, Inst Mol & Cell Biol, Singapore 119076, Singapore; Inst Neurol, London WC1N 1PJ, England	University of Cambridge; GlaxoSmithKline; Agency for Science Technology & Research (A*STAR); A*STAR - Institute of Molecular & Cell Biology (IMCB); National University of Singapore; University of London; University College London	Laue, ED (corresponding author), Univ Cambridge, Dept Biochem, Cambridge Ctr Mol Recognit, 80 Tennis Court Rd, Cambridge CB2 1GA, England.	e.d.laue@bioc.cam.ac.uk	Manser, Edward/ABD-2301-2020; Mott, Helen/AAV-3873-2020	Mott, Helen/0000-0002-7890-7097; Nietlispach, Daniel/0000-0003-4364-9291; Laue, Ernest/0000-0002-7476-4148				Abdul-Manan N, 1999, NATURE, V399, P379, DOI 10.1038/20726; Aspenstrom P, 1996, CURR BIOL, V6, P70, DOI 10.1016/S0960-9822(02)00423-2; BARTON GJ, 1993, PROTEIN ENG, V6, P37, DOI 10.1093/protein/6.1.37; BRUNGER AT, 1992, XPLOR SYSTEM XRAY CR; BURBELO PD, 1995, J BIOL CHEM, V270, P29071, DOI 10.1074/jbc.270.49.29071; DIEKMANN D, 1995, EMBO J, V14, P5297, DOI 10.1002/j.1460-2075.1995.tb00214.x; Feltham JL, 1997, BIOCHEMISTRY-US, V36, P8755, DOI 10.1021/bi970694x; Guo W, 1998, BIOCHEMISTRY-US, V37, P14030, DOI 10.1021/bi981352+; Hirshberg M, 1997, NAT STRUCT BIOL, V4, P147, DOI 10.1038/nsb0297-147; Huang L, 1998, NAT STRUCT BIOL, V5, P422, DOI 10.1038/nsb0698-422; KhosraviFar R, 1998, ADV CANCER RES, V72, P57; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Leonard DA, 1997, BIOCHEMISTRY-US, V36, P1173, DOI 10.1021/bi9622837; MANSER E, 1993, NATURE, V363, P364, DOI 10.1038/363364a0; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; Miki H, 1998, NATURE, V391, P93, DOI 10.1038/34208; NASSAR M, 1995, NATURE, V375, P554, DOI 10.1038/375554a0; Nilges M, 1997, J MOL BIOL, V269, P408, DOI 10.1006/jmbi.1997.1044; Nisimoto Y, 1997, J BIOL CHEM, V272, P18834, DOI 10.1074/jbc.272.30.18834; Ostermeier C, 1999, CELL, V96, P363, DOI 10.1016/S0092-8674(00)80549-8; Rittinger K, 1997, NATURE, V388, P693, DOI 10.1038/41805; Rudolph MG, 1998, J BIOL CHEM, V273, P18067, DOI 10.1074/jbc.273.29.18067; Sells MA, 1997, TRENDS CELL BIOL, V7, P162, DOI 10.1016/S0962-8924(97)01003-9; Symons M, 1996, CELL, V84, P723, DOI 10.1016/S0092-8674(00)81050-8; Tapon N, 1997, CURR OPIN CELL BIOL, V9, P86, DOI 10.1016/S0955-0674(97)80156-1; Thompson G, 1998, BIOCHEMISTRY-US, V37, P7885, DOI 10.1021/bi980140+; Toporik A, 1998, BIOCHEMISTRY-US, V37, P7147, DOI 10.1021/bi9800404; Vetter IR, 1999, NATURE, V398, P39, DOI 10.1038/17969; Yang WN, 1997, J BIOL CHEM, V272, P24819, DOI 10.1074/jbc.272.40.24819; Zwahlen C, 1997, J AM CHEM SOC, V119, P6711, DOI 10.1021/ja970224q	30	143	145	1	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAY 27	1999	399	6734					384	388		10.1038/20732	http://dx.doi.org/10.1038/20732			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	200PA	10360579				2022-12-28	WOS:000080547800066
J	Parker, RA; Hartman, EE				Parker, RA; Hartman, EE			A 55-year-old man with attention-deficit/hyperactivity disorder, 1 year later	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																		Biederman J, 1998, JAMA-J AM MED ASSOC, V280, P1086, DOI 10.1001/jama.280.12.1086	1	1	1	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 26	1999	281	20					1945	1945		10.1001/jama.281.20.1945	http://dx.doi.org/10.1001/jama.281.20.1945			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	198ME	10349899				2022-12-28	WOS:000080427300035
J	Ona, VO; Li, MW; Vonsattel, JPG; Andrews, LJ; Khan, SQ; Chung, WM; Frey, AS; Menon, AS; Li, XJ; Stieg, PE; Yuan, JY; Penney, JB; Young, AB; Cha, JHJ; Friedlander, RM				Ona, VO; Li, MW; Vonsattel, JPG; Andrews, LJ; Khan, SQ; Chung, WM; Frey, AS; Menon, AS; Li, XJ; Stieg, PE; Yuan, JY; Penney, JB; Young, AB; Cha, JHJ; Friedlander, RM			Inhibition of caspase-1 slows disease progression in a mouse model of Huntington's disease	NATURE			English	Article							INTERLEUKIN-1-BETA CONVERTING-ENZYME; NEURONAL INTRANUCLEAR INCLUSIONS; TROPHIC FACTOR WITHDRAWAL; TRANSGENIC MICE; IL-1-BETA-CONVERTING ENZYME; POLYGLUTAMINE TRACT; CYSTEINE PROTEASE; FAMILY PROTEASES; CELL-DEATH; GENE	Huntington's disease is an autosomal-dominant progressive neurodegenerative disorder resulting in specific neuronal loss and dysfunction in the striatum and cortex(1). The disease is universally fatal, with a mean survival following onset of 15-20 years and, at present, there is no effective treatment. The mutation in patients with Huntington's disease is an expanded CAG/polyglutamine repeat in huntingtin, a protein of unknown function with a relative molecular mass of 350,000 (M-r 350K)(2). The length of the CAG/polyglutamine repeat is inversely correlated with the age of disease onset. The molecular pathways mediating the neuropathology of Huntington's disease are poorly understood. Transgenic mice expressing exon 1 of the human huntingtin gene with an expanded CAG/polyglutamine repeat develop a progressive syndrome with many of the characteristics of human Huntington's disease(3). Here we demonstrate evidence of caspase-1 activation in the brains of mice and humans with the disease. In this transgenic mouse model of Huntington's disease, expression of a dominant-negative caspase-1 mutant extends survival and delays the appearance of neuronal inclusions, neurotransmitter receptor alterations and onset of symptoms, indicating that caspase-1 is important in the pathogenesis of the disease. In addition, we demonstrate that intracerebroventricular administration of a caspase inhibitor delays disease progression and mortality in the mouse model of Huntington's disease.	Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Surg,Neurol Serv, Boston, MA 02115 USA; Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Neuropathol, Boston, MA 02114 USA; Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Neurol, Boston, MA 02114 USA; Emory Univ, Sch Med, Dept Genet, Atlanta, GA 30322 USA; Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Harvard Medical School; Massachusetts General Hospital; Harvard University; Harvard Medical School; Massachusetts General Hospital; Emory University; Harvard University; Harvard Medical School	Friedlander, RM (corresponding author), Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Surg,Neurol Serv, Boston, MA 02115 USA.	rfriedlander@rics.bwh.harvard.edu						Alnemri ES, 1996, CELL, V87, P171, DOI 10.1016/S0092-8674(00)81334-3; Burne JF, 1996, J NEUROSCI, V16, P2064; Cha JHJ, 1998, P NATL ACAD SCI USA, V95, P6480, DOI 10.1073/pnas.95.11.6480; Davies SW, 1997, CELL, V90, P537, DOI 10.1016/S0092-8674(00)80513-9; DiFiglia M, 1997, SCIENCE, V277, P1990, DOI 10.1126/science.277.5334.1990; FORSSPETTER S, 1990, NEURON, V5, P187, DOI 10.1016/0896-6273(90)90308-3; Friedlander RM, 1997, NATURE, V388, P31, DOI 10.1038/40299; Friedlander RM, 1996, J EXP MED, V184, P717, DOI 10.1084/jem.184.2.717; Friedlander RM, 1997, J EXP MED, V185, P933, DOI 10.1084/jem.185.5.933; Goldberg YP, 1996, NAT GENET, V13, P442, DOI 10.1038/ng0896-442; Hara H, 1997, P NATL ACAD SCI USA, V94, P2007, DOI 10.1073/pnas.94.5.2007; Hara H, 1997, J CEREBR BLOOD F MET, V17, P370, DOI 10.1097/00004647-199704000-00002; Harper PS, 1991, HUNTINGTONS DIS; Hurlbert MS, 1999, DIABETES, V48, P649, DOI 10.2337/diabetes.48.3.649; Kim M, 1999, J NEUROSCI, V19, P964; Klevenyi P, 1999, NEUROREPORT, V10, P635, DOI 10.1097/00001756-199902250-00035; Kosinski CM, 1997, EXP NEUROL, V144, P239, DOI 10.1006/exnr.1997.6441; Lee SC, 1995, BRAIN BEHAV IMMUN, V9, P345, DOI 10.1006/brbi.1995.1032; LI P, 1995, CELL, V80, P401, DOI 10.1016/0092-8674(95)90490-5; Lunkes A, 1998, HUM MOL GENET, V7, P1355, DOI 10.1093/hmg/7.9.1355; MACDONALD ME, 1993, CELL, V72, P971, DOI 10.1016/0092-8674(93)90585-E; Mangiarini L, 1996, CELL, V87, P493, DOI 10.1016/S0092-8674(00)81369-0; Persichetti F, 1996, NEUROBIOL DIS, V3, P183, DOI 10.1006/nbdi.1996.0018; PORTERACAILLIAU C, 1995, J NEUROSCI, V15, P3775, DOI 10.1523/jneurosci.15-05-03775.1995; Reddy PH, 1998, NAT GENET, V20, P198, DOI 10.1038/2510; Saudou F, 1998, CELL, V95, P55, DOI 10.1016/S0092-8674(00)81782-1; TEWARI M, 1995, CELL, V81, P801, DOI 10.1016/0092-8674(95)90541-3; THORNBERRY NA, 1992, NATURE, V356, P768, DOI 10.1038/356768a0; Troy CM, 1996, P NATL ACAD SCI USA, V93, P5635, DOI 10.1073/pnas.93.11.5635; Wellington CL, 1998, J BIOL CHEM, V273, P9158, DOI 10.1074/jbc.273.15.9158	30	506	575	0	25	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAY 20	1999	399	6733					263	267		10.1038/20446	http://dx.doi.org/10.1038/20446			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	198MF	10353249				2022-12-28	WOS:000080427400057
J	Gould, MK; Dembitzer, AD; Doyle, RL; Hastie, TJ; Garber, AM				Gould, MK; Dembitzer, AD; Doyle, RL; Hastie, TJ; Garber, AM			Low-molecular-weight heparins compared with unfractionated heparin for treatment of acute deep venous thrombosis - A meta-analysis of randomized, controlled trials	ANNALS OF INTERNAL MEDICINE			English	Article						heparin, low-molecular weight; thrombophlebitis; meta-analysis; heparin; outcome and process assessment (health care)	CONTINUOUS INTRAVENOUS HEPARIN; DAILY SUBCUTANEOUS DALTEPARIN; VEIN-THROMBOSIS; PULMONARY-EMBOLISM; STANDARD HEPARIN; INITIAL TREATMENT; SYSTEMATIC REVIEWS; MULTICENTER TRIAL; CLINICAL-TRIALS; METAANALYSIS	Background: Low-molecular-weight heparins may simplify the management of deep venous thrombosis. A critical clinical issue is whether this more convenient therapy is as safe and effective as treatment with unfractionated heparin. Purpose: To compare the safety and efficacy of low-molecular-weight heparins with those of unfractionated heparin for treatment of acute deep venous thrombosis. Data Sources: Reviewers identified studies by searching MEDLINE, reviewing references from retrieved articles, scanning abstracts from conference proceedings, and contacting investigators and pharmaceutical companies. Study Selection: Randomized, controlled trials that compared a low-molecular-weight heparin preparation with unfractionated heparin for treatment of acute deep venous thrombosis. Data Extraction: Two reviewers extracted data independently. Reviewers evaluated study quality using a validated four-item instrument. Data Synthesis: Eleven of 37 studies met inclusion criteria for three major outcomes. Most studies used proper randomization procedures, but only one was double-blinded. Compared with unfractionated heparin, low-molecular-weight heparins reduced mortality rates over 3 to 6 months of patient follow-up (odds ratio, 0.71 [95% CI, 0.53 to 0.94]; P = 0.02). For major bleeding complications, the odds ratio favored low-molecular-weight heparins (0.57 [CI, 0.33 to 0.99]; P = 0.047), but the absolute risk reduction was small and not statistically significant (0.61% [CI, -0.04% to 1.26%]; P = 0.07). For preventing thromboembolic recurrences, low-molecular-weight heparins seemed as effective as unfractionated heparin (odds ratio, 0.85 [CI, 0.63 to 1.14]; P > 0.2). Conclusions: Low-molecular-weight heparin treatment reduces mortality rates after acute deep venous thrombosis. These drugs seem to be as safe as unfractionated heparin with respect to major bleeding complications and appear to be as effective in preventing thromboembolic recurrences.	Vet Affairs Palo Alto Hlth Care Syst, Pulm & Crit Care Med Sect 111P, Palo Alto, CA 94304 USA; Stanford Univ, Stanford, CA 94305 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Palo Alto Health Care System; Stanford University	Gould, MK (corresponding author), Vet Affairs Palo Alto Hlth Care Syst, Pulm & Crit Care Med Sect 111P, 3801 Miranda Ave, Palo Alto, CA 94304 USA.	gould@stanford.edu	Garber, Alan M/F-1476-2010		AHRQ HHS [HS00028-11] Funding Source: Medline	AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)		ALBADA J, 1989, CIRCULATION, V80, P935, DOI 10.1161/01.CIR.80.4.935; ALHENCGELAS M, 1994, THROMB HAEMOSTASIS, V71, P698; Begg C., 1994, HDB RES SYNTHESIS, P399; BRATT G, 1985, THROMB HAEMOSTASIS, V54, P813; BRATT G, 1990, THROMB HAEMOSTASIS, V64, P506; Bratt G A, 1988, Acta Chir Scand Suppl, V543, P96; Counsell C, 1997, ANN INTERN MED, V127, P380, DOI 10.7326/0003-4819-127-5-199709010-00008; DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2; DUROUX P, 1991, THROMB HAEMOSTASIS, V65, P251; FAIVRE R, 1988, PRESSE MED, V17, P197; FAIVRE R, 1987, THROMB HAEMOSTASIS, V58, P120; Fiessinger JN, 1996, THROMB HAEMOSTASIS, V76, P195; FIESSINGER JN, 1994, HAEMOSTASIS S1, V24, P44; Fishman A., 1996, European Journal of Gynaecological Oncology, V17, P365; FLEISS JL, 1991, J CLIN EPIDEMIOL, V44, P127, DOI 10.1016/0895-4356(91)90261-7; HANDELAND GF, 1990, EUR J CLIN PHARMACOL, V39, P107, DOI 10.1007/BF00280041; HARENBERG J, 1990, THROMB RES, V59, P639, DOI 10.1016/0049-3848(90)90422-9; HEILMANN JJ, 1989, REV MED INTERNE, V10, P375; HOLM HA, 1986, HAEMOSTASIS, V16, P30; HOLMSTROM M, 1992, THROMB RES, V67, P49; HUET Y, 1986, HAEMOSTASIS, V16, P165; HUET Y, 1990, ACTA CHIR SCAND, P116; HULL RD, 1992, NEW ENGL J MED, V326, P975, DOI 10.1056/NEJM199204093261502; JANVIER G, 1987, HAEMOSTASIS, V17, P49; JANVIER G, 1991, HAEMOSTASIS, V21, P161; JEKEL JF, 1997, EPIDEMIOLOGY BIOSTAT, P95; KIRCHMAIER CM, 1994, THROMB RES, V73, P337, DOI 10.1016/0049-3848(94)90029-9; Koopman MMW, 1996, NEW ENGL J MED, V334, P682, DOI 10.1056/NEJM199603143341102; Lau J, 1997, ANN INTERN MED, V127, P820, DOI 10.7326/0003-4819-127-9-199711010-00008; LAU J, 1995, J CLIN EPIDEMIOL, V48, P45, DOI 10.1016/0895-4356(94)00106-Z; Leizorovicz A, 1996, DRUGS, V52, P30, DOI 10.2165/00003495-199600527-00006; LEIZOROVICZ A, 1994, BMJ-BRIT MED J, V309, P299, DOI 10.1136/bmj.309.6950.299; LEIZOROVICZ A, 1997, THROMB HAEMOST S, V290; LENSING AWA, 1995, ARCH INTERN MED, V155, P601, DOI 10.1001/archinte.155.6.601; Levine M, 1996, NEW ENGL J MED, V334, P677, DOI 10.1056/NEJM199603143341101; LINDMARKER P, 1994, THROMB HAEMOSTASIS, V72, P186; Lindmarker P, 1996, J INTERN MED, V240, P395, DOI 10.1046/j.1365-2796.1996.81877000.x; LOCKNER D, 1986, HAEMOSTASIS, V16, P25; LOPACIUK S, 1992, THROMB HAEMOSTASIS, V68, P14; Luomanmaki K, 1996, J INTERN MED, V240, P85, DOI 10.1046/j.1365-2796.1996.18845000.x; LUTTICHAU U, 1989, EUR REV MED PHARMACO, V11, P351; McCullagh P., 1989, GEN LINEAR MODELS, V2nd; Meade MO, 1997, ANN INTERN MED, V127, P531, DOI 10.7326/0003-4819-127-7-199710010-00005; NIEUWENHUIS HK, 1991, BLOOD, V78, P2337, DOI 10.1182/blood.V78.9.2337.2337; Partsch H, 1996, J VASC SURG, V24, P774, DOI 10.1016/S0741-5214(96)70012-5; Passman MA, 1997, J VASC SURG, V25, P39, DOI 10.1016/S0741-5214(97)70319-7; Petitti D, 1994, METAANALYSIS DECISIO; PHILBRICK JT, 1988, ARCH INTERN MED, V148, P2131, DOI 10.1001/archinte.148.10.2131; PINEO G, 1997, THROMB HAEMOST S, V384; PRANDONI P, 1990, HAEMOSTASIS, V20, P220; PRANDONI P, 1992, LANCET, V339, P441, DOI 10.1016/0140-6736(92)91054-C; ROBINS J, 1986, BIOMETRICS, V42, P311, DOI 10.2307/2531052; ROSENTHAL R, 1979, PSYCHOL BULL, V86, P638, DOI 10.1037/0033-2909.86.3.638; SCHULZ KF, 1995, JAMA-J AM MED ASSOC, V273, P408, DOI 10.1001/jama.273.5.408; SIEGBAHN A, 1989, THROMB RES, V55, P767, DOI 10.1016/0049-3848(89)90307-1; Simonneau G, 1997, NEW ENGL J MED, V337, P663, DOI 10.1056/NEJM199709043371002; SIMONNEAU G, 1993, ARCH INTERN MED, V153, P1541, DOI 10.1001/archinte.153.13.1541; Siragusa S, 1996, AM J MED, V100, P269, DOI 10.1016/S0002-9343(97)89484-3; SPIRO TE, 1997, THROMB HAEMOST S, V78, P373; SUAREZ C, 1995, THROMB HAEMOSTASIS, V73, P982; tenCate JW, 1997, NEW ENGL J MED, V337, P657; THERY C, 1992, CIRCULATION, V85, P1380, DOI 10.1161/01.CIR.85.4.1380; VOGEL G, 1987, THROMB HAEMOSTASIS, V58, P120; Weitz JI, 1997, NEW ENGL J MED, V337, P688, DOI 10.1056/NEJM199709043371007; WOLF H, 1991, SEMIN THROMB HEMOST, V17, P343, DOI 10.1055/s-2007-1002632; ZANGHI M, 1988, J INT MED RES, V16, P474, DOI 10.1177/030006058801600610	66	485	499	1	10	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAY 18	1999	130	10					800	+		10.7326/0003-4819-130-10-199905180-00003	http://dx.doi.org/10.7326/0003-4819-130-10-199905180-00003			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	196JJ	10366369				2022-12-28	WOS:000080305000002
J	Easmon, C				Easmon, C			Isolate the problem - Commentary	BRITISH MEDICAL JOURNAL			English	Editorial Material											Easmon, C (corresponding author), 101A Pimlico Rd, London SW1W 8PH, England.								0	5	5	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	APR 24	1999	318	7191					1130	1130						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	193YU	10366260				2022-12-28	WOS:000080166000035
J	Sharpe, N				Sharpe, N			Benefit of beta-blockers for heart failure: proven in 1999	LANCET			English	Editorial Material							MORTALITY; MORBIDITY; TRIALS		Auckland Hosp, Dept Med, Auckland, New Zealand	Auckland City Hospital	Sharpe, N (corresponding author), Auckland Hosp, Dept Med, Private Bag 92019, Auckland, New Zealand.							DOUGHTY RN, 1994, J AM COLL CARDIOL, V23, P814, DOI 10.1016/0735-1097(94)90773-0; Doughty RN, 1997, EUR HEART J, V18, P560; GARG R, 1995, JAMA-J AM MED ASSOC, V273, P1450, DOI 10.1001/jama.273.18.1450; Lechat P, 1999, LANCET, V353, P9; LECHAT P, 1994, CIRCULATION, V90, P1765, DOI 10.1161/01.CIR.90.4.1765; MacMahon S, 1997, LANCET, V349, P375; Packer M, 1996, NEW ENGL J MED, V334, P1349, DOI 10.1056/NEJM199605233342101; Richards AM, 1999, CIRCULATION, V99, P786, DOI 10.1161/01.CIR.99.6.786; Swedberg K, 1999, EUR HEART J, V20, P136, DOI 10.1053/euhj.1998.1098; WAAGSTEIN F, 1993, LANCET, V342, P1441, DOI 10.1016/0140-6736(93)92930-R	10	26	28	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUN 12	1999	353	9169					1988	1989		10.1016/S0140-6736(99)90183-6	http://dx.doi.org/10.1016/S0140-6736(99)90183-6			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	205GD	10376609				2022-12-28	WOS:000080812200004
J	Bermingham, NA; Hassan, BA; Price, SD; Vollrath, MA; Ben-Arie, N; Eatock, RA; Bellen, HJ; Lysakowski, A; Zoghbi, HY				Bermingham, NA; Hassan, BA; Price, SD; Vollrath, MA; Ben-Arie, N; Eatock, RA; Bellen, HJ; Lysakowski, A; Zoghbi, HY			Math1: An essential gene for the generation of inner ear hair cells	SCIENCE			English	Article							TECTORIAL MEMBRANE; PRONEURAL GENE; NERVOUS-SYSTEM; MICE; CALRETININ; DEFECTS	The mammalian inner ear contains the cochlea and vestibular organs, which are responsible for hearing and balance, respectively. The epithelia of these sensory organs contain hair cells that function as mechanoreceptors to transduce sound and head motion. The molecular mechanisms underlying hair cell development and differentiation are poorly understood. Math1, a mouse homolog of the Drosophila proneural gene atonal, is expressed in inner ear sensory epithelia. Embryonic Math1-null mice failed to generate cochlear and vestibular hair cells. This gene is thus required for the genesis of hair cells.	Baylor Coll Med, Howard Hughes Med Inst, Houston, TX 77030 USA; Baylor Coll Med, Dept Mol & Human Genet, Houston, TX 77030 USA; Baylor Coll Med, Dept Pediat, Houston, TX 77030 USA; Baylor Coll Med, Dev Biol Program, Houston, TX 77030 USA; Baylor Coll Med, Div Neurosci, Houston, TX 77030 USA; Baylor Coll Med, Bobby R Alford Dept Otorhinolaryngol & Commun Sci, Houston, TX 77030 USA; Univ Illinois, Dept Anat & Cell Biol, Chicago, IL 60612 USA	Baylor College of Medicine; Howard Hughes Medical Institute; Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Zoghbi, HY (corresponding author), Baylor Coll Med, Howard Hughes Med Inst, Houston, TX 77030 USA.		Ben-Arie, Nissim/K-4997-2012; Hassan, Bassem A/D-5221-2012; Eatock, Ruth A/F-6404-2013; Lysakowski, Anna/F-9534-2010	Hassan, Bassem A/0000-0001-9533-4908; Lysakowski, Anna/0000-0001-6259-0294; Zoghbi, Huda/0000-0002-0700-3349; Eatock, Ruth Anne/0000-0001-7547-2051; Bellen, Hugo/0000-0001-5992-5989	NIDCD NIH HHS [R01 DC002290] Funding Source: Medline; NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS [R01DC002290] Funding Source: NIH RePORTER	NIDCD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD)); NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD))		Adam J, 1998, DEVELOPMENT, V125, P4645; AKAZAWA C, 1995, J BIOL CHEM, V270, P8730, DOI 10.1074/jbc.270.15.8730; BenArie N, 1997, NATURE, V390, P169, DOI 10.1038/36579; BenArie N, 1996, HUM MOL GENET, V5, P1207, DOI 10.1093/hmg/5.9.1207; BENARIE N, UNPUB; BERMINGHAM NA, UNPUB; COHEN GM, 1985, HEARING RES, V18, P29, DOI 10.1016/0378-5955(85)90108-X; DECHESNE CJ, 1994, J COMP NEUROL, V346, P517, DOI 10.1002/cne.903460405; EBERL D, COMMUNICATION; Fekete DM, 1998, J NEUROSCI, V18, P7811; FRIEDRICH G, 1991, GENE DEV, V5, P1513, DOI 10.1101/gad.5.9.1513; Haddon C, 1998, DEVELOPMENT, V125, P4637; HASSAN B, UNPUB; Hasson T, 1997, J CELL BIOL, V137, P1287, DOI 10.1083/jcb.137.6.1287; JARMAN AP, 1993, CELL, V73, P1307, DOI 10.1016/0092-8674(93)90358-W; Kim P, 1997, DEV BIOL, V187, P1, DOI 10.1006/dbio.1997.8572; Lanford PJ, 1999, NAT GENET, V21, P289, DOI 10.1038/6804; LO JC, 1991, GENE DEV, V5, P1524; Lysakowski A, 1997, J COMP NEUROL, V389, P419, DOI 10.1002/(SICI)1096-9861(19971222)389:3<419::AID-CNE5>3.0.CO;2-3; MANSOUR SL, 1993, DEVELOPMENT, V117, P13; Ruben R.J., 1967, ACTA OTO-LARYNGOL, DOI DOI 10.3109/00016486709127790; Rusch A, 1998, J NEUROSCI, V18, P7487; SHIEL MJ, 1990, HEARING RES, V47, P147, DOI 10.1016/0378-5955(90)90172-L; Torres MA, 1996, DEVELOPMENT, V122, P3381; Wang WD, 1998, DEVELOPMENT, V125, P621; WEINTRAUB H, 1991, SCIENCE, V251, P761, DOI 10.1126/science.1846704; Xiang MQ, 1997, P NATL ACAD SCI USA, V94, P9445, DOI 10.1073/pnas.94.17.9445; Xiang MQ, 1998, DEVELOPMENT, V125, P3935; Zheng JL, 1997, J NEUROSCI, V17, P8270	29	816	878	3	54	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 11	1999	284	5421					1837	1841		10.1126/science.284.5421.1837	http://dx.doi.org/10.1126/science.284.5421.1837			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	205EU	10364557				2022-12-28	WOS:000080809000051
J	Klausmeier, CA				Klausmeier, CA			Regular and irregular patterns in semiarid vegetation	SCIENCE			English	Article							MODEL	Vegetation in many semiarid regions is strikingly patterned, forming regular stripes on hillsides and irregular mosaics on fiat ground. A simple model of plant and water dynamics based on ecologically realistic assumptions and with reasonable parameter values captures both of these types of patterns. The regular patterns result from a Turing-like instability; the irregular patterns arise when the ecological dynamics amplify slight small-scale topographic variability. Because of the close agreement between observations and these theoretical results, this system provides a clear example of how nonlinear mechanisms can be important in determining the spatial structure of plant communities.	Univ Minnesota, Dept Ecol Evolut & Behav, St Paul, MN 55108 USA	University of Minnesota System; University of Minnesota Twin Cities	Klausmeier, CA (corresponding author), Univ Minnesota, Dept Ecol Evolut & Behav, St Paul, MN 55108 USA.	klaus@biosci.umn.edu	Klausmeier, Christopher A/J-9339-2012	Klausmeier, Christopher/0000-0002-6987-5871				[Anonymous], LANDSCAPE ECOLOGY FU; BELSKY AJ, 1986, J ECOL, V74, P841, DOI 10.2307/2260402; CROSS MC, 1993, REV MOD PHYS, V65, P850; GREIGSMITH P, 1979, J ECOL, V67, P755, DOI 10.2307/2259213; HEMMING CF, 1965, J ECOL, V53, P57, DOI 10.2307/2257565; JORNE J, 1974, J THEOR BIOL, V43, P375, DOI 10.1016/S0022-5193(74)80067-6; Lefever R, 1997, B MATH BIOL, V59, P263, DOI 10.1007/BF02462004; MABBUTT JA, 1987, J ARID ENVIRON, V12, P41; Maron JL, 1997, SCIENCE, V278, P1619, DOI 10.1126/science.278.5343.1619; MAUCHAMP A, 1994, ECOL MODEL, V71, P107, DOI 10.1016/0304-3800(94)90078-7; MAY RM, 1994, FRONTIERS MATH BIOL, P326; MONTANA C, 1990, J ECOL, V78, P789, DOI 10.2307/2260899; Murray J. D., 1989, MATH BIOL, DOI DOI 10.1007/978-3-662-08539-4; Okubo A., 1980, DIFFUSION ECOLOGICAL; Rietkerk M, 1997, OIKOS, V79, P69, DOI 10.2307/3546091; SEGEL LA, 1972, J THEOR BIOL, V37, P545, DOI 10.1016/0022-5193(72)90090-2; Steinberg E.K., 1997, SPATIAL ECOLOGY ROLE, P318; THIERY JM, 1995, J ECOL, V83, P497, DOI 10.2307/2261602; Turchin P, 1998, ENVIRONM INTELL UNIT, P199; TURING AM, 1952, PHILOS T ROY SOC B, V237, P37, DOI 10.1098/rstb.1952.0012; WATT AS, 1947, J ECOL, V35, P1, DOI 10.2307/2256497; WHITE LP, 1970, J ECOL, V58, P549, DOI 10.2307/2258290; WHITE LP, 1971, J ECOL, V59, P615, DOI 10.2307/2258335; WICKENS GE, 1971, GEODERMA, V6, P43, DOI 10.1016/0016-7061(71)90050-4; WORRALL GA, 1959, J SOIL SCI, V10, P34, DOI 10.1111/j.1365-2389.1959.tb00664.x	25	581	604	10	134	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 11	1999	284	5421					1826	1828		10.1126/science.284.5421.1826	http://dx.doi.org/10.1126/science.284.5421.1826			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	205EU	10364553				2022-12-28	WOS:000080809000047
J	Jacob, J; Baltimore, D				Jacob, J; Baltimore, D			Modelling T-cell memory by genetic marking of memory T cells in vivo	NATURE			English	Article							LYMPHOCYTES-T; IMMUNOLOGICAL MEMORY; GERMINAL-CENTERS; VIRUS-INFECTION; ANTIGEN; PERSISTENCE; EXPRESSION; REGION; CD2	Immunological memory is the ability of the immune system to respond with enhanced vigour to pathogens that have been encountered in the past. Following infection or immunization, most effector T cells undergo apoptotic cell death, but a small fraction of these cells, proportional to the early antigen load and initial clonal burst size(1), persist in the host as a stable pool of memory T cells(2-7). The existence of immunological memory has been recognized for over 2,000 years, but our understanding of this phenomenon is limited, primarily because memory lymphocytes cannot be unequivocally identified as they lack specific, permanent markers. Here we have developed a transgenic mouse model system whereby memory T cells and their precursors can be irreversibly marked with a reporter gene and thus can be unambiguously identified. Adoptive transfer of marked CD8(+) T cells specific for lymphocytic choriomeningitis virus protected naive recipients following viral challenge, demonstrating that we have marked memory T cells. We also show that cytotoxic effector lymphocytes that develop into memory T cells can be identified in the primary response.	MIT, Dept Biol, Cambridge, MA 02139 USA	Massachusetts Institute of Technology (MIT)	Baltimore, D (corresponding author), MIT, Dept Biol, 77 Massachusetts Ave, Cambridge, MA 02139 USA.							Ahmed R, 1996, SCIENCE, V272, P54, DOI 10.1126/science.272.5258.54; AHMED R, 1984, J EXP MED, V160, P521, DOI 10.1084/jem.160.2.521; AHMED R, 1984, J VIROL, V51, P34, DOI 10.1128/JVI.51.1.34-41.1984; Butz EA, 1998, IMMUNITY, V8, P167, DOI 10.1016/S1074-7613(00)80469-0; Castan J, 1997, IMMUNOLOGY, V90, P265, DOI 10.1046/j.1365-2567.1997.00162.x; CEPKO C, 1995, METHOD ENZYMOL, V254, P387; Doherty PC, 1996, IMMUNOL REV, V150, P23, DOI 10.1111/j.1600-065X.1996.tb00694.x; FULLER KA, 1993, J IMMUNOL, V151, P4505; GulbransonJudge A, 1996, EUR J IMMUNOL, V26, P1830, DOI 10.1002/eji.1830260825; HANSON RD, 1991, J BIOL CHEM, V266, P24433; HOU S, 1994, NATURE, V369, P652, DOI 10.1038/369652a0; JAMIESON BD, 1989, J EXP MED, V169, P1993, DOI 10.1084/jem.169.6.1993; Kundig TM, 1996, IMMUNOL REV, V150, P63, DOI 10.1111/j.1600-065X.1996.tb00696.x; LASKO M, 1992, P NATL ACAD SCI USA, V89, P6232; LAU LL, 1994, NATURE, V369, P648, DOI 10.1038/369648a0; Mullbacher A, 1996, IMMUNOL REV, V150, P113, DOI 10.1111/j.1600-065X.1996.tb00698.x; Murali-Krishna K, 1998, IMMUNITY, V8, P177, DOI 10.1016/S1074-7613(00)80470-7; Nagy A, 1998, CURR BIOL, V8, P661, DOI 10.1016/S0960-9822(98)70254-4; NAHILL SR, 1993, J EXP MED, V177, P317, DOI 10.1084/jem.177.2.317; SELIN LK, 1994, J EXP MED, V179, P1933, DOI 10.1084/jem.179.6.1933; Swain SL, 1996, IMMUNOL REV, V150, P143, DOI 10.1111/j.1600-065X.1996.tb00700.x; TOUGH DF, 1995, IMMUNOL RES, V14, P1, DOI 10.1007/BF02918494; Welsh RM, 1997, IMMUNOL REV, V159, P79, DOI 10.1111/j.1600-065X.1997.tb01008.x; WILLIAMS AF, 1987, J EXP MED, V165, P368, DOI 10.1084/jem.165.2.368; WOTTON D, 1989, P NATL ACAD SCI USA, V86, P4195, DOI 10.1073/pnas.86.11.4195; YANG HY, 1989, J IMMUNOL, V142, P1710; Zheng B, 1996, NATURE, V384, P263, DOI 10.1038/384263a0; ZHUMABEKOV T, 1991, J BIOL CHEM, V266, P24433; Zimmermann C, 1996, J EXP MED, V183, P1367, DOI 10.1084/jem.183.4.1367; Zinkernagel RM, 1996, ANNU REV IMMUNOL, V14, P333, DOI 10.1146/annurev.immunol.14.1.333	30	235	239	0	9	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUN 10	1999	399	6736					593	597		10.1038/21208	http://dx.doi.org/10.1038/21208			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	204RR	10376601				2022-12-28	WOS:000080778400058
J	Nicoleau, A; Nicoleau, CA				Nicoleau, A; Nicoleau, CA			Hereditary hemorrhagic telangiectasia (Osler-Weber-Rendu disease)	NEW ENGLAND JOURNAL OF MEDICINE			English	Article									New York Hosp, Queens Med Ctr, Flushing, NY 11355 USA	NewYork-Presbyterian Hospital	Nicoleau, A (corresponding author), New York Hosp, Queens Med Ctr, Flushing, NY 11355 USA.								0	2	2	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 10	1999	340	23					1800	1800		10.1056/NEJM199906103402305	http://dx.doi.org/10.1056/NEJM199906103402305			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	203UU	10362824				2022-12-28	WOS:000080726800005
J	Aronson, J				Aronson, J			When I use a word ... X marks the spot	BRITISH MEDICAL JOURNAL			English	Article																			0	2	2	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JUN 5	1999	318	7197					1543	1543		10.1136/bmj.318.7197.1543	http://dx.doi.org/10.1136/bmj.318.7197.1543			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	204HC	10356015	Green Published			2022-12-28	WOS:000080757300033
J	Banerjee, AK				Banerjee, AK			Sexual dysfunction after surgery for rectal cancer	LANCET			English	Editorial Material							PRESERVATION; OPERATION; CARCINOMA; EXCISION		Royal Halifax Infirm, Dept Surg, Halifax HX1 2YP, England		Banerjee, AK (corresponding author), Royal Halifax Infirm, Dept Surg, Halifax HX1 2YP, England.							BALSLEV I, 1983, DIS COLON RECTUM, V26, P785, DOI 10.1007/BF02554748; Dahlberg M, 1998, DIS COLON RECTUM, V41, P543, DOI 10.1007/BF02235256; DANZI M, 1983, DIS COLON RECTUM, V26, P665, DOI 10.1007/BF02553339; HEALD RJ, 1986, LANCET, V1, P1479; HOJO K, 1991, DIS COLON RECTUM, V34, P532, DOI 10.1007/BF02049890; LAMONICA G, 1985, DIS COLON RECTUM, V28, P937; LEVECKIS J, 1995, BRIT J UROL, V76, P752, DOI 10.1111/j.1464-410X.1995.tb00768.x; Maas CP, 1998, BRIT J SURG, V85, P92; Masui H, 1996, DIS COLON RECTUM, V39, P1140, DOI 10.1007/BF02081416; Ooi BS, 1999, DIS COLON RECTUM, V42, P403, DOI 10.1007/BF02236362; Sugihara K, 1996, CANCER-AM CANCER SOC, V78, P1871, DOI 10.1002/(SICI)1097-0142(19961101)78:9<1871::AID-CNCR5>3.3.CO;2-9; WALSH PC, 1988, ANN SURG, V208, P391, DOI 10.1097/00000658-198810000-00001; WILLIAMS NS, 1983, BRIT J SURG, V70, P460, DOI 10.1002/bjs.1800700805	13	46	47	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUN 5	1999	353	9168					1900	1902		10.1016/S0140-6736(99)00127-0	http://dx.doi.org/10.1016/S0140-6736(99)00127-0			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	202TP	10371565				2022-12-28	WOS:000080668500006
J	Feder, G; Griffiths, C; Eldridge, S; Spence, M				Feder, G; Griffiths, C; Eldridge, S; Spence, M			Effect of postal prompts to patients and general practitioners on the quality of primary care after a coronary event (POST): randomised controlled trial	BRITISH MEDICAL JOURNAL			English	Article							ACUTE MYOCARDIAL-INFARCTION; SECONDARY PREVENTION; HEART-DISEASE; INTERVENTIONS; GUIDELINES	Objectives To determine whether postal prompts to patients who have Survived an acute coronary event and to their general practitioners improve secondary prevention of coronary heart disease. Design Randomised controlled trial. Setting 52 general practices in east London, 44 of which had received facilitation of local guidelines for coronary heart disease. Participants 328 patients admitted to hospital for myocardial infarctionor unstable angina. Interventions Postal prompts sent 2 weeks and 3 months after discharge from hospital. The prompts contained recommendations for lowering the risk of another coronary event, including changes to lifestyle, drug treatment, and making an appointment to discuss these issues with the general practitioner or practice nurse. Main outcome measures Proportion of patients: in whom serum cholesterol concentrations were measured; proportion of patients prescribed beta blockers (6 months after discharge); and proportion of patients prescribed cholesterol lowering drugs (1 year after discharge). Results Prescribing of beta bockers (odds ratio 1.7, 95% confidence interval 0.8 to 3.0, P > 0.05) and cholesterol lowering drugs (1.7., 0.8 to 3.4, P > 0.05) did not differ between intervention and control groups: A higher proportion of patients in the intervention group (64%) than in the control group (38%) had their serum cholesterol concentrations measured (2.9, 1.5 to 5.5, P < 0.001). Secondary outcomes were significantly improved for consultations for coronary heart disease, the recording of risk factors, and advice given. There were no significant differences in patients' self reported changes to lifestyle: or to the belief that it is possible to modify the risk of another coronary event Conclusions,Postal prompts to patients who had had acute coronary events and to their general practitioners in a locality where guidelines for coronary heart disease had been disseminated did not improve prescribing of effective drugs for secondary prevention or self reported changes to lifestyle. The prompts did increase consultation,rates related to. 1 coronary heart disease and the recording of risk factors in the practices. Effective secondary prevention of coronary heart disease requires more than postal prompts and the dissemination of guidelines.	Univ London Queen Mary & Westfield Coll, St Bartholomews & Royal London Hosp Med Sch, Dept Gen Practice & Primary Care, London E1 4NS, England; St Bartholomews & Royal London Hosp Med Sch, Wilfson Inst, Dept Med Stat, London EC1M 6BQ, England	Barts Health NHS Trust; Royal London Hospital; University of London; Queen Mary University London; Barts Health NHS Trust; Royal London Hospital; University of London; Queen Mary University London	Feder, G (corresponding author), Univ London Queen Mary & Westfield Coll, St Bartholomews & Royal London Hosp Med Sch, Dept Gen Practice & Primary Care, Mile End Rd, London E1 4NS, England.			Feder, Gene/0000-0002-7890-3926				[Anonymous], 1994, EFF HLTH CAR B; Baxter C, 1998, BMJ-BRIT MED J, V317, P1134; Bradley F, 1997, FAM PRACT, V14, P220, DOI 10.1093/fampra/14.3.220; CAMBELL NC, 1998, BRIT MED J, V316, P1430; Campbell NC, 1998, HEART, V80, P447, DOI 10.1136/hrt.80.5.447; COHEN M, 1994, CIRCULATION, V89, P81, DOI 10.1161/01.CIR.89.1.81; DAVIS DA, 1995, JAMA-J AM MED ASSOC, V274, P700; DONNER A, 1994, AM J EPIDEMIOL, V140, P279, DOI 10.1093/oxfordjournals.aje.a117247; DOVEY S, 1998, EUR J GEN PRACT, V4, P6; FEDER G, 1995, BRIT MED J, V311, P1473, DOI 10.1136/bmj.311.7018.1473; FEDER G, 1997, INFARCT VIEWS E LOND; FREEMANTLE N, 1998, COCHRANE COLLABORATI; Jolly K, 1999, BMJ-BRIT MED J, V318, P706; Lim LLY, 1997, CARDIOLOGY, V88, P460, DOI 10.1159/000177377; MANDELBLATT J, 1995, J FAM PRACTICE, V40, P162; Mehta RH, 1998, BMJ-BRIT MED J, V316, P838, DOI 10.1136/bmj.316.7134.838; Moher D, 1998, LANCET, V352, P609, DOI 10.1016/S0140-6736(98)01085-X; Moher M., 1995, EVIDENCE EFFECTIVENE; MOTT SF, 1998, J CLIN EFFECT, V3, P1; Treasure T, 1998, BRIT MED J, V317, P362; van der Weijden T, 1998, BMJ-BRIT MED J, V316, P1400, DOI 10.1136/bmj.316.7142.1400; Wensing M, 1998, BRIT J GEN PRACT, V48, P991	22	82	83	0	4	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JUN 5	1999	318	7197					1522	1526		10.1136/bmj.318.7197.1522	http://dx.doi.org/10.1136/bmj.318.7197.1522			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	204HC	10356008	Bronze, Green Submitted, Green Published			2022-12-28	WOS:000080757300026
J	Crabbe, JC; Wahlsten, D; Dudek, BC				Crabbe, JC; Wahlsten, D; Dudek, BC			Genetics of mouse behavior: Interactions with laboratory environment	SCIENCE			English	Article							INBRED STRAINS; MICE; ETHANOL; SENSITIVITY; RECEPTOR; TRAIT	Strains of mice;that:show characteristic patterns of behavior are critical for research in neurobehavioral genetics. Possible confounding influences of the Laboratory environment were studied in several inbred strains and one null mutant by:simultaneous testing in three Laboratories on a battery of six behaviors. Apparatus, test protocols, and many environmental variables were rigorously equated. Strains differed markedly in all behaviors, and despite standardization, there were systematic differences in behavior across Labs. For some tests, the magnitude of genetic differences depended upon the specific testing Lab.. Thus, experiments characterizing mutants may yield results that are idiosyncratic to a particular Laboratory.	Vet Affairs Med Ctr, Portland Alcohol Res Ctr, Portland, OR 97201 USA; Oregon Hlth Sci Univ, Dept Behav Neurosci, Portland, OR 97201 USA; Univ Alberta, Dept Psychol, Edmonton, AB T6G 2E9, Canada; SUNY Albany, Dept Psychol, Albany, NY 12222 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); Oregon Health & Science University; University of Alberta; State University of New York (SUNY) System; State University of New York (SUNY) Albany	Crabbe, JC (corresponding author), Vet Affairs Med Ctr, Portland Alcohol Res Ctr, Portland, OR 97201 USA.				NIAAA NIH HHS [AA10760, P60 AA010760, AA00170] Funding Source: Medline; NIDA NIH HHS [DA10731] Funding Source: Medline; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [P60AA010760, P50AA010760] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [R01DA010731] Funding Source: NIH RePORTER	NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)		BELKNAP JK, 1993, PSYCHOPHARMACOLOGY, V112, P503, DOI 10.1007/BF02244901; Cohen J, 1988, STAT POWER ANAL SOCI, V2nd; CRABBE JC, 1982, J COMP PHYSIOL PSYCH, V96, P440, DOI 10.1037/h0077898; DUDEK BC, 1990, PSYCHOPHARMACOLOGY, V101, P93, DOI 10.1007/BF02253724; FLINT J, 1995, SCIENCE, V269, P1432, DOI 10.1126/science.7660127; Gerlai R, 1996, TRENDS NEUROSCI, V19, P177, DOI 10.1016/S0166-2236(96)20020-7; LASALLE JM, 1992, TECHNIQUES GENETIC A, P391; MCCLEARN GE, 1959, Q J STUD ALCOHOL, V20, P691; MITCHELL SA, UNPUB; Nguyen MT, 1997, NATURE, V390, P78, DOI 10.1038/36342; RODRIGUEZ LA, 1995, ALCOHOL CLIN EXP RES, V19, P367, DOI 10.1111/j.1530-0277.1995.tb01517.x; SIBILIA M, 1995, SCIENCE, V269, P234, DOI 10.1126/science.7618085; Simpson EM, 1997, NAT GENET, V16, P19, DOI 10.1038/ng0597-19; Threadgill DW, 1997, MAMM GENOME, V8, P390, DOI 10.1007/s003359900453; WAHLSTEN D, 1990, BEHAV BRAIN SCI, V13, P109, DOI 10.1017/S0140525X00077797; WAHLSTEN D, 1978, PSYCHOPHARMACOLOGY A, P63	16	1239	1266	5	101	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 4	1999	284	5420					1670	1672		10.1126/science.284.5420.1670	http://dx.doi.org/10.1126/science.284.5420.1670			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	202TM	10356397				2022-12-28	WOS:000080668300045
J	Harris, SF; Botchan, MR				Harris, SF; Botchan, MR			Crystal structure of the human papillomavirus type 18 E2 activation domain	SCIENCE			English	Article							DNA-BINDING DOMAIN; BOVINE PAPILLOMAVIRUS; TRANSACTIVATION DOMAIN; TRANSCRIPTIONAL ACTIVATION; FUNCTIONAL INTERACTION; GENETIC-ANALYSIS; IN-VITRO; REPLICATION; PROTEIN; E1	The papillomavirus E2 protein regulates viral transcription and DNA replication through interactions with cellular and viral proteins. The amino-terminal activation domain, which represents a protein class whose structural themes are poorly understood, contains key residues that mediate these functional contacts, The crystal structure of a protease-resistant core of the human papillomavirus type 18 E2 activation domain reveals a novel fold creating a cashew-shaped form with a glutamine-rich alpha helix packed against a beta-sheet framework. The protein surface shows extensive overlap of determinants for replication and transcription. The structure broadens the concept of activators to include proteins with potentially malleable, but certainly ordered, structures.	Univ Calif Berkeley, Dept Mol & Cell Biol, Berkeley, CA 94720 USA	University of California System; University of California Berkeley	Botchan, MR (corresponding author), Univ Calif Berkeley, Dept Mol & Cell Biol, 229 Stanley Hall, Berkeley, CA 94720 USA.				NATIONAL CANCER INSTITUTE [R01CA042414, R37CA030490, R01CA030490] Funding Source: NIH RePORTER; NCI NIH HHS [CA42414, CA30490] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABROI A, 1992, P NATL ACAD SCI USA, V70, P6169; [Anonymous], 1994, ACTA CRYSTALLOGR D, V50, P760; Benson JD, 1997, J VIROL, V71, P8041, DOI 10.1128/JVI.71.10.8041-8047.1997; BOSCH FX, 1995, JNCI-J NATL CANCER I, V87, P796, DOI 10.1093/jnci/87.11.796; Breiding DE, 1997, MOL CELL BIOL, V17, P7208, DOI 10.1128/MCB.17.12.7208; Breiding DE, 1996, VIROLOGY, V221, P34, DOI 10.1006/viro.1996.0350; Brokaw JL, 1996, J VIROL, V70, P23, DOI 10.1128/JVI.70.1.23-29.1996; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; CHIANG CM, 1992, P NATL ACAD SCI USA, V89, P5799, DOI 10.1073/pnas.89.13.5799; Cho HS, 1996, PROTEIN SCI, V5, P262; Cowtan KD, 1996, ACTA CRYSTALLOGR D, V52, P43, DOI 10.1107/S090744499500761X; DELAFORTELLE E, CRYSTALLOGRAPHIC COM, V7; FERGUSON MAJ, UNPUB; Ferguson MK, 1996, J VIROL, V70, P4193, DOI 10.1128/JVI.70.7.4193-4199.1996; Fouts ET, 1999, J BIOL CHEM, V274, P4447, DOI 10.1074/jbc.274.7.4447; FRANKEL AD, 1991, CELL, V65, P717, DOI 10.1016/0092-8674(91)90378-C; FRATTINI MG, 1994, VIROLOGY, V204, P799, DOI 10.1006/viro.1994.1596; Harris S. E., UNPUB; HEGDE RS, 1992, NATURE, V359, P505, DOI 10.1038/359505a0; Hegde RS, 1998, J MOL BIOL, V284, P1479, DOI 10.1006/jmbi.1998.2260; HENDRICKSON WA, 1991, SCIENCE, V254, P51, DOI 10.1126/science.1925561; HOLM L, 1993, J MOL BIOL, V233, P123, DOI 10.1006/jmbi.1993.1489; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kasukawa H, 1998, J VIROL, V72, P8166, DOI 10.1128/JVI.72.10.8166-8173.1998; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Kussie PH, 1996, SCIENCE, V274, P948, DOI 10.1126/science.274.5289.948; Lehman CW, 1998, P NATL ACAD SCI USA, V95, P4338, DOI 10.1073/pnas.95.8.4338; Leslie AGW, 1990, CRYSTALLOGRAPHIC COM; LI R, 1991, CELL, V65, P493, DOI 10.1016/0092-8674(91)90467-D; Liang H, 1996, BIOCHEMISTRY-US, V35, P2095, DOI 10.1021/bi951932w; LU JZJ, 1993, J VIROL, V67, P7131, DOI 10.1128/JVI.67.12.7131-7139.1993; LUSKY M, 1991, P NATL ACAD SCI USA, V88, P6363, DOI 10.1073/pnas.88.14.6363; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; MOHR IJ, 1990, SCIENCE, V250, P1694, DOI 10.1126/science.2176744; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Ptashne M, 1997, NATURE, V386, P569, DOI 10.1038/386569a0; Radhakrishnan I, 1997, CELL, V91, P741, DOI 10.1016/S0092-8674(00)80463-8; RANK NM, 1995, J VIROL, V69, P6323, DOI 10.1128/JVI.69.10.6323-6334.1995; Remm M, 1999, J VIROL, V73, P3062, DOI 10.1128/JVI.73.4.3062-3070.1999; Sakai H, 1996, J VIROL, V70, P1602, DOI 10.1128/JVI.70.3.1602-1611.1996; Sedman J, 1995, EMBO J, V14, P6218, DOI 10.1002/j.1460-2075.1995.tb00312.x; Sedman T, 1997, J VIROL, V71, P2887, DOI 10.1128/JVI.71.4.2887-2896.1997; SEO YS, 1993, P NATL ACAD SCI USA, V90, P702, DOI 10.1073/pnas.90.2.702; Skiadopoulos MH, 1998, J VIROL, V72, P2079, DOI 10.1128/JVI.72.3.2079-2088.1998; SPALHOLZ BA, 1991, J VIROL, V65, P743, DOI 10.1128/JVI.65.2.743-753.1991; Stubenrauch F, 1998, J VIROL, V72, P8115, DOI 10.1128/JVI.72.10.8115-8123.1998; Terwilliger TC, 1997, ACTA CRYSTALLOGR D, V53, P571, DOI 10.1107/S0907444997005398; Uesugi M, 1997, SCIENCE, V277, P1310, DOI 10.1126/science.277.5330.1310; WANG BC, 1985, METHOD ENZYMOL, V115, P90; YANG L, 1991, NATURE, V353, P628, DOI 10.1038/353628a0; Yao JM, 1998, J VIROL, V72, P1013, DOI 10.1128/JVI.72.2.1013-1019.1998; Zou NX, 1998, J VIROL, V72, P3436, DOI 10.1128/JVI.72.4.3436-3441.1998	52	57	61	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 4	1999	284	5420					1673	1677		10.1126/science.284.5420.1673	http://dx.doi.org/10.1126/science.284.5420.1673			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	202TM	10356398				2022-12-28	WOS:000080668300046
J	West, GB; Brown, JH; Enquist, BJ				West, GB; Brown, JH; Enquist, BJ			The fourth dimension of life: Fractal geometry and allometric scaling of organisms	SCIENCE			English	Article							BIOLOGY	Fractal-like networks effectively endow Life with an additional fourth spatial dimension. This is the origin of quarter-power scaling that is so pervasive in biology, Organisms have evolved hierarchical branching networks that terminate in size-invariant units, such as capillaries, Leaves, mitochondria, and oxidase molecules. Natural selection has tended to maximize both metabolic capacity, by maximizing the scaling of exchange surface areas, and internal efficiency, by minimizing the scaling of transport distances and times. These design principles are independent of detailed dynamics and explicit models and should apply to virtually all organisms.	Los Alamos Natl Lab, Div Theoret, Los Alamos, NM 87545 USA; Santa Fe Inst, Santa Fe, NM 87501 USA; Univ New Mexico, Dept Biol, Albuquerque, NM 87131 USA	United States Department of Energy (DOE); Los Alamos National Laboratory; The Santa Fe Institute; University of New Mexico	West, GB (corresponding author), Los Alamos Natl Lab, Div Theoret, MS B285, Los Alamos, NM 87545 USA.	gbw@lanl.gov	Enquist, Brian J/B-6436-2008	Enquist, Brian J/0000-0002-6124-7096				BLUM JJ, 1977, J THEOR BIOL, V64, P599, DOI 10.1016/0022-5193(77)90292-2; BROWN JH, IN PRESS SCALING BIO; Calder WA., 1984, SIZE FUNCTION LIFE H; HAINSWORTH FR, ANIMAL PHYSL ADAPTAT, P170; MANDELBROT BB, 1977, FRACTAL GEOEMTRY NAT; Niklas K.J., 1994, PLANT ALLOMETRY SCAL; Portner HO, 2008, SCIENCE, V322, P690, DOI 10.1126/science.1163156; Rubner M., 1883, Z BIOL, V19, P535; TAKAYASU H, 1992, FRACTALS PHYSICAL SC; Turcotte DL, 1998, J THEOR BIOL, V193, P577, DOI 10.1006/jtbi.1998.0723; West GB, 1997, SCIENCE, V276, P122, DOI 10.1126/science.276.5309.122; WEST GB, SCALING BIOL	12	1147	1207	12	318	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 4	1999	284	5420					1677	1679		10.1126/science.284.5420.1677	http://dx.doi.org/10.1126/science.284.5420.1677			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	202TM	10356399				2022-12-28	WOS:000080668300047
J	Cohn, MJ; Tickle, C				Cohn, MJ; Tickle, C			Developmental basis of limblessness and axial patterning in snakes	NATURE			English	Article							CHICK LIMB BUD; APICAL ECTODERMAL RIDGE; SONIC-HEDGEHOG; VERTEBRATE LIMB; HOMEOBOX GENE; FEEDBACK LOOP; MOUSE EMBRYOS; EXPRESSION; GROWTH; EVOLUTION	The evolution of snakes involved major changes in vertebrate body plan organization, but the developmental basis of those changes is unknown. The python axial skeleton consists of hundreds of similar vertebrae, forelimbs are absent and hindlimbs are severely reduced, Combined limb loss and trunk elongation is found in many vertebrate taxa(1), suggesting that these changes may be linked by a common developmental mechanism. Here we show that Hox gene expression domains are expanded along the body axis in python embryos, and that this can account for both the absence of forelimbs and the expansion of thoracic identity in the axial skeleton, Hindlimb buds are initiated, but apical-ridge and polarizing-region signalling pathways that are normally required for limb development: are not activated, Leg bud outgrowth and signalling by Sonic hedgehog in pythons can be rescued by application of fibroblast growth factor or by recombination with chick apical ridge. The failure to activate these signalling pathways during normal python development may also stem from changes in Hox gene expression that occurred early in snake evolution.	Univ Reading, Sch Anim & Microbial Sci, Div Zool, Reading RG6 6AJ, Berks, England; Univ Dundee, Dept Anat & Physiol, Dundee DD1 5EH, Scotland; UCL, Dept Anat & Dev Biol, London WC1E 6BT, England	University of Reading; University of Dundee; University of London; University College London	Cohn, MJ (corresponding author), Univ Reading, Sch Anim & Microbial Sci, Div Zool, Reading RG6 6AJ, Berks, England.	M.J.Cohn@reading.ac.uk						Altabef M, 1997, DEVELOPMENT, V124, P4547; BURKE AC, 1995, DEVELOPMENT, V121, P333; Carroll RL, 1988, VERTEBRATE PALEONTOL; CHARITE J, 1994, CELL, V78, P589, DOI 10.1016/0092-8674(94)90524-X; Chiang C, 1996, NATURE, V383, P407, DOI 10.1038/383407a0; Cohn MJ, 1997, NATURE, V387, P97, DOI 10.1038/387097a0; DAVIDSON DR, 1991, NATURE, V352, P429, DOI 10.1038/352429a0; DAVIS CA, 1991, DEVELOPMENT, V111, P287; Fang H, 1996, DEV BIOL, V179, P160, DOI 10.1006/dbio.1996.0248; FERRARI D, 1995, MECH DEVELOP, V52, P257, DOI 10.1016/0925-4773(95)98113-O; Gasc JP, 1966, B MUS NATION HISTOIR, V38, P99; GAUNT SJ, 1994, INT J DEV BIOL, V38, P549; GEDUSPAN JS, 1989, ANAT REC, V224, P79, DOI 10.1002/ar.1092240110; LAUFER E, 1994, CELL, V79, P993, DOI 10.1016/0092-8674(94)90030-2; Lee MSY, 1998, PHILOS T ROY SOC B, V353, P1521, DOI 10.1098/rstb.1998.0308; Marigo V, 1996, DEVELOPMENT, V122, P1225; MARTI E, 1995, DEVELOPMENT, V121, P2537; Nelson CE, 1996, DEVELOPMENT, V122, P1449; NISWANDER L, 1994, NATURE, V371, P609, DOI 10.1038/371609a0; OLIVER G, 1988, EMBO J, V7, P3199, DOI 10.1002/j.1460-2075.1988.tb03187.x; OLIVER G, 1990, EMBO J, V9, P3093, DOI 10.1002/j.1460-2075.1990.tb07506.x; PANGANIBAN G, 1995, SCIENCE, V270, P1363, DOI 10.1126/science.270.5240.1363; RANCOURT DE, 1995, GENE DEV, V9, P108, DOI 10.1101/gad.9.1.108; RAYNAUD A, 1995, CR ACAD SCI III-VIE, V318, P573; RIDDLE RD, 1995, CELL, V83, P631, DOI 10.1016/0092-8674(95)90103-5; SAUNDERS JW, 1948, J EXP ZOOL, V108, P363, DOI 10.1002/jez.1401080304; SAVAGE MP, 1993, DEV DYNAM, V198, P159, DOI 10.1002/aja.1001980302; Shashikant CS, 1995, DEVELOPMENT, V121, P4339; WALL NA, 1992, MECH DEVELOP, V37, P111, DOI 10.1016/0925-4773(92)90073-S; Wilson V, 1997, DEV BIOL, V192, P45, DOI 10.1006/dbio.1997.8701; Yang Y, 1997, DEVELOPMENT, V124, P4393; Zeller R, 1997, BIOESSAYS, V19, P541, DOI 10.1002/bies.950190703; 1995, EYEWITNESS ENCY NATU	33	337	343	5	147	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUN 3	1999	399	6735					474	479		10.1038/20944	http://dx.doi.org/10.1038/20944			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	202TH	10365960				2022-12-28	WOS:000080667900050
J	Turner, RC; Cull, CA; Frighi, V; Holman, RR				Turner, RC; Cull, CA; Frighi, V; Holman, RR		UK Prospective Diabet Study Grp	Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus - Progressive requirement for multiple therapies (UKPDS 49)	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PLASMA-GLUCOSE CONCENTRATIONS; MICROVASCULAR COMPLICATIONS; NIDDM PATIENTS; LONG-TERM; TROGLITAZONE; TRIAL	Context Treatment with diet alone, insulin, sulfonylurea, or metformin is known to improve glycemia in patients with type 2 diabetes mellitus, but which treatment most frequently attains target fasting plasma glucose (FPG) concentration of less than 7.8 mmol/L (140 mg/dL) or glycosylated hemoglobin A(1c) (HbA(1c)) below 7% is unknown. Objective To assess how often each therapy can achieve the glycemic control target levels set by the American Diabetes Association. Design Randomized controlled trial conducted between 1977 and 1997. Patients were recruited between 1977 and 1991 and were followed up every 3 months for 3, 6, and 9 years after enrollment. Setting Outpatient diabetes clinics in 15 UK hospitals. Patients A total of 4075 patients newly diagnosed as having type 2 diabetes ranged in age between 25 and 65 years and had a median (interquartile range) FPG concentration of 11.5 (9.0-14.4) mmol/L [207 (162-259) mg/dL], HbA(1c) levels of 9.1% (7.5%-10.7%), and a mean (SD) body mass index of 29 (6) kg/m(2). Interventions After 3 months on a low-fat, high-carbohydrate, high-fiber diet, patients were randomized to therapy with diet alone, insulin, sulfonylurea, or metformin. Main Outcome Measures Fasting plasma glucose and HbA(1c) levels, and the proportion of patients who achieved target levels below 7% HbA(1c) or less than 7.8 mmol/L (140 mg/dL) FPG at 3, 6, or 9 years following diagnosis. Results The proportion of patients who maintained target glycemic levels declined markedly over 9 years of follow-up. After 9 years of monotherapy with diet, insulin, or sulfonylurea, 8%, 42%, and 24%, respectively, achieved FPG levels of less than 7.8 mmol/L (140 mg/dL) and 9%, 28%, and 24% achieved HbA(1c) levels below 7%. In obese patients randomized to metformin, 18% attained FPG levels of less than 7.8 mmol/L (140 mg/dL) and 13% attained HbA(1c) levels below 7%. Patients less likely to achieve target levels were younger, more obese, or more hyperglycemic than other patients. Conclusions Each therapeutic agent, as monotherapy, increased 2- to 3-fold the proportion of patients who attained HbA(1c) below 7% compared with diet alone. However, the progressive deterioration of diabetes control was such that after 3 years approximately 50% of patients could attain this goal with monotherapy, and by 9 years this declined to approximately 25%. The majority of patients need multiple therapies to attain these glycemic target levels in the longer term.	Radcliffe Infirm, Diabet Res Labs, UKPDS Study Grp, Oxford OX2 6HE, England	Radcliffe Infirmary; University of Oxford	Turner, RC (corresponding author), Radcliffe Infirm, Diabet Res Labs, UKPDS Study Grp, Woodstock Rd, Oxford OX2 6HE, England.	robert.turner@dri.ox.ac.uk	Frighi, Valeria/AAD-2648-2022	Frighi, Valeria/0000-0001-8177-8778				ABRAIRA C, 1995, DIABETES CARE, V18, P1113, DOI 10.2337/diacare.18.8.1113; American Diabetes Association, 1995, DIABETES CARE S1, V18, pS1; [Anonymous], 1995, Diabetes, V44, P1249; [Anonymous], 1995, DIABETES, V44, P968; Birkeland KI, 1996, DIABETOLOGIA, V39, P1629, DOI 10.1007/s001250050626; CHOW CC, 1995, DIABETES CARE, V18, P307, DOI 10.2337/diacare.18.3.307; Cull CA, 1997, CLIN CHEM, V43, P1913; CUSI K, 1995, DIABETES CARE, V18, P843, DOI 10.2337/diacare.18.6.843; Engelgau MM, 1997, DIABETES CARE, V20, P785, DOI 10.2337/diacare.20.5.785; Gavin JR, 1999, DIABETES CARE, V22, pS5; Ghazzi MN, 1997, DIABETES, V46, P433, DOI 10.2337/diabetes.46.3.433; Hayward RA, 1997, JAMA-J AM MED ASSOC, V278, P1663, DOI 10.1001/jama.278.20.1663; HENRY RR, 1993, DIABETES CARE, V16, P21, DOI 10.2337/diacare.16.1.21; HOLMAN RR, 1978, METABOLISM, V27, P539, DOI 10.1016/0026-0495(78)90020-3; HOLMAN RR, 1988, DIABETIC MED, V5, P582, DOI 10.1111/j.1464-5491.1988.tb01056.x; Jarrett R J, 1984, Diabet Med, V1, P279; Kumar S, 1996, DIABETOLOGIA, V39, P701; MANLEY SE, 1994, DIABETIC MED, V11, P534; MCCANCE DR, 1994, BRIT MED J, V308, P1323, DOI 10.1136/bmj.308.6940.1323; OHKUBO Y, 1995, DIABETES RES CLIN PR, V28, P103, DOI 10.1016/0168-8227(95)01064-K; PETTITT DJ, 1980, LANCET, V2, P1050; REICHARD P, 1991, J INTERN MED, V230, P101, DOI 10.1111/j.1365-2796.1991.tb00415.x; *SAS I, 1990, STAT ANAL SYSTEM; Turner R, 1996, ANN INTERN MED, V124, P136, DOI 10.7326/0003-4819-124-1_Part_2-199601011-00011; Turner R, 1997, LANCET, V350, P1288, DOI 10.1016/S0140-6736(97)03062-6; TURNER RC, 1991, DIABETOLOGIA, V34, P877; Turner RC, 1998, LANCET, V352, P837, DOI 10.1016/s0140-6736(98)07019-6; United Kingdom Prospective Diabetes Study (UKPDS), 1995, BMJ-BRIT MED J, V310, P83, DOI DOI 10.1136/BMJ.310.6972.83; Wright AD, 1998, DIABETES CARE, V21, P87; YKIJARVINEN H, 1992, NEW ENGL J MED, V327, P1426, DOI 10.1056/NEJM199211123272005	30	1802	1930	5	86	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 2	1999	281	21					2005	2012		10.1001/jama.281.21.2005	http://dx.doi.org/10.1001/jama.281.21.2005			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	200NN	10359389				2022-12-28	WOS:000080546700030
J	Cooke, RWI				Cooke, RWI			New approach to prevention of kernicterus	LANCET			English	Editorial Material							BILIRUBIN PRODUCTION; TERM NEWBORNS; TIN-MESOPORPHYRIN; INHIBITOR; HYPERBILIRUBINEMIA; PROTOPORPHYRIN; PHOTOTHERAPY		Univ Liverpool, Dept Child Hlth, Liverpool Womens Hosp, Liverpool L8 7SS, Merseyside, England	University of Liverpool	Cooke, RWI (corresponding author), Univ Liverpool, Dept Child Hlth, Liverpool Womens Hosp, Liverpool L8 7SS, Merseyside, England.							GALBRAITH RA, 1992, PEDIATRICS, V89, P175; KAPPAS A, 1995, PEDIATRICS, V95, P468; KAPPAS A, 1988, PEDIATRICS, V81, P485; MAISELS MJ, 1995, PEDIATRICS, V96, P730; Martinez JC, 1999, PEDIATRICS, V103, P1, DOI 10.1542/peds.103.1.1; Rodgers PA, 1996, PEDIATR RES, V39, P1041, DOI 10.1203/00006450-199606000-00018; TURKEL SB, 1980, PEDIATRICS, V66, P502; VALAES T, 1994, PEDIATRICS, V93, P1; WATCHKO JF, 1994, PEDIATRICS, V93, P996	9	9	9	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAY 29	1999	353	9167					1814	1815		10.1016/S0140-6736(99)90077-6	http://dx.doi.org/10.1016/S0140-6736(99)90077-6			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	202TG	10359401				2022-12-28	WOS:000080667800004
J	Sykes, M; Preffer, F; McAfee, S; Saidman, SL; Weymouth, D; Andrews, DM; Colby, C; Sackstein, R; Sachs, DH; Spitzer, TR				Sykes, M; Preffer, F; McAfee, S; Saidman, SL; Weymouth, D; Andrews, DM; Colby, C; Sackstein, R; Sachs, DH; Spitzer, TR			Mixed lymphohaemopoietic chimerism and graft-versus-lymphoma effects after non-myeloablative therapy and HLA-mismatched bone-marrow transplantation	LANCET			English	Article							TOTAL-BODY IRRADIATION; NON-HODGKINS-LYMPHOMA; HOST DISEASE; CELL TRANSPLANTATION; LEUKEMIA; AMPLIFICATION; CHEMOTHERAPY; ENGRAFTMENT; TOLERANCE; MICE	Background. HLA-mismatched donor bone-marrow transplantation after standard myeloablative conditioning therapy for haematological malignant disorders has been limited by severe graft-versus-host disease (GVHD) and graft failure. We tested a new approach to find out whether lymphohaemopoietic graft-versus-host reactions could occur without excessive GVHD in mixed haemopoietic chimeras produced across HLA barriers with non-myeloablative conditioning. Methods. Five patients with refractory non-Hodgkin lymphoma underwent bone-marrow transplantation from haploidentical related donors sharing at least one HLA A, B, or DR allele on the mismatched haplotype. Conditioning included cyclophosphamide and thymic irradiation before transplantation, and antithymocyte globulin before and after transplantation. The only other GVHD prophylaxis was cyclosporin. Findings. Four of five patients were evaluable and showed engraftment. Mixed haemopoietic chimerism was established, with a predominance of donor lymphoid tissue and varying degrees of myeloid chimerism. Two patients were in GVHD-free states of complete and partial clinical remission at 460 and 103 days after bone-marrow transplantation. Interpretation. Mixed chimerism can be induced in adult recipients of HLA-mismatched bone-marrow transplantation by a non-myeloablative conditioning regimen. The antilymphoma responses seen in two patients suggest that allogeneic bone-marrow transplantation without myeloablative conditioning might have potent immunotherapeutic benefits.	Massachusetts Gen Hosp, Bone Marrow Transplantat Sect, Transplantat Biol Res Ctr, Surg Serv, Boston, MA 02129 USA; Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02129 USA; Massachusetts Gen Hosp, Dept Med, Bone Marrow Transplantat Program, Boston, MA 02129 USA; Harvard Univ, Sch Med, Boston, MA 02129 USA	Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School	Sykes, M (corresponding author), Massachusetts Gen Hosp, Bone Marrow Transplantat Sect, Transplantat Biol Res Ctr, Surg Serv, Boston, MA 02129 USA.				NATIONAL CANCER INSTITUTE [R01CA061587] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA61587] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AIZAWA S, 1991, TRANSPLANTATION, V52, P885, DOI 10.1097/00007890-199111000-00025; ANASETTI C, 1989, NEW ENGL J MED, V320, P197, DOI 10.1056/NEJM198901263200401; CLIFT RA, 1987, ANNU REV IMMUNOL, V5, P43, DOI 10.1146/annurev.iy.05.040187.000355; Giralt S, 1997, BLOOD, V89, P4531, DOI 10.1182/blood.V89.12.4531; Giralt S., 1997, Blood, V90, p418A; HensleeDowney PJ, 1997, BLOOD, V89, P3864, DOI 10.1182/blood.V89.10.3864.3864_3864_3872; HensleeDowney PJ, 1996, TRANSPLANTATION, V61, P738, DOI 10.1097/00007890-199603150-00012; KAWAI T, 1995, TRANSPLANTATION, V59, P256, DOI 10.1097/00007890-199501270-00018; Khouri IF, 1998, J CLIN ONCOL, V16, P2817, DOI 10.1200/JCO.1998.16.8.2817; LAPIERRE Y, 1990, TRANSFUSION, V30, P1091; NAKAO S, 1992, BONE MARROW TRANSPL, V9, P107; PELOT M, IN PRESS BIOL BLOOD; PREFFER FI, 1993, DIAGNOSTIC IMMUNOPAT, P725; RATANATHARATHORN V, 1994, BLOOD, V84, P1050; SCHWARTZ DWM, 1995, VOX SANG, V68, P139, DOI 10.1111/j.1423-0410.1995.tb02571.x; SHARABI Y, 1989, J EXP MED, V169, P493, DOI 10.1084/jem.169.2.493; Slavin S, 1998, BLOOD, V91, P756, DOI 10.1182/blood.V91.3.756.756_756_763; Storb R, 1997, BLOOD, V89, P3048, DOI 10.1182/blood.V89.8.3048; SYKES M, 1988, J EXP MED, V168, P2391, DOI 10.1084/jem.168.6.2391; SYKES M, 1988, TRANSPLANTATION, V46, P327; SYKES M, 1989, TRANSPLANT P, V21, P3022; Verdonck LF, 1997, BLOOD, V90, P4201, DOI 10.1182/blood.V90.10.4201; XUN CQ, 1994, BLOOD, V83, P2360	23	311	322	1	3	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAY 22	1999	353	9166					1755	1759		10.1016/S0140-6736(98)11135-2	http://dx.doi.org/10.1016/S0140-6736(98)11135-2			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	202TF	10347989				2022-12-28	WOS:000080667700014
J	Wrenn, K; Wright, SW; Kent, LP				Wrenn, K; Wright, SW; Kent, LP			A midlife crisis	LANCET			English	Article							SICKLE-CELL TRAIT; ALTITUDE		Vanderbilt Univ, Sch Med, Nashville, TN 37232 USA; Sabah Med Ctr, Sabah, Malaysia	Vanderbilt University	Wrenn, K (corresponding author), Vanderbilt Univ, Sch Med, Nashville, TN 37232 USA.							GOLDBERG NM, 1985, WESTERN J MED, V143, P670; LANE PA, 1985, JAMA-J AM MED ASSOC, V253, P2251, DOI 10.1001/jama.253.15.2251; NUSSBAUM RL, 1984, SOUTHERN MED J, V77, P1049, DOI 10.1097/00007611-198408000-00031	3	1	1	0	4	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAY 22	1999	353	9166					1760	1760		10.1016/S0140-6736(99)02421-6	http://dx.doi.org/10.1016/S0140-6736(99)02421-6			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	202TF	10347990				2022-12-28	WOS:000080667700015
J	Dora, C				Dora, C			A different route to health: implications of transport policies	BRITISH MEDICAL JOURNAL			English	Article							AMBIENT AIR-POLLUTION; CITIES; NUMBER		WHO, European Ctr Environm Hlth, Rome Div, I-00187 Rome, Italy	World Health Organization	Dora, C (corresponding author), WHO, European Ctr Environm Hlth, Rome Div, I-00187 Rome, Italy.							[Anonymous], 1995, CHILDRENS ENV; Babisch W, 1998, ADV NOISE RES, P312; Berglund B., 1995, ARCH CTR SENSORY RES, V2, P1; British Medical Association, 1997, ROAD TRANSP HLTH; British Medical Association, 1992, CYCL HLTH SAF; Brunekreef B, 1997, EPIDEMIOLOGY, V8, P298, DOI 10.1097/00001648-199705000-00012; Brunekreef B, 1997, OCCUP ENVIRON MED, V54, P781, DOI 10.1136/oem.54.11.781; Burnett RT, 1998, CAN J PUBLIC HEALTH, V89, P152, DOI 10.1007/BF03404464; CICCONE G, 1998, OCCUP ENVIRON MED, V55, P1; *COMM EUR COMM, 1995, COM95196 COMM EUR CO; Davis A, 1997, BRIT MED J, V314, P69, DOI 10.1136/bmj.314.7073.69; DEHORNE LDJ, 1993, INT HDB TRAUMATIC ST; *EPA, 1996, EPA600P95001CF ORD; *EUR C TRANSP MIN, 1998, TRENDS TRANSP SECT 1; *EUR TRANSP SAF CO, 1995, RED TRAFF INJ RES EX; *EUROSTAT, 1997, EU TRANSP FIG; Feychting M, 1998, SCAND J WORK ENV HEA, V24, P8, DOI 10.5271/sjweh.272; Greenwood DC, 1996, J PUBLIC HEALTH MED, V18, P221, DOI 10.1093/oxfordjournals.pubmed.a024483; *HLTH EFF I, 1995, DIES EXH CRIT AN EM; MADDISON D, 1997, TRUE COSTS TRANSPORT; MADERTHANER R, 1995, WOHLBEFINDEN STAD OK; MCMICHAEL AJ, 1996, CLIMATE CHANGE ENV H; MORRIS RD, 1995, AM J PUBLIC HEALTH, V85, P1361, DOI 10.2105/AJPH.85.10.1361; Oja P, 1998, PATIENT EDUC COUNS, V33, pS87, DOI 10.1016/S0738-3991(98)00013-5; *ORG EC COOP DEV, TRANSP ENV ENV SUST; *ORG EC COOP DEV, 1997, OECD ROAD SAF RES IN; *ORG EC COOP DEV, 1997, EUR C MIN TRANSP URB; Peters A, 1997, AM J RESP CRIT CARE, V155, P1376, DOI 10.1164/ajrccm.155.4.9105082; STANNERS D, 1995, EUROPES ENV; TOLOUMI G, 1997, AM J EPIDEMIOL, V146, P177; *UN EC COMM EUR, 1997, STAT ROAD TRAFF ACC; *US SURG GEN, 1996, PHYS ACT HLTH; van Wijnen J. H., 1998, Reviews on Environmental Health, V13, P1; *WHO, 1995, CONC EUR TOM; *WHO, IN PRESS AIR QUAL GU; *WHO, 1998, HLTH ALL DAT BAS; *WHO, 1999, 02059 WHO EUR ICP EH	37	89	89	0	5	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JUN 19	1999	318	7199					1686	1689		10.1136/bmj.318.7199.1686	http://dx.doi.org/10.1136/bmj.318.7199.1686			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	210KY	10373178	Green Published			2022-12-28	WOS:000081105600036
J	Zimov, SA; Davidov, SP; Zimova, GM; Davidova, AI; Chapin, FS; Chapin, MC; Reynolds, JF				Zimov, SA; Davidov, SP; Zimova, GM; Davidova, AI; Chapin, FS; Chapin, MC; Reynolds, JF			Contribution of disturbance to increasing seasonal amplitude of atmospheric CO(2)	SCIENCE			English	Article							HIGH-LATITUDES; ARCTIC VEGETATION; ECOSYSTEMS; CARBON; TEMPERATURE; WINTER	Recent increases in the seasonal amplitude of atmospheric carbon dioxide (CO(2)) at high latitudes suggest a widespread biospheric response to high-latitude warming. The seasonal amplitude of net ecosystem carbon exchange by northern Siberian ecosystems is shown to be greater in disturbed than undisturbed sites, due to increased summer influx and increased winter efflux. Increased disturbance could therefore contribute significantly to the amplified seasonal cycle of atmospheric carbon dioxide at high latitudes. Warm temperatures reduced summer carbon influx, suggesting that high-latitude warming, if it occurred, would be unlikely to increase seasonal amplitude of carbon exchange.	Univ Alaska, Inst Arctic Biol, Fairbanks, AK 99775 USA; Russian Acad Sci, Far E Branch, Pacific Inst Geog, NE Sci Stn, Cherskii 678830, Russia; Duke Univ, Dept Bot, Durham, NC 27708 USA	University of Alaska System; University of Alaska Fairbanks; Pacific Geographical Institute of the Far Eastern Branch of the Russian Academy of Sciences; Russian Academy of Sciences; Duke University	Chapin, FS (corresponding author), Univ Alaska, Inst Arctic Biol, Fairbanks, AK 99775 USA.	fschapin@lter.uaf.edu	Davydova, Anna/AAI-2484-2021; Reynolds, James F/G-6364-2010; Zimov, Sergey/K-3009-2018; Davydov, Sergei P./S-9906-2018; Chapin, F Stuart/AAZ-3931-2020; Gutierrez, Emilia/O-7568-2014	Chapin, F Stuart/0000-0002-2558-9910; Gutierrez, Emilia/0000-0002-6085-5700; Zimov, Sergey/0000-0002-0053-6599; Reynolds, James/0000-0003-2367-879X				BELAEVA NV, 1996, RASTIT RESUR, V32, P22; Braswell BH, 1997, SCIENCE, V278, P870, DOI 10.1126/science.278.5339.870; Chapin FS, 1996, NATURE, V383, P585, DOI 10.1038/383585b0; Chapin FS, 1996, J VEG SCI, V7, P347, DOI 10.2307/3236278; CHAPMAN WL, 1993, B AM METEOROL SOC, V74, P33, DOI 10.1175/1520-0477(1993)074<0033:RVOSIA>2.0.CO;2; FLANNIGAN MD, 1991, CAN J FOREST RES, V21, P66, DOI 10.1139/x91-010; Goulden ML, 1998, SCIENCE, V279, P214, DOI 10.1126/science.279.5348.214; Hobbie SE, 1996, BIOGEOCHEMISTRY, V35, P327, DOI 10.1007/BF02179958; HOBBIE SE, 1992, TRENDS ECOL EVOL, V7, P336, DOI 10.1016/0169-5347(92)90126-V; HOLSTEN EH, 1990, SPRUCE BEETLE ACTIVI; HURLBERT SH, 1984, ECOL MONOGR, V54, P187, DOI 10.2307/1942661; KAMINSKI T, 1997, PHYS CHEM EARTH, V22, P486; KASISCHKE ES, 1999, EOS T AM GEOPHYS UN, V80, P141, DOI DOI 10.1029/99EO00094; Kattenberg A., 1996, CLIMATE CHANGE 1995, P285; Keeling CD, 1996, NATURE, V382, P146, DOI 10.1038/382146a0; Kurz WA, 1996, NATO ASI SER SER I, V40, P173; MONTEITH JL, 1990, PRINCIPLES ENV PHYSI; Myneni RB, 1997, NATURE, V386, P698, DOI 10.1038/386698a0; OBERBAUER SF, 1989, HOLARCTIC ECOL, V12, P312; OECHEL WC, 1993, NATURE, V361, P520, DOI 10.1038/361520a0; RANDERSON JT, 1997, GLOBAL BIOGEOCHEM CY, V11; SHAVER GR, 1991, ECOL MONOGR, V61, P1, DOI 10.2307/1942997; Shvidenko A., 1995, Q J HUNG METEOROL SE, V99, P235; SKRE O, 1981, OECOLOGIA, V48, P50, DOI 10.1007/BF00346987; Trumbore SE, 1997, J GEOPHYS RES-ATMOS, V102, P28817, DOI 10.1029/97JD02231; VIERECK L A, 1973, Quaternary Research (Orlando), V3, P465, DOI 10.1016/0033-5894(73)90009-4; Zimov SA, 1996, CLIMATIC CHANGE, V33, P111, DOI 10.1007/BF00140516; ZIRNOV SA, 1993, J GEOPHYS RES-ATMOSP, V98, P5017; ZIRNOV SA, 1993, CARBON CYCLING BOREA, P21	29	80	86	2	24	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 18	1999	284	5422					1973	1976		10.1126/science.284.5422.1973	http://dx.doi.org/10.1126/science.284.5422.1973			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	207JA	10373112				2022-12-28	WOS:000080932700042
J	Mak, V; Zielenski, J; Tsui, LC; Durie, P; Zini, A; Martin, S; Longley, TB; Jarvi, KA				Mak, V; Zielenski, J; Tsui, LC; Durie, P; Zini, A; Martin, S; Longley, TB; Jarvi, KA			Proportion of cystic fibrosis gene mutations not detected by routine testing in men with obstructive azoospermia	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CONGENITAL BILATERAL ABSENCE; INTRACYTOPLASMIC SPERM INJECTION; TRANSMEMBRANE CONDUCTANCE REGULATOR; IN-VITRO FERTILIZATION; VAS-DEFERENS; CFTR GENE; EPIDIDYMAL SPERM; MALE-INFERTILITY; DISSEMINATED BRONCHIECTASIS; INVITRO FERTILIZATION	Context Infertile men with obstructive azoospermia may have mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene, many of which are rare in classic cystic fibrosis and not evaluated in most routine mutation screening. Objective To assess how often CFTR mutations or sequence alterations undetected by routine screening are detected with more extensive screening in obstructive azoospermia, Design Routine screening for the 31 most common CFTR mutations associated with the CF phenotype in white populations, testing for the 5-thymidine variant of the polythymidine tract of intron 8 (IVS8-5T) by allele-specific oligonucleotide hybridization, and screening of all exons through multiplex heteroduplex shift analysis followed by direct DNA sequencing. Setting Male infertility clinic of a Canadian university-affiliate hospital. Subjects Of 198 men with obstructive (n = 149) or nonobstructive (n = 49; control group) azoospermia, 64 had congenital bilateral absence of the vas deferens (CBAVD), 10 had congenital unilateral absence of the vas deferens (CUAVD), and 75 had epididymal obstruction (56/75 were idiopathic), Main Outcome Measure Frequency of mutations found by routine and nonroutine tests in men with obstructive vs nonobstructive azoospermia, Results Frequency of mutations and the IVS8-5T variant in the nonobstructive azoospermia group (controls) (2% and 5.1% allele frequency, respectively) did not differ significantly from that in the general population (2% and 5,2%, respectively), In the CBAVD group, 72 mutations were found by DNA sequencing and IVS8-5T testing (47 and 25, respectively; P<.001 and P=.002 vs controls) vs 39 by the routine panel (P<.001 vs controls). In the idiopathic epididymal obstruction group, 24 mutations were found by DNA sequencing and IVS8-5T testing (12 each; P=.01 and P=.14 vs controls) vs 5 by the routine panel (P=.33 vs controls). In the CUAVD group, 2 mutations were found by routine testing (P=.07 vs controls) vs 4 (2 each, respectively; P=.07 and P=.40 vs controls) by DNA sequencing and IVS8-5T testing. The routine panel did not identify 33 (46%) of 72, 2 (50%) of 4, and 19 (79%) of 24 detectable CFTR mutations and IVS8-5T in the CBAVD, CUAVD, and idiopathic epididymal obstruction groups, respectively. Conclusions Routine testing for CFTR mutations may miss mild or rare gene alterations. The barrier to conception for men with obstructive infertility has been overcome by assisted reproductive technologies, thus raising the concern of iatrogenically transmitting pathogenic CFTR mutations to the progeny.	Mt Sinai Hosp, Dept Surg, Div Urol, Toronto, ON M5G 1X5, Canada; Hosp Sick Children, Dept Genet, Toronto, ON M5G 1X8, Canada; Hosp Sick Children, Programme Integrat Biol, Toronto, ON M5G 1X8, Canada; Hosp Sick Children, Res Inst, Toronto, ON M5G 1X8, Canada; Univ Toronto, Dept Mol & Med Genet, Toronto, ON, Canada; Univ Toronto, Dept Pediat, Toronto, ON, Canada; Univ Toronto, Dept Surg, Div Urol, Toronto, ON, Canada; Univ Toronto, Inst Med Sci, Toronto, ON M5S 1A1, Canada	University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University of Toronto; University of Toronto; University of Toronto	Jarvi, KA (corresponding author), Mt Sinai Hosp, Dept Surg, Div Urol, 1525-600 Univ Ave, Toronto, ON M5G 1X5, Canada.		Tsui, Lap-chee/A-1081-2010		NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P50DK049096] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK49096-03] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANGUIANO A, 1992, JAMA-J AM MED ASSOC, V267, P1794, DOI 10.1001/jama.267.13.1794; AZNAREZ I, 1998, PEDIATR PULM, V17, P332; Bienvenu T, 1996, CONTRACEPT FERTIL S, V24, P495; Bienvenu T, 1997, ANN GENET-PARIS, V40, P5; Bienvenu T, 1996, HUM MUTAT, V7, P182, DOI 10.1002/(SICI)1098-1004(1996)7:2<182::AID-HUMU19>3.3.CO;2-Y; BLADOU F, 1991, HUM REPROD, V6, P1284, DOI 10.1093/oxfordjournals.humrep.a137527; BURGER J, 1991, LANCET, V337, P974, DOI 10.1016/0140-6736(91)91603-R; CASALS T, 1995, HUM GENET, V95, P205; *CENS OP DIV, 1996, STAT CAN 1996 CENS N; Cha KY, 1997, FERTIL STERIL, V67, P985, DOI 10.1016/S0015-0282(97)81428-8; CHILLON M, 1995, NEW ENGL J MED, V332, P1475, DOI 10.1056/NEJM199506013322204; Cohn JA, 1998, NEW ENGL J MED, V339, P653, DOI 10.1056/NEJM199809033391002; COSTES B, 1995, EUR J HUM GENET, V3, P285; CULARD JF, 1994, HUM GENET, V93, P467; CUMMINS JM, 1995, HUM REPROD, V10, P138, DOI 10.1093/humrep/10.suppl_1.138; CUPPENS H, 1994, HUM MOL GENET, V3, P607, DOI 10.1093/hmg/3.4.607; DEKRETSER DM, 1995, REPROD FERT DEVELOP, V7, P137; Donat R, 1997, BRIT J UROL, V79, P74, DOI 10.1046/j.1464-410X.1997.30816.x; DORK T, 1994, HUM GENET, V93, P67; Dork T, 1997, HUM GENET, V100, P365, DOI 10.1007/s004390050518; Dumur V, 1996, HUM GENET, V97, P7; DURIEU I, 1995, MEDICINE, V74, P42, DOI 10.1097/00005792-199501000-00004; Durieu I, 1997, REV MED INTERNE, V18, P114, DOI 10.1016/S0248-8663(97)84676-0; FRIEDMAN KJ, 1995, AM J RESP CRIT CARE, V152, P1353, DOI 10.1164/ajrccm.152.4.7551394; FUKUGAKI H, 1994, J ASSIST REPROD GEN, V11, P452, DOI 10.1007/BF02215707; HANDYSIDE AH, 1992, NEW ENGL J MED, V327, P905, DOI 10.1056/NEJM199209243271301; HARARI O, 1995, FERTIL STERIL, V64, P360, DOI 10.1016/S0015-0282(16)57736-X; HENDRY WF, 1993, BMJ-BRIT MED J, V307, P1579, DOI 10.1136/bmj.307.6919.1579; Jarvi K, 1998, FERTIL STERIL, V70, P724, DOI 10.1016/S0015-0282(98)00247-7; JARVI K, 1995, LANCET, V345, P1578, DOI 10.1016/S0140-6736(95)91131-6; JEZEQUEL P, 1995, CLIN CHEM, V41, P833; Johnson MD, 1998, FERTIL STERIL, V70, P397, DOI 10.1016/S0015-0282(98)00209-X; Kanavakis E, 1998, MOL HUM REPROD, V4, P333, DOI 10.1093/molehr/4.4.333; KAPLAN E, 1968, NEW ENGL J MED, V279, P65, DOI 10.1056/NEJM196807112790203; KIESEWETTER S, 1993, NAT GENET, V5, P274, DOI 10.1038/ng1193-274; LANDING BH, 1969, ARCH PATHOL, V88, P569; Lawler AM, 1998, FERTIL STERIL, V70, P412; Lissens W, 1996, HUM REPROD, V11, P55, DOI 10.1093/humrep/11.suppl_4.55; Madgar I, 1996, HUM REPROD, V11, P2151; Mak V, 1997, HUM MOL GENET, V6, P2099, DOI 10.1093/hmg/6.12.2099; Mak V, 1996, J UROLOGY, V156, P1245, DOI 10.1016/S0022-5347(01)65561-7; Mansour RT, 1997, HUM REPROD, V12, P1974, DOI 10.1093/humrep/12.9.1974; MATHIEU C, 1992, FERTIL STERIL, V57, P871; MERCIER B, 1995, AM J HUM GENET, V56, P272; MESCHEDE D, 1994, LANCET, V343, P1566, DOI 10.1016/S0140-6736(94)92964-5; MICKLE J, 1995, HUM REPROD, V10, P1728, DOI 10.1093/oxfordjournals.humrep.a136164; Miller PW, 1996, AM J HUM GENET, V59, P45; MILLER SA, 1988, NUCLEIC ACIDS RES, V16, P1215, DOI 10.1093/nar/16.3.1215; MULLIS K, 1986, COLD SPRING HARB SYM, V51, P263, DOI 10.1101/SQB.1986.051.01.032; OATES RD, 1994, J ANDROL, V15, P1; OATES RD, 1992, J ASSIST REPROD GEN, V9, P36, DOI 10.1007/BF01204112; OSBORNE LR, 1993, HUM MOL GENET, V2, P1605, DOI 10.1093/hmg/2.10.1605; PALERMO G, 1992, LANCET, V340, P17, DOI 10.1016/0140-6736(92)92425-F; PATRIZIO P, 1993, HUM REPROD, V8, P215, DOI 10.1093/oxfordjournals.humrep.a138025; Patrizio P, 1996, MOL MED TODAY, V2, P24, DOI 10.1016/1357-4310(96)88755-7; PATRIZIO P, 1988, LANCET, V2, P1364; Pignatti PF, 1996, AM J HUM GENET, V58, P889; PIGNATTI PF, 1995, HUM MOL GENET, V4, P635, DOI 10.1093/hmg/4.4.635; RAVEHAREL N, 1995, AM J HUM GENET, V56, P1359; SCHLEGEL PN, 1995, UROLOGY, V46, P238, DOI 10.1016/S0090-4295(99)80199-X; Schlegel PN, 1996, J UROLOGY, V155, P1644, DOI 10.1016/S0022-5347(01)66152-4; SCHOYSMAN R, 1982, INT J ANDROL S, V5, P120; Sharer N, 1998, NEW ENGL J MED, V339, P645, DOI 10.1056/NEJM199809033391001; Shin D, 1997, J UROLOGY, V158, P1794, DOI 10.1016/S0022-5347(01)64131-4; SILBER SJ, 1988, FERTIL STERIL, V50, P525; SILBER SJ, 1990, NEW ENGL J MED, V323, P1788, DOI 10.1056/NEJM199012273232602; Son IP, 1996, J ASSIST REPROD GEN, V13, P69, DOI 10.1007/BF02068873; TAUSSIG LM, 1972, NEW ENGL J MED, V287, P586, DOI 10.1056/NEJM197209212871204; TEMPLE-SMITH P D, 1985, Journal of In Vitro Fertilization and Embryo Transfer, V2, P119, DOI 10.1007/BF01131497; VALMAN HB, 1969, LANCET, V2, P566; VANSTEIRTEGHEM AC, 1993, HUM REPROD, V8, P1061, DOI 10.1093/oxfordjournals.humrep.a138192; Welsh MJ, 1995, METABOLIC MOL BASES, V3, P3799; YOUNG D, 1970, J REPROD FERTIL, V23, P541; ZIELENSKI J, 1991, GENOMICS, V10, P214, DOI 10.1016/0888-7543(91)90503-7; ZIELENSKI J, 1995, AM J HUM GENET, V57, P958; Zielenski J, 1995, ANNU REV GENET, V29, P777, DOI 10.1146/annurev.ge.29.120195.004021	76	96	97	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 16	1999	281	23					2217	2224		10.1001/jama.281.23.2217	http://dx.doi.org/10.1001/jama.281.23.2217			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	204RB	10376575	Bronze			2022-12-28	WOS:000080777000036
J	Wise, J				Wise, J			Younger women might benefit from breast cancer screening	BRITISH MEDICAL JOURNAL			English	News Item																			0	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JUN 12	1999	318	7198					1575	1575		10.1136/bmj.318.7198.1575	http://dx.doi.org/10.1136/bmj.318.7198.1575			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	207AL	10364105	Green Published			2022-12-28	WOS:000080913100009
J	Winston, FK; Durbin, DR				Winston, FK; Durbin, DR			Buckle up! Is not enough - Enhancing protection of the restrained child	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article									Childrens Hosp Philadelphia, Abramson Res Ctr, Philadelphia, PA 19104 USA; Univ Penn, Philadelphia, PA 19104 USA	University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of Pennsylvania	Winston, FK (corresponding author), Childrens Hosp Philadelphia, Abramson Res Ctr, 3516 Civ Ctr Blvd,Suite 704, Philadelphia, PA 19104 USA.	flaura@mail.med.upenn.edu	Durbin, Dennis/AAD-7829-2022					Agran PF, 1998, PEDIATRICS, V102, part. no., DOI 10.1542/peds.102.3.e39; *AM AC PED, 1999 FAM SHOPP GUID; *AM AC PED, SEL US MOST APPR CAR; ARBOGAST K, 1999, AMB PED ASS 39 ANN M; BASS JL, 1993, PEDIATRICS, V92, P544; *BLUE RIBB PAN 2, 1999, PROT OLD CHILD; *COMM INJ PREV CON, 1999, RED BURD INJ ADV PRE; Decina LE, 1997, ACCIDENT ANAL PREV, V29, P125, DOI 10.1016/S0001-4575(96)00051-6; EDWARDS J, 1997, SOC AUT ENG NOV 12 O; GARRETT J W, 1962, J Trauma, V2, P220, DOI 10.1097/00005373-196205000-00002; GOTSCHALL C, 1998, 42 ANN M ASS ADV AUT; HILL JR, 1994, ACCIDENT ANAL PREV, V26, P11, DOI 10.1016/0001-4575(94)90065-5; *INS I HIGHW SAF, STAT LAW FACTS 1998; Kahane C.J., 1986, EVALUATION CHILD PAS; KING AI, 1995, J TRAUMA, V38, P570, DOI 10.1097/00005373-199504000-00017; KULOWSKI J, 1956, ARCH SURG-CHICAGO, V73, P970, DOI 10.1001/archsurg.1956.01280060070015; *NAT HIGHW TRAFF S, TRAFF SAF FACTS 1997; *NAT HIGHW TRAFF S, UN CHILD RESTR ANCH; *NAT HIGHW TRAFF S, PROT YOUR KIDS CAR; *NAT HIGHW TRAFF S, SPEC CRASH INV AIR B; *SAFEKIDS, FREQ ASK QUEST WHAT; Wilson M., 1991, SAVING CHILDREN GUID; WINSTON F, 1999, AMB PED ASS 39 ANN M	23	38	38	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 9	1999	281	22					2070	2072		10.1001/jama.281.22.2070	http://dx.doi.org/10.1001/jama.281.22.2070			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	202TJ	10367804				2022-12-28	WOS:000080668000001
J	Bengtsson, BA; Johannsson, G				Bengtsson, BA; Johannsson, G			Effect of growth-hormone therapy on early atherosclerotic changes in GH-deficient adults	LANCET			English	Editorial Material							INTIMA-MEDIA THICKNESS; HYPOPITUITARISM; ULTRASOUND; MORTALITY		Sahlgrens Univ Hosp, Res Ctr Endocrinol & Metab, S-41345 Gothenburg, Sweden	Sahlgrenska University Hospital	Bengtsson, BA (corresponding author), Sahlgrens Univ Hosp, Res Ctr Endocrinol & Metab, S-41345 Gothenburg, Sweden.			Johannsson, Gudmundur/0000-0003-3484-8440				BLANKENHORN DH, 1993, CIRCULATION, V88, P20, DOI 10.1161/01.CIR.88.1.20; Boger RH, 1996, J CLIN INVEST, V98, P2706, DOI 10.1172/JCI119095; Capaldo B, 1997, J CLIN ENDOCR METAB, V82, P1378, DOI 10.1210/jc.82.5.1378; Carroll PV, 1998, J CLIN ENDOCR METAB, V83, P382, DOI 10.1210/jc.83.2.382; LEHMANN ED, 1991, LANCET, V338, P1075, DOI 10.1016/0140-6736(91)91929-O; MARKUSSIS V, 1992, LANCET, V340, P1188, DOI 10.1016/0140-6736(92)92892-J; Pfeifer M, 1999, J CLIN ENDOCR METAB, V84, P453, DOI 10.1210/jc.84.2.453; ROSEN T, 1990, LANCET, V336, P285, DOI 10.1016/0140-6736(90)91812-O; Rosen T, 1998, CLIN ENDOCRINOL, V48, P525, DOI 10.1046/j.1365-2265.1998.00473.x; Sverrisdottir YB, 1998, J CLIN ENDOCR METAB, V83, P1881, DOI 10.1210/jc.83.6.1881; WIKSTRAND J, 1994, J INTERN MED, V236, P555, DOI 10.1111/j.1365-2796.1994.tb00845.x	11	25	25	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUN 5	1999	353	9168					1898	1899		10.1016/S0140-6736(99)90092-2	http://dx.doi.org/10.1016/S0140-6736(99)90092-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	202TP	10371563				2022-12-28	WOS:000080668500004
J	Raju, TNK				Raju, TNK			The Nobel Chronicles - 1957: Daniel Bovet (1907-92)	LANCET			English	Biographical-Item									Univ Illinois, Chicago, IL 60612 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Raju, TNK (corresponding author), Univ Illinois, Chicago, IL 60612 USA.								0	0	0	0	7	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUN 5	1999	353	9168					1981	1981		10.1016/S0140-6736(05)77203-2	http://dx.doi.org/10.1016/S0140-6736(05)77203-2			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	202TP	10371612				2022-12-28	WOS:000080668500074
J	Learmont, JC; Geczy, AF; Mills, J; Ashton, LJ; Raynes-Greenow, CH; Garsia, RJ; Dyer, WB; McIntyre, L; Oelrichs, RB; Rhodes, DI; Deacon, NJ; Sullivan, JS				Learmont, JC; Geczy, AF; Mills, J; Ashton, LJ; Raynes-Greenow, CH; Garsia, RJ; Dyer, WB; McIntyre, L; Oelrichs, RB; Rhodes, DI; Deacon, NJ; Sullivan, JS		Sydney Blood Bank Cohort Res Grp	Immunologic and virologic status after 14 to 18 years of infection with an attenuated strain of HIV-1 - A report from the Sydney Blood Bank Cohort	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; PNEUMOCYSTIS-CARINII PNEUMONIA; SYSTEMIC LUPUS-ERYTHEMATOSUS; NEF GENE; MONONUCLEAR-CELLS; TYPE-1 INFECTION; SINGLE-DONOR; AIDS; LYMPHOCYTES; RECIPIENTS	Background and Methods The Sydney Blood Bank Cohort consists of a blood donor and eight transfusion recipients who were infected before 1985 with a strain of human immunodeficiency virus type 1 (HIV-1) with a deletion in the region in which the nef gene and the long terminal repeat overlap. Two recipients have died since 1994, at 77 and 83 years of age, of causes unrelated to HIV infection; one other recipient, who had systemic lupus erythematosus, died in 1987 at 22 years of age of causes possibly related to HIV. We present longitudinal immunologic and virologic data on the six surviving members and one deceased member of this cohort through September 30, 1998. Results The five surviving recipients remain asymptomatic 14 to 18 years after HIV-1 infection without any antiretroviral therapy; however, the donor commenced therapy in February 1999. In three recipients plasma concentrations of HIV-1 RNA are undetectable (<200 copies per milliliter), and in two of these three the CD4 lymphocyte counts have declined by 9 and 30 cells per cubic millimeter per year (P=0.3 and P=0.5, respectively). The donor and two other recipients have median plasma concentrations of HIV-1 RNA of 645 to 2850 copies per milliliter; the concentration has increased in the donor (P<0.001). The CD4 lymphocyte counts in these three cohort members have declined by 16 to 73 cells per cubic millimeter per year (P<0.001). In the recipient who died after 12 years of infection, the median plasma concentration of HIV-1 RNA was 1400 copies per milliliter, with a decline in CD4 lymphocyte counts of 17 cells per cubic millimeter per year (P=0.2). Conclusions After prolonged infection with this attenuated strain of HIV-1, there is evidence of immunologic damage in three of the four subjects with detectable plasma HIV-1 RNA. The CD4 lymphocyte counts appear to be stable in the three subjects in whom plasma HIV-1 RNA remains undetectable. (N Engl J Med 1999;340:1715-22.) (C) 1999, Massachusetts Medical Society.	Australian Red Cross Blood Serv NSW, Sydney, NSW 2000, Australia; Natl Ctr HIV Epidemiol & Clin Res, Fairfield, Vic, Australia; Macfarlane Burnet Ctr Med Res, Fairfield, Vic, Australia; Natl Ctr HIV Epidemiol & Clin Res, Sydney, NSW, Australia; Royal Prince Alfred Hosp, Sydney, NSW, Australia	Australian Red Cross Blood Service; University of New South Wales Sydney; Kirby Institute; University of New South Wales Sydney; Kirby Institute; University of Sydney	Learmont, JC (corresponding author), Australian Red Cross Blood Serv NSW, 153 Clarence St, Sydney, NSW 2000, Australia.	jlearmont@arcbs.redcross.org.au						ARCHER GT, 1988, P 4 INT C ACQ IMM DE, P354; ASHTON LJ, 1994, LANCET, V344, P718, DOI 10.1016/S0140-6736(94)92210-1; Baba TW, 1999, NAT MED, V5, P194, DOI 10.1038/5557; Cameron RG, 1996, AUST NZ J MED, V26, P800, DOI 10.1111/j.1445-5994.1996.tb00628.x; Cohen I, 1997, SCIENCE, V278, P24, DOI 10.1126/science.278.5335.24; Collins KL, 1998, NATURE, V391, P397, DOI 10.1038/34929; DEACON NJ, 1995, SCIENCE, V270, P988, DOI 10.1126/science.270.5238.988; Dean M, 1996, SCIENCE, V274, P1069; Dean M, 1996, SCIENCE, V273, P1856, DOI 10.1126/science.273.5283.1856; Deng HK, 1996, NATURE, V381, P661, DOI 10.1038/381661a0; Desrosiers R.C., 1994, J NIH RES, V6, P54; DESROSIERS RC, 1992, AIDS RES HUM RETROV, V8, P411, DOI 10.1089/aid.1992.8.411; DESROSIERS RC, 1994, J NIH RES, V6, P56; Dyer WB, 1999, J VIROL, V73, P436, DOI 10.1128/JVI.73.1.436-443.1999; Dyer WB, 1997, AIDS, V11, P1565, DOI 10.1097/00002030-199713000-00004; FAIRLEY CK, 1994, INT J STD AIDS, V5, P177, DOI 10.1177/095646249400500304; GIBBS JS, 1994, AIDS RES HUM RETROV, V10, P333, DOI 10.1089/aid.1994.10.333; Greenough TC, 1999, NEW ENGL J MED, V340, P236, DOI 10.1056/NEJM199901213400314; GREENWAY A, 1995, J VIROL, V69, P1842, DOI 10.1128/JVI.69.3.1842-1850.1995; Greenway AL, 1998, AIDS, V12, P555, DOI 10.1097/00002030-199806000-00003; GREENWAY AL, 1994, VIROLOGY, V198, P245, DOI 10.1006/viro.1994.1027; GURUSINGHE AD, 1995, J MED VIROL, V46, P238, DOI 10.1002/jmv.1890460312; Hessol N A, 1996, AIDS, V10 Suppl A, pS69, DOI 10.1097/00002030-199601001-00010; ILYINSKII PO, 1994, J VIROL, V68, P5933, DOI 10.1128/JVI.68.9.5933-5944.1994; Kaslow RA, 1996, NAT MED, V2, P405, DOI 10.1038/nm0496-405; KESTLER HW, 1991, CELL, V65, P651, DOI 10.1016/0092-8674(91)90097-I; KIRCHHOFF F, 1995, NEW ENGL J MED, V332, P228, DOI 10.1056/NEJM199501263320405; KOPECSCHRADER E, 1993, AIDS, V7, P1009, DOI 10.1097/00002030-199307000-00016; LEARMONT J, 1995, AIDS RES HUM RETROV, V11, P1, DOI 10.1089/aid.1995.11.1; LEARMONT J, 1992, LANCET, V340, P863, DOI 10.1016/0140-6736(92)93281-Q; LEARMONT J, 1996, 11 INT C AIDS VANC J, P33; LEARMONT J, 1994, P 10 INT C AIDS YOK, V2, P254; LEONG KH, 1991, ANN RHEUM DIS, V50, P811, DOI 10.1136/ard.50.11.811; Martin MP, 1998, SCIENCE, V282, P1907, DOI 10.1126/science.282.5395.1907; Mellors JW, 1997, ANN INTERN MED, V126, P946, DOI 10.7326/0003-4819-126-12-199706150-00003; MILLER MD, 1994, J EXP MED, V179, P101, DOI 10.1084/jem.179.1.101; Munoz A, 1996, STAT MED, V15, P2459, DOI 10.1002/(SICI)1097-0258(19961130)15:22<2459::AID-SIM464>3.0.CO;2-Q; Munoz A, 1997, AIDS, V11, pS69; NEATE EV, 1987, AUST NZ J MED, V17, P461, DOI 10.1111/j.1445-5994.1987.tb00096.x; Oelrichs R, 1998, AIDS RES HUM RETROV, V14, P811, DOI 10.1089/aid.1998.14.811; OPERSKALSKI EA, 1995, J INFECT DIS, V172, P648, DOI 10.1093/infdis/172.3.648; PORGES AJ, 1992, J RHEUMATOL, V19, P1191; Rosenberg ES, 1997, SCIENCE, V278, P1447, DOI 10.1126/science.278.5342.1447; Ruprecht RM, 1996, SCIENCE, V271, P1790; Smith MW, 1997, SCIENCE, V277, P959, DOI 10.1126/science.277.5328.959; SPINA CA, 1994, J EXP MED, V179, P115, DOI 10.1084/jem.179.1.115; VALERIE K, 1988, NATURE, V333, P78, DOI 10.1038/333078a0; Winkler C, 1998, SCIENCE, V279, P389, DOI 10.1126/science.279.5349.389; 1997, ANTIVIRAL AGENTS B, V10, P353	49	270	279	0	7	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUN 3	1999	340	22					1715	1722		10.1056/NEJM199906033402203	http://dx.doi.org/10.1056/NEJM199906033402203			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	201WQ	10352163				2022-12-28	WOS:000080620200003
J	Long, SH; Marquis, MS				Long, SH; Marquis, MS			Geographic variation in physician visits for uninsured children - The role of the safety net	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HEALTH-CARE SERVICES; LOW-INCOME CHILDREN; 10 STATES; INSURANCE; MEDICAID; IMPACT; ACCESS	Context Although an extensive literature exists comparing national access to health care for uninsured vs insured children, few data exist regarding differences in access across states. Objective To examine variation in access to physician services for uninsured children in 10 states, the safety net's role in explaining this variation, and the potential effects of the State Children's Health Insurance Program (CHIP) on insurance coverage and access. Design and Setting The population-based Robert Wood Johnson Foundation Family Health Insurance Survey, conducted between summer 1993 and spring 1994 in 10 states (Colorado, Florida, Minnesota, New Mexico. New York, North Dakota, Oklahoma, Oregon, Vermont, and Washington), with a response rate of families by state ranging from 61% to 83%, Participants A total of 8565 children who were uninsured (1586), covered by Medicaid (2723), or covered by employer-sponsored private insurance (4256) for 1 full year prior to the survey. Main Outcome Measures Percentage of low-income children who are uninsured and predicted annual physician visits by state if insurance was provided to uninsured children in families with incomes of less than 200% of poverty level, Results In the 10 study states, low-income children ranged from 61% to 86% of all uninsured children and the uninsured rate for low-income children varied from 9% to 31%, On average, providing public coverage would increase annual physician visits from 2.3 to 4.6 (a 105% increase), but the increase would range from 41% to 189% across states. The annual physician visit rate in the 3 states with the highest access for the uninsured was 160% of that in the 3 lowest-access states. Safety net capacity in the high-access states ranged from 120% to 220% of that in the low-access states, Conclusions Our data suggest that the potential effects of CHIP vary substantially across states. Notably, improvements in access to health care by uninsured low-income children should be greater in states with the fewest safety net resources.	Rand Corp, Washington, DC USA	RAND Corporation	Long, SH (corresponding author), 1333 H St NW, Washington, DC 20005 USA.							*ALPH CTR, 1998, STAT INITIATIVES HLT, V29, P6; *AM HOSP ASS, 1993, 1992 ANN SURV HOSP; Atkinson G, 1997, HEALTH AFFAIR, V16, P233, DOI 10.1377/hlthaff.16.4.233; CANTOR JC, 1995, HEALTH AFFAIR, V14, P199, DOI 10.1377/hlthaff.14.2.199; Cantor JC, 1998, HEALTH AFFAIR, V17, P191, DOI 10.1377/hlthaff.17.1.191; Cunningham PJ, 1998, JAMA-J AM MED ASSOC, V280, P921, DOI 10.1001/jama.280.10.921; Duan N., 1982, COMP ALTERNATIVE MOD; *HLTH CAR FIN ADM, 1999, MED MAN CAR TRENDS; *HLTH CAR FIN ADM, 1999, CHILDR HLTH INS PROG; Holahan J, 1998, HEALTH AFFAIR, V17, P43, DOI 10.1377/hlthaff.17.3.43; Lave JR, 1998, JAMA-J AM MED ASSOC, V279, P1820, DOI 10.1001/jama.279.22.1820; LISKA D, 1998, STATE LEVEL DATABOOK; Long SH, 1998, J HEALTH ECON, V17, P105, DOI 10.1016/S0167-6296(97)00014-3; MARQUIS MS, 1994, INQUIRY-J HEALTH CAR, V31, P405; Marquis MS, 1996, HEALTH SERV RES, V30, P791; MCCLOSKEY AH, 1996, REFORMING HLTH CARE; MONHEIT AC, 1992, FUTURE CHILD, V2, P154; Newacheck PW, 1998, NEW ENGL J MED, V338, P513, DOI 10.1056/NEJM199802193380806; Newhouse JP, 1993, FREE ALL LESSONS RAN; ROSENBACH ML, 1989, AM J PUBLIC HEALTH, V79, P1220, DOI 10.2105/AJPH.79.9.1220; Rosenbaum S, 1998, HEALTH AFFAIR, V17, P75, DOI 10.1377/hlthaff.17.1.75; *RW JOHNS FDN, 1991, CALL PROP STAT IN HL; SHORT PF, 1992, MED CARE, V30, P766, DOI 10.1097/00005650-199209000-00002; Sparer MS, 1998, HEALTH AFFAIR, V17, P7, DOI 10.1377/hlthaff.17.3.7; SPILLMAN BC, 1992, INQUIRY-J HEALTH CAR, V29, P457; STODDARD JJ, 1994, NEW ENGL J MED, V330, P1421, DOI 10.1056/NEJM199405193302006; ULLMAN F, 1998, STATE CHILDRENS HLTH; *URB I, 1998, NEW FED STAT DAT; *US BUR PRIM HLTH, 1997, CHILDR HLTH INS PROG	29	21	21	0	3	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 2	1999	281	21					2035	2040		10.1001/jama.281.21.2035	http://dx.doi.org/10.1001/jama.281.21.2035			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	200NN	10359393	Bronze			2022-12-28	WOS:000080546700034
J	Lagergren, J; Bergstrom, R; Nyren, O				Lagergren, J; Bergstrom, R; Nyren, O			Association between body mass and adenocarcinoma of the esophagus and gastric cardia	ANNALS OF INTERNAL MEDICINE			English	Article						body mass index; stomach neoplasms; esophageal neoplasms; adenocarcinoma; obesity	INCREASING INCIDENCE; PORTION SIZE; OBESITY; TOBACCO; ALCOHOL; HEIGHT; INDEX; RISK; PREVALENCE; OVERWEIGHT	Background: The incidence of esophageal and gastric cardia adenocarcinoma is, for unknown reasons, increasing dramatically. A weak and inconsistent association between body mass index (BMI) and adenocarcinoma of the esophagus and gastric cardia has been reported. Objective: To reexamine the association between BMI and development of adenocarcinoma of the esophagus and gastric cardia. Design: Nationwide, population-based case-control study. Setting: Sweden, 1995 through 1997. Patients: Patients younger than 80 years of age who had recently received a diagnosis were eligible. Comprehensive organization ensured rapid case ascertainment. Controls were randomly selected from the continuously updated population register. Interviews were conducted with 189 patients with adenocarcinoma of the esophagus and 262 patients with adenocarcinoma of the gastric cardia; for comparison, 167 patients with incident esophageal squamous-cell carcinoma and 820 controls were also interviewed. Measurements: Odds ratios were determined from BMI and cancer case-control status. Odds ratios estimated the relative risk for the two adenocarcinomas studied and were calculated by multivariate logistic regression with adjustment for potential confounding factors. Results: A strong dose-dependent relation existed between BMI and esophageal adenocarcinoma. The adjusted odds ratio was 7.6 (95% CI, 3.8 to 15.2) among persons in the highest BMI quartile compared with persons in the lowest. Obese persons (persons with a BMI > 30 kg/m(2)) had an odds ratio of 16.2 (CI, 6.3 to 41.4) compared with the leanest persons (persons with a BMI < 22 kg/m(2)). The odds ratio for patients with cardia adenocarcinoma was 2.3 (CI, 1.5 to 3.6) in those in the highest BMI quartile compared with those in the lowest BMI quartile and 4.3 (CI, 2.1 to 8.7) among obese persons. Esophageal squamous-cell carcinoma was not associated with BMI. Conclusions: The association between BMI and esophageal adenocarcinoma is strong and is not explained by bias or confounding. The carcinogenic mechanism, however, remains to be clarified. The increasing prevalence of obesity in western countries could be important in understanding the increasing occurrence of this tumor.	Karolinska Inst, Dept Med Epidemiol, S-17177 Stockholm, Sweden; Uppsala Univ, Dept Stat, S-75120 Uppsala, Sweden	Karolinska Institutet; Uppsala University	Lagergren, J (corresponding author), Karolinska Inst, Dept Med Epidemiol, Box 281, S-17177 Stockholm, Sweden.	Jesper.Lagergren@mep.ki.se		Lagergren, Jesper/0000-0002-5143-5448	NATIONAL CANCER INSTITUTE [R01CA057947] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA57947-03] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ACHESON RM, 1964, BRIT J PREV SOC MED, V18, P25; [Anonymous], 1985, WHO TECH REP SER, P1; BLOT WJ, 1991, JAMA-J AM MED ASSOC, V265, P1287, DOI 10.1001/jama.265.10.1287; Breslow NE, 1980, IARC SCI PUBL, P5; BROWN LM, 1995, J NATL CANCER I, V87, P104, DOI 10.1093/jnci/87.2.104; Chow WH, 1998, JNCI-J NATL CANCER I, V90, P150, DOI 10.1093/jnci/90.2.150; FAGGIANO F, 1992, EPIDEMIOLOGY, V3, P379, DOI 10.1097/00001648-199207000-00015; FERRARA A, 1995, DIABETES CARE, V18, P220, DOI 10.2337/diacare.18.2.220; FLYVBJERG A, 1990, DIABETES ANN, V5, P642; GARROW JS, 1985, INT J OBESITY, V9, P147; HAGEN J, 1987, INT SURG, V72, P1; HANSSON LE, 1993, INT J CANCER, V54, P402, DOI 10.1002/ijc.2910540309; Ji BT, 1997, CANCER EPIDEM BIOMAR, V6, P481; KABAT GC, 1993, CANCER CAUSE CONTROL, V4, P123, DOI 10.1007/BF00053153; Kahn C. R., 1995, ENDOCRINOLOGY, P1373; Kim R, 1997, CANCER EPIDEM BIOMAR, V6, P369; KUCZMARSKI RJ, 1994, JAMA-J AM MED ASSOC, V272, P205, DOI 10.1001/jama.272.3.205; KUSKOWSKAWOLK A, 1993, J EPIDEMIOL COMMUN H, V47, P103, DOI 10.1136/jech.47.2.103; Lagergren J, 1999, NEW ENGL J MED, V340, P825, DOI 10.1056/NEJM199903183401101; LAVECCHIA C, 1990, INT J CANCER, V45, P275, DOI 10.1002/ijc.2910450212; MERCER CD, 1987, J MED, V18, P135; MITCHELL HS, 1962, J AM DIET ASSOC, V40, P521; MUST A, 1993, AM J EPIDEMIOL, V138, P56, DOI 10.1093/oxfordjournals.aje.a116777; Nelson M, 1996, BRIT J NUTR, V76, P31, DOI 10.1079/BJN19960007; PERA M, 1993, GASTROENTEROLOGY, V104, P510, DOI 10.1016/0016-5085(93)90420-H; Powell J, 1992, Eur J Cancer Prev, V1, P265, DOI 10.1097/00008469-199204000-00008; POWER C, 1988, INT J OBESITY, V12, P445; PRESTONMARTIN S, 1990, CANCER RES, V50, P7415; ROTHMAN KJ, 1998, MODERN EPIDEMIOLOGY, P127; Seidell JC, 1997, BRIT MED BULL, V53, P238, DOI 10.1093/oxfordjournals.bmb.a011611; STENELARSEN G, 1988, SCAND J GASTROENTERO, V23, P427, DOI 10.3109/00365528809093890; VAUGHAN TL, 1995, CANCER EPIDEM BIOMAR, V4, P85; Zhang ZF, 1996, CANCER EPIDEM BIOMAR, V5, P761	33	507	521	0	11	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 1	1999	130	11					883	+		10.7326/0003-4819-130-11-199906010-00003	http://dx.doi.org/10.7326/0003-4819-130-11-199906010-00003			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	200PB	10375336				2022-12-28	WOS:000080547900002
J	Pal, DK; Nandy, S; Sander, JWAS				Pal, DK; Nandy, S; Sander, JWAS			Towards a coherent public-health analysis for epilepsy	LANCET			English	Editorial Material									UCL, Inst Child Hlth, Neurosci Unit, London WC1N 3BG, England; UCL, Inst Neurol, Epilepsy Res Grp, London WC1N 3BG, England	University of London; University College London; University of London; University College London	Sander, JWAS (corresponding author), UCL, Inst Child Hlth, Neurosci Unit, London WC1N 3BG, England.		Sander, Josemir W/C-1576-2008	Sander, Josemir W/0000-0001-6041-9661; Nandy, Shailen/0000-0003-1066-9181				Pal DK, 1998, LANCET, V351, P19, DOI 10.1016/S0140-6736(97)06250-8; Sander JWAS, 1996, J NEUROL NEUROSUR PS, V61, P433, DOI 10.1136/jnnp.61.5.433; The World Bank, 1993, INV HLTH WORLD DEV I; *WHO, 1990, IN SUPP PEOPL EP; *WHO, 1978, APPL ADV NEUR CONTR; *WHO, 1975, WHO TECHN REP SER, V564; *WHO, 1985, COMM CONTR EP REP IN; *WORLD BANK, 1999, WORLD DEV IND	8	10	10	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	MAY 29	1999	353	9167					1817	1818		10.1016/S0140-6736(99)00189-0	http://dx.doi.org/10.1016/S0140-6736(99)00189-0			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	202TG	10359404				2022-12-28	WOS:000080667800007
J	Clapham, DE				Clapham, DE			Unlocking family secrets: K+ channel transmembrane domains	CELL			English	Review							POTASSIUM CHANNEL; ACETYLCHOLINE-RECEPTOR; MOLECULAR-BASIS; ION-CHANNEL; OPEN STATE; VOLTAGE; MECHANISM		Harvard Univ, Sch Med, Howard Hughes Med Inst, Boston, MA 02115 USA; Childrens Hosp, Boston, MA 02115 USA	Harvard University; Harvard Medical School; Howard Hughes Medical Institute; Harvard University; Boston Children's Hospital	Clapham, DE (corresponding author), Harvard Univ, Sch Med, Howard Hughes Med Inst, Boston, MA 02115 USA.		Clapham, David/R-5974-2019; Clapham, David/S-1123-2019	Clapham, David/0000-0002-4459-9428				Ackerman MJ, 1997, NEW ENGL J MED, V336, P1575, DOI 10.1056/NEJM199705293362207; Cabral JHM, 1998, CELL, V95, P649, DOI 10.1016/S0092-8674(00)81635-9; Cha A, 1998, J GEN PHYSIOL, V112, P391, DOI 10.1085/jgp.112.4.391; Chang G, 1998, SCIENCE, V282, P2220, DOI 10.1126/science.282.5397.2220; Choe S, 1995, P NATL ACAD SCI USA, V92, P12046, DOI 10.1073/pnas.92.26.12046; Doyle DA, 1998, SCIENCE, V280, P69, DOI 10.1126/science.280.5360.69; Doyle DA, 1996, CELL, V85, P1067, DOI 10.1016/S0092-8674(00)81307-0; Hille B., 1992, IONIC CHANNELS EXCIT; Holmgren M, 1998, NEURON, V21, P617, DOI 10.1016/S0896-6273(00)80571-1; Kreusch A, 1998, NATURE, V392, P945, DOI 10.1038/31978; LOGOTHETIS DE, 1987, NATURE, V325, P321, DOI 10.1038/325321a0; LOPATIN AN, 1994, NATURE, V372, P366, DOI 10.1038/372366a0; Minor DL, 1999, CELL, V96, P879, DOI 10.1016/S0092-8674(00)80597-8; Monks SA, 1999, J GEN PHYSIOL, V113, P415, DOI 10.1085/jgp.113.3.415; Papazian DM, 1997, NEWS PHYSIOL SCI, V12, P203; PAPAZIAN DM, 1995, NEURON, V14, P1293, DOI 10.1016/0896-6273(95)90276-7; Perozo E, 1998, NAT STRUCT BIOL, V5, P459, DOI 10.1038/nsb0698-459; Siegel MS, 1997, NEURON, V19, P735, DOI 10.1016/S0896-6273(00)80955-1; Unwin N, 1998, J STRUCT BIOL, V121, P181, DOI 10.1006/jsbi.1997.3949; UNWIN N, 1995, NATURE, V373, P37, DOI 10.1038/373037a0; Yellen G, 1998, Q REV BIOPHYS, V31, P239, DOI 10.1017/S0033583598003448	21	13	13	0	2	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAY 28	1999	97	5					547	550		10.1016/S0092-8674(00)80765-5	http://dx.doi.org/10.1016/S0092-8674(00)80765-5			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	202VD	10367883	Bronze			2022-12-28	WOS:000080672100003
J	Harkin, DP; Bean, JM; Miklos, D; Song, YH; Truong, VB; Englert, C; Christians, FC; Ellisen, LW; Maheswaran, S; Oliner, JD; Haber, DA				Harkin, DP; Bean, JM; Miklos, D; Song, YH; Truong, VB; Englert, C; Christians, FC; Ellisen, LW; Maheswaran, S; Oliner, JD; Haber, DA			Induction of GADD45 and JNK/SAPK-dependent apoptosis following inducible expression of BRCA1	CELL			English	Article							INTERACT IN-VIVO; CELL-CYCLE; DNA-DAMAGE; BREAST-CANCER; TRANSCRIPTIONAL ACTIVATION; MAMMALIAN-CELLS; GENE-EXPRESSION; PROTEIN; P53; PHOSPHORYLATION	The breast cancer susceptibility gene BRCA1 encodes a protein implicated in the cellular response to DNA damage, with postulated roles in homologous recombination as well as transcriptional regulation. To identify downstream target genes, we established cell lines with tightly regulated inducible expression of BRCA1. High-density oligonucleotide arrays were used to analyze gene expression profiles at various times following BRCA1 induction. A major BRCA1 target is the DNA damage-responsive gene GADD45. Induction of BRCA1 triggers apoptosis through activation of c-Jun N-terminal kinase/stress-activated protein kinase (JNK/SAPK), a signaling pathway potentially linked to GADD45 gene family members. The p53-independent induction of GADD45 by BRCA1 and its activation of JNK/SAPK suggest a pathway for BRCA1-induced apoptosis.	Massachusetts Gen Hosp, Ctr Canc, Charlestown, MA 02129 USA; Harvard Univ, Sch Med, Charlestown, MA 02129 USA; Affymetrix, Santa Clara, CA 95051 USA	Harvard University; Massachusetts General Hospital; Harvard University; Affymetrix	Haber, DA (corresponding author), Massachusetts Gen Hosp, Ctr Canc, Charlestown, MA 02129 USA.		Ellisen, Leif W/AAA-6572-2022	Ellisen, Leif W/0000-0003-0444-7910; Song, Young-Han/0000-0002-0758-3654; Englert, Christoph/0000-0002-5931-3189; Bean, James/0000-0001-6733-5794	NATIONAL CANCER INSTITUTE [R01CA058596, R37CA058596] Funding Source: NIH RePORTER; NCI NIH HHS [CA58596] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDERSON S, 1998, NAT GENET, V19, P1; Chapman MS, 1996, NATURE, V382, P678, DOI 10.1038/382678a0; Chen YR, 1996, J BIOL CHEM, V271, P631, DOI 10.1074/jbc.271.2.631; Cho RJ, 1998, MOL CELL, V2, P65, DOI 10.1016/S1097-2765(00)80114-8; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FORNACE AJ, 1988, P NATL ACAD SCI USA, V85, P8800, DOI 10.1073/pnas.85.23.8800; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; Hakem R, 1997, NAT GENET, V16, P298, DOI 10.1038/ng0797-298; Hakem R, 1996, CELL, V85, P1009, DOI 10.1016/S0092-8674(00)81302-1; HOLLANDER MC, 1993, J BIOL CHEM, V268, P24385; Holt JT, 1996, NAT GENET, V12, P298, DOI 10.1038/ng0396-298; Honkoop AH, 1998, BRIT J CANCER, V77, P621, DOI 10.1038/bjc.1998.99; Hsu LC, 1998, P NATL ACAD SCI USA, V95, P12983, DOI 10.1073/pnas.95.22.12983; Iyer VR, 1999, SCIENCE, V283, P83, DOI 10.1126/science.283.5398.83; Jarvis EM, 1998, CANCER GENET CYTOGEN, V101, P109, DOI 10.1016/S0165-4608(97)00267-7; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; LANE TF, 1995, GENE DEV, V9, P2712, DOI 10.1101/gad.9.21.2712; Lim CP, 1998, ONCOGENE, V16, P2915, DOI 10.1038/sj.onc.1201834; LIU CY, 1996, GENE DEV, V90, P2112; Lockhart DJ, 1996, NAT BIOTECHNOL, V14, P1675, DOI 10.1038/nbt1296-1675; Ludwig T, 1997, GENE DEV, V11, P1226, DOI 10.1101/gad.11.10.1226; MARQUIS ST, 1995, NAT GENET, V11, P17, DOI 10.1038/ng0995-17; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; Monteiro ANA, 1996, P NATL ACAD SCI USA, V93, P13595, DOI 10.1073/pnas.93.24.13595; Ouchi T, 1998, P NATL ACAD SCI USA, V95, P2302, DOI 10.1073/pnas.95.5.2302; Rosette C, 1996, SCIENCE, V274, P1194, DOI 10.1126/science.274.5290.1194; Ruffner H, 1997, P NATL ACAD SCI USA, V94, P7138, DOI 10.1073/pnas.94.14.7138; Scully R, 1997, CELL, V88, P265, DOI 10.1016/S0092-8674(00)81847-4; Scully R, 1997, CELL, V90, P425, DOI 10.1016/S0092-8674(00)80503-6; Scully R, 1997, P NATL ACAD SCI USA, V94, P5605, DOI 10.1073/pnas.94.11.5605; Shao NS, 1996, ONCOGENE, V13, P1; Somasundaram K, 1997, NATURE, V389, P187, DOI 10.1038/38291; Takekawa M, 1998, CELL, V95, P521, DOI 10.1016/S0092-8674(00)81619-0; Thomas JE, 1997, CELL GROWTH DIFFER, V8, P801; Tomlinson GE, 1998, CANCER RES, V58, P3237; VELCULESCU VE, 1995, SCIENCE, V270, P484, DOI 10.1126/science.270.5235.484; Wang Q, 1998, ONCOGENE, V17, P1939, DOI 10.1038/sj.onc.1202403; Wilson CA, 1997, ONCOGENE, V14, P1, DOI 10.1038/sj.onc.1200924; Wodicka L, 1997, NAT BIOTECHNOL, V15, P1359, DOI 10.1038/nbt1297-1359; Wu LJC, 1996, NAT GENET, V14, P430, DOI 10.1038/ng1296-430; Xu XL, 1999, MOL CELL, V3, P389, DOI 10.1016/S1097-2765(00)80466-9; YAN MH, 1994, NATURE, V372, P798; Yu X, 1998, J BIOL CHEM, V273, P25388, DOI 10.1074/jbc.273.39.25388; Zhang HB, 1998, ONCOGENE, V16, P1713, DOI 10.1038/sj.onc.1201932	44	489	505	0	15	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAY 28	1999	97	5					575	586		10.1016/S0092-8674(00)80769-2	http://dx.doi.org/10.1016/S0092-8674(00)80769-2			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	202VD	10367887	Bronze			2022-12-28	WOS:000080672100007
J	Hemler, ME				Hemler, ME			Dystroglycan versatility	CELL			English	Review							LYMPHOCYTIC CHORIOMENINGITIS VIRUS; ALPHA-DYSTROGLYCAN; RECEPTOR; MEMBRANE; LAMININ-1; PROTEIN; AGRIN		Dana Farber Canc Inst, Boston, MA 02115 USA	Harvard University; Dana-Farber Cancer Institute	Hemler, ME (corresponding author), Dana Farber Canc Inst, Boston, MA 02115 USA.							BORROW P, 1994, VIROLOGY, V198, P1, DOI 10.1006/viro.1994.1001; Cao W, 1998, SCIENCE, V282, P2079, DOI 10.1126/science.282.5396.2079; Cartaud A, 1998, J BIOL CHEM, V273, P11321, DOI 10.1074/jbc.273.18.11321; Colognato H, 1999, J CELL BIOL, V145, P619, DOI 10.1083/jcb.145.3.619; Denzer AJ, 1998, EMBO J, V17, P335, DOI 10.1093/emboj/17.2.335; Durbeej M, 1998, CURR OPIN CELL BIOL, V10, P594, DOI 10.1016/S0955-0674(98)80034-3; Gesemann M, 1998, J BIOL CHEM, V273, P600, DOI 10.1074/jbc.273.1.600; Henry MD, 1998, CELL, V95, P859, DOI 10.1016/S0092-8674(00)81708-0; Montanaro F, 1998, J NEUROSCI, V18, P1250; Peng HB, 1998, CELL ADHES COMMUN, V5, P475, DOI 10.3109/15419069809005605; Rambukkana A, 1997, CELL, V88, P811, DOI 10.1016/S0092-8674(00)81927-3; Sasaki T, 1998, EXP CELL RES, V238, P70, DOI 10.1006/excr.1997.3837; Schwarzbauer J, 1999, CURR BIOL, V9, pR242, DOI 10.1016/S0960-9822(99)80153-5; Talts JF, 1999, EMBO J, V18, P863, DOI 10.1093/emboj/18.4.863; Timpl R, 1996, BIOESSAYS, V18, P123, DOI 10.1002/bies.950180208; Williamson RA, 1997, HUM MOL GENET, V6, P831, DOI 10.1093/hmg/6.6.831; WU CY, 1995, CELL, V83, P715, DOI 10.1016/0092-8674(95)90184-1	17	55	60	0	0	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	MAY 28	1999	97	5					543	546		10.1016/S0092-8674(00)80764-3	http://dx.doi.org/10.1016/S0092-8674(00)80764-3			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	202VD	10367882	Bronze			2022-12-28	WOS:000080672100002
J	Hamm, CW; Heeschen, C; Goldmann, B; Vahanian, A; Adgey, J; Miguel, CM; Rutsch, W; Berger, J; Kootstra, J; Simoons, ML				Hamm, CW; Heeschen, C; Goldmann, B; Vahanian, A; Adgey, J; Miguel, CM; Rutsch, W; Berger, J; Kootstra, J; Simoons, ML		CAPTURE Study Investigators	Benefit of abciximab in patients with refractory unstable angina in relation to serum troponin T levels	NEW ENGLAND JOURNAL OF MEDICINE			English	Article; Proceedings Paper	47th Annual Scientific Session of the American-College-of-Cardiology	MAR 29-APR 01, 1998	ATLANTA, GEORGIA	Amer Coll Cardiol			CORONARY-ARTERY DISEASE; ACUTE MYOCARDIAL-INFARCTION; KINASE ISOENZYME-MB; PROGNOSTIC VALUE; RISK STRATIFICATION; DEATH; THROMBOSIS; MASS	Background In patients with refractory unstable angina, the platelet glycoprotein Ilb/IIIa-receptor antibody abciximab reduces the incidence of cardiac events before and during coronary angioplasty. We investigated whether serum troponin T levels identify patients most likely to benefit from therapy with this drug. Methods Among 1265 patients with unstable angina who were enrolled in the c7E3 Fab Antiplatelet Therapy in Unstable Refractory Angina (CAPTURE) trial, serum samples drawn at the time of randomization to abciximab or placebo were available from 890 patients; we used these samples for the determination of troponin T and creatine kinase MB levels. Patients with postinfarction angina were not included. Results Serum troponin T levels at the time of study entry were elevated (above 0.1 ng per milliliter) in 275 patients (30.9 percent). Among patients receiving placebo, the risk of death or nonfatal myocardial infarction was related to troponin T levels. The six-month cumulative event rate was 23.9 percent among patients with elevated troponin T levels, as compared with 7.5 percent among patients without elevated troponin T levels (P < 0.001). Among patients treated with abciximab, the respective six-month event rates were 9.5 percent for patients with elevated troponin T levels and 9.4 percent for those without elevated levels. As compared with placebo, the relative risk of death or nonfatal myocardial infarction associated with treatment with abciximab in patients with elevated troponin T levels was 0.32 (95 percent confidence interval, 0.14 to 0.62; P = 0.002). The lower event rates in patients receiving abciximab were attributable to a reduction in the rate of myocardial infarction (odds ratio, 0.23; 95 percent confidence interval, 0.12 to 0.49; P < 0.001). In patients without elevated troponin T levels, there was no benefit of treatment with respect to the relative risk of death or myocardial infarction at six months (odds ratio, 1.26; 95 percent confidence interval, 0.74 to 2.31; P = 0.47). Conclusions The serum troponin T level, which is considered to be a surrogate marker for thrombus formation, identifies a high-risk subgroup of patients with refractory unstable angina suitable for coronary angioplasty who will particularly benefit from antiplatelet treatment with abciximab. (N Engl J Med 1999;340:1623-9.) (C) 1999, Massachusetts Medical Society.	Univ Hamburg, Hosp Eppendorf, Dept Cardiol, D-20246 Hamburg, Germany; Univ Hamburg, Hosp Eppendorf, Inst Math & Comp Sci Med, D-20246 Hamburg, Germany; Hop Tenon, Serv Cardiol, F-75970 Paris, France; Royal Victoria Hosp, Dept Cardiac, Belfast BT12 6BA, Antrim, North Ireland; Hosp Univ San Carlos, Unidad Hemodinam, Madrid, Spain; Charite Univ Hosp, Dept Cardiol, Berlin, Germany; Erasmus Univ, Rotterdam, Netherlands	University of Hamburg; University of Hamburg; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Tenon - APHP; UDICE-French Research Universities; Sorbonne Universite; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Erasmus University Rotterdam	Hamm, CW (corresponding author), Kerckhoff Heart Ctr, Benekestr 2-8, D-61231 Bad Nauheim, Germany.		Hamm, Christian W./I-3155-2017; Guba, Markus/M-4309-2019	Hamm, Christian W./0000-0001-6763-4161; Heeschen, Christopher/0000-0002-1158-8554				Antman EM, 1996, NEW ENGL J MED, V335, P1342, DOI 10.1056/NEJM199610313351802; BHAYANA V, 1995, CLIN CHEM, V41, P312; BRAUNWALD E, 1989, CIRCULATION, V80, P410, DOI 10.1161/01.CIR.80.2.410; *CAPTURE INV, 1997, LANCET, V350, P744; DAVIES MJ, 1986, CIRCULATION, V73, P418, DOI 10.1161/01.CIR.73.3.418; FALK E, 1985, CIRCULATION, V71, P699, DOI 10.1161/01.CIR.71.4.699; Farb A, 1996, CIRCULATION, V93, P1354, DOI 10.1161/01.CIR.93.7.1354; GERHARDT W, 1991, CLIN CHEM, V37, P1405; Hamm CW, 1997, NEW ENGL J MED, V337, P1648, DOI 10.1056/NEJM199712043372302; HAMM CW, 1992, NEW ENGL J MED, V327, P146, DOI 10.1056/NEJM199207163270302; Lindahl B, 1997, J AM COLL CARDIOL, V29, P43, DOI 10.1016/S0735-1097(96)00447-0; Lindahl B, 1996, CIRCULATION, V93, P1651, DOI 10.1161/01.CIR.93.9.1651; Luscher MS, 1997, CIRCULATION, V96, P2578, DOI 10.1161/01.CIR.96.8.2578; Mueller-Bardorff Margit, 1997, Clinical Chemistry, V43, P458; Ohman EM, 1996, NEW ENGL J MED, V335, P1333, DOI 10.1056/NEJM199610313351801; RAVKILDE J, 1995, J AM COLL CARDIOL, V25, P574, DOI 10.1016/0735-1097(94)00430-X; RAVKILDE J, 1993, SCAND J CLIN LAB INV, V53, P677, DOI 10.3109/00365519309092571; Simoons ML, 1997, LANCET, V349, P1429; Stubbs P, 1996, CIRCULATION, V94, P1291, DOI 10.1161/01.CIR.94.6.1291; Tukey J. W., 1977, EXPLORATORY DATA ANA; WU AHB, 1995, AM J CARDIOL, V76, P970, DOI 10.1016/S0002-9149(99)80274-4	21	533	550	0	5	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAY 27	1999	340	21					1623	1629		10.1056/NEJM199905273402103	http://dx.doi.org/10.1056/NEJM199905273402103			7	Medicine, General & Internal	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	199QY	10341274	Green Published			2022-12-28	WOS:000080494200003
J	Kassirer, JP				Kassirer, JP			Editorial independence	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							PHARMACEUTICAL ADVERTISEMENTS; MEDICAL JOURNALS; REFORM											ANGELL M, 1993, NEW ENGL J MED, V328, P1778, DOI 10.1056/NEJM199306173282409; BAGDIKIAN BH, 1997, MEDIA MONOPOLY, P27; Burchell MC, 1999, NEW ENGL J MED, V340, P1682; CARVAJAL D, 1999, NY TIMES        0208; FLETCHER RH, 1992, ANN INTERN MED, V116, P951, DOI 10.7326/0003-4819-116-11-951; GELINE RA, 1999, PHYSICIANS WEEK 0301, V16; HANEY DQ, 1994, BOSTON GLOBE    1213, P11; Hoey J, 1999, CAN MED ASSOC J, V160, P507; Horton R, 1999, LANCET, V353, P252, DOI 10.1016/S0140-6736(99)00019-7; JURKOWITZ M, 1999, BOSTON GLOBE    0216, pC1; Kassirer JP, 1999, NEW ENGL J MED, V340, P466, DOI 10.1056/NEJM199902113400609; KLAIDMAN S, 1987, VIRTUOUS J; MORSE LJ, 1993, NEW ENGL J MED, V329, P804, DOI 10.1056/NEJM199309093291112; OBRIEN E, 1987, IRISH MED J, V80, P247; OBRIEN E, 1987, IRISH MED J, V80, P335; ODONNELL M, 1991, BRIT MED J, V302, P1259, DOI 10.1136/bmj.302.6787.1259; Parmet AJ, 1999, NEW ENGL J MED, V340, P1682; Smith R, 1999, BRIT MED J, V318, P210; STERNGOLD J, 1997, NY TIMES        1010, P5; Van Der Weyden MB, 1999, MED J AUSTRALIA, V170, P151, DOI 10.5694/j.1326-5377.1999.tb127709.x; WILKES MS, 1992, ANN INTERN MED, V116, P912, DOI 10.7326/0003-4819-116-11-912; 1995, BMJ, V310, P690; 1987, LANCET, V2, P1442	23	29	32	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAY 27	1999	340	21					1671	1672		10.1056/NEJM199905273402109	http://dx.doi.org/10.1056/NEJM199905273402109			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	199QY	10341280				2022-12-28	WOS:000080494200009
J	Harrison, LH; Dwyer, DM; Maples, CT; Billmann, L				Harrison, LH; Dwyer, DM; Maples, CT; Billmann, L			Risk of meningococcal infection in college students	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CAMPUS BAR PATRONAGE; UNITED-STATES; DISEASE; VACCINATION; MENINGITIS; OUTBREAK	Context The number of meningococcal outbreaks on college campuses have been increasing in the past few years. However, no published studies have documented the incidence of invasive meningococcal infection in college students or whether the incidence is higher than in the general population of the same age. Objective To compare the incidence of invasive meningococcal infection in Maryland college students with that of the general population of the same age, Design Retrospective cohort study. Setting and Patients Maryland residents with meningococcal infection from 1992-1997 identified from active, laboratory-based, statewide surveillance for invasive meningococcal disease, Main Outcome Measures Incidence of invasive meningococcal infection. Results Of 228 patients with invasive meningococcal infection, 67 were aged 16 to 30 years; 11 and 3 of these attended Maryland 4- and 2-year colleges, respectively, Of these, 12 (86%) had infection caused by Neisseria meningitidis serogroups included in the current meningococcal vaccine. The average annual incidence was 1.74 per 100 000 among students in 4-year schools vs 1.44 per 100 000 for the general population of the same age (P = .60). Among students in 4-year schools, the incidence was 3.24 per 100 000 in on-campus residents vs 0.96 per 100 000 in off-campus residents (relative risk, 3.4; 95% confidence interval, 1.0-11.6; P = .05). Conclusions The incidence of meningococcal infection in college students is similar to the incidence in the general population of the same age, but college students residing on campus appear to be at higher risk than those residing off campus.	Univ Pittsburgh, Grad Sch Publ Hlth, Dept Epidemiol, Pittsburgh, PA 15261 USA; Univ Pittsburgh, Grad Sch Publ Hlth, Dept Med, Pittsburgh, PA 15261 USA; Johns Hopkins Univ, Sch Hyg & Publ Hlth, Dept Int Hlth, Baltimore, MD USA; Maryland Dept Hlth & Mental Hyg, Epidemiol & Dis Control Program, Community & Publ Hlth Adm, Baltimore, MD USA; George Washington Univ, Dept Epidemiol & Biostat, Sch Publ Hlth & Hlth Serv, Washington, DC USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Johns Hopkins University; Maryland Department of Health & Mental Hygiene; George Washington University	Harrison, LH (corresponding author), Univ Pittsburgh, Grad Sch Publ Hlth, Dept Epidemiol, 521 Parran Hall,130 DeSoto St, Pittsburgh, PA 15261 USA.							*AM COLL HLTH ASS, 1999, REC MEN MEN VACC; BROOME CV, 1986, J ANTIMICROB CHEMOTH, V18, P25, DOI 10.1093/jac/18.Supplement_A.25; BRUNDAGE JF, 1987, EVOLUTION MENINGOCOC, P5; *CONTR PREV MEN DI, 1997, MMWR MORB MORT WKLY, V46, P1; Control and prevention of serogroup C meningococcal disease, 1997, MMWR-MORBID MORTAL W, V46, P13; Fischer M, 1997, PEDIATR INFECT DIS J, V16, P979, DOI 10.1097/00006454-199710000-00015; FISCHER M, 1998, 36 ANN M INF DIS SOC; FROESCHLE JE, IN PRESS CLIN INFECT; HARRISON LH, 1995, JAMA-J AM MED ASSOC, V273, P419, DOI 10.1001/jama.273.5.419; Harrison LH, 1998, J INFECT DIS, V177, P998, DOI 10.1086/515260; HARRISON LH, 1987, EVOLUTION MENINGOCOC, P27; Imrey PB, 1996, AM J EPIDEMIOL, V143, P624, DOI 10.1093/oxfordjournals.aje.a008792; IMREY PB, 1995, J CLIN MICROBIOL, V33, P3133, DOI 10.1128/JCM.33.12.3133-3137.1995; JACKSON LA, 1995, JAMA-J AM MED ASSOC, V273, P383, DOI 10.1001/jama.273.5.383; JACKSON LA, 1995, AM J PUBLIC HEALTH, V85, P843, DOI 10.2105/AJPH.85.6.843; Jackson Lisa A., 1993, Morbidity and Mortality Weekly Report, V42, P21; MOORE PS, 1992, CLIN INFECT DIS, V14, P515, DOI 10.1093/clinids/14.2.515; NGUYENVANTAM JS, 1998, 11 INT PATH NELS C N; Roberts CL, 1996, AM J PUBLIC HEALTH, V86, P1155, DOI 10.2105/AJPH.86.8_Pt_1.1155; Rosenstein N, 1998, JAMA-J AM MED ASSOC, V279, P435, DOI 10.1001/jama.279.6.435; Schuchat A, 1997, NEW ENGL J MED, V337, P970, DOI 10.1056/NEJM199710023371404; *SER Y MEN DIS ILL, 1996, MMWR-MORBID MORTAL W, V45, P1010; WOODS CW, 1998, 36 ANN M INF DIS SOC	23	112	115	0	4	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 26	1999	281	20					1906	1910		10.1001/jama.281.20.1906	http://dx.doi.org/10.1001/jama.281.20.1906			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	198ME	10349894	Bronze			2022-12-28	WOS:000080427300030
J	Swearingen, B; Biller, BMK; Barker, FG; Katznelson, L; Grinspoon, S; Klibanski, A; Zervas, NT				Swearingen, B; Biller, BMK; Barker, FG; Katznelson, L; Grinspoon, S; Klibanski, A; Zervas, NT			Long-term mortality after transsphenoidal surgery for Cushing disease	ANNALS OF INTERNAL MEDICINE			English	Article							MACROADENOMAS; MICROSURGERY	Background: Untreated Cushing disease historically has a high mortality rate, but the long-term survival of patients with Cushing disease after transsphenoidal surgery has not been reported. Objective: To determine long-term mortality rate in patients who are treated for Cushing disease with current management techniques. Design: Retrospective case series. Setting: Tertiary care center. Patients: 161 patients (32 men and 129 women; mean age, 38 years) who were treated for Cushing disease between 1978 and 1996. Intervention: Transsphenoidal adenomectomy and as-needed adjunctive therapy. Measurement: Record review with follow-up interview. Results: The cure rate for patients with microadenomas who had no previous therapy was 90% (123 of 137). No perioperative deaths occurred (0 of 193 procedures [95% CI, 0.0% to 1.9%]). Follow-up data (mean, 8.7 years) were obtained for 99% of patients (159 of 161). Six patients died. The 5- and 10-year survival rates were 99% (CI, 97% to 100%) and 93% (CI, 88% to 99%), respectively. Survival was similar to that seen in an age- and sex-matched sample that was based on U.S. population data (standardized mortality ratio, 0.98 [CI, 0.44 to 2.2]; P > 0.2). Conclusion: Survival of patients treated for Cushing disease with current management techniques between 1978 and 1996 was better than the poor survival historically associated with this disorder.	Massachusetts Gen Hosp, Neurol Serv, Boston, MA 02114 USA; Harvard Univ, Sch Med, Boston, MA USA	Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School	Swearingen, B (corresponding author), Massachusetts Gen Hosp, Neurol Serv, Fruit St, Boston, MA 02114 USA.							BERRY G, 1983, BIOMETRICS, V39, P173, DOI 10.2307/2530817; BIGOS ST, 1980, J CLIN ENDOCR METAB, V50, P348, DOI 10.1210/jcem-50-2-348; Blevins LS, 1998, J CLIN ENDOCR METAB, V83, P63, DOI 10.1210/jc.83.1.63; CHANDLER WF, 1987, J NEUROSURG, V66, P204, DOI 10.3171/jns.1987.66.2.0204; Cushing H, 1932, B JOHNS HOPKINS HOSP, V50, P137; ETXABE J, 1994, CLIN ENDOCRINOL, V40, P479, DOI 10.1111/j.1365-2265.1994.tb02486.x; FAHLBUSCH R, 1986, J ROY SOC MED, V79, P262, DOI 10.1177/014107688607900504; Katznelson L, 1998, J CLIN ENDOCR METAB, V83, P1619, DOI 10.1210/jc.83.5.1619; Klein JP., 2003, SURVIVAL ANAL TECHNI; MAMPALAM TJ, 1988, ANN INTERN MED, V109, P487, DOI 10.7326/0003-4819-109-6-487; Meier CA, 1997, ENDOCRIN METAB CLIN, V26, P741, DOI 10.1016/S0889-8529(05)70280-2; ORIORDAIN DS, 1994, SURGERY, V116, P1088; ORTH DN, 1971, NEW ENGL J MED, V285, P243, DOI 10.1056/NEJM197107292850501; PLOTZ CM, 1952, AM J MED, V13, P597, DOI 10.1016/0002-9343(52)90027-2; SALASSA RM, 1978, MAYO CLIN PROC, V53, P24; *STAT SCI, 1995, S PLUS GUID STAT MAT; TINDALL GT, 1990, J NEUROSURG, V72, P363, DOI 10.3171/jns.1990.72.3.0363; VERHEUL HA, 1993, LANCET, V341, P872, DOI 10.1016/0140-6736(93)93073-A	18	191	194	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAY 18	1999	130	10					821	824		10.7326/0003-4819-130-10-199905180-00015	http://dx.doi.org/10.7326/0003-4819-130-10-199905180-00015			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	196JJ	10366371				2022-12-28	WOS:000080305000004
J	Boulanger, L; Poo, MM				Boulanger, L; Poo, MM			Gating of BDNF-induced synaptic potentiation by cAMP	SCIENCE			English	Article							NERVE GROWTH-FACTOR; LONG-TERM POTENTIATION; CULTURED HIPPOCAMPAL-NEURONS; NEUROTROPHIC FACTOR; CYCLIC-AMP; SIGNALING PATHWAY; CORTICAL-NEURONS; VISUAL-CORTEX; CA1 REGION; BRAIN	Neurotrophins have been implicated in activity-dependent synaptic plasticity, but the underlying intracellular mechanisms remain Largely unknown. Synaptic potentiation induced by brain-derived neurotrophic factor (BDNF), but not neurotrophin 3, was prevented by blockers of adenosine 3',5'-monophosphate (cAMP) signaling. Activators of cAMP signaling alone were ineffective in modifying synaptic efficacy but greatly enhanced the potentiation effect of BDNF. Blocking cAMP signaling abolished the facilitation of BDNF-induced potentiation by presynaptic activity. Thus synaptic actions of BDNF are gated by cAMP. Activity and other coincident signals that modulate cAMP concentrations may specify the action of secreted neurotrophins on developing nerve terminals.	Univ Calif San Diego, Dept Biol, La Jolla, CA 92093 USA	University of California System; University of California San Diego	Poo, MM (corresponding author), Univ Calif San Diego, Dept Biol, La Jolla, CA 92093 USA.			Boulanger, Lisa/0000-0002-6578-7890	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS037831] Funding Source: NIH RePORTER; NINDS NIH HHS [NS 37831] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Agnihotri N, 1997, J NEUROSCI RES, V47, P555, DOI 10.1002/(SICI)1097-4547(19970301)47:5<555::AID-JNR11>3.0.CO;2-X; BARBACID M, 1994, J NEUROBIOL, V25, P1386, DOI 10.1002/neu.480251107; Berninger B, 1996, CURR OPIN NEUROBIOL, V6, P324, DOI 10.1016/S0959-4388(96)80115-2; Blitzer RD, 1995, NEURON, V15, P1403, DOI 10.1016/0896-6273(95)90018-7; BLOCHL A, 1995, EUR J NEUROSCI, V7, P1220, DOI 10.1111/j.1460-9568.1995.tb01112.x; Bonhoeffer T, 1996, CURR OPIN NEUROBIOL, V6, P119, DOI 10.1016/S0959-4388(96)80017-1; Boulanger L, 1999, NAT NEUROSCI, V2, P346, DOI 10.1038/7258; CABELLI RJ, 1995, SCIENCE, V267, P1662, DOI 10.1126/science.7886458; Cabelli RJ, 1997, NEURON, V19, P63, DOI 10.1016/S0896-6273(00)80348-7; CASTELLUCCI VF, 1982, J NEUROSCI, V2, P1673; CHEN JH, 1994, SCIENCE, V263, P1278, DOI 10.1126/science.8122111; COHENCORY S, 1995, NATURE, V378, P192, DOI 10.1038/378192a0; CONDORELLI DF, 1994, J NEUROCHEM, V63, P509; CONNOLLY JL, 1985, J NEUROSCI RES, V13, P183, DOI 10.1002/jnr.490130113; FAN CM, 1995, CELL, V81, P457, DOI 10.1016/0092-8674(95)90398-4; FERRENDELLI JA, 1980, BRAIN RES, V200, P93, DOI 10.1016/0006-8993(80)91097-5; Figurov A, 1996, NATURE, V381, P706, DOI 10.1038/381706a0; FREY U, 1993, SCIENCE, V260, P1661, DOI 10.1126/science.8389057; FUNAKOSHI H, 1995, SCIENCE, V268, P1495, DOI 10.1126/science.7770776; GALL CM, 1989, SCIENCE, V245, P758, DOI 10.1126/science.2549634; Goodman LJ, 1996, MOL CELL NEUROSCI, V7, P222, DOI 10.1006/mcne.1996.0017; Gottschalk W, 1998, J NEUROSCI, V18, P6830; Hempel CM, 1996, NATURE, V384, P166, DOI 10.1038/384166a0; Heumann Rolf, 1994, Current Opinion in Neurobiology, V4, P668, DOI 10.1016/0959-4388(94)90008-6; Heymach JV, 1996, J BIOL CHEM, V271, P25430, DOI 10.1074/jbc.271.41.25430; HUANG YY, 1994, CELL, V79, P69, DOI 10.1016/0092-8674(94)90401-4; Iyengar R, 1996, SCIENCE, V271, P461, DOI 10.1126/science.271.5248.461; KANDEL ER, 1982, SCIENCE, V218, P433, DOI 10.1126/science.6289442; KANG HJ, 1995, SCIENCE, V267, P1658, DOI 10.1126/science.7886457; Kang HJ, 1997, NEURON, V19, P653, DOI 10.1016/S0896-6273(00)80378-5; Kaplan DR, 1997, CURR OPIN CELL BIOL, V9, P213, DOI 10.1016/S0955-0674(97)80065-8; Katz LC, 1996, SCIENCE, V274, P1133, DOI 10.1126/science.274.5290.1133; KIM HG, 1994, P NATL ACAD SCI USA, V91, P12341, DOI 10.1073/pnas.91.25.12341; KNIPPER M, 1993, FEBS LETT, V324, P147, DOI 10.1016/0014-5793(93)81382-A; KNIPPER M, 1993, NEUROREPORT, V4, P483, DOI 10.1097/00001756-199305000-00005; KORTE M, 1995, P NATL ACAD SCI USA, V92, P8856, DOI 10.1073/pnas.92.19.8856; Korte M, 1996, J PHYSIOLOGY-PARIS, V90, P157, DOI 10.1016/S0928-4257(97)81415-5; Korte M, 1996, P NATL ACAD SCI USA, V93, P12547, DOI 10.1073/pnas.93.22.12547; LAUFER R, 1987, EMBO J, V6, P901, DOI 10.1002/j.1460-2075.1987.tb04836.x; LESSMANN V, 1994, NEUROREPORT, V6, P21; Lewin GR, 1996, ANNU REV NEUROSCI, V19, P289, DOI 10.1146/annurev.ne.19.030196.001445; LO DC, 1995, NEURON, V15, P979, DOI 10.1016/0896-6273(95)90085-3; LOHOF AM, 1993, NATURE, V363, P350, DOI 10.1038/363350a0; LU B, 1991, P NATL ACAD SCI USA, V88, P6289, DOI 10.1073/pnas.88.14.6289; LU B, 1993, NATURE, V363, P76, DOI 10.1038/363076a0; MAFFEI L, 1992, J NEUROSCI, V12, P4651; MCALLISTER AK, 1995, NEURON, V15, P791, DOI 10.1016/0896-6273(95)90171-X; Meyer-Franke A, 1998, NEURON, V21, P681, DOI 10.1016/S0896-6273(00)80586-3; MEYERFRANKE A, 1995, NEURON, V15, P805, DOI 10.1016/0896-6273(95)90172-8; Ming GL, 1997, J NEUROSCI, V17, P7860; Patterson SL, 1996, NEURON, V16, P1137, DOI 10.1016/S0896-6273(00)80140-3; REDDY R, 1995, J BIOL CHEM, V270, P14340, DOI 10.1074/jbc.270.24.14340; Sala R, 1998, EUR J NEUROSCI, V10, P2185, DOI 10.1046/j.1460-9568.1998.00227.x; Song HJ, 1997, NATURE, V388, P275, DOI 10.1038/40864; Stoop R, 1996, J NEUROSCI, V16, P3256; THOENEN H, 1995, SCIENCE, V270, P593, DOI 10.1126/science.270.5236.593; Wang Q, 1998, J NEUROSCI, V18, P4973; Wang XH, 1997, NEURON, V19, P825, DOI 10.1016/S0896-6273(00)80964-2; WEISSKOPF MG, 1994, SCIENCE, V265, P1878, DOI 10.1126/science.7916482; ZAFRA F, 1990, EMBO J, V9, P3545, DOI 10.1002/j.1460-2075.1990.tb07564.x	60	103	105	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 18	1999	284	5422					1982	1984		10.1126/science.284.5422.1982	http://dx.doi.org/10.1126/science.284.5422.1982			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	207JA	10373115				2022-12-28	WOS:000080932700045
J	Eisenhofer, G; Lenders, JWM; Linehan, WM; Walther, MM; Goldstein, DS; Keiser, HR				Eisenhofer, G; Lenders, JWM; Linehan, WM; Walther, MM; Goldstein, DS; Keiser, HR			Plasma normetanephrine and metanephrine for detecting pheochromocytoma in Von Hippel-Lindau disease and multiple endocrine neoplasia type 2	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							LIQUID-CHROMATOGRAPHY; DIAGNOSIS; URINARY; CATECHOLAMINES; METABOLISM	Background. The detection of pheochromocytomas in patients at risk for these tumors, such as patients with von Hippel-Lindau disease or multiple endocrine neoplasia type 2 (MEN-2), is hindered by the inadequate sensitivity of commonly available biochemical tests. In this study we evaluated measurements of plasma normetanephrine and metanephrine for detecting pheochromocytomas in patients with von Hippel-Lindau disease or MEN-2. Methods. We studied 26 patients with von Hippel-Lindau disease and 9 patients with MEN-2 who had histologically verified pheochromocytomas and 50 patients with von Hippel-Lindau disease or MEN-2 who had no radiologic evidence of pheochromocytoma. Von Hippel-Lindau disease and MEN-2 were diagnosed on the basis of germ-line mutations of the appropriate genes. The plasma concentrations of normetanephrine and metanephrine were compared with the plasma concentrations of catecholamines (norepinephrine and epinephrine) and urinary excretion of catecholamines, metanephrines, and vanillylmandelic acid. Results. The sensitivity of measurements of plasma normetanephrine and metanephrine for the detection of tumors was 97 percent, whereas the other biochemical tests had a sensitivity of only 47 to 74 percent. All patients with MEN-2 had high plasma concentrations of metanephrine, whereas the patients with von Hippel-Lindau disease had almost exclusively high plasma concentrations of only normetanephrine. One patient with von Hippel-Lindau disease had a normal plasma normetanephrine concentration; this patient had a very small adrenal tumor (< 1 cm). The high sensitivity of measurements of plasma normetanephrine and metanephrine was accompanied by a high level of specificity (96 percent). Conclusions. Measurements of plasma normetanephrine and metanephrine are useful in screening for pheochromocytomas in patients with a familiar predisposition to these tumors. (N Engl J Med 1999; 340:1872-9.) (C) 1999, Massachusetts Medical Society.	NINDS, Clin Neurosci Branch, NIH, Bethesda, MD 20892 USA; NCI, Urol Oncol Branch, NIH, Bethesda, MD 20892 USA; NHLBI, Hypertens Endocrine Branch, NIH, Bethesda, MD 20892 USA; Univ Nijmegen St Radboud Hosp, Dept Gen Internal Med, NL-6500 HB Nijmegen, Netherlands	National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); Radboud University Nijmegen	Eisenhofer, G (corresponding author), NINDS, Clin Neurosci Branch, NIH, Bldg 10,Rm 6N252,10 Ctr Dr,MSC-1620, Bethesda, MD 20892 USA.		Eisenhofer, Graeme/AAU-9829-2021; Lenders, J.W.M./L-4487-2015	Eisenhofer, Graeme/0000-0002-8601-9903; Lenders, J.W.M./0000-0002-7658-4466	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [Z01NS002979] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		APRILL BS, 1994, ANN INTERN MED, V120, P485, DOI 10.7326/0003-4819-120-6-199403150-00006; BRAVO EL, 1994, ENDOCR REV, V15, P356, DOI 10.1210/er.15.3.356; CALMETTES C, 1992, EUR J CLIN INVEST, V22, P755, DOI 10.1111/j.1365-2362.1992.tb01441.x; EISENHOFER G, 1995, CLIN SCI, V88, P533, DOI 10.1042/cs0880533; EISENHOFER G, 1995, J CLIN ENDOCR METAB, V80, P3009, DOI 10.1210/jc.80.10.3009; Eisenhofer G, 1998, J CLIN ENDOCR METAB, V83, P2175, DOI 10.1210/jc.83.6.2175; EISENHOFER G, 1986, CLIN CHEM, V32, P2030; EISENHOFER G, 1994, J AUTONOM NERV SYST, V50, P93, DOI 10.1016/0165-1838(94)90127-9; Eisenhofer G, 1996, J NEUROCHEM, V66, P1565; EISENHOFER G, IN PRESS CLIN EXP PH; GAGEL RF, 1988, NEW ENGL J MED, V318, P478, DOI 10.1056/NEJM198802253180804; GERLO EAM, 1994, CLIN CHEM, V40, P250; HAMILTON BP, 1978, AM J MED, V65, P1027, DOI 10.1016/0002-9343(78)90757-X; Heron E, 1996, ANN INTERN MED, V125, P300, DOI 10.7326/0003-4819-125-4-199608150-00008; HSIAO RJ, 1990, AM J MED, V88, P607, DOI 10.1016/0002-9343(90)90526-J; KARSDORP N, 1994, AM J MED, V97, P158, DOI 10.1016/0002-9343(94)90026-4; LENDERS JWM, 1995, ANN INTERN MED, V123, P101, DOI 10.7326/0003-4819-123-2-199507150-00004; LENDERS JWM, 1993, CLIN CHEM, V39, P97; MANGER WM, 1993, CLEV CLIN J MED, V60, P365; McNemar Q, 1947, PSYCHOMETRIKA, V12, P153, DOI 10.1007/BF02295996; MOYER TP, 1979, CLIN CHEM, V25, P256; NEUMANN HPH, 1993, NEW ENGL J MED, V329, P1531, DOI 10.1056/NEJM199311183292103; NEUMANN HPH, 1994, NEW ENGL J MED, V331, P1535; PEASTON RT, 1993, J CLIN PATHOL, V46, P734, DOI 10.1136/jcp.46.8.734; SATO T, 1975, TOHOKU J EXP MED, V115, P15, DOI 10.1620/tjem.115.15; Shawar L, 1996, J La State Med Soc, V148, P535; SINCLAIR D, 1991, ANN CLIN BIOCHEM, V28, P417, DOI 10.1177/000456329102800420; STEWART MF, 1993, J CLIN PATHOL, V46, P280, DOI 10.1136/jcp.46.3.280; VISTELLE R, 1991, CLIN ENDOCRINOL, V34, P133, DOI 10.1111/j.1365-2265.1991.tb00283.x	29	224	232	0	9	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 17	1999	340	24					1872	1879		10.1056/NEJM199906173402404	http://dx.doi.org/10.1056/NEJM199906173402404			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	206EC	10369850	Bronze			2022-12-28	WOS:000080863500004
J	Goldsmith, DJA; Thomas, P				Goldsmith, DJA; Thomas, P			Von Hippel-Lindau disease	NEW ENGLAND JOURNAL OF MEDICINE			English	Article									Guys Hosp, London SE1 9RT, England; Royal Sussex Cty Hosp, Brighton BN2 5BE, E Sussex, England	Guy's & St Thomas' NHS Foundation Trust; University of Brighton	Goldsmith, DJA (corresponding author), Guys Hosp, London SE1 9RT, England.		Goldsmith, David J A/H-6965-2018	Goldsmith, David J A/0000-0002-4349-9193					0	1	1	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 17	1999	340	24					1880	1880		10.1056/NEJM199906173402405	http://dx.doi.org/10.1056/NEJM199906173402405			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	206EC	10369851				2022-12-28	WOS:000080863500005
J	Dawes, HE; Berlin, DS; Lapidus, DM; Nusbaum, C; Davis, TL; Meyer, BJ				Dawes, HE; Berlin, DS; Lapidus, DM; Nusbaum, C; Davis, TL; Meyer, BJ			Dosage compensation proteins targeted to X chromosomes by a determinant of hermaphrodite fate	SCIENCE			English	Article							ELEGANS SEX DETERMINATION; CAENORHABDITIS-ELEGANS; C-ELEGANS; GENE; NEMATODE; HOMOLOG; COMPLEX; XOL-1; HER-1; LINK	In many organisms, master control genes coordinately regulate sex-specific aspects of development. SDC-2 was shown to induce hermaphrodite sexual differentiation and activate X chromosome dosage compensation in Caenorhabditis elegans, To control these distinct processes, SDC-2 acts as a strong gene-specific repressor and a weaker chromosome-wide repressor. To initiate hermaphrodite development, SDC-2 associates with the promoter of the male sex-determining gene her-1 to repress its transcription. To activate dosage compensation, SDC-2 triggers assembly of a specialized protein complex exclusively on hermaphrodite X chromosomes to reduce gene expression by half. SDC-2 can Localize to X chromosomes without other components of the dosage compensation complex, suggesting that SDC-2 targets dosage compensation machinery to X chromosomes.	Univ Calif Berkeley, Howard Hughes Med Inst, Berkeley, CA 94720 USA; Univ Calif Berkeley, Dept Mol & Cell Biol, Berkeley, CA 94720 USA	Howard Hughes Medical Institute; University of California System; University of California Berkeley; University of California System; University of California Berkeley	Meyer, BJ (corresponding author), Univ Calif Berkeley, Howard Hughes Med Inst, Berkeley, CA 94720 USA.			Meyer, Barbara/0000-0002-6530-4588	NIGMS NIH HHS [R01 GM030702, T32 GM07127, GM30702] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007127, R37GM030702, R01GM030702] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Carmi I, 1998, NATURE, V396, P168, DOI 10.1038/24164; CHUANG PT, 1994, CELL, V79, P459, DOI 10.1016/0092-8674(94)90255-0; Chuang PT, 1996, SCIENCE, V274, P1736, DOI 10.1126/science.274.5293.1736; Cline TW, 1996, ANNU REV GENET, V30, P637, DOI 10.1146/annurev.genet.30.1.637; Davis TL, 1997, DEVELOPMENT, V124, P1019; DELONG L, 1993, GENETICS, V133, P875; GONZALEZSERRICH.A, COMMUNICATION; Heard E, 1997, ANNU REV GENET, V31, P571, DOI 10.1146/annurev.genet.31.1.571; Hirano T, 1997, CELL, V89, P511, DOI 10.1016/S0092-8674(00)80233-0; HODGKIN J, 1983, MOL GEN GENET, V192, P452, DOI 10.1007/BF00392190; HSU DR, 1995, DEVELOPMENT, V121, P3323; KLEIN RD, 1993, CELL, V72, P349, DOI 10.1016/0092-8674(93)90113-5; Lieb JD, 1996, SCIENCE, V274, P1732, DOI 10.1126/science.274.5293.1732; Lieb JD, 1998, CELL, V92, P265, DOI 10.1016/S0092-8674(00)80920-4; Mello C, 1995, METHOD CELL BIOL, V48, P451; MILLER LM, 1988, CELL, V55, P167, DOI 10.1016/0092-8674(88)90019-0; NICOLL M, UNPUB; NONET ML, 1991, NATURE, V351, P65, DOI 10.1038/351065a0; NUSBAUM C, 1989, GENETICS, V122, P579; PERRY MD, 1993, GENE DEV, V7, P216, DOI 10.1101/gad.7.2.216; PLENEFISCH JD, 1989, GENETICS, V121, P57; RHIND NR, 1995, CELL, V80, P71, DOI 10.1016/0092-8674(95)90452-2; SAMBROOK J, 1989, MOL CLONIGN LAB MANU; Straight AF, 1996, CURR BIOL, V6, P1599, DOI 10.1016/S0960-9822(02)70783-5; TRENT C, 1991, MECH DEVELOP, V34, P43, DOI 10.1016/0925-4773(91)90090-S; VILLENEUVE AM, 1987, CELL, V48, P25, DOI 10.1016/0092-8674(87)90352-7	26	101	107	0	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 11	1999	284	5421					1800	1804		10.1126/science.284.5421.1800	http://dx.doi.org/10.1126/science.284.5421.1800			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	205EU	10364546				2022-12-28	WOS:000080809000040
J	Nappo, F; De Rosa, N; Marfella, R; De Lucia, D; Ingrosso, D; Perna, AF; Farzati, B; Giugliano, D				Nappo, F; De Rosa, N; Marfella, R; De Lucia, D; Ingrosso, D; Perna, AF; Farzati, B; Giugliano, D			Impairment of endothelial functions by acute hyperhomocysteinemia and reversal by antioxidant vitamins	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CORONARY-ARTERY DISEASE; PLASMA HOMOCYSTEINE; RISK FACTOR; NITRIC-OXIDE; VASCULAR-DISEASE; L-ARGININE; MYOCARDIAL-INFARCTION; HYPERHOMOCYST(E)INEMIA; ATHEROSCLEROSIS; HOMOCYST(E)INE	Context. Increased levels of homocysteine are associated with risk of cardiovascular disease. Homocysteine may cause this risk by impairing endothelial cell function. Objective. To evaluate the effect of acute hyperhomocysteinemia with and without antioxidant vitamin pretreatment on cardiovascular risk factors and endothelial functions. Design and Setting. Observer-blinded, randomized crossover study conducted at a university hospital in Italy. Subjects. Twenty healthy hospital staff volunteers (10 men, 10 women) aged 25 to 45 years. Interventions. Subjects were given each of 3 loads in random order at 1-week intervals: oral methionine, 100 mg/kg in fruit juice; the same methionine load immediately following ingestion of antioxidant vitamin E, 800 IU, and ascorbic acid, 1000 mg; and methionine-free fruit juice (placebo). Ten of the 20 subjects also ingested a placebo load with vitamins. Main Outcome Measures. Lipid, coagulation, glucose, and circulating adhesion molecule parameters, blood pressure, and endothelial functions as assessed by hemodynamic and theologic responses to L-arginine, evaluated at baseline and 4 hours following ingestion of the loads. Results. The oral methionine load increased mean (SD) plasma homocysteine level from 10.5 (3.8) mu mol/L at baseline to 27.1 (6.7) mu mol/L at 4 hours (P < .001). A similar increase was observed with the same load plus vitamins (10.0 [4.0] to 22.7 [7.8] mu mol/L; P < .001) but no significant increase was observed with placebo (10.1 [3.7] to 10.4 [3.2] mu mol/L; P = .75). Coagulation and circulating adhesion molecule levels significantly increased after methionine ingestion alone (P < .05) but not after placebo or methionine ingestion with vitamins. While the mean (SD) blood pressure (-7.0% [2.7%]; P < .001), platelet aggregation response to adenosine diphosphate (-11.4% [4.5%]; P = .009) and blood viscosity (-3.0% [1.2%]; P = .04) declined in these parameters 10 minutes after an L-arginine load (3 g) following placebo, the increase after methionine alone (-2.3% [1.5%], 4.0% [3.0%], and 1.5% [1.0%], respectively; P < .05), did not occur following methionine load with vitamin pretreatment (-6.3% [2.5%], -7.9% [3.5%], and -1.5% [1.0%], respectively; P = .24). Conclusion. Our data suggest that mild to moderate elevations of plasma homocysteine levels in healthy subjects activate coagulation, modify the adhesive proper ties of endothelium, and impair the vascular responses to L-arginine. Pretreatment with antioxidant vitamin E and ascorbic acid blocks the effects of hyperhomocysteinemia, suggesting an oxidative mechanism.	Univ Naples 2, Dept Geriatr & Metab Dis, Naples, Italy; Univ Naples 2, Dept Immunol, Naples, Italy; Univ Naples 2, Inst Gen Pathol & Oncol, Naples, Italy; Univ Naples 2, Inst Biochem Macromol, Naples, Italy	Universita della Campania Vanvitelli; Universita della Campania Vanvitelli; Universita della Campania Vanvitelli; Universita della Campania Vanvitelli	Giugliano, D (corresponding author), Via Emilia 1, I-80021 Afragola, NA, Italy.		Marfella, Raffaele/C-6899-2012; Perna, Alessandra F/AAC-3952-2022; Ingrosso, Diego/AHE-4980-2022	Marfella, Raffaele/0000-0003-3960-9270; PERNA, Alessandra/0000-0003-4048-9392; Giugliano, Dario/0000-0002-9377-873X				ANDERSON TJ, 1995, J AM COLL CARDIOL, V26, P1235, DOI 10.1016/0735-1097(95)00327-4; Bellamy MF, 1998, CIRCULATION, V98, P1848, DOI 10.1161/01.CIR.98.18.1848; BODEBOGER SM, 1994, CLIN SCI, V87, P303, DOI 10.1042/cs0870303; BORN GVR, 1962, NATURE, V194, P927, DOI 10.1038/194927b0; BOSTOM AG, 1995, ATHEROSCLEROSIS, V116, P147, DOI 10.1016/0021-9150(95)05529-6; BOUSHEY CJ, 1995, JAMA-J AM MED ASSOC, V274, P1049, DOI 10.1001/jama.274.13.1049; CALERMAJER D, 1994, J AM COLL CARDIOL, V24, P1468; Cattaneo M, 1999, BLOOD, V93, P1118, DOI 10.1182/blood.V93.3.1118.403a38h_1118_1120; Chambers JC, 1998, LANCET, V351, P36, DOI 10.1016/S0140-6736(05)78090-9; CLARKE R, 1991, NEW ENGL J MED, V324, P1149, DOI 10.1056/NEJM199104253241701; COOKE JP, 1993, CIRCULATION, V88, P2451, DOI 10.1161/01.CIR.88.5.2451; DAWSONSAUNDERS B, 1990, BASIC CLIN BIOSTATIS; Evans RW, 1997, ARTERIOSCL THROM VAS, V17, P1947, DOI 10.1161/01.ATV.17.10.1947; FREI B, 1989, P NATL ACAD SCI USA, V86, P6377, DOI 10.1073/pnas.86.16.6377; Giugliano D, 1997, AM J PHYSIOL-ENDOC M, V273, pE606, DOI 10.1152/ajpendo.1997.273.3.E606; Giugliano D, 1997, J CLIN INVEST, V99, P433, DOI 10.1172/JCI119177; GIUGLIANO D, 1995, ANN INTERN MED, V123, P338, DOI 10.7326/0003-4819-123-5-199509010-00003; Glasser SP, 1996, AM HEART J, V131, P379, DOI 10.1016/S0002-8703(96)90370-1; Graham IM, 1997, JAMA-J AM MED ASSOC, V277, P1775, DOI 10.1001/jama.277.22.1775; HEINECKE JW, 1993, J LIPID RES, V34, P2051; JAKUBOWSKI H, 1993, FEBS LETT, V317, P237, DOI 10.1016/0014-5793(93)81283-6; JOANNIDES R, 1995, CIRCULATION, V91, P1314, DOI 10.1161/01.CIR.91.5.1314; KOTTKEMARCHANT K, 1990, BLOOD, V76, P511; Leklem JE, 1994, MODERN NUTR HLTH DIS, P383; Loscalzo J, 1996, J CLIN INVEST, V98, P5, DOI 10.1172/JCI118776; LUSCHER TF, 1990, ENDOTHELIUM MODULATO; MALINOW MR, 1990, CIRCULATION, V81, P2004, DOI 10.1161/01.CIR.81.6.2004; Malinow MR, 1997, ARTERIOSCL THROM VAS, V17, P1157, DOI 10.1161/01.ATV.17.6.1157; MONCADA S, 1993, NEW ENGL J MED, V329, P2002; Nygard O, 1997, NEW ENGL J MED, V337, P230, DOI 10.1056/NEJM199707243370403; Omenn GS, 1998, CIRCULATION, V97, P421; Perna AF, 1996, KIDNEY INT, V50, P358, DOI 10.1038/ki.1996.324; REES DD, 1990, BRIT J PHARMACOL, V101, P746, DOI 10.1111/j.1476-5381.1990.tb14151.x; Ridker PM, 1998, LANCET, V351, P88, DOI 10.1016/S0140-6736(97)09032-6; ROBINSON K, 1995, CIRCULATION, V92, P2825, DOI 10.1161/01.CIR.92.10.2825; SARDHARWALLA IB, 1974, ARCH DIS CHILD, V49, P553, DOI 10.1136/adc.49.7.553; SEILER C, 1993, CIRCULATION, V88, P2139, DOI 10.1161/01.CIR.88.5.2139; SELHUB J, 1995, NEW ENGL J MED, V332, P286, DOI 10.1056/NEJM199502023320502; STAMLER JS, 1993, J CLIN INVEST, V91, P308, DOI 10.1172/JCI116187; STAMPFER MJ, 1992, JAMA-J AM MED ASSOC, V268, P877, DOI 10.1001/jama.268.7.877; STARKEBAUM G, 1986, J CLIN INVEST, V77, P1370, DOI 10.1172/JCI112442; UBBINK JB, 1991, J CHROMATOGR-BIOMED, V565, P441, DOI 10.1016/0378-4347(91)80407-4; VITA JA, 1990, CIRCULATION, V81, P491, DOI 10.1161/01.CIR.81.2.491	43	235	254	0	5	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 9	1999	281	22					2113	2118		10.1001/jama.281.22.2113	http://dx.doi.org/10.1001/jama.281.22.2113			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	202TJ	10367822	Bronze			2022-12-28	WOS:000080668000034
J	Diadhiou, F; Goyaux, N; Faye, O; Thonneau, P				Diadhiou, F; Goyaux, N; Faye, O; Thonneau, P			A neglected but prevalent tragedy	BRITISH MEDICAL JOURNAL			English	Article							MATERNAL MORTALITY		Univ Hosp Le Dantac, Dept Obstet & Gynaecol, Dakar, Senegal		Diadhiou, F (corresponding author), Univ Hosp Le Dantac, Dept Obstet & Gynaecol, Dakar, Senegal.			patrick, thonneau/0000-0003-0276-6141				Machungo F, 1997, SOC SCI MED, V45, P1607, DOI 10.1016/S0277-9536(96)00358-9; ROSENFIELD A, 1985, LANCET, V2, P83; Thonneau P, 1996, AM J PUBLIC HEALTH, V86, P1478, DOI 10.2105/AJPH.86.10.1478; *WHO UN CHILDR FUN, 1996, REV 1990 EST MAT MOR	4	3	3	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JUN 5	1999	318	7197					1526	1526		10.1136/bmj.318.7197.1526	http://dx.doi.org/10.1136/bmj.318.7197.1526			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	204HC	10356009	Green Published			2022-12-28	WOS:000080757300027
J	Morgunova, E; Tuuttila, A; Bergmann, U; Isupov, M; Lindqvist, Y; Schneider, G; Tryggvason, K				Morgunova, E; Tuuttila, A; Bergmann, U; Isupov, M; Lindqvist, Y; Schneider, G; Tryggvason, K			Structure of human pro-matrix metalloproteinase-2: Activation mechanism revealed	SCIENCE			English	Article							C-TERMINAL DOMAIN; HEMOPEXIN-LIKE DOMAIN; INHIBITED CATALYTIC DOMAIN; IV COLLAGENASE; GELATINASE-A; EXTRACELLULAR-MATRIX; PROGELATINASE-A; BINDING-PROPERTIES; CRYSTAL-STRUCTURE; KINETIC-ANALYSIS	Matrix metalloproteinases (MMPs) catalyze extracellular matrix degradation. Control of their activity is a promising target for therapy of diseases characterized by abnormal connective tissue turnover. MMPs are expressed as Latent proenzymes that are activated by proteolytic cleavage that triggers a conformational change in the propeptide (cysteine switch). The structure of proMMP-2 reveals how the propeptide shields the catalytic cleft and that the cysteine switch may operate through cleavage of Loops essential for propeptide stability.	Karolinska Inst, Dept Med Biochem & Biophys, Div Matrix Biol, Stockholm, Sweden; Karolinska Inst, Dept Med Biochem & Biophys, Div Mol Struct Biol, Stockholm, Sweden; Univ Exeter, Sch Chem, Exeter EX4 4QJ, Devon, England; Univ Exeter, Sch Biol Sci, Exeter EX4 4QJ, Devon, England	Karolinska Institutet; Karolinska Institutet; University of Exeter; University of Exeter	Schneider, G (corresponding author), Karolinska Inst, Dept Med Biochem & Biophys, Div Matrix Biol, Stockholm, Sweden.	gunter@alfa.mbb.ki.se; karl.tryggvason@mbb.ki.se	Morgunova, Ekaterina/G-2479-2018; Isupov, Mikhail/AAA-8280-2019; Lindqvist, Ylva/F-9009-2010	Morgunova, Ekaterina/0000-0002-7754-9021; Lindqvist, Ylva/0000-0003-3162-8661; Isupov, Michail/0000-0001-6842-4289; Schneider, Gunter/0000-0003-0622-5713				Atkinson SJ, 1995, J BIOL CHEM, V270, P30479, DOI 10.1074/jbc.270.51.30479; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Banyai L, 1996, J BIOL CHEM, V271, P12003, DOI 10.1074/jbc.271.20.12003; Basbaum CB, 1996, CURR OPIN CELL BIOL, V8, P731, DOI 10.1016/S0955-0674(96)80116-5; BECKER JW, 1995, PROTEIN SCI, V4, P1966, DOI 10.1002/pro.5560041002; BERGMANN U, 1995, BIOCHEMISTRY-US, V34, P2819, DOI 10.1021/bi00009a011; BIRKEDALHANSEN H, 1995, CURR OPIN CELL BIOL, V7, P728, DOI 10.1016/0955-0674(95)80116-2; BROWNER MF, 1995, BIOCHEMISTRY-US, V34, P6602, DOI 10.1021/bi00020a004; Brunger A. T., 1992, XPLOR VERSION 3 1 SY; COLLIER IE, 1992, J BIOL CHEM, V267, P6776; CONSTANTINE KL, 1992, J MOL BIOL, V223, P281, DOI 10.1016/0022-2836(92)90731-X; CRABBE T, 1993, EUR J BIOCHEM, V218, P431, DOI 10.1111/j.1432-1033.1993.tb18393.x; DIDEBERG O, 1982, NATURE, V299, P469, DOI 10.1038/299469a0; GHUYSEN JM, 1994, FEBS LETT, V342, P23, DOI 10.1016/0014-5793(94)80577-6; Gohlke U, 1996, FEBS LETT, V378, P126, DOI 10.1016/0014-5793(95)01435-7; GomisRuth FX, 1996, J MOL BIOL, V264, P556, DOI 10.1006/jmbi.1996.0661; GOOLEY PR, 1994, NAT STRUCT BIOL, V1, P111, DOI 10.1038/nsb0294-111; HANGAUER DG, 1984, BIOCHEMISTRY-US, V23, P5730, DOI 10.1021/bi00319a011; HODGSON J, 1995, BIO-TECHNOL, V13, P554, DOI 10.1038/nbt0695-554; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KABSCH W, 1988, J APPL CRYSTALLOGR, V21, P916, DOI 10.1107/S0021889888007903; KOHN EC, 1995, CANCER RES, V55, P1856; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LI J, 1995, STRUCTURE, V3, P541, DOI 10.1016/S0969-2126(01)00188-5; LIBSON AM, 1995, NAT STRUCT BIOL, V2, P938, DOI 10.1038/nsb1195-938; LOVEJOY B, 1994, SCIENCE, V263, P375, DOI 10.1126/science.8278810; Massova I, 1998, FASEB J, V12, P1075, DOI 10.1096/fasebj.12.12.1075; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; MURPHY G, 1992, J BIOL CHEM, V267, P9612; NAGASE H, 1990, BIOCHEMISTRY-US, V29, P5783, DOI 10.1021/bi00476a020; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Olson MW, 1997, J BIOL CHEM, V272, P29975, DOI 10.1074/jbc.272.47.29975; Overall CM, 1999, J BIOL CHEM, V274, P4421, DOI 10.1074/jbc.274.7.4421; Pickford AR, 1997, STRUCTURE, V5, P359, DOI 10.1016/S0969-2126(97)00193-7; PYKE C, 1992, CANCER RES, V52, P1336; REPONEN P, 1992, J BIOL CHEM, V267, P7856; SALO T, 1983, J BIOL CHEM, V258, P3058; SATO H, 1994, NATURE, V370, P61, DOI 10.1038/370061a0; STARNS T, 1994, NAT STRUCT BIOL, V1, P119; STOCKER W, 1995, CURR OPIN STRUC BIOL, V5, P383, DOI 10.1016/0959-440X(95)80101-4; STRONGIN AY, 1993, J BIOL CHEM, V268, P14033; Vaguine AA, 1999, ACTA CRYSTALLOGR D, V55, P191, DOI 10.1107/S0907444998006684; VANWART HE, 1990, P NATL ACAD SCI USA, V87, P5578, DOI 10.1073/pnas.87.14.5578; Wallon UM, 1997, J BIOL CHEM, V272, P7473, DOI 10.1074/jbc.272.11.7473; Watson SA, 1998, BIODRUGS, V9, P325, DOI 10.2165/00063030-199809040-00005; Will H, 1996, J BIOL CHEM, V271, P17119, DOI 10.1074/jbc.271.29.17119; WILLENBROCK F, 1993, BIOCHEMISTRY-US, V32, P4330, DOI 10.1021/bi00067a023; Yu AE, 1997, DRUG AGING, V11, P229, DOI 10.2165/00002512-199711030-00006	49	458	478	3	31	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 4	1999	284	5420					1667	1670		10.1126/science.284.5420.1667	http://dx.doi.org/10.1126/science.284.5420.1667			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	202TM	10356396				2022-12-28	WOS:000080668300044
J	Smith, DE; Zuber, MT; Solomon, SC; Phillips, RJ; Head, JW; Garvin, JB; Banerdt, WB; Muhleman, DO; Pettengill, GH; Neumann, GA; Lemoine, FG; Abshire, JB; Aharonson, O; Brown, CD; Hauck, SA; Ivanov, AB; McGovern, PJ; Zwally, HJ; Duxbury, TC				Smith, DE; Zuber, MT; Solomon, SC; Phillips, RJ; Head, JW; Garvin, JB; Banerdt, WB; Muhleman, DO; Pettengill, GH; Neumann, GA; Lemoine, FG; Abshire, JB; Aharonson, O; Brown, CD; Hauck, SA; Ivanov, AB; McGovern, PJ; Zwally, HJ; Duxbury, TC			The global topography of Mars and implications for surface evolution	SCIENCE			English	Article							RADIO OCCULTATION MEASUREMENTS; MARTIAN MANTLE CONVECTION; IMPACT BASINS; HEMISPHERIC DICHOTOMY; PHASE-TRANSITIONS; CRUSTAL DICHOTOMY; GIANT IMPACT; POLAR-REGION; MARINER-9; THARSIS	Elevations measured by the Mars Orbiter Laser Altimeter have yielded a high-accuracy global map of the topography of Mars. Dominant features include the low northern hemisphere, the Tharsis province, and the Hellas impact basin. The northern hemisphere depression is primarily a long-wavelength effect that has been shaped by an internal mechanism. The topography of Tharsis consists of two broad rises. Material excavated from Hellas contributes to the high elevation of the southern hemisphere and to the scarp along the hemispheric boundary. The present topography has three major drainage centers, with the northern Lowlands being the largest. The two polar cap volumes yield an upper limit of the present surface water inventory of 3.2 to 4.7 million cubic kilometers.	NASA, Goddard Space Flight Ctr, Earth Sci Directorate, Greenbelt, MD 20771 USA; MIT, Dept Earth Atmospher & Planetary Sci, Cambridge, MA 02139 USA; Carnegie Inst Washington, Dept Terr Magnetism, Washington, DC 20015 USA; Washington Univ, Dept Earth & Planetary Sci, St Louis, MO 63130 USA; Brown Univ, Dept Geol Sci, Providence, RI 02912 USA; CALTECH, Div Geol & Planetary Sci, Pasadena, CA 91125 USA; CALTECH, Jet Prop Lab, Pasadena, CA 91109 USA	National Aeronautics & Space Administration (NASA); NASA Goddard Space Flight Center; Massachusetts Institute of Technology (MIT); Carnegie Institution for Science; Washington University (WUSTL); Brown University; California Institute of Technology; California Institute of Technology; National Aeronautics & Space Administration (NASA); NASA Jet Propulsion Laboratory (JPL)	Smith, DE (corresponding author), NASA, Goddard Space Flight Ctr, Earth Sci Directorate, Greenbelt, MD 20771 USA.		Ivanov, Anton B/C-8944-2014; Lemoine, Frank/D-1215-2013; Hauck, Steven A/A-7865-2008; Abshire, James/I-2800-2013; Neumann, Gregory A/I-5591-2013; Banerdt, William/Q-7324-2019	Ivanov, Anton B/0000-0001-8376-8581; Hauck, Steven A/0000-0001-8245-146X; Neumann, Gregory A/0000-0003-0644-9944; Banerdt, William/0000-0003-3125-1542; Lemoine, Frank G./0000-0002-3051-1456; Aharonson, Oded/0000-0001-9930-2495; Garvin, James/0000-0003-1606-5645; McGovern, Patrick/0000-0001-9647-3096				Acuna MH, 1999, SCIENCE, V284, P790, DOI 10.1126/science.284.5415.790; Albee AL, 1998, SCIENCE, V279, P1671, DOI 10.1126/science.279.5357.1671; BAKER VR, 1991, NATURE, V352, P589, DOI 10.1038/352589a0; BANERDT WB, 1982, J GEOPHYS RES, V87, P9723, DOI 10.1029/JB087iB12p09723; BANERDT WB, 1992, MARS, P249; Breuer D, 1998, GEOPHYS RES LETT, V25, P229, DOI 10.1029/97GL03767; Carr M., 1981, SURFACE MARS; Carr M.H, 1996, WATER MARS; CARR MH, 1981, ICARUS, V48, P91, DOI 10.1016/0019-1035(81)90156-1; CLIFFORD SM, 1987, J GEOPHYS RES-SOLID, V92, P9135, DOI 10.1029/JB092iB09p09135; Connerney JEP, 1999, SCIENCE, V284, P794, DOI 10.1126/science.284.5415.794; CONRATH B, 1973, J GEOPHYS RES, V78, P4267, DOI 10.1029/JB078i020p04267; Dohm JM, 1999, PLANET SPACE SCI, V47, P411, DOI 10.1016/S0032-0633(98)00141-X; DOWNS GS, 1982, J GEOPHYS RES, V87, P9747, DOI 10.1029/JB087iB12p09747; DURHAM WB, 1999, LUNAR PLANET SCI, V30, P2017; Folkner WM, 1997, SCIENCE, V278, P1749, DOI 10.1126/science.278.5344.1749; FREY H, 1988, GEOPHYS RES LETT, V15, P229, DOI 10.1029/GL015i003p00229; Frey H, 1998, GEOPHYS RES LETT, V25, P4409, DOI 10.1029/1998GL900095; FREY HV, 1998, EOS T AM GEOPHYS UNI, V79; GARVIN JB, UNPUB; Harder H, 1998, J GEOPHYS RES-PLANET, V103, P16775, DOI 10.1029/98JE01543; Harder H, 1996, NATURE, V380, P507, DOI 10.1038/380507a0; Head JW, 1998, GEOPHYS RES LETT, V25, P4401, DOI 10.1029/1998GL900116; HORD CW, 1972, ICARUS, V17, P443, DOI 10.1016/0019-1035(72)90010-3; Johnson C., UNPUB; KARGEL JS, 1992, GEOLOGY, V20, P3, DOI 10.1130/0091-7613(1992)020<0003:AGOM>2.3.CO;2; KIEFFER HH, 1979, J GEOPHYS RES, V84, P8263, DOI 10.1029/JB084iB14p08263; KLIORE AJ, 1972, ICARUS, V17, P484, DOI 10.1016/0019-1035(72)90014-0; LEMOINE FG, 1999, AIAA SPAC FLIGHT MEC; LINDAL GF, 1979, J GEOPHYS RES, V84, P8443, DOI 10.1029/JB084iB14p08443; Lingenfelter R. E., 1973, Moon, V7, P172, DOI 10.1007/BF00578814; LUCHITTA BK, 1992, MARS, P453; Malin MC, 1999, NATURE, V397, P589, DOI 10.1038/17551; MCEWEN A, 1999, LUNAR PLANET SCI, V30, P1829; MCGILL GE, 1989, J GEOPHYS RES-SOLID, V94, P2753, DOI 10.1029/JB094iB03p02753; MCGILL GE, 1991, ICARUS, V93, P386, DOI 10.1016/0019-1035(91)90221-E; MCGILL GE, 1990, J GEOPHYS RES-SOLID, V95, P12595, DOI 10.1029/JB095iB08p12595; MOORE JM, 1993, GEOPHYS RES LETT, V20, P1599, DOI 10.1029/93GL01302; Mutch T.A., 1976, GEOLOGY MARS; NEUMANN GA, 1995, MAR GEOPHYS RES, V17, P221, DOI 10.1007/BF01203464; NYE JF, UNPUB; PAIGE DA, 1994, J GEOPHYS RES-PLANET, V99, P25993, DOI 10.1029/93JE03429; PARKER TJ, 1989, ICARUS, V82, P111, DOI 10.1016/0019-1035(89)90027-4; PARKER TJ, 1993, J GEOPHYS RES-PLANET, V98, P11061, DOI 10.1029/93JE00618; PHILLIPS RJ, 1990, J GEOPHYS RES-SOLID, V95, P5089, DOI 10.1029/JB095iB04p05089; ROTH LE, 1980, ICARUS, V42, P287, DOI 10.1016/0019-1035(80)90096-2; SCHENK PM, UNPUB; SCHULTZ RA, 1990, J GEOPHYS RES-SOLID, V95, P14175, DOI 10.1029/JB095iB09p14175; SCHULTZ RA, 1994, J GEOPHYS RES-PLANET, V99, P8371, DOI 10.1029/94JE00277; SHARP RP, 1971, J GEOPHYS RES, V76, P331, DOI 10.1029/JB076i002p00331; SHARP RP, 1973, J GEOPHYS RES, V78, P4073, DOI 10.1029/JB078i020p04073; SLEEP NH, 1994, J GEOPHYS RES-PLANET, V99, P5639, DOI 10.1029/94JE00216; Smith DE, 1998, SCIENCE, V279, P1686, DOI 10.1126/science.279.5357.1686; Smith DE, 1996, SCIENCE, V271, P184, DOI 10.1126/science.271.5246.184; SMITH DE, IN PRESS EOS T AM GE; SODERBLOM LA, 1978, ICARUS, V34, P622, DOI 10.1016/0019-1035(78)90050-7; SOLOMON SC, 1982, J GEOPHYS RES, V87, P9755, DOI 10.1029/JB087iB12p09755; TANAKA KL, 1995, J GEOPHYS RES-PLANET, V100, P5407, DOI 10.1029/94JE02804; TURCOTTE DL, 1981, J GEOPHYS RES, V86, P3951, DOI 10.1029/JB086iB05p03951; WICHMAN RW, 1989, J GEOPHYS RES-SOLID, V94, P17333, DOI 10.1029/JB094iB12p17333; WILHELMS DE, 1984, NATURE, V309, P138, DOI 10.1038/309138a0; WISE DU, 1979, J GEOPHYS RES, V84, P7934, DOI 10.1029/JB084iB14p07934; WISE DU, 1979, ICARUS, V38, P456, DOI 10.1016/0019-1035(79)90200-8; WU SSC, 1984, NATURE, V309, P432, DOI 10.1038/309432a0; ZHONG S, UNPUB; Zuber MT, 1997, J GEOPHYS RES-PLANET, V102, P28673, DOI 10.1029/97JE02527; ZUBER MT, 1994, SCIENCE, V266, P1839, DOI 10.1126/science.266.5192.1839; ZUBER MT, 1992, J GEOPHYS RES-PLANET, V97, P7781, DOI 10.1029/92JE00341; Zuber MT, 1998, SCIENCE, V282, P2053, DOI 10.1126/science.282.5396.2053; Zuber MT, 1998, GEOPHYS RES LETT, V25, P4393, DOI 10.1029/1998GL900129; ZUBER MT, 1998, 1 INT C MARS POL SCI	71	658	667	5	81	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAY 28	1999	284	5419					1495	1503		10.1126/science.284.5419.1495	http://dx.doi.org/10.1126/science.284.5419.1495			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	200PD	10348732				2022-12-28	WOS:000080548100029
J	Blasius, B; Huppert, A; Stone, L				Blasius, B; Huppert, A; Stone, L			Complex dynamics and phase synchronization in spatially extended ecological systems	NATURE			English	Article							SNOWSHOE HARE CYCLE; POPULATION-DYNAMICS; SOLAR-ACTIVITY; CHAOS; MODELS; LYNX; OSCILLATORS; CANADA	Population cycles that persist in time and are synchronized over; space pervade ecological systems, but their underlying causes remain a long-standing enigma(1-11). Here we examine the synchronization of complex population oscillations in networks of model communities and in natural systems, where phenomena such as unusual '4- and 10-year cycle' of wildlife are often found. In the proposed spatial model, each local patch sustains a three-level trophic system composed of interacting predators, consumers and vegetation, Populations oscillate regularly and periodically in phase, but with irregular and chaotic peaks together in abundance-twin realistic features that are not found in standard ecological models. In a spatial lattice of patches, only small amounts of local migration are required to induce broad-scale 'phase synchronization,(12,13), with all populations in the lattice phase-locking to the same collective rhythm. Peak population abundances, however, remain chaotic and largely uncorrelated, Although synchronization is often perceived as being detrimental to spatially structured populations(14), phase synchronization leads to the emergence of complex chaotic travelling-wave structures which may be crucial for species persistence.	Tel Aviv Univ, Porter Super Ctr Ecol & Environm Studies, IL-69978 Tel Aviv, Israel; Tel Aviv Univ, Dept Zool, IL-69978 Tel Aviv, Israel	Tel Aviv University; Tel Aviv University	Stone, L (corresponding author), Tel Aviv Univ, Porter Super Ctr Ecol & Environm Studies, IL-69978 Tel Aviv, Israel.		Blasius, Bernd/AAH-1897-2019; Blasius, Bernd/GLU-4137-2022	Blasius, Bernd/0000-0002-6558-1462; Stone, Lewi/0000-0002-6465-579X				Blasius B, 1999, P ROY SOC B-BIOL SCI, V266, P93, DOI 10.1098/rspb.1999.0608; BULMER MG, 1974, J ANIM ECOL, V43, P701, DOI 10.2307/3532; COHEN AH, 1982, J MATH BIOL, V13, P345, DOI 10.1007/BF00276069; Earn DJD, 1998, P ROY SOC B-BIOL SCI, V265, P7, DOI 10.1098/rspb.1998.0256; Elton C, 1942, J ANIM ECOL, V11, P215, DOI 10.2307/1358; GILPIN ME, 1979, AM NAT, V113, P306, DOI 10.1086/283389; Gotelli N.J., 1995, PRIMER ECOLOGY; GURNEY WSC, 1992, J MATH BIOL, V30, P251, DOI 10.1007/BF00176151; HANSKI I, 1993, NATURE, V364, P232, DOI 10.1038/364232a0; HASTINGS A, 1991, ECOLOGY, V72, P896, DOI 10.2307/1940591; KIETH LB, 1963, WILDLIFES 10 YEAR CY; Korpimaki E, 1996, BIOSCIENCE, V46, P754, DOI 10.2307/1312851; May R.M., 1973, STABILITY COMPLEXITY; MAY RM, 1976, NATURE, V261, P459, DOI 10.1038/261459a0; MORAN PAP, 1953, AUST J ZOOL, V1, P291, DOI 10.1071/ZO9530291; O'Donoghue M, 1998, ECOLOGY, V79, P1193, DOI 10.1890/0012-9658(1998)079[1193:FROCAL]2.0.CO;2; PECORA LM, 1990, PHYS REV LETT, V64, P821, DOI 10.1103/PhysRevLett.64.821; Ranta E, 1997, SCIENCE, V278, P1621, DOI 10.1126/science.278.5343.1621; Ranta E, 1997, AM NAT, V149, P765, DOI 10.1086/286019; Ranta E, 1997, NATURE, V390, P456, DOI 10.1038/37261; Rosenblum MG, 1996, PHYS REV LETT, V76, P1804, DOI 10.1103/PhysRevLett.76.1804; Royama T., 1992, ANAL POPULATION ECOL; Schafer C, 1998, NATURE, V392, P239, DOI 10.1038/32567; SCHAFFER WM, 1984, AM NAT, V124, P798, DOI 10.1086/284318; SINCLAIR ARE, 1993, AM NAT, V141, P173, DOI 10.1086/285468; Sinclair ARE, 1997, AM NAT, V149, P776, DOI 10.1086/286020; Stenseth NC, 1997, P NATL ACAD SCI USA, V94, P5147, DOI 10.1073/pnas.94.10.5147; STONE L, 1993, NATURE, V365, P617, DOI 10.1038/365617a0; VANDERMEER J, 1996, PROG THEOR PHYS, V71, P13; WOLF JB, 1982, PHYSICA D, V16, P285	30	723	734	2	169	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAY 27	1999	399	6734					354	359		10.1038/20676	http://dx.doi.org/10.1038/20676			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	200PA	10360572				2022-12-28	WOS:000080547800059
J	Salomaa, V; Matei, C; Aleksic, N; Sansores-Garcia, L; Folsom, AR; Juneja, H; Chambless, LE; Wu, KK				Salomaa, V; Matei, C; Aleksic, N; Sansores-Garcia, L; Folsom, AR; Juneja, H; Chambless, LE; Wu, KK			Soluble thrombomodulin as a predictor of incident coronary heart disease and symptomless carotid artery atherosclerosis in the Atherosclerosis Risk in Communities (ARIC) Study: a case-cohort study	LANCET			English	Article							DEPENDENT DIABETES-MELLITUS; MYOCARDIAL-INFARCTION; VASCULAR-DISEASE; HUMAN-PLASMA; FACTOR-VIII; E-SELECTIN; GENE; DESIGN; EXTENT	Background. Small amounts of soluble thrombomodulin in plasma are thought to reflect endothelial damage. In a case-cohort study, we examined whether soluble thrombomodulin is a predictor of incident coronary heart disease and carotid artery atherosclerosis. Methods. The study population consisted of 14170 black and white participants from the Atherosclerosis Risk in Communities (ARIC) study, who did not have cardiovascular disease at the start of the study and who we followed up for 6 years. After appropriate exclusions, we analysed 258 cases of incident coronary heart disease and 449 cases of carotid atherosclerosis. A stratified random sample of 753 individuals from the ARIC cohort was used as the comparison group. We used EIA to measure soluble thrombomodulin in plasma samples from both groups. For the analysis, we used quintiles of soluble thrombomodulin concentrations (< 24.7, 24.8-30 6, 30.7-40.2, 40.3-55.2, and greater than or equal to 55.3 ng/mL). Findings. Soluble thrombomodulin showed a strong, graded, inverse association with incident coronary heart disease (p = 0.005), The adjusted rate ratio of the highest quintile of soluble thrombomodulin compared with the lowest quintile was 0.29 (95% Cl 0.15-0.57), The association with carotid atherosclerosis, however, tended to be positive, especially among white participants (odds ratio 2.94 [1.15-7.51] for highest vs lowest quintile). The relation of soluble thrombomodulin to incident coronary heart disease and carotid atherosclerosis was dependent. on factor VIII coagulant activity (p = 0.06 and 0.003, respectively). Interpretation. The prospective association of soluble thrombomodulin with incident. coronary heart disease differs from its cross-sectional association with carotid atherosclerosis, In healthy people, plasma concentrations of soluble thrombomodulin may reflect endothelial expression of thrombomodulin. High concentration of soluble thrombomodulin may be associated with decreased risk of coronary heart disease.	Natl Publ Hlth Inst, Dept Epidemiol & Hlth Promot, FIN-00300 Helsinki, Finland; Univ Texas, Sch Med, Div Haematol Oncol, Houston, TX USA; Univ Minnesota, Sch Publ Hlth, Div Epidemiol, Minneapolis, MN 55455 USA; Univ N Carolina, Collaborat Studies Coordinating Ctr, Chapel Hill, NC USA	Finland National Institute for Health & Welfare; University of Texas System; University of Minnesota System; University of Minnesota Twin Cities; University of North Carolina; University of North Carolina Chapel Hill	Salomaa, V (corresponding author), Natl Publ Hlth Inst, Dept Epidemiol & Hlth Promot, FIN-00300 Helsinki, Finland.		Wu, Kenneth Kun-Yu/B-1070-2010	Sansores-Garcia, Leticia/0000-0003-2510-225X	NHLBI NIH HHS [N01-HC-55018, N01-HC-55015, N01-HC-55016] Funding Source: Medline; DIVISION OF EPIDEMIOLOGY AND CLINICAL APPLICATIONS [N01HC055016, N01HC055018, N01HC055015] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); DIVISION OF EPIDEMIOLOGY AND CLINICAL APPLICATIONS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		[Anonymous], 1991, J Neuroimaging, V1, P68; BARLOW WE, 1994, BIOMETRICS, V50, P1064, DOI 10.2307/2533444; Blann AD, 1997, EUR J HAEMATOL, V59, P115; Blann AD, 1997, EUR J CLIN INVEST, V27, P916, DOI 10.1046/j.1365-2362.1997.2180766.x; BRANDT JT, 1993, ARCH PATHOL LAB MED, V117, P48; CatellaLawson F, 1997, CORONARY ARTERY DIS, V8, P105, DOI 10.1097/00019501-199702000-00007; Doggen CJM, 1998, THROMB HAEMOSTASIS, V80, P743; ESMON CT, 1995, FASEB J, V9, P946, DOI 10.1096/fasebj.9.10.7615164; Esmon CT, 1997, CIRCULATION, V96, P9; Folsom AR, 1997, CIRCULATION, V96, P1102, DOI 10.1161/01.CIR.96.4.1102; IBBOTSON SH, 1992, DIABETOLOGIA, V35, P863, DOI 10.1007/BF00399933; Inukai T, 1996, DIABETES RES CLIN PR, V33, P99, DOI 10.1016/0168-8227(96)01283-1; Ireland H, 1997, CIRCULATION, V96, P15; ISHII H, 1985, J CLIN INVEST, V76, P2178, DOI 10.1172/JCI112225; ISHII H, 1991, THROMB HAEMOSTASIS, V65, P618; Jansson JH, 1997, CIRCULATION, V96, P2938, DOI 10.1161/01.CIR.96.9.2938; Mohri M, 1998, THROMB HAEMOSTASIS, V80, P925; Norlund L, 1997, THROMB HAEMOSTASIS, V77, P248; Ohlin AK, 1997, THROMB HAEMOSTASIS, V78, P396; PAPP AC, 1989, THROMB HAEMOSTASIS, V61, P15; Peter K, 1997, ARTERIOSCL THROM VAS, V17, P505, DOI 10.1161/01.ATV.17.3.505; PIGNOLI P, 1986, CIRCULATION, V74, P1339; PRENTICE RL, 1986, BIOMETRIKA, V73, P1; RILEY WA, 1991, J NEUROIMAGING, V1, P168; Rosamond WD, 1998, NEW ENGL J MED, V339, P861, DOI 10.1056/NEJM199809243391301; Sadler JE, 1997, THROMB HAEMOSTASIS, V78, P392; *U N CAR NAT HEAT, 1987, ATH RISK COMM STUD M, V9; White AD, 1996, J CLIN EPIDEMIOL, V49, P223, DOI 10.1016/0895-4356(95)00041-0; WILLIAMS OD, 1989, AM J EPIDEMIOL, V129, P687, DOI 10.1093/oxfordjournals.aje.a115184	29	201	210	0	9	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAY 22	1999	353	9166					1729	1734		10.1016/S0140-6736(98)09057-6	http://dx.doi.org/10.1016/S0140-6736(98)09057-6			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	202TF	10347984				2022-12-28	WOS:000080667700009
J	Tweed, DB; Haslwanter, TP; Happe, V; Fetter, M				Tweed, DB; Haslwanter, TP; Happe, V; Fetter, M			Non-commutativity in the brain	NATURE			English	Article							TO-POSITION TRANSFORMATION; INVARIANT BODY KINEMATICS; VESTIBULOOCULAR REFLEX; DIRECTIONAL PLASTICITY; ROTATIONAL KINEMATICS; MUSCLE PULLEYS; 3 DIMENSIONS; SACCADES; MONKEY; SYSTEM	In non-commutative algebra, order makes a difference to multiplication, so that a x b not equal b x a (refs 1, 2). This feature is necessary for computing rotary motion, because order makes a difference to the combined effect of two rotations(3-6). It has therefore been proposed that there are non-commutative operators in the brain circuits that deal with rotations, including motor circuits that steer the eyes, head and limbs(4,5,7-15), and sensory circuits that handle spatial information(12,15). This idea is controversial(12,13,16-21): Studies of eye and head control have revealed behaviours that are consistent with non-commutativity in the brain(7-9,12-15), but none that clearly rules out all commutative models(17-20). Here we demonstrate noncommutative computation in the vestibule-ocular reflex. We show that subjects rotated in darkness can hold their gaze points stable in space, correctly computing different final eye-position commands when put through the same two rotations in different orders, in a way that is unattainable by any commutative system.	Univ Toronto, Dept Physiol, Toronto, ON M5S 1A8, Canada; Univ Toronto, Dept Med, Toronto, ON M5S 1A8, Canada; Univ Zurich Hosp, Dept Neurol, CH-8091 Zurich, Switzerland; ETH Honggerberg, Dept Phys, CH-8093 Zurich, Switzerland; Univ Tubingen, Dept Neurol, D-72076 Tubingen, Germany	University of Toronto; University of Toronto; University of Zurich; University Zurich Hospital; Swiss Federal Institutes of Technology Domain; ETH Zurich; Eberhard Karls University of Tubingen	Tweed, DB (corresponding author), Univ Toronto, Dept Physiol, 1 Kings Coll Circle, Toronto, ON M5S 1A8, Canada.							Carpenter RHS, 1988, MOVEMENTS EYES; CRAWFORD JD, 1991, J NEUROPHYSIOL, V65, P407, DOI 10.1152/jn.1991.65.3.407; Demer JL, 1996, J PEDIATR OPHTHALMOL, V33, P208; HAMILTON WR, 1953, LECT QUATERNIONS; Henriques DYP, 1998, J NEUROSCI, V18, P1583; HESTENES D, 1994, NEURAL NETWORKS, V7, P65, DOI 10.1016/0893-6080(94)90056-6; HESTENES D, 1994, NEURAL NETWORKS, V7, P79, DOI 10.1016/0893-6080(94)90057-4; Koch Christof, 1999, P1; McCarthy J.M., 1990, INTRO THEORETICAL KI; MERFELD DM, 1995, EXP BRAIN RES, V106, P123; MILLER JM, 1993, OPHTHALMOLOGY, V100, P475; MINKEN AWH, 1993, EXP BRAIN RES, V93, P521, DOI 10.1007/BF00229367; Peng G C, 1994, J Vestib Res, V4, P453; Quaia C, 1998, J NEUROPHYSIOL, V79, P3197, DOI 10.1152/jn.1998.79.6.3197; Raphan T, 1998, J NEUROPHYSIOL, V79, P2653, DOI 10.1152/jn.1998.79.5.2653; RAPHAN T, 1997, 3 DIMENSIONAL KINEMA, P359; ROBINSON DA, 1970, J NEUROPHYSIOL, V33, P393, DOI 10.1152/jn.1970.33.3.393; ROBINSON DA, 1963, IEEE T BIO-MED ENG, VBM10, P137, DOI 10.1109/TBMEL.1963.4322822; SCHNABOLK C, 1994, J NEUROPHYSIOL, V71, P623, DOI 10.1152/jn.1994.71.2.623; SCHULTHEIS LW, 1981, ANN NY ACAD SCI, V374, P504, DOI 10.1111/j.1749-6632.1981.tb30895.x; Schutz B., 1980, GEOMETRICAL METHODS; Smith MA, 1998, J NEUROPHYSIOL, V80, P2295, DOI 10.1152/jn.1998.80.5.2295; STRAUMANN D, 1995, VISION RES, V35, P3321, DOI 10.1016/0042-6989(95)00091-R; TWEED D, 1994, J NEUROPHYSIOL, V72, P1425, DOI 10.1152/jn.1994.72.3.1425; TWEED D, 1987, J NEUROPHYSIOL, V58, P832, DOI 10.1152/jn.1987.58.4.832; TWEED D, 1990, VISION RES, V30, P111, DOI 10.1016/0042-6989(90)90131-4; Tweed D, 1997, J NEUROPHYSIOL, V77, P654, DOI 10.1152/jn.1997.77.2.654; VANOPSTAL AJ, 1991, SCIENCE, V252, P1313, DOI 10.1126/science.1925545; WESTHEIMER G, 1957, J OPT SOC AM, V47, P967, DOI 10.1364/JOSA.47.000967	29	42	43	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAY 20	1999	399	6733					261	263		10.1038/20441	http://dx.doi.org/10.1038/20441			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	198MF	10353248				2022-12-28	WOS:000080427400056
J	Fairchild, AL; Bayer, R				Fairchild, AL; Bayer, R			Essays on science and society - Uses and abuses of Tuskegee	SCIENCE			English	Editorial Material							ETHICS; TRIAL; AIDS		Columbia Univ, Joseph L Mailman Sch Publ Hlth, Div Sociomed Sci, Program Hist Publ Hlth & Med, New York, NY 10032 USA	Columbia University	Fairchild, AL (corresponding author), Columbia Univ, Joseph L Mailman Sch Publ Hlth, Div Sociomed Sci, Program Hist Publ Hlth & Med, New York, NY 10032 USA.		Fairchild, Amy/F-1811-2018	Fairchild, Amy/0000-0002-1292-7212				ALEXANDER D, 1973, ESSENCE          SEP; ANDERSON W, 1991, AM J PUBLIC HEALTH, V81, P1506, DOI 10.2105/AJPH.81.11.1506; Angell M, 1997, NEW ENGL J MED, V337, P847, DOI 10.1056/NEJM199709183371209; BAYER R, 1986, JAMA-J AM MED ASSOC, V256, P1768, DOI 10.1001/jama.256.13.1768; BAYER R, 1993, AM J PUBLIC HEALTH, V83, P496, DOI 10.2105/AJPH.83.4.496; *CAN FED AIDS CTR, 1988, GUID ETH LEG COND AN; CAPLAN AL, 1997, WASHINGTON POST 0211; DALTON HL, 1989, DAEDALUS         SUM; DWYER J, 1995, NEW YORK NEWSDA 0315; HENTOFF N, 1995, WASHINGTON POST 0520; JONES JH, 1992, HASTINGS CENT REP, V22, P38, DOI 10.2307/3562949; Jones JH, 1981, BAD BLOOD TUSKEGEE S; Jones JH., 1981, BAD BLOOD TUSKEGEE S; KIRP DL, 1993, ATLANTIC         JUL; KIRP DL, 1995, TIKKUN, V10, P3; LAMBERT B, 1988, NY TIMES        1113; LURIE P, 1996, COMMUNICATION   1017; LURIE P, 1996, COMMUNICATION   1214; LURIE P, 1996, COMMUNICATION   1212; MOORE W, 1972, JET, V24, P20; *NAT AC SCI I MED, 1986, CONFR AIDS DIR PUBL; *OFF PROT RES RISK, 1988, HIV SER SURV CHILDB; ROTHMAN DJ, 1982, HASTINGS CTR REP APR, P5; RUFFIN FE, 1972, ESSENCE          SEP; RUTLEDGE A, 1973, ESSENCE          SEP, P42; SENCER D, 1985, NY TIMES        0915; SERVAAS C, 1998, SATURDAY EVENIN 0111; SPECTOR SA, 1994, NEW ENGL J MED, V331, P1181, DOI 10.1056/NEJM199411033311802; Thomas S B, 1993, J Public Health Policy, V14, P320, DOI 10.2307/3343042; *WHO, 1987, AIDS DRUG AB; *WHO GLOB PROGR AI, 1989, NL AN SCREEN PUBL HL; 1973, AMSTERDAM NEWS  0331, pA2; 1973, AMSTERDAM NEWS  0127, pA5; 1995, CONGRESSIONAL R 0919, pH9059	34	73	76	0	9	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAY 7	1999	284	5416					919	921		10.1126/science.284.5416.919	http://dx.doi.org/10.1126/science.284.5416.919			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	194MU	10357678				2022-12-28	WOS:000080198800030
J	Kovats, RS; Haines, A; Stanwell-Smith, R; Martens, P; Menne, B; Bertollini, R				Kovats, RS; Haines, A; Stanwell-Smith, R; Martens, P; Menne, B; Bertollini, R			Climate change and human health in Europe	BRITISH MEDICAL JOURNAL			English	Article							WINTER MORTALITY; INFECTION; ENGLAND; WALES		Univ London London Sch Hyg & Trop Med, Dept Epidemiol & Populat Hlth, London WC1E 7HT, England; UCL Royal Free & UCL Med Sch, London NW3 2PF, England; Publ Hlth Lab Serv, Ctr Communicable Dis Surveillance, London NW9 5EQ, England; Univ Maastricht, Int Ctr Integrat Studies, NL-6200 MD Maastricht, Netherlands; WHO, European Ctr Environm & Hlth, I-00187 Rome, Italy	University of London; London School of Hygiene & Tropical Medicine; University of London; University College London; Public Health England; Maastricht University; World Health Organization	Kovats, RS (corresponding author), Univ London London Sch Hyg & Trop Med, Dept Epidemiol & Populat Hlth, Keppel St, London WC1E 7HT, England.	s.kovats@lshtm.ac.uk	Martens, Pim/A-9297-2011	Kovats, Sari/0000-0002-4823-8099; Haines, Andy/0000-0002-8053-4605				Arrow Kenneth J., 1996, CLIMATE CHANGE 1995; BENISTON M, 1998, REGIONAL IMPACTS CLI, P149; BENNET G, 1970, BRIT MED J, V3, P454, DOI 10.1136/bmj.3.5720.454; BENTHAM G, 1995, INT J BIOMETEOROL, V39, P81, DOI 10.1007/BF01212585; *CDCP, 1995, MMWR-MORBID MORTAL W, V44, P841; Curwen M., 1991, HLTH TRENDS, V22, P169; DEDET JP, 1995, PRESSE MED, V24, P1036; Donaldson GC, 1998, BRIT MED J, V316, P514, DOI 10.1136/bmj.316.7130.514; Downing T. E., 1996, CLIMATE CHANGE EXTRE; Guillet P, 1998, TROP MED INT HEALTH, V3, P700; HAINES A, 1993, LANCET, V342, P1464, DOI 10.1016/0140-6736(93)92937-O; HULME M, 1996, 7 CLIM RES UN; International Federation of Red Cross and Red Crescent Societies, 1998, WORLD DIS REP 1997; KATSOUYANNI K, 1988, LANCET, V2, P573; KOVATS RS, 1999, EARLY HUMAN HLTH EFF; KUNST AE, 1993, AM J EPIDEMIOL, V137, P331, DOI 10.1093/oxfordjournals.aje.a116680; LANGFORD IH, 1995, INT J BIOMETEOROL, V38, P141, DOI 10.1007/BF01208491; LIGHTON LL, 1991, PUBLIC HEALTH, V105, P199, DOI 10.1016/S0033-3506(05)80109-X; LINDGREN E, 1998, CONS ECOL, V2, P5; Longstreth J. D., 1989, POTENTIAL EFFECTS GL; Martens WJM, 1998, SOC SCI MED, V46, P331, DOI 10.1016/S0277-9536(97)00162-7; MARTENS WJM, 1996, VULNERABILITY HUMAN; McMichael A.J., 1996, CLIMATE CHANGE HUMAN; Nicholls RJ, 1998, CLIMATE RES, V11, P5, DOI 10.3354/cr011005; Nikolaeva N, 1996, Bull Inst Marit Trop Med Gdynia, V47, P73; Parry M, 1998, NATURE, V395, P741, DOI 10.1038/27316; Rooney C, 1998, J EPIDEMIOL COMMUN H, V52, P482, DOI 10.1136/jech.52.8.482; SAUNDERS MA, 1998, CENTRAL E EUROPEAN F; Talleklint L, 1998, J MED ENTOMOL, V35, P521, DOI 10.1093/jmedent/35.4.521; *UK CLIM CHANG IMP, 1996, REV POT EFF CLIM CHA; *WHO EUR CTR ENV H, 1999, MON WAT RES HUM HLTH; 1998, WEEKLY EPID REC, V72, P285	32	41	43	3	10	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	JUN 19	1999	318	7199					1682	1685		10.1136/bmj.318.7199.1682	http://dx.doi.org/10.1136/bmj.318.7199.1682			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	210KY	10373176	Green Submitted, Green Published			2022-12-28	WOS:000081105600034
J	Levin, G				Levin, G			Arthur Levin - Obituary	BRITISH MEDICAL JOURNAL			English	Biographical-Item																			0	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JUN 19	1999	318	7199					1701	1701		10.1136/bmj.318.7199.1701	http://dx.doi.org/10.1136/bmj.318.7199.1701			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	210KY	10373194	Green Published			2022-12-28	WOS:000081105600058
J	Quartey-Papafio, CM				Quartey-Papafio, CM			Importance of distinguishing between cellulitis and varicose eczema of the leg	BRITISH MEDICAL JOURNAL			English	Review									Pilgrim Hosp NHS Trust, Dept Dermatol, Boston PE21 9QS, England		Quartey-Papafio, CM (corresponding author), Pilgrim Hosp NHS Trust, Dept Dermatol, Boston PE21 9QS, England.							Aly AA, 1996, MED J AUSTRALIA, V165, P553, DOI 10.5694/j.1326-5377.1996.tb138641.x; Semel JD, 1996, CLIN INFECT DIS, V23, P1162, DOI 10.1093/clinids/23.5.1162; Wang JH, 1997, CLIN INFECT DIS, V25, P685, DOI 10.1086/513752	3	8	10	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JUN 19	1999	318	7199					1672	1673		10.1136/bmj.318.7199.1672	http://dx.doi.org/10.1136/bmj.318.7199.1672			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	210KY	10373173	Green Published			2022-12-28	WOS:000081105600024
J	Simpson, WM; Johnstone, FD; Goldberg, DJ; Gormley, SM; Hart, GJ				Simpson, WM; Johnstone, FD; Goldberg, DJ; Gormley, SM; Hart, GJ			Antenatal HIV testing: assessment of a routine voluntary approach	BRITISH MEDICAL JOURNAL			English	Article							WOMEN		Univ Edinburgh, Ctr Reprod Biol, Dept Obstet & Gynaecol, Edinburgh EH3 9EW, Midlothian, Scotland; Scottish Ctr Infect & Environm Hlth, Glasgow G3 7LN, Lanark, Scotland; Univ Glasgow, MRC, Med Sociol Unit, Glasgow G12 8RZ, Lanark, Scotland	University of Edinburgh; University of Glasgow	Simpson, WM (corresponding author), 22 Lumsden Pk, Cupar KY15 5YL, Fife, Scotland.		Hart, Graham J/C-1591-2008	Hart, Graham/0000-0001-9676-6577				*INT CORK PART ENH, 1998, RED MOTH CHILD TRANS; Johnstone F, 1998, AIDS, V12, P911, DOI 10.1097/00002030-199808000-00014; MARTEAU TM, 1992, BRIT J CLIN PSYCHOL, V31, P301, DOI 10.1111/j.2044-8260.1992.tb00997.x; Nicoll A, 1998, BRIT MED J, V316, P253, DOI 10.1136/bmj.316.7127.253; Simpson WM, 1998, BRIT MED J, V316, P262, DOI 10.1136/bmj.316.7127.262	5	63	64	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JUN 19	1999	318	7199					1660	1661		10.1136/bmj.318.7199.1660	http://dx.doi.org/10.1136/bmj.318.7199.1660			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	210KY	10373168	Bronze, Green Published, Green Submitted			2022-12-28	WOS:000081105600020
J	Soderlund, N; Zwi, K; Kinghorn, A; Gray, G				Soderlund, N; Zwi, K; Kinghorn, A; Gray, G			Prevention of vertical transmission of HIV: analysis of cost effectiveness of options available in South Africa	BRITISH MEDICAL JOURNAL			English	Article							TO-CHILD TRANSMISSION; HUMAN-IMMUNODEFICIENCY-VIRUS; INFECTION; ZIDOVUDINE; INTERVENTION; TYPE-1; HEALTH; IMPACT; AIDS	Objective To assess the cost effectiveness of vertical transmission prevention strategies by using a mathematical simulation model, Design A Markov chain model was used to simulate the cost effectiveness of four formula feeding strategies, three antiretroviral interventions, and combined formula feeding and antiretroviral interventions on a cohort of 20 000 pregnancies, All children born to HIV positive mothers were followed up until age of likely death given current life expectancy and a cost per life year gained calculated fur each strategy. Setting Model of working class, urban South African population, Results Low cost antiretroviral regimens were almost as effective as high cost ones and more cost effective when formula feeding interventions were added, With or without formula feeding, low cost antiretroviral interventions were likely to save lives and money. Interventions that allowed breast feeding early on, to be replaced by formula feeding at 4 or 7 months, seemed likely to save fewer lives and offered poorer value for money Conclusions Antiretroviral interventions are probably cost effective across a wide range of settings, with or without formula feeding interventions, The appropriateness of formula feeding was highly cost effective only in settings with high seroprevalence and reasonable levels of child survival and dangerous where infant mortality was high or the protective effect of breast feeding substantial, Pilot projects are now needed to ensure the feasibility of implementation.	Univ Witwatersrand, Ctr Hlth Policy, ZA-2000 Johannesburg, South Africa; Chris Hani Baragwanath Hosp, Dept Paediat, Johannesburg, South Africa; Abt Associates S Africa, Johannesburg, South Africa; Univ Witwatersrand, Perinatal HIV Res Unit, Johannesburg, South Africa	University of Witwatersrand; ABT Associates; University of Witwatersrand	Soderlund, N (corresponding author), Univ Witwatersrand, Ctr Hlth Policy, POB 1038, ZA-2000 Johannesburg, South Africa.		Zwi, Karen/S-4547-2016	Zwi, Karen/0000-0002-5561-5200				Bertolli J, 1996, J INFECT DIS, V174, P722, DOI 10.1093/infdis/174.4.722; Biggar RJ, 1996, LANCET, V347, P1647, DOI 10.1016/S0140-6736(96)91486-5; Briggs A, 1998, PHARMACOECONOMICS, V13, P397, DOI 10.2165/00019053-199813040-00003; BROWN M, 1994, REPORT CONSULTANTS E; *CDCP, 1998, MMWR-MORBID MORTAL W, V47, P151; *CENTR STAT SERV, 1997, STAT BRIEF 1997; CONNOR EM, 1994, NEW ENGL J MED, V331, P1173, DOI 10.1056/NEJM199411033311801; CUNNINGHAM AS, 1991, J PEDIATR-US, V118, P659, DOI 10.1016/S0022-3476(05)80023-X; Dabis F, 1999, LANCET, V353, P786, DOI 10.1016/S0140-6736(98)11046-2; *DEP HLTH POP DEV, 1996, EPIDEMIOL COMMENTS, V23, P4; DUNN DT, 1994, J ACQ IMMUN DEF SYND, V7, P1064; Harrison D., 1995, S AFRICAN HLTH REV 1; KINGHORN A, 1998, PROJECTIONS COSTS AN; Mansergh G, 1996, JAMA-J AM MED ASSOC, V276, P139, DOI 10.1001/jama.276.2.139; Marseille E, 1998, AIDS, V12, P939, DOI 10.1097/00002030-199808000-00017; Mayaux MJ, 1997, J PEDIATR-US, V131, P857, DOI 10.1016/S0022-3476(97)70033-7; Mofenson LM, 1997, ACTA PAEDIATR, V421, P1; *NAT DEP HLTH S AF, 1995, REG HLTH MAN INF SYS; NICOLL A, 1995, AIDS, V9, P107, DOI 10.1097/00002030-199509020-00001; Ratcliffe J, 1998, AIDS, V12, P1381, DOI 10.1097/00002030-199811000-00021; ROSS SM, 1983, S AFR MED J, V63, P23; Sculpher MJ, 1998, AIDS, V12, P1371, DOI 10.1097/00002030-199811000-00020; SEMBA RD, 1994, LANCET, V343, P1593, DOI 10.1016/S0140-6736(94)93056-2; Shaffer N, 1999, LANCET, V353, P773, DOI 10.1016/S0140-6736(98)10411-7; SODERLUND N, 1998, MONOGRAPH CTR HLTH P, V52; SODERLUND N, 1997, LIKELY COSTS HOSP CA; Stover J, 1998, AIDS, V12, pS29; Tess BH, 1998, J ACQ IMMUN DEF SYND, V19, P189, DOI 10.1097/00042560-199810010-00014; *UNAIDS WHO, 1998, GUID MOD ANT TREATM; WAGSTAFF L, 1993, URBANISATION HLTH NE, V18, P9; Wiktor SZ, 1999, LANCET, V353, P781, DOI 10.1016/S0140-6736(98)10412-9; Wilkinson D, 1998, AIDS, V12, P1675, DOI 10.1097/00002030-199813000-00016; ZWI KJ, IN PRESS ANN TROP PA	33	71	73	0	7	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JUN 19	1999	318	7199					1650	1656		10.1136/bmj.318.7199.1650	http://dx.doi.org/10.1136/bmj.318.7199.1650			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	210KY	10373166	Green Submitted, Green Published, Bronze			2022-12-28	WOS:000081105600018
J	Dickinson, MH; Lehmann, FO; Sane, SP				Dickinson, MH; Lehmann, FO; Sane, SP			Wing rotation and the aerodynamic basis of insect flight	SCIENCE			English	Article							LOW REYNOLDS-NUMBERS; DROSOPHILA-MELANOGASTER; LIFT PRODUCTION; MECHANISMS; KINEMATICS; PERFORMANCE; GENERATION; DYNAMICS; ANIMALS; FORCES	The enhanced aerodynamic performance of insects results from an interaction of three distinct yet interactive mechanisms: delayed stall,. rotational circulation, and wake capture. Delayed stall functions-during the translational portions of the stroke, when the wings sweep through the air with a Large angle of attack. In contrast, rotational circulation and wake capture generate aerodynamic forces during stroke reversals, when the wings rapidly rotate and change direction. In addition to contributing to the lift required to keep an insect aloft, these two rotational mechanisms provide a potent means by which the animal can modulate the direction and magnitude of flight forces during steering maneuvers. A comprehensive theory incorporating both translational and rotational mechanisms may explain the diverse patterns of wing motion displayed by different species of insects.	Univ Calif Berkeley, Dept Integrat Biol, Berkeley, CA 94720 USA; Univ Wurzburg, Theodor Boveri Inst, Dept Behav Physiol & Sociobiol Zool, D-97074 Wurzburg, Germany	University of California System; University of California Berkeley; University of Wurzburg	Dickinson, MH (corresponding author), Univ Calif Berkeley, Dept Integrat Biol, Berkeley, CA 94720 USA.	flymanmd@socrates.berkeley.edu	Sikandar, Usama/F-6586-2016					ADAIR R, 1990, PHYSICS BASEBALL; CLOUPEAU M, 1979, J EXP BIOL, V80, P1; COLLETT TS, 1975, J COMP PHYSIOL, V99, P1, DOI 10.1007/BF01464710; Dalton S., 1975, BORNE WIND; Dickinson MH, 1996, AM ZOOL, V36, P537; Dickinson MH, 1996, J EXP BIOL, V199, P2085; DICKINSON MH, 1994, J EXP BIOL, V192, P179; DICKINSON MH, 1993, J EXP BIOL, V174, P45; DICKINSON MH, 1993, J EXP BIOL, V182, P173; Ellington C.P., 1995, Symposia of the Society for Experimental Biology, V49, P109; ELLINGTON CP, 1984, PHILOS T ROY SOC B, V305, P79, DOI 10.1098/rstb.1984.0052; Ellington CP, 1996, NATURE, V384, P626, DOI 10.1038/384626a0; ELLINGTON CP, 1984, PHILOS T ROY SOC B, V305, P1, DOI 10.1098/rstb.1984.0049; ELLINGTON CP, 1984, PHILOS T ROY SOC B, V305, P41, DOI 10.1098/rstb.1984.0051; ENNOS AR, 1989, J EXP BIOL, V142, P49; Fung Y., 1993, INTRO THEORY AEROELA; GOTZ KG, 1987, J EXP BIOL, V128, P35; GOTZ KG, 1984, BIOL CYBERN, V51, P135, DOI 10.1007/BF00357927; LEHMANN FO, 1994, THESIS EBERHAD KARLS; MARDEN JH, 1987, J EXP BIOL, V130, P235; MAXWORTHY T, 1981, ANNU REV FLUID MECH, V13, P329, DOI 10.1146/annurev.fl.13.010181.001553; MAY RM, 1978, S R ENTOMOL SOC LOND, V9, P188; Nachtigall W., 1974, INSECTS FLIGHT; RAYNER JMV, 1991, PHILOS T ROY SOC B, V334, P119, DOI 10.1098/rstb.1991.0101; SPEDDING GR, 1986, J FLUID MECH, V165, P247, DOI 10.1017/S0022112086003087; VandenBerg C, 1997, PHILOS T ROY SOC B, V352, P317, DOI 10.1098/rstb.1997.0023; Wagner H, 1925, Z ANGEW MATH MECH, V5, P17, DOI 10.1002/zamm.19250050103; WEISFOGH T, 1973, J EXP BIOL, V59, P169; WILKIN PJ, 1993, PHYSIOL ZOOL, V66, P1015, DOI 10.1086/physzool.66.6.30163752; Willmott AP, 1997, PHILOS T ROY SOC B, V352, P303, DOI 10.1098/rstb.1997.0022; ZANKER JM, 1990, PHILOS T ROY SOC B, V327, P1, DOI 10.1098/rstb.1990.0040	31	1684	1810	25	328	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 18	1999	284	5422					1954	1960		10.1126/science.284.5422.1954	http://dx.doi.org/10.1126/science.284.5422.1954			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	207JA	10373107				2022-12-28	WOS:000080932700037
J	Perrin, RM; DeRocher, AE; Bar-Peled, M; Zeng, WQ; Norambuena, L; Orellana, A; Raikhel, NV; Keegstra, K				Perrin, RM; DeRocher, AE; Bar-Peled, M; Zeng, WQ; Norambuena, L; Orellana, A; Raikhel, NV; Keegstra, K			Xyloglucan fucosyltransferase, an enzyme involved in plant cell wall biosynthesis	SCIENCE			English	Article							COMPLEX POLYSACCHARIDES; GOLGI-APPARATUS; ARABIDOPSIS; CELLULOSE; GLYCOSYLTRANSFERASES; OLIGOSACCHARIDES; GLYCOPROTEINS; FUCOSYLATION; LOCALIZATION; SIMULATIONS	Cell walls are crucial for development, signal transduction, and disease resistance in plants. Cell walls are made of cellulose, hemicelluloses, and pectins. Xyloglucan (XG), the principal load-bearing hemicellulose of dicotyledonous plants. has a terminal fucosyl residue. A 60-kilodalton fucosyltransferase (FTase) that adds this residue was purified from pea epicotyls. Peptide sequence information from the pea FTase allowed the cloning of a homologous gene, AtFT1, from Arabidopsis. Antibodies raised against recombinant AtFTase immunoprecipitate FTase enzyme activity from solubilized Arabidopsis membrane proteins, and AtFT1 expressed in mammalian COS cells results in the presence of XG FTase activity in these cells.	Michigan State Univ, US DOE, Plant Res Lab, E Lansing, MI 48824 USA; Michigan State Univ, Dept Bot & Plant Pathol, E Lansing, MI 48824 USA; Michigan State Univ, Dept Biochem, E Lansing, MI 48824 USA; Michigan State Univ, Cell & Mol Biol Program, E Lansing, MI 48824 USA; Univ Chile, Fac Sci, Dept Biol, Santiago, Chile	Michigan State University; United States Department of Energy (DOE); Michigan State University; Michigan State University; Michigan State University; Universidad de Chile	Keegstra, K (corresponding author), Michigan State Univ, US DOE, Plant Res Lab, E Lansing, MI 48824 USA.		Orellana, Ariel/E-2166-2014; Zeng, Weiqing/AAA-7045-2019; Norambuena, Lorena/I-1248-2013; Orellana, Ariel/AAE-4866-2021	Orellana, Ariel/0000-0002-9243-808X; Norambuena, Lorena/0000-0002-6031-2394; Orellana, Ariel/0000-0002-9243-808X; Zeng, Weiqing/0000-0002-5466-8693				Arioli T, 1998, SCIENCE, V279, P717, DOI 10.1126/science.279.5351.717; Breton C, 1998, GLYCOBIOLOGY, V8, P87, DOI 10.1093/glycob/8.1.87; CAMIRAND A, 1987, PLANT PHYSIOL, V84, P753, DOI 10.1104/pp.84.3.753; CARPITA N, 1997, PLANT METABOLISM, pCH9; Colley KJ, 1997, GLYCOBIOLOGY, V7, P1, DOI 10.1093/glycob/7.1.1-b; COSGROVE DJ, 1993, PLANT PHYSIOL, V102, P1, DOI 10.1104/pp.102.1.1; Creelman RA, 1997, PLANT CELL, V9, P1211, DOI 10.1105/tpc.9.7.1211; DRIOUICH A, 1993, TRENDS BIOCHEM SCI, V18, P210, DOI 10.1016/0968-0004(93)90191-O; FARKAS V, 1988, ARCH BIOCHEM BIOPHYS, V264, P48, DOI 10.1016/0003-9861(88)90568-1; FRY SC, 1993, PLANT PHYSIOL, V103, P1, DOI 10.1104/pp.103.1.1; FUJIKI Y, 1982, J CELL BIOL, V93, P97, DOI 10.1083/jcb.93.1.97; HAYASHI T, 1989, ANNU REV PLANT PHYS, V40, P139, DOI 10.1146/annurev.pp.40.060189.001035; KIEBER JJ, 1993, CELL, V72, P427, DOI 10.1016/0092-8674(93)90119-B; KLEENE R, 1993, BIOCHIM BIOPHYS ACTA, V1154, P283, DOI 10.1016/0304-4157(93)90003-7; LEVY S, 1991, PLANT J, V1, P195; Levy S, 1997, PLANT J, V11, P373, DOI 10.1046/j.1365-313X.1997.11030373.x; MCDOUGALL GJ, 1989, J EXP BOT, V40, P233, DOI 10.1093/jxb/40.2.233; MOORE PJ, 1991, J CELL BIOL, V112, P589, DOI 10.1083/jcb.112.4.589; Pear JR, 1996, P NATL ACAD SCI USA, V93, P12637, DOI 10.1073/pnas.93.22.12637; PERRIN R, UNPUB; PUHLMANN J, 1994, PLANT PHYSIOL, V104, P699, DOI 10.1104/pp.104.2.699; Purugganan MM, 1997, PLANT PHYSIOL, V115, P181, DOI 10.1104/pp.115.1.181; VARNER JE, 1989, CELL, V56, P231, DOI 10.1016/0092-8674(89)90896-9; WHITNEY SEC, 1995, PLANT J, V8, P491, DOI 10.1046/j.1365-313X.1995.8040491.x; YORK WS, 1984, PLANT PHYSIOL, V75, P295, DOI 10.1104/pp.75.2.295; ZABLACKIS E, 1995, PLANT PHYSIOL, V107, P1129, DOI 10.1104/pp.107.4.1129	26	211	223	1	39	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 18	1999	284	5422					1976	1979		10.1126/science.284.5422.1976	http://dx.doi.org/10.1126/science.284.5422.1976			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	207JA	10373113				2022-12-28	WOS:000080932700043
J	Leibovici, L; Shraga, I; Andreassen, S				Leibovici, L; Shraga, I; Andreassen, S			How do you choose antibiotic treatment?	BRITISH MEDICAL JOURNAL			English	Article							URINARY-TRACT INFECTION; LONG-TERM SURVIVAL; DECISION-SUPPORT; RESISTANCE; BACTEREMIA; SEPSIS; USAGE; AMINOGLYCOSIDES; NEPHROTOXICITY; GUIDELINES		Tel Aviv Univ, Sackler Fac Med, IL-69978 Tel Aviv, Israel; Univ Aalborg, Dept Med Informat, DK-9000 Aalborg, Denmark	Tel Aviv University; Sackler Faculty of Medicine; Aalborg University	Leibovici, L (corresponding author), Rabin Med Ctr, Dept Med, Beilinson Campus, IL-49100 Petah Tiqwa, Israel.			Andreassen, Steen/0000-0001-5379-7373				BALLOW CH, 1992, DIAGN MICR INFEC DIS, V15, pS37; BERMAN JR, 1992, AM J HOSP PHARM, V49, P1701, DOI 10.1093/ajhp/49.7.1701; Burke JP, 1998, JAMA-J AM MED ASSOC, V280, P1270, DOI 10.1001/jama.280.14.1270; BURWEN DR, 1994, J INFECT DIS, V170, P1622, DOI 10.1093/infdis/170.6.1622; CHOW JW, 1991, ANN INTERN MED, V115, P585, DOI 10.7326/0003-4819-115-8-585; COURCOL RJ, 1989, J ANTIMICROB CHEMOTH, V23, P441, DOI 10.1093/jac/23.3.441; DOLAN JG, 1989, J GEN INTERN MED, V4, P190, DOI 10.1007/BF02599521; EISENBERG JM, 1987, ANN INTERN MED, V107, P900, DOI 10.7326/0003-4819-107-6-900; ESPOSITO AL, 1980, J AM GERIATR SOC, V28, P315, DOI 10.1111/j.1532-5415.1980.tb00622.x; EVANS RS, 1994, ARCH INTERN MED, V154, P878, DOI 10.1001/archinte.154.8.878; GARRELTS JC, 1994, PHARMACOTHERAPY, V14, P438; GERDING DN, 1991, ANTIMICROB AGENTS CH, V35, P1284, DOI 10.1128/AAC.35.7.1284; GO ES, 1994, LANCET, V344, P1329, DOI 10.1016/S0140-6736(94)90694-7; GRANSDEN WR, 1990, REV INFECT DIS, V12, P1008; HOLLOWAY JJ, 1984, ANN INTERN MED, V101, P764, DOI 10.7326/0003-4819-101-6-764; Jones GR, 1996, QJM-MON J ASSOC PHYS, V89, P515; Leibovici L, 1997, J INTERN MED, V242, P395, DOI 10.1046/j.1365-2796.1997.00232.x; LEIBOVICI L, 1995, JAMA-J AM MED ASSOC, V274, P807, DOI 10.1001/jama.274.10.807; Leibovici L, 1998, J INTERN MED, V244, P379; LEIBOVICI L, 1998, J HOSP INFECT SA, V40; MARK DB, 1995, ACUTE CORONARY CARE, P167; MEYERS BR, 1989, AM J MED, V86, P379, DOI 10.1016/0002-9343(89)90333-1; MOLLER JK, 1989, J ANTIMICROB CHEMOTH, V24, P983, DOI 10.1093/jac/24.6.983; MOORE RD, 1984, ANN INTERN MED, V100, P352, DOI 10.7326/0003-4819-100-3-352; MORRIS JG, 1995, ANN INTERN MED, V123, P250, DOI 10.7326/0003-4819-123-4-199508150-00002; PERL TM, 1995, JAMA-J AM MED ASSOC, V274, P338, DOI 10.1001/jama.274.4.338; Pestotnik SL, 1996, ANN INTERN MED, V124, P884, DOI 10.7326/0003-4819-124-10-199605150-00004; Quartin AA, 1997, JAMA-J AM MED ASSOC, V277, P1058, DOI 10.1001/jama.277.13.1058; Rahal JJ, 1998, JAMA-J AM MED ASSOC, V280, P1233, DOI 10.1001/jama.280.14.1233; Standing Medical Advisory Committee: Sub-group on Antimicrobial Resistance, 1998, PATH LEAST RES; Sundman K, 1997, EUR J CLIN MICROBIOL, V16, P455, DOI 10.1007/BF02471910; TOMASZ A, 1994, NEW ENGL J MED, V330, P1247, DOI 10.1056/NEJM199404283301725	32	36	36	0	5	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JUN 12	1999	318	7198					1614	1616		10.1136/bmj.318.7198.1614	http://dx.doi.org/10.1136/bmj.318.7198.1614			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	207AL	10364128	Green Published			2022-12-28	WOS:000080913100037
J	Keeley, JE; Fotheringham, CJ; Morais, M				Keeley, JE; Fotheringham, CJ; Morais, M			Reexamining fire suppression impacts on brushland fire regimes	SCIENCE			English	Article							FOREST	California shrubland wildfires are increasingly destructive, and it is widely held that the problem has been intensified by fire suppression, leading to larger, more intense wildfires. However, analysis of the California Statewide Fire History Database shows that, since 1910, fire frequency and area burned have not declined, and fire size has not increased. Fire rotation intervals have declined, and fire season has not changed, implying that fire intensity has not increased. Fire frequency and population density were correlated, and it is suggested that fire suppression plays a critical role in offsetting potential impacts of increased ignitions. Large fires were not dependent on old age classes of fuels, and it is thus unlikely that age class manipulation of fuels can prevent large fires. Expansion of the urban-wildland interface is a key factor in wildland fire destruction.	US Geol Survey, Biol Resources Div, Western Ecol Res Ctr, Sequoia Kings Canyon Field Stn, Three Rivers, CA 93721 USA; Calif State Univ Los Angeles, Ctr Environm Anal, Ctr Res Excellence Sci & Technol, Dept Biol & Microbiol, Los Angeles, CA 90032 USA; Natl Pk Serv, Santa Monica Mt Natl Recreat Area, Thousand Oaks, CA 91360 USA	United States Department of the Interior; United States Geological Survey; California State University System; California State University Los Angeles; United States Department of the Interior	Keeley, JE (corresponding author), US Geol Survey, Biol Resources Div, Western Ecol Res Ctr, Sequoia Kings Canyon Field Stn, 47050 Gen Highway, Three Rivers, CA 93721 USA.		Fotheringham, CJ/AAV-7429-2021					Biswell H, 1989, PRESCRIBED BURNING C; BONNICKSEN TM, 1980, ENVIRON MANAGE, V4, P35, DOI 10.1007/BF01866219; BONNICKSEN TM, 1979, J ENVIRON MANAGE, V8, P277; BRADSHAW TD, 1977, PSW101 US FOR SERV, P15; CALLAHAN RZ, 1985, 5 U CAL WILDL RES CT; Conard S. G., 1998, TALL TIMB FIR EC C P, P342; COUNTRYMAN CM, 1974, PSW7 US FOR SERV; DAVIS FW, 1993, PATCH DYNAMICS, P247; DAVIS JB, 1989, FIRE MANAG NOTES, V50, P22; DODGE M, 1972, SCIENCE, V177, P139, DOI 10.1126/science.177.4044.139; Keeley J. E., 1982, P S DYN MAN MED TYP, P431; KEELEY JE, 1999, N AM TERRESTRIAL VEG, P201; Malamud BD, 1998, SCIENCE, V281, P1840, DOI 10.1126/science.281.5384.1840; MINNICH RA, 1983, SCIENCE, V219, P1287, DOI 10.1126/science.219.4590.1287; MINNICH RA, 1991, CALIFORNIA WATERSHED, P67; MINNISH RA, 1995, BRUSHFIRES CALIFORNI, P133; Moritz MA, 1997, ECOL APPL, V7, P1252, DOI 10.1890/1051-0761(1997)007[1252:AEDEFI]2.0.CO;2; Philpot C. W., 1977, USDA Forest Service General Technical Report, Washington, DC, P12; Pyne S.J., 1996, INTRO WILDLAND FIRE; Pyne S. J, 1995, WORLD FIRE; ROTHERMEL RC, 1973, J FOREST, V71, P640; *U CA CTR WAT WILD, 1996, SIERR NEV EC PROJ FI, V2, P1033; ZIVNUSKA JA, 1950, CALIF AGR, V4, P8	23	292	302	1	65	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 11	1999	284	5421					1829	1832		10.1126/science.284.5421.1829	http://dx.doi.org/10.1126/science.284.5421.1829			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	205EU	10364554				2022-12-28	WOS:000080809000048
J	Treue, S; Trujillo, JCM				Treue, S; Trujillo, JCM			Feature-based attention influences motion processing gain in macaque visual cortex	NATURE			English	Article							AREA-MT; SELECTIVE ATTENTION; NEURAL MECHANISMS; MODULATION; V4; NEURONS; LESIONS; MONKEY; MST; V1	Changes in neural responses based on spatial attention have been demonstrated in many areas of visual cortex(1-4), indicating that the neural correlate of attention is an enhanced response to stimuli at an attended location and reduced responses to stimuli elsewhere. Here we demonstrate non-spatial, feature-based attentional modulation of visual motion processing, and show that attention increases the gain of direction-selective neurons in visual cortical area MT without narrowing the direction-tuning curves. These findings place important constraints on the neural mechanisms of attention and we propose to unify the effects of spatial location, direction of motion and other features of the attended stimuli in a 'feature similarity gain model' of attention.	Univ Tubingen, Dept Neurol, Cognit Neurosci Lab, D-72076 Tubingen, Germany	Eberhard Karls University of Tubingen	Treue, S (corresponding author), Univ Tubingen, Dept Neurol, Cognit Neurosci Lab, Morgenstelle 15, D-72076 Tubingen, Germany.		Martinez-Trujillo, Julio C/M-2146-2015	Martinez-Trujillo, Julio C/0000-0003-3338-578X				Beauchamp MS, 1997, J NEUROPHYSIOL, V78, P516, DOI 10.1152/jn.1997.78.1.516; Britten KH, 1996, VISUAL NEUROSCI, V13, P87, DOI 10.1017/S095252380000715X; CHELAZZI L, 1993, NATURE, V363, P345, DOI 10.1038/363345a0; DESIMONE R, 1995, ANNU REV NEUROSCI, V18, P193, DOI 10.1146/annurev.ne.18.030195.001205; Duncan J, 1996, PERCEPT PSYCHOPHYS, V58, P1076, DOI 10.3758/BF03206834; ITTI L, IN PRESS NEURAL INFO; LANKHEET MJM, 1995, VISION RES, V35, P1401, DOI 10.1016/0042-6989(95)98720-T; Luck SJ, 1997, J NEUROPHYSIOL, V77, P24, DOI 10.1152/jn.1997.77.1.24; Martinez J. C., 1998, Society for Neuroscience Abstracts, V24, P649; McAdams CJ, 1999, J NEUROSCI, V19, P431, DOI 10.1523/JNEUROSCI.19-01-00431.1999; MCADAMS CJ, 1996, NEUR ABSTR, V22, P1197; MORAN J, 1985, SCIENCE, V229, P782, DOI 10.1126/science.4023713; MOTTER BC, 1994, J NEUROSCI, V14, P2178; MOTTER BC, 1993, J NEUROPHYSIOL, V70, P909, DOI 10.1152/jn.1993.70.3.909; NEWSOME WT, 1988, J NEUROSCI, V8, P2201; NEWSOME WT, 1985, J NEUROSCI, V5, P825; OCraven KM, 1997, NEURON, V18, P591, DOI 10.1016/S0896-6273(00)80300-1; Reynolds J. H., 1997, Society for Neuroscience Abstracts, V23, P302; Reynolds JH, 1999, J NEUROSCI, V19, P1736; SNOWDEN RJ, 1992, EXP BRAIN RES, V88, P389, DOI 10.1007/BF02259114; SPITZER H, 1988, SCIENCE, V240, P338, DOI 10.1126/science.3353728; Treue S, 1996, NATURE, V382, P539, DOI 10.1038/382539a0; Treue S., 1998, Society for Neuroscience Abstracts, V24, P1249; TREUE S, UNPUB J NEUROSCI; Valdes-Sosa M, 1998, J COGNITIVE NEUROSCI, V10, P137, DOI 10.1162/089892998563743	25	1008	1025	4	66	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 10	1999	399	6736					575	579		10.1038/21176	http://dx.doi.org/10.1038/21176			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	204RR	10376597	Green Published			2022-12-28	WOS:000080778400053
J	Davies, E				Davies, E			A memorable patient - What a rotten job you've got	BRITISH MEDICAL JOURNAL			English	Article														Davies, Elizabeth/0000-0003-2325-0849					0	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JUN 5	1999	318	7197					1547	1547		10.1136/bmj.318.7197.1547	http://dx.doi.org/10.1136/bmj.318.7197.1547			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	204HC	10356017	Green Published			2022-12-28	WOS:000080757300035
J	Hou, H; Huang, Y; Gulding, SJ; Rettner, CT; Auerbach, DJ; Wodtke, AM				Hou, H; Huang, Y; Gulding, SJ; Rettner, CT; Auerbach, DJ; Wodtke, AM			Enhanced reactivity of highly vibrationally excited molecules on metal surfaces	SCIENCE			English	Article							DYNAMICS	The chemical dynamics of highly vibrationally excited molecules have been studied by measuring the quantum state-resolved scattering probabilities of nitric oxide (Nd) molecules on clean and oxygen-covered copper (111) surfaces, where the incident NO was prepared in single quantum states with vibrational energies of as much as 300 kilojoules per mole. The dependence of vibrationally elastic and inelastic scattering on oxygen coverage strongly suggests that highly excited NO (v = 13 and 15) reacts on clean copper (111) with a probability of 0.87 +/- 0.05, more than three orders of magnitude greater than the reaction probability of ground-state NO. Vibrational promotion of surface chemistry on metals (up to near-unit reaction probability) is possible despite the expected efficient relaxation of vibrational energy at metal surfaces.	IBM Corp, Almaden Res Ctr, Div Res, San Jose, CA 95120 USA; Univ Calif Santa Barbara, Dept Chem, Santa Barbara, CA 93106 USA	International Business Machines (IBM); University of California System; University of California Santa Barbara	Auerbach, DJ (corresponding author), IBM Corp, Almaden Res Ctr, Div Res, San Jose, CA 95120 USA.		Auerbach, Daniel J/J-7109-2014; Wodtke, Alec M/I-4848-2012	Auerbach, Daniel J/0000-0001-9494-3066; Wodtke, Alec/0000-0002-6509-2183				AMIOT C, 1982, J MOL SPECTROSC, V94, P150, DOI 10.1016/0022-2852(82)90301-0; Arnold DW, 1998, CHEM PHYS LETT, V282, P313, DOI 10.1016/S0009-2614(97)01277-3; Drabbels M, 1997, J CHEM PHYS, V106, P3024, DOI 10.1063/1.473047; Drabbels M, 1997, J PHYS CHEM A, V101, P6463, DOI 10.1021/jp963898g; ENGLEMAN R, 1971, J MOL SPECTROSC, V37, P240, DOI 10.1016/0022-2852(71)90295-5; ENGLEMAN R, 1970, LA4364 LOS AL SCI LA; GOSTEIN M, 1995, PHYS REV LETT, V75, P342, DOI 10.1103/PhysRevLett.75.342; HABRAKEN FHPM, 1979, SURF SCI, V83, P45, DOI 10.1016/0039-6028(79)90479-5; HAMILTON CE, 1986, ANNU REV PHYS CHEM, V37, P493; HOU H, IN PRESS J CHEM PHYS; MATLOOB MH, 1977, PHYS SCRIPTA, V16, P420, DOI 10.1088/0031-8949/16/5-6/040; Michaels CA, 1998, J CHEM PHYS, V108, P2744, DOI 10.1063/1.475666; MILLER RL, 1994, SCIENCE, V265, P1831, DOI 10.1126/science.265.5180.1831; Persson BNJ, 1997, SURF SCI, V390, P45, DOI 10.1016/S0039-6028(97)00507-4; Persson BNJ, 1998, SURF SCI, V410, pL779, DOI 10.1016/S0039-6028(98)00411-7; POLANYI JC, 1972, ACCOUNTS CHEM RES, V5, P161, DOI 10.1021/ar50053a001; POLANYI JC, 1969, J CHEM PHYS, V51, P1439, DOI 10.1063/1.1672194; Rettner CT, 1996, J PHYS CHEM-US, V100, P13021, DOI 10.1021/jp9536007; RETTNER CT, 1988, J VAC SCI TECHNOL A, V6, P899, DOI 10.1116/1.575071; SINHA A, 1992, J CHEM PHYS, V96, P372, DOI 10.1063/1.462473; YANG X, 1990, J CHEM PHYS, V92, P116, DOI 10.1063/1.458480; ZARE RN, 1987, ANGULAR MOMENTUM, P314	22	71	76	0	29	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 4	1999	284	5420					1647	1650		10.1126/science.284.5420.1647	http://dx.doi.org/10.1126/science.284.5420.1647			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	202TM	10356389				2022-12-28	WOS:000080668300037
J	Wolk, A; Manson, JE; Stampfer, MJ; Colditz, GA; Hu, FB; Speizer, FE; Hennekens, CH; Willett, WC				Wolk, A; Manson, JE; Stampfer, MJ; Colditz, GA; Hu, FB; Speizer, FE; Hennekens, CH; Willett, WC			Long-term intake of dietary fiber and decreased risk of coronary heart disease among women	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							FOOD FREQUENCY QUESTIONNAIRE; DIABETES-MELLITUS; MORTALITY; CHOLESTEROL; MEN; PRODUCTS; FAT; HEALTH; CONSUMPTION; COAGULATION	Context Epidemiological studies of men suggest that dietary fiber intake protects against coronary heart disease (CHD), but data on this association in women are sparse. Objective To examine the association between long-term intake of total dietary fiber as well as fiber from different sources and risk of CHD in women, Design and Setting The Nurses' Health Study, a large, prospective cohort study of US women followed up for 10 years from 1984, Dietary data were collected in 1984, 1986, and 1990, using a validated semiquantitative food frequency questionnaire. Participants A total of 68 782 women aged 37 to 64 years without previously diagnosed angina, myocardial infarction (MI), stroke, cancer, hypercholesterolemia, or diabetes at baseline. Main Outcome Measure Incidence of acute Anl or death due to CHD by amount of fiber intake. Results Response rate averaged 80% to 90% during the 10-year follow-up. We documented 591 major CHD events (429 nonfatal MIs and 162 CHD deaths). The age-adjusted relative risk (RR) for major CHD events was 0.53 (95% confidence interval [CI], 0.40-0.69) for women in the highest quintile of total dietary fiber intake (median, 22.9 g/d) compared with women in the lowest quintile (median, 11.5 g/d), After controlling for age, cardiovascular risk factors, dietary factors, and multivitamin supplement use, the RR was 0.77 (95% CI, 0.57-1.04). For a 10-g/d increase in total fiber intake (the difference between the lowest and highest quintiles), the multivariate RR of total CHD events was 0.81 (95% CI, 0.66-0.99), Among different sources of dietary fiber (eg, cereal, vegetables, fruit), only cereal fiber was strongly associated with a reduced risk of CHD (multivariate RR, 0.63; 95% CI, 0.49-0.81 for each 5-g/d increase in cereal fiber). Conclusions Our findings in women support the hypothesis that higher fiber intake, particularly from cereal sources, reduces the risk of CHD.	Karolinska Inst, Dept Med Epidemiol, S-17177 Stockholm, Sweden; Brigham & Womens Hosp, Channing Lab, Boston, MA 02115 USA; Brigham & Womens Hosp, Div Prevent Med, Boston, MA 02115 USA; Brigham & Womens Hosp, Dept Med, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Environm Sci, Boston, MA USA; Harvard Univ, Sch Med, Dept Nutr, Boston, MA USA; Harvard Univ, Sch Publ Hlth, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Ambulatory Care & Prevent, Boston, MA USA	Karolinska Institutet; Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard Medical School	Wolk, A (corresponding author), Karolinska Inst, Dept Med Epidemiol, Box 281, S-17177 Stockholm, Sweden.	alicja.wolk@mep.ki.se	Colditz, Graham/A-3963-2009	Colditz, Graham/0000-0002-7307-0291	NATIONAL CANCER INSTITUTE [R37CA040356, R01CA040356] Funding Source: NIH RePORTER; NCI NIH HHS [CA40356] Funding Source: Medline; NHLBI NIH HHS [HL24074, HL0353] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ADLERCREUTZ H, 1987, J STEROID BIOCHEM, V27, P1135, DOI 10.1016/0022-4731(87)90200-7; ANDERSON JW, 1979, AM J CLIN NUTR, V32, P346, DOI 10.1093/ajcn/32.2.346; ANDERSON JW, 1986, AM J GASTROENTEROL, V81, P907; ANDERSON JW, 1980, METABOLISM, V29, P551, DOI 10.1016/0026-0495(80)90081-5; BARRETTCONNOR E, 1983, AM J EPIDEMIOL, V118, P489, DOI 10.1093/oxfordjournals.aje.a113654; *BRIT CARD SOC WOR, 1987, BRIT HEART J, V57, P188; BURR ML, 1982, AM J CLIN NUTR, V36, P873, DOI 10.1093/ajcn/36.5.873; CARA L, 1992, AM J CLIN NUTR, V55, P81, DOI 10.1093/ajcn/55.1.81; CASTELLI WP, 1986, AM HEART J, V112, P432, DOI 10.1016/0002-8703(86)90296-6; CLEEMAN JI, 1988, ARCH INTERN MED, V148, P36, DOI 10.1001/archinte.148.1.36; Colditz GA, 1997, J WOMENS HEALTH, V6, P49, DOI 10.1089/jwh.1997.6.49; CUPPLES LA, 1988, STAT MED, V7, P205, DOI 10.1002/sim.4780070122; EAKER ED, 1993, CIRCULATION, V88, P1999, DOI 10.1161/01.CIR.88.4.1999; FEHILY AM, 1993, BRIT J NUTR, V69, P303, DOI 10.1079/BJN19930035; FESKENS EJM, 1994, AM J EPIDEMIOL, V140, P350, DOI 10.1093/oxfordjournals.aje.a117257; FRASER GE, 1992, ARCH INTERN MED, V152, P1416, DOI 10.1001/archinte.152.7.1416; GABH Rose, 1982, WHO MONOGRAPH SERIES; GRUNDY SM, 1993, JAMA-J AM MED ASSOC, V269, P3015, DOI 10.1001/jama.269.23.3015; HALLFRISCH J, 1995, AM J CLIN NUTR, V61, P379, DOI 10.1093/ajcn/61.2.379; Hu FB, 1997, NEW ENGL J MED, V337, P1491, DOI 10.1056/NEJM199711203372102; HUNNINGHAKE DB, 1994, AM J CLIN NUTR, V59, P1050, DOI 10.1093/ajcn/59.5.1050; Jacobs DR, 1998, AM J CLIN NUTR, V68, P248, DOI 10.1093/ajcn/68.2.248; JENKINS DJA, 1993, NEW ENGL J MED, V329, P21, DOI 10.1056/NEJM199307013290104; KHAW KT, 1987, AM J EPIDEMIOL, V126, P1093, DOI 10.1093/oxfordjournals.aje.a114748; KROMHOUT D, 1982, LANCET, V2, P518; KUSHI LH, 1985, NEW ENGL J MED, V312, P811, DOI 10.1056/NEJM198503283121302; LAW MR, 1994, BMJ-BRIT MED J, V308, P367, DOI 10.1136/bmj.308.6925.367; MANSON JE, 1991, ARCH INTERN MED, V151, P1141, DOI 10.1001/archinte.151.6.1141; MARCKMANN P, 1993, ARTERIOSCLER THROMB, V13, P505, DOI 10.1161/01.ATV.13.4.505; Mennen LI, 1997, AM J CLIN NUTR, V65, P732, DOI 10.1093/ajcn/65.3.732; MORRIS JN, 1977, BMJ-BRIT MED J, V2, P1307, DOI 10.1136/bmj.2.6098.1307; *NAT CTR HLTH STAT, 1993, VIT STAT US 1989, V2; PAN WH, 1986, AM J EPIDEMIOL, V123, P504, DOI 10.1093/oxfordjournals.aje.a114266; Pietinen P, 1996, CIRCULATION, V94, P2720, DOI 10.1161/01.CIR.94.11.2720; PROSKY L, 1985, J ASSOC OFF ANA CHEM, V68, P677; PROSKY L, 1984, J ASSOC OFF ANA CHEM, V67, P1044; PROSKY L, 1988, J ASSOC OFF ANA CHEM, V71, P1017; RICCARDI G, 1987, EUR HEART J, V8, P79, DOI 10.1093/eurheartj/8.suppl_E.79; RICHEDWARDS JW, 1995, NEW ENGL J MED, V332, P1758, DOI 10.1056/NEJM199506293322607; Rimm EB, 1996, JAMA-J AM MED ASSOC, V275, P447, DOI 10.1001/jama.275.6.447; RIPSIN CM, 1992, JAMA-J AM MED ASSOC, V267, P3317, DOI 10.1001/jama.267.24.3317; RIVELLESE A, 1980, LANCET, V2, P447; SALDO BJ, 1985, MILBANK MEM FUND Q, V63, P286; Salmeron J, 1997, JAMA-J AM MED ASSOC, V277, P472, DOI 10.1001/jama.277.6.472; SHEKELLE RB, 1982, AM J EPIDEMIOL, V115, P506, DOI 10.1093/oxfordjournals.aje.a113332; Slavin J, 1997, NUTR CANCER, V27, P14, DOI 10.1080/01635589709514495; SMITH U, 1994, AM J CLIN NUTR, V59, p686S, DOI 10.1093/ajcn/59.3.686S; STAMPFER MJ, 1984, AM J EPIDEMIOL, V119, P837, DOI 10.1093/oxfordjournals.aje.a113804; SUNDELL IB, 1993, HAEMOSTASIS, V23, P45; US Department of Health and Human Services, 1988, SURG GEN REP NUTR HL; *USDA, 1989, USDA AGR HDB SER, V8; VAHOUNY GV, 1980, LIPIDS, V15, P1012, DOI 10.1007/BF02534316; WILLETT W, 1986, AM J EPIDEMIOL, V124, P17, DOI 10.1093/oxfordjournals.aje.a114366; WILLETT WC, 1988, AM J EPIDEMIOL, V127, P188, DOI 10.1093/oxfordjournals.aje.a114780; WILLETT WC, 1987, J AM DIET ASSOC, V87, P43; WILLETT WC, 1985, AM J EPIDEMIOL, V122, P51, DOI 10.1093/oxfordjournals.aje.a114086; Wynder EL, 1996, JAMA-J AM MED ASSOC, V275, P486, DOI 10.1001/jama.275.6.486; 1989, CMAJ, V49, P629	58	279	299	0	13	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 2	1999	281	21					1998	2004		10.1001/jama.281.21.1998	http://dx.doi.org/10.1001/jama.281.21.1998			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	200NN	10359388				2022-12-28	WOS:000080546700029
J	Livingstone, AE				Livingstone, AE			Anything else, sir?	BRITISH MEDICAL JOURNAL			English	Editorial Material																			0	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	MAY 29	1999	318	7196					1497	1497		10.1136/bmj.318.7196.1497	http://dx.doi.org/10.1136/bmj.318.7196.1497			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	202TL	10346801	Green Published			2022-12-28	WOS:000080668200069
J	Niebauer, J; Volk, HD; Kemp, M; Dominguez, M; Schumann, RR; Rauchhaus, M; Poole-Wilson, PA; Coats, AJS; Anker, SD				Niebauer, J; Volk, HD; Kemp, M; Dominguez, M; Schumann, RR; Rauchhaus, M; Poole-Wilson, PA; Coats, AJS; Anker, SD			Endotoxin and immune activation in chronic heart failure: a prospective cohort study	LANCET			English	Article							TUMOR-NECROSIS-FACTOR; IDIOPATHIC DILATED CARDIOMYOPATHY; FAILING HUMAN HEART; FACTOR-ALPHA; SEPTIC SHOCK; BLOOD-FLOW; LPS; CYTOKINES; BINDING; METABOLISM	Background. Immune activation in patients with chronic heart failure may be secondary to endotoxin (lipopolysaccharide) action. We investigated the hypothesis that altered gut permeability with bacterial translocation and endotoxaemia would be increased in patients with oedema secondary to congestive heart failure. Methods. We compared 20 patients who had chronic heart failure with recent-onset peripheral oedema (mean age 64 years [SD 10], New York Heart Association [NYHA] class 3.3 [0.7]), 20 stable non-oedematous patients with chronic heart failure (mean age 63 years [19], NYHA class 2.6 [0.7]), and 14 healthy volunteers (mean age 55 years [16]). Biochemical markers of endotoxaemia, inflammation, and immune activation were measured. Ten patients were studied within 1 week of complete resolution of oedema. Five patients survived longer than 6 months and were restudied again after remaining free of oedema for more than 3 months. Findings. Mean endotoxin concentrations were higher in oedematous patients with chronic heart failure than in stable patients with chronic heart failure (0.74 [SD 0.45] vs 0.37 EU/mL [0.23], p = 0.0009) and controls (0.46 EU/mL [0.21], p = 0.02). Oedematous patients had the highest concentrations of several cytokines. After short-term diuretic treatment, endotoxin concentrations decreased from 0.84 EU/mL [0.49] to 0.45 EU/mL [0.21], p < 0.05) but cytokines remained raised. After freedom of oedema for more than 3 months after oedema resolved, endotoxin concentrations remained unchanged from the previous visit (0.49 EU/mL [0.06], p = 0.45). Interpretation. Raised concentrations of endotoxin and cytokines are found in patients with chronic heart failure during acute oedematous exacerbation. Intensified diuretic treatment can normalise endotoxin concentrations. Our preliminary findings suggest that endotoxin may trigger immune activation in patients with chronic heart failure during oedematous episodes.	Natl Heart & Lung Inst, Imperial Coll Sch Med, London SW3 6LY, England; Univ Leipzig, Herzzentrum, Leipzig, Germany; Univ Klinikum Charite, Inst Med Immunol, Berlin, Germany; Harefield Hosp, Heart Sci Ctr, Harefield, Middx, England; Univ Klinikum Charite, Inst Mikrobiol & Hyg, Berlin, Germany; Max Delbruck Ctr Mol Med, Franz Volhard Klin, Berlin, Germany	Imperial College London; Heart Center Leipzig GMBH; Leipzig University; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Royal Brompton & Harefield NHS Foundation Trust; Harefield Hospital; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Franz-Volhard Clinical Research Center; Helmholtz Association; Max Delbruck Center for Molecular Medicine	Anker, SD (corresponding author), Natl Heart & Lung Inst, Imperial Coll Sch Med, Dovehouse St, London SW3 6LY, England.		Coats, Andrew J Stewart/E-4451-2012; Yen, Hsueh-Wei/A-1539-2010; volk, hans-dieter/AAV-8053-2021	Coats, Andrew J Stewart/0000-0002-2771-4260; volk, hans-dieter/0000-0002-7743-6668				Anker SD, 1997, J AM COLL CARDIOL, V30, P997, DOI 10.1016/S0735-1097(97)00262-3; Anker SD, 1998, QJM-MON J ASSOC PHYS, V91, P199, DOI 10.1093/qjmed/91.3.199; Anker SD, 1997, AM J CARDIOL, V79, P1426, DOI 10.1016/S0002-9149(97)00159-8; Anker SD, 1997, CIRCULATION, V96, P526; ASSICOT M, 1993, LANCET, V341, P515, DOI 10.1016/0140-6736(93)90277-N; Clark AL, 1996, J AM COLL CARDIOL, V28, P1092, DOI 10.1016/S0735-1097(96)00323-3; EGGESBO JB, 1994, CYTOKINE, V6, P521, DOI 10.1016/1043-4666(94)90080-9; GOMEZJIMENEZ J, 1995, CRIT CARE MED, V23, P253, DOI 10.1097/00003246-199502000-00009; Keel M, 1996, J TRAUMA, V41, P430, DOI 10.1097/00005373-199609000-00008; Keith M, 1998, J AM COLL CARDIOL, V31, P1352, DOI 10.1016/S0735-1097(98)00101-6; Lamping N, 1998, J CLIN INVEST, V101, P2065, DOI 10.1172/JCI2338; Lamping N, 1996, J IMMUNOL, V157, P4648; LEVINE B, 1990, NEW ENGL J MED, V323, P236, DOI 10.1056/NEJM199007263230405; Lew WYW, 1997, AM J PHYSIOL-HEART C, V272, pH2989, DOI 10.1152/ajpheart.1997.272.6.H2989; Munger MA, 1996, AM J CARDIOL, V77, P723, DOI 10.1016/S0002-9149(97)89206-5; RANDOW F, 1995, J EXP MED, V181, P1887, DOI 10.1084/jem.181.5.1887; Sautner T, 1998, ANN SURG, V228, P239, DOI 10.1097/00000658-199808000-00014; SCHUMANN RR, 1990, SCIENCE, V249, P429; STARR RG, 1995, SHOCK, V3, P380; Tobias PS, 1997, J BIOL CHEM, V272, P18682, DOI 10.1074/jbc.272.30.18682; TorreAmione G, 1996, CIRCULATION, V93, P704, DOI 10.1161/01.CIR.93.4.704; Vanderheyden M, 1998, EUR HEART J, V19, P747, DOI 10.1053/euhj.1997.0828; Vonhof S, 1998, INT J CARDIOL, V63, P237, DOI 10.1016/S0167-5273(97)00332-X; Wagner DR, 1998, CIRCULATION, V97, P521; YAN SF, 1995, J BIOL CHEM, V270, P11463, DOI 10.1074/jbc.270.19.11463; Yang RB, 1998, NATURE, V395, P284, DOI 10.1038/26239; ZIEGLERHEITBROCK HWL, 1993, IMMUNOL TODAY, V14, P121, DOI 10.1016/0167-5699(93)90212-4	27	639	669	1	17	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAY 29	1999	353	9167					1838	1842		10.1016/S0140-6736(98)09286-1	http://dx.doi.org/10.1016/S0140-6736(98)09286-1			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	202TG	10359409				2022-12-28	WOS:000080667800013
J	Vernon, A; Burman, W; Benator, D; Khan, A; Bozeman, L				Vernon, A; Burman, W; Benator, D; Khan, A; Bozeman, L		TB Trials Consortium	Acquired rifamycin monoresistance in patients with HIV-related tuberculosis treated with once-weekly rifapentine and isoniazid	LANCET			English	Article							DIRECTLY OBSERVED THERAPY; RESISTANT TUBERCULOSIS; MYCOBACTERIUM-TUBERCULOSIS; RIFAMPIN; CHEMOTHERAPY; RIFABUTIN; INFECTION; MICE	Background. Rifapentine is a cyclopentyl-substituted rifamycin whose serum half-life is five times that of rifampin. The US Public Health Service Study 22 compared a once-weekly regimen of isoniazid and rifapentine with twice weekly isoniazid and rifampin in the continuation phase (the last 4 months) of treatment for pulmonary tuberculosis in HIV-seropositive and HIV-seronegative patients. This report concerns only the HIV-seropositive part of the trial, which has ended, The HIV-seronegative part will stop follow-up in 2001. Methods. Adults with culture-positive, drug-susceptible pulmonary tuberculosis who completed 2 months of four-drug (isoniazid, rifampin, pyrazinamide, ethambutol) treatment (induction phase) were randomly assigned 900 mg isoniazid and 600 mg rifapentine once weekly, or 900 mg isoniazid and 600 mg rifampin twice weekly. All therapy was directly observed. Statistical analysis used univariate, Kaplan-Meier, and logistic and proportional hazards regression methods. Findings. 71 HIV-seropositive patients were enrolled: 61 completed therapy and were assessed for relapse, Five of 30 patients in the once-weekly isoniazid/rifapentine group relapsed, compared with three of 31 patients in the twice-weekly isoniazid/rifampin group (log rank chi(2) = 0.69, p = 0.41). However, four of five relapses in the once-weekly isoniazid/rifapentine group had monoresistance to rifamycin, compared with none of three in the rifampin group (p = 0.05). Patients who relapsed with rifamycin monoresistance were younger (median age 29 vs 41 years), had lower baseline CD4 cell counts (median 16 vs 144 mu L), and were more likely to have extrapulmonary involvement (75% vs 18%, p = 0.03) and concomitant therapy with antifungal agents (75% vs 9%, p = 0.006). No rifamycin monoresistant relapse has occurred among 1004 HIV-seronegative patients enrolled to date. Interpretation. Relapse with rifamycin monoresistant tuberculosis occurred among HIV-seropositive tuberculosis patients treated with a once-weekly isoniazid/rifapentine continuation-phase regimen. Until more effective regimens have been identified and assessed in clinical trials, HIV-seropositive people with tuberculosis should not be treated with a once-weekly isoniazid/rifapentine regimen.	Ctr Dis Control & Prevent, Div TB Eliminat, Atlanta, GA 30333 USA; Denver Hlth & Hosp, Dept Publ Hlth, Denver, CO USA; Vet Affairs Med Ctr, Washington, DC 20422 USA; Georgetown Univ, Washington, DC USA	Centers for Disease Control & Prevention - USA; Denver Health Medical Center; US Department of Veterans Affairs; Veterans Health Administration (VHA); Georgetown University	Vernon, A (corresponding author), Ctr Dis Control & Prevent, Div TB Eliminat, Mailstop E-10, Atlanta, GA 30333 USA.							ACOCELLA G, 1988, AM REV RESPIR DIS, V138, P886, DOI 10.1164/ajrccm/138.4.886; [Anonymous], 1998, MMWR Recomm Rep, V47, P1; [Anonymous], 1970, Bull World Health Organ, V43, P143; [Anonymous], 1985, Am Rev Respir Dis, V131, P727; [Anonymous], 1977, Am Rev Respir Dis, V116, P807; ARIOLI V, 1981, J ANTIBIOT, V34, P1026, DOI 10.7164/antibiotics.34.1026; BASS JB, 1994, AM J RESP CRIT CARE, V149, P1359, DOI 10.1164/ajrccm.149.5.8173779; Bishai WR, 1996, NEW ENGL J MED, V334, P1573, DOI 10.1056/NEJM199606133342404; BIYA Y, 1992, GHINA ANTIBIOTIC, V17, P313; Burman WJ, 1997, CHEST, V111, P1168, DOI 10.1378/chest.111.5.1168; CAVE MD, 1994, J CLIN MICROBIOL, V32, P262, DOI 10.1128/JCM.32.1.262-266.1994; Cavenaghi R, 1989, Bull Int Union Tuberc Lung Dis, V64, P36; COMBS DL, 1990, ANN INTERN MED, V112, P397, DOI 10.7326/0003-4819-76-3-112-6-397; DAVID HL, 1970, APPL MICROBIOL, V20, P810, DOI 10.1128/AEM.20.5.810-814.1970; DHILLON J, 1992, TUBERCLE LUNG DIS, V73, P116, DOI 10.1016/0962-8479(92)90066-S; DICKINSON JM, 1987, TUBERCLE, V68, P113, DOI 10.1016/0041-3879(87)90026-2; EAST AFRICAN/BRITISH MEDICAL RESEARCH COUNCILS STUDY, 1981, American Review of Respiratory Disease, V123, P165; ELLARD GA, 1984, TUBERCLE, V65, P211, DOI 10.1016/0041-3879(84)90079-5; FEREBEE SH, 1970, ADV TUBERC RES, V17, P28; Grosset J, 1998, AM J RESP CRIT CARE, V157, P1436, DOI 10.1164/ajrccm.157.5.9709072; HE GJ, 1993, CHUNG HUA CHIEH HO H, V16, P73; HEIFETS LB, DRUG SUSCEPTIBILITY, P21; *HOECHST MAR ROUSS, 1998, PACK INS PRIFT RIF U; *HONG KONG CHEST S, 1981, LANCET, V1, P171; JI BH, 1993, AM REV RESPIR DIS, V148, P1541, DOI 10.1164/ajrccm/148.6_Pt_1.1541; JONES BE, 1993, AM REV RESPIR DIS, V148, P1292, DOI 10.1164/ajrccm/148.5.1292; MASON GR, 1997, AM J RESP CRIT CARE, V155, pA221; MILLER LP, 1994, ANTIMICROB AGENTS CH, V38, P805, DOI 10.1128/AAC.38.4.805; MILLER LP, 1995, LANCET          0914; Mitchison DA, 1998, INT J TUBERC LUNG D, V2, P612; MITCHISON DA, 1970, APPL MICROBIOL, V20, P810; Moore M, 1997, JAMA-J AM MED ASSOC, V278, P833, DOI 10.1001/jama.278.10.833; Munsiff SS, 1997, CLIN INFECT DIS, V25, P1465, DOI 10.1086/516146; Parkin DP, 1997, AM J RESP CRIT CARE, V155, P1717, DOI 10.1164/ajrccm.155.5.9154882; Peloquin CA, 1996, ANN PHARMACOTHER, V30, P919, DOI 10.1177/106002809603000901; PILHEU JA, 1989, MEDICINA-BUENOS AIRE, V49, P43; Ridzon R, 1998, AM J RESP CRIT CARE, V157, P1881, DOI 10.1164/ajrccm.157.6.9712009; Sahai J, 1997, ANN INTERN MED, V127, P289, DOI 10.7326/0003-4819-127-4-199708150-00006; Tam CM, 1998, AM J RESP CRIT CARE, V157, P1726, DOI 10.1164/ajrccm.157.6.9707037; Trapnell CB, 1996, ANN INTERN MED, V124, P573, DOI 10.7326/0003-4819-124-6-199603150-00006; WEIS SE, 1994, NEW ENGL J MED, V330, P1179, DOI 10.1056/NEJM199404283301702; YATES JW, 1980, CANCER, V45, P2220, DOI 10.1002/1097-0142(19800415)45:8<2220::AID-CNCR2820450835>3.0.CO;2-Q	42	257	267	0	3	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAY 29	1999	353	9167					1843	1847		10.1016/S0140-6736(98)11467-8	http://dx.doi.org/10.1016/S0140-6736(98)11467-8			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	202TG	10359410				2022-12-28	WOS:000080667800014
J	Marciano, DK; Russel, M; Simon, SM				Marciano, DK; Russel, M; Simon, SM			An aqueous channel for filamentous phage export	SCIENCE			English	Article							BACTERIAL OUTER MEMBRANES; PROTEIN SECRETION SYSTEMS; ESCHERICHIA-COLI; VIBRIO-CHOLERAE	Filamentous phage f1 exits its Escherichia coli host without killing the bacterial cell. It has been proposed that f1 is secreted through the outer membrane via a phage-encoded channel protein, pIV. A functional pIV mutant was isolated that allowed E. coli to grow on large maltodextrins and rendered E. coli sensitive to large hydrophilic antibiotics that normally do not penetrate the outer membrane. In planar lipid bilayers, both mutant and wild-type pIV formed highly conductive channels with similar permeability characteristics but different gating properties: the probability of the wild-type channel being open was much less than that of the mutant channel. The high conductivity of pIV channels suggests a large-diameter pore, thus implicating pIV as the outer membrane phage-conducting channel.	Rockefeller Univ, New York, NY 10021 USA	Rockefeller University	Russel, M (corresponding author), Rockefeller Univ, 1230 York Ave, New York, NY 10021 USA.			Marciano, Denise/0000-0003-0612-4664; Simon, Sanford/0000-0002-8615-4224	NIGMS NIH HHS [GM07739] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BOULANGER P, 1988, J BIOL CHEM, V263, P9767; DELCOUR AH, 1991, J MEMBRANE BIOL, V119, P267, DOI 10.1007/BF01868731; EMR SD, 1982, J CELL BIOL, V95, P689, DOI 10.1083/jcb.95.3.689; HIRST TR, 1987, P NATL ACAD SCI USA, V84, P7418, DOI 10.1073/pnas.84.21.7418; Hueck CJ, 1998, MICROBIOL MOL BIOL R, V62, P379, DOI 10.1128/MMBR.62.2.379-433.1998; Linderoth NA, 1997, SCIENCE, V278, P1635, DOI 10.1126/science.278.5343.1635; MARCIANO DK, UNPUB; NIKAIDO H, 1992, MOL MICROBIOL, V6, P435, DOI 10.1111/j.1365-2958.1992.tb01487.x; Russel M, 1998, J MOL BIOL, V279, P485, DOI 10.1006/jmbi.1998.1791; Russel M, 1997, GENE, V192, P23, DOI 10.1016/S0378-1119(96)00801-3; SANDKVIST M, 1995, EMBO J, V14, P1664, DOI 10.1002/j.1460-2075.1995.tb07155.x; SIMON SM, 1991, CELL, V65, P371, DOI 10.1016/0092-8674(91)90455-8; STOCK JB, 1977, J BIOL CHEM, V252, P7850; Thanassi DG, 1998, P NATL ACAD SCI USA, V95, P3146, DOI 10.1073/pnas.95.6.3146; WANDERSMAN C, 1979, J BACTERIOL, V140, P1; WEBSTER RE, 1991, MOL MICROBIOL, V5, P1005, DOI 10.1111/j.1365-2958.1991.tb01873.x	16	84	91	0	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAY 28	1999	284	5419					1516	1519		10.1126/science.284.5419.1516	http://dx.doi.org/10.1126/science.284.5419.1516			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	200PD	10348737				2022-12-28	WOS:000080548100034
J	Karaolis, DKR; Somara, S; Maneval, DR; Johnson, JA; Kaper, JB				Karaolis, DKR; Somara, S; Maneval, DR; Johnson, JA; Kaper, JB			A bacteriophage encoding a pathogenicity island, a type-IV pilus and a phage receptor in cholera bacteria	NATURE			English	Article							ENTEROPATHOGENIC ESCHERICHIA-COLI; VIBRIO-CHOLERAE; FILAMENTOUS PHAGE; TOXR REGULON; PROTEIN; EVOLUTION; EXPRESSION; VIRULENCE; SECRETION; CLUSTER	The virulence properties of many pathogenic bacteria are due to proteins encoded by large gene clusters called pathogenicity islands(1,2), which are found in a variety of human pathogens including Escherichia coli, Salmonella, Shigella, Yersinia, Helicobacter pylori, Vibrio cholerae, and animal and plant pathogens such as Dichelobacter nodosus and Pseunomonas syringae(1-3). Although the presence of pathogenicity islands is a prerequisite for many bacterial diseases, little is known about their origins or mechanism of transfer into the bacterium. The bacterial agent of epidemic cholera, Vibrio cholerae, contains a bacteriophage known as cholera-toxin phage (CTX Phi)(4), which encodes the cholera toxin, and a large pathogenicity island called the VPI (for V. cholerae pathogenicity island)(5) which itself encodes a toxin-coregulated pilus that functions as a colonization factor(6) and as a CTX Phi receptor(4). We have now identified the VPI pathogenicity island as the genome of another filamentous bacteriophage, VPI Phi, We show that VPI Phi is transferred between V. cholerae strains and provide evidence that the TcpA subunit of the toxin-coregulated type IV pilus is in fact a coat protein of VPI Phi. Our results are the first description of a phage that encodes a receptor for another phage and of a virus-virus interaction that is necessary for bacterial pathogenicity.	Univ Maryland, Sch Med, Ctr Vaccine Dev, Baltimore, MD 21201 USA; Univ Maryland, Sch Med, Div Hosp Epidemiol, Baltimore, MD 21201 USA; Univ Maryland, Sch Med, Dept Pathol, Baltimore, MD 21201 USA; Univ Maryland, Sch Med, Dept Microbiol & Immunol, Baltimore, MD 21201 USA; Maryland Hlth Care Syst, Dept Vet Affairs, Baltimore, MD 21201 USA	University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore	Karaolis, DKR (corresponding author), Univ Maryland, Sch Med, Ctr Vaccine Dev, Baltimore, MD 21201 USA.	karaolis@umaryland.edu		Kaper, James/0000-0003-0715-2907; Somara, Sita/0000-0001-7688-5560				Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Carroll PA, 1997, MOL MICROBIOL, V25, P1099, DOI 10.1046/j.1365-2958.1997.5371901.x; DALRYMPLE B, 1987, J MOL EVOL, V25, P261, DOI 10.1007/BF02100020; DIRITA VJ, 1991, P NATL ACAD SCI USA, V88, P5403, DOI 10.1073/pnas.88.12.5403; GIRON JA, 1991, SCIENCE, V254, P710, DOI 10.1126/science.1683004; Hacker J, 1997, MOL MICROBIOL, V23, P1089, DOI 10.1046/j.1365-2958.1997.3101672.x; Hase CC, 1998, P NATL ACAD SCI USA, V95, P730, DOI 10.1073/pnas.95.2.730; HERRINGTON DA, 1988, J EXP MED, V168, P1487, DOI 10.1084/jem.168.4.1487; Hicks S, 1998, INFECT IMMUN, V66, P1570, DOI 10.1128/IAI.66.4.1570-1578.1998; HOBBS M, 1993, MOL MICROBIOL, V10, P233, DOI 10.1111/j.1365-2958.1993.tb01949.x; HUANG HC, 1995, MOL PLANT MICROBE IN, V8, P733, DOI 10.1094/MPMI-8-0733; KAPER JB, 1995, CLIN MICROBIOL REV, V8, P48, DOI 10.1128/CMR.8.1.48; Karaolis DKR, 1998, P NATL ACAD SCI USA, V95, P3134, DOI 10.1073/pnas.95.6.3134; Kovach ME, 1996, MICROBIOL-SGM, V142, P2165, DOI 10.1099/13500872-142-8-2165; Lee CA, 1996, INFECT AGENT DIS, V5, P1; Maniatis T., 1982, MOL CLONING LAB MANU; MICHALSKI J, 1993, INFECT IMMUN, V61, P4462, DOI 10.1128/IAI.61.10.4462-4468.1993; PATEL P, 1991, INFECT IMMUN, V59, P4674, DOI 10.1128/IAI.59.12.4674-4676.1991; POLITZER R, 1959, MONOGR SER WHO, V43; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SHAW CE, 1990, INFECT IMMUN, V58, P3042, DOI 10.1128/IAI.58.9.3042-3049.1990; TAYLOR R, 1988, VACCINE, V6, P151, DOI 10.1016/S0264-410X(88)80019-7; TAYLOR RK, 1987, P NATL ACAD SCI USA, V84, P2833, DOI 10.1073/pnas.84.9.2833; Waldor MK, 1996, SCIENCE, V272, P1910, DOI 10.1126/science.272.5270.1910	24	286	310	1	51	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAY 27	1999	399	6734					375	379		10.1038/20715	http://dx.doi.org/10.1038/20715			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	200PA	10360577				2022-12-28	WOS:000080547800064
J	Siegal, FP; Kadowaki, N; Shodell, M; Fitzgerald-Bocarsly, PA; Shah, K; Ho, S; Antonenko, S; Liu, YJ				Siegal, FP; Kadowaki, N; Shodell, M; Fitzgerald-Bocarsly, PA; Shah, K; Ho, S; Antonenko, S; Liu, YJ			The nature of the principal type 1 interferon-producing cells in human blood	SCIENCE			English	Article							ALPHA-PRODUCING CELLS; IMMUNE-DEFICIENCY SYNDROME; HERPES-SIMPLEX VIRUS; DENDRITIC CELLS; OPPORTUNISTIC INFECTIONS; HIV-1 INFECTION; IN-VITRO; PHENOTYPE; MATURE	Interferons (IFNs) are the most important cytokines in antiviral immune responses, "Natural IFN-producing cells" (IPCs) in human blood express CD4 and major histocompatibility complex class II proteins, but have not been isolated and further characterized because of their rarity, rapid apoptosis, and lack of Lineage markers. Purified IPCs are here shown to be the CD4(+)CD11c(-) type 2 dendritic cell precursors (pDC2s), which produce 200 to 1000 times more IFN than other blood cells after microbial challenge. pDC2s are thus an effector cell type of the immune system, critical for antiviral and antitumor immune responses.	St Vincents Hosp & Med Ctr, New York, NY 10011 USA; Long Isl Jewish Med Ctr, Albert Einstein Coll Med, New Hyde Pk, NY 11042 USA; DNAX Res Inst Mol & Cellular Biol Inc, Palo Alto, CA 94304 USA; Long Isl Univ, Brookville, NY 11548 USA; Univ Med & Dent New Jersey, New Jersey Med Sch, Newark, NJ 07103 USA	Saint Vincents Hospital Manhattan; Northwell Health; Yeshiva University; Merck & Company; Dnax Research Institute Of Molecular & Cellular Biology Inc.; Rutgers State University New Brunswick; Rutgers State University Medical Center	Siegal, FP (corresponding author), St Vincents Hosp & Med Ctr, New York, NY 10011 USA.		Yang, Chen/G-1379-2010					ABB J, 1983, CLIN EXP IMMUNOL, V52, P179; CHEHIMI J, 1989, IMMUNOLOGY, V68, P486; FELDMAN M, 1990, J INTERFERON RES, V10, P435, DOI 10.1089/jir.1990.10.435; FERBAS J, 1995, CLIN DIAGN LAB IMMUN, V2, P138, DOI 10.1128/CDLI.2.2.138-142.1995; FERBAS JJ, 1994, J IMMUNOL, V152, P4649; FITZGERALDBOCARSLY P, 1993, PHARMACOL THERAPEUT, V60, P39, DOI 10.1016/0163-7258(93)90021-5; Ghanekar S, 1996, J IMMUNOL, V157, P4028; Grouard G, 1997, J EXP MED, V185, P1101, DOI 10.1084/jem.185.6.1101; HOWELL DM, 1994, CLIN IMMUNOL IMMUNOP, V71, P223, DOI 10.1006/clin.1994.1076; ISAACS A, 1957, PROC R SOC SER B-BIO, V147, P258, DOI 10.1098/rspb.1957.0048; KIRCHNER H, 1979, Z IMMUNITATSFORSCH, V156, P65; LOPEZ C, 1983, J INFECT DIS, V148, P962, DOI 10.1093/infdis/148.6.962; Marrack P, 1999, J EXP MED, V189, P521, DOI 10.1084/jem.189.3.521; ODOHERTY U, 1994, IMMUNOLOGY, V82, P487; ODOHERTY U, 1993, J EXP MED, V178, P1067, DOI 10.1084/jem.178.3.1067; Olweus J, 1997, P NATL ACAD SCI USA, V94, P12551, DOI 10.1073/pnas.94.23.12551; PERUSSIA B, 1985, Natural Immunity and Cell Growth Regulation, V4, P120; PETER HH, 1980, EUR J IMMUNOL, V10, P547, DOI 10.1002/eji.1830100712; Rissoan MC, 1999, SCIENCE, V283, P1183, DOI 10.1126/science.283.5405.1183; SANDBERG K, 1991, SCAND J IMMUNOL, V34, P565, DOI 10.1111/j.1365-3083.1991.tb01580.x; SIEGAL FP, 1994, LEUKEMIA, V8, P1474; SIEGAL FP, 1986, J CLIN INVEST, V78, P115, DOI 10.1172/JCI112539; STARR SE, 1993, ADV EXP MED BIOL, V329, P173; Sun SQ, 1998, J EXP MED, V188, P2335, DOI 10.1084/jem.188.12.2335; Svensson H, 1996, SCAND J IMMUNOL, V44, P164, DOI 10.1046/j.1365-3083.1996.d01-289.x	25	1740	1846	0	44	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 11	1999	284	5421					1835	1837		10.1126/science.284.5421.1835	http://dx.doi.org/10.1126/science.284.5421.1835			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	205EU	10364556				2022-12-28	WOS:000080809000050
J	Fulton, D; Gratton, JP; McCabe, TJ; Fontana, J; Fujio, Y; Walsh, K; Franke, TF; Papapetropoulos, A; Sessa, WC				Fulton, D; Gratton, JP; McCabe, TJ; Fontana, J; Fujio, Y; Walsh, K; Franke, TF; Papapetropoulos, A; Sessa, WC			Regulation of endothelium-derived nitric oxide production by the protein kinase Akt	NATURE			English	Article							FLUID SHEAR-STRESS; GROWTH-FACTOR; TYROSINE PHOSPHORYLATION; CELL-SURVIVAL; MICE LACKING; SYNTHASE; ACTIVATION; CALCIUM; CAVEOLAE; PALMITOYLATION	Endothelial nitric oxide synthase (eNOS) is the nitric oxide synthase isoform responsible for maintaining systemic blood pressure, vascular remodelling and angiogenesis(1-4), eNOS is phosphorylated in response to various forms of cellular stimulation(5-7), but the role of phosphorylation in the regulation of nitric oxide (NO) production and the kinase(s) responsible are not known. Here we show that the serine/threonine protein kinase Akt (protein kinase B) can directly phosphorylate eNOS on serine 1179 and activate the enzyme, leading to NO production, whereas mutant eNOS (S1179A) is resistant to phosphorylation and activation by Akt. Moreover, using adenovirus-mediated gene transfer, activated Akt increases basal NO release from endothelial cells, and activation-deficient Akt attenuates NO production stimulated by vascular endothelial growth factor. Thus, eNOS is a newly described Akt substrate linking signal transduction by Akt to the release of the gaseous second messenger NO.	Yale Univ, Sch Med, Dept Pharmacol, New Haven, CT 06536 USA; Yale Univ, Sch Med, Mol Cardiobiol Program, Boyer Ctr Mol Med, New Haven, CT 06536 USA; St Elizabeths Med Ctr, Boston, MA 02135 USA; Columbia Univ, Dept Pharmacol, New York, NY 10032 USA	Yale University; Yale University; St. Elizabeth's Medical Center; Columbia University	Sessa, WC (corresponding author), Yale Univ, Sch Med, Dept Pharmacol, 333 Cedar St, New Haven, CT 06536 USA.		Fujio, Yasushi/H-3421-2017; Andreas, Papapetropoulos/AAJ-3089-2020; Sessa, William C/B-6844-2011	Fujio, Yasushi/0000-0003-0828-2930; Sessa, William C/0000-0001-5759-1938; Walsh, Kenneth/0000-0001-7580-2276; Gratton, Jean-Philippe/0000-0001-9877-8520; Papapetropoulos, Andreas/0000-0002-4253-5930	NIAMS NIH HHS [R01 AR040197] Funding Source: Medline; NIA NIH HHS [R01 AG015052] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR040197] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG015052] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x; Ayajiki K, 1996, CIRC RES, V78, P750, DOI 10.1161/01.RES.78.5.750; Cardone MH, 1998, SCIENCE, V282, P1318, DOI 10.1126/science.282.5392.1318; Coffer PJ, 1998, BIOCHEM J, V335, P1; Corson MA, 1996, CIRC RES, V79, P984, DOI 10.1161/01.RES.79.5.984; Dimmeler S, 1998, CIRC RES, V83, P334, DOI 10.1161/01.RES.83.3.334; Downward J, 1998, CURR OPIN CELL BIOL, V10, P262, DOI 10.1016/S0955-0674(98)80149-X; Franke TF, 1997, CELL, V88, P435, DOI 10.1016/S0092-8674(00)81883-8; Garcia-Cardena G, 1998, NATURE, V392, P821, DOI 10.1038/33934; GarciaCardena G, 1996, J BIOL CHEM, V271, P27237, DOI 10.1074/jbc.271.44.27237; GarciaCardena G, 1996, P NATL ACAD SCI USA, V93, P6448, DOI 10.1073/pnas.93.13.6448; Gerber HP, 1998, J BIOL CHEM, V273, P30336, DOI 10.1074/jbc.273.46.30336; HUANG PL, 1995, NATURE, V377, P239, DOI 10.1038/377239a0; Kantor DB, 1996, SCIENCE, V274, P1744, DOI 10.1126/science.274.5293.1744; KUCHAN MJ, 1994, AM J PHYSIOL, V266, pC628, DOI 10.1152/ajpcell.1994.266.3.C628; Liu JW, 1997, J CELL BIOL, V137, P1525, DOI 10.1083/jcb.137.7.1525; Liu JW, 1996, BIOCHEMISTRY-US, V35, P13277, DOI 10.1021/bi961720e; MICHEL T, 1993, P NATL ACAD SCI USA, V90, P6252, DOI 10.1073/pnas.90.13.6252; Murga C, 1998, J BIOL CHEM, V273, P19080, DOI 10.1074/jbc.273.30.19080; Murohara T, 1998, J CLIN INVEST, V101, P2567, DOI 10.1172/JCI1560; Papapetropoulos A, 1997, J CLIN INVEST, V100, P3131, DOI 10.1172/JCI119868; Parenti A, 1998, J BIOL CHEM, V273, P4220, DOI 10.1074/jbc.273.7.4220; Rudic RD, 1998, J CLIN INVEST, V101, P731, DOI 10.1172/JCI1699; Salerno JC, 1997, J BIOL CHEM, V272, P29769, DOI 10.1074/jbc.272.47.29769; SESSA WC, 1995, J BIOL CHEM, V270, P17641, DOI 10.1074/jbc.270.30.17641; Shaul PW, 1996, J BIOL CHEM, V271, P6518, DOI 10.1074/jbc.271.11.6518; Shesely EG, 1996, P NATL ACAD SCI USA, V93, P13176, DOI 10.1073/pnas.93.23.13176; Smith RC, 1997, GENE DEV, V11, P1674, DOI 10.1101/gad.11.13.1674; Yano S, 1998, NATURE, V396, P584, DOI 10.1038/25147; Zeng GY, 1996, J CLIN INVEST, V98, P894, DOI 10.1172/JCI118871	30	2134	2197	3	91	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUN 10	1999	399	6736					597	601		10.1038/21218	http://dx.doi.org/10.1038/21218			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	204RR	10376602	Green Accepted			2022-12-28	WOS:000080778400059
J	Dickersin, K				Dickersin, K			Breast screening in women aged 40-49 years: what next?	LANCET			English	Editorial Material							MAMMOGRAPHY		Brown Univ, Dept Community Hlth, Providence, RI 02912 USA	Brown University	Dickersin, K (corresponding author), Brown Univ, Dept Community Hlth, Providence, RI 02912 USA.		Dickersin, Kay/A-4576-2008					KERLIKOWSKE K, 1993, JAMA-J AM MED ASSOC, V270, P2444, DOI 10.1001/jama.270.20.2444; *NAT CANC I, 1997, AN MAMM KNOWL ATT WO; Ries L. A. G., 1999, SEER CANC STAT REV 1; Salzmann P, 1997, ANN INTERN MED, V127, P955, DOI 10.7326/0003-4819-127-11-199712010-00001; Wilson JM, 1968, PUBLIC HLTH PAPERS W, V34	5	15	15	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUN 5	1999	353	9168					1896	1897		10.1016/S0140-6736(99)90074-0	http://dx.doi.org/10.1016/S0140-6736(99)90074-0			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	202TP	10371561				2022-12-28	WOS:000080668500002
J	Jarman, B; Gault, S; Alves, B; Hider, A; Dolan, S; Cook, A; Hurwitz, B; Iezzoni, LI				Jarman, B; Gault, S; Alves, B; Hider, A; Dolan, S; Cook, A; Hurwitz, B; Iezzoni, LI			Explaining differences in English hospital death rates using routinely collected data	BMJ-BRITISH MEDICAL JOURNAL			English	Article							RISK-ADJUSTED MORTALITY; CARE; QUALITY; SEVERITY; PERFORMANCE; VALIDATION; MORBIDITY; ILLNESS	Objectives To ascertain hospital inpatient mortality in England and to determine which factors best explain variation in standardised hospital death ratios. Design Weighted linear regression analysis of routinely collected data over four years, with hospital standardised mortality ratios as the dependent variable. Setting England. Subjects Eight million discharges from NHS hospitals when the primary diagnosis was one of the diagnoses accounting for 80% of inpatient deaths. Main outcome measures Hospital standardised mortality ratios and predictors of variations in these ratios. Results The four year crude death rates varied across hospitals from 3.4% to 13.6% (average for England 8.5%), and standardised hospital mortality ratios ranged from 53 to 137 (average for England 100). The percentage of cases that were emergency admissions (60% of total hospital admissions) was the best predictor of this variation in mortality, with the ratio of hospital doctors to beds and general practitioners to head of population the next best predictors. When analyses were restricted to emergency admissions (which covered 93% of all patient deaths analysed) number of doctors per bed was the best predictor. Conclusion Analysis of hospital episode statistics reveals wide variation in standardised hospital mortality ratios in England. The percentage of total admissions classified as emergencies is the most powerful predictor of variation in mortality. The ratios of doctors to head of population served, both in hospital and in general practice, seem to be critical determinants of standardised hospital death rates; the higher these ratios, the lower the death rates in both cases.	Imperial Coll Sch Med, Dept Primary Hlth Care & Gen Practice, London W2 1PG, England; Hammersmith Hosp, Imperial Coll Sch Med, Dept Med Stat & Evaluat, London W12 0NN, England; Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Dept Med,Div Gen Med & Primary Care, Boston, MA 02215 USA	Imperial College London; Imperial College London; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School	Jarman, B (corresponding author), Imperial Coll Sch Med, Dept Primary Hlth Care & Gen Practice, London W2 1PG, England.							ALHAIDER AS, 1991, HEALTH SERV RES, V26, P303; BLUMBERG MS, 1987, HEALTH SERV RES, V21, P715; BRADBURY RC, 1991, HEALTH SERV RES, V26, P407; BRUSTER S, 1994, BRIT MED J, V309, P1542, DOI 10.1136/bmj.309.6968.1542; BUCKLE F, 1865, VITAL EC STAT HOSP I; Carstairs V., 1991, DEPRIVATION HLTH SCO; CHARLSON ME, 1987, J CHRON DIS, V40, P373, DOI 10.1016/0021-9681(87)90171-8; CHASSIN MR, 1989, HEALTH SERV RES, V24, P1; *COMM PROF HOSP AC, 1987, RISK ADJ HOSP MORT N; Dale A, 1993, 1991 CENSUS USERS GU; *DEP HLTH, 1995, STAT B 1953 3; *DEP HLTH, 1997, GMS GEN MED SERV GMP; *DEP HLTH, 1992, HOSP EP STAT ENGL FI; DUBOIS RW, 1987, NEW ENGL J MED, V317, P1674, DOI 10.1056/NEJM198712243172626; FOTTLER MD, 1987, HOSP HEALTH SERV ADM, V32, P343; GOLDFARB MG, 1987, INQUIRY-J HEALTH CAR, V24, P68; Goldstein H, 1996, J ROY STAT SOC A STA, V159, P385, DOI 10.2307/2983325; GOSS MEW, 1974, MED CARE, V12, P202, DOI 10.1097/00005650-197403000-00002; GREEN J, 1990, JAMA-J AM MED ASSOC, V263, P241, DOI 10.1001/jama.263.2.241; GREENFIELD S, 1988, JAMA-J AM MED ASSOC, V260, P2253, DOI 10.1001/jama.260.15.2253; HARTZ AJ, 1989, NEW ENGL J MED, V321, P1720, DOI 10.1056/NEJM198912213212506; HARTZ AJ, 1993, HEALTH SERV RES, V27, P765; Iezzoni LI, 1996, AM J PUBLIC HEALTH, V86, P1379, DOI 10.2105/AJPH.86.10.1379; Iezzoni LI, 1997, JAMA-J AM MED ASSOC, V278, P1600, DOI 10.1001/jama.278.19.1600; JARMAN B, 1984, BRIT MED J, V289, P1587, DOI 10.1136/bmj.289.6458.1587; JARMAN B, 1997, CONTRIBUTION LONDONS; Kassirer JP, 1999, NEW ENGL J MED, V340, P309, DOI 10.1056/NEJM199901283400410; LIPWORTH L, 1963, LANCET, V1, P71; LUFT HS, 1986, JAMA-J AM MED ASSOC, V255, P2780, DOI 10.1001/jama.255.20.2780; McKee M, 1997, BRIT MED J, V315, P142, DOI 10.1136/bmj.315.7101.142; McKee M, 1995, Qual Health Care, V4, P5, DOI 10.1136/qshc.4.1.5; *NCEPOD, 1992, NAT CONF ENQ PER DEA; *NHS EX, 1995, HOSP AMB SERV PAT CH; *NHS EX, 1999, FAST ACC MOD TREATM; Nightingale F., 1863, NOTES ON HOSP; *OECD, 1998, HLTH DAT COMP AN 29; *OFF POP CENS SURV, 1992, 1991 CENS DEF; Office of Population Censuses and Surveys, 1980, CLASS OCC 1980; ORCHARD C, 1994, BRIT MED J, V308, P1493, DOI 10.1136/bmj.308.6942.1493; Orchard C, 1996, J Eval Clin Pract, V2, P111, DOI 10.1111/j.1365-2753.1996.tb00035.x; PALMER RH, 1979, MED CARE, V17, P693, DOI 10.1097/00005650-197907000-00001; PARK RE, 1990, JAMA-J AM MED ASSOC, V264, P484; Roemer M., 1971, DOCTORS HOSP MED STA; ROYSTON JP, 1983, J ROY STAT SOC D-STA, V32, P297, DOI 10.2307/2987935; ROYSTON P, 1994, J R STAT SOC C-APPL, V43, P429, DOI 10.2307/2986270; SELKER HP, 1993, ANN INTERN MED, V118, P820, DOI 10.7326/0003-4819-118-10-199305150-00010; THOMAS JW, 1993, INQUIRY-J HEALTH CAR, V30, P6; Thomas JW, 1998, MED CARE RES REV, V55, P371, DOI 10.1177/107755879805500401; Townsend P., 1986, INEQUALITIES HLTH NO; Vincent C, 1998, BRIT MED J, V316, P1154, DOI 10.1136/bmj.316.7138.1154; 1993, LANCET, V341, P1183	51	276	281	0	5	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUN 5	1999	318	7197					1515	1520		10.1136/bmj.318.7197.1515	http://dx.doi.org/10.1136/bmj.318.7197.1515			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	204HC	10356004	Bronze, Green Published, Green Submitted			2022-12-28	WOS:000080757300023
J	Arsuaga, JL; Lorenzo, C; Carretero, JM; Gracia, A; Martinez, I; Garcia, N; de Castro, JMB; Carbonell, E				Arsuaga, JL; Lorenzo, C; Carretero, JM; Gracia, A; Martinez, I; Garcia, N; de Castro, JMB; Carbonell, E			A complete human pelvis from the Middle Pleistocene of Spain	NATURE			English	Article							SIERRA-DE-ATAPUERCA; LOS-HUESOS; SEXUAL DIMORPHISM; SIZE VARIATION; SIMA; SITE; HOMINIDS; PATTERNS	The Middle Pleistocene site of Sima de los Huesos in Sierra de Atapuerca, Spain, has yielded around 2,500 fossils from at least 33 different hominid individuals'. These have been dated at more than 200,000 years ago(2-4) and have been classified as ancestors of Neanderthals(5,6), An almost complete human male pelvis (labelled Pelvis 1) has been found, which we associate with two fragmentary femora. Pelvis 1 is robust and very broad with avery long superior pubic ramus, marked iliac flare, and a long femoral neck. This pattern is probably the primitive condition from which modern humans departed. A modern human newborn would pass through the birth canal of Pelvis 1 and this would be even larger in a female individual. We estimate the body mass of this individual at 95 kg or more. Using the cranial capacities of three specimens from Sima de los Huesos, the encephalization quotients are substantially smaller than in Neanderthals and modern humans.	Univ Complutense Madrid, Fac Ciencias Geol, Inst Geol Econ, Dept Paleontol, E-28040 Madrid, Spain; Univ Burgos, Fac Humanidades & Educ, Dept Ciencias Hist & Geog, Burgos 09071, Spain; CSIC, Museo Nacl Ciencias Nat, E-28006 Madrid, Spain; Univ Rovira & Virgili, Lab Arqueol, Tarragona 43005, Spain	Complutense University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC-UCM - Instituto de Geologia Economica (IGE); Universidad de Burgos; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Museo Nacional de Ciencias Naturales (MNCN); Universitat Rovira i Virgili	Arsuaga, JL (corresponding author), Univ Complutense Madrid, Fac Ciencias Geol, Inst Geol Econ, Dept Paleontol, E-28040 Madrid, Spain.		Carretero, José-Miguel/AAN-1926-2020; Carbonell, Eudald/G-3003-2015; Lorenzo, Carlos/E-4290-2015; Díaz, José-Miguel Carretero/L-1703-2018	Carretero, José-Miguel/0000-0003-0409-8087; Lorenzo, Carlos/0000-0001-5706-293X; Díaz, José-Miguel Carretero/0000-0003-0409-8087; martinez, ignacio/0000-0002-1835-9199; Bermudez de Castro, Jose Maria/0000-0003-1314-3273; Arsuaga, Juan Luis/0000-0001-5361-2295				Abitbol MM., 1996, BIRTH HUMAN EVOLUTIO; Arsuaga JL, 1997, J HUM EVOL, V33, P109, DOI 10.1006/jhev.1997.0132; ARSUAGA JL, 1993, NATURE, V362, P534, DOI 10.1038/362534a0; Arsuaga JL, 1997, J HUM EVOL, V33, P219, DOI 10.1006/jhev.1997.0133; Arsuaga JL, 1997, SCIENCE, V277, P1086, DOI 10.1126/science.277.5329.1086; ARSUAGA JL, 1994, AM J PHYS ANTHROPOL, V93, P241, DOI 10.1002/ajpa.1330930208; Bischoff JL, 1997, J HUM EVOL, V33, P129, DOI 10.1006/jhev.1997.0130; CuencaBescos G, 1997, J HUM EVOL, V33, P175, DOI 10.1006/jhev.1997.0153; FELDESMAN MR, 1990, AM J PHYS ANTHROPOL, V83, P359, DOI 10.1002/ajpa.1330830309; Garcia N, 1997, J HUM EVOL, V33, P155, DOI 10.1006/jhev.1997.0154; Kappelman J, 1997, NATURE, V387, P126, DOI 10.1038/387126a0; Lorenzo C, 1998, AM J PHYS ANTHROPOL, V106, P19; Rak Y., 1991, SQUELETTE MOUSTERIEN, P147; Rak Yoel, 1993, P523; Rosenberg KR, 1998, NEANDERTALS AND MODERN HUMANS IN WESTERN ASIA, P367; Ruff CB, 1997, NATURE, V387, P173, DOI 10.1038/387173a0; Ruff Christopher B., 1993, P234; SERRA JA, 1998, CONTRIB ESTUDO ANTHR, V15, P1; TAGUE RG, 1991, J HUM EVOL, V21, P153, DOI 10.1016/0047-2484(91)90059-5; TAGUE RG, 1992, AM J PHYS ANTHROPOL, V88, P1, DOI 10.1002/ajpa.1330880102; TRINKAUS E, 1995, J ARCHAEOL SCI, V22, P121, DOI 10.1016/S0305-4403(95)80170-7; Trotter M, 1952, AM J PHYS ANTHROP-NE, V10, P463, DOI 10.1002/ajpa.1330100407; Walrath DE, 1996, AM J PHYS ANTHROPOL, V100, P89, DOI 10.1002/(SICI)1096-8644(199605)100:1<89::AID-AJPA9>3.0.CO;2-8	23	141	148	0	24	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAY 20	1999	399	6733					255	258		10.1038/20430	http://dx.doi.org/10.1038/20430			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	198MF	10353247				2022-12-28	WOS:000080427400054
J	Boyer, TG; Martin, MED; Lees, E; Ricciardi, RP; Berk, AJ				Boyer, TG; Martin, MED; Lees, E; Ricciardi, RP; Berk, AJ			Mammalian Srb Mediator complex is targeted by adenovirus E1A protein	NATURE			English	Article							RNA-POLYMERASE-II; TRANSCRIPTIONAL REGULATION; ACTIVATED TRANSCRIPTION; KINASE; GENE; HOLOENZYME; PATHWAY; FAMILY; DOMAIN; CELLS	Adenovirus E1A proteins prepare the host cell for viral replication, stimulating cell cycling and viral transcription through interactions with critical cellular regulatory proteins such as RB1,2 and CBP3. Here we show that the E1A zinc-finger domain that is required to activate transcription of viral early genes binds to a host-cell multiprotein complex containing homologues of yeast Srb/Mediator proteins(4,5). This occurs through a stable interaction with the human homologue of Caenorhabditis elegans SUR-2, a protein required for many developmental processes in the nematode(6). This human Srb/Mediator complex stimulates transcription in vitro in response to both the E1A zinc-finger and the herpes simplex virus VP16 activation domains. Interaction with human Sur-2 is also required for transcription to be activated by the activation domain of a transcription factor of the ETS-family in response to activated mitogen-activated protein (MAP) kinase.	Univ Calif Los Angeles, Inst Mol Biol, Los Angeles, CA 90095 USA; DNAX Res Inst Mol & Cellular Biol Inc, Palo Alto, CA 94304 USA; Univ Penn, Sch Dent Med, Dept Microbiol, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Biochem Biophys, Philadelphia, PA 19104 USA	University of California System; University of California Los Angeles; Merck & Company; Dnax Research Institute Of Molecular & Cellular Biology Inc.; University of Pennsylvania; University of Pennsylvania	Berk, AJ (corresponding author), Univ Calif Los Angeles, Inst Mol Biol, Los Angeles, CA 90095 USA.		BERK, ARNOLD/AAF-7052-2020					ARANY Z, 1994, CELL, V77, P799, DOI 10.1016/0092-8674(94)90127-9; BOYER TG, 1993, GENE DEV, V7, P1810, DOI 10.1101/gad.7.9.1810; BRAUER AW, 1984, ANAL BIOCHEM, V137, P134, DOI 10.1016/0003-2697(84)90359-2; Bryant GO, 1996, GENE DEV, V10, P2491, DOI 10.1101/gad.10.19.2491; Cho H, 1998, MOL CELL BIOL, V18, P5355, DOI 10.1128/MCB.18.9.5355; Denhardt DT, 1996, BIOCHEM J, V318, P729, DOI 10.1042/bj3180729; Faris M, 1996, J BIOL CHEM, V271, P27366, DOI 10.1074/jbc.271.44.27366; FLINT J, 1989, ANNU REV GENET, V23, P141, DOI 10.1146/annurev.genet.23.1.141; Gold MO, 1996, NUCLEIC ACIDS RES, V24, P3771, DOI 10.1093/nar/24.19.3771; GRAHAM FL, 1977, J GEN VIROL, V36, P59, DOI 10.1099/0022-1317-36-1-59; Greenblatt J, 1997, CURR OPIN CELL BIOL, V9, P310, DOI 10.1016/S0955-0674(97)80002-6; Gu W, 1999, MOL CELL, V3, P97, DOI 10.1016/S1097-2765(00)80178-1; Holstege FCP, 1998, CELL, V95, P717, DOI 10.1016/S0092-8674(00)81641-4; JANKNECHT R, 1993, BIOCHIM BIOPHYS ACTA, V1155, P346, DOI 10.1016/0304-419X(93)90014-4; Jiang YW, 1998, P NATL ACAD SCI USA, V95, P8538, DOI 10.1073/pnas.95.15.8538; Kaiser K, 1996, TRENDS BIOCHEM SCI, V21, P342, DOI 10.1016/S0968-0004(96)10043-8; LIAO SM, 1995, NATURE, V374, P193, DOI 10.1038/374193a0; MESMASSON AM, 1986, P NATL ACAD SCI USA, V83, P9768, DOI 10.1073/pnas.83.24.9768; Myer VE, 1998, J BIOL CHEM, V273, P27757, DOI 10.1074/jbc.273.43.27757; Myers LC, 1998, GENE DEV, V12, P45, DOI 10.1101/gad.12.1.45; Rickert P, 1996, ONCOGENE, V12, P2631; Ryu SJ, 1999, NATURE, V397, P446, DOI 10.1038/17141; SINGH N, 1995, GENE DEV, V9, P2251, DOI 10.1101/gad.9.18.2251; Sun XQ, 1998, MOL CELL, V2, P213, DOI 10.1016/S1097-2765(00)80131-8; TASSAN JP, 1995, P NATL ACAD SCI USA, V92, P8871, DOI 10.1073/pnas.92.19.8871; WEBSTER LC, 1991, MOL CELL BIOL, V11, P4287, DOI 10.1128/MCB.11.9.4287; WHYTE P, 1989, CELL, V56, P67, DOI 10.1016/0092-8674(89)90984-7; ZHU L, 1994, COLD SPRING HARB SYM, V59, P75, DOI 10.1101/SQB.1994.059.01.011	28	249	257	0	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAY 20	1999	399	6733					276	279		10.1038/20466	http://dx.doi.org/10.1038/20466			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	198MF	10353252				2022-12-28	WOS:000080427400060
J	Sitas, F; Carrara, H; Beral, V; Newton, R; Reeves, G; Bull, D; Jentsch, U; Pacella-Norman, R; Bourboulia, D; Whitby, D; Boshoff, C; Weiss, R				Sitas, F; Carrara, H; Beral, V; Newton, R; Reeves, G; Bull, D; Jentsch, U; Pacella-Norman, R; Bourboulia, D; Whitby, D; Boshoff, C; Weiss, R			Antibodies against human herpesvirus 8 in black South African patients with cancer	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							SARCOMA-ASSOCIATED HERPESVIRUS; KAPOSIS-SARCOMA; MULTIPLE-MYELOMA; SEXUAL TRANSMISSION; PERIPHERAL-BLOOD; NUCLEAR ANTIGEN; DNA-SEQUENCES; INFECTION; AIDS; HUMAN-HERPESVIRUS-8	Background. Infection with human herpesvirus 8 (HHV-8) has been consistently linked to Kaposi's sarcoma, but its mode of transmission, association with other cancers, and interaction with the human immunodeficiency virus type 1 (HIV-1) are largely unknown. Methods. Between January 1992 and December 1997, we interviewed 3591 black patients with cancer in Johannesburg and Soweto, South Africa. Blood was tested for antibodies against HIV-1 and HHV-8 in 3344 of the patients. Antibodies against HHV-8 were detected with an indirect immunofluorescence assay. The intensity of the fluorescent signal correlated well with the titers of antibodies (P < 0.001). The relations among the presence of anti-HHV-8 antibodies, sociodemographic and behavioral factors, type of cancer, and the presence or absence of coexistent HIV-1 infection were examined with the use of unconditional logistic-regression models. Results. Among the 3293 subjects with cancers other than Kaposi's sarcoma, the standardized seroprevalence of antibodies against HHV-8 was 32 percent, which did not differ significantly from the standardized seroprevalence among black blood donors. Among these 3293 patients, the prevalence of antibodies against HHV-8 increased with increasing age (P < 0.001) and an increasing number of sexual partners (P = 0.05) and decreased with increasing years of education (P = 0.007); it was not strongly associated with HIV-1 infection. Anti-HHV-8 antibodies were more frequent among black than white blood donors (P < 0.001). Among the 51 patients with Kaposi's sarcoma, the standardized seroprevalence of antibodies against HHV-8 was 83 percent, significantly higher than the prevalence among those without Kaposi's sarcoma (P < 0.001). For 16 other specific types of cancer, including multiple myeloma (108 cases) and prostate cancer (202 cases), the variation in the standardized seroprevalence of antibodies against HHV-8 was not remarkable. At a given intensity of fluorescence of anti-HHV-8 antibodies, Kaposi's sarcoma was more frequent among HIV-l-positive patients than among those who were HIV-l-negative (P < 0.001). Conclusions. Among black patients with cancer in South Africa, the seroprevalence of anti-HHV-8 antibodies is high and is specifically associated with Kaposi's sarcoma, particularly at high titers. (N Engl J Med 1999;340:1863-71.) (C) 1999, Massachusetts Medical Society.	S African Inst Med Res, Dept Anat Pathol, ZA-2000 Johannesburg, South Africa; Natl Canc Registry, S African Canc Epidemiol Unit, Johannesburg, South Africa; S African Inst Med Res, Dept Serol, ZA-2000 Johannesburg, South Africa; Univ Oxford, Imperial Canc Res Fund, Canc Epidemiol Unit, Oxford, England; UCL, Dept Oncol, London, England; UCL, Dept Mol Pathol, London, England	University of Oxford; University of London; University College London; University of London; University College London	Sitas, F (corresponding author), S African Inst Med Res, Dept Anat Pathol, POB 1038, ZA-2000 Johannesburg, South Africa.	freddys@mail.saimr.wits.ac.za	PACELLA, ROSANA E./F-2774-2010	PACELLA, ROSANA E./0000-0002-9742-1957; O'donnell, Colm/0000-0002-8004-450X; Sitas, Freddy/0000-0001-9679-1481				Ansari MQ, 1996, AM J CLIN PATHOL, V105, P221; BASSETT MT, 1995, INT J CANCER, V63, P29, DOI 10.1002/ijc.2910630107; BASSETT MT, 1995, INT J CANCER, V63, P763; BERAL V, 1990, LANCET, V335, P123, DOI 10.1016/0140-6736(90)90001-L; Boshoff C, 1998, BLOOD, V91, P1671, DOI 10.1182/blood.V91.5.1671.1671_1671_1679; BOSHOFF C, 1995, NAT MED, V1, P1274, DOI 10.1038/nm1295-1274; Boshoff C, 1998, ADV CANCER RES, V75, P57, DOI 10.1016/S0065-230X(08)60739-3; Bourboulia D, 1998, JAMA-J AM MED ASSOC, V280, P31, DOI 10.1001/jama.280.1.31-a; CESARMAN E, 1995, NEW ENGL J MED, V332, P1186, DOI 10.1056/NEJM199505043321802; CHANG Y, 1994, SCIENCE, V266, P1865, DOI 10.1126/science.7997879; Cook-Mozaffari P, 1998, BRIT J CANCER, V78, P1521, DOI 10.1038/bjc.1998.717; DETHE G, 1978, NATURE, V274, P756, DOI 10.1038/274756a0; DETHE G, 1978, IARC SCI PUBLICATION, V20; EASTON DF, 1991, STAT MED, V10, P1025, DOI 10.1002/sim.4780100703; ENSOLI B, 1990, NATURE, V345, P84, DOI 10.1038/345084a0; Gaidano G, 1996, AIDS, V10, P941, DOI 10.1097/00002030-199610090-00003; Gao SJ, 1996, NAT MED, V2, P925, DOI 10.1038/nm0896-925; Kedes DH, 1996, NAT MED, V2, P1041; Kedes DH, 1997, J CLIN INVEST, V100, P2606, DOI 10.1172/JCI119804; Kedes DH, 1996, NAT MED, V2, P918, DOI 10.1038/nm0896-918; Kellam P, 1997, J Hum Virol, V1, P19; Lennette ET, 1996, LANCET, V348, P858, DOI 10.1016/S0140-6736(96)03240-0; Martin JN, 1998, NEW ENGL J MED, V338, P948, DOI 10.1056/NEJM199804023381403; Masood R, 1997, SCIENCE, V278, P1970; Moore PS, 1998, AM J EPIDEMIOL, V147, P217, DOI 10.1093/oxfordjournals.aje.a009440; Moore PS, 1996, AIDS, V10, P175, DOI 10.1097/00002030-199602000-00007; Munker R, 1997, PROSTATE, V33, P286, DOI 10.1002/(SICI)1097-0045(19971201)33:4&lt;286::AID-PROS10&gt;3.0.CO;2-F; Parravicini C, 1997, SCIENCE, V278, P1969, DOI 10.1126/science.278.5345.1969; Rabkin CS, 1998, J INFECT DIS, V178, P304, DOI 10.1086/515649; Rainbow L, 1997, J VIROL, V71, P5915, DOI 10.1128/JVI.71.8.5915-5921.1997; Rettig MB, 1997, SCIENCE, V276, P1851, DOI 10.1126/science.276.5320.1851; Simpson GR, 1996, LANCET, V348, P1133, DOI 10.1016/S0140-6736(96)07560-5; Sitas F, 1997, BRIT J CANCER, V75, P1704, DOI 10.1038/bjc.1997.290; Staskus KA, 1997, J VIROL, V71, P715, DOI 10.1128/JVI.71.1.715-719.1997; WABINGA HR, 1993, INT J CANCER, V54, P26, DOI 10.1002/ijc.2910540106; Whitby D, 1998, J NATL CANCER I, V90, P395, DOI 10.1093/jnci/90.5.395; Whitby D, 1997, SCIENCE, V278, P1971; WHITBY D, 1995, LANCET, V346, P799, DOI 10.1016/S0140-6736(95)91619-9	38	204	216	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUN 17	1999	340	24					1863	1871		10.1056/NEJM199906173402403	http://dx.doi.org/10.1056/NEJM199906173402403			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	206EC	10369849				2022-12-28	WOS:000080863500003
J	Evans, TW; Smithies, M				Evans, TW; Smithies, M			ABC of intensive care - Organ dysfunction	BRITISH MEDICAL JOURNAL			English	Article									Univ London Imperial Coll Sci Technol & Med, Royal Brompton Hosp, London, England; Univ Wales Hosp, Cardiff CF4 4XW, S Glam, Wales	Imperial College London; Royal Brompton Hospital; Cardiff University	Evans, TW (corresponding author), Univ London Imperial Coll Sci Technol & Med, Royal Brompton Hosp, London, England.								0	21	24	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JUN 12	1999	318	7198					1606	1609		10.1136/bmj.318.7198.1606	http://dx.doi.org/10.1136/bmj.318.7198.1606			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	207AL	10364125	Green Published			2022-12-28	WOS:000080913100034
J	Gapstur, SM; Morrow, M; Sellers, TA				Gapstur, SM; Morrow, M; Sellers, TA			Hormone replacement therapy and risk of breast cancer with a favorable histology - Results of the Iowa Women's Health Study	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							POSTMENOPAUSAL WOMEN; FAMILY HISTORY; UNITED-STATES; ESTROGEN; MORTALITY; QUESTIONNAIRE; CARCINOMA; SURVIVAL; DISEASE	Context. Long-term, postmenopausal use of hormone replacement therapy (HRT) appears to increase breast cancer risk. Whether the effect of HRT use on risk of breast cancer varies among histological types of invasive carcinoma is unknown. Objective. To determine associations between HRT use and risk of ductal carcinoma in situ (DCIS), invasive carcinoma with favorable histology, and invasive ductal or lobular carcinoma. Design. Prospective cohort study whose participants were followed up continuously for 11 years from January 1986 to December 1996. Setting and Participants. Iowa Women's Health Study, a population-based random sample of postmenopausal women aged 55 to 69 years in 1986. A total of 1520 incident breast cancer cases occurred in the at-risk cohort of 37105 women. Main outcome Measures. Multivariate-adjusted relative risk (RR) of tumor-specific breast cancers associated with duration of ever, current, or past HRT use. Results. Duration of ever HRT use was associated with risk of invasive carcinoma with a favorable histology, with an RR of 1.81 (95% confidence interval [Cl], 1.07-3.07) for those who used HRT 5 or fewer years vs an RR of 2.65 (95% CI, 1.34-5.23) for those who used HRT for more than 5 years (P for trend = .005) after adjustment for age and other breast cancer risk factors. There was no association between ever HRT use and the incidence of DCIS or invasive ductal or lobular carcinoma. Among current hormone users, after adjusting for age and other breast cancer risk factors, the RRs (95% Cls) of invasive carcinoma with a favorable histology were 4.42 (2.00-9.76) and 2.63 (1.18-5.89) for 5 or fewer years of use and for more than 5 years of use, respectively. Risk of invasive ductal or lobular carcinoma was associated with current use (less than or equal to 5 years) of HRT with an RR of 1.38 (95% Cl, 1.03-1.85). Conclusions. Exposure to HRT was associated most strongly with an increased risk of invasive breast cancer with a favorable prognosis. These data add important clinical information for assessing the risks and benefits of HRT use.	Northwestern Univ, Sch Med, Dept Prevent Med, Chicago, IL 60611 USA; Northwestern Univ, Sch Med, Dept Surg, Chicago, IL 60611 USA; Northwestern Univ, Sch Med, Lynn Sage Comprehens Breast Ctr, Chicago, IL 60611 USA; Mayo Clin & Mayo Fdn, Dept Hlth Sci Res, Rochester, MN 55905 USA	Northwestern University; Northwestern University; Northwestern University; Mayo Clinic	Gapstur, SM (corresponding author), Northwestern Univ, Sch Med, Dept Prevent Med, 680 N Lake Shore Dr,Suite 1102, Chicago, IL 60611 USA.				NATIONAL CANCER INSTITUTE [R01CA039742] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA39742] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BELCHETZ PE, 1994, NEW ENGL J MED, V330, P1062; Beral V, 1997, LANCET, V350, P1047, DOI 10.1016/S0140-6736(97)08233-0; BERGKVIST L, 1989, AM J EPIDEMIOL, V130, P221, DOI 10.1093/oxfordjournals.aje.a115328; BISGARD KM, 1994, AM J EPIDEMIOL, V139, P990, DOI 10.1093/oxfordjournals.aje.a116948; BONNIER P, 1995, OBSTET GYNECOL, V85, P11, DOI 10.1016/0029-7844(94)00324-7; Bush TL, 1996, JAMA-J AM MED ASSOC, V276, P1389, DOI 10.1001/jama.276.17.1389; CLAUS EB, 1993, CANCER, V71, P147, DOI 10.1002/1097-0142(19930101)71:1<147::AID-CNCR2820710124>3.0.CO;2-V; DUBIN N, 1986, AM J EPIDEMIOL, V123, P1101, DOI 10.1093/oxfordjournals.aje.a114338; EWERTZ M, 1991, INT J CANCER, V49, P526, DOI 10.1002/ijc.2910490409; Fisher B, 1998, J NATL CANCER I, V90, P1371, DOI 10.1093/jnci/90.18.1371; GAPSTUR SM, 1992, AM J EPIDEMIOL, V136, P1221, DOI 10.1093/oxfordjournals.aje.a116430; GRADY D, 1992, ANN INTERN MED, V117, P1016, DOI 10.7326/0003-4819-117-12-1016; Grodstein F, 1996, NEW ENGL J MED, V335, P453, DOI 10.1056/NEJM199608153350701; Grodstein F, 1997, NEW ENGL J MED, V336, P1769, DOI 10.1056/NEJM199706193362501; HEMMINKI E, 1988, American Journal of Public Health, V78, P1479, DOI 10.2105/AJPH.78.11.1479; HENDERSON BE, 1991, ARCH INTERN MED, V151, P75, DOI 10.1001/archinte.151.1.75; Holli K, 1998, J CLIN ONCOL, V16, P3115, DOI 10.1200/JCO.1998.16.9.3115; JORDAN VC, 1998, P AM SOC CLIN ONCOL, V17, P46; KUSHI LH, 1988, AM J EPIDEMIOL, V128, P740, DOI 10.1093/oxfordjournals.aje.a115027; Longnecker MP, 1996, CANCER EPIDEM BIOMAR, V5, P961; MUNGER RG, 1992, AM J EPIDEMIOL, V136, P192, DOI 10.1093/oxfordjournals.aje.a116485; NABULSI AA, 1993, NEW ENGL J MED, V328, P1069, DOI 10.1056/NEJM199304153281501; PEREZMESA CM, 1988, CANC BREAST, P206; Ries L, 1998, SEER CANC STAT REV 1; ROSEN PP, 1979, ANN CLIN LAB SCI, V9, P144; SELLERS TA, 1992, NEW ENGL J MED, V326, P1323, DOI 10.1056/NEJM199205143262004; SHAIRER C, 1994, CANCER CAUSE CONTROL, V5, P491; SQUITIERI R, 1994, J AM COLL SURGEONS, V178, P167; STANFORD JL, 1995, JAMA-J AM MED ASSOC, V274, P137, DOI 10.1001/jama.274.2.137; STRICKLAND DM, 1992, OBSTET GYNECOL, V80, P400; WEISS NS, 1978, ANN INTERN MED, V88, P410, DOI 10.7326/0003-4819-88-3-410; WILLETT WC, 1988, AM J EPIDEMIOL, V127, P188, DOI 10.1093/oxfordjournals.aje.a114780; Willis DB, 1996, CANCER CAUSE CONTROL, V7, P449, DOI 10.1007/BF00052671; WYSOWSKI DK, 1995, OBSTET GYNECOL, V85, P6, DOI 10.1016/0029-7844(94)00339-F	34	174	177	0	3	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 9	1999	281	22					2091	2097		10.1001/jama.281.22.2091	http://dx.doi.org/10.1001/jama.281.22.2091			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	202TJ	10367819				2022-12-28	WOS:000080668000031
J	Burstein, HJ; Gelber, S; Guadagnoli, E; Weeks, JC				Burstein, HJ; Gelber, S; Guadagnoli, E; Weeks, JC			Use of alternative medicine by women with early-stage breast cancer	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							QUALITY-OF-LIFE; UNITED-STATES; COMPLEMENTARY THERAPIES; CONVENTIONAL TREATMENT; CONSERVING SURGERY; RISK; PREVALENCE; DISTRESS	Background We analyzed the use of alternative medicine by women who had received standard therapy for early-stage breast cancer diagnosed between September 1993 and September 1995. Methods A cohort of 480 patients with newly diagnosed early-stage breast cancer was recruited from a Massachusetts statewide cohort of women participating in a study of how women choose treatment for cancer. Alternative medical treatments, conventional therapies, and health-related quality of life were examined. Results New use of alternative medicine after surgery for breast cancer was common (reported by 28.1 percent of the women); such use was not associated with choices about standard medical therapies after we controlled for clinical and sociodemographic variables. A total of 10.6 percent of the women had used alternative medicine before they were given a diagnosis of breast cancer. Women who initiated the use of alternative medicine after surgery reported a worse quality of life than women who never used alternative medicine. Mental health scores were similar at base line among women who decided to use alternative medicine and those who did not, but three months after surgery the use of alternative medicine was independently associated with depression, fear of recurrence of cancer, lower scores for mental health and sexual satisfaction, and more physical symptoms as well as symptoms of greater intensity. All groups of women reported improving quality of life one year after surgery. Conclusions Among women with newly diagnosed early-stage breast cancer who had been treated with standard therapies, new use of alternative medicine was a marker of greater psychosocial distress and worse quality of life. (N Engl J Med 1999; 340:1733-9.) (C) 1999, Massachusetts Medical Society.	Dana Farber Canc Inst, Dept Adult Oncol, Boston, MA 02115 USA; Dana Farber Canc Inst, Ctr Outcomes & Policy Res, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Hlth Care Policy, Boston, MA USA	Harvard University; Dana-Farber Cancer Institute; Harvard University; Dana-Farber Cancer Institute; Harvard University; Harvard Medical School	Weeks, JC (corresponding author), Dana Farber Canc Inst, Dept Adult Oncol, 44 Binney St, Boston, MA 02115 USA.				NATIONAL CANCER INSTITUTE [R01CA059408] Funding Source: NIH RePORTER; NCI NIH HHS [CA 59408] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ACKERMAN J, 1998, BOSTON GLOBE    0412, pE1; Angell M, 1998, NEW ENGL J MED, V339, P839, DOI 10.1056/NEJM199809173391210; Astin JA, 1998, JAMA-J AM MED ASSOC, V279, P1548, DOI 10.1001/jama.279.19.1548; Cassileth BR, 1996, CANCER-AM CANCER SOC, V77, P1026, DOI 10.1002/(SICI)1097-0142(19960315)77:6<1026::AID-CNCR4>3.3.CO;2-#; CASSILETH BR, 1984, ANN INTERN MED, V101, P105, DOI 10.7326/0003-4819-101-1-105; Coppes MJ, 1998, NEW ENGL J MED, V339, P846, DOI 10.1056/NEJM199809173391213; Crocetti E, 1998, EUR J CANCER, V34, P324, DOI 10.1016/S0959-8049(97)10043-0; DANIELSON KJ, 1988, CAN MED ASSOC J, V138, P1005; DOWNER SM, 1994, BRIT MED J, V309, P86, DOI 10.1136/bmj.309.6947.86; EISENBERG DM, 1993, NEW ENGL J MED, V328, P246, DOI 10.1056/NEJM199301283280406; Eisenberg DM, 1998, JAMA-J AM MED ASSOC, V280, P1569, DOI 10.1001/jama.280.18.1569; Ganz PA, 1998, J CLIN ONCOL, V16, P501, DOI 10.1200/JCO.1998.16.2.501; GANZ PA, 1993, MED CARE, V31, P419, DOI 10.1097/00005650-199305000-00004; GANZ PA, 1995, JNCI-J NATL CANCER I, V87, P1372, DOI 10.1093/jnci/87.18.1372; Gevitz N, 1988, OTHER HEALERS UNORTH, P1; Guadagnoli E, 1998, J CLIN ONCOL, V16, P101, DOI 10.1200/JCO.1998.16.1.101; HARRIS L, 1987, HLTH INFORMATION USE; LASRY JCM, 1992, CANCER, V69, P2111, DOI 10.1002/1097-0142(19920415)69:8<2111::AID-CNCR2820690817>3.0.CO;2-T; LERNER IJ, 1984, CANCER, V53, P815, DOI 10.1002/1097-0142(19840201)53:3+<815::AID-CNCR2820531334>3.0.CO;2-U; LERNER IJ, 1992, CA-CANCER J CLIN, V42, P181, DOI 10.3322/canjclin.42.3.181; MAUNSELL E, 1992, CANCER-AM CANCER SOC, V70, P120, DOI 10.1002/1097-0142(19920701)70:1<120::AID-CNCR2820700120>3.0.CO;2-U; MEYEROWITZ BE, 1979, CANCER, V43, P1613, DOI 10.1002/1097-0142(197905)43:5<1613::AID-CNCR2820430508>3.0.CO;2-8; Mor V, 1994, J Natl Cancer Inst Monogr, P191; RADLOFF L S, 1977, Applied Psychological Measurement, V1, P385, DOI 10.1177/014662167700100306; Risberg T, 1998, J CLIN ONCOL, V16, P6, DOI 10.1200/JCO.1998.16.1.6; ROWLAND JH, 1996, DIS BREAST, P919; S.A.S. Institute, 1990, SAS STAT US GUID; SCHAG CAC, 1993, J CLIN ONCOL, V11, P783, DOI 10.1200/JCO.1993.11.4.783; Sherbourne CD, 1992, MEASURING FUNCTIONIN, P194; SIEGEL A, 1998, P AM SOC CLIN ONCOL, V17, P667; TAYLOR SE, 1985, CANCER, V55, P2506, DOI 10.1002/1097-0142(19850515)55:10<2506::AID-CNCR2820551033>3.0.CO;2-0; VandeCreek L, 1999, ALTERN THER HEALTH M, V5, P71; WARE JE, 1992, MED CARE, V30, P473, DOI 10.1097/00005650-199206000-00002	33	458	465	0	29	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 3	1999	340	22					1733	1739		10.1056/NEJM199906033402206	http://dx.doi.org/10.1056/NEJM199906033402206			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	201WQ	10352166				2022-12-28	WOS:000080620200006
J	Weiderpass, E; Baron, JA; Adami, HO; Magnusson, C; Lindgren, A; Bergstrom, R; Correia, N; Persson, I				Weiderpass, E; Baron, JA; Adami, HO; Magnusson, C; Lindgren, A; Bergstrom, R; Correia, N; Persson, I			Low-potency oestrogen and risk of endometrial cancer: a case-control study	LANCET			English	Article							HORMONE REPLACEMENT THERAPY; POSTMENOPAUSAL WOMEN; HEART-DISEASE; ESTROGEN; ESTRIOL; PREVENTION; ESTRADIOL; MORTALITY	Background. Urogenital symptoms are common among postmenopausal women. Such symptoms may be alleviated by low-potency oestrogen formulations administered orally or vaginally. Although low-potency oestrogen formulations are assumed to have few, if any, adverse effects on the endometrium, risk of endometrial neoplasia has not been quantified. Methods. In a nationwide population-based case-control study in Sweden of endometrial cancer among postmenopausal women, we obtained detailed information on hormone replacement from 789 cases of endometrial cancer and 3368 population controls. In a histopathological review, 80 cases were reclassified as having endometrial atypical hyperplasia. Odds ratios and 95% Cl were calculated with unconditional logistic regression. Findings. After multivariate adjustment, oral use of oestriol 1-2 mg daily increased the relative risk of endometrial cancer and endometrial atypical hyperplasia: the odds ratios for at least 5 years of use compared with never use were 3.0 (95% Cl 2.0-4.4) and 8.3 (4.0-17.4), respectively. The association was stronger for well-differentiated cancers and those with limited invasion. The excess relative risk was lost rapidly after cessation of treatment. Only weak associations were observed between vaginal application of low-potency oestrogen formulations and relative risk of endometrial neoplasia. Interpretation. Oral, but not vaginal, treatment with low-potency oestrogen formulations increases the relative risk of endometrial neoplasia. Thus close surveillance of patients is needed, and addition of a progestagen should be considered.	Karolinska Inst, Dept Med Epidemiol, S-17177 Stockholm, Sweden; Dartmouth Coll, Hitchcock Med Ctr, Dartmouth Med Sch, Hanover, NH 03756 USA; Falun Hosp, Dept Pathol, Falun, Sweden; Harvard Univ, Sch Publ Hlth, Harvard Ctr Canc Prevent, Boston, MA 02115 USA; Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA	Karolinska Institutet; Dartmouth College; Falun Hospital; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health	Weiderpass, E (corresponding author), Karolinska Inst, Dept Med Epidemiol, POB 281, S-17177 Stockholm, Sweden.		Weiderpass, Elisabete/AAP-2747-2021; Weiderpass, Elisabete/M-4029-2016	Weiderpass, Elisabete/0000-0003-2237-0128; Weiderpass, Elisabete/0000-0003-2237-0128; Correia, Nestor/0000-0003-4852-9985; Magnusson, Cecilia/0000-0002-8567-6725	NATIONAL CANCER INSTITUTE [R01CA058427] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA58427] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Barrett-Connor E, 1998, BMJ-BRIT MED J, V317, P457; BORGLIN N E, 1959, Acta Obstet Gynecol Scand, V38, P157; BOTELLA J, 1995, J STEROID BIOCHEM, V55, P77, DOI 10.1016/0960-0760(95)00156-T; Bygdeman M, 1996, MATURITAS, V23, P259, DOI 10.1016/0378-5122(95)00955-8; Cardozo L, 1998, BRIT J OBSTET GYNAEC, V105, P403, DOI 10.1111/j.1471-0528.1998.tb10124.x; CLARK JH, 1977, ENDOCRINOLOGY, V100, P91, DOI 10.1210/endo-100-1-91; ENGLUND DE, 1980, ACTA OBSTET GYN SCAN, V59, P449, DOI 10.3109/00016348009155427; ESPOSITO G, 1991, GYNECOL ENDOCRINOL, V5, P131, DOI 10.3109/09513599109028436; Genant HK, 1997, ARCH INTERN MED, V157, P2609, DOI 10.1001/archinte.157.22.2609; GRADY D, 1996, CANC EPIDEMIOLOGY PR, P1058; Granberg S, 1997, MATURITAS, V27, P35, DOI 10.1016/S0378-5122(97)01107-9; Grodstein F, 1997, NEW ENGL J MED, V336, P1769, DOI 10.1056/NEJM199706193362501; HEIMER G, 1984, ACTA OBSTET GYN SCAN, V63, P563, DOI 10.3109/00016348409156720; Heimer G, 1996, Acta Obstet Gynecol Scand Suppl, V163, P1; Hulley S, 1998, JAMA-J AM MED ASSOC, V280, P605, DOI 10.1001/jama.280.7.605; KELSEY JL, 1982, AM J EPIDEMIOL, V116, P333, DOI 10.1093/oxfordjournals.aje.a113417; KORACH K, 1980, ENDOCRINOLOGY, V106, P1900, DOI 10.1210/endo-106-6-1900; LAURITZEN C, 1961, ACTA ENDOCRINOL-COP, V38, P73, DOI 10.1530/acta.0.0380073; Minaguchi H, 1996, J Obstet Gynaecol Res, V22, P259; NILSSON K, 1992, MATURITAS, V15, P121, DOI 10.1016/0378-5122(92)90246-Z; PERSSON I, 1986, ACTA PATH MICRO IM A, V94, P187; Petitti DB, 1998, JAMA-J AM MED ASSOC, V280, P650, DOI 10.1001/jama.280.7.650; Salmi T, 1980, Acta Endocrinol Suppl (Copenh), V233, P37; Schairer C, 1997, EPIDEMIOLOGY, V8, P59, DOI 10.1097/00001648-199701000-00010; SCHIFF I, 1980, AM J OBSTET GYNECOL, V138, P1137, DOI 10.1016/S0002-9378(16)32780-6; Speroff L., 1994, CLIN GYNECOLOGIC END, P583; ToozsHobson P, 1996, BMJ-BRIT MED J, V313, P350, DOI 10.1136/bmj.313.7053.350; VERMEULEN A, 1968, STEROIDS, V11, P609, DOI 10.1016/S0039-128X(68)80009-1	28	129	132	0	4	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAY 29	1999	353	9167					1824	1828		10.1016/S0140-6736(98)10233-7	http://dx.doi.org/10.1016/S0140-6736(98)10233-7			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	202TG	10359406				2022-12-28	WOS:000080667800010
J	Behr, MA; Wilson, MA; Gill, WP; Salamon, H; Schoolnik, GK; Rane, S; Small, PM				Behr, MA; Wilson, MA; Gill, WP; Salamon, H; Schoolnik, GK; Rane, S; Small, PM			Comparative genomics of BCG vaccines by whole-genome DNA microarray	SCIENCE			English	Article							MYCOBACTERIUM-TUBERCULOSIS H37RV; MOLECULAR ANALYSIS; BOVIS BCG; GENE; SEQUENCE	Bacille Calmette-Guerin (BCC) vaccines are live attenuated strains of Mycobacterium bovis administered to prevent tuberculosis. To better understand the differences between M. tuberculosis, M. bovis, and the various BCC daughter strains, their genomic compositions were studied by performing comparative hybridization experiments on a DNA microarray. Regions deleted from BCG vaccines relative to the virulent M. tuberculosis H37Rv reference strain were confirmed by sequencing across the missing segment of the H37Rv genome. Eleven regions (encompassing 91 open reading frames) of H37Rv were found that were absent from one or more virulent strains of M. bovis. Five additional regions representing 38 open reading frames were present in M. bovis but absent from some or all BCC strains; this is evidence for the ongoing evolution of BCG strains since their original derivation. A precise understanding of the genetic differences between closely related Mycobacteria suggests rational approaches to the design of improved diagnostics and vaccines.	McGill Univ, Ctr Hlth, Dept Med, Div Infect Dis, Montreal, PQ H3G 1A4, Canada; Stanford Univ, Dept Med, Div Infect Dis & Geog Med, Stanford, CA 94305 USA	McGill University; Stanford University	Behr, MA (corresponding author), McGill Univ, Ctr Hlth, Dept Med, Div Infect Dis, Montreal, PQ H3G 1A4, Canada.	mbgq@musica.mcgill.ca		Salamon, Hugh/0000-0003-1472-5785				Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; [Anonymous], 1998, MMWR Recomm Rep, V47, P1; ARONSON JOSEPH D., 1940, AMER REV TUBERC, V42, P651; Behr MA, 1999, VACCINE, V17, P915, DOI 10.1016/S0264-410X(98)00277-1; Behr MA, 1997, NATURE, V389, P133, DOI 10.1038/38151; Birkhaug K, 1947, PSYCHIAT QUART, V21, P453, DOI 10.1007/BF01562014; Brosch R, 1998, INFECT IMMUN, V66, P2221, DOI 10.1128/IAI.66.5.2221-2229.1998; Calmette A, 1911, ANN I PASTEUR, V2, P625; Calmette A., 1920, ANN I PASTEUR, V34, P553; Cole ST, 1998, NATURE, V393, P537, DOI 10.1038/31159; DeRisi JL, 1997, SCIENCE, V278, P680, DOI 10.1126/science.278.5338.680; Dreyer G, 1931, LANCET, V1, P9; DUBOS RJ, 1956, AM REV TUBERC PULM, V74, P655; GHEORGHIU M, 1983, B I PASTEUR, V81, P281; Jensen K. A., 1946, ACTA TUBERC SCAND, V20, P1; Johansen KA, 1996, INFECT IMMUN, V64, P3259, DOI 10.1128/IAI.64.8.3259-3266.1996; Mahairas GG, 1996, J BACTERIOL, V178, P1274, DOI 10.1128/jb.178.5.1274-1282.1996; OREILLY LM, 1995, TUBERCLE LUNG DIS, V76, P1, DOI 10.1016/0962-8479(95)90591-X; PARRA CA, 1991, INFECT IMMUN, V59, P3411, DOI 10.1128/IAI.59.10.3411-3417.1991; Philipp WJ, 1996, MICROBIOL-UK, V142, P3135, DOI 10.1099/13500872-142-11-3135; Sreevatsan S, 1997, P NATL ACAD SCI USA, V94, P9869, DOI 10.1073/pnas.94.18.9869; 1998, NATURE GENET, V18, P195; 1980, INDIAN J MED RES S, V72, P1	23	1214	1363	0	57	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 28	1999	284	5419					1520	1523		10.1126/science.284.5419.1520	http://dx.doi.org/10.1126/science.284.5419.1520			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	200PD	10348738				2022-12-28	WOS:000080548100035
J	Sandstrom, E; Wahren, B				Sandstrom, E; Wahren, B		Nordic VAC-04 Study Grp	Therapeutic immunisation with recombinant gp160 in HIV-1 infection: a randomised double-blind placebo-controlled trial	LANCET			English	Article							ACTIVE ANTIRETROVIRAL THERAPY; VIRUS TYPE-1 ENVELOPE; T-CELL RESPONSES; HUMORAL RESPONSES; IMMUNE-RESPONSES; VIRAL LOAD; IN-VIVO; IMMUNODEFICIENCY; VACCINE; IMMUNIZATION	Background. The immune system's ability to scavenge and destroy detrimental HIV-1 products has an important effect on virion production and the course of infection. In earlier trials of therapeutic immunisation with envelope protein recombinant gp160 (rgp160) we observed a transient positive effect on CD4-lymphocyte counts. This randomised placebo-controlled study investigated whether our preliminary findings represented a potential for a more benign clinical course. Methods. 835 HIV-seropositive patients from 20 centres in Sweden, Norway, and Finland with CD4-cell counts above 200/mu L were randomly assigned to receive 160 mu g rgp160 or placebo (alum adjuvant alone) every 3 months for 3 years after an induction period, as well as optimum available treatment. Analyses were by intention to treat. Findings. 63 of 416 vaccine-group patients and 61 of 419 placebo-group patients reached a primary clinical endpoint (AIDS-defining event or death), the time to first clinical endpoint did not differ between the groups (p = 0.864). Significantly fewer vaccine-group patients than placebo-group patients reached the primary immunological endpoint of a decrease of more than 30% from baseline CD4-cell count (157 vs 189, p = 0.03). A higher proportion of the vaccine group had CD4-cell counts higher than baseline at 6 months (167 vs 133, p = 0.014). HIV-1-specific T-cell immune reactivity was induced in all vaccine recipients studied. No severe adverse events associated with the vaccine were noted during the study. There were significantly fewer deaths among the vaccine recipients than among the placebo-group patients at 2 years, but not at the end of the study. Interpretation. Therapeutic immunisations with rgp160 have a modest effect on CD4-cell counts, but this treatment alone did not lead to clinical benefit when given in addition to best clinical practice at the time of the trial. Immunisation in conjunction With antiretroviral therapy was also effective, which strongly suggests that a combination with highly active therapy would improve the total effect.	Soder Hosp, Dept Dermatovenereol, S-11883 Stockholm, Sweden; Karolinska Inst, Swedish Inst Infect Dis Control, Ctr Microbiol & Tumor Biol, Stockholm, Sweden	Karolinska Institutet; Swedish Institute for Infectious Disease Control	Sandstrom, E (corresponding author), Soder Hosp, Dept Dermatovenereol, S-11883 Stockholm, Sweden.	eric.sandstrom@venh.sos.sll.se						BIRX DL, 1996, 11 INT C AIDS VANC J; BISELLI R, 1994, J ACQ IMMUN DEF SYND, V7, P1016; Bjorndal A, 1997, J VIROL, V71, P7478; Bratt G, 1998, AIDS, V12, P2193, DOI 10.1097/00002030-199816000-00015; Connors M, 1997, NAT MED, V3, P533, DOI 10.1038/nm0597-533; Corey L, 1998, J INFECT DIS, V177, P301, DOI 10.1086/514202; Eron JJ, 1996, LANCET, V348, P1547; Finzi D, 1997, SCIENCE, V278, P1295, DOI 10.1126/science.278.5341.1295; Fouts TR, 1997, J VIROL, V71, P2779, DOI 10.1128/JVI.71.4.2779-2785.1997; Harrer T, 1996, J IMMUNOL, V156, P2616; HEENEY JL, IN PRESS IMMUNOL TOD; HUGHES MD, 1994, J INFECT DIS, V169, P28, DOI 10.1093/infdis/169.1.28; Kaufmann D, 1998, LANCET, V351, P723, DOI 10.1016/S0140-6736(98)24010-4; KUNDU SK, 1992, P NATL ACAD SCI USA, V89, P11204, DOI 10.1073/pnas.89.23.11204; Leandersson AC, 1998, AIDS, V12, P157, DOI 10.1097/00002030-199802000-00005; LOOMIS LD, 1995, J ACQ IMMUN DEF SYND, V10, P13; Loomis-Price LD, 1998, J INFECT DIS, V178, P1306, DOI 10.1086/314436; PANTALEO G, 1990, P NATL ACAD SCI USA, V87, P4818, DOI 10.1073/pnas.87.12.4818; Perelson AS, 1996, SCIENCE, V271, P1582, DOI 10.1126/science.271.5255.1582; Phillips AN, 1996, SCIENCE, V271, P497, DOI 10.1126/science.271.5248.497; Pontesilli O, 1998, AIDS, V12, P473, DOI 10.1097/00002030-199805000-00008; REDFIELD RR, 1991, NEW ENGL J MED, V324, P1677, DOI 10.1056/NEJM199106133242401; Rosenberg ES, 1997, SCIENCE, V278, P1447, DOI 10.1126/science.278.5342.1447; Rowland-Jones S, 1997, ADV IMMUNOL, V65, P277, DOI 10.1016/S0065-2776(08)60745-2; SELIGMANN M, 1994, LANCET, V343, P871; SHEARER GM, 1986, J IMMUNOL, V137, P2514; TRAUGER RJ, 1998, J ACQUIR IMMUNE D S2, V10, pS74; Tsoukas CM, 1998, AIDS RES HUM RETROV, V14, P483, DOI 10.1089/aid.1998.14.483; WAHREN B, 1986, NEW ENGL J MED, V315, P393; WAHREN B, 1994, J ACQ IMMUN DEF SYND, V7, P220	30	60	62	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAY 22	1999	353	9166					1735	1742		10.1016/S0140-6736(98)06493-9	http://dx.doi.org/10.1016/S0140-6736(98)06493-9			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	202TF	10347985				2022-12-28	WOS:000080667700010
J	Zimetbaum, PJ; Josephson, ME				Zimetbaum, PJ; Josephson, ME			The evolving role of ambulatory arrhythmia monitoring in general clinical practice	ANNALS OF INTERNAL MEDICINE			English	Review							NONSUSTAINED VENTRICULAR-TACHYCARDIA; CONGESTIVE-HEART-FAILURE; IDIOPATHIC DILATED CARDIOMYOPATHY; ACUTE MYOCARDIAL-INFARCTION; PAROXYSMAL ATRIAL-FIBRILLATION; CARDIAC EVENT RECORDERS; HYPERTROPHIC CARDIOMYOPATHY; DIAGNOSTIC YIELD; ANTIARRHYTHMIC THERAPY; UNEXPLAINED SYNCOPE	Purpose: To evaluate the efficacy of various ambulatory electrocardiographic monitors for the diagnosis of arrhythmia-related disorders and to provide recommendations for their use in clinical practice. Data Sources: Studies published since 1988 were identified through search of the MEDLINE database. Study Selection: Studies that met methodologic criteria for minimal bias and had clinical relevance were selected. Data Extraction: Descriptive and analytic data from each study. Data Synthesis: Ambulatory electrocardiographic monitors, specifically-transtelephonic continuous-loop event recorders, are highly effective for establishing a diagnosis in patients with palpitations but are less effective for establishing a diagnosis in patients with syncope. Clinicians may use these devices to monitor for nonsustained ventricular tachycardia in patients at potentially high risk for sudden arrhythmic death; however, few data are available to support this practice. Ambulatory monitors are useful for assessment of the safety and efficacy of antiarrhythmic medications and the recurrence of symptomatic supraventricular arrhythmias. New ambulatory arrhythmia monitoring devices are being developed that may facilitate outpatient management of chronic cardiac disease. Conclusions: Ambulatory electrocardiographic monitors, particularly transtelephonic continuous-loop event recorders, aid in the diagnosis of symptomatic arrhythmias. These devices are also useful for monitoring the effectiveness and safety of antiarrhythmic medications. Guidelines are lacking for use of these devices to assess prognosis in patients at potential risk for sudden arrhythmic death.	Beth Israel Deaconess Med Ctr, Cardiovasc Div GZ435, Boston, MA 02215 USA; Harvard Univ, Sch Med, Boston, MA USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School	Zimetbaum, PJ (corresponding author), Beth Israel Deaconess Med Ctr, Cardiovasc Div GZ435, 330 Brookline Ave, Boston, MA 02215 USA.	pzimetba@Caregroup.harvard.edu						ANDERSON JL, 1989, CIRCULATION, V80, P1557, DOI 10.1161/01.CIR.80.6.1557; ANDERSON KP, 1978, CIRCULATION, V57, P890, DOI 10.1161/01.CIR.57.5.890; BASS EB, 1990, ARCH INTERN MED, V150, P1073, DOI 10.1001/archinte.150.5.1073; BIGGER JT, 1990, AM J CARDIOL, V65, P539, DOI 10.1016/0002-9149(90)91028-5; BIGGER JT, 1986, AM J CARDIOL, V58, P1151, DOI 10.1016/0002-9149(86)90374-7; BUXTON AE, 1984, AM J CARDIOL, V53, P1275, DOI 10.1016/0002-9149(84)90078-X; Cecchi F, 1998, HEART, V79, P331, DOI 10.1136/hrt.79.4.331; CHAKKO CS, 1985, AM HEART J, V109, P497, DOI 10.1016/0002-8703(85)90554-X; COHN JN, 1991, NEW ENGL J MED, V325, P303, DOI 10.1056/NEJM199108013250502; DIMARCO JP, 1990, ANN INTERN MED, V113, P53, DOI 10.7326/0003-4819-113-1-53; DOVAL HC, 1994, LANCET, V344, P493, DOI 10.1016/S0140-6736(94)91895-3; Doval HC, 1996, CIRCULATION, V94, P3198, DOI 10.1161/01.CIR.94.12.3198; FALK RH, 1992, ANN INTERN MED, V117, P141, DOI 10.7326/0003-4819-117-2-141; FANANAPAZIR L, 1992, CIRCULATION, V86, P730, DOI 10.1161/01.CIR.86.3.730; FETTER JG, 1995, PACE, V18, P1531, DOI 10.1111/j.1540-8159.1995.tb06739.x; FLAKER GC, 1992, J AM COLL CARDIOL, V20, P527, DOI 10.1016/0735-1097(92)90003-6; Fogel RI, 1997, AM J CARDIOL, V79, P207, DOI 10.1016/S0002-9149(96)00717-5; Friedman PL, 1996, NEW ENGL J MED, V335, P1984, DOI 10.1056/NEJM199612263352609; GOLDSCHLAGER N, 1995, CLIN CARDIAC PACING, P780; HOLMES J, 1985, AM J CARDIOL, V55, P146, DOI 10.1016/0002-9149(85)90317-0; HOLTER NJ, 1961, SCIENCE, V134, P1214, DOI 10.1126/science.134.3486.1214; HUANG SK, 1983, AM J CARDIOL, V51, P507, DOI 10.1016/S0002-9149(83)80089-7; KAPOOR WN, 1989, AM J CARDIOL, V63, P730, DOI 10.1016/0002-9149(89)90260-9; KAPOOR WN, 1991, AM J MED, V90, P91; KAPOOR WN, 1990, MEDICINE, V69, P160, DOI 10.1097/00005792-199005000-00004; KAPOOR WN, 1983, NEW ENGL J MED, V309, P197, DOI 10.1056/NEJM198307283090401; Kinlay S, 1996, ANN INTERN MED, V124, P16, DOI 10.7326/0003-4819-124-1_Part_1-199601010-00003; KLEIGER RE, 1987, AM J CARDIOL, V59, P256, DOI 10.1016/0002-9149(87)90795-8; KNOEBEL SB, 1989, J AM COLL CARDIOL, V13, P249, DOI 10.1016/0735-1097(89)90578-0; Krahn AD, 1999, CIRCULATION, V99, P406, DOI 10.1161/01.CIR.99.3.406; KRAHN AD, 1995, CIRCULATION, V92, P1819, DOI 10.1161/01.CIR.92.7.1819; KUS T, 1995, CAN J CARDIOL, V11, P891; LACROIX D, 1991, AM HEART J, V122, P1346, DOI 10.1016/0002-8703(91)90576-4; LICHSTEIN E, 1983, CIRCULATION, V67, P5; LINZER M, 1990, AM J CARDIOL, V66, P214, DOI 10.1016/0002-9149(90)90591-N; LINZER M, 1991, J GEN INTERN MED, V6, P113, DOI 10.1007/BF02598305; MARON BJ, 1992, CIRCULATION, V85, P57; MASON JW, 1993, NEW ENGL J MED, V329, P445, DOI 10.1056/NEJM199308123290701; Massie BM, 1996, CIRCULATION, V93, P2128, DOI 10.1161/01.CIR.93.12.2128; MEINERTZ T, 1984, AM J CARDIOL, V53, P902, DOI 10.1016/0002-9149(84)90522-8; MORGANROTH J, 1978, CIRCULATION, V58, P408, DOI 10.1161/01.CIR.58.3.408; MOSS AJ, 1983, NEW ENGL J MED, V309, P331, DOI 10.1056/nejm198308113090602; Moss AJ, 1996, NEW ENGL J MED, V335, P1933, DOI 10.1056/NEJM199612263352601; MUKHARJI J, 1984, AM J CARDIOL, V54, P31, DOI 10.1016/0002-9149(84)90299-6; Naccarelli GV, 1998, J CARDIOVASC ELECTR, V9, P864, DOI 10.1111/j.1540-8167.1998.tb00127.x; NERI R, 1987, AM HEART J, V113, P707, DOI 10.1016/0002-8703(87)90711-3; Nolan J, 1998, CIRCULATION, V98, P1510, DOI 10.1161/01.CIR.98.15.1510; OLSHAUSEN KV, 1988, AM J CARDIOL, V61, P146, DOI 10.1016/0002-9149(88)91321-5; PAGE RL, 1994, CIRCULATION, V89, P224, DOI 10.1161/01.CIR.89.1.224; PRITCHETT ELC, 1991, ANN INTERN MED, V114, P539, DOI 10.7326/0003-4819-114-7-539; Prystowsky EN, 1996, CIRCULATION, V93, P1262, DOI 10.1161/01.CIR.93.6.1262; REIFFEL JA, 1991, J ELECTROCARDIOL, V24, P165, DOI 10.1016/0022-0736(91)90007-9; Roden DM, 1998, AM J CARDIOL, V82, p49I, DOI 10.1016/S0002-9149(98)00472-X; SINGH SN, 1993, AM J CARDIOL, V72, pF99, DOI 10.1016/0002-9149(93)90971-E; Singh SN, 1998, J AM COLL CARDIOL, V32, P942, DOI 10.1016/S0735-1097(98)00338-6; SPIRITO P, 1994, CIRCULATION, V90, P2743, DOI 10.1161/01.CIR.90.6.2743; SUYAMA A, 1986, AM HEART J, V112, P44, DOI 10.1016/0002-8703(86)90676-9; WIGLE ED, 1995, CIRCULATION, V92, P1680, DOI 10.1161/01.CIR.92.7.1680; WILSON JR, 1983, J AM COLL CARDIOL, V2, P403, DOI 10.1016/S0735-1097(83)80265-4; WINKLE RA, 1978, CIRCULATION, V57, P1116, DOI 10.1161/01.CIR.57.6.1116; WU J, 1995, AM J CARDIOL, V75, P184, DOI 10.1016/S0002-9149(00)80075-2; Zimetbaum P, 1998, NEW ENGL J MED, V338, P1369, DOI 10.1056/NEJM199805073381907; Zimetbaum P, 1997, AM J CARDIOL, V79, P371, DOI 10.1016/S0002-9149(96)00766-7; Zimetbaum PJ, 1998, ANN INTERN MED, V128, P890, DOI 10.7326/0003-4819-128-11-199806010-00002; Zimetbaum PJ, 1999, AM J CARDIOL, V83, P450, DOI 10.1016/S0002-9149(98)00885-6	65	87	95	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAY 18	1999	130	10					848	856		10.7326/0003-4819-130-10-199905180-00020	http://dx.doi.org/10.7326/0003-4819-130-10-199905180-00020			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	196JJ	10366376				2022-12-28	WOS:000080305000009
J	Timsit, JF; Bruneel, F; Cheval, C; Mamzer, MF; Garrouste-Orgeas, M; Wolff, M; Misset, B; Chevret, S; Regnier, B; Carlet, J				Timsit, JF; Bruneel, F; Cheval, C; Mamzer, MF; Garrouste-Orgeas, M; Wolff, M; Misset, B; Chevret, S; Regnier, B; Carlet, J			Use of tunneled femoral catheters to prevent catheter-related infection - A randomized, controlled trial	ANNALS OF INTERNAL MEDICINE			English	Article						catheterization, central venous; femoral vein; infection control; sepsis; bacteremia	CRITICALLY ILL ADULTS; VENOUS CATHETERS; SEPSIS; MULTICENTER; DIAGNOSIS; CULTURES	Background: The risk for catheter-related infection seems higher with femoral catheters than with catheters inserted at other sites. Objective: To evaluate the effect of catheter tunneling on femoral catheter-related infection in critically ill patients. Design: Randomized, controlled trial. Setting: Three intensive care units at academic hospitals in Paris, France. Patients: 345 adult patients requiring a femoral venous catheter for more than 48 hours. Intervention: Tunneled or nontunneled femoral catheters. Measurements: Time to occurrence of systemic catheter-related sepsis, catheter-related bloodstream infection, and quantitative catheter tip culture with a cutoff of 10(3) colony-forming units/mL. Results: Of 345 randomly assigned patients, 336 were evaluable. Probable systemic catheter-related sepsis occurred in 15 of 168 patients who received a nontunneled femoral catheter (controls) and in 5 of 168 patients who received a tunneled femoral catheter (estimated absolute risk reduction, 6% [95% CI, 0.9% to 11%]). Time to occurrence of catheter-related bloodstream infection was not significantly modified (relative risk, 0.28 [CI, 0.03 to 1.92]; P = 0.18); 3 events occurred in the control group and 1 event occurred in the tunneled-catheter group. After stratification by treatment center and adjustment for variables that were prognostic (use of broad-spectrum antimicrobial agents at catheter insertion) or imbalanced between both groups (mechanical ventilation at insertion), tunnelized catheterization reduced the proportion of patients who developed systemic catheter-related sepsis (relative risk, 0.25 [CI, 0.09 to 0.72]; P = 0.005) and positive quantitative culture of the catheter tip (relative risk, 0.48 [CI, 0.23 to 0.99]; P = 0.045). Conclusion: The incidence of femoral catheter-related infections in critically ill patients can be reduced by using subcutaneous tunneling.	Hop St Joseph, F-75014 Paris, France; Hop Bichat Claude Bernard, F-75877 Paris 18, France; Hop Necker Enfants Malad, F-75013 Paris, France; Hop St Louis, Dept Biostat, F-75010 Paris, France	Hopital Paris Saint-Joseph; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bichat-Claude Bernard - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; UDICE-French Research Universities; Universite Paris Cite	Timsit, JF (corresponding author), Hop St Joseph, 185 Rue Raymond Losserand, F-75014 Paris, France.		Mamzer, Marie-France/V-1713-2017; Misset, Benoit/P-7817-2018	Mamzer, Marie-France/0000-0001-7570-1803; Misset, Benoit/0000-0001-6466-0065; chevret, sylvie/0000-0001-6449-4730				BJORNSON HS, 1982, SURGERY, V92, P720; BRUNBUISSON C, 1987, ARCH INTERN MED, V147, P873, DOI 10.1001/archinte.147.5.873; CHASTANG C, 1988, STAT MED, V7, P1243, DOI 10.1002/sim.4780071205; Durbec O, 1997, CRIT CARE MED, V25, P1986, DOI 10.1097/00003246-199712000-00014; FAN ST, 1988, J HOSP INFECT, V12, P191, DOI 10.1016/0195-6701(88)90006-0; GAIL M, 1985, BIOMETRICS, V41, P361, DOI 10.2307/2530862; KNAUS WA, 1985, CRIT CARE MED, V13, P818, DOI 10.1097/00003246-198510000-00009; LEGALL JR, 1993, JAMA-J AM MED ASSOC, V270, P2957, DOI 10.1001/jama.270.24.2957; LINARES J, 1985, J CLIN MICROBIOL, V21, P357; MAKI DG, 1977, NEW ENGL J MED, V296, P1305, DOI 10.1056/NEJM197706092962301; Mermel L, 1998, CRIT CARE MED, V26, P1315, DOI 10.1097/00003246-199808000-00011; Pearson ML, 1996, INFECT CONT HOSP EP, V17, P438; RAAD II, 1992, CLIN INFECT DIS, V15, P197, DOI 10.1093/clinids/15.2.197; Randolph AG, 1998, CRIT CARE MED, V26, P1452, DOI 10.1097/00003246-199808000-00038; SEGURA M, 1993, CLIN NUTR, V12, P103, DOI 10.1016/0261-5614(93)90059-D; Smyrnios NA, 1997, CRIT CARE MED, V25, P1943, DOI 10.1097/00003246-199712000-00005; Timsit JF, 1996, JAMA-J AM MED ASSOC, V276, P1416, DOI 10.1001/jama.276.17.1416; TROTTIER SJ, 1995, CRIT CARE MED, V23, P52, DOI 10.1097/00003246-199501000-00011; WILLIAMS JF, 1991, CRIT CARE MED, V19, P550, DOI 10.1097/00003246-199104000-00016	19	72	75	0	3	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAY 4	1999	130	9					729	+		10.7326/0003-4819-130-9-199905040-00004	http://dx.doi.org/10.7326/0003-4819-130-9-199905040-00004			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	192DE	10357691				2022-12-28	WOS:000080062300003
J	Klootwijk, P; Hamm, C				Klootwijk, P; Hamm, C			Acute coronary syndromes: diagnosis	LANCET			English	Article							CARDIAC TROPONIN-T; ACUTE MYOCARDIAL-INFARCTION; UNSTABLE ANGINA-PECTORIS; EARLY RISK STRATIFICATION; ACUTE CHEST PAIN; PROGNOSTIC VALUE; ARTERY DISEASE; ANALYTICAL PERFORMANCE; RECURRENT ISCHEMIA; ELECTROCARDIOGRAM		Erasmus Univ, Hosp Dijkzigt, Heartctr Rotterdam, Div Cardiol,Thoraxctr, NL-3000 CA Rotterdam, Netherlands; Kerckhoff Clin, Bad Nauheim, Germany; Max Planck Inst Physiol & Clin Res, D-6350 Bad Nauheim, Germany	Erasmus University Rotterdam; Erasmus MC; Kerckhoff Clinic; Max Planck Society	Klootwijk, P (corresponding author), Erasmus Univ, Hosp Dijkzigt, Heartctr Rotterdam, Div Cardiol,Thoraxctr, H304,POB 2040, NL-3000 CA Rotterdam, Netherlands.		Hamm, Christian W./I-3155-2017	Hamm, Christian W./0000-0001-6763-4161				Andersen K, 1996, CORONARY ARTERY DIS, V7, P753, DOI 10.1097/00019501-199610000-00008; [Anonymous], 1994, Circulation, V89, P1545; Antman EM, 1996, NEW ENGL J MED, V335, P1342, DOI 10.1056/NEJM199610313351802; Armstrong PW, 1998, CIRCULATION, V98, P1860, DOI 10.1161/01.CIR.98.18.1860; BAKKER AJ, 1993, LANCET, V342, P1220, DOI 10.1016/0140-6736(93)92192-V; Bazzino O, 1998, NEW ENGL J MED, V338, P1498; Bazzino O, 1998, NEW ENGL J MED, V338, P1488; Boden WE, 1998, NEW ENGL J MED, V338, P1785, DOI 10.1056/NEJM199806183382501; BRAUNWALD E, 1989, CIRCULATION, V80, P410, DOI 10.1161/01.CIR.80.2.410; Braunwald E, 1998, CIRCULATION, V98, P2219, DOI 10.1161/01.CIR.98.21.2219; Cannon Christopher P., 1995, Circulation, V92, pI19; Cannon CP, 1997, J AM COLL CARDIOL, V30, P133, DOI 10.1016/S0735-1097(97)00160-5; COHEN M, 1991, AM J CARDIOL, V67, P1368, DOI 10.1016/0002-9149(91)90467-Y; DARGIE HJ, 1993, EUR HEART J, V14, P969; Davies E, 1997, CLIN BIOCHEM, V30, P479, DOI 10.1016/S0009-9120(97)00111-2; DELLBORG M, 1991, J ELECTROCARDIOL, V23, P11, DOI 10.1016/0022-0736(90)90067-C; DEZWAAN C, 1982, AM HEART J, V103, P730, DOI 10.1016/0002-8703(82)90480-X; FALK E, 1985, CIRCULATION, V71, P699, DOI 10.1161/01.CIR.71.4.699; Galvani M, 1997, CIRCULATION, V95, P2053, DOI 10.1161/01.CIR.95.8.2053; Geleijnse ML, 1997, CIRCULATION, V96, P137; GORGELS APM, 1993, AM J CARDIOL, V72, P999, DOI 10.1016/0002-9149(93)90852-4; GOTTLIEB SO, 1986, AM J MED, V81, P7, DOI 10.1016/0002-9343(86)90972-1; GOTTLIEB SO, 1986, NEW ENGL J MED, V314, P1214, DOI 10.1056/NEJM198605083141903; *GUSTO, 1996, NEW ENGL J MED, V12, P335; Hamm CW, 1998, J AM COLL CARDIOL, V31, p185A, DOI 10.1016/S0735-1097(97)84512-3; Hamm CW, 1997, NEW ENGL J MED, V337, P1648, DOI 10.1056/NEJM199712043372302; HAMM CW, 1992, NEW ENGL J MED, V327, P146, DOI 10.1056/NEJM199207163270302; Heeschen C, 1998, CLIN CHEM, V44, P1925; Holmvang L, 1999, AM HEART J, V137, P24, DOI 10.1016/S0002-8703(99)70456-4; Kampmann M, 1997, CLIN CHEM, V43, P244; KATUS HA, 1992, CLIN CHEM, V38, P386; KERNS JR, 1993, ANN EMERG MED, V22, P794, DOI 10.1016/S0196-0644(05)80793-0; Klootwijk P, 1998, CIRCULATION, V98, P1358, DOI 10.1161/01.CIR.98.14.1358; KLOOTWIJK P, 1998, THESIS ERASMUS U ROT; LEWIS WR, 1994, AM J CARDIOL, V74, P987, DOI 10.1016/0002-9149(94)90845-1; Lindahl B, 1997, EUR HEART J, V18, P762; Lindahl B, 1997, J AM COLL CARDIOL, V29, P43, DOI 10.1016/S0735-1097(96)00447-0; Lindahl B, 1996, CIRCULATION, V93, P1651, DOI 10.1161/01.CIR.93.9.1651; Lloyd-Jones D, 1998, AM J CARDIOL, V81, P1182, DOI 10.1016/S0002-9149(98)00155-6; Luscher MS, 1997, CIRCULATION, V96, P2578, DOI 10.1161/01.CIR.96.8.2578; Morrow DA, 1998, J AM COLL CARDIOL, V31, P1460, DOI 10.1016/S0735-1097(98)00136-3; NYMAN I, 1993, J INTERN MED, V234, P293, DOI 10.1111/j.1365-2796.1993.tb00746.x; Ohman EM, 1996, NEW ENGL J MED, V335, P1333, DOI 10.1056/NEJM199610313351801; Patel DJ, 1998, EUR HEART J, V19, P240, DOI 10.1053/euhj.1997.0586; Patel DJ, 1996, HEART, V75, P222, DOI 10.1136/hrt.75.3.222; Polanczyk CA, 1998, AM J CARDIOL, V81, P288, DOI 10.1016/S0002-9149(97)00897-7; RAVKILDE J, 1995, J AM COLL CARDIOL, V25, P574, DOI 10.1016/0735-1097(94)00430-X; SAVONITTO S, 1997, EUR HEART J SUPPL, V18, P812; Simoons ML, 1997, LANCET, V349, P1429; van Domburg RT, 1998, EUR HEART J, V19, P1034, DOI 10.1053/euhj.1998.1011; VANMILTENBURGVANZIJL AJM, 1995, J AM COLL CARDIOL, V25, P1286, DOI 10.1016/0735-1097(95)00009-S; VONMILTENBURGVA.AJ, 1992, THESIS ERASMUS U ROT; WU AHB, 1995, AM J CARDIOL, V76, P970, DOI 10.1016/S0002-9149(99)80274-4	53	10	12	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet		1999	353			2			SII10	SII15						6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	205GJ	10374760				2022-12-28	WOS:000080812700003
J	Schwartz, T; Rould, MA; Lowenhaupt, K; Herbert, A; Rich, A				Schwartz, T; Rould, MA; Lowenhaupt, K; Herbert, A; Rich, A			Crystal structure of the Z alpha domain of the human editing enzyme ADAR1 bound to left-handed Z-DNA	SCIENCE			English	Article							RNA ADENOSINE-DEAMINASE; DOUBLE HELICAL DNA; MOLECULAR-STRUCTURE; ATOMIC RESOLUTION; BINDING DOMAIN; TRANSCRIPTION; RECOGNITION; PROTEINS; COMPLEX; NUCLEI	The editing enzyme double-stranded RNA adenosine deaminase includes a DNA binding domain, Z alpha, which is specific for Left-handed Z-DNA, The 2.1 angstrom crystal structure of Z alpha complexed to DNA reveals that the substrate is in the left-handed Z conformation. The contacts between Z alpha and Z-DNA are made primarily with the "zigzag" sugar-phosphate backbone, which provides a basis for the specificity for the Z conformation. A single base contact is observed to guanine in the syn conformation, characteristic of Z-DNA. Intriguingly, the helix-turn-helix motif, frequently used to recognize B-DNA, is used by Z alpha to contact Z-DNA.	MIT, Dept Biol, Cambridge, MA 02139 USA; Univ Vermont, Dept Mol Physiol & Biophys, Burlington, VT 05405 USA	Massachusetts Institute of Technology (MIT); University of Vermont	Rich, A (corresponding author), MIT, Dept Biol, 77 Massachusetts Ave, Cambridge, MA 02139 USA.		Schwartz, Thomas/ABA-1770-2021; Herbert, Alan/AAY-4286-2020	Schwartz, Thomas/0000-0001-8012-1512; Herbert, Alan/0000-0002-0093-1572; /0000-0002-8187-6498				Berger I, 1998, BIOCHEMISTRY-US, V37, P13313, DOI 10.1021/bi9813126; Brunger A. T., 1992, XPLOR VERSION 3 1 SY; BURLEY SK, 1988, ADV PROTEIN CHEM, V39, P125; Chan SK, 1997, NATURE, V388, P634, DOI 10.1038/41692; CLARK KL, 1993, NATURE, V364, P412, DOI 10.1038/364412a0; Cook WJ, 1998, J MOL BIOL, V275, P337, DOI 10.1006/jmbi.1997.1443; Cowtan KD, 1996, ACTA CRYSTALLOGR D, V52, P43, DOI 10.1107/S090744499500761X; Draper DE, 1999, NUCLEIC ACIDS RES, V27, P381, DOI 10.1093/nar/27.2.381; Esnouf RM, 1997, J MOL GRAPH MODEL, V15, P132, DOI 10.1016/S1093-3263(97)00021-1; Fraenkel E, 1998, J MOL BIOL, V284, P351, DOI 10.1006/jmbi.1998.2147; GESSNER RV, 1989, J BIOL CHEM, V264, P7921; HARRISON SC, 1990, ANNU REV BIOCHEM, V59, P933, DOI 10.1146/annurev.bi.59.070190.004441; Herbert A, 1998, NUCLEIC ACIDS RES, V26, P3486, DOI 10.1093/nar/26.15.3486; Herbert A, 1997, P NATL ACAD SCI USA, V94, P8421, DOI 10.1073/pnas.94.16.8421; HERBERT A, 1995, P NATL ACAD SCI USA, V92, P7550, DOI 10.1073/pnas.92.16.7550; HERBERT AG, 1993, P NATL ACAD SCI USA, V90, P3339, DOI 10.1073/pnas.90.8.3339; HERBERT AG, 1993, NUCLEIC ACIDS RES, V21, P2669, DOI 10.1093/nar/21.11.2669; Herbert JM, 1996, J BIOL CHEM, V271, P25928; KLEMM JD, 1994, CELL, V77, P21, DOI 10.1016/0092-8674(94)90231-3; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Lilley D. M. J., 1995, DNA PROTEIN STRUCTUR; LIU LF, 1987, P NATL ACAD SCI USA, V84, P7024, DOI 10.1073/pnas.84.20.7024; Maas S, 1997, CURR OPIN CELL BIOL, V9, P343, DOI 10.1016/S0955-0674(97)80006-3; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; MORRIS AL, 1992, PROTEINS, V12, P345, DOI 10.1002/prot.340120407; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; PABO CO, 1992, ANNU REV BIOCHEM, V61, P1053, DOI 10.1146/annurev.bi.61.070192.005201; RAMAKRISHNAN V, 1993, NATURE, V362, P219, DOI 10.1038/362219a0; Schade M, 1999, EMBO J, V18, P470, DOI 10.1093/emboj/18.2.470; SCHADE M, UNPUB; SCHULTZ SC, 1991, SCIENCE, V253, P1001, DOI 10.1126/science.1653449; Schwartz T, 1999, J BIOL CHEM, V274, P2899, DOI 10.1074/jbc.274.5.2899; SCHWARTZ T, IN PRESS ACTA CRYSTA; Terwilliger TC, 1996, ACTA CRYSTALLOGR D, V52, P749, DOI 10.1107/S0907444996000832; Wah DA, 1997, NATURE, V388, P97, DOI 10.1038/40446; WANG AHJ, 1979, NATURE, V282, P680, DOI 10.1038/282680a0; WANG AHJ, 1981, SCIENCE, V211, P171, DOI 10.1126/science.7444458; WITTIG B, 1992, EMBO J, V11, P4653, DOI 10.1002/j.1460-2075.1992.tb05567.x; WITTIG B, 1991, P NATL ACAD SCI USA, V88, P2259, DOI 10.1073/pnas.88.6.2259; XU HE, IN PRESS GENES DEV	41	282	296	0	23	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 11	1999	284	5421					1841	1845		10.1126/science.284.5421.1841	http://dx.doi.org/10.1126/science.284.5421.1841			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	205EU	10364558				2022-12-28	WOS:000080809000052
J	Merrow, M; Brunner, M; Roenneberg, T				Merrow, M; Brunner, M; Roenneberg, T			Assignment of circadian function for the Neurospora clock gene frequency	NATURE			English	Article							TEMPERATURE COMPENSATION; BLUE-LIGHT; CRYPTOCHROME; RHYTHM; PHOTORESPONSES; PHOTORECEPTOR; DROSOPHILA; CRASSA; SYSTEM	Circadian clocks consist of three elements: entrainment pathways (inputs), the mechanism generating the rhthmicity (oscillator), and the output pathways that control the circadian rhythms. It is difficult to assign molecular clock components to any one of these elements. Experiments show that inputs can be circadianly regulated(1-3) and outputs can feed back on the oscillator(4,5), Mathematical simulations indicate that under- or overexpression of a gene product can result in arrhythmicity, whether the protein is part of the oscillator or substantially Dart of a rhythmically expressed input pathway(6). To distinguish between these two possibilities, we used traditional circadian entrainment protocols(7,8) on a genetic model system, Neurospora crassa.	Univ Munich, Inst Med Psychol, D-80336 Munich, Germany; Univ Munich, Inst Physiol Chem, D-80336 Munich, Germany	University of Munich; University of Munich	Merrow, M (corresponding author), Univ Munich, Inst Med Psychol, Goethestr 31-33, D-80336 Munich, Germany.			Brunner, Michael/0000-0001-9798-3047				ARONSON BD, 1994, P NATL ACAD SCI USA, V91, P7683, DOI 10.1073/pnas.91.16.7683; ARONSON BD, 1994, SCIENCE, V263, P1578, DOI 10.1126/science.8128244; ARPAIA G, 1993, PLANT PHYSIOL, V102, P1299, DOI 10.1104/pp.102.4.1299; ASCHOFF J, 1981, P 13 INT C SOC CHRON, P105; Aschoff J, 1981, BIOL RHYTHMS; BLOCK G, 1995, CELLULAR ANAL MOLLUS, P51; BRUCE VG, 1960, COLD SPRING HARB SYM, V25, P29, DOI 10.1101/SQB.1960.025.01.005; Chang B, 1997, J PLANT RES, V110, P449, DOI 10.1007/BF02506805; CROSTHWAITE SK, 1995, CELL, V81, P1003, DOI 10.1016/S0092-8674(05)80005-4; Crosthwaite SK, 1997, SCIENCE, V276, P763, DOI 10.1126/science.276.5313.763; DHARMANANDA S, 1980, STUDIES CIRCADIAN CL; Emery P, 1998, CELL, V95, P669, DOI 10.1016/S0092-8674(00)81637-2; FELDMAN J F, 1973, Genetics, V75, P605; Garceau NY, 1997, CELL, V89, P469, DOI 10.1016/S0092-8674(00)80227-5; Lakin-Thomas PL, 1998, J BIOL RHYTHM, V13, P268, DOI 10.1177/074873098129000101; Liu Y, 1998, SCIENCE, V281, P825, DOI 10.1126/science.281.5378.825; Loros J J, 1986, J Biol Rhythms, V1, P187, DOI 10.1177/074873048600100302; Merrow MW, 1997, P NATL ACAD SCI USA, V94, P3877, DOI 10.1073/pnas.94.8.3877; MERROW MW, 1994, EMBO J, V13, P2257, DOI 10.1002/j.1460-2075.1994.tb06507.x; MROSOVSKY N, 1992, J BIOL RHYTHM, V7, P41, DOI 10.1177/074873049200700104; Roenneberg T, 1997, PLANTA, V202, P494, DOI 10.1007/s004250050154; Roenneberg T, 1998, J BIOL RHYTHM, V13, P167, DOI 10.1177/074873098129000011; Roenneberg T, 1997, PHOTOCHEM PHOTOBIOL, V66, P549, DOI 10.1111/j.1751-1097.1997.tb03188.x; ROENNEBERG T, IN PRESS METHODS ENZ, V305; RUSSO VEA, 1988, J PHOTOCH PHOTOBIO B, V2, P59, DOI 10.1016/1011-1344(88)85037-1; SARGENT ML, 1966, PLANT PHYSIOL, V41, P1343, DOI 10.1104/pp.41.8.1343; Somers DE, 1998, DEVELOPMENT, V125, P485; Stanewsky R, 1998, CELL, V95, P681, DOI 10.1016/S0092-8674(00)81638-4; Thresher RJ, 1998, SCIENCE, V282, P1490, DOI 10.1126/science.282.5393.1490; WINFREE AT, 1974, SCIENCE, V183, P970, DOI 10.1126/science.183.4128.970	30	185	185	0	11	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUN 10	1999	399	6736					584	586		10.1038/21190	http://dx.doi.org/10.1038/21190			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	204RR	10376598	Green Published			2022-12-28	WOS:000080778400055
J	Ahmed, T; Ali, M; Choudhary, IA; Haque, ME; Salam, MA; Rabbani, GH; Suskind, RM; Fuchs, GJ				Ahmed, T; Ali, M; Choudhary, IA; Haque, ME; Salam, MA; Rabbani, GH; Suskind, RM; Fuchs, GJ			Mortality in severely malnourished children with diarrhoea and use of a standardised management protocol	LANCET			English	Article							MALNUTRITION	Background. Severely malnourished children have high mortality rates. Death commonly occurs during the first 48 h after hospital admission, and has been attributed to faulty case-management. We developed a standardised protocol for acute-phase treatment of children with severe malnutrition and diarrhoea, with the aim of reducing mortality. Methods. We compared severely malnourished children with diarrhoea aged 0-5 years managed by non protocol conventional treatment, and those treated by our standardised protocol that included slow rehydration with an emphasis on oral rehydration. The standardised-protocol group included children admitted to the ICDDR,B Hospital, Dhaka between Jan 1, 1997, and June 30, 1997, while those admitted between Jan 1, 1996, and June 30, 1996, before the protocol was implemented, were the non-protocol group. Findings. Characteristics on admission of children on standardised protocol (n = 334) and non-protocol children (n = 293) were similar except that more children on standardised protocol had oedema, acidosis, and Vibrio cholerae isolated from stools. 199 (59.9%) of children on standardised protocol were successfully rehydrated with oral rehydration solution, compared with 85 (29%) in the nonprotocol group (p < 0.0001). Use of expensive antibiotics was less frequent in children on standardised protocol than in the other group (p < 0.0001). Children on standardised protocol had fewer episodes of hypoglycaemia than non-protocol children (15 vs 30, p = 0.005). 49 (17%) of children on nonprotocol treatment died, compared with 30 (9%) children on standardised protocol (odds ratio for mortality, 0.49, 95% CI 0.3-0.8, p = 0.003). Interpretation. Compared with non-protocol management, our standardised protocol resulted in fewer episodes of hypoglycaemia, less need for intravenous fluids, and a 47% reduction in mortality. This standardised protocol should be considered in all children with diarrhoea and severe malnutrition.	Int Ctr Diarrhoeal Dis Res, Ctr Hlth & Populat Res, Div Clin Sci, Dhaka 1000, Bangladesh; Louisiana State Univ, Dept Paediat, Sch Med, New Orleans, LA 70112 USA	International Centre for Diarrhoeal Disease Research (ICDDR); Louisiana State University System	Fuchs, GJ (corresponding author), Int Ctr Diarrhoeal Dis Res, Ctr Hlth & Populat Res, Div Clin Sci, GPO Box 128, Dhaka 1000, Bangladesh.	gfuchs@icddrb.org	Fuchs, George/GLV-1285-2022	Fuchs, George/0000-0002-8679-8265				BRIEND A, 1993, EUR J CLIN NUTR, V47, P750; ELMOUGI M, 1988, J PEDIATR GASTR NUTR, V7, P572, DOI 10.1097/00005176-198807000-00016; Friedman LM, 1985, FUNDAMENTALS CLIN TR; GEHAN EA, 1974, NEW ENGL J MED, V290, P198, DOI 10.1056/NEJM197401242900405; GERSONY WM, 1987, NELSON TXB PEDIAT, P1018; Hennekens C.H., 1987, EPIDEMIOLOGY MED; Schofield C, 1996, B WORLD HEALTH ORGAN, V74, P223; SUSKIND D, 1990, NESTLE NUTR WORKS SE, V19, P1; *WHO, 1992, MAN PAT DIARRH PROGR; World Health Organization, 1990, AC RESP INF CHILDR C; World Health Organization, 1997, STRAT PREV BLINDN NA; World Health Organization, 1999, MAN SEV MALN MAN PHY	12	186	189	0	4	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	JUN 5	1999	353	9168					1919	1922		10.1016/S0140-6736(98)07499-6	http://dx.doi.org/10.1016/S0140-6736(98)07499-6			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	202TP	10371570				2022-12-28	WOS:000080668500011
J	Levy, Y; Capitant, C; Houhou, S; Carriere, I; Viard, JP; Goujard, C; Gastaut, JA; Oksenhendler, E; Boumsell, L; Gomard, E; Rabian, C; Weiss, L; Guillet, JG; Delfraissy, JF; Aboulker, JP; Seligmann, M				Levy, Y; Capitant, C; Houhou, S; Carriere, I; Viard, JP; Goujard, C; Gastaut, JA; Oksenhendler, E; Boumsell, L; Gomard, E; Rabian, C; Weiss, L; Guillet, JG; Delfraissy, JF; Aboulker, JP; Seligmann, M		ANRS 048 Study Grp	Comparison of subcutaneous and intravenous interleukin-2 in asymptomatic HIV-1 infection: a randomised controlled trial	LANCET			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; TYPE-1 INFECTION; ANTIRETROVIRAL THERAPY; IMMUNE-RESPONSE; T-LYMPHOCYTES; DISEASE; CD28; EXPRESSION; INCREASES; EFFICACY	Background. Intermittent interleukin-2 therapy for HIV-l by continuous intravenous infusion leads to sustained increase of CD4 T cells. This method of administration is, however, inconvenient and has limiting toxic effects. We did a randomised study to compare safety and efficacy of antiviral treatment alone or combined with various interleukin-2 regimens in HIV-1-infected patients. Methods. 94 symptom-free patients, naive to antiretroviral treatment, with CD4-T-cell counts of 250-550 cells/mu l at baseline were randomly assigned zidovudine and didanosine alone (n = 26) or combined with interleukin-2 administered intravenously (12 million IU/day, n = 22) or subcutaneously (3 million IU/m(2) twice daily, n = 24) for 5 days, or were given polyethyleneglycol-modified (PEG) interleukin-2 (2 million IU/m(2) intravenous bolus, n = 22) administered every 2 months from week 2 to week 50 (seven cycles). Safety and immunological and virological results were monitored until week 56. Findings. CD4-T-cell count increased to higher than baseline by a mean of 564 cells/mu L (subcutaneous group), 676 cells/mu L (intravenous group), 105 cells/mu L (PEG group), and 55 cells/mu L (antiretroviral-therapy group, p = 0.0001). 68% and 77% of patients in the subcutaneous and intravenous; groups, respectively, achieved an 80% increase of CD4 T cells (p < 0.001). In these two groups, 50% of patients restored a CD4/CD8-T-cell ratio of more than 1. The groups did not differ significantly for changes in plasma HIV-1 RNP, loads throughout the study. The duration of common side-effects of interleukin-2 was shorter in the subcutaneous group, which enabled outpatient treatment. Naive and memory CD4 T cells, CD28 expression on CD4 and CD8 T cells, and restoration of in-vitro proliferative response to mitogens and recall antigens increased in the intravenous and subcutaneous groups. Interpretation. Subcutaneous interleukin-2 is a convenient regimen that, as well as intravenous therapy, improves immunological function in HIV-l-infected patients receiving two nucleosides. Larger studies are needed to show whether immunological improvements translate into clinical benefit.	Hop Henri Mondor, Unite Immunol Clin, F-94010 Creteil, France; INSERM, Villejuif, France; ANRS, Study Grp 048, Paris, France	Assistance Publique Hopitaux Paris (APHP); Universite Paris-Est-Creteil-Val-de-Marne (UPEC); Hopital Universitaire Henri-Mondor - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm)	Levy, Y (corresponding author), Hop Henri Mondor, Unite Immunol Clin, F-94010 Creteil, France.	yves.levy@hmn.aphop-paris.fr	WEISS, Laurence/B-1373-2012; Carrière, Isabelle/W-8728-2019	Carriere, Isabelle/0000-0002-3617-0752				[Anonymous], 1996, Lancet, V348, P283; Autran B, 1997, SCIENCE, V277, P112, DOI 10.1126/science.277.5322.112; Barker E, 1997, J IMMUNOL, V159, P5123; BORTHWICK NJ, 1994, AIDS, V8, P431, DOI 10.1097/00002030-199404000-00004; BRINCHMANN JE, 1994, J INFECT DIS, V169, P730, DOI 10.1093/infdis/169.4.730; Carr A, 1998, J INFECT DIS, V178, P992, DOI 10.1086/515653; Connors M, 1997, NAT MED, V3, P533, DOI 10.1038/nm0597-533; Dalod M, 1996, AIDS RES HUM RETROV, V12, P497, DOI 10.1089/aid.1996.12.497; Dalod M, 1998, J INFECT DIS, V178, P61, DOI 10.1086/515587; Davey RT, 1997, J INFECT DIS, V175, P781, DOI 10.1086/513971; De Paoli P, 1997, J CLIN INVEST, V100, P2737, DOI 10.1172/JCI119819; Kelleher AD, 1996, J INFECT DIS, V173, P321, DOI 10.1093/infdis/173.2.321; Kovacs JA, 1996, NEW ENGL J MED, V335, P1350, DOI 10.1056/NEJM199610313351803; KOVACS JA, 1995, NEW ENGL J MED, V332, P567, DOI 10.1056/NEJM199503023320904; Li TS, 1998, LANCET, V351, P1682, DOI 10.1016/S0140-6736(97)10291-4; PANTALEO G, 1995, ANNU REV IMMUNOL, V13, P487, DOI 10.1146/annurev.immunol.13.1.487; Perelson AS, 1997, NATURE, V387, P188, DOI 10.1038/387188a0; Rosenberg ES, 1997, SCIENCE, V278, P1447, DOI 10.1126/science.278.5342.1447; Schiavon V, 1996, TISSUE ANTIGENS, V48, P312, DOI 10.1111/j.1399-0039.1996.tb02650.x; SMITH KA, 1988, SCIENCE, V240, P1169, DOI 10.1126/science.3131876; TEPPLER H, 1993, J INFECT DIS, V167, P291, DOI 10.1093/infdis/167.2.291; TEPPLER H, 1993, J EXP MED, V177, P483, DOI 10.1084/jem.177.2.483; VANHAM G, 1993, J ACQ IMMUN DEF SYND, V6, P749; WOOD R, 1993, J INFECT DIS, V167, P519, DOI 10.1093/infdis/167.3.519	24	135	138	0	6	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUN 5	1999	353	9168					1923	1929		10.1016/S0140-6736(98)07345-0	http://dx.doi.org/10.1016/S0140-6736(98)07345-0			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	202TP	10371571				2022-12-28	WOS:000080668500012
J	Manns, A; Hisada, M; La Grenade, L				Manns, A; Hisada, M; La Grenade, L			Human T-lymphotropic virus type I infection	LANCET			English	Review							TROPICAL SPASTIC PARAPARESIS; CELL LEUKEMIA-VIRUS; POLYMERASE CHAIN-REACTION; TRINIDAD-AND-TOBAGO; HTLV-I; C RETROVIRUS; RISK-FACTORS; MOLECULAR MECHANISMS; CHILD TRANSMISSION; BLOOD-TRANSFUSION	Human T-cell lymphotropic virus type I (HTLV-I) is the first human retrovirus to be associated with malignant disease-namely, adult T-cell leukaemia/lymphoma. HTLV-I has also been associated with several non-malignant conditions, notably the chronic neurodegenerative disorder, HTLV-I associated myelopathy (also known as tropical spastic paraparesis), infective dermatitis of children and uveitis. More recent evidence points to disease associations not previously linked to HTLV-I. Thus, the disease spectrum of HTLV-I is not fully known. HTLV-I has a worldwide distribution with major endemic foci in the Caribbean and southern Japan. The public health importance is confirmed by the major routes of transmission, which are mother-to-child, blood transfusion, and sexual activity. Unfortunately, no vaccine is available yet and there is no proven treatment for advanced HTLV-I disease.	NCI, Viral Epidemiol Branch, Div Canc Epidemiol & Genet, Bethesda, MD 20892 USA; Univ W Indies, Dept Med, Kingston 7, Jamaica	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); University West Indies Mona Jamaica	Manns, A (corresponding author), 6120 Execut Blvd,Room 8008,MSC 7248, Rockville, MD 20852 USA.	mannsa@epndce.nci.nih.gov						[Anonymous], 1996, IARC Monogr Eval Carcinog Risks Hum, V67, P1; Arisawa K, 1998, JPN J CANCER RES, V89, P797, DOI 10.1111/j.1349-7006.1998.tb00631.x; Bartholomew C, 1998, J Hum Virol, V1, P302; BARTHOLOMEW C, 1986, LANCET, V2, P99; Bartholomew C, 1997, ANN NEUROL, V41, P806, DOI 10.1002/ana.410410617; BEILKE MA, 1995, AM J OPHTHALMOL, V119, P104, DOI 10.1016/S0002-9394(14)73827-9; BLATTNER WA, 1990, J ACQ IMMUN DEF SYND, V3, P1102; BLATTNER WA, 1989, HUMAN RETROVIROLOGY; CANN AJ, 1996, FIELDS VIROLOGY; CLEGHORN FR, 1995, JNCI-J NATL CANCER I, V87, P1009, DOI 10.1093/jnci/87.13.1009; CRUICKSHANK E K, 1956, West Indian Med J, V5, P147; DAENKE S, 1990, J VIROL, V64, P1278, DOI 10.1128/JVI.64.3.1278-1282.1990; DEOLIVEIRA MSP, 1995, INT J CANCER, V60, P823, DOI 10.1002/ijc.2910600617; DETHE G, 1993, AIDS RES HUM RETROV, V9, P381, DOI 10.1089/aid.1993.9.381; deThe G, 1996, J ACQ IMMUN DEF SYND, V13, pS191, DOI 10.1097/00042560-199600001-00029; deThe G, 1996, J ACQ IMMUN DEF SYND, V13, pS1, DOI 10.1097/00042560-199600001-00001; Figueroa JP, 1997, J ACQ IMMUN DEF SYND, V15, P232, DOI 10.1097/00042560-199707010-00007; FLIER JS, 1993, NEW ENGL J MED, V328, P1173; FRANCHINI G, 1995, BLOOD, V86, P3619, DOI 10.1182/blood.V86.10.3619.bloodjournal86103619; FURUKAWA Y, 1995, BLOOD, V85, P1865, DOI 10.1182/blood.V85.7.1865.bloodjournal8571865; GALLO RC, 1983, CANCER RES, V43, P3892; GALLO RC, 1995, NEW ENGL J MED, V332, P1783, DOI 10.1056/NEJM199506293322611; GESSAIN A, 1993, J VIROL, V67, P1015, DOI 10.1128/JVI.67.2.1015-1023.1993; GESSAIN A, 1985, LANCET, V2, P407; GILL PS, 1995, NEW ENGL J MED, V332, P1744, DOI 10.1056/NEJM199506293322603; GOUT O, 1991, J NEUROL, V238, P108, DOI 10.1007/BF00315691; GOUT O, 1990, NEW ENGL J MED, V322, P383, DOI 10.1056/NEJM199002083220607; HANCHARD B, 1991, LANCET, V338, P1593, DOI 10.1016/0140-6736(91)92413-V; Hanchard B, 1996, J ACQ IMMUN DEF SYND, V13, pS20, DOI 10.1097/00042560-199600001-00005; HARRINGTON WJ, 1991, AIDS RES HUM RETROV, V7, P1031, DOI 10.1089/aid.1991.7.1031; HERMINE O, 1995, NEW ENGL J MED, V332, P1749, DOI 10.1056/NEJM199506293322604; HINO S, 1985, JPN J CANCER RES, V76, P474; HINO S, 1995, J CLIN INVEST, V95, P2920, DOI 10.1172/JCI117999; Hino Shigeo, 1997, Leukemia (Basingstoke), V11, P57; HINUMA Y, 1981, P NATL ACAD SCI-BIOL, V78, P6476, DOI 10.1073/pnas.78.10.6476; Hisada M, 1998, BLOOD, V92, P3557, DOI 10.1182/blood.V92.10.3557.422k09_3557_3561; Hisada M, 1998, INT J CANCER, V77, P188, DOI 10.1002/(SICI)1097-0215(19980717)77:2&lt;188::AID-IJC3&gt;3.0.CO;2-M; HO GYF, 1991, AM J EPIDEMIOL, V134, P981, DOI 10.1093/oxfordjournals.aje.a116183; IJICHI S, 1995, INTERNAL MED, V34, P713, DOI 10.2169/internalmedicine.34.713; JACOBSON S, 1990, NATURE, V348, P245, DOI 10.1038/348245a0; JACOBSON S, 1996, HUMAN T CELL LYMPHOT, V1, P141; KAMIHIRA S, 1987, VOX SANG, V52, P43, DOI 10.1111/j.1423-0410.1987.tb02987.x; KANNO M, 1998, LANCET, V338, P333; Kaplan JE, 1996, J ACQ IMMUN DEF SYND, V12, P193, DOI 10.1097/00042560-199606010-00014; KATAOKA A, 1993, J NEUROL NEUROSUR PS, V56, P1213, DOI 10.1136/jnnp.56.11.1213; Kazanji M, 1997, VIROLOGY, V231, P258, DOI 10.1006/viro.1997.8528; KHABBAZ RF, 1993, ANN INTERN MED, V118, P448; KIHARA K, 1997, J JPN OPHTHALMOL SOC, V101, P538; KINOSHITA K, 1985, BLOOD, V66, P120; KONDO T, 1989, INT J CANCER, V43, P1061, DOI 10.1002/ijc.2910430618; KORBER B, 1991, J VIROL, V65, P5471, DOI 10.1128/JVI.65.10.5471-5476.1991; Kubota R, 1998, J IMMUNOL, V161, P482; La Grenade L, 1998, ARCH DERMATOL, V134, P439, DOI 10.1001/archderm.134.4.439; LAGRENADE L, 1990, LANCET, V336, P1345; LaGrenade L, 1996, AM J MED GENET, V61, P37, DOI 10.1002/(SICI)1096-8628(19960102)61:1<37::AID-AJMG7>3.0.CO;2-U; LaGrenade L, 1996, CUTIS, V58, P115; LAGRENADE L, 1998, POSTGRAD DOCTOR CARI, V11, P268; Lairmore M D, 1995, Biomed Pept Proteins Nucleic Acids, V1, P117; Lehky TJ, 1996, ANN NEUROL, V40, P714, DOI 10.1002/ana.410400507; LEVINE PH, 1994, INT J CANCER, V59, P491, DOI 10.1002/ijc.2910590410; Levine PH, 1999, INT J CANCER, V80, P662, DOI 10.1002/(SICI)1097-0215(19990301)80:5&lt;662::AID-IJC5&gt;3.0.CO;2-I; MADELEINE MM, 1993, INT J CANCER, V54, P255, DOI 10.1002/ijc.2910540216; MALONEY EM, 1995, J INFECT DIS, V172, P867, DOI 10.1093/infdis/172.3.867; Maloney EM, 1998, J ACQ IMMUN DEF SYND, V17, P167, DOI 10.1097/00042560-199802010-00011; MANNS A, 1992, INT J CANCER, V51, P886, DOI 10.1002/ijc.2910510609; Manns A, 1998, J NATL CANCER I, V90, P617, DOI 10.1093/jnci/90.8.617; MANNS A, 1993, LANCET, V342, P1447, DOI 10.1016/0140-6736(93)92931-I; MANNS A, 1991, BLOOD, V77, P896; MATUTES E, 1992, LEUKEMIA, P416; MOCHIZUKI M, 1992, JPN J CANCER RES, V83, P236, DOI 10.1111/j.1349-7006.1992.tb00092.x; MOCHIZUKI M, 1992, AM J OPHTHALMOL, V114, P123, DOI 10.1016/S0002-9394(14)73974-1; Mueller N, 1996, J ACQ IMMUN DEF SYND, V13, pS2, DOI 10.1097/00042560-199600001-00002; MUELLER NE, 1996, VIRAL INFECT HUMANS; Mufti GJ, 1998, BRIT J HAEMATOL, V100, P453, DOI 10.1046/j.1365-2141.1998.00582.x; Murata N, 1996, LEUKEMIA, V10, P1971; MURPHY EL, 1991, AM J EPIDEMIOL, V133, P1114, DOI 10.1093/oxfordjournals.aje.a115824; MURPHY EL, 1989, ANN INTERN MED, V111, P555, DOI 10.7326/0003-4819-111-7-555; NAKAGAWA M, 1995, J NEUROVIROL, V1, P50, DOI 10.3109/13550289509111010; NISHIMURA M, 1994, J INFECT DIS, V170, P334, DOI 10.1093/infdis/170.2.334; OKOCHI K, 1984, VOX SANG, V46, P245, DOI 10.1111/j.1423-0410.1984.tb00083.x; Ono A, 1997, INVEST OPHTH VIS SCI, V38, P676; Ono A, 1998, JPN J CANCER RES, V89, P608, DOI 10.1111/j.1349-7006.1998.tb03262.x; OSAME M, 1986, LANCET, V1, P1031; POIESZ BJ, 1981, NATURE, V294, P268, DOI 10.1038/294268a0; POIESZ BJ, 1990, MED VIROL, V9, P47; POIESZ BJ, 1980, P NATL ACAD SCI-BIOL, V77, P7415, DOI 10.1073/pnas.77.12.7415; RODGERS P E, 1965, West Indian Med J, V14, P36; SAGAWA K, 1995, J CLIN INVEST, V95, P852, DOI 10.1172/JCI117735; SAWADA T, 1991, J INFECT DIS, V164, P1193, DOI 10.1093/infdis/164.6.1193; Schreiber GB, 1996, NEW ENGL J MED, V334, P1685, DOI 10.1056/NEJM199606273342601; SHIMOYAMA M, 1991, BRIT J HAEMATOL, V79, P428, DOI 10.1111/j.1365-2141.1991.tb08051.x; Sonoda S, 1996, J ACQ IMMUN DEF SYND, V13, pS119, DOI 10.1097/00042560-199600001-00020; STRICKLER HD, 1995, INT J CANCER, V61, P23, DOI 10.1002/ijc.2910610105; STUVER SO, 1993, J INFECT DIS, V167, P57, DOI 10.1093/infdis/167.1.57; STUVER SO, 1995, AM J EPIDEMIOL, V142, P1247, DOI 10.1093/oxfordjournals.aje.a117586; SWEET RD, 1966, BRIT J DERMATOL, V78, P93, DOI 10.1111/j.1365-2133.1966.tb12181.x; TAJIMA K, 1996, GANN MONOGRAPH CANC, V44; TAKAHASHI K, 1991, INT J CANCER, V49, P673, DOI 10.1002/ijc.2910490508; Takatsuki K., 1977, TOPICS HEMATOLOGY, P73; TAKEMOTO S, 1994, BLOOD, V84, P3080; Tamiya S, 1998, BLOOD, V91, P3935; TENDLER CL, 1991, J CELL BIOCHEM, V46, P302, DOI 10.1002/jcb.240460405; TERADA K, 1994, LANCET, V344, P1116, DOI 10.1016/S0140-6736(94)90630-0; UCHIYAMA T, 1977, BLOOD, V50, P481, DOI 10.1182/blood.V50.3.481.481; WALDMANN TA, 1995, BLOOD, V86, P4063, DOI 10.1182/blood.V86.11.4063.bloodjournal86114063; Wharfe G, 1996, W INDIAN MED J, V45, P107; WHITE JD, 1995, CANCER, V75, P1598, DOI 10.1002/1097-0142(19950401)75:7<1598::AID-CNCR2820750708>3.0.CO;2-7; White JD, 1996, CANCER EPIDEM BIOMAR, V5, P873; *WHO, 1989, WHO WKLY EPIDEMIOL R, V49, P382; Wiktor S Z, 1997, J Hum Virol, V1, P37; Wilks R, 1996, INT J CANCER, V65, P272, DOI 10.1002/(SICI)1097-0215(19960117)65:2<272::AID-IJC23>3.0.CO;2-E; YAMAGUCHI K, 1984, BLOOD, V63, P1235; YAMAGUCHI K, 1994, LANCET, V343, P213, DOI 10.1016/S0140-6736(94)90994-6; YOSHIDA M, 1995, J CANCER RES CLIN, V121, P521, DOI 10.1007/BF01197764; 1988, MMWR MORB MORTAL WKL, V37, P736	115	250	265	0	5	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUN 5	1999	353	9168					1951	1958		10.1016/S0140-6736(98)09460-4	http://dx.doi.org/10.1016/S0140-6736(98)09460-4			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	202TP	10371587				2022-12-28	WOS:000080668500045
J	Woolf, CJ; Mannion, RJ				Woolf, CJ; Mannion, RJ			Neuropathic pain: aetiology, symptoms, mechanisms, and management	LANCET			English	Article							PERIPHERAL-NERVE INJURY; SUPERFICIAL DORSAL HORN; POSTHERPETIC NEURALGIA; SENSORY NEURONS; SCIATIC-NERVE; HYPERALGESIA; AMPUTATION; EXPRESSION; CHANNELS; FIBERS	We highlight current theories about peripheral neuropathic pain and show that progress in management is contingent on targeting treatment not at the aetiological factors or the symptoms but at the mechanisms that operate to produce the symptoms. This approach will require substantial progress in our understanding of the pathophysiology of neuropathic pain, the development of accurate diagnostic tools to discover what mechanisms contribute to the pain syndrome in an individual, and effective treatments aimed specifically at the mechanisms.	Massachusetts Gen Hosp, Dept Anesthesia & Crit Care, Neural Plast Res Grp, Charlestown, MA 02129 USA; Harvard Univ, Sch Med, Charlestown, MA 02129 USA	Harvard University; Massachusetts General Hospital; Harvard University	Woolf, CJ (corresponding author), Massachusetts Gen Hosp, Dept Anesthesia & Crit Care, Neural Plast Res Grp, Charlestown, MA 02129 USA.		Woolf, Clifford/A-9784-2010					BARON R, 1993, BRAIN, V116, P1477, DOI 10.1093/brain/116.6.1477; CHEN L, 1992, NATURE, V356, P521, DOI 10.1038/356521a0; DEVOR M, 1990, PAIN, V42, P51, DOI 10.1016/0304-3959(90)91092-W; Devor M, 1994, TXB PAIN, P79; FLOR H, 1995, NATURE, V375, P482, DOI 10.1038/375482a0; GRACELY RH, 1992, PAIN, V51, P175, DOI 10.1016/0304-3959(92)90259-E; GREEN MW, 1991, HEADACHE, V31, P588, DOI 10.1111/j.1526-4610.1991.hed3109588.x; Hinson AW, 1997, GLIA, V21, P339, DOI 10.1002/(SICI)1098-1136(199712)21:4<339::AID-GLIA1>3.0.CO;2-Z; Jensen TS, 1996, MECH NEUROPATHIC PAI; Kingery WS, 1997, PAIN, V73, P123, DOI 10.1016/S0304-3959(97)00049-3; KOLTZENBURG M, 1994, BRAIN, V117, P579, DOI 10.1093/brain/117.3.579; Koltzenburg M, 1998, CURR OPIN NEUROL, V11, P515, DOI 10.1097/00019052-199810000-00014; LINDSAY RM, 1989, NATURE, V337, P362, DOI 10.1038/337362a0; Mannion RJ, 1996, J NEUROSCI, V16, P5189; MCLACHLAN EM, 1993, NATURE, V363, P543, DOI 10.1038/363543a0; Miki K, 1998, NEUROSCIENCE, V82, P1243; Nelson KA, 1997, NEUROLOGY, V48, P1212, DOI 10.1212/WNL.48.5.1212; Nikolajsen L, 1997, LANCET, V350, P1353, DOI 10.1016/S0140-6736(97)06315-0; Novakovic SD, 1998, J NEUROSCI, V18, P2174; Oaklander AL, 1998, ANN NEUROL, V44, P789, DOI 10.1002/ana.410440513; OCHOA J, 1982, MUSCLE NERVE, V5, pS74; OCHOA JL, 1993, ANN NEUROL, V33, P465, DOI 10.1002/ana.410330509; Ophoff RA, 1996, CELL, V87, P543, DOI 10.1016/S0092-8674(00)81373-2; Reynolds M L, 1993, Curr Opin Neurobiol, V3, P683, DOI 10.1016/0959-4388(93)90139-P; Rosenberg JM, 1997, CLIN J PAIN, V13, P251, DOI 10.1097/00002508-199709000-00011; Rowbotham MC, 1996, NEUROBIOL DIS, V3, P205, DOI 10.1006/nbdi.1996.0021; SUGIMOTO T, 1990, PAIN, V42, P205, DOI 10.1016/0304-3959(90)91164-E; TREEDE RD, 1992, BRAIN, V115, P607, DOI 10.1093/brain/115.2.607; Vabnick I, 1996, J NEUROSCI, V16, P4914; Wall P.D., 1994, TXB PAIN, P201; Willis Jr W. D., 1991, SENSORY MECH SPINAL; WOOLF CJ, 1983, NATURE, V306, P686, DOI 10.1038/306686a0; WOOLF CJ, 1992, NATURE, V355, P75, DOI 10.1038/355075a0; Woolf Clifford J., 1994, Current Opinion in Neurobiology, V4, P525, DOI 10.1016/0959-4388(94)90053-1	34	1542	1687	8	189	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUN 5	1999	353	9168					1959	1964		10.1016/S0140-6736(99)01307-0	http://dx.doi.org/10.1016/S0140-6736(99)01307-0			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	202TP	10371588				2022-12-28	WOS:000080668500046
J	Kumai, R; Okimoto, Y; Tokura, Y				Kumai, R; Okimoto, Y; Tokura, Y			Current-induced insulator-metal transition and pattern formation in an organic charge-transfer complex	SCIENCE			English	Article							TRANSFER CRYSTALS; PHASE-TRANSITION; K-TCNQ; TETRACYANOQUINODIMETHANE	Organic molecular Mott insulators, in which carriers are Localized as a result of the electron correlation, showed nonlinear electric conduction upon application of a high electric field along the molecular stacking axis. The current-driven low-resistive state of potassium 7,7,8,8-tetracyanoquinodimethanane was stabilized down to 2 kelvin, where a metallic path was visible with a microscope. The current flow caused a stripe-like periodic phase-segregation into the carrier-rich and carrier-poor regions along the current path.	Joint Res Ctr Atom Technol, Tsukuba, Ibaraki 3050046, Japan; Univ Tokyo, Dept Appl Phys, Tokyo 1130033, Japan	National Institute of Advanced Industrial Science & Technology (AIST); University of Tokyo	Kumai, R (corresponding author), Joint Res Ctr Atom Technol, Tsukuba, Ibaraki 3050046, Japan.		Kumai, Reiji/R-2453-2017; Tokura, Yoshinori/C-7352-2009; Okimoto, Yoichi/K-6099-2012	Kumai, Reiji/0000-0002-5320-0028; Tokura, Yoshinori/0000-0002-2732-4983; Okimoto, Yoichi/0000-0003-0095-4579				Fukui T, 1998, PHYS REV B, V58, P16051, DOI 10.1103/PhysRevB.58.16051; IWASA Y, 1989, PHYS REV B, V39, P10441, DOI 10.1103/PhysRevB.39.10441; LEPINE Y, 1978, PHYS REV B, V18, P3585, DOI 10.1103/PhysRevB.18.3585; MELBY LR, 1962, J AM CHEM SOC, V84, P3374, DOI 10.1021/ja00876a029; Nicolis G, 1977, SELF ORG NONEQUILIBR; OKAMOTO H, 1987, PHYS REV B, V36, P3858, DOI 10.1103/PhysRevB.36.3858; OKIMOTO Y, UNPUB; SAKAI N, 1972, B CHEM SOC JPN, V45, P3321, DOI 10.1246/bcsj.45.3321; SIEMONS WJ, 1963, J CHEM PHYS, V39, P3523, DOI 10.1063/1.1734224; SOOS ZG, 1974, ANNU REV PHYS CHEM, V25, P121, DOI 10.1146/annurev.pc.25.100174.001005; TERAUCHI H, 1978, PHYS REV B, V17, P2446, DOI 10.1103/PhysRevB.17.2446; Vegter JG, 1969, CHEM PHYS LETT, V3, P427, DOI 10.1016/0009-2614(69)80157-0; WATANABE N, 1991, PHYS REV B, V44, P11111, DOI 10.1103/PhysRevB.44.11111; YAKUSHI K, 1979, CHEM PHYS LETT, V68, P139, DOI 10.1016/0009-2614(79)80086-X	14	121	125	4	66	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 4	1999	284	5420					1645	1647		10.1126/science.284.5420.1645	http://dx.doi.org/10.1126/science.284.5420.1645			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	202TM	10356388				2022-12-28	WOS:000080668300036
J	Cohen, JI; Brunell, PA; Straus, SE; Krause, PR				Cohen, JI; Brunell, PA; Straus, SE; Krause, PR			Recent advances in varicella-zoster virus infection	ANNALS OF INTERNAL MEDICINE			English	Editorial Material							PLACEBO-CONTROLLED TRIAL; ACUTE HERPES-ZOSTER; ACQUIRED-IMMUNODEFICIENCY-SYNDROME; HUMAN TRIGEMINAL GANGLIA; POSTHERPETIC NEURALGIA; ORAL ACYCLOVIR; IMMUNOCOMPROMISED PATIENTS; PHARMACOKINETIC PROPERTIES; IMMUNOSUPPRESSED PATIENTS; VIDARABINE THERAPY		NIAID, Med Virol Sect, Clin Invest Lab, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	Cohen, JI (corresponding author), NIAID, Med Virol Sect, Clin Invest Lab, NIH, Bldg 10,Room 11N-228, Bethesda, MD 20892 USA.			Krause, Philip/0000-0002-1045-7536				ABZUG MJ, 1993, J PEDIATR-US, V123, P577, DOI 10.1016/S0022-3476(05)80954-0; [Anonymous], 1993, Pediatrics, V91, P674; ARBETER AM, 1986, PEDIATRICS, V78, P748; Arvin AM, 1996, ADV VIRUS RES, V46, P263, DOI 10.1016/S0065-3527(08)60074-3; ASANO Y, 1980, BIKEN J, V23, P157; ASANO Y, 1977, PEDIATRICS, V59, P3; Asano Y, 1996, J INFECT DIS, V174, pS310, DOI 10.1093/infdis/174.Supplement_3.S310; ASANO Y, 1993, PEDIATRICS, V92, P219; BALFOUR HH, 1983, J ANTIMICROB CHEMOTH, V12, P169, DOI 10.1093/jac/12.suppl_B.169; BALFOUR HH, 1992, J PEDIATR-US, V120, P627, DOI 10.1016/S0022-3476(05)82495-3; BERNSTEIN HH, 1993, PEDIATRICS, V92, P833; BERNSTEIN JE, 1987, J AM ACAD DERMATOL, V17, P93, DOI 10.1016/S0190-9622(87)70178-9; BEUTNER KR, 1995, ANTIMICROB AGENTS CH, V39, P1546, DOI 10.1128/AAC.39.7.1546; BRUNELL PA, 1983, SEMIN PERINATOL, V7, P47; BRUNELL PA, 1987, PEDIATRICS, V79, P922; BRUNELL PA, 1981, J PEDIATR-US, V98, P71, DOI 10.1016/S0022-3476(81)80539-2; BRUNELL PA, 1989, AM J DIS CHILD, V143, P1451, DOI 10.1001/archpedi.1989.02150240073020; BRUNELL PA, 1986, PEDIATRICS, V77, P53; BUCHBINDER SP, 1992, J INFECT DIS, V166, P1153, DOI 10.1093/infdis/166.5.1153; Cohen JI, 1998, J INFECT DIS, V177, P1390, DOI 10.1086/517821; COHEN JI, 1996, FIELDS VIROLOGY, P2525; Cohrs RJ, 1996, J VIROL, V70, P2789, DOI 10.1128/JVI.70.5.2789-2796.1996; CROEN KD, 1988, P NATL ACAD SCI USA, V85, P9773, DOI 10.1073/pnas.85.24.9773; Crumpacker C, 1996, SEMIN DERMATOL, V15, P14; Crumpacker CS, 1996, NEW ENGL J MED, V335, P721, DOI 10.1056/NEJM199609053351007; DeClercq E, 1997, CLIN MICROBIOL REV, V10, P674, DOI 10.1128/CMR.10.4.674; DEGREEF H, 1994, INT J ANTIMICROB AG, V4, P241, DOI 10.1016/0924-8579(94)90024-8; DEMIRANDA P, 1983, J ANTIMICROB CHEMOTH, V12, P29, DOI 10.1093/jac/12.suppl_B.29; DOWELL SF, 1993, PEDIATRICS, V92, P223; DUNKLE LM, 1991, NEW ENGL J MED, V325, P1539, DOI 10.1056/NEJM199111283252203; Dworkin RH, 1997, ANTIVIR RES, V33, P73, DOI 10.1016/S0166-3542(96)01007-8; ENDERS G, 1994, LANCET, V343, P1548, DOI 10.1016/S0140-6736(94)92943-2; Galil K, 1997, ARCH INTERN MED, V157, P1209, DOI 10.1001/archinte.157.11.1209; Gershon AA, 1996, J INFECT DIS, V173, P450, DOI 10.1093/infdis/173.2.450; GILDEN DH, 1987, ANN NEUROL, V22, P377, DOI 10.1002/ana.410220315; GROSSMAN MC, 1993, J AM ACAD DERMATOL, V28, P306, DOI 10.1016/0190-9622(93)70041-Q; GUESS HA, 1986, PEDIATRICS, V78, P723; HALL CB, 1995, PEDIATRICS, V95, P791; HALLORAN ME, 1994, AM J EPIDEMIOL, V140, P81, DOI 10.1093/oxfordjournals.aje.a117238; HARDY I, 1991, NEW ENGL J MED, V325, P1545, DOI 10.1056/NEJM199111283252204; HEINEMAN TC, 1995, J VIROL, V69, P7367, DOI 10.1128/JVI.69.11.7367-7370.1995; HELLINGER WC, 1993, CLIN INFECT DIS, V16, P208, DOI 10.1093/clind/16.2.208; HODGE RAV, 1993, ANTIVIR CHEM CHEMOTH, V4, P67, DOI 10.1177/095632029300400201; HOPESIMPSON RE, 1965, P ROY SOC MED, V58, P9, DOI 10.1177/003591576505800106; HYMAN RW, 1993, LANCET, V342, P814; JACOBSON MA, 1990, ANN INTERN MED, V112, P187, DOI 10.7326/0003-4819-112-3-187; JOSEPHSON A, 1988, J INFECT DIS, V158, P238, DOI 10.1093/infdis/158.1.238; Kann Laura, 1996, Morbidity and Mortality Weekly Report, V45, P1; Kennedy PGE, 1998, P NATL ACAD SCI USA, V95, P4658, DOI 10.1073/pnas.95.8.4658; Kimberlin DW, 1996, J ANTIMICROB CHEMOTH, V37, P403, DOI 10.1093/jac/37.3.403; Kost RG, 1996, NEW ENGL J MED, V335, P32, DOI 10.1056/NEJM199607043350107; KRAUSE PR, 1995, J PEDIATR-US, V127, P518, DOI 10.1016/S0022-3476(95)70106-0; KUPPERMANN BD, 1994, AM J OPHTHALMOL, V118, P589, DOI 10.1016/S0002-9394(14)76574-2; LaRussa P, 1996, J INFECT DIS, V174, pS320, DOI 10.1093/infdis/174.Supplement_3.S320; Levin MJ, 1996, INFECT DIS CLIN N AM, V10, P657, DOI 10.1016/S0891-5520(05)70319-6; LIESEGANG TJ, 1991, OPHTHALMOLOGY, V98, P1216; LUNDU O, 1998, P NATL ACAD SCI USA, V95, P7080; LUNGU O, 1995, P NATL ACAD SCI USA, V92, P10980, DOI 10.1073/pnas.92.24.10980; MAHALINGAM R, 1990, NEW ENGL J MED, V323, P627, DOI 10.1056/NEJM199009063231002; Mahalingam R, 1996, P NATL ACAD SCI USA, V93, P2122, DOI 10.1073/pnas.93.5.2122; MANIAN FA, 1995, CLIN INFECT DIS, V21, P986, DOI 10.1093/clinids/21.4.986; MAX MB, 1994, ANN NEUROL, V35, pS50, DOI 10.1002/ana.410350715; MCKENDRICK MW, 1986, BRIT MED J, V293, P1529, DOI 10.1136/bmj.293.6561.1529; *MED EC, 1917, VAR VAR VIR VACC LIV; MEIER JL, 1993, VIROLOGY, V193, P193, DOI 10.1006/viro.1993.1115; MERIGAN TC, 1978, NEW ENGL J MED, V298, P981, DOI 10.1056/NEJM197805042981801; MILLER E, 1989, LANCET, V2, P371; Moffat JF, 1998, P NATL ACAD SCI USA, V95, P11969, DOI 10.1073/pnas.95.20.11969; MOORE DA, 1991, AM J EPIDEMIOL, V133, P1161, DOI 10.1093/oxfordjournals.aje.a115828; MORTON P, 1989, NEW ZEAL MED J, V102, P93; MYERS MG, 1992, J INFECT DIS, V166, pS48, DOI 10.1093/infdis/166.Supplement_1.S48; Nathwani D, 1998, J INFECTION, V36, P59, DOI 10.1016/S0163-4453(98)80156-4; OZAKI T, 1989, AM J DIS CHILD, V143, P1448, DOI 10.1001/archpedi.1989.02150240070019; PAHWA S, 1988, JAMA-J AM MED ASSOC, V260, P2879, DOI 10.1001/jama.260.19.2879; PASTUSZAK AL, 1994, NEW ENGL J MED, V330, P901, DOI 10.1056/NEJM199403313301305; Perry CM, 1996, DRUGS, V52, P754, DOI 10.2165/00003495-199652050-00009; Peterson CL, 1996, PEDIATR INFECT DIS J, V15, P151, DOI 10.1097/00006454-199602000-00012; PROBER CG, 1982, J PEDIATR-US, V101, P622, DOI 10.1016/S0022-3476(82)80725-7; ROWBOTHAM M, 1998, JAMA-J AM MED ASSOC, V280, P1537; Salzman MB, 1998, PEDIATR INFECT DIS J, V17, P256, DOI 10.1097/00006454-199803000-00020; SAWYER MH, 1994, J INFECT DIS, V169, P91, DOI 10.1093/infdis/169.1.91; SAWYER MH, 1992, J INFECT DIS, V166, P885, DOI 10.1093/infdis/166.4.885; SHEPP DH, 1986, NEW ENGL J MED, V314, P208, DOI 10.1056/NEJM198601233140404; Snoeck R, 1999, DRUGS, V57, P187, DOI 10.2165/00003495-199957020-00005; Spingarn RW, 1998, NEW ENGL J MED, V338, P683, DOI 10.1056/NEJM199803053381011; SRUGO I, 1993, AM J DIS CHILD, V147, P742, DOI 10.1001/archpedi.1993.02160310044016; STEMMER SM, 1993, CLIN INFECT DIS, V16, P497, DOI 10.1093/clind/16.4.497; STRAUS SE, 1988, ANN INTERN MED, V108, P221, DOI 10.7326/0003-4819-108-2-221; TAKAHASH.M, 1974, LANCET, V2, P1288, DOI 10.1016/S0140-6736(74)90144-5; TAKAHASHI M, 1986, PEDIATRICS, V78, P736; TYRING S, 1995, ANN INTERN MED, V123, P89, DOI 10.7326/0003-4819-123-2-199507150-00002; WAGSTAFF AJ, 1994, DRUGS, V48, P199, DOI 10.2165/00003495-199448020-00007; WALLACE MR, 1992, ANN INTERN MED, V117, P358, DOI 10.7326/0003-4819-117-5-358; Wallace MR, 1997, JAMA-J AM MED ASSOC, V278, P1520, DOI 10.1001/jama.278.18.1520; WATSON CP, 1982, NEUROLOGY, V32, P671, DOI 10.1212/WNL.32.6.671; WHITE CJ, 1992, PEDIATR INFECT DIS J, V11, P19, DOI 10.1097/00006454-199201000-00006; WHITLEY R, 1982, J PEDIATR-US, V101, P125, DOI 10.1016/S0022-3476(82)80201-1; WHITLEY RJ, 1982, NEW ENGL J MED, V307, P971, DOI 10.1056/NEJM198210143071602; WHITLEY RJ, 1992, NEW ENGL J MED, V327, P782; Whitley RJ, 1998, J INFECT DIS, V178, pS71, DOI 10.1086/514274; Whitley RJ, 1996, ANN INTERN MED, V125, P376, DOI 10.7326/0003-4819-125-5-199609010-00004; Wood MJ, 1998, J INFECT DIS, V178, pS81, DOI 10.1086/514271; WOOD MJ, 1994, NEW ENGL J MED, V330, P896, DOI 10.1056/NEJM199403313301304; WREGHITT TG, 1992, J HOSP INFECT, V20, P125, DOI 10.1016/0195-6701(92)90116-4	104	131	135	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 1	1999	130	11					922	932		10.7326/0003-4819-130-11-199906010-00017	http://dx.doi.org/10.7326/0003-4819-130-11-199906010-00017			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	200PB	10375341				2022-12-28	WOS:000080547900007
J	Matlack, KES; Misselwitz, B; Plath, K; Rapoport, TA				Matlack, KES; Misselwitz, B; Plath, K; Rapoport, TA			BiP acts as a molecular ratchet during posttranslational transport of prepro-alpha factor across the ER membrane	CELL			English	Article							MITOCHONDRIAL PROTEIN IMPORT; ENDOPLASMIC-RETICULUM; INNER MEMBRANE; SECRETORY PROTEINS; SEC PROTEINS; TRANSLOCATION; YEAST; COMPLEX; HSP70; INSERTION	We have addressed the mechanism by which proteins are posttranslationally transported across the membrane of the yeast endoplasmic reticulum (ER). We demonstrate that BiP (Kar2p), a member of the Hsp70 family resident in the ER lumen, acts as a molecular ratchet during translocation of the secretory protein prepro-cu factor through the channel formed by the Sec complex. Multiple BiP molecules associate with each translocation substrate following interaction with the J domain of the Sec63p component of the Sec complex. Bound BiP minimizes passive backward movements of the substrate through the channel, and BiP's subsequent dissociation results in a free polypeptide in the ER lumen. Antibodies against the substrate can replace BiP, indicating that a Brownian ratchet is sufficient to achieve translocation.	Harvard Univ, Sch Med, Howard Hughes Med Inst, Dept Cell Biol, Boston, MA 02115 USA	Harvard University; Harvard Medical School; Howard Hughes Medical Institute	Rapoport, TA (corresponding author), Harvard Univ, Sch Med, Howard Hughes Med Inst, Dept Cell Biol, Boston, MA 02115 USA.		Misselwitz, Benjamin/L-7193-2016	Misselwitz, Benjamin/0000-0002-8719-5175; Plath, Kathrin/0000-0001-7796-3372	NIGMS NIH HHS [GM54238] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM054238] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Beckmann R, 1997, SCIENCE, V278, P2123, DOI 10.1126/science.278.5346.2123; Bomer U, 1998, EMBO J, V17, P4226, DOI 10.1093/emboj/17.15.4226; BRODSKY JL, 1993, J CELL BIOL, V123, P1355, DOI 10.1083/jcb.123.6.1355; BRODSKY JL, 1995, P NATL ACAD SCI USA, V92, P9643, DOI 10.1073/pnas.92.21.9643; Bukau B, 1998, CELL, V92, P351, DOI 10.1016/S0092-8674(00)80928-9; Corsi AK, 1997, J CELL BIOL, V137, P1483, DOI 10.1083/jcb.137.7.1483; DESHAIES RJ, 1991, NATURE, V349, P806, DOI 10.1038/349806a0; Gaume B, 1998, EMBO J, V17, P6497, DOI 10.1093/emboj/17.22.6497; GLICK BS, 1995, CELL, V80, P11, DOI 10.1016/0092-8674(95)90444-1; GORLICH D, 1993, CELL, V75, P615, DOI 10.1016/0092-8674(93)90483-7; Hamman BD, 1998, CELL, V92, P747, DOI 10.1016/S0092-8674(00)81403-8; Kopito RR, 1997, CELL, V88, P427, DOI 10.1016/S0092-8674(00)81881-4; KRONIDOU NG, 1994, P NATL ACAD SCI USA, V91, P12818, DOI 10.1073/pnas.91.26.12818; Lyman SK, 1997, CELL, V88, P85, DOI 10.1016/S0092-8674(00)81861-9; Matlack KES, 1997, SCIENCE, V277, P938, DOI 10.1126/science.277.5328.938; Matouschek A, 1997, EMBO J, V16, P6727, DOI 10.1093/emboj/16.22.6727; Misselwitz B, 1998, MOL CELL, V2, P593, DOI 10.1016/S1097-2765(00)80158-6; NICCHITTA CV, 1993, CELL, V73, P989, DOI 10.1016/0092-8674(93)90276-V; PANZNER S, 1995, CELL, V81, P561, DOI 10.1016/0092-8674(95)90077-2; Plath K, 1998, CELL, V94, P795, DOI 10.1016/S0092-8674(00)81738-9; RASSOW J, 1994, J CELL BIOL, V127, P1547, DOI 10.1083/jcb.127.6.1547; ROTHBLATT JA, 1989, J CELL BIOL, V109, P2641, DOI 10.1083/jcb.109.6.2641; SADLER I, 1989, J CELL BIOL, V109, P2665, DOI 10.1083/jcb.109.6.2665; SANDERS SL, 1992, CELL, V69, P353, DOI 10.1016/0092-8674(92)90415-9; SCHNEIDER HC, 1994, NATURE, V371, P768, DOI 10.1038/371768a0; SCIDMORE MA, 1993, MOL BIOL CELL, V4, P1145, DOI 10.1091/mbc.4.11.1145; SHAW AS, 1988, P NATL ACAD SCI USA, V85, P7592, DOI 10.1073/pnas.85.20.7592; SIMON SM, 1992, P NATL ACAD SCI USA, V89, P3770, DOI 10.1073/pnas.89.9.3770; VOGEL JP, 1990, J CELL BIOL, V110, P1885, DOI 10.1083/jcb.110.6.1885; Zhu XT, 1996, SCIENCE, V272, P1606, DOI 10.1126/science.272.5268.1606; [No title captured]	31	309	310	3	19	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	MAY 28	1999	97	5					553	564		10.1016/S0092-8674(00)80767-9	http://dx.doi.org/10.1016/S0092-8674(00)80767-9			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	202VD	10367885	Bronze			2022-12-28	WOS:000080672100005
J	Sanders, TAB				Sanders, TAB			Food production and food safety	BMJ-BRITISH MEDICAL JOURNAL			English	Article							SALMONELLA-ENTERITIDIS; UNITED-STATES; OUTBREAK; INFECTIONS; CHALLENGE		Kings Coll London, Nutr Food & Hlth Res Ctr, London SE1 8WA, England	University of London; King's College London	Sanders, TAB (corresponding author), Kings Coll London, Nutr Food & Hlth Res Ctr, London SE1 8WA, England.	Tom.Sanders@kcl.ac.uk		Sanders, Thomas/0000-0001-9529-095X				Ahmed F., 1991, SEAFOOD SAFETY; Bhat RV, 1997, J TOXICOL-CLIN TOXIC, V35, P249, DOI 10.3109/15563659709001208; Calman KC, 1997, BMJ-BRIT MED J, V315, P939; *CDSC, 1999, OUTBR REP CDSC APR 2; Committee on Toxicity of Chemicals in Food, 1998, PEAN ALL; Djuretic T, 1997, Commun Dis Rep CDR Rev, V7, pR41; *EUR COMM SCI COMM, 1997, 9343 EEC EUR COMM SC; *FAO WHO COD AL CO, 1996, CL9621 FAO WHO COD A; Fisher I.S.T., 1999, Euro Surveill, V4, P56; Glynn MK, 1998, NEW ENGL J MED, V338, P1333, DOI 10.1056/NEJM199805073381901; Haque A, 1996, NEUROEPIDEMIOLOGY, V15, P83, DOI 10.1159/000109893; Headrick ML, 1998, AM J PUBLIC HEALTH, V88, P1219, DOI 10.2105/AJPH.88.8.1219; Hennessy TW, 1996, NEW ENGL J MED, V334, P1281, DOI 10.1056/NEJM199605163342001; Herwaldt BL, 1997, NEW ENGL J MED, V336, P1548, DOI 10.1056/NEJM199705293362202; Hogue A, 1997, REV SCI TECH OIE, V16, P542, DOI 10.20506/rst.16.2.1045; Hutin YJF, 1999, NEW ENGL J MED, V340, P595, DOI 10.1056/NEJM199902253400802; Johnson RT, 1998, NEW ENGL J MED, V339, P1994, DOI 10.1056/NEJM199812313392707; Jones L, 1999, BMJ-BRIT MED J, V318, P581, DOI 10.1136/bmj.318.7183.581; Kaferstein FK, 1997, EMERG INFECT DIS, V3, P503, DOI 10.3201/eid0304.970414; *MIN AGR FISH FOOD, 1998, ANN REP ADV COMM NOV; *MIN AGR FISH FOOD, 1999, REV ANT RES FOOD CHA; *MIN AGR FISH FOOD, 1995, PEST REG S; *MIN AGR FISH FOOD, 1999, FOOD CHEM SURV ANN R; *MIN AGR FISH FOOD, 1998, FOOD CHEM SURV; Motarjemi Yasmine, 1997, World Health Statistics Quarterly, V50, P5; SANDERS T, 1991, FOOD REVOLUTION; Sanders TAB, 1996, BIOCHEM SOC T, V24, P771, DOI 10.1042/bst0240771; Scoging A, 1998, LANCET, V352, P117, DOI 10.1016/S0140-6736(98)85023-X; Smith KE, 1999, NEW ENGL J MED, V340, P1525, DOI 10.1056/NEJM199905203402001; Tariq SM, 1996, BRIT MED J, V313, P514, DOI 10.1136/bmj.313.7056.514; Ting JYS, 1998, AUST NZ J PUBL HEAL, V22, P140, DOI 10.1111/j.1467-842X.1998.tb01158.x; Wheeler JG, 1999, BMJ-BRIT MED J, V318, P1046, DOI 10.1136/bmj.318.7190.1046	32	32	32	6	39	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUN 19	1999	318	7199					1689	1693		10.1136/bmj.318.7199.1689	http://dx.doi.org/10.1136/bmj.318.7199.1689			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	210KY	10373179	Green Published			2022-12-28	WOS:000081105600037
J	Ploghaus, A; Tracey, I; Gati, JS; Clare, S; Menon, RS; Matthews, PM; Rawlins, JNP				Ploghaus, A; Tracey, I; Gati, JS; Clare, S; Menon, RS; Matthews, PM; Rawlins, JNP			Dissociating pain from its anticipation in the human brain	SCIENCE			English	Article							POSITRON-EMISSION-TOMOGRAPHY; CORTEX; CINGULATE	The experience of pain is subjectively different from the fear and anxiety caused by threats of pain. Functional magnetic resonance imaging in healthy humans was applied to dissociate neural activation patterns associated with acute pain and its anticipation. Expectation of pain activated sites within the medial frontal lobe, insular cortex, and cerebellum distinct from, but close to, locations mediating pain experience itself. Anticipation of pain can in its own right cause mood changes and behavioral adaptations that exacerbate the suffering experienced by chronic pain patients. Selective manipulations of activity at these sites may offer therapeutic possibilities for treating chronic pain.	Univ Oxford, Dept Clin Neurol, Ctr Funct Magnet Resonance Imaging Brain, Oxford OX3 9DU, England; Univ Oxford, Dept Expt Psychol, Oxford OX1 3UD, England; John P Robarts Res Inst, Lab Funct Magnet Resonance Res, London, ON N6A 5K8, Canada	University of Oxford; University of Oxford; Western University (University of Western Ontario)	Ploghaus, A (corresponding author), Univ Oxford, Dept Clin Neurol, Ctr Funct Magnet Resonance Imaging Brain, Oxford OX3 9DU, England.		Menon, Ravi/ABA-8654-2020; Gati, Joseph S/K-5476-2013; Menon, Ravi S/K-5500-2013	Menon, Ravi/0000-0002-7916-0263; Menon, Ravi S/0000-0002-7916-0263; Tracey, Irene/0000-0003-4134-6115; Matthews, Paul M/0000-0002-1619-8328				Allen G, 1997, SCIENCE, V275, P1940, DOI 10.1126/science.275.5308.1940; Augustine JR, 1996, BRAIN RES REV, V22, P229, DOI 10.1016/S0165-0173(96)00011-2; Bechara A, 1997, SCIENCE, V275, P1293, DOI 10.1126/science.275.5304.1293; BIRBAUMER N, 1995, ADV PAIN RES THER, V22, P331; CASEY KL, 1994, J NEUROPHYSIOL, V71, P802, DOI 10.1152/jn.1994.71.2.802; Craig AD, 1996, NATURE, V384, P258, DOI 10.1038/384258a0; Crombez G, 1996, BEHAV RES THER, V34, P919, DOI 10.1016/S0005-7967(96)00049-6; Darwin Charles, 1998, EXPRESS EMOT MAN, V3rd, DOI [10.1037/h0076058, DOI 10.1037/10001-000]; Derbyshire SWG, 1998, PAIN, V76, P127, DOI 10.1016/S0304-3959(98)00034-7; ELITHORN A, 1955, J NEUROL NEUROSUR PS, V18, P34, DOI 10.1136/jnnp.18.1.34; Hsieh JC, 1996, PAIN, V64, P303, DOI 10.1016/0304-3959(95)00129-8; Hsieh JC, 1999, NEUROSCI LETT, V262, P61, DOI 10.1016/S0304-3940(99)00060-9; HSIEH JC, 1995, PAIN, V63, P225, DOI 10.1016/0304-3959(95)00048-W; James W., 1892, TXB PSYCHOL; JONES AKP, 1991, P ROY SOC B-BIOL SCI, V244, P39, DOI 10.1098/rspb.1991.0048; Kamin L. J., 1969, FUNDAMENTAL ISSUES A, P42; LETHEM J, 1983, BEHAV RES THER, V21, P401, DOI 10.1016/0005-7967(83)90009-8; MELZACK R, 1968, P423; Miltner WHR, 1999, NATURE, V397, P434, DOI 10.1038/17126; Mowrer OH, 1938, PSYCHOL REV, V45, P62, DOI 10.1037/h0060829; Pavlov I.P., 1927, CONDITIONED REFLEXES; Rainville P, 1997, SCIENCE, V277, P968, DOI 10.1126/science.277.5328.968; STEINMETZ JE, 1993, BEHAV NEUROSCI, V107, P941, DOI 10.1037/0735-7044.107.6.941; TALBOT JD, 1991, SCIENCE, V251, P1355, DOI 10.1126/science.2003220; Vogt BA, 1995, HUM BRAIN MAPP, V3, P1, DOI 10.1002/hbm.460030102	25	836	856	1	70	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 18	1999	284	5422					1979	1981		10.1126/science.284.5422.1979	http://dx.doi.org/10.1126/science.284.5422.1979			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	207JA	10373114				2022-12-28	WOS:000080932700044
J	Alexander, FE; Anderson, TJ; Brown, HK; Forrest, APM; Hepburn, W; Kirkpatrick, AE; Muir, BB; Prescott, RJ; Smith, A				Alexander, FE; Anderson, TJ; Brown, HK; Forrest, APM; Hepburn, W; Kirkpatrick, AE; Muir, BB; Prescott, RJ; Smith, A			14 years of follow-up from the Edinbugh randomised trial of breast-cancer screening	LANCET			English	Article							DEATH RATES; MORTALITY; WOMEN; MAMMOGRAPHY	Background. The Edinburgh randomised trial of breast- cancer screening recruited women aged 45-64 years from 1978 to 1981 (cohort 1), and those aged 45-49 years during 1982-85 (cohorts 2 and 3). Results based on 14 years of follow-up and 270000 woman-years of observation are reported. Methods Breast-cancer mortality rates in the intervention group (28628 women offered screening) were compared with those in the control group (26026) with adjustment for socioeconomic status (SES) of general medical practices. Rate ratios were derived by means of logistic regression for the total trial population and for women first offered screening while younger than 50 years. Analyses were by intention to treat. Findings Initial unadjusted results showed a difference of just 13% in breast-cancer mortality rates between the intervention and control groups (156 deaths [5.18 per 10000] vs 167 [6.04 per 10000]; rate ratio 0.87 [95% CI 0.70-1.06]), but the results were influenced by differences in SES by trial group. After adjustment for SES, the rate ratio was 0.79 (95% CI 0.60-1.02). When deaths after diagnosis more than 3 years after the end of the study were censored the rate ratio became 0.71 (0.53-0.95). There was no evidence of heterogeneity by age at entry and no evidence that younger entrants had smaller or delayed benefit (rate ratio 0.70 [0.41-1.20]). No breast-cancer mortality benefit was observed for women whose breast cancers were diagnosed when they were younger than 50 years. Other-cause mortality rates did not differ by trial group when adjusted for SES. Interpretation. Our findings confirm results from randomised trials in Sweden and the USA that screening for breast cancer lowers breast-cancer mortality. Similar results are reported by the UK geographical comparison, UK Trial of Early Detection of Breast Cancer. The results for younger women suggest benefit from introduction of screening before 50 years of age.	Univ Edinburgh, Dept Community Hlth Sci, Edinburgh EH8 9AG, Midlothian, Scotland; Univ Edinburgh, Dept Pathol, Edinburgh EH8 9AG, Midlothian, Scotland; Scottish Breast Screening Programme, SE Scotland Div, Edinburgh, Midlothian, Scotland	University of Edinburgh; University of Edinburgh	Alexander, FE (corresponding author), Univ Edinburgh, Dept Community Hlth Sci, Edinburgh EH8 9AG, Midlothian, Scotland.	freda.alexander@ed.ac.uk						ALEXANDER F, 1989, J EPIDEMIOL COMMUN H, V43, P29, DOI 10.1136/jech.43.1.29; Alexander F E, 1997, J Med Screen, V4, P152; Alexander F E, 1997, J Natl Cancer Inst Monogr, P31; ALEXANDER FE, 1994, BRIT J CANCER, V70, P542, DOI 10.1038/bjc.1994.342; Alexander FE, 1998, J EPIDEMIOLOGY BIOST, V3, P219; ANDERSSON I, 1988, BRIT MED J, V297, P943, DOI 10.1136/bmj.297.6654.943; Bjurstam N, 1997, CANCER, V80, P2091, DOI 10.1002/(SICI)1097-0142(19971201)80:11<2091::AID-CNCR8>3.0.CO;2-#; CARSTAIRS V, 1989, BRIT MED J, V299, P1462, DOI 10.1136/bmj.299.6713.1462-a; DEKONING HJ, 1995, JNCI-J NATL CANCER I, V87, P1217; Eastman P, 1997, J NATL CANCER I, V89, P538, DOI 10.1093/jnci/89.8.538; Fletcher S, 1997, BRIT MED J, V314, P764, DOI 10.1136/bmj.314.7083.764; Forrest APM., 1987, BREAST CANC SCREENIN; Gordis L, 1997, J NATL CANCER I, V89, P1015, DOI 10.1093/jnci/89.14.1015; KERLIKOWSKE K, 1995, JAMA-J AM MED ASSOC, V273, P149, DOI 10.1001/jama.273.2.149; MILLER AB, 1992, CAN MED ASSOC J, V147, P1477; MILLER AB, 1992, CAN MED ASSOC J, V147, P1459; Moss SM, 1999, LANCET, V353, P1909, DOI 10.1016/S0140-6736(98)07412-1; NYSTROM L, 1993, LANCET, V341, P973, DOI 10.1016/0140-6736(93)91067-V; *OPCS, 1985, OPCS MORT STAT C DH2, V11; ROBERTS MM, 1990, LANCET, V335, P241; ROBERTS MM, 1984, BRIT J CANCER, V50, P1, DOI 10.1038/bjc.1984.132; SHAPIRO S, 1982, JNCI-J NATL CANCER I, V69, P349; Tabar L, 1997, J Natl Cancer Inst Monogr, P43; TABAR L, 1992, RADIOL CLIN N AM, V30, P187; *UK BREAST CANC DE, 1981, BRIT J CANCER, V44, P618; WILLIAMS DA, 1982, J R STAT SOC C-APPL, V31, P144	26	289	307	0	2	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUN 5	1999	353	9168					1903	1908		10.1016/S0140-6736(98)07413-3	http://dx.doi.org/10.1016/S0140-6736(98)07413-3			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	202TP	10371567				2022-12-28	WOS:000080668500008
J	Maviglia, SN; Bates, D				Maviglia, SN; Bates, D			Hospitalism in the USA	LANCET			English	Editorial Material									Brigham & Womens Hosp, Div Gen Med, Boston, MA 02125 USA	Harvard University; Brigham & Women's Hospital	Maviglia, SN (corresponding author), Brigham & Womens Hosp, Div Gen Med, Boston, MA 02125 USA.							Craig DE, 1999, ANN INTERN MED, V130, P355, DOI 10.7326/0003-4819-130-4-199902161-00005; *CTR HLTH POL RES, 1997, SOC CHAR MED PRACT; Diamond HS, 1998, ANN INTERN MED, V129, P197, DOI 10.7326/0003-4819-129-3-199808010-00006; Freese RB, 1999, ANN INTERN MED, V130, P350, DOI 10.7326/0003-4819-130-4-199902161-00004; *MED GROUP MAN ASS, 1996, PHYS COMP PROD SURV; Meltzer D., 1999, JGIM, V14, P112; Wachter RM, 1999, ANN INTERN MED, V130, P338, DOI 10.7326/0003-4819-130-4-199902161-00002	7	2	2	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUN 5	1999	353	9168					1902	1902		10.1016/S0140-6736(99)00114-2	http://dx.doi.org/10.1016/S0140-6736(99)00114-2			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	202TP	10371566				2022-12-28	WOS:000080668500007
J	Seymour, A				Seymour, A			A memorable patient - The one neither of us saw	BRITISH MEDICAL JOURNAL			English	Article																		Berwick DM, 1998, BRIT MED J, V316, P1738	1	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JUN 5	1999	318	7197					1552	1552		10.1136/bmj.318.7197.1552	http://dx.doi.org/10.1136/bmj.318.7197.1552			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	204HC	10356020	Green Published			2022-12-28	WOS:000080757300038
J	Saigal, S; Stoskopf, BL; Feeny, D; Furlong, W; Burrows, E; Rosenbaum, PL; Hoult, L				Saigal, S; Stoskopf, BL; Feeny, D; Furlong, W; Burrows, E; Rosenbaum, PL; Hoult, L			Differences in preferences for neonatal outcomes among health care professionals, parents, and adolescents	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article; Proceedings Paper	Annual Meeting of the European-Society-for-Pediatric-Research	SEP 01-05, 1996	LYON, FRANCE	European Soc Pediat Res			BIRTH-WEIGHT INFANTS; LIFE-SUSTAINING TREATMENT; QUALITY-OF-LIFE; AGE 8 YEARS; INTENSIVE-CARE; CHILDREN; DECISIONS; ATTITUDES; UTILITIES; CANCER	Context In neonatal intensive care, parents make important clinical management decisions in conjunction with health care professionals. Yet little information is available on whether preferences of health care professionals and parents for the resulting health outcomes differ. Objective To measure and compare preferences for selected health states from the perspectives of health care professionals (ie, neonatologists and neonatal nurses), parents of extremely low-birth-weight (ELBW) or normal birth-weight infants, and adolescents who were either ELBW or normal birth-weight infants. Design Cross-sectional cohort study. Setting and Participants A total of 742 participants were recruited and interviewed between 1993 and 1995, including 100 neonatologists from hospitals throughout Canada; 103 neonatal nurses from 3 regional neonatal intensive care units; 264 adolescents (aged 12-16 years), including 140 who were ELBW infants and 124 sociodemographically matched term controls; and 275 parents of the recruited adolescents. Main Outcome Measure Preferences (utilities) for 4 to 5 hypothetical health states of children were obtained by direct interviews using the standard gamble method. Results Overall, neonatologists and nurses had similar preferences for the 5 health states, and a similar proportion rated some health states as worse than death (59% of neonatologists and 68% of nurses; P=.20). Health care professionals rated the health states lower than did parents of ELBW and term infants (P<.001). Overall, 64% of health care professionals and 45% of parents rated 1 or more health states to be worse than death (P<.001), Differences in mean utility scores between health care professionals and parents and adolescent respondents were most pronounced for the 2 most severely disabled health states (P<.001). Conclusions When asked to rate the health-related quality of life for the hypothetical conditions of children, health care professionals tend to provide lower utility scores than do adolescents and their parents. These findings have implications for decision making in the neonatal intensive care unit.	McMaster Univ, Dept Pediat, Hamilton, ON L8N 3Z5, Canada; McMaster Univ, Dept Clin Epidemiol & Biostat, Hamilton, ON, Canada; McMaster Univ, Ctr Hlth Econ & Policy Anal, Hamilton, ON, Canada; Hamilton Hlth Sci Corp, Childrens Hosp, Hamilton, ON, Canada; Hlth Util Inc, Dundas, ON, Canada	McMaster University; McMaster University; McMaster University; McMaster University	Saigal, S (corresponding author), McMaster Univ, Dept Pediat, 1200 Main St W, Hamilton, ON L8N 3Z5, Canada.	saigal@fhs.mcmaster.ca	Rosenbaum, Peter/AAW-7913-2021; Furlong, William J/A-1077-2008	Rosenbaum, Peter/0000-0001-6751-5613; 	AHRQ HHS [HS-08385] Funding Source: Medline	AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)		ALLEN AC, 1994, CAN MED ASSOC J, V151, P547; BOYLE MH, 1983, NEW ENGL J MED, V308, P1330, DOI 10.1056/NEJM198306023082206; CADMAN D, 1984, DEV BEHAV PEDIAT, V5, P60; CADMAN D, 1986, 64800633 DM ONT MIN; CHURCHILL DN, 1987, CLIN INVEST MED, V10, P14; deLeeuw R, 1996, J PEDIATR-US, V129, P661, DOI 10.1016/S0022-3476(96)70146-4; Doron MW, 1998, PEDIATRICS, V102, P574, DOI 10.1542/peds.102.3.574; DOYAL L, 1994, ARCH DIS CHILD-FETAL, V70, pF66, DOI 10.1136/fn.70.1.F66; EMANUEL EJ, 1992, JAMA-J AM MED ASSOC, V267, P2221, DOI 10.1001/jama.267.16.2221; FEENY D, 1992, J CLIN ONCOL, V10, P923, DOI 10.1200/JCO.1992.10.6.923; Feeny D. H., 1996, QUALITY LIFE PHARMAC, V2, P239; FURLOG W, 1990, MCMASTER U WORKING P, V909; HARRISON H, 1993, PEDIATRICS, V92, P643; Laine C, 1996, JAMA-J AM MED ASSOC, V275, P152, DOI 10.1001/jama.275.2.152; LANTOS JD, 1994, ARCH DIS CHILD-FETAL, V71, pF218, DOI 10.1136/fn.71.3.F218; LEE SK, 1991, PEDIATRICS, V88, P110; OH W, 1995, PEDIATRICS, V96, P974; PATRICK DL, 1994, MED DECIS MAKING, V14, P9, DOI 10.1177/0272989X9401400102; SAIGAL S, 1991, J PEDIATR-US, V118, P751, DOI 10.1016/S0022-3476(05)80043-5; SAIGAL S, 1994, J PEDIATR-US, V125, P411, DOI 10.1016/S0022-3476(05)83288-3; SAIGAL S, 1994, J PEDIATR-US, V125, P418, DOI 10.1016/S0022-3476(05)83289-5; Saigal S, 1996, JAMA-J AM MED ASSOC, V276, P453, DOI 10.1001/jama.276.6.453; SAIGAL S, 1995, PEDIATR RES, V38, P453; Saigal S, 1998, MEASURING HEALTH-RELATED QUALITY OF LIFE IN CHILDREN AND ADOLESCENTS, P151; SCHNEIDERMAN LJ, 1993, J CLIN ETHIC, V4, P28; SILVERMAN WA, 1992, PEDIATRICS, V90, P971; SLEVIN ML, 1990, BRIT MED J, V300, P1458, DOI 10.1136/bmj.300.6737.1458; STAHLMAN MT, 1990, J PEDIATR-US, V116, P167, DOI 10.1016/S0022-3476(05)82869-0; TORRANCE GW, 1986, J HEALTH ECON, V5, P1, DOI 10.1016/0167-6296(86)90020-2; TORRANCE GW, 1982, OPER RES, V30, P1043, DOI 10.1287/opre.30.6.1043; TORRANCE GW, 1995, PHARMACOECONOMICS, V7, P503, DOI 10.2165/00019053-199507060-00005; Tyson JE, 1996, JAMA-J AM MED ASSOC, V276, P492, DOI 10.1001/jama.276.6.492; van der Heide A, 1998, PEDIATRICS, V101, P413, DOI 10.1542/peds.101.3.413; Wall SN, 1997, PEDIATRICS, V99, P64, DOI 10.1542/peds.99.1.64	34	247	250	0	11	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 2	1999	281	21					1991	1997		10.1001/jama.281.21.1991	http://dx.doi.org/10.1001/jama.281.21.1991			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine	200NN	10359387	Bronze			2022-12-28	WOS:000080546700028
J	Kasumov, AY; Deblock, R; Kociak, M; Reulet, B; Bouchiat, H; Khodos, II; Gorbatov, YB; Volkov, VT; Journet, C; Burghard, M				Kasumov, AY; Deblock, R; Kociak, M; Reulet, B; Bouchiat, H; Khodos, II; Gorbatov, YB; Volkov, VT; Journet, C; Burghard, M			Supercurrents through single-walled carbon nanotubes	SCIENCE			English	Article								Proximity-induced superconductivity in single-walled carbon nanotubes below 1 kelvin, both in a single tube 1 nanometer in diameter and in crystalline ropes containing about 100 nanotubes, was observed. The samples were suspended between two superconducting electrodes, permitting structural study in a transmission electron microscope. When the resistance of the nanotube junction is sufficiently low, it becomes superconducting and can carry high supercurrents. The temperature and magnetic field dependence of the critical current of such junctions exhibits unusual features related to their strong one-dimensional character.	Univ Paris Sud, CNRS, Phys Solides Lab, F-91405 Orsay, France; Russian Acad Sci, Inst Microelect Technol & High Pur Mat, Chernogolovka 142432, Moscow Region, Russia; Univ Montpellier 2, Dynam Phases Condensees Grp, F-34095 Montpellier, France; Max Planck Inst, D-70506 Stuttgart, Germany	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay; Russian Academy of Sciences; Institute of Microelectronics Technology & High-Purity Materials, RAS; Universite de Montpellier; Max Planck Society	Bouchiat, H (corresponding author), Univ Paris Sud, CNRS, Phys Solides Lab, Batiment 510, F-91405 Orsay, France.	bouchiat@lps.u-psud.fr	Khodos, Igor/K-3698-2018; Journet, Catherine/AAE-4068-2021; kociak, mathieu/T-3110-2018	Journet, Catherine/0000-0002-3328-317X; kociak, mathieu/0000-0001-8858-0449; Deblock, Richard/0000-0001-9750-3373; Volkov, Vladimir/0000-0002-6005-9536; Bouchiat, Helene/0000-0003-3178-885X				Bockrath M, 1997, SCIENCE, V275, P1922, DOI 10.1126/science.275.5308.1922; BURGHARD M, 1998, ELECT PROPERTIES NOV, P44; COURTOIS H, 1995, PHYS REV B, V52, P1162, DOI 10.1103/PhysRevB.52.1162; Delaney P, 1998, NATURE, V391, P466, DOI 10.1038/35099; Deutscher G., 1969, Superconductivity, vol.2, P1005; Dresselhaus M.S., 1996, SCI FULLERENES CARBO; Fazio R, 1996, PHYS REV B, V53, P6653, DOI 10.1103/PhysRevB.53.6653; Journet C, 1997, NATURE, V388, P756, DOI 10.1038/41972; Kane CL, 1997, PHYS REV LETT, V78, P1932, DOI 10.1103/PhysRevLett.78.1932; Kasumov AY, 1998, EUROPHYS LETT, V43, P89, DOI 10.1209/epl/i1998-00324-1; Kasumov AY, 1996, EUROPHYS LETT, V34, P429, DOI 10.1209/epl/i1996-00474-0; KASUMOV AY, UNPUB; LIKHAREV KK, 1979, REV MOD PHYS, V51, P101, DOI 10.1103/RevModPhys.51.101; LOSS D, 1994, PHYS REV B, V50, P12160, DOI 10.1103/PhysRevB.50.12160; Maslov DL, 1996, PHYS REV B, V53, P1548, DOI 10.1103/PhysRevB.53.1548; MEYER J, 1972, PHYS LETT A, VA 38, P529, DOI 10.1016/0375-9601(72)90802-X; Tans SJ, 1998, NATURE, V394, P761, DOI 10.1038/29494; VANDOVER RB, 1981, J APPL PHYS, V52, P7327, DOI 10.1063/1.328724	18	409	426	4	78	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 28	1999	284	5419					1508	1511		10.1126/science.284.5419.1508	http://dx.doi.org/10.1126/science.284.5419.1508			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	200PD	10348734				2022-12-28	WOS:000080548100031
J	Vetter, IR; Arndt, A; Kutay, U; Gorlich, D; Wittinghofer, A				Vetter, IR; Arndt, A; Kutay, U; Gorlich, D; Wittinghofer, A			Structural view of the Ran-importin beta interaction at 2.3 angstrom resolution	CELL			English	Article							NUCLEAR-PROTEIN IMPORT; GTPASE-ACTIVATING PROTEIN; PORE-TARGETING COMPLEX; GDP-BOUND FORM; CRYSTAL-STRUCTURE; LOCALIZATION SIGNAL; TRANSPORT FACTORS; KARYOPHERIN-BETA; FACTOR P97; BINDING	Transport receptors of the Importin beta family shuttle between the nucleus and cytoplasm and mediate transport of macromolecules through nuclear pore complexes. They interact specifically with the GTP-binding protein Ran, which in turn regulates their interaction with cargo. Here, we report the three-dimensional structure of a complex between Ran bound to the nonhydrolyzable GTP analog GppNHp and a 462-residue fragment from Importin beta. The structure of Importin beta shows 10 tandem repeats resembling HEAT and Armadillo motifs. They form an irregular crescent, the concave site of which forms the interface with Ran-triphosphate. The importin-binding site of Ran does not overlap with that of the Ran-binding domain of RanBP2.	Max Planck Inst Mol Physiol, D-44227 Dortmund, Germany; Heidelberg Univ, Zentrum Mol Biol, D-69120 Heidelberg, Germany	Max Planck Society; Ruprecht Karls University Heidelberg	Wittinghofer, A (corresponding author), Max Planck Inst Mol Physiol, Otto Hahn Str 11, D-44227 Dortmund, Germany.	wittinghofer@mpi-dortmund.mpg.de	Görlich, Dirk/B-8296-2017	Görlich, Dirk/0000-0002-4343-5210				ADAM EJH, 1994, J CELL BIOL, V125, P547, DOI 10.1083/jcb.125.3.547; ANDRADE MA, 1995, NAT GENET, V11, P115, DOI 10.1038/ng1095-115; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BISCHOFF FR, 1991, NATURE, V354, P80, DOI 10.1038/354080a0; BISCHOFF FR, 1991, P NATL ACAD SCI USA, V88, P10830, DOI 10.1073/pnas.88.23.10830; BISCHOFF FR, 1994, P NATL ACAD SCI USA, V91, P2587, DOI 10.1073/pnas.91.7.2587; BISCHOFF FR, 1995, EMBO J, V14, P705, DOI 10.1002/j.1460-2075.1995.tb07049.x; Bischoff FR, 1997, FEBS LETT, V419, P249, DOI 10.1016/S0014-5793(97)01467-1; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Chi NC, 1997, J BIOL CHEM, V272, P6818, DOI 10.1074/jbc.272.10.6818; CHI NC, 1995, J CELL BIOL, V130, P265, DOI 10.1083/jcb.130.2.265; Chi NC, 1996, J CELL BIOL, V135, P559, DOI 10.1083/jcb.135.3.559; Conti E, 1998, CELL, V94, P193, DOI 10.1016/S0092-8674(00)81419-1; DRIVAS GT, 1990, MOL CELL BIOL, V10, P1793, DOI 10.1128/MCB.10.4.1793; Floer M, 1997, J BIOL CHEM, V272, P19538, DOI 10.1074/jbc.272.31.19538; Fornerod M, 1997, CELL, V90, P1051, DOI 10.1016/S0092-8674(00)80371-2; Fornerod M, 1997, EMBO J, V16, P807, DOI 10.1093/emboj/16.4.807; Gorlich D, 1996, CELL, V87, P21, DOI 10.1016/S0092-8674(00)81319-7; GORLICH D, 1994, CELL, V79, P767, DOI 10.1016/0092-8674(94)90067-1; GORLICH D, 1995, CURR BIOL, V5, P383, DOI 10.1016/S0960-9822(95)00079-0; Gorlich D, 1996, EMBO J, V15, P1810, DOI 10.1002/j.1460-2075.1996.tb00530.x; Gorlich D, 1997, J CELL BIOL, V138, P65, DOI 10.1083/jcb.138.1.65; Gorlich D, 1996, EMBO J, V15, P5584, DOI 10.1002/j.1460-2075.1996.tb00943.x; Groves MR, 1999, CELL, V96, P99, DOI 10.1016/S0092-8674(00)80963-0; Henderson BR, 1997, J MOL BIOL, V274, P693, DOI 10.1006/jmbi.1997.1420; HENDRICKSON WA, 1990, EMBO J, V9, P1665, DOI 10.1002/j.1460-2075.1990.tb08287.x; Hieda M, 1999, J CELL BIOL, V144, P645, DOI 10.1083/jcb.144.4.645; HILLIG R, 1999, IN PRESS MOL CELL; Huang L, 1998, NAT STRUCT BIOL, V5, P422, DOI 10.1038/nsb0698-422; Ihara K, 1998, J BIOL CHEM, V273, P9656, DOI 10.1074/jbc.273.16.9656; IMAMOTO N, 1995, FEBS LETT, V368, P415; Izaurralde E, 1997, EMBO J, V16, P6535, DOI 10.1093/emboj/16.21.6535; Jakel S, 1998, EMBO J, V17, P4491, DOI 10.1093/emboj/17.15.4491; JAKEL S, 1999, IN PRESS EMBO J; Jones TA, 1997, METHOD ENZYMOL, V277, P173, DOI 10.1016/S0076-6879(97)77012-5; KABSCH W, 1993, J APPL CRYSTALLOGR, V26, P795, DOI 10.1107/S0021889893005588; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; Kose S, 1997, J CELL BIOL, V139, P841, DOI 10.1083/jcb.139.4.841; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Kuhlmann J, 1997, BIOCHEMISTRY-US, V36, P12027, DOI 10.1021/bi970524k; Kutay U, 1997, CELL, V90, P1061, DOI 10.1016/S0092-8674(00)80372-4; Kutay U, 1997, EMBO J, V16, P1153, DOI 10.1093/emboj/16.6.1153; Lounsbury KM, 1997, J BIOL CHEM, V272, P551; Mattaj IW, 1998, ANNU REV BIOCHEM, V67, P265, DOI 10.1146/annurev.biochem.67.1.265; MELCHIOR F, 1993, J CELL BIOL, V123, P1649, DOI 10.1083/jcb.123.6.1649; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; MILBURN MV, 1990, SCIENCE, V247, P939, DOI 10.1126/science.2406906; MOORE MS, 1993, NATURE, V365, P661, DOI 10.1038/365661a0; NASSAR M, 1995, NATURE, V375, P554, DOI 10.1038/375554a0; Nassar N, 1998, NAT STRUCT BIOL, V5, P1047, DOI 10.1038/4156; Nassar N, 1996, NAT STRUCT BIOL, V3, P723, DOI 10.1038/nsb0896-723; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; OHTSUBO M, 1989, J CELL BIOL, V109, P1389, DOI 10.1083/jcb.109.4.1389; Ostermeier C, 1999, CELL, V96, P363, DOI 10.1016/S0092-8674(00)80549-8; PAI EF, 1990, EMBO J, V9, P2351, DOI 10.1002/j.1460-2075.1990.tb07409.x; PEIFER M, 1994, CELL, V76, P789, DOI 10.1016/0092-8674(94)90353-0; PRIVE GG, 1992, P NATL ACAD SCI USA, V89, P3649, DOI 10.1073/pnas.89.8.3649; RADU A, 1995, P NATL ACAD SCI USA, V92, P1769, DOI 10.1073/pnas.92.5.1769; Renault L, 1998, NATURE, V392, P97, DOI 10.1038/32204; REXACH M, 1995, CELL, V83, P683, DOI 10.1016/0092-8674(95)90181-7; RICHARDS SA, 1995, J BIOL CHEM, V270, P14405, DOI 10.1074/jbc.270.24.14405; Rittinger K, 1997, NATURE, V389, P758, DOI 10.1038/39651; Scheffzek K, 1997, SCIENCE, V277, P333, DOI 10.1126/science.277.5324.333; SCHEFFZEK K, 1995, NATURE, V374, P378, DOI 10.1038/374378a0; SCHLICHTING I, 1990, NATURE, V345, P309, DOI 10.1038/345309a0; Shah S, 1998, J CELL BIOL, V141, P31, DOI 10.1083/jcb.141.1.31; Siomi MC, 1997, J CELL BIOL, V138, P1181, DOI 10.1083/jcb.138.6.1181; Stewart M, 1998, J MOL BIOL, V277, P635, DOI 10.1006/jmbi.1997.1602; Truant R, 1999, MOL CELL BIOL, V19, P1210; Vetter IR, 1999, NATURE, V398, P39, DOI 10.1038/17969; VETTER IR, 1999, IN PRESS FEBS LETT; Wei YY, 1997, NAT STRUCT BIOL, V4, P699, DOI 10.1038/nsb0997-699; Weis K, 1996, EMBO J, V15, P1818, DOI 10.1002/j.1460-2075.1996.tb00531.x	73	279	282	0	9	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAY 28	1999	97	5					635	646		10.1016/S0092-8674(00)80774-6	http://dx.doi.org/10.1016/S0092-8674(00)80774-6			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	202VD	10367892	Bronze			2022-12-28	WOS:000080672100012
J	Zhang, LQ; Ramratnam, B; Tenner-Racz, K; He, YX; Vesanen, M; Lewin, S; Talal, A; Racz, P; Perelson, AS; Korber, BT; Markowitz, M; Ho, DD				Zhang, LQ; Ramratnam, B; Tenner-Racz, K; He, YX; Vesanen, M; Lewin, S; Talal, A; Racz, P; Perelson, AS; Korber, BT; Markowitz, M; Ho, DD			Quantifying residual HIV-1 replication in patients receiving combination antiretroviral therapy	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; PRIMARY INFECTION; RAPID TURNOVER; CELL COUNTS; LIFE-SPAN; T-CELLS; LYMPHOCYTES; SEQUENCES; INDINAVIR; POOL	Background In patients infected with human immunodeficiency virus type 1 (HIV-1), combination antiretroviral therapy can result in sustained suppression of plasma levels of the virus. However, replication-competent virus can still be recovered from latently infected resting memory CD4 lymphocytes; this finding raises serious doubts about whether antiviral treatment can eradicate HIV-1. Methods We looked for evidence of residual HIV-1 replication in eight patients who began treatment soon after infection and in whom plasma levels of HIV-I RNA were undetectable after two to three years of antiretroviral therapy. We examined whether there had been changes over time in HIV-1 proviral sequences in peripheral-blood mononuclear eel Is, which would indicate residual viral replication. We also performed in situ hybridization studies on tissues from one patient to identify cells actively expressing HIV-1 RNA. We estimated the rate of decrease of latent, replication-competent HIV-1 in resting CD4 lymphocytes on the basis of the decrease in the numbers of proviral sequences identified during primary infection and direct sequential measurements of the size of the latent reservoir. Results Six of the eight patients had no significant variations in proviral sequences during treatment. However, in two patients there was sequence evolution but no evidence of drug-resistant viral genotypes. In one patient, extensive in situ studies provided additional evidence of persistent viral replication in lymphoid tissues. Using two independent approaches, we estimated that the half-life of the latent, replication-competent virus in resting CD4 lymphocytes was approximately six months. Conclusions These findings suggest that combination antiretroviral regimens suppress HIV-1 replication in some but not all patients. Given the half-life of latently infected CD4 lymphocytes of about six months, it may require many years of effective antiretroviral treatment to eliminate this reservoir of HIV-1. (N Engl J Med 1999;340:1605-13.) (C) 1999, Massachusetts Medical Society.	Rockefeller Univ, Aaron Diamond AIDS Res Ctr, New York, NY 10016 USA; Bernhard Nocht Inst Trop Med, Hamburg, Germany; Los Alamos Natl Lab, Div Theoret, Los Alamos, NM USA	Rockefeller University; Bernhard Nocht Institut fur Tropenmedizin; United States Department of Energy (DOE); Los Alamos National Laboratory	Ho, DD (corresponding author), Rockefeller Univ, Aaron Diamond AIDS Res Ctr, 455 1st Ave, New York, NY 10016 USA.	dho@adarc.org	Abrams, William R/A-5782-2008; Perelson, Alan S/Z-1959-2019; Lewin, Sharon/Z-3297-2019; Guo, Yong/ABF-9338-2020	Perelson, Alan S/0000-0002-2455-0002; Korber, Bette/0000-0002-2026-5757; Lewin, Sharon Ruth/0000-0002-0330-8241	NCRR NIH HHS [MO1-RR00102] Funding Source: Medline; NIAID NIH HHS [AI41534, AI40387] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000102] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI040387, U01AI041534] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Chun TW, 1997, NATURE, V387, P183, DOI 10.1038/387183a0; Chun TW, 1998, P NATL ACAD SCI USA, V95, P8869, DOI 10.1073/pnas.95.15.8869; FELSENSTEIN J, 1988, ANNU REV GENET, V22, P521, DOI 10.1146/annurev.ge.22.120188.002513; Finzi D, 1997, SCIENCE, V278, P1295, DOI 10.1126/science.278.5341.1295; Gulick RM, 1997, NEW ENGL J MED, V337, P734, DOI 10.1056/NEJM199709113371102; Hammer SM, 1997, NEW ENGL J MED, V337, P725, DOI 10.1056/NEJM199709113371101; Higgins DG, 1996, METHOD ENZYMOL, V266, P383; HO DD, 1995, NATURE, V373, P123, DOI 10.1038/373123a0; Ho DD, 1998, SCIENCE, V280, P1866, DOI 10.1126/science.280.5371.1866; MARTINEZ MA, 1994, P NATL ACAD SCI USA, V91, P11787, DOI 10.1073/pnas.91.25.11787; MICHIE CA, 1992, NATURE, V360, P264, DOI 10.1038/360264a0; Mohri H, 1998, SCIENCE, V279, P1223, DOI 10.1126/science.279.5354.1223; Perelson AS, 1996, SCIENCE, V271, P1582, DOI 10.1126/science.271.5255.1582; Perelson AS, 1997, NATURE, V387, P188, DOI 10.1038/387188a0; SAITOU N, 1987, MOL BIOL EVOL, V4, P406, DOI 10.1093/oxfordjournals.molbev.a040454; SIMMONDS P, 1990, J VIROL, V64, P864, DOI 10.1128/JVI.64.2.864-872.1990; Tenner-Racz K, 1998, J EXP MED, V187, P949, DOI 10.1084/jem.187.6.949; TOUGH DF, 1994, J EXP MED, V179, P1127, DOI 10.1084/jem.179.4.1127; VARTANIAN JP, 1994, P NATL ACAD SCI USA, V91, P3092, DOI 10.1073/pnas.91.8.3092; Vesanen M, 1996, J VIROL, V70, P9035, DOI 10.1128/JVI.70.12.9035-9040.1996; WEI XP, 1995, NATURE, V373, P117, DOI 10.1038/373117a0; Wong JK, 1997, SCIENCE, V278, P1291, DOI 10.1126/science.278.5341.1291; ZHANG LQ, 1993, J VIROL, V67, P3345, DOI 10.1128/JVI.67.6.3345-3356.1993; ZHU TF, 1993, SCIENCE, V261, P1179, DOI 10.1126/science.8356453	24	685	696	0	15	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAY 27	1999	340	21					1605	1613		10.1056/NEJM199905273402101	http://dx.doi.org/10.1056/NEJM199905273402101			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	199QY	10341272	Bronze			2022-12-28	WOS:000080494200001
J	Thomas, E; Silman, AJ; Croft, PR; Papageorgiou, AC; Jayson, MIV; Macfarlane, GJ				Thomas, E; Silman, AJ; Croft, PR; Papageorgiou, AC; Jayson, MIV; Macfarlane, GJ			Predicting who develops chronic low back pain in primary care: a prospective study	BRITISH MEDICAL JOURNAL			English	Article							GENERAL-PRACTICE; CLINICAL COURSE; OUTCOMES	Objectives To quantify the relative contribution of premorbid and episode specific factors in determining the long term persistence of disabling symptoms of low back pain. Design Prospective cohort study. Setting Two general practices in the south Manchester area. Participants 180 patients, who previously participated in a cross sectional population survey, who consulted because of low back pain during the study period. They were followed at 1 week and 3 and 12 months after consultation. Main outcome measure Persistent disabling low back pain in the 12 months after the consultation. Results Disabling low back pain persisted in one third of participants after consultation and was more common with increasing age, among those with a history of low back pain, and in women. Persistence of symptoms was associated with "premorbid" factors (high levels of psychological distress (odds ratio 3.3; 95% confidence interval 1.5 to 7.2), poor self rated health (3.6; 1.9 to 6.8), low levels of physical activity (2.8; 1.4 to 5.6), smoking(2.1; 1.0 to 4.3), dissatisfaction with employment (2.4; 1.3 to 4.5)) and factors related to thr episode of low back pain (duration of symptoms, pain radiating to the leg (2.6; 1.3 to 5.1), widespread pain (6.4; 2.7 to 15), and restriction in spinal mobility). A multivariate model based on six factors identified groups whose likelihood of persistent symptoms ranged from 6% to 70%. Conclusions The presence of persistent low back pain is determined not only by clinical factors associated with pain but also by the premorbid state.	Univ Manchester, Sch Med, Sch Epidemiol & Hlth Sci, Arthrit Res Campaign,Epidemiol Unit, Manchester M13 9PT, Lancs, England; Keele Univ, Postgrad Med Sch, Ind & Community Hlth Res Ctr, Stoke On Trent ST4 7QB, Staffs, England; Univ Manchester, Hope Hosp, Ctr Rheumat Dis, Salford M6 8HD, Lancs, England	University of Manchester; Keele University; University of Manchester	Macfarlane, GJ (corresponding author), Univ Manchester, Sch Med, Sch Epidemiol & Hlth Sci, Arthrit Res Campaign,Epidemiol Unit, Manchester M13 9PT, Lancs, England.		Macfarlane, Gary J/I-9521-2014	Macfarlane, Gary J/0000-0003-2322-3314				BURTON AK, 1991, SPINE, V16, P7, DOI 10.1097/00007632-199101000-00002; BURTON AK, 1995, SPINE, V20, P722, DOI 10.1097/00007632-199503150-00014; Cherkin DC, 1996, SPINE, V21, P2900, DOI 10.1097/00007632-199612150-00023; COSTE J, 1994, BRIT MED J, V308, P577, DOI 10.1136/bmj.308.6928.577; Croft PR, 1998, BRIT MED J, V316, P1356, DOI 10.1136/bmj.316.7141.1356; CROFT PR, 1996, SPINE, V20, P2731; Dionne CE, 1997, J CLIN EPIDEMIOL, V50, P31, DOI 10.1016/S0895-4356(96)00313-7; Goldberg D.P., 1988, USERS GUIDE GEN HLTH; Kohlmann T, 1996, Rehabilitation (Stuttg), V35, pI; Macfarlane GJ, 1996, J RHEUMATOL, V23, P1617; MAIN CJ, 1992, SPINE, V17, P42, DOI 10.1097/00007632-199201000-00007; McCormick A, 1995, SERIES MB5, V3; Office of Population Censuses and Surveys, 1991, STAND OCC CLASS; PAPAGEORGIOU AC, 1995, SPINE, V20, P1889, DOI 10.1097/00007632-199509000-00009; Papageorgiou AC, 1997, SPINE, V22, P1137, DOI 10.1097/00007632-199705150-00014; PHILIPS HC, 1991, BEHAV RES THER, V29, P435, DOI 10.1016/0005-7967(91)90127-O; POPE MH, 1980, SPINE, V5, P173, DOI 10.1097/00007632-198003000-00012; *STAT, 1997, STAT STAT SOFTW REL; Stewart AL, 1992, MEASURING FUNCTIONIN, P143; Thomas E, 1998, SPINE, V23, P343, DOI 10.1097/00007632-199802010-00011; TROUP DG, 1981, SPINE, V6, P61; *UK DEP HLTH CLIN, 1994, EP REV EP COST BACK; van den Hoogen HJM, 1998, ANN RHEUM DIS, V57, P13, DOI 10.1136/ard.57.1.13; VONKORFF M, 1993, SPINE, V18, P855, DOI 10.1097/00007632-199306000-00008	24	330	336	0	16	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JUN 19	1999	318	7199					1662	1667		10.1136/bmj.318.7199.1662	http://dx.doi.org/10.1136/bmj.318.7199.1662			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	210KY	10373170	Green Submitted, Bronze, Green Published			2022-12-28	WOS:000081105600021
J	Hosler, D; Burkett, SL; Tarkanian, MJ				Hosler, D; Burkett, SL; Tarkanian, MJ			Prehistoric polymers: Rubber processing in ancient Mesoamerica	SCIENCE			English	Article								Ancient Mesoamerican peoples harvested latex from Castilla elastica, processed it using liquid extracted from Ipomoea alba (a species of morning glory vine), and fashioned rubber balls, hollow rubber figurines, and other rubber artifacts from the resulting material. Chemical and mechanical analyses of the latex and of the processed rubber indicate that the enhanced elastic behavior of the. rubber relative to the unprocessed latex is due to purification of the polymer component and to an increase in the strength and number of interchain interactions that are induced by organic compounds present in I. alba. These ancient peoples' control over the properties of latex and processed rubber gave rise to the Mesoamerican ball game, a central ritual element in all ancient Mesoamerican societies.	MIT, Ctr Mat Res Archaeol & Ethnol, Cambridge, MA 02139 USA; MIT, Dept Mat Sci & Engn, Cambridge, MA 02139 USA	Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT)	Hosler, D (corresponding author), MIT, Ctr Mat Res Archaeol & Ethnol, 77 Massachusetts Ave, Cambridge, MA 02139 USA.							[Anonymous], 1971, TXB POLYM SCI; BENAVENTE T, 1984, HIST INDIOS NUEVA ES, P35; COGGINS C, 1992, ARTIFACTS CENOTE SAC, P353; Hill WD, 1998, NATURE, V392, P878, DOI 10.1038/31837; KELLY I, 1943, NOTES MIDDLE AM ARCH, V1, P164; KROSCHWITZ J, 1985, ENCY POLYM SCI ENG; Leyenaar T., 1988, ULAMA BALLGAME MAYAS; Leyenaar Ted. J.J., 1978, ULAMA PERPETUATION M; March J., 1992, ADV ORG CHEM, V4th; MARTYR P, 1964, DECADAS NUEVO MUNDO, V2, P547; Odian G., 1991, PRINCIPLES POLYM, V3; Rodriguez C., 1994, MANATI ESPACIO SAGRA; Scarborough V., 1991, MESOAMERICAN BALL GA; Standley P.C., 1920, TREES SHRUBS MEXICO, VVolume 23; TEDLOCK D, 1985, POPOL VUH; van Ooststroom Simon Jan, 1940, BLUMEA, V3, P547; Wildman S. G., 1943, SCIENCE, V97, P471, DOI 10.1126/science.97.2525.471	17	84	88	1	44	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 18	1999	284	5422					1988	1991		10.1126/science.284.5422.1988	http://dx.doi.org/10.1126/science.284.5422.1988			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	207JA	10373117				2022-12-28	WOS:000080932700047
J	Cummings, SR; Eckert, S; Krueger, KA; Grady, D; Powles, TJ; Cauley, JA; Norton, L; Nickelsen, T; Bjarnason, NH; Morrow, M; Lippman, ME; Black, D; Glusman, JE; Costa, A; Jordan, VC				Cummings, SR; Eckert, S; Krueger, KA; Grady, D; Powles, TJ; Cauley, JA; Norton, L; Nickelsen, T; Bjarnason, NH; Morrow, M; Lippman, ME; Black, D; Glusman, JE; Costa, A; Jordan, VC			The effect of raloxifene on risk of breast cancer in postmenopausal women - Results from the MORE randomized trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							BONE-MINERAL DENSITY; RECEPTOR-POSITIVE TUMORS; SURGICAL-ADJUVANT-BREAST; CORONARY HEART-DISEASE; ESTROGEN-RECEPTOR; ENDOMETRIAL CANCER; OVARIECTOMIZED RATS; SERUM-CHOLESTEROL; TAMOXIFEN THERAPY; PREVENTION	Context Raloxifene hydrochloride is a selective estrogen receptor modulator that has antiestrogenic effects on breast and endometrial tissue and estrogenic effects on bone, lipid metabolism, and blood clotting. Objective To determine whether women taking raloxifene have a lower risk of invasive breast cancer. Design and Setting The Multiple Outcomes of Raloxifene Evaluation (MORE), a multicenter, randomized, double-blind trial, in which women taking raloxifene or placebo were followed up for a median of 40 months (SD, 3 years), from 1994 through 1998, at 180 clinical centers composed of community settings and medical practices in 25 countries, mainly in the United States and Europe. Participants A total of 7705 postmenopausal women, younger than 81 (mean age, 66.5) years, with osteoporosis, defined by the presence of vertebral fractures or a femoral neck or spine T-score of at least 2.5 SDs below the mean for young healthy women. Almost all participants (96%) were white. Women who had a history of breast cancer or who were taking estrogen were excluded. Intervention Raloxifene, 60 mg, 2 tablets daily; or raloxifene, 60 mg, 1 tablet daily and 1 placebo tablet; or 2 placebo tablets. Main Outcome Measures New cases of breast cancer, confirmed by histopathology. Transvaginal ultrasonography was used to assess the endometrial effects of raloxifene in 1781 women. Deep vein thrombosis or pulmonary embolism were determined by chart review. Results Thirteen cases of breast cancer were confirmed among the 5129 women assigned to raloxifene vs 27 among the 2576 women assigned to placebo (relative risk [RR], 0.24; 95% confidence interval [CI], 0.13-0.44; P<.001). To prevent 1 case of breast cancer, 126 women would need to be treated. Raloxifene decreased the risk of estrogen receptor-positive breast cancer by 90% (RR, 0.10; 95% CI, 0.04-0.24), but not estrogen receptor-negative invasive breast cancer (RR, 0.88; 95% CI, 0.26-3.0). Raloxifene increased the risk of venous thromboembolic disease (RR, 3.1; 95% CI, 1.5-6.2), but did not increase the risk of endometrial cancer (RR, 0.8; 95% CI, 0.2-2.7). Conclusion Among postmenopausal women with osteoporosis, the risk of invasive breast cancer was decreased by 76% during 3 years of treatment with raloxifene.	Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA; Eli Lilly & Co, Indianapolis, IN 46285 USA; Royal Marsden NHS Trust Hosp, Breast Unit, Sutton, Surrey, England; Univ Pittsburgh, Dept Epidemiol, Pittsburgh, PA 15261 USA; Mem Sloan Kettering Canc Ctr, Dept Breast Canc Med, New York, NY 10021 USA; Ctr Clin & Basic Res, Ballerup, Denmark; Northwestern Univ, Sch Med, Dept Surg, Chicago, IL 60611 USA; Northwestern Univ, Sch Med, Robert H Lurie Canc Ctr, Chicago, IL 60611 USA; Georgetown Univ, Med Ctr, Vincent T Lombardi Canc Res Ctr, Washington, DC 20007 USA; European Inst Oncol, Milan, Italy	University of California System; University of California San Francisco; University of California System; University of California San Francisco; Eli Lilly; Royal Marsden NHS Foundation Trust; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Memorial Sloan Kettering Cancer Center; Center Clinical & Basic Research; Northwestern University; Northwestern University; Robert H. Lurie Comprehensive Cancer Center; Georgetown University; IRCCS European Institute of Oncology (IEO)	Cummings, SR (corresponding author), Prevent Sci Grp, Suite 600,74 New Montgomery, San Francisco, CA 94105 USA.		JORDAN, V.Craig/AAX-3562-2020; Jordan, V. Craig/H-4491-2011; Cauley, Jane A/N-4836-2015	Cauley, Jane A/0000-0003-0752-4408				Anzano MA, 1996, J NATL CANCER I, V88, P123, DOI 10.1093/jnci/88.2.123; BLACK LJ, 1994, J CLIN INVEST, V93, P63, DOI 10.1172/JCI116985; Brzozowski AM, 1997, NATURE, V389, P753, DOI 10.1038/39645; Cauley JA, 1996, JAMA-J AM MED ASSOC, V276, P1404, DOI 10.1001/jama.276.17.1404; Cauley JA, 1999, ANN INTERN MED, V130, P270, DOI 10.7326/0003-4819-130-4_Part_1-199902160-00004; Clarke M, 1998, LANCET, V351, P1451; Costantino JP, 1997, J NATL CANCER I, V89, P776, DOI 10.1093/jnci/89.11.776; Delmas PD, 1997, NEW ENGL J MED, V337, P1641, DOI 10.1056/NEJM199712043372301; Dijkhuizen FPHLJ, 1996, MATURITAS, V25, P45, DOI 10.1016/0378-5122(96)01043-2; Dorgan JF, 1996, CANCER EPIDEM BIOMAR, V5, P533; Espeland MA, 1998, DIABETES CARE, V21, P1589, DOI 10.2337/diacare.21.10.1589; Fisher B, 1998, J NATL CANCER I, V90, P1371, DOI 10.1093/jnci/90.18.1371; Fisher B, 1996, JNCI-J NATL CANCER I, V88, P1529, DOI 10.1093/jnci/88.21.1529; FISHER B, 1994, J NATL CANCER I, V86, P527, DOI 10.1093/jnci/86.7.527; FISHER B, 1989, NEW ENGL J MED, V320, P479, DOI 10.1056/NEJM198902233200802; GODSLAND IF, 1996, J INTERN MED S, V738, P1; GOLDSTEIN SR, 1994, OBSTET GYNECOL, V83, P738; GOTTARDIS MM, 1988, CANCER RES, V48, P5183; GOTTARDIS MM, 1987, CANCER RES, V47, P4020; GRADY D, 1995, OBSTET GYNECOL, V85, P304, DOI 10.1016/0029-7844(94)00383-O; Grese TA, 1997, P NATL ACAD SCI USA, V94, P14105, DOI 10.1073/pnas.94.25.14105; Hankinson SE, 1998, JNCI-J NATL CANCER I, V90, P1292, DOI 10.1093/jnci/90.17.1292; HOWELL A, 1992, ANN ONCOL, V3, P611, DOI 10.1093/oxfordjournals.annonc.a058286; Hulley S, 1998, JAMA-J AM MED ASSOC, V280, P605, DOI 10.1001/jama.280.7.605; KANIS JA, 1994, J BONE MINER RES, V9, P1137, DOI 10.1002/jbmr.5650090802; Kelsey JL, 1996, ANNU REV PUBL HEALTH, V17, P47, DOI 10.1146/annurev.pu.17.050196.000403; Kleinman D, 1996, ENDOCRINOLOGY, V137, P1089, DOI 10.1210/en.137.3.1089; Landis SH, 1998, CA-CANCER J CLIN, V48, P6, DOI 10.3322/canjclin.48.1.6; LOVE RR, 1992, NEW ENGL J MED, V326, P852, DOI 10.1056/NEJM199203263261302; LOVE RR, 1991, ANN INTERN MED, V115, P860, DOI 10.7326/0003-4819-115-11-860; MADIGAN MP, 1995, J NATL CANCER I, V87, P1681, DOI 10.1093/jnci/87.22.1681; MCDONALD CC, 1995, BRIT MED J, V311, P977; OSBORNE CK, 1991, J NATL CANCER I, V83, P1477, DOI 10.1093/jnci/83.20.1477; Powles T, 1998, LANCET, V352, P98; Pritchard KI, 1998, LANCET, V352, P80, DOI 10.1016/S0140-6736(98)85002-2; RIES LAG, 1998, SEER CANC STAT REV; RUTQVIST LE, 1993, J NATL CANCER I, V85, P1398, DOI 10.1093/jnci/85.17.1398; Sato M, 1996, FASEB J, V10, P905, DOI 10.1096/fasebj.10.8.8666168; Spratt JS, 1996, J SURG ONCOL, V61, P68, DOI 10.1002/1096-9098(199601)61:1<68::AID-JSO2930610102>3.0.CO;2-E; TONIOLO PG, 1995, JNCI-J NATL CANCER I, V87, P190, DOI 10.1093/jnci/87.3.190; Veronesi U, 1998, LANCET, V352, P93; Vuento MH, 1996, ULTRASOUND OBST GYN, V8, P37, DOI 10.1046/j.1469-0705.1996.08010037.x; Walsh BW, 1998, JAMA-J AM MED ASSOC, V279, P1445, DOI 10.1001/jama.279.18.1445; Zhang YQ, 1997, NEW ENGL J MED, V336, P611, DOI 10.1056/NEJM199702273360903	44	1428	1478	1	53	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 16	1999	281	23					2189	2197		10.1001/jama.281.23.2189	http://dx.doi.org/10.1001/jama.281.23.2189			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	204RB	10376571				2022-12-28	WOS:000080777000032
J	Jain, A; Ogden, J				Jain, A; Ogden, J			General practitioners' experiences of patients' complaints: qualitative study	BRITISH MEDICAL JOURNAL			English	Article							HEALTH	Objective To examine how general practitioners experience patients' complaints. Setting General practices in Lambeth, Southwark:and Lewisham health authority. Participants Representative sample of 30 general practitioners who had had complaints made against them under either the old or new complaints system. Design Qualitative study with detailed interviews. Results Participants described their experiences of patients' complaints in three stages: initial impact, conflict and resolution. The first stage described being out of control, feelings of shock and panic, and a sense of indignation towards patients generally. The second stage described the many conflicts generated by the complaint: emotional conflicts such as feelings of anger, depression, and even suicide, conflicts around aspects of professional identity including doubts about clinical competence, conflicts with family and colleagues, and conflicts arising from the management of the complaint. The third stage described a sense of resolution. For many this meant practising defensively, for others it meant planning to leave general practice, and for a minority no resolution was achieved. Not all participants, however, reported such a negative experience. Some described how they had become immune to complaints, and a small minority described the complaint as a learning experience. Conclusion The initial impact stage and conflict stage may be necessary aspects of the experience that general practitioners endure when they have a complaint made against them. Support structures should, however, be in place to help general practitioners through these stages.	Univ London Kings Coll, Guys Kings & St Thomass Med Sch, Dept Gen Practice, London SE11 6SP, England	University of London; King's College London	Ogden, J (corresponding author), Univ London Kings Coll, Guys Kings & St Thomass Med Sch, Dept Gen Practice, London SE11 6SP, England.			Ogden, Jane/0000-0003-4271-5621				Allsop J, 1998, SOCIOL HEALTH ILL, V20, P802, DOI 10.1111/1467-9566.00130; CARLOW J, 1998, PULSE, V58, P4; COOPER CL, 1989, BRIT MED J, V298, P366, DOI 10.1136/bmj.298.6670.366; Department of Health, 1994, BEING HEARD REP REV; Kubler-Ross Elisabeth, 1967, DEATH DYING; *MED DEF UN, 1993, COP PAT COMPL GEN PR, P2; Miles M.B., 1993, QUALITATIVE DATA ANA; NETTLETON S, 1994, SOCIOL HEALTH ILL, V16, P38, DOI 10.1111/1467-9566.ep11347003; [No title captured]; [No title captured]	10	68	68	0	6	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JUN 12	1999	318	7198					1596	1599		10.1136/bmj.318.7198.1596	http://dx.doi.org/10.1136/bmj.318.7198.1596			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	207AL	10364121	Bronze, Green Submitted, Green Published			2022-12-28	WOS:000080913100031
J	Painter, O; Lee, RK; Scherer, A; Yariv, A; O'Brien, JD; Dapkus, PD; Kim, I				Painter, O; Lee, RK; Scherer, A; Yariv, A; O'Brien, JD; Dapkus, PD; Kim, I			Two-dimensional photonic band-gap defect mode laser	SCIENCE			English	Article							ROOM-TEMPERATURE OPERATION; SPONTANEOUS EMISSION; MICRODISK LASERS; MICROCAVITIES; FABRICATION; CRYSTALS; PHYSICS	A laser cavity formed from a single defect in a two-dimensional photon ic crystal is demonstrated. The optical microcavity consists of a half wavelength-thick waveguide for vertical confinement and a two-dimensional photonic crystal mirror for lateral Localization. A defect in the photonic crystal is introduced to trap photons inside a volume of 2.5 cubic half-wavelengths, approximately 0.03 cubic micrometers. The laser is fabricated in the indium gallium arsenic phosphide material system, and optical gain is provided by strained quantum wells designed for a peak emission wavelength of 1.55 micrometers at room temperature. Pulsed lasing action has been observed at a wavelength of 1.5 micrometers from optically pumped devices with a substrate temperature of 143 kelvin.	CALTECH, Dept Elect Engn, Pasadena, CA 91125 USA; CALTECH, Dept Appl Phys, Pasadena, CA 91125 USA; Univ So Calif, Dept Elect Engn, Los Angeles, CA 90089 USA	California Institute of Technology; California Institute of Technology; University of Southern California	Scherer, A (corresponding author), CALTECH, Dept Elect Engn, Pasadena, CA 91125 USA.							Baba T, 1996, JPN J APPL PHYS 1, V35, P1348, DOI 10.1143/JJAP.35.1348; ERDOGAN T, 1993, J OPT SOC AM B, V10, P391, DOI 10.1364/JOSAB.10.000391; JEWELL JL, 1991, IEEE J QUANTUM ELECT, V27, P1332, DOI 10.1109/3.89950; Joannopoulos J. D., 1995, PHOTONIC CRYSTALS; KIM I, 1988, J CRYST GROWTH, V119, P138; Lee RK, 1999, ELECTRON LETT, V35, P569, DOI 10.1049/el:19990415; LEVI AFJ, 1993, ELECTRON LETT, V29, P1666, DOI 10.1049/el:19931109; MCCALL SL, 1992, APPL PHYS LETT, V60, P289, DOI 10.1063/1.106688; OCCIOLOI R, 1998, IEE P-OPTOELECTRON, V145, P391; Painter O, 1999, J OPT SOC AM B, V16, P275, DOI 10.1364/JOSAB.16.000275; PURCELL EM, 1946, PHYS REV, V69, P681; Thiyagarajan SMK, 1998, ELECTRON LETT, V34, P2333, DOI 10.1049/el:19981639; Villeneuve PR, 1998, IEE P-OPTOELECTRON, V145, P384, DOI 10.1049/ip-opt:19982467; Villeneuve PR, 1996, PHYS REV B, V54, P7837, DOI 10.1103/PhysRevB.54.7837; VUCKOVIC J, IN PRESS IEEE J QUAN; YABLONOVITCH E, 1987, PHYS REV LETT, V58, P2059, DOI 10.1103/PhysRevLett.58.2059; YAMAMOTO Y, 1991, PHYS REV A, V44, P657, DOI 10.1103/PhysRevA.44.657; YOKOYAMA H, 1992, SCIENCE, V256, P66, DOI 10.1126/science.256.5053.66; YOSHIE T, 1998, 1998 IEEE 16 INT SEM; ZHOU Y, 1992, IEEE PHOTONIC TECH L, V4, P1315	20	2103	2204	9	626	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 11	1999	284	5421					1819	1821		10.1126/science.284.5421.1819	http://dx.doi.org/10.1126/science.284.5421.1819			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	205EU	10364550				2022-12-28	WOS:000080809000044
J	Zamanillo, D; Sprengel, R; Hvalby, O; Jensen, V; Burnashev, N; Rozov, A; Kaiser, KMM; Koster, HJ; Borchardt, T; Worley, P; Lubke, J; Frotscher, M; Kelly, PH; Sommer, B; Andersen, P; Seeburg, PH; Sakmann, B				Zamanillo, D; Sprengel, R; Hvalby, O; Jensen, V; Burnashev, N; Rozov, A; Kaiser, KMM; Koster, HJ; Borchardt, T; Worley, P; Lubke, J; Frotscher, M; Kelly, PH; Sommer, B; Andersen, P; Seeburg, PH; Sakmann, B			Importance of AMPA receptors for hippocampal synaptic plasticity but not for spatial learning	SCIENCE			English	Article							LONG-TERM POTENTIATION; NON-NMDA RECEPTORS; SUBUNIT GLUR-B; LASTING POTENTIATION; GLUTAMATE RECEPTORS; PYRAMIDAL NEURONS; RAT HIPPOCAMPUS; LTP; MEMORY; MICE	Gene-targeted mice lacking the L-alpha-amino-3-hydroxy-5-methylisoxazole-4-propionate (AM PA) receptor subunit GluR-A exhibited normal development, Life expectancy, and fine structure of neuronal dendrites and synapses. In hippocampal CA1 pyramidal neurons, GluR-A(-/-) mice showed a reduction in functional AMPA receptors, with the remaining receptors preferentially targeted to synapses. Thus, the CA1 soma-patch currents were strongly reduced, but glutamatergic synaptic currents were unaltered; and evoked dendritic and spinous Ca2+ transients, Ca2+-dependent gene activation, and hippocampal field potentials were as in the wild type, in adult GluR-A(-/-) mice, associative Long-term potentiation (LTP) was absent in CA3 to CA1 synapses, but spatial Learning in the water maze was not impaired. The results suggest that CA1 hippocampal LTP is controlled by the number or subunit composition of AMPA receptors and show a dichotomy between LTP in CA1 and acquisition of spatial memory.	Max Planck Inst Med Res, Dept Mol Neurosci, D-69120 Heidelberg, Germany; Max Planck Inst Med Res, Dept Cell Physiol, D-69120 Heidelberg, Germany; Univ Oslo, Dept Physiol, Inst Basic Med Sci, N-0316 Oslo, Norway; Johns Hopkins Univ, Sch Med, Dept Neurosci, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Neurol, Baltimore, MD 21205 USA; Univ Freiburg, Dept Anat, D-79104 Freiburg, Germany; Novartis Pharma AG, NS Res, Basel, Switzerland	Max Planck Society; Max Planck Society; University of Oslo; Johns Hopkins University; Johns Hopkins University; University of Freiburg; Novartis	Sprengel, R (corresponding author), Max Planck Inst Med Res, Dept Mol Neurosci, Jahnstr 29, D-69120 Heidelberg, Germany.	sprengel@mpimf-heidelberg.mpg.de	Rozov, Andrei/C-1997-2015; Borchardt, Thilo/E-7844-2011; Burnashev, Nail/G-4056-2013; Lubke, Joachim/H-8762-2013	Borchardt, Thilo/0000-0002-2960-0267; Lubke, Joachim/0000-0002-4086-3199				ANDERSEN P, 1983, PROG BRAIN RES, V58, P419, DOI 10.1016/S0079-6123(08)60044-8; ANDERSEN P, 1960, ACTA PHYSIOL SCAND, V48, P178, DOI 10.1111/j.1748-1716.1960.tb01856.x; ANDERSEN P, 1977, NATURE, V266, P736, DOI 10.1038/266736a0; BANNERMAN DM, 1995, NATURE, V378, P182, DOI 10.1038/378182a0; Barria A, 1997, SCIENCE, V276, P2042, DOI 10.1126/science.276.5321.2042; BAUDE A, 1995, NEUROSCIENCE, V69, P1031, DOI 10.1016/0306-4522(95)00350-R; BLAKE JF, 1988, NEUROSCI LETT, V89, P182, DOI 10.1016/0304-3940(88)90378-3; BLISS TVP, 1973, J PHYSIOL-LONDON, V232, P331, DOI 10.1113/jphysiol.1973.sp010273; BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0; BURNASHEV N, 1992, NEURON, V8, P189, DOI 10.1016/0896-6273(92)90120-3; DENK W, 1990, SCIENCE, V248, P73, DOI 10.1126/science.2321027; Feldmeyer D, 1999, NAT NEUROSCI, V2, P57, DOI 10.1038/4561; FROTSCHER M, 1992, MICROSC RES TECHNIQ, V23, P306, DOI 10.1002/jemt.1070230406; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; GU H, 1993, CELL, V73, P1155, DOI 10.1016/0092-8674(93)90644-6; Helmchen F, 1996, BIOPHYS J, V70, P1069, DOI 10.1016/S0006-3495(96)79653-4; HOLLMANN M, 1991, SCIENCE, V252, P851, DOI 10.1126/science.1709304; Huang YY, 1995, CELL, V83, P1211, DOI 10.1016/0092-8674(95)90146-9; HUME RI, 1991, SCIENCE, V253, P1028, DOI 10.1126/science.1653450; JONAS P, 1993, J PHYSIOL-LONDON, V472, P615, DOI 10.1113/jphysiol.1993.sp019965; Kask K, 1998, P NATL ACAD SCI USA, V95, P13777, DOI 10.1073/pnas.95.23.13777; KATZ B, 1968, J PHYSIOL-LONDON, V195, P481, DOI 10.1113/jphysiol.1968.sp008469; KEINANEN K, 1990, SCIENCE, V249, P556, DOI 10.1126/science.2166337; KELLY PH, 1993, CAN J PHYSIOL PHARM, V71, P352, DOI 10.1139/y93-055; Koester HJ, 1998, P NATL ACAD SCI USA, V95, P9596, DOI 10.1073/pnas.95.16.9596; KOHLER M, 1994, J BIOL CHEM, V269, P17367; KULLMANN DM, 1995, NEURON, V15, P997, DOI 10.1016/0896-6273(95)90089-6; Lledo PM, 1998, SCIENCE, V279, P399, DOI 10.1126/science.279.5349.399; MADISON DV, 1991, ANNU REV NEUROSCI, V14, P379, DOI 10.1146/annurev.ne.14.030191.002115; Malenka RC, 1997, NEURON, V19, P473, DOI 10.1016/S0896-6273(00)80362-1; Markram H, 1997, J PHYSIOL-LONDON, V500, P409, DOI 10.1113/jphysiol.1997.sp022031; Meiri N, 1998, P NATL ACAD SCI USA, V95, P15037, DOI 10.1073/pnas.95.25.15037; MOLNAR E, 1993, NEUROSCIENCE, V53, P307, DOI 10.1016/0306-4522(93)90198-O; Morris RGM, 1997, PHILOS T ROY SOC B, V352, P1489, DOI 10.1098/rstb.1997.0136; MORRIS RGM, 1986, NATURE, V319, P774, DOI 10.1038/319774a0; NAGY A, 1993, P NATL ACAD SCI USA, V90, P8424, DOI 10.1073/pnas.90.18.8424; Nayak A, 1998, NATURE, V394, P680, DOI 10.1038/29305; NostenBertrand M, 1996, NATURE, V379, P826, DOI 10.1038/379826a0; Okabe S, 1998, J NEUROSCI, V18, P4177; Petralia RS, 1997, J COMP NEUROL, V385, P456, DOI 10.1002/(SICI)1096-9861(19970901)385:3<456::AID-CNE9>3.0.CO;2-2; PHEND KD, 1992, J HISTOCHEM CYTOCHEM, V40, P1011, DOI 10.1177/40.7.1376741; Roche KW, 1996, NEURON, V16, P1179, DOI 10.1016/S0896-6273(00)80144-0; SAFFEN DW, 1988, P NATL ACAD SCI USA, V85, P7795, DOI 10.1073/pnas.85.20.7795; SATHER W, 1992, J PHYSIOL-LONDON, V450, P643, DOI 10.1113/jphysiol.1992.sp019148; Schurmans S, 1997, P NATL ACAD SCI USA, V94, P10415, DOI 10.1073/pnas.94.19.10415; Silver RA, 1996, J PHYSIOL-LONDON, V493, P167, DOI 10.1113/jphysiol.1996.sp021372; Sprengel R, 1998, CELL, V92, P279, DOI 10.1016/S0092-8674(00)80921-6; Tsien JZ, 1996, CELL, V87, P1327, DOI 10.1016/S0092-8674(00)81827-9; Wenthold RJ, 1996, J NEUROSCI, V16, P1982; WIGSTROM H, 1985, ACTA PHYSIOL SCAND, V125, P159, DOI 10.1111/j.1748-1716.1985.tb07703.x; WIGSTROM H, 1983, NATURE, V301, P603, DOI 10.1038/301603a0; WORLEY PF, 1990, COLD SH Q B, V55, P213, DOI 10.1101/SQB.1990.055.01.023	52	609	620	0	44	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 11	1999	284	5421					1805	1811		10.1126/science.284.5421.1805	http://dx.doi.org/10.1126/science.284.5421.1805			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	205EU	10364547				2022-12-28	WOS:000080809000041
J	Henderson, DA; Inglesby, TV; Bartlett, JG; Ascher, MS; Eitzen, E; Jahrling, PB; Hauer, J; Layton, M; McDade, J; Osterholm, MT; O'Toole, T; Parker, G; Perl, T; Russell, PK; Tonat, K				Henderson, DA; Inglesby, TV; Bartlett, JG; Ascher, MS; Eitzen, E; Jahrling, PB; Hauer, J; Layton, M; McDade, J; Osterholm, MT; O'Toole, T; Parker, G; Perl, T; Russell, PK; Tonat, K		Working Grp Civilian Biodefense	Smallpox as a biological weapon - Medical and public health management	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ORTHOPOXVIRUS; DISEASE	Objective. To develop consensus-based recommendations for measures to be taken by medical and public health professionals following the use of smallpox as a biological weapon against a civilian population. Participants. The working group included 21 representatives from staff of major medical centers and research, government, military, public health, and emergency management institutions and agencies. Evidence. The first author (D.A.H..) conducted a literature search in conjunction with the preparation of another publication on smallpox as well as this article. The literature identified was reviewed and opinions were sought from experts in the diagnosis and management of smallpox, including members of the working group. Consensus Process. The first draft of the consensus statement was a synthesis of information obtained in the evidence-gathering process. Members of the working group provided formal written comments that were incorporated into the second draft of the statement. The working group reviewed the second draft on October 30, 1998. No significant disagreements existed and comments were incorporated into a third draft. The fourth and final statement incorporates all relevant evidence obtained by the literature search in conjunction with final consensus recommendations supported by all working group members. Conclusions. Specific recommendations are made regarding smallpox vaccination, therapy, postexposure isolation and infection control, hospital epidemiology and infection control, home care, decontamination of the environment, and additional research needs. In the event of an actual release of smallpox and subsequent epidemic, early detection, isolation of infected individuals, surveillance of contacts, and a focused selective vaccination program will be the essential items of an effective control program.	Johns Hopkins Univ, Ctr Civilian Biodef Studies, Baltimore, MD 21202 USA; Johns Hopkins Univ, Sch Publ Hlth, Baltimore, MD 21202 USA; Johns Hopkins Univ, Sch Med, Baltimore, MD 21202 USA; Calif Dept Hlth, Berkeley, CA USA; USA, Med Res Inst Infect Dis, Frederick, MD USA; New York City Dept Hlth, Off Emergency Management, New York, NY 10013 USA; New York City Dept Hlth, Off Communicable Dis, New York, NY 10013 USA; Ctr Dis Control & Prevent, Atlanta, GA USA; Minnesota Dept Hlth, Minneapolis, MN USA; US Dept HHS, Off Emergency Preparedness, Rockville, MD USA	Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; California Department of Public Health; New York City Department of Health & Mental Hygiene; New York City Department of Health & Mental Hygiene; Centers for Disease Control & Prevention - USA; Minnesota Department of Health (MHD)	Henderson, DA (corresponding author), Johns Hopkins Univ, Ctr Civilian Biodef Studies, Candler Bldg,Suite 850,111 Market Pl, Baltimore, MD 21202 USA.	dahzero@aol.com						Alibek Ken., 1999, BIOHAZARD; ANDERS W, 1962, BUNDESGESUNDHEITSBLA, V17, P265; [Anonymous], 1991, MMWR Recomm Rep, V40, P1; Breman JG, 1998, NEW ENGL J MED, V339, P556, DOI 10.1056/NEJM199808203390811; Centers for Disease Control and Prevention, 1990, MMWR-MORBID MORTAL W, V40, P445; Chapin CV, 1913, J INFECT DIS, V13, P171, DOI 10.1093/infdis/13.2.171; CHAPIN CV, 1932, J PREV MED, V1, P1; DIXON CW, 1948, J HYG-CAMBRIDGE, V46, P351, DOI 10.1017/S0022172400036536; DIXON CW, 1962, SMALLPOX, P1460; DOWNIE A. W., 1958, JOUR HYGIENE, V56, P479; ELAD B, 1990, J INFECT DIS, V161, P446, DOI 10.1093/infdis/161.3.446; Esposito J.J., 1995, CLIN MICROBIOLOGY, P1131; ESPOSITO JJ, 1985, VIROLOGY, V143, P230, DOI 10.1016/0042-6822(85)90111-4; Fenner F., 1988, SMALLPOX ITS ERADICA, P1460; FENNER F, 1988, ORTHOPOXVIRUSES, P432; GOLDSTEIN JA, 1975, PEDIATRICS, V55, P342; HARPER GJ, 1961, J HYG-CAMBRIDGE, V59, P479, DOI 10.1017/S0022172400039176; Hashizume S., 1985, VACCINIA VIRUSES VEC, P87; HENDERSON DA, 1972, SE725 WHO; HIRAYAMA M, 1975, VACCINATION THEORY P, P113; Hopkins DR, 1983, PRINCES PEASANTS; HUQ F, 1976, B WORLD HEALTH ORGAN, V54, P710; Inglesby TV, 1999, JAMA-J AM MED ASSOC, V281, P1735, DOI 10.1001/jama.281.18.1735; Institute of Medicine, 1999, ASS FUT SCI NEED LIV; Jezek Z., 1988, MONOGRAPHS VIROLOGY; JOARDER AK, 1980, ERADICATION SMALLPOX; KEMPE CH, 1960, PEDIATRICS, V26, P176; KNIGHT JC, 1995, PCR PROTOCOLS DIAGNO, P297; KOPLAN JP, 1975, J INFECT DIS, V131, P34, DOI 10.1093/infdis/131.1.34; Lalezari JP, 1997, ANN INTERN MED, V126, P257, DOI 10.7326/0003-4819-126-4-199702150-00001; LANE JM, 1969, NEW ENGL J MED, V281, P1201, DOI 10.1056/NEJM196911272812201; MACK TM, 1972, J INFECT DIS, V125, P161, DOI 10.1093/infdis/125.2.161; MACK TM, 1972, AM J EPIDEMIOL, V95, P157, DOI 10.1093/oxfordjournals.aje.a121380; MARSDEN JP, 1948, B HYG, V23, P735; MCINTOSH K, 1990, J INFECT DIS, V161, P445; MONSUR KA, 1975, J INFECT DIS, V131, P40, DOI 10.1093/infdis/131.1.40; OTOOLE T, IN PRESS EMERG INFEC; Rao AR, 1972, SMALLPOX; Rao AR, 1972, WHOSE7240; REDFIELD RR, 1987, NEW ENGL J MED, V316, P673, DOI 10.1056/NEJM198703123161106; ROPP SL, 1995, J CLIN MICROBIOL, V33, P2069, DOI 10.1128/JCM.33.8.2069-2076.1995; SARKAR JK, 1973, B WORLD HEALTH ORGAN, V48, P523; SHARP JCM, 1973, LANCET, V1, P656; Stearn E. W., 1945, EFFECT SMALLPOX DEST; *US BUR CENS, 1998, RES POP US EST AG SE; WEHRLE PF, 1970, B WORLD HEALTH ORGAN, V43, P669; *WHO, 1972, WHO TECHN REP SERIES, P493; *WHO, 1999, M WHO AD HOC EXP COM; WOLFF HL, 1968, B WORLD HEALTH ORGAN, V38, P492; World Health Organization, 1980, GLOB ER SMALLP FIN R	50	586	608	6	81	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 9	1999	281	22					2127	2137		10.1001/jama.281.22.2127	http://dx.doi.org/10.1001/jama.281.22.2127			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	202TJ	10367824				2022-12-28	WOS:000080668000036
J	Leitzmann, MF; Willett, WC; Rimm, EB; Stampfer, MJ; Spiegelman, D; Colditz, GA; Giovannucci, E				Leitzmann, MF; Willett, WC; Rimm, EB; Stampfer, MJ; Spiegelman, D; Colditz, GA; Giovannucci, E			A prospective study of coffee consumption and the risk of symptomatic gallstone disease in men	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							FOOD FREQUENCY QUESTIONNAIRE; CHOLESTEROL-RAISING FACTOR; LOGISTIC-REGRESSION; LIPID-PEROXIDATION; PHYSICAL-ACTIVITY; BOILED COFFEE; CYCLIC-AMP; CAFFEINE; BILE; SMOKING	Context. Coffee has several metabolic effects that could reduce the risk of gallstone formation. Objective To examine the association between coffee consumption and the risk of symtomatic gallstone disease in men. Design and Setting The Health Professionals Follow-up Study, a prospective cohort study, in which the consumption of coffee and other caffeinated drinks was assessed starting in 1986 as part of the 131-item food frequency questionnaire given to US male health professionals with follow-up through 1996. Participants. A total of 46008 men, aged 40 to 75 years in 1986, without history of gallstone disease. Main Outcome Measures. Newly symptomatic gallstone disease (diagnosed by ultrasonography or x-ray) or a cholecystectomy. Results. During 404166 person-years of follow-up, 1081 subjects reported symptomatic gallstone disease, of whom 885 required cholecystectomy. After adjusting for other known or suspected risk factors, compared with men who did not: consume regular coffee in 1986 and 1990, the adjusted relative risk (RR) for those who consistently drank 2 to 3 cups of regular coffee per day was 0.60 (95% confidence interval [CI], 0.42-0.86) and far those who drank 4 or more cups per day the RR was 0.55 (95% CI, 0.33-0.92). All coffee brewing methods showed a decreased risk. The risk of symptomatic gallstone disease also declined with increasing caffeine intake (P for trend = .005). After controlling for known or suspected risk factors, the RR for men in the highest category of caffeine intake (>800 mg/d) compared with men in the lowest category (less than or equal to 25 mg/d) was 0.55 (95% CI, 0.35-0.87). In contrast, decaffeinated coffee was not associated with a decreased risk. Conclusions. In this cohort of US men, coffee consumption may have helped to prevent symptomatic gallstone disease.	Harvard Univ, Sch Publ Hlth, Dept Nutr, Boston, MA 02115 USA; Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA; Harvard Univ, Sch Publ Hlth, Dept Biostat, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Med, Channing Lab, Boston, MA USA; Brigham & Womens Hosp, Boston, MA 02115 USA	Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital	Leitzmann, MF (corresponding author), Harvard Univ, Sch Publ Hlth, Dept Nutr, 665 Huntington Ave, Boston, MA 02115 USA.	Michael.Leitzmann@channing.harvard.edu	Colditz, Graham/A-3963-2009	Colditz, Graham/0000-0002-7307-0291	NCI NIH HHS [CA55075] Funding Source: Medline; NHLBI NIH HHS [HL35464] Funding Source: Medline; PHS HHS [T4509856] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA055075] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL035464] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Aeschbacher HU, 1991, MUTAGENS FOOD DETECT, P181; ASTRUP A, 1990, AM J CLIN NUTR, V51, P759, DOI 10.1093/ajcn/51.5.759; BARBARA L, 1995, AM J EPIDEMIOL, V141, P158, DOI 10.1093/oxfordjournals.aje.a117403; BASSO L, 1992, EUR J EPIDEMIOL, V8, P629, DOI 10.1007/BF00145375; BOTHAM KM, 1986, BIOCHIM BIOPHYS ACTA, V889, P382, DOI 10.1016/0167-4889(86)90202-8; Breslow NE., 1987, STAT METHODS CANC RE, P81; CONTER RL, 1986, AM J SURG, V151, P184, DOI 10.1016/0002-9610(86)90030-9; CUPPLES LA, 1988, STAT MED, V7, P205, DOI 10.1002/sim.4780070122; CURATOLO PW, 1983, ANN INTERN MED, V98, P641, DOI 10.7326/0003-4819-98-5-641; DAGOSTINO RB, 1990, STAT MED, V9, P1501, DOI 10.1002/sim.4780091214; Devasagayam TPA, 1996, BBA-BIOMEMBRANES, V1282, P63, DOI 10.1016/0005-2736(96)00040-5; DOUGLAS BR, 1990, AM J CLIN NUTR, V52, P553, DOI 10.1093/ajcn/52.3.553; Eder MI, 1996, FREE RADICAL BIO MED, V20, P743, DOI 10.1016/0891-5849(95)02154-X; FESKANICH D, 1993, J AM DIET ASSOC, V93, P790, DOI 10.1016/0002-8223(93)91754-E; FRIEDMAN GD, 1989, J CLIN EPIDEMIOL, V42, P127, DOI 10.1016/0895-4356(89)90086-3; FRIEDMAN GD, 1966, J CHRON DIS, V19, P273, DOI 10.1016/0021-9681(66)90132-9; GIOVANNUCCI E, 1992, JNCI-J NATL CANCER I, V84, P91, DOI 10.1093/jnci/84.2.91; GROBBEE DE, 1990, NEW ENGL J MED, V323, P1026, DOI 10.1056/NEJM199010113231504; GULLESTAD L, 1992, ALCOHOL CLIN EXP RES, V16, P986, DOI 10.1111/j.1530-0277.1992.tb01906.x; HOLSTEGE A, 1993, J HEPATOL, V17, P67, DOI 10.1016/S0168-8278(05)80523-9; JORGENSEN T, 1989, GUT, V30, P528, DOI 10.1136/gut.30.4.528; KALSER SC, 1993, AM J SURG, V165, P390; KANG JY, 1992, GUT, V33, P743, DOI 10.1136/gut.33.6.743; KATO H, 1995, ANGIOLOGY, V46, P169, DOI 10.1177/000331979504600212; Keiner F, 1965, Med Welt, V34, P1907; KLAPDOR R, 1978, ARZNEIMITTEL-FORSCH, V28-2, P1635; KNODELL RG, 1978, P SOC EXP BIOL MED, V157, P306; KONO S, 1991, DEV GASTRO, V12, P129; Kratzer W, 1997, SCAND J GASTROENTERO, V32, P953, DOI 10.3109/00365529709011208; LAVECCHIA C, 1991, INT J EPIDEMIOL, V20, P209, DOI 10.1093/ije/20.1.209; LILLEMOE KD, 1989, SURGERY, V106, P400; MAGNUSON T H, 1989, Current Surgery, V46, P477; MAURER KR, 1989, GASTROENTEROLOGY, V96, P487, DOI 10.1016/0016-5085(89)91575-8; Misciagna G, 1996, EUR J GASTROEN HEPAT, V8, P585, DOI 10.1097/00042737-199606000-00017; *NAT CTR HLTH STAT, 1994, NAT HOSP DISCH SURV; *NAT I DIAB DIG KI, 1995, NIH PUBL; Ortega RM, 1997, J AM COLL NUTR, V16, P88, DOI 10.1080/07315724.1997.10718655; PASTIDES H, 1990, ARCH INTERN MED, V150, P1409, DOI 10.1001/archinte.150.7.1409; Post SM, 1997, ARTERIOSCL THROM VAS, V17, P3064, DOI 10.1161/01.ATV.17.11.3064; Rao SSC, 1998, EUR J GASTROEN HEPAT, V10, P113, DOI 10.1097/00042737-199802000-00003; REYMANN A, 1989, BIOCHIM BIOPHYS ACTA, V1011, P158, DOI 10.1016/0167-4889(89)90203-6; RIMM EB, 1992, AM J EPIDEMIOL, V135, P1114, DOI 10.1093/oxfordjournals.aje.a116211; ROSNER B, 1990, AM J EPIDEMIOL, V132, P734, DOI 10.1093/oxfordjournals.aje.a115715; Rothman K, 1986, MODERN EPIDEMIOLOGY; Rustan AC, 1997, ARTERIOSCL THROM VAS, V17, P2140, DOI 10.1161/01.ATV.17.10.2140; SAHL T, 1998, AM J EPIDEMIOL, V147, P644; STAVRIC B, 1992, FOOD CHEM TOXICOL, V30, P533, DOI 10.1016/0278-6915(92)90106-U; *USDA, 1995, USDA NUTR DAT STAND; WEUSTENVANDERWOUW MPME, 1994, J LIPID RES, V35, P721	49	83	86	0	1	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 9	1999	281	22					2106	2112		10.1001/jama.281.22.2106	http://dx.doi.org/10.1001/jama.281.22.2106			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	202TJ	10367821	Bronze			2022-12-28	WOS:000080668000033
J	Margot, JL; Campbell, DB; Jurgens, RF; Slade, MA				Margot, JL; Campbell, DB; Jurgens, RF; Slade, MA			Topography of the lunar poles from radar interferometry: A survey of cold trap locations	SCIENCE			English	Article							POLAR ANOMALIES; MERCURY; ICE; MOON; CLEMENTINE; STABILITY; IMAGES; REGION	Detailed topographic maps of the lunar poles have been obtained by Earth-based radar-interferometry with the 3.5-centimeter wavelength Goldstone Solar System Radar. The interferometer provided maps 300 kilometers by 1000 kilometers of both polar regions at 150-meter spatial resolution and 50-meter height resolution. Using ray tracing, these digital elevation models were used to locate regions that are in permanent shadow from solar illumination and may harbor ice-deposits. Estimates of the total extent of shadowed areas poleward of 87.5 degrees latitude are 1030 and 2550 square kilometers for the north and south poles, respectively.	Cornell Univ, Dept Astron, Ithaca, NY 14853 USA; CALTECH, Jet Prop Lab, Pasadena, CA 91109 USA	Cornell University; California Institute of Technology; National Aeronautics & Space Administration (NASA); NASA Jet Propulsion Laboratory (JPL)	Campbell, DB (corresponding author), Arecibo Observ, HC3 Box 53995, Arecibo, PR 00612 USA.		Margot, Jean-Luc/A-6154-2012	Margot, Jean-Luc/0000-0001-9798-1797				ARNOLD JR, 1979, J GEOPHYS RES, V84, P5659, DOI 10.1029/JB084iB10p05659; Butler BJ, 1997, J GEOPHYS RES-PLANET, V102, P19283, DOI 10.1029/97JE01347; BUTLER BJ, 1993, J GEOPHYS RES-PLANET, V98, P15003, DOI 10.1029/93JE01581; EVANS JV, 1968, RADAR ASTRONOMYU; Feldman WC, 1998, SCIENCE, V281, P1496, DOI 10.1126/science.281.5382.1496; HARMON JK, 1994, NATURE, V369, P213, DOI 10.1038/369213a0; HARMON JK, 1992, SCIENCE, V258, P640, DOI 10.1126/science.258.5082.640; HARMON JP, UNPUB; INGERSOLL AP, 1992, ICARUS, V100, P40, DOI 10.1016/0019-1035(92)90016-Z; LANZEROTTI LJ, 1981, J GEOPHYS RES, V86, P3949, DOI 10.1029/JB086iB05p03949; MARGOT JL, IN PRESS J GEOPHYS R; MORGAN TH, 1991, J GEOPHYS RES-SPACE, V96, P1351, DOI 10.1029/90JA02127; NOZETTE S, 1994, SCIENCE, V266, P1835, DOI 10.1126/science.266.5192.1835; Nozette S, 1996, SCIENCE, V274, P1495, DOI 10.1126/science.274.5292.1495; SALVAIL JR, 1994, ICARUS, V111, P441, DOI 10.1006/icar.1994.1155; SHAPIRO II, 1972, SCIENCE, V178, P939, DOI 10.1126/science.178.4064.939; SHOEMAKER EM, 1994, SCIENCE, V266, P1851, DOI 10.1126/science.266.5192.1851; Simpson RA, 1999, J GEOPHYS RES-PLANET, V104, P3845, DOI 10.1029/1998JE900038; SLADE MA, 1992, SCIENCE, V258, P635, DOI 10.1126/science.258.5082.635; Smith DE, 1997, J GEOPHYS RES-PLANET, V102, P1591, DOI 10.1029/96JE02940; Stacy NJS, 1997, SCIENCE, V276, P1527, DOI 10.1126/science.276.5318.1527; VASAVADA AR, UNPUB; WARD WR, 1975, SCIENCE, V189, P377, DOI 10.1126/science.189.4200.377; WATSON K, 1961, J GEOPHYS RES, V66, P3033, DOI 10.1029/JZ066i009p03033; Zuber MT, 1997, GEOPHYS RES LETT, V24, P2183, DOI 10.1029/97GL02111; [No title captured]	26	97	110	0	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 4	1999	284	5420					1658	1660		10.1126/science.284.5420.1658	http://dx.doi.org/10.1126/science.284.5420.1658			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	202TM	10356393				2022-12-28	WOS:000080668300041
J	Lee, D; Sohn, H; Kalpana, GV; Choe, J				Lee, D; Sohn, H; Kalpana, GV; Choe, J			Interaction of E1 and hSNF5 proteins stimulates replication of human papillomavirus DNA	NATURE			English	Article							POLYMERASE ALPHA-PRIMASE; TRANSCRIPTIONAL ACTIVATOR; SACCHAROMYCES-CEREVISIAE; TRANSIENT REPLICATION; LARGE-T; E2; HELICASE; YEAST; GENES; SNF5	Mammalian viruses often use components of the host's cellular DNA replication machinery to carry out replication of their genomes, which enables these viruses to be used as tools for characterizing factors that are involved in cellular DNA replication. The human papillomavirus (HPV) E1 protein is essential for replication of the virus DNA(1-3). Here we identify the cellular factor that participates in viral DNA replication by using a two-hybrid assay(4) in the yeast Saccharomyces cerevisiae and E1 protein as bait. Using this assay, we isolated Ini1/hSNF5 (ref. 5), a component of the SWI/SNF complex which facilitates transcription by altering the structure of chromatin(6). In vitro binding and immunoprecipitation confirmed that E1 interacts directly with Ini1/hSNF5. Transient DNA-replication assay revealed that HPV DNA replication is stimulated in a dose-dependent manner by addition of Ini1/hSNF5, and that Ini1/hSNF5 antisense RNA blocks the replication of HPV DNA. Amino-acid substitution at residues that are conserved among E1 proteins prevented the E1-Ini1/hSNF5 interaction and reduced DNA replication of HPV in vivo. Our results indicate that Ini1/hSNF5 is required for the efficient replication of papillomavirus DNA and is therefore needed, either alone or in complex with SWI/SNF complex, for mammalian DNA replication as well.	Korea Adv Inst Sci & Technol, Dept Biol Sci, Taejon 305701, South Korea; Albert Einstein Coll Med, Dept Mol Genet, Bronx, NY 10461 USA	Korea Advanced Institute of Science & Technology (KAIST); Yeshiva University; Albert Einstein College of Medicine	Choe, J (corresponding author), Korea Adv Inst Sci & Technol, Dept Biol Sci, Taejon 305701, South Korea.		Lee, Daeyoup/C-1653-2011; Choe, Joonho/F-3066-2011	Lee, Daeyoup/0000-0003-2006-1823; Kalpana, Ganjam/0000-0003-4111-0604				CHENG LH, 1989, CELL, V59, P541, DOI 10.1016/0092-8674(89)90037-8; CLERTANT P, 1984, NATURE, V311, P276, DOI 10.1038/311276a0; DELVECCHIO AM, 1992, J VIROL, V66, P5949, DOI 10.1128/JVI.66.10.5949-5958.1992; Demeret C, 1995, NUCLEIC ACIDS RES, V23, P4777, DOI 10.1093/nar/23.23.4777; Gause William C., 1995, P293; GUARENTE L, 1983, METHOD ENZYMOL, V101, P181; GYURIS J, 1993, CELL, V75, P791, DOI 10.1016/0092-8674(93)90498-F; KALPANA GV, 1994, SCIENCE, V266, P2002, DOI 10.1126/science.7801128; Kingston RE, 1996, GENE DEV, V10, P905, DOI 10.1101/gad.10.8.905; LAURENT BC, 1990, MOL CELL BIOL, V10, P5616, DOI 10.1128/MCB.10.11.5616; Lee D, 1997, VIRUS RES, V52, P97, DOI 10.1016/S0168-1702(97)00114-7; LI R, 1994, P NATL ACAD SCI USA, V91, P7051, DOI 10.1073/pnas.91.15.7051; Mansky KC, 1997, J VIROL, V71, P7600, DOI 10.1128/JVI.71.10.7600-7608.1997; Masterson PJ, 1998, J VIROL, V72, P7407, DOI 10.1128/JVI.72.9.7407-7419.1998; MOHR IJ, 1990, SCIENCE, V250, P1694, DOI 10.1126/science.2176744; Morozov A, 1998, P NATL ACAD SCI USA, V95, P1120, DOI 10.1073/pnas.95.3.1120; MUCHARDT C, 1995, NUCLEIC ACIDS RES, V23, P1127, DOI 10.1093/nar/23.7.1127; PARK P, 1994, P NATL ACAD SCI USA, V91, P8700, DOI 10.1073/pnas.91.18.8700; PETERSON CL, 1992, CELL, V68, P573, DOI 10.1016/0092-8674(92)90192-F; SEO YS, 1993, P NATL ACAD SCI USA, V90, P702, DOI 10.1073/pnas.90.2.702; TRAVERS AA, 1992, CELL, V69, P573, DOI 10.1016/0092-8674(92)90218-2; USTAV M, 1991, EMBO J, V10, P449, DOI 10.1002/j.1460-2075.1991.tb07967.x; Utley RT, 1997, J BIOL CHEM, V272, P12642, DOI 10.1074/jbc.272.19.12642; YANG L, 1993, P NATL ACAD SCI USA, V90, P5086, DOI 10.1073/pnas.90.11.5086; YANG L, 1991, NATURE, V353, P628, DOI 10.1038/353628a0; Yasugi T, 1997, J VIROL, V71, P891, DOI 10.1128/JVI.71.2.891-899.1997; zurHausen H, 1996, BBA-REV CANCER, V1288, pF55	27	99	107	0	7	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUN 3	1999	399	6735					487	491		10.1038/20966	http://dx.doi.org/10.1038/20966			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	202TH	10365963				2022-12-28	WOS:000080667900053
J	Lebech, M; Andersen, O; Christensen, NC; Hertel, J; Nielsen, HE; Peitersen, B; Rechnitzer, C; Larsen, SO; Norgaard-Pedersen, B; Petersen, E				Lebech, M; Andersen, O; Christensen, NC; Hertel, J; Nielsen, HE; Peitersen, B; Rechnitzer, C; Larsen, SO; Norgaard-Pedersen, B; Petersen, E		Danish Congenital Toxoplasmosis Study Grp	Feasibility of neonatal screening for toxoplasma infection in the absence of prenatal treatment	LANCET			English	Article							IMMUNOGLOBULIN-M IGM; CONGENITAL TOXOPLASMOSIS; PREGNANT-WOMEN; FOLLOW-UP; ANTIBODIES; DIAGNOSIS; ASSAY	Background. The best method for prevention and control of congenital toxoplasma infection is uncertain. Prenatal screening is done in Austria and France, but the effect of treatment during pregnancy is not well documented. The aim of our study was to find out the maternofetal transmission rate and outcome in infants born to mothers who were not treated during pregnancy. Methods. We analysed 89873 eluates from phenylketonuria (PKU) cards from neonates and paired first-trimester serum samples from the mothers for specific IgG antibodies to Toxoplasma gondii. Children born to mothers who seroconverted during pregnancy were followed-up clinically and serologically to 12 months of age. In addition, 21144 PKU cards were analysed for toxoplasma-specific IgM antibodies during the last 12 months of the study. Findings. In 24989 (27.8%) cases both the PKU eluate and the first-trimester samples were IgG positive, which indicates previous maternal infection. 139 of the 64884 seronegative women acquired toxoplasma infection during pregnancy and gave birth to 141 infants (two sets of twins). 27 of these children were diagnosed with congenital toxoplasma infection. The transmission rate was 19.4% (95% Cl 13.2-27.0). Clinical signs and symptoms were found in four (15%) of the 27 children. The additional analysis for toxoplasma-specific IgM antibodies from the PKU card identified seven of nine children with congenital toxoplasma infection. The false-positive rate for the IgM test was 0.19 per 1000, and no false-negatives were found. Interpretation. The risks of transmission of infection and of disease in the infant are low in an area with a low risk of toxoplasma infection. A neonatal screening programme based on detection of toxoplasma-specific IgM antibodies alone will identify between 70% and 80% of cases of congenital toxoplasmosis.	Statens Serum Inst, Parasitol Lab, DK-2300 Copenhagen 5, Denmark; Statens Serum Inst, Dept Biostat, DK-2300 Copenhagen, Denmark; Statens Serum Inst, Dept Clin Biochem, DK-2300 Copenhagen 5, Denmark; Univ Hosp Rigshosp, Dept Paediat, Copenhagen, Denmark; Hillerod Cty Hosp, Dept Paediat, Hillerod, Denmark; Sonderborg Cty Hosp, Dept Paediat, Sonderborg, Denmark; Univ Hosp Gentofte, Dept Paediat, Gentofte, Denmark; Univ Hosp Glostrup, Dept Paediat, Glostrup, Denmark; Hvidovre Univ Hosp, Dept Paediat, Hvidovre, Denmark	Statens Serum Institut; Statens Serum Institut; Statens Serum Institut; Rigshospitalet; University of Copenhagen; Herlev & Gentofte Hospital; University of Copenhagen; University of Copenhagen	Petersen, E (corresponding author), Statens Serum Inst, Parasitol Lab, Artillerivej 5, DK-2300 Copenhagen 5, Denmark.							ADES AE, 1993, AM J EPIDEMIOL, V137, P1022, DOI 10.1093/oxfordjournals.aje.a116758; Aspock H, 1990, Osterr Krankenpflegez, V43, P252; DESMONTS G, 1974, NEW ENGL J MED, V290, P1110, DOI 10.1056/NEJM197405162902003; DESMONTS G, 1974, B NEW YORK ACAD MED, V50, P146; Desmonts G, 1985, Prog Clin Biol Res, V163B, P333; FORSGREN M, 1991, LANCET, V337, P1413, DOI 10.1016/0140-6736(91)93095-Q; FOULON W, 1984, BRIT J OBSTET GYNAEC, V91, P419, DOI 10.1111/j.1471-0528.1984.tb04777.x; GUERINA NG, 1994, NEW ENGL J MED, V330, P1858, DOI 10.1056/NEJM199406303302604; Harning D, 1996, CLIN DIAGN LAB IMMUN, V3, P355, DOI 10.1128/CDLI.3.3.355-357.1996; HOHLFELD P, 1994, NEW ENGL J MED, V331, P695, DOI 10.1056/NEJM199409153311102; JEANNEL D, 1990, LANCET, V336, P359, DOI 10.1016/0140-6736(90)91890-M; KEMP DT, 1991, ACTA OTO-LARYNGOL, P73; KIMBALL AC, 1971, AM J OBSTET GYNECOL, V111, P211, DOI 10.1016/0002-9378(71)90892-1; KOPPE JG, 1989, INT OPHTHALMOL, V13, P387, DOI 10.1007/BF02306486; Lebech M, 1996, EUR J CLIN MICROBIOL, V15, P799, DOI 10.1007/BF01701522; LEBECH M, 1995, SCAND J INFECT DIS, V27, P259, DOI 10.3109/00365549509019019; MCAULEY J, 1994, CLIN INFECT DIS, V18, P38, DOI 10.1093/clinids/18.1.38; Pinon JM, 1996, J CLIN MICROBIOL, V34, P579, DOI 10.1128/JCM.34.3.579-583.1996; PRATLONG F, 1994, PRENATAL DIAG, V14, P191, DOI 10.1002/pd.1970140309; SHARMA SD, 1983, J IMMUNOL, V131, P977; Villena I, 1998, SCAND J INFECT DIS, V30, P295, DOI 10.1080/00365549850160963; WILSON CB, 1980, PEDIATRICS, V66, P767; ZUBER P, 1995, SCHWEIZ MED WOCHENSC, V125, P19	23	143	149	0	3	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAY 29	1999	353	9167					1834	1837		10.1016/S0140-6736(98)11281-3	http://dx.doi.org/10.1016/S0140-6736(98)11281-3			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	202TG	10359408				2022-12-28	WOS:000080667800012
J	Dixon, JM; McDonald, C; Elton, RA; Miller, WR				Dixon, JM; McDonald, C; Elton, RA; Miller, WR		Edinburgh Breast Grp	Risk of breast cancer in women with palpable breast cysts: a prospective study	LANCET			English	Article							DISEASE; SUBSEQUENT; HISTORY	Background. 7% of women in the western world develop palpable breast cysts. Studies of the relation between cysts and breast cancer have conflicting results. There are two clearly defined types of cyst. We investigated whether one cyst type is associated with a higher rate of breast-cancer development than the other. Methods. We studied 1374 women with palpable breast cysts presenting between 1981 and 1987, who had cysts aspirated between 1981 and 1989. Cysts were classified as type I if the sodium/potassium (Na'/K') ratio in the cyst fluid was less than 3, or type II if the Na+/K+ ratio was 3 or more. Data on incidence of breast cancer were available until January, 1995, and we compared them with the expected numbers of cancers calculated from age-specific breast-cancer incidence in Scotland in 1988. Findings. 65 cancers developed during follow-up. The overall standardised incidence rate of breast cancer in patients with palpable cysts was 2.81 (95% Cl 2.17-3.59). The relative incidence rate was increased for all cyst types. The standardised incidence rate of developing breast cancer among women younger than 45 years was highest at 5.94 (2.97-10.63), with a significant trend for decreasing relative incidence rate with age (p < 0.05). Women older than 54 years had a standardised incidence rate of 1.73 (0.86-3.10). The standardised incidence rate of breast cancer was highest in the first year after aspiration (7.02 [3.73-12.00]) but the risk was still raised after 5 years (2.68 [1.84-3.76]). Interpretation. Women with breast cysts are at an increased risk of breast cancer, especially at younger ages. The type of cyst did not alter the associated relative incidence rate of breast-cancer development.	Western Gen Hosp, Edinburgh Breast Unit, Edinburgh EH4 2XU, Midlothian, Scotland	University of Edinburgh	Dixon, JM (corresponding author), Western Gen Hosp, Edinburgh Breast Unit, Edinburgh EH4 2XU, Midlothian, Scotland.		Miller, William/AAY-5398-2020					ARMITAGE P, 1994, STAT METHOS MED RES; BRADLOW HL, 1981, CLIN ONCOL, V7, P388; BRADLOW HL, 1983, ENDOCRINOLOGY CYSTIC, P59; BRISSAUD E, 1884, ARCH PHYSL, V3, P98; Bruzzi P, 1997, BMJ-BRIT MED J, V314, P925, DOI 10.1136/bmj.314.7085.925; BUNDRED NJ, 1991, BRIT J CANCER, V64, P953, DOI 10.1038/bjc.1991.433; CARSTAIRS V, 1991, DEPRIVATION HLTH SCO, P162; CHARDOT C, 1970, B CANCER, V57, P251; CIATTO S, 1990, EUR J CANCER, V26, P555, DOI 10.1016/0277-5379(90)90074-4; CONSTANTINI M, 1994, RECENT DEV STUDY BEN, P227; COOPER AP, 1829, DIS BREAST 1; DIXON JM, 1985, EUR J CANCER CLIN ON, V21, P1047, DOI 10.1016/0277-5379(85)90289-5; DIXON JM, 1983, BRIT J SURG, V70, P604, DOI 10.1002/bjs.1800701012; DIXON JM, 1985, BRIT J SURG, V72, P190, DOI 10.1002/bjs.1800720311; Dixon JM, 1997, BREAST, V6, P12, DOI 10.1016/S0960-9776(97)90536-1; DUPONT WD, 1985, NEW ENGL J MED, V312, P146, DOI 10.1056/NEJM198501173120303; Haagensen C., 1971, DIS BREAST; HAAGENSEN CD, 1981, BREAST CARCINOMA RIS; HARRINGTON LE, 1981, BREAST, V7, P113; HUGHES LE, 1987, LANCET, V2, P1316, DOI 10.1016/S0140-6736(87)91204-9; JOHNSON R, 1924, BRIT J SURG, V12, P630; JONES BM, 1980, BRIT J SURG, V67, P69; MILLER B, 1983, J ACAD LIBR, V9, P227; MILLER WR, 1983, ENDOCRINOLOGY CYSTIC, P77; PAGE DL, 1978, J NATL CANCER I, V61, P106; RECLUS P, 1883, REV CHIR, V3, P761; ROBERTS MM, 1984, BRIT MED J, V288, P275, DOI 10.1136/bmj.288.6413.275; SCHEURCH C, 1982, CANCER, V50, P1899; 1990, SCOTTISH HLTH STAT	29	76	80	0	2	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAY 22	1999	353	9166					1742	1745		10.1016/S0140-6736(98)06408-3	http://dx.doi.org/10.1016/S0140-6736(98)06408-3			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	202TF	10347986				2022-12-28	WOS:000080667700011
J	Cingolani, G; Petosa, C; Weis, K; Muller, CW				Cingolani, G; Petosa, C; Weis, K; Muller, CW			Structure of importin-beta bound to tbe IBB domain of importin-alpha	NATURE			English	Article							NUCLEAR-PROTEIN IMPORT; FACTOR P97; NUCLEOCYTOPLASMIC TRANSPORT; KARYOPHERIN-ALPHA; EXPORT RECEPTOR; PORE COMPLEXES; TRANSFER-RNA; IDENTIFICATION; SEQUENCE; BINDING	Cytosolic proteins bearing a classical nuclear localization signal enter the nucleus bound to a heterodimer of importin-alpha and importin-beta (also called karyopherin-alpha and -beta). The formation of this heterodimer involves the importin-beta-binding (IBB) domain of importin-alpha, a highly basic amino-terminal region of roughly 40 amino-acid residues. Here we report the crystal structure of human importin-beta bound to the IBB domain of importin-alpha, determined at 2.5 Angstrom and 2.3 Angstrom resolution in two crystal forms. Importin-beta consists of 19 tandemly repeated HEAT motifs and wraps intimately around the IBB domain. The association involves two separate regions of importin-beta, recognizing structurally distinct parts of the IBB domain: an amino-terminal extended moiety and a carboxy-terminal helix. The structure indicates that significant conformational changes occur when importin-beta binds or releases the IBB domain domain and suggests how dissociation of the importin-alpha/beta heterodimer may be achieved upon nuclear entry.	European Mol Biol Lab, Grenoble Outstn, ILL, F-38042 Grenoble 9, France; Univ Calif Berkeley, Dept Mol & Cell Biol, Berkeley, CA 94720 USA	European Molecular Biology Laboratory (EMBL); Institut Laue-Langevin (ILL); University of California System; University of California Berkeley	Muller, CW (corresponding author), European Mol Biol Lab, Grenoble Outstn, ILL, BP 156, F-38042 Grenoble 9, France.	mueller@embl-grenoble.fr	Weis, Karsten/F-5719-2011; Müller, Christoph W/I-7420-2012	Weis, Karsten/0000-0001-7224-925X; Müller, Christoph W/0000-0003-2176-8337; Petosa, Carlo/0000-0002-9975-1167				ANDRADE MA, 1995, NAT GENET, V11, P115, DOI 10.1038/ng1095-115; Arts GJ, 1998, CURR BIOL, V8, P305, DOI 10.1016/S0960-9822(98)70130-7; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Battiste JL, 1996, SCIENCE, V273, P1547, DOI 10.1126/science.273.5281.1547; Bischoff FR, 1997, FEBS LETT, V419, P249, DOI 10.1016/S0014-5793(97)01467-1; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; CARSON M, 1991, J APPL CRYSTALLOGR, V24, P958, DOI 10.1107/S0021889891007240; Chi NC, 1997, MOL BIOL CELL, V8, P945, DOI 10.1091/mbc.8.6.945; Chi NC, 1997, J BIOL CHEM, V272, P6818, DOI 10.1074/jbc.272.10.6818; CHI NC, 1995, J CELL BIOL, V130, P265, DOI 10.1083/jcb.130.2.265; Conti E, 1998, CELL, V94, P193, DOI 10.1016/S0092-8674(00)81419-1; DINGWALL C, 1991, TRENDS BIOCHEM SCI, V16, P478, DOI 10.1016/0968-0004(91)90184-W; Doye V, 1997, CURR OPIN CELL BIOL, V9, P401, DOI 10.1016/S0955-0674(97)80014-2; Esnouf RM, 1998, ACTA CRYSTALLOGR D, V54, P938, DOI 10.1107/S0907444998004284; Gorlich D, 1996, SCIENCE, V271, P1513, DOI 10.1126/science.271.5255.1513; GORLICH D, 1994, CELL, V79, P767, DOI 10.1016/0092-8674(94)90067-1; GORLICH D, 1995, CURR BIOL, V5, P383, DOI 10.1016/S0960-9822(95)00079-0; Gorlich D, 1996, EMBO J, V15, P1810, DOI 10.1002/j.1460-2075.1996.tb00530.x; Gorlich D, 1997, J CELL BIOL, V138, P65, DOI 10.1083/jcb.138.1.65; Groves MR, 1999, CELL, V96, P99, DOI 10.1016/S0092-8674(00)80963-0; Hayward S, 1998, PROTEINS, V30, P144, DOI 10.1002/(SICI)1097-0134(19980201)30:2<144::AID-PROT4>3.0.CO;2-N; Huber J, 1998, EMBO J, V17, P4114, DOI 10.1093/emboj/17.14.4114; IMAMOTO N, 1995, FEBS LETT, V368, P415; Izaurralde E, 1997, EMBO J, V16, P6535, DOI 10.1093/emboj/16.21.6535; Jakel S, 1998, EMBO J, V17, P4491, DOI 10.1093/emboj/17.15.4491; Jones TA, 1997, METHOD ENZYMOL, V277, P173, DOI 10.1016/S0076-6879(97)77012-5; KALDERON D, 1984, CELL, V39, P499, DOI 10.1016/0092-8674(84)90457-4; Kobe B, 1999, NAT STRUCT BIOL, V6, P388, DOI 10.1038/7625; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Kutay U, 1998, MOL CELL, V1, P359, DOI 10.1016/S1097-2765(00)80036-2; Kutay U, 1997, EMBO J, V16, P1153, DOI 10.1093/emboj/16.6.1153; Malik HS, 1997, P NATL ACAD SCI USA, V94, P13738, DOI 10.1073/pnas.94.25.13738; Mattaj IW, 1998, ANNU REV BIOCHEM, V67, P265, DOI 10.1146/annurev.biochem.67.1.265; Moore JD, 1999, J CELL BIOL, V144, P213, DOI 10.1083/jcb.144.2.213; MOROIANU J, 1995, P NATL ACAD SCI USA, V92, P2008, DOI 10.1073/pnas.92.6.2008; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Ohno M, 1998, CELL, V92, P327, DOI 10.1016/S0092-8674(00)80926-5; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Palacios I, 1997, EMBO J, V16, P6783, DOI 10.1093/emboj/16.22.6783; Palmeri D, 1999, MOL CELL BIOL, V19, P1218; Pollard VW, 1996, CELL, V86, P985, DOI 10.1016/S0092-8674(00)80173-7; RADU A, 1995, P NATL ACAD SCI USA, V92, P1769, DOI 10.1073/pnas.92.5.1769; ROBBINS J, 1991, CELL, V64, P615, DOI 10.1016/0092-8674(91)90245-T; SCHEFFZEK K, 1995, NATURE, V374, P378, DOI 10.1038/374378a0; TERWILLIGER TC, 1987, ACTA CRYSTALLOGR A, V43, P1, DOI 10.1107/S0108767387099999; Truant R, 1999, MOL CELL BIOL, V19, P1210; Vetter IR, 1999, NATURE, V398, P39, DOI 10.1038/17969; WEIS K, 1995, SCIENCE, V268, P1049, DOI 10.1126/science.7754385; Weis K, 1996, EMBO J, V15, P1818, DOI 10.1002/j.1460-2075.1996.tb00531.x; Weis K, 1998, TRENDS BIOCHEM SCI, V23, P185, DOI 10.1016/S0968-0004(98)01204-3	50	431	442	0	24	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAY 20	1999	399	6733					221	229		10.1038/20367	http://dx.doi.org/10.1038/20367			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	198MF	10353244				2022-12-28	WOS:000080427400046
J	von Boehmer, H; Sarukhan, A				von Boehmer, H; Sarukhan, A			Immunology - GAD, a single autoantigen for diabetes	SCIENCE			English	Editorial Material							GLUTAMIC-ACID DECARBOXYLASE; T-CELL TOLERANCE; MICE; DISEASE		Fac Med Necker, INSERM, U373, F-75015 Paris, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite	Sarukhan, A (corresponding author), Fac Med Necker, INSERM, U373, F-75015 Paris, France.			Sarukhan, Adelaida/0000-0003-3747-6304				BAEKKESKOV S, 1982, NATURE, V298, P167, DOI 10.1038/298167a0; BAEKKESKOV S, 1990, NATURE, V347, P151, DOI 10.1038/347151a0; ELLIOTT JF, 1994, DIABETES, V43, P1494, DOI 10.2337/diabetes.43.12.1494; Geng LP, 1998, P NATL ACAD SCI USA, V95, P10055, DOI 10.1073/pnas.95.17.10055; HARRISON LC, 1993, LANCET, V341, P1365, DOI 10.1016/0140-6736(93)90940-I; JESKE D, UNPUB; KAPPLER JW, 1987, CELL, V49, P273, DOI 10.1016/0092-8674(87)90568-X; KAUFMAN DL, 1993, NATURE, V366, P69, DOI 10.1038/366069a0; KISIELOW P, 1988, NATURE, V333, P742, DOI 10.1038/333742a0; Lanoue A, 1997, J EXP MED, V185, P405, DOI 10.1084/jem.185.3.405; Ma SW, 1997, NAT MED, V3, P793, DOI 10.1038/nm0797-793; ROCHA B, 1991, SCIENCE, V251, P1225, DOI 10.1126/science.1900951; Tian JD, 1996, NAT MED, V2, P1348, DOI 10.1038/nm1296-1348; TISCH R, 1993, NATURE, V366, P72, DOI 10.1038/366072a0; Yoon JW, 1999, SCIENCE, V284, P1183, DOI 10.1126/science.284.5417.1183	15	12	12	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAY 14	1999	284	5417					1135	+						2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	197HJ	10366347				2022-12-28	WOS:000080359100025
J	Novak, R; Henriques, B; Charpentier, E; Normark, S; Tuomanen, E				Novak, R; Henriques, B; Charpentier, E; Normark, S; Tuomanen, E			Emergence of vancomycin tolerance in Streptococcus pneumoniae	NATURE			English	Article							MULTIPLE ANTIBIOTIC-RESISTANCE; ESCHERICHIA-COLI; ENTEROCOCCUS-FAECIUM; PENICILLIN TOLERANCE; BACTERIAL-MENINGITIS; PROTEINS; IDENTIFICATION; PNEUMOCOCCI; INFECTIONS; MECHANISMS	Streptococcus pneumoniae, the pneumococcus, is the most common cause of sepsis and meningitis(1). Mwultiple-antibiotic-resistant strains are widespread, and vancomycin is the antibiotic of last resort(2,3). Emergence of vancomycin resistance In this community-acquired bacterium would be catastrophic. Antibiotic tolerance, the ability of bacteria to survive but not grow in the presence of antibiotics, is a precursor phenotype to resistance(4) Here we show that loss of function of the VncS histidine kinase of a two-component sensor-regulator system in S. pneumoniae produced tolerance to vancomycin and other classes of antibiotic. Bacterial two-component systems monitor environmental parameters through a sensor histidine-kinase/phosphatase, which phosphorylates/dephosphorylates a response regulator that in turn mediates changes in gene expression. These results indicate that signal transduction is critical for the bactericidal activity of antibiotics. Experimental meningitis caused by the vncS mutant failed to respond to vancomycin. Clinical isolates tolerant to vancomycin were identified and DNA sequencing revealed nucleotide alterations in vncS. We conclude that broad antibiotic tolerance of S. pneumoniae has emerged in the community by a molecular mechanism that eliminates sensitivity to the current cornerstone of therapy vancomycin.	St Jude Childrens Res Hosp, Dept Infect Dis, Memphis, TN 38105 USA; Karolinska Inst, Swedish Inst Infect Dis Control, S-17182 Stockholm, Sweden	St Jude Children's Research Hospital; Karolinska Institutet; Swedish Institute for Infectious Disease Control	Tuomanen, E (corresponding author), St Jude Childrens Res Hosp, Dept Infect Dis, 332 N Lauderdale St, Memphis, TN 38105 USA.	elaine.tuomanen@stjude.org	Tuomanen, Elaine I/N-3081-2018	Tuomanen, Elaine I/0000-0003-0349-8716				*AM AC PED, 1997, RED BOOK REP COMM IN, P410; BUGG TDH, 1991, BIOCHEMISTRY-US, V30, P10408, DOI 10.1021/bi00107a007; *CDC, 1997, MMWR-MORBID MORTAL W, V46, P626; CHEN JD, 1987, GENE, V55, P179, DOI 10.1016/0378-1119(87)90278-2; Dowson CG, 1997, J APPL MICROBIOL, V83, pS42, DOI 10.1046/j.1365-2672.83.s1.5.x; Evers S, 1996, J BACTERIOL, V178, P1302, DOI 10.1128/jb.178.5.1302-1309.1996; FRIEDLAND IR, 1992, PEDIATR INFECT DIS J, V11, P433, DOI 10.1097/00006454-199206000-00002; HOLMAN TR, 1994, BIOCHEMISTRY-US, V33, P4625, DOI 10.1021/bi00181a024; HOLTJE JV, 1991, J GEN MICROBIOL, V137, P441, DOI 10.1099/00221287-137-3-441; LACKS S, 1960, BIOCHIM BIOPHYS ACTA, V39, P508, DOI 10.1016/0006-3002(60)90205-5; LIU HH, 1985, J INFECT DIS, V152, P365, DOI 10.1093/infdis/152.2.365; MartinezHackert E, 1997, STRUCTURE, V5, P109, DOI 10.1016/S0969-2126(97)00170-6; MOREILLON P, 1990, ANTIMICROB AGENTS CH, V34, P33, DOI 10.1128/AAC.34.1.33; MURAKAMI K, 1989, J BACTERIOL, V171, P874, DOI 10.1128/jb.171.2.874-879.1989; Novak R, 1998, MOL MICROBIOL, V29, P1285, DOI 10.1046/j.1365-2958.1998.01016.x; PARKINSON JS, 1992, ANNU REV GENET, V26, P71, DOI 10.1146/annurev.ge.26.120192.000443; PEARCE BJ, 1993, MOL MICROBIOL, V9, P1037, DOI 10.1111/j.1365-2958.1993.tb01233.x; QUAGLIARELLO V, 1992, NEW ENGL J MED, V327, P864, DOI 10.1056/NEJM199209173271208; Sambrook J., 1990, MOL CLONING LAB MANU, V2nd; Schuchat A, 1997, NEW ENGL J MED, V337, P970, DOI 10.1056/NEJM199710023371404; SHOCKLEY TE, 1970, GENETICS, V64, P397; Silva JC, 1998, P NATL ACAD SCI USA, V95, P11951, DOI 10.1073/pnas.95.20.11951; STOCK JB, 1989, MICROBIOL REV, V53, P450, DOI 10.1128/MMBR.53.4.450-490.1989; TAUBER MG, 1994, METHOD ENZYMOL, V235, P92; TOMASZ A, 1964, P NATL ACAD SCI USA, V51, P480, DOI 10.1073/pnas.51.3.480; TOMASZ A, 1970, NATURE, V227, P138, DOI 10.1038/227138a0; TUOMANEN E, 1988, J INFECT DIS, V158, P36, DOI 10.1093/infdis/158.1.36; WILLIAMSON R, 1980, J BACTERIOL, V144, P105, DOI 10.1128/JB.144.1.105-113.1980; ZIGHELBOIM S, 1981, REV INFECT DIS, V3, P267	29	271	287	1	35	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 10	1999	399	6736					590	593		10.1038/21202	http://dx.doi.org/10.1038/21202			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	204RR	10376600				2022-12-28	WOS:000080778400057
J	Hofer, TP; Hayward, RA; Greenfield, S; Wagner, EH; Kaplan, SH; Manning, WG				Hofer, TP; Hayward, RA; Greenfield, S; Wagner, EH; Kaplan, SH; Manning, WG			The unreliability of individual physician "report cards" for assessing the costs and quality of care of a chronic disease	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HOSPITAL RESOURCE USE; MANAGED CARE; SELECTION BIAS; COMPLICATIONS; CAPITATION; SURGEONS; HMOS	Context. Physician profiling is widely used by many health care systems, but little is known about the reliability of commonly used profiling systems. Objectives. To determine the reliability of a set of physician performance measures for diabetes care,one of the most common conditions in medical practice, and to examine whether physicians could substantially improve their profiles by preferential patient selection. Design and Setting. Cohort study performed from 1990 to 1993 at 3 geographically and organizationally diverse sites, including a large staff-model health maintenance organization, an urban university teaching clinic, and a group of private-practice physicians in an urban area. Participants. A total of 3642 patients with type 2 diabetes cared for by 232 different physicians. Main Outcome Measures. Physician profiles for their patients' hospitalization and clinic visit rates, total laboratory resource utilization rate and level of glycemic control by average hemoglobin A(1c) level with and without detailed case-mix adjustment. Results. For profiles based on hospitalization rates, visit rates, laboratory utilization rates, and glycemic control, 4% or less of the overall variance was attributable to differences in physician practice and the reliability of the median physician's case-mix-adjusted profile was never better than 0.40. At this low level of physician effect, a physician would need to have more than 100 patients with diabetes in a panel for profiles to have a reliability of 0.80 or better (while more than 90% of all primary care physicians at the health maintenance organization had fewer than 60 patients with diabetes). For profiles of glycemic control, high outlier physicians could dramatically improve their physician profile simply by pruning from their panel the 1 to 3 patients with the highest hemoglobin A(1c) levels during the prior year. This advantage from gaming could not be prevented by even detailed case-mix adjustment. Conclusions. Physician "report cards" for diabetes,one of the highest-prevalence conditions in medical practice, were unable to detect reliably true practice differences within the 3 sites studied. Use of individual physician profiles may foster an environment in which physicians can most easily avoid being penalized by avoiding or deselecting patients with high prior cost, poor adherence;or response to treatments.	Vet Affairs Ctr Practice Management & Outcomes Re, Ann Arbor, MI USA; Univ Michigan, Dept Internal Med, Ann Arbor, MI 48109 USA; New England Med Ctr, Primary Care Outcomes Res Inst, Boston, MA 02111 USA; Grp Hlth Cooperat Puget Sound, Ctr Hlth Studies, Seattle, WA 98101 USA; Univ Chicago, Dept Hlth Studies, Chicago, IL 60637 USA	University of Michigan System; University of Michigan; Tufts Medical Center; Group Health Cooperative; University of Chicago	Hofer, TP (corresponding author), Ann Arbor VA HSR&D US Mail, 3rd Floor,Lobby L,POB 130170, Ann Arbor, MI 48113 USA.		Hofer, Timothy Philip/AAC-9238-2022	Hofer, Timothy/0000-0003-0434-8787; Kaplan, Sherrie/0000-0002-8644-5849; Greenfield, Sheldon/0000-0003-4628-1998	AHRQ HHS [HSO 6665-01] Funding Source: Medline	AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)		Blum JD, 1996, AM J LAW MED, V22, P173; BRAVO G, 1991, J CLIN EPIDEMIOL, V44, P381, DOI 10.1016/0895-4356(91)90076-L; Carmines E.G., 1979, SAGE U PAPER SERIES; Corrigan J M, 1993, Jt Comm J Qual Improv, V19, P566; FEINGLASS J, 1991, HEALTH SERV RES, V26, P183; Gelman Andrew, 1995, BAYESIAN DATA ANAL; GLEASON JR, 1996, STATA TECHNICAL B RE, V6, P167; Goldstein H, 1995, MULTILEVEL STAT MODE, DOI 10.1002/9780470973394; GREEN J, 1995, NEW ENGL J MED, V332, P1229, DOI 10.1056/NEJM199505043321812; GREENFIELD S, 1994, DIABETES CARE, V17, P32; GREENFIELD S, 1995, MED CARE, V33, pAS47; Hayward RA, 1997, JAMA-J AM MED ASSOC, V278, P1663, DOI 10.1001/jama.278.20.1663; HAYWARD RA, 1994, MED CARE, V32, P788, DOI 10.1097/00005650-199408000-00003; HELLINGER FJ, 1995, INQUIRY-J HEALTH CAR, V32, P135; *I ED MULT MOD PRO, 1998, MLWIN COMP PROGR REL; JAMES W, 1961, 4TH P BERK S MATH ST, V1, P361; KASSIRER JP, 1994, NEW ENGL J MED, V330, P634, DOI 10.1056/NEJM199403033300910; KERR EA, 1995, ANN INTERN MED, V123, P500, DOI 10.7326/0003-4819-123-7-199510010-00004; Kuczynski YT, 1997, J VASC SURG, V26, P193, DOI 10.1016/S0741-5214(97)70179-4; LICHTENSTEIN R, 1992, MED CARE, V30, P329, DOI 10.1097/00005650-199204000-00004; Liner RS, 1997, AM J LAW MED, V23, P511; MANT J, 1995, BMJ-BRIT MED J, V311, P793, DOI 10.1136/bmj.311.7008.793; McCullagh P., 1989, GEN LINEAR MODELS, V2nd; MCDOWELL J, 1996, MEASURING HLTH GUIDE; MCMAHON LF, 1989, ANN INTERN MED, V111, P318, DOI 10.7326/0003-4819-111-4-318; MILLER ME, 1993, MED CARE, V31, pYS16, DOI 10.1097/00005650-199305001-00004; Newhouse J P, 1989, Health Care Financ Rev, V10, P41; NEWHOUSE JP, 1994, HEALTH AFFAIR, V13, P132, DOI 10.1377/hlthaff.13.1.132; OHAGAN A, 1994, KENDALLS ADV THEOR B, V2; Orav EJ, 1996, MED CARE, V34, pSS87; PORELL FW, 1990, MED CARE, V28, P604, DOI 10.1097/00005650-199007000-00006; Spoeri RK, 1997, ANN INTERN MED, V127, P726, DOI 10.7326/0003-4819-127-8_Part_2-199710151-00058; *STATA CORP, 1997, STATA STAT SOFTW COM; STEIN C, 1956, P 3 BERK S MATH STAT, V1, P137; Vijan S, 1997, J GEN INTERN MED, V12, P567, DOI 10.1046/j.1525-1497.1997.07111.x; WELCH HG, 1994, NEW ENGL J MED, V330, P607, DOI 10.1056/NEJM199403033300906; Wennberg DE, 1998, ANN INTERN MED, V128, P866, DOI 10.7326/0003-4819-128-10-199805150-00012; 1997, MED HLTH, V51, P1	38	413	434	0	17	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 9	1999	281	22					2098	2105		10.1001/jama.281.22.2098	http://dx.doi.org/10.1001/jama.281.22.2098			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	202TJ	10367820	Bronze			2022-12-28	WOS:000080668000032
J	Rizvi, N; Hayes, DF				Rizvi, N; Hayes, DF			A "'breathalyser" for lung cancer?	LANCET			English	Editorial Material									Georgetown Univ, Med Ctr, Vincent T Lombardi Canc Res Ctr, Washington, DC 20007 USA	Georgetown University	Hayes, DF (corresponding author), Georgetown Univ, Med Ctr, Vincent T Lombardi Canc Res Ctr, Washington, DC 20007 USA.		Hayes, Daniel/ABE-1129-2020					LEE JS, 1994, J CLIN ONCOL, V12, P937, DOI 10.1200/JCO.1994.12.5.937; ONEILL HJ, 1988, CLIN CHEM, V34, P1613; Parker SL, 1996, CA-CANCER J CLIN, V46, P5, DOI 10.3322/canjclin.46.1.5; PAULING L, 1991, P NATL ACAD SCI USA, V68, P2374; Rushton L, 1997, OCCUP ENVIRON MED, V54, P152, DOI 10.1136/oem.54.3.152; STRAUSS GM, 1995, CHEST, V107, pS270, DOI 10.1378/chest.107.6_Supplement.270S; Tockman MS, 1997, CLIN CANCER RES, V3, P2237; Zhou J, 1996, J BIOL CHEM, V271, P10760, DOI 10.1074/jbc.271.18.10760	8	10	10	0	6	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUN 5	1999	353	9168					1897	1898		10.1016/S0140-6736(99)00014-8	http://dx.doi.org/10.1016/S0140-6736(99)00014-8			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	202TP	10371562	hybrid			2022-12-28	WOS:000080668500003
J	Tomlin, Z; Humphrey, C; Rogers, S				Tomlin, Z; Humphrey, C; Rogers, S			General practitioners' perceptions of effective health care	BMJ-BRITISH MEDICAL JOURNAL			English	Article							EVIDENCE-BASED MEDICINE; CLINICAL-PRACTICE	Objectives To explore general practitioners' perceptions of effective health care and its application in their own practice; to examine how these perceptions relate to assumptions about clinicians' values and behaviour implicit in the evidence based medicine approach. Design A qualitative-study using semistructured interviews. Setting Eight general: practices in North Thames region that were parr of the Medical Research Council General Practice Research Framework. Participants 24 general practitioners, three from each practice. Main outcome-measures Respondents' definitions of effective health care, reasons for not practising effectively according to their own criteria sources of information used to answer;clinical questions about patients, reasons for making changes in clinical practice. Results Three categories of definitions emerged:, clinical, patient related, and resource related. Patient: factors were the main reason given for not practising effectively; others were lack of time, doctors' lack of knowledge and skills, lack of resources, and "human failings." Main sources of information used in situations of clinical uncertainty were general practitioner partners and hospital doctors. Contact with hospital doctors and observation of hospital practice were just as likely as information from medical and scientific literature to bring about changes in clinical practice. Conclusions The findings suggest that the central assumptions of the evidence based medicine paradigm may not be shared by many general practitioners, making its application in general practice problematic. The promotion of effective care in:general practice:requires a broader vision and a more pragmatic approach which takes account of practitioners' concerns and is compatible with the complex nature of their work.	UCL, Royal Free & Univ Coll Med Sch, Dept Primary Care & Populat Sci, London NW3 2PF, England	University of London; University College London	Humphrey, C (corresponding author), UCL, Royal Free & Univ Coll Med Sch, Dept Primary Care & Populat Sci, London NW3 2PF, England.	charlot@rfhom.ac.uk	Greiver, Michelle/N-8764-2015	Greiver, Michelle/0000-0001-8957-0285				Allery LA, 1997, BMJ-BRIT MED J, V314, P870; Barrie AR, 1997, BRIT MED J, V315, P1512, DOI 10.1136/bmj.315.7121.1512; COULTER A, 1993, BRIT MED J, V306, P236, DOI 10.1136/bmj.306.6872.236; DANNUO T, 1992, JAMA-J AM MED ASSOC, V267, P253; Dunning M, 1998, BRIT MED J, V316, P243, DOI 10.1136/bmj.316.7127.243; Greenhalgh T, 1996, BRIT MED J, V313, P957; GUYATT G, 1992, JAMA-J AM MED ASSOC, V268, P2420, DOI 10.1001/jama.1992.03490170092032; Haines A, 1996, BRIT J GEN PRACT, V46, P115; Jacobson LD, 1997, BRIT J GEN PRACT, V47, P449; Kernick DP, 1997, BRIT J GEN PRACT, V47, P95; McColl A, 1998, BRIT MED J, V316, P361, DOI 10.1136/bmj.316.7128.361; Milner P, 1997, J PUBLIC HEALTH MED, V19, P127, DOI 10.1093/oxfordjournals.pubmed.a024597; *MRC GEN PRACT RES, 1997, NETW GEN PRACT UK MA; NAYLOR CD, 1995, LANCET, V345, P840, DOI 10.1016/S0140-6736(95)92969-X; OWEN P, 1995, BRIT J GEN PRACT, V45, P557; Sackett DL, 1996, BRIT MED J, V312, P71, DOI 10.1136/bmj.312.7023.71; SACKETT DL, 1995, J PUBLIC HEALTH MED, V17, P330; Sullivan FM, 1996, LANCET, V348, P941, DOI 10.1016/S0140-6736(96)05219-1	18	75	76	0	5	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUN 5	1999	318	7197					1532	1535		10.1136/bmj.318.7197.1532	http://dx.doi.org/10.1136/bmj.318.7197.1532			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	204HC	10356011	Green Submitted, Bronze, Green Published			2022-12-28	WOS:000080757300030
J	Bodenheimer, T; Lo, B; Casalino, L				Bodenheimer, T; Lo, B; Casalino, L			Primary care physicians should be coordinators, not gatekeepers	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							MANAGED CARE; MEDICAL OUTCOMES; CHRONIC ILLNESS; SPECIALTY; SERVICES; INCENTIVES; SYSTEMS; TRIAL	Primary care gatekeeping, in which the goal of the primary care physician (PCP) is to reduce patient referrals to specialists and thereby reduce costs, is not an adequate system in which to practice medicine. However, returning to the pre-managed care model of uncoordinated open access to specialists is a poor solution. The primary care model should be retained, but PCPs should be transformed from gatekeepers into coordinators of care, in which the goal of the PCP is to integrate both primary and special?, care to improve quality. Changes in the PCP's daily work process, as well as the referral and payment processes, need to be implemented to reach this goal. This model would eliminate the requirement that referrals to specialists be authorized by the primary care physician or managed care organization. Financial incentives would be needed, eg, to encourage PCPs to provide management of complex cases and discourage both overreferral and underreferral to specialists. Budgeting specialists should control excess costs that might be created by the elimination of the primary care gatekeeper. Pilot projects are needed to test and refine this model of PCP as coordinator of care.	Univ Calif San Francisco, Sch Med, Dept Family & Community Med, San Francisco, CA 94143 USA; Univ Calif San Francisco, Sch Med, Program Med Eth, San Francisco, CA 94143 USA; Univ Calif San Francisco, Sch Med, Div Gen Internal Med, San Francisco, CA 94143 USA; Stanford Coastside Med Clin, Stanford, CA USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; Stanford University	Bodenheimer, T (corresponding author), 1580 Valencia St,Suite 201, San Francisco, CA 94110 USA.		Casalino, Lawrence/ABE-1245-2020	Casalino, Lawrence/0000-0002-7927-7859	NATIONAL INSTITUTE OF MENTAL HEALTH [P50MH042459] Funding Source: NIH RePORTER; NIMH NIH HHS [2 P50 MH42459] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		AIKEN LH, 1979, NEW ENGL J MED, V300, P1363, DOI 10.1056/NEJM197906143002404; Bindman AB, 1996, J GEN INTERN MED, V11, P269, DOI 10.1007/BF02598266; BROOK RH, 1989, JAMA-J AM MED ASSOC, V262, P3027, DOI 10.1001/jama.262.21.3027; CASALINO LP, 1992, JAMA-J AM MED ASSOC, V267, P403; CHARNEY E, 1967, PEDIATRICS, V40, P188; CHRISTIAN S, 1998, MANAGED HEALTHCA MAY, P7; Donelan K, 1996, HEALTH AFFAIR, V15, P254, DOI 10.1377/hlthaff.15.2.254; Forrest CB, 1997, HEALTH AFFAIR, V16, P157, DOI 10.1377/hlthaff.16.6.157; Franks P, 1999, HEALTH SERV RES, V34, P323; FRANKS P, 1992, NEW ENGL J MED, V327, P424, DOI 10.1056/NEJM199208063270613; FREUDENHEIM M, 1997, NY TIMES        0202, P12; Freudenheim Milt, 1997, N Y Times Web, P20; Gerson V, 1996, Bus Health, V14, P29; GREENFIELD S, 1995, JAMA-J AM MED ASSOC, V274, P1436; GREENFIELD S, 1992, JAMA-J AM MED ASSOC, V267, P1624, DOI 10.1001/jama.267.12.1624; GROBER MS, 1997, SEXUAL ORIENTATION B, P3; Halm EA, 1997, JAMA-J AM MED ASSOC, V278, P1677, DOI 10.1001/jama.278.20.1677; HAYES TM, 1984, BRIT MED J, V289, P728, DOI 10.1136/bmj.289.6447.728; Hellinger FJ, 1996, MED CARE RES REV, V53, P294, DOI 10.1177/107755879605300305; HORNER RD, 1995, HEALTH SERV RES, V30, P275; Institute of Medicine, 1996, PRIM CAR AM HLTH NEW; Jollis JG, 1996, NEW ENGL J MED, V335, P1880, DOI 10.1056/NEJM199612193352505; KAPSNER PE, 1994, MGM J            MAR, P3; KERR EA, 1995, ANN INTERN MED, V123, P500, DOI 10.7326/0003-4819-123-7-199510010-00004; LEAPE LL, 1992, ANNU REV PUBL HEALTH, V13, P363, DOI 10.1146/annurev.pu.13.050192.002051; Manian FA, 1996, JAMA-J AM MED ASSOC, V275, P145; MARTIN DP, 1989, AM J PUBLIC HEALTH, V79, P1628, DOI 10.2105/AJPH.79.12.1628; MCPHEE SJ, 1984, ARCH INTERN MED, V144, P1265, DOI 10.1001/archinte.144.6.1265; O'Connor PJ, 1998, J FAM PRACTICE, V47, P62; OBER KP, 1987, AM J MED, V82, P1009, DOI 10.1016/0002-9343(87)90165-3; RICH MW, 1995, NEW ENGL J MED, V333, P1190, DOI 10.1056/NEJM199511023331806; SCHREIBER TL, 1995, J AM COLL CARDIOL, V26, P577, DOI 10.1016/0735-1097(95)00214-O; SINGH BM, 1984, BRIT MED J, V289, P726, DOI 10.1136/bmj.289.6447.726; STARFIELD B, 1992, PRIMARY CARE; STEIN GF, 1991, HMO PRACT, V5, P132; TERRY K, 1994, MED EC          0822, P124; VIERHOUT WPM, 1995, LANCET, V346, P990, DOI 10.1016/S0140-6736(95)91686-5; Wagner EH, 1997, HEALTH SERV RES, V32, P702; Wagner EH, 1996, MILBANK Q, V74, P511, DOI 10.2307/3350391; Walker L, 1998, Bus Health, V16, P30; WARD MM, 1993, ARCH INTERN MED, V153, P2229, DOI 10.1001/archinte.153.19.2229; WASSON J, 1992, JAMA-J AM MED ASSOC, V267, P1788, DOI 10.1001/jama.267.13.1788; Weiss LJ, 1996, AM J PUBLIC HEALTH, V86, P1742, DOI 10.2105/AJPH.86.12.1742; WHITE KL, 1961, NEW ENGL J MED, V265, P885, DOI 10.1056/NEJM196111022651805; ZEIGER RS, 1991, J ALLERGY CLIN IMMUN, V87, P1160, DOI 10.1016/0091-6749(91)92162-T	45	80	82	0	11	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 2	1999	281	21					2045	2049		10.1001/jama.281.21.2045	http://dx.doi.org/10.1001/jama.281.21.2045			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	200NN	10359396				2022-12-28	WOS:000080546700037
J	Ridker, PM				Ridker, PM			Evaluating novel cardiovascular risk factors: Can we better predict heart attacks?	ANNALS OF INTERNAL MEDICINE			English	Article							C-REACTIVE PROTEIN; CORONARY-ARTERY DISEASE; TISSUE-PLASMINOGEN-ACTIVATOR; ACUTE MYOCARDIAL-INFARCTION; SERUM TOTAL HOMOCYSTEINE; NESTED CASE-CONTROL; PLASMA HOMOCYST(E)INE; ATHEROSCLEROSIS RISK; VASCULAR-DISEASE; ANGINA-PECTORIS	Myocardial infarction often occurs among persons without traditional risk factors, and it has been hypothesized that assessment of "novel" markers may help identify persons who are prone to premature atherothrombosis. However, when considering the clinical utility of screening for any new marker for cardiovascular disease, physicians should consider whether there is a standardized and reproducible assay for the marker of interest; whether there is a consistent series of prospective epidemiologic studies indicating that baseline elevations of the novel marker predict future risk; and whether assessment of the novel marker adds to the predictive value of other plasma-based risk factors, specifically, the ratio of total cholesterol to high-density lipoprotein cholesterol. In this article, these criteria are used to evaluate five promising markers of cardiovascular risk: lipoprotein(a), total plasma homocysteine, fibrinolytic capacity, fibrinogen, and high-sensitivity C-reactive protein. Background is also provided to assist physicians in deciding whether one or more of these novel markers deserve clinical consideration in general outpatient settings.	Brigham & Womens Hosp, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA USA	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School	Ridker, PM (corresponding author), Brigham & Womens Hosp, 75 Francis St, Boston, MA 02115 USA.	pmridker@bics.bwh.harvard.edu						ALFTHAN G, 1994, ATHEROSCLEROSIS, V106, P9, DOI 10.1016/0021-9150(94)90078-7; ANDREOTTI F, 1991, CHRONOBIOL INT, V8, P336, DOI 10.3109/07420529109059170; ANGLETON P, 1989, CIRCULATION, V79, P101, DOI 10.1161/01.CIR.79.1.101; ARNESEN E, 1995, INT J EPIDEMIOL, V24, P704, DOI 10.1093/ije/24.4.704; BOUSHEY CJ, 1995, JAMA-J AM MED ASSOC, V274, P1049, DOI 10.1001/jama.274.13.1049; ChasanTaber L, 1996, J AM COLL NUTR, V15, P136; CREMER P, 1994, EUR J CLIN INVEST, V24, P444, DOI 10.1111/j.1365-2362.1994.tb02373.x; Egerton W, 1996, AM J CARDIOL, V77, P759, DOI 10.1016/S0002-9149(97)89213-2; ERNST E, 1993, ANN INTERN MED, V118, P956, DOI 10.7326/0003-4819-118-12-199306150-00008; Evans RW, 1997, ARTERIOSCL THROM VAS, V17, P1947, DOI 10.1161/01.ATV.17.10.1947; Folsom AR, 1998, CIRCULATION, V98, P204, DOI 10.1161/01.CIR.98.3.204; HAMSTEN A, 1987, LANCET, V2, P3; Haverkate F, 1997, LANCET, V349, P462, DOI 10.1016/S0140-6736(96)07591-5; HEINRICH J, 1994, ARTERIOSCLER THROMB, V14, P54, DOI 10.1161/01.ATV.14.1.54; Hwang SJ, 1997, CIRCULATION, V96, P4219; JANSSON JH, 1993, CIRCULATION, V88, P2030, DOI 10.1161/01.CIR.88.5.2030; JAUHIAINEN M, 1991, ATHEROSCLEROSIS, V89, P59, DOI 10.1016/0021-9150(91)90007-P; JuhanVague I, 1996, CIRCULATION, V94, P2057, DOI 10.1161/01.CIR.94.9.2057; KANNEL WB, 1987, JAMA-J AM MED ASSOC, V258, P1183, DOI 10.1001/jama.258.9.1183; Koenig W, 1999, CIRCULATION, V99, P237, DOI 10.1161/01.CIR.99.2.237; Kuller LH, 1996, AM J EPIDEMIOL, V144, P537, DOI 10.1093/oxfordjournals.aje.a008963; Ledue TB, 1997, CLIN CHEM, V43, P624; LINDGREN A, 1995, STROKE, V26, P795, DOI 10.1161/01.STR.26.5.795; MA J, IN PRESS J AM COLL C; Macy EM, 1997, CLIN CHEM, V43, P52; MAEDA S, 1989, ATHEROSCLEROSIS, V78, P145, DOI 10.1016/0021-9150(89)90218-9; Malinow MR, 1998, NEW ENGL J MED, V338, P1009, DOI 10.1056/NEJM199804093381501; Nygard O, 1997, NEW ENGL J MED, V337, P230, DOI 10.1056/NEJM199707243370403; PERRY IJ, 1995, LANCET, V346, P1395, DOI 10.1016/S0140-6736(95)92407-8; Ridker PM, 1998, CIRCULATION, V97, P2007, DOI 10.1161/01.CIR.97.20.2007; Ridker PM, 1997, THROMB HAEMOSTASIS, V78, P53; RIDKER PM, 1991, CIRCULATION, V83, P1098, DOI 10.1161/01.CIR.83.3.1098; Ridker PM, 1998, CIRCULATION, V97, P425; RIDKER PM, 1993, LANCET, V341, P1165, DOI 10.1016/0140-6736(93)90998-V; RIDKER PM, 1993, JAMA-J AM MED ASSOC, V270, P2195, DOI 10.1001/jama.270.18.2195; Ridker PM, 1998, CIRCULATION, V98, P839, DOI 10.1161/01.CIR.98.9.839; RIDKER PM, 1994, LANCET, V343, P940, DOI 10.1016/S0140-6736(94)90064-7; Ridker PM, 1998, CIRCULATION, V98, P731, DOI 10.1161/01.CIR.98.8.731; Ridker PM, 1998, LANCET, V351, P88, DOI 10.1016/S0140-6736(97)09032-6; Ridker PM, 1997, NEW ENGL J MED, V336, P973, DOI 10.1056/NEJM199704033361401; RIDKER PM, 1995, JAMA-J AM MED ASSOC, V273, P1269, DOI 10.1001/jama.273.16.1269; ROSENGREN A, 1990, BRIT MED J, V301, P1248, DOI 10.1136/bmj.301.6763.1248; SCHAEFER EJ, 1994, JAMA-J AM MED ASSOC, V271, P999, DOI 10.1001/jama.271.13.999; SELHUB J, 1993, JAMA-J AM MED ASSOC, V270, P2693, DOI 10.1001/jama.270.22.2693; SIGURDSSON G, 1992, AM J CARDIOL, V69, P1251, DOI 10.1016/0002-9149(92)91215-P; SLUNGA L, 1992, SCAND J CLIN LAB INV, V52, P95, DOI 10.3109/00365519209088771; STAMPFER MJ, 1991, NEW ENGL J MED, V325, P373, DOI 10.1056/NEJM199108083250601; STAMPFER MJ, 1992, JAMA-J AM MED ASSOC, V268, P877, DOI 10.1001/jama.268.7.877; Tate JR, 1998, CLIN CHEM, V44, P1629; THOMPSON SG, 1995, NEW ENGL J MED, V332, P635, DOI 10.1056/NEJM199503093321003; Tracy RP, 1997, ARTERIOSCL THROM VAS, V17, P1121, DOI 10.1161/01.ATV.17.6.1121; VERHOEF P, 1994, STROKE, V25, P1924, DOI 10.1161/01.STR.25.10.1924; WALD NJ, 1994, LANCET, V343, P75, DOI 10.1016/S0140-6736(94)90814-1; Wald NJ, 1998, ARCH INTERN MED, V158, P862, DOI 10.1001/archinte.158.8.862; WILHELMSEN L, 1984, NEW ENGL J MED, V311, P501, DOI 10.1056/NEJM198408233110804; YARNELL JWG, 1991, CIRCULATION, V83, P836, DOI 10.1161/01.CIR.83.3.836	56	243	256	0	8	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 1	1999	130	11					933	937		10.7326/0003-4819-130-11-199906010-00018	http://dx.doi.org/10.7326/0003-4819-130-11-199906010-00018			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	200PB	10375342				2022-12-28	WOS:000080547900008
J	Maconochie, N; Doyle, P; Roman, E; Davies, G; Smith, PG; Beral, V				Maconochie, N; Doyle, P; Roman, E; Davies, G; Smith, PG; Beral, V			The nuclear industry family study: linkage of occupational exposures to reproduction and child health	BRITISH MEDICAL JOURNAL			English	Article							NON-HODGKINS-LYMPHOMA; CANCER MORTALITY; WEST CUMBRIA; RADIATION-WORKERS; SELLAFIELD PLANT; LEUKEMIA; BORN; WORKFORCES; EMPLOYEES; MORBIDITY		Univ London London Sch Hyg & Trop Med, London WC1E 7HT, England; Univ Leeds, Inst Epidemiol, Leukaemia Res Fund, Leeds LS2 9LN, W Yorkshire, England; Univ Oxford, Radcliffe Infirm, Imperial Canc Res Fund, Oxford OX2 6HE, England	University of London; London School of Hygiene & Tropical Medicine; University of Leeds; Radcliffe Infirmary; University of Oxford	Maconochie, N (corresponding author), Univ London London Sch Hyg & Trop Med, Keppel St, London WC1E 7HT, England.		smith, peter/ABH-9627-2020	smith, peter/0000-0003-0080-7560; Roman, Eve/0000-0001-7603-3704				[Anonymous], 1992, MAN INT STAT CLASS D; BERAL V, 1985, BRIT MED J, V291, P440, DOI 10.1136/bmj.291.6493.440; BERAL V, 1988, BRIT MED J, V297, P757, DOI 10.1136/bmj.297.6651.757; BLACK D, 1984, INVESTIGATINS POSSIB; Bobrow M, 1993, CHILDHOOD CANC NUCL; CARPENTER L, 1994, RADIAT RES, V138, P224, DOI 10.2307/3578592; Carpenter LM, 1998, BRIT J CANCER, V78, P1224, DOI 10.1038/bjc.1998.659; *COMM BIOL EFF ION, 1990, HLTH EFF EXP LOW LEV; *COMM MED ASP RAD, 1988, 2 COMARE; *COMM MED ASP RAD, 1989, 3 COMARE; *COMM MED ASP RAD, 1986, 1 COMARE; DOUGLAS AJ, 1994, BRIT J CANCER, V70, P1232, DOI 10.1038/bjc.1994.479; Draper GJ, 1997, BRIT MED J, V315, P1181, DOI 10.1136/bmj.315.7117.1181; FRASER P, 1993, BRIT J CANCER, V67, P615, DOI 10.1038/bjc.1993.113; GARDNER MJ, 1987, BRIT MED J, V295, P819, DOI 10.1136/bmj.295.6602.819; GARDNER MJ, 1990, BRIT MED J, V300, P423, DOI 10.1136/bmj.300.6722.423; GARDNER MJ, 1987, BRIT MED J, V295, P822, DOI 10.1136/bmj.295.6602.822; HEASMAN MA, 1986, LANCET, V1, P266; KENDALL GM, 1992, BRIT MED J, V304, P220, DOI 10.1136/bmj.304.6821.220; Roman E, 1996, OCCUP ENVIRON MED, V53, P73, DOI 10.1136/oem.53.2.73; ROMAN E, 1987, BRIT MED J, V294, P597, DOI 10.1136/bmj.294.6572.597; ROMAN E, 1993, BMJ-BRIT MED J, V306, P615, DOI 10.1136/bmj.306.6878.615; Smith J. W., 1985, Journal of the Society for Radiological Protection, V5, P159, DOI 10.1088/0260-2814/5/4/001; SMITH PG, 1986, BRIT MED J, V293, P845, DOI 10.1136/bmj.293.6551.845; *STATACORP, 1996, STATA STAT SOFTW REL; TAYLOR N A, 1991, Journal of Radiological Protection, V11, P191, DOI 10.1088/0952-4746/11/3/005; URQUHART J, 1984, LANCET, V1, P217; URQUHART JD, 1991, BRIT MED J, V302, P687, DOI 10.1136/bmj.302.6778.687; *WHO, 1977, MAN INT CLASS DIS	29	2	2	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	MAY 29	1999	318	7196					1453	+		10.1136/bmj.318.7196.1453	http://dx.doi.org/10.1136/bmj.318.7196.1453			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	202TL	10346770	Bronze, Green Submitted, Green Published			2022-12-28	WOS:000080668200022
J	Gilbert, RJC; Jimenez, JL; Chen, SX; Tickle, IJ; Rossjohn, J; Parker, M; Andrew, PW; Saibil, HR				Gilbert, RJC; Jimenez, JL; Chen, SX; Tickle, IJ; Rossjohn, J; Parker, M; Andrew, PW; Saibil, HR			Two structural transitions in membrane pore formation by pneumolysin, the pore-forming toxin of Streptococcus pneumoniae	CELL			English	Article							STREPTOLYSIN-O; PERFRINGOLYSIN-O; CHOLESTEROL-BINDING; LIPOSOMAL MEMBRANES; PROTEIN TOXIN; THETA-TOXIN; VIRULENCE; MECHANISM; CYTOLYSIN; MUTAGENESIS	The human pathogen Streptococcus pneumoniae produces soluble pneumolysin monomers that bind host cell membranes to form ring-shaped, oligomeric pores. We have determined three-dimensional structures of a helical oligomer of pneumolysin and of a membrane-bound ring form by cryo-electron microscopy. Fitting the four domains from the crystal structure of the closely related perfringolysin reveals major domain rotations during pore assembly. Oligomerization results in the expulsion of domain 3 from its original position in the monomer. However, domain 3 reassociates with the other domains in the membrane pore form. The base of domain 4 contacts the bilayer, possibly along with an extension of domain 3. These results reveal a two-stage mechanism for pore formation by the cholesterol-binding toxins.	Univ London Birkbeck Coll, Dept Crystallog, London WC1E 7HX, England; Univ Leicester, Dept Biochem, Leicester LE1 7RH, Leics, England; St Vincents Inst Med Res, Fitzroy, Vic 3065, Australia; Univ Leicester, Dept Microbiol & Immunol, Leicester LE1 8AH, Leics, England	University of London; Birkbeck University London; University of Leicester; St. Vincent's Institute of Medical Research; University of Leicester	Saibil, HR (corresponding author), Univ London Birkbeck Coll, Dept Crystallog, Malet St, London WC1E 7HX, England.		Rossjohn, Jamie/F-9032-2013; Parker, Michael W/F-9069-2013; Andrew, Peter W/G-7526-2012	Rossjohn, Jamie/0000-0002-2020-7522; Parker, Michael W/0000-0002-3101-1138; Tickle, Ian/0000-0003-2977-0650	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Alexander JE, 1998, MICROB PATHOGENESIS, V24, P167, DOI 10.1006/mpat.1997.0185; ALONSODEVELASCO E, 1995, MICROBIOL REV, V59, P591, DOI 10.1128/MMBR.59.4.591-603.1995; Bayley H, 1997, CURR BIOL, V7, pR763, DOI 10.1016/S0960-9822(06)00399-X; BERRY AM, 1989, INFECT IMMUN, V57, P2037, DOI 10.1128/IAI.57.7.2037-2042.1989; BHAKDI S, 1985, INFECT IMMUN, V47, P52; BUCKINGHAM L, 1983, BIOCHIM BIOPHYS ACTA, V729, P115, DOI 10.1016/0005-2736(83)90462-5; *CCP4, 1994, ACTA CRYSTALLOGR D, V50, P750; Crowther RA, 1996, J STRUCT BIOL, V116, P9, DOI 10.1006/jsbi.1996.0003; DEKRUIJFF B, 1990, BIOSCIENCE REP, V10, P127; Esnouf RM, 1997, J MOL GRAPH MODEL, V15, P132, DOI 10.1016/S1093-3263(97)00021-1; Frank J, 1996, J STRUCT BIOL, V116, P190, DOI 10.1006/jsbi.1996.0030; Gilbert RJC, 1998, J MOL BIOL, V284, P1223, DOI 10.1006/jmbi.1998.2258; Grindstaff KK, 1998, CELL, V93, P731, DOI 10.1016/S0092-8674(00)81435-X; HARRIS RW, 1991, J BIOL CHEM, V266, P6936; HILL J, 1994, INFECT IMMUN, V62, P757, DOI 10.1128/IAI.62.2.757-758.1994; Jimenez JL, 1999, EMBO J, V18, P815, DOI 10.1093/emboj/18.4.815; Jones S, 1996, MOL MICROBIOL, V21, P1219, DOI 10.1046/j.1365-2958.1996.00074.x; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Killian JA, 1996, BIOCHEMISTRY-US, V35, P1037, DOI 10.1021/bi9519258; Korchev YE, 1998, BIOCHEM J, V329, P571; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; MITCHELL TJ, 1991, MOL MICROBIOL, V5, P1883, DOI 10.1111/j.1365-2958.1991.tb00812.x; Morgan P, 1996, REV MED MICROBIOL, V7, P221, DOI DOI 10.1097/00013542-199610000-00004; MORGAN PJ, 1994, J BIOL CHEM, V269, P25315; MORGAN PJ, 1995, FEBS LETT, V371, P77, DOI 10.1016/0014-5793(95)00887-F; NAKAMURA M, 1995, BIOCHEMISTRY-US, V34, P6513, DOI 10.1021/bi00019a032; Nakamura M, 1998, J BIOCHEM, V123, P1145; OLOFSSON A, 1993, FEBS LETT, V319, P125, DOI 10.1016/0014-5793(93)80050-5; Olson R, 1999, NAT STRUCT BIOL, V6, P134; PALMER M, 1995, EUR J BIOCHEM, V231, P388, DOI 10.1111/j.1432-1033.1995.tb20711.x; Palmer M, 1996, J BIOL CHEM, V271, P26664, DOI 10.1074/jbc.271.43.26664; Palmer M, 1998, EMBO J, V17, P1598, DOI 10.1093/emboj/17.6.1598; Petosa C, 1997, NATURE, V385, P833, DOI 10.1038/385833a0; Rossjohn J, 1998, J MOL BIOL, V284, P449, DOI 10.1006/jmbi.1998.2167; Rossjohn J, 1997, CELL, V89, P685, DOI 10.1016/S0092-8674(00)80251-2; Schroeter JP, 1996, J STRUCT BIOL, V116, P131, DOI 10.1006/jsbi.1996.0021; SEDDON JM, 1990, BIOCHIM BIOPHYS ACTA, V1031, P1, DOI 10.1016/0304-4157(90)90002-T; SEKIYA K, 1993, J BACTERIOL, V175, P5953, DOI 10.1128/JB.175.18.5953-5961.1993; Shepard LA, 1998, BIOCHEMISTRY-US, V37, P14563, DOI 10.1021/bi981452f; Song LZ, 1996, SCIENCE, V274, P1859, DOI 10.1126/science.274.5294.1859; TWETEN RK, 1995, VIRULENCE MECHANISMS OF BACTERIAL PATHOGENS, 2ND EDITION, P207; vanHeel M, 1996, J STRUCT BIOL, V116, P17, DOI 10.1006/jsbi.1996.0004; WATSON KC, 1972, J CLIN PATHOL, V25, P885, DOI 10.1136/jcp.25.10.885	44	150	160	0	13	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	MAY 28	1999	97	5					647	655		10.1016/S0092-8674(00)80775-8	http://dx.doi.org/10.1016/S0092-8674(00)80775-8			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	202VD	10367893	Bronze			2022-12-28	WOS:000080672100013
J	Lineweaver, CH				Lineweaver, CH			A younger age for the universe	SCIENCE			English	Article							GLOBULAR-CLUSTERS; COSMOLOGICAL CONSTANT; LOCAL SUBDWARFS; GALACTIC DISK; HIPPARCOS; DENSITY; EVOLUTION; DISTANCE; MODELS; STARS	The age of the universe in the Big Bang model can be calculated from three parameters: Hubble's constant, h; the mass density of the universe, Omega(m); and the cosmological constant, Omega(Lambda). Recent observations of the cosmic microwave background and six other cosmological measurements reduce the uncertainty in these three parameters, yielding an age for the universe of 13.4 +/- 1.6 billion years, which is a billion years younger than other recent age estimates. A different standard Big Bang model, which includes cold dark matter with a cosmological constant, provides a consistent and absolutely time-calibrated evolutionary sequence for the universe.	Univ New S Wales, Sch Phys, Sydney, NSW 2052, Australia	University of New South Wales Sydney	Lineweaver, CH (corresponding author), Univ New S Wales, Sch Phys, Sydney, NSW 2052, Australia.	charley@bat.phys.unsw.edu.au		Lineweaver, Charles/0000-0003-2047-1558				Bahcall NA, 1998, ASTROPHYS J, V504, P1, DOI 10.1086/306088; Bahcall NA, 1997, ASTROPHYS J, V485, pL53, DOI 10.1086/310814; Burles S, 1998, ASTROPHYS J, V499, P699, DOI 10.1086/305667; CARLBERG R, 1998, FUNDAMENTAL PARAMETE; Carlberg RG, 1997, ASTROPHYS J, V478, P462, DOI 10.1086/303805; Carraro G, 1999, ASTRON ASTROPHYS, V343, P825; CARROLL SM, 1992, ANNU REV ASTRON ASTR, V30, P499, DOI 10.1146/annurev.aa.30.090192.002435; Chaboyer B, 1998, ASTROPHYS J, V494, P96, DOI 10.1086/305201; Cheng Y., UNPUB; COORAY AR, UNPUB; Cowan JJ, 1997, ASTROPHYS J, V480, P246, DOI 10.1086/303968; DEKEL A, 1998, CRITICAL DIALOGUES C, P175; Driver SP, 1998, ASTROPHYS J, V496, pL93, DOI 10.1086/311257; Efstathiou G, 1999, MON NOT R ASTRON SOC, V303, pL47, DOI 10.1046/j.1365-8711.1999.02433.x; Einstein A, 1917, SITZBER K PREUSS AKA, P142; Evrard AE, 1997, MON NOT R ASTRON SOC, V292, P289, DOI 10.1093/mnras/292.2.289; Falco EE, 1998, ASTROPHYS J, V494, P47, DOI 10.1086/305207; FELTEN JE, 1986, REV MOD PHYS, V58, P689, DOI 10.1103/RevModPhys.58.689; Fukugita M, 1998, ASTROPHYS J, V503, P518, DOI 10.1086/306025; Garnavich PM, 1998, ASTROPHYS J, V509, P74, DOI 10.1086/306495; Gawiser E, 1998, SCIENCE, V280, P1405, DOI 10.1126/science.280.5368.1405; Gratton RG, 1997, ASTROPHYS J, V491, P749, DOI 10.1086/304987; Grundahl F, 1998, ASTROPHYS J, V500, pL179, DOI 10.1086/311419; Guenther DB, 1997, ASTROPHYS J, V484, P937, DOI 10.1086/304367; GUERRA EJ, UNPUB; Hoyle F, 1997, MON NOT R ASTRON SOC, V286, P173, DOI 10.1093/mnras/286.1.173; KRAUSS LM, UNPUB; Leggett SK, 1998, ASTROPHYS J, V497, P294, DOI 10.1086/305463; LINDE A, 1990, PARTICLE PHYSICS INF; Lineweaver CH, 1998, ASTROPHYS J, V496, P624, DOI 10.1086/305408; Lineweaver CH, 1998, ASTROPHYS J, V505, pL69, DOI 10.1086/311613; Marleau FR, 1998, ASTROPHYS J, V507, P585, DOI 10.1086/306356; Olsen KAG, 1998, MON NOT R ASTRON SOC, V300, P665, DOI 10.1046/j.1365-8711.1998.01860.x; Oswalt TD, 1996, NATURE, V382, P692, DOI 10.1038/382692a0; OSWALT TD, COMMUNICATION; PERLMUTTER S, IN PRESS ASTROPHYS J; Phelps RL, 1997, ASTROPHYS J, V483, P826, DOI 10.1086/304272; Pont F, 1998, ASTRON ASTROPHYS, V329, P87; QUAST R, UNPUB; Reid IN, 1997, ASTRON J, V114, P161, DOI 10.1086/118462; Riess AG, 1998, ASTRON J, V116, P1009, DOI 10.1086/300499; Salaris M, 1997, ASTRON ASTROPHYS, V327, P107; Tegmark M, 1999, ASTROPHYS J, V514, pL69, DOI 10.1086/311943; WEBSTER AM, 1999, ASTROPHYS J, V509, P65; White M, 1998, ASTROPHYS J, V506, P495, DOI 10.1086/306278; WHITE SDM, 1993, NATURE, V366, P429, DOI 10.1038/366429a0; Yoshii Y, 1998, ASTROPHYS J, V507, pL113, DOI 10.1086/311690; ZEHAVI I, 1998, MPA ESO COSM C EV LA	49	38	39	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 28	1999	284	5419					1503	1507		10.1126/science.284.5419.1503	http://dx.doi.org/10.1126/science.284.5419.1503			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	200PD	10348733				2022-12-28	WOS:000080548100030
J	Russell, DW				Russell, DW			Nuclear orphan receptors control cholesterol catabolism	CELL			English	Review							LXR-ALPHA; METABOLISM; PATHWAY		Univ Texas, SW Med Ctr, Dallas, TX 75235 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Russell, DW (corresponding author), Univ Texas, SW Med Ctr, 5323 Harry Hines Blvd, Dallas, TX 75235 USA.			Russell, David/0000-0002-0277-403X				Auwerx J, 1999, CELL, V97, P161; Brown MS, 1997, CELL, V89, P331, DOI 10.1016/S0092-8674(00)80213-5; Forman BM, 1997, P NATL ACAD SCI USA, V94, P10588, DOI 10.1073/pnas.94.20.10588; Janowski BA, 1996, NATURE, V383, P728, DOI 10.1038/383728a0; Lehmann JM, 1997, J BIOL CHEM, V272, P3137, DOI 10.1074/jbc.272.6.3137; Lund EG, 1998, J BIOL CHEM, V273, P34316, DOI 10.1074/jbc.273.51.34316; LUND EG, 1999, IN PRESS P NATL ACAD, V96; MAKISHIMA M, 1999, IN PRESS SCIENCE, V284; NITTA M, 1999, IN PRESS P NATL ACAD, V96; Parker KL, 1997, ENDOCR REV, V18, P361, DOI 10.1210/er.18.3.361; Peet DJ, 1998, CELL, V93, P693, DOI 10.1016/S0092-8674(00)81432-4; RUSSELL DW, 1992, BIOCHEMISTRY-US, V31, P4737, DOI 10.1021/bi00135a001; Schwarz M, 1998, CURR OPIN LIPIDOL, V9, P113, DOI 10.1097/00041433-199804000-00006; Wang HB, 1999, MOL CELL, V3, P543, DOI 10.1016/S1097-2765(00)80348-2; Zhou GC, 1998, MOL ENDOCRINOL, V12, P1594, DOI 10.1210/me.12.10.1594	15	178	187	1	8	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAY 28	1999	97	5					539	542		10.1016/S0092-8674(00)80763-1	http://dx.doi.org/10.1016/S0092-8674(00)80763-1			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	202VD	10367881	Bronze			2022-12-28	WOS:000080672100001
J	Glantz, SA; Charlesworth, A				Glantz, SA; Charlesworth, A			Tourism and hotel revenues before and after passage of smoke-free restaurant ordinances	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							LOCAL TOBACCO CONTROL; SALES	Context Claims that ordinances requiring smoke-free restaurants will adversely affect tourism have been used to argue against passing such ordinances. Data exist regarding the validity of these claims. Objective To determine the changes in hotel revenues and international tourism after passage of smoke-free restaurant ordinances in locales where the effect has been debated. Design Comparison of hotel revenues and tourism rates before and after passage of 100% smoke-free restaurant ordinances and comparison with US hotel revenue overall. Setting Three states (California, Utah, and Vermont) and 6 cities (Boulder, Cole; Flagstaff, Ariz; Los Angeles, Calif; Mesa, Ariz; New York, NY; and San Francisco, Calif) in which the effect on tourism of smoke-free restaurant ordinances had been debated. Main Outcome Measures Hotel room revenues and hotel revenues as a fraction of total retail sales compared with preordinance revenues and overall US revenues. Results In constant 1997 dollars, passage of the smoke-free restaurant ordinance was associated with a statistically significant increase in the rate of change of hotel revenues in 4 localities, no significant change in 4 localities, and a significant slowing in the rate of increase (but not a decrease) in 4 locality. There was no significant change in the rate of change of hotel revenues as a fraction of total retail sales (P = .16) or total US hotel revenues associated with the ordinances when pooled across all localities (P = .93). International tourism was either unaffected or increased following implementation of the smoke-free ordinances. Conclusion Smoke-free ordinances do not appear to adversely affect, and may increase, tourist business.	Univ Calif San Francisco, Inst Hlth Policy Studies, Dept Med, Div Cardiol, San Francisco, CA 94143 USA	University of California System; University of California San Francisco	Glantz, SA (corresponding author), Univ Calif San Francisco, Inst Hlth Policy Studies, Dept Med, Div Cardiol, San Francisco, CA 94143 USA.				NATIONAL CANCER INSTITUTE [R01CA061021] Funding Source: NIH RePORTER; NCI NIH HHS [CA-61021] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		*AM NONSM RIGHTS, 1998, 100 SMOK FREE ORD; BARTOSCH W, 1995, EC IMPACT BROOKLINES; Bartosch W J, 1999, J Public Health Manag Pract, V5, P53; BIALOUS SA, 1999, TOBACCO CONTROL ARIZ; *CIC RES I, 1998, MARK PROF OV VIS CAL, V1, pR21; *CIT BOULD, 1998, SAL US TAX REN REP; *D RUN ASS, 1998, CAL TRAV IMP COUNT; EVANS C, 1996, DAILY CAMERA    1228, pA8; EVANS C, 1996, DAILY CAMERA    1228, pA1; Gerlach K K, 1997, Tob Control, V6, P199; GLANTZ S, 1997, AM J PUBLIC HEALTH, V88, P1122; Glantz S A, 1999, J Public Health Manag Pract, V5, pvi; Glantz SA, 1997, AM J PUBLIC HEALTH, V87, P1687, DOI 10.2105/AJPH.87.10.1687; GLANTZ SA, 1994, AM J PUBLIC HEALTH, V84, P1081, DOI 10.2105/AJPH.84.7.1081; Glantz SA, 1998, AM J PUBLIC HEALTH, V88, P1122; HARRIE D, 1992, SALT LAKE TRIBU 0220, pB1; HOUSEKEEPER E, 1996, SUNDAY RUTLAND  0414, P3; HWANG P, 1995, MMWR-MORBID MORTAL W, V44, P370; Hyland A, 1999, J Public Health Manag Pract, V5, P14; INNES C, 1993, ARIZONA DAILY S 0718, P4; Innes Christopher, 1993, ARIZONA DAILY S 0718, P1; LINES LM, 1998, SUMM TOT TRANS OCC T; *LOS ANG COUNT HOT, 1996, CAL SMOK LAW CAUS RE; Macdonald H R, 1997, Tob Control, V6, P41; MARONEY N, 1994, CLAREMONT I EC POLIC; *NAT SMOK ALL, 1996, NSA VOICE        NOV, P4; NOWICKI D, 1995, ARIZONA TRIBUNE 0812, pB1; NOWICKI D, 1995, ARIZONA TRIBUNE 0812, pB4; [Office of Research and Development Office of Health Environmental Assessment United States Environmental Protection Agency], 1992, RESP HLTH EFF PASS S; *PKF COUNS, 1998, NEW YORK CITY; *PRIC WAT, 1993, SO CAL BUS ASS LOS A; *REST RESP CHOIC, 1992, TABLE TENT ADV OPP F; SAMUELS B, 1991, JAMA-J AM MED ASSOC, V266, P2110, DOI 10.1001/jama.266.15.2110; SAMUELS BE, 1992, J HEALTH POLIT POLIC, V17, P329, DOI 10.1215/03616878-17-2-329; Sciacca JP, 1998, AM J HEALTH PROMOT, V12, P176, DOI 10.4278/0890-1171-12.3.176; SEMERAD T, 1994, SALT LAKE TRIBU 1110, pA1; SIEGEL M, 1993, JAMA-J AM MED ASSOC, V270, P490, DOI 10.1001/jama.270.4.490; *STAT BOARD EQ, 1986, TAX SAL CALL SAL US; STAUBER J, 1995, TOX SLUDG GOOD YOU; The Office of Environmental Health Hazard Assessment, 1997, HLTH EFF EXP ENV TOB; *TOB I UN REST HOT, 1994, THIS REST BILL NEW Y; TRAYNOR MP, 1993, JAMA-J AM MED ASSOC, V270, P479, DOI 10.1001/jama.270.4.479; *US CENS BUR, 1999, 1990 CENS DAT LOOK T; WAGNER G, 1993, LODGING HOSP, P48; WOODRUFF TJ, 1993, ARCH INTERN MED, V153, P1485, DOI 10.1001/archinte.153.12.1485; 1994, NY TIMES        0923	46	53	53	1	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 26	1999	281	20					1911	1918		10.1001/jama.281.20.1911	http://dx.doi.org/10.1001/jama.281.20.1911			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	198ME	10349895	Bronze			2022-12-28	WOS:000080427300031
J	Bornstein, SR; Stratakis, CA; Chrousos, GP				Bornstein, SR; Stratakis, CA; Chrousos, GP			Adrenocortical tumors: Recent advances in basic concepts and clinical management	ANNALS OF INTERNAL MEDICINE			English	Review							GLUCOCORTICOID-REMEDIABLE ALDOSTERONISM; ENDOCRINE NEOPLASIA TYPE-1; DISCOVERED ADRENAL MASSES; GROWTH-FACTOR-II; COMPARATIVE GENOMIC HYBRIDIZATION; GASTRIC-INHIBITORY POLYPEPTIDE; DEPENDENT CUSHINGS-SYNDROME; HYPERALDOSTERONISM TYPE-II; ITALIAN STUDY-GROUP; LAPAROSCOPIC ADRENALECTOMY	Adrenocortical masses are among the most common tumors in humans. However, only a small proportion of these tumors cause endocrine diseases (such as primary hyperaldosteronism, hypercortisolism, hyperandrogenism, or hyperestrogenism), and less than 1% are malignant. In recent years, several of the molecular and cellular mechanisms involved in adrenal tumorigenesis have been unraveled. As a result, alterations in intercellular communication, local production of growth factors and cytokines, and aberrant expression of ectopic receptors on adrenal tumor cells have been implicated in adrenal cell growth, hyperplasia, tumor formation, and autonomous hormone production. Genetic and chromosomal abnormalities, including several chromosomal loci and the genes coding for p53, p57, and insulin-like growth factor II, have been reported in adrenal tumors. In addition, chromosomal markers have been identified in several familial syndromes associated with adrenal tumors; these include menin, which is responsible for multiple endocrine neoplasia type I, and the hybrid gene that causes glucocorticoid-remediable hyperaldosteronism. Algorithms for endocrine testing and imaging procedures are now available to codify screening for, confirmation of, and differentiation of causes of primary hyperaldosteronism and the Cushing syndrome. Improved radiologic, computerized radiologic, and magnetic resonance imaging techniques, as well as selective catheterization studies, are useful in localizing adrenal tumors and in distinguishing between benign and malignant lesions and between functional and nonfunctional nodules. Finally, recent refinements in the field of minimally invasive general surgery have made laparoscopic adrenalectomy the method of choice for removing adrenal tumors; this type of surgery allows shorter hospital stays, lower morbidity rates, and faster recovery.	NICHHD, Dev Endocrinol Branch, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)	Bornstein, SR (corresponding author), NICHHD, Dev Endocrinol Branch, NIH, Bldg 10,Room 10N 262,10 Ctr Dr,MSC 1862, Bethesda, MD 20892 USA.	bornstes@ccl.nichd.nih.gov	Stratakis, Constantine/AAP-4745-2020		EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [ZIAHD000642, Z01HD000642] Funding Source: NIH RePORTER	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Adler ML, 1998, TRENDS ENDOCRIN MET, V9, P190, DOI 10.1016/S1043-2760(98)00040-X; ANDRADA JA, 1979, ARCH PATHOL LAB MED, V103, P244; Angeli A, 1997, HORM RES, V47, P279, DOI 10.1159/000185477; AVRUCH J, 1994, TRENDS BIOCHEM SCI, V19, P279, DOI 10.1016/0968-0004(94)90005-1; BAIRD A, 1990, PEPTIDE GROWTH FACTO, V1, P369; BARZILAY JI, 1989, UROL CLIN N AM, V16, P457; Barzon L, 1998, J CLIN ENDOCR METAB, V83, P55, DOI 10.1210/jc.83.1.55; BECKERS A, 1992, J CLIN ENDOCR METAB, V75, P564, DOI 10.1210/jc.75.2.564; Biglieri E G, 1997, Curr Ther Endocrinol Metab, V6, P170; BLUMENFELD JD, 1994, ANN INTERN MED, V121, P877, DOI 10.7326/0003-4819-121-11-199412010-00010; Bondanelli M, 1997, METABOLISM, V46, P107, DOI 10.1016/S0026-0495(97)90176-1; BORNSTEIN SR, 1990, ENDOCRINOLOGY, V127, P900, DOI 10.1210/endo-127-2-900; BORNSTEIN SR, 1992, ENDOCRINOLOGY, V131, P3126, DOI 10.1210/en.131.6.3126; BORNSTEIN SR, 1994, J CLIN ENDOCR METAB, V78, P225, DOI 10.1210/jcem.78.1.7507122; Bornstein SR, 1998, HORM METAB RES, V30, P292, DOI 10.1055/s-2007-978887; BORNSTEIN SR, 1991, CELL TISSUE RES, V265, P1, DOI 10.1007/BF00318133; BOSTON BA, 1994, J CLIN ENDOCR METAB, V79, P890, DOI 10.1210/jc.79.3.890; Casey M, 1998, CIRCULATION, V98, P2560, DOI 10.1161/01.CIR.98.23.2560; Chandrasekharappa SC, 1997, SCIENCE, V276, P404, DOI 10.1126/science.276.5311.404; Chee C, 1998, UROLOGY, V51, P29, DOI 10.1016/S0090-4295(97)00468-8; Chrousos GP, 1998, ANN NY ACAD SCI, V851, P311, DOI 10.1111/j.1749-6632.1998.tb09006.x; CHROUSOS GP, 1985, ANN INTERN MED, V102, P344, DOI 10.7326/0003-4819-102-3-344; CLOUSTON WM, 1989, CLIN ENDOCRINOL, V31, P467, DOI 10.1111/j.1365-2265.1989.tb01270.x; CONN JW, 1955, J LAB CLIN MED, V45, P3; COPELAND PM, 1983, ANN INTERN MED, V98, P940, DOI 10.7326/0003-4819-98-6-940; CRAPO L, 1979, METABOLISM, V28, P955, DOI 10.1016/0026-0495(79)90097-0; DLUHY RG, 1994, ENDOCRIN METAB CLIN, V23, P285, DOI 10.1016/S0889-8529(18)30098-7; Doppman JL, 1996, RADIOLOGY, V198, P309, DOI 10.1148/radiology.198.2.8596821; Doppman JL, 1997, ENDOCRIN METAB CLIN, V26, P973, DOI 10.1016/S0889-8529(05)70290-5; DUMANOIR S, 1993, HUM GENET, V90, P590, DOI 10.1007/BF00202476; DUNNICK NR, 1990, AM J ROENTGENOL, V154, P927, DOI 10.2214/ajr.154.5.2108567; EDWARDS CRW, 1995, ENDOCRINOLOGY, P1775; Ehrhart-Bornstein M, 1998, ENDOCR REV, V19, P101, DOI 10.1210/er.19.2.101; EHRHARTBORNSTEI.M, IN PRESS ADRENAL DIS; EhrhartBornstein M, 1996, EUR J ENDOCRINOL, V135, P19, DOI 10.1530/eje.0.1350019; Engeland WC, 1998, HORM METAB RES, V30, P311, DOI 10.1055/s-2007-978890; FEIGE J-J, 1991, Progress in Growth Factor Research, V3, P103, DOI 10.1016/S0955-2235(05)80002-X; FERRISS JB, 1978, AM HEART J, V95, P375, DOI 10.1016/0002-8703(78)90370-8; Figueiredo BC, 1999, J CLIN ENDOCR METAB, V84, P1116, DOI 10.1210/jc.84.3.1116; FLACK MR, 1996, CANC MED, P1563; FREEMAN D, 1978, ENDOCR REV, V7, P204; Gagner M, 1997, ANN SURG, V226, P238, DOI 10.1097/00000658-199709000-00003; Gicquel C, 1997, J CLIN ENDOCR METAB, V82, P2559, DOI 10.1210/jc.82.8.2559; GOLDSTEIN DS, 1995, CATECHOLAMINES CARDI, P287; GORDON RD, 1994, CLIN EXP PHARMACOL P, V21, P315, DOI 10.1111/j.1440-1681.1994.tb02519.x; GORDON RD, 1995, J ENDOCRINOL INVEST, V18, P495, DOI 10.1007/BF03349761; Gordon RD, 1997, CLIN EXP HYPERTENS, V19, P857, DOI 10.3109/10641969709083191; Haidan A, 1998, PEPTIDES, V19, P1511, DOI 10.1016/S0196-9781(98)00115-6; Hansen P, 1997, ENDOSCOPY, V29, P309, DOI 10.1055/s-2007-1004195; Hatada I, 1996, HUM MOL GENET, V5, P783, DOI 10.1093/hmg/5.6.783; HENRY I, 1989, P NATL ACAD SCI USA, V86, P3247, DOI 10.1073/pnas.86.9.3247; HERRERA MF, 1991, SURGERY, V110, P1014; ILVESMAKI V, 1993, MOL CELL ENDOCRINOL, V91, P59, DOI 10.1016/0303-7207(93)90255-I; ILVESMAKI V, 1993, J CLIN ENDOCR METAB, V77, P852, DOI 10.1210/jc.77.3.852; JAATTELA M, 1991, ENDOCRINOLOGY, V128, P623; JONSSON JR, 1995, BIOCHEM BIOPH RES CO, V207, P565, DOI 10.1006/bbrc.1995.1225; KALLIONIEMI A, 1992, SCIENCE, V258, P818, DOI 10.1126/science.1359641; KAPLAN NM, 1992, WILLIAMS TXB ENDOCRI, P707; KasperlikZaluska AA, 1997, CLIN ENDOCRINOL, V46, P29, DOI 10.1046/j.1365-2265.1997.d01-1751.x; KAYE TB, 1990, ANN INTERN MED, V112, P434, DOI 10.7326/0003-4819-76-3-112-6-434; Khorram-Manesh A, 1998, WORLD J SURG, V22, P605, DOI 10.1007/s002689900442; KHOURY EL, 1987, AM J PATHOL, V127, P580; Kjellman M, 1996, CANCER RES, V56, P4219; Kleihues P, 1997, AM J PATHOL, V150, P1; KLOOS RT, 1995, ENDOCR REV, V16, P460, DOI 10.1210/er.16.4.460; Korman JE, 1997, AM SURGEON, V63, P908; KOROBKIN M, 1995, RADIOLOGY, V197, P411, DOI 10.1148/radiology.197.2.7480685; KOROBKIN M, 1989, UROL RADIOL, V11, P221, DOI 10.1007/BF02926520; Kruger C, 1998, CLIN CHIM ACTA, V274, P15, DOI 10.1016/S0009-8981(98)00044-8; LACROIX A, 1992, NEW ENGL J MED, V327, P974, DOI 10.1056/NEJM199210013271402; Lacroix A, 1997, J CLIN ENDOCR METAB, V82, P2414, DOI 10.1210/jc.82.8.2414; Lacroix A, 1997, NEW ENGL J MED, V337, P1429, DOI 10.1056/NEJM199711133372004; LATRONICO AC, 1995, J CLIN ENDOCR METAB, V80, P875, DOI 10.1210/jc.80.3.875; Latronico AC, 1997, J CLIN ENDOCR METAB, V82, P1317, DOI 10.1210/jc.82.5.1317; LEE JS, 1994, AM J PHYSIOL, V266, pC319, DOI 10.1152/ajpcell.1994.266.2.C319; LEINONEN P, 1991, CLIN ENDOCRINOL, V34, P31, DOI 10.1111/j.1365-2265.1991.tb01732.x; LENDERS JWM, 1995, ANN INTERN MED, V123, P101, DOI 10.7326/0003-4819-123-2-199507150-00004; LEROITH D, 1994, HORM RES, V41, P74, DOI 10.1159/000183964; LIFTON RP, 1992, NATURE, V355, P262, DOI 10.1038/355262a0; LIN SR, 1994, J CLIN ENDOCR METAB, V78, P483, DOI 10.1210/jc.78.2.483; LIPSETT MB, 1963, AM J MED, V35, P374, DOI 10.1016/0002-9343(63)90179-7; Litchfield WR, 1997, J CLIN ENDOCR METAB, V82, P3570, DOI 10.1210/jc.82.11.3570; LIU JQ, 1995, J CLIN ENDOCR METAB, V80, P492, DOI 10.1210/jc.80.2.492; Liu JQ, 1997, J CLIN ENDOCR METAB, V82, P1766, DOI 10.1210/jc.82.6.1766; LUTON JP, 1990, NEW ENGL J MED, V322, P1195, DOI 10.1056/NEJM199004263221705; MALKIN D, 1990, SCIENCE, V250, P1233, DOI 10.1126/science.1978757; Mantero F, 1997, HORM RES, V47, P284, DOI 10.1159/000185478; Marx C, 1997, J CLIN ENDOCR METAB, V82, P3136, DOI 10.1210/jc.82.9.3136; Marx C, 1998, HORM METAB RES, V30, P416, DOI 10.1055/s-2007-978907; Marx C, 1996, J CLIN ENDOCR METAB, V81, P4488, DOI 10.1210/jc.81.12.4488; Marx S, 1998, ANN INTERN MED, V129, P484, DOI 10.7326/0003-4819-129-6-199809150-00011; McDonald TJ, 1998, HORM METAB RES, V30, P297, DOI 10.1055/s-2007-978888; Meier CA, 1997, ENDOCRIN METAB CLIN, V26, P741, DOI 10.1016/S0889-8529(05)70280-2; MELBY JC, 1991, ENDOCRIN METAB CLIN, V20, P247, DOI 10.1016/S0889-8529(18)30266-4; MENDONCA BB, 1995, J UROLOGY, V154, P2004, DOI 10.1016/S0022-5347(01)66673-4; Miyake O, 1998, EUR UROL, V33, P303, DOI 10.1159/000019564; N'Diaye N, 1998, HORM METAB RES, V30, P440, DOI 10.1055/s-2007-978912; NIEMAN LK, 1993, J CLIN ENDOCR METAB, V77, P1308, DOI 10.1210/jc.77.5.1308; Nussdorfer GG, 1996, PHARMACOL REV, V48, P495; OGISHIMA T, 1991, J BIOL CHEM, V266, P10731; ORTH DN, 1995, NEW ENGL J MED, V332, P791, DOI 10.1056/NEJM199503233321207; OUTWATER EK, 1995, AM J ROENTGENOL, V165, P579, DOI 10.2214/ajr.165.3.7645474; PANAYOTOU G, 1993, BIOESSAYS, V15, P171, DOI 10.1002/bies.950150305; Path G, 1996, ENDOCR RES, V22, P867; Path G, 1997, J CLIN ENDOCR METAB, V82, P2343, DOI 10.1210/jc.82.7.2343; Pignatelli D, 1998, HORM METAB RES, V30, P464, DOI 10.1055/s-2007-978915; POMMIER RF, 1992, SURGERY, V112, P963; RECHLER MM, 1990, PEPTIDE GROWTH FACTO, V1, P263; REINCKE M, 1993, J CLIN ENDOCR METAB, V77, P1419, DOI 10.1210/jc.77.5.1419; REINCKE M, 1994, J CLIN ENDOCR METAB, V78, P790, DOI 10.1210/jc.78.3.790; Reincke M, 1998, HORM METAB RES, V30, P447, DOI 10.1055/s-2007-978913; Reincke M, 1997, J CLIN ENDOCR METAB, V82, P3054, DOI 10.1210/jc.82.9.3054; REZNIK Y, 1992, NEW ENGL J MED, V327, P981, DOI 10.1056/NEJM199210013271403; Roberts AB, 1990, PEPTIDE GROWTH FACTO, P419; ROH MS, 1987, SURGERY, V102, P140; ROSS NS, 1990, NEW ENGL J MED, V323, P1401; Sachse R, 1997, EUR J ENDOCRINOL, V137, P262, DOI 10.1530/eje.0.1370262; SAMESHIMA Y, 1992, J NATL CANCER I, V84, P703, DOI 10.1093/jnci/84.9.703; SASANO H, 1994, MODERN PATHOL, V7, P741; Schell S R, 1997, Adv Surg, V31, P333; SCHTEINGART DE, 1992, ENDOCRINOLOGIST, V2, P149; Shapiro B, 1990, Recent Results Cancer Res, V118, P113; SKOGSEID B, 1995, SURGERY, V118, P1077, DOI 10.1016/S0039-6060(05)80117-5; Stratakis CA, 1996, J CLIN INVEST, V97, P699, DOI 10.1172/JCI118467; Stratakis CA, 1998, HORM METAB RES, V30, P456, DOI 10.1055/s-2007-978914; STREETEN DHP, 1979, AM J MED, V67, P403, DOI 10.1016/0002-9343(79)90786-1; Taymans SE, 1998, J CLIN ENDOCR METAB, V83, P1033, DOI 10.1210/jc.83.3.1033; Terzolo M, 1997, ARCH SURG-CHICAGO, V132, P914; TORPY D, 1999, VITAM HORM, V46, P177; Torpy DJ, 1998, J CLIN ENDOCR METAB, V83, P3214, DOI 10.1210/jc.83.9.3214; Torpy DJ, 1998, J CLIN ENDOCR METAB, V83, P1046, DOI 10.1210/jc.83.3.1046; VINSON GP, 1985, J ENDOCRINOL, V105, P285, DOI 10.1677/joe.0.1050285; Voutilainen R, 1998, HORM METAB RES, V30, P432, DOI 10.1055/s-2007-978910; WAGNER J, 1994, JNCI-J NATL CANCER I, V86, P1707, DOI 10.1093/jnci/86.22.1707; Walz MK, 1998, WORLD J SURG, V22, P621, DOI 10.1007/s002689900444; WEGIENKA LC, 1966, LANCET, V1, P741; WENIG BM, 1997, ATLAS ENDOCRINE PATH, P272; WHITCOMB RW, 1988, J CLIN ENDOCR METAB, V66, P33, DOI 10.1210/jcem-66-1-33; Willenberg HS, 1998, NEW ENGL J MED, V339, P27, DOI 10.1056/NEJM199807023390105; Wolkersdorfer GW, 1998, BIOCHEM PHARMACOL, V56, P163, DOI 10.1016/S0006-2952(98)00067-7; YANO T, 1989, J NATL CANCER I, V81, P518, DOI 10.1093/jnci/81.7.518; Young WF, 1997, ENDOCRIN METAB CLIN, V26, P801, DOI 10.1016/S0889-8529(05)70283-8; YOUNG WF, 1988, ENDOCRIN METAB CLIN, V17, P367, DOI 10.1016/S0889-8529(18)30425-0	143	125	136	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAY 4	1999	130	9					759	771		10.7326/0003-4819-130-9-199905040-00017	http://dx.doi.org/10.7326/0003-4819-130-9-199905040-00017			13	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	192DE	10357696				2022-12-28	WOS:000080062300008
